<SEC-DOCUMENT>0000785161-23-000012.txt : 20230227
<SEC-HEADER>0000785161-23-000012.hdr.sgml : 20230227
<ACCEPTANCE-DATETIME>20230227162043
ACCESSION NUMBER:		0000785161-23-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		127
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230227
DATE AS OF CHANGE:		20230227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Encompass Health Corp
		CENTRAL INDEX KEY:			0000785161
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				630860407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10315
		FILM NUMBER:		23675210

	BUSINESS ADDRESS:	
		STREET 1:		9001 LIBERTY PARKWAY
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35242
		BUSINESS PHONE:		205-967-7116

	MAIL ADDRESS:	
		STREET 1:		9001 LIBERTY PARKWAY
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35242

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHSOUTH CORP
		DATE OF NAME CHANGE:	19950113

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHSOUTH REHABILITATION CORP
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ehc-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:6ef5271b-25cf-4941-a7fe-936386c94a75,g:d3e86cc2-acdf-4f67-b511-3ef26c190552,d:94fc0f96aa5b45dfbb4828eadd7a15c2--><html xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ehc="http://www.encompasshealth.com/20221231" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ehc-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl80L2ZyYWc6OTI2YTRiMmM3MDJmNDMyNzlkMDU2YjdjNjc4NWYzYWQvdGFibGU6YWExYzQ2OTEwYmQ0NDgxMDk5OWVkYTJkNTVmYWEyOTYvdGFibGVyYW5nZTphYTFjNDY5MTBiZDQ0ODEwOTk5ZWRhMmQ1NWZhYTI5Nl8zLTEtMS0xLTI0NTQ3Nw_a173a45e-ccfb-442a-8cd6-25b0061bd0c1">0000785161</ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl80L2ZyYWc6OTI2YTRiMmM3MDJmNDMyNzlkMDU2YjdjNjc4NWYzYWQvdGFibGU6YWExYzQ2OTEwYmQ0NDgxMDk5OWVkYTJkNTVmYWEyOTYvdGFibGVyYW5nZTphYTFjNDY5MTBiZDQ0ODEwOTk5ZWRhMmQ1NWZhYTI5Nl81LTEtMS0xLTI0NTQ3Nw_0b3c4935-18ae-4551-9513-f8e5e2482a0e">2022</ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl80L2ZyYWc6OTI2YTRiMmM3MDJmNDMyNzlkMDU2YjdjNjc4NWYzYWQvdGFibGU6YWExYzQ2OTEwYmQ0NDgxMDk5OWVkYTJkNTVmYWEyOTYvdGFibGVyYW5nZTphYTFjNDY5MTBiZDQ0ODEwOTk5ZWRhMmQ1NWZhYTI5Nl82LTEtMS0xLTI0NTQ3Nw_05c30b9c-fcdd-4450-a2cb-7ef889e19944">FY</ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl80L2ZyYWc6OTI2YTRiMmM3MDJmNDMyNzlkMDU2YjdjNjc4NWYzYWQvdGFibGU6YWExYzQ2OTEwYmQ0NDgxMDk5OWVkYTJkNTVmYWEyOTYvdGFibGVyYW5nZTphYTFjNDY5MTBiZDQ0ODEwOTk5ZWRhMmQ1NWZhYTI5Nl83LTEtMS0xLTI0NTQ3Nw_0788e1bd-19cb-4468-8bf5-3526a18bcb82">false</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ie558e5b6f68546dba75679d76bd06892_D20220701-20220701" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjQxL2ZyYWc6MGJkOTVjNTcyMmFhNDYwY2I4YTE5ZDAzNzRkYjdkNWUvdGV4dHJlZ2lvbjowYmQ5NWM1NzIyYWE0NjBjYjhhMTlkMDM3NGRiN2Q1ZV8xNTM5MzE2Mjc4OTA2MA_6237d4d9-87ba-4b43-8067-cd0c7b691be8">0.5</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="ifdef059442d4436a8c8670f4a3fc85d0_D20220701-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjQxL2ZyYWc6MGJkOTVjNTcyMmFhNDYwY2I4YTE5ZDAzNzRkYjdkNWUvdGV4dHJlZ2lvbjowYmQ5NWM1NzIyYWE0NjBjYjhhMTlkMDM3NGRiN2Q1ZV8zODQ4MjkwNjk3NDUx_f8c956a0-9cd0-43ad-be3c-50fb3d9e9489">one</ix:nonFraction><ix:nonNumeric contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonNumeric contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i71b339e9a3244030a7c4194e39cb008c_D20180201-20180228" decimals="2" name="ehc:NoncontrollingInterestExerciseRightToSellRatio" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjgwL2ZyYWc6ZjIzMzA3OGI0NmY1NGY1MTgyNTNlMGViMzA0ODJhY2MvdGFibGU6OGJhMDBiMTEyZmM2NGRkOWE0OWU3ZmYxMzU0NDMyOTcvdGFibGVyYW5nZTo4YmEwMGIxMTJmYzY0ZGQ5YTQ5ZTdmZjEzNTQ0MzI5N18xLTEtMS0xLTMxMDY5Ng_30346d0e-3d62-4e7e-a2b4-19cf28629e22">0.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ehc-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cc06ca4859f40608cdefd3c35ca2b7b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="icf6db76417944ea78fd769dcf53d24ba_I20230213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a64fb1653e8439cadb431d448933fbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1efefea033d94a49ae6d1279523cfa77_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d8604073db4dfc9364cee592afa6f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9242279c10684829b4d9378d04b1edbd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id90643ddde5c45f98d52e4b3afea3306_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0bcbb07d6f643b2b8e55385fae57545_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa1631b09af5498898a4f9704b654317_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2adf3229d1fb4d439bf8228ce1a554d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6826376042e0432c876faeb386c0d683_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac851ca1adc4483f827335b0959d3fb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie195f01f18994a1dbbf00c9ea5162424_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568f78237ee640189be8f0569e1325aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4612a858a134e488b568b7bc4f5b31b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9817c02d1254788bdfed4e092d4d240_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17814712636d499cbd8aa753ae7fd05e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie89258633f59441580a344774a089493_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib906731d97114d82addea69f1bb3d93f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad71d7ff6aa0428593dfb57b61019e26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5df19105bbb4e44ad638452c82235f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2040827da13c48fb8523dcbbee23864e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8e12dea591344c0b2b9c9f457b71126_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1b3eb121a4a4b25a2563b523c8cbe4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e6aa83bba40405785127e8ed8bb4d92_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie516d8d2297a44c8928335358a6b74e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b288a1bbc1e4a36a83f2bca14dee1ea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f7c8b4463341a0a371e690773b666a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if44a6728f6fa4025b928881a0e39236d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic212fffe4100400087e39b038b342ab0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbba5e1af20d45838cbb3098d5f3d99b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied260f5cc55446ac98da4ff1069c95fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffd361313d6f4ca589272589af035b20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39924c6425243f7a6b73371e0e4481e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>ehc:state</xbrli:measure></xbrli:unit><xbrli:unit id="hospital"><xbrli:measure>ehc:hospital</xbrli:measure></xbrli:unit><xbrli:context id="ic9f4a444a849477298194909155a4a2e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i1e1655a7659d44a5848ce4031db00715_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3909299e17d4e9f96039b48644e435f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i434a61101a024049985e7041374c1bad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c9d5eba60544d49a2a58e9b24ce961c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice387dc1f36b45818af7e9c1a280c084_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a52ec290e7476db602a525bdf83e5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3840cc62129543f286c32d03fc7cf594_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib537455ec5074b27bc814bd625721be3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd562e2b20ab46e9a82490a8cca0f618_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i630c01ac29fa4ca1b4254e8c177f88ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee6d97175b5645daab81c40993423b85_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida31c9eb47794f719d9ff1564ca9f77f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc59f2f9d2c34e778b82df851653ec07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c60193a93c54ef0a8b26ce2749c4573_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34ebf32157a548a689b81b59e52d7061_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00dcced69aa245dd932b997347d492c6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica31326e89794cf4a262a71ea82be401_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e2eb0b8b29c4c10b2c019f78880ab94_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65daa5d21414406d9a73be137948b909_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8611bd0ee7e5407987c11b03aa8312b6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ecd39de0ee482b9b66faa630bdf25b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i578490c7d6584a1ba41aa384335fae6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05243f3cbac341b8a9bec5a4f2859f00_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22a983720214ed4a192fcba2d07abcc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0f753c8be14e67b8509c7dd73fd6bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i852b75f329ea4ac08df2108afdf43e72_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:DepartmentAppealsBoardAdverseRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:UnifiedProgramIntegrityContractorsAuditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>ehc:claim</xbrli:measure></xbrli:unit><xbrli:context id="ic18e0c6dae034e2e9081f26733964490_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:UnifiedProgramIntegrityContractorsAuditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i461326ed8069459c9262b7d8a144ce07_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:UnifiedProgramIntegrityContractorsAuditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i870361686c2942fdb9b4a9bc9337f323_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:UnifiedProgramIntegrityContractorsAuditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb58224ff71f435f975b30807048a7fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:RACAuditsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9749632394145f497fe0c2c6ec147a7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe35a06f0eae46efb5c6921fe9db414c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b648e892f9f4468aab25a90a2f09b05_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMedicareAdvantageandOtherDiscountPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec6a14cc3aca48bcaeca480b39030876_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMedicareAdvantageandOtherDiscountPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a03052d15b64c25a269fdcc4216b88c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibefecfaeeeb041849960421b13ca007b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c4d794905dd4fb385b71c4eed009bb7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52751714abc34c4d98dc47a7a77e2370_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e50571d65784dfc9aef9033d5f99181_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c18279fe4d4018bbe852e7b57b1d47_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ab836dfffa54e4b814fbfc5b759b918_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c304bf2ec048b88bf47a3f2c6c5a54_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib014de72370b4cb4a6135adc8af20d7b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc2b37264d734f2d8f5833e77968d634_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cb56d21aab74ac3967968f076197961_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfd7ae0589ea4a128b3e3e4861478b00_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5139d245eba04e15a063f9bc48d18aa7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib932dccdf96b459687584cc4f8701479_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e69d3358704dd18df22349448291f5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i176405163b9c4c37878dcef0b9e741ce_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b43ec38059149d4ba26be2569eb2a25_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d16d99320d0432eae3d9ff01729bc03_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic54237316ac9413084b19847adf7f2fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a65005892243e682dc792c081f8c0a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb79ea3f749d47ffbe3c65d094ac96bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436bf0be46974157827b0ca4b6e81e07_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d936af5f8ec4ce8a15339c7e5b4fa6c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i171d0e9f00ac4274a1c1fb90c3567010_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd848d2dde614489a20f1870d96a944a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib57c2c4651af459192fda104b5d0dd00_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:InternalUseSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i470cf08a07fe4287a486a76f384d82ad_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:InternalUseSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf944ca96a324447a5fead2b5afb9747_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81822404b04248c2bc2b92116b265222_I20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ccb23d1174a4ad1bc94116310a93215_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ehc:segment</xbrli:measure></xbrli:unit><xbrli:context id="i5ee3194559484035acac2abce51ef2bb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ce31a740de9494abb75658e9c4e37c7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie558e5b6f68546dba75679d76bd06892_D20220701-20220701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:EnhabitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdef059442d4436a8c8670f4a3fc85d0_D20220701-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37abe5ebc4f44bebbe9fb494c9c84e1_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="bed"><xbrli:measure>ehc:bed</xbrli:measure></xbrli:unit><xbrli:context id="i9991693278fc408e862976490cf30d98_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:TrinityMedicalCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6820aa09cd604de1a90b41670cea5ea8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:NCHHealthcareSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ff2033f1b3942129102202260af6a35_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia21684f87fae47c5b3a34319790c0769_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d9fe27b422459b8eca401afa6fe33c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b030fcfd4e4d31a741e7594dc965c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33b5d49a11d841d0962f2c16a1a90833_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56015630b11b4e009f45b95de40f5a16_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i926c10b50d5b4dc4952bd8f73e5caf2c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HeritageValleyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42d3a03ae9fb49d2a3c3300daff8071b_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3876cf645ac4e17bb330ae838f085f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3a3de37fca442dbd0a5e70526dbf46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id86e386a397b49d296ca11e4a511d544_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bea87602e1641b0b71e094855c78088_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e5544167514a92ae6527fb86b9e780_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6bdb8e550a4806bb3e1dadfd5e0505_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ae11dbadeb749178d2cc18aceb997a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida60f9410ec942ffa8b96644e1a4982e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d13dc5dde24449a63972bfe6bc1df8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2021AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1070117531644374b85aaa3af7d800d0_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6bc012b46224f569423ad84a5eac16f_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ddfcda5811941ceb891a6ef3548c7c3_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b458d6463a4a96b479e42c0fcc71c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if50b14c350354038b6604d1681524651_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ccbd7406a9458abb7cfc12e90ad1e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8af9ecf91da248c5be27bca52229721d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e3f8c860f1b432e95cc26067ef20e2a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i684d2533374c48a4bd1364edabf0ba08_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9234554fdff644f89fd47fb7f88d0659_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2020AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39884fa7a48547f2a08edcccd93487c8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>ehc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i68baf71a31bd473ba1a1ca647e0b19e2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id743d8949a7a47b99d38df3ba1e3e993_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic427d90f8e7c42bdb0850c9210abaeb6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21818c725feb4e82b4d76043fbe5fddb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie62ccf4631834eb8806f370a09ba24d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d8fb91a17448548b52ddaca926ac5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b96835762340179de2e6054fcf6ad0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:AffiliateCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0338b3236b51417cbf66790b47b14be5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:AffiliateCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8b121e96a3441d8cc4887b3971a2ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:SelfInsuredCaptiveFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5ab8a31d8f4c83a1cc36ca852adfa9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:SelfInsuredCaptiveFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2117424317ae4b25824cbe7ca5a8bbe6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:OtherFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa1fdbdb992e4caeb499c51df7168238_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:OtherFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62625eab8b0d4335a31e9e15249ae70e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34843327cab94b9c8261df7a6ac9bacc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d56907f4eb4436af6dad648f56ce6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb76d50e6f0a4405bff0b4e4b612e7d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b3fd57dd2042f68ac013078eaf240a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13acf526358049fdb887e645c419f111_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6c1d864105a4f598505f09fa76bc1be_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f1644f1897949bb82fd5674d6ae3282_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie60dcfb7b1544c66a69974be0bca5376_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d230a026be94efb95ef13566c7b7b0a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b54adc201247bb9fb60bdf36fff8a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ehc:LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief3ef49cda4a4f22a1347489d45480e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ehc:LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07de7edf6557444789afb4418d5e6c0d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4e52d9e713e4adea7cfd891c3ecaeec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24d1851ef607402d900d6d9f19371197_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802dc5eb74bb429e8814073a20bf7f9b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>ehc:option</xbrli:measure></xbrli:unit><xbrli:context id="i177f96156a934c6d92f90d026d815168_D20221001-20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a2086e6351b40948b88fd941ae8faae_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i104ce402feb14e3c9c5682306cabdd39_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97d33a74e74847b680d36c4c8aa5735e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8e84e7ad92e46d1833a208bce11c4b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie577c85705764e9287e7a571a526dd5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8c2650479a4933998c56d70426ad5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d992d3261104e3a8eb38871bc693f4e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ffe900a66ea42e5864253cf987a4119_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c0ea0e574949d8b18d28a5e6d26be3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:TradeNameEncompassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59d0cf8338b44b91948c16fbb5260dc9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:TradeNameEncompassMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i246e3aa9111b46d18007fd9747ba80fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0887e89510aa430c98ba297311ec7c02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i675d9700b9a44be5a34cdbf2e3579982_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d897ae5c3574e308dff0216d9b948c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7cf3b85aded4187ab1295a58ade6e45_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bf83682496c480f9e42d6fee1080450_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a3402d0382640a1aa58f90238c683e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife432a1f73c54d489020d8e1c0653fb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i966df770ed1a4ca986dd2b7ce6d52c65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b3c2c63d034b5982e9fe8323b7b71e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1214fc63dae4248a98c4032a91b2fec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b519d969150438ca0a24a17a6f87ca8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i005266a587014861b4fc4bdc254e6a15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b5a421f1a804107a53e85439af96f46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03e2cfaa161d423e9fe9d78c1d2484d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idca4e969d39442579877374d995f76bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccae8862dd6a4bac8b4589ffb7e02bba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85aa556fff894922b569241055a48e29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44f0c6fe1d3d4acabec50bcd4c8268f6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848b097591424c609108802124923a5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:FaceAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41b7012b097a470cb13642fec315ce68_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NetAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c1215032fe2415c8d09726a46e245a4_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe73f052bcb64b3b84bdbe9c72aaa76c_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339b11c888494596a3629e3c3f8602a3_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if808e99cfa6f4952a0ae670544ff3a5a_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e6b4e433f554a94aa26022360c2e01d_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b575fc15d22495a9d08298c9bae970f_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i041d58dc5a4a43e5a53c4489ec517413_D20191101-20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia639cd1c8ac549939010774ccd59e3c6_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcac1b02df73495c877b9c7d30a882c4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia18b2e0c059c4ec6baf3c43fbd522a3c_D20200701-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6753a38864e24fe7b3e80115745bd09e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562889873f374783afb9294f8f3e580d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693a1fea14d6475ca0e8f46ce8dfe8fb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i115e2fd9db454724b9f95a8f9e1f70a4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9936400e3d03441c8b1661005d6f279a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a87df56a8f6405f8b9bb8b08241a639_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b3e1118ad2243ae8f2552652e81d1e9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1738ccbe8404bafad9e9c10b06a1540_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53ddc51847dc4ddbae72c2e1b0dd613e_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib298d1d466d644b3a88d10c8864e5755_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ehc:day</xbrli:measure></xbrli:unit><xbrli:context id="i49cf61de567c43ef90aa762bfd0eeb09_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i751e9639a4854331aafc6dd971bd8b76_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i977aaea8b2b34ebc93d72ec5a537716a_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f7042f972104aa8922d830f4c40e428_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1102227aec4db8b50dfac6284decf9_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie134020e1d4c46b8bf2c15a981b6d8c3_I20240930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29afe01aaa2c4a1faa04d57a037e62a5_I20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffee7132fe2a4d46ad166324cc4ac784_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37964c43d1d6497390edcd2c9583717d_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a0ab4d513d4a748593003c9e09d157_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:EnhabitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57239bff51e54e02bfafa24442729469_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a929b250624845875d18fad4623b1c_D20220630-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-30</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeb50e54b2bf431e84d3d94cc9d22afa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i203fce73533d42bdbce407cb83fa7644_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e47e2a132f436290412d3422a81aa9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99bc319d2e0041d082e15bd0afcd2496_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73171c1ff1894cd5ab077095eb011dd2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90e87d090f6f40978450a4a6d7148825_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d3ce01c69d745bc933890c6d0232e0a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e4f418e7b3140e2b36a3a4c1d19f59b_I20211209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04748e0cbb554838bc097423f5562754_D20211201-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e9489eb2374473a2446b5989746133_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa44cd02be2427b83f4285074d6a61c_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa62f19b4e9543c6a31117b7bb708940_I20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4579352e569d4ffc861c231d1d0881ff_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d821c1a27c4513aaef9bf885e8f58a_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f4aa2776e24eebbb23581d16dfab42_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie136f6f5e4de4e5eba9a9453789bcd0c_I20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07b9cc9fc0fa4aa9b201c5317d0c6b56_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b9b243cc2b40eca3256ba9b90f576c_D20150901-20150930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebf5ce77babc4dabb08fd48fb81f0d30_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1afcf433ab7c4f42b650fb3992b5dfaf_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a81a550dc09402898362c8731660c62_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ea5e06878784d1c8ac7d2976c3faae1_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46706a0b927b4c29aa04008703cf93f6_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d6af95f4af4e68ba6868cc4060e8be_D20190901-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie995c3d447e041b09b1095eed8f92f8b_D20190901-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i551a3e6b442f432c9d03ed8b29cef37a_D20190901-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie16678dac8224a06a40d1b5f2983c761_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774caad6b09f45a4b7028e593a0fab36_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd2b81bfc614cf3b6b1ae1a415c9a04_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0231b4cffab42d181cb35d1de3a69f6_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfdfcc3a1e4d49cb802cebf7c87fab08_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72f1191377284bad9d5006ad478e6bf1_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3149f20f82304cdda697d7b9112cdb47_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9778d074309d474e95d5496bad2d2441_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21773a5ded4f4f4a8e0e3fdcbb5ae70d_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if575f492f4ab49a593a29cb5970ee78a_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i387c5b799dc94ed79c28d16aa0afe0a1_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb7fb37acad541dd9f14a7d2fa29fe10_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29770414195047bdb212e4ecdc100bdd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c7b1e35d601476d95db3457cce2e093_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eb949f24cfd47338d5c07380335f00f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i892f9d840d2347f2ac10417c21a2ea1c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie09d6f9c686d4f06bc4e1d29051b98d0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic74b27f5ff584f4dae66883c596ca93e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30931627be4f4491b0b2e533a3d8199d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11699d607063435a811357201af64e8c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51dea7b95c6d4aba83ad9fa892757146_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia822ef25d22e4d039b50ff40539e575a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7a2877ba40e444e80b196cf51e8d9c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a6fcce63a9548dea0e3f5364203fa60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6abe4bfb1a460d92a2904f739f25a2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6600f773078e47c292dfad7ad647a4fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2a545ddce6494e94a8dce995b13eb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98ec873af9eb4796a1d331828822e615_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6efebeb8c8db4120ab1f6ddec403e0b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6727a883db744548c7e8035f88a00e4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib815d2a675ad43128d86aa58ebcb4caf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ded9604e5234c4eb9354741e47453eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41e57dc8508f486cb65383ee270622a7_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71b339e9a3244030a7c4194e39cb008c_D20180201-20180228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7de87991e514ae5b6fea1833e9ded6f_D20180221-20180221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-21</xbrli:startDate><xbrli:endDate>2018-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0817bf7784b548a186c313fe446af8a6_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf81650d421400f8d1135d296737e38_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b1d1c428d764c88a5c1812e2a04cf24_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib793c3abc8744e3b9fffcc21e558e086_D20200218-20200218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-18</xbrli:startDate><xbrli:endDate>2020-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd77fca6ac214fcd9bf9357721bb2a92_I20200218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia001d84255a44455b5a46942a930f42b_I20200218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investor"><xbrli:measure>ehc:investor</xbrli:measure></xbrli:unit><xbrli:context id="idac0372aea0347c49bdba860190d96f3_I20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2779168f690432cac5b38f9bea43674_I20200306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77780a6142904e59b58e560a56e1f9e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i258d06e3e65443fb8a893ee44f342300_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib83e1a16991f4a27add600a1fd239b44_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8dd211c83ae4af8ba738a29bef7f269_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e6598efdf814f82b2b3ac56c39d31b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b15fae4966a432d8dd85f41b1846e97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe76ff36e61642c69f074e2796820502_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica49f9c6106c4bff9919ea82c86a1d10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35e875418cae4ed98afcdddf4b6e3679_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5560a022b19466c9dc3b25d0a6709d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd9b95664334eee863511a1352b258d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc353f9b60ef469f9fb57e8eb5392312_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075bc7bcf82a49f8b9f7a4533e89c0a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if11a95d42a454584afeb7e3be1dd5b60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61147de300ac4b17b16c6aa30fb725e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9b5364226647f4aca43882157f6bb9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba3ea646be7400aa6041fe8bb869254_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if68164d48cd14a36908fa4523153e2b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2fcd0acbafe46d5aee193d414a6d056_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36917653da0f4636ac433b0eefd8ca74_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba67211d13b47e7b5f944000baf621e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd0995116ad432dbf5ecfe84fb0e897_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2062512483de43c6b98ca06b53160b5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5783a522bb14483818de81205d4ddac_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i756531406e134ef495f108a1f1d4ce85_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffe80798844441ff9ba446bee23d99ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288afc94975d4cd1af41f3c46445c4fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88b3ef661e7d406e858898cbe882bb5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c9080bb72a43d387919a7abafe465f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib131caf622a8488480693d868801dfff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdcc92113b74a7d8e07277da2c910f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i800dfcdb85da4e128a32fc9b7f379889_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfd71591191f4bcaac27b10a00b10a7f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5202834b56544309d7d9d8b7bee2a66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0451060ab9de4fbd8016ce801fb4c267_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f7af3cf123430084485f0646aec6b2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ab7e7f086a47feb8e87a9898b27939_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc9bbdd487884af6b55d2a388ce96eb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia760f2e4e675400ca0a4847d612a1345_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6886b561cd61484d89ba422e4d310087_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i997ce4d2148b4c2195cf12ae01cec37a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9453d359deda4140a48a46fd53784a03_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6750e3dddd9447f96d964077958239f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fd5c983c4384e469b96a6e07cd2f730_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb880111df2e4c1592091b713f0fe19f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5494a2b14ffd4637b8184bac94f6987e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21eb7f8154e9461399c33a8e06c6aff2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9512677b078c40578810c4ef579432a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ehc:A2016OmnibusPerformanceIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61258fb59e114ab4be13ec46d31319dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52beb02bfcfb448588dda9dfaf965534_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b3906930f64c70b58328d97278b262_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i463986e3eb5648c5b6f6782f286a2c2c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id44f0a9ab653432d9903ca10012e1b33_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8af94fb3b095489db51ee3b16dd479ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6bbfc0dab6943969098cd57a4bd7417_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i840ae531504149f0837b987fe6ccf313_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01fbaae638d442ca55200524b2ce253_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c577e7192b841b1b95ff17d16f908e0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if262b00fc98d47d0a49e375a4660d68f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb1d8ad1f6e64881a43d9b042ee3fc13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ef0c616638487da568717e4b2e9c7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if693d94dd9bf41cba272ff6915a36cca_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7587a2d34b884d75891d35e0b6e9e5e9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b1d9e9c16f04250bb589217b66999c2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1479ab37bdd64668ad1c87355665ae26_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7def89f3f73f44a5991f33f0d8b3acb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:CurrentAndFormerBoardOfDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a3c2935e68148f990a70aed020917a4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHealthRetirementInvestmentPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1591fbdf586749bf959c3f5eed6dc567_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHealthRetirementInvestmentPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="y"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit><xbrli:context id="i913d390f327f454fa9db31895be317bc_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i271895a47db64e53a3fcdb21e2376d82_I20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i325765d7079c4953b5c202a28adc1d7c_I20140201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4088c2e6d51b4eb4aae4742204a2232a_I20180724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia983a9cc79d34b3bb0ce98f38ebd4ecc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0758e6da4efb498697cc4632c85ce905_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifad81fc0e15246a99a32d666a8e006ab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacdb0a94afd843448af41d30dec91b1f_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id92801372f7742e0be889a3765cde901_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e8efdcf26334badb765a5748295be5a_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i095a5224a8204444bf94150541a11956_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000785161</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTMtMS0xLTI0NTQ3Nw_f2de0a82-9dc8-4a08-a7a5-7f3bcb6108e0 id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTEtMS0xLTI0NTQ3Nw_35ab4c84-49e9-4a51-af7c-17f16f5f209d id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTEtMS0xLTI0NTQ3Nw_1279d20f-075b-4742-bd23-75b6c1e9eed9 id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTMtMS0xLTI0NTQ3Nw_2a843a56-9e04-4f9a-ac50-be6a0201a274" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzM0Mg_20312f68-ddf8-42c0-af6e-5dec32785555" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg4_f239f585-07a3-43e9-a892-27d6899335fd">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6NDJjOWRlYTI1NTk3NGMyOWI5ZTY3NmVmYmE1ZmU0MmYvdGFibGVyYW5nZTo0MmM5ZGVhMjU1OTc0YzI5YjllNjc2ZWZiYTVmZTQyZl8wLTAtMS0xLTI0NTQ3Nw_181a091f-4929-40f5-ab0a-03be13212be3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8xNTU_633d855c-be3d-49b3-a1c7-bf6e0d081022"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8xNTU_a4ca8cf0-c52e-4c53-8ea0-485c7b3ac030">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:5pt;margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6ZWE0ZWZkNjhlNGZkNGI4MmI4NDAyNWY0YTRkMWJjY2IvdGFibGVyYW5nZTplYTRlZmQ2OGU0ZmQ0YjgyYjg0MDI1ZjRhNGQxYmNjYl8wLTAtMS0xLTI0NTQ3Nw_6c0d99d6-9e32-420b-b531-b903dbae0a2c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDk0_e7b7e870-5c41-4f1e-93a1-827f4d4ffd73">001-10315</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg5_d00f5cf2-977e-4c4a-9dc3-b43ec1db8a6d">Encompass Health Corporation</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MmIxOTZhYzdmZWZkNDZlOGJmOGQzNWU2NzgwNTcxY2YvdGFibGVyYW5nZToyYjE5NmFjN2ZlZmQ0NmU4YmY4ZDM1ZTY3ODA1NzFjZl8wLTAtMS0xLTI0NTQ3Nw_e1cfc90c-d028-4cf8-99c4-c2c8e437c54e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MmIxOTZhYzdmZWZkNDZlOGJmOGQzNWU2NzgwNTcxY2YvdGFibGVyYW5nZToyYjE5NmFjN2ZlZmQ0NmU4YmY4ZDM1ZTY3ODA1NzFjZl8wLTEtMS0xLTI0NTQ3Nw_92e17ce1-345c-4ac8-a57f-6114c049e23f">63-0860407</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg0_f1f06c7f-9bb3-411c-9092-9039ae9c7320">9001 Liberty Parkway</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg1_e4071964-21c1-4d85-9b25-10fc5fcb1633">Birmingham</ix:nonNumeric>, <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDgz_1489c4a2-8523-4882-8eea-b94cbebe33a4">Alabama</ix:nonNumeric> <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDgx_e0b2551b-237d-4b0a-92e0-34c430779c99">35242</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDgw_ad102340-2f07-45d3-b229-10e2e73e7006">205</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDc2_ad64a7c3-85a0-4d55-9989-36496b84e979">967-7116</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_____________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities Registered Pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:39.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.812%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MWJiZjIyYWI1YzIyNGYxZDkzZDIyOTJlNjIzN2Q5OWQvdGFibGVyYW5nZToxYmJmMjJhYjVjMjI0ZjFkOTNkMjI5MmU2MjM3ZDk5ZF8xLTAtMS0xLTI0NTQ3Nw_46b556cd-a458-4372-aa15-091b0cfd121b">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MWJiZjIyYWI1YzIyNGYxZDkzZDIyOTJlNjIzN2Q5OWQvdGFibGVyYW5nZToxYmJmMjJhYjVjMjI0ZjFkOTNkMjI5MmU2MjM3ZDk5ZF8xLTEtMS0xLTI0NTQ3Nw_473a8af0-fc80-4b59-b7c3-7f7b38654080">EHC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MWJiZjIyYWI1YzIyNGYxZDkzZDIyOTJlNjIzN2Q5OWQvdGFibGVyYW5nZToxYmJmMjJhYjVjMjI0ZjFkOTNkMjI5MmU2MjM3ZDk5ZF8xLTItMS0xLTI0NTQ3Nw_19a11500-6638-4b0d-adc5-7f9c7910d11d">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities Registered Pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_________________________________________________________</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer as defined in Rule 405 of the Securities Act.  <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDgy_c038c080-817b-41bf-ae52-2b65e7788119">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.  Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDc3_05ed00fa-f8e5-4c1e-b9f7-f6f96057cc6c">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDc4_40e01dec-6680-4bae-9ce4-20f09fb2c933">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDkw_40904835-d6b2-4135-b99f-04e1b400373b">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDkx_664cce08-6cab-4b4d-8e53-0acb9e64de9d">Large accelerated filer</ix:nonNumeric>   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDky_752335e7-bd57-4dfc-9dc4-5b44da64c4db">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Non-Accelerated filer   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company   </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg2_8c4e8a06-bac5-4d1e-9eba-db2499bdffd7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg3_490a05ee-091f-43c2-bbc0-82e9991a4d10">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDc5_57cc767a-af9e-4603-82c1-7e6946b3dcaa">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="i7cc06ca4859f40608cdefd3c35ca2b7b_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zMDM0_a9288ca3-a00d-447b-880c-b4e67b854c3c">5.5</ix:nonFraction> billion. For purposes of the foregoing calculation only, executive officers and directors of the registrant have been deemed to be affiliates. There were <ix:nonFraction unitRef="shares" contextRef="icf6db76417944ea78fd769dcf53d24ba_I20230213" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zMTgz_6e332b4e-ce56-4d60-84f6-3fe4a8b0af72">99,727,422</ix:nonFraction> shares of common stock of the registrant outstanding, net of treasury shares, as of February&#160;13, 2023.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDkz_ea9c8ae9-3b58-450b-b240-5fad75c7cd29" escape="true">The definitive proxy statement relating to the registrant&#8217;s 2023 annual meeting of stockholders is incorporated by reference in Part III to the extent described therein.</ix:nonNumeric></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.758%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_10">Cautionary Statement Regarding Forward-Looking Statements and Summary of Risk Factors</a></span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_10">ii</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_19">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_22">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_25">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_28">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_31">43</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_34">PART II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_37">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_40">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_46">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_46">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_88">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_88">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_88">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_91">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_91">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_91">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_94">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_94">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_94">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_97">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_97">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_97">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_100">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_100">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_100">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_103">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_103">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_103">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_106">PART III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_109">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_109">Directors and Executive Officers of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_109">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_112">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_112">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_112">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_115">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_115">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_115">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_118">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_118">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_118">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_121">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_121">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_121">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_124">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_127">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_127">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_127">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_130">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_130">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_127">72</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_307">Exhibit Index</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE TO READERS</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this report, the terms &#8220;Encompass Health,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to Encompass Health Corporation and its consolidated subsidiaries, unless otherwise stated or indicated by context. This drafting style is suggested by the Securities and Exchange Commission and is not meant to imply that Encompass Health Corporation, the publicly traded parent company, owns or operates any specific asset, business, or property. The hospitals, operations, and businesses described in this filing are primarily owned and operated by subsidiaries of the parent company. In addition, we use the term &#8220;Encompass Health Corporation&#8221; to refer to Encompass Health Corporation alone wherever a distinction between Encompass Health Corporation and its subsidiaries is required or aids in the understanding of this filing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS<br/>AND SUMMARY OF RISK FACTORS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This annual report contains historical information, as well as forward-looking statements that involve known and unknown risks and relate to, among other things, future events, the spread and impact of an infectious disease outbreak, changes to Medicare reimbursement and other healthcare laws and regulations from time to time, our business strategy, dividend and stock repurchase strategies, our financial plans, our growth plans, our future financial performance, our projected business results, or our projected capital expenditures. In some cases, the reader can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;targets,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. Such forward-looking statements are necessarily estimates based upon current information and involve a number of risks and uncertainties, many of which are beyond our control. Any forward-looking statement is based on information current as of the date of this report and speaks only as of the date on which such statement is made. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors that could cause, and in some cases have previously caused, actual results to differ materially from those estimated by us include, but are not limited to, each of the factors discussed in Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, summarized in the list below, as well as uncertainties and factors, if any, discussed elsewhere in this Form 10-K, in our other SEC filings from time to time, or in materials incorporated therein by reference. </span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Spin Off of Our Home Health and Hospice Business, Enhabit, Inc.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">To preserve the tax-free treatment of the Spin Off, we may be limited, for a period of time, in our ability to pursue certain equity issuances, strategic transactions, repurchases, or other transactions (including the certain dispositions of assets) that we may otherwise believe to be in the best interests of our stockholders or that might increase the value of our business.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">If the Spin Off were to fail to qualify as tax-free, including as a result of subsequent acquisitions of our stock or the stock of Enhabit, Inc., we could be subject to significant tax liabilities.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement Risks</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reductions or delays in, or suspension of, reimbursement for our services by governmental or private payors, including our inability to obtain and retain favorable arrangements with third-party payors, could decrease our revenues and adversely affect other operating results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictive interpretations of the regulations governing the claims that are reimbursable by Medicare could decrease our revenues and adversely affect other operating results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New or changing Medicare quality reporting requirements could adversely affect our operating costs or Medicare reimbursement.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement claims are subject to various audits from time to time and such audits may lead to assertions that we have been overpaid or have submitted improper claims, and such assertions may require us to incur additional costs to respond to requests for records and defend the validity of payments and claims and may ultimately require us to refund any amounts determined to have been overpaid.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays and other substantive and procedural deficiencies in the administrative appeals process associated with denied Medicare reimbursement claims, including from various Medicare audit programs, could delay or reduce our reimbursement for services previously provided, including through recoupment from other claims due to us from Medicare.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues or profitability.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in our payor mix or the acuity of our patients could reduce our revenues or profitability.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;padding-right:9pt;text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Regulatory Risks</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the rules and regulations of the healthcare industry at either or both of the federal and state levels, including those contemplated now and in the future as part of national healthcare reform and deficit reduction (such as the re-basing of payment systems, the introduction of site neutral payments or case-mix weightings across post-acute settings, and other payment system reforms) could decrease revenues and increase the costs of complying with the rules and regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, could decrease our reimbursement rate or increase costs associated with our operations.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with the extensive and frequently changing laws and regulations applicable to healthcare providers, including those related to data privacy and security, anti-trust, and employment practices, requires substantial time, effort and expense, and if we fail to comply, we could incur penalties and significant costs of investigating and defending asserted claims, whether meritorious or not, or be required to make significant changes to our operations.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to maintain proper local, state and federal licensing, including compliance with the Medicare conditions of participation and provider enrollment requirements, such as the CMS vaccine mandate, could decrease our revenues.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Operational Risks</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Incidents affecting the proper operation, availability, or security of our or our vendors&#8217; or partners&#8217; information systems, including the patient information stored there, or business continuity could cause substantial losses and adversely affect our operations, and governmental mandates to increase use of electronic records and interoperability exacerbate that risk.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings, including disclosed and undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suits could be difficult to predict and could adversely affect our financial results or condition or our operations, and we could experience increased costs of defending and insuring against alleged professional liability and other claims.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to successfully complete and integrate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> developments, acquisitions, investments, and joint ventures consistent with our growth strategy, including realization of anticipated revenues, cost savings, productivity improvements arising from the related operations and avoidance of unanticipated difficulties, costs or liabilities that could arise from acquisitions or integrations could adversely affect our financial results or condition.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and potential union activity could increase staffing costs and adversely affect other financial and operating results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competitive pressures in the healthcare industry, including from other providers that may be participating in integrated delivery payment arrangements in which we do not participate, and our response to those pressures could adversely affect our revenues or other financial results.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to provide a consistently high quality of care, including as represented in metrics published by Medicare, could decrease our revenues.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to maintain or develop relationships with patient referral sources could decrease our revenues.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A pandemic, epidemic, or other widespread outbreak of an infectious disease or other public health crisis could decrease our patient volumes, pricing, and revenues, lead to staffing and supply shortages and associated cost increases, otherwise interrupt operations, or lead to increased litigation risk and, in the case of the COVID-19 pandemic, has already done so in many instances.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Governmental actions in response to infectious disease outbreaks, such as limitations on elective procedures, vaccine mandates, shelter-in-place orders, new workplace regulations, facility closures and quarantines experienced during the COVID-19 pandemic, could reduce volumes, lead to staffing shortages, increase staffing costs, and otherwise impair our ability to operate and provide care and in many instances already have done so.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Risks</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General conditions in the economy and capital markets, including any disruption, instability, or uncertainty related to armed conflict or an act of terrorism, a governmental impasse over approval of the United States federal budget or an increase to the debt ceiling, rising interest rates, an international trade war, or a sovereign debt crisis could adversely affect our financial results or condition, including access to the capital markets and interest expense on new or existing debt.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our debt and the associated restrictive covenants could have negative consequences for our business and limit our ability to execute aspects of our business plan successfully.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock could adversely affect our willingness and ability to repurchase shares.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be unable or unwilling to continue to declare and pay dividends on our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cautionary statements referred to in this section also should be considered in connection with any subsequent written or oral forward-looking statements that may be issued by us or persons acting on our behalf. We undertake no duty to update these forward-looking statements, even though our situation may change in the future. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_16"></div><div style="margin-bottom:8pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Business </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of the Company</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a national leader in post-acute healthcare services and the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment on an inpatient basis. We operate hospitals in 36 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of December 31, 2022, we operate 153 inpatient rehabilitation hospitals. We are committed to delivering high-quality, cost-effective, integrated patient care.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Effective January 1, 2018, we changed our corporate name from HealthSouth Corporation to Encompass Health Corporation and the NYSE ticker symbol for our common stock from &#8220;HLS&#8221; to &#8220;EHC.&#8221; Our principal executive offices are located at 9001 Liberty Parkway, Birmingham, Alabama 35242, and the telephone number of the principal executive offices is (205)&#160;967-7116. Our website address is www.encompasshealth.com.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2022, we completed the previously announced separation of our home health and hospice business through the distribution (the &#8220;Spin Off&#8221;) of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit, Inc. (&#8220;Enhabit&#8221;) to the stockholders of record of Encompass Health as of the close of business on June 24, 2022 (the &#8220;Record Date&#8221;). The Spin Off was effective at 12:01 a.m., Eastern Time, on July 1, 2022. The Spin Off was structured as a pro rata distribution of one share of Enhabit common stock for every two shares of Encompass Health common stock held of record as of the Record Date. No fractional shares were distributed. A cash payment was made in lieu of any fractional shares. As a result of the Spin Off, Enhabit is now an independent public company and its common stock is listed under the symbol &#8220;EHAB&#8221; on the New York Stock Exchange.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the discussion here, we encourage the reader to review Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Item&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which highlight additional considerations about our company.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides selected operating and financial data.</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:59.319%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of or for the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated data:</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Inpatient rehabilitation:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of hospitals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discharges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of licensed beds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive, high-quality, cost-effective patient care services. As participants in the Medicare program, our hospitals must be licensed and certified and otherwise comply with various requirements that are discussed below in the &#8220;Sources of Revenues&#8212;Medicare Reimbursement&#8221; section. Substantially all (91%) of the patients we serve are admitted from acute-care hospitals following physician referrals for specific acute inpatient rehabilitative care. Most of those patients have experienced significant physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and a variety of debilitating neurological conditions, that are generally nondiscretionary in nature and require rehabilitative healthcare services in a facility-based setting. During the COVID-19 Pandemic (the &#8220;pandemic&#8221;), our hospitals treated thousands of patients with or recovering from the COVID-19 virus. Our focus on specialized rehabilitative care has meant that in many cases our hospitals have been ideal settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity, and malnutrition. Our teams of highly skilled nurses and physical, occupational, and speech therapists utilize proven technology and clinical protocols with the objective of restoring our patients&#8217; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">physical and cognitive abilities. Patient care is provided by nursing and therapy staff as directed by physician orders while case managers monitor each patient&#8217;s progress and provide documentation and oversight of patient status, achievement of goals, discharge planning, and functional outcomes. Our hospitals provide a comprehensive interdisciplinary clinical approach to treatment that leverages innovative technologies and advanced therapies and leads to superior outcomes.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competitive Strengths</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. We also believe our competitive strengths discussed below give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">People</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe our employees share a steadfast commitment to providing outstanding care to our patients. We undertake significant efforts to ensure our clinical and support staff receives the education and training necessary to provide the highest quality care in the most cost-effective manner. We also have hospital staff trained for all patient acuity levels faced in the post-acute setting. We embrace the Encompass Health Way, our core set of values developed through input from a broad cross section of our employees. The Encompass Health Way calls on each of our employees to set the standard, lead with empathy, do what&#8217;s right, focus on the positive, and ensure we are stronger together. We believe our award-winning culture is essential to attracting and retaining talent. For further discussion of our human capital management and our award-winning culture, see the section titled &#8220;Human Capital Management&#8221; below.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Change Agility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have a demonstrated ability to adapt in the face of numerous and significant regulatory, legislative, and operating environment changes. We believe our consistent and disciplined operating model allows us to be nimble and responsive to change. Examples of regulatory and other changes through which we have successfully managed include:</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) adopted a rule, effective beginning in 2007, that conditioned the reimbursement rate for an inpatient rehabilitation facility, or &#8220;IRF,&#8221; on at least 60% of a facility&#8217;s patients having at least one of 13 qualifying medical conditions.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) enacted in 2010 instituted several mandatory Medicare payment reforms, including reimbursement reductions for IRFs, and created the Center for Medicare and Medicaid Innovation (&#8220;CMMI&#8221;) to develop, test, and promote innovative payment and delivery models.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The ACA created the IRF Quality Reporting Program. This program requires IRFs to report quality data, the elements of which are updated annually, and imposes a financial penalty for noncompliance.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The 2010 CMS reimbursement rule for IRFs implemented new IRF coverage requirements, or specifications as to what conditions must be met to qualify for reimbursement, that were effective for all Medicare discharges on or after January 1, 2010. Those IRF coverage requirements replaced coverage criteria that were in place for 25 years.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Budget Control Act of 2011 implemented an automatic 2% reduction, or &#8220;sequestration,&#8221; of Medicare program payments for all healthcare providers beginning in 2013.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The Improving Medicare Post-Acute Care Transformation Act of 2014 directed CMS to promulgate rules requiring the collection and reporting of standardized patient assessment data across post-acute care providers.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In 2019, CMS replaced the long-standing patient assessment measure, a component of Medicare reimbursement, with new assessment measures requiring significant training and operational changes.</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In October 2022, CMS significantly changed the extensive admission and discharge interdisciplinary data elements required to be collected in connection with Medicare reimbursement claims.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the pandemic posed a number of challenges in the operating environment. We demonstrated our ability to change and remain resilient by implementing protocols for the safety of our employees and our patients while managing supply chain constraints, specifically with personal protective equipment, in a timely and effective manner. The formation of our COVID Task Force allowed us to centralize decision-making while </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">empowering the hospitals to enact the protocols needed as the pandemic cycled through the country. Our therapy teams developed plans for COVID patients while maintaining our expected high-quality outcomes.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Strategic Relationships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have a long and successful history of building strategic relationships with major healthcare systems. More than a third of our inpatient rehabilitation hospitals currently operate as joint ventures with acute-care hospitals or systems. Joint ventures with market leading acute-care hospitals establish a solid foundation for providing integrated patient care that can improve the quality of outcomes and reduce the total cost of care.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many patients continue to need nursing and therapy services after they leave the IRF setting to continue their recovery at home. Care collaboration between our hospitals and the home health agencies selected by our patients offers an excellent means to improve patient experience and outcomes and reduce the total cost of care across a post-acute episode.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The post-acute innovation tools we have developed, and will continue to develop, support our strategic relationship initiatives by enhancing the effective and efficient management of patients across multiple post-acute care settings and facilitating high-quality patient care, improved care coordination, and network provider performance and cost management.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have a strategic sponsorship with the American Heart Association/American Stroke Association on a nationwide basis to increase patient independence after a stroke and reduce stroke mortality through community outreach and information campaigns.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Clinical Expertise and High-Quality Outcomes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have extensive clinical experience from which we have developed standardized best practices and protocols. We believe these clinical best practices and protocols, particularly as leveraged with our well-trained clinicians and industry-leading technology, help ensure the delivery of consistently high-quality healthcare services, reduced inefficiencies, and improved performance across a spectrum of operational areas. Currently, we operate 131 hospitals that hold one or more Joint Commission Disease-Specific Care Certifications, such as stroke rehabilitation, hip fracture rehabilitation, brain injury rehabilitation, amputee rehabilitation, Parkinson&#8217;s Disease rehabilitation, and spinal cord injury rehabilitation certification. Our hospitals account for 61% of all stroke rehabilitation accreditations, 97% of hip fracture rehabilitation accreditations, and 78% of all brain injury rehabilitation accreditations.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Cost Effectiveness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our scale, data-driven business practices, consistent and disciplined operating model, and culture help us provide healthcare services on a cost-effective basis. We leverage centralized administrative functions, use data analytics to identify trends and respond on a timely basis, and identify best practices and implement them across our platform of hospitals. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and bed addition strategies incorporate pre-fabrication construction technology to create efficiencies by reducing reliance on subcontractors, improving supply chain efficiencies, providing a consistent construction quality and realizing a speed-to-market benefit.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Financial Resources</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have a proven track record of generating strong cash flows from operations that have allowed us to successfully pursue our growth strategy, manage our financial leverage, and make complementary shareholder distributions. We did not accept any pandemic relief funds under the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;) or any other program or legislation. As of December&#160;31, 2022, we have a strong, well-capitalized balance sheet, including ownership of approximately 76% of our hospital real estate, no significant debt maturities prior to 2025, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our business strategy.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Advanced Technology and Innovation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are focused on developing technology-enabled strategies to further improve our effectiveness at providing integrated healthcare. Our post-acute innovation strategy is based on using our clinical expertise, our large post-acute datasets, and our proven capabilities in enterprise-level electronic medical record technologies, data analytics, data integration, and predictive analytics to drive value-based performance across the healthcare continuum for our patients, our partners, and our payors. We believe our information systems and post-acute innovation solutions, in addition to improving patient care and operating efficiencies, allow us to collect, analyze, and share information on a timely basis making us an ideal partner for other healthcare providers in a coordinated care delivery environment. Our systems also emphasize interoperability with referral sources and other providers coordinating care. We have devoted substantial resources, effort and expertise to leveraging technology to create post-acute solutions that improve patient care and operating efficiencies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patients and Demographic Trends</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030. More specifically, the average age of our Medicare patients is approximately 76, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, inpatient rehabilitation services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Despite the growing demand for inpatient rehabilitation services, the number of inpatient rehabilitation facilities has remained relatively stable &#8212; decreasing modestly from 1,182 in 2015 to 1,180 in 2021. This supply-demand imbalance is partly responsible for the relatively low conversion rate of inpatient rehabilitation eligible patients. We believe the percentage of patients who are discharged from acute-care hospitals with one or more of 13 specified medical conditions that CMS ties to IRF eligibility and subsequently admitted to an IRF is approximately 13% based on Medicare fee-for-service data, which is the only publicly available data on the subject. To respond to the strong demand for our services, we continue to develop our current markets through bed additions and to construct or acquire hospitals in new markets. Since 2012, we have opened or acquired 53 new hospitals and increased the number of licensed beds we operate by approximately 56%, or 3,700 beds.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategy and 2023 Strategic Priorities</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our overall strategy is to expand our network of inpatient rehabilitation hospitals, add capacity to existing hospitals, further strengthen our relationships with healthcare systems, provider networks, and payors in order to connect patient care across the healthcare continuum, and to deliver superior patient outcomes in a cost-effective manner. We believe this strategy, along with our demonstrated ability to adapt to changes in healthcare, positions us for success in the evolving healthcare delivery system. In pursuit of our strategy, we established the following priorities for 2023.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We target the addition of 6 to 10 new inpatient rehabilitation hospitals and 80 to 120 beds to existing hospitals per year. In 2021, we opened 8 new hospitals (350 beds total) and added 117 beds to existing hospitals. In 2022, we opened 9 new hospitals (410 beds total) and added 87 beds to existing hospitals. In 2023, we plan to open 8 hospitals (approximately 395 beds) and add 80 to 100 beds to existing hospitals. We also believe we will continue to have organic growth opportunities based on our track record of growth, planned bed additions at a number of existing hospitals, and the maturation of newly opened locations.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Operational Initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our priorities include operational initiatives that build on momentum from recent years. We believe our care coordination efforts have and will continue to contribute to reductions in discharges to skilled nursing facilities, higher discharges to community, and improved patient experience. Our care coordination program is the integrative approach to a patient&#8217;s care that includes coordination with physicians, acute-care hospitals, and other post-acute providers to ensure the best overall care is provided to the patient.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to demonstrate our value proposition to Medicare Advantage payors by providing superior patient outcomes, including higher discharge to community rates and lower lengths of stay, compared to alternative sites of care. The Medicare Advantage enrollment growth rate is greater than that of traditional Medicare fee-for-service, and our payor mix has shifted accordingly. Medicare Advantage payors represented 8.4% of our net operating revenues in 2017 and 15.1% in 2022. We believe our outcomes and quality of care data have helped drive a significant improvement in the payments we receive from Medicare Advantage payors. For example, reimbursement based on the type of patient/treatment required, commonly referred to as the case mix group basis (&#8220;CMG&#8221;), is typically greater than reimbursement on a per-diem rate basis, and we increased the percentage of our Medicare Advantage revenue paid based on CMG from approximately 58% in 2017 to approximately 88% in 2022.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the significant number of stroke patients in need of post-acute care, we will continue working to build our stroke market share through our strategic sponsorship of the American Heart Association/American Stroke Association, the IRF treatment recommendations published by the Department of Veterans&#8217; Affairs and the Journal of the American Medical Association, our care coordination, and our hospitals&#8217; participation in The Joint Commission&#8217;s Disease-Specific Care Certification Program. As of December&#160;31, 2022, 130 of our 153 hospitals held stroke-specific certifications that required us to demonstrate effective use of evidence-based clinical practice guidelines to manage and optimize stroke care and an organized approach to performance measurement and evaluation of clinical outcomes. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, approximately 6% of patients recovering from a stroke in the U.S. were treated at our hospitals, accounting for approximately 19% of our overall patient mix.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to develop and implement post-acute solutions that allow us to apply our clinical expertise, large post-acute datasets, electronic medical record technologies, and strategic partnerships to drive improved patient outcomes and lower the cost of care across the entire post-acute episode, such as our fall prevention model rolled out to hospitals in late 2021.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will seek to expand efforts and initiatives to recruit and retain a qualified clinical workforce. In 2022, we implemented a centralized nurse recruiting model to create recruiting efficiencies, shorten the hiring process, and improve the candidate experience.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to install in our hospitals a hemodialysis system with which we are now able to provide inpatient dialysis to our patients without relying on third-parties. Historically, our patients have received dialysis from third-party vendors, either onsite or offsite as available, often resulting in interruptions to their therapy schedules. With this new onsite hemodialysis system, we can provide our patients dialysis without interrupting therapy or requiring patient travel, which lowers our cost of treatment and improves patient satisfaction. As of December&#160;31, 2022, we had installed these systems in 41 of our hospitals.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Capital Structure</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We seek to maintain balance sheet flexibility, consider opportunistic refinancings and augment returns from investments in operations with shareholder distributions via common stock dividends and repurchases of our common stock. Our debt portfolio is concentrated in long-dated fixed-rate debt. Our free cash flow is the primary source of funding for the considerable investment in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and bed addition growth plans. As an additional source of liquidity, we can access our $1 billion revolving credit facility of which $912 million was available for borrowing as of December&#160;31, 2022. Our strong balance sheet as well as our leverage and liquidity profiles mitigate exposure to interest rate volatility and near-term refinancing risks.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our strategic priorities as well as our progress toward our priorities in 2022, including operating results, growth, and shareholder distributions, and our business outlook, see Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview,&#8221; &#8220;Results of Operations,&#8221; and &#8220;Liquidity and Capital Resources.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Capital Management</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Overview of Our Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December&#160;31, 2022, we employed approximately 35,000 individuals. In the healthcare services sector, many professionals, such as nurses, desire flexible work arrangements. Accordingly, part-time and per diem employees represent a large percentage of our employee population. Except for 50 employees at one hospital (approximately 15% of that hospital&#8217;s workforce), none of our employees are represented by a labor union as of December&#160;31, 2022. The chart below includes a breakdown of our employees.</span></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.923%"><tr><td style="width:1.0%"></td><td style="width:54.977%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.823%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Type</span></td><td colspan="3" style="border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employees</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total Employees</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34,519</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Full-time Employees</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20,839</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Part-time Employees</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,559</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pool/Per-diem Employees</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11,121</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some markets, the shortage of clinical personnel is a significant operating issue facing healthcare providers. Shortages of nurses and other clinical personnel, including therapists, may, from time to time, require us to increase use of more costly temporary personnel, which we refer to as &#8220;contract labor,&#8221; and other types of premium pay programs. In order to recruit and retain those clinical employees, we maintain a total rewards program that we view as a combination of the tangible components of pay and benefits with the intangible components of a culture that encourages learning, development, and a supportive work environment. We believe our outstanding employee engagement scores, discussed below, evidence that our human capital management efforts have been successful. We also believe our recognition as one of Modern Healthcare&#8217;s &#8220;Best Places to Work&#8221; is further evidence of that success. We focus on the following strategic human capital imperatives:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintaining competitive compensation and benefit programs that reward and recognize employee performance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fostering a strong culture that values diversity, equity, and inclusion; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Emphasizing employee development and engagement to attract talent and reduce turnover.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation and Benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Maintaining competitive compensation and benefit programs that reward and recognize employee performance furthers our goal to attract, retain, and motivate employees who will help us deliver high-quality patient care. We are also committed to providing comprehensive benefit options that will allow our employees and their families to live healthier and more secure lives. In our compensation and benefit programs:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provide employee wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we engage nationally recognized outside compensation and benefits consulting firms to independently evaluate the effectiveness of our compensation and benefit programs, to provide benchmarking against our peers within the industry and by specific market, and to recommend design elements for those programs.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we base annual increases and incentive compensation on merit, which is communicated to employees through our talent management process as part of our annual review procedures.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all full-time and most part-time employees are eligible for health insurance, paid and unpaid leaves, a retirement plan, a wellness program, telemedicine, tuition reimbursement, an employee assistance program, and life and disability/accident coverage.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we provide an employer match on retirement plan contributions.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we also offer a wide variety of voluntary benefits that allow employees to select the options that meet their needs, including pre-paid legal services, dental insurance, vision insurance, hospital indemnity insurance, accident insurance, critical illness insurance, supplemental life insurance, disability insurance, health savings accounts, flexible spending accounts, auto/home insurance, and identity theft insurance.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have various short-term incentive plans for field leadership, most marketing/sales employees, and executives.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we make annual grants of restricted stock to employees at various levels, including non-executive management, to foster a strong sense of ownership and align the interests of management with those of our stockholders.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diversity, Equity, and Inclusion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe fostering a strong culture that values diversity, equity, and inclusion, or DE&amp;I, allows us to recruit and retain diverse employees and provide high-quality care to our diverse patients. We maintain a DE&amp;I program that is overseen by a DE&amp;I department and supported by Hospital Diversity Committees. Together, they design and execute initiatives that strengthen relationships, improve communication, and increase understanding, so we can better serve each other, our patients, and our communities. We believe our DE&amp;I program furthers our efforts to provide culturally competent care. The key components of our DE&amp;I program are:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Workforce Attraction and Development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; We seek to build our workforce to represent and reflect the communities we serve, which allows us to provide culturally competent care. In addition, we are committed to ensuring that all our employees are trained on DE&amp;I topics as a foundational element of our employee and leadership development curriculum. Our other DE&amp;I initiatives include scholastic partnerships with historically black colleges, recruitment tools to help identify and attract diverse talent, a website career tool to help veterans find jobs that closely align with their specific skills, and ongoing policy and procedure reviews to incorporate guidance and practices that align with our DE&amp;I mission.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Community Partnership &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We establish and maintain relationships with local organizations to improve health outcomes in our communities. An example of this type of partnership is our arrangement with Holy Family Cristo Rey Catholic High School in Birmingham. This partnership allows adolescents from disadvantaged groups to gain tangible work experience in our corporate office while earning funds for school tuition. In 2022, we sponsored six students. Our other community initiatives include an annual report that provides information on our DE&amp;I initiatives to people outside the company. We also have memberships and active involvement in local chapters of the National Association of Health Service Executives, an organization that promotes the advancement and development of minority healthcare leaders. We provide training and mentorship to the next generation of healthcare leaders with the goal of helping them develop the skills and passion for inpatient rehabilitation. In addition, we are active participants in a regional working group of Alabama-based businesses convened to discuss and share DE&amp;I best practices.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.02pt">Supplier Diversity &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We maintain a supplier base program that offers contracting opportunities with manufacturers, distributors and service providers that are certified as minority-owned, veteran-owned and small disadvantage-owned businesses, and we continue to research and identify additional diverse supplier certifying organizations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have undertaken other initiatives to emphasize the importance of DE&amp;I in the workplace and its role in providing the best quality patient care. For example, we participate in the CEO Action for Diversity and Inclusion Pledge. This coalition of chief executive officers is dedicated to advancing DE&amp;I in the workplace. Every three to five years, we engage a third-party consulting agency to help us evaluate our program and explore possible enhancements. We then provide the feedback to our board of directors. We have published a series of video conversations with various employees and members of executive management to highlight personal experience to promote DE&amp;I throughout the organization. In addition, the DE&amp;I department works closely with the quality, clinical and case management departments to improve health equity and ensure our interprofessional health care teams have the resources they need to provide culturally competent care.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Development and Engagement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe promoting employee development and engagement furthers our ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment where staffing shortages are not uncommon. We track and measure therapist and nurse turnover for our full-time employees (excluding those at new stores and most at the corporate office) on a quarterly and annual basis for significant trends and outliers, but we do not believe comparisons to benchmarks are material given the variations in survey data across markets, hospital sizes, practice settings, and practice specialties. The table below shows those turnover rates for 2022 and 2021.</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.877%"><tr><td style="width:1.0%"></td><td style="width:38.267%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.350%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Therapist </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nurse</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support the long-term career aspirations of our employees through education and personal development.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Education Opportunities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our nurses an opportunity to advance their academic degrees at a reduced tuition rate of 20% to 50% of the total program cost. To date, approximately 1,521 of our nurses have taken advantage of this opportunity. Additionally, our full-time inpatient nursing and therapy staff have unlimited access to online education and training to ensure continuing education units are available at no cost.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Tuition Reimbursement/Scholarship Programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Employees also have the opportunity to advance their education through our tuition reimbursement and scholarship programs. We reimbursed over $1.2 million in tuition and paid over $2.8 million toward employees&#8217; student loan debt in 2022. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Academic Endowments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We endowed five scholarships for deserving students from underrepresented groups pursuing degrees in nursing and allied health fields.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Therapy Grants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We fund research projects to investigate the impact and effectiveness of therapy in the inpatient rehabilitation setting. In recent years, we have funded studies and research on topics ranging from caregiver education to the effectiveness of occupation-centered interventions. The program is open to qualified candidates, including employees.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Other Employee Development Programs:</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">career ladders that offer paths to develop, demonstrate, and be rewarded for expanded responsibility in nursing, therapy and case management;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">formal coaching online development library that provides access to a wide range of readily available internal and external content on many topics important for success in current or desired jobs;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">developing future leaders program that develops nurses and therapists for supervisory positions and develops nurse and therapy supervisors for higher level positions;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">leadership precepting that provides new leaders 6-12 months of structured mentoring from experienced, high-performing peers;</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">leadership coaching that provides six months of executive coaching to high performing leaders;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">developing future chief nursing officers program that provides 12-18 months of intensive on-the-job experience to develop participants for future chief nursing officer job openings; and</span></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">developing future chief executive officers program that provides 18-24 months of intensive on-the-job experience to develop participants for future hospital chief executive officer openings.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further aid in employee development, we have invested money in best-in-class technology to offer on-demand learning and development programs, and leadership coaching programs. Another important aspect of employee development is succession planning. We annually review our talent to identify potential successors for key positions and to identify candidates for accelerated development based on their performance and potential. The annual process includes an assessment of each employee&#8217;s promotability based on a set of leadership core competencies defined as part of the company&#8217;s talent strategy.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe employee engagement is another important driver of employee retention. We conduct an annual employee engagement survey open to all of our employees. In 2022, 80% of our employees participated in the survey, which measures perceptions based on responses to 38 questions. In 2022, we scored above healthcare benchmarks as a company in each of the following categories on the survey:</span></div><div style="margin-bottom:10pt;padding-left:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">ethics and compliance</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">teamwork</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">culture of safety</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">engagement</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">diversity, equity, and inclusion</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">culture of trust</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">work environment</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">individual value</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">leadership</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">communication</span></div></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inpatient rehabilitation industry, outside of our leading position, is highly fragmented. Our inpatient rehabilitation hospitals compete primarily with rehabilitation units, most of which are within acute-care hospitals, in the markets we serve. An acute-care hospital operating its own unit, particularly one owned or operated by a large public company or not-for-profit that has a dominant position in the local market, can be a formidable competitor because 91% of our patients come from acute-care hospitals. There are several privately held companies offering post-acute rehabilitation services that compete with us primarily in select geographic markets. In addition, there is a public company that is primarily focused on other post-acute care services but also operates 31 freestanding inpatient rehabilitation hospitals. Other providers of post-acute care services compete for some rehabilitation patients. For example, nursing homes may market themselves as offering certain rehabilitation services, particularly to patients not in need of intensive rehabilitation therapy, even though those nursing homes are not required to offer the same level of care, and are not licensed, as hospitals.&#160;The primary competitive factors in any given market include the quality of care and service provided, the treatment outcomes achieved, the relationship and reputation with managed care and other private payors and the acute-care hospitals, physicians, or other referral sources in the market, and the regulatory barriers to entry in certificate of need states. The ability to work as part of an integrated delivery payment model with other providers, including the ability to deliver quality patient outcomes and cost-effective care, could become an increasingly important factor in competition if a significant number of people in a market are participants in one or more of these models. See the &#8220;Regulation&#8212;Relationships with Physicians and Other Providers&#8221; and &#8220;Regulation&#8212;Certificates of Need&#8221; sections below for further discussion of some of these factors. For a list of our inpatient rehabilitation markets by state, see the table in Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory and Reimbursement Challenges</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare is a highly regulated industry facing many well-publicized regulatory and reimbursement challenges driven by escalating costs and the pursuit of better quality of care. The Medicare reimbursement system for inpatient rehabilitation has  changed significantly over the years. The future of many aspects of healthcare regulation remains uncertain. Any regulatory or legislative changes impacting the healthcare industry ultimately may affect, among other things, reimbursement of healthcare providers, consumers&#8217; access to coverage of health services, including among non-Medicare aged population segments within commercial insurance markets and Medicaid enrollees, and competition among providers. Changes may also affect the delivery of healthcare services to patients by providers and the regulatory compliance obligations associated with those services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we have the necessary capabilities &#8212; change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities &#8212; to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so. For more in-depth discussion of the primary challenges and risks related to our business, particularly the changes in Medicare reimbursement, increased compliance and enforcement burdens, and changes to our operating environment resulting from healthcare reform, see &#8220;Sources of Revenues&#8212;Medicare Reimbursement&#8221; and &#8220;Regulation&#8221; below in this section as well as Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sources of Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payment for patient care services from the federal government (primarily under the Medicare program), managed care plans and private insurers, and, to a considerably lesser degree, state governments (under their respective Medicaid or similar programs) and directly from patients. Revenues and receivables from Medicare are significant to our operations. The federal and state governments establish payment rates as described in more detail below. We negotiate the payment rates with non-governmental group purchasers of healthcare services that are included in &#8220;Managed care&#8221; in the tables below, including private insurance companies, employers, health maintenance organizations (&#8220;HMOs&#8221;), preferred provider organizations (&#8220;PPOs&#8221;), and other managed care plans. Patients are generally not responsible for the difference between established gross charges and amounts reimbursed for such services under Medicare, Medicaid, and other private insurance plans, HMOs, or PPOs but are responsible to the extent of any exclusions, deductibles, copayments, or coinsurance features of their coverage. Medicare, through its Medicare Advantage program, offers Medicare-eligible individuals an opportunity to participate in managed care plans. Revenues from Medicare and Medicare Advantage represent approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 80%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total revenues.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sources and relative mix of our revenues for the last three years are:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.005%"><tr><td style="width:1.0%"></td><td style="width:60.019%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Reimbursement</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare is a federal program that provides hospital and medical insurance benefits to persons aged 65 and over, qualified disabled persons, and persons with end-stage renal disease. Medicare, through statutes and regulations, establishes reimbursement methodologies and rates for various types of healthcare providers, facilities, and services. Each year, the Medicare Payment Advisory Commission (&#8220;MedPAC&#8221;), an independent agency that advises the United States Congress on issues affecting Medicare, makes payment policy recommendations to Congress for a variety of Medicare payment systems including, among others, the inpatient rehabilitation facility prospective payment system (the &#8220;IRF-PPS&#8221;). MedPAC also makes recommendations on regulatory actions to CMS. Neither Congress nor CMS is obligated to adopt MedPAC recommendations, and, based on outcomes in previous years, there can be no assurance either will adopt MedPAC&#8217;s recommendations in a given year.&#160;However, MedPAC&#8217;s recommendations have, and could in the future, become the basis for subsequent legislative or, as discussed below, regulatory action.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare statutes are subject to change from time to time. With respect to Medicare reimbursement, the ACA provides for specific reductions to healthcare providers&#8217; annual market basket updates and other payment policy changes. In August 2011, President Obama signed into law the Budget Control Act of 2011 providing for an automatic 2% reduction, or &#8220;sequestration,&#8221; of Medicare program payments for all healthcare providers. Sequestration took effect April 1, 2013 and, as a result of subsequent legislation, will continue through mid-fiscal year 2032 unless Congress and the President take further action. In response to the public health emergency associated with the pandemic, Congress and the President suspended sequestration through March 31, 2022. Additional Medicare payment reductions are also possible under the Statutory Pay-As-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You-Go Act of 2010 (&#8220;Statutory PAYGO&#8221;). Statutory PAYGO requires, among other things, that mandatory spending and revenue legislation not increase the federal budget deficit over a 5- or 10-year period. If the Office of Management and Budget (the &#8220;OMB&#8221;) finds there is a deficit in the federal budget, Statutory PAYGO requires OMB to order sequestration of Medicare. The Congressional Budget Office estimated that the American Rescue Plan Act of 2021 would result in budget deficits necessitating a 4% reduction in Medicare program payments under the Statutory PAYGO, but subsequent legislation enacted by Congress suspended until 2025 the Statutory PAYGO reductions that would have gone into effect. In the future, concerns about the federal deficit, national debt levels and the solvency of the Medicare trust fund could result in enactment of further federal spending reductions, further entitlement reform legislation affecting the Medicare program, or both. Healthcare will almost certainly be the subject of significant regulatory and legislative changes regardless of the party in control of the executive and legislative branches of state and federal governments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, Medicare regulations, including reimbursement methodologies and rates, can be further modified by CMS. Subject to its statutory authority, CMS may make some prospective payment system changes. For example, CMS changed the IRF-PPS, effective October 1, 2019, to replace the FIM&#8482; assessment instrument with new patient assessment measures, which we refer to as &#8220;Section GG functional measures&#8221; or &#8220;Section GG&#8221; based on the designation CMS assigned to them. Section GG affects patients&#8217; classification into case-mix groupings, relative weights, and length-of-stay values under the IRF-PPS, which in turn affect our reimbursement amounts. In some instances, CMS&#8217;s modifications can have a substantial impact on healthcare providers. In accordance with Medicare laws and statutes, CMS makes annual adjustments to Medicare payment rates in prospective payment systems, including the IRF-PPS, by what is commonly known as a &#8220;market basket update.&#8221; CMS may take other regulatory action affecting rates as well. For example, under the ACA, CMS requires IRFs to submit data on certain quality of care measures for the IRF quality reporting program. A facility&#8217;s failure to submit the required quality data results in a two percentage point reduction to that facility&#8217;s annual market basket increase factor for payments made for discharges in a subsequent Medicare fiscal year. IRFs began submitting quality data to CMS in October 2012. All of our inpatient rehabilitation hospitals have met the reporting deadlines to date resulting in no corresponding reimbursement reductions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the adjustments to Medicare payment rates Congress or CMS may make in the future. Congress, MedPAC, and CMS will continue to address reimbursement rates for a variety of healthcare settings. Any additional downward adjustment to rates or limitations on reimbursement for the types of facilities we operate and services we provide could have a material adverse effect on our business, financial position, results of operations, and cash flows. For additional discussion of the risks associated with our concentration of revenues from the federal government or with potential changes to the statutes or regulations governing Medicare reimbursement, see Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges.&#8221;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although reductions or changes in reimbursement from governmental or third-party payors and regulatory changes affecting our business represent one of the most significant challenges to our business, our operations are also affected by other rules and regulations that indirectly affect reimbursement for our services, such as data coding rules and patient coverage rules and determinations. For example, Medicare providers like us can be negatively affected by the adoption of coverage policies, either at the national or local level, that determine whether an item or service is covered and under what clinical circumstances it is considered to be reasonable and necessary. Current CMS coverage rules require inpatient rehabilitation services to be ordered by a physician and be coordinated by an interdisciplinary team and the admission to the IRF must be reviewed and approved by a specialized rehabilitation physician. The interdisciplinary team must meet weekly to review patient status and make any needed adjustments to the individualized plan of care. Qualified personnel must provide the rehabilitation nursing, physical therapy, occupational therapy, speech-language pathology, social services, psychological services, and prosthetic and orthotic services that may be needed. Medicare contractors processing claims for CMS make coverage determinations regarding medical necessity that can represent novel or restrictive interpretations of the CMS coverage rules. Those interpretations are not made through a notice and comment review process. We cannot predict how future CMS coverage rule interpretations or any new local coverage determinations will affect us. However, more restrictive coverage interpretations can limit or delay our reimbursement for services provided to potentially large pools of patients with similar medical conditions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course, Medicare reimbursement claims made by healthcare providers, including inpatient rehabilitation hospitals, are subject to audit from time to time by governmental payors and their agents, such as the Medicare Administrative Contractors (&#8220;MACs&#8221;) that act as fiscal intermediaries for all Medicare billings, as well as the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;), CMS, and state Medicaid programs. In addition to those audits conducted by existing MACs, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. Some contractors are paid a percentage of the overpayments recovered. The Recovery Audit Contractors (&#8220;RACs&#8221;) conduct payment reviews of claims, which can examine coding, overall billing accuracy, and medical necessity. When conducting an audit, the RACs receive claims data directly from MACs on a monthly or quarterly basis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established Unified Program Integrity Contractors (&#8220;UPICs&#8221;), previously known as Zone Program Integrity Contractors, to perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the United States Department of Justice (&#8220;DOJ&#8221;). Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the payment errors they identify.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a matter of course, we undertake significant efforts through training, education, and documentation to ensure compliance with coding and medical necessity coverage rules. Despite our efforts to ensure accurate coding and assessment of patients, audits may lead to assertions that we have been underpaid or overpaid by Medicare or that we have submitted improper claims in some instances. Audits may also require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. We cannot predict when or how these audit programs will affect us. Any denial of a claim for payment, either as a result of an audit or ordinary course payment review by the MAC, is subject to an appeals process that can take years to complete. For additional discussion of these audits and the risks associated with them, see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges.&#8221;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the public health emergency associated with the pandemic, Congress and CMS adopted several statutory and regulatory measures intended to provide relief to healthcare providers in order to ensure patients would continue to have adequate access to care. On March 27, 2020, President Trump signed into law the CARES Act, which authorized the cash distribution of pandemic relief funds from the United States Department of Health and Human Services (&#8220;HHS&#8221;) to healthcare providers. The Consolidated Appropriations Act, 2021 (the &#8220;2021 Budget Act&#8221;), signed into law on December 27, 2020, provided for additional provider relief funds. We did not accept any provider relief funds.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, our inpatient rehabilitation hospitals receive a fixed payment reimbursement amount per discharge under the IRF-PPS based on the patient&#8217;s rehabilitation impairment category and other characteristics and conditions identified by the attending clinicians. In order to qualify for reimbursement under the IRF-PPS, our hospitals must comply with various Medicare rules and regulations including documentation and coverage requirements, or specifications as to what conditions must be met to qualify for reimbursement. These requirements relate to, among other things, pre-admission screening, and individual treatment planning that all delineate the role of physicians in ordering and overseeing patient care. For example, a physician must approve admission of each patient and in doing so determine that the treatment of the patient in an IRF setting is reasonable and necessary. In addition, to qualify as an IRF under Medicare rules, a facility must be primarily focused on treating patients with one of 13 specified medical conditions that typically require intensive therapy and supervision, such as stroke, brain injury, hip fracture, certain neurological conditions, and spinal cord injury. Specifically, at least 60% of a facility&#8217;s patients must have a diagnosis or qualifying comorbidity from at least one of these 13 conditions, which requirement is known as the &#8220;60% Rule.&#8221; Also, each patient admitted to an IRF must be able to tolerate a minimum of three hours of therapy per day for five days per week and must have a registered nurse available 24 hours, each day of the week.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under IRF-PPS, CMS is required to adjust the payment rates based on an IRF-specific market basket index. The annual market basket update is designed to reflect changes over time in the prices of a mix of goods and services used by IRFs. In setting annual market basket updates, CMS uses data furnished by the Bureau of Labor Statistics for price proxy purposes, primarily in three categories: Producer Price Indexes, Consumer Price Indexes, and Employment Cost Indexes. With IRF-PPS, our inpatient rehabilitation hospitals retain the difference, if any, between the fixed payment from Medicare and their operating costs. Accordingly, our hospitals benefit from being cost-effective providers.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2021, CMS released its notice of final rulemaking for fiscal year 2022 IRF-PPS (the &#8220;2022 IRF Rule&#8221;). The 2022 IRF Rule implemented a net 1.9% market basket increase (market basket update of 2.6% reduced by a productivity adjustment of 0.7%) effective for discharges between October 1, 2021 and September 30, 2022. The productivity adjustment equals the trailing 10-year average of changes in annual economy-wide private nonfarm business multi-factor productivity. The 2022 IRF Rule also included changes that impacted our hospital-by-hospital base rate for Medicare reimbursement. Such changes included, but were not limited to, revisions to the wage index and labor-related share values, updates to outlier payments and updates to the case-mix group relative weights and average lengths of stay values. The 2022 IRF Rule also added one new quality reporting measure and updated the denominator of another measure.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2022, CMS released its notice of final rulemaking for fiscal year 2023 IRF-PPS (the &#8220;2023 IRF Rule&#8221;). The 2023 IRF Rule implements a net 3.9% market basket increase (market basket update of 4.2% reduced by a productivity adjustment of 0.3%) effective for discharges between October 1, 2022 and September 30, 2023. The 2023 IRF Rule also includes changes that impact our hospital-by-hospital base rate for Medicare reimbursement. Such changes include, but are not limited to, revisions to the wage index and labor-related share values, updates to outlier payments and updates to the case-mix group relative weights and average lengths of stay values. Based on our analysis, which utilizes, among other things, the acuity of our patients annualized over the twelve-month prior period ended June 30, 2022, our experience with outlier payments over </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that same time frame, and other factors, we believe the 2023 IRF Rule will result in a net increase to our Medicare payment rates of approximately 4.0% effective October 1, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proposed rulemaking for fiscal year 2023 for the IRF-PPS included a request for comment on a potential change that could be included in future rulemaking. Based on a recent HHS-OIG report, CMS is considering whether to modify the IRF &#8220;transfer&#8221; payment policy to reduce reimbursement for early discharges to home health, similar to how early discharges to acute-care hospitals, skilled nursing facilities, long-term acute-care hospitals, or another IRF, are currently treated under the IRF-PPS. HHS-OIG estimated that its recommended change to the policy could reduce total IRF industry reimbursements by approximately 6% based on 2017 and 2018 data. In the 2023 IRF Rule, CMS acknowledged industry comments on the policy and noted those comments would be taken under advisement for future rulemaking.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike our inpatient services, our outpatient services are primarily reimbursed under the Medicare Part B physician fee schedule. On November 1, 2022, CMS released its final notice of rulemaking for the payment policies under the physician fee schedule and other revisions to Part B policies for calendar year 2023. The updates to the fee schedule are not expected to be material to us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of the Medicare payment rules and other regulatory and legislative initiatives affecting Medicare reimbursement that could impact our businesses, see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Executive Overview&#8212;Key Challenges.&#8221;</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Advantage, Managed Care and Other Discount Plans</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We negotiate payment rates with certain large group purchasers of healthcare services, including Medicare Advantage plans, managed care plans, private insurance companies, and third-party administrators. Managed care contracts typically have terms between one and three years, although we have a number of managed care contracts that automatically renew each year (with pre-defined rate increases) unless a party elects to terminate the contract. In 2022, typical rate increases for our contracts ranged from 2-4%. We cannot provide any assurance we will continue to receive increases in the future. Our managed care staff focuses on establishing and re-negotiating contracts that provide equitable reimbursement for the services provided.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the percentage of Medicare-eligible beneficiaries choosing Medicare Advantage over traditional Medicare has grown, we have seen the percentage of our revenue derived from Medicare Advantage payors grow. </span><span style="background-color:#ffffff;color:#393d40;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, approximately </span><span style="color:#393d40;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span><span style="background-color:#ffffff;color:#393d40;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% of M</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">edicare beneficiaries enrolled in Medicare Advantage plans. This percentage has steadily increased over time since 2003. The Congressional Budget Office</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> projects that the share of all Medicare beneficiaries enrolled in Medicare Advantage plans will rise to about 61% by 2032</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect the percentage of our total revenues attributable to Medicare Advantage plans to continue to grow as well. Typically, Medicare Advantage and other managed care plans reimburse us less than traditional Medicare for the same type of care and patient, but that differential has been shrinking in recent years.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid Reimbursement</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid is a jointly administered and funded federal and state program that provides hospital and medical benefits to qualifying individuals who are deemed unable to afford healthcare. As the Medicaid program is administered by the individual states under the oversight of CMS in accordance with certain regulatory and statutory guidelines, there are substantial differences in reimbursement methodologies and coverage policies from state to state. Many states have experienced shortfalls in their Medicaid budgets and are implementing significant cuts in Medicaid reimbursement rates. Additionally, certain states control Medicaid expenditures through restricting or eliminating coverage of some services. Continuing downward pressure on Medicaid payment rates could cause a decline in that portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, for the year ended December&#160;31, 2022, Medicaid payments represented only 4.2% of our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In certain states in which we operate, we are experiencing an increase in Medicaid patients, partially the result of expanded coverage consistent with the intent of the ACA and expanded coverage resulting from regulatory actions during the COVID-19 public health emergency. For additional discussion, see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Changes in our payor mix or the acuity of our patients could adversely affect our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or our profitability.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost Reports</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of our participation in Medicare and Medicaid, we are required to meet certain financial reporting requirements. Federal and, where applicable, state regulations require the submission of annual cost reports covering the revenue, costs, and expenses associated with the services provided by healthcare providers to Medicare beneficiaries and Medicaid recipients. These annual cost reports are subject to routine audits which may result in adjustments to the amounts ultimately determined to be due to us under these reimbursement programs. These audits are used for determining if any under- or over-payments were made to these programs and to set payment levels for future years. Medicare also makes retroactive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adjustments to payments for certain low-income patients after comparing subsequently published statistical data from CMS to the cost report data. We cannot predict what retroactive adjustments, if any, will be made, but we do not anticipate these adjustments will have a material impact on us.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to significant federal, state, and local regulation that affects our business activities by controlling the reimbursement we receive for services provided, requiring licensure or certification of our operations, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and controlling our growth. State and local healthcare regulation may cover additional matters such as nurse staffing ratios, healthcare worker safety, marijuana legalization, and assisted suicide. We are also subject to the broader federal and state regulations that prohibit fraud and abuse in the delivery of healthcare services. Congress, HHS-OIG, and the DOJ have historically focused on fraud and abuse in healthcare. Since the 1980s, a steady stream of changes have stiffened penalties or made it easier for DOJ to impose liability on companies and individuals, and the pace of these changes has only been increasing. The 2018 Budget Act continues this emphasis by increasing the criminal and civil penalties that can be imposed for violating federal&#160;health care laws.&#160;As a healthcare provider, we are subject to periodic audits, examinations and investigations conducted by, or at the direction of, government investigative and oversight agencies. Failure to comply with applicable federal and state healthcare regulations can result in a provider&#8217;s exclusion from participation in government reimbursement programs and in substantial civil and criminal penalties.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We undertake significant effort and expense to provide the medical, nursing, therapy, and ancillary services required to comply with local, state, and federal regulations, as well as, for most hospitals, accreditation standards of The Joint Commission and, for some hospitals, the Commission on Accreditation of Rehabilitation Facilities. Accredited hospitals are subject to periodic resurvey to ensure the standards are being met.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond healthcare specific regulations, we face increasing state and local regulation in areas, such as labor and employment and data privacy, traditionally subject to only or primarily federal regulation. In addition to the risk and burden of new, additional, or more stringent regulatory standards, these state and local regulations often conflict with federal regulation, and with each other. Given the number of locations in which we operate, increasing state and local regulation, which may be more stringent than federal regulation and may even conflict with federal or other state or local regulation, represents a significant burden and risk to us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a comprehensive ethics and compliance program to promote conduct and business practices that meet or exceed requirements under laws, regulations, and industry standards. The program monitors the Company&#8217;s performance on, and raises awareness of, various regulatory requirements among employees and emphasizes the importance of complying with governmental laws and regulations. As part of the compliance program, we provide annual compliance training to our employees, Board members, medical directors, vendors, and other non-employees that operate within our hospitals, and require all employees to report any violations to their supervisor or another person of authority or through a toll-free telephone hotline. Another integral part of our compliance program is a policy of non-retaliation against employees who report compliance concerns.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensure and Certification</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare facility construction and operation are subject to numerous federal, state, and local regulations relating to, among other things, the adequacy of medical care, equipment, personnel, operating policies and procedures, acquisition and dispensing of pharmaceuticals and controlled substances, infection control, maintenance of adequate records and patient privacy, fire prevention, and compliance with building codes and environmental protection laws. Our inpatient rehabilitation hospitals are subject to periodic inspection and other reviews by governmental and non-governmental certification authorities to ensure continued compliance with the various standards necessary for facility licensure. All of our hospitals are required to be licensed.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, inpatient rehabilitation hospitals must be certified by CMS to participate in the Medicare program and generally must be certified by Medicaid state agencies to participate in Medicaid programs. Certification and participation in these programs involve numerous regulatory obligations. For example, hospitals must treat at least 20 patients without reimbursement prior to certification and eligibility for Medicare reimbursement. Once certified by Medicare, hospitals undergo periodic on-site surveys and revalidations in order to maintain their certification. All of our inpatient hospitals participate in the Medicare program.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable certification requirements may make our hospitals ineligible for Medicare or Medicaid reimbursement. In addition, Medicare or Medicaid may seek retroactive reimbursement from noncompliant hospitals </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or otherwise impose sanctions for noncompliance. Non-governmental payors often have the right to terminate provider contracts if the provider loses its Medicare or Medicaid certification.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Medicare providers are subject to employee screening requirements and associated fees. The screening of employees with patient access must include a licensure check and may include other procedures such as fingerprinting, criminal background checks, unscheduled and unannounced site visits, database checks, and other screening procedures prescribed by CMS. If a healthcare provider arranges or contracts with an individual or entity who is excluded by HHS-OIG from participation in a federal healthcare program, the provider may be subject to civil monetary penalties if the excluded person renders services reimbursed, directly or indirectly, by a program.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed operational systems to facilitate compliance with the various standards and requirements of the Medicare program and have established ongoing quality assurance activities; however, given the complex nature of governmental healthcare regulations, there can be no assurance Medicare, Medicaid, or other regulatory authorities will not allege instances of noncompliance. A determination by a regulatory authority that a hospital is not in compliance with applicable requirements could also lead to the assessment of fines or other penalties, loss of licensure, exclusion from participation in Medicare and Medicaid, and the imposition of requirements that the offending hospital must take corrective action.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certificates of Need</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some states and U.S. territories where we operate, the construction or expansion of facilities, the acquisition of existing facilities, or the introduction of new beds or inpatient services may be subject to review by and prior approval of state regulatory bodies under a &#8220;certificate of need,&#8221; or &#8220;CON,&#8221; law. As of December&#160;31, 2022, approximately 40% of our licensed beds are in states or U.S. territories that have CON laws. CON laws require a reviewing authority or agency to determine the public need for additional or expanded healthcare facilities and services. These laws also generally require approvals for capital expenditures involving inpatient rehabilitation hospitals if such capital expenditures exceed certain thresholds. In addition, CON laws in some states require us to abide by certain charity care commitments as a condition for approving a CON. Any instance where we are subject to a CON law, we must obtain it before acquiring, opening, reclassifying, or expanding a healthcare facility or starting a new healthcare program.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We potentially face opposition any time we initiate a project requiring a new or amended CON or seek to acquire an existing CON. This opposition may arise either from competing national or regional companies or from local hospitals or other providers which file competing applications or oppose the proposed CON project. Opposition to our applications may delay or prevent our future addition of beds or hospitals in given markets or increase our costs in seeking those additions. The necessity for these approvals serves as a barrier to entry and has the potential to limit competition for us (in markets where we hold a CON) and for other providers (in markets where we are seeking a CON). We have generally been successful in obtaining CONs or similar approvals, although there can be no assurance we will achieve similar success in the future, and the likelihood of success varies by locality and state.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an attempt to reduce regulation and increase competition, lawmakers in several states have recently proposed modification or even full repeal of CON laws. In 2019, Florida enacted legislation to repeal CON laws for several provider types, including IRFs. We believe CON-related legislation and regulation changes, including both repeal and expansion of CON requirements, will continue to be proposed in various states for the foreseeable future.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">False Claims</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act (the &#8220;FCA&#8221;) imposes liability for the knowing presentation of a false claim to the United States government and provides for penalties equal to three times the actual amount of any overpayments plus up to approximately $25,000 per claim. Federal civil penalties will be adjusted to account for inflation each year. In addition, the FCA allows private persons, known as &#8220;relators,&#8221; to file complaints under seal and provides a period of time for the government to investigate such complaints and determine whether to intervene in them and take over the handling of all or part of such complaints. The government and relators may also allege violations of the FCA for the knowing and improper failure to report and refund amounts owed to the government in a timely manner following identification of an overpayment. This is known as a &#8220;reverse false claim.&#8221; The government deems identification of the overpayment to occur when a person has, or should have through reasonable diligence, determined that an overpayment was received and quantified the overpayment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have hundreds of thousands of claims a year for which we are reimbursed by Medicare and other federal payors and there is a relatively long statute of limitations, a billing error, cost reporting error or disagreement over physician medical judgment could result in significant damages and civil and criminal penalties under the FCA. Many states have also adopted similar laws relating to state government payments for healthcare services. The ACA amended the FCA to expand the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">definition of false claim, to make it easier for the government to initiate and conduct investigations, to enhance the monetary reward to relators where prosecutions are ultimately successful, and to extend the statute of limitations on claims by the government. The federal government has become increasingly aggressive in asserting that incidents of erroneous billing or record keeping represent FCA violations and in challenging the medical judgment of independent physicians as the basis for FCA allegations. Furthermore, well-publicized enforcement actions indicate that the federal government has increasingly sought to use statistical sampling to extrapolate allegations to larger pools of claims or to infer liability without proving knowledge of falsity of individual claims. A violation of the FCA by us could have a material adverse effect upon our business, financial position, results of operations, or cash flows. Even the assertion of a violation could have an adverse effect upon our stock price or reputation. For additional discussion, see Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationships with Physicians and Other Providers</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Anti-Kickback Law</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Various state and federal laws regulate relationships between providers of healthcare services, including management or service contracts and investment relationships. Among the most important of these restrictions is a federal law prohibiting the offer, payment, solicitation, or receipt of remuneration by individuals or entities to induce referrals of patients for services reimbursed under the Medicare or Medicaid programs (the &#8220;Anti-Kickback Law&#8221;). The ACA amended the federal Anti-Kickback Law to provide that proving violations of this law does not require proving actual knowledge or specific intent to commit a violation. Another amendment made it clear that Anti-Kickback Law violations can be the basis for claims under the FCA. These changes and those described above related to the FCA, when combined with other recent federal initiatives, are likely to increase investigation and enforcement efforts in the healthcare industry generally. In addition to standard federal criminal and civil sanctions, including imprisonment and penalties of up to $100,000 for each violation plus tripled damages for improper claims, violators of the Anti-Kickback Law may be subject to exclusion from the Medicare and/or Medicaid programs. Federal civil penalties will be adjusted to account for inflation each year. HHS-OIG regulations itemize compensation arrangements that are not viewed as illegal remuneration under the Anti-Kickback Law. Those regulations provide for certain safe harbors for identified types of compensation arrangements that, if fully complied with, assure participants in the particular arrangement that HHS-OIG will not treat that participation as a criminal offense under the Anti-Kickback Law or as the basis for an exclusion from the Medicare and Medicaid programs or the imposition of civil sanctions. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2020, HHS-OIG finalized a rule to modernize the Anti-Kickback Law by reducing regulatory barriers to care coordination and accelerating adoption of value-based delivery and payment models (the &#8220;2020 AKL Rule&#8221;). The 2020 AKL Rule adds several new safe harbors for value-based arrangements and modifies several existing safe harbors with the goal of encouraging innovations that are beneficial to patients while maintaining necessary safeguards to protect against fraud and abuse. The 2020 AKL Rule also expands the safe harbor for cybersecurity technology by covering remuneration in the form of cybersecurity technology and services. The new and modified value-based safe harbors are available to inpatient rehabilitation providers if the applicable conditions are met. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to fall within a safe harbor does not constitute a violation of the Anti-Kickback Law, but HHS-OIG has indicated failure to fall within a safe harbor may subject an arrangement to increased scrutiny. A violation of the Anti-Kickback Law by us or one or more of our joint ventures could have a material adverse effect upon our business, financial position, results of operations, or cash flows. Even the assertion of a violation could have an adverse effect upon our stock price or reputation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a number of our rehabilitation hospitals through joint ventures with institutional healthcare providers that may be in a position to make or influence referrals to us. In addition, we have a number of relationships with physicians and other healthcare providers, including management or service contracts. Some of these investment relationships and contractual relationships may not fall within the protection offered by a safe harbor. Despite our compliance and monitoring efforts, there can be no assurance violations of the Anti-Kickback Law will not be asserted in the future, nor can there be any assurance our defense against any such assertion would be successful.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have entered into agreements to manage our hospitals that are owned by joint ventures. Most of these agreements incorporate a percentage-based management fee. Although there is a safe harbor for personal services and management contracts, this safe harbor requires, among other things, the aggregate compensation paid to the manager over the term of the agreement be set in advance. Because our management fee may be based on a percentage of revenues, the fee arrangement may not meet this requirement. However, we believe our management arrangements satisfy the other requirements of the safe harbor for personal services and management contracts and comply with the Anti-Kickback Law.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Physician Self-Referral Law</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The federal law commonly known as the &#8220;Stark law&#8221; and CMS regulations promulgated under the Stark law prohibit physicians from making referrals for &#8220;designated health services&#8221; including inpatient and outpatient hospital services, physical therapy, occupational therapy, radiology services, and home health services, to an entity in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the physician (or an immediate family member) has an investment interest or other financial relationship, subject to certain exceptions. The Stark law also prohibits those entities from filing claims or billing Medicare for those referred services. Violators of the Stark law and regulations may be subject to recoupments, civil monetary sanctions (up to $27,750 for each violation and assessments up to three times the amount claimed for each prohibited service) and exclusion from any federal, state, or other governmental healthcare programs. The statute also provides a penalty of up to $185,000 for a circumvention scheme. Federal civil penalties will be adjusted to account for inflation each year. There are statutory exceptions to the Stark law for many of the customary financial arrangements between physicians and providers, including personal services contracts and leases. However, in order to be afforded protection by a Stark law exception, the financial arrangement must comply with every requirement of the applicable exception.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ACA, the exception to the Stark law that currently permits physicians to refer patients to hospitals in which they have an investment or ownership interest has been dramatically limited by providing that only physician-owned hospitals with a provider agreement in place on December 31, 2010 are exempt from the general ban on self-referral. Existing physician-owned hospitals are prohibited from increasing the physician ownership percentage in the hospital after March 23, 2010. Additionally, physician-owned hospitals are prohibited from increasing the number of licensed beds after March 23, 2010, except when certain market and regulatory approval conditions are met. We have no hospitals that would be considered physician-owned under this law.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 20, 2020, CMS finalized a rule implementing various changes to the Stark law to provide better access and outcomes for patients by creating clearer paths for providers to serve patients through enhanced coordinated care agreements (the &#8220;2020 Stark Rule&#8221;). Notably, the 2020 Stark Rule creates permanent exceptions for value-based compensation arrangements that provide at least one value-based activity, which arrangements must further one value-based purpose, which may include: (1) coordinating and managing patient care; (2) improving quality of care for a target population; (3) reducing costs or expenditure growth without reducing quality of care; and (4) transitioning from health care delivery and payment mechanisms that are based on volume to outcome-based delivery and payment systems. In addition, the 2020 Stark Rule adopts a new exception regarding the provision of cybersecurity items to physicians and makes permanent the electronic health record exception under the Stark law. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complexity of the Stark law and the associated regulations and their associated strict liability provisions are a challenge for healthcare providers, who do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. We attempt to structure our relationships to meet one or more exceptions to the Stark law, but the regulations implementing the exceptions are detailed and complex. Accordingly, we cannot assure that every relationship complies fully with the Stark law.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, no assurances can be given that any agency charged with enforcement of the Stark law and regulations might not assert a violation under the Stark law, nor can there be any assurance our defense against any such assertion would be successful or that new federal or state laws governing physician relationships, or new interpretations of existing laws governing such relationships, might not adversely affect relationships we have established with physicians or result in the imposition of penalties on us. A violation of the Stark law by us could have a material adverse effect upon our business, financial position, results of operations, or cash flows. Even the assertion of a violation could have an adverse effect upon our stock price or reputation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HIPAA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act of 1996, commonly known as &#8220;HIPAA,&#8221; broadened the scope of certain fraud and abuse laws by adding several criminal provisions for healthcare fraud offenses that apply to all health benefit programs. HIPAA also added a prohibition against incentives intended to influence decisions by Medicare or Medicaid beneficiaries as to the provider from which they will receive services. In addition, HIPAA created new enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program, and an incentive program under which individuals can receive a monetary reward for providing information on Medicare fraud and abuse that leads to the recovery of Medicare funds. Penalties for violations of HIPAA include civil and criminal monetary penalties. The HHS Office of Civil Rights (&#8220;HHS-OCR&#8221;) implemented a permanent HIPAA audit program for healthcare providers nationwide in 2016. As of December&#160;31, 2022, we have not been selected for audit.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA and related HHS regulations contain certain administrative simplification provisions that require the use of uniform electronic data transmission standards for certain healthcare claims and payment transactions submitted or received electronically. HIPAA regulations also regulate the use and disclosure of individually identifiable health-related information, whether communicated electronically, on paper, or orally. The regulations provide patients with significant rights related to understanding and controlling how their health information is used or disclosed and require healthcare providers to implement administrative, physical, and technical practices to protect the security of individually identifiable health information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act modifies and expands the privacy and security requirements of HIPAA. The HITECH Act applies certain of the HIPAA privacy and security requirements directly to business associates of covered entities. The modifications to existing HIPAA requirements include: expanded accounting requirements for electronic health records, tighter restrictions on marketing and fundraising, and heightened penalties and enforcement associated with noncompliance. Significantly, the HITECH Act also establishes new mandatory federal requirements for notification of breaches of security involving protected health information. HHS-OCR rules implementing the HITECH Act expand the potential liability for a breach involving protected health information to cover some instances where a subcontractor is responsible for the breaches and that individual or entity was acting within the scope of delegated authority under the related contract or engagement. These rules generally define &#8220;breach&#8221; to mean the acquisition, access, use or disclosure of protected health information in a manner not permitted by the HIPAA privacy standards, which compromises the security or privacy of protected health information. Under these rules, improper acquisition, access, use, or disclosure is presumed to be a reportable breach, unless the potentially breaching party can demonstrate a low probability that protected health information has been compromised.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, HHS-OCR proposed a new rule that would modify HIPAA regulations. According to HHS-OCR, the proposed rule is intended to promote care coordination and value-based care. The proposed changes to the HIPAA rules also provide for strengthening individuals&#8217; rights to access their own health information, including electronic information; improving information sharing for care coordination and case management for individuals; facilitating greater family and caregiver involvement in the care of individuals experiencing emergencies or health crises; enhancing flexibilities for disclosures in emergency or threatening circumstances, such as the opioid and COVID-19 public health emergencies; and reducing administrative burdens on HIPAA covered healthcare providers and health plans, while continuing to protect individuals&#8217; health information privacy interests. Although one of the stated purposes of the proposed rules is to reduce healthcare providers burdens, providers would have to engage in a number of activities to come into compliance if the changes are finalized, including changing policies and procedures, changing patient privacy notices and business associate agreements and training workforce members in the new requirements. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HHS-OCR is responsible for enforcing the requirement that covered entities notify HHS and any individual whose protected health information has been improperly acquired, accessed, used, or disclosed. In certain cases, notice of a breach is required to be made to media outlets. The heightened penalties for noncompliance range from $100 to $50,000 per violation for most violations. In the event of violations due to willful neglect that are not corrected within 30 days, penalties start at approximately $64,000 per violation and are not subject to a per violation statutory maximum. Penalties are also subject to an annual cap for multiple identical violations in a single calendar year. Pursuant to guidance from HHS-OCR, this enforcement cap ranges from a minimum of $25,000 per year to a maximum of $1,500,000 per year depending on an entity&#8217;s level of culpability. Importantly, HHS-OCR has indicated that the failure to conduct a security risk assessment or adequately implement HIPAA compliance policies could qualify as willful neglect.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are numerous legislative and regulatory initiatives at the federal and state levels addressing patient privacy concerns. Healthcare providers will continue to remain subject to any federal or state privacy-related laws, including but not limited to the California Consumer Privacy Act, that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties. HHS-OIG and other regulators have also increasingly interpreted laws and regulations in a manner as to increase exposure of healthcare providers to allegations of noncompliance. Any actual or perceived violation of privacy-related laws and regulations, including HIPAA and the HITECH Act, could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil Monetary Penalties Law</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Civil Monetary Penalties Law, HHS may impose civil monetary penalties on healthcare providers that present, or cause to be presented, ineligible reimbursement claims for services. The 2018 Budget Act increased the civil monetary penalties, which vary depending on the offense from $5,000 to $100,000&#160;per violation, plus treble damages for the amount at issue and may include exclusion from federal health care programs such as Medicare and Medicaid. The penalties are adjusted annually to account for inflation. HHS may seek to impose monetary penalties under this law for, among other things, offering inducements to beneficiaries for program services and filing false or fraudulent claims.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available through our website, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.encompasshealth.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the following documents, free of charge: our annual reports (Form 10-K), our quarterly reports (Form 10-Q), our current reports (Form 8-K), and any amendments to those reports promptly after we electronically file such material with, or furnish it to, the United States Securities and Exchange Commission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span><br/></span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_19"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:34.8pt">Risk Factors</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, operations, and financial position are subject to various risks. Some of these risks are described below, and the reader should take such risks into account in evaluating Encompass Health or any investment decision involving Encompass Health. This section does not describe all risks that may be applicable to us, our industry, or our business, and it is intended only as a summary of material risk factors. More detailed information concerning other risks and uncertainties as well as those described below is contained in other sections of this annual report. Still other risks and uncertainties we have not or cannot foresee as material to us may also adversely affect us in the future. If any of the risks below or other risks or uncertainties discussed elsewhere in this annual report are actually realized, our business and financial condition, results of operations, and cash flows could be adversely affected. In the event the impact is materially adverse, the trading price of our common stock could decline.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to the Spin Off of Our Home Health and Hospice Business</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to engage in beneficial capital-raising or strategic transactions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 1, 2022, we completed the previously announced separation of our home health and hospice business through the distribution (the &#8220;Spin Off&#8221;) of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit, Inc. (&#8220;Enhabit&#8221;) to the stockholders of Encompass Health. As a result of the Spin Off, Enhabit is now an independent public company and its common stock is listed under the symbol &#8220;EHAB&#8221; on the New York Stock Exchange. The Spin Off is intended to be a tax-free transaction. Under current U.S. federal income tax law, a spin off that otherwise qualifies for tax-free treatment can be rendered taxable to the parent corporation and its stockholders as a result of certain post-spin-off transactions, including certain acquisitions of shares or assets of the parent corporation. To preserve the tax-free treatment of the Spin Off, we may be limited, for a period of time, in our ability to pursue certain equity issuances, strategic transactions, repurchases, or other transactions (including certain dispositions of assets) that we may otherwise believe to be in the best interests of our stockholders or that might increase the value of our business.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the Spin Off were to fail to qualify as tax-free, including as a result of transactions in our stock or the stock of Enhabit, we could be subject to significant tax liabilities.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a private letter ruling from the Internal Revenue Service regarding certain U.S. federal income tax matters relating to the Spin Off and its associated transactions and an opinion of outside counsel regarding the qualification of certain elements of those transactions. Although we intend for the Spin Off to be tax-free for U.S. federal income tax purposes, there can be no assurance that the Spin Off will not trigger a tax event. Even if the Spin Off were to otherwise qualify as a tax-free transaction under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code, it may result in taxable gain to us (but not our stockholders) under Section 355(e) of the Code if it is deemed to be part of a plan (or series of related transactions) pursuant to which one or more persons acquire, directly or indirectly, shares representing a 50% or greater ownership interest (by vote or value) in us or Enhabit. If the IRS were to determine that any post-Spin Off acquisitions of our stock or that of Enhabit, pursuant to such a plan (when aggregated with any pre-Spin Off acquisitions of our stock or that of Enhabit, as applicable, pursuant to such a plan) would represent a 50% or greater ownership interest therein, such determination could result in significant tax liabilities to us. Any such tax liabilities imposed on us may adversely affect an investment in our stock.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under a tax matters agreement we entered into with Enhabit in connection with the Spin Off, Enhabit is required to indemnify us for any taxes we incur resulting from the Spin Off to the extent such amounts result from certain disqualifying actions by, or acquisition of equity securities of, Enhabit. Additionally, Enhabit is generally required to indemnify us for a specified portion of any taxes we incur (a) arising as a result of the failure of the Spin Off and certain related transactions to qualify as a transaction that is generally tax-free or a failure of the Spin Off that is intended to qualify as a transaction that is generally tax-free to so qualify to the extent such amounts did not result from a disqualifying action by, or acquisition of equity securities of, Enhabit or us or (b) arising from certain audit or other adjustments to tax liabilities incurred with respect to the Spin Off that were not intended to qualify as tax-free. The amount of any such taxes for which we would be responsible may be significant, and if we were unable to obtain indemnification payments from Enhabit to which we are entitled under the tax matters agreement or other agreements entered into in connection with the Spin Off, we would incur significant losses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Reimbursement Risks</span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reductions or changes in reimbursement from government or third-party payors could adversely affect our Net operating revenues and other operating results.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive a substantial portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the Medicare program. See Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Sources of Revenues,&#8221; for a table identifying the sources and relative payor mix of our revenues. In addition to many ordinary course reimbursement rate changes that The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) adopts each year as part of its annual rulemaking process for various healthcare provider categories, Congress and some state legislatures have periodically proposed significant changes in laws and regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in reimbursement freezes and reductions, or reimbursement increases that are less than the increases we experience in our costs of operation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act of 2010 (the &#8220;ACA&#8221;) as a significant healthcare reform. Many provisions within the ACA have impacted or could in the future impact our business, including Medicare reimbursement reductions and promotion of alternative payment models, such as accountable care organizations (&#8220;ACOs&#8221;) and bundled payment initiatives. The nature and substance of state and federal healthcare laws are subject to change, by means of both broad base healthcare reform legislation, like the ACA, and targeted legislative and regulatory action. Any future legislative and regulatory changes may impact the provisions of the ACA discussed below or other laws or regulations that either currently affect, or may in the future affect, our business.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare providers like us, these laws include reductions in CMS&#8217;s annual adjustments to Medicare reimbursement rates, commonly known as a &#8220;market basket update.&#8221; In accordance with Medicare laws and statutes, CMS makes market basket updates by provider type in an effort to compensate providers for rising operating costs. The ACA required reductions, the last of which ended in 2019, in the annual market basket updates for hospital providers ranging from 10 to 75 basis points. In addition, the ACA requires the market basket updates for hospital providers to be reduced by a productivity adjustment on an annual basis. The productivity adjustment equals the trailing 10-year average of changes in annual economy-wide private nonfarm business multi-factor productivity. To date, the productivity adjustments have typically resulted in decreases to the market basket updates ranging from 30 to 100 basis points. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal legislation can also have a significant impact on our Medicare reimbursement. On August 2, 2011, President Obama signed into law the Budget Control Act of 2011, which provided for an automatic 2% reduction of Medicare program payments. This automatic reduction, known as &#8220;sequestration,&#8221; began affecting payments received after April 1, 2013. Under current law, for each year through mid-fiscal year 2032, the reimbursement we receive from Medicare, after first taking into account all annual payment adjustments including the market basket update, will be reduced by sequestration unless it is repealed or modified before then. In response to the public health emergency associated with the COVID-19 pandemic, Congress and the President suspended sequestration from May 1, 2020 through March 31, 2022. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Medicare payment reductions are also possible under the Statutory Pay-As-You-Go Act of 2010 (&#8220;Statutory PAYGO&#8221;). Statutory PAYGO requires, among other things, that mandatory spending and revenue legislation not increase the federal budget deficit over a 5- or 10-year period. If the Office of Management and Budget (the &#8220;OMB&#8221;) finds there is a deficit in the federal budget, Statutory PAYGO requires OMB to order sequestration of Medicare. In March 2021, President Biden signed the American Rescue Plan Act of 2021 (the &#8220;American Rescue Plan Act&#8221;). The Congressional Budget Office estimated that the American Rescue Plan Act would result in budget deficits necessitating a 4% reduction in Medicare program payments for 2022 under the Statutory PAYGO, but subsequent legislation enacted by Congress suspended until 2025 the Statutory PAYGO reductions that would have gone into effect.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, concerns held by federal policymakers about the federal deficit, national debt levels, or healthcare spending specifically, including solvency of the Medicare trust fund, could result in enactment of further federal spending reductions, further entitlement reform legislation affecting the Medicare program, and further reductions to provider payments. In October 2014, President Obama signed into law the Improving Medicare Post-Acute Care Transformation Act of 2014 (the &#8220;IMPACT Act&#8221;). The IMPACT Act directs HHS, in consultation with healthcare stakeholders, to implement standardized data collection processes for post-acute quality and outcome measures. Although the IMPACT Act does not specifically call for the implementation of a new post-acute payment system, we believe this act lays the foundation for possible future post-acute payment policies that would be based on patients&#8217; medical conditions and other clinical factors rather than the setting where the care is provided, also referred to as &#8220;site neutral&#8221; reimbursement. CMS has begun changing current post-acute payment systems to improve comparability of patient assessment data and clinical characteristics across settings, which could make it easier to create a unified payment system in the future. For example, CMS recently established new case-mix classification models for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both home health and skilled nursing facilities which rely on patient characteristics rather than the amount of therapy received to determine payments. Another example is CMS&#8217;s implementation of the new patient assessment measures for IRFs discussed below. The IMPACT Act also creates additional data reporting requirements for our hospitals. The precise details of these new reporting requirements, including timing and content, are being developed and implemented by CMS through the regulatory process that we expect will continue to take place over the next several years. We cannot quantify the potential effects of the IMPACT Act on us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year, the Medicare Payment Advisory Commission (&#8220;MedPAC&#8221;), an independent agency, advises Congress on issues affecting Medicare and makes payment policy recommendations to Congress for a variety of Medicare payment systems including, among others, the inpatient rehabilitation facility prospective payment system (the &#8220;IRF-PPS&#8221;). MedPAC also provides comments to CMS on proposed rules, including the prospective payment system rules. Congress is not obligated to adopt MedPAC recommendations, and, based on outcomes in previous years, there can be no assurance Congress will adopt MedPAC&#8217;s recommendations in a given year. However, MedPAC&#8217;s recommendations have, and could in the future, become the basis for legislative or regulatory action.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with CMS&#8217;s final rulemaking for the IRF-PPS in each year since 2008, MedPAC has recommended either no updates to payments or reductions to payments. For example, in a March 2020 report to Congress, MedPAC recommended, among other things, legislative changes to reduce by 5% the base payment rate under IRF-PPS. The March 2020 report also called on the HHS Secretary to conduct focused medical record reviews on IRFs. In its March 2022 report, MedPAC again recommended reduction of the base payment rate under the IRF-PPS by 5%.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a June 2018 report mandated by the IMPACT Act, MedPAC reiterated its recommendation that Congress adopt a unified payment system for all post-acute care (a &#8220;PAC-PPS&#8221;) in lieu of separate systems for inpatient rehabilitation facilities (&#8220;IRFs&#8221;), skilled nursing facilities, long-term acute-care hospitals, and home health agencies. A PAC-PPS would rely on &#8220;site neutral&#8221; reimbursement based on patients&#8217; medical conditions and other clinical factors rather than the care settings. MedPAC found a PAC-PPS to be feasible and desirable but also suggested many existing regulatory requirements, including, for IRFs, the 60% rule discussed below and the requirement for a minimum of three hours of therapy per day, should be waived or modified as part of implementing a PAC-PPS. MedPAC previously estimated, although we cannot verify the methodology or the accuracy of that estimate, a PAC-PPS would result in a 15% reduction in IRF reimbursements. As a precursor to a PAC-PPS, MedPAC discussed in November 2017 a potential recommendation to change the case-mix weights in each post-acute setting for 2019 and 2020 to a blend of the current setting specific weight and the proposed PAC-PPS weight, which MedPAC suggested would shift money from for-profit and freestanding IRFs to non-profit and hospital-based IRFs. MedPAC has also called for aligning Medicare regulatory requirements across post-acute providers, although the agency has acknowledged it could take years to complete this effort. MedPAC is currently producing another report on the PAC-PPS that is expected to be delivered to Congress before July 2023. Additionally, MedPAC previously has suggested that Medicare should ultimately move from fee-for-service reimbursement to more integrated payment models.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what alternative or additional deficit reduction initiatives, Medicare payment reductions, or post-acute care reforms, if any, will be adopted or enacted into law, or the timing or effect of any initiatives or reductions. Those initiatives or reductions would be in addition to many ordinary course reimbursement rate changes that CMS adopts each year as part of the market basket update rulemaking process for various provider categories. While we do not expect the drive toward integrated payment models, value-based purchasing, and post-acute site neutrality in Medicare reimbursement to subside, there will almost certainly be new or alternative healthcare reforms in the future which may change these initiatives and other healthcare laws and regulations. We cannot predict the nature or timing of any changes to the laws or regulations that either currently affect, or may in the future affect, our business.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance future governmental action will not result in substantial changes to, or material reductions in, our reimbursements. Similarly, we may experience material increases in our operating costs. For example, in 2022, our wage and benefit costs increased at a rate in excess of our aggregate Medicare reimbursement rate increases. In any given year, the net effect of statutory and regulatory changes may result in a decrease in our reimbursement rate, and that decrease may occur at a time when our expenses are increasing. As a result, there could be a material adverse effect on our business, financial position, results of operations, and cash flows. For additional discussion of how we are reimbursed by Medicare, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulatory and Reimbursement Challenges&#8221; and &#8220;Sources of Revenues&#8212;Medicare Reimbursement.&#8221;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are increasing pressures, including as a result of the ACA, from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors, such as health maintenance organizations and preferred provider organizations, are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and our ability to grow our business with these payors could be adversely affected if we are unable to negotiate and maintain favorable agreements with third-party payors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Quality reporting requirements could adversely affect the Medicare reimbursement we receive.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The focus on alternative payment models and value-based purchasing of healthcare services has, in turn, led to more extensive quality of care reporting requirements. In many cases, the new reporting requirements are linked to reimbursement incentives. For example, under the ACA, CMS established new quality data reporting, effective October 1, 2012, for all IRFs. A facility&#8217;s failure to submit the required quality data results in a two percentage point reduction to that facility&#8217;s annual market basket increase factor for payments made for discharges in the subsequent Medicare fiscal year. Hospitals began submitting quality data to CMS in October 2012. All of our hospitals have met the reporting deadlines to date resulting in no corresponding reimbursement reductions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the IMPACT Act mandated that CMS adopt several new quality reporting measures for the various post-acute provider types. The adoption of additional quality reporting measures to track and report will require additional time and expense and could affect reimbursement in the future. In healthcare generally, the burdens associated with collecting, recording, and reporting quality data are increasing. Currently, CMS requires IRF providers to track and submit patient assessment data to support the calculation of 18 quality reporting measures.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance all of our hospitals will meet quality reporting requirements or quality performance in the future which may result in one or more of our hospitals seeing a reduction in its Medicare reimbursements. Regardless, we, like other healthcare providers, are likely to incur additional expenses in an effort to comply with additional and changing quality reporting requirements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement claims are subject to various audits from time to time and such audits may negatively affect our operations and our cash flows from operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a substantial portion of our revenues from the Medicare program. Medicare reimbursement claims made by healthcare providers, including inpatient rehabilitation hospitals, are subject to audit from time to time by governmental payors, such as CMS and state Medicaid programs, their agents, such as the Medicare Administrative Contractors (&#8220;MACs&#8221;) that act as fiscal intermediaries for all Medicare billings and other auditors contracted by CMS, and private insurance carriers, as well as the HHS Office of Inspector General (the &#8220;HHS-OIG&#8221;). As noted above, the clarity and completeness of each patient medical file, some of which is the work product of a physician not employed by us, is essential to successfully challenging any payment denials. If the physicians working with our patients do not adequately document, among other things, their diagnoses and plans of care, our risks related to audits and payment denials in general are greater. Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered systemic, the resolution of these audits could have a material adverse effect in the aggregate on our financial position, results of operation, cash flows, and liquidity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the context of our inpatient rehabilitation business, one of the common grounds cited for denying a claim or challenging a previously paid Medicare claim in an audit is that the patient&#8217;s treatment in a hospital was not medically necessary. The medical record must support that both the documentation and coverage criteria requirements are met for the hospital stay to be considered medically necessary. Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting. A Medicare claim may be denied or challenged based on an opinion of the auditor that the record did not evidence medical necessity for treatment in an IRF or lacked sufficient documentation to support the conclusion. Some MACs have in the past applied and are likely in the future to apply their own unique interpretation of CMS coverage rules or impose otherwise arbitrary conditions not set out in the related rules, which has resulted and may in the future result in payment denials.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, we believe the reviewing party is not merely challenging the sufficiency of the medical record but is substituting its judgment of medical necessity for that of the attending physician or imposing documentation or other requirements that are not set out in the regulations. We argue that doing so is inappropriate and has no basis in law. When the government or its contractors reject the medical judgment of physicians or impose documentation and other requirements beyond the language of the statutes and regulations, patient access to inpatient rehabilitation as well as our Medicare reimbursement from the related claims may be adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, CMS announced the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative.&#160;Under the TPE program, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE program includes up to three rounds of claims review with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). As of December 31, 2022, none of our hospitals have progressed beyond the third round of reviews, so it is unclear how the review process after TPE would proceed. The TPE program takes significant time and effort on the part of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MACs, and MACs may not be adequately staffed to administer the program correctly or in accordance with Medicare coverage rules. We cannot predict whether the TPE initiative or similar probes or reviews will materially impact our reimbursement or the timeliness of collections from Medicare in the future.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has developed and instituted various audit programs under which CMS contracts with private companies to conduct claims and medical record audits. These audits are in addition to those conducted by existing MACs. Some contractors are paid a percentage of the overpayments recovered. One type of audit contractor, the Recovery Audit Contractors (&#8220;RACs&#8221;), receive claims data directly from MACs on a monthly or quarterly basis and are authorized to review previously paid claims. RAC audits of IRFs have focused on reviews of patient coding, medical necessity, and billing accuracy. CMS has, however, authorized RACs to conduct complex reviews of the medical records associated with IRF reimbursement claims. CMS has previously operated a demonstration project that expanded the RAC program to include prepayment review of Medicare fee-for-service claims from primarily acute-care hospitals. It is unclear whether CMS intends to conduct RAC prepayment reviews in the future and if so, what providers and claims would be the focus of those reviews.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established contractors known as the Uniform Program Integrity Contractors (&#8220;UPICs,&#8221; formerly known as Zone Program Integrity Contractors). These contractors conduct audits with a focus on potential fraud and abuse issues. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the United States Department of Justice (&#8220;DOJ&#8221;). Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error. In December 2017, we received notice of a UPIC audit at one of our hospitals. The UPIC sampled 100 claims and challenged the propriety of a subset of the sample representing $1.3 million in previously paid claims. The UPIC extrapolated the alleged error rate to all claims from that hospital during a period of approximately four years, resulting in an alleged overpayment of $33.9 million. Our MAC later reduced the determination of overpayment to $30.5 million, which it collected through recoupment of current claims during 2019. We appealed the overpayment determination to an Administrative Law Judge (&#8220;ALJ&#8221;), who heard the appeal in August 2021. In October 2022, the ALJ overturned $12.5&#160;million of the overpayment determination. We received payment of this amount, plus $3.2 million in interest, in December 2022. We have appealed the remaining $18.0 million of the overpayment determination to the next level of administrative appeal, challenging both the denials and the improper use of extrapolation. It is not possible to predict when this matter will be resolved or the ultimate outcome.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Audits may lead to assertions that we have been underpaid or overpaid by Medicare or have submitted improper claims in some instances. Such assertions may require us to incur additional costs to respond to requests for records and defend the validity of payments and claims and may ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors have the authority to extrapolate denial rationales to large pools of claims not actually audited, which could greatly increase the impact of the audit. As a result, we may suffer reduced profitability, and we may have to elect not to accept patients and conditions physicians believe can benefit from inpatient rehabilitation. We cannot predict when or how these audit programs will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations. Similarly, there can be no assurance that our current or future MACs will not make restrictive or otherwise incorrect interpretations of Medicare coverage rules. Because one MAC has jurisdiction over a significant number of our hospitals and our hospitals derive a substantial portion of their revenue from Medicare, the adoption of restrictive or otherwise incorrect interpretations of coverage rules by that MAC could result in a large number of payment denials and materially and adversely affect our financial position, results of operations, and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in the administrative appeals process associated with denied Medicare reimbursement claims could delay or reduce our reimbursement for services previously provided.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary course Medicare pre-payment denials by MACs, as well as denials resulting from audits, are subject to appeal by providers. HHS provides an appeals process through its ALJs. We have historically appealed a majority of our denials. Due to the sheer number of appeals by all Medicare providers and various administrative inefficiencies, including a shortage of judges, appeals that are required by statute to be resolved in a matter of months have commonly taken years to complete. In recent years, this protracted appeals process led to a significant backlog of appeals of denials, which a federal judge ultimately ordered HHS to resolve by the end of 2022. By December 31, 2022, we cleared substantially all of our backlog awaiting ALJ hearing. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes implemented by CMS to resolve the appeal backlog may have harmed the ability of providers like us to recover on valid Medicare claims. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;). Beginning in March 2020, OMHA increased the frequency of ALJ hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the ALJ appeals process. We are exploring various remedies to counter those deficiencies. We believe it is too early to determine what impact, if any, these recent changes in the appeals process will have on our long-term success rate or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providers may appeal adverse ALJ rulings to the Department of Appeals Boards (the &#8220;DAB&#8221;), the final level of administrative review. As of December 31, 2022, we have appealed approximately $52 million in claims awaiting review at the DAB. In addition, we have appealed approximately $6 million in claims denied by the DAB to several United States District courts, all of which are pending review as of December 31, 2022.  </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the process for resolving individual Medicare payment claims that are denied will continue to take several years. Additionally, the number of new denials frequently exceeds the number of appeals resolved in a given year (CMS suspended payment reviews for several months because of the public health emergency in 2020) as shown in the following summary of our inpatient rehabilitation segment activity: </span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.257%"><tr><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.663%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.827%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">New Denials</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collections of Previously Denied Claims</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue Reserve for New Denials</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$59.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$35.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record our estimates for pre-payment denials and for post-payment audit denials that will ultimately not be collected as a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; to the accompanying consolidated financial statements. We may experience decreases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreases in cash flow as a result of the increasing unresolved denials and the associated increasing accounts receivable, which may in turn force us to change the patients we admit and conditions we treat. Any of these impacts could have an adverse effect on our financial position, results of operations, and liquidity. Although Congress has considered legislation to reform and improve the Medicare audit and appeals process, we cannot predict what, if any, legislation will be adopted or what, if any, effect that legislation might have on the audit and appeals process.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in our payor mix or the acuity of our patients could adversely affect our Net operating revenues or our profitability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many factors affect reimbursement rates for our services and, in turn, our revenues. These factors include the treating facility&#8217;s urban or rural status, the length of stay, the payor and its applicable rate of reimbursement, and the patient&#8217;s medical condition and impairment status (acuity). The reimbursement rates we receive from traditional Medicare fee-for-service are generally higher than those received from other payors, although the difference between traditional Medicare and Medicare Advantage payments for inpatient rehabilitation care has decreased in the last several years. Over the same period, we have seen a shift in the payor mix from traditional Medicare to Medicare Advantage and other managed care providers. Not only do Medicare Advantage and managed care payors generally pay us less, but we would expect bad debt to be slightly higher for patients covered by Medicare Advantage and managed care as patients typically retain more payment responsibility under those arrangements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also experienced a shift in recent years to a slightly larger percentage of Medicaid patients, driven in part by the expansion of coverage consistent with the intent of the ACA and the expansion of coverage resulting from regulatory actions during the COVID-19 public health emergency. Medicaid reimbursement rates are almost always the lowest among those of our payors, and frequently Medicaid patients come to us with other complicating conditions that make treatment more difficult and costly. We cannot predict the growth of, or changes to, Medicaid, but President Biden has stated that he favors extending public health insurance coverage to low income individuals currently ineligible for Medicaid.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also experience a shift to a lower average patient acuity which typically results in lower reimbursement rates regardless of the payor. Both a shift in our payor mix away from Medicare fee-for-service and a shift to a lower patient acuity would likely adversely affect reimbursement. See the &#8220;Results of Operations&#8212;Net Operating Revenues&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the extent to which our payor mix may shift to lower reimbursement rate payors. We have in recent years experienced, and in the future may, experience shifts in our payor mix or the acuity of our patients that could adversely affect our reimbursement, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and profitability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in collection or non-collection of our accounts receivable could adversely affect our business, financial position, results of operations, cash flows, and liquidity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement is typically conditioned on our documenting medical necessity and correctly applying diagnosis codes. Incorrect or incomplete documentation and billing information could result in non-payment for services rendered. Billing and collection of our accounts receivable are further subject to the complex regulations that govern Medicare and Medicaid reimbursement and rules imposed by nongovernment payors. Our inability to bill and collect on a timely basis pursuant to these regulations and rules could subject us to payment delays that could have a material adverse effect on our business, financial position, results of operations, cash flows, and liquidity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, timing delays in billings and collections may increase our working capital burden. Working capital management, including prompt and diligent billing and collection, is an important factor in our financial position and results of operations and in maintaining liquidity. It is possible that Medicare, Medicaid, documentation support, system problems or other provider issues or industry trends, particularly with respect to newly acquired entities for which we have limited operational experience, may extend our collection period, which may materially adversely affect our working capital, and our working capital management procedures may not successfully mitigate this risk.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of payments made under the Medicare and Medicaid programs is subject to governmental budgetary constraints, which may result in an increased period of time between submission of claims and subsequent payment under specific programs, most notably under the Medicare and Medicaid managed care programs, which in many cases pay claims significantly slower than traditional Medicare or state Medicaid programs do as a result of more complicated authorization, billing and collecting processes that are required by Medicare and Medicaid managed care programs. In addition, we may experience delays in reimbursement as a result of the failure to receive prompt approvals related to change of ownership applications for acquired or other facilities or from delays caused by our or other third parties&#8217; information system failures. Furthermore, the proliferation of Medicare and Medicaid managed care programs could have a material adverse impact on the results of our operations as a result of more complicated authorization, billing and collection requirements implemented by such programs.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in our estimates of collectability or a delay in collection of accounts receivable could adversely affect our results of operations and liquidity. The estimates are based on a variety of factors, including the length of time receivables are past due, significant one-time events, contractual rights, client funding, political pressures, discussions with clients, and historical experience. A delay in collecting our accounts receivable, or the non-collection of accounts receivable, including, without limitation, in connection with our transition and integration of acquired companies and the attendant movement of underlying billing and collection operations from legacy systems to future systems, could have a material negative impact on our results of operations and liquidity, and we could be required to record impairment charges on our financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Efforts to reduce payments to healthcare providers undertaken by third-party payors, conveners, and referral sources could adversely affect our revenues and profitability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health insurers and managed care companies, including Medicare Advantage plans, may utilize certain third parties, known as conveners, to attempt to control costs. Conveners offer patient placement and care transition services to those payors as well as bundled payment participants, ACOs, and other healthcare providers with the intent of managing post-acute utilization and associated costs. Conveners may influence referral source decisions on which post-acute setting to recommend, as well as how long to remain in a particular setting. Given their focus on perceived financial savings, conveners customarily suggest that patients avoid higher acuity post-acute settings altogether or move as soon as practicable to lower acuity settings as those settings are reimbursed at lower rates due to the lower level of care they are required to provide. Conveners are not healthcare providers and may suggest a post-acute setting or duration of care that may not be appropriate from a clinical perspective potentially resulting in worse patient outcomes and costly acute-care hospital readmissions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also depend on referrals from physicians, acute-care hospitals, and other healthcare providers in the communities we serve. As a result of various alternative payment models, many referral sources are becoming increasingly focused on reducing post-acute costs by eliminating post-acute care referrals or referring patients to perceived low-cost post-acute settings rather than rehabilitation hospitals, sometimes without understanding the potential impact on patient outcomes over an entire episode of care. Our ability to attract patients could be adversely affected if any of our hospitals fail to provide or maintain a reputation for providing high-quality care on a cost-effective basis as compared to other providers.</span></div><div style="margin-bottom:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Regulatory Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing evolution of the healthcare delivery system, including alternative payment models and value-based purchasing initiatives, in the United States may significantly affect our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry in general is facing regulatory uncertainty around attempts to improve outcomes and reduce costs, including coordinated care and integrated payment models. In an integrated payment model, hospitals, physicians, and other care providers are reimbursed in a fashion meant to encourage coordinated healthcare on a more efficient, patient-centered basis. These providers are then paid based on the overall value and quality (as determined by outcomes) of the services they provide to a patient rather than the number and nature of services they provide. While this is consistent with our goal and proven track record of being a high-quality, cost-effective provider, broad-based implementation of a new payment model would represent a significant evolution or transformation of the healthcare industry, which may have a significant impact on our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, HHS has been studying the feasibility of bundling, including conducting a voluntary, multi-year bundling pilot program to test and evaluate alternative payment methodologies. CMS&#8217; voluntary Bundled Payments for Care Improvement Advanced (&#8220;BPCI Advanced&#8221;) initiative began October 1, 2018, runs through December 31, 2025, and covers 29 types of inpatient, three types of outpatient clinical episodes, and two multi-setting clinical episodes, including stroke and hip fracture. Providers participating in BPCI Advanced are subject to a semi-annual reconciliation process where CMS compares the aggregate Medicare expenditures for all items and services included in a clinical episode against the target price for that type of episode to determine whether the participant is eligible to receive a portion of the savings, or is required to repay a portion of the payment above target. Accordingly, reimbursement may be increased or decreased, compared to what would otherwise be due, based on whether the total Medicare expenditures and patient outcomes meet, exceed or fall short of the targets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, CMS has established per the ACA several separate ACO programs, the largest of which is the Medicare Shared Savings Program (&#8220;MSSP&#8221;), a voluntary ACO program in which hospitals, physicians, and other care providers pursue the delivery of coordinated healthcare on a more efficient, patient-centered basis. Conceptually, ACOs receive a portion of any savings generated above a certain threshold from care coordination as long as benchmarks for the quality of care are maintained. Under the MSSP, there are two ACO tracks from which participants can choose. Each track offers a different degree to which participants share any savings realized or any obligation to repay losses suffered. The ACO rules adopted by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS are extremely complex and remain subject to further refinement by CMS. Based on the CMS data below, the MSSP has not experienced growth in recent years. </span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:37.134%"><tr><td style="width:1.0%"></td><td style="width:16.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of ACOs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assigned Beneficiaries</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate, on a case-by-case basis, appropriate BPCI Advanced and ACO participation opportunities for our hospitals. We are party to 30 participation or preferred provider agreements in connection with these alternative payment models. The associated hospitals have treated only a limited number of patients under these alternative payment models to date. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2015, CMS published its final rule establishing the Comprehensive Care for Joint Replacement (&#8220;CJR&#8221;) payment model, which holds acute-care hospitals accountable for the quality of care they deliver to Medicare fee-for-service beneficiaries for lower extremity joint replacements (i.e., knees and hips) from surgery through recovery. The CJR originally was mandatory for the acute-care hospitals in the 67 geographic areas covered. On November 30, 2017, CMS issued a final rule making the CJR voluntary in 33 of those areas. The CJR model&#8217;s original five-year term ended in December 2020, but CMS extended the model through 2024 for most providers in the 34 geographic areas with mandatory participation. Under CJR, healthcare providers in the mandatory participation areas are paid under existing Medicare payment systems. However, CMS holds the acute-care hospital where a joint replacement takes place accountable for the quality and costs of care for the entire episode of care &#8212; from the time of the original admission through 90 days after discharge. Depending on the quality and cost performance during the entire episode, the acute-care hospital may receive an additional payment or be required to repay Medicare a portion of the episode costs. As a result, CMS believes acute-care hospitals are incented to work with physicians and post-acute care providers to ensure beneficiaries receive the coordinated care they need in an efficient manner. Acute-care hospitals participating in the CJR model may enter into risk-sharing financial arrangements with post-acute providers, including IRFs. CJR has not had a material impact on our hospitals.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HHS and CMS continue to explore ways to encourage and facilitate increased participation in alternative payment models and value-based purchasing initiatives. For example, the HHS-OIG and CMS finalized rules in 2020 modernizing the Anti-Kickback Statute and Stark law to, in part, promote a more coordinated, value-based system of care. The bundling and ACO initiatives have served as motivating factors for regulators and healthcare industry participants to identify and implement workable coordinated care and integrated payment models. Broad-based implementation of a new payment model would represent a significant transformation for us and the healthcare industry generally. The nature and timing of the evolution or transformation of the current healthcare system to coordinated care delivery and integrated payment models and value-based purchasing remain uncertain. The development of new delivery and payment systems will almost certainly take significant time and expense. Many of the alternative approaches, including those discussed above, being explored may not work or could change substantially prior to any nationwide implementations. While only a small percentage of our business currently is or is anticipated to be subject to the alternative payment models discussed above, we cannot be certain these models will not be expanded or made standard or new models will not be implemented broadly.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as the number and types of bundling, direct contracting, and ACO models increase, the number of Medicare beneficiaries who are treated in one of the models increases. Our willingness or inability to participate in integrated payment and other alternative payment models and the referral patterns of other providers participating in those models may limit our access to Medicare patients who would benefit from treatment in inpatient rehabilitation hospitals. In an attempt to reduce costs, ACOs may seek to discourage referrals to post-acute care all together. To the extent that acute-care hospitals participating in those models do not perceive our quality of care or cost efficiency favorably compared to alternative post-acute providers, we may experience a decrease in volumes and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which could adversely affect our financial position, results of operations, and cash flows. For further discussion of coordinated care and integrated payment models and value-based purchasing initiatives, the associated challenges, and our efforts to respond to them, see the &#8220;Executive Overview&#8212;Key Challenges&#8212;Changes to Our Operating Environment Resulting from Healthcare Reform&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other legislative and regulatory initiatives and changes affecting the industry could adversely affect our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the legislative and regulatory actions that directly affect our reimbursement rates or further the evolution of the current healthcare delivery system, other legislative and regulatory changes, including as a result of ongoing healthcare reform, affect healthcare providers like us from time to time. For example, the ACA provides for the expansion of the federal Anti-Kickback Law and the False Claims Act (the &#8220;FCA&#8221;) that, when combined with other recent federal initiatives, are likely to increase investigation and enforcement efforts in the healthcare industry generally. Changes include increased resources for enforcement, lowered burden of proof for the government in healthcare fraud matters, expanded definition of claims under the FCA, enhanced penalties, and increased rewards for relators in successful prosecutions. CMS may also suspend payment for claims prospectively if, in its opinion, credible allegations of fraud exist. The initial suspension period may be up to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the HHS-OIG or DOJ. Any such suspension would adversely affect our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states in which we operate have also undertaken, or are considering, healthcare reform initiatives that address similar issues. While many of the stated goals of other federal and state reform initiatives are consistent with our own goal to provide care that is high-quality and cost-effective, legislation and regulatory proposals may lower reimbursements, increase the cost of compliance, decrease patient volumes, promote frivolous or baseless litigation, and otherwise adversely affect our business. We cannot predict what healthcare initiatives, if any, will be enacted, implemented or amended, or the effect any future legislation or regulation will have on us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2019, CMS adopted a new rule as called for by the IMPACT Act that revises the discharge planning requirements applicable to our inpatient rehabilitation hospitals. Effective November 29, 2019, CMS requires every hospital (including IRFs) to have a discharge planning process that focuses on patients&#8217; goals and preferences and on preparing them and, as appropriate, their caregivers, to be active partners in their post-discharge care. For our hospitals, this rule requires instituting standardized procedures to identify those patients who are likely to suffer adverse health consequences upon discharge in the absence of adequate discharge planning and to provide a discharge planning evaluation for such patients to ensure that appropriate arrangements for post-hospital care are made before discharge. At the time of discharge, a hospital must transfer or refer the patient, along with all necessary medical information pertaining to the patient&#8217;s current course of illness and treatment, post-discharge goals of care, and treatment preferences, to the appropriate post-acute care service providers and suppliers, facilities, agencies, and other outpatient service providers and practitioners responsible for the patient&#8217;s follow-up or ancillary care. Patients must also be informed of all post-acute providers in the area and, for patients enrolled in managed care organizations, in network providers must be identified if the hospital has that information. Additional information must be provided to patients who are discharged home and referred for home health agency services or who are referred to other post-acute care services. In areas where we are not part of a managed care network with significant enrollment, this discharge planning rule may negatively affect the number of patients choosing us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with requirements adopted pursuant to the IMPACT Act, CMS implemented requirements to publish certain Medicare spending per beneficiary measures for each inpatient rehabilitation hospital in October 2016. The intent of tracking and publishing this data is to evaluate a given provider&#8217;s payment efficiency relative to the efficiency of the national median provider in that provider&#8217;s post-acute segment. CMS believes this measure will encourage improved efficiency and coordination of care in the post-acute setting by holding providers accountable for Medicare resource use during an episode of care. However, the measures may be misleading as they do not incorporate patient outcomes associated with those resources used. CMS has not proposed to compare payment efficiency across provider segments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2020, CMS announced the proposal of a five-year review choice demonstration for inpatient rehabilitation services (the &#8220;IRF RCD&#8221;). CMS plans to implement the demonstration in Alabama, and then expand to Pennsylvania, Texas, and California. The proposed timing of this demonstration is not known. We operate 46 inpatient rehabilitation hospitals (representing approximately 32% of our IRF Medicare claims) in those four states. After the initial four states, CMS intends to expand the demonstration to include additional IRFs based on the Medicare Administrative Contractor to which those IRFs submit claims. Under the demonstration, participating IRFs would have an initial choice between pre-claim or post-payment review of 100% of claims submitted to demonstrate compliance with applicable Medicare coverage and clinical documentation requirements. Under the pre-claim review choice, services could begin prior to the submission of the review request and continue while the decision is being made. The pre-claim review request with required documentation must be submitted and reviewed before the final claim is submitted for payment. Under the post-payment review choice, IRFs would provide services, submit all claims for payment following their normal processes, and then submit required documentation for medical review. If 90% or more of its claims are found to be valid, the IRF may then opt out of the RCD review, except for spot reviews of samples consisting of 5% of total claims. The IRF RCD would not create new documentation requirements. A number of key details on this proposal have yet to be released, and it is not clear how or when CMS will implement this </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">demonstration. We may experience temporary decreases in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and in cash flow, or we may incur costs associated with patient care for which the Medicare claim is subsequently denied, which could have an adverse effect on our financial position, results of operations, and liquidity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what legislative or regulatory reforms or changes, if any, will ultimately be enacted, or the timing or effect any of those changes or reforms will have on us. If enacted, they may be challenging for all providers and have the effect of limiting Medicare beneficiaries&#8217; access to healthcare services and could have a material adverse impact on our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, financial position, results of operations, and cash flows. For additional discussion of healthcare reform and other factors affecting reimbursement for our services, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulatory and Reimbursement Challenges&#8221; and &#8220;Sources of Revenues&#8212;Medicare Reimbursement.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with the extensive laws and government regulations applicable to healthcare providers requires substantial time, effort and expense, and if we fail to comply with them, we could suffer penalties or be required to make significant changes to our operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensure, certification, enrollments, and accreditation;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coding and billing for services;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements of the 60% compliance threshold under the 2007 Medicare Act;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality of medical care;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use and maintenance of medical supplies and equipment;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance and security of patient information and medical records;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">minimum staffing;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition and dispensing of pharmaceuticals and controlled substances; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disposal of medical and hazardous waste.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, and contractual arrangements. Those changes could also affect reimbursements as well as future compliance, training, and staffing costs. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Examples of regulatory changes that can affect our business, beyond direct changes to Medicare reimbursement rates, can be found from time to time in CMS&#8217;s annual rulemaking. For example, the final rule for the fiscal year 2010 IRF-PPS implemented new coverage requirements which provided in part that a patient medical record must document a reasonable expectation that, at the time of admission to an IRF, the patient generally required and was able to participate in the intensive rehabilitation therapy services uniquely provided at IRFs. CMS has also taken the position that a patient&#8217;s medical file must appropriately document the rationale for the use of group therapies, as opposed to one-on-one therapy. Beginning on October 1, 2015, CMS instituted a new data collection requirement pursuant to which IRFs must capture the minutes and mode (individual, group, concurrent, or co-treatment) of therapy by specialty. Additionally, from time to time CMS has adopted changes in the medical conditions that will presumptively count toward the 60% compliance threshold to qualify for reimbursement as an inpatient rehabilitation hospital.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of note, the HHS-OIG periodically updates a work plan that identifies areas of compliance focus. In recent years, the HHS-OIG work plans for IRFs have focused on, among other items, the appropriate utilization of concurrent and group therapy and adverse and temporary harm events occurring in IRFs. In January 2020, the HHS-OIG announced an audit to review incentives under the IRF-PPS to </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discharge patients prematurely to home health agencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Following this audit, the HHS-OIG </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">announced in December 2021 its recommendation to CMS to establish an IRF transfer payment policy for early discharges to home health care in which the IRF would only receive a per diem rate in lieu of the full case-mix payment. The HHS-OIG estimated the policy could have reduced total Medicare payments to IRFs in 2017 and 2018 by between 6% and 7%. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the HHS-OIG released a report purporting to identify a high error rate (approximately 80% of&#160;claims) among inpatient rehabilitation hospital admissions in a small sample of 220 claims. Based on its findings, the HHS-OIG extrapolated the error rate to the universe of inpatient rehabilitation claims and, among other things, recommended reevaluation of the IRF-PPS. However, that HHS-OIG report involved an extremely small sample size, was not a random sample of cases, included some citations to coverage requirements that did not match actual regulations, appeared to conflate technical documentation requirements with medical necessity determinations, and was at odds with actual MAC reviews of claims during that same timeframe which found substantially lower error rates. On September 15, 2022, the HHS-OIG updated its work plan to conduct a nationwide audit of IRF claims in order to determine the extent to which CMS could clarify the Medicare IRF claim payment criteria. The HHS-OIG expects to issue a report on this in fiscal year 2024. An  HHS-OIG work plan, audit or similar future efforts could result in proposed changes to the payment systems for providers or increased denials of Medicare claims for patients notwithstanding the referring physicians&#8217; judgment that treatment is appropriate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the recent HHS-OIG work plans demonstrate, the clarity and completeness of each patient medical file, some of which is the work product of a physician not employed by us, are essential to demonstrating our compliance with various regulatory and reimbursement requirements. For example, to support the determination that a patient&#8217;s IRF treatment was medically necessary, the file must contain, among other things, an admitting physician&#8217;s assessment of the patient as well as a post-admission assessment by the treating physician and other information from clinicians relating to the plan of care and the therapies being provided. These physicians are not employees. They exercise independent medical judgment. We and our hospital medical directors, who are independent contractors, provide training on a regular basis to the physicians who treat patients at our hospitals regarding appropriate documentation. However, we ultimately do not and cannot control the physicians&#8217; medical judgment. In connection with subsequent payment audits and investigations, there can be no assurance as to what opinion a third party may take regarding the status of patient files or the physicians&#8217; medical judgment evidenced in those files.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2013, we received document subpoenas from an office of the HHS-OIG addressed to four of our hospitals. On April 24, 2014, we received document subpoenas relating to an additional seven of our hospitals. Those subpoenas requested documents, including copies of patient medical records, related to reimbursement claims submitted during periods ranging from January 2008 through December 2013. The associated investigation led by DOJ was based on whistleblower claims of alleged improper or fraudulent claims submitted to Medicare and Medicaid and requested documents and materials relating to practices, procedures, protocols and policies of certain pre- and post-admissions activities at these hospitals including marketing functions, pre-admission screening, post-admission physician evaluations, patient assessment instruments, individualized patient plans of care, and compliance with the Medicare 60% rule. Under the Medicare rule commonly referred to as the &#8220;60% Rule,&#8221; 60% or more of the patients of an IRF must have at least one of a specified list of medical conditions in order to be reimbursed at the IRF-PPS payment rates, rather than at the lower acute-care hospital payment rates. We settled the DOJ investigation, together with the related </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or whistleblower lawsuits, in 2019 for a total payment of $48 million. In return for the settlement payment, the plaintiffs dismissed with prejudice their pending </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> claims, and DOJ provided Encompass Health and all its subsidiaries with a release from civil liability. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have invested, and will continue to invest, substantial time, effort, and expense in implementing and maintaining training programs as well as internal controls and procedures designed to ensure regulatory compliance, we have in the past been, and could in the future be, required to return portions of reimbursements for discharges alleged after the fact to have not been appropriate under the applicable reimbursement rules and change our patient admissions practices going forward. We could also be subjected to other liabilities, including (1)&#160;criminal penalties, (2)&#160;civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals, and (3)&#160;exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs, which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement or debt instruments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. As discussed above in connection with the ACA, the federal government has in the last couple of years made compliance enforcement and fighting healthcare fraud top priorities. In the past few years, DOJ and HHS as well as federal lawmakers have significantly increased efforts to ensure strict compliance with various reimbursement related regulations as well as combat healthcare fraud. DOJ has pursued and recovered record amounts based on alleged healthcare fraud. The increased enforcement efforts have frequently included aggressive arguments and interpretations of laws and regulations that pose risks for all providers. For example, the federal government has increasingly asserted that incidents of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">erroneous billing or record keeping may represent violations of the FCA. Human error and oversight in record keeping and documentation, particularly where those activities are the responsibility of non-employees, are always a risk in business, and healthcare providers and independent physicians are not immune to this risk. Additionally, the federal government has been willing to challenge the medical judgment of independent physicians in determining issues such as the medical necessity of a given treatment plan.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlements of alleged violations or imposed reductions in reimbursements, substantial damages and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation and could cost us significant time and expense to defend.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The use of sub-regulatory guidance, statistical sampling, and extrapolation by CMS, Medicare contractors, HHS-OIG, and DOJ to deny claims, expand enforcement claims, and advocate for changes in reimbursement policy increases the risk that we could experience reduced revenue, suffer penalties, or be required to make significant changes to our operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. Our ability to operate in a compliant manner impacts the claims denials, compliance enforcement, and regulatory processes discussed in other risks above. The federal government&#8217;s reliance on sub-regulatory guidance, such as handbooks, FAQs, internal memoranda, and press releases, presents a unique challenge to compliance efforts. Such sub-regulatory guidance purports to explain validly promulgated regulations but often expands or supplements existing regulations without constitutionally and statutorily required notice and comment and other procedural protections. Without procedural protections, sub-regulatory guidance poses a risk above and beyond reasonable efforts to follow validly promulgated regulations, particularly when the agency or MAC seeking to enforce such sub-regulatory guidance is not the agency or MAC issuing the guidance and therefore not as familiar with the substance and nature of the underlying regulations or even clinical issues involved.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, CMS issued a proposed rule invoking a rarely used retroactive-rulemaking authority to support CMS&#8217;s application of a Medicare payment methodology that the U.S. Supreme Court found to be procedurally improper in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Azar v. Allina Health Services</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2019. CMS&#8217; invocation of its retroactive-rulemaking authority in response to this Supreme Court decision is an unfavorable precedent for providers because it demonstrates a willingness by CMS to revive adverse reimbursement actions after those actions are deemed deficient on administrative procedural grounds.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the federal government is increasingly turning to statistical sampling and extrapolation to expand claims denials and enforcement efforts and advocate for changes in reimbursement policy. Through sampling and extrapolation, the government takes a review of a small number of reimbursement claims and generalizes the results of that review to a much broader universe of claims, which can result in significant increases in the aggregate number and value of claims at issue. Increasing use of extrapolation can be found in payment review audits, such as those conducted by RACs and UPICs. In addition to payment reviews, government agencies may allege compliance violations, including submission of false claims, based on sampling and extrapolation and seek to change reimbursement policy. For example, the HHS-OIG issued a report in September 2018 purporting to identify a high error rate (approximately 80% of&#160;claims) among inpatient rehabilitation hospital admissions in a small sample of 220 claims. Based on its findings, the HHS-OIG extrapolated the error rate to the universe of inpatient rehabilitation claims and, among other things, recommended reevaluation of the IRF-PPS. However, the HHS-OIG report involves an extremely small sample size, is not a random sample of cases, includes incorrect references to coverage requirement regulations, appears to conflate technical documentation requirements with medical necessity determinations, and is at odds with actual MAC reviews of claims during that same timeframe which found substantially lower error rates. Notwithstanding the technical statistical flaws that can arise in sampling small groups of claims and the extremely problematic nature of extrapolation in the context of individualized decisions of medical judgment as some courts have noted, sampling and extrapolation pose a growing risk to healthcare providers in the form of more significant claims of overpayments and increased legal costs to defend against these problematic regulatory practices. In a recent federal court case, the Fifth Circuit Court of Appeals ruled in favor of CMS and affirmed the application of extrapolation errors identified in a sample of claims to support larger claims for overpayment. As discussed under "Reimbursement Risks&#8221; above, we are currently challenging, among other things, the use of extrapolation in a 2017 UPIC audit. Any associated loss of revenue or increased legal costs could materially and adversely affect our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Efforts to comply with regulatory mandates to increase the use of electronic health data and health system interoperability&#160;may lead to enforcement and negative publicity which could adversely affect our business.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For many years, a primary focus of the healthcare industry has been to increase the use of electronic health records, or &#8220;EHR,&#8221; and the sharing of the health data among providers, payors and other members of the industry. The federal government has been a significant driver of that initiative through rules and regulations. In 2009, as part of the Health Information Technology for Economic and Clinical Health (&#8220;HITECH&#8221;) Act, the federal government set aside $27 billion of incentives for acute-care hospitals and other providers, not including IRFs, to adopt EHR systems. In 2020, CMS and HHS&#8217;s Office of the National Coordinator for Health IT (&#8220;ONC&#8221;) finalized policy changes implementing interoperability, information blocking, and patient access provisions of the 21st Century Cures Act and supporting the MyHealthEData initiative, designed to allow patients to access their health claims information electronically through the application of their choosing. The companion rules will transform the way in which healthcare providers, health information technology developers, health information exchanges/health information networks (&#8220;HIEs/HINs&#8221;), and health plans share patient information. For example, the ONC rule prohibits healthcare providers, health IT developers, and HIEs/HINs from engaging in practices that are likely to interfere with, prevent, materially discourage, or otherwise inhibit the access, exchange or use of electronic health information, also known as &#8220;information blocking.&#8221; The ONC rule also requires regulated actors to respond to requests for electronic health information in the content and manner requested, with some exceptions. Enforcement of ONC&#8217;s and CMS&#8217; new health information access, exchange, and use standards promulgated in the 2020 rules began in 2021, and noncompliance can result in civil monetary penalties, exclusion from participation in federal health care programs and other appropriate &#8220;disincentives&#8221; that have not yet been identified by the agencies. The HHS-OCR patient right of access initiative, which began in late 2019 and has similar objectives to the new ONC initiative, such as promoting and enforcing patient access to health information, has led to dozens of settlements of enforcement actions. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goals of increased use of electronic health data and interoperability are improved quality of care and lower healthcare costs generally. However, increased use of electronic health data and interoperability inherently magnifies the risk of security breaches involving that data and information systems used to share it, which risk is discussed under &#8220;Other Operational Risks&#8221; below. Additionally, interoperability and the sharing of health information have received increasingly negative publicity. There is at least one well publicized instance where organizations received significant negative publicity for sharing health data despite having appeared to comply in all respects with privacy law. There can be no assurance that our efforts to improve the care we deliver and to comply with the law through increasing use of electronic data and system interoperability will not receive negative publicity that may materially and adversely affect our ability to get patient referrals or enter into joint ventures with other providers or may lead to greater regulatory scrutiny. Negative publicity may also lead to federal or state regulation that conflicts with current federal policy and interferes with the healthcare industry&#8217;s efforts to improve care and reduce costs through use of electronic data and interoperability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If any of our hospitals fail to comply with the Medicare enrollment requirements or conditions of participation, that hospital could be terminated from the Medicare program.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our hospitals must comply with extensive enrollment requirements and conditions of participation for the Medicare program. If any of our hospitals fail to meet any of the Medicare enrollment requirements or conditions of participation, we may receive a notice of deficiency from the applicable survey agency or contractor, as applicable. If that hospital then fails to institute an acceptable plan of correction and correct the deficiency within the applicable correction period, it could lose the ability to bill Medicare. A hospital could be terminated from the Medicare program if it fails to address the deficiency within the applicable correction period. If CMS terminates one hospital, it may increase its scrutiny of others under common control. From time to time, we have individual hospitals that receive notices of deficiency. To date, we have addressed those as they have arisen, and we have not experienced a termination.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 5, 2019, CMS released a final rule that will implement over a period of time additional provider enrollment provisions and create several new revocation and denial authorities in an attempt to bolster CMS&#8217; efforts to prevent waste, fraud and abuse. A few provisions of this new rule could significantly increase the complexity of filing enrollment applications for all of our provider entities, including increased burden related to tracking and identifying required reporting data from our joint venture partners. This rule requires Medicare and Medicaid providers and suppliers to disclose any current or previous (in the last five years), direct or indirect affiliation with a provider or supplier that has ever had a disclosable event. A disclosable event is any uncollected debt to Medicare or Medicaid, payment suspension under a federal health care program, denial, revocation or termination of enrollment (even if it is under appeal), or exclusion by the HHS-OIG from participation in a federal health care program. The rule also broadens the definition of an affiliation, including many indirect ownership or control situations such as ownership interests in a publicly traded company. If CMS determines an affiliation with a disclosable event poses an undue risk of fraud, waste or abuse, then the provider reporting that affiliation may be subject to exclusion from Medicare. Currently, information regarding uncollected debt, payment suspensions and enrollment actions are not generally </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available, so obtaining such information on affiliates could prove difficult or impossible in some situations. CMS intends to issue further guidance on the level of effort it expects providers to undertake to uncover information on their affiliates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this new rule, CMS may revoke a provider&#8217;s Medicare enrollment, including all of the provider&#8217;s locations, if the provider bills for services performed at, or items furnished from, one location that it knew or should have known did not comply with Medicare enrollment requirements, including making the disclosures discussed above. CMS has the ability to prevent applicants from enrolling in the program for up to three years if a provider is found to have submitted false or misleading information in its initial enrollment application. Additionally, CMS can now block providers and suppliers who are revoked from re-entering the Medicare program for up to 10 years. CMS may also revoke a provider&#8217;s enrollment if it fails to report on a timely basis any change in ownership or control, revocation or suspension of a federal or state license or certification, or any other change in its enrollment data.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any termination of one or more of our hospitals from the Medicare program for failure to satisfy the enrollment requirements or conditions of participation could materially adversely affect our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found to have violated applicable privacy and security laws and regulations or our contractual obligations, we could be subject to sanctions, fines, damages and other civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial position, results of operation and liquidity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of federal and state laws, rules and regulations, as well as contractual obligations, relating to the protection, collection, storage, use, retention, security, disclosure, transfer and other processing of confidential, sensitive and personal information, including certain patient health information, such as patient records. There are also foreign laws, rules and regulations that address these matters and have extraterritorial application. We do not believe we are currently subject to these non-United States regulatory regimes but that could change in the future. Existing laws and regulations are constantly evolving, and new laws and regulations that apply to our business are being enacted at every level of government in the United States. In many cases, these laws and regulations apply not only to third-party transactions, but also to transfers of information between or among us, our affiliates and other parties with whom we conduct business. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business. We monitor legal developments in data privacy and security regulations at the local, state and federal level, however, the regulatory framework for data privacy and security worldwide is continuously evolving and developing and, as a result, interpretation and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management of protected health information (&#8220;PHI&#8221;) is subject to several regulations at the federal level, including the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) and the HITECH Act. The HIPAA privacy and security regulations protect medical records and other personal health information by limiting their use and disclosure, giving individuals the right to access, amend, and seek accounting of their own health information, and limiting most uses and disclosures of health information to the minimum amount reasonably necessary to accomplish the intended purpose. The HITECH Act strengthened HIPAA enforcement provisions and authorized state attorneys general to bring civil actions for HIPAA violations. It also permits HHS to conduct audits of HIPAA compliance and impose significant civil monetary penalties even if we did not know and could not reasonably have known about a violation. If we are found to have violated the HIPAA privacy or security regulations or other federal or state laws protecting the confidentiality of patient health or personal information, including but not limited to the HITECH Act, we could be subject to litigation, sanctions, fines, damages and other civil or criminal penalties, which could increase our liabilities, harm our reputation, and have a material adverse effect on our business, financial position, results of operations and liquidity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous other federal and state laws protect the confidentiality, privacy, availability, integrity and security of PHI. For example, various states, including Virginia, California, Massachusetts, Florida, Utah, and Colorado, have implemented privacy laws and regulations that impose restrictive requirements regulating the use and disclosure of personally identifiable information, including PHI, and many other states have proposed similar laws and regulations. These laws in many cases are more restrictive or impose more obligations than, and may not be preempted by, the HIPAA rules, apply to employees and business contacts as well as patients, and may be subject to new and varying interpretations by courts and government agencies, creating complex compliance issues and potentially exposing us to additional expense, adverse publicity and liability. We also expect that there will continue to be new laws, regulations and industry standards concerning privacy, data protection and information security proposed and enacted in various jurisdictions. The U.S. Congress has considered, but not yet passed, several comprehensive federal data privacy bills over the past few years, such as the CONSENT Act, which was intended to be similar to the landmark 2018 European Union General Data Protection Regulation. We expect federal data privacy laws to continue to evolve.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of a comprehensive federal privacy law, there is increased focus at the state and local level on regulating the collection, storage, use, retention, security, disclosure, transfer and other processing of confidential, sensitive and personal information. In recent years, we have seen significant changes to data privacy regulations across the United States. New legislation proposed or enacted will continue to shape the data privacy environment. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may conflict with each other, which significantly complicates compliance efforts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all 50 U.S. states and the District of Columbia have enacted breach notification laws that may require us to notify patients, employees or regulators in the event of unauthorized access to or disclosure of personal or confidential information experienced by us or our service providers. These laws are not consistent, and compliance in the event of a widespread data breach is difficult and may be costly. Moreover, states frequently amend existing laws, requiring attention to changing regulatory requirements. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may be contractually required to notify patients or other counterparties of a security breach. Although we have contractual protections with many of our service providers, any actual or perceived security breach could harm our reputation and brand, expose us to potential liability or require us to expend significant resources on data security and in responding to any such actual or perceived breach. Any contractual protections we have from our service providers may not be sufficient to adequately protect us from any such liabilities and losses, and we may be unable to enforce any such contractual protections. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to government regulation, privacy advocates and industry groups have and may in the future propose self-regulatory standards from time to time. These and other industry standards may legally or contractually apply to us, or we may elect to comply with such standards.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with these various laws, rules, regulations and standards could cause us to incur substantial costs that are likely to increase over time, require us to change our business practices in a manner adverse to our business, divert resources from other initiatives and projects, and restrict the way products and services involving data are offered, all of which may have a material adverse effect on our business. Given the rapid development of cybersecurity and data privacy laws, we expect to encounter inconsistent interpretation and enforcement of these laws and regulations, as well as frequent changes to these laws and regulations which may expose us to significant penalties or liability for noncompliance, the possibility of fines, lawsuits (including class action privacy litigation), regulatory investigations, criminal or civil sanctions, audits, adverse media coverage, public censure, other claims, significant costs for remediation and damage to our reputation, or otherwise have a material adverse effect on our business and operations. Any allegations of a failure to adequately address data privacy or security-related concerns, even if unfounded, or to comply with applicable laws, regulations, standards and other obligations relating to data privacy and security, could result in additional cost and liability to us, damage our relationships with patients and have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make public statements about our use and disclosure of personal information through our privacy policies, information provided on our website and press statements. Although we endeavor to comply with our public statements and documentation about patient privacy, we may at times fail to do so or be accused of having failed to do so. The publication of our privacy policies and other statements that provide promises and assurances about data privacy and security can subject us to potential government or legal action if they are found to be deceptive, unfair or misrepresentative of our actual practices. Moreover, from time to time, concerns may be expressed about whether our products and services compromise the privacy of patients and others. Any concerns about our data privacy and security practices, even if unfounded, could damage the reputation of our businesses, discourage potential patients from our products and services and have a material adverse effect on our business.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal, state and local laws and regulations that govern our employment practices, including minimum wage, overtime, living wage and paid-time-off requirements. Failure to comply with these laws and regulations, or changes to these laws and regulations that increase our employment-related expenses, could adversely impact our operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with all applicable federal, state and locals laws and regulations relating to employment, including occupational safety and health requirements, minimum staffing, wage and hour, overtime and other compensation requirements, employee benefits and other leave and sick pay requirements, proper classification of workers as employee or independent contractors, and immigration and equal employment opportunity laws, among others. These laws and regulations can vary significantly among jurisdictions, can change, and can be highly technical and involve strict liability for noncompliance with a seemingly mundane technical detail. Costs and expenses related to these requirements are a significant operating expense and may increase as laws and regulations change. Any failure to comply with these requirements can result in significant penalties or litigation exposure and could have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Hospital Pricing Transparency Rule could adversely affect our business and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective on January 1, 2021, the hospital price transparency rule requires hospitals to publish on the internet in a consumer-friendly format their standard charges based on negotiated rates for all items and services and up to 300 common shoppable services. Shoppable services are those routinely provided in non-urgent situations and include those ancillary services that customarily accompany the primary service being provided. The charges for an individual item or service to be published include: </span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gross charge (charge as reflected on a hospital&#8217;s chargemaster, absent any discounts),</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payer-specific negotiated charge (charge negotiated with a third party payer for an item or service),</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">de-identified minimum negotiated charge (lowest charge negotiated with all third-party payers),</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">de-identified maximum negotiated charge (highest charge negotiated with all third-party payers), and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounted cash price (charge that applies to an individual who pays cash).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This rule imposes significant initial and ongoing burdens on hospitals to track and publish various billing information. In the event a hospital fails to comply with the new requirements and does not complete the prescribed corrective action, CMS may impose a civil monetary penalty of between $300 and $5,500 per day. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have also passed or are debating legislation establishing price transparency websites or mandating that health plans or hospitals make price information available to consumers. The associated reporting obligations vary from state to state. We cannot predict what the adverse effects, if any, of this new CMS rule or any state law or regulation, such as the effect on relations with managed care payors and referral sources, may be for us.&#160;The maximum penalty for violations is more than $2&#160;million per hospital, so our failure to maintain compliance with this rule could adversely affect our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Operational Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The proper function, availability, and security of our information systems are critical to our business and failure to maintain proper function, availability, or security of our information systems or protect our data against unauthorized access could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and will remain dependent on the proper function, availability and security of our and third-party information systems, including our electronic clinical information system, referred to as ACE-IT, which plays a substantial role in the operations of the hospitals, and the cloud service providers we directly and indirectly use. We undertake measures to protect the safety and security of our information systems and the data maintained within those systems, and we periodically test the adequacy of our security, business continuity, and disaster recovery measures. We have implemented administrative, technical and physical controls on our systems and devices in an attempt to prevent unauthorized access to that data, which includes patient information subject to the protections of HIPAA and the HITECH Act and other sensitive information. For additional discussion of these laws, see Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulation.&#8221;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expend significant capital to protect against the threat of security breaches, including cyber attacks, email phishing schemes, malware and ransomware. Substantial additional expenditures may be required to respond to and remediate any problems caused by breaches, including the unauthorized access to or theft of patient data and protected health information stored in our information systems and the introduction of computer malware or ransomware to our systems. We also provide our employees annual training and regular reminders on important measures they can take to prevent breaches and other cyber threats, including phishing schemes. We routinely identify attempts to gain unauthorized access to our systems. However, given the rapidly evolving nature and proliferation of cyber threats, there can be no assurance our training and network security measures or other controls will detect, prevent or remediate security or data breaches in a timely manner or otherwise prevent unauthorized access to, damage to, or interruption of our systems and operations. For example, it has been widely reported that many well-organized international interests, in certain cases with the backing of sovereign governments, are targeting the theft of patient information and the disruption of healthcare services through the use of advanced persistent threats and ransomware attacks. In recent years, several hospitals have reported being victims of ransomware attacks in which they lost access to their systems, including clinical systems, during the course of the attacks. Large, national healthcare systems have reported ransomware attacks that forced their facilities to operate without access to information systems for some time and, to some extent, inhibited their ability to admit patients. We are likely to face attempted attacks in the future. Accordingly, we may be vulnerable to losses associated with the improper functioning, breach or unavailability of our and our vendors&#8217; information systems, including systems used in acquired operations, and third-party systems we use. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Threat actors continue to attempt to exploit commonly used software and services to gain remote access to a large number of the information systems of the businesses using the software and services. For example, in both 2021 and 2022, Microsoft reported a vulnerability within its widely deployed email exchange services. In December 2021, widespread exploitation of a vulnerable logging software installed within commonly used applications, services, and websites gave threat actors the ability to execute code remotely and potentially take control of affected systems. In these instances, we conducted forensics investigations of our systems containing these software applications using all the indicators of compromise provided by leading security experts. Our forensic analysis to date has discovered no indicators of compromise. Generally, we, working with our cyber security vendors, attempt to monitor various channels and sources to identify vulnerabilities and threats in both third-party vendor software and services as well as our own systems and to mitigate the risks promptly. We also routinely work with industry and governmental cyber security partners to identify and combat cyber threats, which are particularly acute in the healthcare industry. There can be no assurance that we will identify or adequately mitigate all threats to our systems, particularly in light of the number of well-funded and organized threat actors working to attack healthcare providers. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we are not aware of having experienced a material compromise from a cyber breach or attack. However, given the increasing cyber security threats in the healthcare industry, there can be no assurance we will not experience business interruptions; data loss, ransom, misappropriation or corruption; theft or misuse of proprietary data, patient or other personally identifiable information; or litigation, investigation, or regulatory action related to any of those, any of which could have a material adverse effect on our patient care, ability to admit patients, financial position, and results of operations and harm our business reputation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A compromise of our network security measures or other controls, or of those businesses or vendors with whom we interact, including our direct and indirect cloud service providers, which results in confidential information being accessed, obtained, damaged or used by unauthorized persons, or unavailability of systems necessary to the operation of our business, could impact patient care, harm our reputation, and expose us to significant remedial costs as well as regulatory actions (fines and penalties) and claims from patients, financial institutions, regulatory and law enforcement agencies, and other persons, any of which could have a material adverse effect on our business, financial position, results of operations and cash flows. The nature of our business requires the sharing of protected health information and other sensitive information among employees and healthcare partners, many of whom carry and access portable devices outside of our physical locations, which in turn increases the risk of loss, theft or inadvertent disclosure of that information. Moreover, a security breach, or threat thereof, could require that we expend significant resources to repair or improve our information systems and infrastructure and could distract management and other key personnel from performing their primary operational duties. In the case of a material breach or cyber attack, the associated expenses and losses may exceed our current insurance coverage for such events. Some adverse consequences are not insurable, such as reputational harm and third-party business interruption. Failure to maintain proper function, security, or availability of our information systems or protect our data against unauthorized access, or the failure of one or more of our key partners, vendors, or other counterparties to do these things, could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACE-IT is subject to a licensing, implementation, technology hosting, and support agreement with Oracle Cerner Corporation. In addition, we have a number of partners and non-software vendors with whom we share data in order to provide patient care and otherwise operate our business. In fact, federal laws and regulations require interoperability among healthcare entities in many circumstances. Our inability, or the inability of our partners or vendors, to continue to maintain and upgrade information systems, software, and hardware could disrupt or reduce the efficiency of our operations, including affecting patient care. A security breach or other system failure involving Oracle Cerner or another third-party with whom we share data or system connectivity could compromise our patient data or proprietary information or disrupt our ability to operate. In addition, costs, unexpected problems, and interruptions associated with the implementation or transition to new systems or technology or with adequate support of those systems or technology across numerous hospitals could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense competition for patients from other healthcare providers.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in the competitive, fragmented inpatient rehabilitation industry. Although we are the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, in any particular market we may encounter competition from local or national entities with longer operating histories or other competitive advantages. For example, acute-care hospitals, including those owned and operated by large public companies, may choose to expand or begin offering post-acute rehabilitation services. Given that approximately 91% of our hospitals&#8217; referrals come from acute-care hospitals, that increase in competition could materially and adversely affect our admission referrals in the related markets. There are also large acute-care systems that may have more resources available to compete than we have. Other providers of post-acute care services may attempt to become competitors in the future. For example, some nursing homes, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including at least one public company operator, have been marketing themselves as offering certain rehabilitation services, even though nursing homes are not required to offer the same level of care, and are not licensed, as hospitals.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competing companies may offer newer or different services from those we offer or have better relationships with referring physicians and may thereby attract patients who are presently, or would be candidates for, receiving our inpatient rehabilitation services. The other public companies and large health insurance companies expanding into post-acute care have or may obtain significantly greater marketing and financial resources or other advantages of scale than we have or may obtain. Other companies, including hospitals and other healthcare organizations that are not currently providing competing services, may expand their services to include inpatient rehabilitation services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance this competition, or other competition which we may encounter in the future, will not adversely affect our business, financial position, results of operations, or cash flows. In addition, from time to time, there are efforts in states with certificate of need (&#8220;CON&#8221;) laws to weaken those laws, which could potentially increase competition in those states. For example, in 2019, Florida enacted legislation to repeal CON regulations for several provider types, including IRFs. Effective July 1, 2021, new IRFs can operate without first obtaining a CON. Conversely, competition and statutory procedural requirements in some CON states may inhibit our ability to expand our operations in those states. For a breakdown of the CON status of the states and territories in which we have operations, see Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to provide a consistently high quality of care, our business will be adversely impacted.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providing quality patient care is fundamental to our business. We believe hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. Clinical quality is becoming increasingly important within our industry. Effective October 2012, Medicare began to impose a financial penalty upon acute-care hospitals that have excessive rates of patient readmissions within 30 days from hospital discharge. We believe this regulation provides a competitive advantage to post-acute providers who can differentiate themselves based upon quality, particularly by achieving low acute-care hospital readmission rates and by implementing disease management programs designed to be responsive to the needs of patients served by referring hospitals. If we should fail to attain our goals regarding acute-care hospital readmission rates and other quality metrics, we expect our ability to generate referrals would be adversely impacted, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or develop relationships with patient referral sources, our growth and profitability could be adversely affected.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on referrals from physicians, hospitals, case managers and other patient referral sources in the communities we serve. By law, referral sources cannot be contractually obligated to refer patients to any specific provider. However, there can be no assurance that individuals will not attempt to steer patients to competing post-acute providers or otherwise limit our access to potential referrals. The establishment of joint ventures or networks between referral sources, such as acute-care hospitals, and other post-acute providers may hinder patient referrals to us. The growing emphasis on integrated care delivery across the healthcare continuum increases that risk.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth and profitability depend on our ability to establish and maintain close working relationships with patient referral sources and to increase awareness and acceptance of the benefits of inpatient rehabilitation care by our referral sources and their patients. We cannot provide assurance that we will be able to maintain our existing referral source relationships or that we will be able to develop and maintain new relationships in existing or new markets. Our loss of, or failure to maintain, existing relationships or our failure to develop new relationships could adversely affect our ability to grow our business and operate profitably.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have difficulty completing joint ventures, investments and transactions that increase our capacity consistent with our growth strategy.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may selectively pursue strategic acquisitions of, and we frequently pursue joint ventures with, other healthcare providers. We may face limitations on our ability to identify sufficient joint venture, acquisition or other development targets and to complete those transactions to meet goals. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the inpatient rehabilitation industry, the costs of constructing new hospitals are increasing faster than reimbursement rates and the general inflation rate. In many states, the need to obtain governmental approvals, such as a CON or an approval of a change in ownership, may represent a significant obstacle to completing transactions. Additionally, in states with CON laws, it is not unusual for third-party providers to challenge the initial awards of CONs, the increase in the number of approved beds </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in an existing CON, or the expansion of the area served, and the adjudication of those challenges and related appeals may take many years.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in federal laws or regulations may also materially adversely impact our ability to acquire hospitals or open</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hospitals. Under the Biden administration, DOJ has announced its intention to be much more aggressive in challenging mergers and acquisitions it believes present anti-trust concerns. In a speech in January 2022, the head of DOJ&#8217;s anti-trust enforcement stated that negotiated settlements are frequently inadequate remedies and that DOJ needs to be more aggressive in its litigation to block business combinations. He also stated that litigation is preferable to settlements because it represents a chance to extend legal precedent for what constitutes unlawful anticompetitive activity. Increased DOJ enforcement of antitrust laws will likely increase the time, effort and expense associated with acquisitions and may ultimately make it less likely to consummate acquisitions. With respect to healthcare combinations specifically, President Biden issued an Executive Order on July 9, 2021 that encourages DOJ and the Federal Trade Commission to review and revise their merger guidelines for hospitals to ensure patients are not harmed by such mergers.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These factors and others may delay, or increase the cost to us associated with, any acquisition or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> development or prevent us from completing one or more acquisitions or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> developments.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may make investments or complete transactions that could expose us to unforeseen risks and liabilities.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments, acquisitions, joint ventures or other development opportunities identified and completed may involve material cash expenditures, debt incurrence, operating losses, amortization of certain intangible assets of acquired companies, issuances of equity securities, liabilities, and expenses, some of which are unforeseen, that could materially and adversely affect our business, financial position, results of operations and liquidity. Acquisitions, investments, and joint ventures involve numerous risks, including:</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations, including state CONs as well as anti-trust, Medicare, and other regulatory approval requirements, on our ability to complete such acquisitions, particularly those involving not-for-profit providers, on terms, timetables, and valuations reasonable to us;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations in obtaining financing for acquisitions at a cost reasonable to us;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties integrating acquired operations, personnel, and information systems, and in realizing projected revenues, efficiencies and cost savings, or returns on invested capital;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entry into markets, businesses or services in which we may have little or no experience;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of business resources or management&#8217;s attention from ongoing business operations; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to undisclosed or unforeseen liabilities of acquired operations, including liabilities for failure to comply with healthcare laws and anti-trust considerations as well as risks and liabilities related to previously compromised information systems.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our development activities, we intend to open new, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, inpatient rehabilitation hospitals. The construction of new hospitals involves numerous risks, including the receipt of all zoning and other regulatory approvals, such as a CON where necessary, construction delays and cost over-runs and unforeseen environmental liability exposure. Once built, new hospitals must undergo the state and Medicare certification process, the duration of which may be beyond our control. We may be unable to operate newly constructed hospitals as profitably as expected, and those hospitals may involve significant additional cash expenditures and operating expenses that could, in the aggregate, have an adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully integrate acquisitions or realize the anticipated benefits of any acquisitions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may undertake strategic acquisitions from time to time. Prior to consummation of any acquisition, the acquired business will have operated independently of us, with its own procedures, corporate culture, locations, employees and systems. We expect to integrate acquired businesses into our existing business utilizing certain common information systems, operating procedures, administrative functions, financial and internal controls and human resources practices to the extent practicable. There may be substantial difficulties, costs and delays involved in the integration of an acquired business with our business. Additionally, an acquisition could cause disruption to our business and operations and our relationships with customers, employees and other parties. In some cases, the acquired business has itself grown through acquisitions, and there may be legacy systems, operating policies and procedures, and financial and administrative practices yet to be fully integrated. To the extent we are attempting to integrate multiple businesses at the same time, we may not be able to do so as efficiently or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectively as we initially anticipate. The failure to successfully integrate on a timely basis any acquired business with our existing business could have an adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate our acquisitions will result in benefits including, among other things, increased revenues. However, acquired businesses may not contribute to our revenues or earnings to the extent anticipated, and any synergies we expect may not be realized after the acquisitions have been completed. If the acquired businesses underperform and any underperformance is other than temporary, we may be required to take an impairment charge. Failure to achieve the anticipated benefits could result in the diversion of management&#8217;s time and energy and could have an adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for staffing, shortages of qualified personnel, union activity or other factors may increase our staffing costs and reduce profitability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are dependent on the efforts, abilities, and experience of our medical personnel, such as physical therapists, occupational therapists, speech pathologists, nurses, and other healthcare professionals. We compete with other healthcare providers in recruiting and retaining qualified personnel responsible for the daily operations of each of our locations. The lack of availability of clinical personnel is a significant operating issue facing healthcare providers. The operating conditions associated with the COVID-19 pandemic significantly affected the availability and turnover of clinical staff and, in turn, increased staffing costs. It has been widely reported that the challenging working conditions in healthcare associated with the COVID-19 pandemic have led to prevalent job dissatisfaction among clinicians. Availability of clinical staff, elevated turnover and staffing costs continue to be a challenge for us and other healthcare providers. The availability of staff may be exacerbated if immigration is limited in the future. Staffing shortages or retention concerns in one or more markets in which we operate have required and may again require us to enhance wages and benefits to recruit and retain qualified personnel or to contract for more expensive temporary personnel. We also depend on the available labor pool of semi-skilled and unskilled employees in each of the markets in which we operate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our staffing costs increase, we may not experience reimbursement rate or pricing increases to offset these additional costs. Because a significant percentage of our revenues consists of fixed, prospective payments, our ability to pass along increased staffing costs is limited. In particular, if staffing costs rise at an annual rate greater than our net annual market basket update from Medicare, as occurred in 2022, or we experience a significant shift in our payor mix to lower rate payors such as Medicaid, our results of operations and cash flows will be adversely affected. Conversely, decreases in reimbursement revenues, such as with sequestration, may limit our ability to increase compensation or benefits to the extent necessary to retain key employees, in turn increasing our turnover and associated costs. Union activity is another factor that may contribute to increased staffing costs. We currently have a minimal number of union employees, so an increase in labor union activity could have a significant impact on our staffing costs. Our failure to recruit and retain qualified medical personnel, or to control our staffing costs, could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a defendant in various lawsuits, and may be subject to liability under qui tam cases, the outcome of which could have a material adverse effect on us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. We are a defendant in a number of lawsuits, most of which are general and professional liability matters inherent in treating patients with medical conditions. Our more significant lawsuits and investigations, if any, are discussed in Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantial damages, fines, or other remedies assessed against us or agreed to in settlements could have a material adverse effect on our business, financial position, results of operations, and cash flows, including indirectly as a result of the covenant defaults under our credit agreement or debt instruments or other claims such as those in securities actions. Additionally, the costs of defending litigation and investigations, even if frivolous or nonmeritorious, could be significant.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FCA allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we settled with DOJ to conclude an investigation that originated in 2013 based on the allegations made by relators. The seven-year investigation produced no evidence of falsity or fraudulent conduct. Eventually, the court overseeing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions refused to give DOJ more time to decide whether to intervene and unsealed the cases. DOJ chose not to intervene and prosecute the matter. We settled the DOJ investigation, together with the related </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or &#8220;whistleblower&#8221; lawsuits, for a payment of $48 million, and we expressly denied any wrongdoing. Even when a matter is without merit, as we believe was the case with this investigation, we may still incur significant costs of defense or settlement costs or both.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the FCA.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare services we provide involve substantial risk of general and professional liability. Inpatient rehabilitative care involves three hours of daily intensive therapy for patients who are usually elderly and come to our hospitals with debilitating medical conditions. Our clinicians must frequently assist patients who have difficulty with mobility. We cannot predict the impact any claims arising out of the care being provided (regardless of their ultimate outcomes) could have on our business or reputation or on our ability to attract and retain patients and employees. We also cannot predict the adequacy of any reserves for such losses or recoveries from any insurance or re-insurance policies.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We self-insure a substantial portion of our professional, general, and workers&#8217; compensation liability risks, which may not include risks related to regulatory fines and penalties, through our captive insurance subsidiary, as discussed further in Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. Changes in the number of these liability claims and the cost to resolve them impact the reserves for these risks. A variance between our estimated and actual number of claims or average cost per claim could have a material impact, either favorable or unfavorable, on the adequacy of the reserves for these liability risks, which could have an effect on our financial position and results of operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we operate in states in which the litigation environment may pose a significant business risk to us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, we have been involved in lawsuits, including putative class actions, brought under California&#8217;s Private Attorneys General Act (&#8220;PAGA&#8221;). Under PAGA, individuals, including aggrieved employees, can bring individual or class-action claims alleging regulatory violations, including alleged violations of employment regulations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, judges and juries in California have demonstrated a willingness to grant large verdicts to plaintiffs in connection with employment and labor related cases.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the California Supreme Court held that plaintiffs bringing suit under PAGA are generally entitled to request and receive a significant amount of information from the employer early in the litigation, which creates pressure for employers to settle early to avoid substantial litigation costs and which has resulted in a significant increase PAGA claims in recent years.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be more vulnerable to the effects of a public health emergency than other businesses due to the nature of our patients, and a regional or global socio-political or other catastrophic event could severely disrupt our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A public health emergency can significantly affect healthcare providers because of the direct impacts on patients, capacity to accept patients, employees, necessary supplies to treat patients, and regulatory requirements related to the emergency. The COVID-19 pandemic and actions taken by local, state and federal authorities in response to the pandemic significantly affected our operations, business and financial condition. Future outbreaks of contagious diseases and associated governmental actions could adversely affect our operations, business and financial condition, including potentially our liquidity, particularly if the provision of healthcare services and the supplies for those services are disrupted for a lengthy period of time. The impact on our operations and financial performance depends on numerous factors, including the rate of spread, duration and geographic coverage of an outbreak; the rate and extent to which the disease mutates and the severity of the symptoms of the disease; the status of testing capabilities; the rates of vaccination and therapeutic remedies for the disease and any variant strains; the legal, regulatory and administrative developments related to the pandemic at federal, state, and local levels, such as vaccine mandates, anti-mandate laws and orders, shelter-in-place orders, facility closures and quarantines; and the infectious disease prevention and control efforts of the Company, governments and third parties. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our patients are elderly individuals with complex medical challenges, many of whom may be more vulnerable than the general public during a contagious disease outbreak or other public health catastrophe. Our employees are also at greater risk of contracting contagious diseases due to their increased exposure to vulnerable patients. For example, if another pandemic were to occur, we could suffer significant losses to our consumer population or a reduction in the availability of our employees and, at a high cost, be required to replace affected workers. Local, regional or national governments might limit or ban public interactions to halt or delay the spread of diseases causing business disruptions and the temporary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suspension of our services. Accordingly, certain public health catastrophes could have a material adverse effect on our financial condition and results of operations. Other unforeseen events, including acts of violence, war, terrorism and other international, regional or local instability or conflicts (including labor issues), embargoes, natural disasters such as earthquakes, whether occurring in the United States or abroad, could restrict or disrupt our operations.</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Risks</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur additional indebtedness in the future, and that debt or the associated increased leverage may have negative consequences for our business. The restrictive covenants included in the terms of our indebtedness could affect our ability to execute aspects of our business plan successfully.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we have approximately $2.4 billion of long-term debt outstanding (including that portion of long-term debt classified as current and excluding $359.8 million in finance leases). See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. Subject to specified limitations, our credit agreement and the indentures governing our debt securities permit us and our subsidiaries to incur material additional debt. If new debt is added to our current debt levels, the risks described here could intensify.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness could have important consequences, including:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to borrow additional amounts to fund working capital, capital expenditures, acquisitions, debt service requirements, execution of our business strategy and other general corporate purposes;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making us more vulnerable to adverse changes in general economic, industry and competitive conditions, in government regulation and in our business by limiting our flexibility in planning for, and making it more difficult for us to react quickly to, changing conditions;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">placing us at a competitive disadvantage compared with competing providers that have less debt; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposing us to risks inherent in interest rate fluctuations for outstanding amounts under our credit facility, which could result in higher interest expense in the event of increases in interest rates, as discussed in Item 7A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to contingent liabilities, prevailing economic conditions, and financial, business, and other factors beyond our control. Although we expect to make scheduled interest payments and principal reductions, we cannot provide assurance that changes in our business or other factors will not occur that may have the effect of preventing us from satisfying obligations under our credit agreement or debt instruments. If we are unable to generate sufficient cash flow from operations in the future to service our debt and meet our other needs or have an unanticipated cash payment obligation, we may have to refinance all or a portion of our debt, obtain additional financing or reduce expenditures or sell assets we deem necessary to our business. We cannot provide assurance these measures would be possible or any additional financing could be obtained.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of our credit agreement and the indentures governing our senior notes do, and our future debt instruments may, impose restrictions on us and our subsidiaries, including restrictions on our ability to, among other things, engage in acquisition and combination transactions, pay dividends on or repurchase our capital stock, engage in transactions with affiliates, or incur or guarantee indebtedness. These covenants could also adversely affect our ability to finance our future operations or capital needs and pursue available business opportunities. For additional discussion of our material debt covenants, see the &#8220;Liquidity and Capital Resources&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our credit agreement requires us to maintain specified financial ratios and satisfy certain financial condition tests. See the &#8220;Liquidity and Capital Resources&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. Although we remained in compliance with the financial ratios and financial condition tests as of December 31, 2022, we cannot provide assurance we will continue to do so. Events beyond our control, including changes in general economic and business conditions, may affect our ability to meet those financial ratios and financial condition tests. A severe downturn in earnings, failure to realize anticipated earnings from acquisitions, or, if we have outstanding borrowings under our credit facility at the time, a rapid increase in interest rates could impair our ability to comply with those financial ratios and financial condition tests and we may need to obtain waivers from the required proportion of the lenders to avoid being in default. If we try to obtain a waiver or other relief from the required lenders, we may not be able to obtain it or such relief might have a material cost to us or be on terms less favorable than those in our existing debt. If a default occurs, the lenders could exercise their rights, including declaring all the funds borrowed (together with accrued and unpaid interest) to be immediately </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due and payable, terminating their commitments or instituting foreclosure proceedings against our assets, which, in turn, could cause the default and acceleration of the maturity of our other indebtedness. A breach of any other restrictive covenants contained in our credit agreement or the indentures governing our senior notes would also (after giving effect to applicable grace periods, if any) result in an event of default with the same outcome.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, approximately 68% of our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was held by our company and its guarantor subsidiaries under its credit agreement. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements, the &#8220;Liquidity and Capital Resources&#8221; section of Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Properties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in the credit markets could adversely affect our financial condition or our growth opportunities.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2022 high yield, investment grade, and sovereign credit markets were affected by geopolitical turmoil, inflationary pressures, and changing central bank policies. These conditions resulted in unsettled credit markets for much of the year. Future market shocks, such as the status of deliberations and legislation to increase the debt ceiling in the United States, could result in reductions in the availability of certain types of debt financing, including access to revolving lines of credit. Future business needs combined with market conditions at the time may cause us to seek alternative sources of potentially less attractive financing and may require us to adjust our business plan accordingly. Tight credit markets, such as might result from further turmoil in the sovereign debt markets, would likely make additional financing more expensive and difficult to obtain. Actions by the United States Federal Reserve system, such as increasing the discount rate, may also increase the interest expense associated with our current or future borrowings. The inability to obtain additional financing at a reasonable cost could have a material adverse effect on our financial condition or our growth opportunities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of credit market uncertainty, we also face potential exposure to counterparties who may be unable to adequately service our needs, including the ability of the lenders under our credit agreement to provide liquidity when needed. We monitor the financial strength of our depositories, creditors, and insurance carriers using publicly available information, as well as qualitative inputs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_22"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">Unresolved Staff Comments</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_25"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Properties </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain our principal executive office at 9001 Liberty Parkway, Birmingham, Alabama, the lease for which expires in 2033 and has multiple renewal options for additional five-year terms. In addition to our principal executive office, we lease or own hospital locations as noted in the table below. All of our hospital leases, which represent the substantial majority of our rent expense, have at least five years remaining on their terms after taking into consideration one or more renewal options. Our consolidated entities associated with our leased hospitals are generally responsible for property taxes, property and casualty insurance, and routine maintenance expenses. We do not believe any one of our individual properties is material to our consolidated operations.</span></div><div style="margin-bottom:5pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding our hospital locations as of December&#160;31, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.707%"><tr><td style="width:1.0%"></td><td style="width:21.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of Hospitals</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">State</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Licensed Beds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Building and Land Owned</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Building Owned and Land Leased</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Building and Land Leased</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Alabama *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Arizona </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Arkansas </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Colorado</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Delaware *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Georgia *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Idaho</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Illinois *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Indiana</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Iowa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kansas</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kentucky *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Louisiana</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Maine *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Maryland *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Massachusetts *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Mississippi *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Missouri *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Nevada *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Hampshire </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Jersey *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">New Mexico</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">North Carolina *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">North Dakota</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Ohio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Oklahoma</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Puerto Rico *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">South Carolina *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">South Dakota</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Tennessee *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Utah</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Virginia *</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">West Virginia *</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,356&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;&#160;Hospital certificate of need state or U.S. territory.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inpatient rehabilitation hospitals in Augusta and Newnan, Georgia are parties to industrial development bond financings that reduce the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad valorem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> taxes payable by each hospital. In connection with each of these bond structures, title to the related property is held by the local development authority. We lease the related hospital property and hold the bonds issued by that authority, the payment on which equals the amount payable under the lease. We may terminate each bond financing and the associated lease at any time at our option without penalty, and fee title to the related hospital property will return to us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive office, hospitals, and other properties are suitable for their respective uses and are, in all material respects, adequate for our present needs. Information regarding the utilization of our licensed beds and other operating statistics can be found in Item&#160;7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_28"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Legal Proceedings</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide services in the highly regulated healthcare industry. In the ordinary course of our business, we are a party to various legal actions, proceedings, and claims as well as regulatory and other governmental audits and investigations. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These matters could potentially subject us to sanctions, damages, recoupments, fines, and other penalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these matters have been material to us in the past, and others in the future </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may, either individually or in the aggregate, be material and adverse to our business, financial position, results of operations, and liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the False Claims Act (the &#8220;FCA&#8221;) allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the FCA. These lawsuits, also known as &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, are common in the healthcare industry and can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. Therefore, from time to time, we may be party to one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the FCA.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to certain legal proceedings in which we are involved is included in Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_31"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Mine Safety Disclosures</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_37"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:42.02pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock trade on the New York Stock Exchange under the ticker symbol &#8220;EHC.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;13, 2023, there were 99,727,422 shares of Encompass Health common stock issued and outstanding, net of treasury shares, held by approximately 6,613 holders of record (participant positions at The Depository Trust Corporation plus record holders).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2023, our board of directors declared a cash dividend of $0.15 per share, payable on April 17, 2023 to stockholders of record on April 3, 2023.&#160;We expect comparable quarterly dividends to continue to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board each quarter after consideration of various factors, including our capital position and alternative uses of funds.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, as of December&#160;31, 2022, information concerning compensation plans under which our securities are authorized for issuance. The table does not reflect grants, awards, exercises, terminations, or expirations since that date. Pursuant to the terms of the equity plans, all share amounts and exercise prices have been adjusted to reflect the spin off of our home health and hospice business on July 1, 2022 and stock splits that occurred after the date on which any particular underlying plan was adopted, to the extent applicable.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:30.732%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities to be issued upon exercise of outstanding options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average exercise price of outstanding options</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of securities available for future issuance</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plans approved by stockholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,084,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,879,281&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plans not approved by stockholders</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,567&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,189,380&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,879,281&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This calculation does not take into account awards of restricted stock, restricted stock units, or performance share units.</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This amount assumes maximum performance by performance-based awards for which the performance has not yet been determined.</span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This amount represents the number of shares available for future equity grants under the 2016 Omnibus Performance Incentive Plan approved by our stockholders in May 2016. </span></div><div style="margin-bottom:10pt;padding-left:27pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This amount represents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 104,567 restr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">icted stock units issued under the 2004 Amended and Restated Director Incentive Plan, the material terms of which are described below.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2004 Amended and Restated Director Incentive Plan</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2004 Amended and Restated Director Incentive Plan (the &#8220;2004 Plan&#8221;) provided for the grant of common stock, awards of restricted common stock, and the right to receive awards of common stock, which we refer to as &#8220;restricted stock units,&#8221; to our non-employee directors. The 2004 Plan expired in March 2008 and was replaced by the 2008 Equity Incentive Plan. Some awards remain outstanding. Awards granted under the 2004 Plan at the time of its termination will continue in effect in accordance with their terms. Awards of restricted stock units were fully vested when awarded and will be settled in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of common stock on the earlier of the six-month anniversary of the date on which the director ceases to serve on the board of directors or certain change in control events. The restricted stock units generally cannot be transferred. Awards are generally protected against dilution upon the issuance of stock dividends and in the event of a stock split, recapitalization, or other major corporate restructuring.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our repurchases of equity securities during the three months ended December&#160;31, 2022:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:18.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.135%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid per Share (or Unit) ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 1 through October 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 1 through November 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 1 through December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,053,924</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Except as noted in the following sentence, the number of shares reported in this column represents shares tendered by an employee as payment of the tax liabilities incident to the vesting of previously awarded shares of restricted stock. In October, 1,418 shares were purchased pursuant to our Directors&#8217; Deferred Stock Investment Plan. This plan is a nonqualified deferral plan allowing non-employee directors to make advance elections to defer a fixed percentage of their director fees. The plan administrator acquires the shares in the open market which are then held in a rabbi trust. The plan also provides that dividends paid on the shares held for the accounts of the directors will be reinvested in shares of our common stock which will also be held in the trust. The directors&#8217; rights to all shares in the trust are nonforfeitable, but the shares are only released to the directors after departure from our board.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">On October 28, 2013, we announced our board of directors authorized the repurchase of up to $200 million of our common stock. On February 14, 2014, our board approved an increase in this common stock repurchase authorization from $200 million to $250 million. On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Stock Performance</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below is a line graph comparing the total returns of our common stock, the Standard &amp; Poor&#8217;s 500 Index (&#8220;S&amp;P 500&#8221;), and the S&amp;P Health Care Services Select Industry Index (&#8220;SPSIHP&#8221;), an equal-weighted index of at least 35 companies in healthcare services that are also part of the S&amp;P Total Market Index and subject to float-adjusted market capitalization and liquidity requirements. Our compensation committee has in prior years used the SPSIHP as a benchmark for a portion of the awards under our long-term incentive program. The graph assumes $100 invested on December&#160;31, 2017 in our common stock and each of the indices. The returns below assume reinvestment of dividends paid on the related common stock. We have paid a quarterly cash dividend on our common stock since October 2013.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in the performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC nor shall such information be deemed incorporated by reference into any future filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent we specifically incorporate it by reference into such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons in the graph below are based upon historical data and are not indicative of, nor intended to forecast, future performance of our common stock. S&amp;P Global Inc. provided the data for the indices presented below. We assume no responsibility for the accuracy of the indices&#8217; data, but we are not aware of any reason to doubt its accuracy.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Among Encompass Health Corporation, the S&amp;P 500 Index, and the S&amp;P Health Care Services Select Industry Index</span></div><div style="text-align:center"><img src="ehc-20221231_g1.jpg" alt="ehc-20221231_g1.jpg" style="height:461px;margin-bottom:5pt;vertical-align:text-bottom;width:680px"/></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Total Return</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company/Index Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass Health Corporation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.89&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.98&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.03&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.00&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.08&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.62&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.58&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SPSIHP</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_40"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.52pt">[Reserved]</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.52pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) should be read in conjunction with the accompanying consolidated financial statements and related notes. This MD&amp;A is designed to provide the reader with information that will assist in understanding our consolidated financial statements, the changes in certain key items in those financial statements from year to year, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our consolidated financial statements. See &#8220;Cautionary Statement Regarding Forward-Looking Statements and Summary of Risk Factors&#8221; on page ii of this report, which is incorporated herein by reference, for a description of important factors that could cause actual results to differ from expected results. See also Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_49"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Business</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment on an inpatient basis. We operate hospitals in 36 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of December 31, 2022, we operate 153 inpatient rehabilitation hospitals. For additional information about our business, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this report.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The onset of the COVID-19 Pandemic (the &#8220;pandemic&#8221;) in the United States resulted in significant changes to our operating environment. For discussion of the financial and operational impacts we have experienced as a result of the pandemic, see Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the &#8220;Key Challenges&#8221; and &#8220;Results of Operations&#8221; sections of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin Off of Home Health and Hospice Business</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2022, we completed the previously announced separation of our home health and hospice business through the distribution (the &#8220;Spin Off&#8221;) of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit, Inc. (&#8220;Enhabit&#8221;) to the stockholders of record of Encompass Health as of the close of business on June 24, 2022 (the &#8220;Record Date&#8221;). The Spin Off was effective at 12:01 a.m., Eastern Time, on July 1, 2022. The Spin Off was structured as a pro rata distribution of one share of Enhabit common stock for every two shares of Encompass Health common stock held of record as of the Record Date. No fractional shares were distributed. A cash payment was made in lieu of any fractional shares. As a result of the Spin Off, Enhabit is now an independent public company and its common stock is listed under the symbol &#8220;EHAB&#8221; on the New York Stock Exchange.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with applicable accounting guidance, the historical results of Enhabit have been presented as discontinued operations and, as such, have been excluded from continuing operations for all periods presented. Our presentation of discontinued operations excludes any allocation of general corporate and overhead costs as well as interest expense. Prior to July 1, 2022, we operated under two reporting segments. We now operate under a single reporting segment. For additional information see Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin Off of Home Health and Hospice Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin Off, on June 30, 2022, we entered into several agreements with Enhabit that govern the relationship of the parties following the Spin Off, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement and an Employee Matters Agreement. See also Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin Off of Home Health and Hospice Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Overview</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased 8.3% over 2021 due primarily to volume growth and increased pricing. See the &#8220;Results of Operations&#8221; section of this Item for additional financial information.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continued our development and expansion efforts in 2022. We:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Shiloh, Illinois with our joint venture partner BJC HealthCare in February 2022;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in St. Augustine, Florida in March 2022;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 60-bed inpatient rehabilitation hospital in Libertyville, Illinois in March 2022;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 50-bed inpatient rehabilitation hospital in Lakeland, Florida in May 2022;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Cape Coral, Florida with our joint venture partner Lee Healthcare Holdings, LLC in June 2022;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 50-bed inpatient rehabilitation hospital in Jacksonville, Florida in June 2022;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Grand Forks, North Dakota with our joint venture partner Altru in August 2022;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 40-bed inpatient rehabilitation hospital in Moline, Illinois with our joint venture partner UnityPoint Health &#8211; Trinity in August 2022;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">began operating our new 50-bed inpatient rehabilitation hospital in Naples, Florida in September 2022 (joint venture partnership with NCH Healthcare System began in December 2022);</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued our capacity expansions by adding 87 new beds to existing hospitals; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announced or continued the development of the following hospitals:</span></div><div style="margin-bottom:4pt;margin-top:5pt;padding-left:24.75pt;padding-right:24.75pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.286%"><tr><td style="width:1.0%"></td><td style="width:40.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of New Beds</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Eau Claire, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Knoxville, Tennessee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Owasso, Oklahoma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Clermont, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Bowie, Maryland</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prosper, Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Columbus, Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fitchburg, Wisconsin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Atlanta, Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Kissimmee, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fort Mill, South Carolina</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Louisville, Kentucky</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Johnston, Rhode Island</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Houston, Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lake Worth, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Fort Myers, Florida</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Palm Beach Gardens, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amarillo, Texas</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Strongsville, Ohio</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Norristown, Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Wildwood, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Athens, Georgia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.17pt;font-weight:400;line-height:100%;position:relative;top:-3.32pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">St. Petersburg, Florida</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Daytona Beach, Florida</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">50</span></td></tr></table></div><div style="padding-left:45pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Expected joint venture</span></div><div style="margin-bottom:10pt;margin-top:2pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Opening dates are tentative</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also continued taking steps to further increase the strength and flexibility of our balance sheet as well as augment returns from investments in operations with shareholder distributions via common stock dividends. For additional information, see the &#8220;Liquidity and Capital Resources&#8221; section of this Item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Outlook</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain optimistic regarding the intermediate and long-term prospects of our business. Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030. More specifically, the average age of our Medicare patients is approximately 76, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, inpatient rehabilitation services.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to delivering high-quality, cost-effective, integrated patient care. As the nation&#8217;s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, we believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. We also believe our competitive strengths discussed in Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Competitive Strengths,&#8221; give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry faces the prospect of ongoing efforts to transform the healthcare system to coordinated care delivery and payment models. The nature, timing and extent of that transformation remains uncertain, as the development and implementation of new care delivery and payment systems will require significant time and resources. Our goal is to position the Company in a prudent manner to be responsive to industry shifts. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2025. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our ability to adapt to changes in reimbursement, sustain our business model, and grow through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de novo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and bed additions. See also Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Competitive Strengths&#8221; and &#8220;Strategy and 2023 Strategic Priorities.&#8221;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key Challenges</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Healthcare is a highly-regulated industry facing many well-publicized regulatory and reimbursement challenges. Medicare reimbursement for inpatient rehabilitation facilities (&#8220;IRFs&#8221;) has recently undergone significant changes. The future of many aspects of healthcare regulation generally and Medicare reimbursement specifically remains uncertain. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities &#8212; change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities &#8212; to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to execute our business plan, the following are some of the key challenges we face.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Operating in a Highly Regulated Industry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. More specifically, because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new capacity to existing hospitals. Ensuring continuous compliance with extensive laws and regulations is an operating requirement for all healthcare providers. See Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Regulation&#8221; and Item&#160;1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Reimbursement Risks&#8221; and &#8220;Other Regulatory Risks&#8221; for detailed discussions of the most important regulations we face and our programs intended to ensure we comply with those regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement claims made by healthcare providers, including inpatient rehabilitation hospitals, are subject to audit from time to time by governmental payors, such as Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) and state Medicaid programs, their agents, such as the Medicare Administrative Contractors (&#8220;MACs&#8221;) that act as fiscal intermediaries for all Medicare billings, other auditors contracted by CMS, and private insurance carriers, as well as the United States Department of Health and Human Services Office of Inspector General. These audits as well as the ordinary course claim reviews of our billings result in payment denials, including recoupment of previously paid claims from current accounts receivable. Healthcare providers can challenge any denials through an administrative appeals process that can be extremely lengthy, taking several years. For additional details of these claim reviews, See Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Sources of Revenues,&#8221; Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Reimbursement Risks,&#8221; and Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues&#8221; and &#8220;Accounts Receivable,&#8221; to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Changes in Medicare Reimbursement and Regulatory Requirements for Operating IRFs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Substantially all of our business consists of inpatient rehabilitation services. From a payor perspective, our reimbursement and regulatory risk is concentrated in the Medicare inpatient rehabilitation rules and regulations. We derive approximately 65% of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from fee-for-service Medicare. </span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its annual rulemaking process for various healthcare provider categories, CMS adopts IRF reimbursement rate changes effective from October through the following September. On July 27, 2022, CMS released its notice of final rulemaking for fiscal year 2023 for IRFs (the &#8220;2023 IRF Rule&#8221;) under the inpatient rehabilitation facility prospective payment system (the &#8220;IRF-PPS&#8221;). Based on our analysis that utilizes, among other things, the acuity of our patients annualized over a twelve-month period ended June 30, 2022, our experience with outlier payments over this same time frame, and other factors, we believe the 2023 IRF Rule will result in a net increase to our Medicare payment rates of approximately 4.0% effective October 1, 2022.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress also regularly adopts legislation that directly affects Medicare reimbursement. These reimbursement changes can result in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments for IRF services. For example, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) enacted in 2010 provides for specific reductions to healthcare providers&#8217; annual reimbursement rate updates and other payment policy changes. The Budget Control Act of 2011 provides for an automatic 2% reduction, or &#8220;sequestration,&#8221; of Medicare program payments for all healthcare providers. Sequestration took effect April 1, 2013 and, as a result of subsequent legislation, will continue through mid-year 2032 unless Congress and the President take further action. In response to the public health emergency associated with the pandemic, Congress and the President suspended sequestration through March 31, 2022. Additional Medicare payment reductions are also possible under the Statutory Pay-As-You-Go Act of 2010 (&#8220;Statutory PAYGO&#8221;). Statutory PAYGO requires, among other things, that mandatory spending and revenue legislation not increase the federal budget deficit over a 5- or 10-year period. There can be no assurance that future federal rulemaking and legislation will not result in reimbursement freezes or reductions, or reimbursement increases that are less than the increases we experience in our costs of operation.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to direct changes to Medicare reimbursement rates, other federal regulatory and legislative actions affect healthcare generally and our business specifically. For example, the ACA also included provisions intended to promote alternative payment models, such as accountable care organizations (&#8220;ACOs&#8221;) and bundled payment initiatives, including the Bundled Payments for Care Improvement Initiative Advanced (&#8220;BPCI Advanced&#8221;) and the Comprehensive Care for Joint Replacement (&#8220;CJR&#8221;) program. Likewise, CMS regulatory proposals can affect our operations. On December 14, 2020, CMS announced a five-year review choice demonstration for inpatient rehabilitation services (the &#8220;IRF RCD&#8221;). The IRF RCD would affect the process in which we submit, and receive reimbursement for, Medicare claims. A number of key details on this demonstration have yet to be released, and it is not clear how or when CMS will implement this demonstration.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of changes to Medicare reimbursement, including the 2023 IRF Rule and Statutory PAYGO, and other proposed and adopted legislative and regulatory actions, including alternative payment models and the IRF RCD, that may be material to our business, see Item 1,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Reimbursement Risks&#8221; and &#8220;Other Regulatory Risks.&#8221;</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concerns held by federal policymakers about the federal deficit, national debt levels, and the solvency of the Medicare trust fund, as well as other healthcare policy priorities, could result in enactment of further federal spending reductions, further entitlement reform legislation affecting the Medicare program, and further reductions to provider payments. We cannot predict what, if any, changes in Medicare spending or modifications to the healthcare laws and regulations will result from future budget or other legislative or regulatory initiatives.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Item 1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, healthcare will almost certainly be the subject of significant regulatory and legislative changes regardless of party in control of the executive and legislative branches of state and federal governments. We will continue to evaluate these laws and regulations and position the Company for this industry shift. Based on our track record, we believe we can adapt to these regulatory and industry changes. Further, we have engaged, and will continue to engage, actively in discussions with key legislators and regulators to attempt to ensure any healthcare laws or regulations adopted or amended promote our goal of high-quality, cost-effective care.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Maintaining Strong Volume Growth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Various factors, including competition and increasing regulatory and administrative burdens, may impact our ability to maintain and grow our hospital volumes. In any particular market, we may encounter competition from local or national entities with longer operating histories or other competitive advantages, such as acute-care hospitals who provide post-acute services similar to ours or other post-acute providers with relationships with referring acute-care hospitals or physicians. Aggressive payment review practices by Medicare contractors, aggressive enforcement of regulatory policies by government agencies, and restrictive or burdensome rules, regulations or statutes governing admissions practices may lead us to not accept patients who would be appropriate for and would benefit from the services we provide. In addition, from time to time, we must get regulatory approval to expand our services and locations in states with certificate of need laws. This approval may be withheld or take longer than expected. In the case of new-store volume growth, the addition of hospitals to our portfolio also may be difficult and take longer than expected. Clinical staffing shortages, recently exacerbated by the pandemic, can also limit our ability to admit patients in a given market.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Recruiting and Retaining High-Quality Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Item 1A,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of competition for staffing, shortages of qualified personnel, and other factors that may increase our labor costs and constrain our ability to take new patients. Recruiting and retaining qualified personnel, including management, for our inpatient hospitals remain a high priority for us. We attempt to maintain a comprehensive compensation and benefits package that allows us to remain competitive in this challenging staffing environment while remaining consistent with our goal of being a high-quality, cost-effective provider of post-acute services. Additionally, our operations have been affected and may in the future be affected by staffing shortages where employees must self-quarantine due to exposure to an infectious disease, where employees are unavailable due to a lack of childcare or care for elderly family, or where competition creates a nursing shortage in a given market. These factors have resulted in increased labor costs, including significant sign-on and shift bonuses, and increased use of contract labor as discussed in the &#8220;Results of Operations&#8221; section of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain confident in the prospects of our business based on the increasing demands for the services we provide to an aging population. This confidence is further supported by our strong financial foundation and the substantial investments we have made in our business. We have a proven track record of working through difficult situations, and we believe in our ability to overcome current and future challenges.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_52"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payor Mix</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derived consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the following payor sources:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our payor mix is weighted heavily towards Medicare. We receive Medicare reimbursements under the IRF-PPS. For additional information regarding Medicare reimbursement, see the &#8220;Sources of Revenues&#8221; section of Item&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Balanced Budget Act of 1997, Congress created a program of private, managed healthcare coverage for Medicare beneficiaries. This program has been referred to as Medicare Part C, or &#8220;Medicare Advantage.&#8221; The program offers beneficiaries a range of Medicare coverage options by providing a choice between the traditional fee-for-service program (under Medicare Parts A and B) or enrollment in a health maintenance organization, preferred provider organization, point-of-service plan, provider sponsor organization, or an insurance plan operated in conjunction with a medical savings account. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consist primarily of revenues derived from patient care services. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> also include other revenues generated from management and administrative fees and other non-patient care services. These other revenues are included in &#8220;other income&#8221; in the above table.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Results</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated results of operations were as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:45.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,903.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,355.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,038.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income tax expense</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net and comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Encompass Health</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses as a % of Net Operating Revenues</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding our operating results is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 vs. 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Percentage Change)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inpatient</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,496.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient and other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Actual Amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discharges</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,116</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,639</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,897</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net patient revenue per discharge</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,139</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,220</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outpatient visits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,644</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,070</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,257</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average length of stay (days)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy %</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"># of licensed beds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,356</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,924</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,505</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full-time equivalents*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,627</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,193</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,076</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees per occupied bed</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.35</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:45pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Full-time equivalents included in the above table represent our employees who participate in or support the operations of our hospitals and include an estimate of full-time equivalents related to contract labor.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage the productive portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> utilizing certain metrics, including employees per occupied bed, or &#8220;EPOB.&#8221; This metric is determined by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by our occupancy percentage.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the discussion that follows, we use &#8220;same-store&#8221; comparisons to explain the changes in certain performance metrics and line items within our financial statements. We calculate same-store comparisons based on hospitals open throughout both the full current period and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on our results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Compared to 2021</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during 2022 compared to 2021 primarily due to increased volumes and favorable pricing. Discharge growth included a 3.1% increase in same-store discharges. Discharge growth from new stores during 2022 compared to 2021 resulted from our joint ventures in San Angelo, Texas (March 2021), Henry County, Georgia (October 2021), Shiloh, Illinois (February 2022), Cape Coral, Florida (June 2022), Moline, Illinois (August 2022), Grand Forks, North Dakota (August 2022), and Naples, Florida (September 2022), as well as wholly owned hospitals in North Tampa, Florida (April 2021), Cumming, Georgia (June 2021), Waco, Texas (August 2021), Shreveport, Louisiana (August 2021), Greenville, South Carolina (August 2021), Pensacola, Florida (September 2021), St. Augustine, Florida (March 2022), Libertyville, Illinois (March 2022), Lakeland, Florida (May 2022), and Jacksonville, Florida (June 2022). Growth in net patient revenue per discharge during 2022 compared to 2021 primarily attributable to an increase in reimbursement rates partially offset by the resumption of sequestration on April 1, 2022.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Salaries and Benefits</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are the most significant cost to us and represent an investment in our most important asset: our employees. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include all amounts paid to full- and part-time employees who directly participate in or support the operations of our hospitals, including all related costs of benefits provided to employees. It also includes amounts paid for contract labor.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in terms of dollars and as a percent of revenue in 2022 compared to 2021 primarily due to increases in contract labor and clinician compensation, including sign-on and shift bonuses, to meet higher patient volumes, and the ramping up of new stores. Total contract labor plus sign-on and shift bonuses increased approximately $70 million from $134.2 million in 2021 to $204.3 million in 2022</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include costs associated with managing and maintaining our hospitals. These expenses include such items as contract services, non-income related taxes, professional fees, utilities, insurance, and repairs and maintenance.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in terms of dollars and as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during 2022 compared to 2021 primarily due to increased provider taxes of approximately $8 million and higher costs associated with recruiting, utilities, and travel of approximately $26 million.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supplies</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expense includes all costs associated with supplies used while providing patient care. Specifically, these costs include personal protective equipment (&#8220;PPE&#8221;), pharmaceuticals, food, syringes, bandages, and other similar items.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">upplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> increased during 2022 compared to 2021 primarily due to higher costs for food and medical supplies. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily include administrative expenses such as information technology services, human resources, corporate accounting, legal services, and internal audit and controls that are managed from our home office in Birmingham, Alabama. These expenses also include stock-based compensation expenses and transaction costs.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">decreased in terms of dollars and as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> during 2022 compared to 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">primarily due to the mark-to-market adjustments on our non-qualified 401k plan, approximately $2 million related to our transition services agreement with Enhabit, and lower incentive compensation costs. For additional information on the transition services agreement with Enhabit, see Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Spin Off of Home Health and Hospice Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Depreciation and Amortization</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during 2022 compared to 2021 due to our capital investments throughout 2021 and 2022. See &#8220;Executive Overview&#8221; section of this Item for information related to our development activity. We expect </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to increase going forward as a result of our recent and ongoing capital investments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense and Amortization of Debt Discounts and Fees</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in 2022 compared to 2021 primarily resulted from the $20.5 million consent solicitation fee paid to bond holders in June 2022 related to the Spin Off of Enhabit partially offset by the March 2022 redemption of the remaining $100 million in outstanding principal amount of the 5.125% Senior Notes due 2023. Cash paid for interest approximated $178 million and $168 million in 2022 and 2021, respectively. For additional information, see Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provision for Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased in 2022 compared to 2021 primarily due to lower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income from continuing operations before income tax expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offset by increases to the valuation allowance and equity compensation shortfalls</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, technical corrections to tax depreciation methods for qualified improvement property, and deferral of employer payroll taxes. The CARES Act did not materially impact our effective tax rate for the year ended December 31, 2022 and 2021, although it has impacted the timing of cash payments for taxes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash payments for income taxes approximated $50 and $130 million, net of refunds, in 2022 and 2021, respectively. These payments were based on estimates of taxable income. We estimate we will pay approximately $85 million to $100 million of cash income taxes, net of refunds, in 2023. These payments are expected to primarily result from federal and state income tax expenses based on estimates of taxable income for 2023. In 2022 and 2021, current income tax expense was $72.2 million and $84.5 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain jurisdictions, we do not expect to generate sufficient income to use all of the available state net operating losses and other credits prior to their expiration. This determination is based on our evaluation of all available evidence in these jurisdictions including results of operations during the preceding three years, our forecast of future earnings, and prudent tax planning strategies. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable tax jurisdiction, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements and the &#8220;Critical Accounting Estimates&#8221; section of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Income Attributable to Noncontrolling Interests</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2022 compared to 2021 resulted from the ramp up of new joint venture de novo locations. For additional information see the &#8220;Executive Overview&#8221; section of this Item.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Compared to 2020</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Operating Revenues</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in 2021 compared to 2020 primarily due to increased volumes and favorable pricing.</span><span style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discharge growth included a 6.2% increase in same-store discharges. Discharge growth from new stores during 2021 resulted from our joint ventures in Coralville, Iowa (June 2020), San Angelo, Texas (March 2021), and Henry County, Georgia (October 2021), as well as wholly owned hospitals in Murrieta, California (February 2020), Sioux Falls, South Dakota (June 2020), Toledo, Ohio (November 2020), North Tampa, Florida (April 2021), Cumming, Georgia (June 2021), Waco, Texas (August 2021), Shreveport, Louisiana (August 2021), Greenville, South Carolina (August 2021), and Pensacola, Florida (September 2021). Growth in net patient revenue per discharge during 2021 compared to 2020 primarily resulted from an increase in reimbursement rates, a higher acuity patient mix and the suspension of sequestration starting in May 2020.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in outpatient and other revenue during 2021 compared to 2020 primarily resulted from an increase of $29.7 million in provider tax revenues (offset by $17.8 million of provider tax expense increases included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Salaries and Benefits</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in terms of dollars increased in 2021 compared to 2020 primarily due to salary and benefit cost increases for our employees, increased contract labor to meet higher patient volumes, and the ramping up of new stores. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and benefits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased in 2021 compared to 2020 primarily due to the additional paid-time-off awarded to employees in the second quarter of 2020 (discussed below) and improved labor productivity (contributing to lower EPOB) partially offset by higher clinician compensation costs due to staffing challenges resulting from the pandemic. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we initiated a program for eligible frontline employees to earn additional paid time off in recognition of their outstanding efforts responding to the pandemic. We accrued approximately $29 million in salary and benefits expense in the second quarter of 2020 in connection with this award.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Operating Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during 2021 compared to 2020 primarily due to the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discussed above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supplies</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">upplies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decreased as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020 primarily due to the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discussed above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">General and Administrative Expenses</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in terms of dollars during 2021 compared to 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to higher costs associated with incentive compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreased as a percent of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily due to the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as discussed above.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Depreciation and Amortization</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and amortization</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased during 2021 compared to 2020 due to our capital expenditures and development activities throughout 2020 and 2021.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Interest Expense and Amortization of Debt Discounts and Fees</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2021 compared to 2020 primarily resulted from the redemption of approximately $700 million in November 2020 for the remaining 5.75% Senior Notes due 2024 as well as the April and June 2021 redemptions of $100&#160;million in outstanding principal amount of the 5.125% Senior Notes due 2023 (the &#8220;2023 Notes&#8221;). Cash paid for interest approximated $168 million in 2021 and 2020, respectively. For additional information, see Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income from Continuing Operations Before Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pre-tax income from continuing operations in 2021 increased compared to 2020 primarily due to the increase in earnings.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Provision for Income Tax Expense</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased in 2021 compared to 2020 primarily due to higher</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income from continuing operations before income tax expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. The CARES Act, as discussed above, did not materially impact our effective tax rate for the year ended December&#160;31, 2020 and 2021, although it has impacted the timing of future cash payments for taxes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash payments for income taxes approximated $130 and $33 million, net of refunds, in 2021 and 2020, respectively. These payments were based on estimates of taxable income. In 2021 and 2020, current income tax expense was $84.5 million and $40.2 million, respectively. See Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements and the &#8220;Critical Accounting Estimates&#8221; section of this Item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Net Income Attributable to Noncontrolling Interests</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during 2021 compared to 2020 resulted from increased profitability of our existing joint ventures due to the impact of the pandemic on 2020.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of Inflation</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of inflation on the Company will be primarily in the area of labor costs. The healthcare industry is labor intensive. Wages and other expenses increase during periods of inflation and when labor shortages occur in the marketplace. There can be no guarantee we will not experience increases in the cost of labor, as the need for clinical healthcare professionals is expected to grow. In addition, increases in healthcare costs are typically higher than inflation and impact our costs under our employee benefit plans. Managing these costs remains a significant challenge and priority for us. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers pass along rising costs to us in the form of higher prices. In addition, we have experienced higher prices for our medical supplies (including PPE) and food as a result of the pandemic. Our supply chain efforts and our continual focus on monitoring and actively managing medical supplies and pharmaceutical costs has enabled us to accommodate increased pricing related to supplies and other operating expenses over the past few years. However, we cannot predict our ability to cover future cost increases including increase in the cost of PPE.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It should be noted that we have little or no ability to pass on these increased costs associated with providing services to Medicare and Medicaid patients due to federal and state laws that establish fixed reimbursement rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relationships and Transactions with Related Parties</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Related party transactions were not material to our operations in 2022, 2021, or 2020, and therefore, are not presented as a separate discussion within this Item.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_58"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are cash on hand, cash flows from operations, and borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objectives of our capital structure strategy are to ensure we maintain adequate liquidity and flexibility. Pursuing and achieving those objectives allow us to support the execution of our operating and strategic plans and weather temporary disruptions in the capital markets and general business environment. Maintaining adequate liquidity is a function of our unrestricted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our available borrowing capacity. Maintaining flexibility in our capital structure is a function of, among other things, the amount of debt maturities in any given year, the options for debt prepayments without onerous penalties, and limiting restrictive terms and maintenance covenants in our debt agreements. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with these objectives, in March 2022, we redeemed the remaining $100&#160;million in outstanding principal amount of the 2023 Notes using capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. As a result of this redemption, we recorded a $0.3&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we amended our credit agreement primarily in preparation for the Spin Off of the home health and hospice business. The modifications are described in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. On June 30, 2022, Enhabit distributed $566.6&#160;million to Encompass Health who used it to fully repay both the $250&#160;million outstanding balance of the Encompass Health revolving credit facility and approximately $236&#160;million of the Encompass Health term loan. As a result of this repayment, we recorded a $1.1&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the second quarter of 2022. In October 2022, we further amended the credit agreement primarily to extend the maturity date to October 2027. For further details on the June 2022 and October 2022 amendments to our credit agreement, see Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2025. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and we have significant availability under our revolving credit facility. We continue to generate strong cash flows from operations, and we have significant flexibility with how we choose to invest our cash and return capital to shareholders.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current Liquidity</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had $21.8 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;This amount excludes $31.6 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $110.0 million of restricted marketable securities ($30.9 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $79.1 million included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our consolidated balance sheet). Our restricted assets pertain primarily to obligations associated with our captive insurance company, as well as obligations we have under agreements with joint venture partners. See Note&#160;5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Marketable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as of December 31, 2022, we had approximately $912 million available to us under our revolving credit facility. Our credit agreement governs the substantial majority of our senior secured borrowing capacity and contains a leverage ratio and an interest coverage ratio as financial covenants. Our leverage ratio is defined in our credit agreement as the ratio of consolidated total debt (less cash on hand) to Adjusted EBITDA for the trailing four quarters. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments, subject to certain limitations, resulting from (1) dispositions and repayments or incurrence of debt and (2) investments, acquisitions, mergers, amalgamations, consolidations and other operational changes to the extent such items or effects are not yet reflected in our trailing four-quarter financial statements. Our interest coverage ratio is defined in our credit agreement as the ratio of Adjusted EBITDA to consolidated interest expense, excluding the amortization of financing fees, for the trailing four quarters. As of December 31, 2022, the maximum leverage ratio requirement per our credit agreement was 4.75x and the minimum interest coverage ratio requirement was 3.0x, and we were in compliance with these covenants. Based on Adjusted EBITDA for 2022 and the interest rate in effect under our credit agreement during the three-month period ended December 31, 2022, if we had drawn on the first day and maintained the maximum amount of outstanding draws under our revolving credit facility for the entire year, we would still be in compliance with the maximum leverage ratio and minimum interest coverage ratio requirements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 5.75% Senior Notes due 2025, 4.50% Senior Notes due 2028 (the &#8220;2028 Notes&#8221;), 4.75% Senior Notes due 2030 (the &#8220;2030 Notes&#8221;), and 4.625% Senior Notes due 2031 (the &#8220;2031 Notes&#8221; and collectively the &#8220;Notes&#8221;) for the adoption of certain amendments to an indenture (the &#8220;Base Indenture&#8221;) dated as of December 1, 2009, as supplemented by each Notes&#8217; respective supplemental indenture (together with the Base Indenture, the &#8220;Indenture&#8221;), which provided us with greater flexibility in effecting the Spin Off discussed in the &#8220;Executive Overview&#8221; section of this Item. Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture for the 2028 Notes, 2030 Notes, and 2031 Notes by $200&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $40.5 million, excluding fees. We paid $20.0 million and $20.5 million in January and June 2022, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not face near-term refinancing risk, as the amounts outstanding under our credit agreement do not mature until 2027, and our bonds all mature in 2025 and beyond. See the &#8220;Contractual Obligations&#8221; section below for information related to our contractual obligations as of December 31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate we will continue to generate strong cash flows from operations that, together with availability under our revolving credit facility, will allow us to invest in growth opportunities and continue to improve our existing business. We also will continue to consider additional shareholder value-enhancing strategies such as repurchases of our common stock and distribution of common stock dividends, including the potential growth of the quarterly cash dividend on our common stock, recognizing that these actions may increase our leverage ratio. See also the &#8220;Authorizations for Returning Capital to Stakeholders&#8221; section of this Item.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a discussion of risks and uncertainties facing us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the cash flows provided by or used in operating, investing, and financing activities of continuing operations (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(547.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(404.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(212.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2022 Compared to 2021</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of continuing operations during 2022 compared to 2021 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily resulted f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rom lower cash tax payments and improved collection of accounts receivable, including the recovery of $12.5 million of previously denied Medicare claims (as discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; to the accompanying consolidated financial statements).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of continuing operations during 2022 compared to 2021 primarily resulted from increased purchases of property and equipment and restricted investments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of continuing operations during 2022 compared to 2021 primarily resulted from increased net debt payments. For additional information, see Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2021 Compared to 2020</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of continuing operations during 2021 compared to 2020 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily resulted f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rom the decrease in payroll accruals partially offset by the increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see the &#8220;Results of Operations&#8221; section of this Item). The decrease in payroll accruals was attributable to the award of additional paid time off to employees during the second quarter of 2020 in response to the pandemic and the deferral of payroll taxes resulting from government relief efforts during the pandemic. Half of the payroll taxes were paid in December 2021, with the remaining half paid in December 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of continuing operations during 2021 compared to 2020 primarily resulted from the increased purchases of property and equipment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash used in financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of continuing operations during 2021 compared to 2020 primarily resulted from increased net debt payments partially offset by the purchase of equity interests held by management investors of our former home health and hospice business during the first quarter of 2020. For additional information, see Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated contractual obligations as of December&#160;31, 2022 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-term</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt obligations:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, excluding revolving credit facility and finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,352.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolving credit facility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on long-term debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">567.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,040.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.53pt">Included in long-term debt are amounts owed on our bonds payable and other notes payable. These borrowings are further explained in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Interest on our fixed rate debt is presented using the stated interest rate. Interest expense on our variable rate debt is estimated using the rate in effect as of December&#160;31, 2022. Interest pertaining to our credit agreement and bonds is included to their respective ultimate maturity dates. Interest related to finance lease obligations is excluded from this line (see Note&#160;8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, and Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements). Amounts exclude amortization of debt discounts, amortization of loan fees, or fees for lines of credit that would be included in interest expense in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.53pt">Amounts include interest portion of future minimum finance lease payments.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">We lease approximately 10% of our hospitals as well as other property and equipment under operating leases in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note&#160;8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Leases,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.53pt">Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on Encompass Health and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support and medical equipment. Purchase obligations are not recognized in our consolidated balance sheet.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital expenditures include costs associated with our hospital refresh program, de novo projects, capacity expansions, technology initiatives, and building and equipment upgrades and purchases. During the year ended December&#160;31, 2022, we made capital expenditures of approximately $584 million for property and equipment, capitalized software, and other intangible assets. During 2023, we expect to spend approximately $565 million to $605 million for capital expenditures using cash on hand and borrowings under our revolving credit facility. Approximately $230 million to $240 million of this budgeted amount is considered nondiscretionary expenditures, which we may refer to in other filings as &#8220;maintenance&#8221; expenditures. Actual amounts spent will be dependent upon the timing of development projects.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Authorizations for Returning Capital to Stakeholders</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, February 2022, and May 2022, our board of directors declared cash dividends of $0.28 per share that were paid in January 2022, April 2022, and July 2022, respectively. In July 2022, our board of directors revised our quarterly dividend in response to the Spin Off of Enhabit and declared a cash dividend of $0.15 per share that was paid in October 2022. Also in October 2022, our board of directors declared cash dividends of $0.15 per share that was paid in January 2023. We expect quarterly dividends to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board of directors after consideration of various factors, including our capital position and alternative uses of funds. Cash dividends are expected to be funded using cash flows from operations, cash on hand, and availability under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 28, 2013, we announced our board of directors authorized the repurchase of up to $200 million of our common stock, which amount was subsequently increased to $250 million. On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. As of December&#160;31, 2022, approximately $198 million remained under this authorization. The repurchase authorization does not require the repurchase of a specific number of shares, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule&#160;10b5-1 under the Securities Exchange Act of 1934, as amended.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supplemental Guarantor Financial Information</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness under our credit agreement and the Notes are guaranteed by certain consolidated subsidiaries. These guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. The Notes are guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The other subsidiaries of Encompass Health do not guarantee the Notes (such subsidiaries are referred to as the &#8220;non-guarantor subsidiaries&#8221;).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1)&#160;we are not in default under our credit agreement, and (2) either (a) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 2x and our leverage ratio (as defined in our credit agreement) remains less than or equal to 4.50x or (b) our leverage ratio remains in compliance with the leverage ratio covenant and there is capacity under the Available Amount as defined in the credit agreement. The terms of our Notes indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture&#8217;s restricted payments covenant to declare and pay dividends. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information is presented below for Encompass Health, the parent company, and the subsidiary guarantors on a combined basis after elimination of intercompany transactions and balances among Encompass Health and the subsidiary guarantors and does not include investments in and equity in the earnings of non-guarantor subsidiaries.</span></div><div style="margin-bottom:5pt;padding-left:3.37pt;padding-right:3.37pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,819.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany revenues generated from non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net operating revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,496.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany expenses incurred in transactions with non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:80.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany receivable due from non-guarantor subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,671.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other noncurrent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,020.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Adjusted EBITDA</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes Adjusted EBITDA as defined in our credit agreement is a measure of our ability to service our debt and our ability to make capital expenditures. We reconcile Adjusted EBITDA to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net cash provided by operating activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use Adjusted EBITDA on a consolidated basis as a liquidity measure. We believe this financial measure on a consolidated basis is important in analyzing our liquidity because it is the key component of certain material covenants contained within our credit agreement, which is discussed in more detail in Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under our credit agreement&#8212;our interest coverage ratio and our leverage ratio&#8212;could result in our lenders requiring us to immediately repay all amounts borrowed. If we anticipated a potential covenant violation, we would seek relief from our lenders, which would have some cost to us, and such relief might be on terms less favorable to us than those in our existing credit agreement. In addition, if we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to our assessment of our liquidity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as &#8220;Adjusted Consolidated EBITDA,&#8221; allows us to add back to consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> interest expense, income taxes, and depreciation and amortization and then add back to consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (1) all unusual or nonrecurring items reducing consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3)&#160;non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4)&#160;share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment debt and acquisitions, and (7) any restructuring charges and certain pro forma cost savings and synergies related to transactions and initiatives, which in the aggregate are not in excess of 25% of Adjusted Consolidated EBITDA. We also subtract from consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> all unusual or nonrecurring items to the extent they increase consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the credit agreement, the Adjusted EBITDA calculation does not require us to deduct net income attributable to noncontrolling interests or&#160;gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or&#160;unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement&#8217;s &#8220;unusual or nonrecurring&#8221; classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, our ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Adjusted EBITDA for the years ended December&#160;31, 2022, 2021, and 2020 was as follows (in millions):</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on sale of investments, excluding impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests in continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt-related items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions from nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in assets and liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by operating activities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliation of Net Income to Adjusted EBITDA</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax, attributable to Encompass Health</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal or impairment of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information see the &#8220;Results of Operations&#8221; section of this Item.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_64"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with GAAP. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures. We base our assumptions, estimates, and judgments on historical experience, current trends, and other factors we believe to be relevant at the time we prepared our consolidated financial statements. On a regular basis, we review the accounting policies, assumptions, estimates, and judgments to ensure our consolidated financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements. We believe the following accounting estimates are the most critical to aid in fully understanding and evaluating our reported financial results, as they require our most difficult, subjective, or complex judgments, resulting from the need to make estimates about the effect of matters that are inherently uncertain. We have reviewed these critical accounting estimates and related disclosures with the audit committee of our board of directors.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_67"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize net operating revenue in the reporting period in which we perform the service based on our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances (principally for patients covered by Medicare, Medicare Advantage, Medicaid, and other third-party payors), potential adjustments that may arise from payment and other reviews, and uncollectible amounts. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; to the accompanying consolidated financial statements of this report for a complete discussion of our revenue recognition policies.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patient accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Certain other factors that are considered and could influence the estimated transaction price are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes, and additional adjustments are provided to account for these factors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. In addition, laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation and review, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. However, we continually review the amounts actually collected in subsequent periods in order to determine the amounts by which our estimates differed. Historically, such differences have not been material from either a quantitative or qualitative perspective.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of outstanding receivables from third-party payors and patients is our primary source of cash and is critical to our operating performance. Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows a summary of our net accounts receivable balances as of December&#160;31, 2022 and 2021. Information on the concentration of total patient accounts receivable by payor class can be found in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Accounts Receivable,&#8221; to the accompanying consolidated financial statements.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 - 30 Days</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 - 60 Days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 - 90 Days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 - 120 Days</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 + Days</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent patient accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in general economic conditions (such as increased unemployment rates or periods of recession), business office operations, payor mix, or trends in federal or state governmental and private employer healthcare coverage could affect our collection of accounts receivable. Our collection risks include patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and co-payments) remain outstanding, pre-payment claim reviews by our respective MACs, and reimbursement claims audits by governmental or other payors and their agents. As of December 31, 2022 and 2021, $73.6 million and $77.8 million, respectively, of our patient accounts receivable represented denials that were under review or audit. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues&#8221; and &#8220;Accounts Receivable,&#8221; to the accompanying consolidated financial statements of this report.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_70"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are self-insured for certain losses related to professional liability, general liability, and workers&#8217; compensation risks. Although we obtain third-party insurance coverage to limit our exposure to these claims, a substantial portion of our professional liability, general liability, and workers&#8217; compensation risks are insured through a wholly owned insurance subsidiary. See Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for a more complete discussion of our self-insured risks.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our self-insured liabilities contain uncertainties because management must make assumptions and apply judgment to estimate the ultimate cost of reported claims and claims incurred but not reported as of the balance sheet date. Our reserves and provisions for professional liability, general liability, and workers&#8217; compensation risks are based largely upon semi-annual actuarial calculations prepared by third-party actuaries. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, we review our assumptions and the valuations provided by third-party actuaries to determine the adequacy of our self-insurance reserves. The following are certain of the key assumptions and other factors that significantly influence our estimate of self-insurance reserves: historical claims experience; trending of loss development factors; trends in the frequency and severity of claims; coverage limits of third-party insurance; demographic information; statistical confidence levels; medical cost inflation; payroll dollars; and hospital patient census.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time period to resolve claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. In addition, if current and future claims differ from historical trends, our estimated reserves for self-insured claims may be significantly affected. Our self-insurance reserves are not discounted.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the number of factors used to establish our self-insurance reserves, we believe there is limited benefit to isolating any individual assumption or parameter from the detailed computational process and calculating the impact of changing that single item. Instead, we believe the sensitivity in our reserve estimates is best illustrated by changes in the statistical confidence level used in the computations. Using a higher statistical confidence level increases the estimated self-insurance reserves. The following table shows the sensitivity of our recorded self-insurance reserves to the statistical confidence level (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.637%"><tr><td style="width:1.0%"></td><td style="width:71.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net self-insurance reserves as of December 31, 2022:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As reported, with 50% statistical confidence level</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">With 70% statistical confidence level</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our efforts to improve patient safety and overall quality of care, as well as our efforts to reduce workplace injuries, have helped contain our ultimate claim costs. See Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for additional information.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our self-insurance reserves are adequate to cover projected costs. Due to the considerable variability that is inherent in such estimates, there can be no assurance the ultimate liability will not exceed management&#8217;s estimates. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_73"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Absent any impairment indicators, we evaluate goodwill for impairment as of October 1st of each year. We test goodwill for impairment at the reporting unit level and are required to make certain subjective and complex judgments on a number of matters, including assumptions and estimates used to determine the fair value of our inpatient rehabilitation reporting unit. We assess qualitative factors in our reporting unit to determine whether it is necessary to perform the quantitative goodwill impairment test. The quantitative impairment test is required only if we conclude it is more likely than not our reporting unit&#8217;s fair value is less than its carrying amount. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If, based on our qualitative assessment, we were to believe we must perform the quantitative goodwill impairment test, we would determine the fair value of the applicable reporting unit using generally accepted valuation techniques including the income approach and the market approach. We would validate our estimates under the income approach by reconciling the estimated fair value of the reporting unit determined under the income approach to our market capitalization and estimated fair value determined under the market approach. Values from the income approach and market approach would then be evaluated and weighted to arrive at the estimated aggregate fair value of the reporting unit.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income approach includes the use of our reporting unit&#8217;s projected operating results and cash flows that are discounted using a weighted-average cost of capital that reflects market participant assumptions. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted period including assumptions for pricing and volume, operating expenses, and capital expenditures. Other significant estimates and assumptions include cost-saving synergies and tax benefits that would accrue to a market participant under a fair value methodology. The market approach estimates fair value through the use of observable inputs, including the Company&#8217;s stock price.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Goodwill and Other Intangibles,&#8221; and Note&#160;9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for additional information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following events and circumstances are certain of the qualitative factors we consider in evaluating whether it is more likely than not the fair value of a reporting unit is less than its carrying amount:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">macroeconomic conditions, such as deterioration in general economic conditions, limitations on accessing capital, or other developments in equity and credit markets;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry and market considerations and changes in healthcare regulations, including reimbursement and compliance requirements under the Medicare and Medicaid programs;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost factors, such as an increase in labor, supply, or other costs;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall financial performance, such as negative or declining cash flows or a decline in actual or forecasted revenue or earnings;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other relevant company-specific events, such as material changes in management or key personnel or outstanding litigation;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">material events, such as a change in the composition or carrying amount of each reporting unit&#8217;s net assets, including acquisitions and dispositions;</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consideration of the relationship of our market capitalization to our book value, as well as a sustained decrease in our share price; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">length of time since most recent quantitative analysis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we performed our annual evaluation of goodwill and determined no adjustment to impair goodwill was necessary. If actual results are not consistent with our assumptions and estimates, we may be exposed to goodwill impairment charges. However, at this time, we continue to believe our inpatient rehabilitation unit is not at risk for any impairment charges.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_76"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the asset and liability method. We also evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Income Taxes,&#8221; and Note&#160;16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for a more complete discussion of income taxes and our policies related to income taxes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application of income tax law is inherently complex. Laws and regulations in this area are voluminous and are often ambiguous. We are required to make many subjective assumptions and judgments regarding our income tax exposures. Interpretations of and guidance surrounding income tax laws and regulations change over time. As such, changes in our subjective assumptions and judgments can materially affect amounts recognized in our consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate recovery of certain of our deferred tax assets is dependent on the amount and timing of taxable income we will ultimately generate in the future, as well as other factors. A high degree of judgment is required to determine the extent a valuation allowance should be provided against deferred tax assets. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our operating performance in recent years, the scheduled reversal of temporary differences, our forecast of taxable income in future periods in each applicable tax jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment. Our forecast of future earnings includes assumptions about patient volumes, payor reimbursement, labor costs, hospital operating expenses, and interest expense. Based on the weight of available evidence, we determine if it is more likely than not our deferred tax assets will be realized in the future.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liability for unrecognized tax benefits contains uncertainties because management is required to make assumptions and to apply judgment to estimate the exposures associated with our various filing positions which are periodically audited by tax authorities. In addition, our effective income tax rate is affected by changes in tax law, the tax jurisdictions in which we operate, and the results of income tax audits.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, we decreased our valuation allowance by $7.3 million. As of December&#160;31, 2022, we had a remaining valuation allowance of $35.8 million which primarily related to state net operating losses. At the state jurisdiction level, we determined it was necessary to maintain a valuation allowance due to uncertainties related to our ability to utilize a portion of the net operating losses before they expire. The amount of the valuation allowance has been determined for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each tax jurisdiction based on the weight of all available evidence, as described above, including management&#8217;s estimates of taxable income for each jurisdiction in which we operate over the periods in which the related deferred tax assets will be recoverable.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While management believes the assumptions included in its forecast of future earnings are reasonable and it is more likely than not the net deferred tax asset balance as of December&#160;31, 2022 will be realized, no such assurances can be provided. If management&#8217;s expectations for future operating results on a consolidated basis or at the state jurisdiction level vary from actual results due to changes in healthcare regulations, general economic conditions, or other factors, we may need to increase our valuation allowance, or reverse amounts recorded currently in the valuation allowance, for all or a portion of our deferred tax assets. Similarly, future adjustments to our valuation allowance may be necessary if the timing of future tax deductions is different than currently expected. Our income tax expense in future periods will be reduced or increased to the extent of offsetting decreases or increases, respectively, in our valuation allowance in the period when the change in circumstances occurs. These changes could have a significant impact on our future earnings.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_79"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assessment of Loss Contingencies</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have legal and other contingencies that could result in significant losses upon the ultimate resolution of such contingencies. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Litigation Reserves,&#8221; and Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements for additional information.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have provided for losses in situations where we have concluded it is probable a loss has been or will be incurred and the amount of loss is reasonably estimable. A significant amount of judgment is involved in determining whether a loss is probable and reasonably estimable due to the uncertainty involved in determining the likelihood of future events and estimating the financial statement impact of such events. If further developments or resolution of a contingent matter are not consistent with our assumptions and judgments, we may need to recognize a significant charge in a future period related to an existing contingent matter.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_85"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding recent accounting pronouncements, see Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the accompanying consolidated financial statements.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_88"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.3pt">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our primary exposure to market risk is to changes in interest rates on our variable rate long-term debt. We use a sensitivity analysis model to evaluate the impact of interest rate changes on our variable rate debt. As of December&#160;31, 2022, our primary variable rate debt outstanding related to $55.0 million in advances under our revolving credit facility. Assuming outstanding balances were to remain the same, a 1% increase in interest rates would result in an incremental negative cash flow of approximately $0.6 million over the next 12 months, while a 1% decrease in interest rates, assuming a floor of zero in the variable rate index, would result in an incremental positive cash flow of approximately $0.6 million over the next 12 months. HCS, Ltd., our wholly owned insurance captive maintains positions in investment securities for other than trading purposes, which, as of December 31, 2022, had a fair market value of approximately $110 million. Changes in the value of these securities is recorded in the accompanying consolidated statements of comprehensive income. During the year ended December&#160;31, 2022, we recorded an unrealized loss of $7.4 million pertaining to these securities. For additional information, see Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Cash and Marketable Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Note&#160;13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to the accompanying consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our fixed rate debt is determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy, and is summarized as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Instrument:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Book Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Book Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign operations, and the related market risks associated with foreign currencies, are currently, and have been, insignificant to our financial position, results of operations, and cash flows. See also Note&#160;10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Long-term Debt,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Note&#160;13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the accompanying consolidated financial statements.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_91"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.52pt">Financial Statements and Supplementary Data</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements and related notes are filed together with this report. See the index to financial statements on page F-1 for a list of financial statements filed with this report.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_94"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.52pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_97"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.3pt">Controls and Procedures</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this report, an evaluation was carried out by our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;). Our disclosure controls and procedures are designed to ensure that information required to be disclosed in reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, to allow timely decisions regarding required disclosures. Based on our evaluation, our chief executive officer and chief financial officer concluded that, as of December&#160;31, 2022, our disclosure controls and procedures were effective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on its financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an assessment of the effectiveness of our internal control over financial reporting as of December&#160;31, 2022. In making this assessment, management used the criteria set forth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, the COSO framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on our evaluation, our chief executive officer and chief financial officer concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in the Company&#8217;s internal controls over financial reporting that occurred during the quarter ended December&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_100"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">Other Information</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_103"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. &#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to file a definitive proxy statement relating to our 2023 Annual Meeting of Stockholders (the &#8220;2023 Proxy Statement&#8221;) with the United States Securities and Exchange Commission, pursuant to Regulation 14A, not later than 120 days after the end of our most recent fiscal year. Accordingly, certain information required by Part&#160;III has been omitted under General Instruction G(3) to Form 10-K. Only the information from the 2023 Proxy Statement that specifically addresses disclosure requirements of Items&#160;10-14 below is incorporated by reference.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_109"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Directors and Executive Officers of the Registrant</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;10 is hereby incorporated by reference from our 2023 Proxy Statement under the captions &#8220;Items of Business Requiring Your Vote&#8212;Proposal 1&#8212;Election of Directors,&#8221; &#8220;Corporate Governance and Board Structure&#8212;Corporate Governance&#8212;Code of Ethics,&#8221; &#8220;&#8212;Board Structure and Committees&#8212;Audit Committee,&#8221; &#8220;&#8212;Board Composition and Director Nomination Process&#8212;Director Nominees Proposed by Stockholders,&#8221; and &#8220;Executive Officers.&#8221;</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_112"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Executive Compensation </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;11 is hereby incorporated by reference from our 2023 Proxy Statement under the captions &#8220;Corporate Governance and Board Structure&#8212;Compensation of Directors,&#8221; &#8220;Compensation and Human Capital Committee Matters,&#8221; and &#8220;Executive Compensation.&#8221;</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_115"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;12 is hereby incorporated by reference from our 2023 Proxy Statement under the captions &#8220;Executive Compensation&#8212;Equity Compensation Plans&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221;</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_118"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Certain Relationships and Related Transactions and Director Independence </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;13 is hereby incorporated by reference from our 2023 Proxy Statement under the captions &#8220;Corporate Governance and Board Structure&#8212;Director Independence&#8221; and &#8220;Certain Relationships and Related Transactions.&#8221;</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_121"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Principal Accountant Fees and Services </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item&#160;14 is hereby incorporated by reference from our 2023 Proxy Statement under the caption &#8220;Items of Business Requiring Your Vote&#8212;Proposal 2&#8212;Ratification of Appointment of Independent Registered Public Accounting Firm.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_127"></div><div style="margin-bottom:10pt;padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See the accompanying index on page F-1 for a list of financial statements filed as part of this report.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statement Schedules</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Exhibit Index immediately following page F-53 of this report.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_130"></div><div style="margin-bottom:10pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:37.02pt">Form 10-K Summary</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ENCOMPASS HEALTH CORPORATION</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160; M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mark J. Tarr</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">[Signatures continue on the following page]</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose signature appears below hereby constitutes and appoints Patrick Darby his true and lawful attorney-in-fact and agent with full power of substitution and re-substitution, for him in his name, place and stead, in any and all capacities, to sign any and all amendments to this Report and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:32.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.539%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Capacity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark J. Tarr</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Douglas E. Coltharp</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">NDREW</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">RICE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Andrew L. Price</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ONALD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> L. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ORRELL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Donald L. Correll</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">REG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> D. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARMICHAEL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Greg D. Carmichael</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OHN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W. C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HIDSEY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John W. Chidsey</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OAN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ERMAN</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joan E. Herman</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ESLYE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> G. K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ATZ</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leslye G. Katz</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ATRICIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARYLAND</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patricia A. Maryland</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EVIN </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">O&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CONNOR</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kevin J. O&#8217;Connor</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">HRISTOPHER </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EIDY</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher R. Reidy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;N</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ANCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M. S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">CHLICHTING</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nancy M. Schlichting</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ERRANCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ILLIAMS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terrance Williams</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="padding-left:67.5pt;text-indent:-67.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:32.52pt">Financial Statements</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_139">Report of Independent Registered Public Accounting Firm (PCAOB ID </a></span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xMzYvZnJhZzphOTM0NTM4OTRmNjQ0M2Y1OTUwYjk5NzRlZjYyYTVmNi90YWJsZTozOTI0MzNmM2U2ZDg0NWNjYTIyNTE1M2QzYjBhMDQ5Mi90YWJsZXJhbmdlOjM5MjQzM2YzZTZkODQ1Y2NhMjI1MTUzZDNiMGEwNDkyXzAtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MzA5ZmNlZDlkYzlhNGZkNTllMWM2MjNlMjJiNTQ0YWJfNzE_fea08ed4-43e3-4b3d-bca1-3119941e8adb">238</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_139">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_139">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_142">Consolidated Statements of Comprehensive Income for each of the years in the three-year period ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_142"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_142">December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_142">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_148">Consolidated Balance Sheets as of December&#160;31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_148">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_151">Consolidated Statements of Shareholders&#8217; Equity for each of the years in the three-year period ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_151"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_151">December 31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_151">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_154">Consolidated Statements of Cash Flows for each of the years in the three-year period ended</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_154"><br/></a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_154">December&#160;31, 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_154">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_157">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_157">10</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Encompass Health Corporation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Encompass Health Corporation and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related consolidated statements of comprehensive income, of shareholders' equity and of cash flows for each of the three years in the period ended December 31, 2022, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Internal Control - Integrated Framework </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control Over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Patient Accounts Receivable - Contractual Allowances and Uncollectible Amounts</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 1 and 6 to the consolidated financial statements, revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on management&#8217;s estimate of the respective transaction price.  Management&#8217;s estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts.  Revenues recognized are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related patient accounts receivable.  Factors considered by management in determining the estimated transaction price include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors.  Management assumes these factors will remain consistent with the experience for patients discharged in similar time periods for the same payor classes.  The Company&#8217;s consolidated accounts receivable balance is $610.1 million as of December 31, 2022.  Management estimates the allowance for uncollectible amounts based on the aging of accounts receivable, historical collection experience for each type of payor, and other relevant factors. As disclosed by management, changes in general economic conditions are also considered.      </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the valuation of patient accounts receivable &#8211; contractual allowances and uncollectible amounts is a critical audit matter are the significant judgment by management to estimate patient accounts receivable and the amount that will ultimately be collected under the terms of the third-party payor contracts, which in turn led to significant auditor judgment and effort to evaluate the audit evidence obtained related to the valuation of patient accounts receivable.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of patient accounts receivable related to contractual allowances and uncollectible amounts, which included controls over management&#8217;s process, assumptions, and data used to estimate contractual allowances and uncollectible amounts and determine patient accounts receivable. These procedures also included, among others, i) evaluating management&#8217;s process for developing the estimate for contractual allowances and uncollectible amounts, ii) testing the completeness and accuracy of underlying data used in the model, iii) evaluating the historical accuracy of management&#8217;s process for developing the estimate of the amount which will ultimately be collected by comparing actual cash collections to the previously recorded patient accounts receivable, and iv) developing an independent expectation of the amount expected to be collected by management.  Developing an independent expectation involved calculating the percentage of cash collections as compared to the recorded patient accounts receivable balance for prior years and comparing that percentage to management&#8217;s collection expectation used to determine the current year estimate for contractual allowances and uncollectible amounts.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Patient Accounts Receivable - Denied Claims</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 1 to the consolidated financial statements, the Company&#8217;s Medicare claims have been subject to review by Medicare Administrative Contractors (&#8220;MACs&#8221;) under various programs such as &#8220;widespread probes&#8221; and the Targeted Probe and Educate initiative.   The MACs reviews have resulted in denial of payment for claims billed under certain diagnosis codes.   As of December 31, 2022, $73.6 million of the Company&#8217;s patient accounts receivable represented denials that were under review or audit.  While the Company generally appeals most of the denials of claims by the MACs, the Medicare appeals adjudication process, which is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;), has been subject to significant delay resulting in a backlog of claims awaiting hearing, the resolution of which may take several years. As disclosed in Note 1, the Company&#8217;s historical experience and success in the adjudication of these appeals is a component of management&#8217;s estimate of the transaction price. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the valuation of patient accounts receivable &#8211; denied claims is a critical audit matter are the significant judgment by management to estimate the ultimate expected amount of collectible accounts receivable related to denied claims. This in turn led to a high degree of auditor judgment and effort to evaluate the audit evidence obtained related to the valuation of such denied claims.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of patient accounts receivable related to denied claims, which included controls around the identification of denied claims at period-end, as well as controls to assess the reasonableness of the success rate estimates.  These procedures also included, among others, i) evaluating management&#8217;s process for developing the estimate for collectible amounts related to denied claims, as well as the relevance and use of the historical billing and collection data as an input to the valuation analysis, ii) evaluating the reasonableness of management&#8217;s analysis and success rate estimate for denied claims by comparing it to the Company&#8217;s adjudicated denied claim results, iii) performing testing over a sample of denied revenue transactions by inspecting evidence that the claim was denied, and iv) performing testing over a sample of cash collections from the historical collection data used in management&#8217;s estimation of collectability.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xMzkvZnJhZzo0MTY3Mzk4ZWFkZjQ0MzU0OTY0ZTFlYzZkMWM3YjJjMy90ZXh0cmVnaW9uOjQxNjczOThlYWRmNDQzNTQ5NjRlMWVjNmQxYzdiMmMzXzEzMTM3_a9ef749b-1c73-4cfc-89cc-be9701cae818">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xMzkvZnJhZzo0MTY3Mzk4ZWFkZjQ0MzU0OTY0ZTFlYzZkMWM3YjJjMy90ZXh0cmVnaW9uOjQxNjczOThlYWRmNDQzNTQ5NjRlMWVjNmQxYzdiMmMzXzEzMTM4_5cfd4daa-e1d6-495c-8282-fb66020a6184">Birmingham, Alabama</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;27, 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2003.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Comprehensive Income</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.029%"><tr><td style="width:1.0%"></td><td style="width:60.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.207%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMtMS0xLTEtMjQ1NDc3_54aa3f78-6d00-43d9-b63d-aa4b1ae9455a">4,348.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMtMy0xLTEtMjQ1NDc3_111b9e84-fe08-4ce8-975c-cd4a558d6e66">4,014.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMtNS0xLTEtMjQ1NDc3_79e8e791-9e59-4545-9389-18da2fac2284">3,566.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzUtMS0xLTEtMjQ1NDc3_171d7f6d-c304-4a43-9ef2-6c5258dde490">2,393.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzUtMy0xLTEtMjQ1NDc3_071cafc5-1611-44db-b334-943231a542b4">2,127.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:LaborAndRelatedExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzUtNS0xLTEtMjQ1NDc3_e36fe79b-e31c-463f-a697-acc229ecd77d">1,903.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzYtMS0xLTEtMjQ1NDc3_4dd23c5b-9afb-4bd2-a829-cbddaa93e275">670.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzYtMy0xLTEtMjQ1NDc3_d584b926-0db1-4af5-8df2-706b409dce4b">595.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzYtNS0xLTEtMjQ1NDc3_431829b8-6b60-4aa0-883e-9dda3a72d588">545.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzctMS0xLTEtMjQ1NDc3_30cb2181-2425-4457-924b-c87c2dca22c7">54.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzctMy0xLTEtMjQ1NDc3_edb0d047-98a6-42b1-bc4f-daf91c4d5159">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="ehc:OccupancyCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzctNS0xLTEtMjQ1NDc3_c3c554cb-d5cf-4995-b213-aec4f751ad16">61.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzgtMS0xLTEtMjQ1NDc3_09a96b97-a836-4528-a0b2-2d5484cbf497">202.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzgtMy0xLTEtMjQ1NDc3_66e4c506-5a9b-4f96-a575-0387b91365fc">184.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:SuppliesExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzgtNS0xLTEtMjQ1NDc3_ead2a824-cd16-406e-9a23-c718e1b6247f">171.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzktMS0xLTEtMjQ1NDc3_07631287-3ccb-4715-96f8-0ae4d9ecb59e">154.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzktMy0xLTEtMjQ1NDc3_ef0afb01-c223-44bb-8343-8faad40400e7">169.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzktNS0xLTEtMjQ1NDc3_6b3705ec-c989-4f7c-9a01-8b4292fe0c9f">151.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEwLTEtMS0xLTI0NTQ3Nw_0b7216e8-7393-4ca8-a9ac-8cf607098987">243.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEwLTMtMS0xLTI0NTQ3Nw_680f5427-e990-4103-ab46-f0f9dd95b9a6">219.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEwLTUtMS0xLTI0NTQ3Nw_43250cb4-ceb0-4c0c-8511-5f031a32ae9d">203.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government, class action, and related settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzExLTEtMS0xLTI0NTQ3Nw_3afdc08c-8cb3-4fab-bff0-5b8f3af8f0d1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzExLTMtMS0xLTI0NTQ3Nw_108effc8-ad7a-4577-a667-ca9a21742e42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzExLTUtMS0xLTI0NTQ3Nw_29e97e35-4ca9-4e57-bbe4-6f7653fcce07">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEzLTEtMS0xLTI0NTQ3Nw_fe5a4ff7-a14b-4c50-a946-57cdf329fa1d">3,718.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEzLTMtMS0xLTI0NTQ3Nw_a75e574b-c9bd-4420-ac89-f8a56070841c">3,355.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEzLTUtMS0xLTI0NTQ3Nw_04ce113c-ce8e-408a-bab5-85e471864ab9">3,038.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE0LTEtMS0xLTI0NTQ3Nw_2283992f-5959-46e2-9aac-8c599a6d269e">1.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE0LTMtMS0xLTI0NTQ3Nw_5f8fa545-1c5d-4a8a-8a3e-859b5e42b43b">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE0LTUtMS0xLTI0NTQ3Nw_89d8a64d-6fb8-42f3-bfcb-a72d00a4e9cf">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE1LTEtMS0xLTI0NTQ3Nw_143ca982-e3bf-44ff-be9f-67a3a5df9e50">175.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE1LTMtMS0xLTI0NTQ3Nw_7859ae82-2712-4b33-83ca-2ae7fbdfe438">164.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE1LTUtMS0xLTI0NTQ3Nw_7215aa7f-d283-4c37-90fb-c6828bcc8f1c">183.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE2LTEtMS0xLTI0NTQ3Nw_a4c35f03-1eb1-4f99-8979-08444888dbda">5.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE2LTMtMS0xLTI0NTQ3Nw_a722de5e-7d05-4721-ac65-6dd410e24b89">7.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE2LTUtMS0xLTI0NTQ3Nw_b4594731-b523-47d1-9a7a-857085c9e65c">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE3LTEtMS0xLTI0NTQ3Nw_76822d18-d70b-4ee1-b2fa-d4368773fffe">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE3LTMtMS0xLTI0NTQ3Nw_ff1f261f-c5b7-4046-8e79-56d19e835182">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE3LTUtMS0xLTI0NTQ3Nw_5dc7690f-821c-4277-90f6-a7bea7dbe350">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE4LTEtMS0xLTI0NTQ3Nw_4ffc3a30-905d-4f0d-98bc-e5a3303e0115">450.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE4LTMtMS0xLTI0NTQ3Nw_3667419f-847b-434e-9aa5-03b4e9c145f6">505.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE4LTUtMS0xLTI0NTQ3Nw_7e9681a6-2880-4b29-897f-c93f7d7260fa">352.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE5LTEtMS0xLTI0NTQ3Nw_9ac0684c-65ec-4ed6-8d74-23ac301be00e">100.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE5LTMtMS0xLTI0NTQ3Nw_eae4f1a4-96c2-479b-9a28-a7303bae17ed">101.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE5LTUtMS0xLTI0NTQ3Nw_2733090c-159e-4f94-9eaf-61eb6d7a6618">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIwLTEtMS0xLTI0NTQ3Nw_c452a07d-286b-4730-b3fe-1d351e74922b">350.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIwLTMtMS0xLTI0NTQ3Nw_a759378e-e5b6-4e14-a915-6a0aff29d6de">403.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIwLTUtMS0xLTI0NTQ3Nw_bf018744-7752-47d9-905e-0162c63d7920">278.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIxLTEtMS0xLTI0NTQ3Nw_a4ebbd93-daf6-46d6-b3ec-4442afaa7284">15.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIxLTMtMS0xLTI0NTQ3Nw_7284edb9-ba97-4821-b72a-c11eb5739af2">114.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIxLTUtMS0xLTI0NTQ3Nw_2057d3b9-421a-4a81-a0a3-a2dd68758239">90.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net and comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTEtMS0xLTI0NTQ3Nw_66836bbc-6ce8-49d9-ad9b-8e0957b76207"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTEtMS0xLTI0NTQ3Nw_9c60111d-c02b-4670-ac65-efd412e31cfc">365.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTMtMS0xLTI0NTQ3Nw_221d0cee-6bce-4bbc-bff1-26de1c140554"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTMtMS0xLTI0NTQ3Nw_a66e61f9-6790-453e-9744-7c3a4d24a96e">517.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTUtMS0xLTI0NTQ3Nw_07d5bfe1-13a7-4e67-a5be-0c2c279dfafc"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTUtMS0xLTI0NTQ3Nw_1b78fbd0-d9df-4c6d-8424-3fc4180d4b08">368.8</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTEtMS0xLTI2NzM5OQ_e4108caa-fb96-4413-8937-aedadb4ed4a4">93.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTMtMS0xLTI2NzM5OQ_982ac596-f6c5-474d-b86f-255443353594">103.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTUtMS0xLTI2NzM5OQ_d99a666b-0a54-405a-adbf-93077a39e0f9">83.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTEtMS0xLTI2NzM5OQ_b6dea59d-0cce-46aa-935b-abecd88c21d2">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTMtMS0xLTI2NzM5OQ_3b9a6836-8b6b-4141-b2af-5c944464d20b">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTUtMS0xLTI2NzM5OQ_f9d2cace-0c36-4ab3-997b-dcb20e4286ad">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net and comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTEtMS0xLTI0NTQ3Nw_4e989b67-af15-4b18-9764-d2fd74b4ad8a"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTEtMS0xLTI0NTQ3Nw_d8eef829-e9b8-43b0-a1dc-e423f4003eae">94.9</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTMtMS0xLTI0NTQ3Nw_c2b132f9-2e69-4697-9f8d-17e9ac55c0be"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTMtMS0xLTI0NTQ3Nw_c5b94c1c-0d7c-4f73-a49e-716a4201efaf">105.0</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTUtMS0xLTI0NTQ3Nw_06329c02-f1e0-4241-bdee-42309e93aa25"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTUtMS0xLTI0NTQ3Nw_406f0e08-60c8-44d9-9d10-8c5a5dcbc687">84.6</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net and comprehensive income attributable to Encompass </span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTEtMS0xLTI0NTQ3Nw_6d2e3f49-4ee5-45d4-8c14-8b1e727dc67b"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTEtMS0xLTI0NTQ3Nw_8d4616d3-70b2-4aac-a337-68d51eda5f9f">271.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTMtMS0xLTI0NTQ3Nw_62105382-7c3f-4743-bec2-27b57aab7afe"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTMtMS0xLTI0NTQ3Nw_de2134b9-20ec-4d0e-b406-66b1aff742c3">412.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTUtMS0xLTI0NTQ3Nw_38586f15-ed3b-4fb1-b6b3-7ec2a0eae7fe"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTUtMS0xLTI0NTQ3Nw_3bccf2b9-d9ed-48e5-9a1f-cdbbc2abcfe2">284.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMwLTEtMS0xLTI0NTQ3Nw_499e4b64-1f4e-4545-b4a5-5de70ab14d5b">99.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMwLTMtMS0xLTI0NTQ3Nw_899b2b01-637b-4b9b-8e4b-1f4320e447b0">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMwLTUtMS0xLTI0NTQ3Nw_b5041217-c1fb-4954-bde9-915915af9b9f">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMxLTEtMS0xLTI0NTQ3Nw_098a77b5-986f-438d-a8f3-d6c843e9b822">100.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMxLTMtMS0xLTI0NTQ3Nw_6b0c49a6-a65d-4efa-bd50-d48654fd980e">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMxLTUtMS0xLTI0NTQ3Nw_5ea198ac-9c84-4a1f-856b-310c8761142f">99.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM0LTEtMS0xLTI0NTQ3Nw_a2d2cd45-78c9-4c9b-a840-2df1a93fe2c6">2.58</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM0LTMtMS0xLTI0NTQ3Nw_22977fa4-cc50-4384-8ce4-2a004a40f843">3.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM0LTUtMS0xLTI0NTQ3Nw_5efb5b0f-169a-43b0-9921-4b603b2620a8">1.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM1LTEtMS0xLTI0NTQ3Nw_0a481894-168f-413e-b02c-0eb2edbe4a20">0.14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM1LTMtMS0xLTI0NTQ3Nw_3c8b0ef4-ee9c-4795-b121-0c6cc37ce327">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM1LTUtMS0xLTI0NTQ3Nw_1ea8f8ac-7a76-4ed9-a949-9e2aeeefa567">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM2LTEtMS0xLTI0NTQ3Nw_ac196598-3cee-40e4-b43a-915eb1a37e97">2.72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM2LTMtMS0xLTI0NTQ3Nw_b18e2da1-f883-48e1-a571-b34ff375e8fc">4.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM2LTUtMS0xLTI0NTQ3Nw_c3aacfd5-c69a-4fcc-acd5-84ea4adac313">2.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM4LTEtMS0xLTI0NTQ3Nw_333afb70-e701-46d7-b972-096c39359d02">2.56</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM4LTMtMS0xLTI0NTQ3Nw_433c0c4b-ad4a-4d99-b5d3-3e36352647bd">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM4LTUtMS0xLTI0NTQ3Nw_5223cdb8-ff8e-4f5c-bc92-06fe77396e9b">1.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM5LTEtMS0xLTI0NTQ3Nw_f5945820-28f4-4f1e-bf7c-25c44a1e4b09">0.14</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM5LTMtMS0xLTI0NTQ3Nw_389a4557-368d-431d-9ee2-5729fcc67d9d">1.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM5LTUtMS0xLTI0NTQ3Nw_cf4c57fe-0d7f-493b-be1a-b4bb78e38201">0.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:33.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQwLTEtMS0xLTI0NTQ3Nw_9d41405c-9367-48ad-83ad-d5600aaed261">2.70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQwLTMtMS0xLTI0NTQ3Nw_8d9a0aeb-a865-437a-bf16-efffc8506aa6">4.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQwLTUtMS0xLTI0NTQ3Nw_1602b038-5ab6-44fa-a09b-4cc4c8409e60">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts attributable to Encompass Health:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQzLTEtMS0xLTI0NTQ3Nw_96f24f91-e650-4882-b1e4-a5a05418f3e9">257.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQzLTMtMS0xLTI0NTQ3Nw_ea0bc75e-6595-4103-bd24-235f3d1ab8e1">299.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQzLTUtMS0xLTI0NTQ3Nw_92eaf174-cd14-45fe-9cb1-86ebabf18194">194.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ0LTEtMS0xLTI0NTQ3Nw_cb97de49-e66d-45ff-a4d5-3d6241523cb7">13.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ0LTMtMS0xLTI0NTQ3Nw_472d4b80-b66c-48db-a4d2-534a0a750f4e">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ0LTUtMS0xLTI0NTQ3Nw_4e5d61e7-638c-4ac7-b10c-88f26e00bc1b">89.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ1LTEtMS0xLTI0NTQ3Nw_d4618e14-93c2-4380-9c84-f75a31c931ba">271.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ1LTMtMS0xLTI0NTQ3Nw_8b62c464-c3f2-41af-97dd-f97d8820e3da">412.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ1LTUtMS0xLTI0NTQ3Nw_14fab8af-9d0f-4793-9b9b-1b160932531f">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to consolidated financial statements are an integral part of these statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_148"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheets</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In Millions, Except Share Data)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzUtMS0xLTEtMjQ1NDc3_86b3d9ca-f8f2-4c87-b278-d90cece2b958">21.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzUtMy0xLTEtMjQ1NDc3_37bc64b6-fe69-4153-9260-bff0af84a332">49.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzYtMS0xLTEtMjQ1NDc3_6f088b6a-cade-400b-b87a-df6c9730f387">31.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzYtMy0xLTEtMjQ1NDc3_60d05a54-13a6-443d-85d2-a8ca9fc141a8">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzctMS0xLTEtMjQ1NDc3_1cd845bb-c6c8-4d0c-a251-b4632ea717db">536.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzctMy0xLTEtMjQ1NDc3_f3f09513-3797-40b6-8432-8f0f7456fc2a">515.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzgtMS0xLTEtMjQ1NDc3_a552fb9d-0706-45f0-bfd2-452778b5e0dd">127.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzgtMy0xLTEtMjQ1NDc3_0673f2d7-efd9-44c6-b96d-2520f0ef126d">114.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzktMS0xLTEtMjY3NDMz_5c76ee53-da02-4bc6-8811-61a48705b3ef">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzktMy0xLTEtMjY3NDMz_0b5ec563-3608-44df-aa77-c3e7b619fdd3">178.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzktMS0xLTEtMjQ1NDc3_d5fc56ff-7a6a-4a6a-bab5-9a441eda7908">717.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzktMy0xLTEtMjQ1NDc3_b3e21b76-98b3-4e47-b2ca-2a653dbcc2d1">921.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEwLTEtMS0xLTI0NTQ3Nw_21ef86a6-8a27-49f5-b498-c40782a0019f">2,939.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEwLTMtMS0xLTI0NTQ3Nw_af185ce1-20ca-4ba1-aed5-3fb1b2887701">2,581.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzExLTEtMS0xLTI0NTQ3Nw_5a256901-859b-4fba-b93a-e7e2f057465f">212.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzExLTMtMS0xLTI0NTQ3Nw_4b56d7b8-e5ce-4adf-8a3a-5dd330c412a4">193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEyLTEtMS0xLTI0NTQ3Nw_43a714b2-1c18-4ced-89ee-aa15796b92b4">1,263.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEyLTMtMS0xLTI0NTQ3Nw_7e5cf555-dea5-4f38-964a-1658cc2ec3e7">1,237.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEzLTEtMS0xLTI0NTQ3Nw_1af6bf1d-1840-44d8-99cc-c6df6cb78a65">282.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEzLTMtMS0xLTI0NTQ3Nw_76a22dd9-248d-4a6b-9f8e-bc74432fb359">158.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE1LTEtMS0xLTI0NTQ3Nw_172861eb-0633-497f-a4c8-b8a13dd8f497">222.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE1LTMtMS0xLTI0NTQ3Nw_a11eb64d-4134-400f-b64a-82e8c4e7a977">230.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE3LTEtMS0xLTI2NzQ0Ng_3992654e-0771-49b6-84ec-e7d773391eec">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE3LTMtMS0xLTI2NzQ0Ng_51c4204b-7632-414d-a401-3ad2639c0e03">1,543.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTEtMS0xLTI0NTQ3Nw_35ab4c84-49e9-4a51-af7c-17f16f5f209d">5,636.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTMtMS0xLTI0NTQ3Nw_f2de0a82-9dc8-4a08-a7a5-7f3bcb6108e0">6,864.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE5LTEtMS0xLTI0NTQ3Nw_7993a922-e2cb-4a96-9f6a-b74acd4a9657">25.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE5LTMtMS0xLTI0NTQ3Nw_3c4e5b8d-99ff-4782-a7ac-e34f2423793c">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIwLTEtMS0xLTI0NTQ3Nw_a13966de-d689-4c96-a4a4-4b025d7b4b1c">25.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIwLTMtMS0xLTI0NTQ3Nw_dff1da63-15e6-418b-ae3e-11c9d1005400">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIxLTEtMS0xLTI0NTQ3Nw_0e914a56-e4b4-4f06-9962-9ffd34d6f3ec">132.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIxLTMtMS0xLTI0NTQ3Nw_3e5dbb2f-8ae1-4850-9e68-da05e75bd9ce">134.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIyLTEtMS0xLTI0NTQ3Nw_03aaa90d-72ef-4597-b666-bf421570922e">168.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIyLTMtMS0xLTI0NTQ3Nw_44c77eb9-1e27-4515-a915-739a021e1282">199.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIzLTEtMS0xLTI0NTQ3Nw_e8f4b30f-8fff-413c-8fee-883c0ccf22ce">42.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIzLTMtMS0xLTI0NTQ3Nw_43930c7c-3318-4739-9d1f-ad3682362068">44.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI0LTEtMS0xLTI0NTQ3Nw_61174347-e788-4341-a9d7-fc6bde872dc2">181.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI0LTMtMS0xLTI0NTQ3Nw_33eea61f-677e-4b3a-9242-cc87dee9b9ad">177.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI3LTEtMS0xLTI2NzQ1Nw_4ddbca2b-563c-40ef-8dfd-962624f0751b">0.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI3LTMtMS0xLTI2NzQ1Nw_f830c6b0-bd5e-4cf4-8beb-e6241ec6d75c">132.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI1LTEtMS0xLTI0NTQ3Nw_5123c602-37b4-45c1-ae6d-eda59f3a01b1">575.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI1LTMtMS0xLTI0NTQ3Nw_4bb4e296-c125-49f7-b3e8-6d24244a0070">748.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI2LTEtMS0xLTI0NTQ3Nw_fbb19063-8dbb-4032-84b2-caee5705e510">2,741.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI2LTMtMS0xLTI0NTQ3Nw_12f4937f-2777-46ae-9a10-5b2fc7ac6a3d">3,240.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI3LTEtMS0xLTI0NTQ3Nw_f3423cd9-8257-425b-b5af-af5232456308">199.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI3LTMtMS0xLTI0NTQ3Nw_aec469e0-477f-4d64-b100-75d83b4dff9f">179.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Self-insured risks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:SelfInsuranceReserveNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI4LTEtMS0xLTI0NTQ3Nw_f54a990c-fbf1-4331-95a3-367d33e026e2">128.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:SelfInsuranceReserveNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI4LTMtMS0xLTI0NTQ3Nw_7d70d539-5ce3-4001-bc32-252e52dd65df">123.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI5LTEtMS0xLTI0NTQ3Nw_9ada5698-b4af-46d6-afb0-ad99aa74bcfd">83.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI5LTMtMS0xLTI0NTQ3Nw_21437bd4-ceb3-4057-a431-429393ebfd64">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMwLTEtMS0xLTI0NTQ3Nw_eec41967-a2c5-464e-a6cc-1cef7979b01d">45.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMwLTMtMS0xLTI0NTQ3Nw_6149a9ed-c825-4284-b0fd-f26922a2eb04">48.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncurrent liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM0LTEtMS0xLTI2NzQ5Nw_66521d47-2055-4a8a-8a6e-40014bbf35ba">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM0LTMtMS0xLTI2NzQ5Nw_0afa94d9-07dd-4be0-a955-df96cc6a46e4">100.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMxLTEtMS0xLTI0NTQ3Nw_37a4a289-1b6f-42c5-9818-78d9e08bf493">3,774.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMxLTMtMS0xLTI0NTQ3Nw_da4dd27a-850f-4a3e-8bc6-1feef3251009">4,465.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMyLTEtMS0xLTI0NTQ3Nw_1475fe36-0fd9-4b8f-86b2-c16f39443372"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMyLTMtMS0xLTI0NTQ3Nw_9700939b-8672-4a29-8d74-954289891fe5"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM0LTEtMS0xLTI0NTQ3Nw_05e4ff2c-7014-452c-8a6b-b1243796a62e">35.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM0LTMtMS0xLTI0NTQ3Nw_b3826879-0890-493e-bbde-3ddfddb194d1">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Encompass Health shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzE4_4b23ff89-82e7-4bc3-86d5-3640c027c17d"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzE4_a5dc4252-812d-4d9a-aadd-35d35e09f35e">.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzMy_79c6d016-b331-481d-aeb6-3d70fe5569cc"><ix:nonFraction unitRef="shares" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzMy_cbfbba63-d4cb-44d2-a2e8-ef54e11572b1">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; issued: <ix:nonFraction unitRef="shares" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzYy_a5dc2acb-2089-42f1-a301-cf5c070cfda4">114,775,056</ix:nonFraction> in 2022; <ix:nonFraction unitRef="shares" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzcy_fbeec94d-8efd-465d-b353-56bc4d5bad43">114,211,057</ix:nonFraction> in 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTEtMS0xLTI0NTQ3Nw_ea60b390-b7e7-4d42-aba5-eb784ccbf3f0">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTMtMS0xLTI0NTQ3Nw_5fffa080-8d17-48c2-ba42-64445496fccc">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital in excess of par value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM4LTEtMS0xLTI0NTQ3Nw_00e2328f-9b2d-4cdb-8045-c44d10ba2f32">1,730.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM4LTMtMS0xLTI0NTQ3Nw_19c56883-dd6e-4051-a64c-077a5be1f55e">2,289.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM5LTEtMS0xLTI0NTQ3Nw_8810dcfe-420a-4784-b6da-b654dce433eb">115.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM5LTMtMS0xLTI0NTQ3Nw_915fb79d-cede-47de-8ee9-aea4d130b5ff">141.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost (<ix:nonFraction unitRef="shares" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQxLTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOmJiNzk3OTI0YzI1ZDQzYTY4YjIxNTg5YTNkZGJlMjFlXzI5_a9866db7-3b8c-49af-8320-869f179fe446">14,992,125</ix:nonFraction> shares in 2022 and <ix:nonFraction unitRef="shares" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQxLTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOmJiNzk3OTI0YzI1ZDQzYTY4YjIxNTg5YTNkZGJlMjFlXzQ5_05ce5e82-a336-4515-aa02-57253442918e">14,719,662</ix:nonFraction> shares in 2021)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQxLTEtMS0xLTI0NTQ3Nw_a3b07ea4-a99f-416a-b893-3b5a71578ec2">536.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQxLTMtMS0xLTI0NTQ3Nw_411adb84-3bb7-4b58-a609-1047d0ca569e">521.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Encompass Health shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQyLTEtMS0xLTI0NTQ3Nw_beca62d8-6da9-40ca-b1ba-40d6769f5473">1,310.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQyLTMtMS0xLTI0NTQ3Nw_1cc7a0d5-9323-47b2-ae1d-188a78378818">1,911.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQzLTEtMS0xLTI0NTQ3Nw_cde80618-0b36-4131-be92-ded66851dfc1">516.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQzLTMtMS0xLTI0NTQ3Nw_6c0d0b7d-ed52-450a-b932-44fecf07dba7">445.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shareholders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ0LTEtMS0xLTI0NTQ3Nw_5c05ae3e-08e6-4a0a-992b-d68ce9d5e46c">1,826.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ0LTMtMS0xLTI0NTQ3Nw_5d5cf628-22cb-4a39-a945-5c8e19029cf3">2,357.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">and shareholders&#8217; equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTEtMS0xLTI0NTQ3Nw_1279d20f-075b-4742-bd23-75b6c1e9eed9">5,636.5</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTMtMS0xLTI0NTQ3Nw_2a843a56-9e04-4f9a-ac50-be6a0201a274">6,864.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzM0Mg_20312f68-ddf8-42c0-af6e-5dec32785555" footnoteRole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Our consolidated assets as of December&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $<ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzEwMg_43008e15-e738-4801-98eb-dc56d8a2b74b">207.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzEwOQ_648e4f53-a221-4a2b-89cd-c08bb553d515">226.2</ix:nonFraction> million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $<ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzMwNw_81e074d3-3831-4f13-8d61-10b9a90d4518">47.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzMxNA_3eaece07-4213-4a4e-bec3-435ddbfccb7c">38.2</ix:nonFraction> million, respectively. See Note&#160;4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></ix:footnote></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to consolidated financial statements are an integral part of these statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_151"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:18.487%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Shareholders&#8217; Equity</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.735%"><tr><td style="width:1.0%"></td><td style="width:34.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Encompass Health Common Shareholders</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Common Shares Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Capital in Excess of Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>(Deficit) Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9242279c10684829b4d9378d04b1edbd_I20191231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMS0xLTEtMjQ1NDc3_1d5e7157-a283-4912-b8b8-a543e7d91580">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9242279c10684829b4d9378d04b1edbd_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMy0xLTEtMjQ1NDc3_0b916895-36c3-443c-ae6c-07e013c59162">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90643ddde5c45f98d52e4b3afea3306_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtNS0xLTEtMjQ1NDc3_a2d296ee-0160-431d-9c19-7fc7566b3422">2,369.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0bcbb07d6f643b2b8e55385fae57545_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtNy0xLTEtMjQ1NDc3_325a15c2-4107-4976-857c-de3c25ce4d7b">526.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa1631b09af5498898a4f9704b654317_I20191231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMTEtMS0xLTI0NTQ3Nw_3463cfb7-3699-43f4-b1e1-de5db7816c66">492.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2adf3229d1fb4d439bf8228ce1a554d8_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMTMtMS0xLTI0NTQ3Nw_61685c2f-8e92-42ba-9fa6-8cc5d623e86d">340.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMTUtMS0xLTI0NTQ3Nw_f52433ef-9961-419a-861d-4aa75c4c8a86">1,693.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6826376042e0432c876faeb386c0d683_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQtNy0xLTEtMjQ1NDc3_63b0132b-4ce8-4058-96d6-8eb6443a17a6">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQtMTMtMS0xLTI0NTQ3Nw_fbe5aaaa-8fb4-46fd-ba96-53513ac9cde5">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQtMTUtMS0xLTI0NTQ3Nw_956d2246-321c-4374-b97b-421d09f8ccb8">361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzYtMS0xLTEtMjQ1NDc3_b901e6cb-8cae-46a7-8307-4417aa5d310d">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzYtMTEtMS0xLTI0NTQ3Nw_c9ee87a4-b25b-4b52-8812-4edc804dc5be">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzYtMTUtMS0xLTI0NTQ3Nw_4790f9ec-52fe-4fb3-8488-fa7b23dda8be">15.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjY5MWJkN2YxMzMyNGQzZjljZGI5MWE5NTZkYmY0N2ZfMjQ_ecfc18cc-b3b8-4a0f-9c90-0f293a5f2d9c">1.12</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzctNS0xLTEtMjQ1NDc3_492a7db5-925a-4544-bbe5-604b795368ff">111.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzctMTUtMS0xLTI0NTQ3Nw_53647786-a72b-4f4d-bd88-0dafd8a7d7c5">111.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange of Holdings shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzgtMS0xLTEtMjQ1NDc3_4537ddb9-5e00-444d-859e-f7fea1fafd38">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzgtNS0xLTEtMjQ1NDc3_e7694d12-f716-409c-9d2d-70a3c0c3ffbd">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzgtMTEtMS0xLTI0NTQ3Nw_b68e4d72-31c5-41c7-a5ad-f45ae699ffa3">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzgtMTUtMS0xLTI0NTQ3Nw_ccaef4fd-0a0d-4a5f-a408-8d39c51453a1">46.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzEwLTUtMS0xLTI0NTQ3Nw_ab69425d-1b57-4a30-9acc-8aded9ce49a3">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzEwLTE1LTEtMS0yNDU0Nzc_5d8b3afb-f3b1-4885-aa44-22244d61ea92">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzExLTEtMS0xLTI0NTQ3Nw_34246ab8-1dca-447b-bf4f-a871380b559f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzExLTUtMS0xLTI0NTQ3Nw_c26aef0c-2592-4e06-bc02-7c841de88bf4">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzExLTE1LTEtMS0yNDU0Nzc_1a2493f3-df34-43f6-9f34-adae1babbf26">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzEzLTEzLTEtMS0yNDU0Nzc_3df9784c-bfc8-415d-990a-5800fc9c4b3c">72.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzEzLTE1LTEtMS0yNDU0Nzc_d53cf2f4-6eb2-4b15-be03-f797f6f8e6c6">72.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchases of common stock in open market</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE0LTEtMS0xLTI0NTQ3Nw_c9772511-bdea-4f1a-8b3b-748c17c27edd">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE0LTExLTEtMS0yNDU0Nzc_0b4384d0-1071-401b-b608-40518faddad5">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE0LTE1LTEtMS0yNDU0Nzc_c43f261c-d2d6-4f6a-b36e-eda69eb6aeaa">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE3LTEzLTEtMS0yNDU0Nzc_0cb9b869-c220-4788-aea9-848a24cf4679">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE3LTE1LTEtMS0yNDU0Nzc_cef16086-89d8-4300-abc7-76836d657844">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value adjustments to redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE4LTUtMS0xLTI0NTQ3Nw_bae69692-9b40-458e-8fb7-942877dfaf54">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE4LTE1LTEtMS0yNDU0Nzc_df539634-a662-43af-98e3-f525237858a7">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTEtMS0xLTI0NTQ3Nw_0a8c599c-1c77-426e-ad9c-55cd42437aec">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTUtMS0xLTI0NTQ3Nw_ddc776fc-303f-45d0-89b5-660a98f6f69c">9.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTExLTEtMS0yNDU0Nzc_308b1776-2175-4fa4-aff5-e2d94c8ee00d">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTEzLTEtMS0yNDU0Nzc_2750e989-bb8b-4dc8-9a50-fd7de6ac4cfe">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTE1LTEtMS0yNDU0Nzc_e5075d9b-6fec-4b8d-b450-29ad1e5ad2a7">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac851ca1adc4483f827335b0959d3fb6_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTEtMS0xLTI0NTQ3Nw_f14b2d47-6b58-4a26-83f3-8e6196714cd3">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac851ca1adc4483f827335b0959d3fb6_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTMtMS0xLTI0NTQ3Nw_01d10336-ac26-4d80-94de-fffd4f16acce">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie195f01f18994a1dbbf00c9ea5162424_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTUtMS0xLTI0NTQ3Nw_03a878cc-da93-451c-91d5-f3e6bd996550">2,326.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i568f78237ee640189be8f0569e1325aa_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTctMS0xLTI0NTQ3Nw_bc875f2a-5231-400c-8717-e3c1958b1d17">242.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4612a858a134e488b568b7bc4f5b31b_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTExLTEtMS0yNDU0Nzc_7b51403a-87dd-4999-baa1-ccf8eda80634">497.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9817c02d1254788bdfed4e092d4d240_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTEzLTEtMS0yNDU0Nzc_40cdeed9-530a-4852-b9bf-5560333e6cca">382.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTE1LTEtMS0yNDU0Nzc_a8aa8dbf-a6b4-49af-b2dd-6269e575124a">1,970.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89258633f59441580a344774a089493_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI0LTctMS0xLTI0NTQ3Nw_ffb874e0-2220-4ae6-a55f-df9859ab4dde">412.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI0LTEzLTEtMS0yNDU0Nzc_47a1c2df-3fce-4a4b-90f1-b7502e0c1a8a">96.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI0LTE1LTEtMS0yNDU0Nzc_234e9105-d09a-4e88-b12c-d1ca6fa9eb6a">508.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib906731d97114d82addea69f1bb3d93f_D20210101-20211231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI2LTEtMS0xLTI0NTQ3Nw_b97cb0c8-6003-4a21-b23d-190de2cb78d7">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad71d7ff6aa0428593dfb57b61019e26_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI2LTExLTEtMS0yNDU0Nzc_b33f4805-3342-44f1-8b92-721d139b1ca4">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI2LTE1LTEtMS0yNDU0Nzc_fa3ad2af-1ca2-40f7-8de4-53a0fd1bba67">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjg4NTU4MzRiNmFjOTQ1NWU5NmFmNjYzYTNkOWRjN2JmXzI0_83de1493-8178-4c68-8750-cdd36ef5a61d">1.12</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5df19105bbb4e44ad638452c82235f5_D20210101-20211231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI3LTUtMS0xLTI0NTQ3Nw_8ece4064-5235-43f0-bc63-b49a3920e9c4">83.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89258633f59441580a344774a089493_D20210101-20211231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI3LTctMS0xLTI0NTQ3Nw_abdc0274-e17d-4248-8753-e42458668a86">28.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI3LTE1LTEtMS0yNDU0Nzc_f5c01b48-efd3-4ad1-94b7-f1ef6d961f00">111.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5df19105bbb4e44ad638452c82235f5_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMwLTUtMS0xLTI0NTQ3Nw_ad3c3608-5b41-4977-a303-a516be42d0ea">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMwLTE1LTEtMS0yNDU0Nzc_9167c0ba-659d-4dfb-a697-e9d828cfce4c">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMzLTEzLTEtMS0yNDU0Nzc_0447886d-28c4-42c4-8e0c-9188a6f4a1a6">87.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMzLTE1LTEtMS0yNDU0Nzc_4a4cae17-cc9f-4cda-ac8d-f3d63333223d">87.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM1LTEzLTEtMS0yNDU0Nzc_d8c29233-44df-4046-8e51-d363dd70e155">72.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM1LTE1LTEtMS0yNDU0Nzc_ac392bbd-28e3-44ee-9002-d1bfcf7cd778">72.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib906731d97114d82addea69f1bb3d93f_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTEtMS0xLTI0NTQ3Nw_24d371ba-d993-4162-bee6-3d3a631b6559">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5df19105bbb4e44ad638452c82235f5_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTUtMS0xLTI0NTQ3Nw_e03a21d0-6c30-434c-9afc-d3eefd3d1071">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad71d7ff6aa0428593dfb57b61019e26_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTExLTEtMS0yNDU0Nzc_d17b5801-e99b-455b-8866-1365d5a7281e">7.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTEzLTEtMS0yNDU0Nzc_62816f35-47d8-4102-9592-6c472c7f372a">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTE1LTEtMS0yNDU0Nzc_138c8af0-dc14-4896-a903-6dab4c02b55f">10.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2040827da13c48fb8523dcbbee23864e_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTEtMS0xLTI0NTQ3Nw_a6d81aab-ef90-4215-9ddb-59a19de3e49c">99.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2040827da13c48fb8523dcbbee23864e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTMtMS0xLTI0NTQ3Nw_4003ede6-6449-48fa-99ff-883234610cd9">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e12dea591344c0b2b9c9f457b71126_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTUtMS0xLTI0NTQ3Nw_c79d3a8c-d38d-4bb2-9e20-aa3f3290974b">2,289.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b3eb121a4a4b25a2563b523c8cbe4e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTctMS0xLTI0NTQ3Nw_47005940-68f5-4660-8085-d2be039bfce7">141.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e6aa83bba40405785127e8ed8bb4d92_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTExLTEtMS0yNDU0Nzc_e40a8147-aa58-4342-bafb-f5feadbc7234">521.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie516d8d2297a44c8928335358a6b74e1_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTEzLTEtMS0yNDU0Nzc_e3e3240a-c709-4730-95d8-e4196b4f054d">445.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTE1LTEtMS0yNDU0Nzc_3083e3d6-acd3-434d-b29c-36717e5b8d93">2,357.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b288a1bbc1e4a36a83f2bca14dee1ea_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQxLTctMS0xLTI0NTQ3Nw_10aa8a1a-a9a6-4a9a-909b-5dcb5d14de6e">271.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQxLTEzLTEtMS0yNDU0Nzc_363cdcb2-a624-4de9-8e1d-832bab567f96">87.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQxLTE1LTEtMS0yNDU0Nzc_a849bb8a-1e66-435b-9b21-54cdb58b8b38">358.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of treasury stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia0f7c8b4463341a0a371e690773b666a_D20220101-20221231" decimals="-5" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQzLTEtMS0xLTI0NTQ3Nw_27c61ddb-7e32-419c-b5c3-3884e72523d4">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if44a6728f6fa4025b928881a0e39236d_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQzLTExLTEtMS0yNDU0Nzc_be175f63-ce03-471c-930a-0f1e87bc4651">7.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQzLTE1LTEtMS0yNDU0Nzc_5defc7dc-12d6-49ac-90ff-a2de916b857b">7.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ0LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjI3MTEzMTE3MWJiYTRkMTdiZDkzY2FkMDUwYjg2MDY0XzI0_cfe31dad-f2e3-4c61-af85-06fd2e6282db">0.86</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ0LTUtMS0xLTI0NTQ3Nw_08beb245-2ff6-4dbc-a2e0-c132e452ebc0">11.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b288a1bbc1e4a36a83f2bca14dee1ea_D20220101-20221231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ0LTctMS0xLTI0NTQ3Nw_d76ff32a-95de-4410-9ce5-d660a773fba8">75.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:DividendsCommonStockCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ0LTE1LTEtMS0yNDU0Nzc_fb071ef5-8a2e-46ea-9e8e-855cdc9fc19b">86.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ2LTUtMS0xLTI0NTQ3Nw_058043cf-23c8-45ed-9c6e-2a771e156ceb">31.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ2LTE1LTEtMS0yNDU0Nzc_bbfd8027-441f-448d-9309-48dba06c6613">31.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ5LTEzLTEtMS0yNDU0Nzc_f3096a34-2d39-4167-ad96-1957c4f39c56">99.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ5LTE1LTEtMS0yNDU0Nzc_7b0a5c47-2cde-4cf0-9b73-b5e77e65bcfa">99.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital contributions from consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzUxLTEzLTEtMS0yNDU0Nzc_c1d38d98-9255-4179-8406-d2b3b038f9e5">100.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PartnersCapitalAccountContributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzUxLTE1LTEtMS0yNDU0Nzc_54f75889-c198-4758-b91b-c33a687c27ae">100.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin off of Enhabit, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTUtMS0xLTI2NzUyMQ_11617ffa-1de3-4e37-b96a-84dade690f68">595.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b288a1bbc1e4a36a83f2bca14dee1ea_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTctMS0xLTI2NzUyMQ_336e4fc0-195b-42a5-9bdb-e33a9af70a39">221.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTEzLTEtMS0yNjc1MjE_300624ad-fbf7-4074-9487-3c508ce5309e">28.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityNoteSpinoffTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTE1LTEtMS0yNzkwNDg_ab89d3f8-f83b-4966-b0d2-e761f0ebf68e">846.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0f7c8b4463341a0a371e690773b666a_D20220101-20221231" decimals="-5" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTEtMS0xLTI0NTQ3Nw_451112c2-80a9-437e-85e8-95c72a7f4d2d">0.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTUtMS0xLTI0NTQ3Nw_ee165b56-9da0-48f7-86fc-2a95a345a5ac">15.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if44a6728f6fa4025b928881a0e39236d_D20220101-20221231" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTExLTEtMS0yNDU0Nzc_7143e026-f19f-4bae-ab1f-7f0c54a040d2">7.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTEzLTEtMS0yNDU0Nzc_ea5883ec-44c0-4127-91b7-4e533fdf6040">10.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTE1LTEtMS0yNDU0Nzc_ed941440-e6c0-46f2-bed5-0ea675c99599">18.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic212fffe4100400087e39b038b342ab0_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTEtMS0xLTI0NTQ3Nw_5d82f09b-4c15-4dc6-a0de-729460c6ceb6">99.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic212fffe4100400087e39b038b342ab0_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTMtMS0xLTI0NTQ3Nw_51a6e042-740c-4188-8c77-9b1ca2a671d9">1.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbba5e1af20d45838cbb3098d5f3d99b_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTUtMS0xLTI0NTQ3Nw_cebd9829-ac64-48a9-8ce8-98d18b3fa509">1,730.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied260f5cc55446ac98da4ff1069c95fe_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTctMS0xLTI0NTQ3Nw_eec0e855-21d5-4518-ae2f-391c66e5b634">115.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iffd361313d6f4ca589272589af035b20_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTExLTEtMS0yNDU0Nzc_8b089783-ce01-4858-933f-e8bf48a69f0e">536.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39924c6425243f7a6b73371e0e4481e_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTEzLTEtMS0yNDU0Nzc_354df608-38cc-4941-bd84-1e1f16f338ec">516.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTE1LTEtMS0yNDU0Nzc_6cda0c2f-7ecd-41e2-ade1-be1e89bb78ee">1,826.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to consolidated financial statements are an integral part of these statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Cash Flows</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQtMS0xLTEtMjQ1NDc3_8e655c8b-447e-46e0-884c-d295b0890281">365.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQtMy0xLTEtMjQ1NDc3_d168432e-8398-4a9a-8a04-191052ce0fd7">517.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQtNS0xLTEtMjQ1NDc3_1375b316-7fe5-4848-ac39-83fa683a24bc">368.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzUtMS0xLTEtMjQ1NDc3_473c1b81-d4c1-42d7-8504-9e522f4501de">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzUtMy0xLTEtMjQ1NDc3_ed4f571a-eea5-4f2f-be90-8c3422784617">114.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzUtNS0xLTEtMjQ1NDc3_c0ce573e-5c93-4fe8-9901-283deaa773b4">90.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities&#8212;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for government, class action, and related settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzctMS0xLTEtMjQ1NDc3_ddc9eaa3-b007-4ca7-8db4-a57f28880ff6">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzctMy0xLTEtMjQ1NDc3_d3591744-6255-4217-8750-dac38d48bba7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzctNS0xLTEtMjQ1NDc3_1b16e5fb-c79f-4cce-8da1-e4b8d47ea51b">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzgtMS0xLTEtMjQ1NDc3_b55b4777-b6a3-440e-9fa8-c9b54a4a7780">243.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzgtMy0xLTEtMjQ1NDc3_28245583-d29f-4494-83f7-115d8e1379df">219.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzgtNS0xLTEtMjQ1NDc3_14346009-8f29-494e-a6d9-f11e3ecd0fc9">203.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt-related items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzktMS0xLTEtMjQ1NDc3_774cad88-865c-4caa-91a7-1bddd743118e">9.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzktMy0xLTEtMjQ1NDc3_15dd8fa9-611c-44fd-a40e-79be29230b49">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzktNS0xLTEtMjQ1NDc3_a8c460ef-b99b-4266-8643-f058174e334f">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEwLTEtMS0xLTI0NTQ3Nw_4f442348-0661-4c69-88d0-07e50e34bfb6">1.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEwLTMtMS0xLTI0NTQ3Nw_b09f84eb-4bcf-462e-a074-b6a30fe7ed7b">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEwLTUtMS0xLTI0NTQ3Nw_2d6f0923-66ca-4a81-806a-ee060e4b3473">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzExLTEtMS0xLTI0NTQ3Nw_0fc66e34-8166-41e6-b564-ef302c723537">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzExLTMtMS0xLTI0NTQ3Nw_003a3dae-d8c3-43c1-8f1c-6708d38b4e80">3.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzExLTUtMS0xLTI0NTQ3Nw_89b6c63e-4e78-4727-87dc-9837bc058887">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions from nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEyLTEtMS0xLTI0NTQ3Nw_a85a500e-79c2-448c-8cd0-a0765814db90">4.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEyLTMtMS0xLTI0NTQ3Nw_af3c72f2-859d-4124-bfb7-559adace43b4">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEyLTUtMS0xLTI0NTQ3Nw_214717a7-b311-4c59-b969-3d372a2fdb63">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEzLTEtMS0xLTI0NTQ3Nw_7e24a14f-032f-4a8f-be4d-adab8684993e">29.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEzLTMtMS0xLTI0NTQ3Nw_4df8acf5-2005-4b1a-bee4-f82370cb60ca">29.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEzLTUtMS0xLTI0NTQ3Nw_b5b6251f-da77-42b6-901e-0377f632c9eb">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE0LTEtMS0xLTI0NTQ3Nw_42a78788-4cbd-47a2-8968-634e1051936d">27.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE0LTMtMS0xLTI0NTQ3Nw_4431fcfb-f3cb-4910-a823-8663e460089e">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE0LTUtMS0xLTI0NTQ3Nw_e9e8bccf-b94a-4e21-993c-dda3fb30b4d9">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE2LTEtMS0xLTI0NTQ3Nw_273a43fb-7dce-4c7e-a3c8-e3d12792827d">20.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE2LTMtMS0xLTI0NTQ3Nw_a76662e0-c6ed-4d86-93c1-9e6884239c29">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE2LTUtMS0xLTI0NTQ3Nw_a43bda7f-5582-44bb-beff-a6c631091a0b">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE4LTEtMS0xLTI0NTQ3Nw_d1120c5d-6c13-4daf-8a34-8199520671d1">16.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE4LTMtMS0xLTI0NTQ3Nw_2b895290-c001-454b-a5fd-849729c0b7c1">39.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE4LTUtMS0xLTI0NTQ3Nw_47197718-8cea-4948-bf0d-f88ba51cf6bb">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE5LTEtMS0xLTI0NTQ3Nw_52f9891b-3974-42b4-a3a6-2318f68fbac4">8.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE5LTMtMS0xLTI0NTQ3Nw_68743966-bee0-41c7-abde-b55c0275c582">41.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE5LTUtMS0xLTI0NTQ3Nw_5d3ce845-62fd-431c-87a0-56fd863ba71a">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIwLTEtMS0xLTI0NTQ3Nw_965180a1-ab44-431f-814f-6adb2ebc5a75">2.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIwLTMtMS0xLTI0NTQ3Nw_d2066cb3-1029-4a6d-bfc3-9fb617857360">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIwLTUtMS0xLTI0NTQ3Nw_a86c4092-07f2-454a-a58e-f67c5f16c396">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIxLTEtMS0xLTI0NTQ3Nw_9a054e84-3cb5-4d73-b11b-797d9f9aafe0">31.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIxLTMtMS0xLTI0NTQ3Nw_bfb849e7-4e85-4dd1-bb45-dcec41845912">30.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIxLTUtMS0xLTI0NTQ3Nw_febccb7d-0e50-49a8-8f2d-52ec8f859a33">79.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIzLTEtMS0xLTI3MTg1MA_d050cb46-d3a5-4064-a512-a544f0609c5c">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIzLTMtMS0xLTI3MTg1MA_a1d0b0cf-6a71-42ea-ada9-4466fbc0715b">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIzLTUtMS0xLTI3MTg1MA_11bfd8d8-6865-45d1-8596-3173d5caf268">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIyLTEtMS0xLTI0NTQ3Nw_56bed37e-6efc-4c7d-b657-81aa0bdbaef6">9.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIyLTMtMS0xLTI0NTQ3Nw_ee9d325e-d6b3-45fb-9ee1-cc7291e2d1c2">11.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIyLTUtMS0xLTI0NTQ3Nw_cfeffe85-f247-4dd7-9cb1-07677b417edc">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI2LTEtMS0xLTI0NTQ3Nw_0d4393a9-2281-4949-a68f-85c5b03db1fc">52.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI2LTMtMS0xLTI0NTQ3Nw_c96ce267-d436-48ca-9de0-ba2ec0a433c5">151.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI2LTUtMS0xLTI0NTQ3Nw_aba9fa0c-1eba-4200-b7e5-ce91b3079dbe">35.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI3LTEtMS0xLTI0NTQ3Nw_b6056c1a-be5c-449d-9483-c46ba9153b82">355.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI3LTMtMS0xLTI0NTQ3Nw_e862eeb3-039d-4382-85d1-cedcda8a8863">312.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI3LTUtMS0xLTI0NTQ3Nw_cdf05355-4aa2-46cb-8401-413cf653990b">426.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI4LTEtMS0xLTI0NTQ3Nw_bd72ce3d-da87-4d05-9915-c355aa6ea764">705.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI4LTMtMS0xLTI0NTQ3Nw_fe4d969a-8ea0-4476-a694-befa0dbea7ee">715.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI4LTUtMS0xLTI0NTQ3Nw_eb44996c-507d-4331-b9ed-a92cd1465e84">704.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of businesses, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMwLTEtMS0xLTI0NTQ3Nw_cbe6114d-1870-4be0-8324-1f2cf455e0b5">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMwLTMtMS0xLTI0NTQ3Nw_ea0bff0c-f626-40a2-98f4-b8659839d21f">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMwLTUtMS0xLTI0NTQ3Nw_ebd6a5f4-2684-494b-b109-d0cb6cc07bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMxLTEtMS0xLTI0NTQ3Nw_905b138b-5d2b-4ba1-ad3d-dea7f8727a51">564.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMxLTMtMS0xLTI0NTQ3Nw_d891eb6b-1303-4abc-a4e7-93abcbe3d9b1">524.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMxLTUtMS0xLTI0NTQ3Nw_609db11e-7bee-482e-bbba-333a3dca4f70">392.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to capitalized software costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMyLTEtMS0xLTI0NTQ3Nw_899ca6fc-bcb4-4244-b7e8-8a87e58dfebe">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMyLTMtMS0xLTI0NTQ3Nw_2f929bf9-7b3e-44d1-a134-febe6ee1e20d">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMyLTUtMS0xLTI0NTQ3Nw_a112bfeb-1b95-4a27-96a6-b059c06711b5">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMzLTEtMS0xLTI0NTQ3Nw_30946aad-15e1-4c29-96c1-e482d4e9660c">10.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMzLTMtMS0xLTI0NTQ3Nw_5ee9c854-5410-4698-94aa-be088df4cab0">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMzLTUtMS0xLTI0NTQ3Nw_273586ef-502d-4db3-9a0f-4923e4db0175">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM2LTEtMS0xLTI0NTQ3Nw_0b3c6522-34bc-4e62-98a9-978ef1e19491">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM2LTMtMS0xLTI0NTQ3Nw_0a040385-deee-406a-a833-484e6f08c08d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM2LTUtMS0xLTI0NTQ3Nw_4766e9e9-0112-456f-ada4-5c65d6d2e2e0">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM3LTEtMS0xLTI0NTQ3Nw_6d367fca-c2ff-4199-bbef-1151daf39df5">35.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM3LTMtMS0xLTI0NTQ3Nw_42da92fe-711f-4da9-9d76-1b3b630bd4dc">9.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireRestrictedInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM3LTUtMS0xLTI0NTQ3Nw_a83501fb-d093-4d5e-8353-7fd851021f21">8.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM4LTEtMS0xLTI0NTQ3Nw_62101482-37c0-48d7-b519-6a581b4c47e5">4.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM4LTMtMS0xLTI0NTQ3Nw_3eb3c0b8-a877-4171-a175-29fbffb76d0d">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM4LTUtMS0xLTI0NTQ3Nw_6fff97b9-972e-4c7e-aa8e-71d480b6ea22">3.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM5LTEtMS0xLTI0NTQ3Nw_480974f1-a336-4317-b432-e9903ba8777d">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM5LTMtMS0xLTI0NTQ3Nw_40980dfd-39c9-4a73-872d-7cadbcfe2343">119.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM5LTUtMS0xLTI0NTQ3Nw_6c0794db-8ba3-4a91-9c07-cb31532858aa">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQwLTEtMS0xLTI0NTQ3Nw_6f13b968-cb53-47b7-9544-9a1d1d1d9db4">627.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQwLTMtMS0xLTI0NTQ3Nw_8cbccaac-0a3b-44b6-8f1f-4bd5d437587a">666.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQwLTUtMS0xLTI0NTQ3Nw_38ea2b92-591f-4cb5-9cb9-96ebe667009c">407.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Continued)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statements of Cash Flows (Continued)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from bond issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzUtMS0xLTEtMjQ1NDc3_d8f7108d-bf13-4c37-b88e-554f608f6ee9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzUtMy0xLTEtMjQ1NDc3_274e877e-adfe-4ff5-b91f-0782ad145b7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzUtNS0xLTEtMjQ1NDc3_ea6fa7cd-7143-41f8-a5aa-f24740a51bd9">992.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on debt, including pre-payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzYtMS0xLTEtMjQ1NDc3_38b324c7-0323-4aba-b8f2-03dfd1736584">345.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzYtMy0xLTEtMjQ1NDc3_cfdaa380-18c0-45f2-b8da-d5ec30f2d055">214.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzYtNS0xLTEtMjQ1NDc3_d9425588-2929-42ef-90c5-25269f5524a5">717.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal borrowings on notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromNotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzctMS0xLTEtMjQ1NDc3_f149bf11-6571-4c38-ace3-98a3ecf21a01">11.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzctMy0xLTEtMjQ1NDc3_7c7af3c8-c211-4428-afa7-88d8fc1cf21b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzctNS0xLTEtMjQ1NDc3_03b128c9-3cdf-40b9-9e96-fb23cdcbcd1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on revolving credit facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzktMS0xLTEtMjQ1NDc3_62fb63d5-f736-47e3-9153-e85f9adec65f">240.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzktMy0xLTEtMjQ1NDc3_7563fb7d-d4a6-4274-8046-7143d72a9037">300.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzktNS0xLTEtMjQ1NDc3_a8ba6ef8-c02d-4714-b243-d103a798c339">330.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on revolving credit facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEwLTEtMS0xLTI0NTQ3Nw_3923f6c8-34c9-4a2f-86aa-5a245ac4fb95">385.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEwLTMtMS0xLTI0NTQ3Nw_7314a869-658c-4a98-ad71-1057a7327f9d">100.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEwLTUtMS0xLTI0NTQ3Nw_b3048e23-6582-40c5-a606-9fb1210e38b1">375.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments under finance lease obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzExLTEtMS0xLTI0NTQ3Nw_313eeb04-cb92-458a-a70f-3c72b3a31c42">19.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzExLTMtMS0xLTI0NTQ3Nw_631f27d3-f7cc-4e3d-87ad-f8a96cae1594">44.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzExLTUtMS0xLTI0NTQ3Nw_46829eac-8b73-458e-9045-40a229f8336b">14.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt amendment and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEyLTEtMS0xLTI0NTQ3Nw_396c7842-a6d3-46df-a27d-2fe36e892f48">24.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEyLTMtMS0xLTI0NTQ3Nw_be7a16d3-c2cb-4310-ad8a-9e0e157a207e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEyLTUtMS0xLTI0NTQ3Nw_2d7c2472-45c5-4374-8d1f-b620037a88de">20.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of common stock, including fees and expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEzLTEtMS0xLTI0NTQ3Nw_df482474-4667-4918-8ce1-9848bb45e2ad">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEzLTMtMS0xLTI0NTQ3Nw_c57559d6-efd1-4cb1-bec7-d052d68ffa8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEzLTUtMS0xLTI0NTQ3Nw_233029ba-2e59-44bd-9f76-28c72f480234">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid on common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE1LTEtMS0xLTI0NTQ3Nw_39376473-783b-4a09-b2bb-c5e3a5467650">99.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE1LTMtMS0xLTI0NTQ3Nw_533668fa-1b06-4b4a-9c17-88f6cdbf6905">112.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE1LTUtMS0xLTI0NTQ3Nw_1d5886e9-20fb-4850-a7eb-5a62732d6754">111.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of equity interests in consolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE2LTEtMS0xLTI0NTQ3Nw_bd0f7780-ec83-4f94-bd49-dfa5ad0c1cf9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE2LTMtMS0xLTI0NTQ3Nw_636a398d-d2fe-4da8-aaf0-823f03c728f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE2LTUtMS0xLTI0NTQ3Nw_d1897de8-24b7-422e-9087-02b6012e4576">162.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions paid to noncontrolling interests of consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE5LTEtMS0xLTI0NTQ3Nw_53efc90a-f887-4394-989a-d591b0efac9c">96.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE5LTMtMS0xLTI0NTQ3Nw_71aabf1a-316e-4db0-b5d1-e6200f13ac5c">101.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE5LTUtMS0xLTI0NTQ3Nw_a54f0b07-196c-4ac3-9d69-63c510419565">70.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid on behalf of employees for shares withheld</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIwLTEtMS0xLTI0NTQ3Nw_08bb0ce5-8e40-47e1-85e8-f9ab6c8a9ef5">7.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIwLTMtMS0xLTI0NTQ3Nw_93dc9e03-8021-4132-8075-52723234d65a">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIwLTUtMS0xLTI0NTQ3Nw_3d6571df-48b6-4fb2-9474-29b201df0070">14.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from noncontrolling interests of consolidated affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIxLTEtMS0xLTI0NTQ3Nw_40f695d1-318b-4a05-a4f6-92edb7c15192">64.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIxLTMtMS0xLTI0NTQ3Nw_90acf71c-08b2-4b69-9888-8f8d00bde917">57.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIxLTUtMS0xLTI0NTQ3Nw_244299f3-bed4-42a3-91f1-bdd54b7d1157">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIyLTEtMS0xLTI0NTQ3Nw_27169ab4-015a-4a05-b466-c8ffacd7afd9">0.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIyLTMtMS0xLTI0NTQ3Nw_ea319ea5-5efc-4253-b175-d3339d002920">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIyLTUtMS0xLTI0NTQ3Nw_3e767600-b832-4d4d-b2d2-5ab84f0bb4f6">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTEtMS0xLTI2NzU1OA_0b21a6eb-8078-489f-a425-1a28f74134ca">515.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTMtMS0xLTI2NzU1OA_f793c4fa-8602-4268-a593-b780754d4d5c">10.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTUtMS0xLTI2NzU1OA_6cc4d622-5296-4fd3-91f0-4156c814ebfc">11.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTEtMS0xLTI0NTQ3Nw_3a20674c-ea5d-46cc-86a7-a5d31677d13a">145.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTMtMS0xLTI0NTQ3Nw_626632c8-655e-433f-882d-45c26121334f">240.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTUtMS0xLTI0NTQ3Nw_2d301530-8f3b-493b-99c4-713892f41b60">145.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Decrease) increase in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI0LTEtMS0xLTI0NTQ3Nw_1ebae159-ab65-4f41-8433-86619e06b650">66.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI0LTMtMS0xLTI0NTQ3Nw_bcfcf166-7a19-4db4-9fd0-e5f2ad408474">190.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI0LTUtMS0xLTI0NTQ3Nw_76413216-bff5-455f-a919-1375fdf87635">151.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI1LTEtMS0xLTI0NTQ3Nw_c5d1b8b0-dc84-47fb-92f2-85321de9f031">120.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI1LTMtMS0xLTI0NTQ3Nw_f65e72a8-c493-4bd5-aed2-a197a85c2899">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI1LTUtMS0xLTI0NTQ3Nw_90c8fd5e-aa53-4a4a-91e9-e75cd66bbc41">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash at end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI2LTEtMS0xLTI0NTQ3Nw_ad63a0df-0a77-4e89-8df9-c14141a12227">53.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI2LTMtMS0xLTI0NTQ3Nw_75aa966f-5a10-42d0-baa2-e2addfb9fabb">120.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI2LTUtMS0xLTI0NTQ3Nw_78fa9dd7-189d-44a3-bcfd-4318e70fd34f">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI5LTEtMS0xLTI0NTQ3Nw_c4e02f8b-7307-4e7f-b26c-9bea8f2f0f98">49.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI5LTMtMS0xLTI0NTQ3Nw_8556401a-9cc6-4287-8c5f-028550c8ecfb">185.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI5LTUtMS0xLTI0NTQ3Nw_19777dcf-a66b-482a-ac5d-cf3eb09254e0">60.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash at beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMwLTEtMS0xLTI0NTQ3Nw_80bf8159-b0fd-4b32-b1ee-fe521ef05305">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMwLTMtMS0xLTI0NTQ3Nw_c45426e3-3d9b-441c-a5a6-bddd030f5957">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMwLTUtMS0xLTI0NTQ3Nw_22c2a81f-7ce2-47f0-8ef6-44ad0507c8f2">57.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other long-term assets at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMxLTEtMS0xLTI0NTQ3Nw_aa0b82dc-683f-40dc-94c3-045f6855a58b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMxLTMtMS0xLTI0NTQ3Nw_58f92cd6-0ace-4946-9bb0-d4e3668b2168">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMxLTUtMS0xLTI0NTQ3Nw_0ceaf3d4-110e-43b2-8226-d999f4911f32">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash in discontinued operations at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMzLTEtMS0xLTI2NzU3Mg_f9cf2daf-408b-4e83-8ff5-3fedf6890387">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMzLTMtMS0xLTI2NzU3Mg_2296e2b9-6cf9-478e-ae85-ea65f9fdf285">39.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMzLTUtMS0xLTI2NzU3Mg_ee196963-11ce-4fa9-9016-fbef9ed8dfbd">34.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMyLTEtMS0xLTI0NTQ3Nw_a53f9155-98d8-4f37-9e2e-b3dbb870047a">120.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMyLTMtMS0xLTI0NTQ3Nw_08092632-04e6-4884-8e9d-e615e130b009">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMyLTUtMS0xLTI0NTQ3Nw_ece8d58e-c350-47fb-be55-0b40d58cf965">159.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM0LTEtMS0xLTI0NTQ3Nw_cce0bdcc-0682-409e-bcd6-9c060fd71f79">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM0LTMtMS0xLTI0NTQ3Nw_c229e556-f2dd-4e97-a1e3-c9277504d92e">49.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM0LTUtMS0xLTI0NTQ3Nw_d9c5fc12-5e0e-45c9-970f-e76713c26f1f">185.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash at end of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM1LTEtMS0xLTI0NTQ3Nw_9792fa6d-9c78-4393-907e-3083500cf56c">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM1LTMtMS0xLTI0NTQ3Nw_a56cdd55-b7ae-4e48-bbbe-9b5346466682">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM1LTUtMS0xLTI0NTQ3Nw_8f33121f-0509-492f-b46b-ca59757b708e">63.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash included in other long-term assets at end of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM2LTEtMS0xLTI0NTQ3Nw_771a2e95-91ea-42dd-874a-c33f94b1dd8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM2LTMtMS0xLTI0NTQ3Nw_4fb2588b-fbc0-4bdb-b8a6-1b6ad9dc7e60">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM2LTUtMS0xLTI0NTQ3Nw_6e0c16a7-458a-488e-ab88-dfd02d48774d">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash in discontinued operations at end of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM5LTEtMS0xLTI2NzYxNg_c0d95ed0-9495-4222-8178-9eedbad470be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM5LTMtMS0xLTI2NzYxNg_9b62b21f-6d3f-4d83-92da-e1d89b695b83">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM5LTUtMS0xLTI2NzYxNg_e9f866c4-b6d5-4472-829c-df9834586836">39.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM3LTEtMS0xLTI0NTQ3Nw_dfc364ea-0991-4e0e-8c4d-2c0a7ddeba62">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM3LTMtMS0xLTI0NTQ3Nw_b8f52d30-f04e-4a52-811b-73e312752299">120.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM3LTUtMS0xLTI0NTQ3Nw_c28f0eac-507c-468d-b679-1eaa5401dde6">310.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (paid) received during the year for &#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQxLTEtMS0xLTI0NTQ3Nw_d9cd01aa-18f9-4117-8d69-0b817bd3f777">178.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQxLTMtMS0xLTI0NTQ3Nw_68aca672-7ca7-44d2-b07c-c8fbfa79a970">168.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQxLTUtMS0xLTI0NTQ3Nw_bbc00c5f-0117-4c40-b71a-6c02396866d0">168.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax refunds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQyLTEtMS0xLTI0NTQ3Nw_05d962b8-6782-4604-bbfc-df4d37a01053">1.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQyLTMtMS0xLTI0NTQ3Nw_4d4175df-e62c-4c44-9af8-fa040d425166">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIncomeTaxRefunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQyLTUtMS0xLTI0NTQ3Nw_55c55393-1177-49e0-86af-3598c3ba7145">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQzLTEtMS0xLTI0NTQ3Nw_8926f931-66fb-4cc4-969d-9f83c0ab9580">51.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQzLTMtMS0xLTI0NTQ3Nw_b1a38320-9f64-4623-a01d-c3a0b02e1495">131.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQzLTUtMS0xLTI0NTQ3Nw_eb765702-6b2a-485c-994b-2dbd2c2df9d1">34.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes to consolidated financial statements are an integral part of these statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_157"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span><br/></span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_160"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjAvZnJhZzo2MDNiYmRjOWIzYjk0ZmM3YjRlODBmMWM5MDY5NTQwZi90ZXh0cmVnaW9uOjYwM2JiZGM5YjNiOTRmYzdiNGU4MGYxYzkwNjk1NDBmXzQ4_fecb6ea0-77bd-4127-bf0d-c9e21963b791" continuedAt="i06588772f4f348859522fa6815ce03cc" escape="true">Summary of Significant Accounting Policies:</ix:nonNumeric> </span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_163"></div><ix:continuation id="i06588772f4f348859522fa6815ce03cc" continuedAt="id9e914ae98ed4bf3b39220f5e1aa67d9"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization and Description of Business&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a provider of inpatient rehabilitation services. We operate hospitals in <ix:nonFraction unitRef="state" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzY1OTcwNjk3Njk0ODg_aec57746-9e51-4c36-b68e-eee2c08ba3e7">36</ix:nonFraction> states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of December&#160;31, 2022, we operate <ix:nonFraction unitRef="hospital" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="ehc:NumberOfInpatientRehabilitationHospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk0Nw_6a82e033-32c5-47ef-93d4-0ab92e22f20e">153</ix:nonFraction> inpatient rehabilitation hospitals. We are the sole owner of <ix:nonFraction unitRef="hospital" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="ehc:NumberOfInpatientRehabilitationHospitalsSoleOwnership" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk1MA_e2582c90-20c5-45a2-85cb-9536cd9ac7ed">95</ix:nonFraction> of these hospitals. We retain <ix:nonFraction unitRef="number" contextRef="ic9f4a444a849477298194909155a4a2e_I20221231" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk1NA_a2059663-fa5f-4600-b83d-26935bfb5805">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1e1655a7659d44a5848ce4031db00715_I20221231" decimals="3" name="ehc:Jointventureownershippercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk1Nw_79d72436-1566-425d-83e4-77c05d3bd5a0">97.5</ix:nonFraction>% ownership in the remaining <ix:nonFraction unitRef="hospital" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="ehc:NumberOfJointlyOwnedInpatientRehabilitationHospitals" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk2MA_b187f73b-a881-4332-a674-fcf42568c8bb">58</ix:nonFraction> jointly owned hospitals.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_166"></div><ix:continuation id="id9e914ae98ed4bf3b39220f5e1aa67d9" continuedAt="ic736fd029bc4457095b6f7cb2e30eeb0"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjYvZnJhZzplMGJhZTVkYjExNDY0MjllYjZlNDVkMTYwNmFhYjA4ZC90ZXh0cmVnaW9uOmUwYmFlNWRiMTE0NjQyOWViNmU0NWQxNjA2YWFiMDhkXzE1MjE_8224523f-a7e0-4ae6-b349-ae16a16d8dca" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Consolidation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Encompass Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We eliminate all significant intercompany accounts and transactions from our financial results.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_169"></div><ix:continuation id="ic736fd029bc4457095b6f7cb2e30eeb0" continuedAt="i1140de55032b4e388b76fa89dbbfa44e"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjkvZnJhZzo5MGRjZGE5YzJkOGU0YTQwOGVkMWJmMGQ5NmJhZjU2Ni90ZXh0cmVnaW9uOjkwZGNkYTljMmQ4ZTRhNDA4ZWQxYmYwZDk2YmFmNTY2XzYzOA_86bdad47-9d6f-4e48-8097-e782582f310d" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any entity considered a variable interest entity (&#8220;VIE&#8221;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_172"></div><ix:continuation id="i1140de55032b4e388b76fa89dbbfa44e" continuedAt="if29a210a3702451fab1c31a56d6746fa"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzIvZnJhZzpiMGFhNGJiZTQyODc0ODViOTAyZGUyNTY3ODJjZWM0NC90ZXh0cmVnaW9uOmIwYWE0YmJlNDI4NzQ4NWI5MDJkZTI1Njc4MmNlYzQ0XzE4MTM_a6997718-769f-4511-96a6-6d63965bdb75" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates and Assumptions&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#8217; compensation, and comprehensive general insurance liability risks; and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_175"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="if29a210a3702451fab1c31a56d6746fa" continuedAt="i5620e0aff41c499b8ef66bc6c54ace11"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a healthcare provider, we are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensure, certification, and accreditation;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coding and billing for services;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements of the 60% compliance threshold under The Medicare, Medicaid and State Children&#8217;s Health Insurance Program (SCHIP) Extension Act of 2007;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality of medical care;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use and maintenance of medical supplies and equipment;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance and security of patient information and medical records;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition and dispensing of pharmaceuticals and controlled substances; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disposal of medical and hazardous waste.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, contractual arrangements, and patient admittance practices.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable laws and regulations, we could be required to return portions of reimbursements deemed after the fact to have not been appropriate. We could also be subjected to liabilities, including (1)&#160;criminal penalties, (2)&#160;civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals, and (3)&#160;exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement. Because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. Specifically, reductions in reimbursements, substantial damages, and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operation, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the United States Congress and some state legislatures have periodically proposed significant changes in regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in pricing roll-backs or freezes or reimbursement reductions. Because we receive a significant percentage of our revenues from Medicare, such changes in legislation might have a material adverse effect on our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are increasing pressures from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. We could be adversely affected in some of the markets where we operate if we are unable to negotiate and maintain favorable agreements with third-party payors.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i5620e0aff41c499b8ef66bc6c54ace11" continuedAt="i9c7d464636bd42178f741306075914ea"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are a party to a number of lawsuits. We cannot predict the outcome of litigation filed against us. Substantial damages or other monetary remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_178"></div><ix:continuation id="i9c7d464636bd42178f741306075914ea" continuedAt="i511e2fff0e094ab48c753e5d636b387f"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues&#8212;</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzE1NTAz_b9a5ff1a-98ed-4dc7-bb3d-5179bda657be" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3909299e17d4e9f96039b48644e435f_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzMtMTMtMS0xLTI0NTQ3Nw_b3af1a5d-a8e0-4739-b46e-660556899b5f">2,843.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i434a61101a024049985e7041374c1bad_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzMtMTUtMS0xLTI0NTQ3Nw_92c02ad0-8461-44d4-8ba2-54e2829a9f18">2,589.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9d5eba60544d49a2a58e9b24ce961c_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzMtMTctMS0xLTI0NTQ3Nw_b68451c4-c9fa-4f26-97f6-6c2c51bc6307">2,375.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice387dc1f36b45818af7e9c1a280c084_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzQtMTMtMS0xLTI0NTQ3Nw_b0b3e004-0c90-4a48-ad8c-575d038eb6e4">654.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a52ec290e7476db602a525bdf83e5a_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzQtMTUtMS0xLTI0NTQ3Nw_c62e4a7b-b7e1-4426-9137-162516bfc61d">609.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3840cc62129543f286c32d03fc7cf594_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzQtMTctMS0xLTI0NTQ3Nw_f199648d-90c1-4376-8e0b-af65bd2d94ce">544.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib537455ec5074b27bc814bd625721be3_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzUtMTMtMS0xLTI0NTQ3Nw_4d960181-386a-4869-b3af-1195858313a1">505.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd562e2b20ab46e9a82490a8cca0f618_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzUtMTUtMS0xLTI0NTQ3Nw_b9da1420-3943-477d-b8de-f7deddc77444">484.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i630c01ac29fa4ca1b4254e8c177f88ae_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzUtMTctMS0xLTI0NTQ3Nw_c47ce774-e70d-4375-96b2-db69a626b024">371.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee6d97175b5645daab81c40993423b85_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzYtMTMtMS0xLTI0NTQ3Nw_b221625f-61eb-45f7-9283-d55470be121e">183.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida31c9eb47794f719d9ff1564ca9f77f_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzYtMTUtMS0xLTI0NTQ3Nw_c2d8dce7-d5b1-4bae-862f-9f1aecf4c688">163.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc59f2f9d2c34e778b82df851653ec07_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzYtMTctMS0xLTI0NTQ3Nw_1036bc1a-9a91-4d73-868c-054cf2c37ed0">140.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c60193a93c54ef0a8b26ce2749c4573_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzctMTMtMS0xLTI0NTQ3Nw_31d9196d-aad2-4755-9a23-ab4d0d741cb9">39.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ebf32157a548a689b81b59e52d7061_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzctMTUtMS0xLTI0NTQ3Nw_345e7ab8-c7f4-4237-8bf9-ec7cead05e1b">46.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00dcced69aa245dd932b997347d492c6_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzctMTctMS0xLTI0NTQ3Nw_c79247a5-33ea-4afb-91a2-18f978a110df">43.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica31326e89794cf4a262a71ea82be401_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzgtMTMtMS0xLTI0NTQ3Nw_80b62807-f106-450b-bcf9-dc7555c4b49b">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2eb0b8b29c4c10b2c019f78880ab94_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzgtMTUtMS0xLTI0NTQ3Nw_0d9f7e9f-a026-4533-8b8c-6d528da8bbf0">23.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65daa5d21414406d9a73be137948b909_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzgtMTctMS0xLTI0NTQ3Nw_eac76d89-a239-47b6-9065-174ad651f335">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8611bd0ee7e5407987c11b03aa8312b6_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzktMTMtMS0xLTI0NTQ3Nw_4b83a6de-48a7-478f-81f5-e4840e331e6d">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46ecd39de0ee482b9b66faa630bdf25b_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzktMTUtMS0xLTI0NTQ3Nw_17d7fa62-7602-4346-b66e-a3032c8be151">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i578490c7d6584a1ba41aa384335fae6a_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzktMTctMS0xLTI0NTQ3Nw_f2f0a5fe-6fd4-4300-b927-99b0fdb21def">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05243f3cbac341b8a9bec5a4f2859f00_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzEwLTEzLTEtMS0yNDU0Nzc_19c4c585-4891-4e98-b7ae-7cb7dcef7730">81.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22a983720214ed4a192fcba2d07abcc_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzEwLTE1LTEtMS0yNDU0Nzc_22c63fe1-f74f-4a4b-93a9-4e91413a8a2c">79.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e0f753c8be14e67b8509c7dd73fd6bf_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzEwLTE3LTEtMS0yNDU0Nzc_7caaf0dd-39d4-4682-af94-a4173dc96269">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzExLTEzLTEtMS0yNDU0Nzc_b6408f65-43e9-4f83-b245-2b8d2e991e38">4,348.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzExLTE1LTEtMS0yNDU0Nzc_687218d1-9773-4441-be7d-818ba16fc963">4,014.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzExLTE3LTEtMS0yNDU0Nzc_216b36a8-02f7-4e18-8d80-69d8ede33fbb">3,566.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzE1NTA4_f3234560-1678-4b21-a906-2a4b44d4bcfc" continuedAt="i0c0eb95553884324a15dfe5b1cb86ddb" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;) or the United States Department of Justice (the &#8220;DOJ&#8221;). Therefore, we are unable to predict if or when we may be </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i511e2fff0e094ab48c753e5d636b387f" continuedAt="i4c67465d6e784ccfb293847371312097"><ix:continuation id="i0c0eb95553884324a15dfe5b1cb86ddb" continuedAt="i6cebe1a877f049719ee5a87ea22c508a"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Administrative Contractors (&#8220;MACs&#8221;), under programs known as &#8220;widespread probes,&#8221; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#8220;appeal,&#8221; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. During 2022, the backlog of &#8220;widespread probe&#8221; claims adjudicated by the administrative law judge (&#8220;ALJ&#8221;) continued and were substantially completed. This OMHA practice resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims. We have appealed certain adverse ALJ rulings to the Department Appeals Boards (&#8220;DAB&#8221;), the final level of administrative review. As of December 31, 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="i852b75f329ea4ac08df2108afdf43e72_I20221231" decimals="-6" name="ehc:LossContingencyClaimsAwaitingReviewAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwMTY_85a5587e-312a-4e47-a902-2916f5dea439">52</ix:nonFraction>&#160;million in claims are awaiting review at the DAB. In addition, we have appealed approximately $<ix:nonFraction unitRef="usd" contextRef="i852b75f329ea4ac08df2108afdf43e72_I20221231" decimals="-6" name="ehc:LossContingencyAppealedClaimsDeniedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwMjk_43ab8efa-aa66-4611-bae2-93a001ed4e66">6</ix:nonFraction>&#160;million in claims denied by the DAB to several United States District Courts, all of which are pending review as of December 31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, CMS announced the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with CMS approved and announced Recovery Audit Contractors (&#8220;RACs&#8221;) audits related to inpatient rehabilitation facilities (&#8220;IRFs&#8221;), we received requests from 2013 to 2022 to review certain patient files for discharges occurring from 2010 to 2022.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established Unified Program Integrity Contractors (&#8220;UPICs&#8221;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors. In December 2017, we received notice of a UPIC audit at one of our hospitals. The UPIC sampled <ix:nonFraction unitRef="claim" contextRef="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231" decimals="INF" name="ehc:LossContingencyNumberOfClaimsSampledForAudit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzM4NDgyOTA3MjEwNDE_1780c845-5f03-4aa0-a9ab-36526fc39ef9">100</ix:nonFraction> claims and challenged the propriety of a subset of the sample representing $<ix:nonFraction unitRef="usd" contextRef="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231" decimals="-5" name="ehc:LossContingencyClaimsSampledForAuditAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwNDE_32048ed8-13e0-4e5a-a71f-f18b5ea4723d">1.3</ix:nonFraction>&#160;million in previously paid claims. The UPIC extrapolated the alleged error rate to all claims from that hospital during a period of approximately <ix:nonNumeric contextRef="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231" name="ehc:LossContingencyExtrapolatedErrorRatePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzM4NDgyOTA3MjEwNjE_1fafda42-f5df-489e-ba9a-58c5a5d5ada2">four years</ix:nonNumeric>, resulting in an alleged overpayment of $<ix:nonFraction unitRef="usd" contextRef="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231" decimals="-5" name="ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwNTU_29693191-2d2b-44ec-9f4f-d7234d6848df">33.9</ix:nonFraction>&#160;million. Our MAC later reduced the determination of overpayment to $<ix:nonFraction unitRef="usd" contextRef="ic18e0c6dae034e2e9081f26733964490_D20190101-20191231" decimals="-5" name="ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzM4NDgyOTA3MjEwNDc_324f9c33-eaaa-419c-846a-de45dd6e67cb">30.5</ix:nonFraction>&#160;million, which it collected through recoupment of current claims during 2019. We appealed the overpayment determination to an Administrative Law Judge (&#8220;ALJ&#8221;), who heard the appeal in August 2021. In October 2022, the ALJ </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i4c67465d6e784ccfb293847371312097" continuedAt="ibc40b738bc7b44708d37061e120cba3f"><ix:continuation id="i6cebe1a877f049719ee5a87ea22c508a"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overturned $<ix:nonFraction unitRef="usd" contextRef="i461326ed8069459c9262b7d8a144ce07_D20221001-20221031" decimals="-5" name="ehc:LossContingencyAmountOverturnedOfOverpaymentDetermination" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwNzE_94a97282-0aa1-4734-bf06-6ffd56dc3156">12.5</ix:nonFraction>&#160;million of the overpayment determination. We received payment of this amount, plus $<ix:nonFraction unitRef="usd" contextRef="i870361686c2942fdb9b4a9bc9337f323_D20221201-20221231" decimals="-5" name="ehc:LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwODY_65c693cf-b12c-4367-b5cd-7f561b76a8f3">3.2</ix:nonFraction>&#160;million in interest, in December 2022. We have appealed the remaining $<ix:nonFraction unitRef="usd" contextRef="i870361686c2942fdb9b4a9bc9337f323_D20221201-20221231" decimals="-5" name="ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIxMDA_c147b995-e39f-4e39-844c-4cc12b572067">18.0</ix:nonFraction>&#160;million of the overpayment determination to the DAB, the next level of administrative appeal, challenging both the denials and the improper use of extrapolation. It is not possible to predict when this matter will be resolved or the ultimate outcome.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Medicare claims that are subject to these post-payment audit requests represent less than <ix:nonFraction unitRef="number" contextRef="idb58224ff71f435f975b30807048a7fa_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgxNjM_72d91f51-a2e5-475e-8691-820ff2c13d6b">1</ix:nonFraction>% of our Medicare patient discharges from 2010 to 2022. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2022, 2021, and 2020, our adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for claims that are part of this post-payment claims review process was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.</span></div></ix:continuation></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_181"></div><ix:continuation id="ibc40b738bc7b44708d37061e120cba3f" continuedAt="i2591eca28ffb42908d764eeb747d4ced"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODEvZnJhZzowZDgwMzA4ZGFlNjc0ZjRiYWQyOGE4ZGM1NmU4OTA0OS90ZXh0cmVnaW9uOjBkODAzMDhkYWU2NzRmNGJhZDI4YThkYzU2ZTg5MDQ5XzUzOA_e8ecea66-05ce-4064-8909-cd127e5eff75" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include highly liquid investments with maturities of three months or less when purchased. Carrying values of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approximate fair value due to the short-term nature of these instruments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_184"></div><ix:continuation id="i2591eca28ffb42908d764eeb747d4ced" continuedAt="id895c5073c3d4d5cb7d0e755ef98a178"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODQvZnJhZzo1OTkzZTkzOGFlYmU0NjA3OGUwZTBlMzNmMmQ4MTBiNi90ZXh0cmVnaW9uOjU5OTNlOTM4YWViZTQ2MDc4ZTBlMGUzM2YyZDgxMGI2XzEzNjA_7f5f082f-9f7a-45ce-9df0-8be6911559ac" continuedAt="i3718b14f22b14bde8ae8c3a873e863f4" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a separate component of shareholders&#8217; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id895c5073c3d4d5cb7d0e755ef98a178" continuedAt="i599d472c784c453a83ac782f9ce8753e"><ix:continuation id="i3718b14f22b14bde8ae8c3a873e863f4">time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.</ix:continuation></ix:continuation></span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_187"></div><ix:continuation id="i599d472c784c453a83ac782f9ce8753e" continuedAt="id70ebc2d0c664b2b9587b16736cd07b9"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90ZXh0cmVnaW9uOjlmNmE0ZjhkNGE2NjRmYWZiYjcwYTgyMjk0NTc5YzllXzM1MTk_ee074128-3ace-4002-8c0c-72faa0d47aa3" continuedAt="i73d3da2d9b304e56a8457dc60ae07f17" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#8217; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90ZXh0cmVnaW9uOjlmNmE0ZjhkNGE2NjRmYWZiYjcwYTgyMjk0NTc5YzllXzM1MjA_6f88053c-903b-47e2-94e7-14f1903bc4e5" continuedAt="i64d0f136154b483b8f215f710a94005f" escape="true">The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="i64d0f136154b483b8f215f710a94005f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9749632394145f497fe0c2c6ec147a7_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzItMS0xLTEtMjQ1NDc3_e90cde4e-1932-4f30-94f7-4135976012d9">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe35a06f0eae46efb5c6921fe9db414c_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzItMy0xLTEtMjQ1NDc3_c0da5bd6-4ff1-48cb-a4d8-6f2d63c7363a">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other discount plans, including Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b648e892f9f4468aab25a90a2f09b05_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzMtMS0xLTEtMjQ1NDc3_2407c5db-8ab6-439d-bc0c-6eeaadd9a507">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iec6a14cc3aca48bcaeca480b39030876_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzMtMy0xLTEtMjQ1NDc3_7b8f1da5-efa4-402f-bcf4-857dc9029593">31.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a03052d15b64c25a269fdcc4216b88c_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzQtMS0xLTEtMjQ1NDc3_b96e16f6-0ef9-476d-8f54-49dae51eae53">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibefecfaeeeb041849960421b13ca007b_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzQtMy0xLTEtMjQ1NDc3_d623ffe3-44ad-41a8-a3ad-028f27bcf86e">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c4d794905dd4fb385b71c4eed009bb7_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzUtMS0xLTEtMjQ1NDc3_4e581e54-7d25-40c9-9a59-f0c22537eb22">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52751714abc34c4d98dc47a7a77e2370_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzUtMy0xLTEtMjQ1NDc3_59477c12-3eb1-4eca-88ba-49dd53385555">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e50571d65784dfc9aef9033d5f99181_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzYtMS0xLTEtMjQ1NDc3_2d2d0c70-3f5e-489e-80ac-144f32459284">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3c18279fe4d4018bbe852e7b57b1d47_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzYtMy0xLTEtMjQ1NDc3_a63d6562-10f4-42c8-85bb-235d3755cdf5">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ab836dfffa54e4b814fbfc5b759b918_D20220101-20221231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzctMS0xLTEtMjQ1NDc3_5420cf4e-08c2-4b28-bb2c-e9de371a160f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i66c304bf2ec048b88bf47a3f2c6c5a54_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzctMy0xLTEtMjQ1NDc3_b38d96ce-b2b2-4f86-9ba0-a34b3b5e9ecf">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib014de72370b4cb4a6135adc8af20d7b_D20220101-20221231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzgtMS0xLTEtMjQ1NDc3_e8a25818-252c-4f65-8e49-548d1246279d">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifc2b37264d734f2d8f5833e77968d634_D20210101-20211231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzgtMy0xLTEtMjQ1NDc3_7c9ecc05-a1ff-4f93-b144-4ea2df73fcb5">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id70ebc2d0c664b2b9587b16736cd07b9" continuedAt="i51bb26aee71b4e62b6a04e1cc75bd855"><ix:continuation id="i73d3da2d9b304e56a8457dc60ae07f17">governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.</ix:continuation></ix:continuation></span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_190"></div><ix:continuation id="i51bb26aee71b4e62b6a04e1cc75bd855" continuedAt="ie9a5702709af48729b7ca380a385aba4"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90ZXh0cmVnaW9uOjdlMjI5NmU1NTYxMzRjZWY4OTcwZWQ3YTE1NzBmNmUyXzE0ODc_0079117b-f342-493d-8aa1-016e570efa51" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90ZXh0cmVnaW9uOjdlMjI5NmU1NTYxMzRjZWY4OTcwZWQ3YTE1NzBmNmUyXzE0ODM_26b9852a-476f-4ddc-bd08-ad750aef0486" continuedAt="iaf7f80e4c7444660afe43e0c65c481f8" escape="true">Useful lives are generally as follows:</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="iaf7f80e4c7444660afe43e0c65c481f8" continuedAt="i5dc0da37401f4e8a89df6f2fc94fb4fa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:84.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4cb56d21aab74ac3967968f076197961_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2NmMzY1ZDA0N2QyNGMyZDlkN2I2MTFjOWI2Y2MxYWJfNA_d3eca5c7-3ccf-4c7d-96dc-66ebf2ab6be7">10</ix:nonNumeric> to <ix:nonNumeric contextRef="idfd7ae0589ea4a128b3e3e4861478b00_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2NmMzY1ZDA0N2QyNGMyZDlkN2I2MTFjOWI2Y2MxYWJfMTA_1d8dbbfd-7aae-44dc-bff4-fa230a7939ad">30</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5139d245eba04e15a063f9bc48d18aa7_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246M2MzYzFjMTZkMTRjNGE5OTg3OGRkODgyZGQzN2YwODBfNA_55f63f3b-1a8c-454f-a5f4-79c65858e174">2</ix:nonNumeric> to <ix:nonNumeric contextRef="ib932dccdf96b459687584cc4f8701479_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246M2MzYzFjMTZkMTRjNGE5OTg3OGRkODgyZGQzN2YwODBfMTA_a09dc7da-78a9-4f31-8205-47a16627bd9d">15</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib1e69d3358704dd18df22349448291f5_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ODBjN2JmMGYyMjk0NDdmODkwN2VjOGM4M2ZiNzdmMzdfNA_a36fa819-246f-439b-8b3d-c4085159a9b8">5</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i176405163b9c4c37878dcef0b9e741ce_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzQtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTk2MDkxMmIzMzIwNGFjYzgzMjk2ZjQ0M2E1Y2M3MzRfNA_52427c57-6818-488d-8785-e291717247df">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i9b43ec38059149d4ba26be2569eb2a25_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzQtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTk2MDkxMmIzMzIwNGFjYzgzMjk2ZjQ0M2E1Y2M3MzRfMTA_0c04d5b2-7447-4e1d-b624-40b159c94f3a">10</ix:nonNumeric></span></div></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_193"></div><ix:continuation id="ie9a5702709af48729b7ca380a385aba4" continuedAt="i6d76e33a09104a7fb09c34796822b912"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTMvZnJhZzplMzU5MGQwM2VhNjM0MzEzYThjNzMxYmQzYTBkMmNiOS90ZXh0cmVnaW9uOmUzNTkwZDAzZWE2MzQzMTNhOGM3MzFiZDNhMGQyY2I5XzE3NTU_8fa622aa-a6d6-4d6f-9bbc-6aaa6d34cea8" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8212;</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. In general, we do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_196"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i6d76e33a09104a7fb09c34796822b912" continuedAt="ie7f762486d794737886792c8405e4083"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90ZXh0cmVnaW9uOjJkMWM2N2I4YWU5YzQ5YThiNGRlNmFkYWUyMDMzODBjXzQ2MTk_4ff65fff-50fa-4015-855f-d6ff296b5237" continuedAt="ibd9c6ec200064e0ab7d79ecb08c26500" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets&#8212; </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors in our single reporting unit to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our reporting unit using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of our reporting unit&#8217;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting unit to our market capitalization. When we dispose of a hospital, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2022, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount.</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90ZXh0cmVnaW9uOjJkMWM2N2I4YWU5YzQ5YThiNGRlNmFkYWUyMDMzODBjXzQ2MDI_39f3b802-376c-4253-90f7-d3fc023add53" escape="true"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90ZXh0cmVnaW9uOjJkMWM2N2I4YWU5YzQ5YThiNGRlNmFkYWUyMDMzODBjXzQ2MjM_2ced868e-dcda-4422-97eb-1c40e18e62e9" continuedAt="i4c03b5215ac643f3bfbb375e1b20c6a8" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:62.953%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1d16d99320d0432eae3d9ff01729bc03_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MGM0ZjIwMTEzYzQ3NDQzNWIwNjc2OWFlOGNiZTMzMzhfNA_ba955688-bbe0-48d5-911b-d60c090fa216">10</ix:nonNumeric> to <ix:nonNumeric contextRef="ic54237316ac9413084b19847adf7f2fb_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MGM0ZjIwMTEzYzQ3NDQzNWIwNjc2OWFlOGNiZTMzMzhfMTA_2433a993-cdb6-41f4-8f42-c55683722920">30</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i59a65005892243e682dc792c081f8c0a_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2FmNGE4YmQ3NDE5NGUxMzhjMmRjMjVkMWNiZTliMGZfNA_3a125d34-4d61-4a27-b186-1bbdc77512d8">10</ix:nonNumeric> to <ix:nonNumeric contextRef="ibb79ea3f749d47ffbe3c65d094ac96bc_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2FmNGE4YmQ3NDE5NGUxMzhjMmRjMjVkMWNiZTliMGZfMTA_57a67411-aacb-4384-8a1d-818fa8c51188">20</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i436bf0be46974157827b0ca4b6e81e07_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NGRkMmY2YmJhNjNhNGQyMGJiNjhhNzgwZTEyZjFlMTZfNA_105834ec-4c35-42e2-bee2-3a6492f14241">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i9d936af5f8ec4ce8a15339c7e5b4fa6c_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NGRkMmY2YmJhNjNhNGQyMGJiNjhhNzgwZTEyZjFlMTZfMTA_e33c321e-9b53-4bd2-a93e-ebeaf1c0bcf4">18</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i171d0e9f00ac4274a1c1fb90c3567010_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzYtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2M5ZTJiNzNkMjlhNDc0MjhjOGY2YzIwOWExN2Y1YjRfNA_a1bb2bff-d4e4-40e0-9023-51fa39dc85f7">10</ix:nonNumeric> to <ix:nonNumeric contextRef="idd848d2dde614489a20f1870d96a944a_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzYtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2M5ZTJiNzNkMjlhNDc0MjhjOGY2YzIwOWExN2Y1YjRfMTA_f51e4134-02ea-4227-bfaa-5bd75c593561">20</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib57c2c4651af459192fda104b5d0dd00_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzctMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjNlMWM2MzM1NjhkNDQ4ODkyMTdmODQxMDZiNmRjZWNfNA_b06717c5-63dc-4027-bcb2-3697cab2223f">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i470cf08a07fe4287a486a76f384d82ad_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzctMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjNlMWM2MzM1NjhkNDQ4ODkyMTdmODQxMDZiNmRjZWNfMTA_2da0ef1d-69ca-47ff-b9ad-c66a81b1704e">7</ix:nonNumeric> years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icf944ca96a324447a5fead2b5afb9747_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzgtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246YmYxMDJmOWYzYTYwNDAwMzk1YjUzNGVjNDYwZTI1MDdfNA_4fdf1835-d97e-477f-8099-fd3812c0f27b">20</ix:nonNumeric> years using accelerated basis</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and certain directly related payroll costs. Amortization begins when the internal-use software is ready for its intended </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ie7f762486d794737886792c8405e4083" continuedAt="ib52c47ca5aaf4bc2b5acff279c12565e"><ix:continuation id="ibd9c6ec200064e0ab7d79ecb08c26500"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#8217;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over <ix:nonNumeric contextRef="icf944ca96a324447a5fead2b5afb9747_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90ZXh0cmVnaW9uOjJkMWM2N2I4YWU5YzQ5YThiNGRlNmFkYWUyMDMzODBjXzQ0Njc_4fdf1835-d97e-477f-8099-fd3812c0f27b">20</ix:nonNumeric> years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.</span></div></ix:continuation></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_199"></div><ix:continuation id="ib52c47ca5aaf4bc2b5acff279c12565e" continuedAt="ibf87a55e8d77481b9a765636d0ced285"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="ehc:LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTkvZnJhZzo4NGM5NDAyY2UzZjI0YTg4OWM0ZjU0MGFjYjNlNTBkYi90ZXh0cmVnaW9uOjg0Yzk0MDJjZTNmMjRhODg5YzRmNTQwYWNiM2U1MGRiXzE1MjU_15247b59-d32c-4c5e-905b-0db0fb62effb" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets and Other Intangible Assets&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_205"></div><ix:continuation id="ibf87a55e8d77481b9a765636d0ced285" continuedAt="idea50f4b6b6e419bb86e8c57cc4d5ae3"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMDUvZnJhZzo2NmIxZDk4NWZiMWQ0ZDU2YWIxYTVhMTlkN2VjYTJmYS90ZXh0cmVnaW9uOjY2YjFkOTg1ZmIxZDRkNTZhYjFhNWExOWQ3ZWNhMmZhXzg5OA_9a434f15-fd01-47c5-b231-58aa5ede861b" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_208"></div><ix:continuation id="idea50f4b6b6e419bb86e8c57cc4d5ae3" continuedAt="i81a4dc7de3cf47cfaf6fa448a0b7ba57"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMDgvZnJhZzo4MzMyOGM4NWUwZmM0ZDNhYTU1OThkOTIxYmRjMDgxZi90ZXh0cmVnaW9uOjgzMzI4Yzg1ZTBmYzRkM2FhNTU5OGQ5MjFiZGMwODFmXzM5MzQ_80ae4d5b-acb5-482c-83f9-a84d7d68b53c" continuedAt="i69d0a2054d4344da80e273135ff8f7b2" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Observable inputs such as quoted prices in active markets;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i81a4dc7de3cf47cfaf6fa448a0b7ba57" continuedAt="i5986dd7bea9a42f8a8106dc57f858bf2"><ix:continuation id="i69d0a2054d4344da80e273135ff8f7b2"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also the &#8220;Redeemable Noncontrolling Interests&#8221; section of this note.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_211"></div><ix:continuation id="i5986dd7bea9a42f8a8106dc57f858bf2" continuedAt="i3de7a93b504c4a6e844c0868b64661d6"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMTEvZnJhZzo2Y2E5NWMyYmI2MTE0Y2UwYjQ5YjEzNDRiMmJhMTQ4Yi90ZXh0cmVnaW9uOjZjYTk1YzJiYjYxMTRjZTBiNDliMTM0NGIyYmExNDhiXzY0NQ_7840b5e8-470f-49b8-a118-3a17e0cdbd26" continuedAt="i32fbf1fdc2494a33b2c502b48239cd62" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interests in Consolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#8217; balance.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_214"></div><ix:continuation id="i3de7a93b504c4a6e844c0868b64661d6" continuedAt="ib5bd2f24a7b641739b3599c559eebe5c"><ix:continuation id="i32fbf1fdc2494a33b2c502b48239cd62" continuedAt="ie7c4587ce0b442f4a3bf22827e028dfa"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future.  Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="ib5bd2f24a7b641739b3599c559eebe5c" continuedAt="ic34a7b3ee5d7460dae8c6c3b3c4c3a56"><ix:continuation id="ie7c4587ce0b442f4a3bf22827e028dfa"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to certain members of the home health and hospice management team&#8217;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-6" name="ehc:RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMTQvZnJhZzoyNzgxZmIxZjIzZjU0OTJjYWMzZDcyODI2MjM1YTBiMy90ZXh0cmVnaW9uOjI3ODFmYjFmMjNmNTQ5MmNhYzNkNzI4MjYyMzVhMGIzXzY1OTcwNjk3NzAxMDE_004b54ca-e767-404d-89fa-fbd883ae6df0">400</ix:nonFraction>&#160;million or more. The fair value of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#8217; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.</span></ix:continuation></ix:continuation></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_217"></div><ix:continuation id="ic34a7b3ee5d7460dae8c6c3b3c4c3a56" continuedAt="i830210ad119c43b4907b0d9fe4620100"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMTcvZnJhZzoyMzRhOGQ1YWFiYmM0NzJlYjY1MGU2MWNlYjliNjhkOC90ZXh0cmVnaW9uOjIzNGE4ZDVhYWJiYzQ3MmViNjUwZTYxY2ViOWI2OGQ4XzY0OQ_49911ccc-6faf-4d54-846a-b76c7d1854c5" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_220"></div><ix:continuation id="i830210ad119c43b4907b0d9fe4620100" continuedAt="ia0f0809150214d3bb62243b71d1ffb35"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjAvZnJhZzozNDliMTM2ODFiOTM0ODI3YTkwOTUxMWM1ODgyMjFjYy90ZXh0cmVnaW9uOjM0OWIxMzY4MWI5MzQ4MjdhOTA5NTExYzU4ODIyMWNjXzc0OA_82427266-74ed-44be-ad2e-d61c6c99f83c" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Reserves&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjAvZnJhZzozNDliMTM2ODFiOTM0ODI3YTkwOTUxMWM1ODgyMjFjYy90ZXh0cmVnaW9uOjM0OWIxMzY4MWI5MzQ4MjdhOTA5NTExYzU4ODIyMWNjXzMwMA_5cb861b8-24c4-493f-94ad-50b72236f4a3">5.0</ix:nonFraction> million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_223"></div><ix:continuation id="ia0f0809150214d3bb62243b71d1ffb35" continuedAt="ife736ec9258148a084f65a046871af10"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjMvZnJhZzplMDg2OWE4MjI0ZjU0ODUxOWJlMmFhZDAzNWQwMmIzMS90ZXh0cmVnaW9uOmUwODY5YTgyMjRmNTQ4NTE5YmUyYWFkMDM1ZDAyYjMxXzM0Mg_a9f3beb0-ed80-461e-b1b9-cfe89a805c03" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the accompanying consolidated statements of comprehensive income, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjMvZnJhZzplMDg2OWE4MjI0ZjU0ODUxOWJlMmFhZDAzNWQwMmIzMS90ZXh0cmVnaW9uOmUwODY5YTgyMjRmNTQ4NTE5YmUyYWFkMDM1ZDAyYjMxXzI1NQ_8723e6d6-5963-437c-b874-c92c88fd0dda">6.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjMvZnJhZzplMDg2OWE4MjI0ZjU0ODUxOWJlMmFhZDAzNWQwMmIzMS90ZXh0cmVnaW9uOmUwODY5YTgyMjRmNTQ4NTE5YmUyYWFkMDM1ZDAyYjMxXzI1OQ_9bbf9bc3-4393-425b-8336-86c51297800d">5.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjMvZnJhZzplMDg2OWE4MjI0ZjU0ODUxOWJlMmFhZDAzNWQwMmIzMS90ZXh0cmVnaW9uOmUwODY5YTgyMjRmNTQ4NTE5YmUyYWFkMDM1ZDAyYjMxXzI2Nw_089c7091-a893-4ec8-a66f-1ebaaa23e988">4.6</ix:nonFraction> million in each of the years ended December 31, 2022, 2021, and 2020, respectively.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_226"></div><ix:continuation id="ife736ec9258148a084f65a046871af10" continuedAt="ib881bfbf08024c6f841e6f37fb8fdc65"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjYvZnJhZzoyN2UwOThiMTNjOTY0ZGRiODU1YjI2OTNkZGYwMWU5Yi90ZXh0cmVnaW9uOjI3ZTA5OGIxM2M5NjRkZGI4NTViMjY5M2RkZjAxZTliXzI0NzQ_c6558730-2ec2-445c-98aa-0e8986e88507" continuedAt="ifc037db9e13041ac86b0ac37ad583cfb" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the asset and liability method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib881bfbf08024c6f841e6f37fb8fdc65" continuedAt="i363c7aa19867425ebb2d76f14252922b"><ix:continuation id="ifc037db9e13041ac86b0ac37ad583cfb">include the allocable portion of each pass-through entity&#8217;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.</ix:continuation> </ix:continuation>We include the activity of Enhabit, Inc. and its subsidiaries in our consolidated and combined tax filings for 2022 up through the date of the Spin Off, which is defined and described in Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin Off of Home Health and Hospice Business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the Spin Off, Enhabit, Inc. and its subsidiaries will no longer be included in our consolidated and combined filings.</span></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_229"></div><ix:continuation id="i363c7aa19867425ebb2d76f14252922b" continuedAt="iebf31a85ea9b48e9ac69e937abea9a4a"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjkvZnJhZzo1OGUwNjVmN2IxZDU0ODY1YTY0YjA2YzUwN2EyYTA4Ni90ZXh0cmVnaW9uOjU4ZTA2NWY3YjFkNTQ4NjVhNjRiMDZjNTA3YTJhMDg2XzE2OTc_cd73bf59-c26e-42ed-926b-643814311d54" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities in and Results of Discontinued Operations&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income from discontinued operations, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current assets of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Noncurrent assets of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current liabilities of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent liabilities of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_232"></div><ix:continuation id="iebf31a85ea9b48e9ac69e937abea9a4a" continuedAt="i36e015473d4c4622a2809dcb6d08c8bb"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMzIvZnJhZzoyMWY1MDc3Y2VjYTE0MDk4YTlkZDY1OGFjMmRlNTFhMC90ZXh0cmVnaW9uOjIxZjUwNzdjZWNhMTQwOThhOWRkNjU4YWMyZGU1MWEwXzk2Mw_2743d94f-6e77-46d5-960d-36b97d6bb734" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_235"></div><ix:continuation id="i36e015473d4c4622a2809dcb6d08c8bb" continuedAt="i08aee3bc73d6457baa7de42589453764"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMzUvZnJhZzplMzZmZGUzNDc1OGE0YzNhOWJlZmFjYzBjOGZkMjY5YS90ZXh0cmVnaW9uOmUzNmZkZTM0NzU4YTRjM2E5YmVmYWNjMGM4ZmQyNjlhXzQwMg_3d581c3f-acbb-45ce-982c-1c4028b12767" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We account for the retirement of treasury stock as a reduction of retained earnings.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_238"></div><ix:continuation id="i08aee3bc73d6457baa7de42589453764" continuedAt="i5b468ec664bd485c8d70fe88808ada61"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMzgvZnJhZzpiZjg4M2NhYjIwMGE0MDViOWZmYjg2NjgyZjgwYmE1YS90ZXh0cmVnaW9uOmJmODgzY2FiMjAwYTQwNWI5ZmZiODY2ODJmODBiYTVhXzIyMg_b2abe590-fd5b-478f-9345-cc5d5c7c111c" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_241"></div><ix:continuation id="i5b468ec664bd485c8d70fe88808ada61"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDEvZnJhZzoyYmJiMWQ4NTE1YTU0OWNmOTc4NmIzYjlmMGRiMTk0ZS90ZXh0cmVnaW9uOjJiYmIxZDg1MTVhNTQ5Y2Y5Nzg2YjNiOWYwZGIxOTRlXzc2Nw_0a34af2d-6dce-42e7-992f-1d48f1511c61" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_2602"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM184MjQ2MzM3MjEyNTI0_51a1f441-dd41-4cda-bcd7-2c10f71896ce" continuedAt="ie59e5e0891bc48a5bcb4424ef41a3194" escape="true">Spin Off of Home Health and Hospice Business</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie59e5e0891bc48a5bcb4424ef41a3194" continuedAt="i81d3b0f22ee04fa2a5b27b011dedda72">On July 1, 2022, we completed the previously announced separation of our home health and hospice business through the distribution (the &#8220;Spin Off&#8221;) of all of the outstanding shares of common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i81822404b04248c2bc2b92116b265222_I20220701" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTYzODY_56091ed0-7d75-446f-a469-41db95b9b89e">0.01</ix:nonFraction> per share, of Enhabit, Inc. (&#8220;Enhabit&#8221;) to the stockholders of record of Encompass Health as of the close of business on June 24, 2022 (the &#8220;Record Date&#8221;). The Spin Off was effective at 12:01 a.m., Eastern Time, on July 1, 2022. The Spin Off was structured as a pro rata distribution of one share of Enhabit common stock for every two shares of Encompass Health common stock held of record as of the Record Date. No fractional shares were distributed. A cash payment was made in lieu of any fractional shares. As a result of the Spin Off, Enhabit is now an independent public company and its common stock is listed under the symbol &#8220;EHAB&#8221; on the New York Stock Exchange.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i81d3b0f22ee04fa2a5b27b011dedda72" continuedAt="iba3fbe3c5d5449cc90f3fbcef383524e"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with applicable accounting guidance, the historical results of Enhabit have been presented as discontinued operations and, as such, have been excluded from continuing operations for all periods presented. Our presentation of discontinued operations excludes any allocation of general corporate and overhead costs as well as interest expense. Prior to July 1, 2022, we operated under <ix:nonFraction unitRef="segment" contextRef="i4ccb23d1174a4ad1bc94116310a93215_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTY0MDE_1b676667-35b7-44bf-8aa6-e40e46a55072">two</ix:nonFraction> reporting segments. We now operate under a single reporting segment. In anticipation of the Spin Off, Enhabit transferred the &#8220;Encompass&#8221; trade name (net book value of $<ix:nonFraction unitRef="usd" contextRef="i5ee3194559484035acac2abce51ef2bb_I20220630" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTY0MjA_c35f4f8e-a563-4e7d-abaf-8935b89f8400">104.2</ix:nonFraction>&#160;million) to us during the second quarter of 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin Off, on June 30, 2022, we entered into several agreements with Enhabit that govern the relationship of the parties following the Spin Off, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement and an Employee Matters Agreement.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide transition services to Enhabit predominately consisting of certain finance, information technology, human resources, employee benefits and other administrative services for a period of up to <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="ehc:DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTY0NDU_9588ff97-0ac8-4d4b-ac61-251b112648ff">two years</ix:nonNumeric> after the Spin Off. For the year ended December 31, 2022, income related to these transition services of $<ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTY0NjA_dc970b21-dcf6-454e-a297-615c2bdb49e3">2.1</ix:nonFraction>&#160;million were reflected as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM184MjQ2MzM3MjEyNTI4_9f2f318b-1139-48be-bdc4-fe461dae62ac" continuedAt="i28c3077b77af4ecabca8e75063dcd7f8" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the results of operations of Enhabit as discontinued operations (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8yLTEtMS0xLTI2NjY4Nw_18e2c57b-bef5-437b-bdf7-a584f2700f55">542.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8yLTMtMS0xLTI2NjY4Nw_a9f8f753-e939-4d5c-a436-0347bc426093">1,106.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8yLTUtMS0xLTI3MjM1Mw_452b77f7-9887-4dc4-b28f-cd0d636130f4">1,078.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF80LTEtMS0xLTI2NjY4Nw_64406213-817b-4623-b438-4e9f6985ccad">376.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF80LTMtMS0xLTI2NjY4Nw_0101c0d7-145c-45be-b222-5a862653dfe6">759.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF80LTUtMS0xLTI3MjM1Mw_20422a56-42ad-4a3d-a357-76206bce04a3">778.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF81LTEtMS0xLTI2NjY4Nw_43738bf1-4859-4dc2-bb64-1115d71ea97a">47.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF81LTMtMS0xLTI2NjY4Nw_546d12f9-b28d-4b0d-82b3-b1853b41e198">89.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF81LTUtMS0xLTI3MjM1Mw_9dd1cbb0-b1c2-4631-a4d8-56ff81bf4fc6">89.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF82LTEtMS0xLTI2NjY4Nw_41f05940-1e5b-4006-8ddd-e02556919883">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF82LTMtMS0xLTI2NjY4Nw_0e4aa7fa-4709-4d2c-85b0-063a21da022e">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF82LTUtMS0xLTI3MjM1Mw_e19bf593-d4ad-4dcb-89a5-ce4842ad82cb">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationSupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF83LTEtMS0xLTI2NjY4Nw_e0f767b5-bb6f-4994-ae03-321bc0944666">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationSupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF83LTMtMS0xLTI2NjY4Nw_53cd4c5d-6548-4ad7-b1e4-60d02380ae4d">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationSupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF83LTUtMS0xLTI3MjM1Mw_ea7a4c35-6acb-4ea1-a25e-231ae31b5e14">29.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF84LTEtMS0xLTI2NjY4Nw_50820ba5-f94f-40d7-9f80-b1e02ebce590">59.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF84LTMtMS0xLTI2NjY4Nw_426fcfa6-c01f-49b2-8413-c7e612c1198b">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF84LTUtMS0xLTI3MjM1Mw_9abd862d-6bae-40b8-a32d-70919944292b">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF85LTEtMS0xLTI2NjY4Nw_adcc502c-aed7-41d2-9e7b-78057a0aedca">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF85LTMtMS0xLTI2NjY4Nw_a8e539ba-4ec7-446d-aaf6-d3f2fb50afc0">36.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF85LTUtMS0xLTI3MjM1Mw_b830b443-7dc2-4f23-b057-8d68f099a21a">40.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMC0xLTEtMS0yNzc1Nzc_4d4ce27a-b86c-458d-824b-5f712d2508ec">522.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMC0zLTEtMS0yNzc1ODE_bfe26759-3061-43c2-88c1-81ba0092b6e0">960.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMC01LTEtMS0yNzc1ODQ_7e9c3e5a-d738-4d86-8390-d98bb158d7f7">960.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMS0xLTEtMS0yNjY2OTQ_2b0a1b11-4ff6-4c3e-a6aa-1e47a9e6a7e5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMS0zLTEtMS0yNjY2OTQ_23d83b5f-26d9-4bdf-ba5c-86efcc551fa0">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMS01LTEtMS0yNzIzNjA_48a278f8-0a30-4bad-a0ee-b4268674b8d6">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMi0xLTEtMS0yNjY2OTQ_361efd48-175b-4da2-9956-115dcf7f96b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMi0zLTEtMS0yNjY2OTQ_c29e148d-43fa-4ab2-b19f-7f08d5e64dc9">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMi01LTEtMS0yNzIzNjA_3805c8be-2bff-403e-afb7-5759886c31b6">2.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMy0xLTEtMS0yNjY2OTQ_5e438b39-ead9-4bc6-9456-895e78e79232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMy0zLTEtMS0yNjY2OTQ_ec1027ab-0c8f-4a64-be57-8b9e95b0341a">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMy01LTEtMS0yNzIzNjA_034a32e4-9056-466a-b5e7-35e2e53e69d7">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNC0xLTEtMS0yNzc1Nzc_a487a613-31f1-4852-bbb3-b026d4f79b02">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNC0zLTEtMS0yNzc1ODE_3340af90-f4bd-43b3-a4a5-917471039a7b">151.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNC01LTEtMS0yNzc1ODQ_9771e6ee-70b6-40a6-9b41-994da03af403">119.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNS0xLTEtMS0yNjY3MDY_5f254c4f-8990-43f9-838d-063a2e2e7d98">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNS0zLTEtMS0yNjY3MDY_3e0b883e-c6f0-4b36-b2d7-ac1673e3db6a">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNS01LTEtMS0yNzIzNjc_41c91512-c5b7-404d-8d8a-b397fd855549">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNi0xLTEtMS0yNzc1Nzc_b94219c7-1890-4968-9cc8-965c5fac477b">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNi0zLTEtMS0yNzc1ODE_f5177ac6-b791-4885-a24c-3a1f0c362513">114.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNi01LTEtMS0yNzc1ODQ_cb9f026f-7087-4dcf-aa8c-4fc73c688e79">90.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNy0xLTEtMS0yNjY3MTM_c158220d-1a6e-40e5-8d70-025ada3b7cf4">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNy0zLTEtMS0yNjY3MTM_09d28578-8cc8-463c-9ac4-527ff2e78fa0">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNy01LTEtMS0yNzIzNzQ_5cc28ac2-3f86-4f9a-9d4d-86bb795e7cc2">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health included in discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xOC0xLTEtMS0yNzc1Nzc_6c33eec3-9ab4-4476-8e93-58506563baf0">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xOC0zLTEtMS0yNzc1ODE_b04778f6-1e37-4b9d-8272-7892a50f03d5">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xOC01LTEtMS0yNzc1ODQ_9dbc5a62-043b-4403-bb2f-9abd66707baf">89.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects amounts through the July 1, 2022 Spin Off date.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of $<ix:nonFraction unitRef="usd" contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTczMDA_1e04a6ef-510f-4936-8599-af68f0162f1c">56.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTczMTU_4934f784-6177-451a-9023-ab86dbc34ebe">22.9</ix:nonFraction>&#160;million incurred during the years ended December&#160;31, 2022 and 2021, respectively, are included in general and administrative expenses in the table above and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the consolidated statements of comprehensive income. These charges primarily relate to third-party advisory, consulting, legal and professional services, that are associated with the Spin Off.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iba3fbe3c5d5449cc90f3fbcef383524e"><ix:continuation id="i28c3077b77af4ecabca8e75063dcd7f8"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying amounts of the assets and liabilities of the discontinued operations of Enhabit (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl80LTMtMS0xLTI2NjgyNA_9cde320c-cace-4b89-ab72-83c4604221fd">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl81LTMtMS0xLTI2NjgyNA_4caae04a-8aeb-4192-8c3e-3d10015c2307">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl82LTMtMS0xLTI2NjgyNA_f2b782c4-141b-4b1f-ae72-80384e5edcc4">164.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl83LTMtMS0xLTI2NjgyNA_ad23cb20-e8ac-460c-ad0f-c1fb5a5376c5">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl84LTMtMS0xLTI2Njg1Mg_eaf28422-4535-44a3-8e41-fc1c98087547">178.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl85LTMtMS0xLTI2NjgzNQ_a58f3db9-1c27-4a81-9997-cdeb15e013b7">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMC0zLTEtMS0yNjY4MzU_6c581a3a-cfb3-4835-9ba0-767f470b4445">48.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMS0zLTEtMS0yNjY4MzU_60928867-277a-43ee-a0ce-394766fe27e2">1,190.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMi0zLTEtMS0yNjY4MzU_7539c9b2-07ce-4c2a-b402-9e859af1587a">259.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMy0zLTEtMS0yNjY4MzU_ce6e2e79-61d3-40a5-99e3-8cfa22b3626a">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMy0xLTEtMS0yNzc2MTk_a285a18f-324c-489d-9cd2-883d4cfd1459">1,543.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets of discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xNC0xLTEtMS0yNzc2MTk_e015bff1-f2aa-43c9-8c1b-1f619d5f95f6">1,722.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xOC0zLTEtMS0yNjY4NDI_0b92d8ac-be2a-4151-9040-81f7f048fed7">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xOS0zLTEtMS0yNjY4NDI_e4d5f56f-66fb-483d-9df5-d9501f7c69c4">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMC0zLTEtMS0yNjY4NDI_6d3a5e04-896d-4dda-a539-23219df19904">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMC0xLTEtMS0yOTc0OTY_889b780f-ab71-4f2c-872f-b13ecdababc5">66.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMS0zLTEtMS0yNjY4NDI_f14ac1b0-7893-47db-9b3c-88211c681de6">42.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMS0xLTEtMS0yNzc2MTk_d2b3b9c0-af44-4763-859d-32527f5986b4">132.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMy0zLTEtMS0yNjY4NDk_4ec22794-8611-4f87-8765-35c296b24cb7">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="ehc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNC0zLTEtMS0yNjY4NDk_24b13cba-e3fb-4f98-92ff-372925c540b8">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNS0zLTEtMS0yNjY4NDk_1fffc391-8367-44a6-a666-2d57bdbc8619">63.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNi0zLTEtMS0yNjY4NDk_609bb5db-65f2-414f-92f8-26e16ef74d62">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNi0xLTEtMS0yNzc2MTk_52f51d33-49c6-41d5-a326-745559c831b3">100.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities of discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNy0xLTEtMS0yNzc2MTk_7822e57c-7a51-4b24-9e52-79cbcf416695">233.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_244"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzE4MzYy_f0e75e2e-36c1-4f11-a064-8698914aef37" continuedAt="id8082807af0d45d9b5742e3be15fbddf" escape="true">Business Combinations:</ix:nonNumeric></span></div><ix:continuation id="id8082807af0d45d9b5742e3be15fbddf" continuedAt="i9261603abcfa4f71ba4aade60925a9f8"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, we acquired <ix:nonFraction unitRef="number" contextRef="ie37abe5ebc4f44bebbe9fb494c9c84e1_I20220831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzMzA0Mg_8cee1423-d37f-4a00-b4a3-24db3268c971">60</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="ie37abe5ebc4f44bebbe9fb494c9c84e1_I20220831" decimals="INF" name="ehc:NumberOfBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzMzA0Nw_913ab8b6-abe8-475a-8beb-7258c699a8fb">23</ix:nonFraction>-bed inpatient rehabilitation unit in Grand Forks, North Dakota when Altru Health System contributed those operations to our existing joint venture.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, we acquired <ix:nonFraction unitRef="number" contextRef="i9991693278fc408e862976490cf30d98_I20220831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzMzA1OA_dad5b54a-5318-482c-b25f-3b330a4389c6">50</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i9991693278fc408e862976490cf30d98_I20220831" decimals="INF" name="ehc:NumberOfBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzMzA2Mw_16b16e9c-70e4-4823-ac33-915de259bd3d">22</ix:nonFraction>-bed inpatient rehabilitation unit in Moline, Illinois when Trinity Medical Center contributed those operations to our existing joint venture.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i9261603abcfa4f71ba4aade60925a9f8" continuedAt="i7b4321aa19ef4ac194f8288862259d86"><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2022, we acquired <ix:nonFraction unitRef="number" contextRef="i6820aa09cd604de1a90b41670cea5ea8_I20221231" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzOTkwNQ_a6659edb-1c58-4710-89f5-9966437c45bd">50</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i6820aa09cd604de1a90b41670cea5ea8_I20221231" decimals="INF" name="ehc:NumberOfBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzOTkxMA_928cf411-6a9b-4a84-a085-34264e491bc0">54</ix:nonFraction>-bed inpatient rehabilitation unit in Naples, Florida when NCH Healthcare System contributed those operations to our joint venture.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from the respective dates of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on an income approach using discounted cash flow techniques for the noncompete intangible assets. The aforementioned income method utilizes management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospitals&#8217; historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. <ix:nonFraction unitRef="usd" contextRef="i8ff2033f1b3942129102202260af6a35_I20221231" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzNDE3OQ_d38634d7-2511-4d79-95d9-d20d1f58a01a">None</ix:nonFraction> of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzgyNDYzMzcyMzMzODE_32148f5f-19df-4036-8e0c-bcc67a843ef0" continuedAt="i77ba2124e8a6406aab365c0d0ae85133" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:87.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of <ix:nonNumeric contextRef="ia21684f87fae47c5b3a34319790c0769_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzctMC0xLTEtMjc1MzQ2L3RleHRyZWdpb246MThhYTc0NzE0M2M3NGUxYTg0ZTlkYjBmZjEzNjMzOTRfNTQ5NzU1ODEzOTQ1_c24902e6-a1e0-4d57-8b65-019c479885f0">2</ix:nonNumeric> to <ix:nonNumeric contextRef="id0d9fe27b422459b8eca401afa6fe33c_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzctMC0xLTEtMjc1MzQ2L3RleHRyZWdpb246MThhYTc0NzE0M2M3NGUxYTg0ZTlkYjBmZjEzNjMzOTRfNTQ5NzU1ODEzOTQ5_919c6430-eb26-496c-a03b-3282cabc79e1">3</ix:nonNumeric> years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b030fcfd4e4d31a741e7594dc965c0_I20221231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzEtMS0xLTEtMjc1NDMz_77ef1f40-c5b8-4eea-a682-f47e6f1bd8b1">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b5d49a11d841d0962f2c16a1a90833_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzItMS0xLTEtMjc1NDQx_1ff9a4d5-527b-4242-8f0f-0058cc9db2de">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b5d49a11d841d0962f2c16a1a90833_I20221231" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzMtMS0xLTEtMjc3NTA1_91424e06-c5e3-4ac8-bee7-ef37c1e73f4f">27.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzgyNDYzMzcyMzMzODA_a7703dcc-d438-412a-808d-6239294e1136" continuedAt="i704ac7ce1ca44ccc90c50f96db1b2373" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2022 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:87.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4ZGY4OWE3MmYxODU0NmIyYWFiZjQ4MDZkZjRmZWVmNy90YWJsZXJhbmdlOjhkZjg5YTcyZjE4NTQ2YjJhYWJmNDgwNmRmNGZlZWY3XzItNy0xLTEtMjc1MzYx_77d9976f-225e-4944-b71c-fe7610460437">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4ZGY4OWE3MmYxODU0NmIyYWFiZjQ4MDZkZjRmZWVmNy90YWJsZXJhbmdlOjhkZjg5YTcyZjE4NTQ2YjJhYWJmNDgwNmRmNGZlZWY3XzMtNy0xLTEtMjc1MzYx_7d7343d3-a3d1-4190-afc4-62bc847ca5c2">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4ZGY4OWE3MmYxODU0NmIyYWFiZjQ4MDZkZjRmZWVmNy90YWJsZXJhbmdlOjhkZjg5YTcyZjE4NTQ2YjJhYWJmNDgwNmRmNGZlZWY3XzUtNy0xLTEtMjc1MzYx_bb4c8f2b-2bd0-4fd9-8e48-b66276eb0496">27.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4ZGY4OWE3MmYxODU0NmIyYWFiZjQ4MDZkZjRmZWVmNy90YWJsZXJhbmdlOjhkZjg5YTcyZjE4NTQ2YjJhYWJmNDgwNmRmNGZlZWY3XzMtMS0xLTEtMjc3NTE2_5d25da93-645b-4223-946c-824fea30aa4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Results of Operations</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzgyNDYzMzcyMzMzNzk_6d21a45b-8170-4332-8bc6-28b0d3235f4b" continuedAt="ib69b7787cc63483881245a3ecd67512f" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above-mentioned acquisitions from the dates of acquisitions included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the dates of the acquisitions been January&#160;1, 2021 (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzEtMS0xLTEtMjk0Njcx_2dd064b7-98a9-4ef1-99d9-76c7c9854640">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzEtMy0xLTEtMjk0Njcx_95943b0a-3e92-49e8-99f3-31602f793a98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2022-12/31/2022 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzQtMS0xLTEtMjc0OTE0_b8fba366-d836-4481-9a6d-23e46aec2cd1">4,369.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzQtMy0xLTEtMjc0OTE0_0e570779-15e5-4846-928c-122d712b5685">273.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzUtMS0xLTEtMjc0OTE0_b0ed3776-5eee-403c-b193-7ee47f477557">4,039.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzUtMy0xLTEtMjc0OTE0_160a1446-2c3e-41b6-b198-66bc79c3b81e">415.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2021 period.</span></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2021, we acquired <ix:nonFraction unitRef="number" contextRef="i56015630b11b4e009f45b95de40f5a16_I20210430" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzQxNw_57067ff1-f47d-4021-ba8c-9ab42ca613eb">51</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i56015630b11b4e009f45b95de40f5a16_I20210430" decimals="INF" name="ehc:NumberOfBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzQ0Mw_01f85942-ef7f-4be4-973b-e3af2ce2b785">14</ix:nonFraction>-bed inpatient rehabilitation unit in San Angelo, Texas when Shannon Medical contributed those operations to our existing joint venture entity.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i7b4321aa19ef4ac194f8288862259d86" continuedAt="i8a966163dae1423dbb9e57bf86470ed0"><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2021, we acquired <ix:nonFraction unitRef="number" contextRef="i926c10b50d5b4dc4952bd8f73e5caf2c_I20210630" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzYxNQ_fe19258f-99da-4960-a943-8cddbf2424f0">75</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i926c10b50d5b4dc4952bd8f73e5caf2c_I20210630" decimals="INF" name="ehc:NumberOfBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzY0MQ_3745338c-3d5f-455d-802f-6703a05cf453">16</ix:nonFraction>-bed inpatient rehabilitation unit in McKees Rocks, Pennsylvania through our existing joint venture with Heritage Valley Health System, Inc. The acquisition was funded using cash on hand.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2021, we acquired <ix:nonFraction unitRef="number" contextRef="i42d3a03ae9fb49d2a3c3300daff8071b_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4Xzg1Nw_304fcc3d-850e-463f-a121-31c419b2a8e0">65</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i42d3a03ae9fb49d2a3c3300daff8071b_I20210731" decimals="INF" name="ehc:NumberOfBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4Xzg4Mw_428fa002-7e67-45f9-a707-166294590abb">22</ix:nonFraction>-bed inpatient rehabilitation unit in Odessa, Texas when ECHD Ventures contributed those operations to our existing joint venture entity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. <ix:nonFraction unitRef="usd" contextRef="ia3876cf645ac4e17bb330ae838f085f4_I20221231" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzIyMDY_accfc5bd-bf30-4d7c-b2f0-f3c5b9cd719e">None</ix:nonFraction> of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.</span></div><ix:continuation id="i77ba2124e8a6406aab365c0d0ae85133" continuedAt="i50f3ea2fe51648b0b6ba82efb42b2c39"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:87.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.665%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of <ix:nonNumeric contextRef="icd3a3de37fca442dbd0a5e70526dbf46_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzMtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTRiZDBmZTNkMDBlNDNiMmI4ODI1YTI0N2VmNzQ3ZGNfNDM_79f31eff-ae1e-4eac-942e-f27195a4b478">3</ix:nonNumeric> to <ix:nonNumeric contextRef="id86e386a397b49d296ca11e4a511d544_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzMtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTRiZDBmZTNkMDBlNDNiMmI4ODI1YTI0N2VmNzQ3ZGNfNDk_9ca03059-6d8f-4c47-87ff-8efffd8ad7a3">5</ix:nonNumeric> years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bea87602e1641b0b71e094855c78088_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzMtMS0xLTEtMjQ1NDc3_a1c24e8b-7b1d-468f-9e92-7cccdd8b2cd0">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of <ix:nonNumeric contextRef="i75e5544167514a92ae6527fb86b9e780_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzQtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZmQ0YmE5MTg0NjExNDc5ZGE2Yjk3NGJhMjEwY2ZjMDlfMzE_aa698278-167e-4118-bf12-469449796e08">20</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6bdb8e550a4806bb3e1dadfd5e0505_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzQtMS0xLTEtMjQ1NDc3_f3a78393-53b4-4545-bd04-15f766c5d4e3">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae11dbadeb749178d2cc18aceb997a3_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzctMS0xLTEtMjQ1NDc3_8661f8cf-49e6-4fde-acd7-6457ac2d7ada">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae11dbadeb749178d2cc18aceb997a3_I20211231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzgtMS0xLTEtMjQ1NDc3_2699d263-c78f-4e5c-b5b9-52181e115976">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae11dbadeb749178d2cc18aceb997a3_I20211231" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzktMS0xLTEtMjQ1NDc3_87424a17-98bb-44c5-94bc-e73be81cefe5">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:continuation id="i704ac7ce1ca44ccc90c50f96db1b2373" continuedAt="ie505ff451c254d4da7a7f8cab3eb5889"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:89.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozNmE5MmYzYTRmNWU0YzBmOWNmODI4MTM4NmM4YmM3Ny90YWJsZXJhbmdlOjM2YTkyZjNhNGY1ZTRjMGY5Y2Y4MjgxMzg2YzhiYzc3XzAtMS0xLTEtMjQ1NDc3_76f6aef5-7f44-4127-9cb3-d5f5628797e4">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozNmE5MmYzYTRmNWU0YzBmOWNmODI4MTM4NmM4YmM3Ny90YWJsZXJhbmdlOjM2YTkyZjNhNGY1ZTRjMGY5Y2Y4MjgxMzg2YzhiYzc3XzEtMS0xLTEtMjQ1NDc3_1f72cea9-2d01-4b0c-8087-2899b9cebd35">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozNmE5MmYzYTRmNWU0YzBmOWNmODI4MTM4NmM4YmM3Ny90YWJsZXJhbmdlOjM2YTkyZjNhNGY1ZTRjMGY5Y2Y4MjgxMzg2YzhiYzc3XzMtMS0xLTEtMjQ1NDc3_c700e3e3-2a5f-4c29-93f4-37b88d1e2203">9.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozNmE5MmYzYTRmNWU0YzBmOWNmODI4MTM4NmM4YmM3Ny90YWJsZXJhbmdlOjM2YTkyZjNhNGY1ZTRjMGY5Y2Y4MjgxMzg2YzhiYzc3XzUtMS0xLTEtMjQ1NDc3_fa75382a-9b22-4830-bd29-c2d39ff2c05d">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Pro Forma Results of Operations</span></div><ix:continuation id="ib69b7787cc63483881245a3ecd67512f" continuedAt="i9737314d0392430aaffb4358df483f22"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned-acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzEtMS0xLTEtMjk3MzYw_a83e8a22-df92-48e4-ac64-4eb94662f9b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzEtMy0xLTEtMjk3MzYw_55fb8779-d70b-4faa-86df-e3b1b9f9bf52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida60f9410ec942ffa8b96644e1a4982e_D20210101-20211231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzUtMS0xLTEtMjQ1NDc3_baba00cb-066e-4a64-be70-9dbe5195faf4">4,021.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida60f9410ec942ffa8b96644e1a4982e_D20210101-20211231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzUtMy0xLTEtMjQ1NDc3_6f7c729e-58af-47f5-8000-9e9525e8be41">412.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d13dc5dde24449a63972bfe6bc1df8_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzYtMS0xLTEtMjQ1NDc3_9208c09a-da89-43b3-8b08-5e2f3d38be69">3,581.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d13dc5dde24449a63972bfe6bc1df8_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzYtMy0xLTEtMjQ1NDc3_276f860d-ab96-4737-b2b3-db6e9c7941c5">285.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 period.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8a966163dae1423dbb9e57bf86470ed0" continuedAt="i3ba5a4d0b80a4851ac66982a74ea721c"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2020, we acquired <ix:nonFraction unitRef="number" contextRef="i1070117531644374b85aaa3af7d800d0_I20200131" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4Xzk4ODg_bdaf1f68-7e11-46f5-8540-4b0b9d26a20d">68</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="i1070117531644374b85aaa3af7d800d0_I20200131" decimals="INF" name="ehc:NumberOfBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4Xzk5MTQ_be10e110-094e-4bbc-9eed-9bcb048b624f">13</ix:nonFraction>-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing <ix:nonFraction unitRef="bed" contextRef="i1070117531644374b85aaa3af7d800d0_I20200131" decimals="INF" name="ehc:NumberofBedsContributed" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwMTAy_f3cbee12-5644-4c13-878c-8a7a1e2dcb13">40</ix:nonFraction>-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a <ix:nonFraction unitRef="bed" contextRef="i1070117531644374b85aaa3af7d800d0_I20200131" decimals="INF" name="ehc:NumberofBedsExpanded" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwMjY2_0bd1e08d-1fad-4692-84fa-252d7bae45e1">20</ix:nonFraction>-bed expansion to the Littleton hospital.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, we acquired <ix:nonFraction unitRef="number" contextRef="ib6bc012b46224f569423ad84a5eac16f_I20200531" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwMzM1_c8b7e83b-c9b5-41ea-96c7-19aa825ff473">51</ix:nonFraction>% of the operations of a <ix:nonFraction unitRef="bed" contextRef="ib6bc012b46224f569423ad84a5eac16f_I20200531" decimals="INF" name="ehc:NumberOfBedsAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwMzYx_babdcf9d-eedd-4934-9ba2-4adda057602f">45</ix:nonFraction>-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a <ix:nonFraction unitRef="bed" contextRef="ib6bc012b46224f569423ad84a5eac16f_I20200531" decimals="INF" name="ehc:NumberofDeNovoBeds" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwNTkx_e7d1913f-c705-44d1-a16e-a07af4757cf6">60</ix:nonFraction>-bed de novo inpatient rehabilitation hospital.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. <ix:nonFraction unitRef="usd" contextRef="i4ddfcda5811941ceb891a6ef3548c7c3_I20200531" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzExODIz_6d9e8d98-a9a5-4f89-9cb5-cae17870af9a">None</ix:nonFraction> of the goodwill recorded as a result from these transactions are deductible for federal income tax purposes.</span></div><ix:continuation id="i50f3ea2fe51648b0b6ba82efb42b2c39"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:87.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of <ix:nonNumeric contextRef="i63b458d6463a4a96b479e42c0fcc71c1_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzMtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MjM3NWU2NWJmZDA0NGJiMmI0MjkzMWY0NzM0ZjVkZWZfNDM_00835f0f-6e6d-41a1-a74a-f950a0393230">2</ix:nonNumeric> to <ix:nonNumeric contextRef="if50b14c350354038b6604d1681524651_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzMtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MjM3NWU2NWJmZDA0NGJiMmI0MjkzMWY0NzM0ZjVkZWZfNDk_18f76c1e-0ad6-496a-bf2b-5284800d7725">3</ix:nonNumeric> years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ccbd7406a9458abb7cfc12e90ad1e6_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzMtMS0xLTEtMjQ1NDc3_2552cfa5-2016-4f6d-b985-9815b04233fa">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of <ix:nonNumeric contextRef="i8af9ecf91da248c5be27bca52229721d_D20200101-20201231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzQtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246ODdlODE0ZjgzNjc3NDA1OTliZjViYWRmMjI2OTMyOGFfMzE_b2a71f05-bf4e-4330-ac00-d0c930689467">20</ix:nonNumeric> years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3f8c860f1b432e95cc26067ef20e2a_I20201231" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzQtMS0xLTEtMjQ1NDc3_b1a5496c-8086-4926-bbef-ff7a24a2bb49">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i684d2533374c48a4bd1364edabf0ba08_I20201231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzctMS0xLTEtMjQ1NDc3_b8861868-a09f-4aeb-92ee-f94d0a0793b0">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i684d2533374c48a4bd1364edabf0ba08_I20201231" decimals="-5" name="ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzgtMS0xLTEtMjQ1NDc3_cc226f77-babd-4a24-bb5f-6b5ec9ca6bd6">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><ix:continuation id="ie505ff451c254d4da7a7f8cab3eb5889"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231" decimals="-5" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozYTAwYTEwNjYwOTk0YTY0YTVjNjQwM2Y1OTFlZmUzNi90YWJsZXJhbmdlOjNhMDBhMTA2NjA5OTRhNjRhNWM2NDAzZjU5MWVmZTM2XzAtMS0xLTEtMjQ1NDc3_3ded6202-394a-452e-8f68-26f50f84f676">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozYTAwYTEwNjYwOTk0YTY0YTVjNjQwM2Y1OTFlZmUzNi90YWJsZXJhbmdlOjNhMDBhMTA2NjA5OTRhNjRhNWM2NDAzZjU5MWVmZTM2XzEtMS0xLTEtMjQ1NDc3_a431d799-4677-40d8-938c-cdc4bae8ab87">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231" decimals="-5" name="ehc:BusinessCombinationNoncontrollingInterestFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozYTAwYTEwNjYwOTk0YTY0YTVjNjQwM2Y1OTFlZmUzNi90YWJsZXJhbmdlOjNhMDBhMTA2NjA5OTRhNjRhNWM2NDAzZjU5MWVmZTM2XzMtMS0xLTEtMjQ1NDc3_a3f34763-a3c7-448e-95ec-92b45da4a173">10.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozYTAwYTEwNjYwOTk0YTY0YTVjNjQwM2Y1OTFlZmUzNi90YWJsZXJhbmdlOjNhMDBhMTA2NjA5OTRhNjRhNWM2NDAzZjU5MWVmZTM2XzUtMS0xLTEtMjQ1NDc3_84b81957-badb-43c5-8b21-ae02079233ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i3ba5a4d0b80a4851ac66982a74ea721c"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Pro Forma Results of Operations</span></div><ix:continuation id="i9737314d0392430aaffb4358df483f22"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above-mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4YTdmODUzYzAwNTg0NzJiYTM4NjNjMmQwMjk5OTJmYS90YWJsZXJhbmdlOjhhN2Y4NTNjMDA1ODQ3MmJhMzg2M2MyZDAyOTk5MmZhXzEtMS0xLTEtMjk3Mzc4_08fd710e-0215-4d72-a49e-8bbd606e7a35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4YTdmODUzYzAwNTg0NzJiYTM4NjNjMmQwMjk5OTJmYS90YWJsZXJhbmdlOjhhN2Y4NTNjMDA1ODQ3MmJhMzg2M2MyZDAyOTk5MmZhXzEtMy0xLTEtMjk3Mzc4_2d82116f-f6c6-441c-9afc-4b3dfb1ce53d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9234554fdff644f89fd47fb7f88d0659_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4YTdmODUzYzAwNTg0NzJiYTM4NjNjMmQwMjk5OTJmYS90YWJsZXJhbmdlOjhhN2Y4NTNjMDA1ODQ3MmJhMzg2M2MyZDAyOTk5MmZhXzUtMS0xLTEtMjQ1NDc3_3d87aa2e-db49-4976-bf56-e2e55496cc49">3,571.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9234554fdff644f89fd47fb7f88d0659_D20200101-20201231" decimals="-5" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4YTdmODUzYzAwNTg0NzJiYTM4NjNjMmQwMjk5OTJmYS90YWJsZXJhbmdlOjhhN2Y4NTNjMDA1ODQ3MmJhMzg2M2MyZDAyOTk5MmZhXzUtMy0xLTEtMjQ1NDc3_e36ea2d6-e8a3-4392-84e4-cbb1a949fb6d">284.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 reporting period.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_250"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEyNjQ_ff7ba167-0fa5-49fc-ba0b-c48916632952" continuedAt="i52b74ab7c8d440c4b75eaa19b0bfbbe6" escape="true">Variable Interest Entities:</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i52b74ab7c8d440c4b75eaa19b0bfbbe6" continuedAt="ibde4ec4018e64669bbe8f44a00aa1d52">As of December&#160;31, 2022 and December&#160;31, 2021, we consolidated <ix:nonFraction unitRef="entity" contextRef="i39884fa7a48547f2a08edcccd93487c8_D20220101-20221231" decimals="INF" name="ehc:VariableInterestEntityNumberofEntitiesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEwOTk1MTE2MjkwNTQ_4691dd4f-2899-43c9-9544-58c9b85ac2b0">eight</ix:nonFraction> and <ix:nonFraction unitRef="entity" contextRef="i68baf71a31bd473ba1a1ca647e0b19e2_D20210101-20211231" decimals="INF" name="ehc:VariableInterestEntityNumberofEntitiesConsolidated" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEwOTk1MTE2MjkwNTk_6f9571cc-5929-42bf-aa8d-474ab1fc0c0c">ten</ix:nonFraction>, respectively, limited partnership-like entities that are VIEs and of which we are the primary beneficiary. Our ownership percentages in these entities range from <ix:nonFraction unitRef="number" contextRef="id743d8949a7a47b99d38df3ba1e3e993_D20220101-20221231" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEwOTk1MTE2MjkwNjQ_409afc4b-a6dd-4121-9831-201cd153a354">50.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ic427d90f8e7c42bdb0850c9210abaeb6_D20220101-20221231" decimals="3" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEwOTk1MTE2MjkwNjg_361ec5d1-6e01-4194-91bc-66844e92895d">75.0</ix:nonFraction>% as of December&#160;31, 2022. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision-making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ibde4ec4018e64669bbe8f44a00aa1d52"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEyNjA_b8e4b1d9-0621-4749-a71a-48f54d9b0f2d" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheets, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzMtMS0xLTEtMjQ1NDc3_3566c303-e322-455e-9f84-8ac3c791ca02">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzMtMy0xLTEtMjQ1NDc3_d5097421-a56a-418b-8aab-3e1205e8cc32">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzQtMS0xLTEtMjQ1NDc3_a8f93b4b-778c-46d6-af22-94aa401cc21b">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzQtMy0xLTEtMjQ1NDc3_10569c26-822c-476c-9be8-3bc48251a790">33.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzUtMS0xLTEtMjQ1NDc3_2d026df0-6371-4ed3-a1ae-e320faec9e0b">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzUtMy0xLTEtMjQ1NDc3_57eb0f6a-ce7b-47fc-be06-16365b1f62b3">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzYtMS0xLTEtMjY2OTg1_57a20931-9244-4bf8-b980-2b46aff8f0a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzYtMy0xLTEtMjY2OTg1_786488bd-c533-475c-95e0-e29abf041999">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzYtMS0xLTEtMjQ1NDc3_11b1156b-0803-45a8-a23d-5a3b3d74351f">40.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzYtMy0xLTEtMjQ1NDc3_3ea761cb-a26f-401f-91c6-efd9e12528ec">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzctMS0xLTEtMjQ1NDc3_5e2cdb81-56dc-4a39-ba94-3dd6ce65bf57">129.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzctMy0xLTEtMjQ1NDc3_f9423d5f-d92f-459f-a228-6a85ade16204">116.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzgtMS0xLTEtMjQ1NDc3_f4edfcfd-4602-4f90-a591-c17f5ae59933">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzgtMy0xLTEtMjQ1NDc3_43b8949c-0070-4e55-8cc7-b3a570f23bb8">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzktMS0xLTEtMjQ1NDc3_e849174f-83dd-4ef2-8ceb-80c08156c746">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzktMy0xLTEtMjQ1NDc3_d232c5e9-752a-4f34-905d-5cc269e4e14b">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEwLTEtMS0xLTI0NTQ3Nw_759debb1-e787-4d40-910d-3693bc7f8afb">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEwLTMtMS0xLTI0NTQ3Nw_28e92555-bb00-46a2-89d1-c55406aa3e44">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEyLTEtMS0xLTI0NTQ3Nw_74863e5c-fd3b-4e10-8df4-abacf8af6efc">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEyLTMtMS0xLTI0NTQ3Nw_5379a05c-7e1e-4f03-8fab-299a65074c64">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE0LTEtMS0xLTI2Njk5Nw_db99efb9-cda1-43f1-a2c1-dfd7b31d1f36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE0LTMtMS0xLTI2Njk5Nw_a6306c5a-c764-4bfc-b0a4-9a70e360bb8f">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEzLTEtMS0xLTI0NTQ3Nw_94aba882-54eb-411e-be17-f54d4eab262f">207.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEzLTMtMS0xLTI0NTQ3Nw_915ce630-b9fe-4347-bf8b-5d800d8daecd">226.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE2LTEtMS0xLTI0NTQ3Nw_fac72976-c114-42fe-aa31-409acc2be56a">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE2LTMtMS0xLTI0NTQ3Nw_a6bc66ff-a874-42a6-978a-308b05856cb0">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE3LTEtMS0xLTI0NTQ3Nw_7dce3af5-4696-415a-b984-d03b3918be83">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE3LTMtMS0xLTI0NTQ3Nw_84ad899b-a0c3-4a51-aeb2-64fc7008c70d">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE4LTEtMS0xLTI0NTQ3Nw_3878ffdc-4810-4a99-9dbb-5d95d7ced649">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE4LTMtMS0xLTI0NTQ3Nw_663245e9-edb5-4579-b3e4-2b1eb1a90ed5">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE5LTEtMS0xLTI0NTQ3Nw_532a1046-82be-4341-926e-503341c77b87">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE5LTMtMS0xLTI0NTQ3Nw_ca69cc09-0346-452b-a1b7-aec9419b0ea5">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIxLTEtMS0xLTI0NTQ3Nw_683c2f46-9422-4b00-bfb1-a78cbc932ec7">15.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIxLTMtMS0xLTI0NTQ3Nw_de4a3060-044d-4ae8-a154-fea0d185aa58">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI0LTEtMS0xLTI2NzAwOQ_4e09af55-8494-4770-855f-139a5f4809f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI0LTMtMS0xLTI2NzAwOQ_2637052e-cd52-4e96-ac49-3ff09e56edea">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIyLTEtMS0xLTI0NTQ3Nw_b3968a1c-d59c-4b4a-a839-e88a6220f10d">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIyLTMtMS0xLTI0NTQ3Nw_a2a59e83-3c32-41bc-9b60-79a9acadd344">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIzLTEtMS0xLTI0NTQ3Nw_4908dc84-9c5c-4bb8-b2b5-cbd8bdfec899">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIzLTMtMS0xLTI0NTQ3Nw_6ed8cdea-563e-49eb-8d3a-b797fc39dbc0">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI0LTEtMS0xLTI0NTQ3Nw_738a6d24-e304-4dd4-9d5d-723df94f2154">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI0LTMtMS0xLTI0NTQ3Nw_822b9dc6-a2e3-4bde-9f89-adafb1269726">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI2LTEtMS0xLTI0NTQ3Nw_dbef0e81-94c1-4fdc-89bc-c7303e1372cb">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI2LTMtMS0xLTI0NTQ3Nw_e8f2f938-531c-4a54-acb1-7db6ea354387">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_253"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzI2MDY_8013baee-bef8-4ec2-855b-38992df9902f" continuedAt="i1179e0aa053d4638af3007147e77cddc" escape="true">Cash and Marketable Securities:</ix:nonNumeric></span></div><ix:continuation id="i1179e0aa053d4638af3007147e77cddc" continuedAt="i8d41efc7dd404a478b68ba16e5dffa90"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzI2Mjk_4f804bfc-5668-41f4-b2a4-9c189728e0df" continuedAt="if5ae73cc42554e179fa356dbfc7aa778" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2022 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzEtMS0xLTEtMjQ1NDc3_1fe522c1-18f2-47e3-b987-30b2f3bc8851">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzEtMy0xLTEtMjQ1NDc3_f941f4e5-41c6-4fbe-a5b7-4dcce52b087e">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzEtNS0xLTEtMjQ1NDc3_64849141-8f99-41f2-ba2c-b4ae469c7415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzEtNy0xLTEtMjQ1NDc3_8b7dd189-fa8d-4982-8967-d29219390a47">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21818c725feb4e82b4d76043fbe5fddb_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzItMS0xLTEtMjQ1NDc3_642bc175-3f27-4e37-ac10-46e9e63a7e4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21818c725feb4e82b4d76043fbe5fddb_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzItMy0xLTEtMjQ1NDc3_83873ef6-b8f1-43d4-ba78-c24b7ee8f10d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21818c725feb4e82b4d76043fbe5fddb_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzItNS0xLTEtMjQ1NDc3_c259c817-da14-4e00-ad27-6137ba290cbf">110.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21818c725feb4e82b4d76043fbe5fddb_I20221231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzItNy0xLTEtMjQ1NDc3_77db10d0-0fb7-432d-9d0d-5342b7416e2d">110.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzQtMS0xLTEtMjQ1NDc3_2edf2014-7442-4def-ac28-e966592011dd">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzQtMy0xLTEtMjQ1NDc3_453ea613-78c1-49cd-8582-93b12b22272b">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzQtNS0xLTEtMjQ1NDc3_38fdf42e-947d-445a-8d6b-84b50a691f51">110.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzQtNy0xLTEtMjQ1NDc3_7053be0b-3129-4eb3-a041-af599912aac9">163.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8d41efc7dd404a478b68ba16e5dffa90" continuedAt="i240d89890c0b4882a4ee92e83fc6cf70"><ix:continuation id="if5ae73cc42554e179fa356dbfc7aa778"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2021 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62ccf4631834eb8806f370a09ba24d1_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzEtMS0xLTEtMjQ1NDc3_356bb402-ad4c-4775-b3b3-683a5e88967b">49.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62ccf4631834eb8806f370a09ba24d1_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzEtMy0xLTEtMjQ1NDc3_b8f8a009-bdc2-4b19-9185-79c34d6a7f6d">62.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62ccf4631834eb8806f370a09ba24d1_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzEtNS0xLTEtMjQ1NDc3_d463a9e4-c682-4d99-b1ab-47266d07e65c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie62ccf4631834eb8806f370a09ba24d1_I20211231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzEtNy0xLTEtMjQ1NDc3_301b005e-8254-4d78-9cd3-0fbaf28688f5">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d8fb91a17448548b52ddaca926ac5d_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzItMS0xLTEtMjQ1NDc3_146d1762-6dea-4f93-a01e-a0007ba6b203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d8fb91a17448548b52ddaca926ac5d_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzItMy0xLTEtMjQ1NDc3_0a7c821f-4d11-43f1-96fd-e3638db737da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d8fb91a17448548b52ddaca926ac5d_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzItNS0xLTEtMjQ1NDc3_aa5b572f-3b5c-4642-ac4f-494f3221d8ea">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d8fb91a17448548b52ddaca926ac5d_I20211231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzItNy0xLTEtMjQ1NDc3_17922247-6a5c-41b9-a4fc-887aef5c9133">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzQtMS0xLTEtMjQ1NDc3_0e2d5c1e-1e1f-4053-b52f-2194f0f18bd5">49.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzQtMy0xLTEtMjQ1NDc3_1cbb3f03-1154-4091-9755-ba79107b26f8">62.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRestricted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzQtNS0xLTEtMjQ1NDc3_cf5a2eee-204b-479a-a008-a16166b1231a">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="ehc:InvestmentsCashandRestrictedCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzQtNy0xLTEtMjQ1NDc3_252b4087-697d-45f6-acca-23bc44149734">194.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash&#8212;</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzI1OTY_c9be40e4-517f-4ab2-90cb-417e498516c1" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliate cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b96835762340179de2e6054fcf6ad0_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzMtMS0xLTEtMjQ1NDc3_fb3064fe-c45d-4ddc-9bca-bf8f948a532d">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0338b3236b51417cbf66790b47b14be5_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzMtMy0xLTEtMjQ1NDc3_0456852c-1692-4fc3-8c14-e6b00dfbb16c">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8b121e96a3441d8cc4887b3971a2ef_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzQtMS0xLTEtMjQ1NDc3_e0e1168a-d43b-4efc-8fd7-96f27d056f8e">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5ab8a31d8f4c83a1cc36ca852adfa9_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzQtMy0xLTEtMjQ1NDc3_145e507d-8e31-4ac7-87db-9540f62c57fe">47.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2117424317ae4b25824cbe7ca5a8bbe6_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzYtMS0xLTEtMjkzNzYw_86dd29a6-08f8-478e-a7f7-fbae215a5666">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1fdbdb992e4caeb499c51df7168238_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzYtMy0xLTEtMjkzNzYw_de35e4a0-7370-416a-9219-afec67dea140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzYtMS0xLTEtMjQ1NDc3_b6225ed6-f9ca-472a-bdce-899b801d63f3">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzYtMy0xLTEtMjQ1NDc3_0098d070-a825-4430-a11e-0f6bbde2002c">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8b121e96a3441d8cc4887b3971a2ef_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzktMS0xLTEtMjQ1NDc3_6d5b1d07-7267-46a6-ae59-c84c340c9bf2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5ab8a31d8f4c83a1cc36ca852adfa9_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzktMy0xLTEtMjQ1NDc3_996dfc03-28dd-4186-97c2-b3efba1b8512">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzExLTEtMS0xLTI0NTQ3Nw_9b8c9b77-f5fd-454f-981b-acdb1955b58d">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzExLTMtMS0xLTI0NTQ3Nw_c89f6e80-7e50-4e83-ba17-aad70ead6a98">62.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliate cash represents cash accounts maintained by joint ventures in which we participate where one or more of our external partners requested, and we agreed, that the joint venture&#8217;s cash not be commingled with other corporate cash accounts and be used only to fund the operations of those joint ventures. Self-insured captive funds represent cash held at our wholly owned insurance captive, HCS, Ltd., as discussed in Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These funds are committed to pay third-party administrators for claims incurred and are restricted by insurance regulations and requirements. These funds cannot be used for purposes outside HCS without the permission of the Cayman Islands Monetary Authority.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification of restricted cash held by HCS as current or noncurrent depends on the classification of the corresponding claims liability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS. HCS insures a substantial portion of Encompass Health&#8217;s professional liability, workers&#8217; compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:RestrictedDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE1NDk_3dcce236-33d8-42cb-98f8-1c86a955acfe">79.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="ehc:RestrictedDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE1NTY_f7d4ea45-4906-4f5f-b5cc-e177976aab5e">82.2</ix:nonFraction> million, respectively, of restricted marketable securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. During the years ended December&#160;31, 2022, 2021, and 2020, $(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE3MjQ_6933478d-0291-4de0-8506-b618e066195f">7.4</ix:nonFraction>)&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE3Mjg_8d529d14-6418-44e6-9ba0-66964f48e161">0.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE3MzY_af3ee488-2a4a-4a9d-aac1-d5e40d9b81e1">0.4</ix:nonFraction>&#160;million, respectively, of unrealized net (losses) gains were recognized in our consolidated statements of comprehensive income on marketable securities still held at the reporting date.</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfRealizedGainLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzI2NDI_d64b8d45-ad76-4dd2-9ef4-c1becb6e90da" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing information related to our available-for-sale marketable securities is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of available-for-sale marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZDExZTM4YWQxNmI0ZDYxYmIxZDNlZTcwNDZkNTkxMC90YWJsZXJhbmdlOmJkMTFlMzhhZDE2YjRkNjFiYjFkM2VlNzA0NmQ1OTEwXzItMS0xLTEtMjQ1NDc3_9af1a070-ded0-4c24-9d94-9fc33ad47e6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZDExZTM4YWQxNmI0ZDYxYmIxZDNlZTcwNDZkNTkxMC90YWJsZXJhbmdlOmJkMTFlMzhhZDE2YjRkNjFiYjFkM2VlNzA0NmQ1OTEwXzItMy0xLTEtMjQ1NDc3_a4681003-7e10-4756-8747-70d7f1eecb8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZDExZTM4YWQxNmI0ZDYxYmIxZDNlZTcwNDZkNTkxMC90YWJsZXJhbmdlOmJkMTFlMzhhZDE2YjRkNjFiYjFkM2VlNzA0NmQ1OTEwXzItNS0xLTEtMjQ1NDc3_b55274bd-04c3-4946-9f7a-b71e2567a5df">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;text-indent:36pt"><ix:continuation id="i240d89890c0b4882a4ee92e83fc6cf70"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketable securities is comprised of investments in mutual funds that hold investments in a variety of industries and geographies. As discussed in Note&#160;1,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Marketable Securities,&#8221; when our portfolio included marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, we examined the severity and duration of the impairments in relation to the cost of the individual investments. We also considered the industry and geography in which each investment is held and the near-term prospects for a recovery in each.</span></ix:continuation></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_256"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90ZXh0cmVnaW9uOjk4M2RiOGQxNzU3MTQxNjFiODFiM2JiOWJhN2I5ZTM1XzUwMA_5ca15a65-8111-4dc1-a1fe-19e914ee45a2" continuedAt="i17dc5e5aed884976bdd831a8dd924376" escape="true">Accounts Receivable:</ix:nonNumeric></span></div><ix:continuation id="i17dc5e5aed884976bdd831a8dd924376"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90ZXh0cmVnaW9uOjk4M2RiOGQxNzU3MTQxNjFiODFiM2JiOWJhN2I5ZTM1XzUwMw_bdbdfbd2-49a3-488d-9c2e-9b93c775d3c8" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzMtMS0xLTEtMjQ1NDc3_1c250aec-e847-4f44-a9ee-b76f8a55351e">524.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzMtMy0xLTEtMjQ1NDc3_f9c2ef9f-bb30-4ea9-ba74-0cfa5927e7bb">502.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzQtMS0xLTEtMjQ1NDc3_47ff8110-6276-4071-8c02-1cc04e7a7e11">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzQtMy0xLTEtMjQ1NDc3_b9a0e679-7b89-4c1c-984c-894554a65174">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzUtMS0xLTEtMjQ1NDc3_6342ccb1-dbbb-472a-a635-821b699faf3a">536.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzUtMy0xLTEtMjQ1NDc3_21e6846c-8143-4e2c-84eb-b3c60da967d2">515.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent patient accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzYtMS0xLTEtMjQ1NDc3_a2966fa4-a495-458c-abd6-9290bf0ff8c0">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzYtMy0xLTEtMjQ1NDc3_729917d5-1c6c-4eda-a9e3-eea94073c1b2">77.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzctMS0xLTEtMjQ1NDc3_ae842460-5325-4f36-8e52-929ecb42297a">610.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzctMy0xLTEtMjQ1NDc3_021a833a-df66-4e41-9969-f118e50e6431">593.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the resolution of claims that are part of Medicare audit programs can take several years, we review the patient receivables that are part of this adjudication process to determine their appropriate classification as either current or noncurrent. Amounts considered noncurrent are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheet. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for additional information.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_259"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90ZXh0cmVnaW9uOjE0NTU0NTFkMjUzMjRkOTg4ZmYzMGMxMDFkNTBkYTRlXzUyOA_741c894e-ca05-405a-b9e6-ddffe82ad7e5" continuedAt="i9bcfb6025a1646829bcdd529e26bfca8" escape="true">Property and Equipment:</ix:nonNumeric></span></div><ix:continuation id="i9bcfb6025a1646829bcdd529e26bfca8" continuedAt="ifa832036a7834153bf35b2c6f4ed8f3e"><ix:continuation id="i5dc0da37401f4e8a89df6f2fc94fb4fa"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62625eab8b0d4335a31e9e15249ae70e_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzItMS0xLTEtMjQ1NDc3_df744d0d-2bc1-429c-9fa5-cf072a76a0b3">286.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34843327cab94b9c8261df7a6ac9bacc_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzItMy0xLTEtMjQ1NDc3_2f3d7dcb-4089-4ef5-afe0-5cc3bb4e4550">259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d56907f4eb4436af6dad648f56ce6d_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzMtMS0xLTEtMjQ1NDc3_b05abfcd-82c6-4bb9-b5ee-b057caa5f700">3,019.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb76d50e6f0a4405bff0b4e4b612e7d6_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzMtMy0xLTEtMjQ1NDc3_1ba78d40-8b54-4d44-a5e2-e9ec6858857b">2,632.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b3fd57dd2042f68ac013078eaf240a_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzQtMS0xLTEtMjQ1NDc3_b4fe845a-aae4-4822-8c9f-34b26bbf83be">281.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13acf526358049fdb887e645c419f111_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzQtMy0xLTEtMjQ1NDc3_960d3b22-94f4-4ccf-99e2-0e15c0f2a6bd">251.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6c1d864105a4f598505f09fa76bc1be_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzUtMS0xLTEtMjQ1NDc3_87898032-e811-4e82-81eb-f74b046e070e">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f1644f1897949bb82fd5674d6ae3282_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzUtMy0xLTEtMjQ1NDc3_92135258-870a-4180-b3ef-e902706e555c">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60dcfb7b1544c66a69974be0bca5376_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzYtMS0xLTEtMjQ1NDc3_22011815-eed2-4b23-9f4a-b3648fb85d6f">647.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d230a026be94efb95ef13566c7b7b0a_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzYtMy0xLTEtMjQ1NDc3_66a0b146-9bc3-4e61-9e6f-a5a1c8e13105">571.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b54adc201247bb9fb60bdf36fff8a2_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzctMS0xLTEtMjQ1NDc3_2649c45e-014f-4def-a834-871d80abb4ca">4,239.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief3ef49cda4a4f22a1347489d45480e0_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzctMy0xLTEtMjQ1NDc3_9a73fca8-b73e-478f-bde5-372d628fe08e">3,718.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5b54adc201247bb9fb60bdf36fff8a2_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzgtMS0xLTEtMjQ1NDc3_e29e2a08-faf2-406b-abad-a043e52d9183">1,659.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief3ef49cda4a4f22a1347489d45480e0_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzgtMy0xLTEtMjQ1NDc3_625c564c-047e-40e2-bc87-3b9fa9f07835">1,490.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5b54adc201247bb9fb60bdf36fff8a2_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzktMS0xLTEtMjQ1NDc3_5edc0d9f-a49e-4602-a5b0-e241f6056564">2,579.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief3ef49cda4a4f22a1347489d45480e0_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzktMy0xLTEtMjQ1NDc3_3006e951-7841-4bca-9803-fdad7509a629">2,228.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07de7edf6557444789afb4418d5e6c0d_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzEwLTEtMS0xLTI0NTQ3Nw_ce9e772a-c0fe-4ae2-99e2-54b659a49c08">359.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e52d9e713e4adea7cfd891c3ecaeec_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzEwLTMtMS0xLTI0NTQ3Nw_3b6366dd-22a9-4762-9830-ed0e912b4822">353.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzExLTEtMS0xLTI0NTQ3Nw_47fba1a3-9a9d-4320-b8f3-70391a6818cb">2,939.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzExLTMtMS0xLTI0NTQ3Nw_0ea3e1e6-8a63-41ca-9eea-b39109e0e610">2,581.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, approximately <ix:nonFraction unitRef="number" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="2" name="ehc:Percentageofassetspledgedtolendersundercreditagreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90ZXh0cmVnaW9uOjE0NTU0NTFkMjUzMjRkOTg4ZmYzMGMxMDFkNTBkYTRlXzEwMA_c4ce0577-7527-4a5b-a3e9-67f4f675d907">68</ix:nonFraction>% of our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> held by Encompass Health Corporation and its guarantor subsidiaries was pledged to the lenders under our credit agreement. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Liquidity and Capital Resources.&#8221;</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ifa832036a7834153bf35b2c6f4ed8f3e"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90ZXh0cmVnaW9uOjE0NTU0NTFkMjUzMjRkOTg4ZmYzMGMxMDFkNTBkYTRlXzUxNg_cd38a86a-acf3-427c-8f30-6afa959c5e57" escape="true"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of depreciation expense and interest capitalized is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzItMS0xLTEtMjQ1NDc3_32c22691-0bae-482a-855c-949f65e58fb1">187.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzItMy0xLTEtMjQ1NDc3_b5618f97-af7e-4b9b-88bf-ebac2ce9505f">160.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzItNS0xLTEtMjQ1NDc3_4ee82920-3ac7-44c9-94ff-468c5c2b8774">145.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest capitalized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzQtMS0xLTEtMjQ1NDc3_220ce9ec-c38f-4716-8f97-534457846b20">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzQtMy0xLTEtMjQ1NDc3_56cfd772-a181-4f18-9f3b-be9f0f1c7ffd">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzQtNS0xLTEtMjQ1NDc3_61206c22-bc5e-451d-9d35-2ec0ea431b30">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_262"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNjg_3f31bfe0-e5e2-437d-84b1-f11021394185" continuedAt="i66bea244ea574390b19c1cc7f02ff087" escape="true"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzQ_a837253b-97ae-4b0c-9e4f-530434304c5c" continuedAt="i0fe2a1d0411d47c39c6d546420c538ad" escape="true">Leases:</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i66bea244ea574390b19c1cc7f02ff087" continuedAt="ifacbc5614fc44739832e2d6a872713c9"><ix:continuation id="i0fe2a1d0411d47c39c6d546420c538ad" continuedAt="i42fcd0c77e94462c86a29b2985613fa3"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have <ix:nonNumeric contextRef="i24d1851ef607402d900d6d9f19371197_D20220101-20221231" name="ehc:OperatingAndFinanceLeaseContractTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzgyNDYzMzcyMDk1MTc_17efdfad-fa4d-46dc-a40a-52e7e52607f8">1</ix:nonNumeric>- to <ix:nonNumeric contextRef="i802dc5eb74bb429e8814073a20bf7f9b_D20220101-20221231" name="ehc:OperatingAndFinanceLeaseContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzY_c5b10cb8-45e9-4167-b3bc-2273494cf6d2">25-year</ix:nonNumeric> terms, with <ix:nonFraction unitRef="option" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="ehc:OperatingAndFinanceLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzM4NDgyOTA2OTg2NDU_0ed159b9-940f-4fc1-9583-d4097812ed11">one</ix:nonFraction> or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzc_2ab1f82f-b378-4f09-af9d-c0c687c27da9" escape="true"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzItMS0xLTEtMjQ1NDc3_9f16cf11-c3c7-4cac-9b09-1ea412950945">38.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzItMy0xLTEtMjQ1NDc3_ecb298c2-741e-404a-9b2e-2cb385e72416">46.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzItNS0xLTEtMjQ1NDc3_fb641310-6298-47c6-9f21-bad3806013e0">50.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzQtMS0xLTEtMjQ1NDc3_00b9f08c-c04a-4272-8a1f-5c2055991311">27.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzQtMy0xLTEtMjQ1NDc3_a4c9b2c8-540d-4954-b87c-c1432aa4bb81">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzQtNS0xLTEtMjQ1NDc3_373bdbeb-6539-4ab8-b007-e0ccff5d57fe">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzUtMS0xLTEtMjQ1NDc3_bb558521-aec4-498a-b65f-9ede9420cf01">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzUtMy0xLTEtMjQ1NDc3_ce8bd93a-a941-485f-84d6-6c49ecdbd3d6">30.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzUtNS0xLTEtMjQ1NDc3_ee65497a-a81b-4e4c-9511-0c8a3530f9bc">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="ehc:Totalfinanceleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzYtMS0xLTEtMjQ1NDc3_e36059e4-12dc-4495-9b4b-4f9fc8df1dc9">56.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="ehc:Totalfinanceleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzYtMy0xLTEtMjQ1NDc3_a06318ce-5ae8-45a7-896b-24dad1ce08c5">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="ehc:Totalfinanceleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzYtNS0xLTEtMjQ1NDc3_c0632e43-454d-4ea6-9374-5a5bd1f056aa">53.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="ehc:Shorttermandvariableleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzctMS0xLTEtMjQ1NDc3_d011a31c-4a82-451a-9913-eae97a9a09bf">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="ehc:Shorttermandvariableleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzctMy0xLTEtMjQ1NDc3_394424a4-cd34-4e86-ab10-c2ed666fe4d7">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="ehc:Shorttermandvariableleasecost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzctNS0xLTEtMjQ1NDc3_f16398f5-1c74-4243-8d1a-1996250adbf9">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzgtMS0xLTEtMjQ1NDc3_a40a5ca5-ab7f-4ad8-a538-9f52595ce110">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzgtMy0xLTEtMjQ1NDc3_d5088348-cdf8-4ea6-80ae-b3e72d2a0000">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzgtNS0xLTEtMjQ1NDc3_b747d8c2-8447-4b32-8ff0-68007406512b">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzktMS0xLTEtMjQ1NDc3_c92e535e-81b4-40f3-8663-8f9d698642f3">97.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzktMy0xLTEtMjQ1NDc3_5206d424-b869-4117-a4ed-27e0c994fff9">105.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzktNS0xLTEtMjQ1NDc3_fa9a09ac-d8e0-44c1-a6c5-7c893e3ed2cc">104.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ifacbc5614fc44739832e2d6a872713c9" continuedAt="i545efe11dc4d41f8947068d296b5fb0c"><ix:continuation id="i42fcd0c77e94462c86a29b2985613fa3" continuedAt="i36b708d7525c4d4b9b548914dc4a3b84"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzA_278cc21d-d5d0-4773-9363-6e585f41f730" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated balance sheet information related to leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzMtNC0xLTEtMjQ1NDc3_79d0e8c9-4a58-4fe2-83a8-49d3a6cd1694">212.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzMtNi0xLTEtMjQ1NDc3_9348807f-d6e2-4d38-a841-eb6fd02c32af">193.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtNC0xLTEtMjQ1NDc3_4f8e2f01-e33f-495f-b711-5b0360eec9fe">272.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtNi0xLTEtMjQ1NDc3_3be27626-bc86-444e-a4ca-dfc94f4aa31c">299.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:Totaloperatingandfinanceleaseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzUtNC0xLTEtMjQ1NDc3_e2ac5b53-2cfc-4450-84c3-a67c2b92f2cc">485.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="ehc:Totaloperatingandfinanceleaseassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzUtNi0xLTEtMjQ1NDc3_15b3e4f1-ac73-4da8-a90b-25f93a2b0276">493.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzktNC0xLTEtMjQ1NDc3_f9f3e65e-1924-4b42-a561-a3f2876d7fc9">25.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzktNi0xLTEtMjQ1NDc3_c4707089-1163-422b-a9e9-f77e33ec97d0">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTQtMS0xLTI0NTQ3Nw_c7eaca33-12e3-4d7f-9dc2-24b363403716">19.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTYtMS0xLTI0NTQ3Nw_ea5f305f-afcf-4f75-b8ac-1a938843ad30">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEyLTQtMS0xLTI0NTQ3Nw_ed1be1a8-6e4b-4f3c-9be3-8891f3f1c2a6">199.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEyLTYtMS0xLTI0NTQ3Nw_cd03cef3-eb8e-4902-b45c-ceab4613e631">179.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTQtMS0xLTI0NTQ3Nw_a6a1d0f3-ea4c-467c-9274-f7dec320dbff">340.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTYtMS0xLTI0NTQ3Nw_574aa81b-cc87-4fe3-88cb-63d5f3cd2c6b">361.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:Totalleaseliabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzE0LTQtMS0xLTI0NTQ3Nw_27fdea4a-1c70-4be5-95c4-0b0a5609425d">585.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="ehc:Totalleaseliabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzE0LTYtMS0xLTI0NTQ3Nw_5fa987cf-ec26-4396-b9e0-260145d7c27b">583.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease assets are recorded net of accumulated amortization of $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1Xzk2NQ_3ef2ffb6-2de5-4027-8abd-d57944c84e42">145.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1Xzk3Mg_65a2f834-baf8-4b11-8da8-e1dbbcc2e368">126.9</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzE_d7980428-4da7-4d6c-b5d3-6f55f983a3ce" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzMtMS0xLTEtMjQ1NDc3_b8501946-4f3f-4aba-822a-bf7241baa4dc">9.3</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzMtMy0xLTEtMjQ1NDc3_e408e669-fff1-432c-8d0f-1563cf25dc7d">9.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzQtMS0xLTEtMjQ1NDc3_9945392f-cb0c-42bb-b81d-3dfdc6db7eb0">11.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzQtMy0xLTEtMjQ1NDc3_67728ecc-3056-4ae4-9c59-6ec322e56d71">12.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzYtMS0xLTEtMjQ1NDc3_58d06c82-fb0e-4179-80be-236ee8d2415c">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzYtMy0xLTEtMjQ1NDc3_0a545f97-7968-4414-9210-812d803ffa0d">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzctMS0xLTEtMjQ1NDc3_306f1365-8e6a-4b85-a791-f6bbb366b9b3">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzctMy0xLTEtMjQ1NDc3_f223f7e7-bdd8-40a4-8850-6ca9e7c625f4">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzI_a4b67d8d-08cd-4214-b61a-feeab59c1cbe" escape="true"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzM_2f5e6981-d97b-4afc-baae-99ae19a891f9" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzEtMS0xLTEtMjQ1NDc3_25183c79-29bd-4ad4-b31a-c97c6fdb4470">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzEtMy0xLTEtMjQ1NDc3_bc4dfd5b-1e73-4096-abc4-6c0eb979a005">45.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzItMS0xLTEtMjQ1NDc3_37f60da1-2aee-43c1-98ce-97257731f5ab">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzItMy0xLTEtMjQ1NDc3_0d98f6cf-3fd1-494b-994e-718ac94ee9f3">46.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzMtMS0xLTEtMjQ1NDc3_cba45854-ca2d-40f3-92b0-30140f86ae89">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzMtMy0xLTEtMjQ1NDc3_0ff1ba16-e5b9-45fd-8acd-b316802ccb0a">47.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzQtMS0xLTEtMjQ1NDc3_caafcc3e-70ec-463e-9feb-d9d16b35f074">34.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzQtMy0xLTEtMjQ1NDc3_f0975561-f55e-4020-8046-75fcd39b0b79">47.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzUtMS0xLTEtMjQ1NDc3_e28e9346-357b-4865-89c0-32a5edcff1eb">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzUtMy0xLTEtMjQ1NDc3_ed9c5453-320f-4d82-bfb7-d60956f6ace7">47.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzYtMS0xLTEtMjQ1NDc3_c7ecd909-909a-45e5-87f6-01cbae28294d">119.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzYtMy0xLTEtMjQ1NDc3_f275db45-e062-4ac3-9bba-746692e17b47">316.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzctMS0xLTEtMjQ1NDc3_64d1e80e-ab8a-48ac-bd7e-3e5057a9d0b3">302.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzctMy0xLTEtMjQ1NDc3_ecff4e6e-bc02-4cc7-93ac-e08d7f83ea7d">551.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzgtMS0xLTEtMjQ1NDc3_3c3a1967-9b4e-4e5a-b9f1-7ebadded9c72">77.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzgtMy0xLTEtMjQ1NDc3_750012b3-06bc-4884-84a9-7e4fda976350">191.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzktMS0xLTEtMjQ1NDc3_f82bafd1-befd-4992-a6be-c352ce1e611d">225.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzktMy0xLTEtMjQ1NDc3_d2b3444e-8107-4579-afbd-ec5702f535d5">359.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i545efe11dc4d41f8947068d296b5fb0c"><ix:continuation id="i36b708d7525c4d4b9b548914dc4a3b84"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="ehc:SupplementalCashFlowInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzU_000ac1af-be93-4180-9c82-62cbf4d94839" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzMtMS0xLTEtMjQ1NDc3_d7796801-9765-4f0b-ab6d-3b7f9868b250">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzMtMy0xLTEtMjQ1NDc3_082c0e29-1e47-4632-b7e3-df9bf58db07a">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzMtNS0xLTEtMjQ1NDc3_8b8147d8-2768-44db-8b36-b31a36d97216">50.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzQtMS0xLTEtMjQ1NDc3_7019ef0c-c1e1-41ec-8588-550099cf1bf8">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzQtMy0xLTEtMjQ1NDc3_59647914-716a-4fae-9dfc-14ae1d9d4e0a">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzQtNS0xLTEtMjQ1NDc3_b092832f-c0c1-4d41-a4fa-10b8fcd17a56">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzUtMS0xLTEtMjQ1NDc3_d5f5685f-f2a2-402a-81a4-479e7b73de4b">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzUtMy0xLTEtMjQ1NDc3_1b2766d8-4d59-49bc-af65-9b12204f9ac2">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzUtNS0xLTEtMjQ1NDc3_0e6357c1-f329-46e4-bfdc-b61d0beef33d">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzgtMS0xLTEtMjQ1NDc3_b20bc872-639d-4ab2-a3ff-20b8b3e3c17b">48.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzgtMy0xLTEtMjQ1NDc3_159066e0-c963-4e4f-8c1a-813940eea5ac">26.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzgtNS0xLTEtMjQ1NDc3_d2346031-4e69-4fda-95eb-83576c87779b">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzktMS0xLTEtMjQ1NDc3_30bba627-d1ab-4b6b-8961-01ea5017da69">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzktMy0xLTEtMjQ1NDc3_9451b653-6aac-4aa6-93a9-437b829e83ff">46.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzktNS0xLTEtMjQ1NDc3_596cdae1-d650-4666-84e3-a72d6a5364c4">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_265"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzE0MTI_5039f897-56d4-4e50-9583-772e6d9294c0" continuedAt="i9bb1928abdef4ec5975f8da36a2ef609" escape="true">Goodwill and Other Intangible Assets:</ix:nonNumeric></span></div><ix:continuation id="i9bb1928abdef4ec5975f8da36a2ef609" continuedAt="i7b9f86458fc74b138a40c92b82570113"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzE0MDc_7993d831-e883-4334-907f-e1e3e1fd821b" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzEtNS0xLTEtMjQ1NDc3_cf50d24e-654f-4b89-8023-6441e6f31334">1,218.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzItNS0xLTEtMjQ1NDc3_d59f3002-5d6c-4ff3-8a90-db1da9d84bfd">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzUtNS0xLTEtMjQ1NDc3_d5b52ce2-78a1-4d4d-a02e-e292fadcc1ca">1,228.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzYtNS0xLTEtMjQ1NDc3_f7d9d3fa-c74c-4e27-93c7-3ee5d85fb92c">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzgtNS0xLTEtMjQ1NDc3_c4bc0a88-9b6e-4d74-a3bf-19027fbdf933">1,237.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzktNS0xLTEtMjQ1NDc3_c9fa5609-d1d3-4d11-80e5-0ee6e4cdf410">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzExLTUtMS0xLTI0NTQ3Nw_d131cda5-f2d9-439b-bd3b-26c9cca000c0">1,263.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in 2020, 2021 and 2022 as a result of our acquisitions of inpatient rehabilitation operations. For additional information on these acquisitions, see Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed impairment reviews as of October&#160;1, 2022, 2021, and 2020 and concluded <ix:nonFraction unitRef="usd" contextRef="i177f96156a934c6d92f90d026d815168_D20221001-20221001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5Xzk4Nw_4148377b-ce20-43db-a302-e34e3acbdcb7"><ix:nonFraction unitRef="usd" contextRef="i8a2086e6351b40948b88fd941ae8faae_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5Xzk4Nw_9f436847-ba61-4dc1-8726-ce97531fa82d"><ix:nonFraction unitRef="usd" contextRef="i104ce402feb14e3c9c5682306cabdd39_D20201001-20201001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5Xzk4Nw_fca2812f-e11f-4a3b-bb21-0a17e0eb9d22">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment existed. As of December&#160;31, 2022, we had <ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzEwMzY_67795d7b-99d4-4dbb-bb2d-d21ee868d314">no</ix:nonFraction> accumulated impairment losses related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i7b9f86458fc74b138a40c92b82570113"><ix:continuation id="i4c03b5215ac643f3bfbb375e1b20c6a8"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our other intangible assets (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certificates of need:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d33a74e74847b680d36c4c8aa5735e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzItMS0xLTEtMjQ1NDc3_9a1e38b0-4ad2-4243-9f43-b822712deb0a">120.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97d33a74e74847b680d36c4c8aa5735e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzItMy0xLTEtMjQ1NDc3_12933e7a-d0ac-401c-9cfc-69e8c5071d0a">41.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97d33a74e74847b680d36c4c8aa5735e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzItNS0xLTEtMjQ1NDc3_1aba47bf-6b29-4d63-8f20-275296b896ae">78.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e84e7ad92e46d1833a208bce11c4b7_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzMtMS0xLTEtMjQ1NDc3_da5ba7e2-e5ba-495c-a5b8-25381a137cf0">115.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8e84e7ad92e46d1833a208bce11c4b7_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzMtMy0xLTEtMjQ1NDc3_4cecd871-afd9-4542-ad63-e58da170060f">36.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e84e7ad92e46d1833a208bce11c4b7_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzMtNS0xLTEtMjQ1NDc3_a05bb0db-d0b5-498f-838b-76ad5dd2758b">79.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie577c85705764e9287e7a571a526dd5e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzUtMS0xLTEtMjQ1NDc3_bc26660d-ebd2-4851-949e-fc1f98680aa9">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie577c85705764e9287e7a571a526dd5e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzUtMy0xLTEtMjQ1NDc3_e2d70852-6bc7-4bf1-bf7e-a3b0095c0097">54.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie577c85705764e9287e7a571a526dd5e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzUtNS0xLTEtMjQ1NDc3_cad2ff57-1717-42c5-a203-b37fbdf9bf65">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8c2650479a4933998c56d70426ad5a_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzYtMS0xLTEtMjQ1NDc3_d66619be-62aa-40e3-be96-e81ce702986c">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief8c2650479a4933998c56d70426ad5a_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzYtMy0xLTEtMjQ1NDc3_219bb0bb-2d4e-4237-8d79-73d6c9153e00">53.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8c2650479a4933998c56d70426ad5a_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzYtNS0xLTEtMjQ1NDc3_1b2aff32-542b-44de-ac27-f5efb0e83ad0">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncompete agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d992d3261104e3a8eb38871bc693f4e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzgtMS0xLTEtMjQ1NDc3_2311f603-37dc-4378-809f-53f0acbd7707">66.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d992d3261104e3a8eb38871bc693f4e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzgtMy0xLTEtMjQ1NDc3_356f7420-2930-46a0-8d2b-823e1766e711">60.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d992d3261104e3a8eb38871bc693f4e_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzgtNS0xLTEtMjQ1NDc3_2f83d274-9788-4854-97c1-ef9d85ab3b99">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffe900a66ea42e5864253cf987a4119_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzktMS0xLTEtMjQ1NDc3_8b1a615c-812f-4fca-b15e-5c0b05fadb39">65.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ffe900a66ea42e5864253cf987a4119_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzktMy0xLTEtMjQ1NDc3_f9dd5ed9-0e89-4cd9-a959-eade68a833a6">58.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ffe900a66ea42e5864253cf987a4119_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzktNS0xLTEtMjQ1NDc3_5219df80-202c-4afe-82f4-553c1cab4f12">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade name - Encompass:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c0ea0e574949d8b18d28a5e6d26be3_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzExLTEtMS0xLTI0NTQ3Nw_c5abaf6f-f279-4789-95eb-6847033b3278">135.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c0ea0e574949d8b18d28a5e6d26be3_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzExLTMtMS0xLTI0NTQ3Nw_1e91824a-231c-4e54-a3f3-0c01ad7fedb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c0ea0e574949d8b18d28a5e6d26be3_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzExLTUtMS0xLTI0NTQ3Nw_da176ece-6a18-4772-85ad-809790eb5a16">135.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d0cf8338b44b91948c16fbb5260dc9_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzEyLTEtMS0xLTI0NTQ3Nw_0eb5078e-1966-43cc-a8cb-0ec75d05e015">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d0cf8338b44b91948c16fbb5260dc9_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzEyLTMtMS0xLTI0NTQ3Nw_2374d6f0-609b-4262-b53c-ca784685992b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59d0cf8338b44b91948c16fbb5260dc9_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzEyLTUtMS0xLTI0NTQ3Nw_d94ff3b2-4820-4c6d-97db-2abb1f2a7482">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade names - all other:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246e3aa9111b46d18007fd9747ba80fa_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE0LTEtMS0xLTI0NTQ3Nw_0060f879-68ae-438f-905a-6d04f0070365">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i246e3aa9111b46d18007fd9747ba80fa_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE0LTMtMS0xLTI0NTQ3Nw_0dbf58d2-895e-41c7-b61c-9a39899eb9e0">20.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i246e3aa9111b46d18007fd9747ba80fa_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE0LTUtMS0xLTI0NTQ3Nw_210f25e2-582c-436d-9a89-658320c5ef15">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0887e89510aa430c98ba297311ec7c02_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE1LTEtMS0xLTI0NTQ3Nw_279440d0-9326-4386-8bec-64645be38287">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0887e89510aa430c98ba297311ec7c02_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE1LTMtMS0xLTI0NTQ3Nw_764a2163-3bd4-4a55-b193-088dcd6da08a">19.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0887e89510aa430c98ba297311ec7c02_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE1LTUtMS0xLTI0NTQ3Nw_b4faa4fd-00a5-446b-9d9c-a3e3433666d7">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal-use software:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675d9700b9a44be5a34cdbf2e3579982_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE3LTEtMS0xLTI0NTQ3Nw_2ab0dbfc-f642-429c-9680-d66aedab6011">183.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i675d9700b9a44be5a34cdbf2e3579982_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE3LTMtMS0xLTI0NTQ3Nw_9c45d7f7-6ca9-4a27-a51c-ed7a79717595">150.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675d9700b9a44be5a34cdbf2e3579982_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE3LTUtMS0xLTI0NTQ3Nw_014de693-2381-4a9b-a1b5-fba0de88cf55">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d897ae5c3574e308dff0216d9b948c1_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE4LTEtMS0xLTI0NTQ3Nw_3535f94e-e4d2-4d3c-ba21-e8076869e3f8">182.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d897ae5c3574e308dff0216d9b948c1_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE4LTMtMS0xLTI0NTQ3Nw_811f71ce-58cf-4c02-8412-a9afac18a71c">142.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d897ae5c3574e308dff0216d9b948c1_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE4LTUtMS0xLTI0NTQ3Nw_97d2db94-4602-4aef-963f-52930c4818a8">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market access assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cf3b85aded4187ab1295a58ade6e45_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIwLTEtMS0xLTI0NTQ3Nw_aab9e893-54c1-4be6-9199-29e12f98bedd">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7cf3b85aded4187ab1295a58ade6e45_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIwLTMtMS0xLTI0NTQ3Nw_6c3f16e5-6312-41dc-a6c7-bd33b20b261a">12.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7cf3b85aded4187ab1295a58ade6e45_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIwLTUtMS0xLTI0NTQ3Nw_c7716a47-3423-446c-b3f0-46ec47f487dc">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf83682496c480f9e42d6fee1080450_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIxLTEtMS0xLTI0NTQ3Nw_280bf404-9a95-44e6-a2b0-9f0456d62259">13.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bf83682496c480f9e42d6fee1080450_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIxLTMtMS0xLTI0NTQ3Nw_f5f91a54-3fd9-44a4-9ed7-936d269c5882">11.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bf83682496c480f9e42d6fee1080450_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIxLTUtMS0xLTI0NTQ3Nw_9a644884-6754-4ea1-9193-d902ed794d77">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIzLTEtMS0xLTI0NTQ3Nw_11d2e594-292a-4953-9c61-44d1b9dae41e">621.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIzLTMtMS0xLTI0NTQ3Nw_e65be31e-9122-49a2-9eb9-df9aca477928">339.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIzLTUtMS0xLTI0NTQ3Nw_2f9b8a6a-4c00-494e-9bbe-cf6ca0a3b6fb">282.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzI0LTEtMS0xLTI0NTQ3Nw_5aa74816-4679-487f-9d82-43d92b6634cb">479.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzI0LTMtMS0xLTI0NTQ3Nw_c7b17740-38eb-4eba-9573-7a7a1aaf9429">321.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzI0LTUtMS0xLTI0NTQ3Nw_89f89e21-76a0-4bc6-8981-4e24e44f46c9">158.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzEzOTY_6b23cc88-f4b3-4be8-bef9-9bdba7481367" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for other intangible assets is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTowZDZmZjVlODY5M2E0NWIyODdmYmRmMWUzODczNTYxNS90YWJsZXJhbmdlOjBkNmZmNWU4NjkzYTQ1YjI4N2ZiZGYxZTM4NzM1NjE1XzItMS0xLTEtMjQ1NDc3_ef71444f-9fde-4022-abce-149af5ddf6ca">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTowZDZmZjVlODY5M2E0NWIyODdmYmRmMWUzODczNTYxNS90YWJsZXJhbmdlOjBkNmZmNWU4NjkzYTQ1YjI4N2ZiZGYxZTM4NzM1NjE1XzItMy0xLTEtMjQ1NDc3_3279369d-4642-4616-aa34-1db995e13ddd">31.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTowZDZmZjVlODY5M2E0NWIyODdmYmRmMWUzODczNTYxNS90YWJsZXJhbmdlOjBkNmZmNWU4NjkzYTQ1YjI4N2ZiZGYxZTM4NzM1NjE1XzItNS0xLTEtMjQ1NDc3_0cb2b624-732d-4db0-8271-409af4569edf">32.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzE0MjY_46487d3f-2173-471f-83ae-f5fb07590855" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzEtMS0xLTEtMjQ1NDc3_bc7aed9e-ab02-4f1d-8864-b861545dee12">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzItMS0xLTEtMjQ1NDc3_fae55b74-7b83-4cf1-ba05-fd9fc1eea33d">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzMtMS0xLTEtMjQ1NDc3_5c8cfe4b-006e-4a0a-b80c-053788e1ad75">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzQtMS0xLTEtMjQ1NDc3_186b39a7-1541-4c9a-b2ff-e5ce8e0e3dee">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzUtMS0xLTEtMjQ1NDc3_2a5eb8a6-2fb2-48a5-b6c1-8e10e486f5aa">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_271"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyOTA5_0418c9df-a022-41de-bcf5-03201abd0bf2" continuedAt="ib0760e8486ef4a47b968daafff5768e3" escape="true">Long-term Debt:</ix:nonNumeric></span></div><ix:continuation id="ib0760e8486ef4a47b968daafff5768e3" continuedAt="i67cdd57e5b114245b55edc040dc04d60"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyODc0_3e88721e-2a6b-4d52-834d-16378fa74417" continuedAt="if9881f8c003a4568a1306e84c77bd82c" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3402d0382640a1aa58f90238c683e9_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzMtMS0xLTEtMjQ1NDc3_f1c24df2-eb1b-45a4-a694-74d46ba0f03e">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife432a1f73c54d489020d8e1c0653fb5_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzMtMy0xLTEtMjQ1NDc3_3ea0cdaa-26a4-4f9f-a9c4-e01213d12667">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966df770ed1a4ca986dd2b7ce6d52c65_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzQtMS0xLTEtMjQ1NDc3_0cbfcc2f-a83e-43f3-a632-e8801ea33894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b3c2c63d034b5982e9fe8323b7b71e_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzQtMy0xLTEtMjQ1NDc3_f219c90b-7d7f-4fec-9f81-80e1d5a974c9">238.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzYtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246OTJiZGQ0NjI0MjdjNDRjMzk3MzE0NGJhY2ZlNjU2YmFfNA_bfd1f1bd-8152-4131-8bbb-ce1f67f02b01"><ix:nonFraction unitRef="number" contextRef="id1214fc63dae4248a98c4032a91b2fec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzYtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246OTJiZGQ0NjI0MjdjNDRjMzk3MzE0NGJhY2ZlNjU2YmFfNA_ca544c63-0aaa-4f72-95a4-0e126ef61ddf">5.125</ix:nonFraction></ix:nonFraction>% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzYtMS0xLTEtMjQ1NDc3_39e6f8a4-6f98-42dc-80c6-f81fe0b8264d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1214fc63dae4248a98c4032a91b2fec_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzYtMy0xLTEtMjQ1NDc3_4e06fc55-bae7-442e-b386-cb06af5e871f">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b519d969150438ca0a24a17a6f87ca8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjdmMTZlMTM1ZTVkNGQwMDk3MzY0ZGM4MGE4NWM3MzZfNA_587a8921-9c37-4326-80f2-03c8348e2e0f"><ix:nonFraction unitRef="number" contextRef="i005266a587014861b4fc4bdc254e6a15_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjdmMTZlMTM1ZTVkNGQwMDk3MzY0ZGM4MGE4NWM3MzZfNA_9f35e6a4-ed99-46da-9667-34167c0ccd5e">5.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i005266a587014861b4fc4bdc254e6a15_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzctMS0xLTEtMjQ1NDc3_4b732489-84be-41b9-92ac-659a8ca38224">347.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b519d969150438ca0a24a17a6f87ca8_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzctMy0xLTEtMjQ1NDc3_bfbf6054-2438-4431-b042-a0acba025135">347.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b5a421f1a804107a53e85439af96f46_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzgtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MDQxMTE5MWNkN2M2NGE2ZTk1NTNhZTdjMmU4ZTExOTZfNA_6bf22234-87a3-4d99-94ff-2c620e0fa16b"><ix:nonFraction unitRef="number" contextRef="i03e2cfaa161d423e9fe9d78c1d2484d8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzgtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MDQxMTE5MWNkN2M2NGE2ZTk1NTNhZTdjMmU4ZTExOTZfNA_ec2505d6-b573-4512-8311-a0ec181aa3ac">4.50</ix:nonFraction></ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b5a421f1a804107a53e85439af96f46_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzgtMS0xLTEtMjQ1NDc3_30b8039b-ea20-46b8-bbc8-63d9e2a658b2">781.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e2cfaa161d423e9fe9d78c1d2484d8_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzgtMy0xLTEtMjQ1NDc3_3e1297c0-da11-44fc-b2f3-76df5b5288af">786.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idca4e969d39442579877374d995f76bc_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzktMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzI0M2FmZTA4NjIxNDA2NzhkZWQ0YjljZGU4OTRkOThfNA_270cfbe1-ec03-4547-8605-31bedc871c65"><ix:nonFraction unitRef="number" contextRef="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzktMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzI0M2FmZTA4NjIxNDA2NzhkZWQ0YjljZGU4OTRkOThfNA_37344c1e-1cca-40f7-a777-6bff36254137">4.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzktMS0xLTEtMjQ1NDc3_41fae1aa-b686-4be7-8ca9-4379ca9cee79">779.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idca4e969d39442579877374d995f76bc_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzktMy0xLTEtMjQ1NDc3_cf17d6f5-f944-4585-85be-c26593d94d8e">784.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iccae8862dd6a4bac8b4589ffb7e02bba_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEwLTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjNkNDk4ZmY1YjM0YzQwZDA4MDc1NGUzZGZiZDM5ZGUwXzQ_744aec19-2df4-4a6c-a72e-b3e24b967433"><ix:nonFraction unitRef="number" contextRef="i85aa556fff894922b569241055a48e29_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEwLTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjNkNDk4ZmY1YjM0YzQwZDA4MDc1NGUzZGZiZDM5ZGUwXzQ_edc8e297-8257-4e91-9857-34aebf99e277">4.625</ix:nonFraction></ix:nonFraction>% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85aa556fff894922b569241055a48e29_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEwLTEtMS0xLTI0NTQ3Nw_6b868724-73e3-4ca9-b00c-9365b105329a">390.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccae8862dd6a4bac8b4589ffb7e02bba_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEwLTMtMS0xLTI0NTQ3Nw_b05000f1-06af-4abe-8877-c39ce8f5b00d">393.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f0c6fe1d3d4acabec50bcd4c8268f6_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzExLTEtMS0xLTI0NTQ3Nw_3f663d94-0dd8-4de5-9d47-2a659315fd7a">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848b097591424c609108802124923a5e_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzExLTMtMS0xLTI0NTQ3Nw_519fa5c8-aff2-457c-b277-360fd2f3bc29">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEyLTEtMS0xLTI0NTQ3Nw_8a2f4f9b-b081-40e5-8bfb-83ea2273c116">359.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEyLTMtMS0xLTI0NTQ3Nw_9f533a0f-81bc-47f4-83de-c892006a7f8f">380.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEzLTEtMS0xLTI0NTQ3Nw_42d497c4-5af7-4e2f-bca2-15a16cc3fd2b">2,767.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEzLTMtMS0xLTI0NTQ3Nw_a0d75e07-0f98-43e6-a39c-632b6366fbed">3,278.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzE0LTEtMS0xLTI0NTQ3Nw_1c0d9193-41e8-47f3-b399-7b8e65c25b64">25.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzE0LTMtMS0xLTI0NTQ3Nw_73ff7530-e372-49c2-88a2-7ab8b83868eb">37.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzE1LTEtMS0xLTI0NTQ3Nw_4e41b007-6ec1-433c-854c-1568611bb3be">2,741.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzE1LTMtMS0xLTI0NTQ3Nw_58866b4f-fde4-4b0d-a060-99b70c1746d3">3,240.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyODcx_30c6b636-4eca-4933-8d85-23750d442c61" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.108%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Face Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzEtMi0xLTEtMjQ1NDc3_da423121-3410-48f5-819f-a3d1f48f3580">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7012b097a470cb13642fec315ce68_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzEtNC0xLTEtMjQ1NDc3_28be3b61-b7ff-41fe-8864-cdbe4e21e310">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzItMi0xLTEtMjQ1NDc3_0b2551af-29c7-4b25-aa19-02e1c4754b00">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7012b097a470cb13642fec315ce68_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzItNC0xLTEtMjQ1NDc3_98e00be5-be51-471e-b632-31b538852f6c">39.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzMtMi0xLTEtMjQ1NDc3_c19e82a0-ef43-45e8-b1cb-8ef2fcfccea9">381.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7012b097a470cb13642fec315ce68_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzMtNC0xLTEtMjQ1NDc3_05ff676d-5fc4-47bb-b31d-88226ebbc43a">379.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzQtMi0xLTEtMjQ1NDc3_7138b38b-3150-4f82-bfe8-c73e03d4b764">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7012b097a470cb13642fec315ce68_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzQtNC0xLTEtMjQ1NDc3_032e2177-7311-4184-956b-1104ffe61125">27.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzUtMi0xLTEtMjQ1NDc3_97e1c8cb-247f-46d1-b590-ffd5f30245b9">96.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7012b097a470cb13642fec315ce68_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzUtNC0xLTEtMjQ1NDc3_fd55a2c0-e053-4fe7-8346-5db95b0f8e75">96.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzYtMi0xLTEtMjQ1NDc3_751aeab6-973d-476e-8fb5-95a32a379466">2,247.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7012b097a470cb13642fec315ce68_I20221231" decimals="-5" name="ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzYtNC0xLTEtMjQ1NDc3_a1f4ab5b-3123-48a1-912a-7ffc1eae4da4">2,198.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzctMi0xLTEtMjQ1NDc3_4d73c6f8-8852-427c-a36e-d65b5ce9dab9">2,817.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b7012b097a470cb13642fec315ce68_I20221231" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzctNC0xLTEtMjQ1NDc3_c547c870-446f-41e0-8661-07136e00d886">2,767.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the redemptions discussed below, we recorded a $<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwOTk1MTE2NDA3MTk_95fca2d0-249a-4ac5-8d16-9e710dfdfaf2">1.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwOTk1MTE2NDA3MjQ_a8e8ec02-9e58-4872-9228-0224d0f81f48">1.0</ix:nonFraction> million, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwOTk1MTE2NDA3Mjk_0ed7c50c-1fe3-458b-a9f9-ff6d04f87fb5">2.3</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Agreement&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="i1c1215032fe2415c8d09726a46e245a4_I20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzQ5OQ_e4037dc0-d3ce-444f-a8d3-7a0ea5443157">1</ix:nonFraction> billion revolving credit facility, with a $<ix:nonFraction unitRef="usd" contextRef="ibe73f052bcb64b3b84bdbe9c72aaa76c_I20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzUzNg_de357a82-1441-4df6-b1ae-729ba2203b57">260</ix:nonFraction> million letter of credit subfacility and a swingline loan subfacility, all of which mature in October 2027. The credit agreement previously provided for a $<ix:nonFraction unitRef="usd" contextRef="i339b11c888494596a3629e3c3f8602a3_I20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk4MDAyMjQ_0561a6bf-85e3-411d-9b46-20f7fd74de23">270</ix:nonFraction> million term loan commitment, the outstanding amount of which was repaid in June 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts drawn on the revolving credit facility bear interest at a rate per annum of, at our option, (1) secured overnight financing rate (&#8220;SOFR&#8221;) or (2)&#160;the higher of (a)&#160;Barclays Bank PLC&#8217;s prime rate and (b)&#160;the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="if808e99cfa6f4952a0ae670544ff3a5a_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyMzM_da1cfc93-5b7a-4193-b817-72b250ea7fe1">0.5</ix:nonFraction>%, in each case, plus, in each case, an applicable margin that varies depending upon our leverage ratio. We are also subject to a commitment fee of <ix:nonFraction unitRef="number" contextRef="i4e6b4e433f554a94aa26022360c2e01d_D20191101-20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEzODI_5f6fbe50-cd44-4fde-9a17-e437026956a6">0.25</ix:nonFraction>% or <ix:nonFraction unitRef="number" contextRef="i1b575fc15d22495a9d08298c9bae970f_D20191101-20191130" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzU0OTc1NTg0Njk5OA_2a75ba50-374b-4097-a1fc-6768d069c7eb">0.30</ix:nonFraction>%, depending on our leverage ratio, per annum on the daily amount of the unutilized commitments under the revolving credit facility. The current interest rate on SOFR borrowings under the credit agreement includes a credit spread of <ix:nonFraction unitRef="number" contextRef="i041d58dc5a4a43e5a53c4489ec517413_D20191101-20191130" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzE1NjM_946ee01d-de39-4f6e-8f35-b694d199e5ba">1.50</ix:nonFraction>%.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i67cdd57e5b114245b55edc040dc04d60" continuedAt="i68119df1776a4de8b14e3f8da1ad6293"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement contains affirmative and negative covenants and default and acceleration provisions, including a minimum interest coverage ratio and a maximum leverage ratio. Under one such negative covenant, we are restricted from paying common stock dividends, prepaying certain senior notes, making certain investments, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the credit agreement and (2) our senior secured leverage ratio, as defined in the credit agreement, does not exceed <ix:nonFraction unitRef="number" contextRef="ia639cd1c8ac549939010774ccd59e3c6_I20191130" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzIxMDg_6d0eaf02-02eb-498e-999f-77ccd5a2b58f">2</ix:nonFraction>x. In the event the senior secured leverage ratio exceeds <ix:nonFraction unitRef="number" contextRef="ia639cd1c8ac549939010774ccd59e3c6_I20191130" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatioMaximum" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzNTc_97aa64e5-4a40-48f0-84e1-0c1331ddcfb7">2</ix:nonFraction>x, these payments are subject to a limit of $<ix:nonFraction unitRef="usd" contextRef="ia639cd1c8ac549939010774ccd59e3c6_I20191130" decimals="-6" name="ehc:DebtInstrumentCovenantAvailableLimitAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzIyMTI_14511136-e1ca-4802-be73-e3297bca01ee">200</ix:nonFraction> million plus the Available Amount, as defined in the credit agreement. Our obligations under the credit agreement are secured by the current and future personal property of the Company and its subsidiary guarantors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we amended our existing credit agreement and the amendments included the following material provisions:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below.</span><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="ehc:ScheduleOfFinancialCovenantsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyODk0_1257d123-ca29-45aa-bca3-7d81e7ee6355" continuedAt="id4f9936a08c241ad9a0847e23112d4a9" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:67.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcac1b02df73495c877b9c7d30a882c4_D20200101-20200331" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTowNTk0NWI1Y2M3OTg0YWQxYWUyMGI1NzRmZTNkNjAyNy90YWJsZXJhbmdlOjA1OTQ1YjVjYzc5ODRhZDFhZTIwYjU3NGZlM2Q2MDI3XzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MjMwY2FjODEwMmQ3NDBjOTk2YzAzZWMxYWM5NGExMmJfNA_d7bb47a8-e621-4dcb-a1f4-4e899adfda47">3.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia18b2e0c059c4ec6baf3c43fbd522a3c_D20200701-20211231" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTowNTk0NWI1Y2M3OTg0YWQxYWUyMGI1NzRmZTNkNjAyNy90YWJsZXJhbmdlOjA1OTQ1YjVjYzc5ODRhZDFhZTIwYjU3NGZlM2Q2MDI3XzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MzAzZjc3YTAxY2RlNDMzZThkN2ZhMzdjOGI0OWUwNGZfNA_d9e8cbf5-f646-4be2-bc69-63fc33c980ce">2.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="INF" name="ehc:DebtInstrumentCovenantInterestCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTowNTk0NWI1Y2M3OTg0YWQxYWUyMGI1NzRmZTNkNjAyNy90YWJsZXJhbmdlOjA1OTQ1YjVjYzc5ODRhZDFhZTIwYjU3NGZlM2Q2MDI3XzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246OGNiNGIzMWU1NzY5NGQ2YzkyMzE3YjZkM2EwNmI2NWRfNA_771aa07d-fd5d-4936-83a4-c8f0de87f95d">3.00</ix:nonFraction> to 1.00</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:67.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6753a38864e24fe7b3e80115745bd09e_I20200331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Zjc3NWUxNjIwYWI0NDFiNDhjYzY3MWJmMDg2ZmEzZWJfNA_802d08df-6866-4485-b9cf-8c7537564bf7">4.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i562889873f374783afb9294f8f3e580d_I20200630" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246YjhkMTE2ZTI2ZTk3NGFiNTllZDg2NTAxZWVlZjQ3NGZfNA_9ae53d50-8c77-4be6-ab0e-c86154e44af3">4.75</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i693a1fea14d6475ca0e8f46ce8dfe8fb_I20200930" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246OWYyMmYwYzE0OTBiNDEzNzkxZTRhZjY5NTcyMmIwN2RfNA_43127dd5-2455-4dbb-a635-41d0ec819bdf">5.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzQtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MDk2NGVhOGU5MDZlNDU0ZGE3MzA4ODNmNDJmZTM1OTVfNA_b8431b29-0fbf-4377-87c7-9cbba20b4966">6.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i115e2fd9db454724b9f95a8f9e1f70a4_I20210331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzUtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MDIyZDFjZTYxZmExNGE2NWFkNzRlNTYxZGI1M2FhYzBfNA_861375d5-55fb-486c-9bee-4fdbf0835294">6.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9936400e3d03441c8b1661005d6f279a_I20210630" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzYtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NDk1OGM4YjVlMjBjNGJhZTgzYjBiOWMzZWM1M2I1NjBfNA_c0ab8753-f391-4a90-8d1f-cdb8c6255801">6.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a87df56a8f6405f8b9bb8b08241a639_I20210930" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzctMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MjRlZjUzYzJmOWQwNDVmYzg4ZTNlNjNlNmExNzU2YjZfNA_2521c4e4-7bd5-419e-b724-8ab725304ebe">5.50</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzgtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NWY0ZmQ3OGM3MTFlNGIwNzhiOGZmOTE5Mzg1NzAzMThfNA_a5f7a394-d88b-4db1-93cd-c7291cc970d3">5.00</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4b3e1118ad2243ae8f2552652e81d1e9_I20220331" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzktMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NWFhNDA1MzFjOGQwNGJhYTk5MjFjNTRkZDE4NmM4OGZfNA_1f6dc59c-cb28-4d09-8871-177e64ee422e">4.25</ix:nonFraction> to 1.00</span></div></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Material Adverse Effect&#8221; to carve out the direct and indirect impacts of pandemic and the related legislative, regulatory and executive actions on us from that definition for a period of <ix:nonNumeric contextRef="ia1738ccbe8404bafad9e9c10b06a1540_D20200401-20200430" name="ehc:DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzNzE_7fb5d349-256d-45a9-ba3a-ccb962621cfb">364</ix:nonNumeric> days; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of <ix:nonFraction unitRef="number" contextRef="i53ddc51847dc4ddbae72c2e1b0dd613e_I20200430" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatioMaximum" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzNTY_90007488-8464-4344-b4ee-bbe086c0be20">4.50</ix:nonFraction>x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of <ix:nonFraction unitRef="number" contextRef="i53ddc51847dc4ddbae72c2e1b0dd613e_I20200430" decimals="INF" name="ehc:DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzNzA_c00f11fe-e35f-4076-884a-ae6bac114374">2.00</ix:nonFraction>x) and the existence of no events of default in addition to the new leverage ratio condition.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we further amended our existing credit agreement and the amendments included the following material provisions:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of definition of &#8220;Consolidated Net Income&#8221; to exclude from the calculation thereof, at Encompass Health&#8217;s option, net income or loss from disposed, abandoned, transferred, closed or discontinued operations until such disposition, abandonment, transfer, closure of discontinuance of operations shall have been consummated.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Addition of Section 1.08, &#8220;SpinCo Credit Facilities Transactions,&#8221; to provide that the Loan Documents will not prevent the consummation of the SpinCo Credit Facilities Transactions and that the SpinCo Credit Facilities Transactions will not give rise to any Default or constitute a utilization of any basket under any Loan Document.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i68119df1776a4de8b14e3f8da1ad6293" continuedAt="i4731227d20ab482681845d91f423a42b"><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of Section 2.11(e) to provide that a Prepayment Notice may be conditioned upon the effectiveness of other credit facilities, indentures or similar agreements or other transactions.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Addition of Section 5.18, &#8220;SpinCo Distribution,&#8221; to provide that within three (<ix:nonFraction unitRef="day" contextRef="ib298d1d466d644b3a88d10c8864e5755_I20220630" decimals="INF" name="ehc:DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzODg_a7e22dae-f1c6-4389-9c5c-304515b46b70">3</ix:nonFraction>) Business Days following the incurrence of indebtedness under the SpinCo Credit Facilities, Encompass will have consummated the SpinCo Distribution in compliance with the Restricted Payments covenants of the Credit Agreement, and following the consummation of the SpinCo Distribution, no obligors in respect of the SpinCo Credit Facilities will be Restricted Subsidiaries.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Senior Notes&#8221; to include Encompass&#8217; <ix:nonFraction unitRef="number" contextRef="i49cf61de567c43ef90aa762bfd0eeb09_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgyOTA_e5cb7606-8edc-44d9-8855-d453c4a9b3e4">4.625</ix:nonFraction>% Senior Notes due 2031 and the definition of &#8220;Consolidated Total Indebtedness&#8221; to exclude Indebtedness under any Senior Note for which an irrevocable notice of redemption has been issued in connection with or incidental to any SpinCo Distribution.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we further amended our existing credit agreement and the amendments included the following material provisions:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Maturity Date&#8221; for the revolving borrowings to October 7, 2027.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Change the reference rate for borrowings from LIBOR to SOFR.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Reduction of the fee for the undrawn portion of the revolving loan commitment from <ix:nonFraction unitRef="number" contextRef="i751e9639a4854331aafc6dd971bd8b76_D20221001-20221031" decimals="INF" name="ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgyOTg_6e6a42d5-e9ac-49ca-8b89-8ab88996ddf8">37.5</ix:nonFraction> basis points to a maximum of <ix:nonFraction unitRef="number" contextRef="i977aaea8b2b34ebc93d72ec5a537716a_D20221001-20221031" decimals="INF" name="ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMDc_09e8b329-8052-4668-90cf-0f4c161a2a2a">30</ix:nonFraction> basis points and a minimum of <ix:nonFraction unitRef="number" contextRef="i7f7042f972104aa8922d830f4c40e428_D20221001-20221031" decimals="INF" name="ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion" scale="-4" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMTQ_cf5aea9e-7c35-45db-814f-130dfd97dea3">25</ix:nonFraction> basis points, with such rate to be determined based on the Leverage Ratio as of the most recently ended four quarter period.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Restatement of the Leverage Ratio maintenance covenant in Section 6.01(b) to the following:</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the last day of each fiscal quarter, the Borrower will not permit the Leverage Ratio, calculated as of the end of each such fiscal quarter occurring during the time periods set forth below on a pro forma basis, to exceed the ratio set forth below opposite the time period during which such fiscal quarter ends; provided, however, that the Borrower may elect (the &#8220;Step-Up Election&#8221;) at any time after the Effective Date to increase the maximum Leverage Ratio permitted hereunder by <ix:nonFraction unitRef="number" contextRef="ifc1102227aec4db8b50dfac6284decf9_I20221031" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMjE_3783349c-d9e0-41ca-80ca-3b55b3c045e5">0.50</ix:nonFraction> to 1.00 for the 4 immediately succeeding fiscal quarters as of and immediately following the consummation of any Significant Acquisition, in each case, by providing a written notice to the Administrative Agent of such Step-Up Election prior to the last day of the first fiscal quarter for which the Step-Up Election is to take effect (this sentence, the &#8220;Leverage Covenant&#8221;). Upon the expiration of the Step-Up Election, the maximum Leverage Ratio permitted under the Leverage Covenant shall revert to the Leverage Ratio set forth below for at least two consecutive fiscal quarters before the Borrower may make another Step-Up Election.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><ix:continuation id="id4f9936a08c241ad9a0847e23112d4a9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"></td><td style="width:67.943%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.857%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022 &#8211; September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie134020e1d4c46b8bf2c15a981b6d8c3_I20240930" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1OTQ2ZmJjYzBkMTg0MjdhOGI5MTFlOGExYjczZDJmOC90YWJsZXJhbmdlOjU5NDZmYmNjMGQxODQyN2E4YjkxMWU4YTFiNzNkMmY4XzEtMS0xLTEtMjgzODg0L3RleHRyZWdpb246NGQ1MjIxZGNiODRkNDZlY2FlMjgyYzM2MWQ2ZDQ3NjdfMzg0ODI5MDY5NzIzNg_b642ed5a-53b4-46f2-910e-72f5df9ad6a9">4.75</ix:nonFraction> to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29afe01aaa2c4a1faa04d57a037e62a5_I20241231" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1OTQ2ZmJjYzBkMTg0MjdhOGI5MTFlOGExYjczZDJmOC90YWJsZXJhbmdlOjU5NDZmYmNjMGQxODQyN2E4YjkxMWU4YTFiNzNkMmY4XzItMS0xLTEtMjgzODg0L3RleHRyZWdpb246ZTU0NzUxMjJhMDk5NDU2ZTk5YzQxOTliNGM5MDY0ZjBfMzg0ODI5MDY5NzIzNg_fdfb0193-f154-453c-b7fe-b74f45284fde">4.50</ix:nonFraction> to 1.00</span></div></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Insertion of an add back of certain restructuring charges and synergies in calculating Adjusted Consolidated EBITDA under the credit agreement.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of definition of &#8220;Available Amount&#8221; to include a $<ix:nonFraction unitRef="usd" contextRef="iffee7132fe2a4d46ad166324cc4ac784_I20221031" decimals="-6" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMzI_6d4bc37a-11a4-4a53-90a8-c36b0136640a">900</ix:nonFraction>&#160;million &#8220;starter amount&#8221; and a &#8220;grower component&#8221; tied to <ix:nonFraction unitRef="number" contextRef="i37964c43d1d6497390edcd2c9583717d_I20221031" decimals="INF" name="ehc:LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMjc_5e9263ac-d41c-4c9a-91e0-f94bccfeeb1d">50</ix:nonFraction>% of cumulative Consolidated Net Income.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of certain negative covenant baskets to include a &#8220;grower component&#8221; tied to a percentage of Adjusted Consolidated EBITDA for a trailing 12-month period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Enhabit distributed $<ix:nonFraction unitRef="usd" contextRef="i43a0ab4d513d4a748593003c9e09d157_D20220630-20220630" decimals="-5" name="us-gaap:PaymentsOfDistributionsToAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3ODk3MjY_eed74caa-613e-44b6-bbbe-e0674e98dfe8">566.6</ix:nonFraction>&#160;million to Encompass Health who used it to fully repay both the $<ix:nonFraction unitRef="usd" contextRef="i57239bff51e54e02bfafa24442729469_D20220630-20220630" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3ODk3ODY_d2e59fb1-7620-49a3-bd4b-8e6ffaa8e476">250</ix:nonFraction>&#160;million outstanding balance of the Encompass Health revolving credit facility and approximately $<ix:nonFraction unitRef="usd" contextRef="i15a929b250624845875d18fad4623b1c_D20220630-20220630" decimals="-6" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3ODk4Nzg_53d8f25e-624e-4d36-bdf2-6ea5f7ecd2d8">236</ix:nonFraction>&#160;million of the Encompass Health term loan. Currently, there are no term loan commitments under the credit agreement. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i4731227d20ab482681845d91f423a42b" continuedAt="i45ed17aae9d041bb854a5a38ea63c14f"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ibeb50e54b2bf431e84d3d94cc9d22afa_I20221231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM0Mzc_e124a91a-5d71-46bd-b3d8-6c26a6118513">55</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were drawn under the revolving credit facility with an interest rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i203fce73533d42bdbce407cb83fa7644_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM1MTI_75f058d8-dc8e-4a5d-82d2-816c5d3f4f90">7.0</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="ib2e47e2a132f436290412d3422a81aa9_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM1Mzk_255b3f8b-8c4c-4f58-8b3e-403bc8cd539c">200</ix:nonFraction> million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were drawn under the revolving credit facility with an interest rate of <ix:nonFraction unitRef="number" contextRef="i99bc319d2e0041d082e15bd0afcd2496_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzU0OTc1NTgyNzk3NA_dfadb2c9-0631-488b-a741-f855081841a3">2.6</ix:nonFraction>%. As of December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="i73171c1ff1894cd5ab077095eb011dd2_I20221231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM2MjY_db840c35-6ce4-40d5-a10b-c6204d36f104">32.7</ix:nonFraction> million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i90e87d090f6f40978450a4a6d7148825_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM2MzM_9164f136-6ba0-45ab-93e8-99b7a7542c48">38.2</ix:nonFraction> million, respectively, were being </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilized under the letter of credit subfacility, which were being used in the ordinary course of business to secure workers&#8217; compensation and other insurance coverages and for general corporate purposes.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bonds Payable&#8212;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Senior Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="number" contextRef="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI0Mjk_967e123e-4336-40b4-8d96-c53a17a24b0b">5.125</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Senior Notes due 2023 (&#8220;the 2023 Notes&#8221;), <ix:nonFraction unitRef="number" contextRef="i005266a587014861b4fc4bdc254e6a15_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI1Mjk_d2ac861e-6479-4d63-83c5-b7cdb8533cf2">5.75</ix:nonFraction>% Senior Notes due 2025 (the &#8220;2025 Notes&#8221;), <ix:nonFraction unitRef="number" contextRef="i6b5a421f1a804107a53e85439af96f46_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI1MzY_893159d8-bd7d-4719-abd1-34d335d739a2">4.50</ix:nonFraction>% Senior Notes due 2028 (the &#8220;2028 Notes&#8221;), <ix:nonFraction unitRef="number" contextRef="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI1NDI_453a717c-7f3e-49e0-8bbd-2d1223174b72">4.75</ix:nonFraction>% Senior Notes due 2030 (the &#8220;2030 Notes&#8221;), and <ix:nonFraction unitRef="number" contextRef="i85aa556fff894922b569241055a48e29_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI1NDQ_5359a1d1-3c75-41c8-955a-9ad2e99219f9">4.625</ix:nonFraction>% Senior Notes due 2031 (the &#8220;2031 Notes&#8221; and collectively the &#8220;Senior Notes&#8221;) were issued pursuant to an indenture (the &#8220;Base Indenture&#8221;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#8217; respective supplemental indenture (together with the Base Indenture, the &#8220;Indenture&#8221;). Pursuant to the terms of the Indenture, the Senior Notes are jointly and severally guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The Senior Notes are senior, unsecured obligations of Encompass Health and rank equally with our other senior indebtedness, senior to any of our subordinated indebtedness, and effectively junior to our secured indebtedness to the extent of the value of the collateral securing such indebtedness.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the Indenture), each holder of the Senior Notes may require us to repurchase all or a portion of the notes in cash at a price equal to <ix:nonFraction unitRef="number" contextRef="i4d3ce01c69d745bc933890c6d0232e0a_D20220101-20221231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzUwNTk_bb42d879-ed12-40de-a632-7f8bd0cadb16">101</ix:nonFraction>% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes contain covenants and default and acceleration provisions, that, among other things, limit our and certain of our subsidiaries&#8217; ability to (1)&#160;incur additional debt, (2)&#160;make certain restricted payments, (3)&#160;consummate specified asset sales, (4)&#160;incur liens, and (5)&#160;merge or consolidate with another person.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of the 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively the &#8220;Notes&#8221;) for the adoption of certain amendments to the Indenture, which provided us with greater flexibility in effecting the Spin Off discussed in Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin Off of Home Health and Hospice Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than <ix:nonFraction unitRef="number" contextRef="i0e4f418e7b3140e2b36a3a4c1d19f59b_I20211209" decimals="INF" name="ehc:DebtInstrumentCovenantLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1MTY_07486e23-e616-47fd-9dce-156eba2b79d7">3.5</ix:nonFraction> to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture for the 2028 Notes, 2030 Notes, and 2031 Notes by $<ix:nonFraction unitRef="usd" contextRef="i0e4f418e7b3140e2b36a3a4c1d19f59b_I20211209" decimals="-6" name="ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY2OTQ_3f4b5698-39b4-4c81-8d68-7283bb5a295b">200</ix:nonFraction>&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $<ix:nonFraction unitRef="usd" contextRef="i04748e0cbb554838bc097423f5562754_D20211201-20220131" decimals="-5" name="ehc:DebtInstrumentAmendmentAgreementAmountToBePaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzcxNTg_2a0b0226-452e-4f86-a9d0-e5972ee17264">40.5</ix:nonFraction>&#160;million, excluding fees. We paid $<ix:nonFraction unitRef="usd" contextRef="ia4e9489eb2374473a2446b5989746133_D20220101-20220131" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzcxODY_9f198bf3-6412-448d-8a6e-e25d4342a60f">20.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3aa44cd02be2427b83f4285074d6a61c_D20220601-20220630" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzU0OTc1NTgzNTE4MQ_594a530f-cd7a-4a33-a6cd-ec2e7da49fbd">20.5</ix:nonFraction> million in January and June 2022, respectively.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i45ed17aae9d041bb854a5a38ea63c14f" continuedAt="i14efe43aac0a420a9e02183fe8296aa1"><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="iaa62f19b4e9543c6a31117b7bb708940_I20150331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzczNjE_893ed006-a8bd-4994-998a-6b42c64f4050">300</ix:nonFraction> million of the 2023 Notes at par. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both April and June 2021, we redeemed $<ix:nonFraction unitRef="usd" contextRef="i4579352e569d4ffc861c231d1d0881ff_D20210401-20210430" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTM0ODY_57824125-2f7d-45fa-ac33-d76ec79c0dee"><ix:nonFraction unitRef="usd" contextRef="id2d821c1a27c4513aaef9bf885e8f58a_D20210601-20210630" decimals="-6" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTM0ODY_be93b493-aaf1-4955-b268-4c122c0e1419">100</ix:nonFraction></ix:nonFraction>&#160;million in outstanding principal amount of the 2023 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, these optional redemptions were made at a price of par. In March 2022, we redeemed the remaining $<ix:nonFraction unitRef="usd" contextRef="i45f4aa2776e24eebbb23581d16dfab42_I20220331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTM5ODU_80621195-23bc-4f7e-b25e-4874054d5c00">100</ix:nonFraction>&#160;million in outstanding principal amount of the 2023 Notes using capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes would have matured on March 15, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of financing costs, the effective interest rate on the 2023 Notes was <ix:nonFraction unitRef="number" contextRef="iaa62f19b4e9543c6a31117b7bb708940_I20150331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzc2NjA_dec211ff-7821-45d6-a930-14042a765baa">5.4</ix:nonFraction>%.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest on the 2023 Notes was payable semiannually in arrears on March 15 and September 15.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="ie136f6f5e4de4e5eba9a9453789bcd0c_I20150930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwMTAy_ad4c98da-54c2-4747-8d90-5885d0e09eac">350</ix:nonFraction> million of the 2025 Notes at par. The 2025 Notes mature on September&#160;15, 2025 and bear interest at a per annum rate of <ix:nonFraction unitRef="number" contextRef="ie136f6f5e4de4e5eba9a9453789bcd0c_I20150930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwMjQ1_be821489-5e7c-431a-b7d0-db0bddcd6250">5.75</ix:nonFraction>%. Inclusive of financing costs, the effective interest rate on the 2025 Notes is <ix:nonFraction unitRef="number" contextRef="ie136f6f5e4de4e5eba9a9453789bcd0c_I20150930" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwMzI4_b26b46bc-26e4-4f32-80d2-799db0c037dd">6.0</ix:nonFraction>%. Interest on the 2025 Notes is payable semiannually in arrears on March 15 and September&#160;15. </span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:DebtInstrumentRedemptionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyODg0_846b4598-6dfa-44a4-b8f8-a6cf00974164" continuedAt="i5c20f8701a984ef2be32aa0ec6b30695" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2022, at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:83.504%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07b9cc9fc0fa4aa9b201c5317d0c6b56_D20150901-20150930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozOWE0YmFhM2UxNTc0N2FmYTcxMTIyMTljYmNmYzMyMy90YWJsZXJhbmdlOjM5YTRiYWEzZTE1NzQ3YWZhNzExMjIxOWNiY2ZjMzIzXzItMi0xLTEtMjQ1NDc3_c30c9327-0d2c-4caf-8fbd-7b8ca3e7c362">100.958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 15, 2023 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76b9b243cc2b40eca3256ba9b90f576c_D20150901-20150930" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozOWE0YmFhM2UxNTc0N2FmYTcxMTIyMTljYmNmYzMyMy90YWJsZXJhbmdlOjM5YTRiYWEzZTE1NzQ3YWZhNzExMjIxOWNiY2ZjMzIzXzMtMi0xLTEtMjQ1NDc3_5542fcbc-e2bb-4dc6-a5ea-7f68522f039b">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 and 2030 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we issued $<ix:nonFraction unitRef="usd" contextRef="iebf5ce77babc4dabb08fd48fb81f0d30_I20190930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwNjU5_3f10c111-dc79-4d87-aed7-138114250908">500</ix:nonFraction> million of the 2028 Notes at par and $<ix:nonFraction unitRef="usd" contextRef="i1afcf433ab7c4f42b650fb3992b5dfaf_I20190930" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwNzIw_d528d016-0129-4b43-902a-f001d9b205b9">500</ix:nonFraction> million of the 2030 Notes at par. Certain of the proceeds from this offering were used to fund the purchase of equity rights from management investors of our former home health and hospice business discussed in Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued an additional $<ix:nonFraction unitRef="usd" contextRef="i2a81a550dc09402898362c8731660c62_I20200531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMTA1_d657536d-2c84-4460-9fc5-84830990d70c">300</ix:nonFraction>&#160;million of the 2028 Notes at a price of <ix:nonFraction unitRef="number" contextRef="i2a81a550dc09402898362c8731660c62_I20200531" decimals="3" name="ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMTQw_65f3ec48-7b29-4c89-999d-6d72f40ed042">99.0</ix:nonFraction>% of the principal amount and an additional $<ix:nonFraction unitRef="usd" contextRef="i3ea5e06878784d1c8ac7d2976c3faae1_I20200531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMTg1_7f4f7eec-a02f-47a7-a5ae-09dcfbb44325">300</ix:nonFraction>&#160;million of the 2030 Notes at a price of <ix:nonFraction unitRef="number" contextRef="i3ea5e06878784d1c8ac7d2976c3faae1_I20200531" decimals="3" name="ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMjIw_930c52ea-90e2-4174-a8a8-8854284b0c01">98.5</ix:nonFraction>% of the principal amount, which resulted in approximately $<ix:nonFraction unitRef="usd" contextRef="i46706a0b927b4c29aa04008703cf93f6_D20200501-20200531" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMjgw_45180eeb-fc47-48fc-b972-4fb15152b6a9">583</ix:nonFraction>&#160;million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes mature on February 1, 2028. Inclusive of financing costs, the effective interest rate on the 2028 Notes is <ix:nonFraction unitRef="number" contextRef="i2a81a550dc09402898362c8731660c62_I20200531" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExNTY2_731e56e6-11e6-42c8-a8f4-adf0abeb4e54">4.8</ix:nonFraction>%. Interest on the 2028 Notes is payable semiannually in arrears on February 1 and August 1. <ix:continuation id="i5c20f8701a984ef2be32aa0ec6b30695" continuedAt="if667fc9bcc6a4cb69b4b114dd71e23fa">We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:</ix:continuation></span></div><ix:continuation id="if667fc9bcc6a4cb69b4b114dd71e23fa" continuedAt="if9cc153bf3a4434b8d98625ad1ed61b3"><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i37d6af95f4af4e68ba6868cc4060e8be_D20190901-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozNjk4YjU2YzY1MDk0YjNmODZjMDI3N2QyZWE1MmMzZC90YWJsZXJhbmdlOjM2OThiNTZjNjUwOTRiM2Y4NmMwMjc3ZDJlYTUyYzNkXzEtMi0xLTEtMjQ1NDc3_6491fdcd-d5af-42bc-afa8-f265ee7238ea">102.250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie995c3d447e041b09b1095eed8f92f8b_D20190901-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozNjk4YjU2YzY1MDk0YjNmODZjMDI3N2QyZWE1MmMzZC90YWJsZXJhbmdlOjM2OThiNTZjNjUwOTRiM2Y4NmMwMjc3ZDJlYTUyYzNkXzItMi0xLTEtMjQ1NDc3_207bd05d-1572-4e5c-9786-70ff4dcbd7d1">101.125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i551a3e6b442f432c9d03ed8b29cef37a_D20190901-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozNjk4YjU2YzY1MDk0YjNmODZjMDI3N2QyZWE1MmMzZC90YWJsZXJhbmdlOjM2OThiNTZjNjUwOTRiM2Y4NmMwMjc3ZDJlYTUyYzNkXzMtMi0xLTEtMjQ1NDc3_5b4eb944-e3ac-43d0-8a40-a457eebd0ed0">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i14efe43aac0a420a9e02183fe8296aa1"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes mature on February 1, 2030. Inclusive of financing costs, the effective interest rate on the 2030 Notes is <ix:nonFraction unitRef="number" contextRef="i3ea5e06878784d1c8ac7d2976c3faae1_I20200531" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExOTY0_2d6e3601-6d42-4d9c-994d-d30bff7bdd2b">5.2</ix:nonFraction>%. Interest on the 2030 Notes is payable semiannually in arrears on February 1 and August 1. <ix:continuation id="if9cc153bf3a4434b8d98625ad1ed61b3" continuedAt="i03e619f6b8ca474a8703a5d4378f9a89">We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:</ix:continuation></span></div><ix:continuation id="i03e619f6b8ca474a8703a5d4378f9a89" continuedAt="i0dbcf5c09cb043fcbd2ef603aec4730c"><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie16678dac8224a06a40d1b5f2983c761_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo4NmY1MjZkZGFhOTY0YTExYmNhNzE2MGZlNjM3MTRjOC90YWJsZXJhbmdlOjg2ZjUyNmRkYWE5NjRhMTFiY2E3MTYwZmU2MzcxNGM4XzEtMi0xLTEtMjQ1NDc3_e334a67c-11f0-4b40-ba6d-92bcdb03361a">102.375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i774caad6b09f45a4b7028e593a0fab36_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo4NmY1MjZkZGFhOTY0YTExYmNhNzE2MGZlNjM3MTRjOC90YWJsZXJhbmdlOjg2ZjUyNmRkYWE5NjRhMTFiY2E3MTYwZmU2MzcxNGM4XzItMi0xLTEtMjQ1NDc3_8a37e5f9-7154-4336-8acc-5bf6fdae0003">101.583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icdd2b81bfc614cf3b6b1ae1a415c9a04_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo4NmY1MjZkZGFhOTY0YTExYmNhNzE2MGZlNjM3MTRjOC90YWJsZXJhbmdlOjg2ZjUyNmRkYWE5NjRhMTFiY2E3MTYwZmU2MzcxNGM4XzMtMi0xLTEtMjQ1NDc3_bf07add0-dfa1-493f-bb4c-5d3ca52ea8c2">100.792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0231b4cffab42d181cb35d1de3a69f6_D20200501-20200531" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo4NmY1MjZkZGFhOTY0YTExYmNhNzE2MGZlNjM3MTRjOC90YWJsZXJhbmdlOjg2ZjUyNmRkYWE5NjRhMTFiY2E3MTYwZmU2MzcxNGM4XzQtMi0xLTEtMjQ1NDc3_bf9b2030-04de-4dcb-9080-1ac6cf26594a">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2031 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we issued $<ix:nonFraction unitRef="usd" contextRef="idfdfcc3a1e4d49cb802cebf7c87fab08_I20201031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyMjc4_6567f766-f759-40be-9b25-fcd8fed3d47c">400</ix:nonFraction>&#160;million of the 2031 Notes at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of <ix:nonFraction unitRef="number" contextRef="idfdfcc3a1e4d49cb802cebf7c87fab08_I20201031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyNDQz_b88c573f-777e-4109-8975-bc49601650f7">4.625</ix:nonFraction>%. Inclusive of financing costs, the effective interest rate on the 2031 Notes is <ix:nonFraction unitRef="number" contextRef="idfdfcc3a1e4d49cb802cebf7c87fab08_I20201031" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyNTI2_a9e974b3-7b87-4ea8-9b71-7797bb58372c">5.0</ix:nonFraction>%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. <ix:continuation id="i0dbcf5c09cb043fcbd2ef603aec4730c" continuedAt="i484bba3aa9f94bbba94479b42c1bd31b">We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:</ix:continuation></span></div><ix:continuation id="i484bba3aa9f94bbba94479b42c1bd31b"><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72f1191377284bad9d5006ad478e6bf1_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZToyYTFmMDllNTdhM2Y0NzBkYjNiMjBiZDE1NGZkZGQ5MS90YWJsZXJhbmdlOjJhMWYwOWU1N2EzZjQ3MGRiM2IyMGJkMTU0ZmRkZDkxXzEtMi0xLTEtMjQ1NDc3_bc4ad88a-4515-4e9e-98a2-d7beb1838fba">102.313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3149f20f82304cdda697d7b9112cdb47_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZToyYTFmMDllNTdhM2Y0NzBkYjNiMjBiZDE1NGZkZGQ5MS90YWJsZXJhbmdlOjJhMWYwOWU1N2EzZjQ3MGRiM2IyMGJkMTU0ZmRkZDkxXzItMi0xLTEtMjQ1NDc3_9c09de53-83cf-41e1-9448-e17ff0033d6c">101.542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9778d074309d474e95d5496bad2d2441_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZToyYTFmMDllNTdhM2Y0NzBkYjNiMjBiZDE1NGZkZGQ5MS90YWJsZXJhbmdlOjJhMWYwOWU1N2EzZjQ3MGRiM2IyMGJkMTU0ZmRkZDkxXzMtMi0xLTEtMjQ1NDc3_2eb455b2-e1e0-49c1-b03d-91d7a5ada72d">100.771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21773a5ded4f4f4a8e0e3fdcbb5ae70d_D20201001-20201031" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZToyYTFmMDllNTdhM2Y0NzBkYjNiMjBiZDE1NGZkZGQ5MS90YWJsZXJhbmdlOjJhMWYwOWU1N2EzZjQ3MGRiM2IyMGJkMTU0ZmRkZDkxXzQtMi0xLTEtMjQ1NDc3_b2ca5c1f-e7a2-4e2a-9704-f3bfc124eb70">100.000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div></ix:continuation><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Former 2024 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we redeemed the remaining $<ix:nonFraction unitRef="usd" contextRef="if575f492f4ab49a593a29cb5970ee78a_I20201130" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTY4NjY_3958510a-bfb9-42fe-a332-2ec1c2c389f9">700</ix:nonFraction>&#160;million of outstanding principal amount of the <ix:nonFraction unitRef="number" contextRef="i387c5b799dc94ed79c28d16aa0afe0a1_I20201130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTg0NzQ_dda74b7a-8992-47e9-9a37-d513bd7e2d16">5.75</ix:nonFraction>% Senior Notes due 2024 (&#8220;the Former 2024 Notes&#8221;). Pursuant to the terms of the Former 2024 Notes, this full redemption was made at a price of par. We used the net proceeds from the 2031 Notes offering, discussed above, together with approximately $<ix:nonFraction unitRef="usd" contextRef="idb7fb37acad541dd9f14a7d2fa29fe10_D20201101-20201130" decimals="-6" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTcxMjM_32e4a6ef-63b9-4be5-9f7c-6f19d54673dc">300</ix:nonFraction>&#160;million of cash on hand to fund the redemption. The Former 2024 Notes would have matured on November&#160;1, 2024. Inclusive of premiums and financing costs, the effective interest rate on the Former 2024 Notes was <ix:nonFraction unitRef="number" contextRef="if575f492f4ab49a593a29cb5970ee78a_I20201130" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTczMTU_24eda0cf-d319-46ae-9c3e-acc516ac916b">5.8</ix:nonFraction>%. Interest was payable semiannually in arrears on May 1 and November&#160;1 of each year. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Notes Payable&#8212;</span></div><ix:continuation id="if9881f8c003a4568a1306e84c77bd82c"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our notes payable consist of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.078%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale/leaseback transactions involving real estate accounted for as financings</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29770414195047bdb212e4ecdc100bdd_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItMS0xLTEtMjQ1NDc3_3b17965e-fbc9-4818-a7ef-70c8161e8b9e">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c7b1e35d601476d95db3457cce2e093_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItMy0xLTEtMjQ1NDc3_07bb9099-ccf3-4eeb-8e56-fd077426420a">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0eb949f24cfd47338d5c07380335f00f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Mzc3MTI1MzJiMzgyNDJjOWFiZmIxYjQ4ZmM5MGQ2NDlfNA_302704f4-c7a0-4143-81f0-a0fc10d81e0c"><ix:nonFraction unitRef="number" contextRef="i892f9d840d2347f2ac10417c21a2ea1c_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Mzc3MTI1MzJiMzgyNDJjOWFiZmIxYjQ4ZmM5MGQ2NDlfNA_da0a4bd1-ae04-4de5-b39e-721c16e5cc90">6.1</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie09d6f9c686d4f06bc4e1d29051b98d0_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Mzc3MTI1MzJiMzgyNDJjOWFiZmIxYjQ4ZmM5MGQ2NDlfMTA_1290045e-e3a3-4e2e-941e-bbfce828c459"><ix:nonFraction unitRef="number" contextRef="ic74b27f5ff584f4dae66883c596ca93e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Mzc3MTI1MzJiMzgyNDJjOWFiZmIxYjQ4ZmM5MGQ2NDlfMTA_d24c6582-dd9b-4382-99ad-1a4645224402">11.2</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction of a new hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30931627be4f4491b0b2e533a3d8199d_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtMS0xLTEtMjQ1NDc3_c6fac51e-a736-4c9b-bbfe-692b130df6af">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11699d607063435a811357201af64e8c_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtMy0xLTEtMjQ1NDc3_c2579399-4952-4825-acd1-03f421080c36">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51dea7b95c6d4aba83ad9fa892757146_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZTQ1YTdmNGY3NmRhNGE4NmEzMmYzMDk5NTVhYTAzOTRfNTQ5NzU1ODEzODk4_ac1d9e5c-b249-4560-a0bf-a441d2ffa9cb"><ix:nonFraction unitRef="number" contextRef="ia822ef25d22e4d039b50ff40539e575a_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZTQ1YTdmNGY3NmRhNGE4NmEzMmYzMDk5NTVhYTAzOTRfNTQ5NzU1ODEzODk4_dffc51a6-92a6-4049-9f31-1bd045e4fa67">5.0</ix:nonFraction></ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ie7a2877ba40e444e80b196cf51e8d9c3_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZTQ1YTdmNGY3NmRhNGE4NmEzMmYzMDk5NTVhYTAzOTRfNA_555f96b1-1bb6-46f6-8f50-7162e04978dd"><ix:nonFraction unitRef="number" contextRef="i6a6fcce63a9548dea0e3f5364203fa60_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZTQ1YTdmNGY3NmRhNGE4NmEzMmYzMDk5NTVhYTAzOTRfNA_f799fe75-650c-4fe2-bdbd-dab1b526cf84">5.5</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6abe4bfb1a460d92a2904f739f25a2_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzUtMS0xLTEtMjQ1NDc3_07b11b7e-88a8-4563-b6a8-a7cb28dfde1f">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6600f773078e47c292dfad7ad647a4fd_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzUtMy0xLTEtMjQ1NDc3_610d71aa-ac26-4399-8cd6-9306c4a04537">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f2a545ddce6494e94a8dce995b13eb9_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzUtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzVlMzc5MjdlYWZlNGM3ZGE3ZGVhZjhhMDg4NzkwNjBfNA_0394d954-6c02-4fa6-bce8-823e52fbdd98"><ix:nonFraction unitRef="number" contextRef="i98ec873af9eb4796a1d331828822e615_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzUtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzVlMzc5MjdlYWZlNGM3ZGE3ZGVhZjhhMDg4NzkwNjBfNA_d16f23dd-369a-4448-837a-33804d06ad66">2.8</ix:nonFraction></ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44f0c6fe1d3d4acabec50bcd4c8268f6_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzYtMS0xLTEtMjQ1NDc3_434c4915-b06d-46a8-9fc4-425609816919">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848b097591424c609108802124923a5e_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzYtMy0xLTEtMjQ1NDc3_6a330084-17a5-4d47-802d-88a47d53ac4b">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_277"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzIzMzU_41b59719-da32-48eb-b03d-bfacb9ea7840" continuedAt="ifa48ded2439744feb6b361c831745bb6" escape="true">Self-Insured Risks:</ix:nonNumeric></span></div><ix:continuation id="ifa48ded2439744feb6b361c831745bb6"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We insure a substantial portion of our professional liability, general liability, and workers&#8217; compensation risks through a self-insured retention program (&#8220;SIR&#8221;) underwritten by our consolidated wholly owned offshore captive insurance subsidiary, HCS, Ltd., which we fund via regularly scheduled premium payments. HCS is an insurance company licensed by the Cayman Island Monetary Authority. We use HCS to fund the first $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-6" name="ehc:MaximumSelfInsuredAmountFirstLayerOfRisk" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzQzMg_bff0a8b9-69c6-47bd-a0d9-bd757547d665">45</ix:nonFraction> million for annual aggregate losses associated with general and professional liability risks. Workers&#8217; compensation exposures are capped on a per claim basis. Risks in excess of specified limits per claim and in excess of our aggregate SIR amount are covered by unrelated commercial carriers.</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzIzNDE_c396056d-1cb7-4fb6-8f64-a0ea3c156645" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our self-insurance reserves (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:53.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEtMS0xLTEtMjQ1NDc3_6a1adfd2-05f5-4c38-9ed0-4c8f75f26980">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEtMy0xLTEtMjQ1NDc3_33eb245a-999c-4fc0-b351-3ef391bd092c">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEtNS0xLTEtMjQ1NDc3_126ad5b3-a920-42b4-bfdc-c9b46276fd3a">157.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzItMS0xLTEtMjQ1NDc3_dd30c80f-fcfe-4994-878a-6b2a19d67f1f">30.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzItMy0xLTEtMjQ1NDc3_3dabd534-04d4-497e-b546-8508c2bb15a6">28.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzItNS0xLTEtMjQ1NDc3_8ea314c4-7122-4030-83d6-93de0b8c623f">26.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzMtMS0xLTEtMjQ1NDc3_c638a8e3-7c55-4870-840b-051c6a935e3e">139.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzMtMy0xLTEtMjQ1NDc3_21b95372-ac0f-441a-b32f-0a0f0c83f0a1">136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzMtNS0xLTEtMjQ1NDc3_e2f9868c-baa0-4661-927f-ecaf8a6ff713">130.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for the provision of current year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzQtMS0xLTEtMjQ1NDc3_3fcad5a0-0701-4ca4-bb10-72f52b25fe42">50.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzQtMy0xLTEtMjQ1NDc3_7d1f5000-1751-44b5-8ee1-ee753d2f5bb8">46.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzQtNS0xLTEtMjQ1NDc3_b7260e8d-8ba6-44e4-a7fd-68f661f5edf0">52.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease for the provision of prior year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzUtMS0xLTEtMjQ1NDc3_a035dcc0-6945-4e82-9141-4eaa37e1d9a1">8.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzUtMy0xLTEtMjQ1NDc3_d2261c0b-1289-4103-9770-0e1c9b35fc4c">6.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzUtNS0xLTEtMjQ1NDc3_a634f122-3dbf-4b42-ab9e-45b3afc96f92">15.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses related to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzctMS0xLTEtMjQ1NDc3_3d2c1848-6466-492a-a421-5e208e2b469a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzctMy0xLTEtMjQ1NDc3_8dc63a02-f03a-43e6-ac5f-3c9837880dfa">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzctNS0xLTEtMjQ1NDc3_348e2742-b98f-4be3-afbb-3d4fccb635ba">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to current year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzgtMS0xLTEtMjQ1NDc3_3c13b24a-5a55-460b-966c-df5fab7456f3">7.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzgtMy0xLTEtMjQ1NDc3_d523d12c-e726-415e-8651-6716e9921502">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzgtNS0xLTEtMjQ1NDc3_e0abf2df-5f45-44c8-b4d7-f323c8fa9f82">8.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to prior year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzktMS0xLTEtMjQ1NDc3_a7eab3d1-143c-4f22-afcf-e9eb12ffd97f">31.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzktMy0xLTEtMjQ1NDc3_e5eb5203-f4c2-4799-8c2a-76c24c558f12">30.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzktNS0xLTEtMjQ1NDc3_3cecdb28-a95d-4889-af02-5b6fe7c7ae4f">22.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzExLTEtMS0xLTI0NTQ3Nw_58ff2746-482e-4b24-8caa-1f371f08b2a4">142.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzExLTMtMS0xLTI0NTQ3Nw_61984058-5674-435b-9845-44304f2ca035">139.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzExLTUtMS0xLTI0NTQ3Nw_9925ae45-f802-480a-8bd1-435fd939a528">136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEyLTEtMS0xLTI0NTQ3Nw_684775ef-a6ae-4606-ac22-a79ed01e26d9">32.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEyLTMtMS0xLTI0NTQ3Nw_24498665-2afd-46d1-8f0f-c65cf9c0ad47">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEyLTUtMS0xLTI0NTQ3Nw_27d1ab09-7e15-40e2-9e6b-b6f7a36e03b0">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, gross</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEzLTEtMS0xLTI0NTQ3Nw_f4afeb28-77c8-4fcf-8922-7454a987f47b">175.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEzLTMtMS0xLTI0NTQ3Nw_5bc4ef81-1f3d-4c47-9378-6291a196b329">169.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231" decimals="-5" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEzLTUtMS0xLTI0NTQ3Nw_a892cc8f-caee-4f4d-8dbd-fe21285a7d4a">165.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:SelfInsuranceReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzkyNA_0b0b22c0-9a2a-43c2-9b34-88f5d77968b9">46.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:SelfInsuranceReserveCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzkzMQ_a47a8a1b-13d1-4727-866d-3cca3a05ee7c">45.6</ix:nonFraction> million, respectively, of these reserves are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these risks are based primarily upon actuarially determined estimates. These reserves represent the unpaid portion of the estimated ultimate cost of all reported and unreported losses incurred through the respective consolidated balance sheet dates. The reserves are estimated using individual case-basis valuations and actuarial analyses. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The changes to the estimated ultimate loss amounts are included in current operating results.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reserves for these self-insured risks cover approximately <ix:nonFraction unitRef="claim" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-2" name="ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzE3NjY_2a285e5b-fceb-4f01-bb40-e7b399178ba9">1,100</ix:nonFraction> and <ix:nonFraction unitRef="claim" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-2" name="ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzE3NzM_68784366-9a4e-4593-8bc6-c6a77de3a5af">1,200</ix:nonFraction> individual claims at December&#160;31, 2022 and 2021, respectively, and estimates for potential unreported claims. The time period required to resolve these claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in reserve estimates, management believes the reserves for losses and loss expenses are adequate; however, there can be no assurance the ultimate liability will not exceed management&#8217;s estimates.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_280"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzQyOTM_c82e5ac6-f59a-4605-83f0-4ae382fe4de1" continuedAt="i4d5193206ff64294ae887835a7358d39" escape="true">Redeemable Noncontrolling Interests:</ix:nonNumeric></span></div><ix:continuation id="i4d5193206ff64294ae887835a7358d39" continuedAt="i17306617881b46339aaf13abdf75c4da"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:RedeemableNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzQyNzU_13c55982-67f8-4bb7-807c-6663a5a819e8" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6efebeb8c8db4120ab1f6ddec403e0b0_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzItMS0xLTEtMjQ1NDc3_4d58ab1a-26c2-404f-b55b-122489fb7776">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6727a883db744548c7e8035f88a00e4_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzItMy0xLTEtMjQ1NDc3_17d06199-502e-410c-9c2f-1a6d674db6d7">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib815d2a675ad43128d86aa58ebcb4caf_I20191231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzItNS0xLTEtMjQ1NDc3_9223ade1-4183-40bd-856d-2af80d831bd5">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzQtMS0xLTEtMjQ1NDc3_8379ebbc-a72d-41a9-b2b1-f16c77153cae">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzQtMy0xLTEtMjQ1NDc3_e888979d-fac9-4531-a3fb-9f28bc47dad4">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzQtNS0xLTEtMjQ1NDc3_98c50531-86cb-4902-b086-c0f428fac17a">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzUtMS0xLTEtMjQ1NDc3_c77d4b41-a087-4daf-870c-5f7e7a6c6d97">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzUtMy0xLTEtMjQ1NDc3_dafb4502-90a9-4a0e-9315-273d946e362d">8.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzUtNS0xLTEtMjQ1NDc3_4fe2fcc2-6342-418d-b794-790a974abe5c">8.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231" decimals="-5" name="ehc:Contributiontojointventure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzYtMS0xLTEtMjQ1NDc3_d80e4aa7-3df9-435d-b898-1dc757e81520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231" decimals="-5" name="ehc:Contributiontojointventure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzYtMy0xLTEtMjQ1NDc3_2091c2bb-028e-48ac-afa1-b4f2ff8edaec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231" decimals="-5" name="ehc:Contributiontojointventure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzYtNS0xLTEtMjQ1NDc3_f213090d-8c68-4c02-a16a-d68e9a1413f2">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzgtMS0xLTEtMjQ1NDc3_2c3f4a32-5f8a-43fd-a5ed-8718e7270743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzgtMy0xLTEtMjQ1NDc3_c03fb8b2-2a97-4998-b652-798515caf99b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzgtNS0xLTEtMjQ1NDc3_1386ade8-6947-49fc-90e3-e2f4a2e5202c">162.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231" decimals="-5" name="ehc:NoncontrollingInterestExchangeTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzktMS0xLTEtMjQ1NDc3_b68b803a-b8f1-49d3-b8e6-4a9fd3b4f97c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231" decimals="-5" name="ehc:NoncontrollingInterestExchangeTransaction" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzktMy0xLTEtMjQ1NDc3_5508d374-4d30-4eb9-9de8-0c9743aab20e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231" decimals="-5" name="ehc:NoncontrollingInterestExchangeTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzktNS0xLTEtMjQ1NDc3_497efbf6-be8d-4e10-89ed-1b6fff568c01">46.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEwLTEtMS0xLTI0NTQ3Nw_d0cdf417-908d-422e-83aa-ce419d65ff29">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEwLTMtMS0xLTI0NTQ3Nw_25cc5502-1bf4-4e2f-95d6-503bc11b55a8">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:MinorityInterestChangeInRedemptionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEwLTUtMS0xLTI0NTQ3Nw_1e7a385f-81b2-41e1-baf0-b9aeb7c644f0">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231" decimals="-5" name="ehc:NoncontrollingInterestOtherAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzExLTEtMS0xLTI0NTQ3Nw_f112bb3a-76bc-43ae-9f5d-7cf7ca7866ed">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231" decimals="-5" name="ehc:NoncontrollingInterestOtherAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzExLTMtMS0xLTI0NTQ3Nw_dfcf6238-7450-458c-a8b4-c596006e28bf">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231" decimals="-5" name="ehc:NoncontrollingInterestOtherAdjustment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzExLTUtMS0xLTI0NTQ3Nw_a74ce440-6579-499a-acc9-98b3943ff6b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spin off of Enhabit, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231" decimals="-5" name="ehc:NoncontrollingInterestSpinOff" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTEtMS0xLTI2ODY5MQ_7d6067df-fadd-4868-83e2-f9381d367715">5.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231" decimals="-5" name="ehc:NoncontrollingInterestSpinOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTMtMS0xLTI2ODY5MQ_7bfa8669-86cd-4d6e-bc8b-eb668ede8773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231" decimals="-5" name="ehc:NoncontrollingInterestSpinOff" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTUtMS0xLTI2ODY5MQ_1377fce5-3937-4494-9276-e5873201ca69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ded9604e5234c4eb9354741e47453eb_I20221231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTEtMS0xLTI0NTQ3Nw_0c0dc071-4f78-41a3-a857-f79c67efa479">35.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6efebeb8c8db4120ab1f6ddec403e0b0_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTMtMS0xLTI0NTQ3Nw_bf91dea9-71ec-4612-9ba4-3265ba13f384">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6727a883db744548c7e8035f88a00e4_I20201231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTUtMS0xLTI0NTQ3Nw_92be21ed-b745-4cb0-ad94-def8674633a3">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzQyODI_b59cfce5-87e3-41a0-8081-35396ed10cad" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:64.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.735%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzItMS0xLTEtMjQ1NDc3_5c61ff92-21af-4aaa-a41b-2c1ec456f749">87.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzItMy0xLTEtMjQ1NDc3_8242186a-bd12-4adf-b7bf-829142190d20">96.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzItNS0xLTEtMjQ1NDc3_2680451f-ae6a-4311-aed6-77cc74a7b6b1">77.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzMtMS0xLTEtMjQ1NDc3_0529851d-898f-4442-94b1-78aa6fffaff1">7.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzMtMy0xLTEtMjQ1NDc3_aecd0558-4224-4cfd-ac3a-d0e81c24d0f2">9.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzMtNS0xLTEtMjQ1NDc3_5c004676-34ed-4b07-8cf2-0b755bcd8817">7.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzQtMS0xLTEtMjQ1NDc3_41e6cc30-9e54-458e-bded-bb7d3827db31">94.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzQtMy0xLTEtMjQ1NDc3_a98bb8e9-29fc-4c37-82ba-ec9f921c5952">105.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzQtNS0xLTEtMjQ1NDc3_a23d6521-cbac-430f-a674-ee0560aee6a8">84.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2014, we acquired <ix:nonFraction unitRef="number" contextRef="i41e57dc8508f486cb65383ee270622a7_I20141231" decimals="3" name="ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzYyNw_78e75af6-a0c1-4560-9508-3735cdeb6604">83.3</ix:nonFraction>% of our former home health and hospice business when we purchased EHHI Holdings, Inc. (&#8220;EHHI&#8221;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#8220;Holdings&#8221;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $<ix:nonFraction unitRef="usd" contextRef="i41e57dc8508f486cb65383ee270622a7_I20141231" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzExOTA_e5b9d3e2-256e-4ee2-bc1e-73bc8143b9d8">64</ix:nonFraction> million on the acquisition date, in exchange for approximately <ix:nonFraction unitRef="number" contextRef="i41e57dc8508f486cb65383ee270622a7_I20141231" decimals="3" name="ehc:SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzEyNDg_a2c02626-a63b-4097-ad2d-81431779aa8d">16.7</ix:nonFraction>% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately <ix:nonFraction unitRef="number" contextRef="i71b339e9a3244030a7c4194e39cb008c_D20180201-20180228" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzE3MTI_b1343962-006e-4d55-85c0-db22fc9a586b">5.6</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="ia7de87991e514ae5b6fea1833e9ded6f_D20180221-20180221" decimals="-6" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzE4ODM_5192b25c-e125-41a6-a23d-788de4c94d3f">65</ix:nonFraction> million in cash. In July 2019, we received additional exercise notices, representing approximately <ix:nonFraction unitRef="number" contextRef="i0817bf7784b548a186c313fe446af8a6_D20190701-20190731" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzE5Nzc_7327491c-f59e-4f45-b18c-4b87e220504b">5.6</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. In September&#160;2019, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i1cf81650d421400f8d1135d296737e38_D20190901-20190930" decimals="-6" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzIxNDU_712b6b95-3448-4e81-9215-fa7ee461de4c">163</ix:nonFraction> million in cash. In January 2020, we received additional exercise notices, representing approximately <ix:nonFraction unitRef="number" contextRef="i2b1d1c428d764c88a5c1812e2a04cf24_D20200101-20200131" decimals="3" name="ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzIzNjc_8935296a-6c92-4b1d-8da0-2eaeb0c6a086">4.3</ix:nonFraction>% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $<ix:nonFraction unitRef="usd" contextRef="ib793c3abc8744e3b9fffcc21e558e086_D20200218-20200218" decimals="-6" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzI1Mzg_fe150b50-d1bc-4b49-a4e3-2a339f5b6b7e">162</ix:nonFraction> million in cash. Upon settlement of these exercises, approximately $<ix:nonFraction unitRef="usd" contextRef="idd77fca6ac214fcd9bf9357721bb2a92_I20200218" decimals="-6" name="us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzI2MDA_8f401c26-b555-4a7c-b203-174d1b235401">46</ix:nonFraction> million of the shares of Holdings held by <ix:nonFraction unitRef="investor" contextRef="ia001d84255a44455b5a46942a930f42b_I20200218" decimals="INF" name="ehc:NumberOfManagementInvestorsOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzM4NDgyOTA3MDE5Mzg_fe7c5f8e-bdc7-43ee-8a7e-439ba6d9fe46">two</ix:nonFraction> management investors remained outstanding. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#8220;Exchange Agreement&#8221;) with these <ix:nonFraction unitRef="investor" contextRef="idac0372aea0347c49bdba860190d96f3_I20200220" decimals="INF" name="ehc:NumberOfManagementInvestorsOutstanding" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzM4NDgyOTA3MDE5NDY_ff6780da-6c0f-4531-9659-59bde4257ef4">two</ix:nonFraction> management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#8220;EHC Shares&#8221;). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an &#8220;Exchange Notice&#8221;) to Encompass Health in order to </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i17306617881b46339aaf13abdf75c4da"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#8217;s common stock on the New York Stock Exchange (the &#8220;NYSE&#8221;) on the date of delivery of the Exchange Notice.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors.  Based on the last sales price of Encompass Health&#8217;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate <ix:nonFraction unitRef="shares" contextRef="idac0372aea0347c49bdba860190d96f3_I20200220" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzM4ODg_50d969a6-4221-4747-a260-3cc5b0ddf770">560,957</ix:nonFraction> EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than <ix:nonFraction unitRef="number" contextRef="ib2779168f690432cac5b38f9bea43674_I20200306" decimals="3" name="ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzQwNDQ_e014e51b-a9aa-46cd-89cf-4471e28a7492">0.6</ix:nonFraction>% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_283"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzIwOTE_ea1c3b4b-1a04-4f3b-9534-95cf90d99a33" continuedAt="i478a4595a7a446068a322d9cd5c5583e" escape="true">Fair Value Measurements:</ix:nonNumeric></span></div><ix:continuation id="i478a4595a7a446068a322d9cd5c5583e" continuedAt="i53704b295b6b4cb3ab450296d4903741"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzIwOTk_50ca6ddf-f4ef-4d6d-adb3-2b8924d66c94" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.876%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77780a6142904e59b58e560a56e1f9e4_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzMtMi0xLTEtMjQ1NDc3_4528d4c6-7841-4df8-b3fb-f4cc908baf5a">110.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258d06e3e65443fb8a893ee44f342300_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzMtNC0xLTEtMjQ1NDc3_1db0e187-00ee-45bc-be9f-8eb81a83d66f">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83e1a16991f4a27add600a1fd239b44_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzMtNi0xLTEtMjQ1NDc3_d65183fe-ecf4-4d91-b261-d415574ae5cb">106.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8dd211c83ae4af8ba738a29bef7f269_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzMtOC0xLTEtMjQ1NDc3_8fb1ad40-e3e0-4fa7-97be-526996a92029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77780a6142904e59b58e560a56e1f9e4_I20221231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzUtMi0xLTEtMjQ1NDc3_e005c3b7-a042-485a-af2c-13e34a4a9929">35.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258d06e3e65443fb8a893ee44f342300_I20221231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzUtNC0xLTEtMjQ1NDc3_cc0c593f-73a4-49cd-bb3b-d2c9efc041f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib83e1a16991f4a27add600a1fd239b44_I20221231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzUtNi0xLTEtMjQ1NDc3_1c46cbe6-15da-4b82-8ec8-cde74c66555e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8dd211c83ae4af8ba738a29bef7f269_I20221231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzUtOC0xLTEtMjQ1NDc3_fb51416e-7c42-414b-85c2-3cf4242a2b50">35.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6598efdf814f82b2b3ac56c39d31b8_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzgtMi0xLTEtMjQ1NDc3_5ce39637-9e4b-488d-9909-fbfaa0c63b46">82.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b15fae4966a432d8dd85f41b1846e97_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzgtNC0xLTEtMjQ1NDc3_53152db7-6ac5-41b5-9a2b-e5f36a2f1d58">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76ff36e61642c69f074e2796820502_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzgtNi0xLTEtMjQ1NDc3_b8458889-45c6-4e68-8069-de5c67a6066f">78.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica49f9c6106c4bff9919ea82c86a1d10_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzgtOC0xLTEtMjQ1NDc3_b7460170-db30-46d8-bd4d-ae209154c2dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6598efdf814f82b2b3ac56c39d31b8_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzEwLTItMS0xLTI0NTQ3Nw_db9219c1-fd90-4996-acdf-c33b6fa9b5e3">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b15fae4966a432d8dd85f41b1846e97_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzEwLTQtMS0xLTI0NTQ3Nw_2e266394-00e2-427e-90d5-a80103179322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76ff36e61642c69f074e2796820502_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzEwLTYtMS0xLTI0NTQ3Nw_25b7b49d-84df-4894-940b-3a9b2bcc9e61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica49f9c6106c4bff9919ea82c86a1d10_I20211231" decimals="-5" name="us-gaap:RedeemableNoncontrollingInterestEquityFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzEwLTgtMS0xLTI0NTQ3Nw_950479ba-3f71-43f8-8de0-bbfd9817ddc9">42.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">As of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i35e875418cae4ed98afcdddf4b6e3679_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzU0OTc1NTgxNjIxMg_6ac818c8-e5bc-46e3-b606-4b58ade62af5">30.9</ix:nonFraction> million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="ic5560a022b19466c9dc3b25d0a6709d2_I20221231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzU0OTc1NTgxNjI3OQ_76168c25-6dc6-4567-b1e7-5bba220983b3">79.1</ix:nonFraction> million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i0cd9b95664334eee863511a1352b258d_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzU0OTc1NTgxNjQ0MQ_df8d2143-ee08-444f-a754-6e298a168fd0">82.2</ix:nonFraction> million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the consolidated balance sheet.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the years ended December 31, 2022, 2021, and 2020, we did not record any material gains or losses related to these assets.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i53704b295b6b4cb3ab450296d4903741"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our consolidated balance sheets. <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzIwODM_783ed431-e86a-468c-ace8-0f556d396e2f" continuedAt="ic92dc82ba0bf498cb9fbf403d37dc25f" escape="true">The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="ic92dc82ba0bf498cb9fbf403d37dc25f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc353f9b60ef469f9fb57e8eb5392312_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzMtMS0xLTEtMjQ1NDc3_82f7036a-95a0-471c-95c2-c6dcae8aa789">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075bc7bcf82a49f8b9f7a4533e89c0a6_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzMtMy0xLTEtMjQ1NDc3_3ae59f75-7885-4b39-be6f-49659cde5aef">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if11a95d42a454584afeb7e3be1dd5b60_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzMtNS0xLTEtMjQ1NDc3_edb18243-cef9-4f92-a8cf-ea3319e6b870">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61147de300ac4b17b16c6aa30fb725e4_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzMtNy0xLTEtMjQ1NDc3_56107362-27d4-47f1-bbe5-3fe5eeac6533">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9b5364226647f4aca43882157f6bb9_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzQtMS0xLTEtMjQ1NDc3_17fc865e-def9-4d83-b711-0a4ca171ca6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba3ea646be7400aa6041fe8bb869254_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzQtMy0xLTEtMjQ1NDc3_3337d409-674b-4e3b-9081-6cc077eb7613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if68164d48cd14a36908fa4523153e2b3_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzQtNS0xLTEtMjQ1NDc3_500775e3-80b7-4232-ab7b-8afb395af17a">238.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fcd0acbafe46d5aee193d414a6d056_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzQtNy0xLTEtMjQ1NDc3_d83296be-bcdc-41bd-af1a-abb04a83304f">239.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MzE1ZWVmNjlmYWY5NDgyNGI1OWNkMGMwNTE4OGM3MGRfNA_bfd1f1bd-8152-4131-8bbb-ce1f67f02b01"><ix:nonFraction unitRef="number" contextRef="id1214fc63dae4248a98c4032a91b2fec_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MzE1ZWVmNjlmYWY5NDgyNGI1OWNkMGMwNTE4OGM3MGRfNA_ca544c63-0aaa-4f72-95a4-0e126ef61ddf">5.125</ix:nonFraction></ix:nonFraction>% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36917653da0f4636ac433b0eefd8ca74_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtMS0xLTEtMjQ1NDc3_17812afd-0e90-4454-b45f-b5bf7b203975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba67211d13b47e7b5f944000baf621e_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtMy0xLTEtMjQ1NDc3_eb6bb66c-b8bb-4435-bd9b-817fc84a405f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd0995116ad432dbf5ecfe84fb0e897_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtNS0xLTEtMjQ1NDc3_be475732-c81e-4eb2-9d7a-b8d98a1bc919">99.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2062512483de43c6b98ca06b53160b5b_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtNy0xLTEtMjQ1NDc3_316050b3-5f83-4203-b0ce-a48d07b8299e">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b519d969150438ca0a24a17a6f87ca8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzAyZjNiMThhOWNhNDU4ZDhhZjJiMTgxNmEyYTczOTRfNA_587a8921-9c37-4326-80f2-03c8348e2e0f"><ix:nonFraction unitRef="number" contextRef="i005266a587014861b4fc4bdc254e6a15_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzAyZjNiMThhOWNhNDU4ZDhhZjJiMTgxNmEyYTczOTRfNA_9f35e6a4-ed99-46da-9667-34167c0ccd5e">5.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5783a522bb14483818de81205d4ddac_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtMS0xLTEtMjQ1NDc3_d1e29541-7d58-45d4-985e-22d18035c640">347.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i756531406e134ef495f108a1f1d4ce85_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtMy0xLTEtMjQ1NDc3_30e0aed2-8a15-4856-8c6f-16ee49a99007">347.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe80798844441ff9ba446bee23d99ab_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtNS0xLTEtMjQ1NDc3_14f47ae5-3bcd-4de4-8e96-5ee58fbc283b">347.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288afc94975d4cd1af41f3c46445c4fc_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtNy0xLTEtMjQ1NDc3_753e9a43-5c13-4a62-a1ba-ee8bd30a7d27">357.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b5a421f1a804107a53e85439af96f46_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTc1ZTBkZGRmZGM3NGZjZDk2NjVhMTgwNWJmODY2MjlfNA_6bf22234-87a3-4d99-94ff-2c620e0fa16b"><ix:nonFraction unitRef="number" contextRef="i03e2cfaa161d423e9fe9d78c1d2484d8_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTc1ZTBkZGRmZGM3NGZjZDk2NjVhMTgwNWJmODY2MjlfNA_ec2505d6-b573-4512-8311-a0ec181aa3ac">4.50</ix:nonFraction></ix:nonFraction>% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88b3ef661e7d406e858898cbe882bb5d_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctMS0xLTEtMjQ1NDc3_a50b2521-4eba-4a67-9dcc-d4278f79dbea">781.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c9080bb72a43d387919a7abafe465f_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctMy0xLTEtMjQ1NDc3_49163ef0-5ce2-41c4-9ea4-d377427b154f">726.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib131caf622a8488480693d868801dfff_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctNS0xLTEtMjQ1NDc3_13e434cc-9923-437a-84ee-e5d88414bc0d">786.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdcc92113b74a7d8e07277da2c910f9_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctNy0xLTEtMjQ1NDc3_41c8a6ee-e779-4857-8bb8-4368d2bcab88">823.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idca4e969d39442579877374d995f76bc_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZGQ0YTViMGQ2Y2FiNDNmOTgzOWI5ZDE2MGI5MWEzZjlfNA_270cfbe1-ec03-4547-8605-31bedc871c65"><ix:nonFraction unitRef="number" contextRef="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZGQ0YTViMGQ2Y2FiNDNmOTgzOWI5ZDE2MGI5MWEzZjlfNA_37344c1e-1cca-40f7-a777-6bff36254137">4.75</ix:nonFraction></ix:nonFraction>% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i800dfcdb85da4e128a32fc9b7f379889_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtMS0xLTEtMjQ1NDc3_d8cd6e86-62bd-4a4e-8966-8b23eabe6aad">779.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd71591191f4bcaac27b10a00b10a7f_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtMy0xLTEtMjQ1NDc3_bdd1832d-8fc5-47d0-ad07-f72cfba25e09">703.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5202834b56544309d7d9d8b7bee2a66_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtNS0xLTEtMjQ1NDc3_5ef95bf6-ca23-438e-aa7d-5ca15596f6b8">784.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0451060ab9de4fbd8016ce801fb4c267_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtNy0xLTEtMjQ1NDc3_8acd70e5-0f74-4e8c-a22e-14c3ebcfbd4b">824.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iccae8862dd6a4bac8b4589ffb7e02bba_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NWExODQyY2ViZTMxNGJjOWEzMjFkYTA5ZDEzNTA1MDZfNA_744aec19-2df4-4a6c-a72e-b3e24b967433"><ix:nonFraction unitRef="number" contextRef="i85aa556fff894922b569241055a48e29_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NWExODQyY2ViZTMxNGJjOWEzMjFkYTA5ZDEzNTA1MDZfNA_edc8e297-8257-4e91-9857-34aebf99e277">4.625</ix:nonFraction></ix:nonFraction>% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f7af3cf123430084485f0646aec6b2_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktMS0xLTEtMjQ1NDc3_e5c7ca40-c0cc-4c72-b827-75bdb9b9eea8">390.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ab7e7f086a47feb8e87a9898b27939_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktMy0xLTEtMjQ1NDc3_db2dfec6-424b-419a-858b-af55f2180688">342.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc9bbdd487884af6b55d2a388ce96eb7_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktNS0xLTEtMjQ1NDc3_c4b65b20-b58e-426b-a072-d82e53114e7b">393.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia760f2e4e675400ca0a4847d612a1345_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktNy0xLTEtMjQ1NDc3_8b3c68d5-0810-4ce9-a830-0f5cb2e7a2a1">407.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6886b561cd61484d89ba422e4d310087_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEwLTEtMS0xLTI0NTQ3Nw_5918acc4-cb4f-4404-af7e-bf1d0959f476">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i997ce4d2148b4c2195cf12ae01cec37a_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEwLTMtMS0xLTI0NTQ3Nw_94eb5743-ccd7-418b-bf52-053f56dbb0e9">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9453d359deda4140a48a46fd53784a03_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEwLTUtMS0xLTI0NTQ3Nw_16cd745b-3fed-40f9-b487-26a32b72dc0f">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6750e3dddd9447f96d964077958239f_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEwLTctMS0xLTI0NTQ3Nw_fc9e7789-96ab-4eb6-be33-6713332097eb">47.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd5c983c4384e469b96a6e07cd2f730_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEyLTEtMS0xLTI0NTQ3Nw_167b8ccb-c655-40c2-8499-cb397546b478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb880111df2e4c1592091b713f0fe19f_I20221231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEyLTMtMS0xLTI0NTQ3Nw_a790bf28-897e-4182-8cc8-4073e600a02e">32.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5494a2b14ffd4637b8184bac94f6987e_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEyLTUtMS0xLTI0NTQ3Nw_df5b0110-4190-49b4-95a4-07023c41913a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21eb7f8154e9461399c33a8e06c6aff2_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEyLTctMS0xLTI0NTQ3Nw_190268bb-ef43-46b5-a940-bb81f5ee1345">38.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements&#8221; and &#8220;Redeemable Noncontrolling Interests.&#8221;</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_286"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc5MDE_c2a5142c-0f16-4cc2-8515-66a1caf9b078" continuedAt="ie1063c1915074afd8ccccfa6ce98343f" escape="true">Share-Based Payments:</ix:nonNumeric></span></div><ix:continuation id="ie1063c1915074afd8ccccfa6ce98343f" continuedAt="i7c2c009f5d3f4120b3c4ef2e61b8d4d6"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has awarded employee stock-based compensation in the form of stock options and restricted stock awards (&#8220;RSAs&#8221;) under the terms of share-based incentive plans designed to align employee and executive interests to those of its stockholders. All employee stock-based compensation awarded during 2022, 2021, and 2020 was issued under the 2016 Omnibus Performance Incentive Plan, a stockholder-approved plan that reserves and provides for the grant of up to <ix:nonFraction unitRef="shares" contextRef="i9512677b078c40578810c4ef579432a8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzQ4Mw_704cb365-4b1a-4f90-a90b-ef2cda97f0bc">16,860,765</ix:nonFraction> shares of common stock after adjustment for the effect of the Spin Off. This plan allows for the grants of nonqualified stock options, incentive stock options, restricted stock, stock appreciate rights, performance shares, performance share units, dividend equivalents, restricted stock units (&#8220;RSUs&#8221;), and/or other stock-based awards. Stock-based compensation expense recognized in continuing operations was $<ix:nonFraction unitRef="usd" contextRef="i61258fb59e114ab4be13ec46d31319dd_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyOTA_e8b74e04-f813-4847-9d91-8d4ca212c31b">29.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i52beb02bfcfb448588dda9dfaf965534_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzMDU_12e79ff6-5060-4aa1-8ee0-2d2e2e409508">29.1</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="ie5b3906930f64c70b58328d97278b262_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzMjA_c4efcdf8-5041-4e83-bc2a-3b992d8b35ef">25.6</ix:nonFraction>&#160;million during 2022, 2021, and 2020, respectively. Stock-based compensation expense classified as discontinued operations was $<ix:nonFraction unitRef="usd" contextRef="i463986e3eb5648c5b6f6782f286a2c2c_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzNjM_08723342-4d49-4acb-bd70-f96945c71b39">2.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="id44f0a9ab653432d9903ca10012e1b33_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzNDk_7076b863-b59c-4756-92a5-d38e9a79b15b">3.6</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i8af94fb3b095489db51ee3b16dd479ce_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzMzU_a0846d6d-19e5-41fd-b0e5-fdde5f253d6c">3.9</ix:nonFraction>&#160;million during 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our share-based incentive plans, officers and employees are given the right to purchase shares of Encompass Health common stock at a fixed grant price determined on the day the options are granted. The terms and conditions of the options, including exercise prices and the periods in which options are exercisable, are generally at the discretion of the compensation and human capital committee of our board of directors. However, no options are exercisable beyond <ix:nonNumeric contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzEyNDI_8db16086-c8db-4fb4-ad49-e3aecd349bf2">ten years</ix:nonNumeric> from the date of grant. Granted options vest over the awards&#8217; requisite service periods, which are generally <ix:nonNumeric contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzEzNTQ_10977b35-2109-4183-950a-3b33d82124f6">three years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i7c2c009f5d3f4120b3c4ef2e61b8d4d6" continuedAt="ifcddee57b40e4aaa898f85ee4e15121c"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4NzU_9a4fb135-168c-4a14-8632-c5651485a07a" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the options granted during the years ended December&#160;31, 2022, 2021, and 2020 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzItMS0xLTEtMjQ1NDc3_989360c4-90e5-43b0-bf4c-f56e601da4cf">28.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzItMy0xLTEtMjQ1NDc3_09031934-0798-4548-a793-de207dff2a00">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzItNS0xLTEtMjQ1NDc3_23b9548e-30fc-42e3-b600-ab1bbcac8ae9">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzMtMS0xLTEtMjQ1NDc3_ce6a4ce7-924f-4c7d-acc8-a07381d17711">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzMtMy0xLTEtMjQ1NDc3_21b02bec-e477-48b9-b266-d1eec56253e0">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzMtNS0xLTEtMjQ1NDc3_85f37de7-97ca-4559-ac89-cee4efe09ded">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzQtMS0xLTEtMjQ1NDc3_bb68286e-6d86-4ccc-abc1-c9533ca26dbf">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzQtMy0xLTEtMjQ1NDc3_231064e5-cb42-419c-b5a7-b57ca28896ca">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzQtNS0xLTEtMjQ1NDc3_d7ed3660-083a-43ac-829f-ad76fd7cf8ba">7.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzUtMS0xLTEtMjQ1NDc3_a3673672-3bb4-45ff-89fa-fc1ee18b55c7">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzUtMy0xLTEtMjQ1NDc3_9c1a6a86-c937-43df-9269-adbc6d63893c">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzUtNS0xLTEtMjQ1NDc3_580dc211-2973-485a-834b-90db3c9cc836">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including the expected stock price volatility. We estimate our expected term through an analysis of actual, historical post-vesting exercise, cancellation, and expiration behavior by our officers and employees and projected post-vesting activity of outstanding options. We calculate volatility based on the historical volatility of our common stock over the period commensurate with the expected term of the options. The risk-free interest rate is the implied daily yield currently available on U.S. Treasury issues with a remaining term closely approximating the expected term used as the input to the Black-Scholes option-pricing model. We estimated our dividend yield based on our annual dividend rate and our stock price on the dividend payment dates. Under the Black-Scholes option-pricing model, the weighted-average grant date fair value per share of employee stock options granted during the years ended December&#160;31, 2022, 2021, and 2020 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzI3NzY_9de4629f-f8df-41c8-990a-f54242c134fa">17.29</ix:nonFraction>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzI3ODA_298e6d54-1dfb-4118-8f01-0fdfdd6dfcae">19.21</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzI3ODg_28ee6f9a-e386-4216-8305-07f61e4c8c24">15.48</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4OTc_450a1c4f-aa75-488a-bf8d-90dfb368de22" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzEtMS0xLTEtMjQ1NDc3_00fb002a-874c-474c-af2f-d8cc81d43283">711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzEtMy0xLTEtMjQ1NDc3_1e2e2763-5e60-4298-87ca-3167922c16a0">54.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzItMS0xLTEtMjQ1NDc3_3fe3faf4-7e4f-4c76-afe0-e571e7a9ba31">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzItMy0xLTEtMjQ1NDc3_22aef9fe-3766-4629-b1c1-2224a0d2eb20">66.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzMtMS0xLTEtMjQ1NDc3_6bfdc73f-61d2-44d0-9139-f95e6491a40c">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzMtMy0xLTEtMjQ1NDc3_4f7dc5ae-bb9d-4421-a42e-b3c727411f66">20.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enhabit spin-off adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-3" name="ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtMS0xLTEtMjg5ODYx_90b9d88c-2db4-4b0a-a575-40d68310cfe5">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtMy0xLTEtMjg5ODYx_1e8a3250-a932-48f3-a720-1f0d95d40bbc">51.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtMS0xLTEtMjQ1NDc3_c65919d7-76c1-47d4-ad4e-2f3154d5807b">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtMy0xLTEtMjQ1NDc3_65a86b20-e8d8-4ac2-bdb9-340ac9e2cc02">47.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtNS0xLTEtMjQ1NDc3_35a9a54d-ed55-431b-93cd-3c776f6f063d">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtNy0xLTEtMjQ1NDc3_8f53e0f0-18b2-4225-9464-a2643164a08b">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzctMS0xLTEtMjQ1NDc3_3e4d1da8-ea85-4445-9cc0-f0458bcad3d0">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzctMy0xLTEtMjQ1NDc3_6cf238f0-1038-4ff4-b620-255f08b94809">42.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzctNS0xLTEtMjQ1NDc3_606c0ede-d6bd-45e4-9fa5-14580ee7187e">4.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzctNy0xLTEtMjQ1NDc3_d520ef9d-23fc-45c5-9f41-53e9d62435d3">11.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Options activity represents historical grant values prior to the Spin Off.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the Spin Off, all outstanding Encompass Health stock options (whether vested or unvested) were converted into adjusted Encompass Health awards for current and former Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyMDM_eff60c49-7116-4f3f-be15-092de7914e3d">1.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyMTc_d3884d96-b9a9-403b-923a-22a0a6bf2f2d">2.2</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyMzE_272946e1-f5c8-4e55-ada3-9952197ce313">1.5</ix:nonFraction>&#160;million of compensation expense related to our stock options for the years ended December 31, 2022, 2021, and 2020, respectively. As of December&#160;31, 2022, there was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMwNTI_2b53eeda-ee69-457e-b7b9-86ab3ccbdb60">1.5</ix:nonFraction> million o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of <ix:nonNumeric contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMxOTc_e7c88df5-668e-4f45-a9b6-68985e4ea5ab">23</ix:nonNumeric> months. The total intrinsic value of options exercised during the years ended December 31, 2022, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMzMTA_86a05663-9446-4e96-9066-21211b5576a9">1.8</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMzMTQ_6311466b-d6d0-4c15-a8a7-85d5475a952f">0.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMzMjI_2bee4256-2f58-4141-a2cb-07988fe02ba5">2.3</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSAs granted in 2022, 2021, and 2020 included service-based awards and performance-based awards (that also included a service requirement). These awards generally vest over a <ix:nonNumeric contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4OTI_538bd035-fc49-486b-a61e-4765a5b3789b">three-year</ix:nonNumeric> requisite service period. For RSAs with a service and/or performance requirement, the fair value of the RSA is determined by the closing price of our common stock on the grant date.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ifcddee57b40e4aaa898f85ee4e15121c"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4NzQ_77d78e84-28ad-45b0-9ba0-94b4651b1d60" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our issued restricted stock awards is as follows (share information in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6bbfc0dab6943969098cd57a4bd7417_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzEtMS0xLTEtMjQ1NDc3_0db544c4-f7b9-499b-8794-2400391f5c36">454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6bbfc0dab6943969098cd57a4bd7417_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzEtMy0xLTEtMjQ1NDc3_ddbbd8d7-b086-4401-8dcb-d8b48aff7d99">74.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzItMS0xLTEtMjQ1NDc3_8947524d-2160-4065-84b9-4db481d82844">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzItMy0xLTEtMjQ1NDc3_88d9aca9-5302-460d-8693-0cb8f604c58e">74.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzMtMS0xLTEtMjQ1NDc3_28c45dc4-646e-480f-bfc8-4a24ccc3873f">306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzMtMy0xLTEtMjQ1NDc3_a2f24079-0967-4f85-b6a0-ff23e3a0e7a0">70.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzQtMS0xLTEtMjQ1NDc3_69c86cda-3da8-467e-97c4-1277d83a4fcc">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzQtMy0xLTEtMjQ1NDc3_42ebe258-9b35-478c-bee6-ca58f4bb57ea">71.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enhabit spin-off adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="-3" name="ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzUtMS0xLTEtMjg5ODgx_66e8c73b-b8f3-4c40-8aa7-03896fe315f5">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="2" name="ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzUtMy0xLTEtMjg5ODgx_9976455b-8fd2-47b0-bc92-c4c777ae4680">62.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i840ae531504149f0837b987fe6ccf313_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzUtMS0xLTEtMjQ1NDc3_a76979a2-2f1c-4acc-b524-68ca5a273477">526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i840ae531504149f0837b987fe6ccf313_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzUtMy0xLTEtMjQ1NDc3_a84c677b-1718-4e00-b27e-049919971530">63.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">RSA activity represents historical grant values prior to the Spin Off.</span></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeiture activity prior to the Spin Off represents historical grant values, while the post-spin forfeitures reflects the impact of Spin Off.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the Spin Off, all outstanding RSAs (whether vested or unvested) were converted into adjusted Encompass Health awards for current Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of restricted stock granted during the years ended&#160;December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia01fbaae638d442ca55200524b2ce253_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzYyMzE_d60f73da-6059-4a08-9b3c-b87d78aeeade">73.89</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i5c577e7192b841b1b95ff17d16f908e0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzYyMzg_0197daa9-9bca-498e-a239-4185f13c25fc">61.81</ix:nonFraction> per share, respectively. We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyNDU_2ed84bcd-a5c9-4373-8b7d-72f24a37682f">26.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ia01fbaae638d442ca55200524b2ce253_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyNjA_76c67c03-4a88-4d4f-9854-da3e54172ab6">24.9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i5c577e7192b841b1b95ff17d16f908e0_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyNzU_5d5f21bc-a189-4436-941c-6c1f0296c36e">22.0</ix:nonFraction>&#160;million of compensation expense related to our restricted stock awards for the years ended December 31, 2022, 2021, and 2020, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i840ae531504149f0837b987fe6ccf313_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY0NDI_b9ef6739-935b-432f-b083-b1997e4af222">30.0</ix:nonFraction> million of unrecognized compensation expense related to unvested restricted stock. This cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY1OTM_216d5563-d80f-4ea1-8d94-1f06fe4bde23">20</ix:nonNumeric> months. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he remaining unrecognized compensation expense for the performance-based awards may vary each reporting period based on changes in the expected achievement of performance measures. The total fair value of shares vested during the years ended December 31, 2022, 2021, and 2020 wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $<ix:nonFraction unitRef="usd" contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY4Nzk_91987572-f089-4d97-b49a-0c86b7bb3cae">20.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia01fbaae638d442ca55200524b2ce253_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY4ODM_4494712e-b46f-4e58-bed7-572f02246ad2">32.6</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $<ix:nonFraction unitRef="usd" contextRef="i5c577e7192b841b1b95ff17d16f908e0_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY4OTE_fd61cc65-ded3-419c-9a9c-61835edbc72a">41.4</ix:nonFraction> million, respectively. We accrue dividends on outstanding RSAs, which are paid upon vesting.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonemployee Stock-Based Compensation Plans&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, we provided incentives to our nonemployee members of our board of directors through the issuance of RSUs out of our share-based incentive plans. RSUs are fully vested when awarded and receive dividend equivalents in the form of additional RSUs upon the payment of a cash dividend on our common stock. During the years ended December&#160;31, 2022, 2021, and 2020, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued <ix:nonFraction unitRef="shares" contextRef="if262b00fc98d47d0a49e375a4660d68f_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0MTI_648aea22-5691-49a9-aed2-0974def62da9">22,469</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="idb1d8ad1f6e64881a43d9b042ee3fc13_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0MTY_d46c07da-e4ad-4767-8ec0-8fe7d1b7fb13">24,043</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i68ef0c616638487da568717e4b2e9c7a_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0MjQ_6608b5da-1699-41b4-aa7a-7224b2360685">32,196</ix:nonFraction> RSUs, respectively, with a fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="if262b00fc98d47d0a49e375a4660d68f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0Njg_4754ea03-d06f-47b3-935e-13b882709fc3">67.42</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="idb1d8ad1f6e64881a43d9b042ee3fc13_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0NzI_e75b98ef-da16-4a97-95ea-c1e9dc1aabb1">84.83</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i68ef0c616638487da568717e4b2e9c7a_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0ODA_f7f1ee53-7eb6-4fc5-aa6a-63b1eb20e53b">65.39</ix:nonFraction>, respectively, per unit. We recognized approximately $<ix:nonFraction unitRef="usd" contextRef="if262b00fc98d47d0a49e375a4660d68f_D20220101-20221231" decimals="-5" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc1MzY_3d57eaa4-6e90-482a-bb6d-0c241d9a038f">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="idb1d8ad1f6e64881a43d9b042ee3fc13_D20210101-20211231" decimals="-5" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc1NDA_c22bc54a-827c-4b80-b4d1-c1f1cbc4a0a1">2.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i68ef0c616638487da568717e4b2e9c7a_D20200101-20201231" decimals="-5" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc1NDg_08195b55-068c-4c85-a6a1-2bcd6f4681c4">2.1</ix:nonFraction> million, respectively, of compensation expense upon their issuance in 2022, 2021, and 2020. There was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="usd" contextRef="if693d94dd9bf41cba272ff6915a36cca_I20221231" decimals="INF" name="ehc:SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc2Mzk_9cba7eb5-7586-4504-9d12-318d10fbf464">no</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrecognized compensation related to unvested shares as of December&#160;31, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we issued an a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dditional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i7587a2d34b884d75891d35e0b6e9e5e9_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc3Njg_1d3f927b-06ae-47d1-9dfb-0ee653a19c60">11,976</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i8b1d9e9c16f04250bb589217b66999c2_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc3NzI_d6b7bf45-0abb-4119-8102-daa55b3aa3c9">8,577</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i1479ab37bdd64668ad1c87355665ae26_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc3ODA_131b6ae9-5222-42f4-8efd-09af2c851c9a">8,987</ix:nonFraction>, respectively, of RSUs as dividend equivalents. As of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="if693d94dd9bf41cba272ff6915a36cca_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4NDE_9de6442a-967d-4675-ab6b-84594124543c">775,312</ix:nonFraction> RSUs were ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tstanding. In addition to the above, we issued <ix:nonFraction unitRef="shares" contextRef="i7def89f3f73f44a5991f33f0d8b3acb8_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzNzc_8c3601ad-63c7-4a38-8751-0023cf8125e7">130,406</ix:nonFraction> additional RSUs to current and former members of our board of directors in connection with the Spin Off. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_289"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzMwMzE_ca5b27ef-0da8-4762-aad7-50863c10ca62" continuedAt="i3d4d135a70f24b1a8215a8cd5832a3c4" escape="true">Employee Benefit Plans:</ix:nonNumeric></span></div><ix:continuation id="i3d4d135a70f24b1a8215a8cd5832a3c4" continuedAt="iec6f242a86d24958ad89f160c0d50836"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all Encompass Health employees are eligible to enroll in Encompass Health-sponsored healthcare plans, including coverage for medical and dental benefits. Our primary healthcare plans are national plans administered by third-party administrators. We are self-insured for these plans. During 2022, 2021, and 2020, costs associated with these plans, net of amounts paid by employees, approximated $<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="ehc:HealthcarePlanExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzQzNw_35588b27-7eb0-46da-b7af-ddda6eb0f851">174.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="ehc:HealthcarePlanExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzQ0MQ_21c51eb6-b8d7-4e75-8fc4-44e65b488d5f">166.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="ehc:HealthcarePlanExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzQ0OQ_06c6d6cf-16ed-42fd-973b-5c1e155f16a9">145.4</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Encompass Health Retirement Investment Plan (the &#8220;RIP&#8221;) is a qualified 401(k) savings plan. The RIP allows eligible employees to contribute up to <ix:nonFraction unitRef="number" contextRef="i7a3c2935e68148f990a70aed020917a4_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzY5Nw_203159ef-bb36-44a0-998e-586171e76db9">100</ix:nonFraction>% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. Encompass Health employees who are at least <ix:nonFraction unitRef="y" contextRef="i1591fbdf586749bf959c3f5eed6dc567_I20221231" decimals="INF" name="ehc:RetirementInvestmentPlanAgeRequirement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzkyMA_a0563176-dfe5-422f-90e8-97afc36ea459">21</ix:nonFraction> years of age are eligible to participate in the RIP and all contributions to the plan are in the form of cash. Encompass </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="iec6f242a86d24958ad89f160c0d50836"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health&#8217;s employer matching contribution under the RIP is <ix:nonFraction unitRef="number" contextRef="i7a3c2935e68148f990a70aed020917a4_D20220101-20221231" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzExMDE_1370f755-a94d-47da-8249-dda2e399cf5d">50</ix:nonFraction>% of the first <ix:nonFraction unitRef="number" contextRef="i1591fbdf586749bf959c3f5eed6dc567_I20221231" decimals="2" name="ehc:RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzExMTc_f0770e35-c6ba-4da3-b8ce-654422607770">6</ix:nonFraction>% of each participant&#8217;s elective deferrals, which vest <ix:nonFraction unitRef="number" contextRef="i1591fbdf586749bf959c3f5eed6dc567_I20221231" decimals="INF" name="ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzExNzM_bbfe3736-f077-404f-a4b1-709dcaaa38c9">100</ix:nonFraction>% after <ix:nonNumeric contextRef="i7a3c2935e68148f990a70aed020917a4_D20220101-20221231" name="ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzExODI_3a11ef1f-c7d4-4d18-b39a-ae474840adc0">three years</ix:nonNumeric> of service. Participants are always fully vested in their own contributions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employer contributions to the RIP approximated $<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzE5NTE_8b9bd6be-b295-4b32-9aac-f944f21f962f">28.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzE5NTU_1796f498-95e3-4b3a-816f-b1dee49fca39">26.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzE5NjM_7f22f248-4366-4646-97c7-7649debc7f6c">23.3</ix:nonFraction> million in 2022, 2021, and 2020, respectively. In 2022, 2021, and 2020, approximately $<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzIwMzI_b939fe47-ce3f-41bd-806d-4ee73ed7db64">1.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzIwMzY_29d7cb7f-7c1b-4c11-8021-0bab620b906b">1.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzIwNDQ_e03d58b5-97de-42cd-9db4-f2f0ec2fab67">1.3</ix:nonFraction> million, respectively, from forfeited accounts were used to fund the matching contributions in accordance with the terms of the RIP.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Management Bonus Program&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a Senior Management Bonus Program to reward senior management for performance based on a combination of corporate or regional goals for all periods presented. The corporate and regional goals are approved on an annual basis by our board of directors as part of our routine budgeting and financial planning process. The program applies to persons who join the Company in, or are promoted to, senior management positions. In 2023, we expect to pay approximately $<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="ehc:SeniorManagementBonusProgramTotalCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzI4NzM_bf93f60a-ab76-410e-95e4-4bf0e0eca137">14.8</ix:nonFraction> million under the program for the year ended December&#160;31, 2022. In March 2022 and 2021, we paid $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="ehc:SeniorManagementBonusProgramTotalCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzI5NTQ_a41347a2-104e-4477-ae46-bc781f47724b">23.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="ehc:SeniorManagementBonusProgramTotalCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzI5NjE_d40d9905-8af8-4cbb-9a13-3719ab4513af">14.1</ix:nonFraction> million, respectively, under the program for the years ended December&#160;31, 2021 and 2020.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_292"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzUxMjY_35fe840c-d412-4351-92da-45d1a98b399a" continuedAt="i8f6f84b342ce40f5af5dcb718fdc18df" escape="true">Income Taxes:</ix:nonNumeric></span></div><ix:continuation id="i8f6f84b342ce40f5af5dcb718fdc18df" continuedAt="ibdb2ad24710448ee96bd642e132606af"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzUxMzA_883add39-d742-49d6-a1ab-4d9a667f851e" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to continuing operations are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzMtMS0xLTEtMjQ1NDc3_6e3197b8-3ea7-490b-ac22-8e38f207a4ba">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzMtMy0xLTEtMjQ1NDc3_57fdfb0e-e0d7-41e3-98b3-2aa2fdc7d810">63.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzMtNS0xLTEtMjQ1NDc3_d72c705a-cdb2-44c1-9e7e-b02437908eb6">29.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzQtMS0xLTEtMjQ1NDc3_0cb834cb-fe6e-400b-b046-2031025e6d6c">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzQtMy0xLTEtMjQ1NDc3_f48c3197-99fe-497b-b7c5-18c56a85dc9d">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzQtNS0xLTEtMjQ1NDc3_9194fb24-11bb-4f69-8ddb-780d8dd87cdf">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzUtMS0xLTEtMjQ1NDc3_d7355733-4dd0-481f-b622-645db6a4853f">72.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzUtMy0xLTEtMjQ1NDc3_b8f934d9-7cb7-4d25-b601-879bd3db9427">84.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzUtNS0xLTEtMjQ1NDc3_776cb7c6-f66a-4aed-bb51-dc15afbe2054">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzctMS0xLTEtMjQ1NDc3_febc6f23-fa1b-45cf-a6b3-7ce66f0c70ca">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzctMy0xLTEtMjQ1NDc3_b229813f-7877-4c92-a0e4-3991a26945a4">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzctNS0xLTEtMjQ1NDc3_2344fdd4-fea2-4786-9ad6-4e8a03f0ed72">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzgtMS0xLTEtMjQ1NDc3_8b951920-b0ec-4c0e-b626-a4021e925178">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzgtMy0xLTEtMjQ1NDc3_c196b16b-7525-491b-ade3-33b14c83a76c">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzgtNS0xLTEtMjQ1NDc3_0a1c2d29-ec27-4e5f-b9a9-fa03a030c2e8">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzktMS0xLTEtMjQ1NDc3_0f3d009a-87ec-4cd7-bc77-70c6c1d2446f">27.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzktMy0xLTEtMjQ1NDc3_f6997e63-953e-4d21-91b4-1442bf094343">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzktNS0xLTEtMjQ1NDc3_477211aa-596a-4e17-a4df-9a1cf39f07f7">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense related to continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzEwLTEtMS0xLTI0NTQ3Nw_37d53a4f-ba37-4a80-99c4-bd0ec5e11e6a">100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzEwLTMtMS0xLTI0NTQ3Nw_9cde39a2-16f1-4bde-9847-bc7d7066aef6">101.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzEwLTUtMS0xLTI0NTQ3Nw_c7207992-8fa5-4269-81d8-1583883a2184">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzUxMzk_b447621e-f097-4c1d-8a7d-fe2eecaf528a" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzItMS0xLTEtMjQ1NDc3_fa3ec99b-442f-41d3-9cea-b8642e5f73fb">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzItMy0xLTEtMjQ1NDc3_7d892093-8d99-40cc-bb17-8bda9ac42350">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzItNS0xLTEtMjQ1NDc3_4d039bd0-8171-4bf4-868a-5dc1795f24e0">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzQtMS0xLTEtMjQ1NDc3_8510d3f9-d28c-4f20-ad99-d7683703656e">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzQtMy0xLTEtMjQ1NDc3_72b29f40-ae2f-40f3-9c9d-1df7f7fa9ba4">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzQtNS0xLTEtMjQ1NDc3_84829a17-af05-4c10-8dbc-7fd2fe9c1ee7">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzUtMS0xLTEtMjQ1NDc3_8b2646ff-eef2-4251-8ce1-27c2c8c8ff95">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzUtMy0xLTEtMjQ1NDc3_0685c890-1905-4ff1-a419-84c8e1d29d20">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzUtNS0xLTEtMjQ1NDc3_de7c2d32-7dcf-41a9-99e0-c823513bab1a">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzctMS0xLTEtMjQ1NDc3_d07478c2-c766-4ae0-abba-8a57d8f21381">4.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzctMy0xLTEtMjQ1NDc3_f74f8a2b-a04d-4898-8f47-4d9418ca146a">4.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzctNS0xLTEtMjQ1NDc3_641669e2-90ca-4a6f-a47a-ce4a97f102aa">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based windfall tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="3" name="ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzktMS0xLTEtMjQ1NDc3_5873efac-5e75-4d40-8d49-1e6d96eac232">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="3" sign="-" name="ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzktMy0xLTEtMjQ1NDc3_dde42df3-eb83-4117-b8c2-a78883603699">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="3" sign="-" name="ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzktNS0xLTEtMjQ1NDc3_2cfb8a47-c68e-4e58-b727-667d640afdf9">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzExLTEtMS0xLTI0NTQ3Nw_7b28b3d3-1db0-4fc5-9a0c-86e19084774f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzExLTMtMS0xLTI0NTQ3Nw_c85ca129-b6aa-40c0-ac02-03a363e9051d">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzExLTUtMS0xLTI0NTQ3Nw_edd3b897-33c2-4898-ba75-49e55228f9ce">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzEyLTEtMS0xLTI0NTQ3Nw_1bc869cb-7f24-4595-beba-9648d8305f18">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzEyLTMtMS0xLTI0NTQ3Nw_f3d77031-45ce-43b0-8944-40beec388b2e">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzEyLTUtMS0xLTI0NTQ3Nw_955325f6-126f-4d6e-91a4-5207a9f95589">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2022 was greater than the federal statutory rate primarily due to state and other income tax expense and the increase in valuation allowance, offset by the impact of noncontrolling interests. The </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="ibdb2ad24710448ee96bd642e132606af" continuedAt="i88e95bb1566443ffbe6a833bd9bacf2a"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2021 was less than the federal statutory rate primarily due to the impact of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">noncontrolling interests, the decrease in valuation allowance and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share-based windfall tax benefits,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offset by state and other income tax expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2020 was greater than the federal statutory rate primarily due to state and other income tax expense and the increase in valuation allowance, offset by the impact of noncontrolling interests and share-based windfall tax benefits.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note&#160;1, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Income Taxes,&#8221; for a discussion of the allocation of income or loss related to pass-through entities, which is referred to as the impact of noncontrolling interests in this discussion.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, technical corrections to tax depreciation methods for qualified improvement property and deferral of employer payroll taxes. The CARES Act did not materially impact our effective tax rate for the years ended December 31, 2022, 2021 and 2020, although it has impacted the timing of cash payments for taxes. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes recognize the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes and the impact of available NOLs. <ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzUxNTI_aa9c039b-26b9-4511-be17-8526c9ed9252" continuedAt="i7e897121919544ec977858f1077bc459" escape="true">The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):</ix:nonNumeric></span></div><div style="margin-bottom:10pt;margin-top:5pt"><ix:continuation id="i7e897121919544ec977858f1077bc459"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzMtMS0xLTEtMjQ1NDc3_2d5b9186-d065-4971-982b-7bdd6e0c994a">36.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzMtMy0xLTEtMjQ1NDc3_eda35452-d11d-42cb-87c9-0366c5f9e284">50.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzUtMS0xLTEtMjQ1NDc3_d93ad53e-551f-43e2-bca6-b4b3070940f0">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzUtMy0xLTEtMjQ1NDc3_33410bf7-d25b-47f7-8120-b9a81239361a">18.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzYtMS0xLTEtMjQ1NDc3_1f90e871-082e-4862-9112-5911c8d77026">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzYtMy0xLTEtMjQ1NDc3_ef89af20-a2ee-4bd1-b2d1-b529253a0501">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzgtMS0xLTEtMjQ1NDc3_80faeb6b-ae50-4fca-bdb5-025ae348babd">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="ehc:DeferredTaxAssetsOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzgtMy0xLTEtMjQ1NDc3_7a807576-8280-44c6-9461-430447d49f9f">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzExLTEtMS0xLTI0NTQ3Nw_41b9f5ad-5018-47e7-a1a9-a13ae9a2db46">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzExLTMtMS0xLTI0NTQ3Nw_85160f79-b25d-4d5f-b530-68b92963415d">23.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzEyLTEtMS0xLTI0NTQ3Nw_d6ade432-87c9-4d3d-8dbd-26d01cceb78f">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzEyLTMtMS0xLTI0NTQ3Nw_faa27c50-127d-4956-932c-7d4a94d5a8d0">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE0LTEtMS0xLTI0NTQ3Nw_921c7cb2-9694-4d61-a5f4-cf90566b927b">115.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE0LTMtMS0xLTI0NTQ3Nw_6747977c-d42b-4733-b3d3-4ddf50037726">123.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE1LTEtMS0xLTI0NTQ3Nw_5f37a7c4-a88f-4a97-bd37-2a6624b39260">35.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE1LTMtMS0xLTI0NTQ3Nw_725ad268-302c-4020-82f1-10b4c42abdef">43.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE2LTEtMS0xLTI0NTQ3Nw_2928883a-a6aa-441d-a8a5-052c5ec845da">80.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE2LTMtMS0xLTI0NTQ3Nw_96189e41-04ab-4138-a473-f9cfcb2c555c">80.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE4LTEtMS0xLTI0NTQ3Nw_8626cee4-be68-4c58-b8da-7ff135933017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE4LTMtMS0xLTI0NTQ3Nw_ca93e5a6-9a9c-4684-867a-0d264dd63cec">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE5LTEtMS0xLTI0NTQ3Nw_86150381-2373-4b98-af51-cae709e44f99">61.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE5LTMtMS0xLTI0NTQ3Nw_eb1fd364-aab1-472b-b459-b0ed4d048efd">30.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIwLTEtMS0xLTI0NTQ3Nw_d6e714d5-b75d-4128-9638-8c99dcf1466b">5.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIwLTMtMS0xLTI0NTQ3Nw_5437b4c5-b5c9-4736-9ae1-a907c8ad1565">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIxLTEtMS0xLTI0NTQ3Nw_009aca52-5e55-4e02-8317-844823e76661">15.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIxLTMtMS0xLTI0NTQ3Nw_aa602829-ac2b-4464-b074-f3586e452e17">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIzLTEtMS0xLTI0NTQ3Nw_d583ebb9-0265-47a9-a077-c1a42822feec">80.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIzLTMtMS0xLTI0NTQ3Nw_80945529-362b-4660-998b-bd5337e86781">66.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI0LTEtMS0xLTI0NTQ3Nw_bdf5bae3-ece0-45d1-9ab9-4dfef49ad085">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI0LTMtMS0xLTI0NTQ3Nw_4c7785ca-31f1-497f-b537-2276c2b563c8">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI1LTEtMS0xLTI0NTQ3Nw_8fba0aaf-d832-4e6a-ae15-98f4a4604fb4">163.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI1LTMtMS0xLTI0NTQ3Nw_6b1bc924-5cb1-4e6d-aa3c-0d3164d820d1">103.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI2LTEtMS0xLTI0NTQ3Nw_6dc6e3f5-90bd-4353-84e4-587b92d4da10">83.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231" decimals="-5" name="us-gaap:DeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI2LTMtMS0xLTI0NTQ3Nw_196df580-bc6a-48d7-9689-a82e4b38889b">23.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have state NOLs of $<ix:nonFraction unitRef="usd" contextRef="i913d390f327f454fa9db31895be317bc_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzI0MDg_cdf50da3-f372-49b6-9750-a0d286567cde">35.3</ix:nonFraction> million that expire in various amounts at varying times through 2031. For the years ended December&#160;31, 2022 and 2021, the net decrease in our valuation allowance was $<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzI1NzY_b30e193b-5697-4666-9805-4ee9b7feeb7d">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzI1ODM_e9e99310-416f-4f14-9a0e-cec712911f6c">3.1</ix:nonFraction> million, respectively. The decrease in our valuation allowance in 2022 related primarily to the expiration of state NOLs. The decrease in our valuation allowance in 2021 related primarily to changes in forecasted income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we have a remaining valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzI5MTk_5f37a7c4-a88f-4a97-bd37-2a6624b39260">35.8</ix:nonFraction> million. This valuation allowance remains recorded due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management&#8217;s estimates of taxable income for each jurisdiction in which we operate over the periods in </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i88e95bb1566443ffbe6a833bd9bacf2a"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during 2022, 2021, and 2020 was not material. Accrued interest income related to income taxes as of December 31, 2022 and 2021 was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we signed an agreement with the IRS to participate in their Compliance Assurance Process (&#8220;CAP&#8221;) for the 2017 tax year and have renewed this agreement each year since. CAP is a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax returns. The IRS is currently examining the 2021 and 2022 tax years. In June 2022, the IRS issued a no change letter effectively closing our 2020 tax year audit. The statute of limitations has expired or we have settled federal income tax examinations with the IRS for all tax years through 2020. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by one state for tax years ranging from 2017 - 2019.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the tax years that remain open under the applicable statutes of limitations, management considered potential unrecognized tax benefits and determined there are no material unrecognized tax benefits that would impact prior years&#8217; income taxes.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_295"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE3MzY_fa005c72-bc06-4f85-84ab-c236dce05b75" continuedAt="icedd66a847d1448ab735df5c6d9cb5d7" escape="true">Earnings per Common Share:</ix:nonNumeric></span></div><ix:continuation id="icedd66a847d1448ab735df5c6d9cb5d7" continuedAt="i8b271d61398b4a3a8ea73c443c4cf15d"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE3NDc_da74f272-e8b1-4385-bdf6-fc03ab005557" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.019%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzQtMS0xLTEtMjQ1NDc3_ccf37878-18c6-4c38-b8b9-742c8a72726a">350.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzQtMy0xLTEtMjQ1NDc3_207d3931-c22c-4826-981b-f6cfc250f46a">403.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzQtNS0xLTEtMjQ1NDc3_abf53e67-6060-4972-b321-daf0f38a6f34">278.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzUtMS0xLTEtMjQ1NDc3_5839903f-76fc-450a-a92a-8af69211119c">93.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzUtMy0xLTEtMjQ1NDc3_877727e6-5c5f-411b-b23d-ed20a8817e1e">103.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzUtNS0xLTEtMjQ1NDc3_38a5b8b1-ffe0-4063-bb63-8e1cd1240d67">83.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income from continuing operations allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzYtMS0xLTEtMjQ1NDc3_fc63c2c6-feeb-4286-9864-58d1a0aad7e9">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzYtMy0xLTEtMjQ1NDc3_37b09649-bcc1-4d8e-b864-3afe882ae24e">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzYtNS0xLTEtMjQ1NDc3_0052312c-ed40-4138-8f40-a7cf4eb49de4">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzktMS0xLTEtMjQ1NDc3_f231fd29-a99a-4153-a2f5-f79ceb0181c4">256.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzktMy0xLTEtMjQ1NDc3_31e7f0b4-2e9a-4ae4-b123-4bf2a980d9af">298.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzktNS0xLTEtMjQ1NDc3_731c095b-7891-48cd-9790-fb0ddfca0b92">194.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEwLTEtMS0xLTI0NTQ3Nw_232c8fb6-6654-4216-a42a-0bb9d8e9a503">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEwLTMtMS0xLTI0NTQ3Nw_a2edeaa3-93a1-45e0-90fb-2818773acfc5">114.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEwLTUtMS0xLTI0NTQ3Nw_8a23e47c-7cdf-4a3e-bd4b-3b961343a616">90.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTEtMS0xLTI3MjA5Mg_a6fd224f-47bb-433d-a6b3-223fad17467a">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTMtMS0xLTI3MjA5Mg_5555e5c1-d2a2-495a-a2b2-205218abde1a">1.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTUtMS0xLTI3MjA5Mg_40093836-326b-4753-8e9f-2df5d022f625">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income from discontinued operations allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTEtMS0xLTI0NTQ3Nw_e81dbbbd-0f49-4c61-a5dd-0a2e29ce96fa">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTMtMS0xLTI0NTQ3Nw_082c75f0-3d29-4439-933e-34e900cb95e7">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTUtMS0xLTI0NTQ3Nw_f34c2836-1e73-4217-973f-09585f17f158">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEzLTEtMS0xLTI3NzcxOA_725e4338-ef54-467d-8b81-994de6ebf987">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEzLTMtMS0xLTI3NzcxOA_b689b1a7-f7b5-4d4e-9941-fa0a15b57306">111.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEzLTUtMS0xLTI3NzcxOA_a07e784f-db16-4209-9515-f93e80c0c63a">88.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEyLTEtMS0xLTI0NTQ3Nw_59105787-23a7-425f-a7dd-689f2d17c4ba">269.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEyLTMtMS0xLTI0NTQ3Nw_e20e261a-5c84-4aac-b4a4-ca97b57103bd">410.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEyLTUtMS0xLTI0NTQ3Nw_b79efc5f-5219-4362-aa0c-dc8d3e097c27">283.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE0LTEtMS0xLTI0NTQ3Nw_499e4b64-1f4e-4545-b4a5-5de70ab14d5b">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE0LTMtMS0xLTI0NTQ3Nw_899b2b01-637b-4b9b-8e4b-1f4320e447b0">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE0LTUtMS0xLTI0NTQ3Nw_b5041217-c1fb-4954-bde9-915915af9b9f">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE2LTEtMS0xLTI0NTQ3Nw_a2d2cd45-78c9-4c9b-a840-2df1a93fe2c6">2.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE2LTMtMS0xLTI0NTQ3Nw_22977fa4-cc50-4384-8ce4-2a004a40f843">3.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE2LTUtMS0xLTI0NTQ3Nw_5efb5b0f-169a-43b0-9921-4b603b2620a8">1.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE3LTEtMS0xLTI0NTQ3Nw_0a481894-168f-413e-b02c-0eb2edbe4a20">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE3LTMtMS0xLTI0NTQ3Nw_3c8b0ef4-ee9c-4795-b121-0c6cc37ce327">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE3LTUtMS0xLTI0NTQ3Nw_1ea8f8ac-7a76-4ed9-a949-9e2aeeefa567">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE4LTEtMS0xLTI0NTQ3Nw_6510b5d7-a894-4942-9000-a1e80a024639">2.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE4LTMtMS0xLTI0NTQ3Nw_2a95d607-89b3-4dc1-8f44-9db5d3a6b6a1">4.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE4LTUtMS0xLTI0NTQ3Nw_35295bd1-925c-49d2-8460-6aabb02f3f87">2.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIyLTEtMS0xLTI0NTQ3Nw_25063d1b-a2c3-4689-93a5-34c41ca35c68">350.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIyLTMtMS0xLTI0NTQ3Nw_47c0ebcf-dc8b-436e-954a-877cd7aaa304">403.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIyLTUtMS0xLTI0NTQ3Nw_9be92d5c-e5a9-4280-b2dc-e76dff957da3">278.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIzLTEtMS0xLTI0NTQ3Nw_e4108caa-fb96-4413-8937-aedadb4ed4a4">93.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIzLTMtMS0xLTI0NTQ3Nw_982ac596-f6c5-474d-b86f-255443353594">103.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIzLTUtMS0xLTI0NTQ3Nw_d99a666b-0a54-405a-adbf-93077a39e0f9">83.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI2LTEtMS0xLTI0NTQ3Nw_9d490e3a-6d32-4fd0-a722-9a6fcabf0b61">257.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI2LTMtMS0xLTI0NTQ3Nw_940b5966-86ab-472e-b595-ae270293fc1d">299.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI2LTUtMS0xLTI0NTQ3Nw_051d2399-c233-461e-bac2-29772878970d">194.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI3LTEtMS0xLTI0NTQ3Nw_9d01369d-ede5-4a27-b384-468ff2fd12ee">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI3LTMtMS0xLTI0NTQ3Nw_5e13d3af-0a0e-4f02-bb8b-31d94baac676">114.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI3LTUtMS0xLTI0NTQ3Nw_665db91e-8911-4917-a74f-f7c3591ac73c">90.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTEtMS0xLTI3MjE3MA_88e801e8-5551-48a3-9c11-1be49470e7d4">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTMtMS0xLTI3MjE3MA_b2878df5-061f-490c-bc63-5d4e20448ca8">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTUtMS0xLTI3MjE3MA_440111da-a916-4dfb-be14-34a26ea18e7f">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMxLTEtMS0xLTI3NzcyNQ_b29e2455-df54-4360-a616-6517bd26868e">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMxLTMtMS0xLTI3NzcyNQ_5ef5fb32-9af2-40f2-ab7d-3c3ef42b675e">112.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMxLTUtMS0xLTI3NzcyNQ_a3048622-9b88-40e7-851a-fd7b7a509b04">89.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI4LTEtMS0xLTI0NTQ3Nw_4741c744-c2ee-43f4-a3db-6c9c6440b53f">271.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI4LTMtMS0xLTI0NTQ3Nw_fd2a177f-1ef5-4186-b74a-4c6a4b4e222d">412.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI4LTUtMS0xLTI0NTQ3Nw_671f9ace-f92f-4019-882f-654cc15aa9dd">284.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTEtMS0xLTI0NTQ3Nw_73b4d35d-daba-4d2e-90c5-19871c95569b">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTMtMS0xLTI0NTQ3Nw_4660d391-1eb1-4d5d-acb0-c62d01de5e58">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTUtMS0xLTI0NTQ3Nw_1d1707e1-eefe-4af1-8bbe-5a5b015b0340">99.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMyLTEtMS0xLTI0NTQ3Nw_68d83ed2-dc1e-4275-9741-1933b4ebb8ca">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMyLTMtMS0xLTI0NTQ3Nw_87d09f70-1759-4e6d-9ab1-33e739b83455">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMyLTUtMS0xLTI0NTQ3Nw_056d6d44-be4b-43e2-963c-60b6da916c44">1.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMzLTEtMS0xLTI0NTQ3Nw_f2ea641b-577a-4871-81be-976cb08d0811">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMzLTMtMS0xLTI0NTQ3Nw_1e844415-4e89-4b5e-a60a-8736e4024a64">1.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMzLTUtMS0xLTI0NTQ3Nw_dcb28453-2e3c-422f-ab50-09c885d7da37">0.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzM0LTEtMS0xLTI0NTQ3Nw_7690ff90-fce2-49a3-957b-43cd89fa7450">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzM0LTMtMS0xLTI0NTQ3Nw_80459181-313e-488b-beb3-cdbf35c0eaf5">4.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzM0LTUtMS0xLTI0NTQ3Nw_513e3ecb-7207-4c07-9916-3a72d08d4d16">2.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i8b271d61398b4a3a8ea73c443c4cf15d"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE3NDQ_5cf32f3d-a113-47b9-a6ae-e209fbce6d0e" escape="true"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzItMS0xLTEtMjQ1NDc3_499e4b64-1f4e-4545-b4a5-5de70ab14d5b">99.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzItMy0xLTEtMjQ1NDc3_899b2b01-637b-4b9b-8e4b-1f4320e447b0">99.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzItNS0xLTEtMjQ1NDc3_b5041217-c1fb-4954-bde9-915915af9b9f">98.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzUtMS0xLTEtMjQ1NDc3_75c050fe-3802-47d9-8401-765d553a5434">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzUtMy0xLTEtMjQ1NDc3_eff4d56c-1250-4511-afd3-68cca3dfca1d">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzUtNS0xLTEtMjQ1NDc3_bd743054-ac3b-47ad-9f20-1dbe5407dbf2">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzYtMS0xLTEtMjQ1NDc3_ee1953cf-671c-45f0-89b9-a6633cd6debb">100.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzYtMy0xLTEtMjQ1NDc3_608050e9-bfed-4a53-80f1-d94ce478b7d0">100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzYtNS0xLTEtMjQ1NDc3_44fc787c-a21b-4806-884d-765d466d071e">99.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase approximately <ix:nonFraction unitRef="shares" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzM2MQ_34831077-5e19-45e3-97d3-16806bfa3d5b">0.4</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzM2NQ_39b109ba-436e-4bff-a64e-8bb77a14e597">0.2</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzM3Mw_ca38efef-965f-46ed-9903-adba9aa6bbf1">0.2</ix:nonFraction> million shares of common stock were outstanding during December&#160;31, 2022, 2021, and 2020, respectively, but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, our board of directors approved an increase in our common stock repurchase authorization from $<ix:nonFraction unitRef="usd" contextRef="i271895a47db64e53a3fcdb21e2376d82_I20140131" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzcwNg_cafbea26-8728-4826-9229-1aeab5743f78">200</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i325765d7079c4953b5c202a28adc1d7c_I20140201" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzcxMg_fffce222-c456-4b2d-b96d-cbb2c04d5b1f">250</ix:nonFraction> million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $<ix:nonFraction unitRef="usd" contextRef="i4088c2e6d51b4eb4aae4742204a2232a_I20180724" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzEwMTQ_5ba11ac8-4647-4563-ae00-e393a578c8fb">250</ix:nonFraction> million. There were <ix:nonFraction unitRef="shares" contextRef="ia983a9cc79d34b3bb0ce98f38ebd4ecc_D20220101-20221231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzEwMjk_7ad944f0-591d-40c5-92e6-f4bbef1d95bc"><ix:nonFraction unitRef="shares" contextRef="i0758e6da4efb498697cc4632c85ce905_D20210101-20211231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzEwMjk_83743077-946c-4d26-9410-3589a62aab3a">no</ix:nonFraction></ix:nonFraction> repurchases of our common stock during 2022 or 2021. During 2020, we repurchased <ix:nonFraction unitRef="shares" contextRef="ifad81fc0e15246a99a32d666a8e006ab_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzExMTQ_9490024b-eefd-47a8-ba7c-3bf561f67799">0.1</ix:nonFraction>&#160;million shares of our common stock in the open market for $<ix:nonFraction unitRef="usd" contextRef="ifad81fc0e15246a99a32d666a8e006ab_D20200101-20201231" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzExNzQ_3ebc87dd-2afb-4f25-8260-b6fca2822f61">6.1</ix:nonFraction> million.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="iacdb0a94afd843448af41d30dec91b1f_D20190701-20190731" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE1NDM_d92979d7-0f36-46db-96aa-e761d49b2512">0.28</ix:nonFraction> per share. The cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="iacdb0a94afd843448af41d30dec91b1f_D20190701-20190731" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE1Nzg_4e69f541-e2f5-492d-bb90-300420f293d3">0.28</ix:nonFraction> per common share was declared and paid in each quarter through July 2022. In July 2022, our board of directors revised our quarterly dividend in response to the Spin Off and declared a cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="id92801372f7742e0be889a3765cde901_D20221001-20221031" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzI3Nzg_d89011c1-aded-4cee-a1ec-a27fdce90220"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e8efdcf26334badb765a5748295be5a_D20220701-20220731" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzI3Nzg_efff65a3-f394-4c23-9088-b75b9bd11b7b">0.15</ix:nonFraction></ix:nonFraction> per share that was paid in October 2022. Also in October 2022, our board of directors declared cash dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="i095a5224a8204444bf94150541a11956_D20230101-20230131" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzY1OTcwNjk3Njk0NDM_491dfc61-8022-4258-bdca-24693214d093"><ix:nonFraction unitRef="usdPerShare" contextRef="id92801372f7742e0be889a3765cde901_D20221001-20221031" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzY1OTcwNjk3Njk0NDM_b36c37ef-9734-48e8-b88d-19ee2c3b8f94">0.15</ix:nonFraction></ix:nonFraction> per share that was paid in January 2023. Future dividend payments are subject to declaration by our board of directors.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_298"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM4MTI_3c7ad017-d654-4a6e-bcdd-40a5a4431d3f" continuedAt="ib7a7806a242242b29d4d300efccc0155" escape="true">Contingencies and Other Commitments:</ix:nonNumeric></span></div><ix:continuation id="ib7a7806a242242b29d4d300efccc0155" continuedAt="i1b6f43b204e947d2b460f50e01ff43ba"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i1b6f43b204e947d2b460f50e01ff43ba"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Commitments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to service and other contracts in connection with conducting our business. Minimum amounts due under these agreements are $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM2NzA_edc43d2f-aaa5-4219-8f31-f013d577fdbf">29.6</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherCommitmentDueInSecondYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM2ODA_228e4011-dbf7-4d04-876f-d6e902731a6d">21.0</ix:nonFraction> million in 2024, $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherCommitmentDueInThirdYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM2OTA_44b657dd-4bb0-4f95-808d-93b232765631">12.5</ix:nonFraction> million in 2025, $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherCommitmentDueInFourthYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM3MDA_e826379b-460e-4fd8-883a-5346eb8c6163">9.8</ix:nonFraction> million in 2026, $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherCommitmentDueInFifthYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM3MTA_6b033a08-1703-4007-8436-de81d8735a08">9.2</ix:nonFraction> million in 2027, and $<ix:nonFraction unitRef="usd" contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231" decimals="-5" name="us-gaap:OtherCommitmentDueAfterFifthYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM3MjQ_389ab17d-97ca-4328-85ad-1975ed3a7475">9.6</ix:nonFraction> million thereafter. These contracts primarily relate to software licensing and support.</span></div></ix:continuation><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_304"></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.5pt"><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90ZXh0cmVnaW9uOjY0OTA4ODUzMDRhNjRjZmE4ZjRjYTZjNzk4MjhlNGJiXzk5OA_1e1be47a-7e4e-481f-bb22-3a1216940e76" continuedAt="i4bcf142341234a0abf20259fe5a28d0e" escape="true">Quarterly Data (Unaudited):</ix:nonNumeric></span></div><ix:continuation id="i4bcf142341234a0abf20259fe5a28d0e" continuedAt="i58bd35f6de514f20b075d8d156a45929"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Spin Off of Enhabit was completed during 2022 and the historical results of Enhabit are now reported as discontinued operations. The quarterly results presented below have been reclassified to conform to this presentation. For additional information, see Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin Off of Home Health and Hospice Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><ix:nonNumeric contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90ZXh0cmVnaW9uOjY0OTA4ODUzMDRhNjRjZmE4ZjRjYTZjNzk4MjhlNGJiXzk4NA_c2aff168-18a9-46ce-82c4-5b3b82e54938" continuedAt="ieaec9fc23d0e487a8fac5de58cb3466b" escape="true"><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtMi0xLTEtMjQ1NDc3_f15d5111-8c7f-481d-b55e-5d393632d6ab">1,059.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtNC0xLTEtMjQ1NDc3_56294f5f-66d8-4304-8d00-f6a8a6ebc01d">1,062.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtNi0xLTEtMjQ1NDc3_a33caf8a-1562-4907-a270-f5d8c2c1f6fb">1,089.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtOC0xLTEtMjQ1NDc3_0b640392-7c1c-4f0f-bf72-772eccc8a1a1">1,137.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtMTAtMS0xLTI0NTQ3Nw_65ecc9fb-3180-4a0c-89eb-bae6cafc1a30">4,348.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtMi0xLTEtMjQ1NDc3_ce663af2-d73c-40de-aa85-ab60a9f5a0db">131.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtNC0xLTEtMjQ1NDc3_a1c36894-0e05-480b-8cc7-ce6e1c933051">128.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtNi0xLTEtMjQ1NDc3_df4f7fb7-1ca1-4f64-96e4-fa8465ea7b37">127.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtOC0xLTEtMjQ1NDc3_9f8cfd73-3e58-434e-bf91-64d6104dbc45">151.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtMTAtMS0xLTI0NTQ3Nw_925caeec-5078-49de-94d3-a11722ff66b7">539.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtMi0xLTEtMjQ1NDc3_5e7c05ec-0ffe-4085-bb8f-6f0f204e0c1b">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtNC0xLTEtMjQ1NDc3_b75a1886-ea6e-4a1a-9c87-afbed3067b94">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtNi0xLTEtMjQ1NDc3_26eae40b-538c-49ad-b2fd-cf9ca71e4a06">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtOC0xLTEtMjQ1NDc3_6baf02c6-5d19-4a0e-8b1b-3df38bbdc85f">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtMTAtMS0xLTI0NTQ3Nw_511e0518-926c-4c67-a919-ecf8324e5be3">100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtMi0xLTEtMjQ1NDc3_796ad2f9-e253-47bf-af6f-6ba45b21b421">86.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtNC0xLTEtMjQ1NDc3_a4532ee8-c25d-4fa0-b029-d6e162591d95">59.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtNi0xLTEtMjQ1NDc3_993633f1-9124-42c9-a6e4-c48d7b5c0ba5">85.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtOC0xLTEtMjQ1NDc3_70a578ab-cac0-4e7c-8e1a-08c1cc4cd982">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtMTAtMS0xLTI0NTQ3Nw_d500bde4-ca98-44aa-820c-89e2caf9b0ae">350.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctMi0xLTEtMjQ1NDc3_5d04840c-4ed2-4151-9e64-d44606b8629a">23.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctNC0xLTEtMjQ1NDc3_8e9df17e-1d86-458f-ac4e-c25aeb58030d">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctNi0xLTEtMjQ1NDc3_3742c63d-c030-4648-897d-8b79c7495044">18.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctOC0xLTEtMjQ1NDc3_5031ba83-8539-41d1-a49f-26e23f0ac382">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctMTAtMS0xLTI0NTQ3Nw_f4f50e2e-52e8-41b4-8b7b-d053e0f5fec9">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtMi0xLTEtMjQ1NDc3_13c03aa7-7feb-4000-88dc-6543e0052bf3">110.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtNC0xLTEtMjQ1NDc3_ddc70ac5-fb55-43b8-b829-75d418f6f33b">71.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtNi0xLTEtMjQ1NDc3_96e48ea3-ab0e-4a24-ab68-a42194affc62">67.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtOC0xLTEtMjQ1NDc3_5eb1ecef-79f8-4c67-b443-d7c93915b1c0">117.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtMTAtMS0xLTI0NTQ3Nw_89bf8d2b-f7da-43ce-94f5-29804c2cd9e3">365.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktMi0xLTEtMjQ1NDc3_c7b4e73c-0954-4727-9c86-b7d65dcae366">22.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktNC0xLTEtMjQ1NDc3_96efa17b-e489-4e92-8466-3e8471e723dc">22.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktNi0xLTEtMjQ1NDc3_2731abe3-0967-46ee-bc98-8e789787611d">21.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktOC0xLTEtMjQ1NDc3_8851fc04-f294-4fc3-9de2-441cd1b00ef8">28.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktMTAtMS0xLTI0NTQ3Nw_b157f24d-b8f3-45e9-8558-b8ef37097ad4">94.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTItMS0xLTI0NTQ3Nw_fb9fa73a-9f87-4f14-a962-b58489eeb088">87.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTQtMS0xLTI0NTQ3Nw_a5893a2f-c819-4ca3-8731-52fc9582ac8f">48.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTYtMS0xLTI0NTQ3Nw_bea6fed6-6c25-4686-ae7a-ffdf6398d5fd">45.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTgtMS0xLTI0NTQ3Nw_28de0136-22e9-4dd3-ac6c-eb2de568b2e9">89.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTEwLTEtMS0yNDU0Nzc_925bb7d7-688a-4270-83dd-ad8fc0c662b9">271.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTItMS0xLTI0NTQ3Nw_84bac366-9194-4dd7-be61-edecc30d01f0">0.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTQtMS0xLTI0NTQ3Nw_ef8130b3-cd60-4df0-9c22-12f54f451792">0.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTYtMS0xLTI0NTQ3Nw_aa338c1d-3833-400a-961a-23faa7016636">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTgtMS0xLTI0NTQ3Nw_c75dea09-64c4-4d49-8c69-c5c59d9c7399">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTEwLTEtMS0yNDU0Nzc_5baa297d-8c08-40a4-88b7-67c1243d1c67">2.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTItMS0xLTI0NTQ3Nw_de62a428-ef70-49bb-8694-2079caf02262">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTQtMS0xLTI0NTQ3Nw_ab6f9134-cc85-4427-baab-6c46ab246151">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTYtMS0xLTI0NTQ3Nw_beece86b-4056-403e-bd90-7ada0eda6279">0.19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTgtMS0xLTI0NTQ3Nw_643dbe59-428c-4660-9f93-84ee60046605">0.02</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTEwLTEtMS0yNDU0Nzc_0ef0bb08-7e43-45ac-b8fc-d0e9604e50d4">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTItMS0xLTI0NTQ3Nw_3394e468-02ab-4663-a1de-579f45db036f">0.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTQtMS0xLTI0NTQ3Nw_0b17828d-abb0-4382-a398-31f7ea4ebe53">0.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTYtMS0xLTI0NTQ3Nw_970b8c24-57b5-489f-ae2c-bbbb5b8b88ce">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTgtMS0xLTI0NTQ3Nw_4233644a-dea7-43d6-898e-eaad2b1081a8">0.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTEwLTEtMS0yNDU0Nzc_885e311d-ef18-4d7f-bb52-dc4df935b699">2.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTItMS0xLTI0NTQ3Nw_fb471fb1-022d-4ca1-a3b2-3db8a986e4fe">0.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTQtMS0xLTI0NTQ3Nw_00d559c2-5729-48cb-a719-7d0c1a6a9693">0.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTYtMS0xLTI0NTQ3Nw_44649f39-1119-4e62-8f3e-9d098fbbfb06">0.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTgtMS0xLTI0NTQ3Nw_5778650a-5f62-4df6-885e-698647d74d02">0.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTEwLTEtMS0yNDU0Nzc_503628a0-47c0-4029-9f35-fc6560de9bd3">2.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTItMS0xLTI0NTQ3Nw_fcd44944-1659-4d9d-b846-3de704072271">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTQtMS0xLTI0NTQ3Nw_58d31b61-c8c6-4742-9dc0-2205295bde1e">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTYtMS0xLTI0NTQ3Nw_e664c73a-2df6-4df8-8aa9-41f8125f15e2">0.18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTgtMS0xLTI0NTQ3Nw_a17150b8-e7b1-45df-b470-9894dd157ed3">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTEwLTEtMS0yNDU0Nzc_1514030b-d3cd-44eb-b7c7-86ba308f4e32">0.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTItMS0xLTI0NTQ3Nw_76e17810-07a1-41ea-aed8-610084568552">0.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTQtMS0xLTI0NTQ3Nw_35af9f9a-f604-4f6a-9520-c28db393ec81">0.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTYtMS0xLTI0NTQ3Nw_b8bbaa58-9e63-487c-b676-57608f948de4">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTgtMS0xLTI0NTQ3Nw_ceec927c-686e-4aa8-83ee-6429a5237b1a">0.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTEwLTEtMS0yNDU0Nzc_deb9e212-4692-497d-bbc7-d5627d31acbd">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt">We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.485%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Encompass Health Corporation and Subsidiaries<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><ix:continuation id="i58bd35f6de514f20b075d8d156a45929"><ix:continuation id="ieaec9fc23d0e487a8fac5de58cb3466b"><div style="margin-bottom:5pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.191%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtMi0xLTEtMjQ1NDc3_ba96ec0f-276e-4fef-82bb-71f394a746a4">959.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtNC0xLTEtMjQ1NDc3_2eede6c1-685c-4c52-856e-bc3d47f52f6a">1,001.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtNi0xLTEtMjQ1NDc3_9f992b13-40bc-4ada-9391-40cea0da3acb">1,010.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtOC0xLTEtMjQ1NDc3_6ff8163b-0e06-4ae4-8abc-3354bde480e9">1,042.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtMTAtMS0xLTI0NTQ3Nw_81490553-5679-4cd0-894b-740b41117407">4,014.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtMi0xLTEtMjQ1NDc3_23f227fe-b4f3-43aa-b08a-40c0c937eb75">143.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtNC0xLTEtMjQ1NDc3_4036843d-668b-4c09-a620-1b1f0d660225">146.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtNi0xLTEtMjQ1NDc3_9d601923-9501-479e-b8cf-513d9c37eb75">141.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtOC0xLTEtMjQ1NDc3_96999d8d-4d6a-477a-8d23-882f2e7b986a">128.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtMTAtMS0xLTI0NTQ3Nw_e62edf57-0e24-4253-96a0-d8d4009dbe01">559.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtMi0xLTEtMjQ1NDc3_723de652-2661-4ea0-8d3f-8b81d0b959c0">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtNC0xLTEtMjQ1NDc3_51988a4a-089e-40dc-b0d0-11e7be6a4744">28.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtNi0xLTEtMjQ1NDc3_3e75671e-afb4-4f83-bb41-c0245bfe77ac">26.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtOC0xLTEtMjQ1NDc3_273f8e86-ee70-445f-a2e1-15dcf382555d">22.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtMTAtMS0xLTI0NTQ3Nw_89ffd02c-76cc-4fde-be04-e95bf668107a">101.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtMi0xLTEtMjQ1NDc3_c3d1e947-574f-48b7-a171-8d1286949fa0">101.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtNC0xLTEtMjQ1NDc3_3dd36e93-80fc-4d29-96bd-670c5c95f1df">107.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtNi0xLTEtMjQ1NDc3_114accfe-fcba-44a0-a019-3b62ce1ce18b">102.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtOC0xLTEtMjQ1NDc3_958e9b2b-d7d7-47b7-9a75-ced5358f2681">92.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtMTAtMS0xLTI0NTQ3Nw_41a805c7-5e5d-4671-b04c-ecbd64028c26">403.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctMi0xLTEtMjQ1NDc3_136643df-f6b2-47d2-adc0-6b67e566d8e5">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctNC0xLTEtMjQ1NDc3_73041bb9-793b-48d6-8a8d-4973101b814f">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctNi0xLTEtMjQ1NDc3_f5b6efb0-fb4e-4bf1-a741-584b64faa8fa">24.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctOC0xLTEtMjQ1NDc3_a0894227-93be-4cbe-915d-e2db4ee9828f">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctMTAtMS0xLTI0NTQ3Nw_0b7412bd-6fec-4bd3-8ca6-dbab9eb23ff1">114.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtMi0xLTEtMjQ1NDc3_7b0ebaa5-0749-47d9-a477-8f7d1517ca1e">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtNC0xLTEtMjQ1NDc3_0554f39f-9320-442c-92e9-1bd8052ac4c2">142.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtNi0xLTEtMjQ1NDc3_070d1004-9e6a-4123-a5f4-b007e39236f9">126.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtOC0xLTEtMjQ1NDc3_a53dc298-7d3b-4d44-8ecf-7f6fa50d3672">115.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtMTAtMS0xLTI0NTQ3Nw_f548cce8-b8b0-44c9-8518-7bb463c44eab">517.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktMi0xLTEtMjQ1NDc3_49662e46-9283-4416-a3a6-7a93bc3e65b0">25.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktNC0xLTEtMjQ1NDc3_0b2f10ab-a52c-4412-a0ce-876aa07578ab">28.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktNi0xLTEtMjQ1NDc3_a8ff5745-7914-41e1-8228-b0b6c9233aef">26.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktOC0xLTEtMjQ1NDc3_c7c05bbc-5c6c-4bba-bd6e-f229bdb05da5">24.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktMTAtMS0xLTI0NTQ3Nw_3fa0daa4-af3f-4d17-a08b-e21cce26afec">105.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTItMS0xLTI0NTQ3Nw_d5b10244-1013-40cf-ac9f-bde7f8a5913a">107.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTQtMS0xLTI0NTQ3Nw_3114a2fd-4e00-4ba8-a3e9-7684da03e376">113.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTYtMS0xLTI0NTQ3Nw_e39ada3a-562e-4b3f-aea1-3939b950d8bf">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTgtMS0xLTI0NTQ3Nw_07eaf34d-accf-4ea2-a75d-1b7fcae6cfb6">91.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTEwLTEtMS0yNDU0Nzc_746a0675-9d1b-4eb3-8c82-87aa9da30941">412.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTItMS0xLTI0NTQ3Nw_229651a7-e790-4f57-804e-955cfde9410c">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTQtMS0xLTI0NTQ3Nw_7e4007a4-64ef-4de0-a5c7-2f54759fa81c">0.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTYtMS0xLTI0NTQ3Nw_284d1208-2d47-415d-b128-4df064aa9b4e">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTgtMS0xLTI0NTQ3Nw_e40b69d5-0998-42c3-8a48-8a52ff82dd73">0.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTEwLTEtMS0yNDU0Nzc_ab9a1996-9294-4291-901a-876daedf4d96">3.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTItMS0xLTI0NTQ3Nw_1a6fea4a-07e1-40ac-bc9f-3aa9d65b576e">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTQtMS0xLTI0NTQ3Nw_e44b9b60-877c-40f3-9d02-05b1c44362ef">0.35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTYtMS0xLTI0NTQ3Nw_cbd81380-bc88-4815-ba45-246324cfcce4">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTgtMS0xLTI0NTQ3Nw_49853575-f3b7-4f0d-a725-e24a437e3b5c">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTEwLTEtMS0yNDU0Nzc_d12d1bd1-abd6-4a00-9d6e-e7bb19b4e703">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTItMS0xLTI0NTQ3Nw_b252ff9d-4d24-4d94-a37f-d5f1bcae8f92">1.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTQtMS0xLTI0NTQ3Nw_c6226364-c2c9-497c-953b-d7409b71e22f">1.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTYtMS0xLTI0NTQ3Nw_77bd272f-b462-4f73-b8ef-7d6b21c6cfce">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTgtMS0xLTI0NTQ3Nw_77dfd8e2-8ebe-43c6-a055-a53b4f1907f2">0.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTEwLTEtMS0yNDU0Nzc_79ae8eb2-bdfc-49bc-a6c1-9c1c8bd5bf82">4.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTItMS0xLTI0NTQ3Nw_df4af2e5-1303-4cb8-ae2c-8a53a0a237c3">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTQtMS0xLTI0NTQ3Nw_9fb4a245-3fc7-4bc3-afb4-0fe841e13547">0.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTYtMS0xLTI0NTQ3Nw_01a04773-90f7-4185-878f-a45a7c9479a5">0.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTgtMS0xLTI0NTQ3Nw_26ec3012-54be-4249-90aa-2c7b502216c3">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTEwLTEtMS0yNDU0Nzc_6011964d-0ca1-427c-9b6c-60d0684723e3">2.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTItMS0xLTI0NTQ3Nw_30d79fa4-582a-4005-a9d7-742bbadc3f67">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTQtMS0xLTI0NTQ3Nw_7e10c2ef-d5ed-4e75-bd4a-fdf10fd4d801">0.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTYtMS0xLTI0NTQ3Nw_77f96435-0206-4710-9fe6-43214b53c08a">0.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTgtMS0xLTI0NTQ3Nw_290ba03d-c79c-4810-ad6c-9303e511a16c">0.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTEwLTEtMS0yNDU0Nzc_97d01d66-6491-43bd-a489-76b9c683df39">1.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTItMS0xLTI0NTQ3Nw_71d209f8-ef9b-4610-8aa1-c64a9e98fab0">1.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTQtMS0xLTI0NTQ3Nw_b4f2272d-1b74-4c17-8110-c6cae561cb71">1.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTYtMS0xLTI0NTQ3Nw_ca27faf4-86c2-4199-93ff-278051ba8d95">1.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTgtMS0xLTI0NTQ3Nw_ff4d01cd-a3e3-4591-b7a4-334f1e4b41cd">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTEwLTEtMS0yNDU0Nzc_5238545d-a10d-424f-9314-c0fd1dba39e3">4.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt">We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.</span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><div id="i94fc0f96aa5b45dfbb4828eadd7a15c2_307"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective as of January 1, 2018, we changed our name to Encompass Health Corporation. By operation of law, any reference to &#8220;HealthSouth&#8221; in these exhibits should be read as &#8220;Encompass Health&#8221; as set forth in the Exhibit List below.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:5.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">No.</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm">2.1.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm">Separation and Distribution Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm">(incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm">.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm">July 7, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/separationanddistributiona.htm">.</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/transitionservicesagreemen.htm">2.1.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/transitionservicesagreemen.htm">Transition Services Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc. (incorporated by reference to Exhibit 2.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on July 7, 2022).</a></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/taxmattersagreement-finalx.htm">2.1.3</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/taxmattersagreement-finalx.htm">Tax Matters Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/taxmattersagreement-finalx.htm">(incorporated by reference to Exhibit 2.3 to Encompass Health&#8217;s Current Report on Form 8-K filed on July 7, 2022).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/employeemattersagreement-f.htm">2.1.4</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/employeemattersagreement-f.htm">Employee Matters Agreement, dated as of June 30, 2022, by and between Encompass Health Corporation and Enhabit, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/employeemattersagreement-f.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/employeemattersagreement-f.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/employeemattersagreement-f.htm">(incorporated by reference to Exhibit 2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/employeemattersagreement-f.htm">.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/employeemattersagreement-f.htm"> to Encompass Health&#8217;s Current Report on Form 8-K filed on July 7, 2022)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000034/employeemattersagreement-f.htm">.</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex31.htm">3.1.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex31.htm">Amended and Restated Certificate of Incorporation of Encompass Health Corporation, effective as of January 1, 2018 (incorporated by reference to Exhibit 3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 25, 2017).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000134100406000665/healthsouthexhibit.txt">3.1.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000134100406000665/healthsouthexhibit.txt">Certificate of Designations of 6.50% Series A Convertible Perpetual Preferred Stock, as filed with the Secretary of State of the State of Delaware on March 7, 2006 (incorporated by reference to Exhibit 3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on March 9, 2006).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000068/hls8kex32.htm">3.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000053/ehc8k121322ex31.htm">Amended and Restated Bylaws of Encompass Health Corporation, effective as of December 8, 2022 (incorporated by reference to Exhibit 3.1 to Encompass Health&#8217;s Current Report on Form 8-K filed on December </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000053/ehc8k121322ex31.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000053/ehc8k121322ex31.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000053/ehc8k121322ex31.htm">, 2022).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000011/exhibit_4-7110k.htm">4.1.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000011/exhibit_4-7110k.htm">Indenture, dated as of December 1, 2009, between Encompass Health Corporation&#160;and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York, relating to Encompass Health&#8217;s 5.125% Senior Notes due 2023, 5.75% Senior Notes due 2024, and 5.75% Senior Notes due 2025 (incorporated by reference to Exhibit&#160;4.7.1 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 23, 2010).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000011/exhibit_4-7210k.htm">4.1.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000011/exhibit_4-7210k.htm">First Supplemental Indenture, dated December 1, 2009, among Encompass Health Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York (incorporated by reference to Exhibit 4.7.2 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 23, 2010).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000053/exhibit_4-2.htm">4.1.3</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000053/exhibit_4-2.htm">Second Supplemental Indenture, dated as of October 7, 2010, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York (incorporated by reference to Exhibit 4.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 12, 2010).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000053/exbibit_4-3.htm">4.1.4</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516110000053/exbibit_4-3.htm">Third Supplemental Indenture, dated October 7, 2010, among Encompass Health Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York (incorporated by reference to Exhibit 4.3 to Encompass Health&#8217;s Current Report on Form 8-K filed on October 12, 2010).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516112000058/ex42fourthsupplementalinde.htm">4.1.5</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516112000058/ex42fourthsupplementalinde.htm">Fourth Supplemental Indenture, dated September 11, 2012, among Encompass Health Corporation, the Subsidiary Guarantors (as defined therein) and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York&#160;(incorporated by reference to Exhibit 4.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on September 11, 2012).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000032/ex42healthsouthfifthsupple.htm">4.1.6</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000032/ex42healthsouthfifthsupple.htm">Fifth Supplemental Indenture, dated as of March 12, 2015, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000032/ex42healthsouthfifthsupple.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000032/ex42healthsouthfifthsupple.htm">(incorporated by reference to Exhibit 4.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on March 12, 2015).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000075/a2015augnotesoffclosingex44.htm">4.1.7</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000075/a2015augnotesoffclosingex44.htm">Sixth Supplemental Indenture, dated as of August 7, 2015, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee (incorporated by reference to Exhibit 4.4 to Encompass Health&#8217;s Current Report on Form 8-K filed on August 12, 2015).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:5.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000082/ex42seventhsupplementalind.htm">4.1.8</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516115000082/ex42seventhsupplementalind.htm">Seventh Supplemental Indenture, dated as of September 16, 2015, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee and successor in interest to The Bank of Nova Scotia Trust Company of New York, relating to Encompass Health&#8217;s 5.75% Senior Notes due 2025 (incorporated by reference to Exhibit 4.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on September 21, 2015).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312519247756/d760186dex42.htm">4.1.9</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312519247756/d760186dex42.htm">Eighth Supplemental Indenture dated as of September&#160;18, 2019, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.500% Notes due 2028 (incorporated by referenced to Exhibit 4.2 to the Encompass Health&#8217;s Current Report on Form 8-K filed on September 18, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312519247756/d760186dex43.htm">4.1.10</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312519247756/d760186dex43.htm">Ninth Supplemental Indenture dated as of September&#160;18, 2019, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.750% Notes due 2030 (incorporated by referenced to Exhibit 4.3 to the Encompass Health&#8217;s Current Report on Form 8-K filed on September 18, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312520263689/d12659dex42.htm">4.1.11</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000119312520263689/d12659dex42.htm">Tenth Supplemental Indenture, dated as of October 5, 2020, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.625% Notes due 2031 (incorporated by reference to Exhibit 4.2 to the Encompass Health&#8217;s Current Report on Form 8-K filed on October 5, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">4.1.12</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516121000057/eleventhsupplementalindent.htm">Eleventh Supplemental Indenture, dated as of December 15, 2021, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 5.75% Notes due 2025 (incorporated by reference to Exhibit 4.3 to the Encompass Health&#8217;s Current Report on Form 8-K filed on December 17, 2021).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000003/twelfthsupplementalindeture.htm">4.1.13</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000003/twelfthsupplementalindeture.htm">Twelfth Supplemental Indenture, dated as of January 24, 2022, among Encompass Health Corporation, the guarantors party thereto and Wells Fargo Bank, National Association, as trustee, relating to the 4.500% Notes due 2028, 4.750% Notes due 2030 and 4.625% Notes due 2031 (incorporated by reference to Exhibit 4.5 to the Encompass Health&#8217;s Current Report on Form 8-K filed on January 25, 2022).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex42.htm">4.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex42.htm">Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (Common Stock)(incorporated by reference to Exhibit 4.2 to Encompass Health's Annual Report on Form 10-K filed on February 27, 2020).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312506065473/dex10121.htm">10.1.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312506065473/dex10121.htm">Encompass Health Corporation Amended and Restated 2004 Director Incentive Plan (incorporated by reference to Exhibit 10.12.1 to Encompass Health&#8217;s Annual Report on Form 10-K filed on March 29, 2006).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312506065473/dex10122.htm">10.1.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312506065473/dex10122.htm">Form of Restricted Stock Unit Agreement (Amended and Restated 2004 Director Incentive Plan)(incorporated by reference to Exhibit 10.12.2 to Encompass Health&#8217;s Annual Report on Form 10-K filed on March 29, 2006).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312505131361/dex1031.htm">10.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000119312505131361/dex1031.htm">Form of Indemnity Agreement entered into between Encompass Health Corporation and the directors of Encompass Health (incorporated by reference to Exhibit 10.31 to Encompass Health&#8217;s Annual Report on Form 10-K filed on June 27, 2005).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex103.htm">10.3</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex103.htm">Encompass Health Corporation Fifth Amended and Restated Change in Control Benefits Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex103.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex103.htm">+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000144264309000050/form10q-32009.htm">10.4</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000144264309000050/form10q-32009.htm">Description of the Encompass Health Corporation Senior Management Compensation Recoupment Policy (incorporated by reference to Item 5, &#8220;Other Matters,&#8221; in Encompass Health&#8217;s Quarterly Report on Form 10-Q filed on November 4, 2009).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000016/a2022proxystatement.htm">10.5</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000016/a2022proxystatement.htm">Description of the Encompass Health Corporation Senior Management Bonus and Long-Term Incentive Plans (incorporated by reference to the section captioned &#8220;Executive Compensation &#8211; Compensation Discussion and Analysis &#8211; Elements of Executive Compensation&#8221; in Encompass Health&#8217;s Definitive Proxy Statement on Schedule&#160;14A filed on April 4, 2022).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000016/a2022proxystatement.htm">10.6</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000016/a2022proxystatement.htm">Description of the annual compensation arrangement for non-employee directors of Encompass Health Corporation (incorporated by reference to the section captioned &#8220;Corporate Governance and Board Structure&#160;&#8211;&#160;Compensation of Directors&#8221; in Encompass Health&#8217;s Definitive Proxy Statement on Schedule 14A, filed on April 4, 2022).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516118000050/ehc10q93018ex102.htm">10.7</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516118000050/ehc10q93018ex102.htm">Encompass Health Corporation Fifth Amended and Restated Executive Severance Plan (incorporated by reference to Exhibit 10.2 to Encompass Health&#8217;s Quarterly Report on Form 10-Q filed on October 31, 2018).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex108.htm">10.8.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516120000011/ehc10k123119ex108.htm">Encompass Health Corporation Nonqualified Retirement Plan (incorporated by reference to Exhibit 10.8 to Encompass Health's Annual Report on Form 10-K filed on February 27, 2020).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex1082.htm">10.8.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex1082.htm">First Amendment to the Encompass Health Corporation Nonqualified Retirement Plan.+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:5.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.042%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000009/hls10-k123116ex10103.htm">10.9.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516117000009/hls10-k123116ex10103.htm">Form of Non-Qualified Stock Option Agreement (Amended and Restated 2008 Equity Incentive Plan)(incorporated by reference to Exhibit 10.10.3 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 22, 2017).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516111000066/exhibit10_1-5.htm">10.9.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516111000066/exhibit10_1-5.htm">Form of Restricted Stock Unit Award (Amended and Restated 2008 Equity Incentive Plan)(incorporated by reference to Exhibit 10.1.5 to Encompass Health&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2011).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516113000012/hls10-k123112ex1015.htm">10.10</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516113000012/hls10-k123112ex1015.htm">Encompass Health Corporation Directors&#8217; Deferred Stock Investment Plan (incorporated by reference to Exhibit 10.15 to Encompass Health&#8217;s Annual Report on Form 10-K filed on February 19, 2013).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1011.htm">10.11.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1011.htm">Encompass Health Corporation 2016 Omnibus Performance Incentive Plan (incorporated by reference to Exhibit&#160;10.1.1 to Quarterly Report on Form 10-Q filed on July 29, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000153/ex101-formofstockoption.htm">10.11.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000153/ex101-formofstockoption.htm">Form of Non-Qualified Stock Option Agreement (2016 Omnibus Performance Incentive Plan)(incorporated by reference to Exhibit&#160;10.1 to Current Report on Form 8-K filed on December 12, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1013.htm">10.11.3</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1013.htm">Form of Restricted Stock Award (2016 Omnibus Performance Incentive Plan)(incorporated by reference to Exhibit&#160;10.1.3 to Quarterly Report on Form 10-Q filed on July 29, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1014.htm">10.11.4</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1014.htm">Form of Performance Share Unit Award (2016 Omnibus Performance Incentive Plan)(incorporated by reference to Exhibit&#160;10.1.4 to Quarterly Report on Form 10-Q filed on July 29, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1015.htm">10.11.5</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516116000136/hls10q63016ex1015.htm">Form of Restricted Stock Unit Award (2016 Omnibus Performance Incentive Plan)(incorporated by reference to Exhibit&#160;10.1.5 to Quarterly Report on Form 10-Q filed on July 29, 2016).+</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516119000049/encompass-collateralan.htm">10.12</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/785161/000078516119000049/encompass-collateralan.htm">Second Amended and Restated Collateral and Guarantee Agreement, dated November 25, 2019, by and among Encompass Health Corporation, certain of its subsidiaries, and Barclays Bank PLC, as collateral agent (incorporated by reference to Exhibit 10.2 to Encompass Health&#8217;s Current Report on Form 8-K filed on December 2, 2019).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000042/ex101to8k.htm">10.13</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000042/ex101to8k.htm">Sixth Amended and Restated Credit Agreement, dated October 7, 2022, by and among Encompass Health Corporation, certain of its subsidiaries, Barclays Bank PLC, as administrative agent and collateral agent, and various other lenders</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000042/ex101to8k.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000042/ex101to8k.htm">(incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000042/ex101to8k.htm">October 13, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/785161/000078516122000042/ex101to8k.htm">).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex211.htm">21.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex211.htm">Subsidiaries of Encompass Health Corporation.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex221.htm">22.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex221.htm">Subsidiary Guarantors and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize Securities of the Registrant.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex231.htm">23.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex231.htm">Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_133">24.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_133">Power of Attorney (included as part of signature page).</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex311.htm">31.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex311.htm">Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex312.htm">31.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex312.htm">Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex321.htm">32.1</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex322.htm">32.2</a></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ehc10k123122ex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sections of the Encompass Health Corporation Annual Report on Form 10-K for the year ended December 31, 2022, formatted in XBRL (eXtensible Business Reporting Language), submitted in the following files:</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i94fc0f96aa5b45dfbb4828eadd7a15c2_7">Table of Contents</a></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:5.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.042%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ &#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Certain portions of this exhibit have been omitted pursuant to a request for confidential treatment. The nonpublic information has been filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>ehc10k123122ex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i73259fb16168479c876b5d387211d859_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.3</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ENCOMPASS HEALTH CORPORATION</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">FIFTH AMENDED AND RESTATED</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CHANGE IN CONTROL</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">BENEFITS PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Encompass Health Corporation, a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), has adopted the Encompass Health Corporation Fifth Amended and Restated Change in Control Benefits Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) for the benefit of certain Participant employees of the Company and its subsidiaries, on the terms and conditions hereinafter stated. The Plan is intended to help retain qualified employees, maintain a stable work environment and provide financial security to certain Participant employees of the Company in the event of a Change in Control. The Plan is intended to be a plan that &#8220;is unfunded and is maintained by an employer primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees&#8221; within the meaning of Sections 201(2), 301(a)(3) and 401(a)(1) of ERISA. Conversely, to the maximum extent permitted by law, the Plan is not intended to provide for any &#8220;deferral of compensation,&#8221; as defined in Section 409A of the Code (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and authoritative Department of Treasury regulations and other interpretive guidance issued thereunder (including the Proposed Treasury Regulations issued June 22, 2016, to the extent the application of such proposed regulations facilitates the administration of this Plan in accordance with the intentions set forth in this paragraph). Instead, payments and benefits under the Plan are intended to fall within the exceptions for &#8220;short-term deferrals,&#8221; as set forth in Treasury Regulations Section 1.409A-1(b)(4), and &#8220;separation pay due to involuntary separation from service or participation in a window program,&#8221; as set forth in Treasury Regulations Section 1.409A-1(b)(9)(iii) and it is further intended that each Participant&#8217;s benefits shall be payable only upon a Participant&#8217;s &#8220;separation from service&#8221; under Treasury Regulations Section 1.409A-1(h). For purposes of Treasury Regulations Section 1.409A-2(b)(2)(iii), the right to each payment under the Plan shall be treated as the right to a separate payment. The Plan shall be administered and interpreted to the extent possible in a manner consistent with these intentions.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE I<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DEFINITIONS AND INTERPRETATIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Capitalized terms used in the Plan shall have the following respective meanings, except as otherwise provided or as the context shall otherwise require&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Annual Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the base salary paid to a Participant immediately prior to his or her Termination Date on an annual basis exclusive of any bonus payments or additional payments under any Benefit Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any grant or award of Options, Stock Appreciation Rights or any other right or interest relating to Common Stock or cash, granted to a Participant pursuant to an equity compensation plan of the Company. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Benefit Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any &#8220;employee benefit plan&#8221; (including any employee benefit plan within the meaning of Section 3(3) of ERISA), program, arrangement or practice maintained, sponsored or provided by the Company, including those relating to compensation, bonuses, profit sharing, stock option, or other stock-related rights or other forms of incentive or deferred compensation, paid time-off benefits, insurance coverage (including any self-insured arrangements) health or medical benefits, Disability benefits, workers&#8217; compensation, supplemental unemployment benefits, severance benefits and post employment or retirement benefits (including&#58;  compensation, pension, health, medical or life insurance, or other benefits).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Board of Directors of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in any individual employment, severance or similar agreement between the Company and a Participant, or in the event that a Participant is not a party to such an agreement, Cause shall mean&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the Company&#8217;s procurement of evidence of the Participant&#8217;s act of fraud, misappropriation, or embezzlement with respect to the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Participant&#8217;s indictment for, conviction of, or plea of guilty or no contest to, any felony (other than a minor traffic violation)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the suspension or debarment of the Participant or of the Company or any of its affiliated companies or entities as a direct result of any willful or grossly negligent act or omission of the Participant in connection with his or her employment with the Company from participation in any Federal or state health care program. For purposes of this clause (iii), the Participant shall not have acted in a &#8220;willful&#8221; manner if the Participant acted, or failed to act, in a manner that he or she believed in good faith to be in, or not opposed to the best interests of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;the Participant&#8217;s admission of liability of, or finding by a court or the SEC (or a similar agency of any applicable state) of liability for, the violation of any &#8220;Securities Laws&#8221; (as hereinafter defined) (excluding any technical violations of the securities laws which are not criminal in nature). As used herein, the term &#8220;securities laws&#8221; means any federal or state law, rule or regulation governing the issuance or exchange of securities, including, without limitation, the Securities Act and the Exchange Act&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;a formal indication from any agency or instrumentality of any state or the United States of America, including, but not limited to, the United States Department of Justice, the SEC or any committee of the United States Congress that the Participant is a target or the subject of any investigation or proceeding into the actions or inactions of the Participant for a violation of any Securities Laws in connection with his or her employment by the Company (excluding any technical violations of the securities law which are not criminal in nature)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;the Participant&#8217;s failure after reasonable prior written notice from the Company to comply with any valid and legal directive of the Chief Executive Officer or the Board that is not remedied within thirty </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(30) days of the Participant being provided written notice thereof from the Company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;other than as provided in clauses (i) through (vi) above, the Participant&#8217;s breach of any material provision of any employment agreement, if applicable, or the Participant&#8217;s breach of the material duties of the Participant&#8217;s job that is not remedied within thirty (30) days or repeated breaches of a similar nature, such as the failure to report to work, perform duties, or follow directions, all as provided herein, which shall not require additional notices as provided in clauses (i) through (vi) above.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Cause shall be determined by the affirmative vote of at least fifty percent (50%) of the members of the Board (excluding the Participant, if a Board member, and excluding any member of the Board involved in events leading to the Board&#8217;s consideration of terminating the Participant for Cause).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the acquisition (other than from the Company) by any person, entity or &#8220;group&#8221; (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act, but excluding, for this purpose, the Company or its subsidiaries, or any employee benefit plan of the Company or its subsidiaries which acquires beneficial ownership of voting securities of the Company) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of thirty percent (30%) or more of either the then-outstanding shares of Common Stock or the combined voting power of the Company&#8217;s then-outstanding voting securities entitled to vote generally in the election of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;during any period of up to twenty-four (24) consecutive months, individuals who at the beginning of such period constituted the Board (together with any new directors whose election by the Board or whose nomination for election by the stockholders of the Company was approved by a vote of a majority of the directors of the Company then still in office who were either directors at the beginning of such period or whose election or nomination for election was previously so approved) cease to constitute at least a majority of the Board&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the Company is liquidated or dissolved or adopts a plan of liquidation or dissolution&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;the merger or consolidation of the Company with or into another person or the merger of another person with or into the Company, or the sale of all or substantially all the assets of the Company (determined on a consolidated basis) to another person, other than a transaction following which (A) in the case of a merger or consolidation transaction, holders of securities that represented one hundred percent (100%) of the combined voting power entitled to vote generally in the election of directors of the Company immediately prior to such transaction (or other securities into which such securities are converted as part of such merger or consolidation transaction) own directly or indirectly at least a majority of the combined voting power entitled to vote generally in the election of directors of the surviving person in such transaction immediately after such transaction and (B) in the case of a sale of assets, each transferee is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">owned by holders of securities that represented at least a majority of the combined voting power entitled to vote generally in the election of directors of the Company immediately prior to such sale.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Internal Revenue Code of 1986, as amended. Reference in the Plan to any Section of the Code shall be deemed to include any amendments or successor provisions to such Section and any regulations under such Section.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean $.01 par value common stock of the Company, and such other securities of the Company as may be substituted for Common Stock.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Compensation Committee of the Board.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a physical or mental condition which is expected to result in death or can be expected to last for a continuous period of not less than twelve (12) months and which renders the Participant incapable of performing the work for which he or she is employed or similar work, as evidenced by eligibility for and actual receipt of benefits payable under a group Disability plan or policy maintained by the Company or any of its subsidiaries that is by its terms applicable to the Participant.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Employee Retirement Income Security Act of 1974, as amended and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Fair Market Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) as of any given date, the closing price at which the shares of Common Stock were traded (or if no transactions were reported on such date on the next preceding date on which transactions were reported) on the New York Stock Exchange on such date, or, if different, the principal exchange or automated quotation system on which such stock is traded, or (ii) should the Compensation Committee elect, the average closing price over a pre-established series of such trading days preceding or following such given date. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, when used with reference to any Participant, any of the following actions or failures to act, but in each case only if it occurs while such Participant is employed by the Company and then only if it is not consented to by such Participant in writing&#58;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;assignment of a position that is of a lesser rank than held by the Participant prior to the assignment and that results in a material adverse change in such Participant&#8217;s reporting position, duties or responsibilities or title or elected or appointed offices as in effect immediately prior to the effective date of such change, or in the case of a Tier 1 or Tier 2 Participant who was immediately prior to the Change in Control an executive officer of the Company, such Participant ceasing to be an executive officer of a company with securities registered under the Exchange Act&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;a material reduction in such Participant&#8217;s total compensation from that in effect immediately prior to the Change in Control. For purposes of this clause (ii), &#8220;total compensation&#8221; shall mean the sum of base salary, target bonus opportunity and the opportunity to receive compensation in the form of equity in the Company. Notwithstanding the foregoing, a reduction will not be deemed to have occurred hereunder on account of (A)&#160;any change to a plan term other than ultimate target bonus opportunity or equity opportunity, (B)&#160;the actual payout of any bonus amount or equity amount, (C)&#160;any reduction resulting from changes in the market value of securities or other instruments paid or payable to the Participant, or (D)&#160;any reduction in the total compensation of a group of similarly situated Participants that includes such Participant&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;any change in a Participant&#8217;s status as a Tier 1 Participant, Tier 2 Participant or Tier 3 Participant to a status that provides a lower benefit hereunder in the event of a Change in Control if such change in status occurs during the period beginning six (6) months prior to a Change in Control and ending twenty-four (24) months after a Change in Control&#59; or</font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;any change of more than fifty (50) miles in the location of the principal place of employment of such Participant immediately prior to the effective date of such change.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this definition, none of the actions described in clauses (i) through (iv) above shall constitute &#8220;Good Reason&#8221; if taken for Cause. Additionally, none of the actions described in clauses (i) through (iv) above shall constitute &#8220;Good Reason&#8221; with respect to any Participant if remedied by the Company within thirty (30) days after receipt of written notice thereof given by such Participant (or, if the matter is not capable of remedy within thirty (30) days, then within a reasonable period of time following such thirty (30) day period, provided that the Company has commenced such remedy within said thirty (30) day period)&#59; provided that &#8220;Good Reason&#8221; shall cease to exist for any action described in clauses (i) through (iv) above on the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) day following the later of the occurrence of such action or the Participant&#8217;s knowledge thereof, unless such Participant has given the Company written notice thereof prior to such date. Furthermore, any benefits under the Plan resulting from the occurrence described in clause (iii) above shall be based on the status of the Participant as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto as of the date of such occurrence.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a right granted pursuant to an equity compensation plan of the Company to purchase Common Stock at a specified price during specified time periods.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an employee of the Company who is included on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto, as that schedule may be amended in accordance with Section 2.01.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean this Encompass Health Corporation Change in Control Benefits Plan, as amended, restated, supplemented or modified from time to time in accordance with its terms.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Potential Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred if the event set forth in any one of the following paragraphs shall have occurred&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the Company enters into an agreement, the consummation of which would result in the occurrence of a Change in Control&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;the Company or any person, entity or &#8220;group&#8221; (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Exchange Act, but excluding, for this purpose, the Company or its subsidiaries, or any employee benefit plan of the Company or its subsidiaries which acquires beneficial ownership of voting securities of the Company) publicly announces an intention to take or to consider taking actions which, if consummated, would constitute a Change in Control&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the acquisition (other than from the Company) by any person, entity or &#8220;group&#8221; (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Exchange Act, but excluding, for this purpose, the Company or its subsidiaries, or any employee benefit plan of the Company or its subsidiaries which acquires beneficial ownership of voting securities of the Company) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifteen (15%) or more of either the then-outstanding shares of Common Stock or the combined voting power of the Company&#8217;s then-outstanding voting securities entitled to vote generally in the election of Directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;the Board adopts a resolution to the effect that a Potential Change in Control has occurred&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provided, however, that no Potential Change in Control shall be deemed pending for purposes of the Plan if such event or condition is no longer in effect or existence or is otherwise rescinded or terminated (by means of a public filing or announcement in the case of clause (ii) above).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Pro-rated Portion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a fraction (i) whose numerator is the number of months elapsed from the beginning of any not yet completed performance period applicable to any cash incentive award or plan through the effective date of termination of a Participant&#8217;s employment in the circumstances described in Section 3.01 below, and (ii) whose denominator is the total number of months in such performance period under the applicable cash incentive award or plan. For purposes of this definition, the months elapsed will include the month in which the effective date of termination occurs if such date is the 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, or a subsequent, day of that month.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Stock Appreciation Right</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">SAR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a right granted to a Participant pursuant to an equity compensation plan of the Company to receive a payment equal to the difference between the Fair Market Value of a share of Common Stock as of the date of exercise of the SAR over the grant price of the SAR. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States Securities Exchange Commission.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Securities Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Successor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a successor to all or substantially all of the business, operations or assets of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, with respect to any Participant, the termination date specified in the Termination Notice delivered by such Participant to the Company in accordance with Section 2.02 or as set forth in any Termination Notice delivered by the Company, or as applicable, the Participant&#8217;s date of death.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Termination Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean, as appropriate, written notice from (a) a Participant to the Company purporting to terminate such Participant&#8217;s employment for Good Reason in accordance with Section 2.02 or (b) the Company to any Participant purporting to terminate such Participant&#8217;s employment for Cause or Disability in accordance with Section 2.03.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Tier 1 Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each Participant designated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto as a Tier 1 Participant, as that schedule may be amended in accordance with Section 2.01.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Tier 2 Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each Participant designated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto as a Tier 2 Participant, as that schedule may be amended in accordance with Section 2.01.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Tier 3 Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean each Participant designated in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Schedule I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto as a Tier 3 Participant, as that schedule may be amended in accordance with Section 2.01.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the Plan, unless a clear contrary intention appears, (a) the words &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder&#8221; refer to the Plan as a whole and not to any particular Article, Section or other subdivision, (b) reference to any Article or Section, means such Article or Section hereof and (c) the words &#8220;including&#8221; (and with correlative meaning &#8220;include&#8221;) means including, without limiting the generality of any description preceding such term. The Article and Section headings herein are for convenience only and shall not affect the construction hereof.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE II<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ELIGIBILITY AND BENEFITS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Eligible Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;An employee of the Company shall be a &#8220;Participant&#8221; in the Plan during each calendar year (or partial calendar year) for which he or she has been designated as a Participant (and in the Tier so designated) by the Chief Executive Officer of the Company and for each succeeding calendar year he or she is employed in such position, unless the Participant is given written notice by December 31 of the preceding year of the determination of the Chief Executive Officer or the Board that such Participant shall cease to be a Participant or shall participate in a different Tier for such succeeding calendar year. Notwithstanding the foregoing, any Participant may not be removed from the Plan, nor placed in a lower tier (with Tier 1 being the highest Tier and Tier 3 being the lowest Tier), during the pendency of a Potential Change in Control or within two years following a Change in Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Plan is only for the benefit of Participants, and no other employees, personnel, consultants or independent contractors shall be eligible to participate in the Plan or to receive any rights or benefits hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Notices from Participants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of the Plan, in order for any Participant to terminate his or her employment for Good Reason, such Participant must give a Termination Notice to the Company in accordance with the requirements specified under the definition of Good Reason in Section 1.01, which notice shall be signed by such Participant, shall be dated the date it is given to the Company, shall specify the Termination Date and shall state that the termination is for Good Reason and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for such Good Reason. Any Termination Notice given by a Participant that does not comply in all material respects with the foregoing requirements as well as the &#8220;Good Reason&#8221; definition provisions set forth in Section 1.01 shall be invalid and ineffective for purposes of the Plan. If the Company receives from any Participant a Termination Notice that states the termination is for Good Reason and which the Company believes is invalid and ineffective as aforesaid, it shall promptly notify such Participant of such belief and the reasons therefor. Any termination of employment by the Participant that either does not constitute Good Reason or fails to meet the Termination Notice requirements set forth above shall be deemed a termination by the Participant without Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Notices from Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of the Plan, in order for the Company to terminate any Participant&#8217;s employment for Cause, the Company must give a Termination Notice to such Participant, which notice shall be dated the date it is given to such Participant, shall specify the Termination Date and shall state that the termination is for Cause and shall set forth in reasonable detail the particulars thereof. For purposes of the Plan, in order for the Company to terminate any Participant&#8217;s employment for Disability, the Company must give a Termination Notice to such Participant, which notice shall be dated the date it is given to such Participant, shall specify the Termination Date and shall state that the termination is for Disability and shall set forth in reasonable detail the particulars thereof. Any Termination Notice given by the Company that does not comply, in all material respects, with the foregoing requirements shall be invalid and ineffective for purposes of the Plan. Any Termination Notice purported to be given by the Company to any Participant after the death or retirement of such Participant shall be invalid and ineffective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accelerated Vesting of Pre-2015 Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With respect to Awards granted prior to January 1, 2015, upon the occurrence of a Change in Control, notwithstanding the provisions of any Benefit Plan or agreement (except as provided in this Section 2.04)&#58;</font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;each outstanding option to purchase Company Common Stock (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall become automatically vested and exercisable and</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;in the case of those Stock Options outstanding as of the Effective Date, such Stock Options shall remain exercisable by such Participant until the later of the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> day of the third month following the date at which, or December 31 of the calendar year in which, the Stock Option would have otherwise expired, but in no event beyond the original term of such Stock Option&#59; and</font></div><div style="margin-bottom:3pt;margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;in the case of all Stock Options granted to a Participant after the Effective Date, such Stock Options shall remain exercisable by such Participant for a period of (x) three years in the case of a Tier 1 Participant, (y) two years in the case of a Tier 2 Participant or (z) one year in the case of a Tier 3 Participant, beyond the date </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">at which the Stock Option would have otherwise expired, but in no event beyond the original term of such Stock Option&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the vesting restrictions based upon continued employment on all other awards relating to Common Stock (including but not limited to restricted stock, restricted stock units and SARs) held by a Participant shall immediately lapse and in the case of restricted stock units and SARs shall become immediately payable, to the extent permitted by Section 409A&#59;</font></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;the vesting restrictions based upon achievement of performance criteria on any awards related to Common Stock (including but not limited to performance shares or performance share units) held by a Participant shall deemed to have been met to the extent determined by the Compensation Committee as constituted immediately prior to the Change of Control&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event that the terms of any award under a Benefit Plan shall provide for vesting treatment of equity awards to such Participant that are more favorable than the provisions of paragraphs (a) through (c) above, the provisions of such award shall control the vesting treatment with respect to any equity awards to which such provisions are applicable. Also notwithstanding the foregoing, payments described in this Section generally shall be made immediately following the accelerated vesting date described in this Section, and in no event later than the last day of the &#8220;applicable 2&#189; month period,&#8221; as defined in Treasury Regulations Section 1.409A-1(b)(4)&#59; provided, however, that payments of amounts described in this Section that are &#8220;deferrals of compensation&#8221; subject to Section 409A may be accelerated only to the extent such acceleration does not trigger a &#8220;plan failure&#8221; pursuant to Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accelerated Vesting of Post-2014 Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;With respect to Awards granted on or after January 1, 2015, upon the occurrence of a Change in Control, notwithstanding the provisions of any Benefit Plan or agreement (except as provided in this Section 2.05)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;with respect to outstanding Options and SARs&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;If (x) the Company is the surviving entity and the Common Stock remains listed, quoted, or traded on a national securities exchange or automated quotation system or (y) the surviving entity assumes such Awards or substitutes in lieu thereof stock options or stock appreciation right relating to the stock of such surviving entity having an equivalent then-current value and remaining term, provided that such stock must be listed, quoted, or traded on a national securities exchange or automated quotation system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Substitute Options&#47;SARs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such Awards or the Substitute Options&#47;SARs, as applicable, shall be governed by their respective terms&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;If (x)(i) the Company is the surviving entity and the Common Stock remains listed, quoted, or traded on a national securities exchange or automated quotation system or (ii) the surviving entity assumes such Awards or issues Substitute Options&#47;SARs and (y) the Participant is terminated without Cause or for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Good Reason within twenty-four&#160;(24) months following the date of the Change in Control, such Awards or Substitute Options&#47;SARs, as applicable, held by the Participant that were not previously vested and exercisable shall become fully vested and exercisable effective as of the date of such termination and remain exercisable until the date that is two (2)&#160;years following the date of such termination, or the original expiration date, whichever first occurs&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;If (x)(i) the Company is not the surviving entity or (ii)&#160;the Common Stock does not remain listed, quoted, or traded on a national securities exchange or automated quotation system and (y)&#160;the surviving entity does not assume such Awards or issue Substitute Options&#47;SARs, each such Award shall become fully vested effective as of the date of the Change in Control and promptly cancelled in exchange for a cash payment in an amount equal to (A)&#160;the excess of Market Value per share of the Common Stock subject to the Award over the exercise or base price (if any) per share of Common Stock subject to such Award multiplied by (B)&#160;the number of shares of Common Stock subject to such Award&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:126pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;with respect to other outstanding Awards not subject to performance-based objectives (other than Options or SARs)(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Time-based Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;if (x) the Company is the surviving entity and the Common Stock remains listed, quoted, or traded on a national securities exchange or automated quotation system or (y) the surviving entity assumes such Awards or substitutes in lieu thereof time-based awards relating to the stock of such surviving entity having an equivalent then-current value and vesting date, provided that such stock must be listed, quoted, or traded on a national securities exchange or automated quotation system (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Substitute Time-based Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), such Awards or the Substitute Time-based Awards, as applicable, shall be governed by their respective terms&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;if (x)(i) the Company is the surviving entity and the Common Stock remains listed, quoted, or traded on a national securities exchange or automated quotation system or (ii) the surviving entity assumes the such Awards or issues Substitute Time-based Awards and the Participant is terminated without Cause or for Good Reason within twenty-four&#160;(24) months following the Change in Control, such Awards or Substitute Time-based Awards, as applicable, held by the Participant that were not previously vested shall become fully vested immediately upon such termination&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;If (x)(i) the Company is not the surviving entity or (ii)&#160;the Common Stock does not remain listed, quoted, or traded on a national securities exchange or automated quotation system and (y) the surviving entity does not assume the such Awards or issue Substitute Time-based Awards, such Awards shall become fully vested effective as of the date of the Change in Control and promptly cancelled in exchange for a cash payment of an amount equal to the Fair Market Value per share of the Common Stock </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subject to the Award immediately prior to the Change in Control multiplied by the number of shares of Common Stock subject to the Award&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;with respect to Awards subject to performance-based objectives (including but not limited to performance shares or performance share units), the vesting restrictions based upon achievement of the performance-based objectives shall deemed to have been met to the extent determined by the Compensation Committee as constituted immediately prior to the Change of Control and such achievement shall result in the deemed issuance of Time-based Awards or Substitute Time-based Awards, as applicable, with the same vesting date as provided in the original Award granted by the Company and such Awards will be subject to paragraphs (ii)(2) and (3) above, if applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Compensation Committee may, in its sole discretion, provide that&#58; (x) an Award shall, upon the occurrence of a Change in Control, be cancelled in exchange for a payment in an amount equal to (i) the Fair Market Value per share of the Common Stock subject to the Award immediately prior to the Change in Control over the exercise or base price (if any) per share of Common Stock subject to such Award multiplied by (ii) the number of shares granted under such Award&#59; and (y) each Award shall, upon the occurrence of a Change in Control, be cancelled without payment therefore if the Fair Market Value per share of the Common Stock subject to such Award immediately prior to the Change in Control is less than the exercise or purchase price (if any) per share of Common Stock subject to such Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, in the event that the terms of any award under a Benefit Plan shall provide for vesting treatment of equity awards to such Participant that are more favorable than the provisions of paragraphs (a) and (b) above, the provisions of such award shall control the vesting treatment with respect to any equity awards to which such provisions are applicable.  Also notwithstanding the foregoing, payments described in this Section generally shall be made immediately following the accelerated vesting date described in this Section, and in no event later than the last day of the &#8220;applicable 2&#189; month period,&#8221; as defined in Treasury Regulations Section 1.409A-1(b)(4)&#59; provided, however, that payments of amounts described in this Section that are &#8220;deferrals of compensation&#8221; subject to Section 409A may be accelerated only to the extent such acceleration does not trigger a &#8220;plan failure&#8221; pursuant to Section 409A.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE III</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">SEVERANCE AND RELATED TERMINATION BENEFITS</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that a Participant&#8217;s employment is terminated within twenty-four (24) months following a Change in Control or during the pendency of a Potential Change in Control provided that a related Change in Control occurs, (x) by the Participant for Good Reason (while such Good Reason exists) or (y) by the Company without Cause (other than for Disability), then in each case, such Participant (or his or her beneficiary) shall be entitled to receive, and the Company shall be obligated to pay to the Participant, subject to Sections 3.02 through 3.04 hereof&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;In the case of a Tier 1 Participant&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to 2.99 times the sum of (A) the Participant&#8217;s highest Annual Salary in the three years preceding the Termination Date plus (B) the average of the actual bonuses received by such Participant for the three (3) years preceding the Termination Date&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to (A) the Pro-rated Portion of the Participant&#8217;s target cash incentive opportunity for any not yet completed incentive performance period in which the termination occurs, plus (B) in the event of termination after a completed incentive performance period but before payment of the award earned, the amount of such cash incentive award based on actual performance&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;a lump sum payment as soon as practicable following the Termination Date in an amount equal to (A) all unused paid time off accrued by such Participant as of the Termination Date under the Company&#8217;s paid time off policy, plus (B) all accrued but unpaid compensation, excluding any nonqualified deferred compensation, earned by such Participant as of the Termination Date to be paid by the Company ((A) and (B) together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;In addition, for a period of thirty-six months following the Termination Date, such Participant and his or her dependents shall continue to be covered by all medical, dental and vision insurance plans and programs (excluding disability) maintained by the Company under which the Participant was covered immediately prior to the Termination Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Continued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) at the same cost sharing between the Company and Participant as a similarly situated active employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In the case of a Tier 2 Participant</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to two times the sum of (A) the Participant&#8217;s highest Annual Salary in the three years preceding the Termination Date plus (B) the average of the actual bonuses received by such Participant for the three (3) years preceding the Termination Date&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to (A) the Pro-rated Portion of the Participant&#8217;s target cash incentive opportunity for any not yet completed incentive performance period in which the termination occurs, plus (B) in the event of termination after a completed incentive performance period but before payment of the award earned, the amount of such cash incentive award based on actual performance&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;a lump sum payment as soon as practicable following the Termination Date in an amount equal to all Accrued Obligations as soon as practicable following the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;In addition, for a period of twenty-four months following the Termination Date, such Participant and his or her dependents shall receive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Continued Benefits at the same cost sharing between the Company and Participant as a similarly situated active employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;In the case of a Tier 3 Participant</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to the sum of (A) the Participant&#8217;s highest Annual Salary in the three years preceding the Termination Date plus (B) the average of the actual bonuses received by such Participant for the three (3) years preceding the Termination Date&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;a lump sum payment within sixty (60) days following the later of such Participant&#8217;s Termination Date or the date of the Change in Control in an amount equal to (A) the Pro-rated Portion of the Participant&#8217;s target cash incentive opportunity for any not yet completed incentive performance period in which the termination occurs, plus (B) in the event of termination after a completed incentive performance period but before payment of the award earned, the amount of such cash incentive award based on actual performance&#59; plus</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;a lump sum payment as soon as practicable following the Termination Date in an amount equal to all Accrued Obligations as soon as practicable following the Termination Date&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;In addition, for a period of twelve months following the Termination Date, such Participant and his or her dependents shall receive Continued Benefits at the same cost sharing between the Company and Participant as a similarly situated active employee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Notwithstanding anything herein to the contrary, in the event that a Participant is deemed to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code, the lump sum severance payment, together with interest at an annual rate (compounded monthly) equal to the federal short-term rate (as in effect under Section 1274(d) of the Code on the Termination Date) shall be paid, to the extent required by Section 409A, to such Participant immediately following the six-month anniversary of the Termination Date and no later than thirty (30) days following such anniversary. In any event, all Accrued Obligations shall be paid to the Participant no later than sixty (60) days following the Termination Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;The cost of the Continued Benefits paid by the Company will be imputed as wage income to the Participant to the extent required to comply with Sections 409A and 105(h) of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Golden Parachute Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Anything in the Plan to the contrary notwithstanding, in the event it shall be determined that any payment or distribution to or for the benefit of any Participant or the acceleration thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Triggering Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) would be subject to the excise tax imposed by Section 4999 of the Code or any interest or penalties with respect to such excise tax (collectively, such excise tax, together with any such interest or penalties, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (all such payments and benefits, including any cash severance payments payable pursuant to any other plan, arrangement or agreement, hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Total Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then, after taking into account any reduction in the Total Payments provided by reason of Section 280G of the Code in such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">other plan, arrangement or agreement, the cash severance payments shall first be reduced, and the noncash severance payments shall thereafter be reduced, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but only if (A) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (B) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which the Participant would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments). For purposes of determining whether a portion of the Total Payments would be subject to the Excise Tax, the value of the Participant&#8217;s non-competition covenant contained in the Release Agreement (defined below in Section 3.03) shall be determined through independent appraisal by the independent accounting firm described in subsection (b), and a corresponding portion of the amount payable pursuant to Section 3.01 shall be allocated as reasonable compensation for the Participant&#8217;s non-competition covenant and therefore exempt from the definition of the term &#8220;parachute payment&#8221; within the meaning of Sections 280G and 4999 of the Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;All determinations required to be made under this Section 3.02 with respect to a particular Participant shall be made in writing within ten (10) business days of the receipt of notice from the Participant that there has been a Triggering Payment (or at such earlier time as is requested by the Company and the Participant) by the independent accounting firm then retained by the Company in the ordinary course of business (which firm shall provide detailed supporting calculations to the Company and such Participant) and such determinations shall be final and binding on the Company (including the Compensation Committee) and all Participants. Any fees incurred as a result of work performed by any independent accounting firm pursuant to this Section 3.02 shall be paid by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Condition to Receipt of Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As a condition to receipt of any payment or benefits under this Article III, such Participant must enter into a restrictive covenant (non-solicitation, non-compete, non-disclosure, non-disparagement) and release agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Release Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) with the Company and its affiliates substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Participant must execute and deliver a Release Agreement, and such Release Agreement must become effective and irrevocable in accordance with its terms, no later than sixty (60) days following such Participant&#8217;s Termination Date. If this requirement is not satisfied, the Participant shall forfeit the right to all benefits, except for the Accrued Obligations and the Continued Benefits as provided, described in this Article III. In the event such Participant&#8217;s receipt of any or all of the payment or benefits under this Article III is subject to Section 409A and such 60-day period extends into a new calendar year, the Company shall deliver such portion of the payments and benefits to the Participant on the later of the first business day of that new year or the effective date of such Release Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Anything in the Plan to the contrary notwithstanding, the Company&#8217;s obligation to provide the Continued Benefits shall cease if and when the Participant becomes employed by a third party that provides such Participant with substantially comparable health and welfare benefits.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Any amounts payable under the Plan shall be in lieu of and not in addition to any other severance or termination payment under any other plan or agreement with the Company. Without limiting the generality of the foregoing, in the event that a Participant becomes entitled to any payment under the Plan, such Participant shall not be entitled to receive any payment under the Company&#8217;s Executive Severance Plan. As a condition to receipt of any payment under the Plan, the Participant shall waive any entitlement to any other severance or termination payment by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan Unfunded&#59; Participant&#8217;s Rights Unsecured</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall not be required to establish any special or separate fund or make any other segregation of funds or assets to assure the payment of any benefit hereunder. The right of any Participant to receive the benefits provided for herein shall be an unsecured obligation against the general assets of the Company.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IV</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DISPUTE RESOLUTION</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Claims Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;It shall not be necessary for a Participant who has become entitled to receive a benefit hereunder to file a claim for such benefit with any person as a condition precedent to receiving a distribution of such benefit. However, any Participant or beneficiary who believes that he or she has become entitled to a benefit hereunder and who has not received, or commenced receiving, a distribution of such benefit, or who believes that he or she is entitled to a benefit hereunder in excess of the benefit which he or she has received, or commenced receiving, may file a written claim for such benefit with the Compensation Committee no later than ninety (90) days following the date on which he or she allegedly became entitled to receive a distribution of such benefit. Such written claim shall set forth the Participant&#8217;s or beneficiary&#8217;s name and address and a statement of the facts and a reference to the pertinent provisions of the Plan upon which such claim is based. The Compensation Committee shall, within ninety (90) days after such written claim is filed, provide the claimant with written notice of its decision with respect to such claim. If such claim is denied in whole or in part, the Compensation Committee shall, in such written notice to the claimant, set forth in a manner calculated to be understood by the claimant the specific reason or reasons for denial&#59; specific references to pertinent provisions of the Plan upon which the denial is based&#59; a description of any additional material or information necessary for the claimant to perfect his or her claim and an explanation of why such material or information is necessary&#59; and an explanation of the provisions for review of claims set forth in Section 4.01(b) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;A Participant or beneficiary who has filed a written claim for benefits with the Compensation Committee which has been denied may appeal such denial to the Compensation Committee and receive a full and fair review of his or her claim by filing with the Compensation Committee a written application for review at any time within sixty (60) days after receipt from the Compensation Committee of the written notice of denial of his or her claim provided for in Section&#160;4.01(a) above. A Participant or beneficiary who submits a timely written application for review shall be entitled to review any and all documents pertinent to his or her claim and may submit issues and comments to the Compensation Committee in writing. Not later than sixty (60) days after receipt of a written application for review, the Compensation Committee shall give the claimant written notice of its decision on review, which written notice shall set forth in a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">manner calculated to be understood by the claimant specific reasons for its decision and specific references to the pertinent provisions of the Plan upon which the decision is based. In the event the claimant disputes the decision of the Compensation Committee, the claimant may not bring suit in court with respect to such dispute under the Plan later than one hundred eighty (180) days after receiving the Compensation Committee&#8217;s written notice of its decision.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Any act permitted or required to be taken by a Participant or beneficiary under this Section 4.01 may be taken for and on behalf of such Participant or beneficiary by such Participant&#8217;s or beneficiary&#8217;s duly authorized representative. Any claim, notice, application or other writing permitted or required to be filed with or given to a party by this Article shall be deemed to have been filed or given when deposited in the U.S. mail, postage prepaid, and properly addressed to the party to whom it is to be given or with whom it is to be filed. Any such claim, notice, application, or other writing deemed filed or given pursuant to the next foregoing sentence shall in the absence of clear and convincing evidence to the contrary, be deemed to have been received on the fifth (5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) business day following the date upon which it was filed or given. Any such notice, application, or other writing directed to a Participant or beneficiary shall be deemed properly addressed if directed to the address set forth in the written claim filed by such Participant or beneficiary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE V<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Miscellaneous Provisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.01&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cumulative Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as provided in Section 3.04, the rights and benefits provided to any Participant under the Plan are in addition to and shall not be a replacement of, all of the other rights and benefits provided to such Participant under any Benefit Plan or any agreement between such Participant and the Company except for any severance or termination benefits.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.02&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Mitigation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. No Participant shall be required to mitigate the amount of any payment provided for in the Plan by seeking or accepting other employment following a termination of his or her employment with the Company or otherwise. Except as otherwise provided in Section 3.04, the amount of any payment provided for in the Plan shall not be reduced by any compensation or benefit earned by a Participant as the result of employment by another employer or by retirement benefits. The Company&#8217;s obligations to make payments to any Participant required under the Plan shall not be affected by any set off, counterclaim, recoupment, defense or other claim, right or action that the Company may have against such Participant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.03&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Board may amend or terminate the Plan at any time&#59; provided, however, that the Plan may not be amended or terminated during the pendency of a Potential Change in Control or within two (2) years following a Change in Control. Notwithstanding the foregoing, nothing herein shall abridge the authority of the Compensation Committee to designate a new Participant or a new participation Tier for a current Participant or to determine that a Participant shall no longer be entitled to participate in the Plan in accordance with Section 2.01(a) hereof. The Plan shall terminate when all of the obligations to Participants hereunder have been satisfied in full.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">To the extent payments and benefits under the Plan remain subject to Section 409A, payments and benefits under the Plan are intended to comply with Section 409A, and all provisions of the Plan and Notice of Participation shall be interpreted in accordance with Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the adoption or amendment of the Plan (and including the Proposed Treasury Regulations issued June 22, 2016, to the extent the application of such proposed regulations facilitates the administration of this Plan in accordance with the intentions set forth in this paragraph). The Plan shall be interpreted and administered, to the extent possible, in accordance with these intentions. Notwithstanding any provision of the Plan to the contrary, in the event that the Board determines that any payments or benefits may or do not comply with Section 409A, the Board may adopt such amendments to the Plan (without Participant consent) or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, that the Board determines are necessary or appropriate to (i) exempt the Plan and any payments or benefits thereunder from the application of Section 409A, or (ii) comply with the requirements of Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.04&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The failure of Participants or the Company to insist upon strict adherence to any term of the Plan on any occasion shall not be considered a waiver of such party&#8217;s rights or deprive such party of the right thereafter to insist upon strict adherence to that term or any other term of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.05&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Compensation Committee shall have full and final authority, subject to the express provisions of the Plan, with respect to designation of Participants and administration of the Plan, including but not limited to, the authority to construe and interpret any provisions of the Plan and to take all other actions deemed necessary or advisable for the proper administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The Company shall indemnify and hold harmless each member of the Compensation Committee and any other employee of the Company that acts at the direction of the Compensation Committee against any and all expenses and liabilities arising out of his or her administrative functions or fiduciary responsibilities, including any expenses and liabilities that are caused by or result from an act or omission constituting the negligence of such member in the performance of such functions or responsibilities, but excluding expenses and liabilities that are caused by or result from such member&#8217;s or employee&#8217;s own gross negligence or willful cause. Expenses against which such member or employee shall be indemnified hereunder shall include, without limitation, the amounts of any settlement or judgment, costs, counsel fees, and related charges reasonably incurred in connection with a claim asserted or a proceeding brought or settlement thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.06&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidations, Mergers, Etc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of a merger, consolidation or other transaction, nothing herein shall relieve the Company from any of the obligations set forth in the Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that nothing in this Section 5.06 shall prevent an acquirer of or Successor to the Company from assuming the obligations, or any portion thereof, of the Company hereunder pursuant to the terms of the Plan provided that such acquirer or Successor provides adequate assurances of its ability to meet this obligation. In the event that an acquirer of or Successor to the Company agrees to perform the Company&#8217;s obligations, or any portion thereof, hereunder, the Company shall require any person, firm or entity which becomes its Successor to expressly assume and agree to perform such obligations in writing, in the same manner and to the same </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent that the Company would be required to perform hereunder if no such succession had taken place.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.07&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan shall be binding upon and inure to the benefit of the Company and its Successors and assigns. The Plan and all rights of each Participant shall inure to the benefit of and be enforceable by such Participant and his or her personal or legal representatives, executors, administrators, heirs and permitted assigns. If any Participant should die while any amounts are due and payable to such Participant hereunder, all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of the Plan to such Participant&#8217;s devisees, legatees or other designees or, if there be no such devisees, legatees or other designees, to such Participant&#8217;s estate. In the event of the death of any Participant during the applicable period of eligibility for the Continued Benefits set forth in Section 3.01, dependents of such Participant shall be eligible during such period to continue participation in any Continued Benefits in which the Participant was enrolled at the time of death. No payments, benefits or rights arising under the Plan may be assigned or pledged by any Participant, except under the laws of descent and distribution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.08&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. All notices and other communications provided for in the Plan shall be in writing and shall be sent, delivered or mailed, addressed as follows&#58; (a) if to the Company, at the Company&#8217;s principal office address or such other address as the Company may have designated by written notice to all Participants for purposes hereof, directed to the attention of the General Counsel, and (b) if to any Participant, at his or her residence address on the records of the Company or to such other address as he or she may have designated to the Company in writing for purposes hereof. Each such notice or other communication shall be deemed to have been duly given or mailed by United States certified or registered mail, return receipt requested, postage prepaid, except that any change of notice address shall be effective only upon receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.09&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall have the right to deduct from any payment hereunder all taxes (federal, state or other) which it is required to be withhold therefrom.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Employment Rights Conferred</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan shall not be deemed to create a contract of employment between any Participant and the Company and&#47;or its affiliates. Nothing contained in the Plan shall (i) confer upon any Participant any right with respect to continuation of employment with the Company or (ii) subject to the rights and benefits of any Participant hereunder, interfere in any way with the right of the Company to terminate such Participant&#8217;s employment at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan contains the entire understanding of the Participants and the Company with respect to Change in Control severance arrangements maintained on behalf of the Participants by the Company. There are no restrictions, agreements, promises, warranties, covenants or undertakings between the Participants and the Company with respect to the subject matter herein other than those expressly set forth herein. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan supersedes all prior agreements, programs and understandings (including verbal agreements and understandings) between the Participants and the Company regarding the terms and conditions of Participant&#8217;s severance arrangements in the event of a Change in Control.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If any provision of the Plan is, becomes or is deemed to be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions of the Plan shall not be affected thereby.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Plan shall be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to its conflict of laws rules, and applicable federal law.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Remainder of the Page Intentionally Left Blank&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">SCHEDULE I</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Tier 1 Participants</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div style="padding-right:-13.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Douglas E. Cotharp, Executive Vice President and Chief Financial Officer &#91;grandfathered&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Patrick Darby, Executive Vice President, General Counsel and Secretary &#91;grandfathered&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Tier 2 Participants</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive Vice Presidents and equivalent offices, including Chief Financial Officer and General Counsel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Regional Presidents</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Accounting Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Human Resources Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Information Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Medical Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Treasurer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Tier 3 Participants</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Strategy &#38; Development Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Compliance Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Investor Relations Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Deputy General Counsel</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SVP, Financial Operations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SVP, Public Policy, Legislation &#38; Regulations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SVP, Reimbursement</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit A</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:25.2pt;padding-right:-13.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RESTRICTED COVENANT AND RELEASE AGREEMENT<br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Release Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is entered into between __________________________ (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and Encompass Health Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), pursuant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to the terms and conditions of the Encompass Health Corporation Fifth Amended and Restated Change in Control Benefits Plan, which is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WITNESSETH</font></div><div style="margin-top:12pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive is employed by the Company as ____________________ and is a &#8220;Participant&#8221; in the Plan (as such term is defined in the Plan)&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive&#8217;s last day of employment with the Company will be ______________ ___, _____, and such date shall be the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; for purposes of this Agreement and the Plan&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive is eligible to receive benefits under Section 3.01 of the Plan, subject to the terms and conditions of the Plan, including, but not limited to, Executive&#8217;s execution and delivery to the Company of this Agreement and it becoming effective&#59;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive has agreed to comply with, among other things, certain confidentiality, noncompetition and nonsolicitation provisions, which are provided below, and such provisions shall be fully enforceable by the Company&#59; and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Executive and the Company wish to settle, fully and finally, all matters between them under the terms and conditions exclusively set forth in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is mutually acknowledged, the Company and Executive agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Benefits under the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Provided that this Agreement becomes effective pursuant to Paragraph 4 of this Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The Company shall pay the amount listed on Line&#160;1 of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto, subject to all applicable federal, state and local withholdings, in accordance with the terms and conditions of the Plan, paid out in a lump sum within sixty (60) days of the Termination Date. In the event any of such payment is subject to Section 409A and such 60-day period extends into a new calendar year, the Company shall deliver such payment to the Participant on the later of the first business day of that new year or the effective date of this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Executive will continue to be eligible to participate in the Company sponsored group healthcare benefits, (excluding disability insurance but specifically including medical, dental and vision plans), under which the Executive was covered immediately prior to the Termination Date, for the number of months listed on Line 2 of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:1.69pt;vertical-align:baseline">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> after the Termination Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), provided that Executive continues to contribute toward the premiums at the level of an active employee of the Company. Thereafter, Executive&#8217;s right to continue coverage under the Company sponsored group healthcare plan at Executive&#8217;s own expense, pursuant to the statutory scheme commonly known as &#8220;COBRA,&#8221; shall be governed by applicable law and the terms of the plans and programs, and will be explained to Executive in a packet to be sent to Executive under separate cover.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Executive acknowledges and agrees that the severance payments and benefits provided in subsection (a) and (b) of Section 1 are subject to forfeiture and repayment and any awards relating to Common Stock shall be cancellable and&#47;or forfeitable in the event of a material violation by Executive of Sections 6, 7, and&#47;or 8 of this Agreement</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Executive, on behalf of Executive, Executive&#8217;s heirs, executors, administrators, successors and assigns, hereby irrevocably and unconditionally releases the Company and its subsidiaries, divisions and affiliates, together with their respective owners, assigns, agents, directors, partners, officers, trustees, members, managers, employees, insurers, employee benefit programs (including, but not limited to, trustees, administrators, fiduciaries, and insurers of such programs), attorneys and representatives and any of their predecessors and successors and each of their estates, heirs and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Releases</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from any and all charges, complaints, claims, liabilities, obligations, promises, agreements, causes of action, rights, costs, losses, debts and expenses of any nature whatsoever, known or unknown, which Executive or Executive&#8217;s heirs, executors, administrators, successors or assigns ever had, now have or hereafter can, will or may have (either directly, indirectly, derivatively or in any other representative capacity) by reason of any matter, fact or cause whatsoever against the Company or any of the other Company Releases from the beginning of time to the date upon which Executive signs this Agreement, including, but not limited to, any claims arising out of or relating to Executive&#8217;s employment with the Company and&#47;or termination of employment from the Company. This release includes, without limitation, all claims arising out of, or relating to, Executive&#8217;s employment with the Company and the termination of Executive&#8217;s employment with the Company, including all claims for severance or termination benefits under Executive&#8217;s employment agreement with the Company, if any, and under any plan, policy or agreement (other than those benefits expressly payable hereunder) and all claims arising under any foreign, federal, state and local labor, laws including, without limitation, the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the Employee Retirement Income Security Act of 1974, the Americans with Disabilities Act, Title VII of the Civil Rights Act of 1964, the Family and Medical Leave Act, the Civil Rights Act of 1991, the Fair Labor Standards Act, the Equal Pay Act, the Immigration and Reform Control Act, the Uniform Services Employment and Re-Employment Act, the Rehabilitation Act of 1973, Sarbanes-Oxley Act, Executive Order 11246, the Lilly Ledbetter Fair Pay Act, the False Claims Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Alabama Age Discrimination Statute and the Workers&#8217; Adjustment and Retraining Notification Act (and any similar state or local law), each as amended.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Nothing in this Paragraph 2 shall be deemed to release (i)&#160;Executive&#8217;s right to enforce the terms of this Agreement&#59; (ii) Executive&#8217;s rights, if any, to any vested benefits or options under any incentive, bonus, or other benefit plan maintained by the Company&#59; (iii) any right to indemnification under the Company&#8217;s Restated Certificate of Incorporation or its Amended and Restated By Laws&#59; or (iv) any claim that cannot be waived under applicable law. Nothing in this Agreement prevents Executive from initiating a complaint with or participating in any legally authorized investigation or proceeding conducted by the Equal Employment Opportunity Commission or any federal, state, or local law enforcement agency. Notwithstanding the foregoing, Executive agrees that Executive is waiving all rights to damages and all other forms of recovery arising out of any charge, complaint or lawsuit filed on behalf of Executive or any third party as to all claims waived in this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Executive acknowledges and agrees that the Company has fully satisfied any and all obligations owed to Executive arising out of Executive&#8217;s employment with the Company, and no further sums are owed to Executive by the Company or by any of the other Company Releases at any time. Executive further acknowledges and agrees that the Company has paid Executive for all earned wages and accrued but unused paid time off through the Termination Date. By entering into this Agreement, Executive explicitly waives any rights to severance or other post-termination benefits under any oral or written plan, policy, employment agreement, contract or arrangement with the Company, other than as provided in this Agreement. Executive acknowledges and agrees that, in the absence of this Agreement, the Company has no obligation to provide any of the consideration set forth in Paragraph 1 of this Agreement. Executive further acknowledges and agrees that Executive has no rights to any unvested benefits or options under any incentive, bonus or other benefit plan, except as otherwise provided in the Plan&#59; and that all such vesting shall cease as of the Termination Date. Executive further acknowledges and agrees that any right to continue to contribute to the Company&#8217;s 401(k) plan for employees ended on the Termination Date. Furthermore, Executive acknowledges and agrees that the payments and benefits provided under Paragraph 1 of this Agreement shall not be included in any computation of earnings under the Company&#8217;s 401(k) plan or any other plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Executive represents that Executive has no lawsuits pending against the Company or any of the other Company Releases. Executive further covenants and agrees that neither Executive nor Executive&#8217;s heirs, executors, administrators, successors or assigns will be entitled to any personal recovery in any(e)&#160;&#160;&#160;&#160; proceeding of any nature whatsoever against the Company or any of the other Company Releases arising out of any of the matters released in Paragraph 2.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consultation with Attorney&#47;Voluntary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive acknowledges that (a) the Company is hereby advising Executive of Executive&#8217;s right to consult with an attorney of Executive&#8217;s own choosing prior to executing this Agreement, (b) Executive has carefully read and fully understands all of the provisions of this Agreement, and (c) Executive is entering into this Agreement, including the releases set forth in Paragraph 2 above, knowingly, freely and voluntarily in exchange for good and valuable consideration, including the obligations of the Company under this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Consideration &#38; Revocation Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Executive acknowledges that Executive has been given at least twenty-one (21) calendar days following receipt of this Agreement to consider the terms of this Agreement, although Executive may execute it sooner.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Executive will have seven (7) calendar days from the date on which Executive signs this Agreement to revoke Executive&#8217;s consent to the terms of this Agreement. Such revocation must be in writing and must be addressed and sent via facsimile as follows&#58; Encompass Health Corporation, Attention&#58; General Counsel, facsimile&#58; (205) 262-8692. Notice of such revocation must be received within the seven (7) calendar days referenced above. In the event of such revocation by Executive, this Agreement shall not become effective and Executive shall not have any rights under this Agreement or the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Provided that Executive does not revoke this Agreement, this Agreement shall become effective on the eighth calendar day after the date on which Executive signs this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acknowledgements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Executive acknowledges and agrees that&#58; (i) the &#8220;Company Business&#8221; (as defined in Paragraph 9(a) below) is intensely competitive and that Executive&#8217;s employment by the Company required Executive to have access to, and knowledge of, &#8220;Confidential Information&#8221; (as defined in Paragraph 9(b) below)&#59; (ii) the use or disclosure of any Confidential Information could place the Company at a serious competitive disadvantage and could do serious damage, financial and otherwise, to the Company&#59; (iii) Executive was given access to, and developed relationships with, employees, clients, patients, physicians and partners of the Company at the time and expense of the Company&#59; and (iv) by Executive&#8217;s training, experience and expertise, Executive&#8217;s services to the Company were extraordinary, special and unique, and the Company invested in training and enhancing Executive&#8217;s skill and experience in the Company Business.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Executive further acknowledges and agrees that (i) Executive&#8217;s experience and capabilities are such that the provisions contained in Paragraphs 6, 7, and 8 will not prevent Executive from earning a livelihood&#59; (ii) the Company would be seriously and irreparably injured if Executive were to engage in &#8220;Competitive Activities&#8221; (as defined below), or to otherwise breach the obligations contained in Paragraphs 6, 7 and 8, no adequate remedy at-law would exist and damages would be difficult to determine&#59; (iii) the provisions contained in Paragraphs 6, 7 and 8 are justified by and reasonably necessary to protect the legitimate business interests of the Company, including the Confidential Information and good will of the Company&#59; and (iv) the provisions in Paragraphs 6, 7 and 8 are fair and reasonable in scope, duration and geographical limitations. Accordingly, Executive agrees to be bound fully by the restrictive covenants in this Agreement to the maximum extent permitted by law, it being the intent and spirit of the parties that the restrictive covenants and the other agreements contained herein shall be valid and enforceable in all respects.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Executive acknowledges and agrees that, from and after the Termination Date, and at all times thereafter, Executive will not communicate, divulge or disclose to any &#8220;Person&#8221; (as defined in Paragraph 9(c) below) or use for Executive&#8217;s own benefit or purpose any Confidential Information of the Company, except as required by law or court order or expressly authorized in writing by the Company&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that Executive shall promptly notify the Company prior to making any disclosure required by law or court order so that the Company may seek a protective order or other appropriate remedy.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Covenant Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">From the Termination Date through the end of the Severance Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Noncompetition Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), Executive shall not, directly or indirectly, participate in the management, operation or control of, or have any financial or ownership interest in, or aid or knowingly assist anyone else in the conduct of, any business or entity that (i) engages in the Company Business in any Restricted Territory (as defined in Paragraph 9(d) below), or (ii) is, to Executive&#8217;s knowledge, making preparations for engaging in the Company Business in any Restricted Territory (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitive Activity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; provided, however, that (x) the &#8220;beneficial ownership&#8221; by Executive, either individually or as a member of a &#8220;group&#8221; (as such terms are used in Rule 13d of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended), of not more than one percent (1%) of the voting stock of any publicly held corporation shall not alone constitute a breach of this Paragraph 7 and (y) Executive may enter into, at arm&#8217;s length, any bona fide joint venture (or partnership or other business arrangement) with any Person who is not directly engaged in the Company Business but which is an affiliate of another Person engaged in the Company Business.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;padding-left:64.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employee Nonsolicitation&#59; Nondisparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Executive shall not, directly or indirectly, within the Noncompetition Period, without the prior written consent of the Company, solicit or direct any other Person to solicit any officer or other employee of the Company to&#58; (i) terminate such officer&#8217;s or employee&#8217;s employment with the Company&#59; or (ii) seek or accept employment or other affiliation with Executive or any Person engaged in any Competitive Activity in which Executive is directly or indirectly involved (other than, in each case, any solicitation directed at the public in general in publications available to the public in general or any contact which Executive can demonstrate was initiated by such officer, director or employee or any contact after such officer&#8217;s or employee&#8217;s employment with the Company is terminated). Executive&#8217;s obligations. under this Paragraph 8(a) with respect to new Company employees hired after the Termination Date shall be subject to the condition that Executive shall have been notified of such new employees.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Executive shall not, directly or indirectly, within the Noncompetition Period, without the prior written consent of the Company, solicit or direct any other Person to solicit any Person or entity in a business relationship with the Company (whether an independent contractor, joint venture partner or otherwise) to terminated such Person or entity&#8217;s business relationship with the Company.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Executive shall not, directly or indirectly, within the Noncompetition Period, make any statements or comments of a defamatory or disparaging nature to third parties regarding the Company or any of their members, principals, officers, managers, directors, personnel, employees, agents, services or products&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that nothing contained in this Paragraph 8(b) shall preclude Executive from providing truthful testimony in response to a valid subpoena, court order, regulatory request or as may be required by law.</font></div><div style="margin-top:12pt;padding-left:64.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;For the purposes of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the business of owning, operating or managing inpatient rehabilitation facilities offering a range of rehabilitative health care services, and services directly ancillary thereto for which the Company receives compensation.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; includes, but is not limited to, certain or all of the Company&#8217;s and its patients&#8217;, physicians&#8217; and third-party managed care providers&#8217; supply agreement arrangements, regulatory packages, registration packages, data compensation packages, methods, information, systems, plans for acquisition or disposition of products, expansion plans, financial status and plans, customer lists, client data, personnel information, consulting reports, investigative reports, Personal Health Information (PHI), strategic plans and trade secrets.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;For the purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean an individual, corporation, joint venture, partnership, limited liability company, association, joint stock or other company, business trust, trust or other entity or organization, including any national, federal, state, territorial agency, local or foreign judicial, legislative, executive, regulatory or administrative authority, commission, court, tribunal, any political or other subdivision, department or branch of any of the foregoing, and any self regulatory organization or arbitrator.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:97.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;For the purposes of this Agreement, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the area within seventy-five (75) miles of any location where an inpatient rehabilitation facility, which is owned or operated by the Company, is located as of the Termination Date.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that Executive accepts employment with another party at any time during the Severance Period, Executive shall inform the Company in writing on or before the commencement date of such employment and provide the Company with such other information relating to available health and welfare benefits as a result of said employment as required by Section 3.03(a) of the Plan. </font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Duty to Inform</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive shall inform in writing any Person, who seeks to employ or engage Executive in any capacity, of Executive&#8217;s obligations under Paragraphs 6, 7 and 8 of this Agreement, prior to accepting such employment or engagement. </font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive represents that Executive has returned to the Company all property of the Company. Such property includes, but is not limited to, laptop computers, BlackBerry, printers, other computer equipment (including computers, printers and equipment paid-for by the Company for use at Executive&#8217;s residence), cellular phones and pagers, keys, security passes, passwords, work files, records, credit cards, building ID&#8217;s and all other Company property in Executive&#8217;s possession on the last day of Executive&#8217;s employment with the Company. Following the Termination Date, the Company shall also have no obligation to continue to make payments under any car loan or corporate membership provided to Executive as an employee of the Company.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Admission of Wrongdoing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Nothing herein is to be deemed to constitute an admission of wrongdoing by the Company or any of the other Company Releases.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement is binding on, and will inure to the benefit of, the Company and the other Company Releases. All rights of Executive under this Agreement shall inure to the benefit of, and be enforceable by, Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributes, devisees and legatees.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive agrees that the Company would suffer irreparable harm if Executive were to breach, or threaten to breach, any provision of this <br>Agreement and that the Company would by reason of such breach, or threatened breach, be entitled to injunctive relief in a court of appropriate jurisdiction, without the need to post any bond, and Executive further consents and stipulates to the entry of such injunctive relief in such a court prohibiting Executive from breaching this Agreement. This Paragraph 15 shall not, however, diminish the right of the Company to claim and recover damages and other appropriate relief, including but not limited to repayment of any severance payments or benefits provided to Executive, in addition to injunctive relief.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that any one or more</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:1.69pt;vertical-align:baseline">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. Moreover, if any one or more of the provisions contained in this Agreement shall be held to be excessively broad as to duration, activity or subject, such provisions shall be construed by limiting and reducing them so as to be enforceable to the maximum extent allowed by applicable law. Furthermore, a determination in any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">jurisdiction that this Agreement, in whole or in part, is invalid, illegal or unenforceable shall not in any way affect or impair the validity, legality or enforceability of this Agreement in any other jurisdiction.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The failure of either party to this Agreement to enforce any of its terms, provisions or covenants shall not be construed as a waiver of the same or of the right of such party to enforce the same. Waiver by either party hereto of any breach or default by the other party of any term or provision of this Agreement shall not operate as a waiver of any other breach or default.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Oral Modifications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may not be changed orally, but may be changed only in a writing signed by Executive and a duly authorized representative of the Company.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law&#59; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, without regard to the application of any choice-of-law rules that would result in the application of another state&#8217;s laws. With respect to any action, suit or proceeding, each party irrevocably (i) submits to the jurisdiction of the courts of the State of Delaware and the United States District Court of the District of Delaware, and (ii) waives any objection which it may have at any time to the laying of venue of any proceeding brought in any such court, waives any claim that such proceedings have been brought in an inconvenient forum and further waives the right to object, with respect to such proceedings, that such court does not have jurisdiction over such party.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> This Agreement sets forth the entire understanding between Executive and the Company, and supersedes all prior agreements, representations, discussions, and understandings concerning their subject matter. Executive represents that, in executing this Agreement, Executive has not relied upon any representation or statement made by the Company or any other Company Releases, other <br>than those set forth herein, with regard to the subject matter, basis or effect of this Agreement or otherwise.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Descriptive Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The paragraph headings contained herein are for reference purposes only and will not in any way affect the meaning or interpretation of this Agreement.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement may be executed simultaneously in counterparts, each of which shall be an original, but all of which shall constitute but one and the same agreement.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, Executive and the Company have executed this Agreement on the date indicated below.</font></div><div style="text-align:justify;text-indent:75.6pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-right:-36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;ENCOMPASS HEALTH CORPORATION</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXECUTIVE</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline"><br>&#91;EXHIBIT A to the Form of Restricted Covenant and Release Agreement&#93;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;INSERT PLAN&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">EXHIBIT B</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Amount Payable&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">$&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Months&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">31</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8 2
<SEQUENCE>3
<FILENAME>ehc10k123122ex1082.htm
<DESCRIPTION>EX-10.8 2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6347ad2c798546da8a050400298f21f2_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exhibit 10.8.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FIRST AMENDMENT </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ENCOMPASS HEALTH CORPORATION NONQUALIFIED 401(k) PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(as Amended and Restated Effective January 2, 2018)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, Encompass Health Corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) established the Encompass Health Corporation Nonqualified 401(k) Plan, which was most recently amended and restated effective January 2, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, pursuant to Section 10.1 of the Plan, the Company has the authority to amend the Plan, by action of the Compensation Committee of the Board of Directors&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company&#8217;s Board of Directors appointed the Encompass Health Corporation Retirement Plan Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Retirement Plan Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and delegated to the Retirement Plan Committee the authority to adopt Plan amendments on behalf of the Company, to the extent such amendments are necessary to comply with applicable laws, rules, or regulations or do not materially increase the cost to the Company of maintaining the Plan&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the Company wishes to amend the Plan to rename the Plan as the Encompass Health Corporation Nonqualified Retirement Plan, reflect the amendment authority given to the Retirement Plan Committee by the Company&#8217;s Board of Directors, and make other clarifying changes&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, the amendments may be adopted by the Retirement Plan Committee because they do not materially increase the cost to the Company of maintaining the Plan, and the Retirement Plan Committee has considered the amendment and approved it.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, the Plan is hereby amended as follows effective January 1, 2021 except as otherwise noted&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Effective January 1, 2023, the cover page, preamble, and Section 2.1(aa) are amended to change the name of the Plan to the Encompass Health Corporation Nonqualified Retirement Plan, and all references in the Plan to the &#8220;Encompass Health Corporation Retirement Investment Plan&#8221; are changed to the &#8220;Encompass Health Corporation 401(k) Retirement Plan.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The first paragraph of Section 2.1(h) (Compensation) is clarified by replacing &#8220;Compensation excludes&#8221; at the conclusion of such paragraph with &#8220;Compensation includes,&#8221; and by adding the following new paragraph at the conclusion thereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Amounts paid after termination of employment will be included in a Participant&#8217;s Compensation only if the Participant terminates employment after the date the applicable payroll is processed and the amount is otherwise included in Compensation for purposes of the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section 2.1(o) (Eligible Employee) is clarified by adding the following sentence at the conclusion thereof&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, an Employee is not eligible for this Plan for any Plan Year unless the Company notifies the Employee that he or she is eligible for that Plan Year.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section 2.1(u)(ii), relating to service by licensed professionals, is deleted in its entirety.   </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section 2.1(x) (Leased Employee) is clarified by replacing &#8220;Period of Service&#8221; with &#8220;period of service.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section 2.1(gg) (Termination of Employment) is clarified by adding the following sentence at the conclusion thereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, an Employee will be deemed to terminate employment if and only if he or she experiences a &#8220;Separation from Service&#8221; from the Employer and its Affiliates, as such term is defined in section 409A of the Code.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">The table in Section 4.3(b) is clarified to read as follows&#58;</font></div><div style="padding-left:113.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.076%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Years of Vesting Service</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:6pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Percentage Vested</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fewer than 3 years</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:6pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">0%</font></td></tr><tr><td colspan="3" style="border-bottom:6pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3 or more years</font></td><td colspan="3" style="border-bottom:6pt solid #000000;border-left:0.5pt solid #000000;border-right:6pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">100%</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Section Article VIII is clarified by removing Sections 8.2 8.3, 8.4 and 8.6, re-designating Section 8.5 as Section 8.2, and modifying Section 8.1 to read as follows&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.1&#160;&#160;&#160;&#160;Retirement Plan Committee </font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Responsibility for administration of this Plan will be with the Retirement Plan Committee, which will be the named Plan Administrator.  The Compensation Committee or the Retirement Plan Committee may appoint a Daily Administrator to administer the Plan on a daily basis.  The Compensation Committee or the Retirement Plan Committee may remove the Daily Administrator with or without cause at any time.  The specific powers and duties of the Retirement Plan Committee and the Daily Administrator may be set forth in a separate charter.  All decisions made by the Retirement Plan Committee, the Daily Administrator, or their respective delegates on any matter within their discretion shall be final, binding, and conclusive upon all Participants and Beneficiaries, and shall be given the maximum possible deference allowed by law.</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9pt">Effective March 1, 2020, a new subsection (d) is added to the end of Section 8.2 (Section 8.5 before this amendment) that reads as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Notwithstanding any Plan provision to the contrary, the period between March 1, 2020 and sixty days after the announced end of the COVID-19 National Emergency (or such other day announced by government agencies) shall be disregarded for up to one year for purposes of determining the deadline for a Participant or Beneficiary to bring a claim or appeal for benefits under the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">Effective February 20, 2020, Section 10.1 is amended to read as follows, to conform the Plan to resolutions approved by the Company&#8217;s Board of Directors on February 20, 2020&#58;</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.1&#160;&#160;&#160;&#160;Amendment</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Compensation Committee may, by resolution, in its absolute discretion, from time to time, amend, any or all of the provisions of the Plan.  In addition, the Retirement Plan Committee may adopt amendments to the Plan, but only to the extent such amendments (i) are necessary to comply with applicable laws, rules or regulations, (ii) do not materially increase the cost to the Company of maintaining the Plan, or (iii) are directed by the Company. No such amendment may adversely impact the amount of benefits a Participant has accrued under the Plan at such time except to the extent required by applicable law.</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3pt">In all other respects, the Plan shall remain unchanged.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXECUTED this 31st day of December, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ENCOMPASS HEALTH CORPORATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; Stephen D. Leasure&#160;&#160;&#160;&#160;</font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;&#160;&#160;Stephen D. Leasure</font></div><div style="padding-left:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Its&#58;&#160;&#160;&#160;&#160;Authorized Signatory</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;First Amendment to the Encompass Health Corporation Nonqualified 401(k) Plan&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ehc10k123122ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie327121314244cfcbe4fa6b4666f940d_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">Exhibit 21.1</font></div><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div><div style="margin-bottom:0.08pt;text-align:right"><font><br></font></div><div style="margin-bottom:0.08pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.222%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Subsidiary Name</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Jurisdiction of Incorporation</font></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DBA</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Advanced Homecare Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AnMed Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">SC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AnMed Health Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Central Arkansas Rehabilitation Associates, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CHI St. Vincent Hot Springs Rehabilitation Hospital, a partner of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CHI St. Vincent Sherwood Rehabilitation Hospital, a partner of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Central Louisiana Rehab Associates, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Alexandria</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CMS Development and Management Company, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CMS Rehab of WF, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Wichita Falls</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Continental Medical Systems, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Continental Rehabilitation Hospital of Arizona, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Acquisition Holdings Subsidiary, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Acquisition Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Alabama Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Alexandria Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Altoona Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Arizona Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Arkansas Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Boise Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Bryan Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health California Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Cape Coral Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Central Arkansas Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Charleston Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Dayton Holdings, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Deaconess Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Deaconess Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">IN</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Deaconess Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Fairlawn Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Fayetteville Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Grand Forks Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Gulfport Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Illinois Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Iowa City Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Johnson City Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Joint Ventures Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Jonesboro Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Kansas Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Kentucky Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Kingsport Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Littleton Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Louisiana Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Lubbock Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Martin County Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Maryland Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Massachusetts Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Methodist Rehabilitation Hospital, LP</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">TN</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Memphis, a partner of Methodist Healthcare</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of North Memphis, a partner of Methodist Healthcare</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Midland Odessa Holdings, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Moline Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Myrtle Beach Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Nevada Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health New Mexico Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Ohio Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Oregon Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Owned Hospitals Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Pennsylvania Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Properties, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Abilene, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Abilene</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Albuquerque, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Albuquerque</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Altamonte Springs, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Altamonte Springs</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Altoona, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Altoona</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Center - Bedford</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Center - Meadowbrook Plaza</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Center - Regency Square</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Center - Tyrone</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Arlington, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Arlington</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Austin, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Austin</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Bakersfield, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Bakersfield</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Bluffton, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Bluffton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Braintree, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Braintree</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Braintree at Framingham</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Braintree at Taunton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Braintree Pediatric Center</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cape Coral, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cape Coral</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cardinal Hill, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cardinal Hill Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cardinal Hill Skilled Rehabilitation Unit</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Charleston, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">SC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MUSC Health Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cincinnati, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cincinnati</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cincinnati at Norwood</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of City View, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of City View</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Colorado Springs, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Colorado Springs</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Columbia, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Columbia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Concord, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Concord</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cumming, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cumming</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cypress, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Cypress</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Dallas, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Dallas</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Dayton, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Rehabilitation Institute of Ohio, a Joint Venture between Premier Health and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Desert Canyon, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Desert Canyon</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Dothan, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Dothan</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of East Valley, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of East Valley</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Erie, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Erie</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Florence, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">SC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Florence</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Fort Smith, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Fort Smith</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Franklin, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Franklin</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Fredericksburg, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Fredericksburg</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Gadsden, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Gadsden</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Greenville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Greenville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Gulfport, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital, a partner of Memorial Hospital at Gulfport</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Harmarville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Harmarville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Henderson, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Henderson</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Humble, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Humble</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Iowa City, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">University of Iowa Health Network Rehabilitation Hospital, a venture with Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Jacksonville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Jacksonville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Jonesboro, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AR</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Jonesboro</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Katy, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Katy</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Kingsport, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of Kingsport, a joint venture of Ballad Health and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Lakeland, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Lakeland</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Lakeview, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Lakeview</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Largo, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Largo</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Las Vegas, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Las Vegas</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Libertyville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Institute of Libertyville</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Manati, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Manati</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Martin County, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital, an affiliate of Martin Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Mechanicsburg, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Mechanicsburg</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Miami, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Miami</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Middletown, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Middletown</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Midland Odessa, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Midland Odessa</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Modesto, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Modesto</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Montgomery, Inc.</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AL</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Montgomery</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Murrieta, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Murrieta</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Naples, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Naples</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of New England, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of New England</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of New England at Beverly</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of New England at Lowell</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Nittany Valley, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Nittany Valley</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of North Tampa, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of North Tampa</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Northern Kentucky, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Northern Kentucky</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Northern Virginia, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Northern Virginia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Northwest Tucson, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Northwest Tucson</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Ocala, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Ocala</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Panama City, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">FL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Panama City</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Pearland, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Pearland</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Pensacola, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Pensacola</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Petersburg, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Petersburg</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Plano, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Plano</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Reading, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Reading</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Richardson, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Richardson</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Rock Hill, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">SC</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Rock Hill</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Round Rock, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Round Rock</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of San Antonio, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of San Antonio</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of San Juan, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of San Juan</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sarasota, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sarasota</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Savannah, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Savannah</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Scottsdale, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Scottsdale</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sewickley, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sewickley</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sewickley at Heritage Valley Kennedy</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Shelby County, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Shelby County</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Shreveport, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Shreveport</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sioux Falls, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sioux Falls</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Spring Hill, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Spring Hill</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of St. Augustine, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of St. Augustine</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sugar Land, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sugar Land</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sunrise, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Sunrise</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Tallahassee, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Tallahassee</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Texarkana, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Texarkana</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of the Mid-Cities, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of the Mid-Cities</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of The Woodlands, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of The Woodlands</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Toledo, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Toledo</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Toms River, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Toms River</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Treasure Coast, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Treasure Coast</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Tustin, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Tustin</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Utah, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Utah</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Vineland, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Vineland</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Waco, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Waco</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Western Massachusetts, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MA</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Western Massachusetts</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Westerville, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mount Carmel Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of York, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of York</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital The Vintage, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital The Vintage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital Vision Park, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital Vision Park</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Institute of Tucson, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Institute of Tucson</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health San Angelo Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Savannah Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Sea Pines Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Sewickley Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health South Carolina Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health South Dakota Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Southern Illinois Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Support Companies, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Texas Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Tucson Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Tulsa Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Tyler Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Utah Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health ValleyofTheSun Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Valley of The Sun Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Virginia Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Walton Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Walton Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health West Tennessee Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health West Virginia Real Estate, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Westerville Holdings, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Wichita Falls Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Winston-Salem Holdings, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Yuma Holdings, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass IP Holdings Corporation</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass PAHS Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CO</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Littleton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Geisinger Encompass Health Limited Liability Company</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Geisinger Encompass Health Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">K.C. Rehabilitation Hospital, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MidAmerica Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kansas Rehabilitation Hospital, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kansas Rehabilitation Hospital, a joint venture of Encompass Health and Stormont Vail Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MMC Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">NJ</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Tinton Falls, a Joint Venture with Monmouth Medical Center</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Myrtle Beach Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tidelands Health Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">New England Rehabilitation Hospital of Portland, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ME</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">New England Rehabilitation Hospital of Portland, a Joint Venture of Maine Medical Center and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">New England Rehabilitation Services of Central Massachusetts, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fairlawn Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Northwest Arkansas Rehabilitation Associates</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AR</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital, a partner of Washington Regional</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Novant Health Rehabilitation Hospital of Winston-Salem, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Novant Health Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Piedmont Encompass Rehabilitation Hospitals, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Piedmont Healthcare Encompass Health Rehabilitation Hospital of Henry, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of Henry</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Piedmont Healthcare Encompass Health Rehabilitation Hospital of Newnan, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of Newnan</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Print Promotions Group, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Print Promotions Group</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Quillen Rehabilitation Hospital of Johnson City, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Quillen Rehabilitation Hospital, a joint venture of Ballad Health and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rebound, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Lakeshore Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Chattanooga</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Huntington</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital Corporation of America, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Parkersburg</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Princeton</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Richmond</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Salisbury</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of Bristol, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of Bristol, a joint venture of Ballad Health and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of Grand Forks, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Altru Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of North Alabama, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of North Alabama</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of Phenix City, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Regional Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rehabilitation Hospital of Plano, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Reliant Blocker Corp.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rusk Rehabilitation Center, L.L.C.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MO</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rusk Rehabilitation Hospital, an affiliation of Encompass Health and MU Health Care</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Saint Alphonsus Regional Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">ID</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Saint Alphonsus Regional Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sea Pines Rehabilitation Hospital Limited Partnership</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sea Pines Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Shannon Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Shannon Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">South Plains Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">TX</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">South Plains Rehabilitation Hospital, an affiliate of UMC and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">St. John Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">St. John Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">St. Joseph Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CHI St. Joseph Health Rehabilitation Hospital, an affiliate of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Texas Hospital Partners, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Quad Cities Rehabilitation Institute, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Quad Cities Rehabilitation Institute</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Rehabilitation Institute of Southern Illinois, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Rehabilitation Institute of Southern Illinois</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Rehabilitation Institute of St. Louis, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MO</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Rehabilitation Institute of St. Louis, an affiliation of BJC HealthCare and Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tyler Rehab Associates, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Christus Trinity Mother Frances Rehabilitation Hospital, a partner of Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">UVA Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">VA</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">UVA Encompass Health Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Van Matre Encompass Health Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">IL</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Van Matre Encompass Health Rehabilitation Institute</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vanderbilt Stallworth Rehabilitation Hospital, L.P.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">TN</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vanderbilt Stallworth Rehabilitation Hospital</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Tennessee Rehabilitation Hospital, LLC</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Tennessee Healthcare Rehabilitation Hospital Cane Creek, a partnership with Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Tennessee Healthcare Rehabilitation Hospital Jackson, a partnership with Encompass Health</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Virginia Rehabilitation Hospital, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">WV</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health MountainView at Bridgeport</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Encompass Health Rehabilitation Hospital of Morgantown</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Western Neuro Care, Inc.</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">DE</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Yuma Rehabilitation Hospital, L.L.C.</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">AZ</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Yuma Rehabilitation Hospital, an affiliation of Encompass Health and Yuma Regional Medical Center</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-22.1
<SEQUENCE>5
<FILENAME>ehc10k123122ex221.htm
<DESCRIPTION>EX-22.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic511b0c2c6d74434b618e92d70866df2_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 22.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subsidiary Guarantors and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize Securities of the Registrant</font></div><div><font><br></font></div><div style="text-indent:42.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The entities listed in the table below are either direct or indirect subsidiaries of Encompass Health Corporation, and they each, jointly and severally, guarantee the payment of each series of unsecured senior notes issued by Encompass Health Corporation. There are no other outstanding debt securities of Encompass Health Corporation or its subsidiaries.</font></div><div style="text-indent:42.4pt"><font><br></font></div><div style="text-indent:42.4pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Subsidiaries of Encompass Health Corporation</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;border-top:0.5pt solid #bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Advanced Homecare Holdings, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Continental Medical Systems, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Continental Rehabilitation Hospital of Arizona, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Acquisition Holdings Subsidiary, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Acquisition Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Alabama Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Arizona Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Arkansas Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Boise Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Bryan Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health C Corp Sub Holdings, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health California Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Cape Coral Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Central Arkansas Holdings, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Charleston Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Colorado Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Dayton Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Deaconess Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Fairlawn Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health GKBJH Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Grand Forks Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Gulfport Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Illinois Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Iowa City Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Iowa Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Johnson City Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Joint Ventures Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Jonesboro Holdings, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Kansas Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Kentucky Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Kingsport Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Littleton Holdings, LLC</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Louisiana Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Lubbock Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Martin County Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Maryland Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Massachusetts Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Midland Odessa Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Moline Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Myrtle Beach Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Nevada Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health New Mexico Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Ohio Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Owned Hospitals Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Pennsylvania Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Properties, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Abilene, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Albuquerque, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Altamonte Springs, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Arlington, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Austin, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Bakersfield, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Bluffton, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Braintree, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Cardinal Hill, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Cincinnati, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of City View, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Colorado Springs, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Columbia, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Concord, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Cumming, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Cypress, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Dallas, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Desert Canyon, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Dothan, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of East Valley, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Erie, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Florence, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Fort Smith, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Franklin, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Fredericksburg, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Gadsden, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Greenville, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Harmarville, LLC</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Henderson, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Humble, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Jacksonville, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Katy, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Lakeland, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Lakeview, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Largo, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Las Vegas, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Libertyville, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Littleton, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Manati, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Mechanicsburg, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Miami, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Middletown, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Modesto, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Montgomery, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Murrieta, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of New England, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Nittany Valley, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of North Tampa, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Northern Kentucky, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Northern Virginia, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Northwest Tucson, L.P.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Ocala, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Panama City, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Pearland, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Pensacola, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Petersburg, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Plano, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Reading, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Richardson, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Round Rock, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of San Antonio, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of San Juan, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Sarasota, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Scottsdale, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Shelby County, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Shreveport, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Sioux Falls, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Spring Hill, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of St. Augustine, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Sugar Land, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Sunrise, LLC</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Tallahassee, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Texarkana, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of the Mid-Cities, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of The Woodlands, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Toledo, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Toms River, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Treasure Coast, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Tustin, L.P.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Utah, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Vineland, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Waco, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of Western Massachusetts, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital of York, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital The Vintage, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Hospital Vision Park, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Rehabilitation Institute of Tucson, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health San Angelo Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Savannah Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Sea Pines Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Sewickley Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health South Carolina Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health South Dakota Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Southern Illinois Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Support Companies, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Texas Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Tucson Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Tulsa Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Tyler Holdings, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Utah Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health ValleyofTheSun Rehabilitation Hospital, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Virginia Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Walton Rehabilitation Hospital, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health West Tennessee Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health West Virginia Real Estate, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Westerville Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Winston-Salem Holdings, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass Health Yuma Holdings, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Encompass IP Holdings Corporation</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">HealthSouth Rehabilitation Hospital of Austin, Inc.</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">HealthSouth Rehabilitation Hospital of Fort Worth, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Print Promotions Group, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Rebound, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Rehabilitation Hospital Corporation of America, LLC</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.076%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Rehabilitation Hospital of North Alabama, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Rehabilitation Hospital of Plano, LLC</font></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Reliant Blocker Corp.</font></div></td></tr><tr><td colspan="3" style="background-color:#bfe4ff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Western Neuro Care, Inc.</font></div></td></tr></table></div><div><font><br></font></div><div style="text-indent:42.4pt"><font><br></font></div><div style="text-indent:42.4pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ehc10k123122ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i66e4940f562846aa8e7ff3e5089ced8b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font><br></font></div><div style="margin-bottom:24pt;margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-157445, 333-175981, and 333-212840) and Form S-3 (No. 333-248942) of Encompass Health Corporation of our report dated February&#160;27, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10&#8209;K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Birmingham, Alabama</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;27, 2023 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ehc10k123122ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i403e8671aec0437498bb880d031374c4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark J. Tarr, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Encompass Health Corporation&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;27, 2023 </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160; Mark J. Tarr</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160; President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ehc10k123122ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i05e9da1f17e24d389608d56d6b3f86aa_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Douglas E. Coltharp, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of Encompass Health Corporation&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;27, 2023 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160; Douglas E. Coltharp</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160; Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ehc10k123122ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0a26aee02f99431a86f01a4287e7e6cd_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATE OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Encompass Health Corporation on Form 10-K for the period ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Mark J. Tarr, President and Chief Executive Officer of Encompass Health Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the &#8220;2002 Act&#8221;), that to the best of my knowledge and belief&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Encompass Health Corporation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;February&#160;27, 2023 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;M</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARK</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> J. T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ARR</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160; Mark J. Tarr</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;President and Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement has been provided to Encompass Health Corporation and will be retained by Encompass Health Corporation and furnished to the Securities and Exchange Commission or its staff upon request.  This written statement shall not, except to the extent required by the 2002 Act, be deemed filed by Encompass Health Corporation for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Encompass Health Corporation specifically incorporates it by reference.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>ehc10k123122ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib76d278b8ffa4e3dadab48a33a1802f1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CERTIFICATE OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Encompass Health Corporation on Form 10-K for the period ended December&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Douglas E. Coltharp, Executive Vice President and Chief Financial Officer of Encompass Health Corporation, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (the &#8220;2002 Act&#8221;), that to the best of my knowledge and belief&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Encompass Health Corporation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;27, 2023 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.731%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OUGLAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> E. C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OLTHARP</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160; Douglas E. Coltharp</font></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160; Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement has been provided to Encompass Health Corporation and will be retained by Encompass Health Corporation and furnished to the Securities and Exchange Commission or its staff upon request.  This written statement shall not, except to the extent required by the 2002 Act, be deemed filed by Encompass Health Corporation for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that Encompass Health Corporation specifically incorporates it by reference.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>ehc-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6ef5271b-25cf-4941-a7fe-936386c94a75,g:d3e86cc2-acdf-4f67-b511-3ef26c190552-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ehc="http://www.encompasshealth.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.encompasshealth.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ehc-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.encompasshealth.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.encompasshealth.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000003 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome_1" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1">
        <link:definition>0000003 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquityParenthetical" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofHomeHealthandHospiceBusiness" roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusiness">
        <link:definition>0000010 - Disclosure - Spin Off of Home Health and Hospice Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.encompasshealth.com/role/BusinessCombinations">
        <link:definition>0000011 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntities" roleURI="http://www.encompasshealth.com/role/VariableInterestEntities">
        <link:definition>0000012 - Disclosure - Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecurities" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecurities">
        <link:definition>0000013 - Disclosure - Cash and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivable" roleURI="http://www.encompasshealth.com/role/AccountsReceivable">
        <link:definition>0000014 - Disclosure - Accounts Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.encompasshealth.com/role/PropertyandEquipment">
        <link:definition>0000015 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.encompasshealth.com/role/Leases">
        <link:definition>0000016 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>0000017 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.encompasshealth.com/role/LongtermDebt">
        <link:definition>0000018 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelfInsuredRisks" roleURI="http://www.encompasshealth.com/role/SelfInsuredRisks">
        <link:definition>0000019 - Disclosure - Self-Insured Risks</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterests" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests">
        <link:definition>0000020 - Disclosure - Redeemable Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.encompasshealth.com/role/FairValueMeasurements">
        <link:definition>0000021 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.encompasshealth.com/role/ShareBasedPayments">
        <link:definition>0000022 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlans">
        <link:definition>0000023 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.encompasshealth.com/role/IncomeTaxes">
        <link:definition>0000024 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShare" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare">
        <link:definition>0000025 - Disclosure - Earnings per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherCommitments" roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments">
        <link:definition>0000026 - Disclosure - Contingencies and Other Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyDataUnaudited" roleURI="http://www.encompasshealth.com/role/QuarterlyDataUnaudited">
        <link:definition>0000027 - Disclosure - Quarterly Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000029 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofHomeHealthandHospiceBusinessTables" roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTables">
        <link:definition>0000030 - Disclosure - Spin Off of Home Health and Hospice Business (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables">
        <link:definition>0000031 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTables" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables">
        <link:definition>0000032 - Disclosure - Variable Interest Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesTables" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables">
        <link:definition>0000033 - Disclosure - Cash and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableTables" roleURI="http://www.encompasshealth.com/role/AccountsReceivableTables">
        <link:definition>0000034 - Disclosure - Accounts Receivable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentTables">
        <link:definition>0000035 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.encompasshealth.com/role/LeasesTables">
        <link:definition>0000036 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>0000037 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.encompasshealth.com/role/LongtermDebtTables">
        <link:definition>0000038 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelfInsuredRisksTables" roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksTables">
        <link:definition>0000039 - Disclosure - Self-Insured Risks (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsTables" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables">
        <link:definition>0000040 - Disclosure - Redeemable Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables">
        <link:definition>0000041 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTables">
        <link:definition>0000042 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.encompasshealth.com/role/IncomeTaxesTables">
        <link:definition>0000043 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareTables" roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTables">
        <link:definition>0000044 - Disclosure - Earnings Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyDataUnauditedTables" roleURI="http://www.encompasshealth.com/role/QuarterlyDataUnauditedTables">
        <link:definition>0000045 - Disclosure - Quarterly Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTextualDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails">
        <link:definition>0000046 - Disclosure - Summary of Significant Accounting Policies - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails">
        <link:definition>0000047 - Disclosure - Summary of Significant Accounting Policies - Net Operating Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails">
        <link:definition>0000048 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails">
        <link:definition>0000049 - Disclosure - Summary of Significant Accounting Policies - PP&amp;E Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails">
        <link:definition>0000050 - Disclosure - Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofHomeHealthandHospiceBusinessTextualDetails" roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails">
        <link:definition>0000051 - Disclosure - Spin Off of Home Health and Hospice Business - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails" roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails">
        <link:definition>0000052 - Disclosure - Spin Off of Home Health and Hospice Business- Summary of Financial Information Related to Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTextualDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails">
        <link:definition>0000053 - Disclosure - Business Combinations - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails">
        <link:definition>0000054 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNetCashPaidforAcquisitionDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails">
        <link:definition>0000055 - Disclosure - Business Combinations - Net Cash Paid for Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsProFormaResultsofOperationDetails" roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails">
        <link:definition>0000056 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesTextualsDetails" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails">
        <link:definition>0000057 - Disclosure - Variable Interest Entities - Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails">
        <link:definition>0000058 - Disclosure - Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesComponentsofInvestmentsDetails" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails">
        <link:definition>0000059 - Disclosure - Cash and Marketable Securities - Components of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesRestrictedCashDetails" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails">
        <link:definition>0000060 - Disclosure - Cash and Marketable Securities - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesTextualDetails" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails">
        <link:definition>0000061 - Disclosure - Cash and Marketable Securities - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails" roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails">
        <link:definition>0000062 - Disclosure - Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsReceivableComponentsofAccountsReceivableDetails" roleURI="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails">
        <link:definition>0000063 - Disclosure - Accounts Receivable - Components of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentComponentsofPropertyandEquipmentDetails" roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails">
        <link:definition>0000064 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTextualDetails" roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails">
        <link:definition>0000065 - Disclosure - Property and Equipment - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails" roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails">
        <link:definition>0000066 - Disclosure - Property and Equipment - Depreciation, Capitalized Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTextualsDetails" roleURI="http://www.encompasshealth.com/role/LeasesTextualsDetails">
        <link:definition>0000067 - Disclosure - Leases - Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseCostsDetails" roleURI="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails">
        <link:definition>0000068 - Disclosure - Leases - Components of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" roleURI="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails">
        <link:definition>0000069 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" roleURI="http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails">
        <link:definition>0000070 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>0000071 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>0000071 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>0000072 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails">
        <link:definition>0000073 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTextualsDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails">
        <link:definition>0000074 - Disclosure - Goodwill and Other Intangible Assets - Textuals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails">
        <link:definition>0000075 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>0000076 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails">
        <link:definition>0000077 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtLongtermDebtOutstandingDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails">
        <link:definition>0000078 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtLongtermDebtOutstandingDetails_1" roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1">
        <link:definition>0000078 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails">
        <link:definition>0000079 - Disclosure - Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTextualDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails">
        <link:definition>0000080 - Disclosure - Long-term Debt - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtFinancialCovenantsDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails">
        <link:definition>0000081 - Disclosure - Long-term Debt - Financial Covenants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtSeniorNotesRedemptionPricesDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails">
        <link:definition>0000082 - Disclosure - Long-term Debt - Senior Notes Redemption Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtScheduleofNotesPayableDetails" roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails">
        <link:definition>0000083 - Disclosure - Long-term Debt - Schedule of Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelfInsuredRisksTextualDetails" roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails">
        <link:definition>0000084 - Disclosure - Self-Insured Risks - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SelfInsuredRisksChangesinSelfinsuranceReservesDetails" roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails">
        <link:definition>0000085 - Disclosure - Self-Insured Risks - Changes in Self-insurance Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails">
        <link:definition>0000086 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails">
        <link:definition>0000087 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableNoncontrollingInterestsTextualDetails" roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails">
        <link:definition>0000088 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>0000089 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails">
        <link:definition>0000090 - Disclosure - Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTextualDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails">
        <link:definition>0000091 - Disclosure - Share-Based Payments - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsWeightedaverageAssumptionsDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails">
        <link:definition>0000092 - Disclosure - Share-Based Payments - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsStockOptionActivityDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails">
        <link:definition>0000093 - Disclosure - Share-Based Payments - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails">
        <link:definition>0000094 - Disclosure - Share-Based Payments - Summary of Restricted Stock Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails">
        <link:definition>0000095 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails">
        <link:definition>0000096 - Disclosure - Income Taxes - Components of Provision for Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails">
        <link:definition>0000097 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails">
        <link:definition>0000098 - Disclosure - Income Taxes - Deferred Tax Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTextualDetails" roleURI="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails">
        <link:definition>0000099 - Disclosure - Income Taxes - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails">
        <link:definition>0000100 - Disclosure - Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails">
        <link:definition>0000101 - Disclosure - Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareTextualDetails" roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails">
        <link:definition>0000102 - Disclosure - Earnings Per Common Share - Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesandOtherCommitmentsDetails" roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails">
        <link:definition>0000103 - Disclosure - Contingencies and Other Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyDataUnauditedScheduleofQuarterlyDataDetails" roleURI="http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails">
        <link:definition>0000104 - Disclosure - Quarterly Data (Unaudited) - Schedule of Quarterly Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_TradeNameEncompassMember" abstract="true" name="TradeNameEncompassMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" abstract="false" name="DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" abstract="false" name="SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" abstract="false" name="ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Contributiontojointventure" abstract="false" name="Contributiontojointventure" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationSupplies" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationSupplies" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberOfInpatientRehabilitationHospitals" abstract="false" name="NumberOfInpatientRehabilitationHospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NumberOfBedsAcquired" abstract="false" name="NumberOfBedsAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" abstract="false" name="LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_SelfInsuredCaptiveFundsMember" abstract="false" name="SelfInsuredCaptiveFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" abstract="true" name="NotesPayableLIBORplus2.5ConstructionFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_HomeHealthandHospiceSegmentMember" abstract="true" name="HomeHealthandHospiceSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" abstract="false" name="DebtInstrumentAmendmentAgreementAmountToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" abstract="false" name="ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_MarketAccessAssetsMember" abstract="false" name="MarketAccessAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestMember" abstract="true" name="RedeemableNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NetAmountMember" abstract="false" name="NetAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_A2016OmnibusPerformanceIncentivePlanMember" abstract="true" name="A2016OmnibusPerformanceIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ShannonMedicalMember" abstract="true" name="ShannonMedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ehc_NCHHealthcareSystemMember" abstract="true" name="NCHHealthcareSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" abstract="true" name="RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" abstract="false" name="RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions" abstract="false" name="OperatingAndFinanceLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_RestrictedDebtSecuritiesNoncurrent" abstract="false" name="RestrictedDebtSecuritiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_UnifiedProgramIntegrityContractorsAuditsMember" abstract="true" name="UnifiedProgramIntegrityContractorsAuditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" abstract="false" name="LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" abstract="false" name="ReconciliationOfNoncontrollingInterestsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_SeniorNotes05.75Due2025Member" abstract="true" name="SeniorNotes05.75Due2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Totaloperatingandfinanceleaseassets" abstract="false" name="Totaloperatingandfinanceleaseassets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_OtherIncomeSourceMember" abstract="true" name="OtherIncomeSourceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_TheCreditAgreementMember" abstract="true" name="TheCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" abstract="true" name="StatementOfComprehensiveIncomeAndIncomeStatementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_A2020AcquisitionsMember" abstract="true" name="A2020AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" abstract="false" name="RetirementInvestmentPlanCompanyMatchVestingPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" abstract="false" name="DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SeniorNotes4.50Due2028Member" abstract="true" name="SeniorNotes4.50Due2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" abstract="false" name="LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" abstract="false" name="NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_NoncontrollingInterestSpinOff" abstract="false" name="NoncontrollingInterestSpinOff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" abstract="false" name="MaximumSelfInsuredAmountFirstLayerOfRisk" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ECHDVenturesMember" abstract="true" name="ECHDVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ehc_NumberOfManagementInvestorsOutstanding" abstract="false" name="NumberOfManagementInvestorsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" abstract="false" name="TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_DepartmentAppealsBoardAdverseRulingMember" abstract="true" name="DepartmentAppealsBoardAdverseRulingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ehc_SupplementalCashFlowInformationTableTextBlock" abstract="false" name="SupplementalCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_PortercareAdventistMember" abstract="true" name="PortercareAdventistMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" abstract="true" name="ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantInterestCoverageRatio" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_A2021AcquisitionsMember" abstract="true" name="A2021AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" abstract="false" name="DebtInstrumentDiscountRateAtIssuanceOfFaceValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_BusinessCombinationNoncontrollingInterestFairValue" abstract="false" name="BusinessCombinationNoncontrollingInterestFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Percentageofassetspledgedtolendersundercreditagreement" abstract="false" name="Percentageofassetspledgedtolendersundercreditagreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_SeniorManagementBonusProgramTotalCosts" abstract="false" name="SeniorManagementBonusProgramTotalCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" abstract="false" name="RetirementInvestmentPlanCompanyMatchVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ehc_AltruHealthSystemMember" abstract="true" name="AltruHealthSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SeniorNotes04.750Due2030Member" abstract="true" name="SeniorNotes04.750Due2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_ManagedCareMember" abstract="true" name="ManagedCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" abstract="false" name="LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" abstract="true" name="RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_LossContingencyClaimsAwaitingReviewAmount" abstract="false" name="LossContingencyClaimsAwaitingReviewAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ScheduleOfFinancialCovenantsTableTextBlock" abstract="false" name="ScheduleOfFinancialCovenantsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_WeightedAverageRemainingLeaseTermAbstract" abstract="true" name="WeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" abstract="false" name="LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_OtherFundsMember" abstract="true" name="OtherFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_WorkersCompensationMember" abstract="true" name="WorkersCompensationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_TrinityMedicalCenterMember" abstract="true" name="TrinityMedicalCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_InvestmentsCashandRestrictedCash" abstract="false" name="InvestmentsCashandRestrictedCash" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NoncontrollingInterestExerciseRightToSellRatio" abstract="false" name="NoncontrollingInterestExerciseRightToSellRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" abstract="false" name="DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ehc_NoncontrollingInterestOtherAdjustment" abstract="false" name="NoncontrollingInterestOtherAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_RACAuditsMember" abstract="true" name="RACAuditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember" abstract="true" name="AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" abstract="true" name="CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" abstract="true" name="ManagedCareMedicareAdvantageandOtherDiscountPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_PremierHealthPartnersMember" abstract="true" name="PremierHealthPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" abstract="false" name="LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_SeniorNotes04625Due2031Member" abstract="true" name="SeniorNotes04625Due2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_PatientsMember" abstract="true" name="PatientsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_VariableInterestEntityNumberofEntitiesConsolidated" abstract="false" name="VariableInterestEntityNumberofEntitiesConsolidated" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_NoncontrollingInterestExchangeTransaction" abstract="false" name="NoncontrollingInterestExchangeTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_CurrentAndFormerBoardOfDirectorsMember" abstract="true" name="CurrentAndFormerBoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_Jointventureownershippercentage" abstract="false" name="Jointventureownershippercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" abstract="false" name="RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_NumberofBedsContributed" abstract="false" name="NumberofBedsContributed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" abstract="true" name="LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SeniorNotes05.125Due2023Member" abstract="true" name="SeniorNotes05.125Due2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership" abstract="false" name="NumberOfInpatientRehabilitationHospitalsSoleOwnership" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberofBedsExpanded" abstract="false" name="NumberofBedsExpanded" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_LossContingencyExtrapolatedErrorRatePeriod" abstract="false" name="LossContingencyExtrapolatedErrorRatePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" abstract="false" name="SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LossContingencyAppealedClaimsDeniedAmount" abstract="false" name="LossContingencyAppealedClaimsDeniedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NonemployeeDirectorsMember" abstract="true" name="NonemployeeDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_FaceAmountMember" abstract="false" name="FaceAmountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_EnhabitMember" abstract="true" name="EnhabitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_InternalUseSoftwareMember" abstract="true" name="InternalUseSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_EncompassHealthRetirementInvestmentPlanMember" abstract="true" name="EncompassHealthRetirementInvestmentPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_TermLoanFacilitiesMember" abstract="true" name="TermLoanFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_WeightedAverageDiscountRateAbstract" abstract="true" name="WeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_HeritageValleyMember" abstract="true" name="HeritageValleyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantLeverageRatio" abstract="false" name="DebtInstrumentCovenantLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_OccupancyCost" abstract="false" name="OccupancyCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NumberofDeNovoBeds" abstract="false" name="NumberofDeNovoBeds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_Totalfinanceleasecost" abstract="false" name="Totalfinanceleasecost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" abstract="false" name="NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_HealthcarePlanExpense" abstract="false" name="HealthcarePlanExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_EHHIMember" abstract="true" name="EHHIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NotesPayableSoftwareContractsMember" abstract="true" name="NotesPayableSoftwareContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" abstract="true" name="NotesPayableRealEstateSaleLeasebackFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" abstract="false" name="ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_PayorSourceMember" abstract="true" name="PayorSourceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Totalleaseliabilities" abstract="false" name="Totalleaseliabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals" abstract="false" name="NumberOfJointlyOwnedInpatientRehabilitationHospitals" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_PortercareAdventistAndPremierHealthPartnersMember" abstract="true" name="PortercareAdventistAndPremierHealthPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion" abstract="false" name="DebtInstrumentCovenantReductionFeeForUndrawnPortion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ehc_DividendEquivalentRSUMember" abstract="true" name="DividendEquivalentRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_Shorttermandvariableleasecost" abstract="false" name="Shorttermandvariableleasecost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" abstract="false" name="FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_OtherThirdpartyPayorsMember" abstract="true" name="OtherThirdpartyPayorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_LossContingencyClaimsSampledForAuditAmount" abstract="false" name="LossContingencyClaimsSampledForAuditAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_CertificateOfNeedMember" abstract="false" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_SeniorNotes0575Due2024Member" abstract="true" name="SeniorNotes0575Due2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_RetirementInvestmentPlanAgeRequirement" abstract="false" name="RetirementInvestmentPlanAgeRequirement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination" abstract="false" name="LossContingencyAmountOverturnedOfOverpaymentDetermination" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_LossContingencyNumberOfClaimsSampledForAudit" abstract="false" name="LossContingencyNumberOfClaimsSampledForAudit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" abstract="false" name="RedeemableNoncontrollingInterestEquityAcquiredPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" abstract="false" name="LongTermDebtAndLeaseObligationsMaturityAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantAvailableLimitAmount" abstract="false" name="DebtInstrumentCovenantAvailableLimitAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ehc_OperatingAndFinanceLeaseContractTerm" abstract="false" name="OperatingAndFinanceLeaseContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" abstract="false" name="DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ehc_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ehc_AffiliateCashMember" abstract="false" name="AffiliateCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>ehc-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6ef5271b-25cf-4941-a7fe-936386c94a75,g:d3e86cc2-acdf-4f67-b511-3ef26c190552-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5f643c0a-d11e-4e79-8f62-4c6fa99b08d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_16cc19ee-88f4-4ba7-97f8-9d2acb27685a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5f643c0a-d11e-4e79-8f62-4c6fa99b08d5" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_16cc19ee-88f4-4ba7-97f8-9d2acb27685a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6c300f42-b559-4529-b1fc-2270d1732646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5f643c0a-d11e-4e79-8f62-4c6fa99b08d5" xlink:to="loc_us-gaap_ProfitLoss_6c300f42-b559-4529-b1fc-2270d1732646" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63691a6a-6f99-4903-aaee-7141f1f2716b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_5ced8392-bc8f-46c2-82ae-72a979db1ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63691a6a-6f99-4903-aaee-7141f1f2716b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_5ced8392-bc8f-46c2-82ae-72a979db1ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_302af1ff-28c5-44af-892e-1fd8a2eed76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_63691a6a-6f99-4903-aaee-7141f1f2716b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_302af1ff-28c5-44af-892e-1fd8a2eed76c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_37acc661-5912-4eeb-9f58-256104f10063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0bdb1946-84f0-4877-a5ee-fd51cb47e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_37acc661-5912-4eeb-9f58-256104f10063" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_0bdb1946-84f0-4877-a5ee-fd51cb47e60e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_944e0957-06d8-4638-8407-324f46f3cd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_37acc661-5912-4eeb-9f58-256104f10063" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_944e0957-06d8-4638-8407-324f46f3cd64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_35a80397-56c5-4826-a8de-d3f43159f955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_a0f87328-edf1-479d-8d44-fc8b977c5f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_35a80397-56c5-4826-a8de-d3f43159f955" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_a0f87328-edf1-479d-8d44-fc8b977c5f25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_81c0f4a3-45f9-4499-8565-8d94f30c6409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_35a80397-56c5-4826-a8de-d3f43159f955" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_81c0f4a3-45f9-4499-8565-8d94f30c6409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7739456-02c0-41c2-a1e0-5708be6a46aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a2a77e6f-ef48-41f2-bb01-bcde7e2e95c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7739456-02c0-41c2-a1e0-5708be6a46aa" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_a2a77e6f-ef48-41f2-bb01-bcde7e2e95c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fb3e5abe-c87f-4c9d-9875-d5166e8d8625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c7739456-02c0-41c2-a1e0-5708be6a46aa" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_fb3e5abe-c87f-4c9d-9875-d5166e8d8625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c080e4f7-4a52-4224-952f-72e1d63c5ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6cd1ee5d-8925-4618-a4c8-fc27b458f9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_c080e4f7-4a52-4224-952f-72e1d63c5ba0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6cd1ee5d-8925-4618-a4c8-fc27b458f9fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e9cff89c-f44a-4b2b-b9df-1129799af9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_c080e4f7-4a52-4224-952f-72e1d63c5ba0" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e9cff89c-f44a-4b2b-b9df-1129799af9e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_711a2974-7770-4107-9a03-9d16ab236fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2906e627-55d1-4830-baab-f9e850bc142c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_711a2974-7770-4107-9a03-9d16ab236fb1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2906e627-55d1-4830-baab-f9e850bc142c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c46af8d4-15ce-4ea2-b8db-160ceda417ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_711a2974-7770-4107-9a03-9d16ab236fb1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c46af8d4-15ce-4ea2-b8db-160ceda417ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a57c4a2b-4880-46e5-b6f8-87aa82d6e38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6aea6c76-f41b-4d14-916e-7980a6a4ce16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a57c4a2b-4880-46e5-b6f8-87aa82d6e38f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6aea6c76-f41b-4d14-916e-7980a6a4ce16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0facd34f-4478-4dfc-8228-85e426711dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a57c4a2b-4880-46e5-b6f8-87aa82d6e38f" xlink:to="loc_us-gaap_CostsAndExpenses_0facd34f-4478-4dfc-8228-85e426711dbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4a10a18c-400c-4759-9af4-d5e408a3f148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a57c4a2b-4880-46e5-b6f8-87aa82d6e38f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4a10a18c-400c-4759-9af4-d5e408a3f148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_dd2c735e-d275-4bae-bf61-b2f57c9ed318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a57c4a2b-4880-46e5-b6f8-87aa82d6e38f" xlink:to="loc_us-gaap_InterestExpense_dd2c735e-d275-4bae-bf61-b2f57c9ed318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2939423d-b0fb-4da2-9208-cfa72a932e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a57c4a2b-4880-46e5-b6f8-87aa82d6e38f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2939423d-b0fb-4da2-9208-cfa72a932e03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0a5657c0-b6ef-4af8-b664-3289bd257bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a57c4a2b-4880-46e5-b6f8-87aa82d6e38f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0a5657c0-b6ef-4af8-b664-3289bd257bc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c85e569f-3ac9-462e-b964-12d131fa8b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_b6a336be-48c8-4f93-8151-c647b0ffd96e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c85e569f-3ac9-462e-b964-12d131fa8b59" xlink:to="loc_us-gaap_LaborAndRelatedExpense_b6a336be-48c8-4f93-8151-c647b0ffd96e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_d6776f54-ec42-4a84-821f-2e5c8b90dfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c85e569f-3ac9-462e-b964-12d131fa8b59" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_d6776f54-ec42-4a84-821f-2e5c8b90dfaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_95098e3f-20e1-47b1-9bb9-cca137170c21" xlink:href="ehc-20221231.xsd#ehc_OccupancyCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c85e569f-3ac9-462e-b964-12d131fa8b59" xlink:to="loc_ehc_OccupancyCost_95098e3f-20e1-47b1-9bb9-cca137170c21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_a5a9d668-8126-4cd4-93bc-7ae965aebe78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c85e569f-3ac9-462e-b964-12d131fa8b59" xlink:to="loc_us-gaap_SuppliesExpense_a5a9d668-8126-4cd4-93bc-7ae965aebe78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eebfca51-caf4-496e-aafc-5348c4d3a9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c85e569f-3ac9-462e-b964-12d131fa8b59" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eebfca51-caf4-496e-aafc-5348c4d3a9df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2b13b27d-5a62-44ef-a670-e0bcd4c5cdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c85e569f-3ac9-462e-b964-12d131fa8b59" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2b13b27d-5a62-44ef-a670-e0bcd4c5cdec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_d8159b95-6111-430a-b20f-d0e37ffcd1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c85e569f-3ac9-462e-b964-12d131fa8b59" xlink:to="loc_us-gaap_LitigationSettlementExpense_d8159b95-6111-430a-b20f-d0e37ffcd1f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e1514dfc-e483-4680-b296-97c76a05e78e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_98011fe9-ab64-499e-81d4-109791572ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e1514dfc-e483-4680-b296-97c76a05e78e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_98011fe9-ab64-499e-81d4-109791572ac6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_24444eb0-1081-4df6-a02e-923566082138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_e1514dfc-e483-4680-b296-97c76a05e78e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_24444eb0-1081-4df6-a02e-923566082138" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome_1"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cbd1509c-6310-496b-8c0c-72e0860b7901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cc3d90b4-1593-47f8-8441-28613511764f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cbd1509c-6310-496b-8c0c-72e0860b7901" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_cc3d90b4-1593-47f8-8441-28613511764f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_41eda3d4-a6de-4152-8ede-49e5e393dacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_cbd1509c-6310-496b-8c0c-72e0860b7901" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_41eda3d4-a6de-4152-8ede-49e5e393dacb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d3c8c594-decf-4f61-bd35-755042fc8ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_79924d27-d7ed-48d4-886f-d5ba989d8a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3c8c594-decf-4f61-bd35-755042fc8ab8" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_79924d27-d7ed-48d4-886f-d5ba989d8a95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_bea51b2e-017e-4a48-ba6a-e3a3567794c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3c8c594-decf-4f61-bd35-755042fc8ab8" xlink:to="loc_us-gaap_ReceivablesNetCurrent_bea51b2e-017e-4a48-ba6a-e3a3567794c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_46a1e065-ed1f-4b0f-bcf2-f0c32e271624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3c8c594-decf-4f61-bd35-755042fc8ab8" xlink:to="loc_us-gaap_RestrictedCashCurrent_46a1e065-ed1f-4b0f-bcf2-f0c32e271624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f7d84193-2839-493d-a56a-87c8eb633014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3c8c594-decf-4f61-bd35-755042fc8ab8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f7d84193-2839-493d-a56a-87c8eb633014" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4356a348-d276-49fd-9530-09f31c2b01bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d3c8c594-decf-4f61-bd35-755042fc8ab8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4356a348-d276-49fd-9530-09f31c2b01bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a71dd344-0afd-458d-8d59-368137280997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c4e6313a-97cf-43d4-a1f7-3edf91ac67db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a71dd344-0afd-458d-8d59-368137280997" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_c4e6313a-97cf-43d4-a1f7-3edf91ac67db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_62fc58c0-cc63-4233-9998-769a601ccaba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a71dd344-0afd-458d-8d59-368137280997" xlink:to="loc_us-gaap_AccountsPayableCurrent_62fc58c0-cc63-4233-9998-769a601ccaba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a648ef6e-5fa8-4a4c-b71a-0f8f67460cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a71dd344-0afd-458d-8d59-368137280997" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a648ef6e-5fa8-4a4c-b71a-0f8f67460cbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_6c061932-43b1-4998-8bed-b67756684260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a71dd344-0afd-458d-8d59-368137280997" xlink:to="loc_us-gaap_InterestPayableCurrent_6c061932-43b1-4998-8bed-b67756684260" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_be7ea98e-37f0-4080-b973-cf41a834d4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a71dd344-0afd-458d-8d59-368137280997" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_be7ea98e-37f0-4080-b973-cf41a834d4b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_65151a2d-a8c7-4f16-98d0-6bedd6a2bd78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a71dd344-0afd-458d-8d59-368137280997" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_65151a2d-a8c7-4f16-98d0-6bedd6a2bd78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f0718830-c8a8-4060-b141-647130ab490d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a71dd344-0afd-458d-8d59-368137280997" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_f0718830-c8a8-4060-b141-647130ab490d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a76f7c00-22c4-4427-b34d-b0375c7392a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f00861c0-c65d-49d4-8caf-567153a72709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a76f7c00-22c4-4427-b34d-b0375c7392a7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f00861c0-c65d-49d4-8caf-567153a72709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5af55c7b-b87a-4e27-8e30-45129be8b84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a76f7c00-22c4-4427-b34d-b0375c7392a7" xlink:to="loc_us-gaap_Goodwill_5af55c7b-b87a-4e27-8e30-45129be8b84c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ad32c191-5062-4751-a74e-9dfef31defeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a76f7c00-22c4-4427-b34d-b0375c7392a7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ad32c191-5062-4751-a74e-9dfef31defeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_b4281ce4-f1fb-4a33-aac4-9f7b3d251cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a76f7c00-22c4-4427-b34d-b0375c7392a7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_b4281ce4-f1fb-4a33-aac4-9f7b3d251cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29d32dd6-f6de-47b7-94ae-38cec797ab96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a76f7c00-22c4-4427-b34d-b0375c7392a7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_29d32dd6-f6de-47b7-94ae-38cec797ab96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5be6b580-43d8-46e2-b801-fbe7544afe4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a76f7c00-22c4-4427-b34d-b0375c7392a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5be6b580-43d8-46e2-b801-fbe7544afe4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7b7e233e-3d0b-494a-ba82-0b879fb0a366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a76f7c00-22c4-4427-b34d-b0375c7392a7" xlink:to="loc_us-gaap_AssetsCurrent_7b7e233e-3d0b-494a-ba82-0b879fb0a366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b92b0fa7-292f-4d2b-8044-7933e2a1b1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_923954bd-4f8c-46f2-9cf2-cc7e91e94f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b92b0fa7-292f-4d2b-8044-7933e2a1b1d1" xlink:to="loc_us-gaap_StockholdersEquity_923954bd-4f8c-46f2-9cf2-cc7e91e94f34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_597836d6-7cdc-4ff5-9189-c1d8008bd848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b92b0fa7-292f-4d2b-8044-7933e2a1b1d1" xlink:to="loc_us-gaap_MinorityInterest_597836d6-7cdc-4ff5-9189-c1d8008bd848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4f733759-12a0-4e32-a9f1-21ab83408e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3370e32a-a1b3-462d-afc7-f4318f28ef93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4f733759-12a0-4e32-a9f1-21ab83408e1e" xlink:to="loc_us-gaap_CommonStockValue_3370e32a-a1b3-462d-afc7-f4318f28ef93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0be6f7cc-2746-4cca-baab-d7a0421e4548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4f733759-12a0-4e32-a9f1-21ab83408e1e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0be6f7cc-2746-4cca-baab-d7a0421e4548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd09167d-9e7a-43e9-83ff-26c355fea115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4f733759-12a0-4e32-a9f1-21ab83408e1e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bd09167d-9e7a-43e9-83ff-26c355fea115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_5aa77420-efbd-4221-b569-85dccb6b839f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4f733759-12a0-4e32-a9f1-21ab83408e1e" xlink:to="loc_us-gaap_TreasuryStockCommonValue_5aa77420-efbd-4221-b569-85dccb6b839f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_37894e67-79cb-4107-843a-0894a5b34caa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0ac9013b-1206-4c4b-b741-14dd23e2aeab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37894e67-79cb-4107-843a-0894a5b34caa" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_0ac9013b-1206-4c4b-b741-14dd23e2aeab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_921de851-932e-4487-9daf-255bc9a66914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37894e67-79cb-4107-843a-0894a5b34caa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_921de851-932e-4487-9daf-255bc9a66914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8f1ab9e7-b254-4120-a58f-61b3e4aba732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37894e67-79cb-4107-843a-0894a5b34caa" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_8f1ab9e7-b254-4120-a58f-61b3e4aba732" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_562b3a01-c7b3-4c7c-aebc-00fb8e4305bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37894e67-79cb-4107-843a-0894a5b34caa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_562b3a01-c7b3-4c7c-aebc-00fb8e4305bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_389c38d5-ab61-4890-86d9-81d92eb88060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37894e67-79cb-4107-843a-0894a5b34caa" xlink:to="loc_us-gaap_LiabilitiesCurrent_389c38d5-ab61-4890-86d9-81d92eb88060" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent_cb74b7b7-121e-4d86-879e-5a3192589183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37894e67-79cb-4107-843a-0894a5b34caa" xlink:to="loc_us-gaap_SelfInsuranceReserveNoncurrent_cb74b7b7-121e-4d86-879e-5a3192589183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_3d92199c-4e9f-483f-84bb-a5cd1b8790ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_37894e67-79cb-4107-843a-0894a5b34caa" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_3d92199c-4e9f-483f-84bb-a5cd1b8790ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d36b6df-7bd6-4d3c-ac02-5cb45f051522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7531471a-2f0f-49f3-b728-05737ec57d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d36b6df-7bd6-4d3c-ac02-5cb45f051522" xlink:to="loc_us-gaap_Liabilities_7531471a-2f0f-49f3-b728-05737ec57d1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_92cbdf4a-b4a6-44b2-95e4-02cc83fe5519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d36b6df-7bd6-4d3c-ac02-5cb45f051522" xlink:to="loc_us-gaap_CommitmentsAndContingencies_92cbdf4a-b4a6-44b2-95e4-02cc83fe5519" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_88069757-da64-4c17-be7f-fb91a3c66ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d36b6df-7bd6-4d3c-ac02-5cb45f051522" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_88069757-da64-4c17-be7f-fb91a3c66ce7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aade3e73-7ac5-4af5-9f92-e2a9482406d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d36b6df-7bd6-4d3c-ac02-5cb45f051522" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_aade3e73-7ac5-4af5-9f92-e2a9482406d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_f835bd15-87a3-4498-a8ed-02ff74bfe8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_f835bd15-87a3-4498-a8ed-02ff74bfe8b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_b54d93b5-1c39-41d4-bffb-3b6ad824897c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:to="loc_us-gaap_PaymentsForSoftware_b54d93b5-1c39-41d4-bffb-3b6ad824897c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5f01c9d-f769-4b90-9080-d0577cc1518b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5f01c9d-f769-4b90-9080-d0577cc1518b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8ac68736-1a13-4206-b022-69962773671b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_8ac68736-1a13-4206-b022-69962773671b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f16df3e-27cd-4f66-92a2-81e31a9bfbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f16df3e-27cd-4f66-92a2-81e31a9bfbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_c716b588-e3a9-4f8c-813b-ad450a9a9e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_c716b588-e3a9-4f8c-813b-ad450a9a9e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_50e049e9-e58a-4b87-aa21-95aa65bf89c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_50e049e9-e58a-4b87-aa21-95aa65bf89c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fe2daad0-86c7-4984-a959-2958f591918b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_327637e5-83c5-44c7-9067-c6bf2cfd575b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fe2daad0-86c7-4984-a959-2958f591918b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b5737729-5a10-43ca-bc87-cc1c451cc29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_b5737729-5a10-43ca-bc87-cc1c451cc29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_0434507e-5925-4cd7-ae05-92653e398550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_0434507e-5925-4cd7-ae05-92653e398550" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_dd9c13ee-0ada-4c51-89d4-18c4799f4500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_dd9c13ee-0ada-4c51-89d4-18c4799f4500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7e400aa9-8808-400f-92ed-c6585dd1a04c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7e400aa9-8808-400f-92ed-c6585dd1a04c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ff3b26b2-5951-472f-873d-06e19a76ea08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_ff3b26b2-5951-472f-873d-06e19a76ea08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_fee19588-7d5d-49d0-808f-31d60afbc2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_fee19588-7d5d-49d0-808f-31d60afbc2c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_115c7359-7336-4127-a2c0-c2e3bb94e7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_115c7359-7336-4127-a2c0-c2e3bb94e7e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_422b772b-2c4c-4588-81f4-4879be04462f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_422b772b-2c4c-4588-81f4-4879be04462f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_4d58a601-d53c-48ac-aad8-c509697abeec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_4d58a601-d53c-48ac-aad8-c509697abeec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_3f7a074a-e3a3-4a0b-a0e0-06a3e82e9b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_3f7a074a-e3a3-4a0b-a0e0-06a3e82e9b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_5e2f8bf4-0f99-49be-9650-e97535da4557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_5e2f8bf4-0f99-49be-9650-e97535da4557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_3d1722dd-0053-4cf9-9f5f-5f0f9476e23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_3d1722dd-0053-4cf9-9f5f-5f0f9476e23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_1a954ae8-a33f-4d04-a3d1-d3a7ce5159b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_1a954ae8-a33f-4d04-a3d1-d3a7ce5159b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8786273b-ed13-48bd-b10c-bb9a980997cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8786273b-ed13-48bd-b10c-bb9a980997cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_55fa792a-dd3f-4d73-8cee-46cfc8570c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5051732-a666-47ca-bea8-979ea6bd4f8d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_55fa792a-dd3f-4d73-8cee-46cfc8570c70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a595254-1bdb-44aa-9e57-1bcd4569d405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d030da1-0c41-475d-b129-ab598d252a83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a595254-1bdb-44aa-9e57-1bcd4569d405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d030da1-0c41-475d-b129-ab598d252a83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb3d3d7-0938-4d62-a172-8b541c402083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a595254-1bdb-44aa-9e57-1bcd4569d405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7cb3d3d7-0938-4d62-a172-8b541c402083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f44b480e-e735-4a2f-9881-8a82476e021c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a595254-1bdb-44aa-9e57-1bcd4569d405" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f44b480e-e735-4a2f-9881-8a82476e021c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_3b1663ab-4e30-4a30-afb7-e499759d3723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_3b1663ab-4e30-4a30-afb7-e499759d3723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_97b33c50-9d83-4985-8912-802858c61dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_97b33c50-9d83-4985-8912-802858c61dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_39f34961-afe2-4cf5-bbf4-046a0954a5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_39f34961-afe2-4cf5-bbf4-046a0954a5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_cb2f8cdd-11b4-47cf-9a2b-76cb7c33b5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_LitigationSettlementExpense_cb2f8cdd-11b4-47cf-9a2b-76cb7c33b5fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_5913fafa-16d6-4940-ad65-c438a3e81ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_ShareBasedCompensation_5913fafa-16d6-4940-ad65-c438a3e81ec3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_47a3f730-0db7-4384-a8da-55b640ba5e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_47a3f730-0db7-4384-a8da-55b640ba5e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b1de1f24-0f9e-44a5-8652-8543da778d43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b1de1f24-0f9e-44a5-8652-8543da778d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_ed4ac3d6-dba9-46d2-bb16-265033f2ef13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_ed4ac3d6-dba9-46d2-bb16-265033f2ef13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_0f1f5181-86ef-4271-bdb5-c2ed717c0483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_0f1f5181-86ef-4271-bdb5-c2ed717c0483" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7d2012a5-058e-4cd5-94dd-a4f2d44219f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7d2012a5-058e-4cd5-94dd-a4f2d44219f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_aced0191-708a-4973-af60-ebad7c3d4c64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_aced0191-708a-4973-af60-ebad7c3d4c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e536ae54-efc2-4476-83e3-e6097768007e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e536ae54-efc2-4476-83e3-e6097768007e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_94cd8e9d-905b-4ca0-891e-56ea97d86c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_94cd8e9d-905b-4ca0-891e-56ea97d86c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d26f9198-cbcd-430d-ae8b-7ca5e072682c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d26f9198-cbcd-430d-ae8b-7ca5e072682c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_eb99cec7-ab16-4956-837b-2a87051788ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_eb99cec7-ab16-4956-837b-2a87051788ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1a0a69a6-ebc7-400a-82a7-ef6df972bf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_a06ae730-cbe9-401c-86ac-927242b66582" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1a0a69a6-ebc7-400a-82a7-ef6df972bf0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6e74ac5-f758-4c7f-baab-597a5b447159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3697dc8c-0a02-44b6-8634-4817af467e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6e74ac5-f758-4c7f-baab-597a5b447159" xlink:to="loc_us-gaap_ProfitLoss_3697dc8c-0a02-44b6-8634-4817af467e5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_93c74bf1-474b-43ec-abc4-b18cd957843b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6e74ac5-f758-4c7f-baab-597a5b447159" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_93c74bf1-474b-43ec-abc4-b18cd957843b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f9bafdec-72f6-4be9-9481-45af86158a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6e74ac5-f758-4c7f-baab-597a5b447159" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_f9bafdec-72f6-4be9-9481-45af86158a95" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_baa26166-72e6-42b1-897f-990e41d8fd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_a55c3115-f58d-45a7-afdd-53c5ef43d8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_baa26166-72e6-42b1-897f-990e41d8fd5c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_a55c3115-f58d-45a7-afdd-53c5ef43d8f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_5ac2e26d-4057-4507-bc25-e5599397b920" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_baa26166-72e6-42b1-897f-990e41d8fd5c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_5ac2e26d-4057-4507-bc25-e5599397b920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_528db49c-3839-42b7-b494-a45ca397b76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_baa26166-72e6-42b1-897f-990e41d8fd5c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_528db49c-3839-42b7-b494-a45ca397b76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6eced410-9488-482d-a61b-dec4517c1db9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_baa26166-72e6-42b1-897f-990e41d8fd5c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6eced410-9488-482d-a61b-dec4517c1db9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_cfabd09d-1f60-4dfa-b375-cd20c1cdfaa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_baa26166-72e6-42b1-897f-990e41d8fd5c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_cfabd09d-1f60-4dfa-b375-cd20c1cdfaa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_6c5dfa1c-502c-4258-b9f8-053f48d8dc42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_5fd04a6a-320f-45fa-ad01-4e0718017b0f" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_6c5dfa1c-502c-4258-b9f8-053f48d8dc42" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_5fd04a6a-320f-45fa-ad01-4e0718017b0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_ca0f98dc-5ad9-46c5-a557-be14eb6bcbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_6c5dfa1c-502c-4258-b9f8-053f48d8dc42" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_ca0f98dc-5ad9-46c5-a557-be14eb6bcbd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_6261b3b3-8263-4861-813c-62b319a1c552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_6c5dfa1c-502c-4258-b9f8-053f48d8dc42" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_6261b3b3-8263-4861-813c-62b319a1c552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_7b83667a-b93b-499f-8a9a-81f6e18ba1d7" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_6c5dfa1c-502c-4258-b9f8-053f48d8dc42" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_7b83667a-b93b-499f-8a9a-81f6e18ba1d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_225deff0-9667-430e-be7d-30ff66119532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_6c5dfa1c-502c-4258-b9f8-053f48d8dc42" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_225deff0-9667-430e-be7d-30ff66119532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_af4ead56-c1d8-45cd-ac9e-a5aa968a1a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_f265d551-9ec5-4b60-a87c-aff9de4590f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_af4ead56-c1d8-45cd-ac9e-a5aa968a1a4a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_f265d551-9ec5-4b60-a87c-aff9de4590f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_da1942e3-6d9f-4b84-a2dc-04d07b755d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_af4ead56-c1d8-45cd-ac9e-a5aa968a1a4a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_da1942e3-6d9f-4b84-a2dc-04d07b755d38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e27509fe-3ec5-4ab6-b2c7-274f63646d72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_91a7f3d6-1828-4719-8bd4-7f48e4c44b64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e27509fe-3ec5-4ab6-b2c7-274f63646d72" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_91a7f3d6-1828-4719-8bd4-7f48e4c44b64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_e325c1fe-db9c-4e63-aad5-4dbcfe1e25fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_e27509fe-3ec5-4ab6-b2c7-274f63646d72" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_e325c1fe-db9c-4e63-aad5-4dbcfe1e25fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_08ccc5ad-9f64-4c10-94c8-f75ad6fda010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_34e0ff45-3e0e-48f4-9fb5-9405b678afa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_08ccc5ad-9f64-4c10-94c8-f75ad6fda010" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_34e0ff45-3e0e-48f4-9fb5-9405b678afa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_54abdd99-20b8-492f-bbdf-de6e380515a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_08ccc5ad-9f64-4c10-94c8-f75ad6fda010" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_54abdd99-20b8-492f-bbdf-de6e380515a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_8e83f090-bb5b-48d2-a49d-2e26c44d7d3e" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_08ccc5ad-9f64-4c10-94c8-f75ad6fda010" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_8e83f090-bb5b-48d2-a49d-2e26c44d7d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_d702e975-5820-4d7e-9459-71952164bfff" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_08ccc5ad-9f64-4c10-94c8-f75ad6fda010" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_d702e975-5820-4d7e-9459-71952164bfff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9a10515e-05dd-47e1-b81c-9e2e08b58780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_5e370aee-b825-443a-9bfd-0452eb9fae04" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9a10515e-05dd-47e1-b81c-9e2e08b58780" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_5e370aee-b825-443a-9bfd-0452eb9fae04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_6dcf2e76-6ad3-4827-a704-69fd43a838da" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9a10515e-05dd-47e1-b81c-9e2e08b58780" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_6dcf2e76-6ad3-4827-a704-69fd43a838da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_c907bfe0-9eee-4bb3-ba70-74c85c047b80" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9a10515e-05dd-47e1-b81c-9e2e08b58780" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_c907bfe0-9eee-4bb3-ba70-74c85c047b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_bcd0b23f-1755-4be4-9767-c499b50a5224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9a10515e-05dd-47e1-b81c-9e2e08b58780" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_bcd0b23f-1755-4be4-9767-c499b50a5224" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_e0493141-50d2-4004-a94a-d08614b1bccf" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9a10515e-05dd-47e1-b81c-9e2e08b58780" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_e0493141-50d2-4004-a94a-d08614b1bccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_51875c70-1241-4728-af92-2b398cbbe2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_aa9c065a-1c7a-486e-8270-3d199ce8a377" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationSupplies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_51875c70-1241-4728-af92-2b398cbbe2dd" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_aa9c065a-1c7a-486e-8270-3d199ce8a377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_9caf5478-bd21-463c-bfae-449fa3a94ef5" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_51875c70-1241-4728-af92-2b398cbbe2dd" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_9caf5478-bd21-463c-bfae-449fa3a94ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_23b47b14-de1a-4902-997b-e1eb2678812e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_51875c70-1241-4728-af92-2b398cbbe2dd" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_23b47b14-de1a-4902-997b-e1eb2678812e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_255923a6-ced1-46f5-9e17-e2e016ff68cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_51875c70-1241-4728-af92-2b398cbbe2dd" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_255923a6-ced1-46f5-9e17-e2e016ff68cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_8c16da15-7f52-4165-92d3-24d582d5ccc7" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_51875c70-1241-4728-af92-2b398cbbe2dd" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_8c16da15-7f52-4165-92d3-24d582d5ccc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_9bbf5258-ceb6-4814-b486-0c689dba28ab" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_51875c70-1241-4728-af92-2b398cbbe2dd" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_9bbf5258-ceb6-4814-b486-0c689dba28ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f208175-f0fd-415a-86ee-3121ca5a6875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_3fd9d26e-8296-43d0-a2b2-71a023d5740a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f208175-f0fd-415a-86ee-3121ca5a6875" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_3fd9d26e-8296-43d0-a2b2-71a023d5740a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6776d626-4d23-4c33-89ca-36d8d0ad6716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_2f208175-f0fd-415a-86ee-3121ca5a6875" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_6776d626-4d23-4c33-89ca-36d8d0ad6716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6abcf9a7-2603-4543-893f-43378d34bdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_ec9628aa-3784-4a2f-8ab2-a53b6013ff4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6abcf9a7-2603-4543-893f-43378d34bdfe" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_ec9628aa-3784-4a2f-8ab2-a53b6013ff4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_048a0f55-f6ad-4272-866d-6848d5cddb82" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6abcf9a7-2603-4543-893f-43378d34bdfe" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_048a0f55-f6ad-4272-866d-6848d5cddb82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_ed764a24-90c8-4e78-8ae3-a9fe799c52ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6abcf9a7-2603-4543-893f-43378d34bdfe" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_ed764a24-90c8-4e78-8ae3-a9fe799c52ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_a68dedc2-6e6f-4b7f-9959-37fc7a8ad6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_6abcf9a7-2603-4543-893f-43378d34bdfe" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_a68dedc2-6e6f-4b7f-9959-37fc7a8ad6ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_2e3db663-5664-4171-8d09-a8d4488514d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_64416ca7-e217-48b7-8444-6f2de4f8c728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_2e3db663-5664-4171-8d09-a8d4488514d6" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_64416ca7-e217-48b7-8444-6f2de4f8c728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9c1c4297-141c-4862-af6e-253e14abf740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_2e3db663-5664-4171-8d09-a8d4488514d6" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_9c1c4297-141c-4862-af6e-253e14abf740" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_552669fa-573b-465c-af19-75b84d3b7bc1" xlink:href="ehc-20221231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d1ab0e91-5f6b-42e0-ab1f-c0f83d24df60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_552669fa-573b-465c-af19-75b84d3b7bc1" xlink:to="loc_us-gaap_Goodwill_d1ab0e91-5f6b-42e0-ab1f-c0f83d24df60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_5b4380e9-22b5-4f8c-b5d0-9caeb83583ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_552669fa-573b-465c-af19-75b84d3b7bc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_5b4380e9-22b5-4f8c-b5d0-9caeb83583ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c47e3505-e5e1-4f6b-a4c3-3e190e1791fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_552669fa-573b-465c-af19-75b84d3b7bc1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c47e3505-e5e1-4f6b-a4c3-3e190e1791fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecuritiesComponentsofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InvestmentsCashandRestrictedCash_c91a3942-61f3-4f47-ac63-0f5cabaed5fe" xlink:href="ehc-20221231.xsd#ehc_InvestmentsCashandRestrictedCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f30e7bfd-714c-458b-b628-b4ba38721f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_InvestmentsCashandRestrictedCash_c91a3942-61f3-4f47-ac63-0f5cabaed5fe" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f30e7bfd-714c-458b-b628-b4ba38721f80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_020b241f-8d3f-4f9e-a0d8-2de30733c18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_InvestmentsCashandRestrictedCash_c91a3942-61f3-4f47-ac63-0f5cabaed5fe" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_020b241f-8d3f-4f9e-a0d8-2de30733c18a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_62d41b0b-c9b9-4544-902e-c1144040b565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRestricted"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_InvestmentsCashandRestrictedCash_c91a3942-61f3-4f47-ac63-0f5cabaed5fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_62d41b0b-c9b9-4544-902e-c1144040b565" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#AccountsReceivableComponentsofAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_595e873d-7bbb-4a4f-853f-37ec97ee42c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_ba344f45-b631-44c1-8ddc-422e55798b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_595e873d-7bbb-4a4f-853f-37ec97ee42c2" xlink:to="loc_us-gaap_ReceivablesNetCurrent_ba344f45-b631-44c1-8ddc-422e55798b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_2579ee4a-0297-48e1-b1c3-48a1c772268e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNet_595e873d-7bbb-4a4f-853f-37ec97ee42c2" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_2579ee4a-0297-48e1-b1c3-48a1c772268e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d71c234a-a082-466d-9ea3-30d85187430d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_bac06aac-b92c-467f-aad2-3d3973e8676e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_d71c234a-a082-466d-9ea3-30d85187430d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_bac06aac-b92c-467f-aad2-3d3973e8676e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_7fdc9984-c925-4cab-aabe-544774f8cbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ReceivablesNetCurrent_d71c234a-a082-466d-9ea3-30d85187430d" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_7fdc9984-c925-4cab-aabe-544774f8cbfa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c2ef6e7c-67f2-42cf-bbf9-56b5c8422ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0cdf461f-9671-4bc7-a5c4-c2f8aa47265c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c2ef6e7c-67f2-42cf-bbf9-56b5c8422ab4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0cdf461f-9671-4bc7-a5c4-c2f8aa47265c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_ab20f913-f1eb-41ad-b52c-0d699a12bddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c2ef6e7c-67f2-42cf-bbf9-56b5c8422ab4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_ab20f913-f1eb-41ad-b52c-0d699a12bddc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalfinanceleasecost_b577b4e9-5cf4-439e-a776-ce3c9dbc9bb4" xlink:href="ehc-20221231.xsd#ehc_Totalfinanceleasecost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ffcc88e4-dbfa-46cf-84b9-85430e51b877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalfinanceleasecost_b577b4e9-5cf4-439e-a776-ce3c9dbc9bb4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ffcc88e4-dbfa-46cf-84b9-85430e51b877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_82ee19fa-2d9b-42ea-ab8d-152c257c6173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalfinanceleasecost_b577b4e9-5cf4-439e-a776-ce3c9dbc9bb4" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_82ee19fa-2d9b-42ea-ab8d-152c257c6173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_25b88f40-ec0d-4041-98aa-ea8496caf670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_64deff7e-6a20-4d9a-bed1-0e5ab7cae21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_25b88f40-ec0d-4041-98aa-ea8496caf670" xlink:to="loc_us-gaap_OperatingLeaseCost_64deff7e-6a20-4d9a-bed1-0e5ab7cae21f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Shorttermandvariableleasecost_46c817c1-0932-46a1-94bc-1d613425f513" xlink:href="ehc-20221231.xsd#ehc_Shorttermandvariableleasecost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_25b88f40-ec0d-4041-98aa-ea8496caf670" xlink:to="loc_ehc_Shorttermandvariableleasecost_46c817c1-0932-46a1-94bc-1d613425f513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_48ef1500-f0e0-4384-b4d7-2911c48604f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_25b88f40-ec0d-4041-98aa-ea8496caf670" xlink:to="loc_us-gaap_SubleaseIncome_48ef1500-f0e0-4384-b4d7-2911c48604f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalfinanceleasecost_333e3bbe-d093-40ca-b7e6-9cedf7e23da9" xlink:href="ehc-20221231.xsd#ehc_Totalfinanceleasecost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_25b88f40-ec0d-4041-98aa-ea8496caf670" xlink:to="loc_ehc_Totalfinanceleasecost_333e3bbe-d093-40ca-b7e6-9cedf7e23da9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalleaseliabilities_26140267-0758-4e3e-adef-dc9454f0e680" xlink:href="ehc-20221231.xsd#ehc_Totalleaseliabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_72275f10-d7bd-4acb-8f01-641ad1d54261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalleaseliabilities_26140267-0758-4e3e-adef-dc9454f0e680" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_72275f10-d7bd-4acb-8f01-641ad1d54261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a0071925-065c-4df7-92e2-d68cf1d941d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalleaseliabilities_26140267-0758-4e3e-adef-dc9454f0e680" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_a0071925-065c-4df7-92e2-d68cf1d941d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_86c71893-ffa2-47ef-a1ff-3c4cb11dfd13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalleaseliabilities_26140267-0758-4e3e-adef-dc9454f0e680" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_86c71893-ffa2-47ef-a1ff-3c4cb11dfd13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_82c19e19-31fa-4dd0-964a-d15ff33680ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totalleaseliabilities_26140267-0758-4e3e-adef-dc9454f0e680" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_82c19e19-31fa-4dd0-964a-d15ff33680ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totaloperatingandfinanceleaseassets_b53c393c-43aa-40fe-9f9a-900723607747" xlink:href="ehc-20221231.xsd#ehc_Totaloperatingandfinanceleaseassets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_beb93e66-9080-49e8-9860-56fe4642b9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totaloperatingandfinanceleaseassets_b53c393c-43aa-40fe-9f9a-900723607747" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_beb93e66-9080-49e8-9860-56fe4642b9cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_a1127707-f3a5-46c7-920a-8729523bb695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ehc_Totaloperatingandfinanceleaseassets_b53c393c-43aa-40fe-9f9a-900723607747" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_a1127707-f3a5-46c7-920a-8729523bb695" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ee942607-ed67-4c55-989e-9501cf007f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b98cc952-be18-48fa-a185-7e8322b3d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ee942607-ed67-4c55-989e-9501cf007f21" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b98cc952-be18-48fa-a185-7e8322b3d74d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cbacd85f-d133-4d45-b54d-ffe7d193dac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ee942607-ed67-4c55-989e-9501cf007f21" xlink:to="loc_us-gaap_OperatingLeaseLiability_cbacd85f-d133-4d45-b54d-ffe7d193dac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_462ebd64-1fdb-4067-9524-3d9d93a81758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_98b9773d-64a1-41bb-8dce-c5ade89a7f61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_462ebd64-1fdb-4067-9524-3d9d93a81758" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_98b9773d-64a1-41bb-8dce-c5ade89a7f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5cbb646d-5d8e-4e44-a278-d479c08301e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_462ebd64-1fdb-4067-9524-3d9d93a81758" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_5cbb646d-5d8e-4e44-a278-d479c08301e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_25970323-3f4e-427a-9725-62aacaa8f23b" xlink:href="ehc-20221231.xsd#ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_462ebd64-1fdb-4067-9524-3d9d93a81758" xlink:to="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_25970323-3f4e-427a-9725-62aacaa8f23b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_3826bb5b-e43a-4fe4-b56a-7ae611f4e662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_462ebd64-1fdb-4067-9524-3d9d93a81758" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_3826bb5b-e43a-4fe4-b56a-7ae611f4e662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4c04ab02-e630-4b61-8759-5baeb880e131" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_462ebd64-1fdb-4067-9524-3d9d93a81758" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_4c04ab02-e630-4b61-8759-5baeb880e131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5c32774d-b3da-4922-aaff-8b8b618df56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_462ebd64-1fdb-4067-9524-3d9d93a81758" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5c32774d-b3da-4922-aaff-8b8b618df56d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cc6ab5a8-bf5b-429e-8d65-58fce0dd0214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_58c8c8bb-335d-4943-ab77-5265352f6d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cc6ab5a8-bf5b-429e-8d65-58fce0dd0214" xlink:to="loc_us-gaap_FinanceLeaseLiability_58c8c8bb-335d-4943-ab77-5265352f6d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_97af7bd5-6350-4ef7-aee0-c7bacb5605a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_cc6ab5a8-bf5b-429e-8d65-58fce0dd0214" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_97af7bd5-6350-4ef7-aee0-c7bacb5605a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea4fd809-f3c6-4b33-a426-bf78f5605564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_40de34b5-4c4e-4a67-8ea3-0234425ef07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea4fd809-f3c6-4b33-a426-bf78f5605564" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_40de34b5-4c4e-4a67-8ea3-0234425ef07c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_04371719-38c6-48ed-8360-47a3e43e09f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea4fd809-f3c6-4b33-a426-bf78f5605564" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_04371719-38c6-48ed-8360-47a3e43e09f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ab4d6ae6-7aca-4a47-9b3e-4e7cb582c8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea4fd809-f3c6-4b33-a426-bf78f5605564" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ab4d6ae6-7aca-4a47-9b3e-4e7cb582c8b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ee4ecf3b-d863-4bbd-a83f-450969267208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea4fd809-f3c6-4b33-a426-bf78f5605564" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_ee4ecf3b-d863-4bbd-a83f-450969267208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bf154469-4201-46c5-94ff-342945523f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea4fd809-f3c6-4b33-a426-bf78f5605564" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bf154469-4201-46c5-94ff-342945523f85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_99268f08-db3c-4e3f-8c31-626b83609c1a" xlink:href="ehc-20221231.xsd#ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ea4fd809-f3c6-4b33-a426-bf78f5605564" xlink:to="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_99268f08-db3c-4e3f-8c31-626b83609c1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ceb764b0-d24f-4b32-bc37-c7962bb72aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4193bfc5-ee76-4796-8f55-38f1acdc52f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ceb764b0-d24f-4b32-bc37-c7962bb72aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4193bfc5-ee76-4796-8f55-38f1acdc52f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aff6ed05-b1c3-48d0-ad9d-ccad01633e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ceb764b0-d24f-4b32-bc37-c7962bb72aae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_aff6ed05-b1c3-48d0-ad9d-ccad01633e0d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_af4ce17b-14f0-4911-9064-97738d457e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9bb76515-8f7a-40aa-a47b-58f2f28cb6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_af4ce17b-14f0-4911-9064-97738d457e93" xlink:to="loc_us-gaap_LongTermDebt_9bb76515-8f7a-40aa-a47b-58f2f28cb6db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_02462189-ed8a-4917-a895-823bd900f296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_af4ce17b-14f0-4911-9064-97738d457e93" xlink:to="loc_us-gaap_FinanceLeaseLiability_02462189-ed8a-4917-a895-823bd900f296" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtLongtermDebtOutstandingDetails_1"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_5a246c4c-5554-4b7e-8a61-5062ec9f279c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_dd0ac655-e820-49b2-880a-a02b997fa2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_5a246c4c-5554-4b7e-8a61-5062ec9f279c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_dd0ac655-e820-49b2-880a-a02b997fa2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_bf9b2eec-9694-4099-a0f1-6099aceeddda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_5a246c4c-5554-4b7e-8a61-5062ec9f279c" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_bf9b2eec-9694-4099-a0f1-6099aceeddda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_b581af32-6c37-44d7-a34c-1cd1b0c06ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_73ab5155-65a8-4dcf-951c-5fdb19429351" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearOne"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_b581af32-6c37-44d7-a34c-1cd1b0c06ffb" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_73ab5155-65a8-4dcf-951c-5fdb19429351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_44190c4b-f90f-4c44-b8b4-893e822f8411" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_b581af32-6c37-44d7-a34c-1cd1b0c06ffb" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_44190c4b-f90f-4c44-b8b4-893e822f8411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_7afcbce3-a624-4b17-81c9-53766c2e49f3" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_b581af32-6c37-44d7-a34c-1cd1b0c06ffb" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_7afcbce3-a624-4b17-81c9-53766c2e49f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_1bdd7fda-fce7-496b-9096-48ab8c2c7cc3" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_b581af32-6c37-44d7-a34c-1cd1b0c06ffb" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_1bdd7fda-fce7-496b-9096-48ab8c2c7cc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_8f9ea896-538d-49d4-86ad-35253bd6c7e9" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_b581af32-6c37-44d7-a34c-1cd1b0c06ffb" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_8f9ea896-538d-49d4-86ad-35253bd6c7e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_7559c8c1-8dfa-4d47-9d2f-a8ea967e1e45" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_b581af32-6c37-44d7-a34c-1cd1b0c06ffb" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_7559c8c1-8dfa-4d47-9d2f-a8ea967e1e45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SelfInsuredRisksChangesinSelfinsuranceReservesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_fa8fa30a-0357-42e2-9ff2-5727b7300107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_118ea2d5-ce72-45f5-a39c-e7ceeb69677f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_fa8fa30a-0357-42e2-9ff2-5727b7300107" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_118ea2d5-ce72-45f5-a39c-e7ceeb69677f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_e9de3539-ba60-4076-846c-338eb7396a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_fa8fa30a-0357-42e2-9ff2-5727b7300107" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_e9de3539-ba60-4076-846c-338eb7396a2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fe255b17-4f91-4919-8861-13616f2a423f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_3e0a767b-ea49-4d7f-8183-5dc950ced9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fe255b17-4f91-4919-8861-13616f2a423f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_3e0a767b-ea49-4d7f-8183-5dc950ced9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_b5f602cd-7ab4-41f3-8c03-c6fc49e4da3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fe255b17-4f91-4919-8861-13616f2a423f" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_b5f602cd-7ab4-41f3-8c03-c6fc49e4da3e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1ded20c9-3a79-41af-a470-5e8f79e5b2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2e25d734-b35c-42e7-86be-09add61d8f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1ded20c9-3a79-41af-a470-5e8f79e5b2ef" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2e25d734-b35c-42e7-86be-09add61d8f77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a799226e-89df-46ba-86f1-d9545be33b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1ded20c9-3a79-41af-a470-5e8f79e5b2ef" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a799226e-89df-46ba-86f1-d9545be33b5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2de2e392-d13b-4f9d-b946-ea9ce2c14971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1c287d2e-bae4-4165-abc6-65f85c654cad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2de2e392-d13b-4f9d-b946-ea9ce2c14971" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1c287d2e-bae4-4165-abc6-65f85c654cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_53247d09-e9a8-49aa-ad31-96a3d9b6da4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2de2e392-d13b-4f9d-b946-ea9ce2c14971" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_53247d09-e9a8-49aa-ad31-96a3d9b6da4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a57d8095-342f-4436-81a1-58e12f05122e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5d290e7d-f174-4695-9ff7-55eb3a674d04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a57d8095-342f-4436-81a1-58e12f05122e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5d290e7d-f174-4695-9ff7-55eb3a674d04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c65fb451-612f-40f1-aade-93942a677761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a57d8095-342f-4436-81a1-58e12f05122e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c65fb451-612f-40f1-aade-93942a677761" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f99280d0-a62e-42c6-8a09-360db7a6ac5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_eab05616-8e32-430e-832f-1501e39362c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f99280d0-a62e-42c6-8a09-360db7a6ac5a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_eab05616-8e32-430e-832f-1501e39362c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_f23a8e07-5494-4be0-a480-a15be07a244f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f99280d0-a62e-42c6-8a09-360db7a6ac5a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_f23a8e07-5494-4be0-a480-a15be07a244f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b6455163-d8d5-471f-b99a-32fddb5b37f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f99280d0-a62e-42c6-8a09-360db7a6ac5a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_b6455163-d8d5-471f-b99a-32fddb5b37f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1f8a4f07-1b1a-40c8-aaf4-ba217a8bc830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f99280d0-a62e-42c6-8a09-360db7a6ac5a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1f8a4f07-1b1a-40c8-aaf4-ba217a8bc830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d7e15c52-a53e-40c8-9451-109e7e2c791a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f99280d0-a62e-42c6-8a09-360db7a6ac5a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d7e15c52-a53e-40c8-9451-109e7e2c791a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_49451fcd-51d0-4a17-9448-b58c6c67b89d" xlink:href="ehc-20221231.xsd#ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f99280d0-a62e-42c6-8a09-360db7a6ac5a" xlink:to="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_49451fcd-51d0-4a17-9448-b58c6c67b89d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_91e5ed25-4c8c-44ff-b39a-86f4e92f6b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_75ba0b53-ec6c-448b-a2bb-99f1aa8d96ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91e5ed25-4c8c-44ff-b39a-86f4e92f6b9d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_75ba0b53-ec6c-448b-a2bb-99f1aa8d96ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c18fb9a1-f229-4a89-a279-95d03f533700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91e5ed25-4c8c-44ff-b39a-86f4e92f6b9d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c18fb9a1-f229-4a89-a279-95d03f533700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_aa8ab47b-50d9-4db6-ac1c-fb957ad0e446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91e5ed25-4c8c-44ff-b39a-86f4e92f6b9d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_aa8ab47b-50d9-4db6-ac1c-fb957ad0e446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_7e0cab04-4192-4fba-a55f-cc2fa649dbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91e5ed25-4c8c-44ff-b39a-86f4e92f6b9d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_7e0cab04-4192-4fba-a55f-cc2fa649dbe7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_8332308b-d0b2-4777-9ada-22ef8edea019" xlink:href="ehc-20221231.xsd#ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91e5ed25-4c8c-44ff-b39a-86f4e92f6b9d" xlink:to="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_8332308b-d0b2-4777-9ada-22ef8edea019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_01dfb382-fa6a-4f38-bbc9-39c8c0d8bfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_91e5ed25-4c8c-44ff-b39a-86f4e92f6b9d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_01dfb382-fa6a-4f38-bbc9-39c8c0d8bfc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_c294538a-a198-485a-b4c5-ac9b2126e8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_da7dea0c-67ef-4c0c-8e94-3c75ff4af3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c294538a-a198-485a-b4c5-ac9b2126e8e8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_da7dea0c-67ef-4c0c-8e94-3c75ff4af3e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_ee5b4972-3683-4cf4-9cbe-d9fa0c2bf530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_c294538a-a198-485a-b4c5-ac9b2126e8e8" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_ee5b4972-3683-4cf4-9cbe-d9fa0c2bf530" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2efff79c-c198-46dd-8a3e-79bf78b1dad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e18e539f-9c1a-4ba4-a3b9-df4b9f618230" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2efff79c-c198-46dd-8a3e-79bf78b1dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e18e539f-9c1a-4ba4-a3b9-df4b9f618230" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_fa9bb9a3-6b1c-4dad-ae59-a5abf89998cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2efff79c-c198-46dd-8a3e-79bf78b1dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_fa9bb9a3-6b1c-4dad-ae59-a5abf89998cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a79270ee-2862-43c5-b793-62177ec74aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2efff79c-c198-46dd-8a3e-79bf78b1dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a79270ee-2862-43c5-b793-62177ec74aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_a686b579-f19c-4575-b614-70de9bc36bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2efff79c-c198-46dd-8a3e-79bf78b1dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_a686b579-f19c-4575-b614-70de9bc36bf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_16ade91d-de1e-425a-8c16-f1d1062a4742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2efff79c-c198-46dd-8a3e-79bf78b1dad1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_16ade91d-de1e-425a-8c16-f1d1062a4742" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability_519abd20-8811-493b-afb4-3e4578b3e529" xlink:href="ehc-20221231.xsd#ehc_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2efff79c-c198-46dd-8a3e-79bf78b1dad1" xlink:to="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability_519abd20-8811-493b-afb4-3e4578b3e529" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1269ef73-6647-49ce-bdb2-f0475659135e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3ec4cbf2-5b8e-445e-b344-c5ef08d9c41a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1269ef73-6647-49ce-bdb2-f0475659135e" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_3ec4cbf2-5b8e-445e-b344-c5ef08d9c41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b1df8e7e-5650-4762-bbde-1fd38206b4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1269ef73-6647-49ce-bdb2-f0475659135e" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b1df8e7e-5650-4762-bbde-1fd38206b4bb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_2dd49d41-0191-4dd8-abcb-5501f752dd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7e0cf5d4-ea82-4d22-9ff4-613bd16c9166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_2dd49d41-0191-4dd8-abcb-5501f752dd32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7e0cf5d4-ea82-4d22-9ff4-613bd16c9166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_cd37d386-f163-4cfa-8ad0-99f6c35f4a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_2dd49d41-0191-4dd8-abcb-5501f752dd32" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_cd37d386-f163-4cfa-8ad0-99f6c35f4a18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_8a22b8bd-6f52-4bc6-a789-dff37c97f1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_2dd49d41-0191-4dd8-abcb-5501f752dd32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_8a22b8bd-6f52-4bc6-a789-dff37c97f1e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_dc1685fb-9760-41be-83a9-12c096a2649e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dbb7094a-2084-46f4-935c-e17a8d365371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_dc1685fb-9760-41be-83a9-12c096a2649e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_dbb7094a-2084-46f4-935c-e17a8d365371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_eabd023b-d46b-40e7-af0e-92bb909cf38e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_dc1685fb-9760-41be-83a9-12c096a2649e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_eabd023b-d46b-40e7-af0e-92bb909cf38e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c685fc72-4bba-4b01-b309-47dd1bb78cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_7e66e886-2c31-481d-8380-4abc334f9cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c685fc72-4bba-4b01-b309-47dd1bb78cec" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_7e66e886-2c31-481d-8380-4abc334f9cb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_63ab6a30-f565-44cb-8448-5b8e582b4994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_c685fc72-4bba-4b01-b309-47dd1bb78cec" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_63ab6a30-f565-44cb-8448-5b8e582b4994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_72fac771-c3df-454d-a22d-fa8bcde8490c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_8586367e-bd13-41b6-8629-3765778dd301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_72fac771-c3df-454d-a22d-fa8bcde8490c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_8586367e-bd13-41b6-8629-3765778dd301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_51a06029-54d8-4cd3-bc27-4917c3bcc8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_72fac771-c3df-454d-a22d-fa8bcde8490c" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_51a06029-54d8-4cd3-bc27-4917c3bcc8f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_93a8f67c-da53-4638-b6f4-bb71ec905409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_72fac771-c3df-454d-a22d-fa8bcde8490c" xlink:to="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_93a8f67c-da53-4638-b6f4-bb71ec905409" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_807655d3-7fec-4f86-a7fe-624b3e3a90f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_14871a92-0300-449f-bcd1-ee81c1fff390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_807655d3-7fec-4f86-a7fe-624b3e3a90f3" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_14871a92-0300-449f-bcd1-ee81c1fff390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_24e97def-8472-4ce7-96d0-bb68cc7beb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_807655d3-7fec-4f86-a7fe-624b3e3a90f3" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_24e97def-8472-4ce7-96d0-bb68cc7beb71" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_152cdde2-0892-40ec-838f-52145bafe0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c1aa4f47-3dd5-4e4b-b434-a97a968dd662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_152cdde2-0892-40ec-838f-52145bafe0ba" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c1aa4f47-3dd5-4e4b-b434-a97a968dd662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2a159f21-1d10-417f-a6e0-b4a712b643ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_152cdde2-0892-40ec-838f-52145bafe0ba" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2a159f21-1d10-417f-a6e0-b4a712b643ec" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>ehc-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6ef5271b-25cf-4941-a7fe-936386c94a75,g:d3e86cc2-acdf-4f67-b511-3ef26c190552-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ib533c9323d7a4a4197b0db8bad80e927_ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_38e735b7-b15e-4e56-97b1-50e5b9508673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_38e735b7-b15e-4e56-97b1-50e5b9508673" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0205c810-4829-459c-8e13-262481b22799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0205c810-4829-459c-8e13-262481b22799" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b1fee44-8fac-43bb-8ae8-2b8223ea09ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_CommonStockSharesIssued_4b1fee44-8fac-43bb-8ae8-2b8223ea09ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_8b894944-fa73-44a4-bff7-6e203ffcee5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_8b894944-fa73-44a4-bff7-6e203ffcee5f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a3a29ff5-3e53-4801-ba80-3c4ced2e3e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_Assets_a3a29ff5-3e53-4801-ba80-3c4ced2e3e43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_79c6869a-9871-4293-af78-cbd6f8322553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_Liabilities_79c6869a-9871-4293-af78-cbd6f8322553" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a6e36405-99ba-4b23-9057-0d7b53fbe42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_StatementTable_a6e36405-99ba-4b23-9057-0d7b53fbe42b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_cd546aeb-da48-444c-b6aa-b5e31ba36165" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a6e36405-99ba-4b23-9057-0d7b53fbe42b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_cd546aeb-da48-444c-b6aa-b5e31ba36165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_cd546aeb-da48-444c-b6aa-b5e31ba36165_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_cd546aeb-da48-444c-b6aa-b5e31ba36165" xlink:to="loc_srt_ConsolidatedEntitiesDomain_cd546aeb-da48-444c-b6aa-b5e31ba36165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ce8c46f7-d395-4d7d-bb2d-75525d6c4cc6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_cd546aeb-da48-444c-b6aa-b5e31ba36165" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ce8c46f7-d395-4d7d-bb2d-75525d6c4cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_811b8c42-3b65-48a7-b020-83758d71544e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ce8c46f7-d395-4d7d-bb2d-75525d6c4cc6" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_811b8c42-3b65-48a7-b020-83758d71544e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="ibf26bd0516294463a44a82a1873434a5_ConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fd9cbdc7-852e-43d5-ad15-3d0d473e9a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fd9cbdc7-852e-43d5-ad15-3d0d473e9a15" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d246c58b-5e43-4650-a49b-15835789ecd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d246c58b-5e43-4650-a49b-15835789ecd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1818e9d1-ae7c-428c-b0ed-5efacdd2b181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1818e9d1-ae7c-428c-b0ed-5efacdd2b181" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ca8a694c-69c7-49bd-82ec-863d6e223e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ca8a694c-69c7-49bd-82ec-863d6e223e7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4bbea44b-18bd-4960-92b8-9cc5df8cd6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4bbea44b-18bd-4960-92b8-9cc5df8cd6c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_badc25da-cff1-4404-aefc-02b52a6d60c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_badc25da-cff1-4404-aefc-02b52a6d60c4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_6e02cc27-8928-454f-a92f-d908f30f8196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_DividendsCommonStockCash_6e02cc27-8928-454f-a92f-d908f30f8196" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_706c6462-7b3f-408d-81c4-ffc52293ccbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_706c6462-7b3f-408d-81c4-ffc52293ccbd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_75c9a2cc-6153-44c7-86f4-7dd9ff994284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_75c9a2cc-6153-44c7-86f4-7dd9ff994284" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f37caf3-27b4-4359-bf59-3c3d9038dda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f37caf3-27b4-4359-bf59-3c3d9038dda1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf260988-d609-4742-9e66-7cfd7c39fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf260988-d609-4742-9e66-7cfd7c39fb65" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d7afe94e-f5ad-4b29-b84b-92c322f91679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d7afe94e-f5ad-4b29-b84b-92c322f91679" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_37cc3600-5b39-4676-9025-b8564bc62ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_37cc3600-5b39-4676-9025-b8564bc62ec1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d8c9add3-acad-493e-b288-8f1951a29904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d8c9add3-acad-493e-b288-8f1951a29904" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_20cd6b32-8eb9-45f9-875c-16634c0b56e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_20cd6b32-8eb9-45f9-875c-16634c0b56e8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_3e7b3a0e-7c46-407f-8ed7-3d0f4e649a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_3e7b3a0e-7c46-407f-8ed7-3d0f4e649a61" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_22485589-794c-4e5e-855d-3e2675358bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_22485589-794c-4e5e-855d-3e2675358bc2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_765631e4-2651-44b4-a64b-802924108c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_765631e4-2651-44b4-a64b-802924108c3f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_4293640c-f0e1-4cda-88fe-1cde6c00c3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_4293640c-f0e1-4cda-88fe-1cde6c00c3e8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_24d323e3-bf2d-4831-9f58-a9afbcef7d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityOther_24d323e3-bf2d-4831-9f58-a9afbcef7d0e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_38174d4f-57ae-491d-9514-308614eccc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f43d0f4-c6ad-45d5-adfe-a3b7894dfbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0db65af2-4a67-484c-9a96-c9dd1344e2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fd9cbdc7-852e-43d5-ad15-3d0d473e9a15" xlink:to="loc_us-gaap_StatementTable_0db65af2-4a67-484c-9a96-c9dd1344e2de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8192a9bb-e545-469e-a75a-1aecf52a8312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0db65af2-4a67-484c-9a96-c9dd1344e2de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8192a9bb-e545-469e-a75a-1aecf52a8312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8192a9bb-e545-469e-a75a-1aecf52a8312_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8192a9bb-e545-469e-a75a-1aecf52a8312" xlink:to="loc_us-gaap_EquityComponentDomain_8192a9bb-e545-469e-a75a-1aecf52a8312_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8192a9bb-e545-469e-a75a-1aecf52a8312" xlink:to="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_06aa045d-5684-4aa0-8781-7fd747c67175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_CommonStockMember_06aa045d-5684-4aa0-8781-7fd747c67175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0d077fdf-3efa-445f-9070-6e55b6f5b82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0d077fdf-3efa-445f-9070-6e55b6f5b82f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bbb47ede-e37d-40c0-b303-d10012ff2511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_RetainedEarningsMember_bbb47ede-e37d-40c0-b303-d10012ff2511" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_18297df9-ab25-4e7f-8d60-39ac855888da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_TreasuryStockCommonMember_18297df9-ab25-4e7f-8d60-39ac855888da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_cccd02f4-63b9-45c6-808c-a9403d5187d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_cccd02f4-63b9-45c6-808c-a9403d5187d8" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="extended" id="ib6a0d1f1aa974fceb169358f9cb8eb51_SummaryofSignificantAccountingPoliciesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_4a881725-be58-4d2e-a7e9-98b1f8b71802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_4a881725-be58-4d2e-a7e9-98b1f8b71802" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals_75d48f8f-202f-4939-8a76-5ba59c37f12c" xlink:href="ehc-20221231.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitals_75d48f8f-202f-4939-8a76-5ba59c37f12c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership_fb23b1c8-da57-42f5-8ac7-4e9ef8244344" xlink:href="ehc-20221231.xsd#ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership_fb23b1c8-da57-42f5-8ac7-4e9ef8244344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage_95e2719a-fab1-4d6c-bd5c-60abf3c23a6f" xlink:href="ehc-20221231.xsd#ehc_Jointventureownershippercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_Jointventureownershippercentage_95e2719a-fab1-4d6c-bd5c-60abf3c23a6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals_a372221e-3f54-46aa-a124-63854483a268" xlink:href="ehc-20221231.xsd#ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals_a372221e-3f54-46aa-a124-63854483a268" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyClaimsAwaitingReviewAmount_5f3bafb2-80cc-42b3-9202-baafa33c474b" xlink:href="ehc-20221231.xsd#ehc_LossContingencyClaimsAwaitingReviewAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyClaimsAwaitingReviewAmount_5f3bafb2-80cc-42b3-9202-baafa33c474b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAppealedClaimsDeniedAmount_daf7bce1-ff65-4431-905b-b769fb4d9674" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAppealedClaimsDeniedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyAppealedClaimsDeniedAmount_daf7bce1-ff65-4431-905b-b769fb4d9674" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyNumberOfClaimsSampledForAudit_f4476c62-551e-4b35-8afc-14533b3c3eaa" xlink:href="ehc-20221231.xsd#ehc_LossContingencyNumberOfClaimsSampledForAudit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyNumberOfClaimsSampledForAudit_f4476c62-551e-4b35-8afc-14533b3c3eaa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyClaimsSampledForAuditAmount_6f5b7aa0-ca28-4f90-8361-583c6f886924" xlink:href="ehc-20221231.xsd#ehc_LossContingencyClaimsSampledForAuditAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyClaimsSampledForAuditAmount_6f5b7aa0-ca28-4f90-8361-583c6f886924" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyExtrapolatedErrorRatePeriod_9d76ca9f-60b5-43d9-b4f3-22bac972c510" xlink:href="ehc-20221231.xsd#ehc_LossContingencyExtrapolatedErrorRatePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyExtrapolatedErrorRatePeriod_9d76ca9f-60b5-43d9-b4f3-22bac972c510" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount_93b74103-29cd-44e8-a6c8-83b1dd08e83b" xlink:href="ehc-20221231.xsd#ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount_93b74103-29cd-44e8-a6c8-83b1dd08e83b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination_ba840c1e-a4e6-4619-a0a9-dfe63f7343c7" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination_ba840c1e-a4e6-4619-a0a9-dfe63f7343c7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest_5d0b5eb1-632a-4600-b4dd-a085860c7281" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest_5d0b5eb1-632a-4600-b4dd-a085860c7281" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fa075fc2-bdeb-4519-aca4-f4011e0f23b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fa075fc2-bdeb-4519-aca4-f4011e0f23b5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_269320d0-aa0b-46d6-9dfe-6ff11bf3a189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_269320d0-aa0b-46d6-9dfe-6ff11bf3a189" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_8868de80-1e11-4fa0-b098-d5d1fc43c86a" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_8868de80-1e11-4fa0-b098-d5d1fc43c86a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_df81d028-cec3-4fe8-ae19-781d2b54d9ec" xlink:href="ehc-20221231.xsd#ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_df81d028-cec3-4fe8-ae19-781d2b54d9ec" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_a88aff10-cee9-4566-9702-297b5e85f5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_AdvertisingExpense_a88aff10-cee9-4566-9702-297b5e85f5ea" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb683c1d-5c93-4400-8ca4-5990e4ff3ade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_srt_RangeAxis_cb683c1d-5c93-4400-8ca4-5990e4ff3ade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb683c1d-5c93-4400-8ca4-5990e4ff3ade_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cb683c1d-5c93-4400-8ca4-5990e4ff3ade" xlink:to="loc_srt_RangeMember_cb683c1d-5c93-4400-8ca4-5990e4ff3ade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_457181d8-27ad-4414-aae1-f4754b53b035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cb683c1d-5c93-4400-8ca4-5990e4ff3ade" xlink:to="loc_srt_RangeMember_457181d8-27ad-4414-aae1-f4754b53b035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c9dc6c9-957f-4cf1-b67d-edbeeb0510de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_457181d8-27ad-4414-aae1-f4754b53b035" xlink:to="loc_srt_MinimumMember_5c9dc6c9-957f-4cf1-b67d-edbeeb0510de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_660c865e-cc1b-47a9-9588-b121afb142ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_457181d8-27ad-4414-aae1-f4754b53b035" xlink:to="loc_srt_MaximumMember_660c865e-cc1b-47a9-9588-b121afb142ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_805e0178-41bd-41c0-bfff-2af8ce42c445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_805e0178-41bd-41c0-bfff-2af8ce42c445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_805e0178-41bd-41c0-bfff-2af8ce42c445_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_805e0178-41bd-41c0-bfff-2af8ce42c445" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_805e0178-41bd-41c0-bfff-2af8ce42c445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_67dcfe2d-c4b4-4d28-afc3-60b343aeeec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_805e0178-41bd-41c0-bfff-2af8ce42c445" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_67dcfe2d-c4b4-4d28-afc3-60b343aeeec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember_8ea09059-3654-4a73-8a8e-6c00f4bc227b" xlink:href="ehc-20221231.xsd#ehc_PayorSourceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_67dcfe2d-c4b4-4d28-afc3-60b343aeeec7" xlink:to="loc_ehc_PayorSourceMember_8ea09059-3654-4a73-8a8e-6c00f4bc227b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9d7492b0-5ae6-4873-8504-348deb42abfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9d7492b0-5ae6-4873-8504-348deb42abfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9d7492b0-5ae6-4873-8504-348deb42abfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9d7492b0-5ae6-4873-8504-348deb42abfa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9d7492b0-5ae6-4873-8504-348deb42abfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b3ccd4b-9af4-4861-820c-58e7151bb396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9d7492b0-5ae6-4873-8504-348deb42abfa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b3ccd4b-9af4-4861-820c-58e7151bb396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_18cc2d8a-e023-4452-afcd-3673d69d5999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b3ccd4b-9af4-4861-820c-58e7151bb396" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_18cc2d8a-e023-4452-afcd-3673d69d5999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b33700da-8fad-46cb-90d3-34910b5c6495" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_srt_CounterpartyNameAxis_b33700da-8fad-46cb-90d3-34910b5c6495" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b33700da-8fad-46cb-90d3-34910b5c6495_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b33700da-8fad-46cb-90d3-34910b5c6495" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b33700da-8fad-46cb-90d3-34910b5c6495_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26c54555-8805-4b4c-9a4d-45ffd95d8b35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b33700da-8fad-46cb-90d3-34910b5c6495" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26c54555-8805-4b4c-9a4d-45ffd95d8b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_1a22908a-bdb9-488f-a54b-ed8243dfe653" xlink:href="ehc-20221231.xsd#ehc_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26c54555-8805-4b4c-9a4d-45ffd95d8b35" xlink:to="loc_ehc_MedicareMember_1a22908a-bdb9-488f-a54b-ed8243dfe653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe" xlink:to="loc_us-gaap_LossContingencyNatureDomain_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DepartmentAppealsBoardAdverseRulingMember_623f751b-a219-469d-a256-946a21ae2d04" xlink:href="ehc-20221231.xsd#ehc_DepartmentAppealsBoardAdverseRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:to="loc_ehc_DepartmentAppealsBoardAdverseRulingMember_623f751b-a219-469d-a256-946a21ae2d04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_UnifiedProgramIntegrityContractorsAuditsMember_81e4ca47-f4be-432e-945a-d777da4e4e1d" xlink:href="ehc-20221231.xsd#ehc_UnifiedProgramIntegrityContractorsAuditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:to="loc_ehc_UnifiedProgramIntegrityContractorsAuditsMember_81e4ca47-f4be-432e-945a-d777da4e4e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RACAuditsMember_6c4c9d58-da1f-4c63-a6e2-07006be70dc1" xlink:href="ehc-20221231.xsd#ehc_RACAuditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:to="loc_ehc_RACAuditsMember_6c4c9d58-da1f-4c63-a6e2-07006be70dc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_724ab165-9bef-48fa-9679-21f6dc5481a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_724ab165-9bef-48fa-9679-21f6dc5481a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_ba542229-3df6-45cb-b3a4-c695bbca7ae2" xlink:href="ehc-20221231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_724ab165-9bef-48fa-9679-21f6dc5481a1" xlink:to="loc_ehc_MarketAccessAssetsMember_ba542229-3df6-45cb-b3a4-c695bbca7ae2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails" xlink:type="extended" id="if9a474ddaf444efbb5d11ab7ef7c47b8_SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8bd8b2b2-2dd4-4961-b6fa-37c654414086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bbb834a5-44b9-4ebc-9a22-5a3d3da891ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bd8b2b2-2dd4-4961-b6fa-37c654414086" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bbb834a5-44b9-4ebc-9a22-5a3d3da891ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6aff50cf-b536-4a4e-9210-7ced34ae49ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bd8b2b2-2dd4-4961-b6fa-37c654414086" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6aff50cf-b536-4a4e-9210-7ced34ae49ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e10cfc57-e4dd-436d-a38c-0f3b07f6922a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6aff50cf-b536-4a4e-9210-7ced34ae49ca" xlink:to="loc_srt_CounterpartyNameAxis_e10cfc57-e4dd-436d-a38c-0f3b07f6922a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e10cfc57-e4dd-436d-a38c-0f3b07f6922a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e10cfc57-e4dd-436d-a38c-0f3b07f6922a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e10cfc57-e4dd-436d-a38c-0f3b07f6922a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e10cfc57-e4dd-436d-a38c-0f3b07f6922a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_c59ecd4c-7e20-468e-a4fc-3c7c1167c4ea" xlink:href="ehc-20221231.xsd#ehc_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_MedicareMember_c59ecd4c-7e20-468e-a4fc-3c7c1167c4ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember_50ed0b93-86a4-4984-9490-9c9e6687f22e" xlink:href="ehc-20221231.xsd#ehc_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_MedicareAdvantageMember_50ed0b93-86a4-4984-9490-9c9e6687f22e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember_7c614c1c-8100-4513-a888-166bae51ea35" xlink:href="ehc-20221231.xsd#ehc_ManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_ManagedCareMember_7c614c1c-8100-4513-a888-166bae51ea35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_145e69d9-b36f-4b56-8194-93269385f289" xlink:href="ehc-20221231.xsd#ehc_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_MedicaidMember_145e69d9-b36f-4b56-8194-93269385f289" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_b2534fcd-718a-40dc-8296-617440ab0d75" xlink:href="ehc-20221231.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_b2534fcd-718a-40dc-8296-617440ab0d75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_4c11f4e0-b65f-400a-896b-c372442669e7" xlink:href="ehc-20221231.xsd#ehc_WorkersCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_WorkersCompensationMember_4c11f4e0-b65f-400a-896b-c372442669e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_ac5ffd5b-f406-4aa2-bdfb-e7c3c74056eb" xlink:href="ehc-20221231.xsd#ehc_PatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_PatientsMember_ac5ffd5b-f406-4aa2-bdfb-e7c3c74056eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember_692e298c-4617-4bd1-9b99-75a854713bc6" xlink:href="ehc-20221231.xsd#ehc_OtherIncomeSourceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_OtherIncomeSourceMember_692e298c-4617-4bd1-9b99-75a854713bc6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended" id="i1542e4277f504a8ea7caa19606ffedb9_SummaryofSignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0f484f8a-a8c3-4417-9546-b7b6be686858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1c8e63d8-c5f4-4eab-96bb-f845c5c11da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0f484f8a-a8c3-4417-9546-b7b6be686858" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1c8e63d8-c5f4-4eab-96bb-f845c5c11da7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0f484f8a-a8c3-4417-9546-b7b6be686858" xlink:to="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e4460344-f9a8-42b8-95c8-e10798dca697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e4460344-f9a8-42b8-95c8-e10798dca697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e4460344-f9a8-42b8-95c8-e10798dca697_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4460344-f9a8-42b8-95c8-e10798dca697" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e4460344-f9a8-42b8-95c8-e10798dca697_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_35852916-8a14-4427-b510-fa75b8c87a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4460344-f9a8-42b8-95c8-e10798dca697" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_35852916-8a14-4427-b510-fa75b8c87a33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember_7f7ccdd4-2ab7-4ada-ac1d-5ca393127bb4" xlink:href="ehc-20221231.xsd#ehc_PayorSourceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_35852916-8a14-4427-b510-fa75b8c87a33" xlink:to="loc_ehc_PayorSourceMember_7f7ccdd4-2ab7-4ada-ac1d-5ca393127bb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_69030d55-d694-4303-b627-10fd2ac8b135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_69030d55-d694-4303-b627-10fd2ac8b135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8fa6e092-62e8-496c-971e-d5b4b6e47c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_69030d55-d694-4303-b627-10fd2ac8b135" xlink:to="loc_us-gaap_AccountsReceivableMember_8fa6e092-62e8-496c-971e-d5b4b6e47c76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f63e837f-53ae-46ba-8c24-f852ea85c2a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_srt_CounterpartyNameAxis_f63e837f-53ae-46ba-8c24-f852ea85c2a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f63e837f-53ae-46ba-8c24-f852ea85c2a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f63e837f-53ae-46ba-8c24-f852ea85c2a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f63e837f-53ae-46ba-8c24-f852ea85c2a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f63e837f-53ae-46ba-8c24-f852ea85c2a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_6c4b833f-0288-4dd8-ade9-20202d4478eb" xlink:href="ehc-20221231.xsd#ehc_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_MedicareMember_6c4b833f-0288-4dd8-ade9-20202d4478eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_c8951776-a983-4f5e-b95d-6316805b5b11" xlink:href="ehc-20221231.xsd#ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_c8951776-a983-4f5e-b95d-6316805b5b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_2818411c-ce7e-4206-b8a6-3d1ed08ac6ca" xlink:href="ehc-20221231.xsd#ehc_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_MedicaidMember_2818411c-ce7e-4206-b8a6-3d1ed08ac6ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_90f3864f-802c-4836-802b-99c54dc5838d" xlink:href="ehc-20221231.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_90f3864f-802c-4836-802b-99c54dc5838d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_a1eebdd8-86f3-4fb0-8cb7-e616dcd98005" xlink:href="ehc-20221231.xsd#ehc_WorkersCompensationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_WorkersCompensationMember_a1eebdd8-86f3-4fb0-8cb7-e616dcd98005" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_c290221c-636e-4276-a368-824d4049c7c2" xlink:href="ehc-20221231.xsd#ehc_PatientsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_PatientsMember_c290221c-636e-4276-a368-824d4049c7c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_ec40c33d-f63e-4e64-9e18-a86ca74eb18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_ec40c33d-f63e-4e64-9e18-a86ca74eb18a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_ec40c33d-f63e-4e64-9e18-a86ca74eb18a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_ec40c33d-f63e-4e64-9e18-a86ca74eb18a" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_ec40c33d-f63e-4e64-9e18-a86ca74eb18a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_bae19a40-a533-47e8-a9f6-51c4a091ff66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_ec40c33d-f63e-4e64-9e18-a86ca74eb18a" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_bae19a40-a533-47e8-a9f6-51c4a091ff66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_3e29975a-bdeb-427b-bff7-db19c03303fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_bae19a40-a533-47e8-a9f6-51c4a091ff66" xlink:to="loc_us-gaap_ThirdPartyPayorMember_3e29975a-bdeb-427b-bff7-db19c03303fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfPayMember_f92200fe-314f-4f21-b3f5-da40fd13f3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfPayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_bae19a40-a533-47e8-a9f6-51c4a091ff66" xlink:to="loc_us-gaap_SelfPayMember_f92200fe-314f-4f21-b3f5-da40fd13f3f3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" xlink:type="extended" id="ia9b8a397bcc741f99e9aa429e41f764c_SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_382a44e4-2831-451a-84fe-e7cd491b4ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_87acf37c-2bb7-4b82-a5d3-f36031e67f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_382a44e4-2831-451a-84fe-e7cd491b4ba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_87acf37c-2bb7-4b82-a5d3-f36031e67f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_382a44e4-2831-451a-84fe-e7cd491b4ba3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951cfb32-a997-4ace-be47-fbb5061a2354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951cfb32-a997-4ace-be47-fbb5061a2354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_951cfb32-a997-4ace-be47-fbb5061a2354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951cfb32-a997-4ace-be47-fbb5061a2354" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_951cfb32-a997-4ace-be47-fbb5061a2354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951cfb32-a997-4ace-be47-fbb5061a2354" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_13d6e003-f295-4f5c-b019-5ddffd617b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:to="loc_us-gaap_BuildingMember_13d6e003-f295-4f5c-b019-5ddffd617b8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_49a3e3be-e4b0-477a-8445-af03077af984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_49a3e3be-e4b0-477a-8445-af03077af984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_a54c63e7-17e5-4ab6-b362-03a477ed9c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:to="loc_us-gaap_VehiclesMember_a54c63e7-17e5-4ab6-b362-03a477ed9c41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c73ffa0a-461c-4ed8-bb7f-5f10cd732a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c73ffa0a-461c-4ed8-bb7f-5f10cd732a6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18333ca7-eb84-4cc8-8f97-2b1a590de63c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:to="loc_srt_RangeAxis_18333ca7-eb84-4cc8-8f97-2b1a590de63c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18333ca7-eb84-4cc8-8f97-2b1a590de63c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_18333ca7-eb84-4cc8-8f97-2b1a590de63c" xlink:to="loc_srt_RangeMember_18333ca7-eb84-4cc8-8f97-2b1a590de63c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03eed013-cd5e-4ed3-b74f-1b8bd7b39a90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_18333ca7-eb84-4cc8-8f97-2b1a590de63c" xlink:to="loc_srt_RangeMember_03eed013-cd5e-4ed3-b74f-1b8bd7b39a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a50bd660-3c6f-46ab-b7fa-149868e3afa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_03eed013-cd5e-4ed3-b74f-1b8bd7b39a90" xlink:to="loc_srt_MinimumMember_a50bd660-3c6f-46ab-b7fa-149868e3afa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_00ef55ca-b185-4ddf-8e77-5198a5864446" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_03eed013-cd5e-4ed3-b74f-1b8bd7b39a90" xlink:to="loc_srt_MaximumMember_00ef55ca-b185-4ddf-8e77-5198a5864446" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" xlink:type="extended" id="i3f72597d7543411b9a7e32c92969df63_SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b629af96-61b0-4f03-aaed-499fa12a045d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee966d34-4ce0-4c0e-8836-a220fd39d6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b629af96-61b0-4f03-aaed-499fa12a045d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee966d34-4ce0-4c0e-8836-a220fd39d6f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b629af96-61b0-4f03-aaed-499fa12a045d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ed0784fc-62a4-4231-85fb-afb196098192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ed0784fc-62a4-4231-85fb-afb196098192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed0784fc-62a4-4231-85fb-afb196098192_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ed0784fc-62a4-4231-85fb-afb196098192" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ed0784fc-62a4-4231-85fb-afb196098192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ed0784fc-62a4-4231-85fb-afb196098192" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_53bc405e-aa62-475d-b61b-06d1f640b1b6" xlink:href="ehc-20221231.xsd#ehc_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_ehc_CertificateOfNeedMember_53bc405e-aa62-475d-b61b-06d1f640b1b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5f176eb0-859a-437c-8d07-1cc38447650e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_us-gaap_LicensingAgreementsMember_5f176eb0-859a-437c-8d07-1cc38447650e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_9bbb0b52-2140-47e4-ad3f-99bfd11e6df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_9bbb0b52-2140-47e4-ad3f-99bfd11e6df7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_2a7c64f5-c529-43ec-9fed-dc512b4e50be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_us-gaap_TradeNamesMember_2a7c64f5-c529-43ec-9fed-dc512b4e50be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InternalUseSoftwareMember_061d5ae7-4094-4fac-b74a-c20296a386f9" xlink:href="ehc-20221231.xsd#ehc_InternalUseSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_ehc_InternalUseSoftwareMember_061d5ae7-4094-4fac-b74a-c20296a386f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_58f2ae65-740c-42ae-9c5f-7266f180c74d" xlink:href="ehc-20221231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_ehc_MarketAccessAssetsMember_58f2ae65-740c-42ae-9c5f-7266f180c74d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_950329ff-c579-43fb-ae8e-aa432a27d053" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:to="loc_srt_RangeAxis_950329ff-c579-43fb-ae8e-aa432a27d053" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_950329ff-c579-43fb-ae8e-aa432a27d053_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_950329ff-c579-43fb-ae8e-aa432a27d053" xlink:to="loc_srt_RangeMember_950329ff-c579-43fb-ae8e-aa432a27d053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0bca2b5-70bc-40a3-bf81-1db691810063" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_950329ff-c579-43fb-ae8e-aa432a27d053" xlink:to="loc_srt_RangeMember_e0bca2b5-70bc-40a3-bf81-1db691810063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b0d3ad32-d1f7-418a-8fdf-0b8a02c1ec8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0bca2b5-70bc-40a3-bf81-1db691810063" xlink:to="loc_srt_MinimumMember_b0d3ad32-d1f7-418a-8fdf-0b8a02c1ec8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_14fae65e-06ee-4fce-8761-c74f006ee937" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0bca2b5-70bc-40a3-bf81-1db691810063" xlink:to="loc_srt_MaximumMember_14fae65e-06ee-4fce-8761-c74f006ee937" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SpinOffofHomeHealthandHospiceBusinessTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails" xlink:type="extended" id="ib962321e28f7414285888b910a5c9a36_SpinOffofHomeHealthandHospiceBusinessTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_be46f429-1cd9-4635-92c6-9e7f4d7a871e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_be46f429-1cd9-4635-92c6-9e7f4d7a871e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_04a1fee2-b184-4016-b4d7-4e68ea0d2849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_04a1fee2-b184-4016-b4d7-4e68ea0d2849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9e16e0f4-1440-47d5-b7ac-3597304840f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9e16e0f4-1440-47d5-b7ac-3597304840f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8696c745-64b7-421f-8ce1-8f93e59dfef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8696c745-64b7-421f-8ce1-8f93e59dfef0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm_b5449400-7037-465e-a857-bd9b09008449" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm_b5449400-7037-465e-a857-bd9b09008449" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome_6c10d542-6f1c-41dc-9abc-aa62111d2e4e" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome_6c10d542-6f1c-41dc-9abc-aa62111d2e4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_6915191e-7bd5-4020-ab5a-97cbe114977f" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_6915191e-7bd5-4020-ab5a-97cbe114977f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7cd1bec5-7245-4aad-999e-e608bad41213" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_dei_LegalEntityAxis_7cd1bec5-7245-4aad-999e-e608bad41213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7cd1bec5-7245-4aad-999e-e608bad41213_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7cd1bec5-7245-4aad-999e-e608bad41213" xlink:to="loc_dei_EntityDomain_7cd1bec5-7245-4aad-999e-e608bad41213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d1e7967c-f130-4204-aa33-deebb1cf3584" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7cd1bec5-7245-4aad-999e-e608bad41213" xlink:to="loc_dei_EntityDomain_d1e7967c-f130-4204-aa33-deebb1cf3584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember_cb068502-0771-4e3d-8ba4-5df9aa211275" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d1e7967c-f130-4204-aa33-deebb1cf3584" xlink:to="loc_ehc_EnhabitMember_cb068502-0771-4e3d-8ba4-5df9aa211275" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a" xlink:to="loc_us-gaap_EquityComponentDomain_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6bcf021-7910-42d2-9754-e76637d36e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a" xlink:to="loc_us-gaap_EquityComponentDomain_a6bcf021-7910-42d2-9754-e76637d36e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_236dba7d-29d9-4f1c-af11-9a2c3475b5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6bcf021-7910-42d2-9754-e76637d36e5b" xlink:to="loc_us-gaap_CommonStockMember_236dba7d-29d9-4f1c-af11-9a2c3475b5dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6cd78a0e-b1e5-43e9-817b-1fa63c563e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6cd78a0e-b1e5-43e9-817b-1fa63c563e26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cd78a0e-b1e5-43e9-817b-1fa63c563e26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6cd78a0e-b1e5-43e9-817b-1fa63c563e26" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6cd78a0e-b1e5-43e9-817b-1fa63c563e26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_414f81f3-1a9e-425c-b987-788821295cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6cd78a0e-b1e5-43e9-817b-1fa63c563e26" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_414f81f3-1a9e-425c-b987-788821295cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember_0dee43b8-cafe-4894-840c-07bbb6697f66" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_414f81f3-1a9e-425c-b987-788821295cf6" xlink:to="loc_ehc_EnhabitMember_0dee43b8-cafe-4894-840c-07bbb6697f66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5e38c01d-ceae-45df-9ba3-3ab1fb52f061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5e38c01d-ceae-45df-9ba3-3ab1fb52f061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_8b970b16-6adc-46cf-a4fe-3095106a4a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5e38c01d-ceae-45df-9ba3-3ab1fb52f061" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_8b970b16-6adc-46cf-a4fe-3095106a4a4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8c1fee6e-e806-4512-9f82-d16d62e39ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8c1fee6e-e806-4512-9f82-d16d62e39ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_ebf6998e-714f-4323-887c-39ad82019dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8c1fee6e-e806-4512-9f82-d16d62e39ec9" xlink:to="loc_us-gaap_TradeNamesMember_ebf6998e-714f-4323-887c-39ad82019dff" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails" xlink:type="extended" id="i6ac16bf01d9f4f8dabbc776d836330e8_SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_45433919-7c32-49a4-9e27-b53b61863489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_45433919-7c32-49a4-9e27-b53b61863489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_af50d993-81f0-4919-a6bc-08369cb1da5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_45433919-7c32-49a4-9e27-b53b61863489" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_af50d993-81f0-4919-a6bc-08369cb1da5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_45433919-7c32-49a4-9e27-b53b61863489" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_7c5d7d59-e58e-4e0c-af30-aa3d4d4792c3" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_7c5d7d59-e58e-4e0c-af30-aa3d4d4792c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_550954e2-d28a-4e78-93fd-6fc4c0214403" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_550954e2-d28a-4e78-93fd-6fc4c0214403" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_9699cc95-f4c2-48dd-a76d-4a365e65038d" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_9699cc95-f4c2-48dd-a76d-4a365e65038d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_0bfd3def-fe63-442f-9d15-d9b47539e971" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationSupplies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_0bfd3def-fe63-442f-9d15-d9b47539e971" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_955c9b02-47fe-4274-89a5-94c4d0c294a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_955c9b02-47fe-4274-89a5-94c4d0c294a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_d2f2ab29-83d1-44e2-ab95-3a03a212fca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_d2f2ab29-83d1-44e2-ab95-3a03a212fca5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4070d596-2b3d-4b25-a744-b74cc35552db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4070d596-2b3d-4b25-a744-b74cc35552db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_18846f50-6f97-4f39-a674-60a7ea81e51d" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_18846f50-6f97-4f39-a674-60a7ea81e51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_50dd1c27-dbac-4190-b25d-f2fba8e1826c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_50dd1c27-dbac-4190-b25d-f2fba8e1826c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_4cd56f3f-6f28-467a-aa86-2c85ccaacfb9" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_4cd56f3f-6f28-467a-aa86-2c85ccaacfb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4a79594f-3f46-441f-914e-7f734c82d375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4a79594f-3f46-441f-914e-7f734c82d375" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6abc9154-e3ca-4067-9ec4-842a3527380c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6abc9154-e3ca-4067-9ec4-842a3527380c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b6b5b642-c2c6-4c32-9078-5e6225148fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b6b5b642-c2c6-4c32-9078-5e6225148fba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_989ed76f-22bf-4278-8ae7-9e0f62db0708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_989ed76f-22bf-4278-8ae7-9e0f62db0708" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a9710f16-0840-4bd5-a1b4-51440d83eea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a9710f16-0840-4bd5-a1b4-51440d83eea3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_b27010b3-5838-43dd-8dfd-20d8f7e86acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_b27010b3-5838-43dd-8dfd-20d8f7e86acf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_b27010b3-5838-43dd-8dfd-20d8f7e86acf" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_58dda624-1f3b-4f73-9a35-50882631b253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_58dda624-1f3b-4f73-9a35-50882631b253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_0f61a0ed-0d68-45cf-ac46-90bf85d4aabc" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_0f61a0ed-0d68-45cf-ac46-90bf85d4aabc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_fc7c8994-d332-455b-9c1a-c123fc0323d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_fc7c8994-d332-455b-9c1a-c123fc0323d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_2fbcd1f9-ce63-400a-891e-aa5545c53b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_2fbcd1f9-ce63-400a-891e-aa5545c53b2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a5b81366-02a4-4861-8b09-ee2cd3210558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a5b81366-02a4-4861-8b09-ee2cd3210558" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_fb51bb79-27ac-4b1c-87d1-192af4bf8d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_fb51bb79-27ac-4b1c-87d1-192af4bf8d95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_4408920e-abdb-424d-b338-c383b47af034" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_4408920e-abdb-424d-b338-c383b47af034" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_da4e90e1-faac-4297-8c5e-d2f478223902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_da4e90e1-faac-4297-8c5e-d2f478223902" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_62328f85-f204-4397-b268-50538ab41c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_62328f85-f204-4397-b268-50538ab41c0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_fbaa922b-b800-4986-ae0b-c1f63b8dd6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_fbaa922b-b800-4986-ae0b-c1f63b8dd6f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_5fa40300-e32e-4eb9-af0c-137798a805b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_5fa40300-e32e-4eb9-af0c-137798a805b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ebd76bac-51f8-4e5f-a2d7-67c305319752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ebd76bac-51f8-4e5f-a2d7-67c305319752" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_09e7ffd2-88a4-4d51-9ce4-fd406df7529c" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_09e7ffd2-88a4-4d51-9ce4-fd406df7529c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_5c6a32ad-120f-4bde-a057-0bcd05c40b28" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_5c6a32ad-120f-4bde-a057-0bcd05c40b28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_3e275703-bf74-47ae-8944-dd2a8b92651c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_3e275703-bf74-47ae-8944-dd2a8b92651c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_cc5a6fa7-3faf-4588-a5fb-4ed5f7b4a7ac" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_cc5a6fa7-3faf-4588-a5fb-4ed5f7b4a7ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_92c40127-3466-4f57-b468-893b94bf82ae" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_92c40127-3466-4f57-b468-893b94bf82ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_e3ac38e2-f617-4e33-b5a7-9af9deff286b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_e3ac38e2-f617-4e33-b5a7-9af9deff286b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_32526ccd-a696-4847-a516-40917c11203e" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_32526ccd-a696-4847-a516-40917c11203e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_d15c4042-a9ab-4117-b746-60517da65729" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_d15c4042-a9ab-4117-b746-60517da65729" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_60547e83-46a3-4e64-84b1-19b1c5551397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_60547e83-46a3-4e64-84b1-19b1c5551397" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_d03f5ba8-01a2-483a-9e3f-757dc11a3ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_d03f5ba8-01a2-483a-9e3f-757dc11a3ede" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4395306b-bfa6-4ce7-8697-1e0a3677756a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4395306b-bfa6-4ce7-8697-1e0a3677756a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_6c04369c-30ac-48de-8dce-2a736e293e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_6c04369c-30ac-48de-8dce-2a736e293e01" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2269a1b3-25ee-41e3-a9f7-d15d45228603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2269a1b3-25ee-41e3-a9f7-d15d45228603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2269a1b3-25ee-41e3-a9f7-d15d45228603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2269a1b3-25ee-41e3-a9f7-d15d45228603" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2269a1b3-25ee-41e3-a9f7-d15d45228603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af236ca9-b1be-4441-bae2-36cb63dd8216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2269a1b3-25ee-41e3-a9f7-d15d45228603" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af236ca9-b1be-4441-bae2-36cb63dd8216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember_03dee694-d87f-42ce-bf75-08b6f8bb533e" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af236ca9-b1be-4441-bae2-36cb63dd8216" xlink:to="loc_ehc_EnhabitMember_03dee694-d87f-42ce-bf75-08b6f8bb533e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7c58f671-90e4-4ba9-807f-472435682848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7c58f671-90e4-4ba9-807f-472435682848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7c58f671-90e4-4ba9-807f-472435682848_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7c58f671-90e4-4ba9-807f-472435682848" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7c58f671-90e4-4ba9-807f-472435682848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_76520308-ddc6-4f3c-ad76-8b895f0a503c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7c58f671-90e4-4ba9-807f-472435682848" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_76520308-ddc6-4f3c-ad76-8b895f0a503c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_d703f9e5-d35a-49dd-b6ff-8b7627c05c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_76520308-ddc6-4f3c-ad76-8b895f0a503c" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_d703f9e5-d35a-49dd-b6ff-8b7627c05c67" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended" id="i975aca0232964c90bd8e3b3cc2af3926_BusinessCombinationsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7862c18b-24b6-499f-8c89-ff43bf138327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7862c18b-24b6-499f-8c89-ff43bf138327" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfBedsAcquired_41929da1-5000-4317-a499-0111e53952c6" xlink:href="ehc-20221231.xsd#ehc_NumberOfBedsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_ehc_NumberOfBedsAcquired_41929da1-5000-4317-a499-0111e53952c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c39ca78c-557a-458a-a262-953541812a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c39ca78c-557a-458a-a262-953541812a3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed_7a9e548c-0f40-4c8b-9e8c-33803616c707" xlink:href="ehc-20221231.xsd#ehc_NumberofBedsContributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_ehc_NumberofBedsContributed_7a9e548c-0f40-4c8b-9e8c-33803616c707" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded_3f764083-6663-4716-823e-84624c518e62" xlink:href="ehc-20221231.xsd#ehc_NumberofBedsExpanded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_ehc_NumberofBedsExpanded_3f764083-6663-4716-823e-84624c518e62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds_9294aae3-96f6-46c9-97b6-5fb0feed5292" xlink:href="ehc-20221231.xsd#ehc_NumberofDeNovoBeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_ehc_NumberofDeNovoBeds_9294aae3-96f6-46c9-97b6-5fb0feed5292" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c77a7b5-ce7e-4497-a409-d84a19a34c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c77a7b5-ce7e-4497-a409-d84a19a34c20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2c77a7b5-ce7e-4497-a409-d84a19a34c20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c77a7b5-ce7e-4497-a409-d84a19a34c20" xlink:to="loc_us-gaap_RelatedPartyDomain_2c77a7b5-ce7e-4497-a409-d84a19a34c20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9c7470b9-15cd-43bc-94d0-2e346ab3c49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c77a7b5-ce7e-4497-a409-d84a19a34c20" xlink:to="loc_us-gaap_RelatedPartyDomain_9c7470b9-15cd-43bc-94d0-2e346ab3c49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_fbbcab01-9c46-4500-8a45-12ac32bdfc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9c7470b9-15cd-43bc-94d0-2e346ab3c49b" xlink:to="loc_us-gaap_CorporateJointVentureMember_fbbcab01-9c46-4500-8a45-12ac32bdfc59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9591d4ab-acd6-484f-b172-351e2e9e8e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9591d4ab-acd6-484f-b172-351e2e9e8e2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9591d4ab-acd6-484f-b172-351e2e9e8e2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9591d4ab-acd6-484f-b172-351e2e9e8e2f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9591d4ab-acd6-484f-b172-351e2e9e8e2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9591d4ab-acd6-484f-b172-351e2e9e8e2f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemMember_dfe9ca9f-624d-415e-975a-271217fb1e3e" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_AltruHealthSystemMember_dfe9ca9f-624d-415e-975a-271217fb1e3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TrinityMedicalCenterMember_b3a8a7ba-b4ac-4322-beb9-86d733f81cb4" xlink:href="ehc-20221231.xsd#ehc_TrinityMedicalCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_TrinityMedicalCenterMember_b3a8a7ba-b4ac-4322-beb9-86d733f81cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NCHHealthcareSystemMember_208871b6-c892-4463-b6ea-412208934b43" xlink:href="ehc-20221231.xsd#ehc_NCHHealthcareSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_NCHHealthcareSystemMember_208871b6-c892-4463-b6ea-412208934b43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_3964be3f-fe7a-46f1-9f63-a2dd410eb216" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_3964be3f-fe7a-46f1-9f63-a2dd410eb216" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalMember_f3e858e6-ed8c-4726-af4d-d5c28514296a" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_ShannonMedicalMember_f3e858e6-ed8c-4726-af4d-d5c28514296a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeritageValleyMember_21a52277-1f57-48b8-b5b0-77a1c4f7f2ac" xlink:href="ehc-20221231.xsd#ehc_HeritageValleyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_HeritageValleyMember_21a52277-1f57-48b8-b5b0-77a1c4f7f2ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ECHDVenturesMember_c2212b9e-1a4a-4059-9933-b595554eadc5" xlink:href="ehc-20221231.xsd#ehc_ECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_ECHDVenturesMember_c2212b9e-1a4a-4059-9933-b595554eadc5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_b5b3ffb6-1053-484f-91d4-a85a1c6e768a" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_b5b3ffb6-1053-484f-91d4-a85a1c6e768a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember_851b1d79-8a10-45c2-a0a2-41c1f0062200" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_PortercareAdventistMember_851b1d79-8a10-45c2-a0a2-41c1f0062200" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember_a37deb71-6ce7-4fc5-bd77-4af592271e13" xlink:href="ehc-20221231.xsd#ehc_PremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_PremierHealthPartnersMember_a37deb71-6ce7-4fc5-bd77-4af592271e13" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_98e29899-ffe6-4f63-9d8d-6d724e81c091" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_98e29899-ffe6-4f63-9d8d-6d724e81c091" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46d201f7-5cd4-4b32-abd7-327d35061c00" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:to="loc_srt_RangeAxis_46d201f7-5cd4-4b32-abd7-327d35061c00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46d201f7-5cd4-4b32-abd7-327d35061c00_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_46d201f7-5cd4-4b32-abd7-327d35061c00" xlink:to="loc_srt_RangeMember_46d201f7-5cd4-4b32-abd7-327d35061c00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6fb91dd-1b2b-4c6a-adb4-1355e36c332c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_46d201f7-5cd4-4b32-abd7-327d35061c00" xlink:to="loc_srt_RangeMember_e6fb91dd-1b2b-4c6a-adb4-1355e36c332c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eb5226dc-afdf-44c8-a049-7e61ea134d52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6fb91dd-1b2b-4c6a-adb4-1355e36c332c" xlink:to="loc_srt_MinimumMember_eb5226dc-afdf-44c8-a049-7e61ea134d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9928ade9-5d38-45e2-9b8f-7f439747d4cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e6fb91dd-1b2b-4c6a-adb4-1355e36c332c" xlink:to="loc_srt_MaximumMember_9928ade9-5d38-45e2-9b8f-7f439747d4cc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended" id="i3b4a952f636540a08074865a81de62c5_BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3082d3c9-93fb-4436-b1aa-45c0fd675205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3082d3c9-93fb-4436-b1aa-45c0fd675205" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e9a5a353-dfa5-4647-9ef1-2afab75b9099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_Goodwill_e9a5a353-dfa5-4647-9ef1-2afab75b9099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_dc2e920e-d956-4b05-b64b-06ca598bd38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_dc2e920e-d956-4b05-b64b-06ca598bd38f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_ec42ab4c-5f24-48b4-a945-0f0c24666425" xlink:href="ehc-20221231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_ec42ab4c-5f24-48b4-a945-0f0c24666425" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a3a8a774-00b1-49ff-b55a-d9a297b2915f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a3a8a774-00b1-49ff-b55a-d9a297b2915f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_25d02c0b-56c9-4c9e-851c-ed00c273bd35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:to="loc_srt_RangeAxis_25d02c0b-56c9-4c9e-851c-ed00c273bd35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_25d02c0b-56c9-4c9e-851c-ed00c273bd35_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_25d02c0b-56c9-4c9e-851c-ed00c273bd35" xlink:to="loc_srt_RangeMember_25d02c0b-56c9-4c9e-851c-ed00c273bd35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a13259d5-5b01-4fba-b93d-a3672b66cf02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_25d02c0b-56c9-4c9e-851c-ed00c273bd35" xlink:to="loc_srt_RangeMember_a13259d5-5b01-4fba-b93d-a3672b66cf02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5241098e-a658-48bb-840c-4dc0bcd53f85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a13259d5-5b01-4fba-b93d-a3672b66cf02" xlink:to="loc_srt_MinimumMember_5241098e-a658-48bb-840c-4dc0bcd53f85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7213bb42-ad91-46ec-9673-95d4ce6f2b4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a13259d5-5b01-4fba-b93d-a3672b66cf02" xlink:to="loc_srt_MaximumMember_7213bb42-ad91-46ec-9673-95d4ce6f2b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7291ddd-03c0-420f-8021-2948d2489bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7291ddd-03c0-420f-8021-2948d2489bd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7291ddd-03c0-420f-8021-2948d2489bd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7291ddd-03c0-420f-8021-2948d2489bd7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7291ddd-03c0-420f-8021-2948d2489bd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f15425c2-1ef4-4854-a977-db139bc68d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7291ddd-03c0-420f-8021-2948d2489bd7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f15425c2-1ef4-4854-a977-db139bc68d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_47694101-6483-4108-91ed-4c6c354ccd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f15425c2-1ef4-4854-a977-db139bc68d4c" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_47694101-6483-4108-91ed-4c6c354ccd3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3f52d1f2-2a2f-4c1a-98f3-38bb30abdbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f15425c2-1ef4-4854-a977-db139bc68d4c" xlink:to="loc_us-gaap_TradeNamesMember_3f52d1f2-2a2f-4c1a-98f3-38bb30abdbd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_b4c16771-15f5-419b-92dd-6cf69012fa31" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:to="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_b4c16771-15f5-419b-92dd-6cf69012fa31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_e57a5f43-104d-4f41-bab3-663c84ffbb39" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_e57a5f43-104d-4f41-bab3-663c84ffbb39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_62d8e171-413a-4b84-b1ad-e56952ca990b" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_62d8e171-413a-4b84-b1ad-e56952ca990b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsNetCashPaidforAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails" xlink:type="extended" id="i1669f593e78349d5b07b675c22aad371_BusinessCombinationsNetCashPaidforAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_7e376b81-b856-49a9-b16b-589584e364d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_7e376b81-b856-49a9-b16b-589584e364d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_d482a417-6b44-455b-a8b6-8a083e2e7e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_d482a417-6b44-455b-a8b6-8a083e2e7e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_b09831ba-3f5b-4d61-9e16-42cf99256f07" xlink:href="ehc-20221231.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_b09831ba-3f5b-4d61-9e16-42cf99256f07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ad496634-7c22-4358-bcf8-2af6793adb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ad496634-7c22-4358-bcf8-2af6793adb7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_55ee2c34-7ac4-4b17-a8d1-873e3adca17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_55ee2c34-7ac4-4b17-a8d1-873e3adca17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55ee2c34-7ac4-4b17-a8d1-873e3adca17c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55ee2c34-7ac4-4b17-a8d1-873e3adca17c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_55ee2c34-7ac4-4b17-a8d1-873e3adca17c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55ee2c34-7ac4-4b17-a8d1-873e3adca17c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_fda73c73-69da-4a6b-8483-002e0c7c9596" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:to="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_fda73c73-69da-4a6b-8483-002e0c7c9596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_f2ca09c9-3016-416c-ae03-3b6f5d4f0386" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_f2ca09c9-3016-416c-ae03-3b6f5d4f0386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_7a153856-8e0d-4295-9a7b-f9e3e3603c4d" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_7a153856-8e0d-4295-9a7b-f9e3e3603c4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59db9bfb-56c0-46fb-a794-a941e91473c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59db9bfb-56c0-46fb-a794-a941e91473c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59db9bfb-56c0-46fb-a794-a941e91473c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59db9bfb-56c0-46fb-a794-a941e91473c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_59db9bfb-56c0-46fb-a794-a941e91473c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77f22c62-442c-45f3-a8c1-9a748b316e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59db9bfb-56c0-46fb-a794-a941e91473c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77f22c62-442c-45f3-a8c1-9a748b316e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_e0919007-b120-4188-85b5-a67e064119b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77f22c62-442c-45f3-a8c1-9a748b316e78" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_e0919007-b120-4188-85b5-a67e064119b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended" id="i34853a74b2504c539960aad39878adb1_BusinessCombinationsProFormaResultsofOperationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_00d1fc90-d278-4322-bc36-0a1584a8abbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_00d1fc90-d278-4322-bc36-0a1584a8abbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_1bfbfcd7-0143-4774-80ea-b840eba3d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_1bfbfcd7-0143-4774-80ea-b840eba3d1a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_14e8d48d-6d4c-49a2-b59e-2c8b2d902730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_14e8d48d-6d4c-49a2-b59e-2c8b2d902730" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_fcadfa3f-1ad9-418e-a073-a2f0d0078807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_fcadfa3f-1ad9-418e-a073-a2f0d0078807" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e904a52c-574a-4433-9ca8-81a3c90627c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e904a52c-574a-4433-9ca8-81a3c90627c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_773b18b8-3abc-4202-a64f-5085469a26d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e904a52c-574a-4433-9ca8-81a3c90627c4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_773b18b8-3abc-4202-a64f-5085469a26d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_773b18b8-3abc-4202-a64f-5085469a26d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_773b18b8-3abc-4202-a64f-5085469a26d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_773b18b8-3abc-4202-a64f-5085469a26d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_773b18b8-3abc-4202-a64f-5085469a26d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_3f5151c3-e7e1-46fd-bd7f-cb477c6e987c" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_3f5151c3-e7e1-46fd-bd7f-cb477c6e987c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_96c4f764-93e2-4b57-8ad1-0c22a0bc0cf4" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_96c4f764-93e2-4b57-8ad1-0c22a0bc0cf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2021AcquisitionsMember_e0b13086-d12d-42e8-8f00-4e591073633e" xlink:href="ehc-20221231.xsd#ehc_A2021AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_A2021AcquisitionsMember_e0b13086-d12d-42e8-8f00-4e591073633e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_a276a9e3-3c37-44a4-b399-8ab2d835536b" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_a276a9e3-3c37-44a4-b399-8ab2d835536b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2020AcquisitionsMember_2bb16ea5-c991-48e9-bf15-165de1f9dba2" xlink:href="ehc-20221231.xsd#ehc_A2020AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_A2020AcquisitionsMember_2bb16ea5-c991-48e9-bf15-165de1f9dba2" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#VariableInterestEntitiesTextualsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails" xlink:type="extended" id="i4d0585d31e214459b9d61a32c6e0b197_VariableInterestEntitiesTextualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_e66ca92c-3d34-4af1-9d95-dec79980c0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_7f0ed48c-2aa5-44fc-9476-33dbb64b0a6f" xlink:href="ehc-20221231.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e66ca92c-3d34-4af1-9d95-dec79980c0f4" xlink:to="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_7f0ed48c-2aa5-44fc-9476-33dbb64b0a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_482cb369-6b41-4c2d-b22b-a1dcd57503bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e66ca92c-3d34-4af1-9d95-dec79980c0f4" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_482cb369-6b41-4c2d-b22b-a1dcd57503bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e66ca92c-3d34-4af1-9d95-dec79980c0f4" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_54178f9d-487f-4c00-8968-36792f4382fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:to="loc_srt_ConsolidatedEntitiesAxis_54178f9d-487f-4c00-8968-36792f4382fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_54178f9d-487f-4c00-8968-36792f4382fe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_54178f9d-487f-4c00-8968-36792f4382fe" xlink:to="loc_srt_ConsolidatedEntitiesDomain_54178f9d-487f-4c00-8968-36792f4382fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_be6c26a0-ceff-4696-898f-781ac0c5ccc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_54178f9d-487f-4c00-8968-36792f4382fe" xlink:to="loc_srt_ConsolidatedEntitiesDomain_be6c26a0-ceff-4696-898f-781ac0c5ccc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0119f344-0819-4b9f-998a-b9e25afdb24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_be6c26a0-ceff-4696-898f-781ac0c5ccc5" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0119f344-0819-4b9f-998a-b9e25afdb24e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b611d83e-fc95-4973-9cec-19a2c7c0eaa7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:to="loc_srt_RangeAxis_b611d83e-fc95-4973-9cec-19a2c7c0eaa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b611d83e-fc95-4973-9cec-19a2c7c0eaa7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b611d83e-fc95-4973-9cec-19a2c7c0eaa7" xlink:to="loc_srt_RangeMember_b611d83e-fc95-4973-9cec-19a2c7c0eaa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7f8cda5-5529-4d48-a134-3ab784107283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b611d83e-fc95-4973-9cec-19a2c7c0eaa7" xlink:to="loc_srt_RangeMember_b7f8cda5-5529-4d48-a134-3ab784107283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e8534004-dc8e-4d1a-816c-700258f0ac8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7f8cda5-5529-4d48-a134-3ab784107283" xlink:to="loc_srt_MinimumMember_e8534004-dc8e-4d1a-816c-700258f0ac8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb69756e-012a-4f7e-ae84-74dfef6cc47a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b7f8cda5-5529-4d48-a134-3ab784107283" xlink:to="loc_srt_MaximumMember_bb69756e-012a-4f7e-ae84-74dfef6cc47a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="extended" id="i567b49c3f6f64d53a3632440a82b59ed_VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_39fa8e5d-2684-4be8-be4c-c1f48012eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_39fa8e5d-2684-4be8-be4c-c1f48012eca2" xlink:to="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0671a99-e2e1-4b2b-a679-1edb3621c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0671a99-e2e1-4b2b-a679-1edb3621c73f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d4ec6d14-9110-40a3-9cfb-6880133323ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d4ec6d14-9110-40a3-9cfb-6880133323ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_543b9fde-4ffa-4261-8c09-3085b4df7cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_OtherAssetsCurrent_543b9fde-4ffa-4261-8c09-3085b4df7cb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_01c0c730-444e-449e-9abc-75560540d207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_01c0c730-444e-449e-9abc-75560540d207" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4681ce44-366c-4db1-a7b9-a49e8725366d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_AssetsCurrent_4681ce44-366c-4db1-a7b9-a49e8725366d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d572c380-819b-4390-9d02-646f519ed557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d572c380-819b-4390-9d02-646f519ed557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95f612c5-08bd-48c1-abac-d973965b2152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95f612c5-08bd-48c1-abac-d973965b2152" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31fabc2d-eaa3-4b43-b174-910a2c6525b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_Goodwill_31fabc2d-eaa3-4b43-b174-910a2c6525b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d550e282-9933-4fd2-8033-65c97724271b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d550e282-9933-4fd2-8033-65c97724271b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c3a4cc46-a7d5-4890-a8fb-614df74c0cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c3a4cc46-a7d5-4890-a8fb-614df74c0cc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_94b62074-4ed9-431e-a7e8-3fce0d5bc05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_94b62074-4ed9-431e-a7e8-3fce0d5bc05f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7810d202-3ee0-43be-a085-38b9fe478007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_Assets_7810d202-3ee0-43be-a085-38b9fe478007" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_39fa8e5d-2684-4be8-be4c-c1f48012eca2" xlink:to="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_350a952f-cf39-4a40-b997-88a71c57256b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_350a952f-cf39-4a40-b997-88a71c57256b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ee4eb22-07df-4336-a36f-86c122a356d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ee4eb22-07df-4336-a36f-86c122a356d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_87ef38fa-64c4-4a30-a481-84dc33c6620d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_AccountsPayableCurrent_87ef38fa-64c4-4a30-a481-84dc33c6620d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c821dfe5-fb7f-4069-bf1e-870c7089ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c821dfe5-fb7f-4069-bf1e-870c7089ab64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_54f8d4b3-ad2e-4e3d-b4aa-a3a47952e336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_54f8d4b3-ad2e-4e3d-b4aa-a3a47952e336" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_f0556d40-85af-407f-ba05-33f6d091a3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_f0556d40-85af-407f-ba05-33f6d091a3be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_14e8d977-a4a6-4ba6-82c9-d3856c4ef4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_LiabilitiesCurrent_14e8d977-a4a6-4ba6-82c9-d3856c4ef4df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_91842087-3e05-4d34-882f-881e1c4a2c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_91842087-3e05-4d34-882f-881e1c4a2c8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc73c5e9-5cf1-40fb-9a5a-1b57eb1766f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc73c5e9-5cf1-40fb-9a5a-1b57eb1766f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7b264b28-41e3-4d01-a8d4-a0f0d293d964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:to="loc_us-gaap_Liabilities_7b264b28-41e3-4d01-a8d4-a0f0d293d964" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_87e87225-a2a8-4478-8479-e1ad3b0e1070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_39fa8e5d-2684-4be8-be4c-c1f48012eca2" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_87e87225-a2a8-4478-8479-e1ad3b0e1070" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8461c6ed-3980-4452-95dc-85aeb9a485da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_87e87225-a2a8-4478-8479-e1ad3b0e1070" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8461c6ed-3980-4452-95dc-85aeb9a485da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8461c6ed-3980-4452-95dc-85aeb9a485da_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8461c6ed-3980-4452-95dc-85aeb9a485da" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8461c6ed-3980-4452-95dc-85aeb9a485da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_201a3698-30be-4042-a010-a98284d7cd1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8461c6ed-3980-4452-95dc-85aeb9a485da" xlink:to="loc_srt_ConsolidatedEntitiesDomain_201a3698-30be-4042-a010-a98284d7cd1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ec837abd-26fd-478b-a64e-05dd88f602ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_201a3698-30be-4042-a010-a98284d7cd1b" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ec837abd-26fd-478b-a64e-05dd88f602ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecuritiesComponentsofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="extended" id="icdd7c17f169646bfb6c905bc86324c30_CashandMarketableSecuritiesComponentsofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93c8f1df-3de6-4685-8255-5a94b3838e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93c8f1df-3de6-4685-8255-5a94b3838e0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_c9bc06f3-fc90-49ee-8082-3769ab981ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_c9bc06f3-fc90-49ee-8082-3769ab981ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_94a6a9de-fd27-451a-bc0a-09ebfcf5af89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRestricted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_94a6a9de-fd27-451a-bc0a-09ebfcf5af89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InvestmentsCashandRestrictedCash_3f819dbe-eb1f-4cfc-b5d4-2ee42259d05c" xlink:href="ehc-20221231.xsd#ehc_InvestmentsCashandRestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_ehc_InvestmentsCashandRestrictedCash_3f819dbe-eb1f-4cfc-b5d4-2ee42259d05c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_c789ade1-bf09-4ed9-91ee-1c0cfa82a748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_c789ade1-bf09-4ed9-91ee-1c0cfa82a748" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b1c51208-3299-4b2a-9da6-f95b74585497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_c789ade1-bf09-4ed9-91ee-1c0cfa82a748" xlink:to="loc_us-gaap_InvestmentTypeAxis_b1c51208-3299-4b2a-9da6-f95b74585497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b1c51208-3299-4b2a-9da6-f95b74585497_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_b1c51208-3299-4b2a-9da6-f95b74585497" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b1c51208-3299-4b2a-9da6-f95b74585497_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7125d88e-4b55-4785-8e73-dabaa8dae431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_b1c51208-3299-4b2a-9da6-f95b74585497" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7125d88e-4b55-4785-8e73-dabaa8dae431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_737a2511-0221-46be-9a38-7ddd8000708b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7125d88e-4b55-4785-8e73-dabaa8dae431" xlink:to="loc_us-gaap_CashMember_737a2511-0221-46be-9a38-7ddd8000708b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_797a000c-f55d-4670-8f92-f1379089f882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7125d88e-4b55-4785-8e73-dabaa8dae431" xlink:to="loc_us-gaap_EquitySecuritiesMember_797a000c-f55d-4670-8f92-f1379089f882" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecuritiesRestrictedCashDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails" xlink:type="extended" id="i849f51439a574b898d61b11028d03218_CashandMarketableSecuritiesRestrictedCashDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fcbe1cfc-eb1d-410e-872c-e7df156fba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4bd3f23a-d3c6-425b-8efd-0118f7b10c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fcbe1cfc-eb1d-410e-872c-e7df156fba3c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4bd3f23a-d3c6-425b-8efd-0118f7b10c3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b24b2205-859c-4a89-b311-b1b3615afd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fcbe1cfc-eb1d-410e-872c-e7df156fba3c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b24b2205-859c-4a89-b311-b1b3615afd1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b7fbcdd-5775-4b7a-a0df-5e6ffe3476a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fcbe1cfc-eb1d-410e-872c-e7df156fba3c" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b7fbcdd-5775-4b7a-a0df-5e6ffe3476a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_7c546b91-0de8-473b-80ac-93871746d212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b7fbcdd-5775-4b7a-a0df-5e6ffe3476a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_7c546b91-0de8-473b-80ac-93871746d212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c546b91-0de8-473b-80ac-93871746d212_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_7c546b91-0de8-473b-80ac-93871746d212" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7c546b91-0de8-473b-80ac-93871746d212_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_7c546b91-0de8-473b-80ac-93871746d212" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliateCashMember_7c0001ae-93a4-4a94-8b93-1bb8266914fd" xlink:href="ehc-20221231.xsd#ehc_AffiliateCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:to="loc_ehc_AffiliateCashMember_7c0001ae-93a4-4a94-8b93-1bb8266914fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SelfInsuredCaptiveFundsMember_d41e641a-47ae-4748-84f6-9f6923aaeee3" xlink:href="ehc-20221231.xsd#ehc_SelfInsuredCaptiveFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:to="loc_ehc_SelfInsuredCaptiveFundsMember_d41e641a-47ae-4748-84f6-9f6923aaeee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherFundsMember_c43bdba7-f382-4dae-b66c-93945894f80b" xlink:href="ehc-20221231.xsd#ehc_OtherFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:to="loc_ehc_OtherFundsMember_c43bdba7-f382-4dae-b66c-93945894f80b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended" id="i31aca5d6cd3c42e7aecdc506b2ca7e7d_PropertyandEquipmentComponentsofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a536be52-31b7-48fa-9b3c-6b3d981708a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a536be52-31b7-48fa-9b3c-6b3d981708a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b42fc50c-ee80-4b01-8bc4-c7f013220ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b42fc50c-ee80-4b01-8bc4-c7f013220ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_14212e21-9d15-46f8-9e6d-2509cd0c1b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_14212e21-9d15-46f8-9e6d-2509cd0c1b4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7b80e8b8-050d-4ac0-a43b-d653ae545b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7b80e8b8-050d-4ac0-a43b-d653ae545b45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad30071b-9ca1-4728-9ae9-dbe41c85fb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a536be52-31b7-48fa-9b3c-6b3d981708a4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad30071b-9ca1-4728-9ae9-dbe41c85fb4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7688fe87-c16a-4ca8-9908-47e60526f93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad30071b-9ca1-4728-9ae9-dbe41c85fb4c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7688fe87-c16a-4ca8-9908-47e60526f93b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7688fe87-c16a-4ca8-9908-47e60526f93b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7688fe87-c16a-4ca8-9908-47e60526f93b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7688fe87-c16a-4ca8-9908-47e60526f93b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2b65e3a-a9f5-494d-8524-58ffc5334e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7688fe87-c16a-4ca8-9908-47e60526f93b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2b65e3a-a9f5-494d-8524-58ffc5334e21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:href="ehc-20221231.xsd#ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2b65e3a-a9f5-494d-8524-58ffc5334e21" xlink:to="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0f7f8bd4-aa3e-489f-9464-7360fad14bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_LandMember_0f7f8bd4-aa3e-489f-9464-7360fad14bf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_dbb1251b-ff5d-4dc9-91fd-712640e9bb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_BuildingMember_dbb1251b-ff5d-4dc9-91fd-712640e9bb26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e7915364-b4af-464a-80dc-4b1659842431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e7915364-b4af-464a-80dc-4b1659842431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_b792b73d-67b9-4d50-8f89-5713ef978bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_VehiclesMember_b792b73d-67b9-4d50-8f89-5713ef978bbf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0d477761-1d83-4557-bed4-5af49a29aef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0d477761-1d83-4557-bed4-5af49a29aef6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_62accf48-597b-496b-934f-bef328ca42d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2b65e3a-a9f5-494d-8524-58ffc5334e21" xlink:to="loc_us-gaap_ConstructionInProgressMember_62accf48-597b-496b-934f-bef328ca42d7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesTextualsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesTextualsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LeasesTextualsDetails" xlink:type="extended" id="i6ed55741ed4145db962a3eff7b3fb5d1_LeasesTextualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7aa02b5a-ddba-4a52-92e8-97d53a1fb4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OperatingAndFinanceLeaseContractTerm_88506fd6-e8ce-451f-baed-bb39d8cbda5c" xlink:href="ehc-20221231.xsd#ehc_OperatingAndFinanceLeaseContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7aa02b5a-ddba-4a52-92e8-97d53a1fb4ba" xlink:to="loc_ehc_OperatingAndFinanceLeaseContractTerm_88506fd6-e8ce-451f-baed-bb39d8cbda5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions_f3289af0-f7bd-47fe-a6f6-36c8f136a8c8" xlink:href="ehc-20221231.xsd#ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7aa02b5a-ddba-4a52-92e8-97d53a1fb4ba" xlink:to="loc_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions_f3289af0-f7bd-47fe-a6f6-36c8f136a8c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ece31663-a8ee-401a-8775-c89483c77e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7aa02b5a-ddba-4a52-92e8-97d53a1fb4ba" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ece31663-a8ee-401a-8775-c89483c77e18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2319c8b2-4982-49d6-94dc-d62405cf4e2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ece31663-a8ee-401a-8775-c89483c77e18" xlink:to="loc_srt_RangeAxis_2319c8b2-4982-49d6-94dc-d62405cf4e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2319c8b2-4982-49d6-94dc-d62405cf4e2f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2319c8b2-4982-49d6-94dc-d62405cf4e2f" xlink:to="loc_srt_RangeMember_2319c8b2-4982-49d6-94dc-d62405cf4e2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d77ba136-5a2b-46cb-9a2e-e2875cca037e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2319c8b2-4982-49d6-94dc-d62405cf4e2f" xlink:to="loc_srt_RangeMember_d77ba136-5a2b-46cb-9a2e-e2875cca037e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3498f06e-8963-4268-b240-fa5d8aead52f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d77ba136-5a2b-46cb-9a2e-e2875cca037e" xlink:to="loc_srt_MinimumMember_3498f06e-8963-4268-b240-fa5d8aead52f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb2195f8-d246-45ad-88cc-2089d4c9b90d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d77ba136-5a2b-46cb-9a2e-e2875cca037e" xlink:to="loc_srt_MaximumMember_fb2195f8-d246-45ad-88cc-2089d4c9b90d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="extended" id="i42be7e9260074258a042921ff9e4a5b6_GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e26aa01c-a7aa-4274-80e5-0287ca4a1bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e26aa01c-a7aa-4274-80e5-0287ca4a1bca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b232ce3a-cd58-4059-b464-a181ecb10491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b232ce3a-cd58-4059-b464-a181ecb10491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3c91d452-0cbd-4e6f-b823-f9403349ef3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3c91d452-0cbd-4e6f-b823-f9403349ef3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4e3b66e-31d9-4e25-b9d4-e2d94f518dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4e3b66e-31d9-4e25-b9d4-e2d94f518dc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e6f177e-7734-4807-abb1-08489acbf04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e26aa01c-a7aa-4274-80e5-0287ca4a1bca" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e6f177e-7734-4807-abb1-08489acbf04a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d61fb1ae-e677-4663-943b-79f05fcabb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e6f177e-7734-4807-abb1-08489acbf04a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d61fb1ae-e677-4663-943b-79f05fcabb61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d61fb1ae-e677-4663-943b-79f05fcabb61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d61fb1ae-e677-4663-943b-79f05fcabb61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d61fb1ae-e677-4663-943b-79f05fcabb61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d61fb1ae-e677-4663-943b-79f05fcabb61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_a4246278-3b8a-44c9-9731-1515d16f2144" xlink:href="ehc-20221231.xsd#ehc_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_ehc_CertificateOfNeedMember_a4246278-3b8a-44c9-9731-1515d16f2144" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_53b6f1ab-b019-42cf-b6b2-3eba8cef4097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_us-gaap_LicensingAgreementsMember_53b6f1ab-b019-42cf-b6b2-3eba8cef4097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_cbb14940-9fa5-4648-b6cb-669ace5aee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_cbb14940-9fa5-4648-b6cb-669ace5aee5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TradeNameEncompassMember_00335f23-a896-4fca-8baa-cadc5e0df508" xlink:href="ehc-20221231.xsd#ehc_TradeNameEncompassMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_ehc_TradeNameEncompassMember_00335f23-a896-4fca-8baa-cadc5e0df508" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_1a668d5c-54cc-46e5-b047-3de8e1cec534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_us-gaap_TradeNamesMember_1a668d5c-54cc-46e5-b047-3de8e1cec534" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_2d8ebfbc-3e0e-4097-8ecf-89592160337f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_2d8ebfbc-3e0e-4097-8ecf-89592160337f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_5d3ac657-8cc0-46ab-b037-41382b5df597" xlink:href="ehc-20221231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_ehc_MarketAccessAssetsMember_5d3ac657-8cc0-46ab-b037-41382b5df597" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended" id="ib07e87085a15464fbf1bba7ffbbb276b_LongtermDebtLongtermDebtOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15d7282b-2d00-4374-8143-856d4591e5df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d7282b-2d00-4374-8143-856d4591e5df" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_21b0e5d8-f836-4556-a649-cd6141631a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_21b0e5d8-f836-4556-a649-cd6141631a12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3ee108c2-4c75-489f-b949-0a5b64f19cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_LongTermDebt_3ee108c2-4c75-489f-b949-0a5b64f19cef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_84ee87ef-1022-40da-99d8-61ec0177e579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_FinanceLeaseLiability_84ee87ef-1022-40da-99d8-61ec0177e579" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_adedcb60-2407-4096-a0dd-82438074ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_adedcb60-2407-4096-a0dd-82438074ce02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b4f82c92-ac05-4ad5-ad2e-d2d126191861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b4f82c92-ac05-4ad5-ad2e-d2d126191861" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_cbb228b1-a424-41b1-b4bc-05a14d7cf8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_cbb228b1-a424-41b1-b4bc-05a14d7cf8f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d7282b-2d00-4374-8143-856d4591e5df" xlink:to="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a4a1a201-3f0b-4ff6-adfe-4384127a0bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:to="loc_us-gaap_CreditFacilityAxis_a4a1a201-3f0b-4ff6-adfe-4384127a0bba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a4a1a201-3f0b-4ff6-adfe-4384127a0bba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a4a1a201-3f0b-4ff6-adfe-4384127a0bba" xlink:to="loc_us-gaap_CreditFacilityDomain_a4a1a201-3f0b-4ff6-adfe-4384127a0bba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_65a61b16-ddcf-4c92-9625-98c153d83a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a4a1a201-3f0b-4ff6-adfe-4384127a0bba" xlink:to="loc_us-gaap_CreditFacilityDomain_65a61b16-ddcf-4c92-9625-98c153d83a54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d24426fc-7bdb-497a-a0c5-b4cec1404be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_65a61b16-ddcf-4c92-9625-98c153d83a54" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d24426fc-7bdb-497a-a0c5-b4cec1404be0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_cbebeb49-cc10-4b7b-8bb9-009761f12767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_65a61b16-ddcf-4c92-9625-98c153d83a54" xlink:to="loc_us-gaap_SecuredDebtMember_cbebeb49-cc10-4b7b-8bb9-009761f12767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_be3d1753-b99b-4486-826a-0fc781948db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_be3d1753-b99b-4486-826a-0fc781948db7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_be3d1753-b99b-4486-826a-0fc781948db7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_be3d1753-b99b-4486-826a-0fc781948db7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_be3d1753-b99b-4486-826a-0fc781948db7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_be3d1753-b99b-4486-826a-0fc781948db7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_170a5503-5cf7-464c-9079-e7ba0d593dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:to="loc_us-gaap_LineOfCreditMember_170a5503-5cf7-464c-9079-e7ba0d593dbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_15af5447-88fc-4034-a2ca-34de6efbfd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:to="loc_us-gaap_SeniorNotesMember_15af5447-88fc-4034-a2ca-34de6efbfd3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f641837c-df8b-44c0-bb16-f6a2c1001338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f641837c-df8b-44c0-bb16-f6a2c1001338" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e1428893-ac1c-46c6-89f9-246f31fdbffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:to="loc_us-gaap_DebtInstrumentAxis_e1428893-ac1c-46c6-89f9-246f31fdbffd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e1428893-ac1c-46c6-89f9-246f31fdbffd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e1428893-ac1c-46c6-89f9-246f31fdbffd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e1428893-ac1c-46c6-89f9-246f31fdbffd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e1428893-ac1c-46c6-89f9-246f31fdbffd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TheCreditAgreementMember_f5dd02ca-fefd-4994-b720-61d32989fcaf" xlink:href="ehc-20221231.xsd#ehc_TheCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_TheCreditAgreementMember_f5dd02ca-fefd-4994-b720-61d32989fcaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_45897bc1-e13e-4385-80f9-3db58a9b4314" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_45897bc1-e13e-4385-80f9-3db58a9b4314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_ec374597-300c-4186-acb0-99c40c8cd6cd" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_ec374597-300c-4186-acb0-99c40c8cd6cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_633b5849-6f7c-4972-b121-65d383dc2469" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_633b5849-6f7c-4972-b121-65d383dc2469" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_04e0112e-5ed6-453d-a0f6-5ee77c073f40" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_04e0112e-5ed6-453d-a0f6-5ee77c073f40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_93521221-52f9-4aeb-9d20-1adde59e920b" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_93521221-52f9-4aeb-9d20-1adde59e920b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="extended" id="ife06cad252d24a9d99ecc87102f1d6e2_LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_80b526af-c2de-4056-acc7-62ae2a7f2da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80b526af-c2de-4056-acc7-62ae2a7f2da6" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_cdaad997-7f86-4912-849e-1a748e06991c" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_cdaad997-7f86-4912-849e-1a748e06991c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_08e4dd3d-5850-4a3e-b9e3-82bc131a6ec4" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_08e4dd3d-5850-4a3e-b9e3-82bc131a6ec4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_eff3a5ff-a578-4c49-8f0a-9302ef57e186" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_eff3a5ff-a578-4c49-8f0a-9302ef57e186" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_a7d3d45a-f861-459a-9f95-75c5e65febdb" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_a7d3d45a-f861-459a-9f95-75c5e65febdb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_c6a37db7-00be-4aa6-a99f-91a487655153" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_c6a37db7-00be-4aa6-a99f-91a487655153" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_22e70126-561f-4e09-8051-dbd189364bb2" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_22e70126-561f-4e09-8051-dbd189364bb2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_77753571-370d-46aa-a872-465f7c53d1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_77753571-370d-46aa-a872-465f7c53d1c2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_342c2270-b5ac-4696-aa56-1228cf945330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80b526af-c2de-4056-acc7-62ae2a7f2da6" xlink:to="loc_us-gaap_DebtInstrumentTable_342c2270-b5ac-4696-aa56-1228cf945330" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c19f8c56-bc08-4926-b1ad-d0a46a3012fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_342c2270-b5ac-4696-aa56-1228cf945330" xlink:to="loc_us-gaap_DebtInstrumentAxis_c19f8c56-bc08-4926-b1ad-d0a46a3012fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c19f8c56-bc08-4926-b1ad-d0a46a3012fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c19f8c56-bc08-4926-b1ad-d0a46a3012fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c19f8c56-bc08-4926-b1ad-d0a46a3012fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a922964-0f6d-4975-bfa9-692236ad6ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c19f8c56-bc08-4926-b1ad-d0a46a3012fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a922964-0f6d-4975-bfa9-692236ad6ab0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FaceAmountMember_a11dcedb-7f68-4182-8eac-b04bf0c5a7ca" xlink:href="ehc-20221231.xsd#ehc_FaceAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a922964-0f6d-4975-bfa9-692236ad6ab0" xlink:to="loc_ehc_FaceAmountMember_a11dcedb-7f68-4182-8eac-b04bf0c5a7ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetAmountMember_7df513e5-e234-424b-9bb4-e5e277e1c390" xlink:href="ehc-20221231.xsd#ehc_NetAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a922964-0f6d-4975-bfa9-692236ad6ab0" xlink:to="loc_ehc_NetAmountMember_7df513e5-e234-424b-9bb4-e5e277e1c390" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended" id="i41f7e765a441457d98845e0223f20f37_LongtermDebtTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c7e5d4d5-9cb1-43da-93bf-e5d608787d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c7e5d4d5-9cb1-43da-93bf-e5d608787d1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8aee5262-a488-4c89-8b11-8244147118be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8aee5262-a488-4c89-8b11-8244147118be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_dbe34cc4-3681-4a34-84a6-de36aa419204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_dbe34cc4-3681-4a34-84a6-de36aa419204" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_062009b7-07d7-4f72-9c8d-3fed92316a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_062009b7-07d7-4f72-9c8d-3fed92316a95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum_ad1191e3-8698-49b7-954d-223a6784d842" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum_ad1191e3-8698-49b7-954d-223a6784d842" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantAvailableLimitAmount_b1b4e921-224c-4e0f-a652-f1d3a9bd8d4c" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantAvailableLimitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantAvailableLimitAmount_b1b4e921-224c-4e0f-a652-f1d3a9bd8d4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod_f135ba14-f30f-4b3d-9330-c0841a20aa66" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod_f135ba14-f30f-4b3d-9330-c0841a20aa66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum_25576601-a660-4156-9fc5-f5af35cf80c0" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum_25576601-a660-4156-9fc5-f5af35cf80c0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays_3ab32265-10aa-47d6-933c-c5fc0187262a" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays_3ab32265-10aa-47d6-933c-c5fc0187262a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e77d2045-4040-4aab-8626-15ed3403b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e77d2045-4040-4aab-8626-15ed3403b43a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion_adc6a161-d762-4b99-92e1-13b73d907c11" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion_adc6a161-d762-4b99-92e1-13b73d907c11" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_64f5d31b-b31c-43f1-be08-12d6d90a3963" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_64f5d31b-b31c-43f1-be08-12d6d90a3963" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_97a04313-01d3-42b6-9e4b-c02e9de5f7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_97a04313-01d3-42b6-9e4b-c02e9de5f7f3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome_d1250c7c-b1c1-45b1-9428-efcdfda4a4e8" xlink:href="ehc-20221231.xsd#ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome_d1250c7c-b1c1-45b1-9428-efcdfda4a4e8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_57aa79bc-df38-4819-b306-8681f5c2eb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_57aa79bc-df38-4819-b306-8681f5c2eb43" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_27ae3fa9-5742-43e6-932a-97f1d281438e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_27ae3fa9-5742-43e6-932a-97f1d281438e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_d88533ab-c72b-4594-8252-6f8f4a63fa00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_d88533ab-c72b-4594-8252-6f8f4a63fa00" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cd1e4c44-a20c-45da-a826-61bd0d5add2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LongTermDebt_cd1e4c44-a20c-45da-a826-61bd0d5add2a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_075725cc-8fc2-45e7-869d-c5ac98f333b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_075725cc-8fc2-45e7-869d-c5ac98f333b9" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_178876d9-3cf2-4d5a-9de4-75ea78acca99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_178876d9-3cf2-4d5a-9de4-75ea78acca99" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5e965fb2-07de-4d0c-a7f9-f7bc330e8d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5e965fb2-07de-4d0c-a7f9-f7bc330e8d89" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_da952a97-8cf1-4b77-ad51-b29601fcd6d9" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_da952a97-8cf1-4b77-ad51-b29601fcd6d9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_f969acc0-f959-4013-bb71-7fa3f90d7265" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_f969acc0-f959-4013-bb71-7fa3f90d7265" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_7209167d-71c5-49d9-a38d-7fc721018fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_RepaymentsOfDebt_7209167d-71c5-49d9-a38d-7fc721018fdc" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_782230b9-5b39-493a-9981-a3aba2d6e323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_782230b9-5b39-493a-9981-a3aba2d6e323" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_4cf5b344-e16d-4040-be50-67bf086a24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_4cf5b344-e16d-4040-be50-67bf086a24fb" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_604af134-c52b-4ad9-8f20-5f6f9e81dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_604af134-c52b-4ad9-8f20-5f6f9e81dfea" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_751c4c43-c48e-4fd2-9ee2-4fe1dbdecee5" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_751c4c43-c48e-4fd2-9ee2-4fe1dbdecee5" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_37f26f92-da66-4194-9695-4fb7fdc19a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_37f26f92-da66-4194-9695-4fb7fdc19a32" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed58d72e-e218-494e-827b-c2916b544ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed58d72e-e218-494e-827b-c2916b544ffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ed58d72e-e218-494e-827b-c2916b544ffd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed58d72e-e218-494e-827b-c2916b544ffd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ed58d72e-e218-494e-827b-c2916b544ffd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed58d72e-e218-494e-827b-c2916b544ffd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TheCreditAgreementMember_51488001-1836-4009-8578-91c05e68105d" xlink:href="ehc-20221231.xsd#ehc_TheCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_TheCreditAgreementMember_51488001-1836-4009-8578-91c05e68105d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_51f3e640-c479-4a3b-b932-3dc0700e9695" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_51f3e640-c479-4a3b-b932-3dc0700e9695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_4f93c259-ade7-448f-aea1-17837ee88e51" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_4f93c259-ade7-448f-aea1-17837ee88e51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_ea0a5813-390d-44d9-98b9-f0c23668ae90" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_ea0a5813-390d-44d9-98b9-f0c23668ae90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_7bdbe180-9407-4d7c-b217-079c206e8760" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_7bdbe180-9407-4d7c-b217-079c206e8760" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_5fec2a5e-6323-43f6-a3bb-d809d194a5d8" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_5fec2a5e-6323-43f6-a3bb-d809d194a5d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_b1a1d2e8-dbd1-4588-96d8-a1591896ee05" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_b1a1d2e8-dbd1-4588-96d8-a1591896ee05" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_844b2cb4-9327-4bb4-8d63-14d3851c2559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_CreditFacilityAxis_844b2cb4-9327-4bb4-8d63-14d3851c2559" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_844b2cb4-9327-4bb4-8d63-14d3851c2559_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_844b2cb4-9327-4bb4-8d63-14d3851c2559" xlink:to="loc_us-gaap_CreditFacilityDomain_844b2cb4-9327-4bb4-8d63-14d3851c2559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_844b2cb4-9327-4bb4-8d63-14d3851c2559" xlink:to="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_6b2fe79d-0a8d-4a84-9834-1f7e6342c4e4" xlink:href="ehc-20221231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:to="loc_ehc_TermLoanFacilitiesMember_6b2fe79d-0a8d-4a84-9834-1f7e6342c4e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_bfe62490-fcb5-429f-ac01-f885148dc889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_bfe62490-fcb5-429f-ac01-f885148dc889" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c3b7bb37-e77c-4ca8-ae83-39e98e61cdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:to="loc_us-gaap_LetterOfCreditMember_c3b7bb37-e77c-4ca8-ae83-39e98e61cdc6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_22199179-549c-401b-a929-262d7644f2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:to="loc_us-gaap_SecuredDebtMember_22199179-549c-401b-a929-262d7644f2cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_VariableRateAxis_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a" xlink:to="loc_us-gaap_VariableRateDomain_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e3148212-28bc-45d3-acb7-48e745ca1de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a" xlink:to="loc_us-gaap_VariableRateDomain_e3148212-28bc-45d3-acb7-48e745ca1de6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_3e8fa060-fade-4173-baa4-f208e0ca3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e3148212-28bc-45d3-acb7-48e745ca1de6" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_3e8fa060-fade-4173-baa4-f208e0ca3bed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SecuredOvernightFinancingRateSOFRMember_1a3ff148-cb98-4ab5-b8e2-c4ed55b3572b" xlink:href="ehc-20221231.xsd#ehc_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e3148212-28bc-45d3-acb7-48e745ca1de6" xlink:to="loc_ehc_SecuredOvernightFinancingRateSOFRMember_1a3ff148-cb98-4ab5-b8e2-c4ed55b3572b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_14a846b2-c6e5-41a5-9318-699683c1cde3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_14a846b2-c6e5-41a5-9318-699683c1cde3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_14a846b2-c6e5-41a5-9318-699683c1cde3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_14a846b2-c6e5-41a5-9318-699683c1cde3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_14a846b2-c6e5-41a5-9318-699683c1cde3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_14a846b2-c6e5-41a5-9318-699683c1cde3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_81a3ce9b-991e-4424-9c0f-c1805b882ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:to="loc_us-gaap_LoansPayableMember_81a3ce9b-991e-4424-9c0f-c1805b882ca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_29d5219a-076f-490c-8820-ff172314bff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:to="loc_us-gaap_SeniorNotesMember_29d5219a-076f-490c-8820-ff172314bff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ae1e25fe-5599-490a-9f7e-660f94894e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:to="loc_us-gaap_LineOfCreditMember_ae1e25fe-5599-490a-9f7e-660f94894e04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83b7587f-7ba3-41e9-9e40-3ece83f24ca2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_srt_RangeAxis_83b7587f-7ba3-41e9-9e40-3ece83f24ca2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_83b7587f-7ba3-41e9-9e40-3ece83f24ca2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_83b7587f-7ba3-41e9-9e40-3ece83f24ca2" xlink:to="loc_srt_RangeMember_83b7587f-7ba3-41e9-9e40-3ece83f24ca2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6b2363d-ec2f-4bd2-bfeb-db662a5f860e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_83b7587f-7ba3-41e9-9e40-3ece83f24ca2" xlink:to="loc_srt_RangeMember_a6b2363d-ec2f-4bd2-bfeb-db662a5f860e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_98a1f531-e76f-4e34-8d10-44019de20b72" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6b2363d-ec2f-4bd2-bfeb-db662a5f860e" xlink:to="loc_srt_MaximumMember_98a1f531-e76f-4e34-8d10-44019de20b72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_448d1525-9053-43d2-9f4d-79e3cee47a18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6b2363d-ec2f-4bd2-bfeb-db662a5f860e" xlink:to="loc_srt_MinimumMember_448d1525-9053-43d2-9f4d-79e3cee47a18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e3aecc3e-9b9e-427b-8519-33c37a98dd30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_dei_LegalEntityAxis_e3aecc3e-9b9e-427b-8519-33c37a98dd30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e3aecc3e-9b9e-427b-8519-33c37a98dd30_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e3aecc3e-9b9e-427b-8519-33c37a98dd30" xlink:to="loc_dei_EntityDomain_e3aecc3e-9b9e-427b-8519-33c37a98dd30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0042a1ee-dbf3-4b44-9bd1-2ab0f98cf656" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e3aecc3e-9b9e-427b-8519-33c37a98dd30" xlink:to="loc_dei_EntityDomain_0042a1ee-dbf3-4b44-9bd1-2ab0f98cf656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember_45a9c6d7-4342-4589-9d72-31bb276fbb9f" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0042a1ee-dbf3-4b44-9bd1-2ab0f98cf656" xlink:to="loc_ehc_EnhabitMember_45a9c6d7-4342-4589-9d72-31bb276fbb9f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtFinancialCovenantsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="extended" id="i21ccf1df184146d8975349e835fe7468_LongtermDebtFinancialCovenantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems_a5f32a5d-77f7-4f03-ab05-73527325905d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_b04e7ddf-8a6f-46ad-8ca9-66e00af3b5fa" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_a5f32a5d-77f7-4f03-ab05-73527325905d" xlink:to="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_b04e7ddf-8a6f-46ad-8ca9-66e00af3b5fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_84e765b7-380f-445a-905f-757357253b9e" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_a5f32a5d-77f7-4f03-ab05-73527325905d" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_84e765b7-380f-445a-905f-757357253b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f18ead9a-b9e9-4c54-a77c-e7b670c4c87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_a5f32a5d-77f7-4f03-ab05-73527325905d" xlink:to="loc_us-gaap_DebtInstrumentTable_f18ead9a-b9e9-4c54-a77c-e7b670c4c87f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7b6d5524-3603-470d-a0cf-a57f2b8453d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f18ead9a-b9e9-4c54-a77c-e7b670c4c87f" xlink:to="loc_srt_StatementScenarioAxis_7b6d5524-3603-470d-a0cf-a57f2b8453d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7b6d5524-3603-470d-a0cf-a57f2b8453d8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7b6d5524-3603-470d-a0cf-a57f2b8453d8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7b6d5524-3603-470d-a0cf-a57f2b8453d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e7c369ee-f767-45b3-bb5c-308b03ffee93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7b6d5524-3603-470d-a0cf-a57f2b8453d8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e7c369ee-f767-45b3-bb5c-308b03ffee93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3910d19d-12b9-4be1-9b49-259e6530a114" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e7c369ee-f767-45b3-bb5c-308b03ffee93" xlink:to="loc_srt_ScenarioForecastMember_3910d19d-12b9-4be1-9b49-259e6530a114" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtSeniorNotesRedemptionPricesDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails" xlink:type="extended" id="icb45335b026747e98a240c244b66f720_LongtermDebtSeniorNotesRedemptionPricesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems_41c1ce4d-bf19-4674-907c-1c89520a0494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_65593585-c9a4-4961-8045-fd4a62ca3d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_41c1ce4d-bf19-4674-907c-1c89520a0494" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_65593585-c9a4-4961-8045-fd4a62ca3d52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_41c1ce4d-bf19-4674-907c-1c89520a0494" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7a885289-f6a1-41c6-86e7-fd90208de745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7a885289-f6a1-41c6-86e7-fd90208de745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7a885289-f6a1-41c6-86e7-fd90208de745_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7a885289-f6a1-41c6-86e7-fd90208de745" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7a885289-f6a1-41c6-86e7-fd90208de745_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3748f2a5-0e65-45f5-a310-a5eb4c847499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7a885289-f6a1-41c6-86e7-fd90208de745" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3748f2a5-0e65-45f5-a310-a5eb4c847499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_0a0dbc58-875e-461d-9c8a-8f0afaaec802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3748f2a5-0e65-45f5-a310-a5eb4c847499" xlink:to="loc_us-gaap_SeniorNotesMember_0a0dbc58-875e-461d-9c8a-8f0afaaec802" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_08722f77-b4a4-4a8e-94c9-795dd917d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:to="loc_us-gaap_DebtInstrumentAxis_08722f77-b4a4-4a8e-94c9-795dd917d02b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_08722f77-b4a4-4a8e-94c9-795dd917d02b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_08722f77-b4a4-4a8e-94c9-795dd917d02b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_08722f77-b4a4-4a8e-94c9-795dd917d02b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_08722f77-b4a4-4a8e-94c9-795dd917d02b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_83e838c9-4c28-4fb8-b621-0c996d173116" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_83e838c9-4c28-4fb8-b621-0c996d173116" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_839888b9-38ad-4bce-b5d7-e008c3c38215" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_839888b9-38ad-4bce-b5d7-e008c3c38215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_dad9ee0c-93dc-4369-950d-1e71a8336e50" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_dad9ee0c-93dc-4369-950d-1e71a8336e50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_8afb9472-4a9c-448b-8138-ea583c247de6" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_8afb9472-4a9c-448b-8138-ea583c247de6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1aadd554-78ef-4cfc-a3d3-a7626b51755f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1aadd554-78ef-4cfc-a3d3-a7626b51755f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4ad425e0-39ef-4383-9800-3fc4aaf13112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4ad425e0-39ef-4383-9800-3fc4aaf13112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a653141b-63e6-47e3-b03d-b360862e8ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a653141b-63e6-47e3-b03d-b360862e8ebd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_b7ec0467-89ef-49ac-9475-f2d1aa5edfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_b7ec0467-89ef-49ac-9475-f2d1aa5edfea" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtScheduleofNotesPayableDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails" xlink:type="extended" id="i25dab2357bd34a2fb21ecec4bd059945_LongtermDebtScheduleofNotesPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3cd5f3ec-e1e3-42ed-99b0-dd942a396763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_25bfef24-e791-4aa0-a3e7-b97819bf568c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cd5f3ec-e1e3-42ed-99b0-dd942a396763" xlink:to="loc_us-gaap_LongTermDebt_25bfef24-e791-4aa0-a3e7-b97819bf568c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ab42bd6e-65de-424d-a361-81f5420f8beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cd5f3ec-e1e3-42ed-99b0-dd942a396763" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ab42bd6e-65de-424d-a361-81f5420f8beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cd5f3ec-e1e3-42ed-99b0-dd942a396763" xlink:to="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d3877316-119a-4be7-b716-895a45f7bfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d3877316-119a-4be7-b716-895a45f7bfb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d3877316-119a-4be7-b716-895a45f7bfb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d3877316-119a-4be7-b716-895a45f7bfb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d3877316-119a-4be7-b716-895a45f7bfb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d1de78b1-2cec-47a9-bc1f-fb033024004e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d3877316-119a-4be7-b716-895a45f7bfb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d1de78b1-2cec-47a9-bc1f-fb033024004e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ea2f9536-2e57-46da-9330-4e9c68596467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1de78b1-2cec-47a9-bc1f-fb033024004e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ea2f9536-2e57-46da-9330-4e9c68596467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5e78b9d2-88b6-478c-b659-3b74c70feff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_us-gaap_DebtInstrumentAxis_5e78b9d2-88b6-478c-b659-3b74c70feff6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5e78b9d2-88b6-478c-b659-3b74c70feff6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e78b9d2-88b6-478c-b659-3b74c70feff6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5e78b9d2-88b6-478c-b659-3b74c70feff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e78b9d2-88b6-478c-b659-3b74c70feff6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_29e2098a-ed0f-400c-8db3-0c99516b876d" xlink:href="ehc-20221231.xsd#ehc_NotesPayableRealEstateSaleLeasebackFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:to="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_29e2098a-ed0f-400c-8db3-0c99516b876d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_3c4b973b-c66d-431e-a646-d3aa9572b606" xlink:href="ehc-20221231.xsd#ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:to="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_3c4b973b-c66d-431e-a646-d3aa9572b606" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableSoftwareContractsMember_bf6eded1-e0d1-4728-8f3b-674a04e87d60" xlink:href="ehc-20221231.xsd#ehc_NotesPayableSoftwareContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:to="loc_ehc_NotesPayableSoftwareContractsMember_bf6eded1-e0d1-4728-8f3b-674a04e87d60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ef34d42-ce61-4d2d-8b6e-043e838373fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_srt_RangeAxis_9ef34d42-ce61-4d2d-8b6e-043e838373fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ef34d42-ce61-4d2d-8b6e-043e838373fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9ef34d42-ce61-4d2d-8b6e-043e838373fd" xlink:to="loc_srt_RangeMember_9ef34d42-ce61-4d2d-8b6e-043e838373fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a4cb3db-4236-4516-93ad-c7602ac21a0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9ef34d42-ce61-4d2d-8b6e-043e838373fd" xlink:to="loc_srt_RangeMember_7a4cb3db-4236-4516-93ad-c7602ac21a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0783243b-6c4b-4463-9e79-682325808df8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a4cb3db-4236-4516-93ad-c7602ac21a0d" xlink:to="loc_srt_MinimumMember_0783243b-6c4b-4463-9e79-682325808df8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56fc3453-8e76-4817-8864-bec276668bf8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7a4cb3db-4236-4516-93ad-c7602ac21a0d" xlink:to="loc_srt_MaximumMember_56fc3453-8e76-4817-8864-bec276668bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_us-gaap_VariableRateAxis_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b" xlink:to="loc_us-gaap_VariableRateDomain_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b226df75-1acb-4b5c-bb70-d9538a9d3b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b" xlink:to="loc_us-gaap_VariableRateDomain_b226df75-1acb-4b5c-bb70-d9538a9d3b4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SecuredOvernightFinancingRateSOFRMember_06c7a0e3-2f9d-44b9-b7df-d7927553d6c2" xlink:href="ehc-20221231.xsd#ehc_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b226df75-1acb-4b5c-bb70-d9538a9d3b4b" xlink:to="loc_ehc_SecuredOvernightFinancingRateSOFRMember_06c7a0e3-2f9d-44b9-b7df-d7927553d6c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended" id="i26d9271505d34f61990402d885eb1459_RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_96fedd16-d8fd-4c69-869e-f4040337a021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_96fedd16-d8fd-4c69-869e-f4040337a021" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9e7200ce-1e74-4f06-8d23-05edbb0b24b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9e7200ce-1e74-4f06-8d23-05edbb0b24b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_0a9e8039-ae2f-476d-b928-75bfad299231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_0a9e8039-ae2f-476d-b928-75bfad299231" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_be055e5f-8c19-45c4-9a52-8b88cac5b819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_be055e5f-8c19-45c4-9a52-8b88cac5b819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure_c3a18ef0-32f1-4ae5-b834-1daeb3c3363d" xlink:href="ehc-20221231.xsd#ehc_Contributiontojointventure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_ehc_Contributiontojointventure_c3a18ef0-32f1-4ae5-b834-1daeb3c3363d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8b882fdf-fc50-451b-82bc-b800ee935eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8b882fdf-fc50-451b-82bc-b800ee935eb2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction_5018039d-4c17-4142-a3fb-c8204d7512db" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_ehc_NoncontrollingInterestExchangeTransaction_5018039d-4c17-4142-a3fb-c8204d7512db" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_87af73a6-93a6-4c8a-83f6-95aadb41941c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_87af73a6-93a6-4c8a-83f6-95aadb41941c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestOtherAdjustment_1a23d18b-399f-4f85-abb1-9476a7ba5a63" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestOtherAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_ehc_NoncontrollingInterestOtherAdjustment_1a23d18b-399f-4f85-abb1-9476a7ba5a63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestSpinOff_3bb5aaa6-7419-4ad3-bc42-bfbf264afc15" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestSpinOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_ehc_NoncontrollingInterestSpinOff_3bb5aaa6-7419-4ad3-bc42-bfbf264afc15" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c3f316d6-b255-406a-ad2f-34ecf0cfdae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_7b4846ea-9d04-461d-8364-92a8cccb1825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_96fedd16-d8fd-4c69-869e-f4040337a021" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_7b4846ea-9d04-461d-8364-92a8cccb1825" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_dc2926d9-41ea-41f0-9f46-1fa2bf55648a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_7b4846ea-9d04-461d-8364-92a8cccb1825" xlink:to="loc_dei_LegalEntityAxis_dc2926d9-41ea-41f0-9f46-1fa2bf55648a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_dc2926d9-41ea-41f0-9f46-1fa2bf55648a_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_dc2926d9-41ea-41f0-9f46-1fa2bf55648a" xlink:to="loc_dei_EntityDomain_dc2926d9-41ea-41f0-9f46-1fa2bf55648a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3a739c5a-2772-4e24-9b37-8b200cbf804c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_dc2926d9-41ea-41f0-9f46-1fa2bf55648a" xlink:to="loc_dei_EntityDomain_3a739c5a-2772-4e24-9b37-8b200cbf804c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember_cee16614-4209-46b5-8f2d-30c3cd4b23c3" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3a739c5a-2772-4e24-9b37-8b200cbf804c" xlink:to="loc_ehc_RedeemableNoncontrollingInterestMember_cee16614-4209-46b5-8f2d-30c3cd4b23c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#RedeemableNoncontrollingInterestsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="extended" id="ie0d9b4b253e647f7b77e8df8ff48d0d8_RedeemableNoncontrollingInterestsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_6043fe19-30a6-426d-97a4-e66ae45156c1" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_6043fe19-30a6-426d-97a4-e66ae45156c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_338330a5-8795-4078-a4cf-cb8b932ac9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_338330a5-8795-4078-a4cf-cb8b932ac9d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent_5902c7e2-3916-4c80-9322-c01711798d2b" xlink:href="ehc-20221231.xsd#ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent_5902c7e2-3916-4c80-9322-c01711798d2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExerciseRightToSellRatio_04b72633-e661-4afd-9fa7-78bcf245527e" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestExerciseRightToSellRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_NoncontrollingInterestExerciseRightToSellRatio_04b72633-e661-4afd-9fa7-78bcf245527e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_9adc1b15-e319-4ad0-b8ee-e6fe8c17b5a0" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_9adc1b15-e319-4ad0-b8ee-e6fe8c17b5a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dc737d40-2705-4d4d-8af4-7f869cac91e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dc737d40-2705-4d4d-8af4-7f869cac91e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_1c98b955-cc7e-4044-8da7-695969432700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_1c98b955-cc7e-4044-8da7-695969432700" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfManagementInvestorsOutstanding_0a3a37f7-8777-4aa6-ad09-3cfacd0f4efd" xlink:href="ehc-20221231.xsd#ehc_NumberOfManagementInvestorsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_NumberOfManagementInvestorsOutstanding_0a3a37f7-8777-4aa6-ad09-3cfacd0f4efd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_16ca4838-55fc-4889-a44d-bee39d00fb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_16ca4838-55fc-4889-a44d-bee39d00fb5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_91a771f3-4d8e-49cb-97f9-fe47af39c70b" xlink:href="ehc-20221231.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_91a771f3-4d8e-49cb-97f9-fe47af39c70b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0758f625-6b41-4b16-9248-d36088753726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0758f625-6b41-4b16-9248-d36088753726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0758f625-6b41-4b16-9248-d36088753726_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0758f625-6b41-4b16-9248-d36088753726" xlink:to="loc_us-gaap_SegmentDomain_0758f625-6b41-4b16-9248-d36088753726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7cb6cd75-b712-4d3e-9777-465267abe02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0758f625-6b41-4b16-9248-d36088753726" xlink:to="loc_us-gaap_SegmentDomain_7cb6cd75-b712-4d3e-9777-465267abe02a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_e193dc21-8c17-4893-a11c-ed4b1c5194c2" xlink:href="ehc-20221231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7cb6cd75-b712-4d3e-9777-465267abe02a" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_e193dc21-8c17-4893-a11c-ed4b1c5194c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a38b96e-edba-415b-9bfa-6c56e275068e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a38b96e-edba-415b-9bfa-6c56e275068e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember_d426caa8-2f6c-4d4f-a7b4-65d4d20cecc8" xlink:href="ehc-20221231.xsd#ehc_EHHIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a38b96e-edba-415b-9bfa-6c56e275068e" xlink:to="loc_ehc_EHHIMember_d426caa8-2f6c-4d4f-a7b4-65d4d20cecc8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="ie89936c6e6634c5c8477a0a4c46f1c35_FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9f42961d-cbf8-4211-8e05-1aad205e416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9f42961d-cbf8-4211-8e05-1aad205e416e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_4a1ac868-63e9-4aec-b83d-89e6ed0a26f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_4a1ac868-63e9-4aec-b83d-89e6ed0a26f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_cf58bbd5-763b-4554-9d02-a274b5c80446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_cf58bbd5-763b-4554-9d02-a274b5c80446" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b189bf-cfbe-40d0-866b-d234507430ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b189bf-cfbe-40d0-866b-d234507430ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ac9c1e5b-15ce-4156-9293-78a9c09e0d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b189bf-cfbe-40d0-866b-d234507430ea" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ac9c1e5b-15ce-4156-9293-78a9c09e0d81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fa66260-e671-44a4-9b9c-13b725707663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fa66260-e671-44a4-9b9c-13b725707663" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4fa66260-e671-44a4-9b9c-13b725707663_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fa66260-e671-44a4-9b9c-13b725707663" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4fa66260-e671-44a4-9b9c-13b725707663_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fa66260-e671-44a4-9b9c-13b725707663" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9d273f7a-cb00-41b2-a788-2a0d7a6bcd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9d273f7a-cb00-41b2-a788-2a0d7a6bcd4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1b02bd37-36bc-4f3e-8dd5-1bad34cdfe87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1b02bd37-36bc-4f3e-8dd5-1bad34cdfe87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0c098e3f-c33d-4c5e-a57a-6ae43a30d69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0c098e3f-c33d-4c5e-a57a-6ae43a30d69d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_09edb743-33ac-4cfe-be4d-71264ceb59ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_09edb743-33ac-4cfe-be4d-71264ceb59ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_09edb743-33ac-4cfe-be4d-71264ceb59ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_09edb743-33ac-4cfe-be4d-71264ceb59ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_09edb743-33ac-4cfe-be4d-71264ceb59ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_78349595-6695-4e46-ad35-4b6286e88786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_09edb743-33ac-4cfe-be4d-71264ceb59ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_78349595-6695-4e46-ad35-4b6286e88786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_d0f1aaa3-3f07-40f6-a0e0-f81995315ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_78349595-6695-4e46-ad35-4b6286e88786" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_d0f1aaa3-3f07-40f6-a0e0-f81995315ac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_32a07005-df23-4818-ae59-6ce2fefca80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_78349595-6695-4e46-ad35-4b6286e88786" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_32a07005-df23-4818-ae59-6ce2fefca80a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" xlink:type="extended" id="i96d416a7395a423d87e17c912c25d500_FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8978d092-b6b8-4645-a932-e37e36f3f706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7559bde5-d7e3-4219-a75e-85666adea755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8978d092-b6b8-4645-a932-e37e36f3f706" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7559bde5-d7e3-4219-a75e-85666adea755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_0f5f5165-1d0d-4cb4-84c1-f70becda32c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8978d092-b6b8-4645-a932-e37e36f3f706" xlink:to="loc_us-gaap_LongTermDebtFairValue_0f5f5165-1d0d-4cb4-84c1-f70becda32c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8978d092-b6b8-4645-a932-e37e36f3f706" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_DebtInstrumentAxis_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_1aa581ef-5ba7-4120-b5b0-dd00e1ddfaf3" xlink:href="ehc-20221231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_TermLoanFacilitiesMember_1aa581ef-5ba7-4120-b5b0-dd00e1ddfaf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_6370c0f5-7692-4c3b-a055-055a94afe94f" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_6370c0f5-7692-4c3b-a055-055a94afe94f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_d120c698-4378-4712-a045-b9a01526e74a" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_d120c698-4378-4712-a045-b9a01526e74a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_e65a2cd7-0dc3-40d8-ba8f-fb3f626a1e20" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_e65a2cd7-0dc3-40d8-ba8f-fb3f626a1e20" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_a528ba35-c1a6-4b50-9427-d8a2b3c06a96" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_a528ba35-c1a6-4b50-9427-d8a2b3c06a96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_f2566278-88b7-46c5-86a2-afea431f4a30" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_f2566278-88b7-46c5-86a2-afea431f4a30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3e9aa83b-223e-49fc-82a8-fab5b7d6e706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_CreditFacilityAxis_3e9aa83b-223e-49fc-82a8-fab5b7d6e706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3e9aa83b-223e-49fc-82a8-fab5b7d6e706_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_3e9aa83b-223e-49fc-82a8-fab5b7d6e706" xlink:to="loc_us-gaap_CreditFacilityDomain_3e9aa83b-223e-49fc-82a8-fab5b7d6e706_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_518fcd2d-22b1-48bf-ac50-a8d76e5c439d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_3e9aa83b-223e-49fc-82a8-fab5b7d6e706" xlink:to="loc_us-gaap_CreditFacilityDomain_518fcd2d-22b1-48bf-ac50-a8d76e5c439d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a672f160-79aa-4b78-b4dc-f6f7b8e310c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_518fcd2d-22b1-48bf-ac50-a8d76e5c439d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a672f160-79aa-4b78-b4dc-f6f7b8e310c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_fc8c0422-b63b-4850-861e-73f280bcd668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_518fcd2d-22b1-48bf-ac50-a8d76e5c439d" xlink:to="loc_us-gaap_LetterOfCreditMember_fc8c0422-b63b-4850-861e-73f280bcd668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_e71962b3-0043-4af2-ac97-a7acab905541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_e71962b3-0043-4af2-ac97-a7acab905541" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e71962b3-0043-4af2-ac97-a7acab905541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e71962b3-0043-4af2-ac97-a7acab905541" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_e71962b3-0043-4af2-ac97-a7acab905541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e71962b3-0043-4af2-ac97-a7acab905541" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9d20057f-32d2-4e40-92fe-f468083c64b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9d20057f-32d2-4e40-92fe-f468083c64b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9dfd2324-d0c5-4c2c-88c0-17288bd5566e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9dfd2324-d0c5-4c2c-88c0-17288bd5566e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d417f5a4-9d6d-43bd-8e0c-6c7580114272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d417f5a4-9d6d-43bd-8e0c-6c7580114272" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_96266c49-2c68-4353-ae97-e17bc7675dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:to="loc_us-gaap_LoansPayableMember_96266c49-2c68-4353-ae97-e17bc7675dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_318ddb9e-3ec8-4fad-bc5f-a357b4ec0cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:to="loc_us-gaap_SeniorNotesMember_318ddb9e-3ec8-4fad-bc5f-a357b4ec0cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_6c256914-39e1-4f53-a108-fd6fdd4288d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_6c256914-39e1-4f53-a108-fd6fdd4288d8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPaymentsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails" xlink:type="extended" id="ida6c5f1425484000b2bd11f9959064be_ShareBasedPaymentsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14ae83bb-f855-4927-a0a7-6aa05405e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14ae83bb-f855-4927-a0a7-6aa05405e3ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4474e850-7cca-464f-8356-78c64eda228e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4474e850-7cca-464f-8356-78c64eda228e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2846cdf9-5a75-48eb-80b2-ea897eea6aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2846cdf9-5a75-48eb-80b2-ea897eea6aca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5fd2f495-1abc-4eb4-8d6a-036f226e8775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5fd2f495-1abc-4eb4-8d6a-036f226e8775" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a774e30a-7689-4899-a7a9-1051b3bedb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a774e30a-7689-4899-a7a9-1051b3bedb80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b626119a-f7bc-4d61-a498-9e6c018c2c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b626119a-f7bc-4d61-a498-9e6c018c2c9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_23b92f90-8f6e-47bb-ab05-ff8bb02d6a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_23b92f90-8f6e-47bb-ab05-ff8bb02d6a6f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ef14cf50-549f-4e15-b906-2135ba4f6ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ef14cf50-549f-4e15-b906-2135ba4f6ab4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_21cff375-50ab-471d-bbe4-50159dbb2917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_21cff375-50ab-471d-bbe4-50159dbb2917" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108dd24c-5849-4f3e-acb9-a9073a1283b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108dd24c-5849-4f3e-acb9-a9073a1283b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9e6411c0-2908-4f4c-a71e-fb4270979c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9e6411c0-2908-4f4c-a71e-fb4270979c45" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0a960ccc-f094-4e90-8b48-55549cec6f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0a960ccc-f094-4e90-8b48-55549cec6f3b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_88bca7cf-ff81-4f9c-a674-c2f3b8ccd585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_88bca7cf-ff81-4f9c-a674-c2f3b8ccd585" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_aed53bed-d195-45e0-b4d1-284be6867e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_aed53bed-d195-45e0-b4d1-284be6867e3d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_e164007b-bf40-493a-8e51-7f85ae4fff74" xlink:href="ehc-20221231.xsd#ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_e164007b-bf40-493a-8e51-7f85ae4fff74" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_94517e97-6a9b-4fb5-940b-29eef3f50ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_94517e97-6a9b-4fb5-940b-29eef3f50ea9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dd2a6bde-855b-4967-bf69-f864543cf7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dd2a6bde-855b-4967-bf69-f864543cf7f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_dd2a6bde-855b-4967-bf69-f864543cf7f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dd2a6bde-855b-4967-bf69-f864543cf7f6" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_dd2a6bde-855b-4967-bf69-f864543cf7f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_a80a1bba-e11b-473d-95ea-541d6b4c9650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dd2a6bde-855b-4967-bf69-f864543cf7f6" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_a80a1bba-e11b-473d-95ea-541d6b4c9650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_e0cedb02-3822-4b48-88d2-ba2479fb25b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_a80a1bba-e11b-473d-95ea-541d6b4c9650" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_e0cedb02-3822-4b48-88d2-ba2479fb25b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_21088f3d-07ad-4896-a441-f8ab65020540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_a80a1bba-e11b-473d-95ea-541d6b4c9650" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_21088f3d-07ad-4896-a441-f8ab65020540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e323e3be-2974-4599-8cb8-713704a80abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_us-gaap_PlanNameAxis_e323e3be-2974-4599-8cb8-713704a80abf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e323e3be-2974-4599-8cb8-713704a80abf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e323e3be-2974-4599-8cb8-713704a80abf" xlink:to="loc_us-gaap_PlanNameDomain_e323e3be-2974-4599-8cb8-713704a80abf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_99787d58-ae96-4cd7-8470-3c232f893c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e323e3be-2974-4599-8cb8-713704a80abf" xlink:to="loc_us-gaap_PlanNameDomain_99787d58-ae96-4cd7-8470-3c232f893c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember_1c13bbba-2691-46ae-9181-947676f2b655" xlink:href="ehc-20221231.xsd#ehc_A2016OmnibusPerformanceIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_99787d58-ae96-4cd7-8470-3c232f893c81" xlink:to="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember_1c13bbba-2691-46ae-9181-947676f2b655" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a06cc3dd-8f27-441d-9502-0a58feb09fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_us-gaap_AwardTypeAxis_a06cc3dd-8f27-441d-9502-0a58feb09fe3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a06cc3dd-8f27-441d-9502-0a58feb09fe3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a06cc3dd-8f27-441d-9502-0a58feb09fe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a06cc3dd-8f27-441d-9502-0a58feb09fe3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a06cc3dd-8f27-441d-9502-0a58feb09fe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5ef1f952-5ed9-4e4a-8df7-f5099403c1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5ef1f952-5ed9-4e4a-8df7-f5099403c1d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2505f25c-6299-40aa-bcfe-e0568fa044c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:to="loc_us-gaap_RestrictedStockMember_2505f25c-6299-40aa-bcfe-e0568fa044c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd864852-24c7-4a57-85dc-b71b1e1b48dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd864852-24c7-4a57-85dc-b71b1e1b48dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DividendEquivalentRSUMember_61942d36-3f70-43cd-a290-9e8655b2e0ce" xlink:href="ehc-20221231.xsd#ehc_DividendEquivalentRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:to="loc_ehc_DividendEquivalentRSUMember_61942d36-3f70-43cd-a290-9e8655b2e0ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_srt_TitleOfIndividualAxis_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d2088c5-52e0-4916-b8a6-8a7b8489c728" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d2088c5-52e0-4916-b8a6-8a7b8489c728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NonemployeeDirectorsMember_5574fe97-ba61-4f8f-a641-2057a24809b8" xlink:href="ehc-20221231.xsd#ehc_NonemployeeDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d2088c5-52e0-4916-b8a6-8a7b8489c728" xlink:to="loc_ehc_NonemployeeDirectorsMember_5574fe97-ba61-4f8f-a641-2057a24809b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CurrentAndFormerBoardOfDirectorsMember_da2d5356-5a4b-4463-8a0b-b99babc8a051" xlink:href="ehc-20221231.xsd#ehc_CurrentAndFormerBoardOfDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d2088c5-52e0-4916-b8a6-8a7b8489c728" xlink:to="loc_ehc_CurrentAndFormerBoardOfDirectorsMember_da2d5356-5a4b-4463-8a0b-b99babc8a051" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPaymentsWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails" xlink:type="extended" id="i7d4f570134154514b28b88bcaa7076e0_ShareBasedPaymentsWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dbb7fef9-e02d-4058-be4e-0b3a61b354e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dbb7fef9-e02d-4058-be4e-0b3a61b354e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_025d3e48-3915-4825-a0e4-de41b597c598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_025d3e48-3915-4825-a0e4-de41b597c598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_21579a10-f05b-48ad-9227-fbc2edf77d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_21579a10-f05b-48ad-9227-fbc2edf77d9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4a82e753-8209-4774-9e5c-2fb97ca227b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4a82e753-8209-4774-9e5c-2fb97ca227b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50aa73c7-61df-4416-81f1-57d0e11cbbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50aa73c7-61df-4416-81f1-57d0e11cbbe8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91a480b0-d177-4249-95a2-7f59d27ae38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dbb7fef9-e02d-4058-be4e-0b3a61b354e3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91a480b0-d177-4249-95a2-7f59d27ae38c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5445c20d-3f2d-4186-a799-f33cfcdf00b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91a480b0-d177-4249-95a2-7f59d27ae38c" xlink:to="loc_us-gaap_AwardTypeAxis_5445c20d-3f2d-4186-a799-f33cfcdf00b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5445c20d-3f2d-4186-a799-f33cfcdf00b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5445c20d-3f2d-4186-a799-f33cfcdf00b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5445c20d-3f2d-4186-a799-f33cfcdf00b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8824d614-0aa3-4b82-ac90-1e72f0e134cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5445c20d-3f2d-4186-a799-f33cfcdf00b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8824d614-0aa3-4b82-ac90-1e72f0e134cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_602fed21-be08-4a25-95b5-90c2f4a78ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8824d614-0aa3-4b82-ac90-1e72f0e134cb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_602fed21-be08-4a25-95b5-90c2f4a78ba9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" xlink:type="extended" id="i45f537e21d52468592ffa618497bcfa7_ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b35197b-4cb6-4f92-bba0-27bfe49fdcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b35197b-4cb6-4f92-bba0-27bfe49fdcc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1b346037-cc8b-498b-b5b9-b748e753affa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1b346037-cc8b-498b-b5b9-b748e753affa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dbb6aa3d-0135-4828-a42b-890e6f7f3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dbb6aa3d-0135-4828-a42b-890e6f7f3bee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff18cece-9edc-414c-97f3-21fa9ebfb494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff18cece-9edc-414c-97f3-21fa9ebfb494" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c552821-7d5f-4965-8251-d72178f18961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c552821-7d5f-4965-8251-d72178f18961" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod_2aded41e-ce43-4d61-ac51-71a526397340" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod_2aded41e-ce43-4d61-ac51-71a526397340" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_32470d7f-3d71-4ad9-b5b6-98cf45ad9c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b35197b-4cb6-4f92-bba0-27bfe49fdcc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55bf02ca-ed53-4e25-b7bf-16f4101918cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55bf02ca-ed53-4e25-b7bf-16f4101918cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77093962-4c21-463a-a432-e5c03b204e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77093962-4c21-463a-a432-e5c03b204e1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f407e3ff-f8ae-4640-bb5a-f3a1dd7ba0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f407e3ff-f8ae-4640-bb5a-f3a1dd7ba0fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c7f6b6f2-9bc4-45f5-9f46-4bd326dcd6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c7f6b6f2-9bc4-45f5-9f46-4bd326dcd6dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_2854b202-a9e8-45a9-9ea9-62f787c44c3f" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_2854b202-a9e8-45a9-9ea9-62f787c44c3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f80c3bd-6728-451b-b2d9-12be8e240e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01dea954-2fe3-4b51-8d12-d03eab36d915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b35197b-4cb6-4f92-bba0-27bfe49fdcc2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01dea954-2fe3-4b51-8d12-d03eab36d915" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d89598a3-6cce-4611-ab07-1dc7ad3c64a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01dea954-2fe3-4b51-8d12-d03eab36d915" xlink:to="loc_us-gaap_AwardTypeAxis_d89598a3-6cce-4611-ab07-1dc7ad3c64a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d89598a3-6cce-4611-ab07-1dc7ad3c64a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d89598a3-6cce-4611-ab07-1dc7ad3c64a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d89598a3-6cce-4611-ab07-1dc7ad3c64a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aab61c86-0e93-4632-bd19-5e88ace8ab90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d89598a3-6cce-4611-ab07-1dc7ad3c64a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aab61c86-0e93-4632-bd19-5e88ace8ab90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_16f1645a-1988-4de4-bb72-fb03bdb65900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aab61c86-0e93-4632-bd19-5e88ace8ab90" xlink:to="loc_us-gaap_RestrictedStockMember_16f1645a-1988-4de4-bb72-fb03bdb65900" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails" xlink:type="extended" id="ia7cb8e28e8364689b6a6b1dd91054231_EmployeeBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HealthcarePlanExpense_62e54e1c-df69-477d-a47c-52676e6dbd3c" xlink:href="ehc-20221231.xsd#ehc_HealthcarePlanExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_HealthcarePlanExpense_62e54e1c-df69-477d-a47c-52676e6dbd3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_398ad314-2309-4d6f-83d9-7f7b2e763053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_398ad314-2309-4d6f-83d9-7f7b2e763053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanAgeRequirement_4bd1136e-cd81-4ff4-9111-fd19fd38dbe2" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanAgeRequirement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_RetirementInvestmentPlanAgeRequirement_4bd1136e-cd81-4ff4-9111-fd19fd38dbe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_4506d9e6-a8d2-4714-9bbe-d3e4dbf36422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_4506d9e6-a8d2-4714-9bbe-d3e4dbf36422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_6a08c4f8-507e-484f-ba63-61898aed516c" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_6a08c4f8-507e-484f-ba63-61898aed516c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_96bdeffc-31ba-4e03-b07b-fe29f9867010" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_96bdeffc-31ba-4e03-b07b-fe29f9867010" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_dab9e03e-c644-4886-a761-33a0c025af67" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_dab9e03e-c644-4886-a761-33a0c025af67" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f6e4c787-2b4b-4c6f-abf2-962be113c63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f6e4c787-2b4b-4c6f-abf2-962be113c63f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_d0aa5614-fa31-418e-9525-a7dc9264904e" xlink:href="ehc-20221231.xsd#ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_d0aa5614-fa31-418e-9525-a7dc9264904e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorManagementBonusProgramTotalCosts_d1f55cd7-baa4-49d8-acc4-c305a05d434d" xlink:href="ehc-20221231.xsd#ehc_SeniorManagementBonusProgramTotalCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_SeniorManagementBonusProgramTotalCosts_d1f55cd7-baa4-49d8-acc4-c305a05d434d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_68e68a2e-2806-4e54-ad87-c8728318e334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_us-gaap_DefinedContributionPlanTable_68e68a2e-2806-4e54-ad87-c8728318e334" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_0dec2b07-4900-4211-a24a-fc53feffe407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_68e68a2e-2806-4e54-ad87-c8728318e334" xlink:to="loc_us-gaap_RetirementPlanNameAxis_0dec2b07-4900-4211-a24a-fc53feffe407" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_0dec2b07-4900-4211-a24a-fc53feffe407_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanNameAxis_0dec2b07-4900-4211-a24a-fc53feffe407" xlink:to="loc_us-gaap_RetirementPlanNameDomain_0dec2b07-4900-4211-a24a-fc53feffe407_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_28cf2ca9-e15b-415c-a047-571238d8b4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanNameAxis_0dec2b07-4900-4211-a24a-fc53feffe407" xlink:to="loc_us-gaap_RetirementPlanNameDomain_28cf2ca9-e15b-415c-a047-571238d8b4f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHealthRetirementInvestmentPlanMember_23810dfb-2409-4860-a5ff-9ec8047753b5" xlink:href="ehc-20221231.xsd#ehc_EncompassHealthRetirementInvestmentPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanNameDomain_28cf2ca9-e15b-415c-a047-571238d8b4f8" xlink:to="loc_ehc_EncompassHealthRetirementInvestmentPlanMember_23810dfb-2409-4860-a5ff-9ec8047753b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails" xlink:type="extended" id="iafa130a0741f4cd1a714063e241e8431_IncomeTaxesTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a5faf301-950f-4e11-8bfc-f4f1fb29cf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a5faf301-950f-4e11-8bfc-f4f1fb29cf8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_410c09db-7777-4942-8820-230fb0bb8865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_410c09db-7777-4942-8820-230fb0bb8865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e7b21d3a-18ef-471a-a7b8-5d9e0535cc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e7b21d3a-18ef-471a-a7b8-5d9e0535cc6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_73e5da71-8490-4c06-9316-01f104424850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:to="loc_us-gaap_ValuationAllowanceTable_73e5da71-8490-4c06-9316-01f104424850" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_85179353-b6c6-4dfa-960b-1f1e54e48118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ValuationAllowanceTable_73e5da71-8490-4c06-9316-01f104424850" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_85179353-b6c6-4dfa-960b-1f1e54e48118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_85179353-b6c6-4dfa-960b-1f1e54e48118_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_85179353-b6c6-4dfa-960b-1f1e54e48118" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_85179353-b6c6-4dfa-960b-1f1e54e48118_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2ffd4e8d-b9a5-42c0-b0ad-8a2d05911422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_85179353-b6c6-4dfa-960b-1f1e54e48118" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2ffd4e8d-b9a5-42c0-b0ad-8a2d05911422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1231b2ab-c2ee-4344-9b2c-272874d21aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2ffd4e8d-b9a5-42c0-b0ad-8a2d05911422" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1231b2ab-c2ee-4344-9b2c-272874d21aba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#EarningsPerCommonShareTextualDetails"/>
  <link:definitionLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails" xlink:type="extended" id="icd612504ee1d44c59f21876f99bb6518_EarningsPerCommonShareTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bcca758-4f6e-4bc2-a3c8-02e02e6370b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bcca758-4f6e-4bc2-a3c8-02e02e6370b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_02aebb18-1e09-408c-afb8-945f4bd3fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_02aebb18-1e09-408c-afb8-945f4bd3fc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_108cceab-94e5-4672-8fe4-44adb021c782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_108cceab-94e5-4672-8fe4-44adb021c782" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e98eb57f-3d5a-463e-8916-3abaa66c0154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e98eb57f-3d5a-463e-8916-3abaa66c0154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c1436b4a-3155-4cde-8995-4b88317d2a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c1436b4a-3155-4cde-8995-4b88317d2a39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_85e4067a-50b7-4bc2-b8b4-f98a0dec2ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_85e4067a-50b7-4bc2-b8b4-f98a0dec2ab2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1" xlink:to="loc_us-gaap_ClassOfStockDomain_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d391e6d-557b-47a0-874a-15c69f6f3e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1" xlink:to="loc_us-gaap_ClassOfStockDomain_4d391e6d-557b-47a0-874a-15c69f6f3e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_784613a6-2b81-4f2d-bcbb-f9d32b3f724d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4d391e6d-557b-47a0-874a-15c69f6f3e54" xlink:to="loc_us-gaap_CommonStockMember_784613a6-2b81-4f2d-bcbb-f9d32b3f724d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e6d0de25-889e-488d-9fa6-d95b7101de90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e6d0de25-889e-488d-9fa6-d95b7101de90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e6d0de25-889e-488d-9fa6-d95b7101de90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e6d0de25-889e-488d-9fa6-d95b7101de90" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e6d0de25-889e-488d-9fa6-d95b7101de90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7e5535a-09ae-4d31-a8df-afe76321080e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e6d0de25-889e-488d-9fa6-d95b7101de90" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7e5535a-09ae-4d31-a8df-afe76321080e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_05c7418e-aeeb-447e-9bd0-1ff4d8cb4efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c7e5535a-09ae-4d31-a8df-afe76321080e" xlink:to="loc_us-gaap_SubsequentEventMember_05c7418e-aeeb-447e-9bd0-1ff4d8cb4efd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>ehc-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6ef5271b-25cf-4941-a7fe-936386c94a75,g:d3e86cc2-acdf-4f67-b511-3ef26c190552-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_09593b09-25d1-40cd-865d-9a39238df814_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_4a46db94-0a2a-4330-82c2-65586f0f60c2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_e51dab33-78b7-46d4-9db2-60fe6e0c41f0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_5216dff3-82f5-4463-99d9-42f6dbf8a852_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_c3aa6f2f-8895-4873-9578-f31add3a33a2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_61db386f-5a38-44b2-887f-c912d4c0ce3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Self-Insurance Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_e94cb6f3-c8e1-4a4b-9cba-3940516e77f5_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of face value (percent)</link:label>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_label_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Discount Rate At Issuance Of Face Value</link:label>
    <link:label id="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Discount Rate at Issuance of Face Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:to="lab_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_904866dd-7fee-4a1a-9745-d9f1c7364411_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_5fc53edd-8c19-47d2-9248-01439816c99d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Basis of Other Indefinite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_fa5a2bb6-e5c9-4477-8a6b-8e401d5f0a30_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_9fb85ceb-8457-4d67-8d80-f81ae99afa73_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_f03f2b32-bbcb-41af-a955-7614b2cd72ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid on common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_80c5d566-abab-4bc8-9a65-c7cf83e845b8_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to nonredeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TrinityMedicalCenterMember_e07aed8b-bcd6-48c0-be83-5e5ba07b6aee_terseLabel_en-US" xlink:label="lab_ehc_TrinityMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trinity Medical Center</link:label>
    <link:label id="lab_ehc_TrinityMedicalCenterMember_label_en-US" xlink:label="lab_ehc_TrinityMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trinity Medical Center [Member]</link:label>
    <link:label id="lab_ehc_TrinityMedicalCenterMember_documentation_en-US" xlink:label="lab_ehc_TrinityMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trinity Medical Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TrinityMedicalCenterMember" xlink:href="ehc-20221231.xsd#ehc_TrinityMedicalCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TrinityMedicalCenterMember" xlink:to="lab_ehc_TrinityMedicalCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_d0f2cd1d-8162-42be-a4c9-45f27afd481b_terseLabel_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Covenants</link:label>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Financial Covenants [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Financial Covenants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:href="ehc-20221231.xsd#ehc_ScheduleOfFinancialCovenantsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:to="lab_ehc_ScheduleOfFinancialCovenantsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5a1626a8-5842-4041-9f1d-a2f6d6d09cfa_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_7b557849-e738-4fc5-a7d5-4d1bb3427bd8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_504bd004-cdd6-4cab-9749-c00290151524_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period, gross</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9ed76bcd-222a-4554-8e56-aa0c757a4825_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period, gross</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_3b44e941-457d-49b3-860b-f46345d07202_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_e3e13529-c3ee-46d4-979b-423076a5d230_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Disclosure Item Amounts [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_3e7d81d3-1fe3-40a0-8751-6726ce16d9ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_bcbbf97e-86e2-49c8-af59-53b15f18ef79_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spread on variable rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_b9748cea-4158-4b17-bd51-46fbb8ecf89a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5f92625d-a842-4e57-8ce9-c43f512c1311_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d4c65ad9-a222-40cd-ad58-b0082a4275a9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a204cb84-aa15-402e-b198-cbc26c8c4208_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_3ce32460-71d1-4ed1-a58f-86adcc7cdf4b_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year One</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod_8b130112-2420-4b70-9da5-f5fbad16444d_negatedTerseLabel_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhabit spin-off adjustment (in shares)</link:label>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod_label_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment In Period</link:label>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod_documentation_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" xlink:to="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2ffd5595-693a-46fe-ac70-20598c78109f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_75f2e25a-5441-4adb-b080-cf37745d60a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_7fefe614-3faf-446c-8398-d0a6e607565e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_2bfbfa36-62ae-4ec4-9a43-da1609a06346_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_79d084c9-d913-40fb-a29e-fca04cb1e322_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_c3ce543f-0626-4e15-be5b-ca809d591a5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4ac950fd-d28b-45af-adc8-5a88c0e31b24_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_f19f67aa-34be-494c-995b-35bb93e48319_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_af52e5b5-37d8-4709-b705-1e9dd4a4ef51_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70868803-a338-4caa-8c09-d28786b01369_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive shares excluded from computation of diluted weighted-average shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_d9130be1-d71b-42f0-8400-3a35d010e4b3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equity interests in consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_f381e93b-0c47-4d10-92ee-8e295bd95b63_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of distributions to affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDistributionsToAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Distributions to Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:to="lab_us-gaap_PaymentsOfDistributionsToAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_92f95a12-5e60-4941-822f-4b4920231143_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_511a4dac-7664-473d-a9a0-16867f96411b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_94ac4b5f-b43c-45ea-a5e4-8aff76e28aba_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_133706ce-7e10-47b0-b8cd-7f5e2c37216b_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3dbb5219-0a9b-45f9-9429-d7e7f27b5a94_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ec7de9f7-498e-4798-9a79-2e844ccab2db_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_4b505deb-e357-4b09-9bcb-8d7654326e45_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_54ddad91-5448-4936-acc8-2e96a51a9082_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_c6c8df31-ea06-4f0d-a2ce-1868117fef49_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in tax rate resulting from:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_eaf68dd0-e8cd-4c32-8417-0d3d500f7404_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_577fcad9-d82f-41f9-a2e6-b3951527ac8b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_6d496417-8c75-4495-b12e-5a8a338affa9_verboseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fbe02d8e-9280-4823-b878-09efa446cfd4_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_bd100d08-96cf-4dcd-8125-d0dac368d754_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d8578955-d3c6-47f3-9c6e-fe02f1927776_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost related to unvested restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_6472005e-b8ff-4f55-865e-81d1ca17e8be_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f8d660a5-c1ed-4bc2-9c7c-cd59cb312df2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d50b87f3-7f4a-46c8-99ac-e17ee1a2a22f_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Life (Years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_278c80ec-5e25-4661-9c9b-f2f10efecdcc_terseLabel_en-US" xlink:label="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options</link:label>
    <link:label id="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_documentation_en-US" xlink:label="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:href="ehc-20221231.xsd#ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:to="lab_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_00e52202-98ac-4b82-b92d-a0276d87f7d4_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentOperatingActivitiesDomain_label_en-US" xlink:label="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain" xlink:to="lab_us-gaap_SegmentOperatingActivitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7d491883-7338-46ea-804c-24eca36e7fb3_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership_4190ec53-6592-4f4e-8234-9a498971513b_terseLabel_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation hospitals, sole ownership</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership_label_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Hospitals, Sole Ownership</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership_documentation_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Hospitals, Sole Ownership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership" xlink:href="ehc-20221231.xsd#ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership" xlink:to="lab_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_6df8c16d-44a6-4610-8754-5737c0fd00b3_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_754d1d51-805c-4eee-a2e5-d43b3cdf1733_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_930d1c6d-d647-44fb-958b-23cb9b634f24_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_3d6f31ba-4452-4c7e-9a5b-91afd9ccf332_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8ebb42ae-86df-4458-b069-25c3186ca21c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_f098e262-3330-4b0a-b6fe-5046ebf06a1e_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_885a0e3b-a1b5-4b38-8bea-338a6e4477d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50ac0b5a-ea51-4993-8d53-680f7a07601d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_e511a5e5-12d0-4520-b48f-9540f8ac05a5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3d459d0e-3a39-43e8-af6a-5ae1054fbe14_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2e7c022a-52f4-4653-ad78-b2c975384c78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PremierHealthPartnersMember_b4bec71b-a579-49ba-8165-a7734aa43772_terseLabel_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners</link:label>
    <link:label id="lab_ehc_PremierHealthPartnersMember_label_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners [Member]</link:label>
    <link:label id="lab_ehc_PremierHealthPartnersMember_documentation_en-US" xlink:label="lab_ehc_PremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premier Health Partners [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember" xlink:href="ehc-20221231.xsd#ehc_PremierHealthPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PremierHealthPartnersMember" xlink:to="lab_ehc_PremierHealthPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_10c83bfc-8506-43bd-bd90-f15bec78ba65_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes due 2025</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_100d273d-6fa1-416a-aba8-b9c30119b23e_verboseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes due 2025</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_label_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2025 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes05.75Due2025Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes05.75Due2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes05.75Due2025Member" xlink:to="lab_ehc_SeniorNotes05.75Due2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_aff7c091-749c-47aa-bc1b-f569f44c2654_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances under revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_196008d2-b6fa-4f80-96b8-aa0b7ddd969b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_83f98ba8-e12a-43f5-9992-2ecf97f75b78_terseLabel_en-US" xlink:label="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:href="ehc-20221231.xsd#ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:to="lab_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2eeffa82-b833-4dee-a43c-53066c5494fc_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_85be325b-7ae1-473f-9ec3-5f17daa2b283_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_f97e7689-ba4c-42c9-9c55-94db484c76c2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicaidMember_ab634b9c-8896-424a-afae-03dc334450a0_terseLabel_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ehc_MedicaidMember_label_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ehc_MedicaidMember_documentation_en-US" xlink:label="lab_ehc_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember" xlink:href="ehc-20221231.xsd#ehc_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicaidMember" xlink:to="lab_ehc_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6afda931-3128-4196-8c07-6fd1046ae788_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_992b1f18-8be4-4340-83d1-a6434f84ad00_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived or Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_31749fd3-1ef3-414c-bbc1-81da9a75595d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested shares, Beginning Balance (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8874dd53-52e6-4245-a6c5-764f53af1780_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested shares, Ending Balance (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_b48525bc-6b35-44de-addb-5848886ff03c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_26e82231-c8cb-431f-83a7-7cc7d8414e84_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_323859ea-264a-4a4c-b4c3-778c4ed7b381_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_5e7e5631-acc2-49af-be31-41bbfe605d99_terseLabel_en-US" xlink:label="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual claims covered by reserves</link:label>
    <link:label id="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_label_en-US" xlink:label="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Individual Claims Covered by Self-Insured Risk Reserves</link:label>
    <link:label id="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_documentation_en-US" xlink:label="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of individual claims covered by the Company's self-insured risk reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:href="ehc-20221231.xsd#ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:to="lab_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_29a02e0f-6206-4f64-acad-7b62c1cd57f8_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameDomain" xlink:to="lab_us-gaap_RetirementPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_a8556208-7228-4ac3-9722-7af618e5c5ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_5e7222dc-8588-42f3-b91d-0ce304aa6ef8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod_69b9528f-66da-41e5-b3ea-8a64e2d2b220_terseLabel_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhabit spin-off adjustment (in shares)</link:label>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod_label_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period</link:label>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod_documentation_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" xlink:to="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_3b515de3-02ad-429e-adda-ffa46ee3011b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_982a416e-0a6b-4076-a5df-642fa0a8e4b5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_54c8c615-aa69-42d6-8f48-a105ab18a66c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_fca4f8a5-931e-42b2-aada-cba84ea18071_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_516552b0-5d60-4f2f-9f39-75e9fc988eaa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_ebc552e7-d17e-4337-a442-3b486390cb6e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b6d4470f-fb54-4502-8c64-f620402c19c0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4b1ec441-0201-4ecd-bcf2-6f009bfa5efe_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_c3096d72-86de-44d3-969e-d100e2acc459_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_eb076b85-9a94-4710-aa67-ce910f04281a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Assumptions Used to Determine Fair Value of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_cb300dbc-69d0-4027-939f-0f5f25f9eb82_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_53c37af7-ff06-4f58-be84-0dd77e96c2b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fce4e63a-cade-475d-90ce-3f2b72ba1fe8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in valuation allowance (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7bf5b293-ac93-499a-95ab-b6280d4e007d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average recognition period for unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3c491f58-a381-48a3-bcaa-956da8802379_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Life (Years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_cf80cfba-5c27-4d3e-a5b1-f762a536d410_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives and Amortization Basis of Other Finite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_ae6b6e1b-a5cd-461a-8186-ff5a0e0e4d40_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f7883c24-2e0c-4e4e-b882-25a927f63f71_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_9b112093-42b3-45d2-9605-df426d4cec23_totalLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total adjustments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_9271c2d1-dd75-4aed-9f74-c25ae78f195a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_27f98844-56ac-45ef-9578-b7d3a641a465_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_7f678e6a-0c7b-4b2c-9c66-e84bfe328d94_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest, equity, acquired percent</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Acquired Percent</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Acquired Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:to="lab_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyClaimsAwaitingReviewAmount_ddb7acd1-4fe2-4821-a87b-24cac742337c_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyClaimsAwaitingReviewAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of claims pending review</link:label>
    <link:label id="lab_ehc_LossContingencyClaimsAwaitingReviewAmount_label_en-US" xlink:label="lab_ehc_LossContingencyClaimsAwaitingReviewAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Awaiting Review, Amount</link:label>
    <link:label id="lab_ehc_LossContingencyClaimsAwaitingReviewAmount_documentation_en-US" xlink:label="lab_ehc_LossContingencyClaimsAwaitingReviewAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Awaiting Review, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyClaimsAwaitingReviewAmount" xlink:href="ehc-20221231.xsd#ehc_LossContingencyClaimsAwaitingReviewAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyClaimsAwaitingReviewAmount" xlink:to="lab_ehc_LossContingencyClaimsAwaitingReviewAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice_2093d496-9895-4e9c-ab7f-44e5d5d52d3e_terseLabel_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhabit spin-off adjustment (in dollars per share)</link:label>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" xlink:to="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_813dff3d-d943-48e1-91f4-e51c124b3370_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7d0371e5-6165-4a94-9083-6cbfd40cd8df_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca1e6ab5-89e2-41de-8871-9322561293c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64fafe36-c0b1-416f-b9ab-73ad1995bf5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c953994a-e6dc-4be0-bd27-df1381cff616_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_28e8cd99-2243-400e-ace7-00c478286387_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_cda79557-1bff-4abc-8a4a-65c1c91758e6_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestLineItems_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2bcec497-626a-48ac-a77e-e4326b7cc177_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c3821fab-ad37-4fc4-8fbf-82447266c78e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_33966287-8828-4b00-bafe-7fe74dee449c_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_7912c60a-3223-464f-83bc-0b8088cf5379_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Operating Lease Right Of Use Asset</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_15589abd-0204-45a0-a7dc-94d94c75808c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0a0e9183-3e14-42ab-9ae5-0d05673e935a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_837faec0-80ff-418d-9d11-7a92d347563d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_29a09d5d-03a9-4f2c-98d9-b9fafc89877e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5677ccc6-b593-4023-8684-ffe69a6dc8f4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_12f0f951-46be-4d8c-af55-c2b3c7128beb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_c42e8418-055d-4d98-9245-3b7e6c35615c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOperatingActivitiesSegmentAxis_label_en-US" xlink:label="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="lab_us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_659048df-bb01-4388-ba3f-30722f87f4ff_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_5622e55b-4974-4e97-9a28-bb14e146fe36_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_9132c32e-a834-423d-ad2f-54940e80d353_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net and comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_f98c2890-cd61-4532-83b4-04a274676a1d_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment agreement, amount to be paid</link:label>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_label_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amendment Agreement, Amount To Be Paid</link:label>
    <link:label id="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amendment Agreement, Amount To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:to="lab_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_72bbcb0e-5486-40b5-9267-9bf17320c9e9_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4bd4eb5b-e954-4367-bcbd-222f5d33f3e6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards issued during period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ecd6d01f-028b-4686-af77-ee978a4de024_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aeefa48e-d7dd-41ed-9c54-ee723671205d_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_b5949cad-25d0-49d9-98ca-7a032381c338_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInSecondYear_02c553d4-5593-4c2b-9182-e6ef2bc12e9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:to="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_4ee16845-4c30-445a-8500-e0b9faac653f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome_4cddc284-f623-4f27-92df-43a09abfc2dc_terseLabel_en-US" xlink:label="lab_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cumulative consolidated net income</link:label>
    <link:label id="lab_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome_label_en-US" xlink:label="lab_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Covenant, Percentage of Cumulative Consolidated Net Income</link:label>
    <link:label id="lab_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome_documentation_en-US" xlink:label="lab_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Covenant, Percentage of Cumulative Consolidated Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" xlink:href="ehc-20221231.xsd#ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" xlink:to="lab_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_7425f4eb-74fe-4190-abfa-d2506a63698d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_bd25e14d-4166-4022-8416-725b037a7592_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_f89d48b6-a27f-4ddd-bd9c-f4deede91737_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_43c2d92d-6e46-4fe6-8d08-02f03fdaad7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_0e74c35d-32d8-4ef4-b65d-80777f7290ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_29e63523-b9a3-4a25-8afa-e38f90500dd9_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Medicare patient discharges (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_6ee6aec1-1dd4-4a84-8593-72c24980cb53_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues by payor source (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_5091bed2-fdc5-4064-a845-50cedc09fbf2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, pro forma net income (loss)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_44fda40b-109b-4312-80f8-28e066d13a8f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_87d66ab3-c6dc-4ae1-93ab-186dd88e0cc5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4c7f6e7d-4b0f-4df0-9b05-0fdd3dc5b544_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_f1a07c2d-3b91-45fa-bc51-ea0d26bce049_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NCHHealthcareSystemMember_3996d3d2-7d22-4f42-adb8-00f6caabc46f_terseLabel_en-US" xlink:label="lab_ehc_NCHHealthcareSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NCH Healthcare System</link:label>
    <link:label id="lab_ehc_NCHHealthcareSystemMember_label_en-US" xlink:label="lab_ehc_NCHHealthcareSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NCH Healthcare System [Member]</link:label>
    <link:label id="lab_ehc_NCHHealthcareSystemMember_documentation_en-US" xlink:label="lab_ehc_NCHHealthcareSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NCH Healthcare System</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NCHHealthcareSystemMember" xlink:href="ehc-20221231.xsd#ehc_NCHHealthcareSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NCHHealthcareSystemMember" xlink:to="lab_ehc_NCHHealthcareSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_16b95413-bff6-476d-8060-06819bc86a38_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_66f2ac78-32de-4b80-94f4-0ed943847813_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c84f7106-cb1d-47c2-b952-ff3036dbbf6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of vested shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SecuredOvernightFinancingRateSOFRMember_533f8b4b-49b0-49f2-83b3-14db48751328_terseLabel_en-US" xlink:label="lab_ehc_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(SOFR)</link:label>
    <link:label id="lab_ehc_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_ehc_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_ehc_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_ehc_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SecuredOvernightFinancingRateSOFRMember" xlink:href="ehc-20221231.xsd#ehc_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_ehc_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_f27e72fb-a5cb-4782-998a-7d7af16b2b3d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFourthYear_7ccc90fc-17e9-4bf5-9a42-f8d661e48058_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_f2378adc-6b99-44bd-b3de-d89389a80f52_verboseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Insured Risks</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_e722fc2f-6f25-43ce-8e4a-931bf04d8ff9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions paid to noncontrolling interests of consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_1d23a9e1-96ff-4c92-8872-e91b6c331f79_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_731aa672-665e-465d-8224-6daa7103d9bf_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expenses [Abstract]</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_08958235-16e6-40a1-9a25-7d2282112a7e_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_87ed2135-1b9a-4b85-90f6-76ccceae99c7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_9b356723-d03d-4be8-a22f-fc64ba2b39c2_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_27fac8ec-722a-4d38-af65-51992f41992b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fea4e427-2683-4785-8b98-a14683c2c32f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_ece43091-74d8-4faf-9fca-4f0f46cd9c6b_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_1b441595-67aa-40f4-815b-72ab4e55abdd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_6869fb50-1579-4683-a31c-a32f40ca7af3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_f5ee04c4-294f-4f97-9887-4ce27f340d2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_5e6198e5-6ea1-4e8c-ab8c-586253dcf32f_verboseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities in and Results of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_47a68625-ac73-4775-a02c-2564b0a1fbe2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock, including fees and expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_ac7c5939-22f7-4a04-b573-1e222f34311d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e18cd256-7c0f-4e5e-b07e-10dc62a6abd8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement_01a3661f-c699-4a85-ae59-47035becdf3c_terseLabel_en-US" xlink:label="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of property and equipment, net pledged to lenders under credit agreement (percent)</link:label>
    <link:label id="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement_label_en-US" xlink:label="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of assets pledged to lenders under credit agreement</link:label>
    <link:label id="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement_documentation_en-US" xlink:label="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of assets pledged to lenders under credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:href="ehc-20221231.xsd#ehc_Percentageofassetspledgedtolendersundercreditagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:to="lab_ehc_Percentageofassetspledgedtolendersundercreditagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_11b32066-a608-4f93-9882-1aaaaeb26785_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherIncomeSourceMember_bb5c6608-c2e8-49a8-acdf-d910de0d7cd3_terseLabel_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_ehc_OtherIncomeSourceMember_label_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Source [Member]</link:label>
    <link:label id="lab_ehc_OtherIncomeSourceMember_documentation_en-US" xlink:label="lab_ehc_OtherIncomeSourceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Source [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember" xlink:href="ehc-20221231.xsd#ehc_OtherIncomeSourceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherIncomeSourceMember" xlink:to="lab_ehc_OtherIncomeSourceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_0a591ae6-b6ee-40d2-993a-a006db500a40_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance reserve</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_02e96641-d606-474d-8567-977de284ac5f_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_448d5d33-a787-4c30-b710-07938acf7803_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_c897914f-c32b-40f8-b86a-7f7cbbbb6927_totalLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, current</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_d236188a-4811-4eb4-ad32-439648a60307_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delivering EHC shares to management investors (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_04d580d8-ff77-408f-98ae-0e573946373c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_218a769b-1b94-4606-b4bd-c4282cfbbe4a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6db07798-4507-45be-aa61-4cfde59e126c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated income</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_2c16558f-1297-4313-9566-4880a0010abb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_45379dc0-72fe-4f35-8e31-25fd0ee55bc4_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_3ea4a36e-2f0e-4f65-b8df-d4ca35806b23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income from discontinued operations allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Discontinued Operation Earnings (Loss), Allocation to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5047d2ca-f4e4-4ed6-971a-14b054e781ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_cf18199f-1d8c-496a-be70-bc2edcfba26b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, December 31, 2021 (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_bf399fc7-4d4f-4256-9b90-324f48088915_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Actual and Pro Forma Results of Operations for Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_475d2816-7c8e-43e6-922d-bbb26317ccd1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TradeNameEncompassMember_0463ce91-3df8-4f9a-ae2f-03a2b35c062a_terseLabel_en-US" xlink:label="lab_ehc_TradeNameEncompassMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name - Encompass</link:label>
    <link:label id="lab_ehc_TradeNameEncompassMember_label_en-US" xlink:label="lab_ehc_TradeNameEncompassMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name - Encompass [Member]</link:label>
    <link:label id="lab_ehc_TradeNameEncompassMember_documentation_en-US" xlink:label="lab_ehc_TradeNameEncompassMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name - Encompass [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TradeNameEncompassMember" xlink:href="ehc-20221231.xsd#ehc_TradeNameEncompassMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TradeNameEncompassMember" xlink:to="lab_ehc_TradeNameEncompassMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_18c46164-ebde-4eec-b9a0-4490979cf3e5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amortization Expense, Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33d9a3d2-480a-4ed9-9b30-591b99122c29_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CurrentAndFormerBoardOfDirectorsMember_a8749ea4-d3db-4248-aa5c-74bc07724e4c_terseLabel_en-US" xlink:label="lab_ehc_CurrentAndFormerBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current And Former Board Of Directors</link:label>
    <link:label id="lab_ehc_CurrentAndFormerBoardOfDirectorsMember_label_en-US" xlink:label="lab_ehc_CurrentAndFormerBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current And Former Board Of Directors [Member]</link:label>
    <link:label id="lab_ehc_CurrentAndFormerBoardOfDirectorsMember_documentation_en-US" xlink:label="lab_ehc_CurrentAndFormerBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current And Former Board Of Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CurrentAndFormerBoardOfDirectorsMember" xlink:href="ehc-20221231.xsd#ehc_CurrentAndFormerBoardOfDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CurrentAndFormerBoardOfDirectorsMember" xlink:to="lab_ehc_CurrentAndFormerBoardOfDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_2c3757c0-75d5-4fdd-a31f-6afc519a9136_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_795f5d5c-a4e7-4e4b-92e0-928d82cb5414_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_beeabe15-ec65-4e68-a651-ee286823433d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_62555a61-6f0b-468a-acec-c001516b876f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_0e69d75b-625b-45fb-a5a9-59f85d86635f_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current expense</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_c8abdb3d-8bed-497f-8144-7c086acea0ff_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount_52e85e11-96d5-412d-a6a8-5a59787d4b81_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alleged overpayment amount</link:label>
    <link:label id="lab_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount_label_en-US" xlink:label="lab_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Extrapolated Error Rate, Alleged Overpayment Amount</link:label>
    <link:label id="lab_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount_documentation_en-US" xlink:label="lab_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Extrapolated Error Rate, Alleged Overpayment Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" xlink:href="ehc-20221231.xsd#ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" xlink:to="lab_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_8ffe4b99-07de-4d75-80aa-8b6c95f62ce6_totalLabel_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets acquired</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_label_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets</link:label>
    <link:label id="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:href="ehc-20221231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:to="lab_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrentAbstract_952304ea-5b27-48e4-974e-ac98187f0ac4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Net, Current</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:to="lab_us-gaap_AccountsReceivableNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AuditInformationAbstract_label_en-US" xlink:label="lab_ehc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ehc_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ehc_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AuditInformationAbstract" xlink:href="ehc-20221231.xsd#ehc_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AuditInformationAbstract" xlink:to="lab_ehc_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_6b91a604-abea-4c7a-9e2c-d01c13cd8d8b_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, by Legal Entity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ab07406d-c11f-4a4e-b18a-20abf3b14d7d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Contributiontojointventure_1b778ed9-1df4-4be9-b13f-d01d124db2e1_terseLabel_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to joint ventures</link:label>
    <link:label id="lab_ehc_Contributiontojointventure_label_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to joint venture</link:label>
    <link:label id="lab_ehc_Contributiontojointventure_documentation_en-US" xlink:label="lab_ehc_Contributiontojointventure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of primarily intangible assets relating to a joint venture agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure" xlink:href="ehc-20221231.xsd#ehc_Contributiontojointventure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Contributiontojointventure" xlink:to="lab_ehc_Contributiontojointventure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrentAbstract_3b493ae3-ed5c-416f-a811-317c277d4430_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:to="lab_us-gaap_OtherReceivablesNetCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e67099ce-89c0-4ecb-9f88-5a1bff9a05ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_dee53efe-21d9-4aca-a0c0-8fb0f04ef311_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_23cd2a13-65ab-4018-9321-1c12277fc2ca_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_cdce59de-6d81-43a5-83db-a1003b08e391_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_708f9214-8f1e-4f07-b8b6-f7e39acad5ff_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_815859a4-37b7-49b9-a2c9-7e27961630a9_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EHHIMember_6c3d5dbc-b1e8-4dda-9fa4-71d5a519120d_terseLabel_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI</link:label>
    <link:label id="lab_ehc_EHHIMember_label_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI [Member]</link:label>
    <link:label id="lab_ehc_EHHIMember_documentation_en-US" xlink:label="lab_ehc_EHHIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EHHI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember" xlink:href="ehc-20221231.xsd#ehc_EHHIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EHHIMember" xlink:to="lab_ehc_EHHIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfManagementInvestorsOutstanding_8e0bae5a-2241-46f3-a209-68bb3b97c87a_terseLabel_en-US" xlink:label="lab_ehc_NumberOfManagementInvestorsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of management investors remaining outstanding</link:label>
    <link:label id="lab_ehc_NumberOfManagementInvestorsOutstanding_label_en-US" xlink:label="lab_ehc_NumberOfManagementInvestorsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Management Investors Outstanding</link:label>
    <link:label id="lab_ehc_NumberOfManagementInvestorsOutstanding_documentation_en-US" xlink:label="lab_ehc_NumberOfManagementInvestorsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Management Investors Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfManagementInvestorsOutstanding" xlink:href="ehc-20221231.xsd#ehc_NumberOfManagementInvestorsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfManagementInvestorsOutstanding" xlink:to="lab_ehc_NumberOfManagementInvestorsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e09299b-9779-4cd9-8914-937d5abc5ac4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8b021b24-fc17-4106-a6f2-b06279a44e19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_010284e2-908a-45bb-8462-24bcbf390480_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax expense related to continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f4214e9c-65e1-494b-b1d7-c5ffd663ac31_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f1011826-a590-40a8-ba1b-b122a86c7b32_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_38fbcc2d-45c7-4398-8431-a20e1c677451_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_768e5581-29d1-4dd9-81fe-b8299b59b70d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_8ca612e5-3934-42b5-a03d-b72a1f49c654_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyExtrapolatedErrorRatePeriod_3a4299bd-aacc-42a4-a59e-4fb3a2728445_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyExtrapolatedErrorRatePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extrapolated error rate period</link:label>
    <link:label id="lab_ehc_LossContingencyExtrapolatedErrorRatePeriod_label_en-US" xlink:label="lab_ehc_LossContingencyExtrapolatedErrorRatePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Extrapolated Error Rate, Period</link:label>
    <link:label id="lab_ehc_LossContingencyExtrapolatedErrorRatePeriod_documentation_en-US" xlink:label="lab_ehc_LossContingencyExtrapolatedErrorRatePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Extrapolated Error Rate, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyExtrapolatedErrorRatePeriod" xlink:href="ehc-20221231.xsd#ehc_LossContingencyExtrapolatedErrorRatePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyExtrapolatedErrorRatePeriod" xlink:to="lab_ehc_LossContingencyExtrapolatedErrorRatePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_01e96526-4dfd-42a1-9972-7500b8403200_verboseLabel_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_label_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment [Member]</link:label>
    <link:label id="lab_ehc_HomeHealthandHospiceSegmentMember_documentation_en-US" xlink:label="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Health and Hospice Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember" xlink:href="ehc-20221231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HomeHealthandHospiceSegmentMember" xlink:to="lab_ehc_HomeHealthandHospiceSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_1e07a6c7-23fb-4037-ba90-30aa6b92aec3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_cc9bff72-32f3-41e7-9e3d-d63e9fdb8a7f_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Salaries And Benefits</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Salaries And Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ff76d608-9462-4524-bfe4-aab87406d83f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $.01 par value; 200,000,000 shares authorized; issued: 114,775,056 in 2022; 114,211,057 in 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_eff98f85-450f-43b5-940e-db426d2000c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_4afcc648-fbb0-4592-8dc7-ca2567f53895_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_0d8ce00e-288e-47e0-93a6-df3d8c3e610c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_7330f32e-971d-4f32-aee7-695029f09033_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_5251ea78-5f2f-4942-923e-0e5364be84a9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Reserves</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_2bb3c0da-2693-46ab-a6f1-6a0b2e620b91_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_133ff21f-5633-4f31-9f94-e522bcd3f2bb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_865f3a5a-6ade-48d8-a0ac-10576bf1664a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ae4e8ee-b364-4042-80bb-4e1c6bf777a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestExerciseRightToSellRatio_f7aca9d8-a019-49f7-a53c-7e8d0623f3ae_terseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestExerciseRightToSellRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise, right to sell, ratio</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestExerciseRightToSellRatio_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestExerciseRightToSellRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Exercise, Right To Sell, Ratio</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestExerciseRightToSellRatio_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestExerciseRightToSellRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Exercise, Right To Sell, Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExerciseRightToSellRatio" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestExerciseRightToSellRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestExerciseRightToSellRatio" xlink:to="lab_ehc_NoncontrollingInterestExerciseRightToSellRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2440638d-4200-4a9d-b713-952a51cd82b1_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_be51c148-eebd-49be-8d06-0201f48d0460_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_d1bd3b2b-da32-48cc-aa43-4b222707441f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_a6833ac3-c28a-4be9-8a87-49915ff4424c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6c772391-7f1e-496e-b79d-a10ec3e61d62_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c7050e25-993d-4203-a0d0-82de86f8de8f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_23bdf746-796a-486a-81b8-99ab83c6a01a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_abf048e2-04c2-47fb-b721-e4cc7c66daa1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_d89f9234-64a4-4bb8-aaf7-6af38241c3c1_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_e00e3987-2df4-4d1e-a219-86497a407f8c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_127b9b16-dc2b-4f31-a5d5-f91f97cee609_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Supplies</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_dcb1b089-069a-46db-a773-283fc1cf1e1b_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_e360fa3b-4c5d-4f91-9a22-000997161d8a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueAfterFifthYear_da0ccb16-d056-47ff-8fa7-fa3557d4ee49_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_12e5dbd4-3742-4588-855a-4868ff062b73_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, pro forma revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_19c9cc19-66df-4ac8-846f-f264f302d269_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_b14f6c49-ab83-4da1-9bb8-2ce6e0040459_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_52c65b16-4ee5-4f74-b3a4-81d3a49a9eb2_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, reduction in capacity under restricted payments builder basket</link:label>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_label_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</link:label>
    <link:label id="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:to="lab_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_126118a4-2061-480d-a6e3-4319364c6929_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6c676fd4-5a1b-4d1b-9dce-6a135b014710_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b59667ed-2d5c-4f0f-b5b1-81dff6a04f2b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_480c0b42-b592-46b1-b6dc-08f5a1a6c1b9_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_676fa7b6-cf13-4f80-b5f6-3dd15f1c03d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Life (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c00ce1b5-c179-4abb-9abf-f9aea5af56d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, December 31, 2021 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_17a98063-3416-4613-8427-e72e0c326345_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Information Related to Restricted Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Realized Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a57193cf-1a7e-487e-981f-a2aa55e49ae1_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_538c9b80-3554-4faf-acc8-7bd8f6fbcb84_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Shorttermandvariableleasecost_5f30be7d-d62e-4870-b72f-72f783423e94_terseLabel_en-US" xlink:label="lab_ehc_Shorttermandvariableleasecost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and variable lease cost</link:label>
    <link:label id="lab_ehc_Shorttermandvariableleasecost_label_en-US" xlink:label="lab_ehc_Shorttermandvariableleasecost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term and variable lease cost</link:label>
    <link:label id="lab_ehc_Shorttermandvariableleasecost_documentation_en-US" xlink:label="lab_ehc_Shorttermandvariableleasecost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of short-term lease cost, excluding expense for lease with term of one month or less, plus the amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Shorttermandvariableleasecost" xlink:href="ehc-20221231.xsd#ehc_Shorttermandvariableleasecost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Shorttermandvariableleasecost" xlink:to="lab_ehc_Shorttermandvariableleasecost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_acd86753-e261-4a6f-ae36-1713f2a5b490_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from bond issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Senior Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7a50d5c8-f722-49a7-b94d-6b339cdc70d3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantAvailableLimitAmount_8e89935d-eb0f-4c00-a7bc-f57261ef1a85_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantAvailableLimitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available limit amount</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantAvailableLimitAmount_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantAvailableLimitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Available Limit Amount</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantAvailableLimitAmount_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantAvailableLimitAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Available Limit Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantAvailableLimitAmount" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantAvailableLimitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantAvailableLimitAmount" xlink:to="lab_ehc_DebtInstrumentCovenantAvailableLimitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NetAmountMember_615152a2-ea9d-495c-9650-2ea2a4f21bb4_terseLabel_en-US" xlink:label="lab_ehc_NetAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount</link:label>
    <link:label id="lab_ehc_NetAmountMember_label_en-US" xlink:label="lab_ehc_NetAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Amount [Member]</link:label>
    <link:label id="lab_ehc_NetAmountMember_documentation_en-US" xlink:label="lab_ehc_NetAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetAmountMember" xlink:href="ehc-20221231.xsd#ehc_NetAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NetAmountMember" xlink:to="lab_ehc_NetAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0ed34946-b6fa-4880-b1c8-d6e88fc30c32_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4789fed7-3b6f-4ff8-a4d0-af556588e17a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_b130ade3-5969-4b5f-857c-17d77d19f9f1_terseLabel_en-US" xlink:label="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical, Heritage Valley &amp; ECHD Ventures</link:label>
    <link:label id="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_label_en-US" xlink:label="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical, Heritage Valley Health System And ECHD Ventures [Member]</link:label>
    <link:label id="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_documentation_en-US" xlink:label="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical, Heritage Valley Health System And ECHD Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:to="lab_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InternalUseSoftwareMember_01694957-2707-4e23-a1f5-bfc7d43db737_terseLabel_en-US" xlink:label="lab_ehc_InternalUseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_ehc_InternalUseSoftwareMember_label_en-US" xlink:label="lab_ehc_InternalUseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Use Software [Member]</link:label>
    <link:label id="lab_ehc_InternalUseSoftwareMember_documentation_en-US" xlink:label="lab_ehc_InternalUseSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalizable costs for computer software developed internally by the Company which will have future probable benefits to the Company.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InternalUseSoftwareMember" xlink:href="ehc-20221231.xsd#ehc_InternalUseSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InternalUseSoftwareMember" xlink:to="lab_ehc_InternalUseSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_d3b6f915-5f7e-45c6-89df-5ac666815999_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a52e91ef-cc6c-4aca-846c-d2bc58f5f511_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_c5d83a91-e916-45fa-85f8-6693d85c6204_terseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and benefits</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_351d980a-edf4-484a-8a69-a473adc941bc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a333774c-8baa-4300-9df4-066f4141e737_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b81ed783-55ab-482c-8830-cb6fe3cf8d88_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c8281056-b060-4375-814c-2f51f05dd04b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofBedsContributed_fd91240d-5e84-4e01-b8e5-53c9211410fd_terseLabel_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds contributed</link:label>
    <link:label id="lab_ehc_NumberofBedsContributed_label_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Contributed</link:label>
    <link:label id="lab_ehc_NumberofBedsContributed_documentation_en-US" xlink:label="lab_ehc_NumberofBedsContributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Contributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed" xlink:href="ehc-20221231.xsd#ehc_NumberofBedsContributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofBedsContributed" xlink:to="lab_ehc_NumberofBedsContributed" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_3c200855-680b-48fe-8ef7-934e443898e1_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Coverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:to="lab_ehc_DebtInstrumentCovenantInterestCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_5c59ea1d-64bd-4273-9fd3-3d522f615268_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and amortization of debt discounts and fees</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense And Amortization Of Debt Discounts And Fees</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense And Amortization Of Debt Discounts And Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_90b2c839-c964-43dd-a5ef-cd9e826ef3ad_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_ec680a17-9253-41a0-a386-873767fa7e60_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests in Consolidated Affiliates and Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_eda8a8bf-2658-4373-95c3-d1ac387d19bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_de3fc18e-b3a2-4f48-a609-8bd4e25ada40_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0ef4ce28-ab01-4302-9273-b0c48f3b1fa8_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d55ec857-d740-43ae-a55c-a2c646d06dd6_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_644912c7-d9e7-4119-a33c-24a5257e834a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5749d3b8-8f86-4da5-8932-88ba5b2e8d8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash &amp; Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_0f357120-96fb-4b90-8c75-d9c035b36f45_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_95dc8318-556e-4ef7-a1cb-db58ef40f726_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_dc540823-4ea1-482a-b674-be480d01af80_terseLabel_en-US" xlink:label="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care and other discount plans, including Medicare Advantage</link:label>
    <link:label id="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_label_en-US" xlink:label="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care, Medicare Advantage and Other Discount Plans [Member]</link:label>
    <link:label id="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_documentation_en-US" xlink:label="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care, Medicare Advantage and Other Discount Plans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:href="ehc-20221231.xsd#ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:to="lab_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_3fd8a564-c68b-4f4f-ba81-203131d34d9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_2862c5f2-96ef-4767-aa32-64a887e4a0c3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6f1d1947-1a4e-4082-90ea-4096f1859b44_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_76b27e35-a00c-4ba0-ab9d-47774fe6c3a6_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_1d84ad72-a428-42df-9545-1fced6c69ac3_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_139ecdd1-148a-441a-97a4-7cb7283cda20_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_9ed04e68-3bed-473c-9023-7a21d6016565_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome_01fa3d3d-61fb-40a4-87aa-bbc933621576_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transition Services Income</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transition Services Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_db7726ac-7e0c-450e-8fd4-b31c2db5a6b1_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations before income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_4c066143-b104-42ea-9ea3-e2f5def4e86d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_26086e12-da4b-4f5c-9161-28be71d77d39_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0418ed1f-7b02-4a7b-b21a-1b2c32a5664c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0720a399-4a77-48b2-96e1-9b3ab0ed02e0_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_90e8d149-2756-4ce4-8c06-9000cdceb8ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_adfbdf3d-8ba0-4607-b547-bdeb0a01bca9_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_c332a0dc-dd15-4c2e-b2d5-fd2dd54b61a6_terseLabel_en-US" xlink:label="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_label_en-US" xlink:label="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Six And Thereafter</link:label>
    <link:label id="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_documentation_en-US" xlink:label="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payments for finance lease, due in the sixth fiscal year following the latest fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:href="ehc-20221231.xsd#ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:to="lab_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_75899d45-76bf-4c13-ab18-147ac0713821_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_579b445a-dec6-4dca-8de0-557b15017153_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_UnifiedProgramIntegrityContractorsAuditsMember_ba1016cd-35df-4cc4-8995-5e85e88ef179_terseLabel_en-US" xlink:label="lab_ehc_UnifiedProgramIntegrityContractorsAuditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPICs Audits</link:label>
    <link:label id="lab_ehc_UnifiedProgramIntegrityContractorsAuditsMember_label_en-US" xlink:label="lab_ehc_UnifiedProgramIntegrityContractorsAuditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unified Program Integrity Contractors, Audits [Member]</link:label>
    <link:label id="lab_ehc_UnifiedProgramIntegrityContractorsAuditsMember_documentation_en-US" xlink:label="lab_ehc_UnifiedProgramIntegrityContractorsAuditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unified Program Integrity Contractors, Audits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_UnifiedProgramIntegrityContractorsAuditsMember" xlink:href="ehc-20221231.xsd#ehc_UnifiedProgramIntegrityContractorsAuditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_UnifiedProgramIntegrityContractorsAuditsMember" xlink:to="lab_ehc_UnifiedProgramIntegrityContractorsAuditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8074912-3beb-4b2a-9457-b9101c46ea87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_7fecd7cd-4b05-4699-b323-afb388ec1aa3_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_26338708-304b-4279-beff-974b8c6e2401_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_f4a8d5f4-344b-42b7-8c98-111626d0f1e4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase for the provision of current year claims</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_81746cdc-65c9-41d9-bcc4-d34666a9176c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ff1e409d-ff69-4c5b-bf73-c611f13bd4dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_59a29210-08f7-466d-b05f-019d15ffbba5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_691202e7-ddc8-4ac1-9df6-4385ec9745e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_f8b25328-081e-4652-980b-b6a8141df7dd_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aa505c9d-0ff4-4da5-9445-6ea1a711bafa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_07d7efbb-67c2-4e14-a9ea-2268c8ddfbee_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HealthcarePlanExpense_53e11d37-586f-4f6c-9c67-c37d0f05cdbb_terseLabel_en-US" xlink:label="lab_ehc_HealthcarePlanExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company healthcare plan costs, net of employee payments</link:label>
    <link:label id="lab_ehc_HealthcarePlanExpense_label_en-US" xlink:label="lab_ehc_HealthcarePlanExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare Plan Expense</link:label>
    <link:label id="lab_ehc_HealthcarePlanExpense_documentation_en-US" xlink:label="lab_ehc_HealthcarePlanExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs for the period associated with the Company's sponsored self-insured healthcare plans that include coverage for medical and dental benefits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HealthcarePlanExpense" xlink:href="ehc-20221231.xsd#ehc_HealthcarePlanExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HealthcarePlanExpense" xlink:to="lab_ehc_HealthcarePlanExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_cd96f632-7f3e-4c33-a4ce-3bae6e89c50c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_32794bd7-7574-4198-b7b9-addbe28e8bf6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_a92249b7-1ad1-4ab4-bca1-4453fa628c05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease for the provision of prior year claims</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_8ba9caa2-614f-430a-8b47-4706eed1ece1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_316145c4-55f6-4ba8-a5dd-873018daf077_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_1202b4a1-58ac-4569-9fd7-a53088f9e45f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_83e1d968-82f7-4b7b-8b37-80c6993a7e26_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_53443103-cc81-41c5-8666-c7d3e889aecc_periodStartLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_6c0d8149-4351-4c69-8aff-5b8e4345b3fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_1b8153ef-5572-4953-9fb1-1637470961f8_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_95ae2bbc-796f-44f8-94d5-c18cf859ee4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_5eb686d8-e744-4e39-8e85-15206e6a45a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_9f3a1f0a-f749-4ea7-8c03-854d1be87860_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_dc066a75-126f-40d6-aa94-968fffaf5cb3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_ff16291b-2db7-44ed-a206-58499fab9989_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyClaimsSampledForAuditAmount_8b0270a2-5269-41e4-9e91-0e939506515e_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyClaimsSampledForAuditAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid claims, amount from sample</link:label>
    <link:label id="lab_ehc_LossContingencyClaimsSampledForAuditAmount_label_en-US" xlink:label="lab_ehc_LossContingencyClaimsSampledForAuditAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Sampled For Audit, Amount</link:label>
    <link:label id="lab_ehc_LossContingencyClaimsSampledForAuditAmount_documentation_en-US" xlink:label="lab_ehc_LossContingencyClaimsSampledForAuditAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Sampled For Audit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyClaimsSampledForAuditAmount" xlink:href="ehc-20221231.xsd#ehc_LossContingencyClaimsSampledForAuditAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyClaimsSampledForAuditAmount" xlink:to="lab_ehc_LossContingencyClaimsSampledForAuditAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a4b8e66e-421f-42b1-80da-eae445acb6b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_cd7b3935-d045-451a-92c1-65b25ec5b7ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_7b220f48-7d7b-467d-a686-5948889b3625_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_26a5ce9e-4565-4648-900f-d7b1159a2030_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_bdfa3484-4c58-4caf-95e9-000e26bbfa13_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_dc8c8429-3031-457a-931e-5a1a41d21aae_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bf387a2b-079a-41a1-9c93-2ede7ecc30da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_31890a05-45cd-4c58-85b5-57acf944dbca_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d909aea9-aaf9-4c7c-acd3-2afae09eeaf5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_ce9d8e28-86f1-43d8-a9d7-f26cc944d52d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_7e74c08a-cffd-4cf8-9ea2-eb9074b3f91f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_38d9a807-94b2-4347-824b-3b37e6f3a4a2_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt redeemed</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_8b606824-e25a-4a9a-98b3-2722813ee366_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_a5e3e7a7-5f75-4942-a6e7-3a15351257ea_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions_8c032bc6-03d1-4098-b6c1-846d45fa9996_terseLabel_en-US" xlink:label="lab_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options (or more)</link:label>
    <link:label id="lab_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions" xlink:href="ehc-20221231.xsd#ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions" xlink:to="lab_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_36447536-32ef-45b9-aa14-92a623a07427_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_16693216-0a51-43ab-bce9-f80762a2f7bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards, dilutive stock options, and restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_c583f647-c0ef-4267-a0f6-335dc62f157f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_42ff4dce-ed27-49a9-9e26-4850fbdf5fd7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Encompass Health common shareholders: (b)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm_3661c8c6-7afd-4003-b79a-9e0f8ea58efa_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transition services, term</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transition Services, Term</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transition Services, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_61d615f7-1283-4c43-b271-32a9a73e059a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4edb3a41-4e9b-42d4-bb19-d0e3c3d25885_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_19bd7110-b59b-4756-bdf3-897281e5481b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2aee0ef5-64ae-4284-a75f-d1cfc5f1a0b7_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bfc6c113-f17f-465c-8407-7cf717037108_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_db881fd9-e75e-4704-874a-a2fbae691a62_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill expected to be tax-deductible</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_5527c6c0-e889-4668-83c1-9a25dec42828_terseLabel_en-US" xlink:label="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contributions funded by forfeited accounts</link:label>
    <link:label id="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_label_en-US" xlink:label="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount</link:label>
    <link:label id="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_documentation_en-US" xlink:label="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:href="ehc-20221231.xsd#ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:to="lab_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_f7056d4e-9dfd-4f5c-b47d-3ce78231df55_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Costs</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_08a1ceec-2fc3-4dd7-b552-e5066e7a4a29_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_58d047e7-7013-4f45-aaa3-9449f0eb3cf8_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RetirementInvestmentPlanAgeRequirement_19a36f3f-757a-459a-9d34-5020633364b1_terseLabel_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanAgeRequirement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Age requirement to participate in the Plan</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanAgeRequirement_label_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanAgeRequirement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Age Requirement</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanAgeRequirement_documentation_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanAgeRequirement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum age required for an employee to be eligible to participate in the Company's Retirement Investment Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanAgeRequirement" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanAgeRequirement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RetirementInvestmentPlanAgeRequirement" xlink:to="lab_ehc_RetirementInvestmentPlanAgeRequirement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_36283b86-72f5-4e2c-b4c2-6802315f497b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Four</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_120382ce-2632-4f5f-95ab-1a696be543ef_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b84d35c7-cc25-4d92-9fe5-86cb5866e05b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_58d6d87a-fc4b-4831-a35d-2669c20e6a7c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ca402577-6b9c-470d-ada9-ba21cf6b8543_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_68924ec2-881f-4746-a731-58f14d35ef49_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PatientsMember_6da2113c-6b5a-42d0-a33a-86b76d6fcadb_terseLabel_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients</link:label>
    <link:label id="lab_ehc_PatientsMember_label_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:label id="lab_ehc_PatientsMember_documentation_en-US" xlink:label="lab_ehc_PatientsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patients [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember" xlink:href="ehc-20221231.xsd#ehc_PatientsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PatientsMember" xlink:to="lab_ehc_PatientsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_977d9687-d24c-4d9f-96b5-3bf9bd20cec9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin off of Enhabit, Inc.</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTable_3b1e1590-c325-481a-96ec-0445ac526373_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable" xlink:to="lab_us-gaap_DebtInstrumentRedemptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_8b04781d-f95f-4a3e-88a2-985bb8bb1935_verboseLabel_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_label_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:label id="lab_ehc_TermLoanFacilitiesMember_documentation_en-US" xlink:label="lab_ehc_TermLoanFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember" xlink:href="ehc-20221231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TermLoanFacilitiesMember" xlink:to="lab_ehc_TermLoanFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_f4a3e8b4-ba37-4270-975a-97ecd461c172_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro rata distribution of common stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d1328f1e-6401-48e9-8fd5-ecb5662baf94_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_fb829ba3-fc3c-49c7-99ff-7074cb6e01d7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e18a4bd2-1833-4f98-958f-bb697e45ed0a_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_93aa0a15-ba58-4f0c-8c3f-28b6dc8b544b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_03d19e0d-a156-45ce-a9fb-c78e05a3d864_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_fbad20c8-4390-4d97-84ea-b52d92bc0c1f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_8100b93e-79a1-4450-8f60-6603a019dd14_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_5c967d3d-801d-429d-a29a-91ea95335ee5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_1ec30e2f-6233-43b7-a591-1a6413a23f2c_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_f9b416c5-642d-4f60-b1a3-8f50165aba6c_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period, net</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_8da7f9eb-85c2-4088-8a1f-b286d90041ad_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin Off of Home Health and Hospice Business</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9670c5ab-d3b7-43ea-8e97-045652402865_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_55461016-293f-45a4-a53f-477d2aa02ab5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_acc96d71-b001-474b-8af4-a3b869abd6e7_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized net gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_3390b8d6-ae59-4813-832e-81cdb3a3dfab_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_841bf18a-7277-4fde-bd54-9f98433db14c_terseLabel_en-US" xlink:label="lab_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altru Health System, Trinity Medical Center And NCH Healthcare System</link:label>
    <link:label id="lab_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_label_en-US" xlink:label="lab_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altru Health System, Trinity Medical Center And NCH Healthcare System [Member]</link:label>
    <link:label id="lab_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_documentation_en-US" xlink:label="lab_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altru Health System, Trinity Medical Center And NCH Healthcare System</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember" xlink:to="lab_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_370bea45-b1b7-4fb0-bec8-3c690f9fd824_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_97f8bab2-477f-42ea-997e-b29b6c9ac15f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_a4140cde-b0fc-4efe-90c9-59e769581d5a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_22ff05f8-5423-463a-afd1-1833d7b144ab_verboseLabel_en-US" xlink:label="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets and Other Intangible Assets</link:label>
    <link:label id="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_label_en-US" xlink:label="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets and Other Intangible Assets, Impairment [Policy Text Block]</link:label>
    <link:label id="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_documentation_en-US" xlink:label="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for assessing and recognizing impairments of the Company's long-lived assets and intangible assets with finite lives.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:href="ehc-20221231.xsd#ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:to="lab_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_WorkersCompensationMember_04b6f097-cf4b-499b-a894-d44739330726_terseLabel_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers&#8217; compensation</link:label>
    <link:label id="lab_ehc_WorkersCompensationMember_label_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation [Member]</link:label>
    <link:label id="lab_ehc_WorkersCompensationMember_documentation_en-US" xlink:label="lab_ehc_WorkersCompensationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember" xlink:href="ehc-20221231.xsd#ehc_WorkersCompensationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_WorkersCompensationMember" xlink:to="lab_ehc_WorkersCompensationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e505ef1b-da71-4a9f-a715-33efd21767da_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes to valuation allowance during the period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_54b1c588-12b0-41f5-ace3-73aac6b9ffe1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease (in years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_d5ba0d33-2078-4ae6-9f84-d3b967aadc02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4c34cb60-9911-407e-8ae8-6ae41ba081c5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_6073b306-aec9-4f46-8485-0018858018e8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_0b3ef270-fbac-44f8-89ae-308ffa13c934_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_e0bd5f66-431b-44ab-b882-eb628c791aca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_3b5500a0-0291-4933-b1b3-0420898e86c4_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_232f2db7-63a2-41b3-b47f-9ac3df202716_negatedTerseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange transaction</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Exchange Transaction</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestExchangeTransaction_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Exchange Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestExchangeTransaction" xlink:to="lab_ehc_NoncontrollingInterestExchangeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6a1b0f4b-a2cc-4582-aa13-7a647a2e4c93_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5efd9e88-6d37-4e5d-9534-a0a8f3e1984e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_dc064b40-74a9-49bd-86ba-937f151a9e2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized for grant under the Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserveNoncurrent_e7e25136-97c6-4995-933a-0b4058641750_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insured risks</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveNoncurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_97713867-7d34-4943-8b95-9209b97ad0ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of remaining shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_d02f2d55-0424-4b78-9c4b-89b74015c2f8_terseLabel_en-US" xlink:label="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Building, Improvements, Equipment, Vehicles and Furniture</link:label>
    <link:label id="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_label_en-US" xlink:label="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Building, Improvements, Equipment, Vehicles and Furniture [Member]</link:label>
    <link:label id="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_documentation_en-US" xlink:label="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Building, Improvements, Equipment, Vehicles and Furniture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:href="ehc-20221231.xsd#ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:to="lab_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AffiliateCashMember_b4c2e0a2-47be-4b17-8cb6-bbb22f5f9a82_terseLabel_en-US" xlink:label="lab_ehc_AffiliateCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate cash</link:label>
    <link:label id="lab_ehc_AffiliateCashMember_label_en-US" xlink:label="lab_ehc_AffiliateCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliate Cash [Member]</link:label>
    <link:label id="lab_ehc_AffiliateCashMember_documentation_en-US" xlink:label="lab_ehc_AffiliateCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held and maintained by joint ventures in which we have an ownership interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliateCashMember" xlink:href="ehc-20221231.xsd#ehc_AffiliateCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AffiliateCashMember" xlink:to="lab_ehc_AffiliateCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_593a8157-3131-4adb-b9a7-ac697415fbc4_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_1fe7b445-8aba-42b0-9658-076abb36b1f9_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_7c657892-f509-4140-aeeb-788b6692adee_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_9d334b0f-b676-4240-85f6-e1c478c991e0_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4c0b0bbf-3a7f-4d62-a1a7-9e8d9f311354_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_4a09ba26-0769-4caf-a208-2d0c1f16066b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government, class action, and related settlements</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_ef9acce5-c754-4455-810a-fe9b7082921c_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for government, class action, and related settlements</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cd698b07-6d0b-42f3-88e1-eeabbc0fc35d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted_ea4dbe37-d0b2-48b9-b0d0-2c7e5a6064f0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Restricted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRestricted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRestricted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_414fde80-a2c5-40ac-8b57-61a9767ed927_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_f9ecddee-872d-4d83-9925-c1087b5545b8_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of secured debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_71ee7f66-1529-4480-96a8-d76549002f9e_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Estimated Amortization Expense, Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PortercareAdventistMember_0d80a449-491a-41cf-b860-67da00963a91_terseLabel_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist</link:label>
    <link:label id="lab_ehc_PortercareAdventistMember_label_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist [Member]</link:label>
    <link:label id="lab_ehc_PortercareAdventistMember_documentation_en-US" xlink:label="lab_ehc_PortercareAdventistMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PortercareAdventistMember" xlink:to="lab_ehc_PortercareAdventistMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f33d801d-9679-40eb-8463-86730365589e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_30e8e5e3-0111-47d7-8dc5-217e4fa7ea14_netLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_6c6aca7c-0f30-488d-8245-472b74af4cf3_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipt of treasury stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_56629cf6-53f2-4496-8bde-75bf487ff878_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays_43efd036-efd8-4a38-bb0b-d53874e0f2c4_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurrence of indebtedness, business days</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Incurrence Of Indebtedness, Business Days</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Incurrence Of Indebtedness, Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" xlink:to="lab_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_02603fab-7035-43a6-8c3d-2d6139219cde_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, After Year Five</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, After Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_WeightedAverageRemainingLeaseTermAbstract_531fc8de-91a1-42db-be8a-7e7b3070d0f7_terseLabel_en-US" xlink:label="lab_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_ehc_WeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:label id="lab_ehc_WeightedAverageRemainingLeaseTermAbstract_documentation_en-US" xlink:label="lab_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:href="ehc-20221231.xsd#ehc_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ehc_WeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_be2269ad-c1c4-4ebc-a0e5-26300687ed29_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c9ec3b0c-0ed8-428c-9af3-5d1eb1f6a709_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_730011c8-bb0c-4f02-b81d-b780eda0556a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_870bf5e3-95fd-4437-a6a3-671b2606513d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_8393fd48-6df1-43fc-bdf0-08bda047bcf8_terseLabel_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_label_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Company Match, Vesting Period</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_documentation_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time over which the Company's contributions to a participant's retirement account fully vests.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:to="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareMember_c9325392-9d30-49f3-af8b-379d0dad6c87_terseLabel_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ehc_MedicareMember_label_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ehc_MedicareMember_documentation_en-US" xlink:label="lab_ehc_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember" xlink:href="ehc-20221231.xsd#ehc_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareMember" xlink:to="lab_ehc_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_1680b849-8ffe-4a61-8412-cc18e8cdc786_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to capitalized software costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_37537e1b-95b7-49a9-bbfe-ef915fc567cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_bfa7569c-224f-44f1-a4cb-057a238bbdf3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5943f11e-6bd8-405d-a0b2-e2739fdf4360_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8db3662d-96c7-4abe-b7c1-21ac38c9ec7e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_561dc8b8-e80b-4681-8ae4-e184d74513b2_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_5ef80a0b-cfc5-4b36-b240-63bfd7b0e416_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on debt, including pre-payments</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4e109f75-c398-4f06-82ee-ab31f9ee3a53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8ede8f25-8966-489f-b768-4dd9a2437c83_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_9292eaf5-2d96-4e5b-bc6b-7bf8626d7647_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_06910052-7d8b-4fb5-8ee4-c5e93a3ca1c2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations</link:label>
    <link:label id="lab_us-gaap_SegmentContinuingOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentContinuingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentContinuingOperationsMember" xlink:to="lab_us-gaap_SegmentContinuingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e4537ac6-bd77-4dce-866c-a0d0af45c461_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8759bb4a-593e-45f6-a782-86601c5ddb0a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_0e3b24c1-40a9-4ced-b348-c6d462689753_negatedLabel_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of noncontrolling interest owned by joint venture partner</link:label>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncontrolling Interest, Fair Value</link:label>
    <link:label id="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue_documentation_en-US" xlink:label="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:href="ehc-20221231.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:to="lab_ehc_BusinessCombinationNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_e66b6821-b8ab-4b62-9227-9591a060d5cf_verboseLabel_en-US" xlink:label="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of depreciation expense and interest capitalized</link:label>
    <link:label id="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Depreciation, Interest Capitalized Expense [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of depreciation expense, interest capitalized, under operating leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:href="ehc-20221231.xsd#ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:to="lab_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_46366268-fbfb-40da-a895-58e8a89b71b9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_dd1d8b73-12cb-49de-89c9-5d0a886e5f34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability_6a86b2e0-5d8e-4503-bbb2-e27854b69a52_terseLabel_en-US" xlink:label="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="ehc-20221231.xsd#ehc_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_ehc_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0986757f-355d-429d-9e2d-25ebfacff3cb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applicable interest rate under credit facility (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fabf4e6e-a59d-40cf-81e8-89395fa8777c_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_570c7245-e5da-4eac-bea5-20ef73bf5c0c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to settle the acquisition of Holdings common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialDataAbstract_1565b7bd-74eb-42e2-a244-6cb6c517273f_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialDataAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialDataAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b80abb53-230f-4e03-98d0-ba35c0772e60_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5d044d53-b78b-487c-8690-f54c09f9f8b1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_29dab991-032e-4a19-a8ff-33d4416ff490_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_2c7fa28c-ce5f-4a68-bab7-ed850dc1ba0d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_8dce8cdc-0e2c-442f-8698-f88143f7337d_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_56febfa0-c9ef-4485-b91c-414e48ece249_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% Senior Notes due 2023</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_594c785f-483a-4fb2-a803-c9dd0c0508ee_verboseLabel_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.125% Senior Notes due 2023</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_label_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 05.125%, Due 2023 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes05.125Due2023Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes05.125Due2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 05.125%, Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes05.125Due2023Member" xlink:to="lab_ehc_SeniorNotes05.125Due2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_2b064ba8-f774-4e62-a399-dec28590c0ed_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_68b64e33-289f-47e4-b053-726410f3e9ff_terseLabel_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor</link:label>
    <link:label id="lab_us-gaap_ThirdPartyPayorMember_label_en-US" xlink:label="lab_us-gaap_ThirdPartyPayorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ThirdPartyPayorMember" xlink:to="lab_us-gaap_ThirdPartyPayorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_117554c2-2946-4708-83f2-6dfe4aed53bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_2e4cf76a-c2c2-4f12-9def-8dee4ce9e5e7_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Two</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_3a6c3068-0b99-4cdd-a333-8f6e8190115c_terseLabel_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consolidated limited partnership-like entities</link:label>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_label_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Number of Entities Consolidated</link:label>
    <link:label id="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated_documentation_en-US" xlink:label="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities consolidated as variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:href="ehc-20221231.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:to="lab_ehc_VariableInterestEntityNumberofEntitiesConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_663e4fd5-3ecf-4865-8922-9a489d7bc141_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments to redeemable noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_7b36df27-06a4-49fb-8d83-9d7166654817_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_MinorityInterestChangeInRedemptionValue_label_en-US" xlink:label="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Change in Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:to="lab_us-gaap_MinorityInterestChangeInRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Totalfinanceleasecost_e074977a-01c7-4680-b540-0364a99aa886_totalLabel_en-US" xlink:label="lab_ehc_Totalfinanceleasecost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_ehc_Totalfinanceleasecost_label_en-US" xlink:label="lab_ehc_Totalfinanceleasecost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease cost</link:label>
    <link:label id="lab_ehc_Totalfinanceleasecost_documentation_en-US" xlink:label="lab_ehc_Totalfinanceleasecost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of finance lease cost recognized by lessee for lease contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalfinanceleasecost" xlink:href="ehc-20221231.xsd#ehc_Totalfinanceleasecost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Totalfinanceleasecost" xlink:to="lab_ehc_Totalfinanceleasecost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_7d3b9c2e-3b33-4d1e-881b-ff00acbb758b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceLineItems_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceLineItems" xlink:to="lab_us-gaap_ValuationAllowanceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_39d78e80-eee1-45e6-9684-fe5112287e3f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3e1b4fef-9d70-4787-8d0b-478ae3ebe6c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_9fdbbc05-870f-487b-a2ee-071c3c8aae8c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8a3ccb25-c38f-4bf0-a64d-25f43643ee4c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_685af085-84fc-4fdb-8d30-3a68bb71e44b_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_65206e15-f03a-4719-9ae9-dbc179fc5d35_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2915e950-6633-4722-8156-f5297136022c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Components</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_74e77126-41fa-40fe-b177-0fcefa84ed7a_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fc9d7c00-aa24-4c20-9e58-bb54906f936c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_478f523b-0e47-48af-be00-ab5afe02ff5f_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_708aa88f-eefa-4cae-aff6-200a0a8d88c1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_97e9e597-3c21-478e-9be0-4cb7f77fbb2a_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Means Other than Sale, Spinoff</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_b4be2c92-4dde-48ed-9a43-5b3c7fa276c1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment information related to restricted marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e9f5071-6b79-436f-8e7f-9c057590ab25_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_5929482d-abae-4eff-bd4e-7f6aa8699d8e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Holdings shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OccupancyCost_1be36dae-acd4-4341-8706-9b8d93a275f1_terseLabel_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy costs</link:label>
    <link:label id="lab_ehc_OccupancyCost_label_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy Cost</link:label>
    <link:label id="lab_ehc_OccupancyCost_documentation_en-US" xlink:label="lab_ehc_OccupancyCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost" xlink:href="ehc-20221231.xsd#ehc_OccupancyCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OccupancyCost" xlink:to="lab_ehc_OccupancyCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_24632289-d493-48ea-b167-3404b0f08143_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofDeNovoBeds_5fea564a-b1f5-4be0-aa3c-8fade66f6126_terseLabel_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of de novo beds</link:label>
    <link:label id="lab_ehc_NumberofDeNovoBeds_label_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of De Novo Beds</link:label>
    <link:label id="lab_ehc_NumberofDeNovoBeds_documentation_en-US" xlink:label="lab_ehc_NumberofDeNovoBeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of De Novo Beds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds" xlink:href="ehc-20221231.xsd#ehc_NumberofDeNovoBeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofDeNovoBeds" xlink:to="lab_ehc_NumberofDeNovoBeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_cf991fd5-9689-4bef-bc25-23c198cbcd8f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_c17baccf-338e-4cf4-99fa-343d39ca7640_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_13b0834b-e91a-4e56-adc9-3c2166ca8d9b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_df3b7679-bb21-4809-85c6-453971c6579d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_9436e892-dd19-4373-ac1b-d9c147c705cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock in open market</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_8b05ce91-1a2c-4bec-9567-0f2a5209528b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MarketAccessAssetsMember_9c25d3af-3cef-4fab-956a-eb7f6e56d1ab_verboseLabel_en-US" xlink:label="lab_ehc_MarketAccessAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market access assets</link:label>
    <link:label id="lab_ehc_MarketAccessAssetsMember_label_en-US" xlink:label="lab_ehc_MarketAccessAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Access Assets [Member]</link:label>
    <link:label id="lab_ehc_MarketAccessAssetsMember_documentation_en-US" xlink:label="lab_ehc_MarketAccessAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalizable costs associated with gaining access to and pentetrating a historical market base.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember" xlink:href="ehc-20221231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MarketAccessAssetsMember" xlink:to="lab_ehc_MarketAccessAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_23919e9c-607d-4288-908f-ac7382cf8cf2_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income attributable to Encompass Health</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_920e01ce-5535-4727-b7a2-ea9f08a967c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_3449256c-3fed-413f-9d10-7c9902530d28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0fb7b865-6b94-47b6-a417-2c67815aa7c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_342ac7ba-78cd-4ac2-a4d4-14e4ac19c9ec_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_b5037c5d-267c-4340-83ce-18c6bf17ae03_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherFundsMember_3ea04dac-e63e-40ed-8af0-9c246724a03f_terseLabel_en-US" xlink:label="lab_ehc_OtherFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ehc_OtherFundsMember_label_en-US" xlink:label="lab_ehc_OtherFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Funds [Member]</link:label>
    <link:label id="lab_ehc_OtherFundsMember_documentation_en-US" xlink:label="lab_ehc_OtherFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherFundsMember" xlink:href="ehc-20221231.xsd#ehc_OtherFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherFundsMember" xlink:to="lab_ehc_OtherFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_08c82a7a-8f6d-4234-8359-4b41c0175fef_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_f7777927-da90-4706-abbd-8cc9aed1543a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_47444034-149f-4573-b0f8-7a613d6a3bed_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_fc15ce5b-ce0b-48cf-a9ca-fcdbc693d390_terseLabel_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insured amount</link:label>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_label_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Self Insured Amount, First Layer of Risk</link:label>
    <link:label id="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_documentation_en-US" xlink:label="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Self Insured Amount, First Layer of Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:href="ehc-20221231.xsd#ehc_MaximumSelfInsuredAmountFirstLayerOfRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:to="lab_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_b6b7fdd8-e6bd-4766-9865-5ee9d23c65c0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of restricted investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_502cf4f5-ed58-4267-b05c-b9130ed68978_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_ec7b1416-7e95-4089-b3d5-bf308a5e2021_totalLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and Capital lease obligations</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_label_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income and Income Statement [Abstract]</link:label>
    <link:label id="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_documentation_en-US" xlink:label="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income and Income Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:href="ehc-20221231.xsd#ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:to="lab_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_50b2ffdb-a652-46ca-a48f-cfb2f3a201c7_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost (14,992,125 shares in 2022 and 14,719,662 shares in 2021)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_3239dbc3-1399-4b16-8033-70ea5055e8d2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_9ee34224-ecb7-4c6b-9962-aefedefd1704_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_084b980b-8566-49c4-8751-005f8a232877_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2ad485b0-c123-4281-b4fc-0836a3d3fb95_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_068ac67e-c1cc-4ca0-ae2c-1b47d38f9c63_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_8cd77cfe-7912-45e0-b7e7-146137ea5a26_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_b83d9b47-1ace-4d2d-8492-43ee6dae5cf9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_76e394de-86ea-4cfd-aaee-93a2ada096ef_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7d806f49-083d-4319-bc13-1447be386ad1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_7963cf1a-decb-4f16-933a-6c8da1856cb1_terseLabel_en-US" xlink:label="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations:</link:label>
    <link:label id="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_label_en-US" xlink:label="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]</link:label>
    <link:label id="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_documentation_en-US" xlink:label="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:href="ehc-20221231.xsd#ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:to="lab_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_2ef594cb-33b3-4dc4-a166-6154831f9849_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Weighted Average Number of Shares Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_cb1e38f8-73e0-4f3d-aa49-8b11f328bda0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c7a05107-c9cb-4ee4-918e-45fec1b3a3c2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PayorSourceMember_739aee7d-7489-49d4-9c7c-99274299d014_terseLabel_en-US" xlink:label="lab_ehc_PayorSourceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Source</link:label>
    <link:label id="lab_ehc_PayorSourceMember_label_en-US" xlink:label="lab_ehc_PayorSourceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Source [Member]</link:label>
    <link:label id="lab_ehc_PayorSourceMember_documentation_en-US" xlink:label="lab_ehc_PayorSourceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor Source [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember" xlink:href="ehc-20221231.xsd#ehc_PayorSourceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PayorSourceMember" xlink:to="lab_ehc_PayorSourceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_f70ff15b-62f3-4606-ab70-25049ea8ea8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_efd17f04-69b6-421a-b9ca-3708952dd55f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b37c5568-e755-4107-bb1f-e4f983255306_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities&#8212;</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_361ab3d0-9b39-4935-9ecd-21a5c2df194a_terseLabel_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage in employer contributions (percent)</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_label_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_documentation_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:to="lab_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_fd8147eb-581c-4fa6-8da3-8b65db037ee5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution as percentage of salary allowed under the Plan (percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_AltruHealthSystemMember_c678ee8b-4d19-4fff-9fe8-b52b26f65a20_terseLabel_en-US" xlink:label="lab_ehc_AltruHealthSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altru Health System</link:label>
    <link:label id="lab_ehc_AltruHealthSystemMember_label_en-US" xlink:label="lab_ehc_AltruHealthSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altru Health System [Member]</link:label>
    <link:label id="lab_ehc_AltruHealthSystemMember_documentation_en-US" xlink:label="lab_ehc_AltruHealthSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Altru Health System</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemMember" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_AltruHealthSystemMember" xlink:to="lab_ehc_AltruHealthSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_8295b554-9cbe-4172-9e0e-4f7c698a6d0c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_432fc1da-611f-4c0e-9e28-e46b4a664cfd_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_6916ec7f-84b9-482d-afe4-785836361282_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_9565160e-0da3-4ddd-9d30-d5c914834cd4_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_1b5a12ef-631d-4df1-b530-793c0490af5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_94ad7097-a140-429e-a9a0-d39a20e90ca9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from noncontrolling interests of consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributionsFromAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributions from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="lab_us-gaap_ProceedsFromContributionsFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_ae94c828-87f3-4ee5-b5f2-97d58d6b3300_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_a0451d3c-3d84-4170-89df-e316369ece51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to prior year claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a8c19b93-0b8a-4361-b916-ff80feb11650_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Useful Lives of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5786c82e-1619-4311-9bcb-4bfd150c6901_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1e5cb31a-7a17-4491-adf4-dffa92969e67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_44052527-2692-419c-a5f6-9c5b619f02cb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_9b129458-ba15-4554-9742-947ca6da6573_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_53b860b8-cf3b-4bad-96b1-fca86b5d6e32_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_35076ff3-5bb3-4d17-975a-e7759ab5dd1c_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SupplementalCashFlowInformationTableTextBlock_d14ca2e5-ff63-425f-8b10-7d0d09fc5f78_terseLabel_en-US" xlink:label="lab_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information</link:label>
    <link:label id="lab_ehc_SupplementalCashFlowInformationTableTextBlock_label_en-US" xlink:label="lab_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Table Text Block]</link:label>
    <link:label id="lab_ehc_SupplementalCashFlowInformationTableTextBlock_documentation_en-US" xlink:label="lab_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:href="ehc-20221231.xsd#ehc_SupplementalCashFlowInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:to="lab_ehc_SupplementalCashFlowInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ecbda438-0fff-4ce9-a2b9-89fec78d8341_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a8bcd5fb-e38c-4835-8e1c-37ce0f124e9a_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_3a753550-2042-4a69-8005-7a8b50261dab_verboseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4d67e4c2-e65c-4882-b08b-79432c166cb3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_a6acc9f4-5c34-4b9c-ad11-1ac56576cc12_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt by Maturity</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Including Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_f38b1dde-2c16-4f7a-b388-27a0706736cc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f51b1949-37fe-44e2-917b-e81d4c233eb4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_80b18930-e8ff-4635-a99f-403e6f3954a2_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions &#8212;</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_040b3d17-e701-4645-a3cd-aa512db429c9_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_90b84abf-2986-495b-b153-859ea6515f65_negatedTerseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net income of nonconsolidated affiliates</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income (Loss) Of Equity Method Investments</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income (Loss) Of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VehiclesMember_2f5de3a7-2f3c-434e-8bbd-3273637bb320_terseLabel_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles</link:label>
    <link:label id="lab_us-gaap_VehiclesMember_label_en-US" xlink:label="lab_us-gaap_VehiclesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VehiclesMember" xlink:to="lab_us-gaap_VehiclesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_4a674e63-29c8-43a3-a25a-971a96865a73_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9ca4d005-b4d0-4597-92b6-54daf4fa42f5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_HeritageValleyMember_3ca31e8a-9d18-4d58-abbc-3e0d7ed96c21_terseLabel_en-US" xlink:label="lab_ehc_HeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Valley</link:label>
    <link:label id="lab_ehc_HeritageValleyMember_label_en-US" xlink:label="lab_ehc_HeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Valley [Member]</link:label>
    <link:label id="lab_ehc_HeritageValleyMember_documentation_en-US" xlink:label="lab_ehc_HeritageValleyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Heritage Valley [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeritageValleyMember" xlink:href="ehc-20221231.xsd#ehc_HeritageValleyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_HeritageValleyMember" xlink:to="lab_ehc_HeritageValleyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFifthYear_a7d84280-0503-4aa3-9795-e30f7c4c19b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_6e685b2b-f843-4bfe-af44-c01b8ff628f8_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Notes due 2028</link:label>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_label_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due 2028 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes4.50Due2028Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes4.50Due2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes4.50Due2028Member" xlink:to="lab_ehc_SeniorNotes4.50Due2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9fee545e-d076-4c6a-97e4-32b6c97f309b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_76484fdf-4442-49bf-865d-15c994068768_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_049f9ab8-edcb-4f50-8a2f-16580195bfe9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b81e2030-d5b3-4d2f-99c9-60bcf3b369bc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_c0f7d7d5-5b76-4c67-897a-65ee12acbee4_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Senior Notes due 2030</link:label>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_label_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.750%, Due 2030 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes04.750Due2030Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes04.750Due2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.750%, Due 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes04.750Due2030Member" xlink:to="lab_ehc_SeniorNotes04.750Due2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_b3bebbf4-fac0-45bb-ade0-88bb6493a24f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_291815dd-cd9f-4bcd-8f5e-441ff5097767_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_46b57a14-89a9-46ca-baa0-b48a7a3025ed_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NotesPayableSoftwareContractsMember_590766db-6334-4d0b-8685-96decd409e4d_terseLabel_en-US" xlink:label="lab_ehc_NotesPayableSoftwareContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software contracts</link:label>
    <link:label id="lab_ehc_NotesPayableSoftwareContractsMember_label_en-US" xlink:label="lab_ehc_NotesPayableSoftwareContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Software Contracts [Member]</link:label>
    <link:label id="lab_ehc_NotesPayableSoftwareContractsMember_documentation_en-US" xlink:label="lab_ehc_NotesPayableSoftwareContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Software Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableSoftwareContractsMember" xlink:href="ehc-20221231.xsd#ehc_NotesPayableSoftwareContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NotesPayableSoftwareContractsMember" xlink:to="lab_ehc_NotesPayableSoftwareContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bb28fad7-3e4d-432d-9298-69d5604f77c8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_f3f0b3dc-279b-4b52-852a-814fb5769b36_terseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of redeemable noncontrolling interests, percent</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests, Decrease from Redemptions or Purchase of Interests, Percent</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:to="lab_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_970203b4-954d-4065-94f3-525c4a76a7cb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_9ff2b259-4e8a-4edb-8f15-ea449a89bbe9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amounts and estimated fair values of financial instruments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_9bf9f02e-cf05-4683-92c0-8f907453f8cb_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchase authorization</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0ea70e72-4deb-4e71-8dc9-b385b249ca9f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a2dda13f-7ad2-45a6-8b56-2bc9f1f70456_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_3cdce16e-be2d-421d-97a9-7f49c5fb4214_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_0cd0562c-bc9e-4b1e-9fab-9dc158e6ccb7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred to discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a36031f0-01fc-4ef8-b3ea-39d46569a4da_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt-related items</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7d992468-5cc7-46e7-8ee2-ea2e7c55eca6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_a564f420-cb92-4a9a-b050-c293cc70ca3a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_4d794518-e212-43b9-9ef6-eb39ae198ba0_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_e141cfcd-941b-4aaf-bc65-120faa144d78_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Reinsurance receivables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_4a86fdde-4bf9-4803-b4ae-4155e4852e49_periodEndLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Reinsurance receivables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable for Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:to="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_7cb29650-155f-499c-ae3d-6e95dbb5f782_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a3957f79-5109-4858-a03d-5ac7b7b22b98_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1649164e-f584-4ada-9d5a-0ac4f6216883_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_42fb54ed-76a5-4ead-a8da-caf6f7cc5d50_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a3dafc58-3068-4427-b14f-025a7cda6db1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on early extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionLineItems_5b54ce21-906b-4a22-9cbb-8f35d54c7870_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems" xlink:to="lab_us-gaap_DebtInstrumentRedemptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_a7e6bbef-3a1d-4b8a-b98f-e3a6f4098a4a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_d156a47e-3875-468e-bd45-82f7f8eb94bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_f14dd2ff-996c-4e76-9d40-b537b7db6650_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_c5d8bd96-fc35-4956-aa11-2e41da8201d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfPayMember_6d39c2f9-4ac1-4d34-9110-47734ba82d2c_terseLabel_en-US" xlink:label="lab_us-gaap_SelfPayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay</link:label>
    <link:label id="lab_us-gaap_SelfPayMember_label_en-US" xlink:label="lab_us-gaap_SelfPayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Pay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfPayMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfPayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfPayMember" xlink:to="lab_us-gaap_SelfPayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ManagedCareMember_bc92b444-844f-4a98-ac6d-1ffa66c16624_terseLabel_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care</link:label>
    <link:label id="lab_ehc_ManagedCareMember_label_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:label id="lab_ehc_ManagedCareMember_documentation_en-US" xlink:label="lab_ehc_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember" xlink:href="ehc-20221231.xsd#ehc_ManagedCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ManagedCareMember" xlink:to="lab_ehc_ManagedCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInThirdYear_53e7696f-7ac0-471b-a056-d59076830b7f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:to="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SelfInsuredCaptiveFundsMember_d60ac403-5de1-469f-bbb2-22dded4f5ab3_terseLabel_en-US" xlink:label="lab_ehc_SelfInsuredCaptiveFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insured captive funds</link:label>
    <link:label id="lab_ehc_SelfInsuredCaptiveFundsMember_label_en-US" xlink:label="lab_ehc_SelfInsuredCaptiveFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insured Captive Funds [Member]</link:label>
    <link:label id="lab_ehc_SelfInsuredCaptiveFundsMember_documentation_en-US" xlink:label="lab_ehc_SelfInsuredCaptiveFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held by the Company's wholly owned captive subsidiary which is restricted for use in paying self-insured work comp or professional liability claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SelfInsuredCaptiveFundsMember" xlink:href="ehc-20221231.xsd#ehc_SelfInsuredCaptiveFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SelfInsuredCaptiveFundsMember" xlink:to="lab_ehc_SelfInsuredCaptiveFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c127e138-c664-48a3-9e48-d36937da7ad5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_82d001b4-e060-42e2-b9ad-4ca3884ba6d1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_fa09807f-cd87-4705-af8c-4e6499dd046f_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_35e36257-3a01-43de-8c25-10708ae32d74_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_30044e7a-ab09-403a-b2d4-0b7df41301ee_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Five</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Totaloperatingandfinanceleaseassets_61cf4900-01c2-4f85-8d0b-daacf1fb0d04_totalLabel_en-US" xlink:label="lab_ehc_Totaloperatingandfinanceleaseassets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leased assets</link:label>
    <link:label id="lab_ehc_Totaloperatingandfinanceleaseassets_label_en-US" xlink:label="lab_ehc_Totaloperatingandfinanceleaseassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating and finance lease assets</link:label>
    <link:label id="lab_ehc_Totaloperatingandfinanceleaseassets_documentation_en-US" xlink:label="lab_ehc_Totaloperatingandfinanceleaseassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lessee's right to use underlying asset under operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totaloperatingandfinanceleaseassets" xlink:href="ehc-20221231.xsd#ehc_Totaloperatingandfinanceleaseassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Totaloperatingandfinanceleaseassets" xlink:to="lab_ehc_Totaloperatingandfinanceleaseassets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7d24d0d0-cfb4-4153-87ab-405a0b2ea501_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_a6b324a3-63b2-44f0-aba9-a0667401cc5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_30b73159-c1d7-4a4c-bc0b-3fa455faaf9f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_6edfccfb-33b2-4e35-8a44-809366232db0_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_MedicareAdvantageMember_fda950c6-1656-4e80-9abe-5b4f9b3fa0c7_terseLabel_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage</link:label>
    <link:label id="lab_ehc_MedicareAdvantageMember_label_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_ehc_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_ehc_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember" xlink:href="ehc-20221231.xsd#ehc_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_MedicareAdvantageMember" xlink:to="lab_ehc_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_91d9089a-6d6e-47ca-8f61-1312752a08d9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_f27e685d-403b-4b75-839d-2bc8095e8665_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable noncontrolling interest, fair value determination based on home health acquisitions, value threshold</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:to="lab_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember_e43dd774-e1cd-4b99-bdf9-576d8d326197_terseLabel_en-US" xlink:label="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners</link:label>
    <link:label id="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember_label_en-US" xlink:label="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners [Member]</link:label>
    <link:label id="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember_documentation_en-US" xlink:label="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portercare Adventist and Premier Health Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:to="lab_ehc_PortercareAdventistAndPremierHealthPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_ae601089-40a9-4366-bd6f-31cf1167680f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_ff5cf5e8-24de-4fc6-8172-38096b998a5c_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_dd8d5055-eed1-44df-9966-260989c3fd8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_8c25cf60-9e57-470c-b8d7-8e737534b573_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_0b50fb94-b3dc-4c1b-aeb9-2ca0b59a3df8_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum accrual of loss contingency needed to accrue for related legal fees</link:label>
    <link:label id="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_label_en-US" xlink:label="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Minimum Amount to Consider Accruing an Estimate of Related Legal Fees</link:label>
    <link:label id="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_documentation_en-US" xlink:label="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum dollar amount that must be accrued for a loss contingency related to a specific legal dispute that can be utilized for consideration prior to accruing an estimate of the legal fees related to this specific legal dispute.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:href="ehc-20221231.xsd#ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:to="lab_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_f9d8cab2-c0ae-45a2-a915-a4b8f95afbd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Income from continuing operations allocated to participating securities</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyNumberOfClaimsSampledForAudit_7d7860f0-525c-4686-b9ae-9991daedec07_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyNumberOfClaimsSampledForAudit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims sampled</link:label>
    <link:label id="lab_ehc_LossContingencyNumberOfClaimsSampledForAudit_label_en-US" xlink:label="lab_ehc_LossContingencyNumberOfClaimsSampledForAudit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claims Sampled For Audit</link:label>
    <link:label id="lab_ehc_LossContingencyNumberOfClaimsSampledForAudit_documentation_en-US" xlink:label="lab_ehc_LossContingencyNumberOfClaimsSampledForAudit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Claims Sampled For Audit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyNumberOfClaimsSampledForAudit" xlink:href="ehc-20221231.xsd#ehc_LossContingencyNumberOfClaimsSampledForAudit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyNumberOfClaimsSampledForAudit" xlink:to="lab_ehc_LossContingencyNumberOfClaimsSampledForAudit" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_79c8234a-3422-4ef1-93b4-a33ea135b1e8_verboseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, leverage ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_d7e0600c-9b6e-4c04-901d-0e6c2840f282_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatio_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantLeverageRatio" xlink:to="lab_ehc_DebtInstrumentCovenantLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_784ea555-644e-4c25-b3fe-3654174892e6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_902e6bdd-136e-41cb-b5ea-d80695e21972_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_a3c08e30-50a2-4a67-8acf-0b15861802fe_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_4bb3b15f-5be7-4944-a337-beb706f38cb6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_b205e98a-d2df-4951-a546-e89f9f12797e_terseLabel_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_label_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Investment Plan, Company Match, Vesting Percentage</link:label>
    <link:label id="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_documentation_en-US" xlink:label="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total percentage of the Company's matching contributions that will vest in the Retirement Investment Plan after an employee service requirement has been met.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:to="lab_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_6184f19c-218d-4eda-b9c9-33f737504ea3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7546d4dc-023d-4058-b84c-6923c138dd89_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_4fbe7e84-171e-4c05-a5b9-e0b786b6ca7a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_bae6e291-dc4e-4646-8333-fc2d9ef552fa_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_929c3ea7-685a-49e5-9809-bba865004cb4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Carrying Amount of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_81bc5abe-e821-4eb0-91d2-4cab69f8d432_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_00e6cf10-1158-4e4f-a493-7d626413e38c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_27db0110-5c3b-4c67-ac3c-61b5f10bd58b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_8f9d7b04-24ad-4fc2-b624-ce9f02c9a021_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a4c7c449-d2b2-4ebe-b8df-cba3763608f6_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5417ca7b-b76c-4480-bc3a-882dfc54919e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Encompass Health shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_94f9c1b7-efdb-40ba-abfd-2de7ef25521f_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_f1c71888-049e-4df0-be6a-3b28eecebcb5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b0cd43ef-f607-49ce-bfb3-b68944792de8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_7ddad1b1-99c8-417a-a620-0fea4bb1a73c_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Three</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_20038a27-4c9d-4236-a882-91ba00a83a3f_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d38a125b-766f-4861-8408-50da2362fdf5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_33e1a05d-b161-411d-af94-3917436e2d06_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts attributable to Encompass Health:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_2a5fa55f-6588-4f94-9ff9-ecc5a6e11d10_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of available-for-sale marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_be555281-0869-4d5f-ba48-50f17a3d931c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated (Deficit) Income</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3f778431-aa9f-4d1a-b380-821673642cb2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_2c1366c7-a800-431a-bb56-cdb8b4a81f51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_bbca0b19-1352-4b97-be1c-919888670ede_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_22a4a49c-afde-4b19-b8f5-869ab3b41b3b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_644952eb-8dba-485b-8a62-c47bb8356710_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceTable_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceTable" xlink:to="lab_us-gaap_ValuationAllowanceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_191579e3-8868-41ec-98e0-dbe0dfaf95e2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Least Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9e162dc7-c10f-40c5-9760-78a54bece509_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_d3ef1f40-03a0-480c-a662-60c669f17940_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Information Related to Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_45a2ef1a-e8f6-4836-9342-3ad272a4f391_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_3c82c5b8-ae47-4e78-a897-4741c5f5e4d6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_92255ade-09a5-402f-83a0-c9b92a86dfdd_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of partnerships</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_40ec6235-7436-4104-a2f8-b22d2a7d3607_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest_ffc29bc0-e045-4935-9d80-921b40e2751d_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount overturned of overpayment determination, interest</link:label>
    <link:label id="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest_label_en-US" xlink:label="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Amount Overturned Of Overpayment Determination, Interest</link:label>
    <link:label id="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest_documentation_en-US" xlink:label="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Amount Overturned Of Overpayment Determination, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" xlink:to="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestOtherAdjustment_53bbd659-9007-47d7-940d-1503568db422_terseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestOtherAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestOtherAdjustment_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestOtherAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Other Adjustment</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestOtherAdjustment_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestOtherAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Other Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestOtherAdjustment" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestOtherAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestOtherAdjustment" xlink:to="lab_ehc_NoncontrollingInterestOtherAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_ea1675f3-b107-4cb6-a544-20efdb29bea3_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture, fixtures, and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ed9b95d3-b249-49a2-8570-1ac67e15fc2d_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NonemployeeDirectorsMember_0a298033-a47a-44b1-b7de-2a063c3e7eae_terseLabel_en-US" xlink:label="lab_ehc_NonemployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors</link:label>
    <link:label id="lab_ehc_NonemployeeDirectorsMember_label_en-US" xlink:label="lab_ehc_NonemployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:label id="lab_ehc_NonemployeeDirectorsMember_documentation_en-US" xlink:label="lab_ehc_NonemployeeDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NonemployeeDirectorsMember" xlink:href="ehc-20221231.xsd#ehc_NonemployeeDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NonemployeeDirectorsMember" xlink:to="lab_ehc_NonemployeeDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_28983156-0c7a-4776-8ee4-3b0ab7cd1aaf_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_860fcca4-66ef-4851-ba65-bff737bdf84f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock in open market (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_8869147b-0e4f-491a-987c-f8ccda6520a7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_c158a5fa-cdab-4ba6-9b0b-e839f1e3367a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests included in discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9084081c-d823-42ef-9d73-6c947a5d426d_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1d2d3e87-dc6b-4ab5-bce6-b7e435661f89_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ee23ca11-8d8e-490c-a58a-7feb5d79d6c5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ebd0ff85-2c38-4ad0-b894-c633506725f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_8e81024b-1dee-43a6-a005-d06e347d8d7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_199a129b-f997-44d5-97a3-3f665908dbce_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d4418ae4-6425-434f-80fd-3f5314497510_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested shares, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dceb044b-1274-40b1-8ef6-dcc464d7af88_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested shares, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_238f1a80-5f49-444b-987a-60ed9a51b49a_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestMember" xlink:to="lab_ehc_RedeemableNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_c9fee215-4636-4b14-804d-a279c872e743_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_c97aea8f-1bfc-46c1-90b0-c35621eb434f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_ef21aaea-393d-43e9-a821-ce1287c0672e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_38a04b16-b4b4-4509-9377-c6ca03677cbe_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_31f45931-66a5-4847-a2e6-309691b7d0ae_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6e726f11-f413-4fe4-8ecd-0c0e53d1d993_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_cb1ccc87-1676-4185-9897-b4956d506f97_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_42b51c23-03a8-4d58-b07f-588a63ae4a6a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ShannonMedicalMember_84bb6237-7000-415a-bced-2ff8b55bc28e_terseLabel_en-US" xlink:label="lab_ehc_ShannonMedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical</link:label>
    <link:label id="lab_ehc_ShannonMedicalMember_label_en-US" xlink:label="lab_ehc_ShannonMedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical [Member]</link:label>
    <link:label id="lab_ehc_ShannonMedicalMember_documentation_en-US" xlink:label="lab_ehc_ShannonMedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shannon Medical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalMember" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ShannonMedicalMember" xlink:to="lab_ehc_ShannonMedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_27d41113-2827-4e41-ae54-fb72b4cf17fb_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6b928bf8-a1cf-41be-8e64-2d9b79438390_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6020d407-d7cc-48b4-b42c-cceba26df4ec_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5d51525f-0c77-486d-8fbe-42f06108c498_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c30cb185-1fef-42f5-8fd9-d32e318f70ea_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_a14003aa-a3c2-4a89-86b0-e493eaa744a3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ECHDVenturesMember_8ff516d5-e5c8-4ee7-aa84-98f1beb7b0ec_terseLabel_en-US" xlink:label="lab_ehc_ECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ECHD Ventures</link:label>
    <link:label id="lab_ehc_ECHDVenturesMember_label_en-US" xlink:label="lab_ehc_ECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ECHD Ventures [Member]</link:label>
    <link:label id="lab_ehc_ECHDVenturesMember_documentation_en-US" xlink:label="lab_ehc_ECHDVenturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ECHD Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ECHDVenturesMember" xlink:href="ehc-20221231.xsd#ehc_ECHDVenturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ECHDVenturesMember" xlink:to="lab_ehc_ECHDVenturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9f0dfe5d-eb15-478f-937e-c737c7a513e0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_5423618f-ff01-465b-80ef-7888446d660b_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5256fc56-1b64-44e9-b9c2-f65a860d3d3f_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_96e9d091-2072-4352-9bc4-2408a84437dc_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income tax expense</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_edd08791-4961-46e3-9ed9-55f50a7a89b7_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625% Senior Notes due 2031</link:label>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_label_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.625%, Due 2031 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes04625Due2031Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes04625Due2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 04.625%, Due 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes04625Due2031Member" xlink:to="lab_ehc_SeniorNotes04625Due2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_13bdb3f5-f802-4643-a075-66d9ad716b17_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_WeightedAverageDiscountRateAbstract_1ce55505-d9db-43ec-8ac4-44fb4e3e898d_terseLabel_en-US" xlink:label="lab_ehc_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_ehc_WeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ehc_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:label id="lab_ehc_WeightedAverageDiscountRateAbstract_documentation_en-US" xlink:label="lab_ehc_WeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WeightedAverageDiscountRateAbstract" xlink:href="ehc-20221231.xsd#ehc_WeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_WeightedAverageDiscountRateAbstract" xlink:to="lab_ehc_WeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_abf71b55-4cc2-442e-ac76-86f6cf766668_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_8b11e63d-564e-4cf0-ba27-eb086300a630_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fa301aee-0208-4388-ad85-3037a84f2f54_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_270d1f5d-2177-4e75-af93-ca8b8729d02a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_A2021AcquisitionsMember_52c2a712-3bd0-4a2d-abb3-b842f2b293b3_terseLabel_en-US" xlink:label="lab_ehc_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions</link:label>
    <link:label id="lab_ehc_A2021AcquisitionsMember_label_en-US" xlink:label="lab_ehc_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions [Member]</link:label>
    <link:label id="lab_ehc_A2021AcquisitionsMember_documentation_en-US" xlink:label="lab_ehc_A2021AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2021AcquisitionsMember" xlink:href="ehc-20221231.xsd#ehc_A2021AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_A2021AcquisitionsMember" xlink:to="lab_ehc_A2021AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f6bfe939-4019-485a-b458-f030d078c698_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_eeb4e2ff-f5bf-4aad-98fc-c36db65bfe2a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in Excess of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_a05c488e-947a-4df9-b7cc-fec4e2475f99_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_47c4827f-bb3b-4d13-b5ad-cd6cc91336a9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_A2020AcquisitionsMember_02abc42d-52ca-4b14-a92d-982bccf67e3b_terseLabel_en-US" xlink:label="lab_ehc_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:label id="lab_ehc_A2020AcquisitionsMember_label_en-US" xlink:label="lab_ehc_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions [Member]</link:label>
    <link:label id="lab_ehc_A2020AcquisitionsMember_documentation_en-US" xlink:label="lab_ehc_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2020AcquisitionsMember" xlink:href="ehc-20221231.xsd#ehc_A2020AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_A2020AcquisitionsMember" xlink:to="lab_ehc_A2020AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_036821ba-0d18-4af3-b183-7cb3e755caba_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other long-term assets at beginning of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_52b4c732-8c6d-4a98-8b69-65e9c09d5edd_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash included in other long-term assets at end of period</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_195f1d5c-6674-48d6-a841-77b67e498d0a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Encompass Health common shareholders:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_6067b9a3-e8c7-403d-95c3-61a48b7db43a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Encompass Health common shareholders: (b)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_283b66ba-8ea2-4253-a950-961005c94b12_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_097e3119-2022-4d4b-9892-27e3bcf7033e_terseLabel_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third-party payors</link:label>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_label_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third-party Payors [Member]</link:label>
    <link:label id="lab_ehc_OtherThirdpartyPayorsMember_documentation_en-US" xlink:label="lab_ehc_OtherThirdpartyPayorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third-party Payors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember" xlink:href="ehc-20221231.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OtherThirdpartyPayorsMember" xlink:to="lab_ehc_OtherThirdpartyPayorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_c153f280-b817-4f48-8eb8-6db2f51b4de8_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Occupancy costs</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Occupancy Costs</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Occupancy Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b3b5bd0f-ce07-44b7-93cf-c33dee798983_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8fc9a953-53d3-45d8-8e38-280e26d4b318_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_299efb2f-6cbc-4027-8bcc-95c4b3afd1a8_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum_90e34c0b-9164-48fa-9272-400f07c364d9_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured leverage ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Senior Secured Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Senior Secured Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" xlink:to="lab_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_79675b60-61a4-4efd-a8e7-0423e494b22d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c77f215f-f132-4ed0-8d69-21fc3a18c430_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_664b3be1-db1c-45d6-80e3-1900c5bc1e36_terseLabel_en-US" xlink:label="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based windfall tax benefits (percent)</link:label>
    <link:label id="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_label_en-US" xlink:label="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, Percent</link:label>
    <link:label id="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_documentation_en-US" xlink:label="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:href="ehc-20221231.xsd#ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:to="lab_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_56f716d5-df0b-4102-96c2-7ff57c08b62c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, FV-NI</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_aa8b4492-f3e7-403f-ad8d-05a504babee9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_OperatingAndFinanceLeaseContractTerm_fc15ee5e-343c-4818-bfcd-6ebe670ef5fb_terseLabel_en-US" xlink:label="lab_ehc_OperatingAndFinanceLeaseContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and finance lease contract term</link:label>
    <link:label id="lab_ehc_OperatingAndFinanceLeaseContractTerm_label_en-US" xlink:label="lab_ehc_OperatingAndFinanceLeaseContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Contract Term</link:label>
    <link:label id="lab_ehc_OperatingAndFinanceLeaseContractTerm_documentation_en-US" xlink:label="lab_ehc_OperatingAndFinanceLeaseContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of lessee's operating and finance leases, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OperatingAndFinanceLeaseContractTerm" xlink:href="ehc-20221231.xsd#ehc_OperatingAndFinanceLeaseContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_OperatingAndFinanceLeaseContractTerm" xlink:to="lab_ehc_OperatingAndFinanceLeaseContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_cdb44bc2-2e56-4f44-91a4-49eacbe6afd2_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals_91987016-d8b1-477d-b886-1969c5ffac80_terseLabel_en-US" xlink:label="lab_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of jointly owned inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals_label_en-US" xlink:label="lab_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Jointly Owned Inpatient Rehabilitation Hospitals</link:label>
    <link:label id="lab_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals_documentation_en-US" xlink:label="lab_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals" xlink:href="ehc-20221231.xsd#ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals" xlink:to="lab_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_33dd7639-6eca-44d4-a679-4d12b6081553_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_83d422cb-b53f-47ba-b8cd-c7951b210107_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Payroll, Current</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Payroll, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c37ca6cf-6cf3-4950-9f29-89013c766767_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value per share of awards granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4192b141-7e83-4997-aa3c-d598b38539cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_6e43fa72-d092-426b-967e-2bedfcb2a394_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_111332bc-9419-40d6-a5ad-8ab161e51a2b_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent_166c99c8-c395-46dc-bf6c-6252e397701a_terseLabel_en-US" xlink:label="lab_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary's common stock held by subsidiary 's management, percent</link:label>
    <link:label id="lab_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent_label_en-US" xlink:label="lab_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary's Common Stock Held By Subsidiary's Management, Percent</link:label>
    <link:label id="lab_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent_documentation_en-US" xlink:label="lab_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of subsidiary's common stock held by subsidiary 's management, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" xlink:href="ehc-20221231.xsd#ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" xlink:to="lab_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_4f77c3e9-bd88-48dd-a9ea-cea3fa9568e3_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facilities</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_97977410-69a5-4cbf-8a4a-64f2ae158bf6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net and comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7130f0b1-fc8e-483e-b2a7-d3db993f6714_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fd92afbd-82be-47dd-a1ec-1f2760414c07_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net and comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fbf05f9e-0022-407f-bb8a-7ad412d00982_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies and Other Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ee2b9d7d-ab46-4ab9-b08a-7d230796fad3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8eaf37f4-7f50-44d8-9d3c-f778ca6bd42f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_4276a8af-b8de-47dc-8f8b-d46ecad37e0f_terseLabel_en-US" xlink:label="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases</link:label>
    <link:label id="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:href="ehc-20221231.xsd#ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:to="lab_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_3331c21f-ae02-4765-9595-21e72ac5fddf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of restricted investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Restricted Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfRestrictedInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3f6f21f7-a955-4fc9-b135-2828ad6c8f48_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_67c42265-3601-406f-9b93-5f023e1baee7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_b9562f77-d903-4af0-b0fe-0fc7e8882129_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_fff7a4af-93f8-49e5-962a-39fefb5679b0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserveCurrent_4779e3e3-d27e-4deb-84b9-f7bf6d085130_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insurance reserves included in Other current liabilities</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserveCurrent_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_63afd210-72cb-416a-8be5-89b0e1123f46_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4d7695fe-dc54-402b-afd6-9734e142b956_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4438d1a-d100-4b57-b3e8-2ef428eab671_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_InvestmentsCashandRestrictedCash_2d9b1d16-6271-430b-b043-717a8cbd4c49_totalLabel_en-US" xlink:label="lab_ehc_InvestmentsCashandRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_ehc_InvestmentsCashandRestrictedCash_label_en-US" xlink:label="lab_ehc_InvestmentsCashandRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Cash and Restricted Cash</link:label>
    <link:label id="lab_ehc_InvestmentsCashandRestrictedCash_documentation_en-US" xlink:label="lab_ehc_InvestmentsCashandRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investments of the Company which includes cash, cash equivalents, restricted cash, and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InvestmentsCashandRestrictedCash" xlink:href="ehc-20221231.xsd#ehc_InvestmentsCashandRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_InvestmentsCashandRestrictedCash" xlink:to="lab_ehc_InvestmentsCashandRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b2f0c75c-5d54-458a-83a2-5312cace9f4f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_c3190f3b-9536-4010-bdd0-ea7e0b362f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on revolving credit facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_CertificateOfNeedMember_2d4ed9df-4a59-4681-90a9-c8290e7064a8_verboseLabel_en-US" xlink:label="lab_ehc_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of need</link:label>
    <link:label id="lab_ehc_CertificateOfNeedMember_label_en-US" xlink:label="lab_ehc_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of Need [Member]</link:label>
    <link:label id="lab_ehc_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_ehc_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A statement or certificate issued by a governmental agency for proposed construction or modification of a health facility. The certificate process is intended to prevent duplication of services in a community.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember" xlink:href="ehc-20221231.xsd#ehc_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_CertificateOfNeedMember" xlink:to="lab_ehc_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_37d04f3d-f1ec-4199-9dd2-478097a7b710_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net and comprehensive income attributable to Encompass Health</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DividendEquivalentRSUMember_eba6c2b1-285a-4ea8-a020-7c432c758c96_terseLabel_en-US" xlink:label="lab_ehc_DividendEquivalentRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Equivalent, RSU</link:label>
    <link:label id="lab_ehc_DividendEquivalentRSUMember_label_en-US" xlink:label="lab_ehc_DividendEquivalentRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Equivalent, RSU [Member]</link:label>
    <link:label id="lab_ehc_DividendEquivalentRSUMember_documentation_en-US" xlink:label="lab_ehc_DividendEquivalentRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend Equivalent, RSU [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DividendEquivalentRSUMember" xlink:href="ehc-20221231.xsd#ehc_DividendEquivalentRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DividendEquivalentRSUMember" xlink:to="lab_ehc_DividendEquivalentRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock_747120c9-e404-46fc-b2a6-2407b7cf72c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Redemption Prices for Senior Notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Redemption [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:to="lab_us-gaap_DebtInstrumentRedemptionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_cd9d4c80-a209-4bd2-bb15-41a82dfeb409_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod_01a44a81-1518-44af-be93-a74830ffdb4e_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and executive action period</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Regulatory And Executive Action, Period</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Regulatory And Executive Action, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" xlink:to="lab_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_8f4ba07e-6c19-43b1-a7f0-93ff937c45e3_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4852c675-9d3d-4612-a4ef-6010c5e77965_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_029329a4-ebbd-47d8-a7f1-b91e63aec9e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_c6f574a5-f4a1-4afe-9738-54a9fe2e4ea5_terseLabel_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhabit spin-off adjustment (in dollar per share)</link:label>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:to="lab_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_1de523b5-47b2-4aaa-bc29-c4c781cecd00_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_15479ac4-2869-45c5-90cc-62fd3e5aab2d_terseLabel_en-US" xlink:label="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Net Income Attributable to Noncontrolling Interests</link:label>
    <link:label id="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_label_en-US" xlink:label="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Noncontrolling Interests [Table Text Block]</link:label>
    <link:label id="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Noncontrolling Interests [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:href="ehc-20221231.xsd#ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:to="lab_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_36eb47d8-25ed-4752-af4e-a16521911a57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d998c028-def2-49a9-981b-2cb4419abb87_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health included in discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberofBedsExpanded_8371b159-e412-465d-a9f9-29192ad4938b_terseLabel_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds expanded</link:label>
    <link:label id="lab_ehc_NumberofBedsExpanded_label_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Expanded</link:label>
    <link:label id="lab_ehc_NumberofBedsExpanded_documentation_en-US" xlink:label="lab_ehc_NumberofBedsExpanded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Expanded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded" xlink:href="ehc-20221231.xsd#ehc_NumberofBedsExpanded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberofBedsExpanded" xlink:to="lab_ehc_NumberofBedsExpanded" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_6e07b5aa-5051-4ff0-9d2a-e05bc5890da5_terseLabel_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2024</link:label>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_label_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes; 05.75%; Due 2024 [Member]</link:label>
    <link:label id="lab_ehc_SeniorNotes0575Due2024Member_documentation_en-US" xlink:label="lab_ehc_SeniorNotes0575Due2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75% Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorNotes0575Due2024Member" xlink:to="lab_ehc_SeniorNotes0575Due2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_de786a54-08bf-4b31-ac51-53d9c877c1a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum_f95c2101-d024-4880-943b-c6bd46369a7e_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leverage ratio</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Max senior secured leverage ratio to permit restricted payments under credit agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ehc_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_bfe14b7b-1c90-4406-a2e4-2a213e893394_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5749027f-15e9-4b07-a3a4-85e476ccc4de_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense at statutory rate (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_658646a5-a1b2-4a7c-b06f-7a6df4899f1d_terseLabel_en-US" xlink:label="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale/leaseback transactions involving real estate accounted for as financings</link:label>
    <link:label id="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_label_en-US" xlink:label="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Real Estate Sale / Leaseback Financing [Member]</link:label>
    <link:label id="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_documentation_en-US" xlink:label="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Real Estate Sale / Leaseback Financing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:href="ehc-20221231.xsd#ehc_NotesPayableRealEstateSaleLeasebackFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:to="lab_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_2f6f9695-05b9-45d3-b94e-3e5ac24d4b9a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6301b511-a6c9-46ca-a657-023159016c94_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5f8fe076-c7fc-4799-81f8-dad5f619fffd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination_bf8bce51-3fdb-47aa-87d2-78bd1d9d1b85_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount overturned of overpayment determination</link:label>
    <link:label id="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination_label_en-US" xlink:label="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Amount Overturned Of Overpayment Determination</link:label>
    <link:label id="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination_documentation_en-US" xlink:label="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Amount Overturned Of Overpayment Determination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination" xlink:to="lab_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_b9530974-6957-498d-a1b5-4b36e678b926_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and other income taxes, net of federal tax benefit (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_acbfdeeb-e1f1-4862-99f6-2fd84fb6a504_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_a4d18569-fb39-44f1-b438-6ec1332fbb21_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_c9e06fbf-fd97-4264-8dc1-8759defc17d5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DepartmentAppealsBoardAdverseRulingMember_245f1a71-a024-4e3d-8e1f-cad6735e3c36_terseLabel_en-US" xlink:label="lab_ehc_DepartmentAppealsBoardAdverseRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DAB, Adverse Ruling</link:label>
    <link:label id="lab_ehc_DepartmentAppealsBoardAdverseRulingMember_label_en-US" xlink:label="lab_ehc_DepartmentAppealsBoardAdverseRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Appeals Board, Adverse Ruling [Member]</link:label>
    <link:label id="lab_ehc_DepartmentAppealsBoardAdverseRulingMember_documentation_en-US" xlink:label="lab_ehc_DepartmentAppealsBoardAdverseRulingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Appeals Board, Adverse Ruling</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DepartmentAppealsBoardAdverseRulingMember" xlink:href="ehc-20221231.xsd#ehc_DepartmentAppealsBoardAdverseRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DepartmentAppealsBoardAdverseRulingMember" xlink:to="lab_ehc_DepartmentAppealsBoardAdverseRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_8b8612e6-9287-4bc8-9654-ff628902dfcd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax refunds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIncomeTaxRefunds_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Income Tax Refunds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="lab_us-gaap_ProceedsFromIncomeTaxRefunds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_82138199-c13f-492e-a17b-fab4d15f51e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Estimated Amortization Expense, Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_d5e0db32-7203-4b3a-92bf-fd0ef3820450_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0f4f4d0c-c0b2-4956-92e6-068cb838c63b_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_32fbefcc-acd7-456b-8945-d9a0413b3856_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of outstanding shares of Holdings</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Other, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_5089f2cc-be86-4dfe-ad7d-08b278c9139a_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_08427de1-b476-4daa-a516-444ea0f77c33_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_822732ba-5d33-4ed7-b94a-2714515a0563_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fed12ba1-4b97-48f5-bde5-643c1c298bad_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_28bdbb63-7b94-4785-becd-101e29ee0d1d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_76f9ca3d-0ba6-4b54-823d-fafd00e14a1a_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4f13f56a-212c-45d7-8d88-c7cfb40de9d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_69319b87-f852-487d-90b8-268777c23ef0_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_0c104eb6-d297-441c-b485-5907cbe4d188_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EnhabitMember_4d039879-c01d-4e47-9685-34747ddbd309_terseLabel_en-US" xlink:label="lab_ehc_EnhabitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhabit</link:label>
    <link:label id="lab_ehc_EnhabitMember_label_en-US" xlink:label="lab_ehc_EnhabitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhabit [Member]</link:label>
    <link:label id="lab_ehc_EnhabitMember_documentation_en-US" xlink:label="lab_ehc_EnhabitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enhabit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EnhabitMember" xlink:to="lab_ehc_EnhabitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Totalleaseliabilities_c48ab30a-a911-471d-b886-b7d7f1723259_totalLabel_en-US" xlink:label="lab_ehc_Totalleaseliabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_ehc_Totalleaseliabilities_label_en-US" xlink:label="lab_ehc_Totalleaseliabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_ehc_Totalleaseliabilities_documentation_en-US" xlink:label="lab_ehc_Totalleaseliabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lessee's discounted obligation for lease payments from operating and finance leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalleaseliabilities" xlink:href="ehc-20221231.xsd#ehc_Totalleaseliabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Totalleaseliabilities" xlink:to="lab_ehc_Totalleaseliabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion_bc681047-a795-471b-bbce-78ca86006f76_terseLabel_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction fee for undrawn portion</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion_label_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Reduction Fee For Undrawn Portion</link:label>
    <link:label id="lab_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion_documentation_en-US" xlink:label="lab_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Reduction Fee For Undrawn Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion" xlink:to="lab_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f4e8a5aa-eee4-4ca8-a3e0-f625ea5e9e42_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_115cf9f0-942f-4234-84fe-9a24338aa7ba_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_9ce5496e-8eb6-457e-ac14-5645124ef2b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_f7ca36d2-7ff9-41e3-8b02-61015027846a_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Expenses and Other Current Liabilities, Current</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Expenses and Other Current Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_39a79856-c47c-4baa-8919-bc49ce54fea3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7db6a2a0-007c-4c64-9538-4757f702f3ae_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_d2757b0e-5166-462b-bdba-3260e8958b91_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_856815c6-320d-4c97-b6a2-57478e372d7b_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions declared</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_22e86f2c-32c1-485a-8d9b-eb50d295e0c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions declared</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_b58f1e92-5bb6-4624-869a-711d6112da4f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4cf8a72d-ff92-484b-a0cf-623575e6ba16_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_afc187bc-0a47-4357-9363-a25623acd424_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_56d6fcb4-84a0-4349-894c-63411895829f_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Net Operating Revenues and Net Patient Service Accounts Receivable by Payor and Payor Class</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9db6a872-04d5-40ef-9bcc-4fe0deed9cd4_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_763904e1-1e65-4df5-b920-1e5ccd778080_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_b120d875-ba2c-427c-9066-b96d1ac1ca24_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_b9ce236d-51b4-4bc6-a131-0667c67e218c_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_589fb8dc-f241-4c58-952f-11a5ac7a8dbc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use asset accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_9c65f4a5-eeb8-4db3-96df-1fe0d3bf4b37_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions from nonconsolidated affiliates</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6c0b21a7-9937-4d31-bfcd-21c3b98e38ed_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_f5d2111b-467c-4ac0-86bf-b7339a75865f_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities of discontinued operations</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Financing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_f674e096-47ba-4f39-b15c-499ae5af7aa5_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:label id="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis_label_en-US" xlink:label="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Sources [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="lab_us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_e0bca23e-7f95-4e80-8b18-ab25779b77a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_dda23c56-025e-445d-8aa8-7e3122239c4e_terseLabel_en-US" xlink:label="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction of a new hospital</link:label>
    <link:label id="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_label_en-US" xlink:label="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, LIBOR plus 2.5% Construction Financing [Member]</link:label>
    <link:label id="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_documentation_en-US" xlink:label="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, LIBOR plus 2.5% Construction Financing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:href="ehc-20221231.xsd#ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:to="lab_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_26aaf821-0349-4c9e-9926-f8a1f3b86c74_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt amendment and issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0ff42001-4af6-4d9f-b2fb-46a9d86a0866_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_068e2b1b-1969-4e64-becf-3c45c93bebe2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a399dc3-27c7-42fc-8972-29b3ce165bc4_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_a9db761b-3d1a-489f-8477-e74681bff116_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finance Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_a041093b-c455-4858-9244-9f4e50212ddc_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1bc995a8-0527-4ac3-a3fd-30910ef5d752_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_286d2444-0061-4f00-94d7-d8169eb7d38b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_12acc662-e0ba-4936-a8b8-553cc487689c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember_daa06846-6158-4ba3-a82f-6fe874a36ab2_terseLabel_en-US" xlink:label="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Omnibus Performance Incentive Plan</link:label>
    <link:label id="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember_label_en-US" xlink:label="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Omnibus Performance Incentive Plan [Member]</link:label>
    <link:label id="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember_documentation_en-US" xlink:label="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Omnibus Performance Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:href="ehc-20221231.xsd#ehc_A2016OmnibusPerformanceIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:to="lab_ehc_A2016OmnibusPerformanceIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfBedsAcquired_58174bbb-2102-4a58-92b5-42e2133efe03_terseLabel_en-US" xlink:label="lab_ehc_NumberOfBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of beds acquired</link:label>
    <link:label id="lab_ehc_NumberOfBedsAcquired_label_en-US" xlink:label="lab_ehc_NumberOfBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Acquired</link:label>
    <link:label id="lab_ehc_NumberOfBedsAcquired_documentation_en-US" xlink:label="lab_ehc_NumberOfBedsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Beds Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfBedsAcquired" xlink:href="ehc-20221231.xsd#ehc_NumberOfBedsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfBedsAcquired" xlink:to="lab_ehc_NumberOfBedsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_68ead747-fe29-4eda-82ae-686e77da5b23_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Debt, Noncurrent</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_00c30876-ac40-4f46-b4d6-7c86a272308f_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PartnersCapitalAccountContributions_5387b011-987f-4c0a-bcab-35d6423cd679_terseLabel_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions from consolidated affiliates</link:label>
    <link:label id="lab_us-gaap_PartnersCapitalAccountContributions_label_en-US" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partners' Capital Account, Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountContributions" xlink:to="lab_us-gaap_PartnersCapitalAccountContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_52922cda-1168-4f01-946d-2857d6176e66_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_f0c0ffe2-180b-4151-b02c-afbdadb1b41d_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3c9dac2a-5e9e-4045-9829-2db61b29f47d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_020e6515-9d24-40ce-b775-eb6cefe18146_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_8965dd6b-eb3f-4943-accf-1fae1668a272_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_8acafde8-0fc7-4e49-8626-81f5b82f91d3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_42ec9371-4d12-4d60-9333-f72aa3af88a0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_6cd6ef48-0a92-4a7b-b865-e4a17d64d1ad_terseLabel_en-US" xlink:label="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term and Discount Rate</link:label>
    <link:label id="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_label_en-US" xlink:label="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]</link:label>
    <link:label id="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_documentation_en-US" xlink:label="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:href="ehc-20221231.xsd#ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:to="lab_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4416e0e2-7fb0-41c6-9826-ef98fd7b9664_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_5fbc3405-15c6-4e45-9a69-e83d59ae41ca_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash in discontinued operations at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_5fbf6165-583a-4ad7-9a61-73d133a7c998_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash in discontinued operations at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_01c051c1-c25a-4c3d-a142-cdaba8287068_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b93c6605-c8ca-4b3a-b656-ef4bb9eacdee_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff5d2536-7d0e-4b49-ad05-6d0c3e42462d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LossContingencyAppealedClaimsDeniedAmount_37c6af8a-dc71-4d32-8d76-3d226971c682_terseLabel_en-US" xlink:label="lab_ehc_LossContingencyAppealedClaimsDeniedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Appealed claims denied</link:label>
    <link:label id="lab_ehc_LossContingencyAppealedClaimsDeniedAmount_label_en-US" xlink:label="lab_ehc_LossContingencyAppealedClaimsDeniedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Appealed Claims Denied, Amount</link:label>
    <link:label id="lab_ehc_LossContingencyAppealedClaimsDeniedAmount_documentation_en-US" xlink:label="lab_ehc_LossContingencyAppealedClaimsDeniedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Appealed Claims Denied, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAppealedClaimsDeniedAmount" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAppealedClaimsDeniedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LossContingencyAppealedClaimsDeniedAmount" xlink:to="lab_ehc_LossContingencyAppealedClaimsDeniedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_05ab902d-19cc-4b22-a191-28581bc356a7_terseLabel_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract] [Abstract]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_label_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract]</link:label>
    <link:label id="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_documentation_en-US" xlink:label="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:to="lab_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_db7b4fbf-be7d-4ef4-83c0-549965123f7a_terseLabel_en-US" xlink:label="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028 and thereafter</link:label>
    <link:label id="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_label_en-US" xlink:label="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Six And Thereafter</link:label>
    <link:label id="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_documentation_en-US" xlink:label="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth fiscal year following latest fiscal year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:href="ehc-20221231.xsd#ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:to="lab_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_d152a085-dcd3-4458-b7d8-9b790c5e019d_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_d89e9747-0c39-4083-adcc-640a3452765d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_c0ac98b0-9173-4540-94e8-f6f6380282a4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_91e3b6d2-a40f-49ea-af2b-4fb4db510c23_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Quarterly Data (Unaudited) Table</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_ecae9d37-f528-4889-b707-b77bf5521245_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_555a78b8-3155-4efd-a5c6-0e2ac461e0af_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets of discontinued operations</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_95105772-5b3a-4de7-9a5d-f45071a05230_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under letter of credit facility</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_4dc9df38-8acc-4994-bb1a-b2f16ad0d6c7_negatedTerseLabel_en-US" xlink:label="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to discontinued operations</link:label>
    <link:label id="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_label_en-US" xlink:label="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations</link:label>
    <link:label id="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_documentation_en-US" xlink:label="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:href="ehc-20221231.xsd#ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:to="lab_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_73e752bd-f593-40c4-a80c-333f1d980627_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a550aa51-9086-4e9f-93b2-d089d8e15bda_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange of Holdings shares (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_794d645a-c46f-4edd-8a99-f6944211399e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_54e10db1-43d1-47e2-a762-e135348bec03_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_8991b6af-66b4-4ba3-b9ea-22590d227d3e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_39a401f2-4fc6-4d53-9bc7-73669b580fce_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_4fa7e65e-1f96-405f-9977-715542784624_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d9ac7101-036e-4e21-bab3-294ed3a25457_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_68cdae15-cf2f-4827-aff6-1f389752bd06_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease (in percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_e5ea3795-91f4-40c5-a988-7c922077cf52_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_08a92b54-faa0-4c80-a666-b88fd5b0cc00_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_9a8731a0-cf33-4fd9-a30d-f3765a89436a_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5be00612-d289-41e9-aacf-6a3fa7e0d966_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_43f9fd3f-ad2b-4ad2-80eb-fdbefaad7a37_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_38c5c49c-71dc-4cb7-8050-02f77e72d0a3_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanNameAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanNameAxis" xlink:to="lab_us-gaap_RetirementPlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2fb38bdf-b17e-4faf-8fa2-fd717835c90d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid on behalf of employees for shares withheld</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b17a0b1b-c047-4d4d-8699-677fb3e3eb3f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity, Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_67000700-75a4-47a2-ad19-f0532c770195_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to current year claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0d15d27f-c828-46e8-8937-d46e9a20c778_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_79fb697b-5bbc-4c21-82d5-f0c134311d1e_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating expenses</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Operating Expense</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_9f9dde0d-8cf0-4c99-817a-0d7063f6fb6c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (shares)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4c8fa518-bef1-4ae5-af70-a997f05eadb1_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RACAuditsMember_6d3c00c1-1063-4732-8a6d-6dca36a6c501_terseLabel_en-US" xlink:label="lab_ehc_RACAuditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RAC Audits</link:label>
    <link:label id="lab_ehc_RACAuditsMember_label_en-US" xlink:label="lab_ehc_RACAuditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RAC Audits [Member]</link:label>
    <link:label id="lab_ehc_RACAuditsMember_documentation_en-US" xlink:label="lab_ehc_RACAuditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS post-payment audit initiative of inpatient rehabilitation providers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RACAuditsMember" xlink:href="ehc-20221231.xsd#ehc_RACAuditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RACAuditsMember" xlink:to="lab_ehc_RACAuditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e15fa357-e979-486c-8321-fbd03d71045d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest portion</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_428d2193-b5d1-4ded-941b-0a2e7aa8bc2a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_df99b6cd-5cc9-41d3-94de-16bf145bac6a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Encompass Health common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_44e3e453-43ec-4dc2-a9a4-76f2a6405447_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_e49022fc-b7fd-412a-b7e2-d884bdc8abac_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fe6bbafc-4e5e-4b1a-869c-5b863e03b812_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c4fa35e2-7944-47f9-832e-7523cf2b2a7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0749ec2e-3e3b-4a7d-a358-c5d2295569ba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_00dc6551-c7dd-4ba4-85c7-46e3534468e2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_bd33ede4-f798-4d0c-aae3-6899d4a12746_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2a7282e0-f8fb-42ad-81dd-554d90059342_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_d8435e82-2b24-48ac-8598-ec9145d5733d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_b0a1fa23-9e5b-4886-992c-2d20071f6352_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_b3054aab-cb6e-440e-9ddd-9bb1d839d713_terseLabel_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of inpatient rehabilitation hospitals</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_label_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Inpatient Rehabilitation Hospitals</link:label>
    <link:label id="lab_ehc_NumberOfInpatientRehabilitationHospitals_documentation_en-US" xlink:label="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals" xlink:href="ehc-20221231.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NumberOfInpatientRehabilitationHospitals" xlink:to="lab_ehc_NumberOfInpatientRehabilitationHospitals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_2aa47103-13f7-4371-a7c2-6b4e2295b396_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_bde29dd4-59a0-4c00-aad9-5aee439347a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3ef28961-5ddd-4d52-9e88-baefa1e962ee_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d965b192-4f8c-46dd-8a72-fdda6664dea5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9807a808-71a5-4b17-a744-58a5f8bac10c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ada38194-01d1-416e-99b8-32abfdfdf877_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_ce64c8a4-5247-45e1-a4fb-148d6f4f8c67_terseLabel_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_label_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Debt, Current</link:label>
    <link:label id="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_documentation_en-US" xlink:label="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" xlink:to="lab_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_55ccdfe0-313b-4ad7-b63d-a90613d7433b_negatedTerseLabel_en-US" xlink:label="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="ehc-20221231.xsd#ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_SeniorManagementBonusProgramTotalCosts_869daf71-db63-4110-9461-38b7ff5fcec6_terseLabel_en-US" xlink:label="lab_ehc_SeniorManagementBonusProgramTotalCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments under the Senior Management Bonus Program</link:label>
    <link:label id="lab_ehc_SeniorManagementBonusProgramTotalCosts_label_en-US" xlink:label="lab_ehc_SeniorManagementBonusProgramTotalCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Management Bonus Program, Total Costs</link:label>
    <link:label id="lab_ehc_SeniorManagementBonusProgramTotalCosts_documentation_en-US" xlink:label="lab_ehc_SeniorManagementBonusProgramTotalCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of payments made or expected to be made during a reporting period to participants that are entitled under the Senior Management Bonus Program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorManagementBonusProgramTotalCosts" xlink:href="ehc-20221231.xsd#ehc_SeniorManagementBonusProgramTotalCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_SeniorManagementBonusProgramTotalCosts" xlink:to="lab_ehc_SeniorManagementBonusProgramTotalCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_afb93b97-ad0a-41cb-9718-a126faf5fa8c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_FaceAmountMember_3edacb09-d4aa-483f-860a-a8492a1c8652_terseLabel_en-US" xlink:label="lab_ehc_FaceAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face Amount</link:label>
    <link:label id="lab_ehc_FaceAmountMember_label_en-US" xlink:label="lab_ehc_FaceAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face Amount [Member]</link:label>
    <link:label id="lab_ehc_FaceAmountMember_documentation_en-US" xlink:label="lab_ehc_FaceAmountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FaceAmountMember" xlink:href="ehc-20221231.xsd#ehc_FaceAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_FaceAmountMember" xlink:to="lab_ehc_FaceAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_d47a86b1-52fe-4a9e-88db-32eaee059ab6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_2c512096-df03-406a-8c09-9b973a511aad_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense and amortization of debt discounts and fees</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_a927149b-a1de-4fd3-9eb2-a99d00df11ae_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_ae44b0f1-1490-46fd-b8b3-a8f04a28b05a_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_29de51ee-5e6b-4909-a15f-2cbb7bc025c5_terseLabel_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_label_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Four</link:label>
    <link:label id="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_documentation_en-US" xlink:label="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt And Lease Obligations, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:to="lab_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_859aa393-e8c8-41ec-ad36-369b698ed192_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_3fb8db37-9551-4d7e-9a07-fd0c17695127_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_NoncontrollingInterestSpinOff_e928ecb5-105a-40c9-a002-928ab292f5ba_negatedTerseLabel_en-US" xlink:label="lab_ehc_NoncontrollingInterestSpinOff" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spin off of Enhabit, Inc.</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestSpinOff_label_en-US" xlink:label="lab_ehc_NoncontrollingInterestSpinOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Spin Off</link:label>
    <link:label id="lab_ehc_NoncontrollingInterestSpinOff_documentation_en-US" xlink:label="lab_ehc_NoncontrollingInterestSpinOff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Spin Off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestSpinOff" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestSpinOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_NoncontrollingInterestSpinOff" xlink:to="lab_ehc_NoncontrollingInterestSpinOff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_94caa63d-be70-4fe6-ba2f-66473ee66b33_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_9aa2d28a-9169-4f10-a8f9-107588c4b5f3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_356f788d-5657-4850-8a3a-0c08479dc8d1_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_f98e4fb4-cc49-4695-b085-2530bbfea16f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration of Net Operating Revenues by Payor</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_5af0e802-d4b7-4180-9654-eb431ea414bd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_fbf2157d-dfa4-43a2-be5d-6e3df6b4440d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal borrowings on notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_1488bb3d-855d-425b-893a-c7141c7042c1_terseLabel_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete agreements</link:label>
    <link:label id="lab_us-gaap_NoncompeteAgreementsMember_label_en-US" xlink:label="lab_us-gaap_NoncompeteAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompete Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncompeteAgreementsMember" xlink:to="lab_us-gaap_NoncompeteAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_0e6bae0d-fbfe-4aa0-90bd-02c2e7012365_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_ddb8ba45-bd1c-4176-88af-a15165de19d7_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in the consolidated entities (percent)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_b94eb0ac-5d6c-4aa0-870e-228a711acf19_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_RestrictedDebtSecuritiesNoncurrent_32a55aba-1371-40db-8e74-dd26b1547bf2_terseLabel_en-US" xlink:label="lab_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted marketable securities</link:label>
    <link:label id="lab_ehc_RestrictedDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Debt Securities, Noncurrent</link:label>
    <link:label id="lab_ehc_RestrictedDebtSecuritiesNoncurrent_documentation_en-US" xlink:label="lab_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for greater than one year or the normal operating cycle, whichever is longer and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:href="ehc-20221231.xsd#ehc_RestrictedDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:to="lab_ehc_RestrictedDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_07cfb9e9-3385-4420-84f7-cd952c55c1b9_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_25caf060-2326-4c61-a97d-2b0a41220392_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2492c853-bbab-41b8-8bd1-9ba9704dbfbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff6be086-5774-440f-8ab4-9d1cb5acf54d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_1bc6c276-7456-4a02-b634-590ddf3c954b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_1c4f83cc-e946-4273-aa23-af91b4f9f282_terseLabel_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares to issued to the management investors pursuant to the exchange agreements represents (in percent)</link:label>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_label_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</link:label>
    <link:label id="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_documentation_en-US" xlink:label="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:href="ehc-20221231.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:to="lab_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_TheCreditAgreementMember_f9ba0b1d-7a0b-4126-9e85-1ec2b7cfd505_terseLabel_en-US" xlink:label="lab_ehc_TheCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Agreement</link:label>
    <link:label id="lab_ehc_TheCreditAgreementMember_label_en-US" xlink:label="lab_ehc_TheCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Agreement [Member]</link:label>
    <link:label id="lab_ehc_TheCreditAgreementMember_documentation_en-US" xlink:label="lab_ehc_TheCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TheCreditAgreementMember" xlink:href="ehc-20221231.xsd#ehc_TheCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_TheCreditAgreementMember" xlink:to="lab_ehc_TheCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_4eb94621-b8fb-4c89-9bdd-e3db19b25d1c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies by Nature of Contingency [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_5d742c48-bdeb-4009-bd09-89faf915ba4c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_fbccb2cb-1436-43ab-94d1-baffd7608425_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_52aa12fb-3139-48ee-a459-437878a2eaff_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_EncompassHealthRetirementInvestmentPlanMember_69ad3fea-32d1-4859-ac6a-65c59ea6ea93_terseLabel_en-US" xlink:label="lab_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health Retirement Investment Plan</link:label>
    <link:label id="lab_ehc_EncompassHealthRetirementInvestmentPlanMember_label_en-US" xlink:label="lab_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health Retirement Investment Plan [Member]</link:label>
    <link:label id="lab_ehc_EncompassHealthRetirementInvestmentPlanMember_documentation_en-US" xlink:label="lab_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Encompass Health Retirement Investment Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:href="ehc-20221231.xsd#ehc_EncompassHealthRetirementInvestmentPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:to="lab_ehc_EncompassHealthRetirementInvestmentPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4dd208ed-0764-4911-9b39-514cf1ef2c72_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_cf1558c4-6beb-474c-a408-0a1101e129ae_verboseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_438857bb-a93e-48bc-b5d6-59ecbd8afbdd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f022d621-5ec9-4174-b2fe-700c3695c522_negatedLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_e3727b75-7a68-47dc-b2ed-dd547426fd7c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_45f19523-418c-435b-ab7d-4c2186979e35_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ehc_Jointventureownershippercentage_fc6d479e-2d01-41f0-9b07-ccccbf0e354f_terseLabel_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_ehc_Jointventureownershippercentage_label_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:label id="lab_ehc_Jointventureownershippercentage_documentation_en-US" xlink:label="lab_ehc_Jointventureownershippercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint venture ownership percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage" xlink:href="ehc-20221231.xsd#ehc_Jointventureownershippercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ehc_Jointventureownershippercentage" xlink:to="lab_ehc_Jointventureownershippercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_b7fe54a7-a306-47a1-8308-aa527e9d1ba7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests included in continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_71c2d129-0b30-4b56-912d-bf22f0216cbf_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests included in continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_b53ad012-3c2c-413a-9f8d-0929fa427116_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net income attributable to noncontrolling interests included in continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>ehc-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:6ef5271b-25cf-4941-a7fe-936386c94a75,g:d3e86cc2-acdf-4f67-b511-3ef26c190552-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CoverPage" xlink:type="simple" xlink:href="ehc-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_acaf9a37-d499-47f0-9775-95e3ed66d003" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_DocumentType_acaf9a37-d499-47f0-9775-95e3ed66d003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_6417bcdf-c26d-455a-aa73-e9df4e0262e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_DocumentAnnualReport_6417bcdf-c26d-455a-aa73-e9df4e0262e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_449477f6-c8e6-4e3b-b051-9cca7d139a83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_DocumentPeriodEndDate_449477f6-c8e6-4e3b-b051-9cca7d139a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dc51586c-f620-4d37-9e3e-49da15cf6df9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_CurrentFiscalYearEndDate_dc51586c-f620-4d37-9e3e-49da15cf6df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6d37624a-753c-42e3-b12c-57d3210a8a2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_DocumentTransitionReport_6d37624a-753c-42e3-b12c-57d3210a8a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a44c8c0c-5e8a-4c23-90c1-cc1831340c20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityFileNumber_a44c8c0c-5e8a-4c23-90c1-cc1831340c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fcdf9cdc-bd24-4646-8cd4-abbc8f79072b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityRegistrantName_fcdf9cdc-bd24-4646-8cd4-abbc8f79072b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3c2cf15d-5a77-455e-a6ef-21ccb89d5da1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3c2cf15d-5a77-455e-a6ef-21ccb89d5da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e2bcb06e-5700-4986-868d-00617a09834c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityTaxIdentificationNumber_e2bcb06e-5700-4986-868d-00617a09834c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_844b7aa8-d542-4676-be52-493e66403ce8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityAddressAddressLine1_844b7aa8-d542-4676-be52-493e66403ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f472caf3-802a-4127-9cc5-f00390afdaa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityAddressCityOrTown_f472caf3-802a-4127-9cc5-f00390afdaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_31355bfe-1277-4e88-8233-449b5a877e45" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityAddressStateOrProvince_31355bfe-1277-4e88-8233-449b5a877e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c87fc36b-a919-4296-8283-272bc5382aa8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityAddressPostalZipCode_c87fc36b-a919-4296-8283-272bc5382aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5a4741fa-90e3-4c52-8a58-ffe427dcd392" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_CityAreaCode_5a4741fa-90e3-4c52-8a58-ffe427dcd392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6ab7a94b-e861-4094-9df5-1f2707957a7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_LocalPhoneNumber_6ab7a94b-e861-4094-9df5-1f2707957a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ced5057a-3ddf-4800-8804-86a743de5f2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_Security12bTitle_ced5057a-3ddf-4800-8804-86a743de5f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_933cbb4e-c87a-4c25-807a-b1fc2aaec85d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_TradingSymbol_933cbb4e-c87a-4c25-807a-b1fc2aaec85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_74e4397e-7840-40ed-a1ff-136c0f39f95a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_SecurityExchangeName_74e4397e-7840-40ed-a1ff-136c0f39f95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_3a8d27f9-30cc-4673-96ef-c0e52dc7acc8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_3a8d27f9-30cc-4673-96ef-c0e52dc7acc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_30a713d7-41b8-4c25-a838-14ac4c52bb1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityVoluntaryFilers_30a713d7-41b8-4c25-a838-14ac4c52bb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c0fa8779-16db-40a4-a216-df1fc866a359" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityCurrentReportingStatus_c0fa8779-16db-40a4-a216-df1fc866a359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e8aeb375-c34e-424f-8223-f549d4d694a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityInteractiveDataCurrent_e8aeb375-c34e-424f-8223-f549d4d694a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_bc10ada0-c887-4fdf-9c9c-613b1d0e4129" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityFilerCategory_bc10ada0-c887-4fdf-9c9c-613b1d0e4129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_e22d4d3e-0d8e-470a-b653-a1273b09f3fb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityEmergingGrowthCompany_e22d4d3e-0d8e-470a-b653-a1273b09f3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d3425f96-9637-49f1-943a-1656103ece5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntitySmallBusiness_d3425f96-9637-49f1-943a-1656103ece5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_addad76a-c3bd-478b-ae69-20f5498c3f69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_IcfrAuditorAttestationFlag_addad76a-c3bd-478b-ae69-20f5498c3f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_897d0414-be12-42b7-848a-e6a52d7a6140" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityShellCompany_897d0414-be12-42b7-848a-e6a52d7a6140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_b3a6efb0-a345-4abf-b096-f2e66862e473" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityPublicFloat_b3a6efb0-a345-4abf-b096-f2e66862e473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_97007b43-db50-495f-b7a4-7688567b4d89" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_97007b43-db50-495f-b7a4-7688567b4d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ff937c26-b26c-4b46-b8e7-c432b4948b1e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ff937c26-b26c-4b46-b8e7-c432b4948b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cdc0d8da-fdf3-481c-bcd8-4f1da55ae72e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_EntityCentralIndexKey_cdc0d8da-fdf3-481c-bcd8-4f1da55ae72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_244fa1ca-609d-4a04-a2bb-fb948c78cd43" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_DocumentFiscalYearFocus_244fa1ca-609d-4a04-a2bb-fb948c78cd43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_938874e2-e7df-4256-a0bb-a622e4e3857d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_DocumentFiscalPeriodFocus_938874e2-e7df-4256-a0bb-a622e4e3857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_69ca175a-38ed-4db8-b277-17e4b74cf111" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5f3657e7-665c-42fe-83bc-9839f6abc404" xlink:to="loc_dei_AmendmentFlag_69ca175a-38ed-4db8-b277-17e4b74cf111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AuditInformation" xlink:type="simple" xlink:href="ehc-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AuditInformationAbstract_19e3e0da-09ba-4323-accf-b75ef683e46f" xlink:href="ehc-20221231.xsd#ehc_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_0b25ae15-dcac-4340-b252-0b9b2e700647" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_AuditInformationAbstract_19e3e0da-09ba-4323-accf-b75ef683e46f" xlink:to="loc_dei_AuditorFirmId_0b25ae15-dcac-4340-b252-0b9b2e700647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_f20b245d-762e-466a-8249-cfcdd0b8ee31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_AuditInformationAbstract_19e3e0da-09ba-4323-accf-b75ef683e46f" xlink:to="loc_dei_AuditorName_f20b245d-762e-466a-8249-cfcdd0b8ee31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_d8c431d9-e3cf-4265-b236-9e07f778127a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_AuditInformationAbstract_19e3e0da-09ba-4323-accf-b75ef683e46f" xlink:to="loc_dei_AuditorLocation_d8c431d9-e3cf-4265-b236-9e07f778127a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:href="ehc-20221231.xsd#ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afc0f79b-4e37-4c80-936c-966fa9413082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_afc0f79b-4e37-4c80-936c-966fa9413082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_a8deea15-0199-4bf3-aaa1-6d2c6801f0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:to="loc_us-gaap_LaborAndRelatedExpense_a8deea15-0199-4bf3-aaa1-6d2c6801f0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_1e281df1-f64e-4498-a478-abfed7a6a85c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_1e281df1-f64e-4498-a478-abfed7a6a85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OccupancyCost_0528525e-71e0-49ec-8b7c-ea124e28a4b7" xlink:href="ehc-20221231.xsd#ehc_OccupancyCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:to="loc_ehc_OccupancyCost_0528525e-71e0-49ec-8b7c-ea124e28a4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_f0cdbbe6-d95b-40cb-a145-efdcbd489a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:to="loc_us-gaap_SuppliesExpense_f0cdbbe6-d95b-40cb-a145-efdcbd489a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9df0f574-8d01-473a-a0a5-acce9ff16ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9df0f574-8d01-473a-a0a5-acce9ff16ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_41c17b1f-1b73-4e4e-9551-98f9efb584f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_41c17b1f-1b73-4e4e-9551-98f9efb584f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_3bd017df-8d85-4553-8632-2afcc8de1824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:to="loc_us-gaap_LitigationSettlementExpense_3bd017df-8d85-4553-8632-2afcc8de1824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_efb97ad8-b8cb-4633-9065-9dca80243aab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_82aaaca6-67ee-4350-8e9c-47e1c45506b7" xlink:to="loc_us-gaap_CostsAndExpenses_efb97ad8-b8cb-4633-9065-9dca80243aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7928033b-2347-43a2-a5e6-0f3f1c84b5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7928033b-2347-43a2-a5e6-0f3f1c84b5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_243e7341-d41d-4901-8503-fb709fdd5c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_InterestExpense_243e7341-d41d-4901-8503-fb709fdd5c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8cad023a-9802-430f-838c-a0dbe8b24802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8cad023a-9802-430f-838c-a0dbe8b24802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75f261f3-94c8-4c10-b0fa-1e14eb16fcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_75f261f3-94c8-4c10-b0fa-1e14eb16fcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c57de68b-9400-4c1e-b837-e83fa3e864a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c57de68b-9400-4c1e-b837-e83fa3e864a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f1f057d-94f2-4aa8-99e8-8124f57f6b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4f1f057d-94f2-4aa8-99e8-8124f57f6b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_925d968a-e534-485d-a67c-d054550cfe5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_925d968a-e534-485d-a67c-d054550cfe5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_5990da71-785c-402c-a324-9bb27234aa63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_5990da71-785c-402c-a324-9bb27234aa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_472c11d2-f6a7-4537-87d9-6375e0fb9162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_ProfitLoss_472c11d2-f6a7-4537-87d9-6375e0fb9162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_167b805b-634c-41cf-bcd8-26bdf645b139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_167b805b-634c-41cf-bcd8-26bdf645b139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_0150f460-c02b-4368-8b27-a9058f1b154b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_0150f460-c02b-4368-8b27-a9058f1b154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_5b4ca4df-eea5-44c4-9411-56884efb0237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_5b4ca4df-eea5-44c4-9411-56884efb0237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0e13ff32-9e5f-42c1-9290-03a7c88983cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0e13ff32-9e5f-42c1-9290-03a7c88983cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_20d6f23a-bb8f-4efd-8e64-5c60075c169b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_20d6f23a-bb8f-4efd-8e64-5c60075c169b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9b285953-75a3-4a41-8132-7eb7baf0666d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_NetIncomeLoss_9b285953-75a3-4a41-8132-7eb7baf0666d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a78c0d81-b45a-4f71-b4eb-8434d4d2c492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a78c0d81-b45a-4f71-b4eb-8434d4d2c492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cc9fe82f-193c-4449-b546-03052185e4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cc9fe82f-193c-4449-b546-03052185e4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9d9fc17-1144-4d2c-8980-63f95fe21dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cc9fe82f-193c-4449-b546-03052185e4ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9d9fc17-1144-4d2c-8980-63f95fe21dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5454b95c-d381-4fd0-bc18-371a37d5773b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_cc9fe82f-193c-4449-b546-03052185e4ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5454b95c-d381-4fd0-bc18-371a37d5773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7a84e4c4-29c3-46b0-90e3-ade9df37f1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract_86a1245b-225b-4a7a-99df-84a0946b4433" xlink:to="loc_us-gaap_EarningsPerShareAbstract_7a84e4c4-29c3-46b0-90e3-ade9df37f1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_43f1dcd7-9657-469e-9aa4-2914be3c861d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7a84e4c4-29c3-46b0-90e3-ade9df37f1f9" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_43f1dcd7-9657-469e-9aa4-2914be3c861d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_cb2aad9e-ea89-4089-a8d4-cf6832430809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_43f1dcd7-9657-469e-9aa4-2914be3c861d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_cb2aad9e-ea89-4089-a8d4-cf6832430809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_cfcafff5-1f14-4f35-b6a9-485dde2b0cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_43f1dcd7-9657-469e-9aa4-2914be3c861d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_cfcafff5-1f14-4f35-b6a9-485dde2b0cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7bc33334-e196-4889-a3be-c976eae6e588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_43f1dcd7-9657-469e-9aa4-2914be3c861d" xlink:to="loc_us-gaap_EarningsPerShareBasic_7bc33334-e196-4889-a3be-c976eae6e588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_d4d1d2b7-6502-4573-9324-38baa4637fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7a84e4c4-29c3-46b0-90e3-ade9df37f1f9" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_d4d1d2b7-6502-4573-9324-38baa4637fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a7b4c968-3d43-4411-939d-8cfc9f361714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d4d1d2b7-6502-4573-9324-38baa4637fe2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_a7b4c968-3d43-4411-939d-8cfc9f361714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_048a2bbe-e0a3-4bbe-a210-f8378b43ffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d4d1d2b7-6502-4573-9324-38baa4637fe2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_048a2bbe-e0a3-4bbe-a210-f8378b43ffc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_33641af1-a1b0-461c-a32f-f54b70713abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_d4d1d2b7-6502-4573-9324-38baa4637fe2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_33641af1-a1b0-461c-a32f-f54b70713abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_8be89e9f-d044-419f-9eee-b25344f43f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7a84e4c4-29c3-46b0-90e3-ade9df37f1f9" xlink:to="loc_us-gaap_NetIncomeLossAbstract_8be89e9f-d044-419f-9eee-b25344f43f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_3168317e-3aee-4b92-b26c-99db0d67b571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_8be89e9f-d044-419f-9eee-b25344f43f88" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_3168317e-3aee-4b92-b26c-99db0d67b571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_53e15da2-47af-4cf8-9f2c-92ace739c443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_8be89e9f-d044-419f-9eee-b25344f43f88" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_53e15da2-47af-4cf8-9f2c-92ace739c443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e8f8e00-f91e-4199-82c0-95f0c974c5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_8be89e9f-d044-419f-9eee-b25344f43f88" xlink:to="loc_us-gaap_NetIncomeLoss_9e8f8e00-f91e-4199-82c0-95f0c974c5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome_1"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_44607c72-46cd-4d81-80ab-103245ccb28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_44607c72-46cd-4d81-80ab-103245ccb28c" xlink:to="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f3d72b43-dfb6-4bde-ad40-83593847c480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f3d72b43-dfb6-4bde-ad40-83593847c480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31a05e67-f0dc-4688-a8c5-a8effa02f6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f3d72b43-dfb6-4bde-ad40-83593847c480" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31a05e67-f0dc-4688-a8c5-a8effa02f6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_e505ede1-d4b1-4ec5-8585-116305186a28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f3d72b43-dfb6-4bde-ad40-83593847c480" xlink:to="loc_us-gaap_RestrictedCashCurrent_e505ede1-d4b1-4ec5-8585-116305186a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e09493b4-bdd0-45c0-9c34-78db2aef7bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f3d72b43-dfb6-4bde-ad40-83593847c480" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e09493b4-bdd0-45c0-9c34-78db2aef7bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_494a51e2-049d-49a7-a357-576cc83fd11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f3d72b43-dfb6-4bde-ad40-83593847c480" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_494a51e2-049d-49a7-a357-576cc83fd11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2ccd9ed2-4fee-4c83-aecf-cc4417a03d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f3d72b43-dfb6-4bde-ad40-83593847c480" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_2ccd9ed2-4fee-4c83-aecf-cc4417a03d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f0f2cffd-67e5-4882-8414-13a8abb985e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f3d72b43-dfb6-4bde-ad40-83593847c480" xlink:to="loc_us-gaap_AssetsCurrent_f0f2cffd-67e5-4882-8414-13a8abb985e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e15d023d-d9a0-471a-87a4-daea67854b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e15d023d-d9a0-471a-87a4-daea67854b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0242141c-9bd3-42ed-8d0f-986860f55b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0242141c-9bd3-42ed-8d0f-986860f55b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e9cc6562-ba36-45fb-a2c2-99b175f719a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:to="loc_us-gaap_Goodwill_e9cc6562-ba36-45fb-a2c2-99b175f719a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a0d1040-30f6-41ef-8fc8-622030fbc932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9a0d1040-30f6-41ef-8fc8-622030fbc932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_47bc6dbb-eba7-46e7-a1b0-fa744df885e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_47bc6dbb-eba7-46e7-a1b0-fa744df885e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_431748c8-72a5-4c88-99d5-df51ef7b2ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_431748c8-72a5-4c88-99d5-df51ef7b2ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0c3345e8-8e05-4d16-98ba-e16ab6ad9a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_593562b3-e886-4e4f-a4cf-9ab3a724c301" xlink:to="loc_us-gaap_Assets_0c3345e8-8e05-4d16-98ba-e16ab6ad9a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_44607c72-46cd-4d81-80ab-103245ccb28c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_95ad1d76-2692-48e7-80e1-4837f334c318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_95ad1d76-2692-48e7-80e1-4837f334c318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a3feedb4-73ac-475c-87b6-c90d59ec644b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a3feedb4-73ac-475c-87b6-c90d59ec644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9f16af97-8466-48f0-b8f6-7d8dd8cd6f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:to="loc_us-gaap_AccountsPayableCurrent_9f16af97-8466-48f0-b8f6-7d8dd8cd6f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a8855fbb-9292-4cb2-9d61-7a29019925f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a8855fbb-9292-4cb2-9d61-7a29019925f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_c6c15b95-f7c6-4005-813d-453c04ad2aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:to="loc_us-gaap_InterestPayableCurrent_c6c15b95-f7c6-4005-813d-453c04ad2aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3efb74c0-5fb6-41a0-b48d-043ae4a97ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3efb74c0-5fb6-41a0-b48d-043ae4a97ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ca787bc2-0131-4893-bd5d-8f224ed89e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_ca787bc2-0131-4893-bd5d-8f224ed89e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_88d502e8-5ef4-4250-aff4-21f02f2493b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7a26057c-7999-4395-80ad-297e395b417b" xlink:to="loc_us-gaap_LiabilitiesCurrent_88d502e8-5ef4-4250-aff4-21f02f2493b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d624442e-d7f1-4bab-8ee9-359bfef7168f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_d624442e-d7f1-4bab-8ee9-359bfef7168f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35e1daab-150c-4e35-bf29-0fe5b9a0c8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35e1daab-150c-4e35-bf29-0fe5b9a0c8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent_63d25db9-6374-4366-a034-faeee320c020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_SelfInsuranceReserveNoncurrent_63d25db9-6374-4366-a034-faeee320c020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_872ffabc-5a7f-4e76-a6cf-3425729a4118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_872ffabc-5a7f-4e76-a6cf-3425729a4118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_adc00515-b44d-4ea9-a6fc-a1228df8b1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_adc00515-b44d-4ea9-a6fc-a1228df8b1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_81d8a895-2fb2-4695-afb1-f361bdfd8ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_81d8a895-2fb2-4695-afb1-f361bdfd8ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f2fd1133-147d-4f8f-93b1-a8595fc2f8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_Liabilities_f2fd1133-147d-4f8f-93b1-a8595fc2f8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_108a087c-5272-4294-aaf2-1bc6be996d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_108a087c-5272-4294-aaf2-1bc6be996d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_318f1ba4-2961-48f0-8a23-81a4400622f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_318f1ba4-2961-48f0-8a23-81a4400622f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_743b9dd4-fb24-48b1-960a-0659007b3a08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_743b9dd4-fb24-48b1-960a-0659007b3a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_fd68276a-907f-4157-9ff2-2fd402fe617f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_743b9dd4-fb24-48b1-960a-0659007b3a08" xlink:to="loc_us-gaap_StockholdersEquityAbstract_fd68276a-907f-4157-9ff2-2fd402fe617f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2d575847-f758-459f-bbe1-3c3edf1d9444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fd68276a-907f-4157-9ff2-2fd402fe617f" xlink:to="loc_us-gaap_CommonStockValue_2d575847-f758-459f-bbe1-3c3edf1d9444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e4f5c0f0-8ba5-4aac-9860-450efaf813cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fd68276a-907f-4157-9ff2-2fd402fe617f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e4f5c0f0-8ba5-4aac-9860-450efaf813cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b619fcf7-ca39-4f6b-aacb-cb88e10eda42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fd68276a-907f-4157-9ff2-2fd402fe617f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b619fcf7-ca39-4f6b-aacb-cb88e10eda42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_c00072c1-b42e-493c-b98b-c64ad564fc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fd68276a-907f-4157-9ff2-2fd402fe617f" xlink:to="loc_us-gaap_TreasuryStockCommonValue_c00072c1-b42e-493c-b98b-c64ad564fc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4be29324-1ddb-42bc-8102-c818292fd5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_fd68276a-907f-4157-9ff2-2fd402fe617f" xlink:to="loc_us-gaap_StockholdersEquity_4be29324-1ddb-42bc-8102-c818292fd5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_289603c3-0741-4266-bc23-c11f6c2af623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_743b9dd4-fb24-48b1-960a-0659007b3a08" xlink:to="loc_us-gaap_MinorityInterest_289603c3-0741-4266-bc23-c11f6c2af623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5a54f168-d498-4ecc-9866-25551d71a0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_743b9dd4-fb24-48b1-960a-0659007b3a08" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5a54f168-d498-4ecc-9866-25551d71a0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_af0d0cdf-8ccd-47f1-b243-08df60021a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_442c4acb-e6c3-47d6-b6b3-60eb38af8b1f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_af0d0cdf-8ccd-47f1-b243-08df60021a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f3870dbe-1b67-4512-a8b8-85616ef838c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a6e36405-99ba-4b23-9057-0d7b53fbe42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3870dbe-1b67-4512-a8b8-85616ef838c4" xlink:to="loc_us-gaap_StatementTable_a6e36405-99ba-4b23-9057-0d7b53fbe42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_cd546aeb-da48-444c-b6aa-b5e31ba36165" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a6e36405-99ba-4b23-9057-0d7b53fbe42b" xlink:to="loc_srt_ConsolidatedEntitiesAxis_cd546aeb-da48-444c-b6aa-b5e31ba36165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ce8c46f7-d395-4d7d-bb2d-75525d6c4cc6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_cd546aeb-da48-444c-b6aa-b5e31ba36165" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ce8c46f7-d395-4d7d-bb2d-75525d6c4cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_811b8c42-3b65-48a7-b020-83758d71544e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ce8c46f7-d395-4d7d-bb2d-75525d6c4cc6" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_811b8c42-3b65-48a7-b020-83758d71544e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a6e36405-99ba-4b23-9057-0d7b53fbe42b" xlink:to="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_38e735b7-b15e-4e56-97b1-50e5b9508673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_38e735b7-b15e-4e56-97b1-50e5b9508673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0205c810-4829-459c-8e13-262481b22799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0205c810-4829-459c-8e13-262481b22799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b1fee44-8fac-43bb-8ae8-2b8223ea09ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_CommonStockSharesIssued_4b1fee44-8fac-43bb-8ae8-2b8223ea09ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_8b894944-fa73-44a4-bff7-6e203ffcee5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_8b894944-fa73-44a4-bff7-6e203ffcee5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a3a29ff5-3e53-4801-ba80-3c4ced2e3e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_Assets_a3a29ff5-3e53-4801-ba80-3c4ced2e3e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_79c6869a-9871-4293-af78-cbd6f8322553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7cae41e9-928d-4485-bb17-c3775d72450e" xlink:to="loc_us-gaap_Liabilities_79c6869a-9871-4293-af78-cbd6f8322553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f3613965-4a75-4d49-ae88-cb088e4f0587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0db65af2-4a67-484c-9a96-c9dd1344e2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f3613965-4a75-4d49-ae88-cb088e4f0587" xlink:to="loc_us-gaap_StatementTable_0db65af2-4a67-484c-9a96-c9dd1344e2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8192a9bb-e545-469e-a75a-1aecf52a8312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0db65af2-4a67-484c-9a96-c9dd1344e2de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8192a9bb-e545-469e-a75a-1aecf52a8312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8192a9bb-e545-469e-a75a-1aecf52a8312" xlink:to="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_06aa045d-5684-4aa0-8781-7fd747c67175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_CommonStockMember_06aa045d-5684-4aa0-8781-7fd747c67175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0d077fdf-3efa-445f-9070-6e55b6f5b82f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0d077fdf-3efa-445f-9070-6e55b6f5b82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bbb47ede-e37d-40c0-b303-d10012ff2511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_RetainedEarningsMember_bbb47ede-e37d-40c0-b303-d10012ff2511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_18297df9-ab25-4e7f-8d60-39ac855888da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_TreasuryStockCommonMember_18297df9-ab25-4e7f-8d60-39ac855888da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_cccd02f4-63b9-45c6-808c-a9403d5187d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_71fdedf7-cfe4-4f03-98b6-8c559919638a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_cccd02f4-63b9-45c6-808c-a9403d5187d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fd9cbdc7-852e-43d5-ad15-3d0d473e9a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0db65af2-4a67-484c-9a96-c9dd1344e2de" xlink:to="loc_us-gaap_StatementLineItems_fd9cbdc7-852e-43d5-ad15-3d0d473e9a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fd9cbdc7-852e-43d5-ad15-3d0d473e9a15" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d246c58b-5e43-4650-a49b-15835789ecd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d246c58b-5e43-4650-a49b-15835789ecd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1818e9d1-ae7c-428c-b0ed-5efacdd2b181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1818e9d1-ae7c-428c-b0ed-5efacdd2b181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ca8a694c-69c7-49bd-82ec-863d6e223e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest_ca8a694c-69c7-49bd-82ec-863d6e223e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4bbea44b-18bd-4960-92b8-9cc5df8cd6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_4bbea44b-18bd-4960-92b8-9cc5df8cd6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_badc25da-cff1-4404-aefc-02b52a6d60c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_badc25da-cff1-4404-aefc-02b52a6d60c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_6e02cc27-8928-454f-a92f-d908f30f8196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_DividendsCommonStockCash_6e02cc27-8928-454f-a92f-d908f30f8196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_706c6462-7b3f-408d-81c4-ffc52293ccbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_706c6462-7b3f-408d-81c4-ffc52293ccbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_75c9a2cc-6153-44c7-86f4-7dd9ff994284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_75c9a2cc-6153-44c7-86f4-7dd9ff994284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f37caf3-27b4-4359-bf59-3c3d9038dda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f37caf3-27b4-4359-bf59-3c3d9038dda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf260988-d609-4742-9e66-7cfd7c39fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bf260988-d609-4742-9e66-7cfd7c39fb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d7afe94e-f5ad-4b29-b84b-92c322f91679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_d7afe94e-f5ad-4b29-b84b-92c322f91679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_37cc3600-5b39-4676-9025-b8564bc62ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_37cc3600-5b39-4676-9025-b8564bc62ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_d8c9add3-acad-493e-b288-8f1951a29904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_d8c9add3-acad-493e-b288-8f1951a29904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_20cd6b32-8eb9-45f9-875c-16634c0b56e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_20cd6b32-8eb9-45f9-875c-16634c0b56e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_3e7b3a0e-7c46-407f-8ed7-3d0f4e649a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountContributions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_3e7b3a0e-7c46-407f-8ed7-3d0f4e649a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_22485589-794c-4e5e-855d-3e2675358bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_22485589-794c-4e5e-855d-3e2675358bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_765631e4-2651-44b4-a64b-802924108c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_765631e4-2651-44b4-a64b-802924108c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_4293640c-f0e1-4cda-88fe-1cde6c00c3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_4293640c-f0e1-4cda-88fe-1cde6c00c3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_24d323e3-bf2d-4831-9f58-a9afbcef7d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityOther_24d323e3-bf2d-4831-9f58-a9afbcef7d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_38174d4f-57ae-491d-9514-308614eccc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_38174d4f-57ae-491d-9514-308614eccc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f43d0f4-c6ad-45d5-adfe-a3b7894dfbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_def10e20-3080-41ec-a945-3efaad0744b1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f43d0f4-c6ad-45d5-adfe-a3b7894dfbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_74a2f55c-2b8f-4bdd-820b-3c04ab67b330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_5815f2cd-19bf-4b27-a188-eafcf81de52d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_74a2f55c-2b8f-4bdd-820b-3c04ab67b330" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_5815f2cd-19bf-4b27-a188-eafcf81de52d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ehc-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b43d2a5-b2fc-4b58-84be-382afaee2417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b43d2a5-b2fc-4b58-84be-382afaee2417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4bcea883-56a7-4ef4-9b21-213b31cc14a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b43d2a5-b2fc-4b58-84be-382afaee2417" xlink:to="loc_us-gaap_ProfitLoss_4bcea883-56a7-4ef4-9b21-213b31cc14a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b7121910-b41d-4194-8994-b53269ff86c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b43d2a5-b2fc-4b58-84be-382afaee2417" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b7121910-b41d-4194-8994-b53269ff86c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b43d2a5-b2fc-4b58-84be-382afaee2417" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_b31ccf63-3a1a-4372-8cf6-bc3a5e09c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_LitigationSettlementExpense_b31ccf63-3a1a-4372-8cf6-bc3a5e09c2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5b0ccc59-b34e-4a5c-8ce4-8241b7b1a469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5b0ccc59-b34e-4a5c-8ce4-8241b7b1a469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_eeda0c18-c9b8-4368-8110-8d04a762645e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_eeda0c18-c9b8-4368-8110-8d04a762645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fec8452f-412a-4f41-9061-e12fe93acf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fec8452f-412a-4f41-9061-e12fe93acf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4089ebf3-fb00-4dd4-9231-3e992f792ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_4089ebf3-fb00-4dd4-9231-3e992f792ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_1658b833-e315-496a-b584-090fb485749a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_1658b833-e315-496a-b584-090fb485749a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_83d4cabe-f249-48d5-85eb-2c91ee9a8431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_ShareBasedCompensation_83d4cabe-f249-48d5-85eb-2c91ee9a8431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b34ebec9-96e2-415a-9cce-dc327c06c062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b34ebec9-96e2-415a-9cce-dc327c06c062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_405201dc-ea95-49d4-9407-5c1054c4a36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_405201dc-ea95-49d4-9407-5c1054c4a36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0e2b8876-e54f-4846-a772-883f587054b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0e2b8876-e54f-4846-a772-883f587054b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_659eab69-96f0-4a09-96f2-02f8dffca3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0e2b8876-e54f-4846-a772-883f587054b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_659eab69-96f0-4a09-96f2-02f8dffca3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_674f887a-db7e-4fa0-8111-da5b956b6675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0e2b8876-e54f-4846-a772-883f587054b6" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_674f887a-db7e-4fa0-8111-da5b956b6675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_448c1639-b500-470c-bcce-625a863fbbea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0e2b8876-e54f-4846-a772-883f587054b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_448c1639-b500-470c-bcce-625a863fbbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_9e5ccff2-3d97-4dac-a1e6-eb14f9c19c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0e2b8876-e54f-4846-a772-883f587054b6" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_9e5ccff2-3d97-4dac-a1e6-eb14f9c19c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_eb2e4abd-dc34-4272-92e3-23048514861c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0e2b8876-e54f-4846-a772-883f587054b6" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_eb2e4abd-dc34-4272-92e3-23048514861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f16af7fa-9ec4-443f-a710-f9cbc1a8c9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0e2b8876-e54f-4846-a772-883f587054b6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_f16af7fa-9ec4-443f-a710-f9cbc1a8c9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_8ac67299-304a-4ca7-afe1-7f4d295db270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_8ac67299-304a-4ca7-afe1-7f4d295db270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_68c45b8d-ea4a-4e08-ab5f-786c66d2df7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_92e06ae2-7b46-44ad-b368-12066f79d317" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_68c45b8d-ea4a-4e08-ab5f-786c66d2df7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbcd24ef-102d-4ef1-aded-cdcec696d562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0b43d2a5-b2fc-4b58-84be-382afaee2417" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cbcd24ef-102d-4ef1-aded-cdcec696d562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5521f603-d53d-438e-a726-bcc435533618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_5521f603-d53d-438e-a726-bcc435533618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f86ffe5f-c2ac-4af0-a660-4213cc52605e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f86ffe5f-c2ac-4af0-a660-4213cc52605e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_53ec2c49-bf16-437f-bd0c-4fcbc4c03f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_PaymentsForSoftware_53ec2c49-bf16-437f-bd0c-4fcbc4c03f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a6099bee-92e7-4192-842b-00d5438c2240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_a6099bee-92e7-4192-842b-00d5438c2240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_2dab23d0-7a15-42a1-99c2-88081aa17742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfRestrictedInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_ProceedsFromSaleOfRestrictedInvestments_2dab23d0-7a15-42a1-99c2-88081aa17742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_4398cd01-fbc1-4dfd-b893-ccfd03cf63fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireRestrictedInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_PaymentsToAcquireRestrictedInvestments_4398cd01-fbc1-4dfd-b893-ccfd03cf63fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_19236275-a3a4-4ebb-9986-f040a626d222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_19236275-a3a4-4ebb-9986-f040a626d222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_934cb08f-4c4b-42b3-867b-be03d4bc2a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_934cb08f-4c4b-42b3-867b-be03d4bc2a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f50342a6-111c-457f-b9fa-8d148a336283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9e5677ee-62d0-46a4-aed0-66379ad3d06a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f50342a6-111c-457f-b9fa-8d148a336283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_10be6948-81cf-4293-819f-a1f8dd40135c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_10be6948-81cf-4293-819f-a1f8dd40135c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_5299852c-fc19-4133-99f1-486310f40a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_5299852c-fc19-4133-99f1-486310f40a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_3147a3f6-3c03-45be-a609-cc169c84f333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_3147a3f6-3c03-45be-a609-cc169c84f333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_c2e522a5-4111-45b8-b6f0-bfebe7abc0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_c2e522a5-4111-45b8-b6f0-bfebe7abc0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_7506f534-5000-4b38-8537-8a8d011578b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_7506f534-5000-4b38-8537-8a8d011578b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_e510f673-727d-482f-886d-31860d90e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_e510f673-727d-482f-886d-31860d90e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3be872fd-ce11-402e-aa57-79180ec5e427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_3be872fd-ce11-402e-aa57-79180ec5e427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1c25342e-4a35-42e2-b706-3b48be028cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1c25342e-4a35-42e2-b706-3b48be028cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_79b4be02-74a4-4614-a040-fbdaba2af437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_79b4be02-74a4-4614-a040-fbdaba2af437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_4b2294de-a2ac-4162-be97-14e9410d002e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_4b2294de-a2ac-4162-be97-14e9410d002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_47e2248d-d752-49dc-a435-fabb0d582247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_47e2248d-d752-49dc-a435-fabb0d582247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5a1cfa64-5ad0-4cb6-81aa-db8767b6d0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5a1cfa64-5ad0-4cb6-81aa-db8767b6d0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributionsFromAffiliates_0ba4fc92-b07d-408a-9c01-80cf41ee8e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_ProceedsFromContributionsFromAffiliates_0ba4fc92-b07d-408a-9c01-80cf41ee8e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e2498e8f-e628-421c-8827-1e14380dc31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e2498e8f-e628-421c-8827-1e14380dc31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_3d3c48a4-4ea9-42e2-a425-3309314f2a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations_3d3c48a4-4ea9-42e2-a425-3309314f2a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43ce6895-2d17-4f10-959c-01a934b4fc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_164b1be1-c1c2-45fd-bda3-78a9962b4fe4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43ce6895-2d17-4f10-959c-01a934b4fc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_95485d5b-bdb7-4359-8dde-8050320f7f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_95485d5b-bdb7-4359-8dde-8050320f7f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f4cbc28-2fd4-4743-81d1-83c7381e07b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f4cbc28-2fd4-4743-81d1-83c7381e07b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7178aa1-a9c6-4d75-9caf-21597da7e7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7178aa1-a9c6-4d75-9caf-21597da7e7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0769b3ce-d44c-48b2-b5e1-7d92df71e005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0769b3ce-d44c-48b2-b5e1-7d92df71e005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ff27a0e0-302c-44a4-8bf1-50f42e4ddeca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_RestrictedCashCurrent_ff27a0e0-302c-44a4-8bf1-50f42e4ddeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e29cbb98-9558-4a8c-ade0-ac11004b6b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e29cbb98-9558-4a8c-ade0-ac11004b6b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_3771f2fd-239b-4b3a-a0a9-a1265d7c1256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_3771f2fd-239b-4b3a-a0a9-a1265d7c1256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54ec60fe-2d29-4b96-972f-10c2d5f1efc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_54ec60fe-2d29-4b96-972f-10c2d5f1efc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c414261c-5c7d-4df0-b1ff-6bfbc3a97cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c414261c-5c7d-4df0-b1ff-6bfbc3a97cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_edb135f0-7bf4-4072-9d54-a5ac540ae7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_RestrictedCashCurrent_edb135f0-7bf4-4072-9d54-a5ac540ae7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_127f47da-4702-4c43-a869-4d749268b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_127f47da-4702-4c43-a869-4d749268b3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_159ccbde-f958-43db-b0dc-eefe0c10e68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations_159ccbde-f958-43db-b0dc-eefe0c10e68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f302035d-1584-4b55-98b5-5a2af77d1e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_70928869-1260-4bd5-9843-19b702103322" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f302035d-1584-4b55-98b5-5a2af77d1e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_33825963-e172-42c5-9e3c-23c982ab9f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ccb19946-a7db-4d98-8438-e0c372956121" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_33825963-e172-42c5-9e3c-23c982ab9f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8e010b65-1e37-45c6-8145-5a7d6d0ae399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33825963-e172-42c5-9e3c-23c982ab9f14" xlink:to="loc_us-gaap_InterestPaidNet_8e010b65-1e37-45c6-8145-5a7d6d0ae399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIncomeTaxRefunds_829d922a-6390-497c-a018-6f9743781289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33825963-e172-42c5-9e3c-23c982ab9f14" xlink:to="loc_us-gaap_ProceedsFromIncomeTaxRefunds_829d922a-6390-497c-a018-6f9743781289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_3da5a103-b7dc-4e7c-a7d4-7a0d889a671c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_33825963-e172-42c5-9e3c-23c982ab9f14" xlink:to="loc_us-gaap_IncomeTaxesPaid_3da5a103-b7dc-4e7c-a7d4-7a0d889a671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5aa7d676-ae18-46f0-b747-77a14fad00e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8b989531-34ca-40ef-949f-398ab3a5139d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5aa7d676-ae18-46f0-b747-77a14fad00e4" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8b989531-34ca-40ef-949f-398ab3a5139d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusiness" xlink:type="simple" xlink:href="ehc-20221231.xsd#SpinOffofHomeHealthandHospiceBusiness"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9ebc9d70-ea99-47d6-b472-ad27b3379378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e898af52-bdd9-42ca-8b00-e9b63a4f8663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9ebc9d70-ea99-47d6-b472-ad27b3379378" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_e898af52-bdd9-42ca-8b00-e9b63a4f8663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9b10db97-8478-46f1-9834-a66440cf611f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7c1adf6f-d279-4bab-882a-5f838675660a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9b10db97-8478-46f1-9834-a66440cf611f" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7c1adf6f-d279-4bab-882a-5f838675660a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="simple" xlink:href="ehc-20221231.xsd#VariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68f54de4-f208-4eb9-9db3-d7a10524847c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_02426ee5-e3f4-42ad-93a4-e2fa84de6405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68f54de4-f208-4eb9-9db3-d7a10524847c" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_02426ee5-e3f4-42ad-93a4-e2fa84de6405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecurities" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_94f025d8-fa4b-4ebe-b837-d6163a1d47dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_696c23dd-5f92-4ad9-ac47-f48dfb0a1485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_94f025d8-fa4b-4ebe-b837-d6163a1d47dc" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_696c23dd-5f92-4ad9-ac47-f48dfb0a1485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AccountsReceivable" xlink:type="simple" xlink:href="ehc-20221231.xsd#AccountsReceivable"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/AccountsReceivable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_000ec3fa-41af-41d5-af15-707fb45cefa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_4c78e95e-e8c2-4129-bba1-9e5b0dfeeb05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_000ec3fa-41af-41d5-af15-707fb45cefa5" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_4c78e95e-e8c2-4129-bba1-9e5b0dfeeb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="ehc-20221231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_db3ed380-08b0-4cbc-b014-42772f69e93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_38d40efe-ea7b-45fb-a8f7-31aed77227ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_db3ed380-08b0-4cbc-b014-42772f69e93a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_38d40efe-ea7b-45fb-a8f7-31aed77227ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/Leases" xlink:type="simple" xlink:href="ehc-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_31e87c10-8814-4087-bd28-167caa82ba4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_2ed7d2a2-3ff5-4c22-9cdc-77f1bb4edddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_31e87c10-8814-4087-bd28-167caa82ba4c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_2ed7d2a2-3ff5-4c22-9cdc-77f1bb4edddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_6c2ba73a-01b4-4325-885b-b9797f1dd10e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_31e87c10-8814-4087-bd28-167caa82ba4c" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_6c2ba73a-01b4-4325-885b-b9797f1dd10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_027cb73b-e20f-4d01-a9ce-aeba5c9973b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_cba61d39-ffbc-45f5-b67f-2bc895b59d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_027cb73b-e20f-4d01-a9ce-aeba5c9973b9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_cba61d39-ffbc-45f5-b67f-2bc895b59d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1795b2af-5fe4-4257-a648-362ff16b1a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_d745bbc6-f9bc-4b79-b51e-adc5d88b8abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1795b2af-5fe4-4257-a648-362ff16b1a80" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_d745bbc6-f9bc-4b79-b51e-adc5d88b8abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisks" xlink:type="simple" xlink:href="ehc-20221231.xsd#SelfInsuredRisks"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisks" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_6ba1411a-bfd9-4ad3-9cb6-085899813034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_1fd88e5e-4179-470f-a9d2-cc0eb6243f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_6ba1411a-bfd9-4ad3-9cb6-085899813034" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_1fd88e5e-4179-470f-a9d2-cc0eb6243f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="simple" xlink:href="ehc-20221231.xsd#RedeemableNoncontrollingInterests"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_2f3eb8ab-20d7-4932-8246-5421a84510c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_582690f5-8bbe-49cd-9299-d031eff6bab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_2f3eb8ab-20d7-4932-8246-5421a84510c0" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_582690f5-8bbe-49cd-9299-d031eff6bab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ehc-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aae03e16-ed5a-4851-8d75-772a3395e30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ace2ca3f-b38f-4022-b8f3-07d3f703001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aae03e16-ed5a-4851-8d75-772a3395e30d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ace2ca3f-b38f-4022-b8f3-07d3f703001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPayments"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0bfa6e1d-846c-4990-98df-7f20dc0d0f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f33325b8-ef6b-40da-b5b4-6184910ae9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0bfa6e1d-846c-4990-98df-7f20dc0d0f2f" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_f33325b8-ef6b-40da-b5b4-6184910ae9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="ehc-20221231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_34697687-f802-46db-b97b-313663b205ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_91c67235-4178-4aae-983a-96e17c6c0120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_34697687-f802-46db-b97b-313663b205ba" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_91c67235-4178-4aae-983a-96e17c6c0120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b3807dc8-ce6d-465d-b3bb-aec72e0eefc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_8786bfe4-480e-4163-b1ad-4f836aa5b4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b3807dc8-ce6d-465d-b3bb-aec72e0eefc8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_8786bfe4-480e-4163-b1ad-4f836aa5b4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="simple" xlink:href="ehc-20221231.xsd#EarningsperCommonShare"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_af6190fe-dfb1-41da-8cb5-00a61b959ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_aeb35c14-934d-432d-82a5-ad0107b84a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_af6190fe-dfb1-41da-8cb5-00a61b959ca6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_aeb35c14-934d-432d-82a5-ad0107b84a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="simple" xlink:href="ehc-20221231.xsd#ContingenciesandOtherCommitments"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c3a61472-6e95-4877-a8dc-a46e109dbf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7ecb988d-ba1d-4e1c-a77f-0a1c2f0137dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c3a61472-6e95-4877-a8dc-a46e109dbf0f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7ecb988d-ba1d-4e1c-a77f-0a1c2f0137dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/QuarterlyDataUnaudited" xlink:type="simple" xlink:href="ehc-20221231.xsd#QuarterlyDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/QuarterlyDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_343261d7-5c8d-449f-95c5-7a60622da669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_c3d463c9-3a15-4de1-ac69-65ee3302d601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_343261d7-5c8d-449f-95c5-7a60622da669" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_c3d463c9-3a15-4de1-ac69-65ee3302d601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_694aff35-5045-4b7e-b960-13e42ab0fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_694aff35-5045-4b7e-b960-13e42ab0fcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_b8779133-afe0-416e-a5dc-7080534983ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_b8779133-afe0-416e-a5dc-7080534983ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1386e9af-9819-46ce-a868-038723dcd407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_UseOfEstimates_1386e9af-9819-46ce-a868-038723dcd407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7b6201ec-9c7e-4dd1-bf67-9c19e103d4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7b6201ec-9c7e-4dd1-bf67-9c19e103d4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d81e07d6-234c-46d4-8d3c-2587e5ecbdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d81e07d6-234c-46d4-8d3c-2587e5ecbdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_4c299d01-06d5-4a24-b3ca-883cda73a55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_4c299d01-06d5-4a24-b3ca-883cda73a55e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_8c9e30b3-81ca-4279-afea-4c2051112c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_8c9e30b3-81ca-4279-afea-4c2051112c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5c4a644e-db18-4489-8bb7-78b2442facb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5c4a644e-db18-4489-8bb7-78b2442facb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_5291cff3-46c7-410a-a262-a222151c8277" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_5291cff3-46c7-410a-a262-a222151c8277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b864e360-348a-4241-b520-0e244b6e35d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b864e360-348a-4241-b520-0e244b6e35d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_1764c900-d2c9-4949-bcb9-14c28f050036" xlink:href="ehc-20221231.xsd#ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock_1764c900-d2c9-4949-bcb9-14c28f050036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_409a81f9-6d18-4691-9c44-0222423d08f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_DebtPolicyTextBlock_409a81f9-6d18-4691-9c44-0222423d08f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_fd720301-185f-4024-8ce8-49030a7623ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_fd720301-185f-4024-8ce8-49030a7623ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_3f45bdf6-220e-484e-8424-ea2b0d718faa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_3f45bdf6-220e-484e-8424-ea2b0d718faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_aa3fce5a-b8a6-4f13-b9e6-54a801f56576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_aa3fce5a-b8a6-4f13-b9e6-54a801f56576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_3e75d2c2-e7ec-4fd9-b1a6-97e19eac45c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_3e75d2c2-e7ec-4fd9-b1a6-97e19eac45c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_bf37b1b3-db95-4a69-b060-7eaae32dff9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_bf37b1b3-db95-4a69-b060-7eaae32dff9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_bf3ad2c9-0598-4ba6-b5bb-33aa2974ad45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_bf3ad2c9-0598-4ba6-b5bb-33aa2974ad45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_854a2c3b-d936-4d8d-9366-ce3a289bac06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_854a2c3b-d936-4d8d-9366-ce3a289bac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_aa5d5903-1f3d-4039-a746-c944df51e2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_aa5d5903-1f3d-4039-a746-c944df51e2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_5fd4e798-f7b1-414a-9877-e764a15215b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_5fd4e798-f7b1-414a-9877-e764a15215b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62fe34b7-b679-4877-91ea-1a7b7b333619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_62fe34b7-b679-4877-91ea-1a7b7b333619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3a21c96e-21d7-46d9-8095-32bdf0cb6c79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_afd73a6e-57f5-48a3-aaaf-297798d1374a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3a21c96e-21d7-46d9-8095-32bdf0cb6c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_228e71c9-57cb-4d6d-9a4f-dc220668314e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0371202f-fd02-4d75-89d4-783bfaa0e532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_228e71c9-57cb-4d6d-9a4f-dc220668314e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_0371202f-fd02-4d75-89d4-783bfaa0e532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1f7e7e40-2ae6-4800-8b37-68ea0367824d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_228e71c9-57cb-4d6d-9a4f-dc220668314e" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1f7e7e40-2ae6-4800-8b37-68ea0367824d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_eceb3133-9939-43dc-8465-a7ff7d489fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_228e71c9-57cb-4d6d-9a4f-dc220668314e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_eceb3133-9939-43dc-8465-a7ff7d489fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_35a776a1-caa4-4482-b6c2-3e4fe539ec36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_228e71c9-57cb-4d6d-9a4f-dc220668314e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_35a776a1-caa4-4482-b6c2-3e4fe539ec36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_cae2562b-44b8-40d3-84a8-3a87d691a500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_228e71c9-57cb-4d6d-9a4f-dc220668314e" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_cae2562b-44b8-40d3-84a8-3a87d691a500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#SpinOffofHomeHealthandHospiceBusinessTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ee0c078f-e14a-4feb-b11c-42fa8b5d577f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_780307e2-85c0-4c82-9178-61ce51d2ed3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ee0c078f-e14a-4feb-b11c-42fa8b5d577f" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_780307e2-85c0-4c82-9178-61ce51d2ed3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_27e90af2-ca61-467c-bbca-cba2a0f09461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_be97b67e-465f-4d0a-bbf2-2d3dd1d3fad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_27e90af2-ca61-467c-bbca-cba2a0f09461" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_be97b67e-465f-4d0a-bbf2-2d3dd1d3fad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_aba3d612-70c7-4dbf-b2d2-a695b4871642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_27e90af2-ca61-467c-bbca-cba2a0f09461" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_aba3d612-70c7-4dbf-b2d2-a695b4871642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_eff3012f-84b5-49ee-9208-78365e710297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_27e90af2-ca61-467c-bbca-cba2a0f09461" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_eff3012f-84b5-49ee-9208-78365e710297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#VariableInterestEntitiesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72441d69-e532-4d76-b176-58de41cdebbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_fab69c2f-0c4d-4250-b770-8a4254850826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_72441d69-e532-4d76-b176-58de41cdebbb" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_fab69c2f-0c4d-4250-b770-8a4254850826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7efdd79d-7cdf-44e5-a25a-8535fbe83f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8974f73e-f9da-46f0-8623-655e026639b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7efdd79d-7cdf-44e5-a25a-8535fbe83f0c" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8974f73e-f9da-46f0-8623-655e026639b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_361ee742-ae50-4224-9aad-206d64872289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7efdd79d-7cdf-44e5-a25a-8535fbe83f0c" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_361ee742-ae50-4224-9aad-206d64872289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_bc0c9481-483b-4269-a342-b7a5b46f1551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7efdd79d-7cdf-44e5-a25a-8535fbe83f0c" xlink:to="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_bc0c9481-483b-4269-a342-b7a5b46f1551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AccountsReceivableTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#AccountsReceivableTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/AccountsReceivableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_39bc5222-91b9-4cce-a115-d1b6732de27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_35f7c536-b9f6-4d97-9031-83c240f167e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_39bc5222-91b9-4cce-a115-d1b6732de27f" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_35f7c536-b9f6-4d97-9031-83c240f167e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e8d2522-7b8a-4a3f-adf2-c82a55729fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c4b7c2e0-0996-4b96-9fac-e2ac4efedb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e8d2522-7b8a-4a3f-adf2-c82a55729fe1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c4b7c2e0-0996-4b96-9fac-e2ac4efedb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_c8c3a228-a90b-4b57-9829-c959d7435a1c" xlink:href="ehc-20221231.xsd#ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3e8d2522-7b8a-4a3f-adf2-c82a55729fe1" xlink:to="loc_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock_c8c3a228-a90b-4b57-9829-c959d7435a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2b6f25cb-47dd-4665-be16-59bfaa116e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_6e51f392-69b2-459f-a05f-0958227985c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b6f25cb-47dd-4665-be16-59bfaa116e49" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_6e51f392-69b2-459f-a05f-0958227985c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_7279a9e9-30c2-4aee-a7ae-efd5f92b0d71" xlink:href="ehc-20221231.xsd#ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b6f25cb-47dd-4665-be16-59bfaa116e49" xlink:to="loc_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock_7279a9e9-30c2-4aee-a7ae-efd5f92b0d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_82b75f73-8e39-4cae-b7c7-e9f3869719c2" xlink:href="ehc-20221231.xsd#ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b6f25cb-47dd-4665-be16-59bfaa116e49" xlink:to="loc_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock_82b75f73-8e39-4cae-b7c7-e9f3869719c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ebe04da3-1b9e-46c0-b433-c1ace7ced39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b6f25cb-47dd-4665-be16-59bfaa116e49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ebe04da3-1b9e-46c0-b433-c1ace7ced39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_82b48617-c80a-4f06-bdd9-c25ac349217b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b6f25cb-47dd-4665-be16-59bfaa116e49" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_82b48617-c80a-4f06-bdd9-c25ac349217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SupplementalCashFlowInformationTableTextBlock_02944241-0169-4e21-94ce-e1d729475c04" xlink:href="ehc-20221231.xsd#ehc_SupplementalCashFlowInformationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2b6f25cb-47dd-4665-be16-59bfaa116e49" xlink:to="loc_ehc_SupplementalCashFlowInformationTableTextBlock_02944241-0169-4e21-94ce-e1d729475c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07fcfaca-bc18-4a72-beda-2c57c0024402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_2bab72a9-b52c-4f1b-a579-778e055f0bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07fcfaca-bc18-4a72-beda-2c57c0024402" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_2bab72a9-b52c-4f1b-a579-778e055f0bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05dc260b-91aa-4257-aae3-45e835975dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07fcfaca-bc18-4a72-beda-2c57c0024402" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_05dc260b-91aa-4257-aae3-45e835975dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_dbeb6e51-a677-48ff-a26e-5cfaf18a76d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07fcfaca-bc18-4a72-beda-2c57c0024402" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_dbeb6e51-a677-48ff-a26e-5cfaf18a76d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1fe9ebdf-7fda-4597-96c5-33205917ea84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_07fcfaca-bc18-4a72-beda-2c57c0024402" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1fe9ebdf-7fda-4597-96c5-33205917ea84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d56ec67e-1b19-4eb7-a940-b28a5e5dc8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_18ce0751-02bd-42aa-abf8-b78618198050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d56ec67e-1b19-4eb7-a940-b28a5e5dc8f9" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_18ce0751-02bd-42aa-abf8-b78618198050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3ae926ab-19de-48da-a4e1-a303086455bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d56ec67e-1b19-4eb7-a940-b28a5e5dc8f9" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_3ae926ab-19de-48da-a4e1-a303086455bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock_3a93cc37-3f52-4d6d-81b3-48a05da7ab22" xlink:href="ehc-20221231.xsd#ehc_ScheduleOfFinancialCovenantsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d56ec67e-1b19-4eb7-a940-b28a5e5dc8f9" xlink:to="loc_ehc_ScheduleOfFinancialCovenantsTableTextBlock_3a93cc37-3f52-4d6d-81b3-48a05da7ab22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock_a8b67d10-728f-4c77-972b-f553f3bfcc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d56ec67e-1b19-4eb7-a940-b28a5e5dc8f9" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTableTextBlock_a8b67d10-728f-4c77-972b-f553f3bfcc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#SelfInsuredRisksTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisksTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_8be9ea76-af37-405e-97bb-afa6a2418a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_06f1bce4-2541-46e4-8962-e11914d3087d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_8be9ea76-af37-405e-97bb-afa6a2418a3e" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_06f1bce4-2541-46e4-8962-e11914d3087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#RedeemableNoncontrollingInterestsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_d6efc3cd-b782-4d25-aea8-0dbed9c56dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_99b1ce74-8679-4754-b2f3-c6e1ddb28a35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_d6efc3cd-b782-4d25-aea8-0dbed9c56dc3" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestTableTextBlock_99b1ce74-8679-4754-b2f3-c6e1ddb28a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_522e5fa4-4993-4547-a3cd-336484890aab" xlink:href="ehc-20221231.xsd#ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_d6efc3cd-b782-4d25-aea8-0dbed9c56dc3" xlink:to="loc_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock_522e5fa4-4993-4547-a3cd-336484890aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3a29d9a0-7f26-4888-8736-01d39888d4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a41552eb-57f0-4f0e-ab23-65a93b2d5d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3a29d9a0-7f26-4888-8736-01d39888d4e5" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a41552eb-57f0-4f0e-ab23-65a93b2d5d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_179727d0-6cf9-48d7-9630-6b281cad56de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3a29d9a0-7f26-4888-8736-01d39888d4e5" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_179727d0-6cf9-48d7-9630-6b281cad56de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9903c08d-1ea2-4901-81cb-bd13a65b9802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ac659f9-c781-400a-8067-f432d26da0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9903c08d-1ea2-4901-81cb-bd13a65b9802" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6ac659f9-c781-400a-8067-f432d26da0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b57ed862-6007-4047-8fb5-b939cb8597fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9903c08d-1ea2-4901-81cb-bd13a65b9802" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b57ed862-6007-4047-8fb5-b939cb8597fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_edfab0df-9773-4b6a-8938-d8ceb6705c78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9903c08d-1ea2-4901-81cb-bd13a65b9802" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_edfab0df-9773-4b6a-8938-d8ceb6705c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_10392734-ac83-4fd1-97e9-fad505d1bdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_85c88d64-e37d-41e0-aa1c-f5971555a351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_10392734-ac83-4fd1-97e9-fad505d1bdf8" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_85c88d64-e37d-41e0-aa1c-f5971555a351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_307b85e4-b530-4008-ade4-24af702482f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_10392734-ac83-4fd1-97e9-fad505d1bdf8" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_307b85e4-b530-4008-ade4-24af702482f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_17db6178-da0a-4295-855c-818d8409d657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_10392734-ac83-4fd1-97e9-fad505d1bdf8" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_17db6178-da0a-4295-855c-818d8409d657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#EarningsPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3b87a582-d04e-4842-aa22-41604f71f94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5439d0b3-82a1-44ae-bc40-b54b1b7d512b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3b87a582-d04e-4842-aa22-41604f71f94a" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5439d0b3-82a1-44ae-bc40-b54b1b7d512b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_c224272e-86c4-413e-b15a-9910beb67cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3b87a582-d04e-4842-aa22-41604f71f94a" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_c224272e-86c4-413e-b15a-9910beb67cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/QuarterlyDataUnauditedTables" xlink:type="simple" xlink:href="ehc-20221231.xsd#QuarterlyDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/QuarterlyDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_a1ac6749-030a-45fc-946c-93ef40ce9d49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2f07ef83-b0a8-43b0-b03d-92298e4734b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_a1ac6749-030a-45fc-946c-93ef40ce9d49" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_2f07ef83-b0a8-43b0-b03d-92298e4734b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ba461af9-2ffa-4ca5-8362-3ac2f0efec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ba461af9-2ffa-4ca5-8362-3ac2f0efec4e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb683c1d-5c93-4400-8ca4-5990e4ff3ade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_srt_RangeAxis_cb683c1d-5c93-4400-8ca4-5990e4ff3ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_457181d8-27ad-4414-aae1-f4754b53b035" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cb683c1d-5c93-4400-8ca4-5990e4ff3ade" xlink:to="loc_srt_RangeMember_457181d8-27ad-4414-aae1-f4754b53b035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5c9dc6c9-957f-4cf1-b67d-edbeeb0510de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_457181d8-27ad-4414-aae1-f4754b53b035" xlink:to="loc_srt_MinimumMember_5c9dc6c9-957f-4cf1-b67d-edbeeb0510de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_660c865e-cc1b-47a9-9588-b121afb142ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_457181d8-27ad-4414-aae1-f4754b53b035" xlink:to="loc_srt_MaximumMember_660c865e-cc1b-47a9-9588-b121afb142ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_805e0178-41bd-41c0-bfff-2af8ce42c445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_805e0178-41bd-41c0-bfff-2af8ce42c445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_67dcfe2d-c4b4-4d28-afc3-60b343aeeec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_805e0178-41bd-41c0-bfff-2af8ce42c445" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_67dcfe2d-c4b4-4d28-afc3-60b343aeeec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember_8ea09059-3654-4a73-8a8e-6c00f4bc227b" xlink:href="ehc-20221231.xsd#ehc_PayorSourceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_67dcfe2d-c4b4-4d28-afc3-60b343aeeec7" xlink:to="loc_ehc_PayorSourceMember_8ea09059-3654-4a73-8a8e-6c00f4bc227b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9d7492b0-5ae6-4873-8504-348deb42abfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9d7492b0-5ae6-4873-8504-348deb42abfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b3ccd4b-9af4-4861-820c-58e7151bb396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9d7492b0-5ae6-4873-8504-348deb42abfa" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b3ccd4b-9af4-4861-820c-58e7151bb396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_18cc2d8a-e023-4452-afcd-3673d69d5999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2b3ccd4b-9af4-4861-820c-58e7151bb396" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_18cc2d8a-e023-4452-afcd-3673d69d5999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b33700da-8fad-46cb-90d3-34910b5c6495" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_srt_CounterpartyNameAxis_b33700da-8fad-46cb-90d3-34910b5c6495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26c54555-8805-4b4c-9a4d-45ffd95d8b35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b33700da-8fad-46cb-90d3-34910b5c6495" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26c54555-8805-4b4c-9a4d-45ffd95d8b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_1a22908a-bdb9-488f-a54b-ed8243dfe653" xlink:href="ehc-20221231.xsd#ehc_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26c54555-8805-4b4c-9a4d-45ffd95d8b35" xlink:to="loc_ehc_MedicareMember_1a22908a-bdb9-488f-a54b-ed8243dfe653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_394f62fc-fc36-40f6-8a8e-cf7aabb17dfe" xlink:to="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DepartmentAppealsBoardAdverseRulingMember_623f751b-a219-469d-a256-946a21ae2d04" xlink:href="ehc-20221231.xsd#ehc_DepartmentAppealsBoardAdverseRulingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:to="loc_ehc_DepartmentAppealsBoardAdverseRulingMember_623f751b-a219-469d-a256-946a21ae2d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_UnifiedProgramIntegrityContractorsAuditsMember_81e4ca47-f4be-432e-945a-d777da4e4e1d" xlink:href="ehc-20221231.xsd#ehc_UnifiedProgramIntegrityContractorsAuditsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:to="loc_ehc_UnifiedProgramIntegrityContractorsAuditsMember_81e4ca47-f4be-432e-945a-d777da4e4e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RACAuditsMember_6c4c9d58-da1f-4c63-a6e2-07006be70dc1" xlink:href="ehc-20221231.xsd#ehc_RACAuditsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_1cde9426-c43c-4773-9009-95308d29a399" xlink:to="loc_ehc_RACAuditsMember_6c4c9d58-da1f-4c63-a6e2-07006be70dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_724ab165-9bef-48fa-9679-21f6dc5481a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2f9b4d2a-3eba-441d-89ad-59d0a9a8c54d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_724ab165-9bef-48fa-9679-21f6dc5481a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_ba542229-3df6-45cb-b3a4-c695bbca7ae2" xlink:href="ehc-20221231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_724ab165-9bef-48fa-9679-21f6dc5481a1" xlink:to="loc_ehc_MarketAccessAssetsMember_ba542229-3df6-45cb-b3a4-c695bbca7ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d00b655e-6ec3-4972-9348-8fd02911292d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_4a881725-be58-4d2e-a7e9-98b1f8b71802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_4a881725-be58-4d2e-a7e9-98b1f8b71802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitals_75d48f8f-202f-4939-8a76-5ba59c37f12c" xlink:href="ehc-20221231.xsd#ehc_NumberOfInpatientRehabilitationHospitals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitals_75d48f8f-202f-4939-8a76-5ba59c37f12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership_fb23b1c8-da57-42f5-8ac7-4e9ef8244344" xlink:href="ehc-20221231.xsd#ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership_fb23b1c8-da57-42f5-8ac7-4e9ef8244344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Jointventureownershippercentage_95e2719a-fab1-4d6c-bd5c-60abf3c23a6f" xlink:href="ehc-20221231.xsd#ehc_Jointventureownershippercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_Jointventureownershippercentage_95e2719a-fab1-4d6c-bd5c-60abf3c23a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals_a372221e-3f54-46aa-a124-63854483a268" xlink:href="ehc-20221231.xsd#ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals_a372221e-3f54-46aa-a124-63854483a268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyClaimsAwaitingReviewAmount_5f3bafb2-80cc-42b3-9202-baafa33c474b" xlink:href="ehc-20221231.xsd#ehc_LossContingencyClaimsAwaitingReviewAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyClaimsAwaitingReviewAmount_5f3bafb2-80cc-42b3-9202-baafa33c474b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAppealedClaimsDeniedAmount_daf7bce1-ff65-4431-905b-b769fb4d9674" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAppealedClaimsDeniedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyAppealedClaimsDeniedAmount_daf7bce1-ff65-4431-905b-b769fb4d9674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyNumberOfClaimsSampledForAudit_f4476c62-551e-4b35-8afc-14533b3c3eaa" xlink:href="ehc-20221231.xsd#ehc_LossContingencyNumberOfClaimsSampledForAudit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyNumberOfClaimsSampledForAudit_f4476c62-551e-4b35-8afc-14533b3c3eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyClaimsSampledForAuditAmount_6f5b7aa0-ca28-4f90-8361-583c6f886924" xlink:href="ehc-20221231.xsd#ehc_LossContingencyClaimsSampledForAuditAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyClaimsSampledForAuditAmount_6f5b7aa0-ca28-4f90-8361-583c6f886924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyExtrapolatedErrorRatePeriod_9d76ca9f-60b5-43d9-b4f3-22bac972c510" xlink:href="ehc-20221231.xsd#ehc_LossContingencyExtrapolatedErrorRatePeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyExtrapolatedErrorRatePeriod_9d76ca9f-60b5-43d9-b4f3-22bac972c510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount_93b74103-29cd-44e8-a6c8-83b1dd08e83b" xlink:href="ehc-20221231.xsd#ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount_93b74103-29cd-44e8-a6c8-83b1dd08e83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination_ba840c1e-a4e6-4619-a0a9-dfe63f7343c7" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination_ba840c1e-a4e6-4619-a0a9-dfe63f7343c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest_5d0b5eb1-632a-4600-b4dd-a085860c7281" xlink:href="ehc-20221231.xsd#ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest_5d0b5eb1-632a-4600-b4dd-a085860c7281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fa075fc2-bdeb-4519-aca4-f4011e0f23b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fa075fc2-bdeb-4519-aca4-f4011e0f23b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_269320d0-aa0b-46d6-9dfe-6ff11bf3a189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_269320d0-aa0b-46d6-9dfe-6ff11bf3a189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_8868de80-1e11-4fa0-b098-d5d1fc43c86a" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold_8868de80-1e11-4fa0-b098-d5d1fc43c86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_df81d028-cec3-4fe8-ae19-781d2b54d9ec" xlink:href="ehc-20221231.xsd#ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees_df81d028-cec3-4fe8-ae19-781d2b54d9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_a88aff10-cee9-4566-9702-297b5e85f5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_16d1d090-c4a9-4479-90c0-cc8e7f0bbaef" xlink:to="loc_us-gaap_AdvertisingExpense_a88aff10-cee9-4566-9702-297b5e85f5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_29e38f14-2db8-47ad-97ef-a15065a544fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6aff50cf-b536-4a4e-9210-7ced34ae49ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_29e38f14-2db8-47ad-97ef-a15065a544fe" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6aff50cf-b536-4a4e-9210-7ced34ae49ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e10cfc57-e4dd-436d-a38c-0f3b07f6922a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6aff50cf-b536-4a4e-9210-7ced34ae49ca" xlink:to="loc_srt_CounterpartyNameAxis_e10cfc57-e4dd-436d-a38c-0f3b07f6922a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e10cfc57-e4dd-436d-a38c-0f3b07f6922a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_c59ecd4c-7e20-468e-a4fc-3c7c1167c4ea" xlink:href="ehc-20221231.xsd#ehc_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_MedicareMember_c59ecd4c-7e20-468e-a4fc-3c7c1167c4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareAdvantageMember_50ed0b93-86a4-4984-9490-9c9e6687f22e" xlink:href="ehc-20221231.xsd#ehc_MedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_MedicareAdvantageMember_50ed0b93-86a4-4984-9490-9c9e6687f22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMember_7c614c1c-8100-4513-a888-166bae51ea35" xlink:href="ehc-20221231.xsd#ehc_ManagedCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_ManagedCareMember_7c614c1c-8100-4513-a888-166bae51ea35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_145e69d9-b36f-4b56-8194-93269385f289" xlink:href="ehc-20221231.xsd#ehc_MedicaidMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_MedicaidMember_145e69d9-b36f-4b56-8194-93269385f289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_b2534fcd-718a-40dc-8296-617440ab0d75" xlink:href="ehc-20221231.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_b2534fcd-718a-40dc-8296-617440ab0d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_4c11f4e0-b65f-400a-896b-c372442669e7" xlink:href="ehc-20221231.xsd#ehc_WorkersCompensationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_WorkersCompensationMember_4c11f4e0-b65f-400a-896b-c372442669e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_ac5ffd5b-f406-4aa2-bdfb-e7c3c74056eb" xlink:href="ehc-20221231.xsd#ehc_PatientsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_PatientsMember_ac5ffd5b-f406-4aa2-bdfb-e7c3c74056eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherIncomeSourceMember_692e298c-4617-4bd1-9b99-75a854713bc6" xlink:href="ehc-20221231.xsd#ehc_OtherIncomeSourceMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_607dccd3-6883-453f-9d1f-cc4bf49b41bd" xlink:to="loc_ehc_OtherIncomeSourceMember_692e298c-4617-4bd1-9b99-75a854713bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8bd8b2b2-2dd4-4961-b6fa-37c654414086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6aff50cf-b536-4a4e-9210-7ced34ae49ca" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8bd8b2b2-2dd4-4961-b6fa-37c654414086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bbb834a5-44b9-4ebc-9a22-5a3d3da891ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8bd8b2b2-2dd4-4961-b6fa-37c654414086" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bbb834a5-44b9-4ebc-9a22-5a3d3da891ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d7c43bdc-3392-41a7-a81d-5312482d47f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7c43bdc-3392-41a7-a81d-5312482d47f6" xlink:to="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e4460344-f9a8-42b8-95c8-e10798dca697" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e4460344-f9a8-42b8-95c8-e10798dca697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_35852916-8a14-4427-b510-fa75b8c87a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4460344-f9a8-42b8-95c8-e10798dca697" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_35852916-8a14-4427-b510-fa75b8c87a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PayorSourceMember_7f7ccdd4-2ab7-4ada-ac1d-5ca393127bb4" xlink:href="ehc-20221231.xsd#ehc_PayorSourceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_35852916-8a14-4427-b510-fa75b8c87a33" xlink:to="loc_ehc_PayorSourceMember_7f7ccdd4-2ab7-4ada-ac1d-5ca393127bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_69030d55-d694-4303-b627-10fd2ac8b135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_dc1c7d0d-5ea8-4a74-8730-4cfe622bec32" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_69030d55-d694-4303-b627-10fd2ac8b135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_8fa6e092-62e8-496c-971e-d5b4b6e47c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_69030d55-d694-4303-b627-10fd2ac8b135" xlink:to="loc_us-gaap_AccountsReceivableMember_8fa6e092-62e8-496c-971e-d5b4b6e47c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f63e837f-53ae-46ba-8c24-f852ea85c2a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_srt_CounterpartyNameAxis_f63e837f-53ae-46ba-8c24-f852ea85c2a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f63e837f-53ae-46ba-8c24-f852ea85c2a6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicareMember_6c4b833f-0288-4dd8-ade9-20202d4478eb" xlink:href="ehc-20221231.xsd#ehc_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_MedicareMember_6c4b833f-0288-4dd8-ade9-20202d4478eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_c8951776-a983-4f5e-b95d-6316805b5b11" xlink:href="ehc-20221231.xsd#ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember_c8951776-a983-4f5e-b95d-6316805b5b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MedicaidMember_2818411c-ce7e-4206-b8a6-3d1ed08ac6ca" xlink:href="ehc-20221231.xsd#ehc_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_MedicaidMember_2818411c-ce7e-4206-b8a6-3d1ed08ac6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherThirdpartyPayorsMember_90f3864f-802c-4836-802b-99c54dc5838d" xlink:href="ehc-20221231.xsd#ehc_OtherThirdpartyPayorsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_OtherThirdpartyPayorsMember_90f3864f-802c-4836-802b-99c54dc5838d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WorkersCompensationMember_a1eebdd8-86f3-4fb0-8cb7-e616dcd98005" xlink:href="ehc-20221231.xsd#ehc_WorkersCompensationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_WorkersCompensationMember_a1eebdd8-86f3-4fb0-8cb7-e616dcd98005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PatientsMember_c290221c-636e-4276-a368-824d4049c7c2" xlink:href="ehc-20221231.xsd#ehc_PatientsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_59a942da-0cca-4880-9082-47d8f3f3a539" xlink:to="loc_ehc_PatientsMember_c290221c-636e-4276-a368-824d4049c7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_ec40c33d-f63e-4e64-9e18-a86ca74eb18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_ec40c33d-f63e-4e64-9e18-a86ca74eb18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_bae19a40-a533-47e8-a9f6-51c4a091ff66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesAxis_ec40c33d-f63e-4e64-9e18-a86ca74eb18a" xlink:to="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_bae19a40-a533-47e8-a9f6-51c4a091ff66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ThirdPartyPayorMember_3e29975a-bdeb-427b-bff7-db19c03303fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ThirdPartyPayorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_bae19a40-a533-47e8-a9f6-51c4a091ff66" xlink:to="loc_us-gaap_ThirdPartyPayorMember_3e29975a-bdeb-427b-bff7-db19c03303fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfPayMember_f92200fe-314f-4f21-b3f5-da40fd13f3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfPayMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HealthCareOrganizationRevenueSourcesDomain_bae19a40-a533-47e8-a9f6-51c4a091ff66" xlink:to="loc_us-gaap_SelfPayMember_f92200fe-314f-4f21-b3f5-da40fd13f3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_0f484f8a-a8c3-4417-9546-b7b6be686858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8ec5d733-034d-4467-acab-da511739004c" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_0f484f8a-a8c3-4417-9546-b7b6be686858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1c8e63d8-c5f4-4eab-96bb-f845c5c11da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_0f484f8a-a8c3-4417-9546-b7b6be686858" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1c8e63d8-c5f4-4eab-96bb-f845c5c11da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_89ecc36f-81e8-4abe-a031-9b3d4ce02714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_89ecc36f-81e8-4abe-a031-9b3d4ce02714" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951cfb32-a997-4ace-be47-fbb5061a2354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951cfb32-a997-4ace-be47-fbb5061a2354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_951cfb32-a997-4ace-be47-fbb5061a2354" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_13d6e003-f295-4f5c-b019-5ddffd617b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:to="loc_us-gaap_BuildingMember_13d6e003-f295-4f5c-b019-5ddffd617b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_49a3e3be-e4b0-477a-8445-af03077af984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_49a3e3be-e4b0-477a-8445-af03077af984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_a54c63e7-17e5-4ab6-b362-03a477ed9c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:to="loc_us-gaap_VehiclesMember_a54c63e7-17e5-4ab6-b362-03a477ed9c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c73ffa0a-461c-4ed8-bb7f-5f10cd732a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae50ef2b-04f7-4810-aa03-57355c97271d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c73ffa0a-461c-4ed8-bb7f-5f10cd732a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_18333ca7-eb84-4cc8-8f97-2b1a590de63c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:to="loc_srt_RangeAxis_18333ca7-eb84-4cc8-8f97-2b1a590de63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03eed013-cd5e-4ed3-b74f-1b8bd7b39a90" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_18333ca7-eb84-4cc8-8f97-2b1a590de63c" xlink:to="loc_srt_RangeMember_03eed013-cd5e-4ed3-b74f-1b8bd7b39a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a50bd660-3c6f-46ab-b7fa-149868e3afa3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_03eed013-cd5e-4ed3-b74f-1b8bd7b39a90" xlink:to="loc_srt_MinimumMember_a50bd660-3c6f-46ab-b7fa-149868e3afa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_00ef55ca-b185-4ddf-8e77-5198a5864446" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_03eed013-cd5e-4ed3-b74f-1b8bd7b39a90" xlink:to="loc_srt_MaximumMember_00ef55ca-b185-4ddf-8e77-5198a5864446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_382a44e4-2831-451a-84fe-e7cd491b4ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b6599c54-f3c0-4305-9237-0a7b0ca1ec08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_382a44e4-2831-451a-84fe-e7cd491b4ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_87acf37c-2bb7-4b82-a5d3-f36031e67f29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_382a44e4-2831-451a-84fe-e7cd491b4ba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_87acf37c-2bb7-4b82-a5d3-f36031e67f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7338cb4b-be12-4ea2-b41e-02b72b966a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7338cb4b-be12-4ea2-b41e-02b72b966a85" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ed0784fc-62a4-4231-85fb-afb196098192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ed0784fc-62a4-4231-85fb-afb196098192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ed0784fc-62a4-4231-85fb-afb196098192" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_53bc405e-aa62-475d-b61b-06d1f640b1b6" xlink:href="ehc-20221231.xsd#ehc_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_ehc_CertificateOfNeedMember_53bc405e-aa62-475d-b61b-06d1f640b1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5f176eb0-859a-437c-8d07-1cc38447650e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_us-gaap_LicensingAgreementsMember_5f176eb0-859a-437c-8d07-1cc38447650e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_9bbb0b52-2140-47e4-ad3f-99bfd11e6df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_9bbb0b52-2140-47e4-ad3f-99bfd11e6df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_2a7c64f5-c529-43ec-9fed-dc512b4e50be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_us-gaap_TradeNamesMember_2a7c64f5-c529-43ec-9fed-dc512b4e50be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InternalUseSoftwareMember_061d5ae7-4094-4fac-b74a-c20296a386f9" xlink:href="ehc-20221231.xsd#ehc_InternalUseSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_ehc_InternalUseSoftwareMember_061d5ae7-4094-4fac-b74a-c20296a386f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_58f2ae65-740c-42ae-9c5f-7266f180c74d" xlink:href="ehc-20221231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_095fd942-3bb5-4050-bbe5-9fdc252a9031" xlink:to="loc_ehc_MarketAccessAssetsMember_58f2ae65-740c-42ae-9c5f-7266f180c74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_950329ff-c579-43fb-ae8e-aa432a27d053" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:to="loc_srt_RangeAxis_950329ff-c579-43fb-ae8e-aa432a27d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0bca2b5-70bc-40a3-bf81-1db691810063" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_950329ff-c579-43fb-ae8e-aa432a27d053" xlink:to="loc_srt_RangeMember_e0bca2b5-70bc-40a3-bf81-1db691810063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b0d3ad32-d1f7-418a-8fdf-0b8a02c1ec8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0bca2b5-70bc-40a3-bf81-1db691810063" xlink:to="loc_srt_MinimumMember_b0d3ad32-d1f7-418a-8fdf-0b8a02c1ec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_14fae65e-06ee-4fce-8761-c74f006ee937" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0bca2b5-70bc-40a3-bf81-1db691810063" xlink:to="loc_srt_MaximumMember_14fae65e-06ee-4fce-8761-c74f006ee937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b629af96-61b0-4f03-aaed-499fa12a045d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3d586990-956a-4d16-9bd0-4bb3840ffb11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b629af96-61b0-4f03-aaed-499fa12a045d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee966d34-4ce0-4c0e-8836-a220fd39d6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_b629af96-61b0-4f03-aaed-499fa12a045d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee966d34-4ce0-4c0e-8836-a220fd39d6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SpinOffofHomeHealthandHospiceBusinessTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c970fb4c-9935-4a5f-b1ec-5fe7430fd912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c970fb4c-9935-4a5f-b1ec-5fe7430fd912" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7cd1bec5-7245-4aad-999e-e608bad41213" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_dei_LegalEntityAxis_7cd1bec5-7245-4aad-999e-e608bad41213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d1e7967c-f130-4204-aa33-deebb1cf3584" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7cd1bec5-7245-4aad-999e-e608bad41213" xlink:to="loc_dei_EntityDomain_d1e7967c-f130-4204-aa33-deebb1cf3584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember_cb068502-0771-4e3d-8ba4-5df9aa211275" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d1e7967c-f130-4204-aa33-deebb1cf3584" xlink:to="loc_ehc_EnhabitMember_cb068502-0771-4e3d-8ba4-5df9aa211275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6bcf021-7910-42d2-9754-e76637d36e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0ae07160-c6a4-4365-9b3f-4731f0ce9a1a" xlink:to="loc_us-gaap_EquityComponentDomain_a6bcf021-7910-42d2-9754-e76637d36e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_236dba7d-29d9-4f1c-af11-9a2c3475b5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6bcf021-7910-42d2-9754-e76637d36e5b" xlink:to="loc_us-gaap_CommonStockMember_236dba7d-29d9-4f1c-af11-9a2c3475b5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6cd78a0e-b1e5-43e9-817b-1fa63c563e26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6cd78a0e-b1e5-43e9-817b-1fa63c563e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_414f81f3-1a9e-425c-b987-788821295cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6cd78a0e-b1e5-43e9-817b-1fa63c563e26" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_414f81f3-1a9e-425c-b987-788821295cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember_0dee43b8-cafe-4894-840c-07bbb6697f66" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_414f81f3-1a9e-425c-b987-788821295cf6" xlink:to="loc_ehc_EnhabitMember_0dee43b8-cafe-4894-840c-07bbb6697f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5e38c01d-ceae-45df-9ba3-3ab1fb52f061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8a0249a-6ec9-42f3-a03d-4bfb119c25ee" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5e38c01d-ceae-45df-9ba3-3ab1fb52f061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_8b970b16-6adc-46cf-a4fe-3095106a4a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5e38c01d-ceae-45df-9ba3-3ab1fb52f061" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_8b970b16-6adc-46cf-a4fe-3095106a4a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8c1fee6e-e806-4512-9f82-d16d62e39ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_f1ee18fa-2fe4-463e-8183-f352ff0ee2c3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8c1fee6e-e806-4512-9f82-d16d62e39ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_ebf6998e-714f-4323-887c-39ad82019dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8c1fee6e-e806-4512-9f82-d16d62e39ec9" xlink:to="loc_us-gaap_TradeNamesMember_ebf6998e-714f-4323-887c-39ad82019dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cb5ba886-bfb6-44ca-8dcb-9429f05eda97" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_be46f429-1cd9-4635-92c6-9e7f4d7a871e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_be46f429-1cd9-4635-92c6-9e7f4d7a871e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_04a1fee2-b184-4016-b4d7-4e68ea0d2849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_04a1fee2-b184-4016-b4d7-4e68ea0d2849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9e16e0f4-1440-47d5-b7ac-3597304840f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9e16e0f4-1440-47d5-b7ac-3597304840f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8696c745-64b7-421f-8ce1-8f93e59dfef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_8696c745-64b7-421f-8ce1-8f93e59dfef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm_b5449400-7037-465e-a857-bd9b09008449" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm_b5449400-7037-465e-a857-bd9b09008449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome_6c10d542-6f1c-41dc-9abc-aa62111d2e4e" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome_6c10d542-6f1c-41dc-9abc-aa62111d2e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_6915191e-7bd5-4020-ab5a-97cbe114977f" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_3fe0157d-c39f-4116-a294-c3ebbdfa9a84" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts_6915191e-7bd5-4020-ab5a-97cbe114977f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c31405d8-999b-48b6-a66f-46bc476bdb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_c31405d8-999b-48b6-a66f-46bc476bdb67" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2269a1b3-25ee-41e3-a9f7-d15d45228603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2269a1b3-25ee-41e3-a9f7-d15d45228603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af236ca9-b1be-4441-bae2-36cb63dd8216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_2269a1b3-25ee-41e3-a9f7-d15d45228603" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af236ca9-b1be-4441-bae2-36cb63dd8216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember_03dee694-d87f-42ce-bf75-08b6f8bb533e" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_af236ca9-b1be-4441-bae2-36cb63dd8216" xlink:to="loc_ehc_EnhabitMember_03dee694-d87f-42ce-bf75-08b6f8bb533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7c58f671-90e4-4ba9-807f-472435682848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7c58f671-90e4-4ba9-807f-472435682848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_76520308-ddc6-4f3c-ad76-8b895f0a503c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7c58f671-90e4-4ba9-807f-472435682848" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_76520308-ddc6-4f3c-ad76-8b895f0a503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_d703f9e5-d35a-49dd-b6ff-8b7627c05c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_76520308-ddc6-4f3c-ad76-8b895f0a503c" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember_d703f9e5-d35a-49dd-b6ff-8b7627c05c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_599f8c29-416d-4b36-8ff2-c3e1878683d1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_45433919-7c32-49a4-9e27-b53b61863489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_45433919-7c32-49a4-9e27-b53b61863489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_af50d993-81f0-4919-a6bc-08369cb1da5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_45433919-7c32-49a4-9e27-b53b61863489" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_af50d993-81f0-4919-a6bc-08369cb1da5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_45433919-7c32-49a4-9e27-b53b61863489" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_7c5d7d59-e58e-4e0c-af30-aa3d4d4792c3" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits_7c5d7d59-e58e-4e0c-af30-aa3d4d4792c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_550954e2-d28a-4e78-93fd-6fc4c0214403" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense_550954e2-d28a-4e78-93fd-6fc4c0214403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_9699cc95-f4c2-48dd-a76d-4a365e65038d" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts_9699cc95-f4c2-48dd-a76d-4a365e65038d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_0bfd3def-fe63-442f-9d15-d9b47539e971" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationSupplies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies_0bfd3def-fe63-442f-9d15-d9b47539e971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_955c9b02-47fe-4274-89a5-94c4d0c294a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_955c9b02-47fe-4274-89a5-94c4d0c294a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_d2f2ab29-83d1-44e2-ab95-3a03a212fca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_d2f2ab29-83d1-44e2-ab95-3a03a212fca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4070d596-2b3d-4b25-a744-b74cc35552db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract_f0815f88-22c7-4bbd-b842-2c7ca2e9949c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4070d596-2b3d-4b25-a744-b74cc35552db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_18846f50-6f97-4f39-a674-60a7ea81e51d" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees_18846f50-6f97-4f39-a674-60a7ea81e51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_50dd1c27-dbac-4190-b25d-f2fba8e1826c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome_50dd1c27-dbac-4190-b25d-f2fba8e1826c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_4cd56f3f-6f28-467a-aa86-2c85ccaacfb9" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments_4cd56f3f-6f28-467a-aa86-2c85ccaacfb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4a79594f-3f46-441f-914e-7f734c82d375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4a79594f-3f46-441f-914e-7f734c82d375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6abc9154-e3ca-4067-9ec4-842a3527380c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6abc9154-e3ca-4067-9ec4-842a3527380c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b6b5b642-c2c6-4c32-9078-5e6225148fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b6b5b642-c2c6-4c32-9078-5e6225148fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_989ed76f-22bf-4278-8ae7-9e0f62db0708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_989ed76f-22bf-4278-8ae7-9e0f62db0708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a9710f16-0840-4bd5-a1b4-51440d83eea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_a9710f16-0840-4bd5-a1b4-51440d83eea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_b27010b3-5838-43dd-8dfd-20d8f7e86acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_b27010b3-5838-43dd-8dfd-20d8f7e86acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_b27010b3-5838-43dd-8dfd-20d8f7e86acf" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_58dda624-1f3b-4f73-9a35-50882631b253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_58dda624-1f3b-4f73-9a35-50882631b253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_0f61a0ed-0d68-45cf-ac46-90bf85d4aabc" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash_0f61a0ed-0d68-45cf-ac46-90bf85d4aabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_fc7c8994-d332-455b-9c1a-c123fc0323d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_fc7c8994-d332-455b-9c1a-c123fc0323d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_2fbcd1f9-ce63-400a-891e-aa5545c53b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_2fbcd1f9-ce63-400a-891e-aa5545c53b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a5b81366-02a4-4861-8b09-ee2cd3210558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_83db257e-10f7-469e-a3e9-9efa1b9c348f" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_a5b81366-02a4-4861-8b09-ee2cd3210558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_fb51bb79-27ac-4b1c-87d1-192af4bf8d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_fb51bb79-27ac-4b1c-87d1-192af4bf8d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_4408920e-abdb-424d-b338-c383b47af034" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset_4408920e-abdb-424d-b338-c383b47af034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_da4e90e1-faac-4297-8c5e-d2f478223902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_da4e90e1-faac-4297-8c5e-d2f478223902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_62328f85-f204-4397-b268-50538ab41c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_62328f85-f204-4397-b268-50538ab41c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_fbaa922b-b800-4986-ae0b-c1f63b8dd6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_fbaa922b-b800-4986-ae0b-c1f63b8dd6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_5fa40300-e32e-4eb9-af0c-137798a805b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_e957f103-e3d5-4c98-a416-d0b7809a04f6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_5fa40300-e32e-4eb9-af0c-137798a805b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ebd76bac-51f8-4e5f-a2d7-67c305319752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_ebd76bac-51f8-4e5f-a2d7-67c305319752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_09e7ffd2-88a4-4d51-9ce4-fd406df7529c" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent_09e7ffd2-88a4-4d51-9ce4-fd406df7529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_5c6a32ad-120f-4bde-a057-0bcd05c40b28" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent_5c6a32ad-120f-4bde-a057-0bcd05c40b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_3e275703-bf74-47ae-8944-dd2a8b92651c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_3e275703-bf74-47ae-8944-dd2a8b92651c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_cc5a6fa7-3faf-4588-a5fb-4ed5f7b4a7ac" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent_cc5a6fa7-3faf-4588-a5fb-4ed5f7b4a7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_92c40127-3466-4f57-b468-893b94bf82ae" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent_92c40127-3466-4f57-b468-893b94bf82ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_e3ac38e2-f617-4e33-b5a7-9af9deff286b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_cfd9dcd1-64c3-484e-b9db-4ef40a7474aa" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_e3ac38e2-f617-4e33-b5a7-9af9deff286b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_32526ccd-a696-4847-a516-40917c11203e" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent_32526ccd-a696-4847-a516-40917c11203e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_d15c4042-a9ab-4117-b746-60517da65729" xlink:href="ehc-20221231.xsd#ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent_d15c4042-a9ab-4117-b746-60517da65729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_60547e83-46a3-4e64-84b1-19b1c5551397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_60547e83-46a3-4e64-84b1-19b1c5551397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_d03f5ba8-01a2-483a-9e3f-757dc11a3ede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_d03f5ba8-01a2-483a-9e3f-757dc11a3ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4395306b-bfa6-4ce7-8697-1e0a3677756a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_a4a03e7d-57f9-408c-9d97-c5356d0ef419" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_4395306b-bfa6-4ce7-8697-1e0a3677756a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_6c04369c-30ac-48de-8dce-2a736e293e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_efd87dbe-cd1b-4d72-8a35-1a0761e544e4" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_6c04369c-30ac-48de-8dce-2a736e293e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1e6aeded-35b5-4005-9ffe-74a24f09a235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1e6aeded-35b5-4005-9ffe-74a24f09a235" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c77a7b5-ce7e-4497-a409-d84a19a34c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c77a7b5-ce7e-4497-a409-d84a19a34c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9c7470b9-15cd-43bc-94d0-2e346ab3c49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2c77a7b5-ce7e-4497-a409-d84a19a34c20" xlink:to="loc_us-gaap_RelatedPartyDomain_9c7470b9-15cd-43bc-94d0-2e346ab3c49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_fbbcab01-9c46-4500-8a45-12ac32bdfc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9c7470b9-15cd-43bc-94d0-2e346ab3c49b" xlink:to="loc_us-gaap_CorporateJointVentureMember_fbbcab01-9c46-4500-8a45-12ac32bdfc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9591d4ab-acd6-484f-b172-351e2e9e8e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9591d4ab-acd6-484f-b172-351e2e9e8e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9591d4ab-acd6-484f-b172-351e2e9e8e2f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemMember_dfe9ca9f-624d-415e-975a-271217fb1e3e" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_AltruHealthSystemMember_dfe9ca9f-624d-415e-975a-271217fb1e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TrinityMedicalCenterMember_b3a8a7ba-b4ac-4322-beb9-86d733f81cb4" xlink:href="ehc-20221231.xsd#ehc_TrinityMedicalCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_TrinityMedicalCenterMember_b3a8a7ba-b4ac-4322-beb9-86d733f81cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NCHHealthcareSystemMember_208871b6-c892-4463-b6ea-412208934b43" xlink:href="ehc-20221231.xsd#ehc_NCHHealthcareSystemMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_NCHHealthcareSystemMember_208871b6-c892-4463-b6ea-412208934b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_3964be3f-fe7a-46f1-9f63-a2dd410eb216" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_3964be3f-fe7a-46f1-9f63-a2dd410eb216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalMember_f3e858e6-ed8c-4726-af4d-d5c28514296a" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_ShannonMedicalMember_f3e858e6-ed8c-4726-af4d-d5c28514296a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HeritageValleyMember_21a52277-1f57-48b8-b5b0-77a1c4f7f2ac" xlink:href="ehc-20221231.xsd#ehc_HeritageValleyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_HeritageValleyMember_21a52277-1f57-48b8-b5b0-77a1c4f7f2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ECHDVenturesMember_c2212b9e-1a4a-4059-9933-b595554eadc5" xlink:href="ehc-20221231.xsd#ehc_ECHDVenturesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_ECHDVenturesMember_c2212b9e-1a4a-4059-9933-b595554eadc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_b5b3ffb6-1053-484f-91d4-a85a1c6e768a" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_b5b3ffb6-1053-484f-91d4-a85a1c6e768a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistMember_851b1d79-8a10-45c2-a0a2-41c1f0062200" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_PortercareAdventistMember_851b1d79-8a10-45c2-a0a2-41c1f0062200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PremierHealthPartnersMember_a37deb71-6ce7-4fc5-bd77-4af592271e13" xlink:href="ehc-20221231.xsd#ehc_PremierHealthPartnersMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_PremierHealthPartnersMember_a37deb71-6ce7-4fc5-bd77-4af592271e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_98e29899-ffe6-4f63-9d8d-6d724e81c091" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_86e732d0-3213-4d03-b1bd-ec5b888c7ee0" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_98e29899-ffe6-4f63-9d8d-6d724e81c091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_46d201f7-5cd4-4b32-abd7-327d35061c00" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:to="loc_srt_RangeAxis_46d201f7-5cd4-4b32-abd7-327d35061c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e6fb91dd-1b2b-4c6a-adb4-1355e36c332c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_46d201f7-5cd4-4b32-abd7-327d35061c00" xlink:to="loc_srt_RangeMember_e6fb91dd-1b2b-4c6a-adb4-1355e36c332c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eb5226dc-afdf-44c8-a049-7e61ea134d52" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6fb91dd-1b2b-4c6a-adb4-1355e36c332c" xlink:to="loc_srt_MinimumMember_eb5226dc-afdf-44c8-a049-7e61ea134d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9928ade9-5d38-45e2-9b8f-7f439747d4cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e6fb91dd-1b2b-4c6a-adb4-1355e36c332c" xlink:to="loc_srt_MaximumMember_9928ade9-5d38-45e2-9b8f-7f439747d4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_52396af4-fc09-4a73-ba40-05876c04218d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7862c18b-24b6-499f-8c89-ff43bf138327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_7862c18b-24b6-499f-8c89-ff43bf138327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfBedsAcquired_41929da1-5000-4317-a499-0111e53952c6" xlink:href="ehc-20221231.xsd#ehc_NumberOfBedsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_ehc_NumberOfBedsAcquired_41929da1-5000-4317-a499-0111e53952c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c39ca78c-557a-458a-a262-953541812a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_c39ca78c-557a-458a-a262-953541812a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsContributed_7a9e548c-0f40-4c8b-9e8c-33803616c707" xlink:href="ehc-20221231.xsd#ehc_NumberofBedsContributed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_ehc_NumberofBedsContributed_7a9e548c-0f40-4c8b-9e8c-33803616c707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofBedsExpanded_3f764083-6663-4716-823e-84624c518e62" xlink:href="ehc-20221231.xsd#ehc_NumberofBedsExpanded"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_ehc_NumberofBedsExpanded_3f764083-6663-4716-823e-84624c518e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberofDeNovoBeds_9294aae3-96f6-46c9-97b6-5fb0feed5292" xlink:href="ehc-20221231.xsd#ehc_NumberofDeNovoBeds"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b33799a5-974e-4d06-ab5e-ce98f3ee577b" xlink:to="loc_ehc_NumberofDeNovoBeds_9294aae3-96f6-46c9-97b6-5fb0feed5292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2344668c-d1a5-4fcd-95f4-db75926de312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2344668c-d1a5-4fcd-95f4-db75926de312" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_25d02c0b-56c9-4c9e-851c-ed00c273bd35" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:to="loc_srt_RangeAxis_25d02c0b-56c9-4c9e-851c-ed00c273bd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a13259d5-5b01-4fba-b93d-a3672b66cf02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_25d02c0b-56c9-4c9e-851c-ed00c273bd35" xlink:to="loc_srt_RangeMember_a13259d5-5b01-4fba-b93d-a3672b66cf02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5241098e-a658-48bb-840c-4dc0bcd53f85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a13259d5-5b01-4fba-b93d-a3672b66cf02" xlink:to="loc_srt_MinimumMember_5241098e-a658-48bb-840c-4dc0bcd53f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7213bb42-ad91-46ec-9673-95d4ce6f2b4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a13259d5-5b01-4fba-b93d-a3672b66cf02" xlink:to="loc_srt_MaximumMember_7213bb42-ad91-46ec-9673-95d4ce6f2b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7291ddd-03c0-420f-8021-2948d2489bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7291ddd-03c0-420f-8021-2948d2489bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f15425c2-1ef4-4854-a977-db139bc68d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e7291ddd-03c0-420f-8021-2948d2489bd7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f15425c2-1ef4-4854-a977-db139bc68d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_47694101-6483-4108-91ed-4c6c354ccd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f15425c2-1ef4-4854-a977-db139bc68d4c" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_47694101-6483-4108-91ed-4c6c354ccd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3f52d1f2-2a2f-4c1a-98f3-38bb30abdbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f15425c2-1ef4-4854-a977-db139bc68d4c" xlink:to="loc_us-gaap_TradeNamesMember_3f52d1f2-2a2f-4c1a-98f3-38bb30abdbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7abbb83e-8206-4b09-a0c2-5c77fca2ebf5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_b4c16771-15f5-419b-92dd-6cf69012fa31" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:to="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_b4c16771-15f5-419b-92dd-6cf69012fa31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_e57a5f43-104d-4f41-bab3-663c84ffbb39" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_e57a5f43-104d-4f41-bab3-663c84ffbb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_62d8e171-413a-4b84-b1ad-e56952ca990b" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af8d662-0055-410e-a688-d2890b79f60b" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_62d8e171-413a-4b84-b1ad-e56952ca990b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_07fba194-ab2b-4295-a4fb-019cfce11c31" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3082d3c9-93fb-4436-b1aa-45c0fd675205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_3082d3c9-93fb-4436-b1aa-45c0fd675205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e9a5a353-dfa5-4647-9ef1-2afab75b9099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_Goodwill_e9a5a353-dfa5-4647-9ef1-2afab75b9099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_dc2e920e-d956-4b05-b64b-06ca598bd38f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_dc2e920e-d956-4b05-b64b-06ca598bd38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_ec42ab4c-5f24-48b4-a945-0f0c24666425" xlink:href="ehc-20221231.xsd#ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets_ec42ab4c-5f24-48b4-a945-0f0c24666425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a3a8a774-00b1-49ff-b55a-d9a297b2915f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_28e991d2-e1f6-4062-a4fb-c9f8bb341aee" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a3a8a774-00b1-49ff-b55a-d9a297b2915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsNetCashPaidforAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8300f282-ccee-45b8-8ed2-c86ddd97cbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_8300f282-ccee-45b8-8ed2-c86ddd97cbc0" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_55ee2c34-7ac4-4b17-a8d1-873e3adca17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_55ee2c34-7ac4-4b17-a8d1-873e3adca17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55ee2c34-7ac4-4b17-a8d1-873e3adca17c" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_fda73c73-69da-4a6b-8483-002e0c7c9596" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:to="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_fda73c73-69da-4a6b-8483-002e0c7c9596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_f2ca09c9-3016-416c-ae03-3b6f5d4f0386" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_f2ca09c9-3016-416c-ae03-3b6f5d4f0386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_7a153856-8e0d-4295-9a7b-f9e3e3603c4d" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_dff9d28e-5dc9-42d6-b6ba-5e0c39587bc8" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_7a153856-8e0d-4295-9a7b-f9e3e3603c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59db9bfb-56c0-46fb-a794-a941e91473c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59db9bfb-56c0-46fb-a794-a941e91473c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77f22c62-442c-45f3-a8c1-9a748b316e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_59db9bfb-56c0-46fb-a794-a941e91473c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77f22c62-442c-45f3-a8c1-9a748b316e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_e0919007-b120-4188-85b5-a67e064119b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_77f22c62-442c-45f3-a8c1-9a748b316e78" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_e0919007-b120-4188-85b5-a67e064119b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_45760b77-7791-48fb-a7ec-c8de23a391cd" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_7e376b81-b856-49a9-b16b-589584e364d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_7e376b81-b856-49a9-b16b-589584e364d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_d482a417-6b44-455b-a8b6-8a083e2e7e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_d482a417-6b44-455b-a8b6-8a083e2e7e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_b09831ba-3f5b-4d61-9e16-42cf99256f07" xlink:href="ehc-20221231.xsd#ehc_BusinessCombinationNoncontrollingInterestFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_ehc_BusinessCombinationNoncontrollingInterestFairValue_b09831ba-3f5b-4d61-9e16-42cf99256f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ad496634-7c22-4358-bcf8-2af6793adb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_81f8fbc5-7ae9-4d21-b88a-3223691afca5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ad496634-7c22-4358-bcf8-2af6793adb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#BusinessCombinationsProFormaResultsofOperationDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_65874e72-d4ec-4b91-a151-a09e6f456aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e904a52c-574a-4433-9ca8-81a3c90627c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_65874e72-d4ec-4b91-a151-a09e6f456aa1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e904a52c-574a-4433-9ca8-81a3c90627c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_773b18b8-3abc-4202-a64f-5085469a26d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e904a52c-574a-4433-9ca8-81a3c90627c4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_773b18b8-3abc-4202-a64f-5085469a26d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_773b18b8-3abc-4202-a64f-5085469a26d9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_3f5151c3-e7e1-46fd-bd7f-cb477c6e987c" xlink:href="ehc-20221231.xsd#ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember_3f5151c3-e7e1-46fd-bd7f-cb477c6e987c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_96c4f764-93e2-4b57-8ad1-0c22a0bc0cf4" xlink:href="ehc-20221231.xsd#ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember_96c4f764-93e2-4b57-8ad1-0c22a0bc0cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2021AcquisitionsMember_e0b13086-d12d-42e8-8f00-4e591073633e" xlink:href="ehc-20221231.xsd#ehc_A2021AcquisitionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_A2021AcquisitionsMember_e0b13086-d12d-42e8-8f00-4e591073633e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_a276a9e3-3c37-44a4-b399-8ab2d835536b" xlink:href="ehc-20221231.xsd#ehc_PortercareAdventistAndPremierHealthPartnersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_PortercareAdventistAndPremierHealthPartnersMember_a276a9e3-3c37-44a4-b399-8ab2d835536b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2020AcquisitionsMember_2bb16ea5-c991-48e9-bf15-165de1f9dba2" xlink:href="ehc-20221231.xsd#ehc_A2020AcquisitionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0820560e-4620-4812-b398-920566e6f6f3" xlink:to="loc_ehc_A2020AcquisitionsMember_2bb16ea5-c991-48e9-bf15-165de1f9dba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e904a52c-574a-4433-9ca8-81a3c90627c4" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_00d1fc90-d278-4322-bc36-0a1584a8abbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_00d1fc90-d278-4322-bc36-0a1584a8abbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_1bfbfcd7-0143-4774-80ea-b840eba3d1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual_1bfbfcd7-0143-4774-80ea-b840eba3d1a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_14e8d48d-6d4c-49a2-b59e-2c8b2d902730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_14e8d48d-6d4c-49a2-b59e-2c8b2d902730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_fcadfa3f-1ad9-418e-a073-a2f0d0078807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_382a2242-5254-4a00-be2f-4e2d80dd261b" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_fcadfa3f-1ad9-418e-a073-a2f0d0078807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#VariableInterestEntitiesTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_420e0f06-a351-4448-94e5-6118a19c46c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_420e0f06-a351-4448-94e5-6118a19c46c2" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_54178f9d-487f-4c00-8968-36792f4382fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:to="loc_srt_ConsolidatedEntitiesAxis_54178f9d-487f-4c00-8968-36792f4382fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_be6c26a0-ceff-4696-898f-781ac0c5ccc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_54178f9d-487f-4c00-8968-36792f4382fe" xlink:to="loc_srt_ConsolidatedEntitiesDomain_be6c26a0-ceff-4696-898f-781ac0c5ccc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0119f344-0819-4b9f-998a-b9e25afdb24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_be6c26a0-ceff-4696-898f-781ac0c5ccc5" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0119f344-0819-4b9f-998a-b9e25afdb24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b611d83e-fc95-4973-9cec-19a2c7c0eaa7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:to="loc_srt_RangeAxis_b611d83e-fc95-4973-9cec-19a2c7c0eaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b7f8cda5-5529-4d48-a134-3ab784107283" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b611d83e-fc95-4973-9cec-19a2c7c0eaa7" xlink:to="loc_srt_RangeMember_b7f8cda5-5529-4d48-a134-3ab784107283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e8534004-dc8e-4d1a-816c-700258f0ac8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7f8cda5-5529-4d48-a134-3ab784107283" xlink:to="loc_srt_MinimumMember_e8534004-dc8e-4d1a-816c-700258f0ac8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bb69756e-012a-4f7e-ae84-74dfef6cc47a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b7f8cda5-5529-4d48-a134-3ab784107283" xlink:to="loc_srt_MaximumMember_bb69756e-012a-4f7e-ae84-74dfef6cc47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_e66ca92c-3d34-4af1-9d95-dec79980c0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_0a09910c-0a11-46bb-b7fe-e1faa4d29d00" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_e66ca92c-3d34-4af1-9d95-dec79980c0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_7f0ed48c-2aa5-44fc-9476-33dbb64b0a6f" xlink:href="ehc-20221231.xsd#ehc_VariableInterestEntityNumberofEntitiesConsolidated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e66ca92c-3d34-4af1-9d95-dec79980c0f4" xlink:to="loc_ehc_VariableInterestEntityNumberofEntitiesConsolidated_7f0ed48c-2aa5-44fc-9476-33dbb64b0a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_482cb369-6b41-4c2d-b22b-a1dcd57503bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_e66ca92c-3d34-4af1-9d95-dec79980c0f4" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_482cb369-6b41-4c2d-b22b-a1dcd57503bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833b24dc-1e81-443f-b50e-283430c48490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_87e87225-a2a8-4478-8479-e1ad3b0e1070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_833b24dc-1e81-443f-b50e-283430c48490" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_87e87225-a2a8-4478-8479-e1ad3b0e1070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8461c6ed-3980-4452-95dc-85aeb9a485da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_87e87225-a2a8-4478-8479-e1ad3b0e1070" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8461c6ed-3980-4452-95dc-85aeb9a485da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_201a3698-30be-4042-a010-a98284d7cd1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8461c6ed-3980-4452-95dc-85aeb9a485da" xlink:to="loc_srt_ConsolidatedEntitiesDomain_201a3698-30be-4042-a010-a98284d7cd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ec837abd-26fd-478b-a64e-05dd88f602ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_201a3698-30be-4042-a010-a98284d7cd1b" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ec837abd-26fd-478b-a64e-05dd88f602ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_39fa8e5d-2684-4be8-be4c-c1f48012eca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_87e87225-a2a8-4478-8479-e1ad3b0e1070" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_39fa8e5d-2684-4be8-be4c-c1f48012eca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_39fa8e5d-2684-4be8-be4c-c1f48012eca2" xlink:to="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0671a99-e2e1-4b2b-a679-1edb3621c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0671a99-e2e1-4b2b-a679-1edb3621c73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d4ec6d14-9110-40a3-9cfb-6880133323ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d4ec6d14-9110-40a3-9cfb-6880133323ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_543b9fde-4ffa-4261-8c09-3085b4df7cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_OtherAssetsCurrent_543b9fde-4ffa-4261-8c09-3085b4df7cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_01c0c730-444e-449e-9abc-75560540d207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_01c0c730-444e-449e-9abc-75560540d207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4681ce44-366c-4db1-a7b9-a49e8725366d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c7a0871a-32d3-4f28-983b-09705600ae5c" xlink:to="loc_us-gaap_AssetsCurrent_4681ce44-366c-4db1-a7b9-a49e8725366d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d572c380-819b-4390-9d02-646f519ed557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_d572c380-819b-4390-9d02-646f519ed557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95f612c5-08bd-48c1-abac-d973965b2152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95f612c5-08bd-48c1-abac-d973965b2152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_31fabc2d-eaa3-4b43-b174-910a2c6525b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_Goodwill_31fabc2d-eaa3-4b43-b174-910a2c6525b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d550e282-9933-4fd2-8033-65c97724271b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d550e282-9933-4fd2-8033-65c97724271b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c3a4cc46-a7d5-4890-a8fb-614df74c0cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c3a4cc46-a7d5-4890-a8fb-614df74c0cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_94b62074-4ed9-431e-a7e8-3fce0d5bc05f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent_94b62074-4ed9-431e-a7e8-3fce0d5bc05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7810d202-3ee0-43be-a085-38b9fe478007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_e3c47ef4-b41a-4619-8bdf-eb2298fc10a6" xlink:to="loc_us-gaap_Assets_7810d202-3ee0-43be-a085-38b9fe478007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_39fa8e5d-2684-4be8-be4c-c1f48012eca2" xlink:to="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_350a952f-cf39-4a40-b997-88a71c57256b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_350a952f-cf39-4a40-b997-88a71c57256b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ee4eb22-07df-4336-a36f-86c122a356d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_0ee4eb22-07df-4336-a36f-86c122a356d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_87ef38fa-64c4-4a30-a481-84dc33c6620d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_AccountsPayableCurrent_87ef38fa-64c4-4a30-a481-84dc33c6620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c821dfe5-fb7f-4069-bf1e-870c7089ab64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c821dfe5-fb7f-4069-bf1e-870c7089ab64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_54f8d4b3-ad2e-4e3d-b4aa-a3a47952e336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_54f8d4b3-ad2e-4e3d-b4aa-a3a47952e336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_f0556d40-85af-407f-ba05-33f6d091a3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_f0556d40-85af-407f-ba05-33f6d091a3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_14e8d977-a4a6-4ba6-82c9-d3856c4ef4df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_43eacd51-1da5-4f0a-be38-eb8780163813" xlink:to="loc_us-gaap_LiabilitiesCurrent_14e8d977-a4a6-4ba6-82c9-d3856c4ef4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_91842087-3e05-4d34-882f-881e1c4a2c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_91842087-3e05-4d34-882f-881e1c4a2c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc73c5e9-5cf1-40fb-9a5a-1b57eb1766f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dc73c5e9-5cf1-40fb-9a5a-1b57eb1766f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7b264b28-41e3-4d01-a8d4-a0f0d293d964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_7a270c6e-4cbf-40fc-bc9d-47ba20918962" xlink:to="loc_us-gaap_Liabilities_7b264b28-41e3-4d01-a8d4-a0f0d293d964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecuritiesComponentsofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_35b04873-f1cd-4d3c-b5e2-c7d9dccacdba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_c789ade1-bf09-4ed9-91ee-1c0cfa82a748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_35b04873-f1cd-4d3c-b5e2-c7d9dccacdba" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_c789ade1-bf09-4ed9-91ee-1c0cfa82a748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b1c51208-3299-4b2a-9da6-f95b74585497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_c789ade1-bf09-4ed9-91ee-1c0cfa82a748" xlink:to="loc_us-gaap_InvestmentTypeAxis_b1c51208-3299-4b2a-9da6-f95b74585497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7125d88e-4b55-4785-8e73-dabaa8dae431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_b1c51208-3299-4b2a-9da6-f95b74585497" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7125d88e-4b55-4785-8e73-dabaa8dae431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_737a2511-0221-46be-9a38-7ddd8000708b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7125d88e-4b55-4785-8e73-dabaa8dae431" xlink:to="loc_us-gaap_CashMember_737a2511-0221-46be-9a38-7ddd8000708b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_797a000c-f55d-4670-8f92-f1379089f882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7125d88e-4b55-4785-8e73-dabaa8dae431" xlink:to="loc_us-gaap_EquitySecuritiesMember_797a000c-f55d-4670-8f92-f1379089f882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_c789ade1-bf09-4ed9-91ee-1c0cfa82a748" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93c8f1df-3de6-4685-8255-5a94b3838e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_93c8f1df-3de6-4685-8255-5a94b3838e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_c9bc06f3-fc90-49ee-8082-3769ab981ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_c9bc06f3-fc90-49ee-8082-3769ab981ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_94a6a9de-fd27-451a-bc0a-09ebfcf5af89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRestricted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRestricted_94a6a9de-fd27-451a-bc0a-09ebfcf5af89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_InvestmentsCashandRestrictedCash_3f819dbe-eb1f-4cfc-b5d4-2ee42259d05c" xlink:href="ehc-20221231.xsd#ehc_InvestmentsCashandRestrictedCash"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_4a281c5c-b744-4503-9369-5651f6f01c1c" xlink:to="loc_ehc_InvestmentsCashandRestrictedCash_3f819dbe-eb1f-4cfc-b5d4-2ee42259d05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecuritiesRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_40f3c848-3c8a-4f25-9f20-cb1ca1c1c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b7fbcdd-5775-4b7a-a0df-5e6ffe3476a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_40f3c848-3c8a-4f25-9f20-cb1ca1c1c16b" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b7fbcdd-5775-4b7a-a0df-5e6ffe3476a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_7c546b91-0de8-473b-80ac-93871746d212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b7fbcdd-5775-4b7a-a0df-5e6ffe3476a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_7c546b91-0de8-473b-80ac-93871746d212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_7c546b91-0de8-473b-80ac-93871746d212" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_AffiliateCashMember_7c0001ae-93a4-4a94-8b93-1bb8266914fd" xlink:href="ehc-20221231.xsd#ehc_AffiliateCashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:to="loc_ehc_AffiliateCashMember_7c0001ae-93a4-4a94-8b93-1bb8266914fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SelfInsuredCaptiveFundsMember_d41e641a-47ae-4748-84f6-9f6923aaeee3" xlink:href="ehc-20221231.xsd#ehc_SelfInsuredCaptiveFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:to="loc_ehc_SelfInsuredCaptiveFundsMember_d41e641a-47ae-4748-84f6-9f6923aaeee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OtherFundsMember_c43bdba7-f382-4dae-b66c-93945894f80b" xlink:href="ehc-20221231.xsd#ehc_OtherFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_d1cf636a-c1ca-4df7-8696-4261c55c33f2" xlink:to="loc_ehc_OtherFundsMember_c43bdba7-f382-4dae-b66c-93945894f80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fcbe1cfc-eb1d-410e-872c-e7df156fba3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_9b7fbcdd-5775-4b7a-a0df-5e6ffe3476a2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fcbe1cfc-eb1d-410e-872c-e7df156fba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4bd3f23a-d3c6-425b-8efd-0118f7b10c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fcbe1cfc-eb1d-410e-872c-e7df156fba3c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_4bd3f23a-d3c6-425b-8efd-0118f7b10c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b24b2205-859c-4a89-b311-b1b3615afd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fcbe1cfc-eb1d-410e-872c-e7df156fba3c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b24b2205-859c-4a89-b311-b1b3615afd1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecuritiesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0a8c4cca-8d83-4db7-a130-68ad32b03671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RestrictedDebtSecuritiesNoncurrent_964d0f2e-dbc2-410e-a99a-e4d186e855e8" xlink:href="ehc-20221231.xsd#ehc_RestrictedDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0a8c4cca-8d83-4db7-a130-68ad32b03671" xlink:to="loc_ehc_RestrictedDebtSecuritiesNoncurrent_964d0f2e-dbc2-410e-a99a-e4d186e855e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4b170bfc-0227-475d-a7af-587f7dfea137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0a8c4cca-8d83-4db7-a130-68ad32b03671" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4b170bfc-0227-475d-a7af-587f7dfea137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_a35eef16-1468-4d45-81a5-8de40a4b3f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_4d5e7d7d-504c-4568-b094-426a0f6957b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_a35eef16-1468-4d45-81a5-8de40a4b3f16" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_4d5e7d7d-504c-4568-b094-426a0f6957b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e324e17c-dc86-4353-b90b-9991c3258e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract_4d5e7d7d-504c-4568-b094-426a0f6957b7" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e324e17c-dc86-4353-b90b-9991c3258e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#AccountsReceivableComponentsofAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_2413c731-40f8-4e3a-a659-fd85508ea670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrentAbstract_7e9f4d3c-cc7d-4157-a7bf-71f5f051e6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2413c731-40f8-4e3a-a659-fd85508ea670" xlink:to="loc_us-gaap_AccountsReceivableNetCurrentAbstract_7e9f4d3c-cc7d-4157-a7bf-71f5f051e6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrentAbstract_8bed0bb4-bb7d-4a07-aac7-d60916ba0ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNetCurrentAbstract_7e9f4d3c-cc7d-4157-a7bf-71f5f051e6c6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrentAbstract_8bed0bb4-bb7d-4a07-aac7-d60916ba0ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c1bc58b8-c29a-4de1-aa49-a6ee2a85de2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherReceivablesNetCurrentAbstract_8bed0bb4-bb7d-4a07-aac7-d60916ba0ebc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c1bc58b8-c29a-4de1-aa49-a6ee2a85de2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_d77a2b87-75ef-44cf-bd80-30858c2568b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherReceivablesNetCurrentAbstract_8bed0bb4-bb7d-4a07-aac7-d60916ba0ebc" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_d77a2b87-75ef-44cf-bd80-30858c2568b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c5536c8b-7227-481e-8f86-320a771abdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2413c731-40f8-4e3a-a659-fd85508ea670" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c5536c8b-7227-481e-8f86-320a771abdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_c968882d-ea61-40ac-b1c4-22cdac107e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2413c731-40f8-4e3a-a659-fd85508ea670" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_c968882d-ea61-40ac-b1c4-22cdac107e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_d81c9fe2-cb50-420c-a8a2-0396a16e5216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2413c731-40f8-4e3a-a659-fd85508ea670" xlink:to="loc_us-gaap_AccountsReceivableNet_d81c9fe2-cb50-420c-a8a2-0396a16e5216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#PropertyandEquipmentComponentsofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4622bd97-2d23-4ffe-b454-0315846e83f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad30071b-9ca1-4728-9ae9-dbe41c85fb4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4622bd97-2d23-4ffe-b454-0315846e83f1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad30071b-9ca1-4728-9ae9-dbe41c85fb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7688fe87-c16a-4ca8-9908-47e60526f93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad30071b-9ca1-4728-9ae9-dbe41c85fb4c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7688fe87-c16a-4ca8-9908-47e60526f93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2b65e3a-a9f5-494d-8524-58ffc5334e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7688fe87-c16a-4ca8-9908-47e60526f93b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2b65e3a-a9f5-494d-8524-58ffc5334e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:href="ehc-20221231.xsd#ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2b65e3a-a9f5-494d-8524-58ffc5334e21" xlink:to="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0f7f8bd4-aa3e-489f-9464-7360fad14bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_LandMember_0f7f8bd4-aa3e-489f-9464-7360fad14bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_dbb1251b-ff5d-4dc9-91fd-712640e9bb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_BuildingMember_dbb1251b-ff5d-4dc9-91fd-712640e9bb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_e7915364-b4af-464a-80dc-4b1659842431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_e7915364-b4af-464a-80dc-4b1659842431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VehiclesMember_b792b73d-67b9-4d50-8f89-5713ef978bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VehiclesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_VehiclesMember_b792b73d-67b9-4d50-8f89-5713ef978bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0d477761-1d83-4557-bed4-5af49a29aef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember_c6fa5923-96b4-4c70-aeae-16ba104d363a" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0d477761-1d83-4557-bed4-5af49a29aef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_62accf48-597b-496b-934f-bef328ca42d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a2b65e3a-a9f5-494d-8524-58ffc5334e21" xlink:to="loc_us-gaap_ConstructionInProgressMember_62accf48-597b-496b-934f-bef328ca42d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a536be52-31b7-48fa-9b3c-6b3d981708a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ad30071b-9ca1-4728-9ae9-dbe41c85fb4c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a536be52-31b7-48fa-9b3c-6b3d981708a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a536be52-31b7-48fa-9b3c-6b3d981708a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b42fc50c-ee80-4b01-8bc4-c7f013220ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_b42fc50c-ee80-4b01-8bc4-c7f013220ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_14212e21-9d15-46f8-9e6d-2509cd0c1b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_14212e21-9d15-46f8-9e6d-2509cd0c1b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7b80e8b8-050d-4ac0-a43b-d653ae545b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_bef554dc-33b8-42c4-822f-dd9707d1296b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7b80e8b8-050d-4ac0-a43b-d653ae545b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#PropertyandEquipmentTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_40270788-101f-4f77-9a0d-fe6dd3cc458f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Percentageofassetspledgedtolendersundercreditagreement_eac5fae2-eca5-4351-8383-cfc933912b99" xlink:href="ehc-20221231.xsd#ehc_Percentageofassetspledgedtolendersundercreditagreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_40270788-101f-4f77-9a0d-fe6dd3cc458f" xlink:to="loc_ehc_Percentageofassetspledgedtolendersundercreditagreement_eac5fae2-eca5-4351-8383-cfc933912b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2692c458-81b5-41d2-81d8-fd0da7513989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_f24f3700-6162-4a6e-b2f1-931639cb8be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2692c458-81b5-41d2-81d8-fd0da7513989" xlink:to="loc_us-gaap_Depreciation_f24f3700-6162-4a6e-b2f1-931639cb8be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_89071939-5f0d-4f83-b037-a52083818b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2692c458-81b5-41d2-81d8-fd0da7513989" xlink:to="loc_us-gaap_InterestCostsCapitalized_89071939-5f0d-4f83-b037-a52083818b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesTextualsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f4a16ec6-f651-41a5-aeab-da89b99f9bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ece31663-a8ee-401a-8775-c89483c77e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f4a16ec6-f651-41a5-aeab-da89b99f9bcc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ece31663-a8ee-401a-8775-c89483c77e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2319c8b2-4982-49d6-94dc-d62405cf4e2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ece31663-a8ee-401a-8775-c89483c77e18" xlink:to="loc_srt_RangeAxis_2319c8b2-4982-49d6-94dc-d62405cf4e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d77ba136-5a2b-46cb-9a2e-e2875cca037e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2319c8b2-4982-49d6-94dc-d62405cf4e2f" xlink:to="loc_srt_RangeMember_d77ba136-5a2b-46cb-9a2e-e2875cca037e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3498f06e-8963-4268-b240-fa5d8aead52f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d77ba136-5a2b-46cb-9a2e-e2875cca037e" xlink:to="loc_srt_MinimumMember_3498f06e-8963-4268-b240-fa5d8aead52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb2195f8-d246-45ad-88cc-2089d4c9b90d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d77ba136-5a2b-46cb-9a2e-e2875cca037e" xlink:to="loc_srt_MaximumMember_fb2195f8-d246-45ad-88cc-2089d4c9b90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7aa02b5a-ddba-4a52-92e8-97d53a1fb4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ece31663-a8ee-401a-8775-c89483c77e18" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_7aa02b5a-ddba-4a52-92e8-97d53a1fb4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OperatingAndFinanceLeaseContractTerm_88506fd6-e8ce-451f-baed-bb39d8cbda5c" xlink:href="ehc-20221231.xsd#ehc_OperatingAndFinanceLeaseContractTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7aa02b5a-ddba-4a52-92e8-97d53a1fb4ba" xlink:to="loc_ehc_OperatingAndFinanceLeaseContractTerm_88506fd6-e8ce-451f-baed-bb39d8cbda5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions_f3289af0-f7bd-47fe-a6f6-36c8f136a8c8" xlink:href="ehc-20221231.xsd#ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7aa02b5a-ddba-4a52-92e8-97d53a1fb4ba" xlink:to="loc_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions_f3289af0-f7bd-47fe-a6f6-36c8f136a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesComponentsofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_50a1340e-9c34-4878-87cf-de060df29ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_08bafea3-e5eb-45d8-ae7c-2a3218f1225b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50a1340e-9c34-4878-87cf-de060df29ef5" xlink:to="loc_us-gaap_OperatingLeaseCost_08bafea3-e5eb-45d8-ae7c-2a3218f1225b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_e51af2e3-8245-4608-8145-261fa116686e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50a1340e-9c34-4878-87cf-de060df29ef5" xlink:to="loc_us-gaap_LeaseCostAbstract_e51af2e3-8245-4608-8145-261fa116686e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ae88ebc5-f20f-4d65-bcd6-fcdd7634f375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_e51af2e3-8245-4608-8145-261fa116686e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_ae88ebc5-f20f-4d65-bcd6-fcdd7634f375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_b6556e4e-ca16-4da3-b4a4-1489eb09b705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_e51af2e3-8245-4608-8145-261fa116686e" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_b6556e4e-ca16-4da3-b4a4-1489eb09b705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalfinanceleasecost_62d35479-84db-40f2-bbae-7ccc9598a602" xlink:href="ehc-20221231.xsd#ehc_Totalfinanceleasecost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_e51af2e3-8245-4608-8145-261fa116686e" xlink:to="loc_ehc_Totalfinanceleasecost_62d35479-84db-40f2-bbae-7ccc9598a602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Shorttermandvariableleasecost_2e89fd40-5371-4ffa-b2a9-92cc3a0ebd48" xlink:href="ehc-20221231.xsd#ehc_Shorttermandvariableleasecost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50a1340e-9c34-4878-87cf-de060df29ef5" xlink:to="loc_ehc_Shorttermandvariableleasecost_2e89fd40-5371-4ffa-b2a9-92cc3a0ebd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_184816b2-ab46-4092-91d0-0225dc821296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50a1340e-9c34-4878-87cf-de060df29ef5" xlink:to="loc_us-gaap_SubleaseIncome_184816b2-ab46-4092-91d0-0225dc821296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7ec906b7-1d35-4c15-a578-d02e32532d21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50a1340e-9c34-4878-87cf-de060df29ef5" xlink:to="loc_us-gaap_LeaseCost_7ec906b7-1d35-4c15-a578-d02e32532d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2d5e77c8-f5e9-4060-8b0f-a3c89ab561f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1735e107-e6de-4c0a-a39b-d1eccc23ce33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2d5e77c8-f5e9-4060-8b0f-a3c89ab561f8" xlink:to="loc_us-gaap_AssetsAbstract_1735e107-e6de-4c0a-a39b-d1eccc23ce33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7b415154-e22c-45d2-b23b-09d5a069b48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1735e107-e6de-4c0a-a39b-d1eccc23ce33" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7b415154-e22c-45d2-b23b-09d5a069b48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_d48b81ac-33d9-43f2-8f58-a6a4d38650f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1735e107-e6de-4c0a-a39b-d1eccc23ce33" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_d48b81ac-33d9-43f2-8f58-a6a4d38650f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totaloperatingandfinanceleaseassets_853eca84-ab53-4b65-a54e-53b662ed82cd" xlink:href="ehc-20221231.xsd#ehc_Totaloperatingandfinanceleaseassets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1735e107-e6de-4c0a-a39b-d1eccc23ce33" xlink:to="loc_ehc_Totaloperatingandfinanceleaseassets_853eca84-ab53-4b65-a54e-53b662ed82cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_4be5f7a6-8af0-47d5-a42c-4c111c298ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2d5e77c8-f5e9-4060-8b0f-a3c89ab561f8" xlink:to="loc_us-gaap_LiabilitiesAbstract_4be5f7a6-8af0-47d5-a42c-4c111c298ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c2236722-0748-4cb3-9c50-23c1c44ffd32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4be5f7a6-8af0-47d5-a42c-4c111c298ff8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c2236722-0748-4cb3-9c50-23c1c44ffd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f665bd9-2aba-42c3-99bd-94d4739067aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c2236722-0748-4cb3-9c50-23c1c44ffd32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8f665bd9-2aba-42c3-99bd-94d4739067aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5937cb4f-10c6-4a60-9126-d1bdfc83baa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c2236722-0748-4cb3-9c50-23c1c44ffd32" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5937cb4f-10c6-4a60-9126-d1bdfc83baa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_f3c370e9-64f4-4fe5-8e27-cdee9594bf07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_4be5f7a6-8af0-47d5-a42c-4c111c298ff8" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_f3c370e9-64f4-4fe5-8e27-cdee9594bf07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_209ac18c-0d30-4e44-83ea-d43ac4831e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f3c370e9-64f4-4fe5-8e27-cdee9594bf07" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_209ac18c-0d30-4e44-83ea-d43ac4831e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_250d659d-6d70-4d1a-9285-3fe83927f433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f3c370e9-64f4-4fe5-8e27-cdee9594bf07" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_250d659d-6d70-4d1a-9285-3fe83927f433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Totalleaseliabilities_71ba7ef7-f26e-4863-9613-9881d42cdd02" xlink:href="ehc-20221231.xsd#ehc_Totalleaseliabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2d5e77c8-f5e9-4060-8b0f-a3c89ab561f8" xlink:to="loc_ehc_Totalleaseliabilities_71ba7ef7-f26e-4863-9613-9881d42cdd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_da94ed04-dc2a-44cd-aed5-1ba90322515c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2d5e77c8-f5e9-4060-8b0f-a3c89ab561f8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_da94ed04-dc2a-44cd-aed5-1ba90322515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_df351ebd-491e-4b25-b702-acbc7e7de0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2d5e77c8-f5e9-4060-8b0f-a3c89ab561f8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_df351ebd-491e-4b25-b702-acbc7e7de0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1759dca0-ad08-4e54-b7e6-c72576cab70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2d5e77c8-f5e9-4060-8b0f-a3c89ab561f8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1759dca0-ad08-4e54-b7e6-c72576cab70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_701a9dd5-808c-4a4e-a365-47457e14d192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2d5e77c8-f5e9-4060-8b0f-a3c89ab561f8" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_701a9dd5-808c-4a4e-a365-47457e14d192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f99dc311-6a6d-4df6-b235-e60f89603088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WeightedAverageRemainingLeaseTermAbstract_25a3695c-cf16-4c0e-b8a7-95e57f7145aa" xlink:href="ehc-20221231.xsd#ehc_WeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f99dc311-6a6d-4df6-b235-e60f89603088" xlink:to="loc_ehc_WeightedAverageRemainingLeaseTermAbstract_25a3695c-cf16-4c0e-b8a7-95e57f7145aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ad228ab7-ca3d-4710-94dd-8c91be7d9001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_WeightedAverageRemainingLeaseTermAbstract_25a3695c-cf16-4c0e-b8a7-95e57f7145aa" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ad228ab7-ca3d-4710-94dd-8c91be7d9001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_dc5b1a8f-2f8f-46fb-85cd-9327ec352bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_WeightedAverageRemainingLeaseTermAbstract_25a3695c-cf16-4c0e-b8a7-95e57f7145aa" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_dc5b1a8f-2f8f-46fb-85cd-9327ec352bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_WeightedAverageDiscountRateAbstract_97a4f47a-d147-481d-bc91-58602c929a14" xlink:href="ehc-20221231.xsd#ehc_WeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f99dc311-6a6d-4df6-b235-e60f89603088" xlink:to="loc_ehc_WeightedAverageDiscountRateAbstract_97a4f47a-d147-481d-bc91-58602c929a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ce73fe69-61a9-42d0-8089-507361f2f11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_WeightedAverageDiscountRateAbstract_97a4f47a-d147-481d-bc91-58602c929a14" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ce73fe69-61a9-42d0-8089-507361f2f11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_36f38286-75ee-4d8e-a2cf-3d74d55d6c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_WeightedAverageDiscountRateAbstract_97a4f47a-d147-481d-bc91-58602c929a14" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_36f38286-75ee-4d8e-a2cf-3d74d55d6c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2e4bfd81-79b3-48fa-8035-df8f55e00846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2e4bfd81-79b3-48fa-8035-df8f55e00846" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b8c16412-a8a8-40b5-9bb6-0f67fcff86f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b8c16412-a8a8-40b5-9bb6-0f67fcff86f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0f7cd921-9804-4147-ba9d-9dc1fe5be98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0f7cd921-9804-4147-ba9d-9dc1fe5be98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c4281730-2761-4599-bb32-abf60b2a00c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c4281730-2761-4599-bb32-abf60b2a00c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5701b4cc-d339-4437-a6b5-6fe34e2c057c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5701b4cc-d339-4437-a6b5-6fe34e2c057c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_814c16c0-dbc7-4b31-aa66-21d63681bbf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_814c16c0-dbc7-4b31-aa66-21d63681bbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_959525b8-283c-4ca9-9454-d40ae6aaa53e" xlink:href="ehc-20221231.xsd#ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter_959525b8-283c-4ca9-9454-d40ae6aaa53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f82ec3cc-d1e9-4a65-b54a-c2945dbfdb41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f82ec3cc-d1e9-4a65-b54a-c2945dbfdb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1ddd9f0-3f3d-4ee8-9216-f013d0cc486c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d1ddd9f0-3f3d-4ee8-9216-f013d0cc486c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b88bee19-327a-49b0-87cc-9645d09f8a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_86e1bc80-2492-4dd1-8860-736f261cb16b" xlink:to="loc_us-gaap_OperatingLeaseLiability_b88bee19-327a-49b0-87cc-9645d09f8a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2e4bfd81-79b3-48fa-8035-df8f55e00846" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d3e8e5e8-e80c-4261-96d9-152363abb4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d3e8e5e8-e80c-4261-96d9-152363abb4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_40b64e56-f1ee-4651-8434-065006d49267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_40b64e56-f1ee-4651-8434-065006d49267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1400ead5-8fa5-4166-8756-bb85062fb1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1400ead5-8fa5-4166-8756-bb85062fb1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2beeb515-ba25-4e0d-b85b-0fce085ad5b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_2beeb515-ba25-4e0d-b85b-0fce085ad5b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f976db83-fec2-4bdb-8586-74b17e72c169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_f976db83-fec2-4bdb-8586-74b17e72c169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_9fc31fba-14ae-4f05-aadb-3862c8ac4d2b" xlink:href="ehc-20221231.xsd#ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter_9fc31fba-14ae-4f05-aadb-3862c8ac4d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_af28accb-c52b-4e7c-9581-ea0a16501530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_af28accb-c52b-4e7c-9581-ea0a16501530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b7825ca8-97c8-4ce1-8286-63298f5b67f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_b7825ca8-97c8-4ce1-8286-63298f5b67f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_817a08b9-6988-4574-8a32-d646e5fb3f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_557e8b30-c529-438b-bebf-7e8d139d5a39" xlink:to="loc_us-gaap_FinanceLeaseLiability_817a08b9-6988-4574-8a32-d646e5fb3f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d48e741c-a4f0-45ce-a73d-7d52a21d6302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_3317cc3b-4353-43e4-96c2-fbcf61483ce2" xlink:href="ehc-20221231.xsd#ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d48e741c-a4f0-45ce-a73d-7d52a21d6302" xlink:to="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_3317cc3b-4353-43e4-96c2-fbcf61483ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_9a44db02-fa33-4e7e-85f9-10edc5ed08b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_3317cc3b-4353-43e4-96c2-fbcf61483ce2" xlink:to="loc_us-gaap_OperatingLeasePayments_9a44db02-fa33-4e7e-85f9-10edc5ed08b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_1965b257-cf2e-4299-9513-cddaf0d83d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_3317cc3b-4353-43e4-96c2-fbcf61483ce2" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_1965b257-cf2e-4299-9513-cddaf0d83d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_62aa93d6-acf0-4076-a723-9f81f3c2d715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract_3317cc3b-4353-43e4-96c2-fbcf61483ce2" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_62aa93d6-acf0-4076-a723-9f81f3c2d715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_d8b76012-c696-4f96-a72e-905eebda385d" xlink:href="ehc-20221231.xsd#ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d48e741c-a4f0-45ce-a73d-7d52a21d6302" xlink:to="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_d8b76012-c696-4f96-a72e-905eebda385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_430c1d3d-f540-46a1-b23e-a758292df318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_d8b76012-c696-4f96-a72e-905eebda385d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_430c1d3d-f540-46a1-b23e-a758292df318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_248ee5f7-ebbb-470c-9eac-307b7862d8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract_d8b76012-c696-4f96-a72e-905eebda385d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_248ee5f7-ebbb-470c-9eac-307b7862d8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e2947f6a-94e1-48cc-a046-4dd0f1852af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_c2986edd-69e0-4662-b8f5-5d23277172e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e2947f6a-94e1-48cc-a046-4dd0f1852af5" xlink:to="loc_us-gaap_GoodwillRollForward_c2986edd-69e0-4662-b8f5-5d23277172e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a5a775a-fdcc-4b46-966b-0768b3412b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c2986edd-69e0-4662-b8f5-5d23277172e7" xlink:to="loc_us-gaap_Goodwill_3a5a775a-fdcc-4b46-966b-0768b3412b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_f9430826-8c2e-4e87-96c7-64f5f5b9b57b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c2986edd-69e0-4662-b8f5-5d23277172e7" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_f9430826-8c2e-4e87-96c7-64f5f5b9b57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_a5604ade-214c-4d0f-a436-e448bda553b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_c2986edd-69e0-4662-b8f5-5d23277172e7" xlink:to="loc_us-gaap_Goodwill_a5604ade-214c-4d0f-a436-e448bda553b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssetsTextualsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b097f2ca-4e07-4373-aa47-e55e99148c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_ffb3d44c-9502-46c1-8a4b-54635cbd8590" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b097f2ca-4e07-4373-aa47-e55e99148c7a" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_ffb3d44c-9502-46c1-8a4b-54635cbd8590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_8182aa6a-d24e-4045-8e5f-35ecfa76cda7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b097f2ca-4e07-4373-aa47-e55e99148c7a" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_8182aa6a-d24e-4045-8e5f-35ecfa76cda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3632b7ed-eacf-406c-833f-00f50880191c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e6f177e-7734-4807-abb1-08489acbf04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3632b7ed-eacf-406c-833f-00f50880191c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e6f177e-7734-4807-abb1-08489acbf04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d61fb1ae-e677-4663-943b-79f05fcabb61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e6f177e-7734-4807-abb1-08489acbf04a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d61fb1ae-e677-4663-943b-79f05fcabb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d61fb1ae-e677-4663-943b-79f05fcabb61" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CertificateOfNeedMember_a4246278-3b8a-44c9-9731-1515d16f2144" xlink:href="ehc-20221231.xsd#ehc_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_ehc_CertificateOfNeedMember_a4246278-3b8a-44c9-9731-1515d16f2144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_53b6f1ab-b019-42cf-b6b2-3eba8cef4097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_us-gaap_LicensingAgreementsMember_53b6f1ab-b019-42cf-b6b2-3eba8cef4097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncompeteAgreementsMember_cbb14940-9fa5-4648-b6cb-669ace5aee5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncompeteAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_us-gaap_NoncompeteAgreementsMember_cbb14940-9fa5-4648-b6cb-669ace5aee5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TradeNameEncompassMember_00335f23-a896-4fca-8baa-cadc5e0df508" xlink:href="ehc-20221231.xsd#ehc_TradeNameEncompassMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_ehc_TradeNameEncompassMember_00335f23-a896-4fca-8baa-cadc5e0df508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_1a668d5c-54cc-46e5-b047-3de8e1cec534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_us-gaap_TradeNamesMember_1a668d5c-54cc-46e5-b047-3de8e1cec534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_2d8ebfbc-3e0e-4097-8ecf-89592160337f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_2d8ebfbc-3e0e-4097-8ecf-89592160337f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MarketAccessAssetsMember_5d3ac657-8cc0-46ab-b037-41382b5df597" xlink:href="ehc-20221231.xsd#ehc_MarketAccessAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e0e3b735-b557-4961-b5b2-3b23850849db" xlink:to="loc_ehc_MarketAccessAssetsMember_5d3ac657-8cc0-46ab-b037-41382b5df597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e26aa01c-a7aa-4274-80e5-0287ca4a1bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9e6f177e-7734-4807-abb1-08489acbf04a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e26aa01c-a7aa-4274-80e5-0287ca4a1bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_e26aa01c-a7aa-4274-80e5-0287ca4a1bca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b232ce3a-cd58-4059-b464-a181ecb10491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b232ce3a-cd58-4059-b464-a181ecb10491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3c91d452-0cbd-4e6f-b823-f9403349ef3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3c91d452-0cbd-4e6f-b823-f9403349ef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4e3b66e-31d9-4e25-b9d4-e2d94f518dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_43fdca2f-d346-4d95-adef-0be57ae45dfc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c4e3b66e-31d9-4e25-b9d4-e2d94f518dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1011e638-f5e5-4153-b277-0a153a6ed937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_09facda2-dcaa-495c-bbae-2aca9699084f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1011e638-f5e5-4153-b277-0a153a6ed937" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_09facda2-dcaa-495c-bbae-2aca9699084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad0a29d8-1a6a-45b3-a70a-661b393ba911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c0c65248-1d7f-4845-af1a-0fbf7bd01d88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ad0a29d8-1a6a-45b3-a70a-661b393ba911" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c0c65248-1d7f-4845-af1a-0fbf7bd01d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_68656ad8-d036-444a-8b4a-1f7ed250a158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c0c65248-1d7f-4845-af1a-0fbf7bd01d88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_68656ad8-d036-444a-8b4a-1f7ed250a158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_047f6756-af89-47ea-bf8c-0e33cd23a77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c0c65248-1d7f-4845-af1a-0fbf7bd01d88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_047f6756-af89-47ea-bf8c-0e33cd23a77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dc4ae375-1de6-4b69-b5ca-e50c6c14b31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c0c65248-1d7f-4845-af1a-0fbf7bd01d88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_dc4ae375-1de6-4b69-b5ca-e50c6c14b31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1686623b-9ce3-4cff-9c8e-820b26298f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c0c65248-1d7f-4845-af1a-0fbf7bd01d88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1686623b-9ce3-4cff-9c8e-820b26298f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e2f91392-41e4-4e1a-bb9d-af6f5fd5fab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_c0c65248-1d7f-4845-af1a-0fbf7bd01d88" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e2f91392-41e4-4e1a-bb9d-af6f5fd5fab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtLongtermDebtOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_80e8467f-3d16-4de0-b350-269180e756e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_80e8467f-3d16-4de0-b350-269180e756e3" xlink:to="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a4a1a201-3f0b-4ff6-adfe-4384127a0bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:to="loc_us-gaap_CreditFacilityAxis_a4a1a201-3f0b-4ff6-adfe-4384127a0bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_65a61b16-ddcf-4c92-9625-98c153d83a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a4a1a201-3f0b-4ff6-adfe-4384127a0bba" xlink:to="loc_us-gaap_CreditFacilityDomain_65a61b16-ddcf-4c92-9625-98c153d83a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_d24426fc-7bdb-497a-a0c5-b4cec1404be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_65a61b16-ddcf-4c92-9625-98c153d83a54" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_d24426fc-7bdb-497a-a0c5-b4cec1404be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_cbebeb49-cc10-4b7b-8bb9-009761f12767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_65a61b16-ddcf-4c92-9625-98c153d83a54" xlink:to="loc_us-gaap_SecuredDebtMember_cbebeb49-cc10-4b7b-8bb9-009761f12767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_be3d1753-b99b-4486-826a-0fc781948db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_be3d1753-b99b-4486-826a-0fc781948db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_be3d1753-b99b-4486-826a-0fc781948db7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_170a5503-5cf7-464c-9079-e7ba0d593dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:to="loc_us-gaap_LineOfCreditMember_170a5503-5cf7-464c-9079-e7ba0d593dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_15af5447-88fc-4034-a2ca-34de6efbfd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:to="loc_us-gaap_SeniorNotesMember_15af5447-88fc-4034-a2ca-34de6efbfd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_f641837c-df8b-44c0-bb16-f6a2c1001338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b1891633-86a0-4e0a-82a2-6f763d2fcfe2" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_f641837c-df8b-44c0-bb16-f6a2c1001338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e1428893-ac1c-46c6-89f9-246f31fdbffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:to="loc_us-gaap_DebtInstrumentAxis_e1428893-ac1c-46c6-89f9-246f31fdbffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e1428893-ac1c-46c6-89f9-246f31fdbffd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TheCreditAgreementMember_f5dd02ca-fefd-4994-b720-61d32989fcaf" xlink:href="ehc-20221231.xsd#ehc_TheCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_TheCreditAgreementMember_f5dd02ca-fefd-4994-b720-61d32989fcaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_45897bc1-e13e-4385-80f9-3db58a9b4314" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_45897bc1-e13e-4385-80f9-3db58a9b4314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_ec374597-300c-4186-acb0-99c40c8cd6cd" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_ec374597-300c-4186-acb0-99c40c8cd6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_633b5849-6f7c-4972-b121-65d383dc2469" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_633b5849-6f7c-4972-b121-65d383dc2469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_04e0112e-5ed6-453d-a0f6-5ee77c073f40" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_04e0112e-5ed6-453d-a0f6-5ee77c073f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_93521221-52f9-4aeb-9d20-1adde59e920b" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_82a1d9a0-31ab-492a-9194-884aa6a47145" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_93521221-52f9-4aeb-9d20-1adde59e920b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_15d7282b-2d00-4374-8143-856d4591e5df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f8968178-93e0-474e-a448-8eadbaa0177f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_15d7282b-2d00-4374-8143-856d4591e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_15d7282b-2d00-4374-8143-856d4591e5df" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_21b0e5d8-f836-4556-a649-cd6141631a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_21b0e5d8-f836-4556-a649-cd6141631a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3ee108c2-4c75-489f-b949-0a5b64f19cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_LongTermDebt_3ee108c2-4c75-489f-b949-0a5b64f19cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_84ee87ef-1022-40da-99d8-61ec0177e579" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_FinanceLeaseLiability_84ee87ef-1022-40da-99d8-61ec0177e579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_adedcb60-2407-4096-a0dd-82438074ce02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_adedcb60-2407-4096-a0dd-82438074ce02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b4f82c92-ac05-4ad5-ad2e-d2d126191861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_b4f82c92-ac05-4ad5-ad2e-d2d126191861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_cbb228b1-a424-41b1-b4bc-05a14d7cf8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract_b0127916-3b8e-4a41-9ed5-cb8ca007fed4" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_cbb228b1-a424-41b1-b4bc-05a14d7cf8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtLongtermDebtOutstandingDetails_1"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c187fc97-66e8-4462-83c6-5faa98b525c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_342c2270-b5ac-4696-aa56-1228cf945330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c187fc97-66e8-4462-83c6-5faa98b525c5" xlink:to="loc_us-gaap_DebtInstrumentTable_342c2270-b5ac-4696-aa56-1228cf945330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c19f8c56-bc08-4926-b1ad-d0a46a3012fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_342c2270-b5ac-4696-aa56-1228cf945330" xlink:to="loc_us-gaap_DebtInstrumentAxis_c19f8c56-bc08-4926-b1ad-d0a46a3012fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8a922964-0f6d-4975-bfa9-692236ad6ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c19f8c56-bc08-4926-b1ad-d0a46a3012fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8a922964-0f6d-4975-bfa9-692236ad6ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_FaceAmountMember_a11dcedb-7f68-4182-8eac-b04bf0c5a7ca" xlink:href="ehc-20221231.xsd#ehc_FaceAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a922964-0f6d-4975-bfa9-692236ad6ab0" xlink:to="loc_ehc_FaceAmountMember_a11dcedb-7f68-4182-8eac-b04bf0c5a7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NetAmountMember_7df513e5-e234-424b-9bb4-e5e277e1c390" xlink:href="ehc-20221231.xsd#ehc_NetAmountMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8a922964-0f6d-4975-bfa9-692236ad6ab0" xlink:to="loc_ehc_NetAmountMember_7df513e5-e234-424b-9bb4-e5e277e1c390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_80b526af-c2de-4056-acc7-62ae2a7f2da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_342c2270-b5ac-4696-aa56-1228cf945330" xlink:to="loc_us-gaap_DebtInstrumentLineItems_80b526af-c2de-4056-acc7-62ae2a7f2da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_80b526af-c2de-4056-acc7-62ae2a7f2da6" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_cdaad997-7f86-4912-849e-1a748e06991c" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne_cdaad997-7f86-4912-849e-1a748e06991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_08e4dd3d-5850-4a3e-b9e3-82bc131a6ec4" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo_08e4dd3d-5850-4a3e-b9e3-82bc131a6ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_eff3a5ff-a578-4c49-8f0a-9302ef57e186" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree_eff3a5ff-a578-4c49-8f0a-9302ef57e186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_a7d3d45a-f861-459a-9f95-75c5e65febdb" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour_a7d3d45a-f861-459a-9f95-75c5e65febdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_c6a37db7-00be-4aa6-a99f-91a487655153" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive_c6a37db7-00be-4aa6-a99f-91a487655153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_22e70126-561f-4e09-8051-dbd189364bb2" xlink:href="ehc-20221231.xsd#ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive_22e70126-561f-4e09-8051-dbd189364bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_77753571-370d-46aa-a872-465f7c53d1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract_86ba5da3-5cc5-4f5f-b50a-36163ea8f3f5" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities_77753571-370d-46aa-a872-465f7c53d1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2932af86-35eb-445d-8abe-76f09f23895b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2932af86-35eb-445d-8abe-76f09f23895b" xlink:to="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ed58d72e-e218-494e-827b-c2916b544ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_DebtInstrumentAxis_ed58d72e-e218-494e-827b-c2916b544ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ed58d72e-e218-494e-827b-c2916b544ffd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TheCreditAgreementMember_51488001-1836-4009-8578-91c05e68105d" xlink:href="ehc-20221231.xsd#ehc_TheCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_TheCreditAgreementMember_51488001-1836-4009-8578-91c05e68105d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_51f3e640-c479-4a3b-b932-3dc0700e9695" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_51f3e640-c479-4a3b-b932-3dc0700e9695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes0575Due2024Member_4f93c259-ade7-448f-aea1-17837ee88e51" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes0575Due2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes0575Due2024Member_4f93c259-ade7-448f-aea1-17837ee88e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_ea0a5813-390d-44d9-98b9-f0c23668ae90" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_ea0a5813-390d-44d9-98b9-f0c23668ae90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_7bdbe180-9407-4d7c-b217-079c206e8760" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_7bdbe180-9407-4d7c-b217-079c206e8760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_5fec2a5e-6323-43f6-a3bb-d809d194a5d8" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_5fec2a5e-6323-43f6-a3bb-d809d194a5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_b1a1d2e8-dbd1-4588-96d8-a1591896ee05" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c866eca-2a3d-4ae6-8a32-71873994bb9a" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_b1a1d2e8-dbd1-4588-96d8-a1591896ee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_844b2cb4-9327-4bb4-8d63-14d3851c2559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_CreditFacilityAxis_844b2cb4-9327-4bb4-8d63-14d3851c2559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_844b2cb4-9327-4bb4-8d63-14d3851c2559" xlink:to="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_6b2fe79d-0a8d-4a84-9834-1f7e6342c4e4" xlink:href="ehc-20221231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:to="loc_ehc_TermLoanFacilitiesMember_6b2fe79d-0a8d-4a84-9834-1f7e6342c4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_bfe62490-fcb5-429f-ac01-f885148dc889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_bfe62490-fcb5-429f-ac01-f885148dc889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c3b7bb37-e77c-4ca8-ae83-39e98e61cdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:to="loc_us-gaap_LetterOfCreditMember_c3b7bb37-e77c-4ca8-ae83-39e98e61cdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_22199179-549c-401b-a929-262d7644f2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_f55b03bd-9f5f-455f-bbff-c53f6383f37e" xlink:to="loc_us-gaap_SecuredDebtMember_22199179-549c-401b-a929-262d7644f2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_VariableRateAxis_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e3148212-28bc-45d3-acb7-48e745ca1de6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_e6d6898c-80f4-4b1c-811c-2dc56bbaf19a" xlink:to="loc_us-gaap_VariableRateDomain_e3148212-28bc-45d3-acb7-48e745ca1de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_3e8fa060-fade-4173-baa4-f208e0ca3bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e3148212-28bc-45d3-acb7-48e745ca1de6" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_3e8fa060-fade-4173-baa4-f208e0ca3bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SecuredOvernightFinancingRateSOFRMember_1a3ff148-cb98-4ab5-b8e2-c4ed55b3572b" xlink:href="ehc-20221231.xsd#ehc_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e3148212-28bc-45d3-acb7-48e745ca1de6" xlink:to="loc_ehc_SecuredOvernightFinancingRateSOFRMember_1a3ff148-cb98-4ab5-b8e2-c4ed55b3572b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_14a846b2-c6e5-41a5-9318-699683c1cde3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_14a846b2-c6e5-41a5-9318-699683c1cde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_14a846b2-c6e5-41a5-9318-699683c1cde3" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_81a3ce9b-991e-4424-9c0f-c1805b882ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:to="loc_us-gaap_LoansPayableMember_81a3ce9b-991e-4424-9c0f-c1805b882ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_29d5219a-076f-490c-8820-ff172314bff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:to="loc_us-gaap_SeniorNotesMember_29d5219a-076f-490c-8820-ff172314bff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ae1e25fe-5599-490a-9f7e-660f94894e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_64a9d21a-b61b-49f0-b0d0-07d4f0832a58" xlink:to="loc_us-gaap_LineOfCreditMember_ae1e25fe-5599-490a-9f7e-660f94894e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_83b7587f-7ba3-41e9-9e40-3ece83f24ca2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_srt_RangeAxis_83b7587f-7ba3-41e9-9e40-3ece83f24ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6b2363d-ec2f-4bd2-bfeb-db662a5f860e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_83b7587f-7ba3-41e9-9e40-3ece83f24ca2" xlink:to="loc_srt_RangeMember_a6b2363d-ec2f-4bd2-bfeb-db662a5f860e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_98a1f531-e76f-4e34-8d10-44019de20b72" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6b2363d-ec2f-4bd2-bfeb-db662a5f860e" xlink:to="loc_srt_MaximumMember_98a1f531-e76f-4e34-8d10-44019de20b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_448d1525-9053-43d2-9f4d-79e3cee47a18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6b2363d-ec2f-4bd2-bfeb-db662a5f860e" xlink:to="loc_srt_MinimumMember_448d1525-9053-43d2-9f4d-79e3cee47a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e3aecc3e-9b9e-427b-8519-33c37a98dd30" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_dei_LegalEntityAxis_e3aecc3e-9b9e-427b-8519-33c37a98dd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0042a1ee-dbf3-4b44-9bd1-2ab0f98cf656" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e3aecc3e-9b9e-427b-8519-33c37a98dd30" xlink:to="loc_dei_EntityDomain_0042a1ee-dbf3-4b44-9bd1-2ab0f98cf656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EnhabitMember_45a9c6d7-4342-4589-9d72-31bb276fbb9f" xlink:href="ehc-20221231.xsd#ehc_EnhabitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0042a1ee-dbf3-4b44-9bd1-2ab0f98cf656" xlink:to="loc_ehc_EnhabitMember_45a9c6d7-4342-4589-9d72-31bb276fbb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_44782a66-38a2-49d3-be8a-d6cf5cb9fe4d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c7e5d4d5-9cb1-43da-93bf-e5d608787d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c7e5d4d5-9cb1-43da-93bf-e5d608787d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8aee5262-a488-4c89-8b11-8244147118be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_8aee5262-a488-4c89-8b11-8244147118be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_dbe34cc4-3681-4a34-84a6-de36aa419204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_dbe34cc4-3681-4a34-84a6-de36aa419204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_062009b7-07d7-4f72-9c8d-3fed92316a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_062009b7-07d7-4f72-9c8d-3fed92316a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum_ad1191e3-8698-49b7-954d-223a6784d842" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatioMaximum_ad1191e3-8698-49b7-954d-223a6784d842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantAvailableLimitAmount_b1b4e921-224c-4e0f-a652-f1d3a9bd8d4c" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantAvailableLimitAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantAvailableLimitAmount_b1b4e921-224c-4e0f-a652-f1d3a9bd8d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod_f135ba14-f30f-4b3d-9330-c0841a20aa66" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod_f135ba14-f30f-4b3d-9330-c0841a20aa66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum_25576601-a660-4156-9fc5-f5af35cf80c0" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum_25576601-a660-4156-9fc5-f5af35cf80c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays_3ab32265-10aa-47d6-933c-c5fc0187262a" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays_3ab32265-10aa-47d6-933c-c5fc0187262a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e77d2045-4040-4aab-8626-15ed3403b43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e77d2045-4040-4aab-8626-15ed3403b43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion_adc6a161-d762-4b99-92e1-13b73d907c11" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion_adc6a161-d762-4b99-92e1-13b73d907c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_64f5d31b-b31c-43f1-be08-12d6d90a3963" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_64f5d31b-b31c-43f1-be08-12d6d90a3963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_97a04313-01d3-42b6-9e4b-c02e9de5f7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_97a04313-01d3-42b6-9e4b-c02e9de5f7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome_d1250c7c-b1c1-45b1-9428-efcdfda4a4e8" xlink:href="ehc-20221231.xsd#ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome_d1250c7c-b1c1-45b1-9428-efcdfda4a4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDistributionsToAffiliates_57aa79bc-df38-4819-b306-8681f5c2eb43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDistributionsToAffiliates"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_PaymentsOfDistributionsToAffiliates_57aa79bc-df38-4819-b306-8681f5c2eb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_27ae3fa9-5742-43e6-932a-97f1d281438e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_27ae3fa9-5742-43e6-932a-97f1d281438e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_d88533ab-c72b-4594-8252-6f8f4a63fa00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_d88533ab-c72b-4594-8252-6f8f4a63fa00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cd1e4c44-a20c-45da-a826-61bd0d5add2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LongTermDebt_cd1e4c44-a20c-45da-a826-61bd0d5add2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_075725cc-8fc2-45e7-869d-c5ac98f333b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_075725cc-8fc2-45e7-869d-c5ac98f333b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_178876d9-3cf2-4d5a-9de4-75ea78acca99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_178876d9-3cf2-4d5a-9de4-75ea78acca99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5e965fb2-07de-4d0c-a7f9-f7bc330e8d89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5e965fb2-07de-4d0c-a7f9-f7bc330e8d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_da952a97-8cf1-4b77-ad51-b29601fcd6d9" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket_da952a97-8cf1-4b77-ad51-b29601fcd6d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_f969acc0-f959-4013-bb71-7fa3f90d7265" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentAmendmentAgreementAmountToBePaid"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid_f969acc0-f959-4013-bb71-7fa3f90d7265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_7209167d-71c5-49d9-a38d-7fc721018fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_RepaymentsOfDebt_7209167d-71c5-49d9-a38d-7fc721018fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_782230b9-5b39-493a-9981-a3aba2d6e323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_782230b9-5b39-493a-9981-a3aba2d6e323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_4cf5b344-e16d-4040-be50-67bf086a24fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_4cf5b344-e16d-4040-be50-67bf086a24fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_604af134-c52b-4ad9-8f20-5f6f9e81dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_604af134-c52b-4ad9-8f20-5f6f9e81dfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_751c4c43-c48e-4fd2-9ee2-4fe1dbdecee5" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue_751c4c43-c48e-4fd2-9ee2-4fe1dbdecee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_37f26f92-da66-4194-9695-4fb7fdc19a32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8bc16da9-1dae-43a8-9e08-fc8993520787" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_37f26f92-da66-4194-9695-4fb7fdc19a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtFinancialCovenantsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9454f574-71e6-4e30-9c71-ecf0322907ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f18ead9a-b9e9-4c54-a77c-e7b670c4c87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9454f574-71e6-4e30-9c71-ecf0322907ca" xlink:to="loc_us-gaap_DebtInstrumentTable_f18ead9a-b9e9-4c54-a77c-e7b670c4c87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7b6d5524-3603-470d-a0cf-a57f2b8453d8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f18ead9a-b9e9-4c54-a77c-e7b670c4c87f" xlink:to="loc_srt_StatementScenarioAxis_7b6d5524-3603-470d-a0cf-a57f2b8453d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e7c369ee-f767-45b3-bb5c-308b03ffee93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7b6d5524-3603-470d-a0cf-a57f2b8453d8" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e7c369ee-f767-45b3-bb5c-308b03ffee93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_3910d19d-12b9-4be1-9b49-259e6530a114" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_e7c369ee-f767-45b3-bb5c-308b03ffee93" xlink:to="loc_srt_ScenarioForecastMember_3910d19d-12b9-4be1-9b49-259e6530a114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems_a5f32a5d-77f7-4f03-ab05-73527325905d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f18ead9a-b9e9-4c54-a77c-e7b670c4c87f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionLineItems_a5f32a5d-77f7-4f03-ab05-73527325905d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_b04e7ddf-8a6f-46ad-8ca9-66e00af3b5fa" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantInterestCoverageRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_a5f32a5d-77f7-4f03-ab05-73527325905d" xlink:to="loc_ehc_DebtInstrumentCovenantInterestCoverageRatio_b04e7ddf-8a6f-46ad-8ca9-66e00af3b5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DebtInstrumentCovenantLeverageRatio_84e765b7-380f-445a-905f-757357253b9e" xlink:href="ehc-20221231.xsd#ehc_DebtInstrumentCovenantLeverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_a5f32a5d-77f7-4f03-ab05-73527325905d" xlink:to="loc_ehc_DebtInstrumentCovenantLeverageRatio_84e765b7-380f-445a-905f-757357253b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtSeniorNotesRedemptionPricesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0b9b4d3b-8390-4dee-810d-78dd9baff145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0b9b4d3b-8390-4dee-810d-78dd9baff145" xlink:to="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7a885289-f6a1-41c6-86e7-fd90208de745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7a885289-f6a1-41c6-86e7-fd90208de745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3748f2a5-0e65-45f5-a310-a5eb4c847499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7a885289-f6a1-41c6-86e7-fd90208de745" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3748f2a5-0e65-45f5-a310-a5eb4c847499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_0a0dbc58-875e-461d-9c8a-8f0afaaec802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3748f2a5-0e65-45f5-a310-a5eb4c847499" xlink:to="loc_us-gaap_SeniorNotesMember_0a0dbc58-875e-461d-9c8a-8f0afaaec802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_08722f77-b4a4-4a8e-94c9-795dd917d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:to="loc_us-gaap_DebtInstrumentAxis_08722f77-b4a4-4a8e-94c9-795dd917d02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_08722f77-b4a4-4a8e-94c9-795dd917d02b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_83e838c9-4c28-4fb8-b621-0c996d173116" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_83e838c9-4c28-4fb8-b621-0c996d173116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_839888b9-38ad-4bce-b5d7-e008c3c38215" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_839888b9-38ad-4bce-b5d7-e008c3c38215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_dad9ee0c-93dc-4369-950d-1e71a8336e50" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_dad9ee0c-93dc-4369-950d-1e71a8336e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_8afb9472-4a9c-448b-8138-ea583c247de6" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2254b05d-eb30-4075-ba12-513699a62f21" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_8afb9472-4a9c-448b-8138-ea583c247de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_250cdb68-5b5f-4fbc-b6fe-5703c77b7dc7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1aadd554-78ef-4cfc-a3d3-a7626b51755f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1aadd554-78ef-4cfc-a3d3-a7626b51755f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4ad425e0-39ef-4383-9800-3fc4aaf13112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_4ad425e0-39ef-4383-9800-3fc4aaf13112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a653141b-63e6-47e3-b03d-b360862e8ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_a653141b-63e6-47e3-b03d-b360862e8ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_b7ec0467-89ef-49ac-9475-f2d1aa5edfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_28782bbb-f45f-44b5-9552-50e3075c7d3a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodFourMember_b7ec0467-89ef-49ac-9475-f2d1aa5edfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionLineItems_41c1ce4d-bf19-4674-907c-1c89520a0494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionTable_34916122-97c0-4dd0-b0e0-26f89b6d11ce" xlink:to="loc_us-gaap_DebtInstrumentRedemptionLineItems_41c1ce4d-bf19-4674-907c-1c89520a0494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_65593585-c9a4-4961-8045-fd4a62ca3d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionLineItems_41c1ce4d-bf19-4674-907c-1c89520a0494" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_65593585-c9a4-4961-8045-fd4a62ca3d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#LongtermDebtScheduleofNotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6ebe5dea-f03f-4011-8b52-23286b3fb61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6ebe5dea-f03f-4011-8b52-23286b3fb61b" xlink:to="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d3877316-119a-4be7-b716-895a45f7bfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d3877316-119a-4be7-b716-895a45f7bfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d1de78b1-2cec-47a9-bc1f-fb033024004e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d3877316-119a-4be7-b716-895a45f7bfb1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d1de78b1-2cec-47a9-bc1f-fb033024004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_ea2f9536-2e57-46da-9330-4e9c68596467" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d1de78b1-2cec-47a9-bc1f-fb033024004e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_ea2f9536-2e57-46da-9330-4e9c68596467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5e78b9d2-88b6-478c-b659-3b74c70feff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_us-gaap_DebtInstrumentAxis_5e78b9d2-88b6-478c-b659-3b74c70feff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5e78b9d2-88b6-478c-b659-3b74c70feff6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_29e2098a-ed0f-400c-8db3-0c99516b876d" xlink:href="ehc-20221231.xsd#ehc_NotesPayableRealEstateSaleLeasebackFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:to="loc_ehc_NotesPayableRealEstateSaleLeasebackFinancingMember_29e2098a-ed0f-400c-8db3-0c99516b876d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_3c4b973b-c66d-431e-a646-d3aa9572b606" xlink:href="ehc-20221231.xsd#ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:to="loc_ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember_3c4b973b-c66d-431e-a646-d3aa9572b606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NotesPayableSoftwareContractsMember_bf6eded1-e0d1-4728-8f3b-674a04e87d60" xlink:href="ehc-20221231.xsd#ehc_NotesPayableSoftwareContractsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0391cf60-bae4-483f-b487-ac627064f51f" xlink:to="loc_ehc_NotesPayableSoftwareContractsMember_bf6eded1-e0d1-4728-8f3b-674a04e87d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ef34d42-ce61-4d2d-8b6e-043e838373fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_srt_RangeAxis_9ef34d42-ce61-4d2d-8b6e-043e838373fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a4cb3db-4236-4516-93ad-c7602ac21a0d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9ef34d42-ce61-4d2d-8b6e-043e838373fd" xlink:to="loc_srt_RangeMember_7a4cb3db-4236-4516-93ad-c7602ac21a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0783243b-6c4b-4463-9e79-682325808df8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a4cb3db-4236-4516-93ad-c7602ac21a0d" xlink:to="loc_srt_MinimumMember_0783243b-6c4b-4463-9e79-682325808df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_56fc3453-8e76-4817-8864-bec276668bf8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7a4cb3db-4236-4516-93ad-c7602ac21a0d" xlink:to="loc_srt_MaximumMember_56fc3453-8e76-4817-8864-bec276668bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_us-gaap_VariableRateAxis_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b226df75-1acb-4b5c-bb70-d9538a9d3b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7aa2a4fc-4789-4b63-8fbd-5b5154200f1b" xlink:to="loc_us-gaap_VariableRateDomain_b226df75-1acb-4b5c-bb70-d9538a9d3b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SecuredOvernightFinancingRateSOFRMember_06c7a0e3-2f9d-44b9-b7df-d7927553d6c2" xlink:href="ehc-20221231.xsd#ehc_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b226df75-1acb-4b5c-bb70-d9538a9d3b4b" xlink:to="loc_ehc_SecuredOvernightFinancingRateSOFRMember_06c7a0e3-2f9d-44b9-b7df-d7927553d6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_3cd5f3ec-e1e3-42ed-99b0-dd942a396763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_461600ed-7518-449b-a3f1-feaf1c3f40ab" xlink:to="loc_us-gaap_DebtInstrumentLineItems_3cd5f3ec-e1e3-42ed-99b0-dd942a396763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_25bfef24-e791-4aa0-a3e7-b97819bf568c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cd5f3ec-e1e3-42ed-99b0-dd942a396763" xlink:to="loc_us-gaap_LongTermDebt_25bfef24-e791-4aa0-a3e7-b97819bf568c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ab42bd6e-65de-424d-a361-81f5420f8beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_3cd5f3ec-e1e3-42ed-99b0-dd942a396763" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_ab42bd6e-65de-424d-a361-81f5420f8beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SelfInsuredRisksTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_50ee1754-8f85-453d-9c70-a79971420583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_c9fb7553-45fe-46a2-ade5-2f03b0d9d62b" xlink:href="ehc-20221231.xsd#ehc_MaximumSelfInsuredAmountFirstLayerOfRisk"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_50ee1754-8f85-453d-9c70-a79971420583" xlink:to="loc_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk_c9fb7553-45fe-46a2-ade5-2f03b0d9d62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent_822da2a6-3b15-44f4-abbe-d9d71da1ac8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_50ee1754-8f85-453d-9c70-a79971420583" xlink:to="loc_us-gaap_SelfInsuranceReserveCurrent_822da2a6-3b15-44f4-abbe-d9d71da1ac8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_5ac2d2fc-f7ae-4037-9d49-0a46b54d6fce" xlink:href="ehc-20221231.xsd#ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_50ee1754-8f85-453d-9c70-a79971420583" xlink:to="loc_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves_5ac2d2fc-f7ae-4037-9d49-0a46b54d6fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#SelfInsuredRisksChangesinSelfinsuranceReservesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_be4bbf23-c3fb-449e-a316-f918a9043185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_be4bbf23-c3fb-449e-a316-f918a9043185" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_e1d70baf-0d15-4bb1-b93c-e3caf8a050d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_e1d70baf-0d15-4bb1-b93c-e3caf8a050d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_8290b53a-253d-4429-9142-e74d67e1124f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_8290b53a-253d-4429-9142-e74d67e1124f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_db48e5ff-4d2f-476f-b5b8-d26365742e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_db48e5ff-4d2f-476f-b5b8-d26365742e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_bd81b787-720b-4e77-8adf-5c052624a431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_bd81b787-720b-4e77-8adf-5c052624a431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_60e05cbc-955a-4d8e-a965-c600f0804093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_60e05cbc-955a-4d8e-a965-c600f0804093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_4628e84d-09c0-4639-bc36-45f953e3fc77" xlink:href="ehc-20221231.xsd#ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations_4628e84d-09c0-4639-bc36-45f953e3fc77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_07e10388-7996-4332-86ef-192a9bb7a62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_07e10388-7996-4332-86ef-192a9bb7a62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_786192e9-7ba4-4ff0-9259-98421a1cde1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_786192e9-7ba4-4ff0-9259-98421a1cde1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_476abbb7-fe34-4780-a93b-8d30eb5aad15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet_476abbb7-fe34-4780-a93b-8d30eb5aad15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ba010886-6dcf-4673-beb0-d833fb6312e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ba010886-6dcf-4673-beb0-d833fb6312e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c67df88a-6c2b-4c13-83c4-dfbfe81ed3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_78022587-5a0a-4842-a657-c186fe7a7ed9" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c67df88a-6c2b-4c13-83c4-dfbfe81ed3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_334c20c2-b60c-4532-9ba3-d4fe221cd0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_7b4846ea-9d04-461d-8364-92a8cccb1825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_334c20c2-b60c-4532-9ba3-d4fe221cd0d2" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_7b4846ea-9d04-461d-8364-92a8cccb1825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_dc2926d9-41ea-41f0-9f46-1fa2bf55648a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_7b4846ea-9d04-461d-8364-92a8cccb1825" xlink:to="loc_dei_LegalEntityAxis_dc2926d9-41ea-41f0-9f46-1fa2bf55648a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3a739c5a-2772-4e24-9b37-8b200cbf804c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_dc2926d9-41ea-41f0-9f46-1fa2bf55648a" xlink:to="loc_dei_EntityDomain_3a739c5a-2772-4e24-9b37-8b200cbf804c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestMember_cee16614-4209-46b5-8f2d-30c3cd4b23c3" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3a739c5a-2772-4e24-9b37-8b200cbf804c" xlink:to="loc_ehc_RedeemableNoncontrollingInterestMember_cee16614-4209-46b5-8f2d-30c3cd4b23c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_96fedd16-d8fd-4c69-869e-f4040337a021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable_7b4846ea-9d04-461d-8364-92a8cccb1825" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_96fedd16-d8fd-4c69-869e-f4040337a021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestLineItems_96fedd16-d8fd-4c69-869e-f4040337a021" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9e7200ce-1e74-4f06-8d23-05edbb0b24b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_9e7200ce-1e74-4f06-8d23-05edbb0b24b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_0a9e8039-ae2f-476d-b928-75bfad299231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_0a9e8039-ae2f-476d-b928-75bfad299231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_be055e5f-8c19-45c4-9a52-8b88cac5b819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_be055e5f-8c19-45c4-9a52-8b88cac5b819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_Contributiontojointventure_c3a18ef0-32f1-4ae5-b834-1daeb3c3363d" xlink:href="ehc-20221231.xsd#ehc_Contributiontojointventure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_ehc_Contributiontojointventure_c3a18ef0-32f1-4ae5-b834-1daeb3c3363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8b882fdf-fc50-451b-82bc-b800ee935eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_8b882fdf-fc50-451b-82bc-b800ee935eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExchangeTransaction_5018039d-4c17-4142-a3fb-c8204d7512db" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestExchangeTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_ehc_NoncontrollingInterestExchangeTransaction_5018039d-4c17-4142-a3fb-c8204d7512db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestChangeInRedemptionValue_87af73a6-93a6-4c8a-83f6-95aadb41941c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestChangeInRedemptionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_MinorityInterestChangeInRedemptionValue_87af73a6-93a6-4c8a-83f6-95aadb41941c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestOtherAdjustment_1a23d18b-399f-4f85-abb1-9476a7ba5a63" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestOtherAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_ehc_NoncontrollingInterestOtherAdjustment_1a23d18b-399f-4f85-abb1-9476a7ba5a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestSpinOff_3bb5aaa6-7419-4ad3-bc42-bfbf264afc15" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestSpinOff"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_ehc_NoncontrollingInterestSpinOff_3bb5aaa6-7419-4ad3-bc42-bfbf264afc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c3f316d6-b255-406a-ad2f-34ecf0cfdae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract_c06f5046-b960-4ae2-9c07-a154e2306edc" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_c3f316d6-b255-406a-ad2f-34ecf0cfdae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_b4d2e6a6-8bd5-488d-82f4-262f41df3da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_3e0662c6-80b6-4375-9c71-afb9aa782a03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_b4d2e6a6-8bd5-488d-82f4-262f41df3da4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest_3e0662c6-80b6-4375-9c71-afb9aa782a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_0b479757-e1b5-4154-a184-aad178cd6fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_b4d2e6a6-8bd5-488d-82f4-262f41df3da4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_0b479757-e1b5-4154-a184-aad178cd6fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0ee2f870-a957-4ec0-9879-e22d0d29a687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_b4d2e6a6-8bd5-488d-82f4-262f41df3da4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0ee2f870-a957-4ec0-9879-e22d0d29a687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#RedeemableNoncontrollingInterestsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_f7b447b6-4fb6-461f-b169-7d8055cecf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_f7b447b6-4fb6-461f-b169-7d8055cecf32" xlink:to="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0758f625-6b41-4b16-9248-d36088753726" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0758f625-6b41-4b16-9248-d36088753726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7cb6cd75-b712-4d3e-9777-465267abe02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0758f625-6b41-4b16-9248-d36088753726" xlink:to="loc_us-gaap_SegmentDomain_7cb6cd75-b712-4d3e-9777-465267abe02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HomeHealthandHospiceSegmentMember_e193dc21-8c17-4893-a11c-ed4b1c5194c2" xlink:href="ehc-20221231.xsd#ehc_HomeHealthandHospiceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7cb6cd75-b712-4d3e-9777-465267abe02a" xlink:to="loc_ehc_HomeHealthandHospiceSegmentMember_e193dc21-8c17-4893-a11c-ed4b1c5194c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a38b96e-edba-415b-9bfa-6c56e275068e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e9b1aebf-23af-4d2f-8291-a2ec468fb0d2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a38b96e-edba-415b-9bfa-6c56e275068e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EHHIMember_d426caa8-2f6c-4d4f-a7b4-65d4d20cecc8" xlink:href="ehc-20221231.xsd#ehc_EHHIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3a38b96e-edba-415b-9bfa-6c56e275068e" xlink:to="loc_ehc_EHHIMember_d426caa8-2f6c-4d4f-a7b4-65d4d20cecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_6ad41134-1cea-4965-be24-7123e5778671" xlink:to="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_6043fe19-30a6-426d-97a4-e66ae45156c1" xlink:href="ehc-20221231.xsd#ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent_6043fe19-30a6-426d-97a4-e66ae45156c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_338330a5-8795-4078-a4cf-cb8b932ac9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_338330a5-8795-4078-a4cf-cb8b932ac9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent_5902c7e2-3916-4c80-9322-c01711798d2b" xlink:href="ehc-20221231.xsd#ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent_5902c7e2-3916-4c80-9322-c01711798d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestExerciseRightToSellRatio_04b72633-e661-4afd-9fa7-78bcf245527e" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestExerciseRightToSellRatio"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_NoncontrollingInterestExerciseRightToSellRatio_04b72633-e661-4afd-9fa7-78bcf245527e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_9adc1b15-e319-4ad0-b8ee-e6fe8c17b5a0" xlink:href="ehc-20221231.xsd#ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent_9adc1b15-e319-4ad0-b8ee-e6fe8c17b5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dc737d40-2705-4d4d-8af4-7f869cac91e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_dc737d40-2705-4d4d-8af4-7f869cac91e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_1c98b955-cc7e-4044-8da7-695969432700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue_1c98b955-cc7e-4044-8da7-695969432700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NumberOfManagementInvestorsOutstanding_0a3a37f7-8777-4aa6-ad09-3cfacd0f4efd" xlink:href="ehc-20221231.xsd#ehc_NumberOfManagementInvestorsOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_NumberOfManagementInvestorsOutstanding_0a3a37f7-8777-4aa6-ad09-3cfacd0f4efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_16ca4838-55fc-4889-a44d-bee39d00fb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_16ca4838-55fc-4889-a44d-bee39d00fb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_91a771f3-4d8e-49cb-97f9-fe47af39c70b" xlink:href="ehc-20221231.xsd#ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_07387354-b4a9-4618-add4-0b6ca8c4f376" xlink:to="loc_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages_91a771f3-4d8e-49cb-97f9-fe47af39c70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_032a812e-1dce-473f-985c-1dfcec2197d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_032a812e-1dce-473f-985c-1dfcec2197d8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b189bf-cfbe-40d0-866b-d234507430ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1fe9bf9-7c0a-4b20-b9ad-92c6fc92e975" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b189bf-cfbe-40d0-866b-d234507430ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ac9c1e5b-15ce-4156-9293-78a9c09e0d81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e7b189bf-cfbe-40d0-866b-d234507430ea" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ac9c1e5b-15ce-4156-9293-78a9c09e0d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fa66260-e671-44a4-9b9c-13b725707663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fa66260-e671-44a4-9b9c-13b725707663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4fa66260-e671-44a4-9b9c-13b725707663" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9d273f7a-cb00-41b2-a788-2a0d7a6bcd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9d273f7a-cb00-41b2-a788-2a0d7a6bcd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1b02bd37-36bc-4f3e-8dd5-1bad34cdfe87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1b02bd37-36bc-4f3e-8dd5-1bad34cdfe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_0c098e3f-c33d-4c5e-a57a-6ae43a30d69d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_824f096b-6a2d-41d1-8cb6-3d22ddbd9221" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_0c098e3f-c33d-4c5e-a57a-6ae43a30d69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_09edb743-33ac-4cfe-be4d-71264ceb59ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_09edb743-33ac-4cfe-be4d-71264ceb59ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_78349595-6695-4e46-ad35-4b6286e88786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_09edb743-33ac-4cfe-be4d-71264ceb59ae" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_78349595-6695-4e46-ad35-4b6286e88786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_d0f1aaa3-3f07-40f6-a0e0-f81995315ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_78349595-6695-4e46-ad35-4b6286e88786" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_d0f1aaa3-3f07-40f6-a0e0-f81995315ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_32a07005-df23-4818-ae59-6ce2fefca80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_78349595-6695-4e46-ad35-4b6286e88786" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_32a07005-df23-4818-ae59-6ce2fefca80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01df4eab-f7eb-4232-9761-3cc248dcd4ed" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9f42961d-cbf8-4211-8e05-1aad205e416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9f42961d-cbf8-4211-8e05-1aad205e416e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_4a1ac868-63e9-4aec-b83d-89e6ed0a26f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RedeemableNoncontrollingInterestEquityFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityFairValue_4a1ac868-63e9-4aec-b83d-89e6ed0a26f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_cf58bbd5-763b-4554-9d02-a274b5c80446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_72ad23ea-9dc6-4ea5-8e6d-465587c61e78" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_cf58bbd5-763b-4554-9d02-a274b5c80446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6d385c5e-ef79-4703-9e86-ab92456487fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6d385c5e-ef79-4703-9e86-ab92456487fd" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_DebtInstrumentAxis_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e43d5126-3468-4e82-a6b3-5b6dd6a5bc78" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_TermLoanFacilitiesMember_1aa581ef-5ba7-4120-b5b0-dd00e1ddfaf3" xlink:href="ehc-20221231.xsd#ehc_TermLoanFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_TermLoanFacilitiesMember_1aa581ef-5ba7-4120-b5b0-dd00e1ddfaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.125Due2023Member_6370c0f5-7692-4c3b-a055-055a94afe94f" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.125Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes05.125Due2023Member_6370c0f5-7692-4c3b-a055-055a94afe94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes05.75Due2025Member_d120c698-4378-4712-a045-b9a01526e74a" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes05.75Due2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes05.75Due2025Member_d120c698-4378-4712-a045-b9a01526e74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes4.50Due2028Member_e65a2cd7-0dc3-40d8-ba8f-fb3f626a1e20" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes4.50Due2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes4.50Due2028Member_e65a2cd7-0dc3-40d8-ba8f-fb3f626a1e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04.750Due2030Member_a528ba35-c1a6-4b50-9427-d8a2b3c06a96" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04.750Due2030Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes04.750Due2030Member_a528ba35-c1a6-4b50-9427-d8a2b3c06a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorNotes04625Due2031Member_f2566278-88b7-46c5-86a2-afea431f4a30" xlink:href="ehc-20221231.xsd#ehc_SeniorNotes04625Due2031Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_caaaf886-6973-4e87-870d-da2fda69342c" xlink:to="loc_ehc_SeniorNotes04625Due2031Member_f2566278-88b7-46c5-86a2-afea431f4a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3e9aa83b-223e-49fc-82a8-fab5b7d6e706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_CreditFacilityAxis_3e9aa83b-223e-49fc-82a8-fab5b7d6e706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_518fcd2d-22b1-48bf-ac50-a8d76e5c439d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_3e9aa83b-223e-49fc-82a8-fab5b7d6e706" xlink:to="loc_us-gaap_CreditFacilityDomain_518fcd2d-22b1-48bf-ac50-a8d76e5c439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a672f160-79aa-4b78-b4dc-f6f7b8e310c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_518fcd2d-22b1-48bf-ac50-a8d76e5c439d" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a672f160-79aa-4b78-b4dc-f6f7b8e310c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_fc8c0422-b63b-4850-861e-73f280bcd668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_518fcd2d-22b1-48bf-ac50-a8d76e5c439d" xlink:to="loc_us-gaap_LetterOfCreditMember_fc8c0422-b63b-4850-861e-73f280bcd668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_e71962b3-0043-4af2-ac97-a7acab905541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_e71962b3-0043-4af2-ac97-a7acab905541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_e71962b3-0043-4af2-ac97-a7acab905541" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9d20057f-32d2-4e40-92fe-f468083c64b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_9d20057f-32d2-4e40-92fe-f468083c64b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9dfd2324-d0c5-4c2c-88c0-17288bd5566e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_9dfd2324-d0c5-4c2c-88c0-17288bd5566e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d417f5a4-9d6d-43bd-8e0c-6c7580114272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_fb5f585c-ba1c-491b-8fc9-d87a7be6412d" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d417f5a4-9d6d-43bd-8e0c-6c7580114272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ab99bfba-50fb-4d39-99e5-418cf3c5c2d6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_96266c49-2c68-4353-ae97-e17bc7675dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:to="loc_us-gaap_LoansPayableMember_96266c49-2c68-4353-ae97-e17bc7675dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_318ddb9e-3ec8-4fad-bc5f-a357b4ec0cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:to="loc_us-gaap_SeniorNotesMember_318ddb9e-3ec8-4fad-bc5f-a357b4ec0cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_6c256914-39e1-4f53-a108-fd6fdd4288d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_0d1ef884-4af1-4ae1-91dd-1ed81bbb2e7e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_6c256914-39e1-4f53-a108-fd6fdd4288d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8978d092-b6b8-4645-a932-e37e36f3f706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_efe590f5-7505-49e2-89b2-adef8be16e69" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8978d092-b6b8-4645-a932-e37e36f3f706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7559bde5-d7e3-4219-a75e-85666adea755" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8978d092-b6b8-4645-a932-e37e36f3f706" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7559bde5-d7e3-4219-a75e-85666adea755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_0f5f5165-1d0d-4cb4-84c1-f70becda32c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8978d092-b6b8-4645-a932-e37e36f3f706" xlink:to="loc_us-gaap_LongTermDebtFairValue_0f5f5165-1d0d-4cb4-84c1-f70becda32c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPaymentsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2263004b-9135-4f92-be9a-2448ea00d766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2263004b-9135-4f92-be9a-2448ea00d766" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dd2a6bde-855b-4967-bf69-f864543cf7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dd2a6bde-855b-4967-bf69-f864543cf7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentOperatingActivitiesDomain_a80a1bba-e11b-473d-95ea-541d6b4c9650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentOperatingActivitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOperatingActivitiesSegmentAxis_dd2a6bde-855b-4967-bf69-f864543cf7f6" xlink:to="loc_us-gaap_SegmentOperatingActivitiesDomain_a80a1bba-e11b-473d-95ea-541d6b4c9650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentContinuingOperationsMember_e0cedb02-3822-4b48-88d2-ba2479fb25b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentContinuingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_a80a1bba-e11b-473d-95ea-541d6b4c9650" xlink:to="loc_us-gaap_SegmentContinuingOperationsMember_e0cedb02-3822-4b48-88d2-ba2479fb25b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_21088f3d-07ad-4896-a441-f8ab65020540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentOperatingActivitiesDomain_a80a1bba-e11b-473d-95ea-541d6b4c9650" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_21088f3d-07ad-4896-a441-f8ab65020540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e323e3be-2974-4599-8cb8-713704a80abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_us-gaap_PlanNameAxis_e323e3be-2974-4599-8cb8-713704a80abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_99787d58-ae96-4cd7-8470-3c232f893c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e323e3be-2974-4599-8cb8-713704a80abf" xlink:to="loc_us-gaap_PlanNameDomain_99787d58-ae96-4cd7-8470-3c232f893c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember_1c13bbba-2691-46ae-9181-947676f2b655" xlink:href="ehc-20221231.xsd#ehc_A2016OmnibusPerformanceIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_99787d58-ae96-4cd7-8470-3c232f893c81" xlink:to="loc_ehc_A2016OmnibusPerformanceIncentivePlanMember_1c13bbba-2691-46ae-9181-947676f2b655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a06cc3dd-8f27-441d-9502-0a58feb09fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_us-gaap_AwardTypeAxis_a06cc3dd-8f27-441d-9502-0a58feb09fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a06cc3dd-8f27-441d-9502-0a58feb09fe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5ef1f952-5ed9-4e4a-8df7-f5099403c1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5ef1f952-5ed9-4e4a-8df7-f5099403c1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2505f25c-6299-40aa-bcfe-e0568fa044c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:to="loc_us-gaap_RestrictedStockMember_2505f25c-6299-40aa-bcfe-e0568fa044c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_dd864852-24c7-4a57-85dc-b71b1e1b48dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_dd864852-24c7-4a57-85dc-b71b1e1b48dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DividendEquivalentRSUMember_61942d36-3f70-43cd-a290-9e8655b2e0ce" xlink:href="ehc-20221231.xsd#ehc_DividendEquivalentRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50031ba4-1e39-42ac-b45b-4fc8fe30941e" xlink:to="loc_ehc_DividendEquivalentRSUMember_61942d36-3f70-43cd-a290-9e8655b2e0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_srt_TitleOfIndividualAxis_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d2088c5-52e0-4916-b8a6-8a7b8489c728" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_055b5e79-a4bb-4c6b-a03f-e5f3d69419f6" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d2088c5-52e0-4916-b8a6-8a7b8489c728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_NonemployeeDirectorsMember_5574fe97-ba61-4f8f-a641-2057a24809b8" xlink:href="ehc-20221231.xsd#ehc_NonemployeeDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d2088c5-52e0-4916-b8a6-8a7b8489c728" xlink:to="loc_ehc_NonemployeeDirectorsMember_5574fe97-ba61-4f8f-a641-2057a24809b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_CurrentAndFormerBoardOfDirectorsMember_da2d5356-5a4b-4463-8a0b-b99babc8a051" xlink:href="ehc-20221231.xsd#ehc_CurrentAndFormerBoardOfDirectorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d2088c5-52e0-4916-b8a6-8a7b8489c728" xlink:to="loc_ehc_CurrentAndFormerBoardOfDirectorsMember_da2d5356-5a4b-4463-8a0b-b99babc8a051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_18e2658e-c082-4274-b710-7abe428feceb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14ae83bb-f855-4927-a0a7-6aa05405e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_14ae83bb-f855-4927-a0a7-6aa05405e3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4474e850-7cca-464f-8356-78c64eda228e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4474e850-7cca-464f-8356-78c64eda228e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2846cdf9-5a75-48eb-80b2-ea897eea6aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_2846cdf9-5a75-48eb-80b2-ea897eea6aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5fd2f495-1abc-4eb4-8d6a-036f226e8775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_5fd2f495-1abc-4eb4-8d6a-036f226e8775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a774e30a-7689-4899-a7a9-1051b3bedb80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a774e30a-7689-4899-a7a9-1051b3bedb80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b626119a-f7bc-4d61-a498-9e6c018c2c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b626119a-f7bc-4d61-a498-9e6c018c2c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_23b92f90-8f6e-47bb-ab05-ff8bb02d6a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_23b92f90-8f6e-47bb-ab05-ff8bb02d6a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ef14cf50-549f-4e15-b906-2135ba4f6ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_ef14cf50-549f-4e15-b906-2135ba4f6ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_21cff375-50ab-471d-bbe4-50159dbb2917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_21cff375-50ab-471d-bbe4-50159dbb2917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108dd24c-5849-4f3e-acb9-a9073a1283b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_108dd24c-5849-4f3e-acb9-a9073a1283b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9e6411c0-2908-4f4c-a71e-fb4270979c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9e6411c0-2908-4f4c-a71e-fb4270979c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0a960ccc-f094-4e90-8b48-55549cec6f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0a960ccc-f094-4e90-8b48-55549cec6f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_88bca7cf-ff81-4f9c-a674-c2f3b8ccd585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_88bca7cf-ff81-4f9c-a674-c2f3b8ccd585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_aed53bed-d195-45e0-b4d1-284be6867e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_aed53bed-d195-45e0-b4d1-284be6867e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_e164007b-bf40-493a-8e51-7f85ae4fff74" xlink:href="ehc-20221231.xsd#ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions_e164007b-bf40-493a-8e51-7f85ae4fff74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_94517e97-6a9b-4fb5-940b-29eef3f50ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1535a1ec-9f3d-4e0b-9393-9e43484ff1eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_94517e97-6a9b-4fb5-940b-29eef3f50ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPaymentsWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35239dc0-b521-4fcc-8e7a-f4b77f293288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91a480b0-d177-4249-95a2-7f59d27ae38c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_35239dc0-b521-4fcc-8e7a-f4b77f293288" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91a480b0-d177-4249-95a2-7f59d27ae38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5445c20d-3f2d-4186-a799-f33cfcdf00b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91a480b0-d177-4249-95a2-7f59d27ae38c" xlink:to="loc_us-gaap_AwardTypeAxis_5445c20d-3f2d-4186-a799-f33cfcdf00b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8824d614-0aa3-4b82-ac90-1e72f0e134cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5445c20d-3f2d-4186-a799-f33cfcdf00b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8824d614-0aa3-4b82-ac90-1e72f0e134cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_602fed21-be08-4a25-95b5-90c2f4a78ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8824d614-0aa3-4b82-ac90-1e72f0e134cb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_602fed21-be08-4a25-95b5-90c2f4a78ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dbb7fef9-e02d-4058-be4e-0b3a61b354e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_91a480b0-d177-4249-95a2-7f59d27ae38c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dbb7fef9-e02d-4058-be4e-0b3a61b354e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dbb7fef9-e02d-4058-be4e-0b3a61b354e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_025d3e48-3915-4825-a0e4-de41b597c598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_025d3e48-3915-4825-a0e4-de41b597c598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_21579a10-f05b-48ad-9227-fbc2edf77d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_21579a10-f05b-48ad-9227-fbc2edf77d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4a82e753-8209-4774-9e5c-2fb97ca227b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4a82e753-8209-4774-9e5c-2fb97ca227b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50aa73c7-61df-4416-81f1-57d0e11cbbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_bcdd33f0-06a7-4e11-9d98-e45b780c211e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50aa73c7-61df-4416-81f1-57d0e11cbbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPaymentsStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e953798f-5abe-4a0f-87ab-08d8eeb6a498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57979547-0053-4a5c-b4fd-d94a3b59902d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e953798f-5abe-4a0f-87ab-08d8eeb6a498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57979547-0053-4a5c-b4fd-d94a3b59902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9bdfb8f8-16e3-4bf3-95f4-a485e7f01de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57979547-0053-4a5c-b4fd-d94a3b59902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9bdfb8f8-16e3-4bf3-95f4-a485e7f01de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_103f3891-7d29-457a-a832-a960b2618cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57979547-0053-4a5c-b4fd-d94a3b59902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_103f3891-7d29-457a-a832-a960b2618cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96ab0435-5e6a-4507-8f7c-1f912135b549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57979547-0053-4a5c-b4fd-d94a3b59902d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_96ab0435-5e6a-4507-8f7c-1f912135b549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod_cfc22dbb-3371-423a-9b17-a2b349956048" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57979547-0053-4a5c-b4fd-d94a3b59902d" xlink:to="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod_cfc22dbb-3371-423a-9b17-a2b349956048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5716523-ae8c-4d3c-8409-00c76d3107b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_57979547-0053-4a5c-b4fd-d94a3b59902d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d5716523-ae8c-4d3c-8409-00c76d3107b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7592d6e3-9f5b-457e-8d03-b7cb6e55c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e953798f-5abe-4a0f-87ab-08d8eeb6a498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7592d6e3-9f5b-457e-8d03-b7cb6e55c2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0b5a834-f0c8-4be8-bb75-0b0b77953c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e953798f-5abe-4a0f-87ab-08d8eeb6a498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0b5a834-f0c8-4be8-bb75-0b0b77953c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f17f6b02-73a9-4cd5-9a28-67b8c8538dba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0b5a834-f0c8-4be8-bb75-0b0b77953c63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f17f6b02-73a9-4cd5-9a28-67b8c8538dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4dddf972-6e05-43c8-94f0-80f736b9b0ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0b5a834-f0c8-4be8-bb75-0b0b77953c63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4dddf972-6e05-43c8-94f0-80f736b9b0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7387025f-cdc0-4544-9d8a-89bba24ed5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0b5a834-f0c8-4be8-bb75-0b0b77953c63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7387025f-cdc0-4544-9d8a-89bba24ed5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice_b3c9a4fd-5ed0-438b-809c-f59f49768686" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0b5a834-f0c8-4be8-bb75-0b0b77953c63" xlink:to="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice_b3c9a4fd-5ed0-438b-809c-f59f49768686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e2e6f35b-4069-4dd8-8679-3286d6f073ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0b5a834-f0c8-4be8-bb75-0b0b77953c63" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e2e6f35b-4069-4dd8-8679-3286d6f073ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2f5b0667-d03b-49fd-b39c-39860b785204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e953798f-5abe-4a0f-87ab-08d8eeb6a498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2f5b0667-d03b-49fd-b39c-39860b785204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_75fb3781-7124-4bc9-8a18-363d2df155a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e953798f-5abe-4a0f-87ab-08d8eeb6a498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_75fb3781-7124-4bc9-8a18-363d2df155a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f2351830-ff8c-43dd-abbb-5c97559f73db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_75fb3781-7124-4bc9-8a18-363d2df155a0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f2351830-ff8c-43dd-abbb-5c97559f73db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5ee0716d-b1c3-4516-9dd7-2e6360a711c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_75fb3781-7124-4bc9-8a18-363d2df155a0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5ee0716d-b1c3-4516-9dd7-2e6360a711c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_933aae5a-8e30-44b8-9eb5-022072269240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e953798f-5abe-4a0f-87ab-08d8eeb6a498" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_933aae5a-8e30-44b8-9eb5-022072269240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_533d62a5-a294-46c1-bba4-9ec464f6d62c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_933aae5a-8e30-44b8-9eb5-022072269240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_533d62a5-a294-46c1-bba4-9ec464f6d62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_88efa57a-55fd-4f22-a0f4-fda3368a897e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_933aae5a-8e30-44b8-9eb5-022072269240" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_88efa57a-55fd-4f22-a0f4-fda3368a897e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd741504-6a4d-489e-98b9-f711340f8c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01dea954-2fe3-4b51-8d12-d03eab36d915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cd741504-6a4d-489e-98b9-f711340f8c3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01dea954-2fe3-4b51-8d12-d03eab36d915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d89598a3-6cce-4611-ab07-1dc7ad3c64a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01dea954-2fe3-4b51-8d12-d03eab36d915" xlink:to="loc_us-gaap_AwardTypeAxis_d89598a3-6cce-4611-ab07-1dc7ad3c64a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aab61c86-0e93-4632-bd19-5e88ace8ab90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d89598a3-6cce-4611-ab07-1dc7ad3c64a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aab61c86-0e93-4632-bd19-5e88ace8ab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_16f1645a-1988-4de4-bb72-fb03bdb65900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aab61c86-0e93-4632-bd19-5e88ace8ab90" xlink:to="loc_us-gaap_RestrictedStockMember_16f1645a-1988-4de4-bb72-fb03bdb65900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b35197b-4cb6-4f92-bba0-27bfe49fdcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_01dea954-2fe3-4b51-8d12-d03eab36d915" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b35197b-4cb6-4f92-bba0-27bfe49fdcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b35197b-4cb6-4f92-bba0-27bfe49fdcc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1b346037-cc8b-498b-b5b9-b748e753affa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1b346037-cc8b-498b-b5b9-b748e753affa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dbb6aa3d-0135-4828-a42b-890e6f7f3bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_dbb6aa3d-0135-4828-a42b-890e6f7f3bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff18cece-9edc-414c-97f3-21fa9ebfb494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ff18cece-9edc-414c-97f3-21fa9ebfb494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c552821-7d5f-4965-8251-d72178f18961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c552821-7d5f-4965-8251-d72178f18961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod_2aded41e-ce43-4d61-ac51-71a526397340" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod_2aded41e-ce43-4d61-ac51-71a526397340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_32470d7f-3d71-4ad9-b5b6-98cf45ad9c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b6c31ea8-906f-44a2-8b29-43df40e13288" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_32470d7f-3d71-4ad9-b5b6-98cf45ad9c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b35197b-4cb6-4f92-bba0-27bfe49fdcc2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55bf02ca-ed53-4e25-b7bf-16f4101918cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_55bf02ca-ed53-4e25-b7bf-16f4101918cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77093962-4c21-463a-a432-e5c03b204e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_77093962-4c21-463a-a432-e5c03b204e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f407e3ff-f8ae-4640-bb5a-f3a1dd7ba0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f407e3ff-f8ae-4640-bb5a-f3a1dd7ba0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c7f6b6f2-9bc4-45f5-9f46-4bd326dcd6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c7f6b6f2-9bc4-45f5-9f46-4bd326dcd6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_2854b202-a9e8-45a9-9ea9-62f787c44c3f" xlink:href="ehc-20221231.xsd#ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue_2854b202-a9e8-45a9-9ea9-62f787c44c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f80c3bd-6728-451b-b2d9-12be8e240e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_066391b7-9d4c-47bf-bdf8-c94807cd673d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2f80c3bd-6728-451b-b2d9-12be8e240e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d390fa9f-b738-4829-8fa9-968c85a31e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_68e68a2e-2806-4e54-ad87-c8728318e334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_d390fa9f-b738-4829-8fa9-968c85a31e8c" xlink:to="loc_us-gaap_DefinedContributionPlanTable_68e68a2e-2806-4e54-ad87-c8728318e334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameAxis_0dec2b07-4900-4211-a24a-fc53feffe407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_68e68a2e-2806-4e54-ad87-c8728318e334" xlink:to="loc_us-gaap_RetirementPlanNameAxis_0dec2b07-4900-4211-a24a-fc53feffe407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanNameDomain_28cf2ca9-e15b-415c-a047-571238d8b4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameAxis_0dec2b07-4900-4211-a24a-fc53feffe407" xlink:to="loc_us-gaap_RetirementPlanNameDomain_28cf2ca9-e15b-415c-a047-571238d8b4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EncompassHealthRetirementInvestmentPlanMember_23810dfb-2409-4860-a5ff-9ec8047753b5" xlink:href="ehc-20221231.xsd#ehc_EncompassHealthRetirementInvestmentPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanNameDomain_28cf2ca9-e15b-415c-a047-571238d8b4f8" xlink:to="loc_ehc_EncompassHealthRetirementInvestmentPlanMember_23810dfb-2409-4860-a5ff-9ec8047753b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_68e68a2e-2806-4e54-ad87-c8728318e334" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_HealthcarePlanExpense_62e54e1c-df69-477d-a47c-52676e6dbd3c" xlink:href="ehc-20221231.xsd#ehc_HealthcarePlanExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_HealthcarePlanExpense_62e54e1c-df69-477d-a47c-52676e6dbd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_398ad314-2309-4d6f-83d9-7f7b2e763053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_398ad314-2309-4d6f-83d9-7f7b2e763053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanAgeRequirement_4bd1136e-cd81-4ff4-9111-fd19fd38dbe2" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanAgeRequirement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_RetirementInvestmentPlanAgeRequirement_4bd1136e-cd81-4ff4-9111-fd19fd38dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_4506d9e6-a8d2-4714-9bbe-d3e4dbf36422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_4506d9e6-a8d2-4714-9bbe-d3e4dbf36422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_6a08c4f8-507e-484f-ba63-61898aed516c" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution_6a08c4f8-507e-484f-ba63-61898aed516c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_96bdeffc-31ba-4e03-b07b-fe29f9867010" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage_96bdeffc-31ba-4e03-b07b-fe29f9867010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_dab9e03e-c644-4886-a761-33a0c025af67" xlink:href="ehc-20221231.xsd#ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod_dab9e03e-c644-4886-a761-33a0c025af67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f6e4c787-2b4b-4c6f-abf2-962be113c63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f6e4c787-2b4b-4c6f-abf2-962be113c63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_d0aa5614-fa31-418e-9525-a7dc9264904e" xlink:href="ehc-20221231.xsd#ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount_d0aa5614-fa31-418e-9525-a7dc9264904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_SeniorManagementBonusProgramTotalCosts_d1f55cd7-baa4-49d8-acc4-c305a05d434d" xlink:href="ehc-20221231.xsd#ehc_SeniorManagementBonusProgramTotalCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_19865a49-a02a-455c-9fcd-7da8927a7567" xlink:to="loc_ehc_SeniorManagementBonusProgramTotalCosts_d1f55cd7-baa4-49d8-acc4-c305a05d434d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_74c59792-1612-4f88-aa25-e785704530ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_95f088f8-5aa3-48de-ba35-b54812adf5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74c59792-1612-4f88-aa25-e785704530ca" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_95f088f8-5aa3-48de-ba35-b54812adf5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b478be6-b470-4694-8ef9-0a3d1557826a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_95f088f8-5aa3-48de-ba35-b54812adf5ee" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b478be6-b470-4694-8ef9-0a3d1557826a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_89cbc9d2-2192-439f-8971-1c0900066055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b478be6-b470-4694-8ef9-0a3d1557826a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_89cbc9d2-2192-439f-8971-1c0900066055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b6499850-3a9d-44bd-aa28-3ab81ba7c123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b478be6-b470-4694-8ef9-0a3d1557826a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b6499850-3a9d-44bd-aa28-3ab81ba7c123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_eea5d125-ba0a-48cb-9b4d-749d5e833ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b478be6-b470-4694-8ef9-0a3d1557826a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_eea5d125-ba0a-48cb-9b4d-749d5e833ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4a0974cc-ed90-48b7-80ce-ece296bbc44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_95f088f8-5aa3-48de-ba35-b54812adf5ee" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4a0974cc-ed90-48b7-80ce-ece296bbc44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5ad07a0e-5931-4416-ab05-954b050a09b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4a0974cc-ed90-48b7-80ce-ece296bbc44c" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5ad07a0e-5931-4416-ab05-954b050a09b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1c6c1867-bafa-4230-ae4c-5cc24293b52a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4a0974cc-ed90-48b7-80ce-ece296bbc44c" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1c6c1867-bafa-4230-ae4c-5cc24293b52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bd6bcadf-2237-49ed-8c8d-b7bd26768eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_4a0974cc-ed90-48b7-80ce-ece296bbc44c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bd6bcadf-2237-49ed-8c8d-b7bd26768eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72be023a-af13-4536-ae76-bada71571fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_95f088f8-5aa3-48de-ba35-b54812adf5ee" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72be023a-af13-4536-ae76-bada71571fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_afe664a8-1795-4a84-87f9-a8a782dc06b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3534f322-c80b-40a1-843b-fb444fb55cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afe664a8-1795-4a84-87f9-a8a782dc06b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3534f322-c80b-40a1-843b-fb444fb55cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ab6caea1-d89e-43ce-8965-3326eca2fe0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afe664a8-1795-4a84-87f9-a8a782dc06b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ab6caea1-d89e-43ce-8965-3326eca2fe0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6ff0209f-6d64-4ce0-9192-5bc93f2037a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ab6caea1-d89e-43ce-8965-3326eca2fe0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6ff0209f-6d64-4ce0-9192-5bc93f2037a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7ad90c29-9aca-4acd-930d-a2fb9ab979a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ab6caea1-d89e-43ce-8965-3326eca2fe0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_7ad90c29-9aca-4acd-930d-a2fb9ab979a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_47876ef6-8199-49c1-8059-5d48e0dfcdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ab6caea1-d89e-43ce-8965-3326eca2fe0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense_47876ef6-8199-49c1-8059-5d48e0dfcdd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_cc15311c-4447-42cb-b5ef-f76deee3a4b9" xlink:href="ehc-20221231.xsd#ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ab6caea1-d89e-43ce-8965-3326eca2fe0c" xlink:to="loc_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent_cc15311c-4447-42cb-b5ef-f76deee3a4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_85e353f4-2d93-4dea-a737-9e7a075ef247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_ab6caea1-d89e-43ce-8965-3326eca2fe0c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_85e353f4-2d93-4dea-a737-9e7a075ef247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8fbb7d0d-14bf-4158-95d6-7ebdac9b9e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afe664a8-1795-4a84-87f9-a8a782dc06b0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8fbb7d0d-14bf-4158-95d6-7ebdac9b9e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_dbc08421-71cd-42dd-b857-55f5f3c28c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dbc08421-71cd-42dd-b857-55f5f3c28c21" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a3236a26-6dc2-456f-ad36-2f6d0c77ea39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a3236a26-6dc2-456f-ad36-2f6d0c77ea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_33f1c3bd-5d2b-4e23-b954-1005258499de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_33f1c3bd-5d2b-4e23-b954-1005258499de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7c96d850-8714-4ad2-b389-13de47465797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7c96d850-8714-4ad2-b389-13de47465797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability_9614e7d1-6630-427e-8ebe-064e9fe2babd" xlink:href="ehc-20221231.xsd#ehc_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_ehc_DeferredTaxAssetsOperatingLeaseLiability_9614e7d1-6630-427e-8ebe-064e9fe2babd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_5863ad32-4d3d-4c41-8f22-c6f09bf80a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_5863ad32-4d3d-4c41-8f22-c6f09bf80a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_dac4f1bc-c611-45c4-ae2d-2ef89e1d1abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_dac4f1bc-c611-45c4-ae2d-2ef89e1d1abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_71a5f3a9-10ff-420f-8089-88d5eeafc742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_71a5f3a9-10ff-420f-8089-88d5eeafc742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_17cf59c7-ebea-4b01-b1e3-c7b09be5fe70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_17cf59c7-ebea-4b01-b1e3-c7b09be5fe70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_24186ad2-bfe6-456e-a370-99d5a46036af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_e0444dd7-90c7-4be9-8047-2198fdee5ad2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_24186ad2-bfe6-456e-a370-99d5a46036af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dbc08421-71cd-42dd-b857-55f5f3c28c21" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_5a96141a-aa02-489d-b859-b7ab71122f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome_5a96141a-aa02-489d-b859-b7ab71122f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_3005b4c4-9280-49c9-87cc-9d14191e0b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_3005b4c4-9280-49c9-87cc-9d14191e0b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_2da89c47-54ea-47cf-a351-615777006b31" xlink:href="ehc-20221231.xsd#ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:to="loc_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_2da89c47-54ea-47cf-a351-615777006b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4843bf28-42c6-40a4-848d-515a2f457f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4843bf28-42c6-40a4-848d-515a2f457f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestments_4c79e492-591c-4678-bf60-359d448ce408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestments_4c79e492-591c-4678-bf60-359d448ce408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_5f311f22-41ca-4fa8-a459-38310afa1c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_5f311f22-41ca-4fa8-a459-38310afa1c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_197aa773-5968-48b6-934f-c7942dab23d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_490c4d57-3abc-4c53-a17b-7c1dd6b78198" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_197aa773-5968-48b6-934f-c7942dab23d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_c3b8931f-4e88-4cf5-9333-a89e6bb53d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_dbc08421-71cd-42dd-b857-55f5f3c28c21" xlink:to="loc_us-gaap_DeferredTaxLiabilities_c3b8931f-4e88-4cf5-9333-a89e6bb53d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#IncomeTaxesTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/IncomeTaxesTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_023df4fe-c028-4b4d-abe6-278287ec7403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceTable_73e5da71-8490-4c06-9316-01f104424850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_023df4fe-c028-4b4d-abe6-278287ec7403" xlink:to="loc_us-gaap_ValuationAllowanceTable_73e5da71-8490-4c06-9316-01f104424850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_85179353-b6c6-4dfa-960b-1f1e54e48118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_73e5da71-8490-4c06-9316-01f104424850" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_85179353-b6c6-4dfa-960b-1f1e54e48118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2ffd4e8d-b9a5-42c0-b0ad-8a2d05911422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_85179353-b6c6-4dfa-960b-1f1e54e48118" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2ffd4e8d-b9a5-42c0-b0ad-8a2d05911422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1231b2ab-c2ee-4344-9b2c-272874d21aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_2ffd4e8d-b9a5-42c0-b0ad-8a2d05911422" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1231b2ab-c2ee-4344-9b2c-272874d21aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceTable_73e5da71-8490-4c06-9316-01f104424850" xlink:to="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_a5faf301-950f-4e11-8bfc-f4f1fb29cf8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_a5faf301-950f-4e11-8bfc-f4f1fb29cf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_410c09db-7777-4942-8820-230fb0bb8865" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_410c09db-7777-4942-8820-230fb0bb8865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e7b21d3a-18ef-471a-a7b8-5d9e0535cc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceLineItems_67aa26b8-708c-4441-b41f-cacf5448ebe0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e7b21d3a-18ef-471a-a7b8-5d9e0535cc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a070304c-d19c-458e-932b-8b52b369d3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a070304c-d19c-458e-932b-8b52b369d3d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f4735687-81a9-4f4c-831b-dbc59639e891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f4735687-81a9-4f4c-831b-dbc59639e891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_f04282d0-8263-454d-884b-59396edec052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_f04282d0-8263-454d-884b-59396edec052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4d7d0040-8c2d-4d46-8db8-3ebf8b61a0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_4d7d0040-8c2d-4d46-8db8-3ebf8b61a0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_28667bcf-594b-41e1-82a1-96318980f0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_28667bcf-594b-41e1-82a1-96318980f0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ff6669b6-2481-4ef6-b8f7-a939ffe655fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_ff6669b6-2481-4ef6-b8f7-a939ffe655fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_7ef35205-519b-4575-8449-6d6eaaa1464a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_7ef35205-519b-4575-8449-6d6eaaa1464a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_1f859d07-8093-487e-a393-969fccdefac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic_1f859d07-8093-487e-a393-969fccdefac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_33297bda-2db2-4ba7-bde9-e51e3643e4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic_33297bda-2db2-4ba7-bde9-e51e3643e4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d53185e5-9d7a-4b3f-bf2e-2442517b5a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5b0b4c4b-2720-4494-832e-0b5e763e92f8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d53185e5-9d7a-4b3f-bf2e-2442517b5a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bf4aa7c3-179d-4583-a46c-bb1d3a133292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a070304c-d19c-458e-932b-8b52b369d3d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bf4aa7c3-179d-4583-a46c-bb1d3a133292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ad247c1-c715-4aff-a04c-24cbb616c2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_bf4aa7c3-179d-4583-a46c-bb1d3a133292" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ad247c1-c715-4aff-a04c-24cbb616c2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_0bdaeca4-f185-4185-893e-fb49d21a2e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a070304c-d19c-458e-932b-8b52b369d3d7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_0bdaeca4-f185-4185-893e-fb49d21a2e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7a18b9e0-4a8f-4145-808d-ef756f3df3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0bdaeca4-f185-4185-893e-fb49d21a2e7d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7a18b9e0-4a8f-4145-808d-ef756f3df3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d6cd46fb-8a53-4a33-bfd1-4e2301ac7f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0bdaeca4-f185-4185-893e-fb49d21a2e7d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d6cd46fb-8a53-4a33-bfd1-4e2301ac7f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_35759481-f961-4297-88ce-ef0f15ca2014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0bdaeca4-f185-4185-893e-fb49d21a2e7d" xlink:to="loc_us-gaap_EarningsPerShareBasic_35759481-f961-4297-88ce-ef0f15ca2014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a070304c-d19c-458e-932b-8b52b369d3d7" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_23870141-2622-44ad-a1ab-c2be7b5b8474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_23870141-2622-44ad-a1ab-c2be7b5b8474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_c12ec545-7fcd-4f19-815f-a8a65153e952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_c12ec545-7fcd-4f19-815f-a8a65153e952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_a79baa96-4fd2-46f5-9e60-48fc119671f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:to="loc_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted_a79baa96-4fd2-46f5-9e60-48fc119671f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aa9ecf07-113d-45b3-9dc4-a61d337e0bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aa9ecf07-113d-45b3-9dc4-a61d337e0bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_0377bff6-c794-4132-8aaa-182edbd77746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_0377bff6-c794-4132-8aaa-182edbd77746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_1aff3e0b-e269-432d-bacb-80c6bc0efe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:to="loc_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted_1aff3e0b-e269-432d-bacb-80c6bc0efe1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5f664f6c-4ea0-490e-b233-e7070c84dd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2c2ca349-7bc6-4a87-bb21-84e84772f7b5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5f664f6c-4ea0-490e-b233-e7070c84dd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e2d57b28-90c0-4495-b125-24685916c764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a070304c-d19c-458e-932b-8b52b369d3d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e2d57b28-90c0-4495-b125-24685916c764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5cf161b-ed4d-4eea-b444-f50b0c063c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e2d57b28-90c0-4495-b125-24685916c764" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b5cf161b-ed4d-4eea-b444-f50b0c063c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_def56b4b-060d-4b61-badf-57649f7035fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a070304c-d19c-458e-932b-8b52b369d3d7" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_def56b4b-060d-4b61-badf-57649f7035fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_2504c43a-97c0-4c3b-a439-8386993f2e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_def56b4b-060d-4b61-badf-57649f7035fc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_2504c43a-97c0-4c3b-a439-8386993f2e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_596c4778-a8bc-406e-9150-1c613ea93cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_def56b4b-060d-4b61-badf-57649f7035fc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_596c4778-a8bc-406e-9150-1c613ea93cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bc8d494e-4431-4ac3-97be-6e4e9c09e731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_def56b4b-060d-4b61-badf-57649f7035fc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bc8d494e-4431-4ac3-97be-6e4e9c09e731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ebba01e6-8a61-483b-90b0-b0c36811bccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e44fc57-55b1-4aea-8207-98d02ab6c354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ebba01e6-8a61-483b-90b0-b0c36811bccd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e44fc57-55b1-4aea-8207-98d02ab6c354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_662b8c6f-3951-4532-8a32-3b0193306433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ebba01e6-8a61-483b-90b0-b0c36811bccd" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_662b8c6f-3951-4532-8a32-3b0193306433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2526187f-06ef-461a-aaa1-e94a0a4a6595" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ebba01e6-8a61-483b-90b0-b0c36811bccd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2526187f-06ef-461a-aaa1-e94a0a4a6595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#EarningsPerCommonShareTextualDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3d63fb71-e086-41d8-80bb-bb27c26ee327" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3d63fb71-e086-41d8-80bb-bb27c26ee327" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4d391e6d-557b-47a0-874a-15c69f6f3e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5c4d9c7c-1005-4c7c-9a27-7f14b2e535e1" xlink:to="loc_us-gaap_ClassOfStockDomain_4d391e6d-557b-47a0-874a-15c69f6f3e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_784613a6-2b81-4f2d-bcbb-f9d32b3f724d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4d391e6d-557b-47a0-874a-15c69f6f3e54" xlink:to="loc_us-gaap_CommonStockMember_784613a6-2b81-4f2d-bcbb-f9d32b3f724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e6d0de25-889e-488d-9fa6-d95b7101de90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e6d0de25-889e-488d-9fa6-d95b7101de90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c7e5535a-09ae-4d31-a8df-afe76321080e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e6d0de25-889e-488d-9fa6-d95b7101de90" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c7e5535a-09ae-4d31-a8df-afe76321080e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_05c7418e-aeeb-447e-9bd0-1ff4d8cb4efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c7e5535a-09ae-4d31-a8df-afe76321080e" xlink:to="loc_us-gaap_SubsequentEventMember_05c7418e-aeeb-447e-9bd0-1ff4d8cb4efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_2aa8c43f-ad93-4e8d-b97b-b52f9894813d" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bcca758-4f6e-4bc2-a3c8-02e02e6370b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9bcca758-4f6e-4bc2-a3c8-02e02e6370b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_02aebb18-1e09-408c-afb8-945f4bd3fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_02aebb18-1e09-408c-afb8-945f4bd3fc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_108cceab-94e5-4672-8fe4-44adb021c782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_108cceab-94e5-4672-8fe4-44adb021c782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e98eb57f-3d5a-463e-8916-3abaa66c0154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_e98eb57f-3d5a-463e-8916-3abaa66c0154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_c1436b4a-3155-4cde-8995-4b88317d2a39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_c1436b4a-3155-4cde-8995-4b88317d2a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_85e4067a-50b7-4bc2-b8b4-f98a0dec2ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_80eeeadb-eb23-41e8-95b9-b5c37cb939a9" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_85e4067a-50b7-4bc2-b8b4-f98a0dec2ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#ContingenciesandOtherCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5edf59ac-0bfe-46e5-9b15-e997e430a226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_2ccd18e3-8d06-416d-bb12-297fcdf7bbfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5edf59ac-0bfe-46e5-9b15-e997e430a226" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_2ccd18e3-8d06-416d-bb12-297fcdf7bbfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_b2158fa4-378e-4513-a600-300d621f1fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5edf59ac-0bfe-46e5-9b15-e997e430a226" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_b2158fa4-378e-4513-a600-300d621f1fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_85e5097f-61b7-4f09-b0b2-7788b845dc9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5edf59ac-0bfe-46e5-9b15-e997e430a226" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_85e5097f-61b7-4f09-b0b2-7788b845dc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_7c4fe912-efc8-4dd3-8f77-55c865247abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5edf59ac-0bfe-46e5-9b15-e997e430a226" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_7c4fe912-efc8-4dd3-8f77-55c865247abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_cac4ab81-2877-44ef-94e9-9b06a1865dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5edf59ac-0bfe-46e5-9b15-e997e430a226" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_cac4ab81-2877-44ef-94e9-9b06a1865dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear_68827df5-0f1a-47af-9b4a-b83e07e63d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5edf59ac-0bfe-46e5-9b15-e997e430a226" xlink:to="loc_us-gaap_OtherCommitmentDueAfterFifthYear_68827df5-0f1a-47af-9b4a-b83e07e63d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails" xlink:type="simple" xlink:href="ehc-20221231.xsd#QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"/>
  <link:presentationLink xlink:role="http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1b25f8a8-8fb5-42b6-bc00-c962aabc0970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialDataAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_1b25f8a8-8fb5-42b6-bc00-c962aabc0970" xlink:to="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b14947f-7eff-44a5-8c7a-15f00fe19e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b14947f-7eff-44a5-8c7a-15f00fe19e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fd02522e-caac-42ca-947f-c60423de656d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_OperatingIncomeLoss_fd02522e-caac-42ca-947f-c60423de656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ae8d41a9-6df2-446f-bf6c-7c212246f694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ae8d41a9-6df2-446f-bf6c-7c212246f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f7c565b2-6ea8-4e93-bb79-4718d333e814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_f7c565b2-6ea8-4e93-bb79-4718d333e814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aaf46a67-b922-4ed2-aabe-94d823765ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aaf46a67-b922-4ed2-aabe-94d823765ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1f161bc3-1ea5-47dd-b158-66fe5094e3ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_ProfitLoss_1f161bc3-1ea5-47dd-b158-66fe5094e3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b75d68c2-24a2-42a6-9640-1592fc1d41da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b75d68c2-24a2-42a6-9640-1592fc1d41da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb625d01-5e7f-4660-8bdc-787d6b01700c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_NetIncomeLoss_bb625d01-5e7f-4660-8bdc-787d6b01700c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_eceeb4ab-6840-401b-85a2-972288319996" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialDataAbstract_a7c65a9b-554d-419c-a478-f49af5306376" xlink:to="loc_us-gaap_EarningsPerShareAbstract_eceeb4ab-6840-401b-85a2-972288319996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_6b2648a3-fd4a-4113-b8f1-9d05bda7c9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eceeb4ab-6840-401b-85a2-972288319996" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_6b2648a3-fd4a-4113-b8f1-9d05bda7c9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_476f05a5-3803-48df-bcbf-f71f39eeba0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_6b2648a3-fd4a-4113-b8f1-9d05bda7c9f3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_476f05a5-3803-48df-bcbf-f71f39eeba0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f7d583e9-4578-42ae-a25c-2389debc41e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_6b2648a3-fd4a-4113-b8f1-9d05bda7c9f3" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_f7d583e9-4578-42ae-a25c-2389debc41e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_357bb39b-cdaf-4b4c-9b51-0e5de538c0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_6b2648a3-fd4a-4113-b8f1-9d05bda7c9f3" xlink:to="loc_us-gaap_EarningsPerShareBasic_357bb39b-cdaf-4b4c-9b51-0e5de538c0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_e8baac5e-a6d7-4ccf-9046-48a5869275ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eceeb4ab-6840-401b-85a2-972288319996" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_e8baac5e-a6d7-4ccf-9046-48a5869275ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_90654dc8-db67-4c04-89e2-3993f5008323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e8baac5e-a6d7-4ccf-9046-48a5869275ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_90654dc8-db67-4c04-89e2-3993f5008323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_2dca1def-d302-4675-bc06-dae4342dcd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e8baac5e-a6d7-4ccf-9046-48a5869275ff" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_2dca1def-d302-4675-bc06-dae4342dcd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_70f0437c-a14c-4e33-a2ff-ad23f01490d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_e8baac5e-a6d7-4ccf-9046-48a5869275ff" xlink:to="loc_us-gaap_EarningsPerShareDiluted_70f0437c-a14c-4e33-a2ff-ad23f01490d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ehc-20221231_g1.jpg
<TEXT>
begin 644 ehc-20221231_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7G7['_QINOVD?V2_A=^T/?6L<$_CSX=Z)XBG@B&%B>]L(;ED [ &0C'M7HM
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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M4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\
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M21G&5!["G?$/X*_!OXNRZ?/\6/A+X9\3OI%QY^DOXBT&WO392\?O(C,C>6W
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MGO\ \D3U;_L>]9_]*37NE !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?\
MP3W_ .2)ZM_V/>L_^E)KW2O"_P#@GO\ \D3U;_L>]9_]*37NE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !5?5]7TGP_I-UKVOZI;V-C
M8V[W%[>WDZQ16\2*6>1W8@(JJ"2Q(  )-<+^U+^U3\!/V+O@EK/[0_[2OQ%L
MO#'A30X@UWJ%V2S22-PD$,:@O-,YX6- 68]!P<? NC_!7]L7_@O1JUK\0/VN
M-%\1_!3]DE;A+KPW\&TN6M/$GQ'B5@T5UK<D9#6=DV RVJ'<PYSQ%<$ ^TOA
MO\?/V??^"E/[,OBW4/V5/VA[^?0=4?5O"W_"=>"YY+6ZTZ]C4PR3V<TB#+QE
MUDCF4,C91E+ UXA:_P#!O'_P2>O/V=]"_9J\>?LYW7B;1M&U:36+S4M1\8:I
M;:CKFK21E)-1U"XLKB!KR<AG"F3*Q"618EC5V!^OOAQ\-OA_\'O FE?"_P"%
M7@O3/#OAS0[)+31]$T:S2WM;.!1\L<<: *H^@ZDGJ:VZ /@#_B%Q_P""%'_1
MC/\ YDWQ/_\ +.C_ (A<?^"%'_1C/_F3?$__ ,LZ^_Z* /A#PG_P;.?\$2_
MGBK3/''@[]C.XTW5]&U"&^TK4;3XH^*$EM;F%Q)%*C#4_E9756![$"OJ;]JO
M]D#]FO\ ;<^$MY\#_P!J7X0Z1XP\.7F6%IJ</[RUEP0)[>92)+:8 D"2)E8
MD9P2#Z310!^:2^!O^"H7_!%IA-\)I/$O[6/[-%D?F\(7TPE^(/@BT'&+.7 &
ML6\:](2!( %51$BLY_2#PWK+>(O#MAX@;2+W3S?V45P;#4H1'<6V] WE2H"0
MLBYVL 3@@C)J[7CG[<W[/OQV_:0^!K>#/V:_VKM?^#GC/3]7M]5T/Q9HEE#=
M1RS0;BMI>02J1/:2%AYD8*D[%SN4-&X!['17Y\?!S_@L%\5?V6?B/IG[*?\
MP6R^$]C\)_%5_.+/PK\9]#=Y? GC%AT9;IA_Q+9R/F:&?:!RS&(,B'] K*]L
M]2LXM1TZ[BGMYXED@GAD#I(C#*LK#@@@@@C@YH EHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$
M]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP3P_X)6_"G]ARZU?XR^,_&&I?%'XX^,QYGQ ^,WBX"34M2<X+6]LI+"RLU(
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M'T+7RS^WK_P23_9O_;DUNQ^,EO?ZO\-/C+X> ?PE\:?A[<?8=<TZ15PB2NA
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HKX _P"#H[_E!1\<_P#N6?\ U)])K^0*@#^_RBOX Z*
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M_3WAWP[X?\(:!9>%/">A6>EZ7IMK':Z=ING6J06]K BA4BCC0!415  50
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M*#:)IEK^T3\.6EUOP_<)<>%O&^@7KZ=KVARHX<-:7T.)8QN&=A)0G#%=P4@
M]XHKPS]N?]N/X=_\$Z_A#I'QC^*GPU\=Z]X1&M0Z=XBUGPCHDFJGPW9F)R=3
MOOF\P6R,B*[C>^900&/!]%^!?Q\^"W[37PQTSXS_ +/WQ.T;Q?X6U>+?I^MZ
M%>K/#)ZH2.4D4\-&P#H<A@""* .NHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]
MCWK/_I2:]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X _X.CO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4?A'I'P(_9V^&NE^$_">A0>5IVCZ5!L1?[TCL<M+*Q^9Y7+.[$LS$DFNUHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY8_X*&?L^?\ !0SQ
M3XG\-_M(_P#!.W]JB+0?%/@RPG@NOA-XSM5F\*>,H'=9'CN"BB:WNOD"I<!C
MM VJ80\KM]3T4 >4?L5_'/XT_M$? '3OB+^T-^S#KGPA\8?:[FRUOP9KE_!=
M&*:WE,33030L1+;2,I:.1@I=<, 4*._J]8OQ(\%Q_$CX>:[\/)?$VKZ*FO:/
M<Z>^L:!>"WO[$31-&9[>4JWE3(&W(^#M8 X.*^-?V0/"_P#P5J_8N_:"T/\
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M57=FE'Z-_6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$
M]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH ****
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MI#6-9M=>\'>$?!7@K3;[PQX:E@)>&#58I8G_ +8N6.WS;@L=K@D&=551]*?
MG_@L3X]^ 7Q0TS]D+_@L]\)[+X,?$"^E^S>&/B;I\S2>!?&S#CS+6^?BQF(P
M3!<$;<C<R,ZQT ?<'PL^%7PV^!_P\TCX2_!_P-I?AKPSH-FMKH^AZ-9K!;6D
M*]%1%  Y))/4DDDDDFN@IL,T5Q$MQ;RJ\;J&1T;(8'D$$=13J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKXM_;>_X)@_%[QE\=KK]O;_@G?\ M.:K\*OCJUA;VNK6^K7<U]X6\9VMNFR&
MRU.Q8L(U"C:LT*YCW,P0N0X^TJ* .-^$/B;XG0_!#PUXD_:?L?#?A[QC-H]H
M?%UGHFHL^FVFHR!5DA@EFPS)YK;%SDDD %N">RK@/VHOV7_@C^V7\"]?_9O_
M &BO!::_X0\26Z1:IIK7,D+$I(LD<B21,KQNDB(ZLI!#**\'_P""?W[('[=7
M[$WQ-U?X,>-OVMH/BQ^S_!HI?P#-XW@DD\8Z#="5%33Y;I,17EHL)D(E?]X"
MJ(J1H.0#ZWHK.T?QAX2\0ZOJGA_0/%&G7U_H=REOK=E9WT<LVGS/$DR1SHI+
M1.T4B2!6 )5U8<$&M&@ HHHH **** /G+]O;_@EM^RK_ ,%"=,L-7^*>@W_A
M_P >>'B)?!GQ5\%WAT[Q'X>G4ED>WNXQN958D^5)N3)) #88<]_P3[T#_@JG
M\'/'FO?LZ_MU:YX2^)G@C1-)2?P-\==*N!8:MJY\T(+'4M, (%PL>YVN$8(0
MJ@F5W9D^KJ* $61'+*C@E3A@#T.,X/X$?G2U\(_M3?\ !-/]JKX6_'OQ'^WE
M_P $H_VD;GPS\0O$EVM_X^^%/Q U"?4/"'CF5(U0;T=C)I]SY:*BRQ$* J(/
M)4LQZ;]B?_@L9\+/V@/B;_PR1^U1\.-5^ O[05DJI??"SQU*JKJC<CSM(O>(
MM2A;!*["'(#$*RKO(!]D45Q/Q\_:1^ /[+/@"X^*?[1WQC\.>"?#UMD/JOB3
M5HK6-WQD1Q[R#+(>T:!F8\ $U\177_!8_P#:A_;;NI/"O_!&3]AO5_'6F22-
M%_PO/XN13^'O!MOR1YUNCA;O4E!QE(A&ZYSM(H _!7_@Z._Y3K_'/_N6?_48
MTFO@"OKG_@NWX1_:2\#?\%5_BGX;_:\^+.C^./B-%_8<OB7Q)X?T4:?8S/+H
M>GRQ0P0 #;'!"\5N&8!I!#O;YG-?(U !7W__ ,&N/_*=?X&?]S-_ZC&K5\ 5
M]_\ _!KC_P IU_@9_P!S-_ZC&K4 ?U^T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!X7_P3W_Y(GJW_ &/>L_\ I2:]
MTKPO_@GO_P D3U;_ +'O6?\ TI->Z4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVO["^MTN+*^LIUEAN(G4,DB.I*NK @A@2"#D4 6:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XE_;)_
MX)"S>,_C3>_MR_\ !/#XW7GP*_: F4-J>N:>AFT'QB% Q;:UIYRDZM@#SU7>
MI.\K*RIM^J;WXF:+\&_AGH&M_M,_%#PGHNH3KI^FZGK$UTNFZ==ZO,$C\NV%
MS*2HEG)$43.[X(&6()KL:\__ &G/V5_V>_VR_@_J/P&_:<^%6E>,/"NIX:?3
M-4B)\J4 A9X9%(>"90S;98V5UW'##)H ] HKY>_X)X_L+?'W]@W5O$_PKU#]
ML?7/B1\&UM[;_A6'AKQK8BXUKPN0TGG6K:B&!N;54$0B5DRHRH"!,R>Y_##X
M^_!'XUZGXDT3X1?%CP_XDO?!^N2Z-XKL]%U6*XETB_B8J]M<HC%H9 01M8#H
M<=* .NHHHH **^/_ -K#_@M]^PU^S+XW/P.\(>(M9^,'Q6F=H;'X4_!K2VU[
M6'F'!CE\@^5;%3C<LLBN <A&KRC_ (03_@NQ_P %'OWOQ+\=Z-^QE\,+SD^'
M_!US'KOCR^MS_#+?\6^G%A@AH0)HSE65J /I[]M#_@IM^PY_P3^T=;[]J3]H
M+1M!U*XC#:9X6MG:\UG42>$$%C 'G<,V%#[0@)&YEZU\-_M C_@H!_P6^?PY
M!\(_^"=/A3X,^ /#NNV^L>%OC+^TKH:77B:VFBE26.YTO1(R6@8LD;%;EFMY
MT^5LCBOK_P#8O_X(^?L&?L,:P_C_ .%GPB.N^/KES+J?Q0\>WC:UXCO9R,/,
MUY<9,+-_$(%B5L<K7T]0!^1_[2'[ 'P?_P""<7BKPC^VK^U_^S9\5?VX[U;B
MX/Q-^*7B[58M5E\#0*(VBN;'PXV87M=WF,R@-]F6+<)!D+7Z4?LI_M4_LT?M
MA_!S3?C'^RC\5-$\5^$[B-8K>YT60#[(RJ/]'FA(5[:501F&14=01E0"*](K
MX5_:B_X(SPV?Q:OOVR_^"6_Q?;]GSXUW'[W5O[*M=_A;QC@EC!J^F*#&V]B<
MW$:[U9VD*2/M8 '5_M1_\$%?^"3W[:/QVUW]I?\ :7_93_X27QMXE^R_VWK?
M_"=:[9_:?L]K%:P_N;6^BA3;#!$GRH,[<G+$D^?_ /$+C_P0H_Z,9_\ ,F^)
M_P#Y9U]<_LT^*_V@[W]G/0?%?[:/A3PKX3\?1:=+)XRL?#&L-<Z5:O&[CS8I
MI0"L;1*LI5BWE[BI=]NX_(W_  <B?\%(Q_P3P_X)Q:\?!.O_ &3X@_$WS/"_
M@CR9=LUMYL9^V7ZXY'D6Y;:X^[--!ZT '_$+C_P0H_Z,9_\ ,F^)_P#Y9UZ!
M^RY_P05_X)/?L7?';0OVE_V:/V4_^$:\;>&OM7]B:W_PG6NWGV;[1:RVLW[F
MZOI87W0SRI\R'&[(PP!'G_\ P;=?\%(O^'B'_!./0?\ A-=>^U_$+X9>5X7\
M;^=+NFN?*C'V._;/)\^W"[G/WIHI_2OO^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_R1/5O^Q[UG_P!*
M37NE>%_\$]_^2)ZM_P!CWK/_ *4FO=* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **Y#XY_'[X*?LR_#74/C%^T%\4M$\'>&-+3=>
MZUK^H);P(3G:@+'YY&QA8UR['A02<5\%W'_!0?\ X*(?\%4KB3PG_P $D/A,
MWPR^%=PYBO/VG_BUH;)]LBS@R:#I$@#W9X)6:<>7G*LL3 &@#ZL_;C_X*4?L
M>_\ !/#PE;^(?VE_BK#8ZGJ?R^'/!VDQ&]US792=JQ6=E'F24L^$WD+&K, S
MKFOE#_A$_P#@KS_P5Z_>_$/4=9_8Z_9_ONGA[29U?XC>*+0]KB?&S18W7^ #
MSE^9'65&#5[Q^P[_ ,$>_P!EO]C'Q;<?';6)]9^*GQFU7Y_$'QF^)MX=2UNY
ME*X86[296RBP2H2$!MF%9W %?5U 'CG[&/[ ?[)/_!/[X<_\*S_93^#.F>&;
M6?:VJZDBF;4=6E&?WUW=R$RW#Y)(WL0N2%"CBO8Z** "BBB@ HHHH **** "
MBBB@ KYD_P""CG[0O[='PUL?"WP2_P""?7[+TGC'Q[\0I;JWM_'6OR+%X8\$
MPPB/S+W4G4F1GQ(#% %_>E'P7*>4_C?B?XW_ /!2W_@HC^U%=?"3]E+0==_9
M\^"'PW\:?9O&GQ;\6^'U&O>,[JQN1YMAH]E<J5CLV>,H]U(I$BD@='@?[_H
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M-_%^F:_H.KVJW.E:UHU]'<VMY"PRLD4L9*NI[$$BM6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKA?V@_VG/V
M>?V3_ $WQ2_:4^,_ASP1H$&1_:7B/58[9)7 SY<08[II#VC0,Y[ T =U7Q)^
MW!_P28^#'B'XE7'[>O[,GQ]F_9E^,6DJ;G6OBAX>6%-+UBV#!I(];L962VO(
MB!S(Y5L[2YD"*M<-<?\ !8+]K;]N2=_#7_!&C]AG5/%>C3.8U^/'QFBG\/\
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M'WA'QM-'=/X,M51A)96]YCSIX69EV(Y"Q+&JJ-Q=W .R_9/_ &&OV1?V&?!
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M\J,?8[]L\GS[<+N<_>FBG]* /O\ HHHH **** "BBB@ HHHH **** "BBB@
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M?_&/XF:1^QM\,+SD^%? %TFM>.KV _P3:F<6^GL1@A[<"5#E70U[_P#L6_\
M!(?]@S]A'47\9_!SX-QZGXWNF:35/B7XUNFUCQ%?3-]^5[VXRT1?^)81&C'D
MKF@#P#_AJC_@M1_P48_T3]B[]F>R_9>^'%YPGQ4^.UBMWXFN8#TELM!0E8'P
M01]J+1N#E7!KN_V?/^"#O[(W@3Q_#^T!^UMX@\3?M)?%5<._CCXT7YU.*U?.
M[;9Z<V;6UB5L%%*R-'@;7%?;E% #+>W@M8$M;6%(XHT"1QQJ JJ!@  = !VI
M]%% !1110!\I_M,?\$B?V=OCI^T;X?\ VROA=XE\1?"#XO:+JMO-?^/_ (:7
M265SK]DLJ&>QU&%E:&]26-2F^1&8?)DNB^6?2OVH_P!OC]D[]BSQ3X&\*_M0
M_%RT\&GXB:I/IWAK4]7MY4L#<Q(KLEQ=!3#:@AU"M,R*QS@\''L5<K\:O@?\
M(/VC?AIJGP<^._PWT?Q9X7UJ#RM3T/7+%9X)E[':P^5U.&5UPRL RD$ T =/
M:W5M?6T=[97$<T,T8>*6)PRNI&0P(X((Y!%/KPO]AK]AGX9_\$YOA'K7P@^$
MGQ#\=:SX/.MS:GX>T/Q7KDNJ_P#"-6AB0?V;894R"V5D=TC.]R93DL>2O[$?
M_!1S]DC_ (*#^%]1US]F[XE"[U+0KE[;Q/X1UFT>PUO0YU<H8[NQFQ+%\P(#
MX*$@@,2I  /<Z*** /S _P""S?\ P;M_$?\ X+"_M':5\9O$W_!0/_A"O#WA
MOP^FE^&/!<?PP.HI8Y8R7,[3_P!J0B26:3&2(UPD42<[-Q^0/^(&/_K*+_YA
M/_[]5^_U% 'X _\ $#'_ -91?_,)_P#WZKZ__P"",G_!NW\1_P#@CU^T=JOQ
MF\,_\% _^$U\/>)/#[Z7XG\%R?# Z<E]AA);3K/_ &I,(Y89,X)C;*2RIQOW
M#]/Z* "BBB@ HHHH **** "BBB@ HHHH **** "N5^.'P3^%_P"TA\(?$7P'
M^-7A*WUWPIXKTJ73M=TFZ+!;B"08(#*0R,.&5U(96564@@&NJKR_]LKX*_$_
M]H']GS5/AO\ !7XL6_@?Q:-7T?5_#GB>\T@W\%I>:;JMIJ,:RVXEB,L4C6@B
M==X^25CAL;2 ?D9X/U3]J_\ X-N?VAO'W_"/+KGQQ_9*T<>'H/%MSJ4P?Q)X
M!LKHW"V1A.X+/;0EI$("K&Q=1BW)#-^QWCWQ3H'CC]G36O&OA34X[W2]8\%7
M-]IMY%G;/;RVC21R#/.&5@1]:^+/BU^Q-^WY^VQK/Q;_ &?_ -H67X?> O!/
MQ&TOPS8>./%W@V]OM1NM7L+3SWN+73(;JWA2TDER(WEE>?R5D^596(9?LCXD
M_#?Q1I?[.]U\&OV>M&T&TFC\-'0]"AUV]GBL["W%N8(V/E1R/((UVX3Y=V,;
MUZT ?*?_  ;._P#*#SX#_P#8,UK_ -/NHU%^WG_P;V_L2_MD^-=>_:0\$W'B
MKX8_'74;K^T=-^+GA/Q9J NX-11 L$CPO.8S&NQ%VQ")PBA4=,#'J?\ P2'_
M &-OC1_P3V_8B\*?L9_%SQ+X8\01^"$NX])\1^'9+A&OH[F^N;MA-;S1CRBA
MG"AED<.!DA,<Y?A'X8?\%G-(^)7C'P[XC_:E^"6I^!-7UZZN/"/B2Y\ WI\0
M:#82N3':FUAFAM+AHD(1))'8EEWR"0'RZ /SE_X*"?M!?M7_ +37_!K'\1I/
MVE_]*^(?PZ^)47@KXDZK9J!'JLFD>);>T:[PH .9!!O8  R1NV%!P/MS_@M9
M?>&;'_@@!\5KBU>+^S6^$VG1V!&-I#R6B08_%DQ^%?1$?[!/[/$W[%^K?L(Z
MYH5WJG@GQ#HE_8>(I=0N ]]J<]]))->:A+,% ^URW,TER954 2MN55  'S]X
MC_X)D_M*_';]E3P5_P $Y?VH/C!X5U;X-^$;C28/$&O:1%=+K_CG2-*ECDL-
M.NH'40V!)M[;[1<1S3M-Y+;$@,A*@'O7_!,JP\1Z5_P3=_9]TSQ@LBZM;_!'
MPI%J:S9WBX72+42!L\[MP.??->WU':VMK8VL=E96T<,,,82&&) JHH& H X
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MQS=\%>"/!GPV\):=X!^'?A/3=!T+2+1+72M&T>QCMK6S@086***,!(T X"J
M!6I0!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2U\Z?\ !5G_ (**:?\ \$XOV%O''[3^L^'BFJV%
M@;'P=9WCKMO=:N 8[2(KG+J'S*X'/E0R'M6[^WI_P4T_9P_X)Y6GAS3OB[IW
MC#Q!XJ\:O<Q>!? ?@+PG<ZMJ_B&:#R_-CMDC41AE\V+/F2)]\8S7\UG_  <3
M?\%BOVA/^"BWQHT[]GSX@_ RX^%?ASX8:C<$^!K[6%O+]M3E15:;4&C"QQSQ
MQ?NQ;@%K=I)T9F8L% /S\_X6K\1_^%I_\+O_ .$TU#_A+O\ A(/[<_X2+[0?
MM7]I>?\ :/M6_KYOG?O-W][FOZ3_ /@G'X%^)W_!P/X4\-?\% O^"C_C+3?%
M?PY\.:J]KX-_9[\'%XM"M]6L\1RW^MJYW7=PQ_>I;MF-8IDZI(\1_F0K]?O^
M#0C_ (*1?\,V?MDZA^Q#\1M>\GPC\9=O]@_:)<1V?B2!#Y&,\+]IB#0'NTB6
MR]J /Z8+#5[G2[&'3-,\!SVUM;1+%;V\"HB1(HPJJHX50   . !4W_"2ZO\
M]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK
M_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2ZO_T*%[_WTM'_  DNK_\
M0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\ ]"A>_P#?2UL44 8__"2Z
MO_T*%[_WTM'_  DNK_\ 0H7O_?2UL44 8_\ PDNK_P#0H7O_ 'TM'_"2ZO\
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M*6BV8E\;^"K4=#JUL#_Q,[>-?O72'> KN[+\D5 'Z+_\)+J__0H7O_?2T?\
M"2ZO_P!"A>_]]+7-?LV_M0?L_?M@?"?3_CA^S/\ %C1_&7A;4U_T?5-'N=X1
MP 6BE0X>"5<C=%(JNI.&45WM &/_ ,)+J_\ T*%[_P!]+1_PDNK_ /0H7O\
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M% !1110 4444 %%%% !114=W=VMA:RWU]<QPP0QM)--*X5(T R68G@  9)-
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M_@C9JW@?XL:A^V7_ ,$D/B[#\!?B]=MYVO:!%;%_!OC8@EC#JFG("D3,2?\
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M* "BBB@#PO\ X)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH
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M-/@_P/&8A'/=Z'HL:7ERO_3>Z8&><\#F1V/%>LT ?GF/^"(OQM_:C/\ :?\
MP57_ ."FWQ0^+5M/\UU\.? LR^$/"C*>L$MM9'S;I5'RB1GC<C)/)-?5O[+?
M[ /[%7[$^D+H_P"RK^S'X/\ !/[KRIK_ $C1T^W7"^DUV^ZXG_[:2-7K]% '
M\ =%?W^44 ?P!U^_W_!C'_S=%_W)/_N?K]_J* "BBB@ HHHH **** "BBB@
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M,![B=LRW+XXWRN[>]>F444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M >9*^U1P JJJHBJBJH]HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\
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M?\%6/^"AGQ9^/S.XDN?!%CJ/_"*^$B<YV_V;IS*6(Z!_-4D#D<\ 'I7[2/\
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M?M@?\%#OV*_V"?"X\4_M9_M%>'/!ZR0F2RTN[NC-J-\!D?Z/90A[B?D8RD9
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M?#O]E3X!>&O VEE5%PFAZ<J3W97H]Q<-F:Y<?WY7=O>O3J** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX^ O[-?A%/ /[/?P8\+>"-%3'_$L\*Z%!80L0,;F6%%#MZLV2<DDG-?R9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >%_\ !/?_ )(GJW_8]ZS_ .E)KW2O"_\ @GO_ ,D3U;_L>]9_]*37NE !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\O_MM
M_P#!7W]BG]A?6X?AIXY\;WWB[XE:@PCT/X2?#G3VUGQ)J,S#*1BTA/[G<.0T
MS1A@#M+'BO _^%=_\%K?^"HO[[XO>,O^&-?@Y>_\RKX-O4U#X@ZQ;'M/?X\K
M2MRX($0\U#N1T8<T >^?MM_\%??V*?V%];A^&GCGQO?>+OB5J#"/0_A)\.=/
M;6?$FHS,,I&+2$_N=PY#3-&& .TL>*\#_P"%=_\ !:W_ (*B_OOB]XR_X8U^
M#E[_ ,RKX-O4U#X@ZQ;'M/?X\K2MRX($0\U#N1T8<U]0?L2?\$Q_V*?^"?&B
M36?[,_P6L=/UF_4_VYXSU1VOM<U=V.YWN;Z;=*^YLL4!6,,251:]\H \#_8D
M_P""8_[%/_!/C1)K/]F?X+6.GZS?J?[<\9ZH[7VN:N['<[W-]-NE?<V6* K&
M&)*HM?G[_P %1_\ @U*_X>4?MV>.?VUO^&\_^$+_ .$T_LS_ (IG_A5W]H_8
M_L>EVEA_Q\?VI!YF_P"R^9_JUV[]O.W<?U^HH _ '_B!C_ZRB_\ F$__ +]4
M?\0,?_647_S"?_WZK]_J* /R!_X)<?\ !J5_P[7_ &[/ W[:W_#>?_":?\(7
M_:?_ !3/_"KO[.^V?;-+N[#_ (^/[4G\O9]J\S_5MNV;>-VX?K]110 4444
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M!( /XY/VX?VF?B+^U_\ M5>,_C]\4/B!?>)]2UG5FCM]9U%$26:S@ @M<I&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#PO_@GO_P D3U;_ +'O6?\ TI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO
M=* "BBB@ HHHH **^7_VV_\ @K[^Q3^POK</PT\<^-[[Q=\2M081Z'\)/ASI
M[:SXDU&9AE(Q:0G]SN'(:9HPP!VECQ7@?_"N_P#@M;_P5%_??%[QE_PQK\'+
MW_F5?!MZFH?$'6+8]I[_ !Y6E;EP0(AYJ'<CHPYH ]\_;;_X*^_L4_L+ZW#\
M-/'/C>^\7?$K4&$>A_"3X<Z>VL^)-1F892,6D)_<[AR&F:,, =I8\5X'_P *
M[_X+6_\ !47]]\7O&7_#&OP<O?\ F5?!MZFH?$'6+8]I[_'E:5N7! B'FH=R
M.C#FOJ#]B3_@F/\ L4_\$^-$FL_V9_@M8Z?K-^I_MSQGJCM?:YJ[L=SO<WTV
MZ5]S98H"L88DJBU[Y0!X'^Q)_P $Q_V*?^"?&B36?[,_P6L=/UF_4_VYXSU1
MVOM<U=V.YWN;Z;=*^YLL4!6,,251:]\HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HKYH_:I_X+&_\ !,3]BGQ-/X'_ &D_VR_".@Z]:MMO
M= LY9M3U"T;&=LUK8QS2PDCD!U4D'BC]E;_@L;_P3%_;6\30>"/V;/VR_".O
M:]=-MLM O)9M,U"[;&=L-K?1PRS$#DA%8@=: /I>BBB@ HHKXT_:L_X+*>"?
M@M\=M;_9$_9N_9/^+7QT^+N@>0NL>%O _A6:#3])>>".>'[=J=RJP6\;Q2QN
M)4$JC> <'( !]EUS?C'XR?"+X>>)-#\&>/OBEX=T36/$UX+3PWI.K:U!;W.J
MW!SB*VBD</._!^5 3P:Y/P;!\:?VA_V25TSXX^%=3^#_ (Y\7>$KBTUO3_#'
MB>*\O/"UW/')'YEK?0CRWEBRLB2*,!@,C@BO$OV4_P#@AW_P3]_97^(5M\=&
M\ :O\2OB?;W,=T?BE\7M>E\0:V;E#E+A))_W4$JMRLD4:.#_ !<"@#O_ -O'
MX^_ML_!C1_#>A?L.?L5Q?%WQ'XEN;F"YN]4\8V^CZ7X;6-8RMS>/*-\R-O;$
M<6&/ED Y(!;^P=X/_P""DFB:9XE\5_\ !1OXQ_#?6]5UR>UD\/>$OACX=GMM
M/\,QHLGG1B[N6\^\,A:+_6*-AB.&8/\ +] 44 >7?#[]B;]D7X5?&+Q#^T+\
M/OV</!VF>//%6HR7^O\ C&'0H3J=W/(/WC&Y93(@;J54A223C))KU&O#?VW/
M^"CW['?_  3S\&P^*_VH/B_9Z1=Z@-N@>%[)3=ZSK<I.U8[2RBS+,2^$WX$:
MEAN=0<U>^"'Q(U3]N_\ 8^?Q3XT^$?Q(^#Q\=Z/J-B=$UV;^RO$>E6TC2P17
M2M"Y:TG:+9.ASOC9E[KD@'FW[;__  6&_90_8O\ %D'P.LI-9^*'QBU0^7H/
MP:^&-B=4UVZE(ROG)'E;-,$,6F*MLRRH^"*S?V&K#_@KQ\7/C/+^TS^W3KW@
M[X7^![C1I[7P]^SSX8M8]4N[<RM&Z7FI:L2,W483:$@S$5D;*HV17I/[$'_!
M-C]CG_@GEX3G\._LR?".UTW4=1&[Q!XNU*0WFMZW*3N:2[O9<RRY?+[ 1&K$
ME47->[4 ,6W@29[E($$D@ DD"C<P&< GOC)_.GT44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%1W5U:V-K)>W
MMS'###&7FFE<*J*!DL2>  .230!)17SWX4_X*K?\$]_&?Q+NOA;HW[5O@T7L
M,MK#8ZC<ZY!%IVJS3B0I#9W;.(;J3]TPVQL23TSSCWCQ!XAT#PGHEWXF\4ZY
M9Z9IMA;M/?:AJ%RD,%O$HRTDDCD*B@<DD@"@"Y17-?"#XR?"K]H#X>6'Q;^"
M7Q TKQ3X8U5YUTS7]#O%N+2[\F>2"0Q2KE9%$L4B[E)!VY!(YKG/C9^V!^S%
M^SEK-KX<^-WQNT#P[J-Y827\6G7UWFX6RC;;)>/&@+16R,<-<.%B4\,PH ](
MHJIH6NZ'XIT2S\3>&=9M-1TW4;6.YT_4+"X6:"YA=0R2QR(2KHRD$,"00017
MF_A#]MW]D;Q]\3A\&_!?[0_A;4O$<E[<65KI]IJB,+N[MP3<6T$O^KN)X@K>
M9#&S21[&WJNTX /4Z*** "BOR!_X.M?^"H_[=G_!-?\ X4+_ ,,4_'/_ (0O
M_A-/^$I_X2;_ (IG2]1^V?8_[(^S_P#'_;3^7L^U3_<V[M_S9VKC\@/^(H[_
M (+K_P#1\W_F,O#'_P K* /ZB?\ @GO_ ,D3U;_L>]9_]*37NE?QR_#W_@Y#
M_P""T/PKT2;PYX"_;+^P6<]_->RP_P#"N_#DNZ>5MTCYDT]B,MSC.!V K=_X
MBCO^"Z__ $?-_P"8R\,?_*R@#^OVBOE_]MO_ (*^_L4_L+ZW#\-/'/C>^\7?
M$K4&$>A_"3X<Z>VL^)-1F892,6D)_<[AR&F:,, =I8\5X'_PKO\ X+6_\%1?
MWWQ>\9?\,:_!R]_YE7P;>IJ'Q!UBV/:>_P >5I6Y<$"(>:AW(Z,.: /?/VV_
M^"OO[%/["^MP_#3QSXWOO%WQ*U!A'H?PD^'.GMK/B349F&4C%I"?W.X<AIFC
M# ':6/%>!_\ "N_^"UO_  5%_??%[QE_PQK\'+W_ )E7P;>IJ'Q!UBV/:>_Q
MY6E;EP0(AYJ'<CHPYKZ@_8D_X)C_ +%/_!/C1)K/]F?X+6.GZS?J?[<\9ZH[
M7VN:N['<[W-]-NE?<V6* K&&)*HM>^4 >!_L2?\ !,?]BG_@GQHDUG^S/\%K
M'3]9OU/]N>,]4=K[7-7=CN=[F^FW2ON;+% 5C#$E46O?*** "BBB@ HHHH *
M*** "BBB@ HHJEXA\1^'O".BW'B3Q7KUEI>G6B;[N_U&Z2"&%<@;G=R%49(&
M2>] %VBO//#_ .UU^RAXM\9V?PX\*_M._#S4_$.HRM'I^@Z?XUL9KVZ=59F6
M.!)2[D*C$@ X"D]C53]I;]M']D[]C;3=+UC]JC]H/PKX!MM;DFCT>7Q-JR6O
MVUX@AD6(,<N5$B$@9QN% 'IU%>,?LK_\%#OV*/VWM8UW0/V3?VC/#WCN[\,P
MP3:['H4LCBT29I%B9F9 IW&*3&"?N^XSY=^U?_P7(_X)M_L6_&[4_P!F_P".
MOQBUNW\<:/!;3:EH&C^ -8U!X4GA6>(^;;VK0MNB<-\KG'(.""* /KBBO./V
M4/VIOA7^V;\$=,_:!^#"ZR/#^K3W,5H/$&ASZ==!H)GA??!.JN@W(<$CD8(X
M-?)NI_\ !>6.34KC2O __!(#]M[Q T$[QB]M/@3Y=G)M)&5F>[&0>"#CD,#0
M!]\T5Y_^T)\7/B+\)_@!J_Q<^%7P"UKXA^(;"SMY]/\  .EWL-I?:@TDL:/&
MLDWR(R([.=W:,CJ17SU^S1^W=_P4Q^-/QPT'P/\ %C_@C'XA^&O@C4)IAKGC
M[6_C-HMRVDQK!(Z/]@A3SI]\JQ1;48%?,+\A"" ?8M?CI_P=7?\ !:3XD?L0
M>"-$_8?_ &5O%\^A_$'Q[HS:GXG\3Z?*4NM#T5I'AC2V<?ZNXN'CF'F AXHX
M6*X:1'3]$?VY/B-_P4-\ 6/AI?V OV;_  /\0;J]ENQXF;QOXP;28]-1!$8#
M&%4F8N3,"!C;L7UK^5G_ (.%]:_;!\0_\%0_%^K_ +</@GPWX=\<2Z'HV[2/
M!^I37>F06@L8A%]GEF 9@V'9N,"1I!VH ^)KJZN;VYDO;VX>::9R\LLKEF=B
M<EB3R23SFBUNKFRN8[VRN'AFA</%+$Y5D8'(8$<@@\YIE% ']$__  ;R_P#!
MR<GC;X=:7^Q;^WEK?BKQ/\0(->T[2/A]XCTK0;G5+[6[*YD\H_;C$I(-I\K/
M<N=SPMDAGC9I/UI_;F\!?MV_$GX;Z5X2_8*^/?@SX;:[=:VJ>)/%?BSPN^K2
MV6FF&3=)8P%O)>Y$OE868;"A<[E*@-_,9_P:A?\ "4_\/MOAM_PC_F?9/[!\
M1?VYLSC[+_9%UMW8[?:/L_7C..^*_K?H ^;/V$/^"?/BG]D#7O$7Q+^*O[;'
MQ7^-'C;Q?:6\&O:OX]UI?[/A6%G9%L-/C'EV*9D?Y59OO'FOI)41"S*@!8Y8
M@=3C&3^ 'Y4M% !117Y_?%S_ (*V_M$?M*?%#7_V7/\ @CI^RY=?$'Q'X?U:
M?1_%WQA^(5K<:3X*\*7D3F.:-G=5GU"XB<,&@A (X9?-7(H ^[?$WCGP5X*D
MTZ+QEXPTO26U?4HM/TE=3U".W-[>29\NWAWL/,E;!VHN6.. :\#_ ."@?AW_
M (*:?$*/PO\ "K_@GMXW\ ^!+'76NE\=_$_Q9;27U_X=@7RO*_LZPV^5<SR;
MI>93L7R\':6##RS]F/\ X(L^&]-^,.D_MC?\%&OCMK?[1?QLTNX2\T76/$R"
MW\/^%9U82*-(TJ,^3;['"E9&!.Y%D58GS7W'0!\G?L1_\$<_V5?V./&4WQZU
MZ36OBO\ &;4CYFN?&7XH7IU/6II2,'[.9,I91CE56$!@F$9W %?6-%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ'\+ZAKEZEK#J'A#5+>$07T<DA"O'";-XYW!(BE)5B.,@'QM-^WC\4/V*O\
M@DE^W[^S7\-/$MU:2_!/X^:GX'^%EY#,5DT71-8U9H(X(6!S&8(A>O&PY1G4
M+@*,?9/_  5$_9XT+X$?\&ZH\*_#!!H&K_!3P)X7\0>"-8TX".XTK5M,FLY1
M>1.!\LS_ +\,_5O/D)R6-?,7A+_@F/\ &+]MC_@C]^VC\9=#\(7T'BG]I?XQ
MZG\2?A;HEU;M%<WFD66I?;--3RW 97NHQ=+$& !2>%\X;-?0W_!1S]I_1OVP
M?^""FB> O@/=0Z[\1OC_ *!X?\)>$O!EK,IOI-9DN+4:E:R1?>B-FD5X;AF
M6'R&WE1S0!]\?L?_ !INOVD?V2_A=^T/?6L<$_CSX=Z)XBG@B&%B>]L(;ED
M[ &0C'M7HM</^S'\&;/]G']FWX>_L]:?>BYM_ ?@?2?#L%RJX$J65G%;!\'I
MD19_&NXH _ '_@^<_P";7?\ N=O_ ' 5^ -?O]_P?.?\VN_]SM_[@*_ &@ H
MHHH _K+_ &7_ -J/_@VM_P""5RZGX2^"_P"TA\-M(\3BXEM_%/BB\O9]7\0:
MC<+(PF%W>^7),Q,BL3&I6,,3M1<BOO/XO?M.?!?X&?L[ZE^U5\1/%4L'@72M
M$BU>\UBRTVXNF%G($*2K#"C2OD2*<*A.#TX->5?LI?\ !*#]CC]D/X;)\-?
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M#QE%\6=)T&TGE=,O$$NT9P48A23P>2.E>,CQ=_P<>>$/^1B_8Y_9L\8;>O\
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M#_Q5\=^-+:PNKB<>(/B1XE;5M6N&FE:1A+<LJEP"Q"C'RC [5V7_  @^D?\
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M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V
M**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#
M8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C
M_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_
M^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_
MY^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_
M )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P
M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
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M+G.!7H7C#P/X*^(6C'P[X^\'Z7KFGF19#8ZQI\=S"77[K;)%*Y&3@XXK4HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\ X)[_ /)$]6_[
M'O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_ '_@\V_P""D7_(J?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \+_ .">_P#R1/5O^Q[UG_TI->Z5X7_P3W_Y
M(GJW_8]ZS_Z4FO=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_^">__)$]6_['
MO6?_ $I->Z5X7_P3W_Y(GJW_ &/>L_\ I2:]TH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH \+_X)[_\ )$]6_P"Q[UG_ -*37NE>%_\ !/?_ )(GJW_8]ZS_ .E)
MKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#PO_ ()[_P#)$]6_['O6?_2DU[I7
MA?\ P3W_ .2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO\
MX)[_ /)$]6_['O6?_2DU[I7A?_!/?_DB>K?]CWK/_I2:]TH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \+_X)[_\D3U;_L>]9_\ 2DU[I7A?_!/?_DB>K?\ 8]ZS
M_P"E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#PO_@GO_P D3U;_ +'O6?\
MTI->Z5X7_P $]_\ DB>K?]CWK/\ Z4FO=* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /"_\ @GO_ ,D3U;_L>]9_]*37NE>%_P#!/?\ Y(GJW_8]ZS_Z4FO=* "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /"_P#@GO\ \D3U;_L>]9_]*37NE>%_\$]_
M^2)ZM_V/>L_^E)KW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M? I?$_@W0+?6/B9=_&F\U'R85O6<6-G:1:<&E:81P2SS%QM2.:VYS(*^<O\
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M]<N[2 R0:38LHFNFR/D0MQGZ^E>0_P##6'QL_P"C'_'?_@5;?_%4 '_!/?\
MY(GJW_8]ZS_Z4FO=*^,OV0_VA_B?X'^&%]I7AK]ECQ9XC@F\4ZE<27NGRQ*D
M4CSDM 0<_,AX)Z5ZG_PUS\</^C&?'?\ X$P4 >]45X+_ ,-<_'#_ *,9\=_^
M!,%'_#7/QP_Z,9\=_P#@3!0![U17@O\ PUS\</\ HQGQW_X$P4?\-<_'#_HQ
MGQW_ .!,% 'O5%>"_P##7/QP_P"C&?'?_@3!1_PUS\</^C&?'?\ X$P4 >]4
M5X+_ ,-<_'#_ *,9\=_^!,%'_#7/QP_Z,9\=_P#@3!0![U17@O\ PUS\</\
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M_AKGXX?]&,^._P#P)@H_X:Y^.'_1C/CO_P "8* />J*\%_X:Y^.'_1C/CO\
M\"8*/^&N?CA_T8SX[_\  F"@#WJBO!?^&N?CA_T8SX[_ / F"C_AKGXX?]&,
M^.__  )@H ]ZHKYLLOV\_B9?^-KWX?VO[&7B]]4T^SCNKJQ34(3-%%(2%=EV
MX"G'!R?I6S_PUS\</^C&?'?_ ($P4 >]45X+_P -<_'#_HQGQW_X$P4?\-<_
M'#_HQGQW_P"!,% 'O5%>"_\ #7/QP_Z,9\=_^!,%'_#7/QP_Z,9\=_\ @3!0
M![U17@O_  US\</^C&?'?_@3!1_PUS\</^C&?'?_ ($P4 >]45X+_P -<_'#
M_HQGQW_X$P4?\-<_'#_HQGQW_P"!,% 'O5%>"_\ #7/QP_Z,9\=_^!,%'_#7
M/QP_Z,9\=_\ @3!0![U17@O_  US\</^C&?'?_@3!1_PUS\</^C&?'?_ ($P
M4 >]45X+_P -<_'#_HQGQW_X$P4?\-<_'#_HQGQW_P"!,% 'O5%>"_\ #7/Q
MP_Z,9\=_^!,%'_#7/QP_Z,9\=_\ @3!0![U17@O_  US\</^C&?'?_@3!1_P
MUS\</^C&?'?_ ($P4 >]45X+_P -<_'#_HQGQW_X$P4?\-<_'#_HQGQW_P"!
M,% 'O5%>"_\ #7/QP_Z,9\=_^!,%'_#7/QP_Z,9\=_\ @3!0![U17@O_  US
M\</^C&?'?_@3!1_PUS\</^C&?'?_ ($P4 >]45X+_P -<_'#_HQGQW_X$P4?
M\-<_'#_HQGQW_P"!,% 'O5%>"_\ #7/QP_Z,9\=_^!,%8W@C]O/XF?$'2)=;
M\*_L9>+[ZVAO);62:RU"%T66-MKH25'S \$8X]: /I.BO!?^&N?CA_T8SX[_
M / F"C_AKGXX?]&,^.__  )@H ]ZHKP7_AKGXX?]&,^._P#P)@H_X:Y^.'_1
MC/CO_P "8* />J*\%_X:Y^.'_1C/CO\ \"8*/^&N?CA_T8SX[_\  F"@#WJB
MO!?^&N?CA_T8SX[_ / F"C_AKGXX?]&,^.__  )@H ]ZHKP7_AKGXX?]&,^.
M_P#P)@H_X:Y^.'_1C/CO_P "8* />J*\%_X:Y^.'_1C/CO\ \"8*/^&N?CA_
MT8SX[_\  F"@#WJBO!?^&N?CA_T8SX[_ / F"C_AKGXX?]&,^.__  )@H ]Z
MHKP7_AKGXX?]&,^._P#P)@H_X:Y^.'_1C/CO_P "8* />J*\%_X:Y^.'_1C/
MCO\ \"8*/^&N?CA_T8SX[_\  F"@#WJBO!?^&N?CA_T8SX[_ / F"C_AKGXX
M?]&,^.__  )@H ]ZHKP7_AKGXX?]&,^._P#P)@H_X:Y^.'_1C/CO_P "8* /
M>J*\%_X:Y^.'_1C/CO\ \"8*/^&N?CA_T8SX[_\  F"@#WJBO!?^&N?CA_T8
MSX[_ / F"C_AKGXX?]&,^.__  )@H ]ZHKP7_AKGXX?]&,^._P#P)@H_X:Y^
M.'_1C/CO_P "8* />J*X?]G_ .-EC\?/ DGCBP\.W.EB'5;FPEL[J57=9(7V
M,<KQC-=Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %>!_&_P"#O[8.
MG?M/Z;^TG^S!\0/!=UILG@Y?#_BWX<^.(KNU@U(174MQ;WL&H6HF:VFC,\T>
MUK:5665L\[2OOE% 'PC^P/\ \$\?C3?>(/V>?VJ?VSKK2--USX'_  0M/"OP
MV^'F@QRN=$N+K3+:VU&^U"ZE"&:\>*(0>1'&L4(#X>8D..\\(_##_@LYI'Q*
M\8^'?$?[4OP2U/P)J^O75QX1\27/@&]/B#0;"5R8[4VL,T-I<-$A"))([$LN
M^02 ^77UE10!XO'^P3^SQ-^Q?JW[".N:%=ZIX)\0Z)?V'B*74+@/?:G/?223
M7FH2S!0/M<MS-)<F55 $K;E50 !\_>(_^"9/[2OQV_94\%?\$Y?VH/C!X5U;
MX-^$;C28/$&O:1%=+K_CG2-*ECDL-.NH'40V!)M[;[1<1S3M-Y+;$@,A*_=-
M% $=K:VMC:QV5E;1PPPQA(88D"JB@8"@#@ #@ 5)110 4444 >%_\$]_^2)Z
MM_V/>L_^E)KW2H-/TO3-(@-MI6G06L;2,[1V\*HI8G);  Y)ZFIZ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#RC]N?_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I6Q?6%CJEI)I^IV45
MQ;RKME@GC#HX]"IX(I\444$2P01JB(H5$08"@= !V% #J*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_P!K
M#_DMGP/_ .Q[E_\ 29J]TJ"[TO3+^>"YOM.@FDM9-]M)-"K-$V,;E)'RG'<4
M 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_2UL]!%SI[7%I9".,)"&@26)GC4!1L$B$@8W#K7YL_LA>/?VZ/V+O^"V&O\
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M?"'5/^"@FO>'O@-J7@3PS&NJ^+/@9IMM?2:GI>B[@9?^)J2%N+J&,[I9$41
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MQ:60CC"0AH$EB9XU 4;!(A(&-PZT ?%'_!/']L3]OV+_ (* ?$__ ()I?\%
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M7/%?QO\ A7!X+^)?PZ\>:CX(^)7A^Q=FM8=8LA$97@W,S+&1*HV%F*.KKN8
M,WNW[2/Q\T7]G;X9S>,[G0KK7=9O+A=/\(^$M,9?MOB+5I5;[/86X/&YRK,T
MC?)#$DLTA6.)V7SS_@FM^QI>_L5?LZW'A7QIJMGJ?CWQQXMU3QO\4M8T]"MO
M>^(]4F\^[,(;GR8_W<$9(!:.!6(!8B@#Z!HHHH **** "BBB@ HHHH ****
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MC.Z=\--++)(5C#+&GNE%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#"SN )IRL;7$P :5HT7B.*.-.Y\)?L5?\%#_ (C? [Q3\-OVWOVM?"WCR_\
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MX6ANS>?$/4]/C9;.2_BN%$>GV^]O/FMHWNO.D  DC0$'[+HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KYM_X*P?LD_&7]O+]B?Q?^Q[\(?$
M'AG0SXZLXK35/$7B.:X;[!%'<P3CRK>&,^<S^4RDM(@3@X?.!])44 >4?#'P
M9^TGX _9(T_X9Q3^"8_B'H'A*'2=&U$S7=QH\US!;)#%=31[(YE0LN]H5).!
MM$O.X?%/PI_8+_X. /@]#K<OA7_@HC\"IM2\2ZQ+JOB+7=3^%=S<7VI7;X4/
M+*S\K'&J111@".**-(T554"OTMHH ^<?@O\ LF_M :7XU^#_ (O_ &E?C;:^
M.[[X;^$M:N-7U=HFBEU3Q;JDD:R7L<(01V]K;VC7UM!&I!6.]*;5"#.[^UWX
M?_X*(WWB7P;X@_86^(7PKL;'3[FY_P"$W\.?$[1[YX]7A<1^28+JS8O;NF)>
M-A!+J3D+L;W&B@#P7X5_LI>/=9_:1M/VR_VJ/$^@ZMXXT;PK/X>\&Z'X5LIH
M]*\,V=S+'+>O')<,9;JZN&AA5YV6)5BA2-(ES(\O _\ !93]A3X\?\%(_P!D
M^?\ 9/\ A#XP\)^&+74M:T[4M1\1>(FN9I(S9W*W"0QV\,>"&9$S(T@P,C8<
M[A]<44 >,_M%?!7XO_M-?LUP_!/Q>WAO2;CQ#K.F0?$&*QU"XGM;C0X[Z*74
M;6W9X$9FNK6-[?:ZJ$%R_P S; 6VOVOO"W[4?CCX ZYX._8Y^(_AOP?X\U.$
M6VF>*O%&G27<&E(V1)<1PI_K)E'^K#Y0,0S!@NQO3** /S6^&O[!W_!?[X1?
M#&V^$7PS_P""B?P+T+3+>*15O;7X3SW%Z9I79YKR26X=S<74DCO*\LV]I)'9
MW+%B:^[?B!X)^)%G^S_/\,?A5J-GJNN_\(Z-)M=5\::I/AS]G\G[5<21QR23
MR9P[#Y3(2<NN<UWE% 'R[_P2 _8P^-/_  3O_8A\+?L7_%OQ/X7\0Q>"?MJZ
M1XD\.R7$;7J75_<WC+-;S1@1%#<;0RR-O R54CGZBHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#XW_X* ?L+_M1?M5_M>? /]H/X8>)_ >D
M:/\  ;Q=<Z];:?KMS>R7.OO<0PQ21.8H=MF%5)%5AYV2RL0,%*]/_;Z^%G[;
MOQU_9MF^%O[&_P 9/"WPT\6:X%@UWQ1JT-U=O86C(?.CL6A$;+*Q^07!"LB;
MF0)(5=/>:* /SL^'O[#O_!=3PWX;T#X-2_\ !0?X,>&?A_8_9=/OK+X?_"I[
M&_MM)5E6:*RE=F6"8P[U27&Y7(8$,-U?87P.^!WB7P)\8_BK\:_'NJ6-YJOC
MSQ#9)I LI'<6&@V%E'!9V;,ZJ2_GO?W3 94/?. 2!D^HT4 ?.'C70/\ @J_I
M7[36O:W\+O'_ ,#=7^$FI06XT/1/%.E:I::UHLJPJLI\ZV+QW:M('?#;"0RJ
M"FTENS_9-_91TW]FJU\8>*M;\5?\)-X[^)/BE_$7Q"\6?V>+1=0O3#';Q100
M;W-O:P6\,4$,)DD943+/([N[>N44 ?&7[3'[#/[5_P 7_P#@IU\&_P!O?P5K
M_P /K71O@SI.N:=8^%]4O[[[3K<>IVSV\LDD\=N5M652I50DPRIRQW<>^>._
M@?XH^(7[5/P^^,.MZE8?\(O\/M"UB;3]*$CFXDU^]6&UCNR-FP)#8G4(0=VY
MC?OP O/J-% 'RC_P5$_9?_;Z_:U\*Z'\+OV3/CQ\/O!/A87(N?&]KXPT"ZU!
M_$*HV4L)$B95^Q-@&:(Y\\?NW_=&2.7E?@/^S+_P6H3XS^$]0_:L_;]^&VH_
M#G1M3%YKWAOX=_#Y]+OM56*-FM[;[2Y8QP>>(6D5<>9&CQG*NP/VQ10!^?7Q
MJ_8L_P""V/C/]KS6_P!IGX7?MG_!'1;-;:33/ NA:UX O-1_X1S3&?+K$SN
M+B?;&;B< -(8T0;8T1!]!_L)_!C]O'X:IXJ\3_M\_M2Z'\1M?UBXM8- M/"/
MAXZ7I6D6,*.3MA/+SRRS.7D8L2L42@@+BOH*B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEJVHK=Z=;6+P37$.HV]\J1B:V>""23+QQNJ@$H 02 ?4=%?&/CK_ (*S^,_
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M\?$;X _LP_ RQ\=ZM\(K;36\?)J7C6/2)%N;^U^V6UE9(;>87$QM]CEIFMH
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MVV*\"JI;]PTG )Z"O?=.U"SU;3X-4TZ<2V]S"LL$J]'1@"I'U!!K\R/V?/\
M@IQ_P36_X+D?LK>(/^"=7QBT#3_AE\1M7\.S:#?_  @\<6*VLNF:E'$8HWTL
MNJ+,]O*H>-$"7$?E?-$@&3^DVA6UIX$\"6=GKFJV\4&C:1&EY?32".)$AB >
M1F8X50%))/0=: /-/%/_  4$_8J\$_%.7X+>*?VEO"MGXDMM4M]+O[*3408[
M&_G($%G<S@&&VN)"RA(9721]R[5.1GV*OP1_X)1^)/&G[;W[(/[0/_!$SPDN
MBW_B.\^+6LWWQ"^,$NKVL]E+X;OKZ*1M9M%5VFU2]G:*18'1?(16MI9)US''
M)^M'[+__  4 \,_M+?';Q]^SEX'_ &;_ (IZ9)\*-=.@>+_%?B6TTN/2H;Y8
M1*D4<T>H22W+/$8W_=Q,5$T9E\O>* +WB_\ X*C_ /!-WX?>*KKP+X]_;M^$
M^B:Y8'%]HVK^/+&VN[<[=_SPR2AT^4AN0.#GI7I_P@^.7P5_:#\()\0/@-\7
MO#'C;0I)3&FM>$M>M]1M2X )3S;=W3< 1D9R,U^:W@/Q-X,\%?\ !VO\4-2\
M6^(=,TF*[_9)MHX[C4;N.!9IO[2TDA0SD!GV(QP.=J'L#7%_\$W;;1O$?_!R
MQ^T7X^_8.D@?X$GP+;V_Q(O_  R!_P ([=^*-EH0L!C_ '+W(E^TL63G/VLY
MPYW '[#5XG\6_P#@I-_P3W^ ?Q O_A1\;OVW/A5X2\3Z7Y?]I^'_ !%X\L+.
M\M/,C66/S(990Z;HW1QD#*L#T(KUCQQJOB30?!6L:YX-\*MKNL6>EW$^E:(E
MW';G4+E(V:*W$LA"1^8X5-[$*N[). :_%?X!?&KX0?LW_&OP[\&?^"_/_!%7
MP'X5\9?$?Q5<R6O[1_B#PUHWB?3]=UJ\NI+C9=WIAE^R*&DV1()Y!!$L2E(H
MHRZ@'[.>-/BQ\,?AQ\.;OXO_ !!^(.C:'X5L+!;V]\1ZMJ,=O906Y *RO-(0
MBJ=RX)/.X =16-\%?VEO@-^T5#J3_!;XHZ7K\NBRQQZS96LI2ZL&D7?%Y]O(
M%EA$B@LA=0'494D<U\*_\%1/B'J?QB_X+-_L3?\ !/S4)"_A"ZUG6?B)XJTU
M^8M0N=*LKB?3!(O1TBGM9GV'*EG0D90&IO\ @I=\1=2_97_X+6_L5?&CP5<&
MV;XL/X@^&OCRWC.!JNGL;.6P63^]Y%W<O,I/()('#," ?;?QL_:N_9R_9RO-
M/TOXV?&#1O#]]JL,L^G:;=7!>[N((L>=.L$8:0PQY&^7;L3<-S#(KL?"/B_P
MG\0/"^G^./ GB?3]:T75K..[TO5])O$N+:\@=0R2Q2QDK(C @AE)!!XK\[?^
M")'Q#U3]J_\ ;=_;6_;(\;2&\OX/C$/AUX5FG^8Z=H.C"40V\(/^J20S+/(J
MX#RDL<GFIO\ @AK\1=2\(?M7?MJ?L#VEP1X5^$OQM_M?P/I^?W>E6&N->7+V
M$ Z)!%+;NRH. 9V]: /T=HHHH **** "BBB@ HHHH *^3_VC_P#@N9_P27_9
M.\8W/P^^.'[<'A&RURRF:&_TK14NM9GLY5.&CF73H9S"X/5'VL.XK\[/^#MW
M_@L9\4?V=K?2/^"<?[,OC*ZT'6/%.@?VM\2/$.ESF*ZATV9WB@TZ*13F,S>7
M*\Q&&\ORE!VRN#_.-0!_<5^R3_P4L_8,_;L\Z#]DW]J;PGXRO;>$S7&C65Z8
M-1BB!P9&L[A8[A4R0-YCVYXS7N5?P/?#CXD>/_@_X[TKXG_"OQGJ7A[Q%H5Z
MEWH^MZ/>/;W-G.ARLD<B$,I'L?4=#7]@?_! /_@J)J7_  5/_8*T_P"*7Q"^
MSQ_$+PCJ+>'O'Z6T0C2YNXXTDBOD0<*L\+HY  42B95 510!]O4444 %%%5-
M?M-3O]"O;'1=2%G>36DD=I>&,/Y$I4A9-IZ[20<=\4 >-_$'_@I/^P9\*O'F
MI?#7XA?M5^#M+U?0[A;?Q EQJ@,&C3-C$5[<*##9/@@[9W0@$'&#78VW[4W[
M-]Y\*KOXZ6?QQ\+S>"K&YN(+OQ;#K,3:;$\#,LV;D-Y>$9'#-NV@J>>*_)S_
M ((\?\%3?@__ ,$Y/"K?\$>O^"L'@67X0_$70-<U0MXU\40%]$\;"^O9YVOI
M[QQC=+YK+]HE)AE2-295;]V/TE_9N_96^%G[)?[)7BGX0_!V/33X-U#4/$FO
M>'K+2U!M+:SU.XN+U;>+&5,2>>53;\NP*!Q0!#H?_!63_@EYXDO[?2]#_P""
MB/P4N)[J<0VT:?$W2_WLAZ(I,^"QXPO4YKW+6_%OA7PSX7NO''B3Q-I^GZ+8
MV+WM[K%]>QQ6MO;*F]IGE8A$C"@L7)  &<XK\6_^".OQ$_8ET[_@UYUGPQ^V
M-XP\(CPPMIXN76M*UJ^MS.97NKDVXAB8[_M1;88-@\S?L*<X-<K\!/V:_P#@
MI-\5_P#@U/T/P58>"]8\1>(M*\9V_B3P_P##[68I&NO$/@VSU!+B/33"V'EB
M<H\T<'62!(TC!#1J0#]6]*_X*N_\$X-7BEN(OVR_ MM$EA+>V\^I:P+.._MX
MEWO+:/.$6]4+SF R9&".M>@?'C]K;]E_]ENUM;_]I/\ :"\'^ K:^8+9W/B_
MQ!!I\4['=A4>=E5F^5N <_*:^#?AC_P42_X)I?\ !P=^R3XD_8A\036'@?XF
M:GHLMNGPR\>6ZPZAH.M01MY-U8%@JW7V>9=P\G$H1&$D489EJW_P=HPQ2?\
M!%;QN\D:L8_%?A]HR1]T_P!HQ#(]."1^- 'VOXK_ &X?V._ ?PPL?C9XW_:<
M\#Z/X.U/']G>*]4\26]OIUSG;M*7#L(V!WI@AN=PQFN@^'W[1/P)^+/PY?XP
M?"[XN>'_ !%X52(R'Q'HFIQW5DR 9++-&2C#W!(KY%_X+RV=HO\ P05^,-HM
MM&(H_AYIGEQA!M7;=V17 [8P,>F*N_\ !/3_ (*;_P#!-#P)^P'\#O!'BO\
MX*$? O1M4T;X/^&;'4M(U'XL:-;W%C<1:5;1R02Q/<AHI$=65D8 J5((!% '
MT+\*?V]OV)_CMKFH^&?@G^U;X \7ZCI$3R:K8>&?%-M?362(KLQE2%V,>!&_
MW@/N'TKF-4_X*Q_\$PM#UF\\.ZW_ ,%!O@W97^G3/#J%E>?$;3HI;61&V.LJ
MO,#&5;@AL8/!KXN_X-O_ !)X*\<?M*_M[^/?AWX@TO6-$UK]J+4[S1]:T6[C
MN+6_M);F^DAFAFB)26)U?>KJ2I#9!(-4_P#@ECXS^%/@?_@M/_P4>MOB3XL\
M/Z19WGB+PL[QZY?P6\4T(MM1,Y(E8!D&\%^PW#/6@#]1OA_\1OA[\6?"-GX_
M^%?CO1O$V@ZBA?3];\/ZI%>VERH)!:.:%F1QD$9!/2MFOR'_ .#<+2;F3]M_
M]LWQC^S)#/#^S!J7Q%'_  KDVL;)H]SJ2SW'VB33!]SR1'M4F/"^6;4=%4#]
M>* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *\0_;>_97^,_[5'A70] ^#'[:WCCX*W6E:
MA)<7NJ>![6VEEU*-DVB&43@@*I^88YS7M]% 'P#_ ,.?OVZ_^D]/[0'_ (*=
M+_\ B*/^'/W[=?\ TGI_: _\%.E__$5]_44 ? /_  Y^_;K_ .D]/[0'_@IT
MO_XBOY :_O\ *_@#H **** /Z/O^""O_  3>_:P^/?\ P2=^%/Q9^&G_  5N
M^,'PQT35O[=^Q>!_"VGV$EAIOE:[J$+^4TJ%SYCQO,V3]Z5L<8K[ _X<_?MU
M_P#2>G]H#_P4Z7_\12?\&N/_ "@H^!G_ ',W_J3ZM7W_ $ ? /\ PY^_;K_Z
M3T_M ?\ @ITO_P"(KV_]B']B;]H3]E?Q5KGB#XS_ /!1/XD?&JUU73X[>RTO
MQQ9VD46FR*^XS1&!02S#Y3GC%?1]% 'S_P#\%8-<T;P]_P $OOVBM1U[5;>S
M@/P/\50K-=3+&K22:3<QQH"Q&69V557JS, ,D@5\]?\ !!O]HS]F'3?^"-/P
M.\'^./CKX#MY8?!,MKJVE:MXFLD9/]*N%DBFBDD!'&058=#S7W5XW^&?PW^)
MMI!I_P 2/A]HGB""VD,EM!KFDPW:1.1@LHE5@IQQD5S?_#)_[+/_ $;5\/\
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M_!6;_@GG::GKMG;S'XC^*6$4URJMMDTZVB0X)Z-(RH/5B .:9^TOXE\.VO\
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MZRTV'PGI$0W0ZA;VDULEMIUWJ:3>9%+<1MY,,DCRQ[MPCX;]D+XP_LF^"O\
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MW_"(_"3X<:#X6TGSVF_LOPYH\%C;^8V-S^7"JKN.!DXR<4 ?G[_P2B\(V/[
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MJ7V#XB?!@36#ZQ!,03%):32W$-K=6TR*[Q3^;&'5#P"4# 'U#17Y_P#[*_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599121118304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-10315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Encompass Health Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">63-0860407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9001 Liberty Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Birmingham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">35242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-7116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EHC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,727,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">The definitive proxy statement relating to the registrant&#8217;s 2023 annual meeting of stockholders is incorporated by reference in Part III to the extent described therein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000785161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599120918240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Birmingham, Alabama<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116413600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract', window );"><strong>Statement of Comprehensive Income and Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 4,348.6<span></span>
</td>
<td class="nump">$ 4,014.9<span></span>
</td>
<td class="nump">$ 3,566.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Salaries and benefits</a></td>
<td class="nump">2,393.3<span></span>
</td>
<td class="nump">2,127.3<span></span>
</td>
<td class="nump">1,903.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other operating expenses</a></td>
<td class="nump">670.4<span></span>
</td>
<td class="nump">595.9<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_OccupancyCost', window );">Occupancy costs</a></td>
<td class="nump">54.7<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">61.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies</a></td>
<td class="nump">202.1<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">171.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">154.3<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="nump">151.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">243.6<span></span>
</td>
<td class="nump">219.6<span></span>
</td>
<td class="nump">203.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,718.4<span></span>
</td>
<td class="nump">3,355.5<span></span>
</td>
<td class="nump">3,038.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense and amortization of debt discounts and fees</a></td>
<td class="nump">175.7<span></span>
</td>
<td class="nump">164.3<span></span>
</td>
<td class="nump">183.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income)</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income tax expense</a></td>
<td class="nump">450.8<span></span>
</td>
<td class="nump">505.0<span></span>
</td>
<td class="nump">352.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">100.1<span></span>
</td>
<td class="nump">101.9<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">350.7<span></span>
</td>
<td class="nump">403.1<span></span>
</td>
<td class="nump">278.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">114.1<span></span>
</td>
<td class="nump">90.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net and comprehensive income</a></td>
<td class="nump">365.9<span></span>
</td>
<td class="nump">517.2<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Net and comprehensive income</a></td>
<td class="nump">365.9<span></span>
</td>
<td class="nump">517.2<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests included in continuing operations</a></td>
<td class="num">(93.6)<span></span>
</td>
<td class="num">(103.2)<span></span>
</td>
<td class="num">(83.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests included in discontinued operations</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net and comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(94.9)<span></span>
</td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Net and comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(94.9)<span></span>
</td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net and comprehensive income attributable to Encompass Health</a></td>
<td class="nump">271.0<span></span>
</td>
<td class="nump">412.2<span></span>
</td>
<td class="nump">284.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net and comprehensive income attributable to Encompass Health</a></td>
<td class="nump">$ 271.0<span></span>
</td>
<td class="nump">$ 412.2<span></span>
</td>
<td class="nump">$ 284.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">99.2<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">100.4<span></span>
</td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">99.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
<td class="nump">0.90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">2.72<span></span>
</td>
<td class="nump">4.15<span></span>
</td>
<td class="nump">2.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">2.56<span></span>
</td>
<td class="nump">2.99<span></span>
</td>
<td class="nump">1.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">1.12<span></span>
</td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Amounts attributable to Encompass Health:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations</a></td>
<td class="nump">$ 257.1<span></span>
</td>
<td class="nump">$ 299.9<span></span>
</td>
<td class="nump">$ 194.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">89.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net and comprehensive income attributable to Encompass Health</a></td>
<td class="nump">$ 271.0<span></span>
</td>
<td class="nump">$ 412.2<span></span>
</td>
<td class="nump">$ 284.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OccupancyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OccupancyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Statement of Comprehensive Income and Income Statement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599122635088">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="nump">$ 49.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">536.8<span></span>
</td>
<td class="nump">515.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">127.0<span></span>
</td>
<td class="nump">114.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">178.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">717.2<span></span>
</td>
<td class="nump">921.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,939.2<span></span>
</td>
<td class="nump">2,581.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">212.5<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,263.2<span></span>
</td>
<td class="nump">1,237.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">282.3<span></span>
</td>
<td class="nump">158.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222.0<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Noncurrent assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1,543.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,636.5<span></span>
</td>
<td class="nump">6,864.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">132.9<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">168.3<span></span>
</td>
<td class="nump">199.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42.8<span></span>
</td>
<td class="nump">44.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">181.0<span></span>
</td>
<td class="nump">177.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">575.9<span></span>
</td>
<td class="nump">748.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,741.8<span></span>
</td>
<td class="nump">3,240.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199.7<span></span>
</td>
<td class="nump">179.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveNoncurrent', window );">Self-insured risks</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128.5<span></span>
</td>
<td class="nump">123.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">48.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Noncurrent liabilities of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">100.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,774.6<span></span>
</td>
<td class="nump">4,465.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35.6<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Encompass Health shareholders&#8217; equity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.01 par value; 200,000,000 shares authorized; issued: 114,775,056 in 2022; 114,211,057 in 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Capital in excess of par value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,730.2<span></span>
</td>
<td class="nump">2,289.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115.7<span></span>
</td>
<td class="nump">141.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost (14,992,125 shares in 2022 and 14,719,662 shares in 2021)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(536.7)<span></span>
</td>
<td class="num">(521.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Encompass Health shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,310.3<span></span>
</td>
<td class="nump">1,911.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">516.0<span></span>
</td>
<td class="nump">445.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,826.3<span></span>
</td>
<td class="nump">2,357.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and Equity, Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,636.5<span></span>
</td>
<td class="nump">$ 6,864.9<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Our consolidated assets as of December&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $207.8 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $47.9 million and $38.2 million, respectively. See Note&#160;4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599117273776">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114,775,056<span></span>
</td>
<td class="nump">114,211,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,992,125<span></span>
</td>
<td class="nump">14,719,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 5,636.5<span></span>
</td>
<td class="nump">$ 6,864.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,774.6<span></span>
</td>
<td class="nump">4,465.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">207.8<span></span>
</td>
<td class="nump">226.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 47.9<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Our consolidated assets as of December&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $207.8 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $47.9 million and $38.2 million, respectively. See Note&#160;4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111652992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated (Deficit) Income</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">$ 1,693.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 2,369.9<span></span>
</td>
<td class="num">$ (526.5)<span></span>
</td>
<td class="num">$ (492.3)<span></span>
</td>
<td class="nump">$ 340.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">361.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(15.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(111.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(111.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange of Holdings shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange of Holdings shares</a></td>
<td class="nump">46.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock options exercised</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(72.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchases of common stock in open market (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchases of common stock in open market</a></td>
<td class="num">(6.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">42.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Fair value adjustments to redeemable noncontrolling interests</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(6.8)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="nump">1,970.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,326.6<span></span>
</td>
<td class="num">(242.3)<span></span>
</td>
<td class="num">(497.4)<span></span>
</td>
<td class="nump">382.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">508.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(16.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(111.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83.8)<span></span>
</td>
<td class="num">(28.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(87.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">72.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(10.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.4)<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">2,357.0<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">2,289.6<span></span>
</td>
<td class="nump">141.8<span></span>
</td>
<td class="num">(521.2)<span></span>
</td>
<td class="nump">445.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">358.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Receipt of treasury stock</a></td>
<td class="num">(7.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends declared</a></td>
<td class="num">(86.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
<td class="num">(75.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 31.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (shares)</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">$ (99.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(99.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contributions from consolidated affiliates</a></td>
<td class="nump">100.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Spin off of Enhabit, Inc.</a></td>
<td class="num">(846.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(595.7)<span></span>
</td>
<td class="num">(221.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Other (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7.8)<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 1,826.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1,730.2<span></span>
</td>
<td class="nump">$ 115.7<span></span>
</td>
<td class="num">$ (536.7)<span></span>
</td>
<td class="nump">$ 516.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total contributions made by each class of partners (i.e., general, limited and preferred partners).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599211944240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599122210592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 365.9<span></span>
</td>
<td class="nump">$ 517.2<span></span>
</td>
<td class="nump">$ 368.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="num">(15.2)<span></span>
</td>
<td class="num">(114.1)<span></span>
</td>
<td class="num">(90.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities&#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Provision for government, class action, and related settlements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">243.6<span></span>
</td>
<td class="nump">219.6<span></span>
</td>
<td class="nump">203.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt-related items</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(3.4)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distributions from nonconsolidated affiliates</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">29.2<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense</a></td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">20.3<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions &#8212;</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(16.9)<span></span>
</td>
<td class="num">(39.5)<span></span>
</td>
<td class="num">(5.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="num">(41.8)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued payroll</a></td>
<td class="num">(31.2)<span></span>
</td>
<td class="num">(30.4)<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="num">(11.2)<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Net cash provided by operating activities of discontinued operations</a></td>
<td class="nump">52.3<span></span>
</td>
<td class="nump">151.1<span></span>
</td>
<td class="nump">35.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">355.1<span></span>
</td>
<td class="nump">312.7<span></span>
</td>
<td class="nump">426.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">705.8<span></span>
</td>
<td class="nump">715.8<span></span>
</td>
<td class="nump">704.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(564.8)<span></span>
</td>
<td class="num">(524.6)<span></span>
</td>
<td class="num">(392.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to capitalized software costs</a></td>
<td class="num">(9.2)<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of intangible assets</a></td>
<td class="num">(10.1)<span></span>
</td>
<td class="num">(6.5)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments', window );">Proceeds from sale of restricted investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedInvestments', window );">Purchases of restricted investments</a></td>
<td class="num">(35.2)<span></span>
</td>
<td class="num">(9.0)<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(4.2)<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Net cash used in investing activities of discontinued operations</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(119.2)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(627.0)<span></span>
</td>
<td class="num">(666.3)<span></span>
</td>
<td class="num">(407.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from bond issuance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">992.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Principal payments on debt, including pre-payments</a></td>
<td class="num">(345.8)<span></span>
</td>
<td class="num">(214.5)<span></span>
</td>
<td class="num">(717.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Principal borrowings on notes</a></td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings on revolving credit facility</a></td>
<td class="nump">240.0<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="nump">330.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payments on revolving credit facility</a></td>
<td class="num">(385.0)<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
<td class="num">(375.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments under finance lease obligations</a></td>
<td class="num">(19.2)<span></span>
</td>
<td class="num">(44.6)<span></span>
</td>
<td class="num">(14.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt amendment and issuance costs</a></td>
<td class="num">(24.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(20.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases of common stock, including fees and expenses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid on common stock</a></td>
<td class="num">(99.0)<span></span>
</td>
<td class="num">(112.2)<span></span>
</td>
<td class="num">(111.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Purchase of equity interests in consolidated affiliates</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions paid to noncontrolling interests of consolidated affiliates</a></td>
<td class="num">(96.6)<span></span>
</td>
<td class="num">(101.1)<span></span>
</td>
<td class="num">(70.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on behalf of employees for shares withheld</a></td>
<td class="num">(7.3)<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Contributions from noncontrolling interests of consolidated affiliates</a></td>
<td class="nump">64.1<span></span>
</td>
<td class="nump">57.2<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations', window );">Net cash provided by (used in) financing activities of discontinued operations</a></td>
<td class="nump">515.1<span></span>
</td>
<td class="num">(10.2)<span></span>
</td>
<td class="num">(11.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(145.7)<span></span>
</td>
<td class="num">(240.1)<span></span>
</td>
<td class="num">(145.9)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(66.9)<span></span>
</td>
<td class="num">(190.6)<span></span>
</td>
<td class="nump">151.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of year</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
<td class="nump">159.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of Cash, Cash Equivalents, and Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">49.4<span></span>
</td>
<td class="nump">185.6<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash at beginning of period</a></td>
<td class="nump">62.5<span></span>
</td>
<td class="nump">63.9<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other long-term assets at beginning of period</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash in discontinued operations at beginning of period</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">39.9<span></span>
</td>
<td class="nump">34.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of year</a></td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
<td class="nump">159.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">49.4<span></span>
</td>
<td class="nump">185.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash at end of period</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="nump">63.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in other long-term assets at end of period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash in discontinued operations at end of period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">39.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of year</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">120.3<span></span>
</td>
<td class="nump">310.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="num">(178.4)<span></span>
</td>
<td class="num">(168.4)<span></span>
</td>
<td class="num">(168.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Income tax refunds</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax payments</a></td>
<td class="num">$ (51.2)<span></span>
</td>
<td class="num">$ (131.4)<span></span>
</td>
<td class="num">$ (34.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfRestrictedInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfRestrictedInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599117924512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies:<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization and Description of Business&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a provider of inpatient rehabilitation services. We operate hospitals in 36 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of December&#160;31, 2022, we operate 153 inpatient rehabilitation hospitals. We are the sole owner of 95 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 58 jointly owned hospitals.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Consolidation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Encompass Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We eliminate all significant intercompany accounts and transactions from our financial results.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any entity considered a variable interest entity (&#8220;VIE&#8221;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates and Assumptions&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#8217; compensation, and comprehensive general insurance liability risks; and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a healthcare provider, we are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">licensure, certification, and accreditation;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coding and billing for services;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requirements of the 60% compliance threshold under The Medicare, Medicaid and State Children&#8217;s Health Insurance Program (SCHIP) Extension Act of 2007;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality of medical care;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">use and maintenance of medical supplies and equipment;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintenance and security of patient information and medical records;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisition and dispensing of pharmaceuticals and controlled substances; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disposal of medical and hazardous waste.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, contractual arrangements, and patient admittance practices.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable laws and regulations, we could be required to return portions of reimbursements deemed after the fact to have not been appropriate. We could also be subjected to liabilities, including (1)&#160;criminal penalties, (2)&#160;civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals, and (3)&#160;exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement. Because Medicare comprises a significant portion of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. Specifically, reductions in reimbursements, substantial damages, and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operation, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, the United States Congress and some state legislatures have periodically proposed significant changes in regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in pricing roll-backs or freezes or reimbursement reductions. Because we receive a significant percentage of our revenues from Medicare, such changes in legislation might have a material adverse effect on our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are increasing pressures from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. We could be adversely affected in some of the markets where we operate if we are unable to negotiate and maintain favorable agreements with third-party payors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies and Other Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are a party to a number of lawsuits. We cannot predict the outcome of litigation filed against us. Substantial damages or other monetary remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Operating Revenues&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;) or the United States Department of Justice (the &#8220;DOJ&#8221;). Therefore, we are unable to predict if or when we may be </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Administrative Contractors (&#8220;MACs&#8221;), under programs known as &#8220;widespread probes,&#8221; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#8220;appeal,&#8221; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. During 2022, the backlog of &#8220;widespread probe&#8221; claims adjudicated by the administrative law judge (&#8220;ALJ&#8221;) continued and were substantially completed. This OMHA practice resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims. We have appealed certain adverse ALJ rulings to the Department Appeals Boards (&#8220;DAB&#8221;), the final level of administrative review. As of December 31, 2022, approximately $52&#160;million in claims are awaiting review at the DAB. In addition, we have appealed approximately $6&#160;million in claims denied by the DAB to several United States District Courts, all of which are pending review as of December 31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, CMS announced the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with CMS approved and announced Recovery Audit Contractors (&#8220;RACs&#8221;) audits related to inpatient rehabilitation facilities (&#8220;IRFs&#8221;), we received requests from 2013 to 2022 to review certain patient files for discharges occurring from 2010 to 2022.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established Unified Program Integrity Contractors (&#8220;UPICs&#8221;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors. In December 2017, we received notice of a UPIC audit at one of our hospitals. The UPIC sampled 100 claims and challenged the propriety of a subset of the sample representing $1.3&#160;million in previously paid claims. The UPIC extrapolated the alleged error rate to all claims from that hospital during a period of approximately four years, resulting in an alleged overpayment of $33.9&#160;million. Our MAC later reduced the determination of overpayment to $30.5&#160;million, which it collected through recoupment of current claims during 2019. We appealed the overpayment determination to an Administrative Law Judge (&#8220;ALJ&#8221;), who heard the appeal in August 2021. In October 2022, the ALJ </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overturned $12.5&#160;million of the overpayment determination. We received payment of this amount, plus $3.2&#160;million in interest, in December 2022. We have appealed the remaining $18.0&#160;million of the overpayment determination to the DAB, the next level of administrative appeal, challenging both the denials and the improper use of extrapolation. It is not possible to predict when this matter will be resolved or the ultimate outcome.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Medicare claims that are subject to these post-payment audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2022. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2022, 2021, and 2020, our adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for claims that are part of this post-payment claims review process was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include highly liquid investments with maturities of three months or less when purchased. Carrying values of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approximate fair value due to the short-term nature of these instruments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a separate component of shareholders&#8217; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of </span></div>time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#8217; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other discount plans, including Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state </span></div>governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:84.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8212;</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. In general, we do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets&#8212; </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors in our single reporting unit to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our reporting unit using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of our reporting unit&#8217;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting unit to our market capitalization. When we dispose of a hospital, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2022, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and certain directly related payroll costs. Amortization begins when the internal-use software is ready for its intended </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#8217;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets and Other Intangible Assets&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Observable inputs such as quoted prices in active markets;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also the &#8220;Redeemable Noncontrolling Interests&#8221; section of this note.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interests in Consolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#8217; balance.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future.  Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to certain members of the home health and hospice management team&#8217;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $400&#160;million or more. The fair value of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#8217; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.</span><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Reserves&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the accompanying consolidated statements of comprehensive income, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.6 million, and $4.6 million in each of the years ended December 31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the asset and liability method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We </span></div>include the allocable portion of each pass-through entity&#8217;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes. <div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities in and Results of Discontinued Operations&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income from discontinued operations, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current assets of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Noncurrent assets of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current liabilities of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent liabilities of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We account for the retirement of treasury stock as a reduction of retained earnings.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119869408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin Off of Home Health and Hospice Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Spin Off of Home Health and Hospice Business</a></td>
<td class="text">Spin Off of Home Health and Hospice BusinessOn July 1, 2022, we completed the previously announced separation of our home health and hospice business through the distribution (the &#8220;Spin Off&#8221;) of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit, Inc. (&#8220;Enhabit&#8221;) to the stockholders of record of Encompass Health as of the close of business on June 24, 2022 (the &#8220;Record Date&#8221;). The Spin Off was effective at 12:01 a.m., Eastern Time, on July 1, 2022. The Spin Off was structured as a pro rata distribution of one share of Enhabit common stock for every two shares of Encompass Health common stock held of record as of the Record Date. No fractional shares were distributed. A cash payment was made in lieu of any fractional shares. As a result of the Spin Off, Enhabit is now an independent public company and its common stock is listed under the symbol &#8220;EHAB&#8221; on the New York Stock Exchange.<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with applicable accounting guidance, the historical results of Enhabit have been presented as discontinued operations and, as such, have been excluded from continuing operations for all periods presented. Our presentation of discontinued operations excludes any allocation of general corporate and overhead costs as well as interest expense. Prior to July 1, 2022, we operated under two reporting segments. We now operate under a single reporting segment. In anticipation of the Spin Off, Enhabit transferred the &#8220;Encompass&#8221; trade name (net book value of $104.2&#160;million) to us during the second quarter of 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Spin Off, on June 30, 2022, we entered into several agreements with Enhabit that govern the relationship of the parties following the Spin Off, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement and an Employee Matters Agreement.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide transition services to Enhabit predominately consisting of certain finance, information technology, human resources, employee benefits and other administrative services for a period of up to two years after the Spin Off. For the year ended December 31, 2022, income related to these transition services of $2.1&#160;million were reflected as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the results of operations of Enhabit as discontinued operations (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health included in discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects amounts through the July 1, 2022 Spin Off date.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of $56.7&#160;million and $22.9&#160;million incurred during the years ended December&#160;31, 2022 and 2021, respectively, are included in general and administrative expenses in the table above and in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from discontinued operations, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the consolidated statements of comprehensive income. These charges primarily relate to third-party advisory, consulting, legal and professional services, that are associated with the Spin Off.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying amounts of the assets and liabilities of the discontinued operations of Enhabit (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets of discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities of discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599121038480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations:<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, we acquired 60% of the operations of a 23-bed inpatient rehabilitation unit in Grand Forks, North Dakota when Altru Health System contributed those operations to our existing joint venture.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2022, we acquired 50% of the operations of a 22-bed inpatient rehabilitation unit in Moline, Illinois when Trinity Medical Center contributed those operations to our existing joint venture.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2022, we acquired 50% of the operations of a 54-bed inpatient rehabilitation unit in Naples, Florida when NCH Healthcare System contributed those operations to our joint venture.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from the respective dates of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on an income approach using discounted cash flow techniques for the noncompete intangible assets. The aforementioned income method utilizes management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospitals&#8217; historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. None of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 2 to 3 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2022 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pro Forma Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above-mentioned acquisitions from the dates of acquisitions included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the dates of the acquisitions been January&#160;1, 2021 (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2022-12/31/2022 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,039.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2021 period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2021, we acquired 51% of the operations of a 14-bed inpatient rehabilitation unit in San Angelo, Texas when Shannon Medical contributed those operations to our existing joint venture entity.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In June 2021, we acquired 75% of the operations of a 16-bed inpatient rehabilitation unit in McKees Rocks, Pennsylvania through our existing joint venture with Heritage Valley Health System, Inc. The acquisition was funded using cash on hand.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2021, we acquired 65% of the operations of a 22-bed inpatient rehabilitation unit in Odessa, Texas when ECHD Ventures contributed those operations to our existing joint venture entity.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 3 to 5 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:89.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Pro Forma Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned-acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Acquisitions</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In January 2020, we acquired 68% of the operations of a 13-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing 40-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a 20-bed expansion to the Littleton hospital.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, we acquired 51% of the operations of a 45-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a 60-bed de novo inpatient rehabilitation hospital.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#8217;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#8217;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions are deductible for federal income tax purposes.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 2 to 3 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Pro Forma Results of Operations</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above-mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 reporting period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599121038480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities</a></td>
<td class="text">Variable Interest Entities:As of December&#160;31, 2022 and December&#160;31, 2021, we consolidated eight and ten, respectively, limited partnership-like entities that are VIEs and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 75.0% as of December&#160;31, 2022. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision-making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheets, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599211959200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash and Marketable Securities</a></td>
<td class="text">Cash and Marketable Securities:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2022 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2021 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliate cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Affiliate cash represents cash accounts maintained by joint ventures in which we participate where one or more of our external partners requested, and we agreed, that the joint venture&#8217;s cash not be commingled with other corporate cash accounts and be used only to fund the operations of those joint ventures. Self-insured captive funds represent cash held at our wholly owned insurance captive, HCS, Ltd., as discussed in Note&#160;11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Self-Insured Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These funds are committed to pay third-party administrators for claims incurred and are restricted by insurance regulations and requirements. These funds cannot be used for purposes outside HCS without the permission of the Cayman Islands Monetary Authority.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classification of restricted cash held by HCS as current or noncurrent depends on the classification of the corresponding claims liability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS. HCS insures a substantial portion of Encompass Health&#8217;s professional liability, workers&#8217; compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of December&#160;31, 2022 and 2021, $79.1 million and $82.2 million, respectively, of restricted marketable securities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. During the years ended December&#160;31, 2022, 2021, and 2020, $(7.4)&#160;million, $0.6 million, and $0.4&#160;million, respectively, of unrealized net (losses) gains were recognized in our consolidated statements of comprehensive income on marketable securities still held at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing information related to our available-for-sale marketable securities is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of available-for-sale marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of marketable securities is comprised of investments in mutual funds that hold investments in a variety of industries and geographies. As discussed in Note&#160;1,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Marketable Securities,&#8221; when our portfolio included marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, we examined the severity and duration of the impairments in relation to the cost of the individual investments. We also considered the industry and geography in which each investment is held and the near-term prospects for a recovery in each.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599213836304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Accounts Receivable</a></td>
<td class="text">Accounts Receivable:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent patient accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the resolution of claims that are part of Medicare audit programs can take several years, we review the patient receivables that are part of this adjudication process to determine their appropriate classification as either current or noncurrent. Amounts considered noncurrent are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheet. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Net Operating Revenues,&#8221; for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599124283360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,019.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,239.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,490.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, approximately 68% of our consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and equipment, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> held by Encompass Health Corporation and its guarantor subsidiaries was pledged to the lenders under our credit agreement. See Note&#160;10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-term Debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Liquidity and Capital Resources.&#8221;</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of depreciation expense and interest capitalized is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest capitalized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118243120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1- to 25-year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated balance sheet information related to leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease assets are recorded net of accumulated amortization of $145.8 million and $126.9 million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1- to 25-year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.</span></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated balance sheet information related to leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease assets are recorded net of accumulated amortization of $145.8 million and $126.9 million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599121011616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text">Goodwill and Other Intangible Assets:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased in 2020, 2021 and 2022 as a result of our acquisitions of inpatient rehabilitation operations. For additional information on these acquisitions, see Note&#160;3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We performed impairment reviews as of October&#160;1, 2022, 2021, and 2020 and concluded no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment existed. As of December&#160;31, 2022, we had no accumulated impairment losses related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our other intangible assets (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certificates of need:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncompete agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade name - Encompass:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade names - all other:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal-use software:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market access assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for other intangible assets is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599123281904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,240.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Face Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,817.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the redemptions discussed below, we recorded a $1.4 million, $1.0 million, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Agreement&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement provides for a $1 billion revolving credit facility, with a $260 million letter of credit subfacility and a swingline loan subfacility, all of which mature in October 2027. The credit agreement previously provided for a $270 million term loan commitment, the outstanding amount of which was repaid in June 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts drawn on the revolving credit facility bear interest at a rate per annum of, at our option, (1) secured overnight financing rate (&#8220;SOFR&#8221;) or (2)&#160;the higher of (a)&#160;Barclays Bank PLC&#8217;s prime rate and (b)&#160;the federal funds rate plus 0.5%, in each case, plus, in each case, an applicable margin that varies depending upon our leverage ratio. We are also subject to a commitment fee of 0.25% or 0.30%, depending on our leverage ratio, per annum on the daily amount of the unutilized commitments under the revolving credit facility. The current interest rate on SOFR borrowings under the credit agreement includes a credit spread of 1.50%.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit agreement contains affirmative and negative covenants and default and acceleration provisions, including a minimum interest coverage ratio and a maximum leverage ratio. Under one such negative covenant, we are restricted from paying common stock dividends, prepaying certain senior notes, making certain investments, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the credit agreement and (2) our senior secured leverage ratio, as defined in the credit agreement, does not exceed 2x. In the event the senior secured leverage ratio exceeds 2x, these payments are subject to a limit of $200 million plus the Available Amount, as defined in the credit agreement. Our obligations under the credit agreement are secured by the current and future personal property of the Company and its subsidiary guarantors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we amended our existing credit agreement and the amendments included the following material provisions:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Material Adverse Effect&#8221; to carve out the direct and indirect impacts of pandemic and the related legislative, regulatory and executive actions on us from that definition for a period of 364 days; and</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of 4.50x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of 2.00x) and the existence of no events of default in addition to the new leverage ratio condition.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we further amended our existing credit agreement and the amendments included the following material provisions:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of definition of &#8220;Consolidated Net Income&#8221; to exclude from the calculation thereof, at Encompass Health&#8217;s option, net income or loss from disposed, abandoned, transferred, closed or discontinued operations until such disposition, abandonment, transfer, closure of discontinuance of operations shall have been consummated.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Addition of Section 1.08, &#8220;SpinCo Credit Facilities Transactions,&#8221; to provide that the Loan Documents will not prevent the consummation of the SpinCo Credit Facilities Transactions and that the SpinCo Credit Facilities Transactions will not give rise to any Default or constitute a utilization of any basket under any Loan Document.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of Section 2.11(e) to provide that a Prepayment Notice may be conditioned upon the effectiveness of other credit facilities, indentures or similar agreements or other transactions.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Addition of Section 5.18, &#8220;SpinCo Distribution,&#8221; to provide that within three (3) Business Days following the incurrence of indebtedness under the SpinCo Credit Facilities, Encompass will have consummated the SpinCo Distribution in compliance with the Restricted Payments covenants of the Credit Agreement, and following the consummation of the SpinCo Distribution, no obligors in respect of the SpinCo Credit Facilities will be Restricted Subsidiaries.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Senior Notes&#8221; to include Encompass&#8217; 4.625% Senior Notes due 2031 and the definition of &#8220;Consolidated Total Indebtedness&#8221; to exclude Indebtedness under any Senior Note for which an irrevocable notice of redemption has been issued in connection with or incidental to any SpinCo Distribution.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we further amended our existing credit agreement and the amendments included the following material provisions:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of the definition of &#8220;Maturity Date&#8221; for the revolving borrowings to October 7, 2027.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Change the reference rate for borrowings from LIBOR to SOFR.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Reduction of the fee for the undrawn portion of the revolving loan commitment from 37.5 basis points to a maximum of 30 basis points and a minimum of 25 basis points, with such rate to be determined based on the Leverage Ratio as of the most recently ended four quarter period.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Restatement of the Leverage Ratio maintenance covenant in Section 6.01(b) to the following:</span></div><div style="margin-bottom:10pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the last day of each fiscal quarter, the Borrower will not permit the Leverage Ratio, calculated as of the end of each such fiscal quarter occurring during the time periods set forth below on a pro forma basis, to exceed the ratio set forth below opposite the time period during which such fiscal quarter ends; provided, however, that the Borrower may elect (the &#8220;Step-Up Election&#8221;) at any time after the Effective Date to increase the maximum Leverage Ratio permitted hereunder by 0.50 to 1.00 for the 4 immediately succeeding fiscal quarters as of and immediately following the consummation of any Significant Acquisition, in each case, by providing a written notice to the Administrative Agent of such Step-Up Election prior to the last day of the first fiscal quarter for which the Step-Up Election is to take effect (this sentence, the &#8220;Leverage Covenant&#8221;). Upon the expiration of the Step-Up Election, the maximum Leverage Ratio permitted under the Leverage Covenant shall revert to the Leverage Ratio set forth below for at least two consecutive fiscal quarters before the Borrower may make another Step-Up Election.</span></div><div style="margin-bottom:10pt;padding-left:54pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022 &#8211; September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Insertion of an add back of certain restructuring charges and synergies in calculating Adjusted Consolidated EBITDA under the credit agreement.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of definition of &#8220;Available Amount&#8221; to include a $900&#160;million &#8220;starter amount&#8221; and a &#8220;grower component&#8221; tied to 50% of cumulative Consolidated Net Income.</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Amendment of certain negative covenant baskets to include a &#8220;grower component&#8221; tied to a percentage of Adjusted Consolidated EBITDA for a trailing 12-month period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Enhabit distributed $566.6&#160;million to Encompass Health who used it to fully repay both the $250&#160;million outstanding balance of the Encompass Health revolving credit facility and approximately $236&#160;million of the Encompass Health term loan. Currently, there are no term loan commitments under the credit agreement. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, $55 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were drawn under the revolving credit facility with an interest rate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $200 million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were drawn under the revolving credit facility with an interest rate of 2.6%. As of December&#160;31, 2022 and 2021, $32.7 million and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $38.2 million, respectively, were being </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">utilized under the letter of credit subfacility, which were being used in the ordinary course of business to secure workers&#8217; compensation and other insurance coverages and for general corporate purposes.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bonds Payable&#8212;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Senior Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 5.125%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Senior Notes due 2023 (&#8220;the 2023 Notes&#8221;), 5.75% Senior Notes due 2025 (the &#8220;2025 Notes&#8221;), 4.50% Senior Notes due 2028 (the &#8220;2028 Notes&#8221;), 4.75% Senior Notes due 2030 (the &#8220;2030 Notes&#8221;), and 4.625% Senior Notes due 2031 (the &#8220;2031 Notes&#8221; and collectively the &#8220;Senior Notes&#8221;) were issued pursuant to an indenture (the &#8220;Base Indenture&#8221;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#8217; respective supplemental indenture (together with the Base Indenture, the &#8220;Indenture&#8221;). Pursuant to the terms of the Indenture, the Senior Notes are jointly and severally guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The Senior Notes are senior, unsecured obligations of Encompass Health and rank equally with our other senior indebtedness, senior to any of our subordinated indebtedness, and effectively junior to our secured indebtedness to the extent of the value of the collateral securing such indebtedness.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the Indenture), each holder of the Senior Notes may require us to repurchase all or a portion of the notes in cash at a price equal to 101% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes contain covenants and default and acceleration provisions, that, among other things, limit our and certain of our subsidiaries&#8217; ability to (1)&#160;incur additional debt, (2)&#160;make certain restricted payments, (3)&#160;consummate specified asset sales, (4)&#160;incur liens, and (5)&#160;merge or consolidate with another person.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 9, 2021, we announced the commencement of a consent solicitation of holders of the 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively the &#8220;Notes&#8221;) for the adoption of certain amendments to the Indenture, which provided us with greater flexibility in effecting the Spin Off discussed in Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin Off of Home Health and Hospice Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#8220;Distribution&#8221;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture for the 2028 Notes, 2030 Notes, and 2031 Notes by $200&#160;million and amends the definition of &#8220;Consolidated Net Income&#8221; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $40.5&#160;million, excluding fees. We paid $20.0&#160;million and $20.5 million in January and June 2022, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2023 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, we issued $300 million of the 2023 Notes at par. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both April and June 2021, we redeemed $100&#160;million in outstanding principal amount of the 2023 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, these optional redemptions were made at a price of par. In March 2022, we redeemed the remaining $100&#160;million in outstanding principal amount of the 2023 Notes using capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Notes would have matured on March 15, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of financing costs, the effective interest rate on the 2023 Notes was 5.4%.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Interest on the 2023 Notes was payable semiannually in arrears on March 15 and September 15.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we issued $350 million of the 2025 Notes at par. The 2025 Notes mature on September&#160;15, 2025 and bear interest at a per annum rate of 5.75%. Inclusive of financing costs, the effective interest rate on the 2025 Notes is 6.0%. Interest on the 2025 Notes is payable semiannually in arrears on March 15 and September&#160;15. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2022, at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 15, 2023 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2028 and 2030 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we issued $500 million of the 2028 Notes at par and $500 million of the 2030 Notes at par. Certain of the proceeds from this offering were used to fund the purchase of equity rights from management investors of our former home health and hospice business discussed in Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we issued an additional $300&#160;million of the 2028 Notes at a price of 99.0% of the principal amount and an additional $300&#160;million of the 2030 Notes at a price of 98.5% of the principal amount, which resulted in approximately $583&#160;million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2028 Notes mature on February 1, 2028. Inclusive of financing costs, the effective interest rate on the 2028 Notes is 4.8%. Interest on the 2028 Notes is payable semiannually in arrears on February 1 and August 1. We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2030 Notes mature on February 1, 2030. Inclusive of financing costs, the effective interest rate on the 2030 Notes is 5.2%. Interest on the 2030 Notes is payable semiannually in arrears on February 1 and August 1. We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2031 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we issued $400&#160;million of the 2031 Notes at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of 4.625%. Inclusive of financing costs, the effective interest rate on the 2031 Notes is 5.0%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Former 2024 Notes</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we redeemed the remaining $700&#160;million of outstanding principal amount of the 5.75% Senior Notes due 2024 (&#8220;the Former 2024 Notes&#8221;). Pursuant to the terms of the Former 2024 Notes, this full redemption was made at a price of par. We used the net proceeds from the 2031 Notes offering, discussed above, together with approximately $300&#160;million of cash on hand to fund the redemption. The Former 2024 Notes would have matured on November&#160;1, 2024. Inclusive of premiums and financing costs, the effective interest rate on the Former 2024 Notes was 5.8%. Interest was payable semiannually in arrears on May 1 and November&#160;1 of each year. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Notes Payable&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our notes payable consist of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.078%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale/leaseback transactions involving real estate accounted for as financings</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1% to 11.2%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction of a new hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0% to 5.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599122367392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Self-Insured Risks<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Self-Insured Risks</a></td>
<td class="text">Self-Insured Risks:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We insure a substantial portion of our professional liability, general liability, and workers&#8217; compensation risks through a self-insured retention program (&#8220;SIR&#8221;) underwritten by our consolidated wholly owned offshore captive insurance subsidiary, HCS, Ltd., which we fund via regularly scheduled premium payments. HCS is an insurance company licensed by the Cayman Island Monetary Authority. We use HCS to fund the first $45 million for annual aggregate losses associated with general and professional liability risks. Workers&#8217; compensation exposures are capped on a per claim basis. Risks in excess of specified limits per claim and in excess of our aggregate SIR amount are covered by unrelated commercial carriers.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our self-insurance reserves (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:53.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for the provision of current year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease for the provision of prior year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses related to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to current year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to prior year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, gross</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, $46.6 million and $45.6 million, respectively, of these reserves are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these risks are based primarily upon actuarially determined estimates. These reserves represent the unpaid portion of the estimated ultimate cost of all reported and unreported losses incurred through the respective consolidated balance sheet dates. The reserves are estimated using individual case-basis valuations and actuarial analyses. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The changes to the estimated ultimate loss amounts are included in current operating results.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reserves for these self-insured risks cover approximately 1,100 and 1,200 individual claims at December&#160;31, 2022 and 2021, respectively, and estimates for potential unreported claims. The time period required to resolve these claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in reserve estimates, management believes the reserves for losses and loss expenses are adequate; however, there can be no assurance the ultimate liability will not exceed management&#8217;s estimates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599117880208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Redeemable Noncontrolling Interests</a></td>
<td class="text">Redeemable Noncontrolling Interests:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:51.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spin off of Enhabit, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:64.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2014, we acquired 83.3% of our former home health and hospice business when we purchased EHHI Holdings, Inc. (&#8220;EHHI&#8221;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#8220;Holdings&#8221;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. In July 2019, we received additional exercise notices, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. In September&#160;2019, Encompass Health settled the acquisition of those shares upon payment of approximately $163 million in cash. In January 2020, we received additional exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#8220;Exchange Agreement&#8221;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#8220;EHC Shares&#8221;). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an &#8220;Exchange Notice&#8221;) to Encompass Health in order to </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#8217;s common stock on the New York Stock Exchange (the &#8220;NYSE&#8221;) on the date of delivery of the Exchange Notice.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors.  Based on the last sales price of Encompass Health&#8217;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599124524656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">As of December&#160;31, 2022, $30.9 million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and $79.1 million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. As of December&#160;31, 2021, $82.2 million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the consolidated balance sheet.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the years ended December 31, 2022, 2021, and 2020, we did not record any material gains or losses related to these assets.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements,&#8221; the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our consolidated balance sheets. The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs within the fair value hierarchy. See Note&#160;1, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Fair Value Measurements&#8221; and &#8220;Redeemable Noncontrolling Interests.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599123281904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has awarded employee stock-based compensation in the form of stock options and restricted stock awards (&#8220;RSAs&#8221;) under the terms of share-based incentive plans designed to align employee and executive interests to those of its stockholders. All employee stock-based compensation awarded during 2022, 2021, and 2020 was issued under the 2016 Omnibus Performance Incentive Plan, a stockholder-approved plan that reserves and provides for the grant of up to 16,860,765 shares of common stock after adjustment for the effect of the Spin Off. This plan allows for the grants of nonqualified stock options, incentive stock options, restricted stock, stock appreciate rights, performance shares, performance share units, dividend equivalents, restricted stock units (&#8220;RSUs&#8221;), and/or other stock-based awards. Stock-based compensation expense recognized in continuing operations was $29.2&#160;million, $29.1&#160;million, and $25.6&#160;million during 2022, 2021, and 2020, respectively. Stock-based compensation expense classified as discontinued operations was $2.5&#160;million, $3.6&#160;million, and $3.9&#160;million during 2022, 2021, and 2020, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our share-based incentive plans, officers and employees are given the right to purchase shares of Encompass Health common stock at a fixed grant price determined on the day the options are granted. The terms and conditions of the options, including exercise prices and the periods in which options are exercisable, are generally at the discretion of the compensation and human capital committee of our board of directors. However, no options are exercisable beyond ten years from the date of grant. Granted options vest over the awards&#8217; requisite service periods, which are generally three years.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the options granted during the years ended December&#160;31, 2022, 2021, and 2020 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including the expected stock price volatility. We estimate our expected term through an analysis of actual, historical post-vesting exercise, cancellation, and expiration behavior by our officers and employees and projected post-vesting activity of outstanding options. We calculate volatility based on the historical volatility of our common stock over the period commensurate with the expected term of the options. The risk-free interest rate is the implied daily yield currently available on U.S. Treasury issues with a remaining term closely approximating the expected term used as the input to the Black-Scholes option-pricing model. We estimated our dividend yield based on our annual dividend rate and our stock price on the dividend payment dates. Under the Black-Scholes option-pricing model, the weighted-average grant date fair value per share of employee stock options granted during the years ended December&#160;31, 2022, 2021, and 2020 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.29,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $19.21, and $15.48, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enhabit spin-off adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Options activity represents historical grant values prior to the Spin Off.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the Spin Off, all outstanding Encompass Health stock options (whether vested or unvested) were converted into adjusted Encompass Health awards for current and former Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized approximately $1.2&#160;million, $2.2&#160;million, and $1.5&#160;million of compensation expense related to our stock options for the years ended December 31, 2022, 2021, and 2020, respectively. As of December&#160;31, 2022, there was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.5 million o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 23 months. The total intrinsic value of options exercised during the years ended December 31, 2022, 2021, and 2020 was $1.8 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $0.1 million, and $2.3 million, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RSAs granted in 2022, 2021, and 2020 included service-based awards and performance-based awards (that also included a service requirement). These awards generally vest over a three-year requisite service period. For RSAs with a service and/or performance requirement, the fair value of the RSA is determined by the closing price of our common stock on the grant date.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our issued restricted stock awards is as follows (share information in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enhabit spin-off adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">RSA activity represents historical grant values prior to the Spin Off.</span></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeiture activity prior to the Spin Off represents historical grant values, while the post-spin forfeitures reflects the impact of Spin Off.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the Spin Off, all outstanding RSAs (whether vested or unvested) were converted into adjusted Encompass Health awards for current Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of restricted stock granted during the years ended&#160;December&#160;31, 2021 and 2020 was $73.89 and $61.81 per share, respectively. We recognized approximately $26.4&#160;million, $24.9&#160;million, and $22.0&#160;million of compensation expense related to our restricted stock awards for the years ended December 31, 2022, 2021, and 2020, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, there was $30.0 million of unrecognized compensation expense related to unvested restricted stock. This cost is expected to be recognized over a weighted-average period of 20 months. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he remaining unrecognized compensation expense for the performance-based awards may vary each reporting period based on changes in the expected achievement of performance measures. The total fair value of shares vested during the years ended December 31, 2022, 2021, and 2020 wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s $20.0 million, $32.6 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and $41.4 million, respectively. We accrue dividends on outstanding RSAs, which are paid upon vesting.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nonemployee Stock-Based Compensation Plans&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022, 2021, and 2020, we provided incentives to our nonemployee members of our board of directors through the issuance of RSUs out of our share-based incentive plans. RSUs are fully vested when awarded and receive dividend equivalents in the form of additional RSUs upon the payment of a cash dividend on our common stock. During the years ended December&#160;31, 2022, 2021, and 2020, we </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued 22,469, 24,043, and 32,196 RSUs, respectively, with a fair value of $67.42, $84.83, and $65.39, respectively, per unit. We recognized approximately $1.5 million, $2.0 million, and $2.1 million, respectively, of compensation expense upon their issuance in 2022, 2021, and 2020. There was</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unrecognized compensation related to unvested shares as of December&#160;31, 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we issued an a</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dditional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,976</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 8,577, and 8,987, respectively, of RSUs as dividend equivalents. As of December&#160;31, 2022, 775,312 RSUs were ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tstanding. In addition to the above, we issued 130,406 additional RSUs to current and former members of our board of directors in connection with the Spin Off. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116293120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all Encompass Health employees are eligible to enroll in Encompass Health-sponsored healthcare plans, including coverage for medical and dental benefits. Our primary healthcare plans are national plans administered by third-party administrators. We are self-insured for these plans. During 2022, 2021, and 2020, costs associated with these plans, net of amounts paid by employees, approximated $174.5 million, $166.0 million, and $145.4 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Encompass Health Retirement Investment Plan (the &#8220;RIP&#8221;) is a qualified 401(k) savings plan. The RIP allows eligible employees to contribute up to 100% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. Encompass Health employees who are at least 21 years of age are eligible to participate in the RIP and all contributions to the plan are in the form of cash. Encompass </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health&#8217;s employer matching contribution under the RIP is 50% of the first 6% of each participant&#8217;s elective deferrals, which vest 100% after three years of service. Participants are always fully vested in their own contributions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employer contributions to the RIP approximated $28.7 million, $26.4 million, and $23.3 million in 2022, 2021, and 2020, respectively. In 2022, 2021, and 2020, approximately $1.4 million, $1.1 million, and $1.3 million, respectively, from forfeited accounts were used to fund the matching contributions in accordance with the terms of the RIP.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Management Bonus Program&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a Senior Management Bonus Program to reward senior management for performance based on a combination of corporate or regional goals for all periods presented. The corporate and regional goals are approved on an annual basis by our board of directors as part of our routine budgeting and financial planning process. The program applies to persons who join the Company in, or are promoted to, senior management positions. In 2023, we expect to pay approximately $14.8 million under the program for the year ended December&#160;31, 2022. In March 2022 and 2021, we paid $23.4 million and $14.1 million, respectively, under the program for the years ended December&#160;31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119673376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to continuing operations are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense related to continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based windfall tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2022 was greater than the federal statutory rate primarily due to state and other income tax expense and the increase in valuation allowance, offset by the impact of noncontrolling interests. The </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2021 was less than the federal statutory rate primarily due to the impact of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">noncontrolling interests, the decrease in valuation allowance and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">share-based windfall tax benefits,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offset by state and other income tax expense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2020 was greater than the federal statutory rate primarily due to state and other income tax expense and the increase in valuation allowance, offset by the impact of noncontrolling interests and share-based windfall tax benefits.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note&#160;1, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, &#8220;Income Taxes,&#8221; for a discussion of the allocation of income or loss related to pass-through entities, which is referred to as the impact of noncontrolling interests in this discussion.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#8220;CARES Act&#8221;)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, technical corrections to tax depreciation methods for qualified improvement property and deferral of employer payroll taxes. The CARES Act did not materially impact our effective tax rate for the years ended December 31, 2022, 2021 and 2020, although it has impacted the timing of cash payments for taxes. </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes recognize the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes and the impact of available NOLs. The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have state NOLs of $35.3 million that expire in various amounts at varying times through 2031. For the years ended December&#160;31, 2022 and 2021, the net decrease in our valuation allowance was $7.3 million and $3.1 million, respectively. The decrease in our valuation allowance in 2022 related primarily to the expiration of state NOLs. The decrease in our valuation allowance in 2021 related primarily to changes in forecasted income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we have a remaining valuation allowance of $35.8 million. This valuation allowance remains recorded due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management&#8217;s estimates of taxable income for each jurisdiction in which we operate over the periods in </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during 2022, 2021, and 2020 was not material. Accrued interest income related to income taxes as of December 31, 2022 and 2021 was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, we signed an agreement with the IRS to participate in their Compliance Assurance Process (&#8220;CAP&#8221;) for the 2017 tax year and have renewed this agreement each year since. CAP is a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax returns. The IRS is currently examining the 2021 and 2022 tax years. In June 2022, the IRS issued a no change letter effectively closing our 2020 tax year audit. The statute of limitations has expired or we have settled federal income tax examinations with the IRS for all tax years through 2020. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by one state for tax years ranging from 2017 - 2019.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the tax years that remain open under the applicable statutes of limitations, management considered potential unrecognized tax benefits and determined there are no material unrecognized tax benefits that would impact prior years&#8217; income taxes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119673376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Common Share</a></td>
<td class="text">Earnings per Common Share:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income from continuing operations allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income from discontinued operations allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase approximately 0.4 million, 0.2 million, and 0.2 million shares of common stock were outstanding during December&#160;31, 2022, 2021, and 2020, respectively, but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, our board of directors approved an increase in our common stock repurchase authorization from $200 million to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. There were no repurchases of our common stock during 2022 or 2021. During 2020, we repurchased 0.1&#160;million shares of our common stock in the open market for $6.1 million.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.28 per share. The cash dividend of $0.28 per common share was declared and paid in each quarter through July 2022. In July 2022, our board of directors revised our quarterly dividend in response to the Spin Off and declared a cash dividend of $0.15 per share that was paid in October 2022. Also in October 2022, our board of directors declared cash dividends of $0.15 per share that was paid in January 2023. Future dividend payments are subject to declaration by our board of directors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599117243776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Other Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Other Commitments</a></td>
<td class="text">Contingencies and Other Commitments:<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act allows private citizens, called &#8220;relators,&#8221; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#8220;whistleblower&#8221; or &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; actions, can involve significant monetary damages, fines, attorneys&#8217; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cases brought pursuant to the False Claims Act.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Commitments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to service and other contracts in connection with conducting our business. Minimum amounts due under these agreements are $29.6 million in 2023, $21.0 million in 2024, $12.5 million in 2025, $9.8 million in 2026, $9.2 million in 2027, and $9.6 million thereafter. These contracts primarily relate to software licensing and support.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599117852752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Data (Unaudited)</a></td>
<td class="text">Quarterly Data (Unaudited):<div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Spin Off of Enhabit was completed during 2022 and the historical results of Enhabit are now reported as discontinued operations. The quarterly results presented below have been reclassified to conform to this presentation. For additional information, see Note&#160;2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin Off of Home Health and Hospice Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt">We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.</span></div><div style="margin-bottom:5pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt">We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI https://asc.fasb.org/topic&amp;trid=2126967<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL124452896-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111609504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Consolidation&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to Encompass Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We eliminate all significant intercompany accounts and transactions from our financial results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any entity considered a variable interest entity (&#8220;VIE&#8221;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Assumptions</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates and Assumptions&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#8217; compensation, and comprehensive general insurance liability risks; and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Net Operating Revenues</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#8220;HHS-OIG&#8221;) or the United States Department of Justice (the &#8220;DOJ&#8221;). Therefore, we are unable to predict if or when we may be </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Administrative Contractors (&#8220;MACs&#8221;), under programs known as &#8220;widespread probes,&#8221; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#8220;appeal,&#8221; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#8220;OMHA&#8221;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. During 2022, the backlog of &#8220;widespread probe&#8221; claims adjudicated by the administrative law judge (&#8220;ALJ&#8221;) continued and were substantially completed. This OMHA practice resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims. We have appealed certain adverse ALJ rulings to the Department Appeals Boards (&#8220;DAB&#8221;), the final level of administrative review. As of December 31, 2022, approximately $52&#160;million in claims are awaiting review at the DAB. In addition, we have appealed approximately $6&#160;million in claims denied by the DAB to several United States District Courts, all of which are pending review as of December 31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, CMS announced the Targeted Probe and Educate (&#8220;TPE&#8221;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with CMS approved and announced Recovery Audit Contractors (&#8220;RACs&#8221;) audits related to inpatient rehabilitation facilities (&#8220;IRFs&#8221;), we received requests from 2013 to 2022 to review certain patient files for discharges occurring from 2010 to 2022.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#8217;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has also established Unified Program Integrity Contractors (&#8220;UPICs&#8221;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors. In December 2017, we received notice of a UPIC audit at one of our hospitals. The UPIC sampled 100 claims and challenged the propriety of a subset of the sample representing $1.3&#160;million in previously paid claims. The UPIC extrapolated the alleged error rate to all claims from that hospital during a period of approximately four years, resulting in an alleged overpayment of $33.9&#160;million. Our MAC later reduced the determination of overpayment to $30.5&#160;million, which it collected through recoupment of current claims during 2019. We appealed the overpayment determination to an Administrative Law Judge (&#8220;ALJ&#8221;), who heard the appeal in August 2021. In October 2022, the ALJ </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overturned $12.5&#160;million of the overpayment determination. We received payment of this amount, plus $3.2&#160;million in interest, in December 2022. We have appealed the remaining $18.0&#160;million of the overpayment determination to the DAB, the next level of administrative appeal, challenging both the denials and the improper use of extrapolation. It is not possible to predict when this matter will be resolved or the ultimate outcome.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Medicare claims that are subject to these post-payment audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2022. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2022, 2021, and 2020, our adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for claims that are part of this post-payment claims review process was not material.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#8217;s total length of stay for in-house patients, each patient&#8217;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> include highly liquid investments with maturities of three months or less when purchased. Carrying values of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approximate fair value due to the short-term nature of these instruments.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a separate component of shareholders&#8217; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of </span></div>time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#8217; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other discount plans, including Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#8217;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state </span></div>governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:84.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases&#8212;</span></div><div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. In general, we do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.</span></div><div style="margin-bottom:10pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets&#8212; </span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors in our single reporting unit to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our reporting unit using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of our reporting unit&#8217;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting unit to our market capitalization. When we dispose of a hospital, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2022, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and certain directly related payroll costs. Amortization begins when the internal-use software is ready for its intended </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#8217;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock', window );">Impairment of Long-Lived Assets and Other Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Long-Lived Assets and Other Intangible Assets&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#8217;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Financing Costs</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense and amortization of debt discounts and fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated statements of comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Observable inputs such as quoted prices in active markets;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cost approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and</span></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling Interests in Consolidated Affiliates and Redeemable Noncontrolling Interests</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling Interests in Consolidated Affiliates&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#8217; balance.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future.  Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to certain members of the home health and hospice management team&#8217;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $400&#160;million or more. The fair value of our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#8217; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inputs. The projected operating results use management&#8217;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Payments&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Litigation Reserves</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Reserves&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising Costs&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other operating expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the accompanying consolidated statements of comprehensive income, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.6 million, and $4.6 million in each of the years ended December 31, 2022, 2021, and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for income taxes using the asset and liability method</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We </span></div>include the allocable portion of each pass-through entity&#8217;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Assets and Liabilities in and Results of Discontinued Operations</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities in and Results of Discontinued Operations&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income from discontinued operations, net of tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current assets of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Noncurrent assets of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current liabilities of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncurrent liabilities of discontinued operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Common Share</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Common Share&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Treasury Stock&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital in excess of par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We account for the retirement of treasury stock as a reduction of retained earnings.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is comprised of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of the Company's long-lived assets and intangible assets with finite lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599120190096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Concentration of Net Operating Revenues by Payor</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net operating revenues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disaggregated by payor source are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,589.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Advantage</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">609.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers&#8217; compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration of Net Operating Revenues and Net Patient Service Accounts Receivable by Payor and Payor Class</a></td>
<td class="text">The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care and other discount plans, including Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party payors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Workers' compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Useful Lives of Property and Equipment</a></td>
<td class="text">Useful lives are generally as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:84.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10</span></div></td></tr></table><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,019.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,239.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,490.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Estimated Useful Lives and Amortization Basis of Other Finite-lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our other intangible assets (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certificates of need:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncompete agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade name - Encompass:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade names - all other:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal-use software:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market access assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Estimated Basis of Other Indefinite-lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599123401392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin Off of Home Health and Hospice Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Summary of Financial Information Related to Discontinued Operations</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the results of operations of Enhabit as discontinued operations (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">778.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense and amortization of debt discounts and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net income of nonconsolidated affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health included in discontinued operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects amounts through the July 1, 2022 Spin Off date.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the carrying amounts of the assets and liabilities of the discontinued operations of Enhabit (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,190.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,543.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets of discontinued operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total noncurrent liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities of discontinued operations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119963744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 2 to 3 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition dates were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 3 to 5 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the assets acquired at the acquisition date were as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:87.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements (useful lives of 2 to 3 years)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name (useful life of 20 years)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2022 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:87.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:89.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.753%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of noncontrolling interest owned by joint venture partner</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Actual and Pro Forma Results of Operations for Acquisitions</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above-mentioned acquisitions from the dates of acquisitions included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the dates of the acquisitions been January&#160;1, 2021 (in millions):</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2022-12/31/2022 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,039.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2021 period.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above mentioned-acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the above-mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2020 (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Operating Revenues</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Income Attributable to Encompass Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired entities only: Actual from acquisition date to December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,571.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118071904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and classifications of the consolidated VIEs&#8217; assets and liabilities, which are included in our consolidated balance sheets, are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term assets of discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities of discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119632768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Investment Components</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2022 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our investments as of December&#160;31, 2021 are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Marketable Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consisted of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliate cash</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Self-insured captive funds</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock', window );">Schedule of Investment Information Related to Restricted Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing information related to our available-for-sale marketable securities is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of available-for-sale marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118122176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patient accounts receivable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent patient accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599120161168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and equipment</a></td>
<td class="text">Useful lives are generally as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:84.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 to 15</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10</span></div></td></tr></table><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,019.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">647.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,239.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,718.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,659.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,490.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,579.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,228.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,939.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,581.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock', window );">Schedule of depreciation expense and interest capitalized</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of depreciation expense and interest capitalized is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest capitalized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of depreciation expense, interest capitalized, under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599110751504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Least Costs</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease cost:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finance lease cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term and variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information Related to Leases</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated balance sheet information related to leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.254%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.213%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44">Current portion of long-term debt</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncurrent liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4">Long-term debt, net of current portion</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Finance lease assets are recorded net of accumulated amortization of $145.8 million and $126.9 million as of December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock', window );">Schedule of Weighted Average Remaining Lease Term and Discount Rate</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Finance Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows (in millions): </span></div><div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Finance<br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(191.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_SupplementalCashFlowInformationTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to our leases is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental Cash Flow Information [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118219536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in the Carrying Amount of Goodwill</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows changes in the carrying amount of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill as of December 31, 2022</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets by Major Class</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:62.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.781%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life<br/>and Amortization Basis</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 30 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompete agreements</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 to 18 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names:</span></td><td colspan="15" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Encompass</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">indefinite-lived asset</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 to 20 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 7 years using straight-line basis</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Market access assets</span></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years using accelerated basis</span></div></td></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our other intangible assets (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certificates of need:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Licenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncompete agreements:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade name - Encompass:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trade names - all other:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Internal-use software:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market access assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense, Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for other intangible assets is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Estimated Amortization Expense, Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated<br/>Amortization Expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599122311056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Outstanding Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term debt outstanding consists of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Agreement&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonds payable&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,278.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,741.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,240.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our notes payable consist of the following (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.078%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Rates</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale/leaseback transactions involving real estate accounted for as financings</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1% to 11.2%</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction of a new hospital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0% to 5.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Debt Maturities</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.108%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Face Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,247.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,198.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,817.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,767.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ScheduleOfFinancialCovenantsTableTextBlock', window );">Schedule of Financial Covenants</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interest Coverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00 to 1.00</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019 and March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021 </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25 to 1.00</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"><tr><td style="width:1.0%"/><td style="width:67.943%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal Quarters Ending</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leverage Ratio</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2022 &#8211; September 30, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75 to 1.00</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50 to 1.00</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionTableTextBlock', window );">Schedule of Redemption Prices for Senior Notes</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2022, at the redemption prices set forth below:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:83.504%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 15, 2023 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div>We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:<div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025 and thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div>We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:<div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div>We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:<div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.790%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Redemption<br/>Price*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Expressed in percentage of principal amount</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ScheduleOfFinancialCovenantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Financial Covenants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ScheduleOfFinancialCovenantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118062704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Self-Insured Risks (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Self-Insurance Reserves</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in our self-insurance reserves (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:53.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase for the provision of current year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease for the provision of prior year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses related to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to current year claims</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments related to prior year claims</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Reinsurance receivables</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period, gross</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599120113872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock', window );">Schedule of Redeemable Noncontrolling Interest</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the activity related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:51.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.273%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions declared</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution to joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of redeemable noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spin off of Enhabit, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock', window );">Schedule of Reconciliation of Net Income Attributable to Noncontrolling Interests</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the net income attributable to nonredeemable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the shareholders&#8217; equity section of the consolidated balance sheets, and the net income attributable to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as recorded in the mezzanine section of the consolidated balance sheets, to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> presented in the consolidated statements of comprehensive income (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:64.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.735%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to nonredeemable noncontrolling interests</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to redeemable noncontrolling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of Noncontrolling Interests [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599120935376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:34.876%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation Technique </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span></td></tr></table></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).</span></div><div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">As of December&#160;31, 2022, $30.9 million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and $79.1 million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the consolidated balance sheet. As of December&#160;31, 2021, $82.2 million are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Other long-term assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments</a></td>
<td class="text">The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances under revolving credit facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan facilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.125% Senior Notes due 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.75% Senior Notes due 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Senior Notes due 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">786.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">823.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Senior Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">703.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.625% Senior Notes due 2031</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other notes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial commitments:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letters of credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599117880864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions Used to Determine Fair Value of Stock Options</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of the options granted during the years ended December&#160;31, 2022, 2021, and 2020 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information is as follows:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:38.049%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.566%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares<br/>(In Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value<br/>(In Millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enhabit spin-off adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Options activity represents historical grant values prior to the Spin Off.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the Spin Off, all outstanding Encompass Health stock options (whether vested or unvested) were converted into adjusted Encompass Health awards for current and former Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our issued restricted stock awards is as follows (share information in thousands):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enhabit spin-off adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested shares at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">RSA activity represents historical grant values prior to the Spin Off.</span></div><div style="margin-bottom:4pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Forfeiture activity prior to the Spin Off represents historical grant values, while the post-spin forfeitures reflects the impact of Spin Off.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">In connection with the Spin Off, all outstanding RSAs (whether vested or unvested) were converted into adjusted Encompass Health awards for current Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118051424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant components of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for income tax expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to continuing operations are as follows (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense related to continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax expense at statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in tax rate resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and other income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based windfall tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accruals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue reserves</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value of partnerships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163.1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119606720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings per Common Share</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):</span></div><div style="margin-bottom:7pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.019%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income from continuing operations allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income from discontinued operations allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.87&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in continuing operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests included in discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations attributable to Encompass Health common shareholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health common shareholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Reconciliation of Weighted Average Number of Shares Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:60.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards, dilutive stock options, and restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118140304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Quarterly Data (Unaudited) Table</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,059.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.89&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt">We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.</span></div><div style="margin-bottom:5pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:46.191%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">First</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Second</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Third</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fourth</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In Millions, Except Per Share Data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">959.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,010.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,042.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,014.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Encompass Health</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">412.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per share attributable to Encompass Health common shareholders: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.07&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.13&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt">We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111167936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>hospital </div>
<div>state</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>hospital </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfInpatientRehabilitationHospitals', window );">Number of inpatient rehabilitation hospitals | hospital</a></td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership', window );">Number of inpatient rehabilitation hospitals, sole ownership | hospital</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals', window );">Number of jointly owned inpatient rehabilitation hospitals | hospital</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold', window );">Redeemable noncontrolling interest, fair value determination based on home health acquisitions, value threshold</a></td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees', window );">Minimum accrual of loss contingency needed to accrue for related legal fees</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember', window );">Market access assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_DepartmentAppealsBoardAdverseRulingMember', window );">DAB, Adverse Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyClaimsAwaitingReviewAmount', window );">Amount of claims pending review</a></td>
<td class="nump">52.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyAppealedClaimsDeniedAmount', window );">Appealed claims denied</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_UnifiedProgramIntegrityContractorsAuditsMember', window );">UPICs Audits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyNumberOfClaimsSampledForAudit', window );">Number of claims sampled | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyClaimsSampledForAuditAmount', window );">Paid claims, amount from sample</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyExtrapolatedErrorRatePeriod', window );">Extrapolated error rate period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount', window );">Alleged overpayment amount</a></td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination', window );">Amount overturned of overpayment determination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest', window );">Amount overturned of overpayment determination, interest</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Payor Source | Revenue from Contract with Customer Benchmark | Medicare | RAC Audits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of Medicare patient discharges (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_Jointventureownershippercentage', window );">Joint venture ownership percentage</a></td>
<td class="nump">97.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Jointventureownershippercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Joint venture ownership percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Jointventureownershippercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Amount Overturned Of Overpayment Determination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Amount Overturned Of Overpayment Determination, Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyAppealedClaimsDeniedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Appealed Claims Denied, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyAppealedClaimsDeniedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyClaimsAwaitingReviewAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Awaiting Review, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyClaimsAwaitingReviewAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyClaimsSampledForAuditAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Sampled For Audit, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyClaimsSampledForAuditAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Extrapolated Error Rate, Alleged Overpayment Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyExtrapolatedErrorRatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Extrapolated Error Rate, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyExtrapolatedErrorRatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum dollar amount that must be accrued for a loss contingency related to a specific legal dispute that can be utilized for consideration prior to accruing an estimate of the legal fees related to this specific legal dispute.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LossContingencyNumberOfClaimsSampledForAudit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Claims Sampled For Audit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LossContingencyNumberOfClaimsSampledForAudit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfInpatientRehabilitationHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfInpatientRehabilitationHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Inpatient Rehabilitation Hospitals, Sole Ownership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_DepartmentAppealsBoardAdverseRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_DepartmentAppealsBoardAdverseRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_UnifiedProgramIntegrityContractorsAuditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_UnifiedProgramIntegrityContractorsAuditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_RACAuditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ehc_RACAuditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599110971968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Net Operating Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,137.3<span></span>
</td>
<td class="nump">$ 1,089.5<span></span>
</td>
<td class="nump">$ 1,062.5<span></span>
</td>
<td class="nump">$ 1,059.3<span></span>
</td>
<td class="nump">$ 1,042.5<span></span>
</td>
<td class="nump">$ 1,010.8<span></span>
</td>
<td class="nump">$ 1,001.7<span></span>
</td>
<td class="nump">$ 959.9<span></span>
</td>
<td class="nump">$ 4,348.6<span></span>
</td>
<td class="nump">$ 4,014.9<span></span>
</td>
<td class="nump">$ 3,566.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ehc_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843.1<span></span>
</td>
<td class="nump">2,589.6<span></span>
</td>
<td class="nump">2,375.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ehc_MedicareAdvantageMember', window );">Medicare Advantage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654.6<span></span>
</td>
<td class="nump">609.6<span></span>
</td>
<td class="nump">544.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ehc_ManagedCareMember', window );">Managed care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505.2<span></span>
</td>
<td class="nump">484.5<span></span>
</td>
<td class="nump">371.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ehc_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183.3<span></span>
</td>
<td class="nump">163.1<span></span>
</td>
<td class="nump">140.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ehc_OtherThirdpartyPayorsMember', window );">Other third-party payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
<td class="nump">46.0<span></span>
</td>
<td class="nump">43.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ehc_WorkersCompensationMember', window );">Workers&#8217; compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.7<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ehc_PatientsMember', window );">Patients</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">19.3<span></span>
</td>
<td class="nump">19.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ehc_OtherIncomeSourceMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.6<span></span>
</td>
<td class="nump">$ 79.7<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_ManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_ManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_OtherThirdpartyPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_OtherThirdpartyPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_WorkersCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_WorkersCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_PatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_PatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_OtherIncomeSourceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_OtherIncomeSourceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111692720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Accounts Receivable (Details) - Payor Source - Accounts Receivable<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Medicare | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">57.90%<span></span>
</td>
<td class="nump">57.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Managed care and other discount plans, including Medicare Advantage | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">31.10%<span></span>
</td>
<td class="nump">31.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Medicaid | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Other third-party payors | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Workers&#8217; compensation | Third-Party Payor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember', window );">Patients | Self-Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Net operating revenues by payor source (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=ehc_PayorSourceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_OtherThirdpartyPayorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_OtherThirdpartyPayorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_WorkersCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_WorkersCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ehc_PatientsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ehc_PatientsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111690112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - PP&amp;E Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures, and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures, and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599110676448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember', window );">Certificates of need | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember', window );">Certificates of need | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">18 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_InternalUseSoftwareMember', window );">Internal-use software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_InternalUseSoftwareMember', window );">Internal-use software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember', window );">Market access assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_InternalUseSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_InternalUseSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111036256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin Off of Home Health and Hospice Business - Textual (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>segment </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm', window );">Transition services, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ehc_EnhabitMember', window );">Enhabit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ehc_EnhabitMember', window );">Enhabit | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome', window );">Transition services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56.7<span></span>
</td>
<td class="nump">$ 22.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ehc_EnhabitMember', window );">Enhabit | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Transferred to discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ehc_EnhabitMember', window );">Enhabit | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Pro rata distribution of common stock</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transition Services Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Transition Services, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ehc_EnhabitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ehc_EnhabitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ehc_EnhabitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ehc_EnhabitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599115521216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin Off of Home Health and Hospice Business- Summary of Financial Information Related to Discontinued Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (18.5)<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="nump">$ 31.0<span></span>
</td>
<td class="nump">$ 15.2<span></span>
</td>
<td class="nump">$ 114.1<span></span>
</td>
<td class="nump">$ 90.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests included in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income attributable to Encompass Health included in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">89.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets of discontinued operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">178.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total noncurrent assets of discontinued operations</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1,543.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent', window );">Accrued payroll</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total noncurrent liabilities of discontinued operations</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">100.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ehc_EnhabitMember', window );">Enhabit | Discontinued Operations, Disposed of by Means Other than Sale, Spinoff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Income from discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Net operating revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542.3<span></span>
</td>
<td class="nump">1,106.6<span></span>
</td>
<td class="nump">1,078.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits', window );">Salaries and benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">376.4<span></span>
</td>
<td class="nump">759.2<span></span>
</td>
<td class="nump">778.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.5<span></span>
</td>
<td class="nump">89.7<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts', window );">Occupancy costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="nump">19.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies', window );">Supplies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">29.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.3<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">36.9<span></span>
</td>
<td class="nump">40.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522.6<span></span>
</td>
<td class="nump">960.0<span></span>
</td>
<td class="nump">960.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees', window );">Interest expense and amortization of debt discounts and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(4.8)<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments', window );">Equity in net income of nonconsolidated affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income from discontinued operations before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">151.7<span></span>
</td>
<td class="nump">119.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Provision for income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">114.1<span></span>
</td>
<td class="nump">90.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests included in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income attributable to Encompass Health included in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">$ 89.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Total noncurrent assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred income tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Total noncurrent liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accrued Expenses and Other Current Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Accrued Payroll, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Assets, Operating Lease Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Income (Loss) Of Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Interest Expense And Amortization Of Debt Discounts And Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Long-term Debt, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Long-term Debt, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Occupancy Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Operating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Salaries And Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DisposalGroupIncludingDiscontinuedOperationSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Supplies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DisposalGroupIncludingDiscontinuedOperationSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ehc_EnhabitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ehc_EnhabitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599115059600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combinations - Textual (Details) - Corporate Joint Venture<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>bed</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>bed</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>bed</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>bed</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>bed</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>bed</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>bed</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Altru Health System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Trinity Medical Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">NCH Healthcare System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfBedsAcquired', window );">Number of beds acquired</a></td>
<td class="nump">54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Altru Health System, Trinity Medical Center And NCH Healthcare System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be tax-deductible | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Shannon Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Heritage Valley</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be tax-deductible | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Portercare Adventist</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberofBedsContributed', window );">Number of beds contributed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberofBedsExpanded', window );">Number of beds expanded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition percentage of voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfBedsAcquired', window );">Number of beds acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberofDeNovoBeds', window );">Number of de novo beds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be tax-deductible | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfBedsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Beds Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfBedsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofBedsContributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Beds Contributed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofBedsContributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofBedsExpanded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Beds Expanded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofBedsExpanded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberofDeNovoBeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of De Novo Beds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberofDeNovoBeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_TrinityMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_TrinityMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_NCHHealthcareSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_NCHHealthcareSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_HeritageValleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_HeritageValleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599122273728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Fair Value of Assets and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,263.2<span></span>
</td>
<td class="nump">$ 1,237.0<span></span>
</td>
<td class="nump">$ 1,228.2<span></span>
</td>
<td class="nump">$ 1,218.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember', window );">Altru Health System, Trinity Medical Center And NCH Healthcare System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets', window );">Total assets acquired</a></td>
<td class="nump">27.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember', window );">Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember', window );">Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets', window );">Total assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements | Altru Health System, Trinity Medical Center And NCH Healthcare System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Noncompete agreements | Altru Health System, Trinity Medical Center And NCH Healthcare System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Noncompete agreements | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Noncompete agreements | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Noncompete agreements | Altru Health System, Trinity Medical Center And NCH Healthcare System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Noncompete agreements | Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Noncompete agreements | Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Finite-lived intangible asset useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599115260288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Net Cash Paid for Acquisition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember', window );">Altru Health System, Trinity Medical Center And NCH Healthcare System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_BusinessCombinationNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="num">(27.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember', window );">Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_BusinessCombinationNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember', window );">Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_BusinessCombinationNoncontrollingInterestFairValue', window );">Fair value of noncontrolling interest owned by joint venture partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_BusinessCombinationNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Noncontrolling Interest, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_BusinessCombinationNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111511632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Pro Forma Results of Operation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisition, pro forma revenue</a></td>
<td class="nump">$ 4,369.0<span></span>
</td>
<td class="nump">$ 4,039.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisition, pro forma net income (loss)</a></td>
<td class="nump">273.7<span></span>
</td>
<td class="nump">415.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember', window );">Altru Health System, Trinity Medical Center And NCH Healthcare System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember', window );">Shannon Medical, Heritage Valley &amp; ECHD Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_A2021AcquisitionsMember', window );">2021 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisition, pro forma revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,021.1<span></span>
</td>
<td class="nump">$ 3,581.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisition, pro forma net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412.5<span></span>
</td>
<td class="nump">285.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember', window );">Portercare Adventist and Premier Health Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, revenue of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual', window );">Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_A2020AcquisitionsMember', window );">2020 Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Business acquisition, pro forma revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,571.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Business acquisition, pro forma net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 284.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_A2021AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_A2021AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_PortercareAdventistAndPremierHealthPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_A2020AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_A2020AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111633232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities - Textuals (Details) - Variable Interest Entity, Primary Beneficiary - entity<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_VariableInterestEntityNumberofEntitiesConsolidated', window );">Number of consolidated limited partnership-like entities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership interest in the consolidated entities (percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Ownership interest in the consolidated entities (percent)</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_VariableInterestEntityNumberofEntitiesConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of facilities consolidated as variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_VariableInterestEntityNumberofEntitiesConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116555088">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="nump">$ 49.4<span></span>
</td>
<td class="nump">$ 185.6<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">536.8<span></span>
</td>
<td class="nump">515.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">178.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">717.2<span></span>
</td>
<td class="nump">921.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,939.2<span></span>
</td>
<td class="nump">2,581.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">212.5<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,263.2<span></span>
</td>
<td class="nump">1,237.0<span></span>
</td>
<td class="nump">$ 1,228.2<span></span>
</td>
<td class="nump">$ 1,218.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">282.3<span></span>
</td>
<td class="nump">158.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">222.0<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Long-term assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1,543.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,636.5<span></span>
</td>
<td class="nump">6,864.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">37.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">132.9<span></span>
</td>
<td class="nump">134.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">168.3<span></span>
</td>
<td class="nump">199.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">181.0<span></span>
</td>
<td class="nump">177.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">132.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">575.9<span></span>
</td>
<td class="nump">748.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,741.8<span></span>
</td>
<td class="nump">3,240.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199.7<span></span>
</td>
<td class="nump">179.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,774.6<span></span>
</td>
<td class="nump">4,465.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34.0<span></span>
</td>
<td class="nump">33.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40.9<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">129.0<span></span>
</td>
<td class="nump">116.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15.9<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18.8<span></span>
</td>
<td class="nump">31.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent', window );">Long-term assets of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">207.8<span></span>
</td>
<td class="nump">226.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15.7<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Current liabilities of discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32.1<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 47.9<span></span>
</td>
<td class="nump">$ 38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Our consolidated assets as of December&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $207.8 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $47.9 million and $38.2 million, respectively. See Note&#160;4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2510-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2473-110228<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119451248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Components of Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="nump">$ 49.4<span></span>
</td>
<td class="nump">$ 185.6<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRestricted', window );">Restricted Marketable Securities</a></td>
<td class="nump">110.0<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_InvestmentsCashandRestrictedCash', window );">Total</a></td>
<td class="nump">163.4<span></span>
</td>
<td class="nump">194.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">49.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRestricted', window );">Restricted Marketable Securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_InvestmentsCashandRestrictedCash', window );">Total</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash &amp; Cash Equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted Cash</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRestricted', window );">Restricted Marketable Securities</a></td>
<td class="nump">110.0<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_InvestmentsCashandRestrictedCash', window );">Total</a></td>
<td class="nump">$ 110.0<span></span>
</td>
<td class="nump">$ 82.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_InvestmentsCashandRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total investments of the Company which includes cash, cash equivalents, restricted cash, and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_InvestmentsCashandRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRestricted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRestricted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111255776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Marketable Securities - Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 31.6<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Noncurrent restricted cash</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">62.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_AffiliateCashMember', window );">Affiliate cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_SelfInsuredCaptiveFundsMember', window );">Self-insured captive funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">17.3<span></span>
</td>
<td class="nump">47.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Noncurrent restricted cash</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_OtherFundsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_AffiliateCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_AffiliateCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_SelfInsuredCaptiveFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_SelfInsuredCaptiveFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_OtherFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ehc_OtherFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111732848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RestrictedDebtSecuritiesNoncurrent', window );">Restricted marketable securities</a></td>
<td class="nump">$ 79.1<span></span>
</td>
<td class="nump">$ 82.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized net gain (loss) on marketable securities</a></td>
<td class="num">$ (7.4)<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RestrictedDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for greater than one year or the normal operating cycle, whichever is longer and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RestrictedDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118166944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract', window );"><strong>Investment information related to restricted marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales and maturities of available-for-sale marketable securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 12.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119378912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Receivable - Components of Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrentAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Patient accounts receivable</a></td>
<td class="nump">$ 524.8<span></span>
</td>
<td class="nump">$ 502.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other accounts receivable</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Accounts receivable, current</a></td>
<td class="nump">536.8<span></span>
</td>
<td class="nump">515.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">Noncurrent patient accounts receivable</a></td>
<td class="nump">73.3<span></span>
</td>
<td class="nump">77.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 610.1<span></span>
</td>
<td class="nump">$ 593.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111146816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Components of Property and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">$ 2,939.2<span></span>
</td>
<td class="nump">$ 2,581.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember', window );">Land, Building, Improvements, Equipment, Vehicles and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">4,239.1<span></span>
</td>
<td class="nump">3,718.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(1,659.4)<span></span>
</td>
<td class="num">(1,490.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">2,579.7<span></span>
</td>
<td class="nump">2,228.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">286.1<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">3,019.8<span></span>
</td>
<td class="nump">2,632.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">281.5<span></span>
</td>
<td class="nump">251.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures, and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization</a></td>
<td class="nump">647.2<span></span>
</td>
<td class="nump">571.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Components of Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="nump">$ 359.5<span></span>
</td>
<td class="nump">$ 353.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599118147200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Textual (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_Percentageofassetspledgedtolendersundercreditagreement', window );">Percentage of property and equipment, net pledged to lenders under credit agreement (percent)</a></td>
<td class="nump">68.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Percentageofassetspledgedtolendersundercreditagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of assets pledged to lenders under credit agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Percentageofassetspledgedtolendersundercreditagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116279504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Depreciation, Capitalized Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 187.3<span></span>
</td>
<td class="nump">$ 160.4<span></span>
</td>
<td class="nump">$ 145.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest capitalized</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116216368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Textuals (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>option</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions', window );">Number of renewal options (or more)</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_OperatingAndFinanceLeaseContractTerm', window );">Operating and finance lease contract term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_OperatingAndFinanceLeaseContractTerm', window );">Operating and finance lease contract term</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OperatingAndFinanceLeaseContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating and finance leases, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OperatingAndFinanceLeaseContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111257568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 38.7<span></span>
</td>
<td class="nump">$ 46.7<span></span>
</td>
<td class="nump">$ 50.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">29.0<span></span>
</td>
<td class="nump">30.7<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_Totalfinanceleasecost', window );">Total finance lease cost</a></td>
<td class="nump">56.5<span></span>
</td>
<td class="nump">58.7<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_Shorttermandvariableleasecost', window );">Short-term and variable lease cost</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 97.5<span></span>
</td>
<td class="nump">$ 105.4<span></span>
</td>
<td class="nump">$ 104.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Shorttermandvariableleasecost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less, plus the amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Shorttermandvariableleasecost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Totalfinanceleasecost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of finance lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Totalfinanceleasecost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111637600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease</a></td>
<td class="nump">$ 212.5<span></span>
</td>
<td class="nump">$ 193.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease</a></td>
<td class="nump">272.9<span></span>
</td>
<td class="nump">299.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_Totaloperatingandfinanceleaseassets', window );">Total leased assets</a></td>
<td class="nump">485.4<span></span>
</td>
<td class="nump">493.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">25.6<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">199.7<span></span>
</td>
<td class="nump">179.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease</a></td>
<td class="nump">340.3<span></span>
</td>
<td class="nump">361.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_Totalleaseliabilities', window );">Total lease liabilities</a></td>
<td class="nump">$ 585.1<span></span>
</td>
<td class="nump">$ 583.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Property and equipment, net<span></span>
</td>
<td class="text">Property and equipment, net<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Current portion of long-term debt<span></span>
</td>
<td class="text">Current portion of long-term debt<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Long-term debt, net of current portion<span></span>
</td>
<td class="text">Long-term debt, net of current portion<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Finance lease right-of-use asset accumulated amortization</a></td>
<td class="nump">$ 145.8<span></span>
</td>
<td class="nump">$ 126.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Totalleaseliabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Totalleaseliabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Totaloperatingandfinanceleaseassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Totaloperatingandfinanceleaseassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599121037504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease (in years)</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance lease (in years)</a></td>
<td class="text">11 years 7 months 6 days<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease (in percent)</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance lease (in percent)</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Discount Rate [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Remaining Lease Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111097488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 38.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">40.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">34.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">32.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter', window );">2028 and thereafter</a></td>
<td class="nump">119.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">302.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest portion</a></td>
<td class="num">(77.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">225.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">45.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">47.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter', window );">2028 and thereafter</a></td>
<td class="nump">316.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">551.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest portion</a></td>
<td class="num">(191.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 359.8<span></span>
</td>
<td class="nump">$ 380.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease, due in the sixth fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111138224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 40.5<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">29.7<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">29.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">19.2<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">48.7<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 46.4<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599121156720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">$ 1,237.0<span></span>
</td>
<td class="nump">$ 1,228.2<span></span>
</td>
<td class="nump">$ 1,218.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 1,263.2<span></span>
</td>
<td class="nump">$ 1,237.0<span></span>
</td>
<td class="nump">$ 1,228.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119478256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Textuals (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599115956608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Other Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 621.4<span></span>
</td>
<td class="nump">$ 479.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(339.1)<span></span>
</td>
<td class="num">(321.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">282.3<span></span>
</td>
<td class="nump">158.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember', window );">Certificates of need</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">120.4<span></span>
</td>
<td class="nump">115.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(41.5)<span></span>
</td>
<td class="num">(36.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">78.9<span></span>
</td>
<td class="nump">79.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">65.7<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(54.3)<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember', window );">Noncompete agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">66.2<span></span>
</td>
<td class="nump">65.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(60.2)<span></span>
</td>
<td class="num">(58.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_TradeNameEncompassMember', window );">Trade name - Encompass</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">135.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">135.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(20.8)<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Internal-use Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">183.2<span></span>
</td>
<td class="nump">182.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(150.3)<span></span>
</td>
<td class="num">(142.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">32.9<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember', window );">Market access assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Schedule of Intangible Assets by Major Class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">13.2<span></span>
</td>
<td class="nump">13.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(12.0)<span></span>
</td>
<td class="num">(11.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_TradeNameEncompassMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_TradeNameEncompassMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ehc_MarketAccessAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599124377232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 28.8<span></span>
</td>
<td class="nump">$ 31.2<span></span>
</td>
<td class="nump">$ 32.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599122584240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Schedule of Future Estimated Amortization Expense, Other Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 25.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">11.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599110975344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Long-term Debt Outstanding (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance lease obligations</a></td>
<td class="nump">$ 359.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt and Capital lease obligations</a></td>
<td class="nump">2,767.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,278.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current portion</a></td>
<td class="num">(25.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt, net of current portion</a></td>
<td class="nump">$ 2,741.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,240.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.125% Senior Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 5.75% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 347.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.50% Senior Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 781.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 786.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.75% Senior Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 779.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.625% Senior Notes due 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 390.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Advances under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Advances under revolving credit facility | Line of Credit | The Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Term loan facilities | Line of Credit | The Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Schedule of Outstanding Long-term Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111644848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_FaceAmountMember', window );">Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract', window );"><strong>Long-term Debt by Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne', window );">2023</a></td>
<td class="nump">$ 25.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo', window );">2024</a></td>
<td class="nump">39.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree', window );">2025</a></td>
<td class="nump">381.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour', window );">2026</a></td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive', window );">2027</a></td>
<td class="nump">96.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,247.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total</a></td>
<td class="nump">2,817.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_NetAmountMember', window );">Net Amount</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract', window );"><strong>Long-term Debt by Maturity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne', window );">2023</a></td>
<td class="nump">25.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo', window );">2024</a></td>
<td class="nump">39.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree', window );">2025</a></td>
<td class="nump">379.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour', window );">2026</a></td>
<td class="nump">27.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive', window );">2027</a></td>
<td class="nump">96.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,198.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities', window );">Total</a></td>
<td class="nump">$ 2,767.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt And Lease Obligations, Maturity, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, including portion classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_FaceAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_FaceAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_NetAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_NetAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599100956944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Textual (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 09, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Debt instrument, covenant, leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="nump">4.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome', window );">Percentage of cumulative consolidated net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Payments of distributions to affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 162,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,000,000.0<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="nump">$ 375,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ehc_EnhabitMember', window );">Enhabit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDistributionsToAffiliates', window );">Payments of distributions to affiliates</a></td>
<td class="nump">$ 566,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Debt instrument, covenant, leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket', window );">Debt instrument, reduction in capacity under restricted payments builder basket</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid', window );">Amendment agreement, amount to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 583,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Advances under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatioMaximum', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod', window );">Regulatory and executive action period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum', window );">Senior secured leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays', window );">Incurrence of indebtedness, business days | day</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Amounts outstanding under letter of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,700,000<span></span>
</td>
<td class="nump">$ 38,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Debt instrument, covenant, leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatioMaximum', window );">Leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantAvailableLimitAmount', window );">Available limit amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility, remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Term loan facilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Term loan facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Fed Funds Effective Rate Overnight Index Swap Rate | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | (SOFR) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion', window );">Reduction fee for undrawn portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | (SOFR) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion', window );">Reduction fee for undrawn portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | (SOFR) | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Advances under revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Applicable interest rate under credit facility (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Advances under revolving credit facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Advances under revolving credit facility | (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion', window );">Reduction fee for undrawn portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember', window );">The Credit Agreement | Term loan facilities | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayments of secured debt</a></td>
<td class="nump">$ 236,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 238,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 99,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Debt redeemed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member', window );">Senior Notes; 05.75%; Due 2024 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member', window );">5.75% Senior Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,700,000<span></span>
</td>
<td class="nump">$ 347,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member', window );">4.50% Senior Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 781,800,000<span></span>
</td>
<td class="nump">$ 786,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue', window );">Issuance of face value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member', window );">4.75% Senior Notes due 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 779,000,000.0<span></span>
</td>
<td class="nump">$ 784,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue', window );">Issuance of face value (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member', window );">4.625% Senior Notes due 2031 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390,600,000<span></span>
</td>
<td class="nump">$ 393,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentAmendmentAgreementAmountToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amendment Agreement, Amount To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentAmendmentAgreementAmountToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantAvailableLimitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Available Limit Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantAvailableLimitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Incurrence Of Indebtedness, Business Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Max senior secured leverage ratio to permit restricted payments under credit agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Reduction Fee For Undrawn Portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Regulatory And Executive Action, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Senior Secured Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Discount Rate at Issuance of Face Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Covenant, Percentage of Cumulative Consolidated Net Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDistributionsToAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDistributionsToAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ehc_EnhabitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ehc_EnhabitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TheCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ehc_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ehc_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes0575Due2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119476000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Financial Covenants (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantInterestCoverageRatio', window );">Interest Coverage Ratio</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">3.00<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="nump">4.25<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">6.00<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="nump">6.50<span></span>
</td>
<td class="nump">5.50<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DebtInstrumentCovenantLeverageRatio', window );">Leverage Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50<span></span>
</td>
<td class="nump">4.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantInterestCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantInterestCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DebtInstrumentCovenantLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DebtInstrumentCovenantLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116467072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Senior Notes Redemption Prices (Details) - Senior Notes<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">5.75% Senior Notes due 2025 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.958%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">5.75% Senior Notes due 2025 | Debt Instrument, Redemption, Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.50% Senior Notes due 2028 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.50% Senior Notes due 2028 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.50% Senior Notes due 2028 | Debt Instrument, Redemption, Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.75% Senior Notes due 2030 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.75% Senior Notes due 2030 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.583%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.75% Senior Notes due 2030 | Debt Instrument, Redemption, Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.75% Senior Notes due 2030 | Debt Instrument, Redemption, Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.625% Senior Notes due 2031 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="nump">102.313%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.625% Senior Notes due 2031 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="nump">101.542%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.625% Senior Notes due 2031 | Debt Instrument, Redemption, Period Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="nump">100.771%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">4.625% Senior Notes due 2031 | Debt Instrument, Redemption, Period Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionLineItems', window );"><strong>Debt Instrument, Redemption [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111529344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Schedule of Notes Payable (Details) - Other notes payable - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">$ 53.1<span></span>
</td>
<td class="nump">$ 47.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Sale/leaseback transactions involving real estate accounted for as financings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Sale/leaseback transactions involving real estate accounted for as financings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Sale/leaseback transactions involving real estate accounted for as financings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">11.20%<span></span>
</td>
<td class="nump">11.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Construction of a new hospital | (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">$ 20.7<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Construction of a new hospital | Minimum | (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Construction of a new hospital | Maximum | (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Software contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Software contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate (percent)</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_NotesPayableRealEstateSaleLeasebackFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_NotesPayableRealEstateSaleLeasebackFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ehc_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ehc_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_NotesPayableSoftwareContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_NotesPayableSoftwareContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599115505552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Self-Insured Risks - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk', window );">Self-insured amount</a></td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveCurrent', window );">Self-insurance reserves included in Other current liabilities</a></td>
<td class="nump">$ 46.6<span></span>
</td>
<td class="nump">$ 45.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves', window );">Number of individual claims covered by reserves | claim</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_MaximumSelfInsuredAmountFirstLayerOfRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Self Insured Amount, First Layer of Risk</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_MaximumSelfInsuredAmountFirstLayerOfRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of individual claims covered by the Company's self-insured risk reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599110713696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Self-Insured Risks - Changes in Self-insurance Reserves (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance at beginning of period, gross</a></td>
<td class="nump">$ 169.4<span></span>
</td>
<td class="nump">$ 165.2<span></span>
</td>
<td class="nump">$ 157.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Less: Reinsurance receivables</a></td>
<td class="num">(30.0)<span></span>
</td>
<td class="num">(28.3)<span></span>
</td>
<td class="num">(26.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Balance at beginning of period, net</a></td>
<td class="nump">139.4<span></span>
</td>
<td class="nump">136.9<span></span>
</td>
<td class="nump">130.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Increase for the provision of current year claims</a></td>
<td class="nump">50.5<span></span>
</td>
<td class="nump">46.9<span></span>
</td>
<td class="nump">52.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Decrease for the provision of prior year claims</a></td>
<td class="num">(8.2)<span></span>
</td>
<td class="num">(6.8)<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations', window );">Expenses related to discontinued operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Payments related to current year claims</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="num">(8.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Payments related to prior year claims</a></td>
<td class="num">(31.8)<span></span>
</td>
<td class="num">(30.4)<span></span>
</td>
<td class="num">(22.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet', window );">Balance at end of period, net</a></td>
<td class="nump">142.8<span></span>
</td>
<td class="nump">139.4<span></span>
</td>
<td class="nump">136.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Add: Reinsurance receivables</a></td>
<td class="nump">32.3<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">28.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance at end of period, gross</a></td>
<td class="nump">$ 175.1<span></span>
</td>
<td class="nump">$ 169.4<span></span>
</td>
<td class="nump">$ 165.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116266880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract', window );"><strong>Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(99.5)<span></span>
</td>
<td class="num">(87.8)<span></span>
</td>
<td class="num">(72.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">35.6<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember', window );">Redeemable Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract', window );"><strong>Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract] [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at beginning of period</a></td>
<td class="nump">42.2<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">239.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions declared</a></td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_Contributiontojointventure', window );">Contribution to joint ventures</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NoncontrollingInterestExchangeTransaction', window );">Exchange transaction</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(46.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestChangeInRedemptionValue', window );">Change in fair value</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NoncontrollingInterestOtherAdjustment', window );">Other</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NoncontrollingInterestSpinOff', window );">Spin off of Enhabit, Inc.</a></td>
<td class="num">(5.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Balance at end of period</a></td>
<td class="nump">$ 35.6<span></span>
</td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="nump">$ 31.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_Contributiontojointventure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contribution of primarily intangible assets relating to a joint venture agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_Contributiontojointventure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestExchangeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Exchange Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestExchangeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestOtherAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Other Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestOtherAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestSpinOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Spin Off</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestSpinOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestChangeInRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 16(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestChangeInRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ehc_RedeemableNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599121292848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest', window );">Net income attributable to nonredeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.7<span></span>
</td>
<td class="nump">$ 96.0<span></span>
</td>
<td class="nump">$ 77.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net income attributable to redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="nump">$ 28.1<span></span>
</td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="nump">$ 22.6<span></span>
</td>
<td class="nump">$ 24.1<span></span>
</td>
<td class="nump">$ 26.7<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">$ 25.5<span></span>
</td>
<td class="nump">$ 94.9<span></span>
</td>
<td class="nump">$ 105.0<span></span>
</td>
<td class="nump">$ 84.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of net income (loss) attributable to nonredeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599115159632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Noncontrolling Interests - Textual (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 18, 2020 </div>
<div>USD ($) </div>
<div>investor</div>
</th>
<th class="th">
<div>Feb. 21, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 06, 2020</div></th>
<th class="th">
<div>Feb. 20, 2020 </div>
<div>investor </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.6<span></span>
</td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NoncontrollingInterestExerciseRightToSellRatio', window );">Exercise, right to sell, ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent', window );">Purchase of redeemable noncontrolling interests, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Payments to settle the acquisition of Holdings common stock</a></td>
<td class="nump">$ 162.0<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 163.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_NumberOfManagementInvestorsOutstanding', window );">Number of management investors remaining outstanding | investor</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Delivering EHC shares to management investors (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages', window );">Shares to issued to the management investors pursuant to the exchange agreements represents (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember', window );">EHHI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue', window );">Value of outstanding shares of Holdings</a></td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember', window );">Home Health and Hospice Segment | EHHI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent', window );">Redeemable noncontrolling interest, equity, acquired percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent', window );">Subsidiary's common stock held by subsidiary 's management, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestExerciseRightToSellRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Exercise, Right To Sell, Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestExerciseRightToSellRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_NumberOfManagementInvestorsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Management Investors Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_NumberOfManagementInvestorsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redeemable Noncontrolling Interest, Equity, Acquired Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of subsidiary's common stock held by subsidiary 's management, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares to Management Investors Exchange Agreements Percentages</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of noncontrolling interests which are redeemable by the parent entity and classified as other equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ehc_EHHIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ehc_HomeHealthandHospiceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116266176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 110.0<span></span>
</td>
<td class="nump">$ 82.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">35.6<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities, FV-NI</a></td>
<td class="nump">30.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Other Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Equity securities, FV-NI</a></td>
<td class="nump">79.1<span></span>
</td>
<td class="nump">82.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">106.3<span></span>
</td>
<td class="nump">78.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue', window );">Redeemable noncontrolling interests</a></td>
<td class="nump">$ 35.6<span></span>
</td>
<td class="nump">$ 42.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599114963200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 53.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value | Other notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Advances under revolving credit facility | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Advances under revolving credit facility | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">32.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember', window );">Term loan facilities | Carrying Amount | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember', window );">Term loan facilities | Estimated Fair Value | Term loan facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Carrying Amount | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member', window );">5.125% Senior Notes due 2023 | Estimated Fair Value | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member', window );">5.75% Senior Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member', window );">5.75% Senior Notes due 2025 | Carrying Amount | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 347.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member', window );">5.75% Senior Notes due 2025 | Estimated Fair Value | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 347.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member', window );">4.50% Senior Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member', window );">4.50% Senior Notes due 2028 | Carrying Amount | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 781.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 786.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member', window );">4.50% Senior Notes due 2028 | Estimated Fair Value | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 726.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 823.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member', window );">4.75% Senior Notes due 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member', window );">4.75% Senior Notes due 2030 | Carrying Amount | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 779.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 784.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member', window );">4.75% Senior Notes due 2030 | Estimated Fair Value | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 703.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 824.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member', window );">4.625% Senior Notes due 2031 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument interest rate (percent)</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member', window );">4.625% Senior Notes due 2031 | Carrying Amount | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 390.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 393.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member', window );">4.625% Senior Notes due 2031 | Estimated Fair Value | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Carrying amounts and estimated fair values of financial instruments</a></td>
<td class="nump">$ 342.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 407.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_TermLoanFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.125Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes05.75Due2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes4.50Due2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04.750Due2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ehc_SeniorNotes04625Due2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599115211136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share (in dollars per share)</a></td>
<td class="nump">$ 17.29<span></span>
</td>
<td class="nump">$ 19.21<span></span>
</td>
<td class="nump">$ 15.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period for unrecognized compensation cost</a></td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 26,400,000<span></span>
</td>
<td class="nump">$ 24,900,000<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average recognition period for unrecognized compensation cost</a></td>
<td class="text">20 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share of awards granted (in dollars per share)</a></td>
<td class="nump">$ 74.08<span></span>
</td>
<td class="nump">$ 73.89<span></span>
</td>
<td class="nump">$ 61.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to unvested restricted stock</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested shares</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 32,600,000<span></span>
</td>
<td class="nump">$ 41,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards issued during period (in shares)</a></td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Non-employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value per share of awards granted (in dollars per share)</a></td>
<td class="nump">$ 67.42<span></span>
</td>
<td class="nump">$ 84.83<span></span>
</td>
<td class="nump">$ 65.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards issued during period (in shares)</a></td>
<td class="nump">22,469<span></span>
</td>
<td class="nump">24,043<span></span>
</td>
<td class="nump">32,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Compensation expense</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of remaining shares (in shares)</a></td>
<td class="nump">775,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Current And Former Board Of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards issued during period (in shares)</a></td>
<td class="nump">130,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ehc_DividendEquivalentRSUMember', window );">Dividend Equivalent, RSU | Non-employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards issued during period (in shares)</a></td>
<td class="nump">11,976<span></span>
</td>
<td class="nump">8,577<span></span>
</td>
<td class="nump">8,987<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ehc_A2016OmnibusPerformanceIncentivePlanMember', window );">2016 Omnibus Performance Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for grant under the Plan (in shares)</a></td>
<td class="nump">16,860,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="nump">$ 29,100,000<span></span>
</td>
<td class="nump">$ 25,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ehc_NonemployeeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ehc_NonemployeeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ehc_CurrentAndFormerBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ehc_CurrentAndFormerBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ehc_DividendEquivalentRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ehc_DividendEquivalentRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ehc_A2016OmnibusPerformanceIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ehc_A2016OmnibusPerformanceIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119714672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Weighted-average Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility (percent)</a></td>
<td class="nump">28.30%<span></span>
</td>
<td class="nump">28.40%<span></span>
</td>
<td class="nump">24.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (percent)</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (percent)</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599110941728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Stock Option Activity (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning (in shares) | shares</a></td>
<td class="nump">711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod', window );">Enhabit spin-off adjustment (in shares) | shares</a></td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending (in shares) | shares</a></td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, December 31, 2021 (in shares) | shares</a></td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 54.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">66.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">20.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice', window );">Enhabit spin-off adjustment (in dollars per share) | $ / shares</a></td>
<td class="nump">51.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">47.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, December 31, 2021 (in USD per share) | $ / shares</a></td>
<td class="nump">$ 42.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Life (Years), Outstanding</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Life (Years), Exercisable</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599119316832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Summary of Restricted Stock Awards (Details) - Restricted Stock - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested shares, Beginning Balance (in shares)</a></td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(31)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod', window );">Enhabit spin-off adjustment (in shares)</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested shares, Ending Balance (in shares)</a></td>
<td class="nump">526<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested shares, Beginning Balance (in dollar per share)</a></td>
<td class="nump">$ 74.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollar per share)</a></td>
<td class="nump">74.08<span></span>
</td>
<td class="nump">$ 73.89<span></span>
</td>
<td class="nump">$ 61.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollar per share)</a></td>
<td class="nump">70.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollar per share)</a></td>
<td class="nump">71.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue', window );">Enhabit spin-off adjustment (in dollar per share)</a></td>
<td class="nump">62.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested shares, Ending Balance (in dollar per share)</a></td>
<td class="nump">$ 63.35<span></span>
</td>
<td class="nump">$ 74.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111603056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>yr</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_HealthcarePlanExpense', window );">Company healthcare plan costs, net of employee payments</a></td>
<td class="nump">$ 174.5<span></span>
</td>
<td class="nump">$ 166.0<span></span>
</td>
<td class="nump">$ 145.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">28.7<span></span>
</td>
<td class="nump">26.4<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount', window );">Employer contributions funded by forfeited accounts</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_SeniorManagementBonusProgramTotalCosts', window );">Payments under the Senior Management Bonus Program</a></td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="nump">$ 23.4<span></span>
</td>
<td class="nump">$ 14.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=ehc_EncompassHealthRetirementInvestmentPlanMember', window );">Encompass Health Retirement Investment Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Contribution as percentage of salary allowed under the Plan (percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanAgeRequirement', window );">Age requirement to participate in the Plan | yr</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution', window );">Vesting percentage in employer contributions (percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage', window );">Vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_HealthcarePlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs for the period associated with the Company's sponsored self-insured healthcare plans that include coverage for medical and dental benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_HealthcarePlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RetirementInvestmentPlanAgeRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum age required for an employee to be eligible to participate in the Company's Retirement Investment Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RetirementInvestmentPlanAgeRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total percentage of the Company's matching contributions that will vest in the Retirement Investment Plan after an employee service requirement has been met.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time over which the Company's contributions to a participant's retirement account fully vests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_SeniorManagementBonusProgramTotalCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of payments made or expected to be made during a reporting period to participants that are entitled under the Senior Management Bonus Program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_SeniorManagementBonusProgramTotalCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=ehc_EncompassHealthRetirementInvestmentPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=ehc_EncompassHealthRetirementInvestmentPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599110846224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Provision for Income Tax Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.7<span></span>
</td>
<td class="nump">$ 63.7<span></span>
</td>
<td class="nump">$ 29.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">20.8<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.2<span></span>
</td>
<td class="nump">84.5<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.9<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">34.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense related to continuing operations</a></td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="nump">$ 22.8<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="nump">$ 26.2<span></span>
</td>
<td class="nump">$ 28.2<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">$ 100.1<span></span>
</td>
<td class="nump">$ 101.9<span></span>
</td>
<td class="nump">$ 74.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111268080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax expense at statutory rate (percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Increase (decrease) in tax rate resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and other income taxes, net of federal tax benefit (percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">(Increase) decrease in valuation allowance (percent)</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense', window );">Noncontrolling interests (percent)</a></td>
<td class="num">(4.40%)<span></span>
</td>
<td class="num">(4.30%)<span></span>
</td>
<td class="num">(4.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent', window );">Share-based windfall tax benefits (percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, net (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense (percent)</a></td>
<td class="nump">22.20%<span></span>
</td>
<td class="nump">20.20%<span></span>
</td>
<td class="nump">21.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599122234528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Asset and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 36.9<span></span>
</td>
<td class="nump">$ 50.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance', window );">Insurance reserve</a></td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DeferredTaxAssetsOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Other accruals</a></td>
<td class="nump">24.8<span></span>
</td>
<td class="nump">23.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">115.9<span></span>
</td>
<td class="nump">123.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(35.8)<span></span>
</td>
<td class="num">(43.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">80.1<span></span>
</td>
<td class="nump">80.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome', window );">Revenue reserves</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangibles</a></td>
<td class="num">(61.2)<span></span>
</td>
<td class="num">(30.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, net</a></td>
<td class="num">(15.9)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Carrying value of partnerships</a></td>
<td class="num">(80.2)<span></span>
</td>
<td class="num">(66.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(163.1)<span></span>
</td>
<td class="num">(103.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax liabilities</a></td>
<td class="num">$ (83.0)<span></span>
</td>
<td class="num">$ (23.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ehc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599122311056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Textual (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Changes to valuation allowance during the period</a></td>
<td class="num">$ (7.3)<span></span>
</td>
<td class="num">$ (3.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Remaining valuation allowance</a></td>
<td class="nump">35.8<span></span>
</td>
<td class="nump">$ 43.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceLineItems', window );"><strong>Valuation Allowance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599115307360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 119.0<span></span>
</td>
<td class="nump">$ 85.5<span></span>
</td>
<td class="nump">$ 59.8<span></span>
</td>
<td class="nump">$ 86.4<span></span>
</td>
<td class="nump">$ 92.2<span></span>
</td>
<td class="nump">$ 102.1<span></span>
</td>
<td class="nump">$ 107.0<span></span>
</td>
<td class="nump">$ 101.8<span></span>
</td>
<td class="nump">$ 350.7<span></span>
</td>
<td class="nump">$ 403.1<span></span>
</td>
<td class="nump">$ 278.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests included in continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93.6)<span></span>
</td>
<td class="num">(103.2)<span></span>
</td>
<td class="num">(83.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Less: Income from continuing operations allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Income from continuing operations attributable to Encompass Health common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256.0<span></span>
</td>
<td class="nump">298.8<span></span>
</td>
<td class="nump">194.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (18.5)<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="nump">$ 31.0<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">114.1<span></span>
</td>
<td class="nump">90.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests included in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic', window );">Less: Income from discontinued operations allocated to participating securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic', window );">Income from discontinued operations attributable to Encompass Health common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">111.6<span></span>
</td>
<td class="nump">88.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Encompass Health common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 269.8<span></span>
</td>
<td class="nump">$ 410.4<span></span>
</td>
<td class="nump">$ 283.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.2<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="num">(0.02)<span></span>
</td>
<td class="num">(0.19)<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
<td class="nump">0.31<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
<td class="nump">0.90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="nump">$ 0.88<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="nump">$ 1.08<span></span>
</td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 119.0<span></span>
</td>
<td class="nump">$ 85.5<span></span>
</td>
<td class="nump">$ 59.8<span></span>
</td>
<td class="nump">$ 86.4<span></span>
</td>
<td class="nump">$ 92.2<span></span>
</td>
<td class="nump">$ 102.1<span></span>
</td>
<td class="nump">$ 107.0<span></span>
</td>
<td class="nump">$ 101.8<span></span>
</td>
<td class="nump">$ 350.7<span></span>
</td>
<td class="nump">$ 403.1<span></span>
</td>
<td class="nump">$ 278.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests included in continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.6<span></span>
</td>
<td class="nump">103.2<span></span>
</td>
<td class="nump">83.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted', window );">Income from continuing operations attributable to Encompass Health common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257.1<span></span>
</td>
<td class="nump">299.9<span></span>
</td>
<td class="nump">194.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="num">$ (1.5)<span></span>
</td>
<td class="num">$ (18.5)<span></span>
</td>
<td class="nump">$ 11.5<span></span>
</td>
<td class="nump">$ 23.7<span></span>
</td>
<td class="nump">$ 23.5<span></span>
</td>
<td class="nump">$ 24.6<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="nump">$ 31.0<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">114.1<span></span>
</td>
<td class="nump">90.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests included in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted', window );">Income from discontinued operations attributable to Encompass Health common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">89.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Encompass Health common shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271.0<span></span>
</td>
<td class="nump">$ 412.2<span></span>
</td>
<td class="nump">$ 284.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.4<span></span>
</td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">99.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.90<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(0.18)<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="nump">0.31<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">1.12<span></span>
</td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from discontinued operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) from discontinued operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 65<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2793-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 66<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2814-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599120926368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding (in shares)</a></td>
<td class="nump">99.2<span></span>
</td>
<td class="nump">99.0<span></span>
</td>
<td class="nump">98.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Restricted stock awards, dilutive stock options, and restricted stock units (in shares)</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">100.4<span></span>
</td>
<td class="nump">100.2<span></span>
</td>
<td class="nump">99.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599116351232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share - Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jul. 24, 2018</div></th>
<th class="th"><div>Feb. 01, 2014</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from computation of diluted weighted-average shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock repurchase authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Common stock repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid per common share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid per common share (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111714944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contingencies and Other Commitments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 29.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">2024</a></td>
<td class="nump">21.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">2025</a></td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthYear', window );">2026</a></td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFifthYear', window );">2027</a></td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">$ 9.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140599111596304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Data (Unaudited) - Schedule of Quarterly Data (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialDataAbstract', window );"><strong>Quarterly Financial Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net operating revenues</a></td>
<td class="nump">$ 1,137.3<span></span>
</td>
<td class="nump">$ 1,089.5<span></span>
</td>
<td class="nump">$ 1,062.5<span></span>
</td>
<td class="nump">$ 1,059.3<span></span>
</td>
<td class="nump">$ 1,042.5<span></span>
</td>
<td class="nump">$ 1,010.8<span></span>
</td>
<td class="nump">$ 1,001.7<span></span>
</td>
<td class="nump">$ 959.9<span></span>
</td>
<td class="nump">$ 4,348.6<span></span>
</td>
<td class="nump">$ 4,014.9<span></span>
</td>
<td class="nump">$ 3,566.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings</a></td>
<td class="nump">151.9<span></span>
</td>
<td class="nump">127.5<span></span>
</td>
<td class="nump">128.6<span></span>
</td>
<td class="nump">131.5<span></span>
</td>
<td class="nump">128.4<span></span>
</td>
<td class="nump">141.4<span></span>
</td>
<td class="nump">146.8<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
<td class="nump">539.5<span></span>
</td>
<td class="nump">559.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax expense</a></td>
<td class="nump">31.9<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="nump">22.8<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">22.5<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">28.2<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">100.1<span></span>
</td>
<td class="nump">101.9<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">119.0<span></span>
</td>
<td class="nump">85.5<span></span>
</td>
<td class="nump">59.8<span></span>
</td>
<td class="nump">86.4<span></span>
</td>
<td class="nump">92.2<span></span>
</td>
<td class="nump">102.1<span></span>
</td>
<td class="nump">107.0<span></span>
</td>
<td class="nump">101.8<span></span>
</td>
<td class="nump">350.7<span></span>
</td>
<td class="nump">403.1<span></span>
</td>
<td class="nump">278.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">(Loss) income from discontinued operations, net of tax</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="num">(18.5)<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">23.7<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">31.0<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
<td class="nump">114.1<span></span>
</td>
<td class="nump">90.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net and comprehensive income</a></td>
<td class="nump">117.5<span></span>
</td>
<td class="nump">67.0<span></span>
</td>
<td class="nump">71.3<span></span>
</td>
<td class="nump">110.1<span></span>
</td>
<td class="nump">115.7<span></span>
</td>
<td class="nump">126.7<span></span>
</td>
<td class="nump">142.0<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
<td class="nump">365.9<span></span>
</td>
<td class="nump">517.2<span></span>
</td>
<td class="nump">368.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net and comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(28.1)<span></span>
</td>
<td class="num">(21.6)<span></span>
</td>
<td class="num">(22.6)<span></span>
</td>
<td class="num">(22.6)<span></span>
</td>
<td class="num">(24.1)<span></span>
</td>
<td class="num">(26.7)<span></span>
</td>
<td class="num">(28.7)<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
<td class="num">(94.9)<span></span>
</td>
<td class="num">(105.0)<span></span>
</td>
<td class="num">(84.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net and comprehensive income attributable to Encompass Health</a></td>
<td class="nump">$ 89.4<span></span>
</td>
<td class="nump">$ 45.4<span></span>
</td>
<td class="nump">$ 48.7<span></span>
</td>
<td class="nump">$ 87.5<span></span>
</td>
<td class="nump">$ 91.6<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 113.3<span></span>
</td>
<td class="nump">$ 107.3<span></span>
</td>
<td class="nump">$ 271.0<span></span>
</td>
<td class="nump">$ 412.2<span></span>
</td>
<td class="nump">$ 284.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic earnings per share attributable to Encompass Health common shareholders: (b)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.76<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="num">(0.02)<span></span>
</td>
<td class="num">(0.19)<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
<td class="nump">0.31<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">1.13<span></span>
</td>
<td class="nump">0.90<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (in dollars per share)</a></td>
<td class="nump">0.89<span></span>
</td>
<td class="nump">0.45<span></span>
</td>
<td class="nump">0.49<span></span>
</td>
<td class="nump">0.88<span></span>
</td>
<td class="nump">0.92<span></span>
</td>
<td class="nump">1.00<span></span>
</td>
<td class="nump">1.14<span></span>
</td>
<td class="nump">1.08<span></span>
</td>
<td class="nump">2.72<span></span>
</td>
<td class="nump">4.15<span></span>
</td>
<td class="nump">2.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted earnings per share attributable to Encompass Health common shareholders: (b)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="nump">0.90<span></span>
</td>
<td class="nump">0.63<span></span>
</td>
<td class="nump">0.38<span></span>
</td>
<td class="nump">0.64<span></span>
</td>
<td class="nump">0.68<span></span>
</td>
<td class="nump">0.76<span></span>
</td>
<td class="nump">0.79<span></span>
</td>
<td class="nump">0.76<span></span>
</td>
<td class="nump">2.56<span></span>
</td>
<td class="nump">2.99<span></span>
</td>
<td class="nump">1.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="num">(0.01)<span></span>
</td>
<td class="num">(0.18)<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
<td class="nump">0.24<span></span>
</td>
<td class="nump">0.34<span></span>
</td>
<td class="nump">0.31<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">1.12<span></span>
</td>
<td class="nump">0.89<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (in dollars per share)</a></td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="nump">$ 0.91<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.07<span></span>
</td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="nump">$ 4.11<span></span>
</td>
<td class="nump">$ 2.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialDataAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialDataAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>ehc-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ehc="http://www.encompasshealth.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ehc-20221231.xsd" xlink:type="simple"/>
    <context id="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7cc06ca4859f40608cdefd3c35ca2b7b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icf6db76417944ea78fd769dcf53d24ba_I20230213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2023-02-13</instant>
        </period>
    </context>
    <context id="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7012cb8cd6b7476f9630c73b12ab4420_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a64fb1653e8439cadb431d448933fbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1efefea033d94a49ae6d1279523cfa77_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if7d8604073db4dfc9364cee592afa6f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9242279c10684829b4d9378d04b1edbd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id90643ddde5c45f98d52e4b3afea3306_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id0bcbb07d6f643b2b8e55385fae57545_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifa1631b09af5498898a4f9704b654317_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2adf3229d1fb4d439bf8228ce1a554d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6826376042e0432c876faeb386c0d683_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac851ca1adc4483f827335b0959d3fb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie195f01f18994a1dbbf00c9ea5162424_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i568f78237ee640189be8f0569e1325aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia4612a858a134e488b568b7bc4f5b31b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9817c02d1254788bdfed4e092d4d240_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17814712636d499cbd8aa753ae7fd05e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie89258633f59441580a344774a089493_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib906731d97114d82addea69f1bb3d93f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad71d7ff6aa0428593dfb57b61019e26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib5df19105bbb4e44ad638452c82235f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2040827da13c48fb8523dcbbee23864e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8e12dea591344c0b2b9c9f457b71126_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if1b3eb121a4a4b25a2563b523c8cbe4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e6aa83bba40405785127e8ed8bb4d92_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie516d8d2297a44c8928335358a6b74e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b288a1bbc1e4a36a83f2bca14dee1ea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia0f7c8b4463341a0a371e690773b666a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if44a6728f6fa4025b928881a0e39236d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic212fffe4100400087e39b038b342ab0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbba5e1af20d45838cbb3098d5f3d99b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ied260f5cc55446ac98da4ff1069c95fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffd361313d6f4ca589272589af035b20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic39924c6425243f7a6b73371e0e4481e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9f4a444a849477298194909155a4a2e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1e1655a7659d44a5848ce4031db00715_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3909299e17d4e9f96039b48644e435f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i434a61101a024049985e7041374c1bad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c9d5eba60544d49a2a58e9b24ce961c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice387dc1f36b45818af7e9c1a280c084_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i08a52ec290e7476db602a525bdf83e5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3840cc62129543f286c32d03fc7cf594_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareAdvantageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib537455ec5074b27bc814bd625721be3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd562e2b20ab46e9a82490a8cca0f618_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i630c01ac29fa4ca1b4254e8c177f88ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee6d97175b5645daab81c40993423b85_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida31c9eb47794f719d9ff1564ca9f77f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc59f2f9d2c34e778b82df851653ec07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c60193a93c54ef0a8b26ce2749c4573_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34ebf32157a548a689b81b59e52d7061_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i00dcced69aa245dd932b997347d492c6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ica31326e89794cf4a262a71ea82be401_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e2eb0b8b29c4c10b2c019f78880ab94_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65daa5d21414406d9a73be137948b909_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8611bd0ee7e5407987c11b03aa8312b6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i46ecd39de0ee482b9b66faa630bdf25b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i578490c7d6584a1ba41aa384335fae6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i05243f3cbac341b8a9bec5a4f2859f00_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic22a983720214ed4a192fcba2d07abcc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e0f753c8be14e67b8509c7dd73fd6bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherIncomeSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i852b75f329ea4ac08df2108afdf43e72_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:DepartmentAppealsBoardAdverseRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:UnifiedProgramIntegrityContractorsAuditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ic18e0c6dae034e2e9081f26733964490_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:UnifiedProgramIntegrityContractorsAuditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i461326ed8069459c9262b7d8a144ce07_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:UnifiedProgramIntegrityContractorsAuditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i870361686c2942fdb9b4a9bc9337f323_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:UnifiedProgramIntegrityContractorsAuditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb58224ff71f435f975b30807048a7fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ehc:RACAuditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie9749632394145f497fe0c2c6ec147a7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe35a06f0eae46efb5c6921fe9db414c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7b648e892f9f4468aab25a90a2f09b05_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMedicareAdvantageandOtherDiscountPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec6a14cc3aca48bcaeca480b39030876_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:ManagedCareMedicareAdvantageandOtherDiscountPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a03052d15b64c25a269fdcc4216b88c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibefecfaeeeb041849960421b13ca007b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c4d794905dd4fb385b71c4eed009bb7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i52751714abc34c4d98dc47a7a77e2370_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:OtherThirdpartyPayorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4e50571d65784dfc9aef9033d5f99181_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib3c18279fe4d4018bbe852e7b57b1d47_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:WorkersCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ab836dfffa54e4b814fbfc5b759b918_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i66c304bf2ec048b88bf47a3f2c6c5a54_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ehc:PatientsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib014de72370b4cb4a6135adc8af20d7b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc2b37264d734f2d8f5833e77968d634_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ehc:PayorSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4cb56d21aab74ac3967968f076197961_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idfd7ae0589ea4a128b3e3e4861478b00_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5139d245eba04e15a063f9bc48d18aa7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib932dccdf96b459687584cc4f8701479_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1e69d3358704dd18df22349448291f5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i176405163b9c4c37878dcef0b9e741ce_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b43ec38059149d4ba26be2569eb2a25_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1d16d99320d0432eae3d9ff01729bc03_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic54237316ac9413084b19847adf7f2fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i59a65005892243e682dc792c081f8c0a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibb79ea3f749d47ffbe3c65d094ac96bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i436bf0be46974157827b0ca4b6e81e07_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9d936af5f8ec4ce8a15339c7e5b4fa6c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i171d0e9f00ac4274a1c1fb90c3567010_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd848d2dde614489a20f1870d96a944a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib57c2c4651af459192fda104b5d0dd00_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i470cf08a07fe4287a486a76f384d82ad_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:InternalUseSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icf944ca96a324447a5fead2b5afb9747_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i81822404b04248c2bc2b92116b265222_I20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-01</instant>
        </period>
    </context>
    <context id="i4ccb23d1174a4ad1bc94116310a93215_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ee3194559484035acac2abce51ef2bb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ce31a740de9494abb75658e9c4e37c7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ehc:EnhabitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie558e5b6f68546dba75679d76bd06892_D20220701-20220701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:EnhabitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="ifdef059442d4436a8c8670f4a3fc85d0_D20220701-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie37abe5ebc4f44bebbe9fb494c9c84e1_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i9991693278fc408e862976490cf30d98_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:TrinityMedicalCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i6820aa09cd604de1a90b41670cea5ea8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:NCHHealthcareSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8ff2033f1b3942129102202260af6a35_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia21684f87fae47c5b3a34319790c0769_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0d9fe27b422459b8eca401afa6fe33c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if1b030fcfd4e4d31a741e7594dc965c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33b5d49a11d841d0962f2c16a1a90833_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i56015630b11b4e009f45b95de40f5a16_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i926c10b50d5b4dc4952bd8f73e5caf2c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:HeritageValleyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i42d3a03ae9fb49d2a3c3300daff8071b_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ia3876cf645ac4e17bb330ae838f085f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icd3a3de37fca442dbd0a5e70526dbf46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id86e386a397b49d296ca11e4a511d544_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1bea87602e1641b0b71e094855c78088_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i75e5544167514a92ae6527fb86b9e780_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b6bdb8e550a4806bb3e1dadfd5e0505_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ae11dbadeb749178d2cc18aceb997a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida60f9410ec942ffa8b96644e1a4982e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2021AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9d13dc5dde24449a63972bfe6bc1df8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2021AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1070117531644374b85aaa3af7d800d0_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ib6bc012b46224f569423ad84a5eac16f_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i4ddfcda5811941ceb891a6ef3548c7c3_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i63b458d6463a4a96b479e42c0fcc71c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if50b14c350354038b6604d1681524651_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1ccbd7406a9458abb7cfc12e90ad1e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8af9ecf91da248c5be27bca52229721d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e3f8c860f1b432e95cc26067ef20e2a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i684d2533374c48a4bd1364edabf0ba08_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:PortercareAdventistAndPremierHealthPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9234554fdff644f89fd47fb7f88d0659_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:A2020AcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39884fa7a48547f2a08edcccd93487c8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i68baf71a31bd473ba1a1ca647e0b19e2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id743d8949a7a47b99d38df3ba1e3e993_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic427d90f8e7c42bdb0850c9210abaeb6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i21818c725feb4e82b4d76043fbe5fddb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie62ccf4631834eb8806f370a09ba24d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62d8fb91a17448548b52ddaca926ac5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53b96835762340179de2e6054fcf6ad0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:AffiliateCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0338b3236b51417cbf66790b47b14be5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:AffiliateCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff8b121e96a3441d8cc4887b3971a2ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:SelfInsuredCaptiveFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c5ab8a31d8f4c83a1cc36ca852adfa9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:SelfInsuredCaptiveFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2117424317ae4b25824cbe7ca5a8bbe6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:OtherFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifa1fdbdb992e4caeb499c51df7168238_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ehc:OtherFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i62625eab8b0d4335a31e9e15249ae70e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i34843327cab94b9c8261df7a6ac9bacc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5d56907f4eb4436af6dad648f56ce6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifb76d50e6f0a4405bff0b4e4b612e7d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81b3fd57dd2042f68ac013078eaf240a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13acf526358049fdb887e645c419f111_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6c1d864105a4f598505f09fa76bc1be_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4f1644f1897949bb82fd5674d6ae3282_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie60dcfb7b1544c66a69974be0bca5376_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d230a026be94efb95ef13566c7b7b0a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5b54adc201247bb9fb60bdf36fff8a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ehc:LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief3ef49cda4a4f22a1347489d45480e0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ehc:LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i07de7edf6557444789afb4418d5e6c0d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4e52d9e713e4adea7cfd891c3ecaeec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i24d1851ef607402d900d6d9f19371197_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i802dc5eb74bb429e8814073a20bf7f9b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i177f96156a934c6d92f90d026d815168_D20221001-20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="i8a2086e6351b40948b88fd941ae8faae_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i104ce402feb14e3c9c5682306cabdd39_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i97d33a74e74847b680d36c4c8aa5735e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie8e84e7ad92e46d1833a208bce11c4b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie577c85705764e9287e7a571a526dd5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief8c2650479a4933998c56d70426ad5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d992d3261104e3a8eb38871bc693f4e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ffe900a66ea42e5864253cf987a4119_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0c0ea0e574949d8b18d28a5e6d26be3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:TradeNameEncompassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i59d0cf8338b44b91948c16fbb5260dc9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:TradeNameEncompassMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i246e3aa9111b46d18007fd9747ba80fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0887e89510aa430c98ba297311ec7c02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i675d9700b9a44be5a34cdbf2e3579982_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8d897ae5c3574e308dff0216d9b948c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id7cf3b85aded4187ab1295a58ade6e45_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2bf83682496c480f9e42d6fee1080450_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ehc:MarketAccessAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a3402d0382640a1aa58f90238c683e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ife432a1f73c54d489020d8e1c0653fb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i966df770ed1a4ca986dd2b7ce6d52c65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9b3c2c63d034b5982e9fe8323b7b71e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id1214fc63dae4248a98c4032a91b2fec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b519d969150438ca0a24a17a6f87ca8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i005266a587014861b4fc4bdc254e6a15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b5a421f1a804107a53e85439af96f46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03e2cfaa161d423e9fe9d78c1d2484d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idca4e969d39442579877374d995f76bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccae8862dd6a4bac8b4589ffb7e02bba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85aa556fff894922b569241055a48e29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44f0c6fe1d3d4acabec50bcd4c8268f6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i848b097591424c609108802124923a5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:FaceAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41b7012b097a470cb13642fec315ce68_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NetAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c1215032fe2415c8d09726a46e245a4_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ibe73f052bcb64b3b84bdbe9c72aaa76c_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i339b11c888494596a3629e3c3f8602a3_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="if808e99cfa6f4952a0ae670544ff3a5a_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i4e6b4e433f554a94aa26022360c2e01d_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i1b575fc15d22495a9d08298c9bae970f_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="i041d58dc5a4a43e5a53c4489ec517413_D20191101-20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="ia639cd1c8ac549939010774ccd59e3c6_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="ibcac1b02df73495c877b9c7d30a882c4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia18b2e0c059c4ec6baf3c43fbd522a3c_D20200701-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6753a38864e24fe7b3e80115745bd09e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i562889873f374783afb9294f8f3e580d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i693a1fea14d6475ca0e8f46ce8dfe8fb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i115e2fd9db454724b9f95a8f9e1f70a4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9936400e3d03441c8b1661005d6f279a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6a87df56a8f6405f8b9bb8b08241a639_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4b3e1118ad2243ae8f2552652e81d1e9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia1738ccbe8404bafad9e9c10b06a1540_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i53ddc51847dc4ddbae72c2e1b0dd613e_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ib298d1d466d644b3a88d10c8864e5755_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i49cf61de567c43ef90aa762bfd0eeb09_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i751e9639a4854331aafc6dd971bd8b76_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i977aaea8b2b34ebc93d72ec5a537716a_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i7f7042f972104aa8922d830f4c40e428_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="ifc1102227aec4db8b50dfac6284decf9_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ie134020e1d4c46b8bf2c15a981b6d8c3_I20240930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="i29afe01aaa2c4a1faa04d57a037e62a5_I20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="iffee7132fe2a4d46ad166324cc4ac784_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i37964c43d1d6497390edcd2c9583717d_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i43a0ab4d513d4a748593003c9e09d157_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:EnhabitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i57239bff51e54e02bfafa24442729469_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i15a929b250624845875d18fad4623b1c_D20220630-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-30</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibeb50e54b2bf431e84d3d94cc9d22afa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i203fce73533d42bdbce407cb83fa7644_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2e47e2a132f436290412d3422a81aa9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99bc319d2e0041d082e15bd0afcd2496_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i73171c1ff1894cd5ab077095eb011dd2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i90e87d090f6f40978450a4a6d7148825_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TheCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4d3ce01c69d745bc933890c6d0232e0a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e4f418e7b3140e2b36a3a4c1d19f59b_I20211209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-09</instant>
        </period>
    </context>
    <context id="i04748e0cbb554838bc097423f5562754_D20211201-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="ia4e9489eb2374473a2446b5989746133_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i3aa44cd02be2427b83f4285074d6a61c_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaa62f19b4e9543c6a31117b7bb708940_I20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i4579352e569d4ffc861c231d1d0881ff_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="id2d821c1a27c4513aaef9bf885e8f58a_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45f4aa2776e24eebbb23581d16dfab42_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie136f6f5e4de4e5eba9a9453789bcd0c_I20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="i07b9cc9fc0fa4aa9b201c5317d0c6b56_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i76b9b243cc2b40eca3256ba9b90f576c_D20150901-20150930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="iebf5ce77babc4dabb08fd48fb81f0d30_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1afcf433ab7c4f42b650fb3992b5dfaf_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2a81a550dc09402898362c8731660c62_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i3ea5e06878784d1c8ac7d2976c3faae1_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i46706a0b927b4c29aa04008703cf93f6_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i37d6af95f4af4e68ba6868cc4060e8be_D20190901-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ie995c3d447e041b09b1095eed8f92f8b_D20190901-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i551a3e6b442f432c9d03ed8b29cef37a_D20190901-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ie16678dac8224a06a40d1b5f2983c761_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i774caad6b09f45a4b7028e593a0fab36_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="icdd2b81bfc614cf3b6b1ae1a415c9a04_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="ic0231b4cffab42d181cb35d1de3a69f6_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="idfdfcc3a1e4d49cb802cebf7c87fab08_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i72f1191377284bad9d5006ad478e6bf1_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i3149f20f82304cdda697d7b9112cdb47_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i9778d074309d474e95d5496bad2d2441_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="i21773a5ded4f4f4a8e0e3fdcbb5ae70d_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="if575f492f4ab49a593a29cb5970ee78a_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i387c5b799dc94ed79c28d16aa0afe0a1_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="idb7fb37acad541dd9f14a7d2fa29fe10_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes0575Due2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i29770414195047bdb212e4ecdc100bdd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c7b1e35d601476d95db3457cce2e093_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0eb949f24cfd47338d5c07380335f00f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i892f9d840d2347f2ac10417c21a2ea1c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie09d6f9c686d4f06bc4e1d29051b98d0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic74b27f5ff584f4dae66883c596ca93e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableRealEstateSaleLeasebackFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30931627be4f4491b0b2e533a3d8199d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i11699d607063435a811357201af64e8c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i51dea7b95c6d4aba83ad9fa892757146_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia822ef25d22e4d039b50ff40539e575a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie7a2877ba40e444e80b196cf51e8d9c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a6fcce63a9548dea0e3f5364203fa60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableLIBORplus2.5ConstructionFinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ehc:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e6abe4bfb1a460d92a2904f739f25a2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6600f773078e47c292dfad7ad647a4fd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f2a545ddce6494e94a8dce995b13eb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98ec873af9eb4796a1d331828822e615_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:NotesPayableSoftwareContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6efebeb8c8db4120ab1f6ddec403e0b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6727a883db744548c7e8035f88a00e4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib815d2a675ad43128d86aa58ebcb4caf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ded9604e5234c4eb9354741e47453eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ehc:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i41e57dc8508f486cb65383ee270622a7_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ehc:HomeHealthandHospiceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i71b339e9a3244030a7c4194e39cb008c_D20180201-20180228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="ia7de87991e514ae5b6fea1833e9ded6f_D20180221-20180221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2018-02-21</startDate>
            <endDate>2018-02-21</endDate>
        </period>
    </context>
    <context id="i0817bf7784b548a186c313fe446af8a6_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i1cf81650d421400f8d1135d296737e38_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2b1d1c428d764c88a5c1812e2a04cf24_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ib793c3abc8744e3b9fffcc21e558e086_D20200218-20200218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2020-02-18</startDate>
            <endDate>2020-02-18</endDate>
        </period>
    </context>
    <context id="idd77fca6ac214fcd9bf9357721bb2a92_I20200218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ehc:EHHIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-18</instant>
        </period>
    </context>
    <context id="ia001d84255a44455b5a46942a930f42b_I20200218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-02-18</instant>
        </period>
    </context>
    <context id="idac0372aea0347c49bdba860190d96f3_I20200220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="ib2779168f690432cac5b38f9bea43674_I20200306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <instant>2020-03-06</instant>
        </period>
    </context>
    <context id="i77780a6142904e59b58e560a56e1f9e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i258d06e3e65443fb8a893ee44f342300_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib83e1a16991f4a27add600a1fd239b44_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id8dd211c83ae4af8ba738a29bef7f269_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e6598efdf814f82b2b3ac56c39d31b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6b15fae4966a432d8dd85f41b1846e97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibe76ff36e61642c69f074e2796820502_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica49f9c6106c4bff9919ea82c86a1d10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i35e875418cae4ed98afcdddf4b6e3679_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5560a022b19466c9dc3b25d0a6709d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0cd9b95664334eee863511a1352b258d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc353f9b60ef469f9fb57e8eb5392312_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i075bc7bcf82a49f8b9f7a4533e89c0a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if11a95d42a454584afeb7e3be1dd5b60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i61147de300ac4b17b16c6aa30fb725e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f9b5364226647f4aca43882157f6bb9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0ba3ea646be7400aa6041fe8bb869254_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if68164d48cd14a36908fa4523153e2b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2fcd0acbafe46d5aee193d414a6d056_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:TermLoanFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36917653da0f4636ac433b0eefd8ca74_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ba67211d13b47e7b5f944000baf621e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccd0995116ad432dbf5ecfe84fb0e897_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2062512483de43c6b98ca06b53160b5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.125Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5783a522bb14483818de81205d4ddac_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i756531406e134ef495f108a1f1d4ce85_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffe80798844441ff9ba446bee23d99ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i288afc94975d4cd1af41f3c46445c4fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes05.75Due2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88b3ef661e7d406e858898cbe882bb5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85c9080bb72a43d387919a7abafe465f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib131caf622a8488480693d868801dfff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9bdcc92113b74a7d8e07277da2c910f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes4.50Due2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i800dfcdb85da4e128a32fc9b7f379889_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfd71591191f4bcaac27b10a00b10a7f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5202834b56544309d7d9d8b7bee2a66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0451060ab9de4fbd8016ce801fb4c267_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04.750Due2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80f7af3cf123430084485f0646aec6b2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69ab7e7f086a47feb8e87a9898b27939_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc9bbdd487884af6b55d2a388ce96eb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia760f2e4e675400ca0a4847d612a1345_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ehc:SeniorNotes04625Due2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6886b561cd61484d89ba422e4d310087_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i997ce4d2148b4c2195cf12ae01cec37a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9453d359deda4140a48a46fd53784a03_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic6750e3dddd9447f96d964077958239f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2fd5c983c4384e469b96a6e07cd2f730_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb880111df2e4c1592091b713f0fe19f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5494a2b14ffd4637b8184bac94f6987e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21eb7f8154e9461399c33a8e06c6aff2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9512677b078c40578810c4ef579432a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ehc:A2016OmnibusPerformanceIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i61258fb59e114ab4be13ec46d31319dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i52beb02bfcfb448588dda9dfaf965534_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5b3906930f64c70b58328d97278b262_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i463986e3eb5648c5b6f6782f286a2c2c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id44f0a9ab653432d9903ca10012e1b33_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8af94fb3b095489db51ee3b16dd479ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id6bbfc0dab6943969098cd57a4bd7417_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i840ae531504149f0837b987fe6ccf313_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia01fbaae638d442ca55200524b2ce253_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c577e7192b841b1b95ff17d16f908e0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if262b00fc98d47d0a49e375a4660d68f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb1d8ad1f6e64881a43d9b042ee3fc13_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68ef0c616638487da568717e4b2e9c7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if693d94dd9bf41cba272ff6915a36cca_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7587a2d34b884d75891d35e0b6e9e5e9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8b1d9e9c16f04250bb589217b66999c2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1479ab37bdd64668ad1c87355665ae26_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:NonemployeeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ehc:DividendEquivalentRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7def89f3f73f44a5991f33f0d8b3acb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ehc:CurrentAndFormerBoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7a3c2935e68148f990a70aed020917a4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHealthRetirementInvestmentPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1591fbdf586749bf959c3f5eed6dc567_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">ehc:EncompassHealthRetirementInvestmentPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i913d390f327f454fa9db31895be317bc_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i271895a47db64e53a3fcdb21e2376d82_I20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="i325765d7079c4953b5c202a28adc1d7c_I20140201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-01</instant>
        </period>
    </context>
    <context id="i4088c2e6d51b4eb4aae4742204a2232a_I20180724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-24</instant>
        </period>
    </context>
    <context id="ia983a9cc79d34b3bb0ce98f38ebd4ecc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0758e6da4efb498697cc4632c85ce905_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifad81fc0e15246a99a32d666a8e006ab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iacdb0a94afd843448af41d30dec91b1f_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="id92801372f7742e0be889a3765cde901_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i4e8efdcf26334badb765a5748295be5a_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i095a5224a8204444bf94150541a11956_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2bdf108006d84903900224006bd7eecc_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000785161</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="state">
        <measure>ehc:state</measure>
    </unit>
    <unit id="hospital">
        <measure>ehc:hospital</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="claim">
        <measure>ehc:claim</measure>
    </unit>
    <unit id="segment">
        <measure>ehc:segment</measure>
    </unit>
    <unit id="bed">
        <measure>ehc:bed</measure>
    </unit>
    <unit id="entity">
        <measure>ehc:entity</measure>
    </unit>
    <unit id="option">
        <measure>ehc:option</measure>
    </unit>
    <unit id="day">
        <measure>ehc:day</measure>
    </unit>
    <unit id="investor">
        <measure>ehc:investor</measure>
    </unit>
    <unit id="y">
        <measure>utr:Y</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl80L2ZyYWc6OTI2YTRiMmM3MDJmNDMyNzlkMDU2YjdjNjc4NWYzYWQvdGFibGU6YWExYzQ2OTEwYmQ0NDgxMDk5OWVkYTJkNTVmYWEyOTYvdGFibGVyYW5nZTphYTFjNDY5MTBiZDQ0ODEwOTk5ZWRhMmQ1NWZhYTI5Nl8zLTEtMS0xLTI0NTQ3Nw_a173a45e-ccfb-442a-8cd6-25b0061bd0c1">0000785161</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl80L2ZyYWc6OTI2YTRiMmM3MDJmNDMyNzlkMDU2YjdjNjc4NWYzYWQvdGFibGU6YWExYzQ2OTEwYmQ0NDgxMDk5OWVkYTJkNTVmYWEyOTYvdGFibGVyYW5nZTphYTFjNDY5MTBiZDQ0ODEwOTk5ZWRhMmQ1NWZhYTI5Nl81LTEtMS0xLTI0NTQ3Nw_0b3c4935-18ae-4551-9513-f8e5e2482a0e">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl80L2ZyYWc6OTI2YTRiMmM3MDJmNDMyNzlkMDU2YjdjNjc4NWYzYWQvdGFibGU6YWExYzQ2OTEwYmQ0NDgxMDk5OWVkYTJkNTVmYWEyOTYvdGFibGVyYW5nZTphYTFjNDY5MTBiZDQ0ODEwOTk5ZWRhMmQ1NWZhYTI5Nl82LTEtMS0xLTI0NTQ3Nw_05c30b9c-fcdd-4450-a2cb-7ef889e19944">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl80L2ZyYWc6OTI2YTRiMmM3MDJmNDMyNzlkMDU2YjdjNjc4NWYzYWQvdGFibGU6YWExYzQ2OTEwYmQ0NDgxMDk5OWVkYTJkNTVmYWEyOTYvdGFibGVyYW5nZTphYTFjNDY5MTBiZDQ0ODEwOTk5ZWRhMmQ1NWZhYTI5Nl83LTEtMS0xLTI0NTQ3Nw_0788e1bd-19cb-4468-8bf5-3526a18bcb82">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ie558e5b6f68546dba75679d76bd06892_D20220701-20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjQxL2ZyYWc6MGJkOTVjNTcyMmFhNDYwY2I4YTE5ZDAzNzRkYjdkNWUvdGV4dHJlZ2lvbjowYmQ5NWM1NzIyYWE0NjBjYjhhMTlkMDM3NGRiN2Q1ZV8xNTM5MzE2Mjc4OTA2MA_6237d4d9-87ba-4b43-8067-cd0c7b691be8"
      unitRef="number">0.5</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ifdef059442d4436a8c8670f4a3fc85d0_D20220701-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjQxL2ZyYWc6MGJkOTVjNTcyMmFhNDYwY2I4YTE5ZDAzNzRkYjdkNWUvdGV4dHJlZ2lvbjowYmQ5NWM1NzIyYWE0NjBjYjhhMTlkMDM3NGRiN2Q1ZV8zODQ4MjkwNjk3NDUx_f8c956a0-9cd0-43ad-be3c-50fb3d9e9489"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd">http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4">http://fasb.org/us-gaap/2022#LongTermDebtAndCapitalLeaseObligations</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <ehc:NoncontrollingInterestExerciseRightToSellRatio
      contextRef="i71b339e9a3244030a7c4194e39cb008c_D20180201-20180228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjgwL2ZyYWc6ZjIzMzA3OGI0NmY1NGY1MTgyNTNlMGViMzA0ODJhY2MvdGFibGU6OGJhMDBiMTEyZmM2NGRkOWE0OWU3ZmYxMzU0NDMyOTcvdGFibGVyYW5nZTo4YmEwMGIxMTJmYzY0ZGQ5YTQ5ZTdmZjEzNTQ0MzI5N18xLTEtMS0xLTMxMDY5Ng_30346d0e-3d62-4e7e-a2b4-19cf28629e22"
      unitRef="number">0.33</ehc:NoncontrollingInterestExerciseRightToSellRatio>
    <dei:DocumentType
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg4_f239f585-07a3-43e9-a892-27d6899335fd">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6NDJjOWRlYTI1NTk3NGMyOWI5ZTY3NmVmYmE1ZmU0MmYvdGFibGVyYW5nZTo0MmM5ZGVhMjU1OTc0YzI5YjllNjc2ZWZiYTVmZTQyZl8wLTAtMS0xLTI0NTQ3Nw_181a091f-4929-40f5-ab0a-03be13212be3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8xNTU_633d855c-be3d-49b3-a1c7-bf6e0d081022">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8xNTU_a4ca8cf0-c52e-4c53-8ea0-485c7b3ac030">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6ZWE0ZWZkNjhlNGZkNGI4MmI4NDAyNWY0YTRkMWJjY2IvdGFibGVyYW5nZTplYTRlZmQ2OGU0ZmQ0YjgyYjg0MDI1ZjRhNGQxYmNjYl8wLTAtMS0xLTI0NTQ3Nw_6c0d99d6-9e32-420b-b531-b903dbae0a2c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDk0_e7b7e870-5c41-4f1e-93a1-827f4d4ffd73">001-10315</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg5_d00f5cf2-977e-4c4a-9dc3-b43ec1db8a6d">Encompass Health Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MmIxOTZhYzdmZWZkNDZlOGJmOGQzNWU2NzgwNTcxY2YvdGFibGVyYW5nZToyYjE5NmFjN2ZlZmQ0NmU4YmY4ZDM1ZTY3ODA1NzFjZl8wLTAtMS0xLTI0NTQ3Nw_e1cfc90c-d028-4cf8-99c4-c2c8e437c54e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MmIxOTZhYzdmZWZkNDZlOGJmOGQzNWU2NzgwNTcxY2YvdGFibGVyYW5nZToyYjE5NmFjN2ZlZmQ0NmU4YmY4ZDM1ZTY3ODA1NzFjZl8wLTEtMS0xLTI0NTQ3Nw_92e17ce1-345c-4ac8-a57f-6114c049e23f">63-0860407</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg0_f1f06c7f-9bb3-411c-9092-9039ae9c7320">9001 Liberty Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg1_e4071964-21c1-4d85-9b25-10fc5fcb1633">Birmingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDgz_1489c4a2-8523-4882-8eea-b94cbebe33a4">AL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDgx_e0b2551b-237d-4b0a-92e0-34c430779c99">35242</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDgw_ad102340-2f07-45d3-b229-10e2e73e7006">205</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDc2_ad64a7c3-85a0-4d55-9989-36496b84e979">967-7116</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MWJiZjIyYWI1YzIyNGYxZDkzZDIyOTJlNjIzN2Q5OWQvdGFibGVyYW5nZToxYmJmMjJhYjVjMjI0ZjFkOTNkMjI5MmU2MjM3ZDk5ZF8xLTAtMS0xLTI0NTQ3Nw_46b556cd-a458-4372-aa15-091b0cfd121b">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MWJiZjIyYWI1YzIyNGYxZDkzZDIyOTJlNjIzN2Q5OWQvdGFibGVyYW5nZToxYmJmMjJhYjVjMjI0ZjFkOTNkMjI5MmU2MjM3ZDk5ZF8xLTEtMS0xLTI0NTQ3Nw_473a8af0-fc80-4b59-b7c3-7f7b38654080">EHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGFibGU6MWJiZjIyYWI1YzIyNGYxZDkzZDIyOTJlNjIzN2Q5OWQvdGFibGVyYW5nZToxYmJmMjJhYjVjMjI0ZjFkOTNkMjI5MmU2MjM3ZDk5ZF8xLTItMS0xLTI0NTQ3Nw_19a11500-6638-4b0d-adc5-7f9c7910d11d">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDgy_c038c080-817b-41bf-ae52-2b65e7788119">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDc3_05ed00fa-f8e5-4c1e-b9f7-f6f96057cc6c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDc4_40e01dec-6680-4bae-9ce4-20f09fb2c933">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDkw_40904835-d6b2-4135-b99f-04e1b400373b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDkx_664cce08-6cab-4b4d-8e53-0acb9e64de9d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDky_752335e7-bd57-4dfc-9dc4-5b44da64c4db">false</dei:EntityEmergingGrowthCompany>
    <dei:EntitySmallBusiness
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg2_8c4e8a06-bac5-4d1e-9eba-db2499bdffd7">false</dei:EntitySmallBusiness>
    <dei:IcfrAuditorAttestationFlag
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDg3_490a05ee-091f-43c2-bbc0-82e9991a4d10">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDc5_57cc767a-af9e-4603-82c1-7e6946b3dcaa">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i7cc06ca4859f40608cdefd3c35ca2b7b_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zMDM0_a9288ca3-a00d-447b-880c-b4e67b854c3c"
      unitRef="usd">5500000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="icf6db76417944ea78fd769dcf53d24ba_I20230213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zMTgz_6e332b4e-ce56-4d60-84f6-3fe4a8b0af72"
      unitRef="shares">99727422</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xL2ZyYWc6ZWRmZmZlNGUxNDc3NGI5Zjg0NzRmM2EwMzUxMDg5N2UvdGV4dHJlZ2lvbjplZGZmZmU0ZTE0Nzc0YjlmODQ3NGYzYTAzNTEwODk3ZV8zNDkz_ea9c8ae9-3b58-450b-b240-5fad75c7cd29">The definitive proxy statement relating to the registrant&#x2019;s 2023 annual meeting of stockholders is incorporated by reference in Part III to the extent described therein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xMzYvZnJhZzphOTM0NTM4OTRmNjQ0M2Y1OTUwYjk5NzRlZjYyYTVmNi90YWJsZTozOTI0MzNmM2U2ZDg0NWNjYTIyNTE1M2QzYjBhMDQ5Mi90YWJsZXJhbmdlOjM5MjQzM2YzZTZkODQ1Y2NhMjI1MTUzZDNiMGEwNDkyXzAtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MzA5ZmNlZDlkYzlhNGZkNTllMWM2MjNlMjJiNTQ0YWJfNzE_fea08ed4-43e3-4b3d-bca1-3119941e8adb">238</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xMzkvZnJhZzo0MTY3Mzk4ZWFkZjQ0MzU0OTY0ZTFlYzZkMWM3YjJjMy90ZXh0cmVnaW9uOjQxNjczOThlYWRmNDQzNTQ5NjRlMWVjNmQxYzdiMmMzXzEzMTM3_a9ef749b-1c73-4cfc-89cc-be9701cae818">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xMzkvZnJhZzo0MTY3Mzk4ZWFkZjQ0MzU0OTY0ZTFlYzZkMWM3YjJjMy90ZXh0cmVnaW9uOjQxNjczOThlYWRmNDQzNTQ5NjRlMWVjNmQxYzdiMmMzXzEzMTM4_5cfd4daa-e1d6-495c-8282-fb66020a6184">Birmingham, Alabama</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMtMS0xLTEtMjQ1NDc3_54aa3f78-6d00-43d9-b63d-aa4b1ae9455a"
      unitRef="usd">4348600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMtMy0xLTEtMjQ1NDc3_111b9e84-fe08-4ce8-975c-cd4a558d6e66"
      unitRef="usd">4014900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMtNS0xLTEtMjQ1NDc3_79e8e791-9e59-4545-9389-18da2fac2284"
      unitRef="usd">3566300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LaborAndRelatedExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzUtMS0xLTEtMjQ1NDc3_171d7f6d-c304-4a43-9ef2-6c5258dde490"
      unitRef="usd">2393300000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzUtMy0xLTEtMjQ1NDc3_071cafc5-1611-44db-b334-943231a542b4"
      unitRef="usd">2127300000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzUtNS0xLTEtMjQ1NDc3_e36fe79b-e31c-463f-a697-acc229ecd77d"
      unitRef="usd">1903800000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzYtMS0xLTEtMjQ1NDc3_4dd23c5b-9afb-4bd2-a829-cbddaa93e275"
      unitRef="usd">670400000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzYtMy0xLTEtMjQ1NDc3_d584b926-0db1-4af5-8df2-706b409dce4b"
      unitRef="usd">595900000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzYtNS0xLTEtMjQ1NDc3_431829b8-6b60-4aa0-883e-9dda3a72d588"
      unitRef="usd">545100000</us-gaap:OtherCostAndExpenseOperating>
    <ehc:OccupancyCost
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzctMS0xLTEtMjQ1NDc3_30cb2181-2425-4457-924b-c87c2dca22c7"
      unitRef="usd">54700000</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzctMy0xLTEtMjQ1NDc3_edb0d047-98a6-42b1-bc4f-daf91c4d5159"
      unitRef="usd">59000000.0</ehc:OccupancyCost>
    <ehc:OccupancyCost
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzctNS0xLTEtMjQ1NDc3_c3c554cb-d5cf-4995-b213-aec4f751ad16"
      unitRef="usd">61400000</ehc:OccupancyCost>
    <us-gaap:SuppliesExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzgtMS0xLTEtMjQ1NDc3_09a96b97-a836-4528-a0b2-2d5484cbf497"
      unitRef="usd">202100000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzgtMy0xLTEtMjQ1NDc3_66e4c506-5a9b-4f96-a575-0387b91365fc"
      unitRef="usd">184200000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzgtNS0xLTEtMjQ1NDc3_ead2a824-cd16-406e-9a23-c718e1b6247f"
      unitRef="usd">171000000.0</us-gaap:SuppliesExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzktMS0xLTEtMjQ1NDc3_07631287-3ccb-4715-96f8-0ae4d9ecb59e"
      unitRef="usd">154300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzktMy0xLTEtMjQ1NDc3_ef0afb01-c223-44bb-8343-8faad40400e7"
      unitRef="usd">169500000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzktNS0xLTEtMjQ1NDc3_6b3705ec-c989-4f7c-9a01-8b4292fe0c9f"
      unitRef="usd">151600000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEwLTEtMS0xLTI0NTQ3Nw_0b7216e8-7393-4ca8-a9ac-8cf607098987"
      unitRef="usd">243600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEwLTMtMS0xLTI0NTQ3Nw_680f5427-e990-4103-ab46-f0f9dd95b9a6"
      unitRef="usd">219600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEwLTUtMS0xLTI0NTQ3Nw_43250cb4-ceb0-4c0c-8511-5f031a32ae9d"
      unitRef="usd">203000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:LitigationSettlementExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzExLTEtMS0xLTI0NTQ3Nw_3afdc08c-8cb3-4fab-bff0-5b8f3af8f0d1"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzExLTMtMS0xLTI0NTQ3Nw_108effc8-ad7a-4577-a667-ca9a21742e42"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzExLTUtMS0xLTI0NTQ3Nw_29e97e35-4ca9-4e57-bbe4-6f7653fcce07"
      unitRef="usd">2800000</us-gaap:LitigationSettlementExpense>
    <us-gaap:CostsAndExpenses
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEzLTEtMS0xLTI0NTQ3Nw_fe5a4ff7-a14b-4c50-a946-57cdf329fa1d"
      unitRef="usd">3718400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEzLTMtMS0xLTI0NTQ3Nw_a75e574b-c9bd-4420-ac89-f8a56070841c"
      unitRef="usd">3355500000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzEzLTUtMS0xLTI0NTQ3Nw_04ce113c-ce8e-408a-bab5-85e471864ab9"
      unitRef="usd">3038700000</us-gaap:CostsAndExpenses>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE0LTEtMS0xLTI0NTQ3Nw_2283992f-5959-46e2-9aac-8c599a6d269e"
      unitRef="usd">-1400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE0LTMtMS0xLTI0NTQ3Nw_5f8fa545-1c5d-4a8a-8a3e-859b5e42b43b"
      unitRef="usd">-1000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE0LTUtMS0xLTI0NTQ3Nw_89d8a64d-6fb8-42f3-bfcb-a72d00a4e9cf"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE1LTEtMS0xLTI0NTQ3Nw_143ca982-e3bf-44ff-be9f-67a3a5df9e50"
      unitRef="usd">175700000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE1LTMtMS0xLTI0NTQ3Nw_7859ae82-2712-4b33-83ca-2ae7fbdfe438"
      unitRef="usd">164300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE1LTUtMS0xLTI0NTQ3Nw_7215aa7f-d283-4c37-90fb-c6828bcc8f1c"
      unitRef="usd">183700000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE2LTEtMS0xLTI0NTQ3Nw_a4c35f03-1eb1-4f99-8979-08444888dbda"
      unitRef="usd">-5200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE2LTMtMS0xLTI0NTQ3Nw_a722de5e-7d05-4721-ac65-6dd410e24b89"
      unitRef="usd">7500000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE2LTUtMS0xLTI0NTQ3Nw_b4594731-b523-47d1-9a7a-857085c9e65c"
      unitRef="usd">8400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE3LTEtMS0xLTI0NTQ3Nw_76822d18-d70b-4ee1-b2fa-d4368773fffe"
      unitRef="usd">2900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE3LTMtMS0xLTI0NTQ3Nw_ff1f261f-c5b7-4046-8e79-56d19e835182"
      unitRef="usd">3400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE3LTUtMS0xLTI0NTQ3Nw_5dc7690f-821c-4277-90f6-a7bea7dbe350"
      unitRef="usd">2900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE4LTEtMS0xLTI0NTQ3Nw_4ffc3a30-905d-4f0d-98bc-e5a3303e0115"
      unitRef="usd">450800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE4LTMtMS0xLTI0NTQ3Nw_3667419f-847b-434e-9aa5-03b4e9c145f6"
      unitRef="usd">505000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE4LTUtMS0xLTI0NTQ3Nw_7e9681a6-2880-4b29-897f-c93f7d7260fa"
      unitRef="usd">352900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE5LTEtMS0xLTI0NTQ3Nw_9ac0684c-65ec-4ed6-8d74-23ac301be00e"
      unitRef="usd">100100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE5LTMtMS0xLTI0NTQ3Nw_eae4f1a4-96c2-479b-9a28-a7303bae17ed"
      unitRef="usd">101900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzE5LTUtMS0xLTI0NTQ3Nw_2733090c-159e-4f94-9eaf-61eb6d7a6618"
      unitRef="usd">74700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIwLTEtMS0xLTI0NTQ3Nw_c452a07d-286b-4730-b3fe-1d351e74922b"
      unitRef="usd">350700000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIwLTMtMS0xLTI0NTQ3Nw_a759378e-e5b6-4e14-a915-6a0aff29d6de"
      unitRef="usd">403100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIwLTUtMS0xLTI0NTQ3Nw_bf018744-7752-47d9-905e-0162c63d7920"
      unitRef="usd">278200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIxLTEtMS0xLTI0NTQ3Nw_a4ebbd93-daf6-46d6-b3ec-4442afaa7284"
      unitRef="usd">15200000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIxLTMtMS0xLTI0NTQ3Nw_7284edb9-ba97-4821-b72a-c11eb5739af2"
      unitRef="usd">114100000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIxLTUtMS0xLTI0NTQ3Nw_2057d3b9-421a-4a81-a0a3-a2dd68758239"
      unitRef="usd">90600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTEtMS0xLTI0NTQ3Nw_66836bbc-6ce8-49d9-ad9b-8e0957b76207"
      unitRef="usd">365900000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTEtMS0xLTI0NTQ3Nw_9c60111d-c02b-4670-ac65-efd412e31cfc"
      unitRef="usd">365900000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTMtMS0xLTI0NTQ3Nw_221d0cee-6bce-4bbc-bff1-26de1c140554"
      unitRef="usd">517200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTMtMS0xLTI0NTQ3Nw_a66e61f9-6790-453e-9744-7c3a4d24a96e"
      unitRef="usd">517200000</us-gaap:ProfitLoss>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTUtMS0xLTI0NTQ3Nw_07d5bfe1-13a7-4e67-a5be-0c2c279dfafc"
      unitRef="usd">368800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIyLTUtMS0xLTI0NTQ3Nw_1b78fbd0-d9df-4c6d-8424-3fc4180d4b08"
      unitRef="usd">368800000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTEtMS0xLTI2NzM5OQ_e4108caa-fb96-4413-8937-aedadb4ed4a4"
      unitRef="usd">93600000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTMtMS0xLTI2NzM5OQ_982ac596-f6c5-474d-b86f-255443353594"
      unitRef="usd">103200000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTUtMS0xLTI2NzM5OQ_d99a666b-0a54-405a-adbf-93077a39e0f9"
      unitRef="usd">83300000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTEtMS0xLTI2NzM5OQ_b6dea59d-0cce-46aa-935b-abecd88c21d2"
      unitRef="usd">1300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTMtMS0xLTI2NzM5OQ_3b9a6836-8b6b-4141-b2af-5c944464d20b"
      unitRef="usd">1800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTUtMS0xLTI2NzM5OQ_f9d2cace-0c36-4ab3-997b-dcb20e4286ad"
      unitRef="usd">1300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTEtMS0xLTI0NTQ3Nw_4e989b67-af15-4b18-9764-d2fd74b4ad8a"
      unitRef="usd">94900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTEtMS0xLTI0NTQ3Nw_d8eef829-e9b8-43b0-a1dc-e423f4003eae"
      unitRef="usd">94900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTMtMS0xLTI0NTQ3Nw_c2b132f9-2e69-4697-9f8d-17e9ac55c0be"
      unitRef="usd">105000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTMtMS0xLTI0NTQ3Nw_c5b94c1c-0d7c-4f73-a49e-716a4201efaf"
      unitRef="usd">105000000.0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTUtMS0xLTI0NTQ3Nw_06329c02-f1e0-4241-bdee-42309e93aa25"
      unitRef="usd">84600000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzIzLTUtMS0xLTI0NTQ3Nw_406f0e08-60c8-44d9-9d10-8c5a5dcbc687"
      unitRef="usd">84600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTEtMS0xLTI0NTQ3Nw_6d2e3f49-4ee5-45d4-8c14-8b1e727dc67b"
      unitRef="usd">271000000.0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTEtMS0xLTI0NTQ3Nw_8d4616d3-70b2-4aac-a337-68d51eda5f9f"
      unitRef="usd">271000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTMtMS0xLTI0NTQ3Nw_62105382-7c3f-4743-bec2-27b57aab7afe"
      unitRef="usd">412200000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTMtMS0xLTI0NTQ3Nw_de2134b9-20ec-4d0e-b406-66b1aff742c3"
      unitRef="usd">412200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTUtMS0xLTI0NTQ3Nw_38586f15-ed3b-4fb1-b6b3-7ec2a0eae7fe"
      unitRef="usd">284200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzI0LTUtMS0xLTI0NTQ3Nw_3bccf2b9-d9ed-48e5-9a1f-cdbbc2abcfe2"
      unitRef="usd">284200000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMwLTEtMS0xLTI0NTQ3Nw_499e4b64-1f4e-4545-b4a5-5de70ab14d5b"
      unitRef="shares">99200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMwLTMtMS0xLTI0NTQ3Nw_899b2b01-637b-4b9b-8e4b-1f4320e447b0"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMwLTUtMS0xLTI0NTQ3Nw_b5041217-c1fb-4954-bde9-915915af9b9f"
      unitRef="shares">98600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMxLTEtMS0xLTI0NTQ3Nw_098a77b5-986f-438d-a8f3-d6c843e9b822"
      unitRef="shares">100400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMxLTMtMS0xLTI0NTQ3Nw_6b0c49a6-a65d-4efa-bd50-d48654fd980e"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzMxLTUtMS0xLTI0NTQ3Nw_5ea198ac-9c84-4a1f-856b-310c8761142f"
      unitRef="shares">99800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM0LTEtMS0xLTI0NTQ3Nw_a2d2cd45-78c9-4c9b-a840-2df1a93fe2c6"
      unitRef="usdPerShare">2.58</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM0LTMtMS0xLTI0NTQ3Nw_22977fa4-cc50-4384-8ce4-2a004a40f843"
      unitRef="usdPerShare">3.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM0LTUtMS0xLTI0NTQ3Nw_5efb5b0f-169a-43b0-9921-4b603b2620a8"
      unitRef="usdPerShare">1.97</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM1LTEtMS0xLTI0NTQ3Nw_0a481894-168f-413e-b02c-0eb2edbe4a20"
      unitRef="usdPerShare">0.14</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM1LTMtMS0xLTI0NTQ3Nw_3c8b0ef4-ee9c-4795-b121-0c6cc37ce327"
      unitRef="usdPerShare">1.13</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM1LTUtMS0xLTI0NTQ3Nw_1ea8f8ac-7a76-4ed9-a949-9e2aeeefa567"
      unitRef="usdPerShare">0.90</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM2LTEtMS0xLTI0NTQ3Nw_ac196598-3cee-40e4-b43a-915eb1a37e97"
      unitRef="usdPerShare">2.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM2LTMtMS0xLTI0NTQ3Nw_b18e2da1-f883-48e1-a571-b34ff375e8fc"
      unitRef="usdPerShare">4.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM2LTUtMS0xLTI0NTQ3Nw_c3aacfd5-c69a-4fcc-acd5-84ea4adac313"
      unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM4LTEtMS0xLTI0NTQ3Nw_333afb70-e701-46d7-b972-096c39359d02"
      unitRef="usdPerShare">2.56</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM4LTMtMS0xLTI0NTQ3Nw_433c0c4b-ad4a-4d99-b5d3-3e36352647bd"
      unitRef="usdPerShare">2.99</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM4LTUtMS0xLTI0NTQ3Nw_5223cdb8-ff8e-4f5c-bc92-06fe77396e9b"
      unitRef="usdPerShare">1.96</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM5LTEtMS0xLTI0NTQ3Nw_f5945820-28f4-4f1e-bf7c-25c44a1e4b09"
      unitRef="usdPerShare">0.14</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM5LTMtMS0xLTI0NTQ3Nw_389a4557-368d-431d-9ee2-5729fcc67d9d"
      unitRef="usdPerShare">1.12</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzM5LTUtMS0xLTI0NTQ3Nw_cf4c57fe-0d7f-493b-be1a-b4bb78e38201"
      unitRef="usdPerShare">0.89</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQwLTEtMS0xLTI0NTQ3Nw_9d41405c-9367-48ad-83ad-d5600aaed261"
      unitRef="usdPerShare">2.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQwLTMtMS0xLTI0NTQ3Nw_8d9a0aeb-a865-437a-bf16-efffc8506aa6"
      unitRef="usdPerShare">4.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQwLTUtMS0xLTI0NTQ3Nw_1602b038-5ab6-44fa-a09b-4cc4c8409e60"
      unitRef="usdPerShare">2.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQzLTEtMS0xLTI0NTQ3Nw_96f24f91-e650-4882-b1e4-a5a05418f3e9"
      unitRef="usd">257100000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQzLTMtMS0xLTI0NTQ3Nw_ea0bc75e-6595-4103-bd24-235f3d1ab8e1"
      unitRef="usd">299900000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQzLTUtMS0xLTI0NTQ3Nw_92eaf174-cd14-45fe-9cb1-86ebabf18194"
      unitRef="usd">194900000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ0LTEtMS0xLTI0NTQ3Nw_cb97de49-e66d-45ff-a4d5-3d6241523cb7"
      unitRef="usd">13900000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ0LTMtMS0xLTI0NTQ3Nw_472d4b80-b66c-48db-a4d2-534a0a750f4e"
      unitRef="usd">112300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ0LTUtMS0xLTI0NTQ3Nw_4e5d61e7-638c-4ac7-b10c-88f26e00bc1b"
      unitRef="usd">89300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ1LTEtMS0xLTI0NTQ3Nw_d4618e14-93c2-4380-9c84-f75a31c931ba"
      unitRef="usd">271000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ1LTMtMS0xLTI0NTQ3Nw_8b62c464-c3f2-41af-97dd-f97d8820e3da"
      unitRef="usd">412200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDIvZnJhZzo3YWE2YmQyMzEzNmY0YTNhOTUyZDYyODc5YTcyNzQ3NC90YWJsZTpiMDc3N2ViZTRiODE0MWM0YjQ4YzU4N2U3OWRmM2JiNC90YWJsZXJhbmdlOmIwNzc3ZWJlNGI4MTQxYzRiNDhjNTg3ZTc5ZGYzYmI0XzQ1LTUtMS0xLTI0NTQ3Nw_14fab8af-9d0f-4793-9b9b-1b160932531f"
      unitRef="usd">284200000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzUtMS0xLTEtMjQ1NDc3_86b3d9ca-f8f2-4c87-b278-d90cece2b958"
      unitRef="usd">21800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzUtMy0xLTEtMjQ1NDc3_37bc64b6-fe69-4153-9260-bff0af84a332"
      unitRef="usd">49400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzYtMS0xLTEtMjQ1NDc3_6f088b6a-cade-400b-b87a-df6c9730f387"
      unitRef="usd">31600000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzYtMy0xLTEtMjQ1NDc3_60d05a54-13a6-443d-85d2-a8ca9fc141a8"
      unitRef="usd">62500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzctMS0xLTEtMjQ1NDc3_1cd845bb-c6c8-4d0c-a251-b4632ea717db"
      unitRef="usd">536800000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzctMy0xLTEtMjQ1NDc3_f3f09513-3797-40b6-8432-8f0f7456fc2a"
      unitRef="usd">515800000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzgtMS0xLTEtMjQ1NDc3_a552fb9d-0706-45f0-bfd2-452778b5e0dd"
      unitRef="usd">127000000.0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzgtMy0xLTEtMjQ1NDc3_0673f2d7-efd9-44c6-b96d-2520f0ef126d"
      unitRef="usd">114900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzktMS0xLTEtMjY3NDMz_5c76ee53-da02-4bc6-8811-61a48705b3ef"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzktMy0xLTEtMjY3NDMz_0b5ec563-3608-44df-aa77-c3e7b619fdd3"
      unitRef="usd">178800000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzktMS0xLTEtMjQ1NDc3_d5fc56ff-7a6a-4a6a-bab5-9a441eda7908"
      unitRef="usd">717200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzktMy0xLTEtMjQ1NDc3_b3e21b76-98b3-4e47-b2ca-2a653dbcc2d1"
      unitRef="usd">921400000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEwLTEtMS0xLTI0NTQ3Nw_21ef86a6-8a27-49f5-b498-c40782a0019f"
      unitRef="usd">2939200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEwLTMtMS0xLTI0NTQ3Nw_af185ce1-20ca-4ba1-aed5-3fb1b2887701"
      unitRef="usd">2581200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzExLTEtMS0xLTI0NTQ3Nw_5a256901-859b-4fba-b93a-e7e2f057465f"
      unitRef="usd">212500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzExLTMtMS0xLTI0NTQ3Nw_4b56d7b8-e5ce-4adf-8a3a-5dd330c412a4"
      unitRef="usd">193700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEyLTEtMS0xLTI0NTQ3Nw_43a714b2-1c18-4ced-89ee-aa15796b92b4"
      unitRef="usd">1263200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEyLTMtMS0xLTI0NTQ3Nw_7e5cf555-dea5-4f38-964a-1658cc2ec3e7"
      unitRef="usd">1237000000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEzLTEtMS0xLTI0NTQ3Nw_1af6bf1d-1840-44d8-99cc-c6df6cb78a65"
      unitRef="usd">282300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzEzLTMtMS0xLTI0NTQ3Nw_76a22dd9-248d-4a6b-9f8e-bc74432fb359"
      unitRef="usd">158400000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE1LTEtMS0xLTI0NTQ3Nw_172861eb-0633-497f-a4c8-b8a13dd8f497"
      unitRef="usd">222000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE1LTMtMS0xLTI0NTQ3Nw_a11eb64d-4134-400f-b64a-82e8c4e7a977"
      unitRef="usd">230000000.0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE3LTEtMS0xLTI2NzQ0Ng_3992654e-0771-49b6-84ec-e7d773391eec"
      unitRef="usd">100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE3LTMtMS0xLTI2NzQ0Ng_51c4204b-7632-414d-a401-3ad2639c0e03"
      unitRef="usd">1543200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTEtMS0xLTI0NTQ3Nw_35ab4c84-49e9-4a51-af7c-17f16f5f209d"
      unitRef="usd">5636500000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTMtMS0xLTI0NTQ3Nw_f2de0a82-9dc8-4a08-a7a5-7f3bcb6108e0"
      unitRef="usd">6864900000</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE5LTEtMS0xLTI0NTQ3Nw_7993a922-e2cb-4a96-9f6a-b74acd4a9657"
      unitRef="usd">25200000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE5LTMtMS0xLTI0NTQ3Nw_3c4e5b8d-99ff-4782-a7ac-e34f2423793c"
      unitRef="usd">37800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIwLTEtMS0xLTI0NTQ3Nw_a13966de-d689-4c96-a4a4-4b025d7b4b1c"
      unitRef="usd">25600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIwLTMtMS0xLTI0NTQ3Nw_dff1da63-15e6-418b-ae3e-11c9d1005400"
      unitRef="usd">23500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIxLTEtMS0xLTI0NTQ3Nw_0e914a56-e4b4-4f06-9962-9ffd34d6f3ec"
      unitRef="usd">132900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIxLTMtMS0xLTI0NTQ3Nw_3e5dbb2f-8ae1-4850-9e68-da05e75bd9ce"
      unitRef="usd">134000000.0</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIyLTEtMS0xLTI0NTQ3Nw_03aaa90d-72ef-4597-b666-bf421570922e"
      unitRef="usd">168300000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIyLTMtMS0xLTI0NTQ3Nw_44c77eb9-1e27-4515-a915-739a021e1282"
      unitRef="usd">199400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIzLTEtMS0xLTI0NTQ3Nw_e8f4b30f-8fff-413c-8fee-883c0ccf22ce"
      unitRef="usd">42800000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzIzLTMtMS0xLTI0NTQ3Nw_43930c7c-3318-4739-9d1f-ad3682362068"
      unitRef="usd">44400000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI0LTEtMS0xLTI0NTQ3Nw_61174347-e788-4341-a9d7-fc6bde872dc2"
      unitRef="usd">181000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI0LTMtMS0xLTI0NTQ3Nw_33eea61f-677e-4b3a-9242-cc87dee9b9ad"
      unitRef="usd">177300000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI3LTEtMS0xLTI2NzQ1Nw_4ddbca2b-563c-40ef-8dfd-962624f0751b"
      unitRef="usd">100000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI3LTMtMS0xLTI2NzQ1Nw_f830c6b0-bd5e-4cf4-8beb-e6241ec6d75c"
      unitRef="usd">132400000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI1LTEtMS0xLTI0NTQ3Nw_5123c602-37b4-45c1-ae6d-eda59f3a01b1"
      unitRef="usd">575900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI1LTMtMS0xLTI0NTQ3Nw_4bb4e296-c125-49f7-b3e8-6d24244a0070"
      unitRef="usd">748800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI2LTEtMS0xLTI0NTQ3Nw_fbb19063-8dbb-4032-84b2-caee5705e510"
      unitRef="usd">2741800000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI2LTMtMS0xLTI0NTQ3Nw_12f4937f-2777-46ae-9a10-5b2fc7ac6a3d"
      unitRef="usd">3240500000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI3LTEtMS0xLTI0NTQ3Nw_f3423cd9-8257-425b-b5af-af5232456308"
      unitRef="usd">199700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI3LTMtMS0xLTI0NTQ3Nw_aec469e0-477f-4d64-b100-75d83b4dff9f"
      unitRef="usd">179600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SelfInsuranceReserveNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI4LTEtMS0xLTI0NTQ3Nw_f54a990c-fbf1-4331-95a3-367d33e026e2"
      unitRef="usd">128500000</us-gaap:SelfInsuranceReserveNoncurrent>
    <us-gaap:SelfInsuranceReserveNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI4LTMtMS0xLTI0NTQ3Nw_7d70d539-5ce3-4001-bc32-252e52dd65df"
      unitRef="usd">123800000</us-gaap:SelfInsuranceReserveNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI5LTEtMS0xLTI0NTQ3Nw_9ada5698-b4af-46d6-afb0-ad99aa74bcfd"
      unitRef="usd">83000000.0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzI5LTMtMS0xLTI0NTQ3Nw_21437bd4-ceb3-4057-a431-429393ebfd64"
      unitRef="usd">23300000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMwLTEtMS0xLTI0NTQ3Nw_eec41967-a2c5-464e-a6cc-1cef7979b01d"
      unitRef="usd">45300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMwLTMtMS0xLTI0NTQ3Nw_6149a9ed-c825-4284-b0fd-f26922a2eb04"
      unitRef="usd">48900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM0LTEtMS0xLTI2NzQ5Nw_66521d47-2055-4a8a-8a6e-40014bbf35ba"
      unitRef="usd">400000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM0LTMtMS0xLTI2NzQ5Nw_0afa94d9-07dd-4be0-a955-df96cc6a46e4"
      unitRef="usd">100800000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:Liabilities
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMxLTEtMS0xLTI0NTQ3Nw_37a4a289-1b6f-42c5-9818-78d9e08bf493"
      unitRef="usd">3774600000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMxLTMtMS0xLTI0NTQ3Nw_da4dd27a-850f-4a3e-8bc6-1feef3251009"
      unitRef="usd">4465700000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMyLTEtMS0xLTI0NTQ3Nw_1475fe36-0fd9-4b8f-86b2-c16f39443372"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzMyLTMtMS0xLTI0NTQ3Nw_9700939b-8672-4a29-8d74-954289891fe5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM0LTEtMS0xLTI0NTQ3Nw_05e4ff2c-7014-452c-8a6b-b1243796a62e"
      unitRef="usd">35600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM0LTMtMS0xLTI0NTQ3Nw_b3826879-0890-493e-bbde-3ddfddb194d1"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzE4_4b23ff89-82e7-4bc3-86d5-3640c027c17d"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzE4_a5dc4252-812d-4d9a-aadd-35d35e09f35e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzMy_79c6d016-b331-481d-aeb6-3d70fe5569cc"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzMy_cbfbba63-d4cb-44d2-a2e8-ef54e11572b1"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzYy_a5dc2acb-2089-42f1-a301-cf5c070cfda4"
      unitRef="shares">114775056</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjQyZDQ2ZjI2YmU4MTQ4M2RiYzgzNTk3NThmYTYzYjVhXzcy_fbeec94d-8efd-465d-b353-56bc4d5bad43"
      unitRef="shares">114211057</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTEtMS0xLTI0NTQ3Nw_ea60b390-b7e7-4d42-aba5-eb784ccbf3f0"
      unitRef="usd">1100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM3LTMtMS0xLTI0NTQ3Nw_5fffa080-8d17-48c2-ba42-64445496fccc"
      unitRef="usd">1100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM4LTEtMS0xLTI0NTQ3Nw_00e2328f-9b2d-4cdb-8045-c44d10ba2f32"
      unitRef="usd">1730200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM4LTMtMS0xLTI0NTQ3Nw_19c56883-dd6e-4051-a64c-077a5be1f55e"
      unitRef="usd">2289600000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM5LTEtMS0xLTI0NTQ3Nw_8810dcfe-420a-4784-b6da-b654dce433eb"
      unitRef="usd">115700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzM5LTMtMS0xLTI0NTQ3Nw_915fb79d-cede-47de-8ee9-aea4d130b5ff"
      unitRef="usd">141800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQxLTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOmJiNzk3OTI0YzI1ZDQzYTY4YjIxNTg5YTNkZGJlMjFlXzI5_a9866db7-3b8c-49af-8320-869f179fe446"
      unitRef="shares">14992125</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQxLTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOmJiNzk3OTI0YzI1ZDQzYTY4YjIxNTg5YTNkZGJlMjFlXzQ5_05ce5e82-a336-4515-aa02-57253442918e"
      unitRef="shares">14719662</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQxLTEtMS0xLTI0NTQ3Nw_a3b07ea4-a99f-416a-b893-3b5a71578ec2"
      unitRef="usd">536700000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQxLTMtMS0xLTI0NTQ3Nw_411adb84-3bb7-4b58-a609-1047d0ca569e"
      unitRef="usd">521200000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQyLTEtMS0xLTI0NTQ3Nw_beca62d8-6da9-40ca-b1ba-40d6769f5473"
      unitRef="usd">1310300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQyLTMtMS0xLTI0NTQ3Nw_1cc7a0d5-9323-47b2-ae1d-188a78378818"
      unitRef="usd">1911300000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQzLTEtMS0xLTI0NTQ3Nw_cde80618-0b36-4131-be92-ded66851dfc1"
      unitRef="usd">516000000.0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQzLTMtMS0xLTI0NTQ3Nw_6c0d0b7d-ed52-450a-b932-44fecf07dba7"
      unitRef="usd">445700000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ0LTEtMS0xLTI0NTQ3Nw_5c05ae3e-08e6-4a0a-992b-d68ce9d5e46c"
      unitRef="usd">1826300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ0LTMtMS0xLTI0NTQ3Nw_5d5cf628-22cb-4a39-a945-5c8e19029cf3"
      unitRef="usd">2357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTEtMS0xLTI0NTQ3Nw_1279d20f-075b-4742-bd23-75b6c1e9eed9"
      unitRef="usd">5636500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTMtMS0xLTI0NTQ3Nw_2a843a56-9e04-4f9a-ac50-be6a0201a274"
      unitRef="usd">6864900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzEwMg_43008e15-e738-4801-98eb-dc56d8a2b74b"
      unitRef="usd">207800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzEwOQ_648e4f53-a221-4a2b-89cd-c08bb553d515"
      unitRef="usd">226200000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzMwNw_81e074d3-3831-4f13-8d61-10b9a90d4518"
      unitRef="usd">47900000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzMxNA_3eaece07-4213-4a4e-bec3-435ddbfccb7c"
      unitRef="usd">38200000</us-gaap:Liabilities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9242279c10684829b4d9378d04b1edbd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMS0xLTEtMjQ1NDc3_1d5e7157-a283-4912-b8b8-a543e7d91580"
      unitRef="shares">98600000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9242279c10684829b4d9378d04b1edbd_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMy0xLTEtMjQ1NDc3_0b916895-36c3-443c-ae6c-07e013c59162"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id90643ddde5c45f98d52e4b3afea3306_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtNS0xLTEtMjQ1NDc3_a2d296ee-0160-431d-9c19-7fc7566b3422"
      unitRef="usd">2369900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0bcbb07d6f643b2b8e55385fae57545_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtNy0xLTEtMjQ1NDc3_325a15c2-4107-4976-857c-de3c25ce4d7b"
      unitRef="usd">-526500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa1631b09af5498898a4f9704b654317_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMTEtMS0xLTI0NTQ3Nw_3463cfb7-3699-43f4-b1e1-de5db7816c66"
      unitRef="usd">-492300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2adf3229d1fb4d439bf8228ce1a554d8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMTMtMS0xLTI0NTQ3Nw_61685c2f-8e92-42ba-9fa6-8cc5d623e86d"
      unitRef="usd">340900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMtMTUtMS0xLTI0NTQ3Nw_f52433ef-9961-419a-861d-4aa75c4c8a86"
      unitRef="usd">1693100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i6826376042e0432c876faeb386c0d683_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQtNy0xLTEtMjQ1NDc3_63b0132b-4ce8-4058-96d6-8eb6443a17a6"
      unitRef="usd">284200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQtMTMtMS0xLTI0NTQ3Nw_fbe5aaaa-8fb4-46fd-ba96-53513ac9cde5"
      unitRef="usd">77200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQtMTUtMS0xLTI0NTQ3Nw_956d2246-321c-4374-b97b-421d09f8ccb8"
      unitRef="usd">361400000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzYtMS0xLTEtMjQ1NDc3_b901e6cb-8cae-46a7-8307-4417aa5d310d"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzYtMTEtMS0xLTI0NTQ3Nw_c9ee87a4-b25b-4b52-8812-4edc804dc5be"
      unitRef="usd">15700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzYtMTUtMS0xLTI0NTQ3Nw_4790f9ec-52fe-4fb3-8488-fa7b23dda8be"
      unitRef="usd">15700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjY5MWJkN2YxMzMyNGQzZjljZGI5MWE5NTZkYmY0N2ZfMjQ_ecfc18cc-b3b8-4a0f-9c90-0f293a5f2d9c"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzctNS0xLTEtMjQ1NDc3_492a7db5-925a-4544-bbe5-604b795368ff"
      unitRef="usd">111600000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzctMTUtMS0xLTI0NTQ3Nw_53647786-a72b-4f4d-bd88-0dafd8a7d7c5"
      unitRef="usd">111600000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzgtMS0xLTEtMjQ1NDc3_4537ddb9-5e00-444d-859e-f7fea1fafd38"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzgtNS0xLTEtMjQ1NDc3_e7694d12-f716-409c-9d2d-70a3c0c3ffbd"
      unitRef="usd">27100000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzgtMTEtMS0xLTI0NTQ3Nw_b68e4d72-31c5-41c7-a5ad-f45ae699ffa3"
      unitRef="usd">19200000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzgtMTUtMS0xLTI0NTQ3Nw_ccaef4fd-0a0d-4a5f-a408-8d39c51453a1"
      unitRef="usd">46300000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzEwLTUtMS0xLTI0NTQ3Nw_ab69425d-1b57-4a30-9acc-8aded9ce49a3"
      unitRef="usd">29500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzEwLTE1LTEtMS0yNDU0Nzc_5d8b3afb-f3b1-4885-aa44-22244d61ea92"
      unitRef="usd">29500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzExLTEtMS0xLTI0NTQ3Nw_34246ab8-1dca-447b-bf4f-a871380b559f"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzExLTUtMS0xLTI0NTQ3Nw_c26aef0c-2592-4e06-bc02-7c841de88bf4"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzExLTE1LTEtMS0yNDU0Nzc_1a2493f3-df34-43f6-9f34-adae1babbf26"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzEzLTEzLTEtMS0yNDU0Nzc_3df9784c-bfc8-415d-990a-5800fc9c4b3c"
      unitRef="usd">72100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzEzLTE1LTEtMS0yNDU0Nzc_d53cf2f4-6eb2-4b15-be03-f797f6f8e6c6"
      unitRef="usd">72100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE0LTEtMS0xLTI0NTQ3Nw_c9772511-bdea-4f1a-8b3b-748c17c27edd"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE0LTExLTEtMS0yNDU0Nzc_0b4384d0-1071-401b-b608-40518faddad5"
      unitRef="usd">6100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE0LTE1LTEtMS0yNDU0Nzc_c43f261c-d2d6-4f6a-b36e-eda69eb6aeaa"
      unitRef="usd">6100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE3LTEzLTEtMS0yNDU0Nzc_0cb9b869-c220-4788-aea9-848a24cf4679"
      unitRef="usd">42800000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE3LTE1LTEtMS0yNDU0Nzc_cef16086-89d8-4300-abc7-76836d657844"
      unitRef="usd">42800000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE4LTUtMS0xLTI0NTQ3Nw_bae69692-9b40-458e-8fb7-942877dfaf54"
      unitRef="usd">1400000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzE4LTE1LTEtMS0yNDU0Nzc_df539634-a662-43af-98e3-f525237858a7"
      unitRef="usd">1400000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ib9e06af2377c45eeb2be6b022a0a7a6b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTEtMS0xLTI0NTQ3Nw_0a8c599c-1c77-426e-ad9c-55cd42437aec"
      unitRef="shares">400000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="ia1da11d3aff34d16811e6124dc49db71_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTUtMS0xLTI0NTQ3Nw_ddc776fc-303f-45d0-89b5-660a98f6f69c"
      unitRef="usd">-9200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia79530d679f940d681b3f28b59f828c0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTExLTEtMS0yNDU0Nzc_308b1776-2175-4fa4-aff5-e2d94c8ee00d"
      unitRef="usd">2500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ie82964cfc1e84a65900199ea00072af5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTEzLTEtMS0yNDU0Nzc_2750e989-bb8b-4dc8-9a50-fd7de6ac4cfe"
      unitRef="usd">6800000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIyLTE1LTEtMS0yNDU0Nzc_e5075d9b-6fec-4b8d-b450-29ad1e5ad2a7"
      unitRef="usd">100000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac851ca1adc4483f827335b0959d3fb6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTEtMS0xLTI0NTQ3Nw_f14b2d47-6b58-4a26-83f3-8e6196714cd3"
      unitRef="shares">99400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iac851ca1adc4483f827335b0959d3fb6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTMtMS0xLTI0NTQ3Nw_01d10336-ac26-4d80-94de-fffd4f16acce"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie195f01f18994a1dbbf00c9ea5162424_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTUtMS0xLTI0NTQ3Nw_03a878cc-da93-451c-91d5-f3e6bd996550"
      unitRef="usd">2326600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i568f78237ee640189be8f0569e1325aa_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTctMS0xLTI0NTQ3Nw_bc875f2a-5231-400c-8717-e3c1958b1d17"
      unitRef="usd">-242300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4612a858a134e488b568b7bc4f5b31b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTExLTEtMS0yNDU0Nzc_7b51403a-87dd-4999-baa1-ccf8eda80634"
      unitRef="usd">-497400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9817c02d1254788bdfed4e092d4d240_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTEzLTEtMS0yNDU0Nzc_40cdeed9-530a-4852-b9bf-5560333e6cca"
      unitRef="usd">382000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzIzLTE1LTEtMS0yNDU0Nzc_a8aa8dbf-a6b4-49af-b2dd-6269e575124a"
      unitRef="usd">1970000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="ie89258633f59441580a344774a089493_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI0LTctMS0xLTI0NTQ3Nw_ffb874e0-2220-4ae6-a55f-df9859ab4dde"
      unitRef="usd">412200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI0LTEzLTEtMS0yNDU0Nzc_47a1c2df-3fce-4a4b-90f1-b7502e0c1a8a"
      unitRef="usd">96000000.0</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI0LTE1LTEtMS0yNDU0Nzc_234e9105-d09a-4e88-b12c-d1ca6fa9eb6a"
      unitRef="usd">508200000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ib906731d97114d82addea69f1bb3d93f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI2LTEtMS0xLTI0NTQ3Nw_b97cb0c8-6003-4a21-b23d-190de2cb78d7"
      unitRef="shares">200000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iad71d7ff6aa0428593dfb57b61019e26_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI2LTExLTEtMS0yNDU0Nzc_b33f4805-3342-44f1-8b92-721d139b1ca4"
      unitRef="usd">16400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI2LTE1LTEtMS0yNDU0Nzc_fa3ad2af-1ca2-40f7-8de4-53a0fd1bba67"
      unitRef="usd">16400000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI3LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjg4NTU4MzRiNmFjOTQ1NWU5NmFmNjYzYTNkOWRjN2JmXzI0_83de1493-8178-4c68-8750-cdd36ef5a61d"
      unitRef="usdPerShare">1.12</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="ib5df19105bbb4e44ad638452c82235f5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI3LTUtMS0xLTI0NTQ3Nw_8ece4064-5235-43f0-bc63-b49a3920e9c4"
      unitRef="usd">83800000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie89258633f59441580a344774a089493_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI3LTctMS0xLTI0NTQ3Nw_abdc0274-e17d-4248-8753-e42458668a86"
      unitRef="usd">28100000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzI3LTE1LTEtMS0yNDU0Nzc_f5c01b48-efd3-4ad1-94b7-f1ef6d961f00"
      unitRef="usd">111900000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib5df19105bbb4e44ad638452c82235f5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMwLTUtMS0xLTI0NTQ3Nw_ad3c3608-5b41-4977-a303-a516be42d0ea"
      unitRef="usd">32800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMwLTE1LTEtMS0yNDU0Nzc_9167c0ba-659d-4dfb-a697-e9d828cfce4c"
      unitRef="usd">32800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMzLTEzLTEtMS0yNDU0Nzc_0447886d-28c4-42c4-8e0c-9188a6f4a1a6"
      unitRef="usd">87800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzMzLTE1LTEtMS0yNDU0Nzc_4a4cae17-cc9f-4cda-ac8d-f3d63333223d"
      unitRef="usd">87800000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM1LTEzLTEtMS0yNDU0Nzc_d8c29233-44df-4046-8e51-d363dd70e155"
      unitRef="usd">72500000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM1LTE1LTEtMS0yNDU0Nzc_ac392bbd-28e3-44ee-9002-d1bfcf7cd778"
      unitRef="usd">72500000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ib906731d97114d82addea69f1bb3d93f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTEtMS0xLTI0NTQ3Nw_24d371ba-d993-4162-bee6-3d3a631b6559"
      unitRef="shares">300000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="ib5df19105bbb4e44ad638452c82235f5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTUtMS0xLTI0NTQ3Nw_e03a21d0-6c30-434c-9afc-d3eefd3d1071"
      unitRef="usd">-14000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="iad71d7ff6aa0428593dfb57b61019e26_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTExLTEtMS0yNDU0Nzc_d17b5801-e99b-455b-8866-1365d5a7281e"
      unitRef="usd">7400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if0beee507e7e4bdb907efe0f9e339dcb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTEzLTEtMS0yNDU0Nzc_62816f35-47d8-4102-9592-6c472c7f372a"
      unitRef="usd">17000000.0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzM5LTE1LTEtMS0yNDU0Nzc_138c8af0-dc14-4896-a903-6dab4c02b55f"
      unitRef="usd">10400000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2040827da13c48fb8523dcbbee23864e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTEtMS0xLTI0NTQ3Nw_a6d81aab-ef90-4215-9ddb-59a19de3e49c"
      unitRef="shares">99500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2040827da13c48fb8523dcbbee23864e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTMtMS0xLTI0NTQ3Nw_4003ede6-6449-48fa-99ff-883234610cd9"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8e12dea591344c0b2b9c9f457b71126_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTUtMS0xLTI0NTQ3Nw_c79d3a8c-d38d-4bb2-9e20-aa3f3290974b"
      unitRef="usd">2289600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1b3eb121a4a4b25a2563b523c8cbe4e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTctMS0xLTI0NTQ3Nw_47005940-68f5-4660-8085-d2be039bfce7"
      unitRef="usd">141800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e6aa83bba40405785127e8ed8bb4d92_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTExLTEtMS0yNDU0Nzc_e40a8147-aa58-4342-bafb-f5feadbc7234"
      unitRef="usd">-521200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie516d8d2297a44c8928335358a6b74e1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTEzLTEtMS0yNDU0Nzc_e3e3240a-c709-4730-95d8-e4196b4f054d"
      unitRef="usd">445700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQwLTE1LTEtMS0yNDU0Nzc_3083e3d6-acd3-434d-b29c-36717e5b8d93"
      unitRef="usd">2357000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i6b288a1bbc1e4a36a83f2bca14dee1ea_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQxLTctMS0xLTI0NTQ3Nw_10aa8a1a-a9a6-4a9a-909b-5dcb5d14de6e"
      unitRef="usd">271000000.0</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQxLTEzLTEtMS0yNDU0Nzc_363cdcb2-a624-4de9-8e1d-832bab567f96"
      unitRef="usd">87700000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQxLTE1LTEtMS0yNDU0Nzc_a849bb8a-1e66-435b-9b21-54cdb58b8b38"
      unitRef="usd">358700000</us-gaap:NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="ia0f7c8b4463341a0a371e690773b666a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQzLTEtMS0xLTI0NTQ3Nw_27c61ddb-7e32-419c-b5c3-3884e72523d4"
      unitRef="shares">100000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if44a6728f6fa4025b928881a0e39236d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQzLTExLTEtMS0yNDU0Nzc_be175f63-ce03-471c-930a-0f1e87bc4651"
      unitRef="usd">7700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQzLTE1LTEtMS0yNDU0Nzc_5defc7dc-12d6-49ac-90ff-a2de916b857b"
      unitRef="usd">7700000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ0LTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjI3MTEzMTE3MWJiYTRkMTdiZDkzY2FkMDUwYjg2MDY0XzI0_cfe31dad-f2e3-4c61-af85-06fd2e6282db"
      unitRef="usdPerShare">0.86</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash
      contextRef="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ0LTUtMS0xLTI0NTQ3Nw_08beb245-2ff6-4dbc-a2e0-c132e452ebc0"
      unitRef="usd">11100000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6b288a1bbc1e4a36a83f2bca14dee1ea_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ0LTctMS0xLTI0NTQ3Nw_d76ff32a-95de-4410-9ce5-d660a773fba8"
      unitRef="usd">75200000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ0LTE1LTEtMS0yNDU0Nzc_fb071ef5-8a2e-46ea-9e8e-855cdc9fc19b"
      unitRef="usd">86300000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ2LTUtMS0xLTI0NTQ3Nw_058043cf-23c8-45ed-9c6e-2a771e156ceb"
      unitRef="usd">31700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ2LTE1LTEtMS0yNDU0Nzc_bbfd8027-441f-448d-9309-48dba06c6613"
      unitRef="usd">31700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ5LTEzLTEtMS0yNDU0Nzc_f3096a34-2d39-4167-ad96-1957c4f39c56"
      unitRef="usd">99500000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzQ5LTE1LTEtMS0yNDU0Nzc_7b0a5c47-2cde-4cf0-9b73-b5e77e65bcfa"
      unitRef="usd">99500000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzUxLTEzLTEtMS0yNDU0Nzc_c1d38d98-9255-4179-8406-d2b3b038f9e5"
      unitRef="usd">100100000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzUxLTE1LTEtMS0yNDU0Nzc_54f75889-c198-4758-b91b-c33a687c27ae"
      unitRef="usd">100100000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTUtMS0xLTI2NzUyMQ_11617ffa-1de3-4e37-b96a-84dade690f68"
      unitRef="usd">-595700000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i6b288a1bbc1e4a36a83f2bca14dee1ea_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTctMS0xLTI2NzUyMQ_336e4fc0-195b-42a5-9bdb-e33a9af70a39"
      unitRef="usd">-221900000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTEzLTEtMS0yNjc1MjE_300624ad-fbf7-4074-9487-3c508ce5309e"
      unitRef="usd">-28400000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityNoteSpinoffTransaction
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTE1LTEtMS0yNzkwNDg_ab89d3f8-f83b-4966-b0d2-e761f0ebf68e"
      unitRef="usd">-846000000.0</us-gaap:StockholdersEquityNoteSpinoffTransaction>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="ia0f7c8b4463341a0a371e690773b666a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTEtMS0xLTI0NTQ3Nw_451112c2-80a9-437e-85e8-95c72a7f4d2d"
      unitRef="shares">400000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="idc59c79c483d40ad9f92ae6049f9e55a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTUtMS0xLTI0NTQ3Nw_ee165b56-9da0-48f7-86fc-2a95a345a5ac"
      unitRef="usd">-15700000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if44a6728f6fa4025b928881a0e39236d_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTExLTEtMS0yNDU0Nzc_7143e026-f19f-4bae-ab1f-7f0c54a040d2"
      unitRef="usd">7800000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2ba76c1a0b7047c19b62830b92d60356_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTEzLTEtMS0yNDU0Nzc_ea5883ec-44c0-4127-91b7-4e533fdf6040"
      unitRef="usd">-10400000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU1LTE1LTEtMS0yNDU0Nzc_ed941440-e6c0-46f2-bed5-0ea675c99599"
      unitRef="usd">-18300000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic212fffe4100400087e39b038b342ab0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTEtMS0xLTI0NTQ3Nw_5d82f09b-4c15-4dc6-a0de-729460c6ceb6"
      unitRef="shares">99800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic212fffe4100400087e39b038b342ab0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTMtMS0xLTI0NTQ3Nw_51a6e042-740c-4188-8c77-9b1ca2a671d9"
      unitRef="usd">1100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icbba5e1af20d45838cbb3098d5f3d99b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTUtMS0xLTI0NTQ3Nw_cebd9829-ac64-48a9-8ce8-98d18b3fa509"
      unitRef="usd">1730200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied260f5cc55446ac98da4ff1069c95fe_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTctMS0xLTI0NTQ3Nw_eec0e855-21d5-4518-ae2f-391c66e5b634"
      unitRef="usd">115700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iffd361313d6f4ca589272589af035b20_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTExLTEtMS0yNDU0Nzc_8b089783-ce01-4858-933f-e8bf48a69f0e"
      unitRef="usd">-536700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic39924c6425243f7a6b73371e0e4481e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTEzLTEtMS0yNDU0Nzc_354df608-38cc-4941-bd84-1e1f16f338ec"
      unitRef="usd">516000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTEvZnJhZzo5ODZiZDIzODM0ZjQ0NDI3YjQ5ZGI0YjZiZjEwYjhlYS90YWJsZTozODE1MDVkYzQ4NTk0ZTRhYTE1YjMwY2E3ZDcyODU4Mi90YWJsZXJhbmdlOjM4MTUwNWRjNDg1OTRlNGFhMTViMzBjYTdkNzI4NTgyXzU2LTE1LTEtMS0yNDU0Nzc_6cda0c2f-7ecd-41e2-ade1-be1e89bb78ee"
      unitRef="usd">1826300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQtMS0xLTEtMjQ1NDc3_8e655c8b-447e-46e0-884c-d295b0890281"
      unitRef="usd">365900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQtMy0xLTEtMjQ1NDc3_d168432e-8398-4a9a-8a04-191052ce0fd7"
      unitRef="usd">517200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQtNS0xLTEtMjQ1NDc3_1375b316-7fe5-4848-ac39-83fa683a24bc"
      unitRef="usd">368800000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzUtMS0xLTEtMjQ1NDc3_473c1b81-d4c1-42d7-8504-9e522f4501de"
      unitRef="usd">15200000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzUtMy0xLTEtMjQ1NDc3_ed4f571a-eea5-4f2f-be90-8c3422784617"
      unitRef="usd">114100000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzUtNS0xLTEtMjQ1NDc3_c0ce573e-5c93-4fe8-9901-283deaa773b4"
      unitRef="usd">90600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:LitigationSettlementExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzctMS0xLTEtMjQ1NDc3_ddc9eaa3-b007-4ca7-8db4-a57f28880ff6"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzctMy0xLTEtMjQ1NDc3_d3591744-6255-4217-8750-dac38d48bba7"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzctNS0xLTEtMjQ1NDc3_1b16e5fb-c79f-4cce-8da1-e4b8d47ea51b"
      unitRef="usd">2800000</us-gaap:LitigationSettlementExpense>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzgtMS0xLTEtMjQ1NDc3_b55b4777-b6a3-440e-9fa8-c9b54a4a7780"
      unitRef="usd">243600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzgtMy0xLTEtMjQ1NDc3_28245583-d29f-4494-83f7-115d8e1379df"
      unitRef="usd">219600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzgtNS0xLTEtMjQ1NDc3_14346009-8f29-494e-a6d9-f11e3ecd0fc9"
      unitRef="usd">203000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzktMS0xLTEtMjQ1NDc3_774cad88-865c-4caa-91a7-1bddd743118e"
      unitRef="usd">9700000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzktMy0xLTEtMjQ1NDc3_15dd8fa9-611c-44fd-a40e-79be29230b49"
      unitRef="usd">7800000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzktNS0xLTEtMjQ1NDc3_a8c460ef-b99b-4266-8643-f058174e334f"
      unitRef="usd">7200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEwLTEtMS0xLTI0NTQ3Nw_4f442348-0661-4c69-88d0-07e50e34bfb6"
      unitRef="usd">-1400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEwLTMtMS0xLTI0NTQ3Nw_b09f84eb-4bcf-462e-a074-b6a30fe7ed7b"
      unitRef="usd">-1000000.0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEwLTUtMS0xLTI0NTQ3Nw_2d6f0923-66ca-4a81-806a-ee060e4b3473"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzExLTEtMS0xLTI0NTQ3Nw_0fc66e34-8166-41e6-b564-ef302c723537"
      unitRef="usd">2900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzExLTMtMS0xLTI0NTQ3Nw_003a3dae-d8c3-43c1-8f1c-6708d38b4e80"
      unitRef="usd">3400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzExLTUtMS0xLTI0NTQ3Nw_89b6c63e-4e78-4727-87dc-9837bc058887"
      unitRef="usd">2900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEyLTEtMS0xLTI0NTQ3Nw_a85a500e-79c2-448c-8cd0-a0765814db90"
      unitRef="usd">4000000.0</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEyLTMtMS0xLTI0NTQ3Nw_af3c72f2-859d-4124-bfb7-559adace43b4"
      unitRef="usd">2600000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEyLTUtMS0xLTI0NTQ3Nw_214717a7-b311-4c59-b969-3d372a2fdb63"
      unitRef="usd">3400000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:ShareBasedCompensation
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEzLTEtMS0xLTI0NTQ3Nw_7e24a14f-032f-4a8f-be4d-adab8684993e"
      unitRef="usd">29200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEzLTMtMS0xLTI0NTQ3Nw_4df8acf5-2005-4b1a-bee4-f82370cb60ca"
      unitRef="usd">29100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzEzLTUtMS0xLTI0NTQ3Nw_b5b6251f-da77-42b6-901e-0377f632c9eb"
      unitRef="usd">25600000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE0LTEtMS0xLTI0NTQ3Nw_42a78788-4cbd-47a2-8968-634e1051936d"
      unitRef="usd">27900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE0LTMtMS0xLTI0NTQ3Nw_4431fcfb-f3cb-4910-a823-8663e460089e"
      unitRef="usd">17400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE0LTUtMS0xLTI0NTQ3Nw_e9e8bccf-b94a-4e21-993c-dda3fb30b4d9"
      unitRef="usd">34500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE2LTEtMS0xLTI0NTQ3Nw_273a43fb-7dce-4c7e-a3c8-e3d12792827d"
      unitRef="usd">-20300000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE2LTMtMS0xLTI0NTQ3Nw_a76662e0-c6ed-4d86-93c1-9e6884239c29"
      unitRef="usd">2600000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE2LTUtMS0xLTI0NTQ3Nw_a43bda7f-5582-44bb-beff-a6c631091a0b"
      unitRef="usd">-6800000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE4LTEtMS0xLTI0NTQ3Nw_d1120c5d-6c13-4daf-8a34-8199520671d1"
      unitRef="usd">16900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE4LTMtMS0xLTI0NTQ3Nw_2b895290-c001-454b-a5fd-849729c0b7c1"
      unitRef="usd">39500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE4LTUtMS0xLTI0NTQ3Nw_47197718-8cea-4948-bf0d-f88ba51cf6bb"
      unitRef="usd">5100000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE5LTEtMS0xLTI0NTQ3Nw_52f9891b-3974-42b4-a3a6-2318f68fbac4"
      unitRef="usd">-8000000.0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE5LTMtMS0xLTI0NTQ3Nw_68743966-bee0-41c7-abde-b55c0275c582"
      unitRef="usd">41800000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzE5LTUtMS0xLTI0NTQ3Nw_5d3ce845-62fd-431c-87a0-56fd863ba71a"
      unitRef="usd">1200000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIwLTEtMS0xLTI0NTQ3Nw_965180a1-ab44-431f-814f-6adb2ebc5a75"
      unitRef="usd">2300000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIwLTMtMS0xLTI0NTQ3Nw_d2066cb3-1029-4a6d-bfc3-9fb617857360"
      unitRef="usd">15600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIwLTUtMS0xLTI0NTQ3Nw_a86c4092-07f2-454a-a58e-f67c5f16c396"
      unitRef="usd">14100000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIxLTEtMS0xLTI0NTQ3Nw_9a054e84-3cb5-4d73-b11b-797d9f9aafe0"
      unitRef="usd">-31200000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIxLTMtMS0xLTI0NTQ3Nw_bfb849e7-4e85-4dd1-bb45-dcec41845912"
      unitRef="usd">-30400000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIxLTUtMS0xLTI0NTQ3Nw_febccb7d-0e50-49a8-8f2d-52ec8f859a33"
      unitRef="usd">79200000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIzLTEtMS0xLTI3MTg1MA_d050cb46-d3a5-4064-a512-a544f0609c5c"
      unitRef="usd">-1700000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIzLTMtMS0xLTI3MTg1MA_a1d0b0cf-6a71-42ea-ada9-4466fbc0715b"
      unitRef="usd">-2600000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIzLTUtMS0xLTI3MTg1MA_11bfd8d8-6865-45d1-8596-3173d5caf268"
      unitRef="usd">14700000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIyLTEtMS0xLTI0NTQ3Nw_56bed37e-6efc-4c7d-b657-81aa0bdbaef6"
      unitRef="usd">9100000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIyLTMtMS0xLTI0NTQ3Nw_ee9d325e-d6b3-45fb-9ee1-cc7291e2d1c2"
      unitRef="usd">-11200000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzIyLTUtMS0xLTI0NTQ3Nw_cfeffe85-f247-4dd7-9cb1-07677b417edc"
      unitRef="usd">6300000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI2LTEtMS0xLTI0NTQ3Nw_0d4393a9-2281-4949-a68f-85c5b03db1fc"
      unitRef="usd">52300000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI2LTMtMS0xLTI0NTQ3Nw_c96ce267-d436-48ca-9de0-ba2ec0a433c5"
      unitRef="usd">151100000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI2LTUtMS0xLTI0NTQ3Nw_aba9fa0c-1eba-4200-b7e5-ce91b3079dbe"
      unitRef="usd">35800000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI3LTEtMS0xLTI0NTQ3Nw_b6056c1a-be5c-449d-9483-c46ba9153b82"
      unitRef="usd">355100000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI3LTMtMS0xLTI0NTQ3Nw_e862eeb3-039d-4382-85d1-cedcda8a8863"
      unitRef="usd">312700000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI3LTUtMS0xLTI0NTQ3Nw_cdf05355-4aa2-46cb-8401-413cf653990b"
      unitRef="usd">426500000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI4LTEtMS0xLTI0NTQ3Nw_bd72ce3d-da87-4d05-9915-c355aa6ea764"
      unitRef="usd">705800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI4LTMtMS0xLTI0NTQ3Nw_fe4d969a-8ea0-4476-a694-befa0dbea7ee"
      unitRef="usd">715800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzI4LTUtMS0xLTI0NTQ3Nw_eb44996c-507d-4331-b9ed-a92cd1465e84"
      unitRef="usd">704700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMwLTEtMS0xLTI0NTQ3Nw_cbe6114d-1870-4be0-8324-1f2cf455e0b5"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMwLTMtMS0xLTI0NTQ3Nw_ea0bff0c-f626-40a2-98f4-b8659839d21f"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMwLTUtMS0xLTI0NTQ3Nw_ebd6a5f4-2684-494b-b109-d0cb6cc07bf2"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMxLTEtMS0xLTI0NTQ3Nw_905b138b-5d2b-4ba1-ad3d-dea7f8727a51"
      unitRef="usd">564800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMxLTMtMS0xLTI0NTQ3Nw_d891eb6b-1303-4abc-a4e7-93abcbe3d9b1"
      unitRef="usd">524600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMxLTUtMS0xLTI0NTQ3Nw_609db11e-7bee-482e-bbba-333a3dca4f70"
      unitRef="usd">392800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForSoftware
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMyLTEtMS0xLTI0NTQ3Nw_899ca6fc-bcb4-4244-b7e8-8a87e58dfebe"
      unitRef="usd">9200000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMyLTMtMS0xLTI0NTQ3Nw_2f929bf9-7b3e-44d1-a134-febe6ee1e20d"
      unitRef="usd">14600000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMyLTUtMS0xLTI0NTQ3Nw_a112bfeb-1b95-4a27-96a6-b059c06711b5"
      unitRef="usd">8300000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMzLTEtMS0xLTI0NTQ3Nw_30946aad-15e1-4c29-96c1-e482d4e9660c"
      unitRef="usd">10100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMzLTMtMS0xLTI0NTQ3Nw_5ee9c854-5410-4698-94aa-be088df4cab0"
      unitRef="usd">6500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzMzLTUtMS0xLTI0NTQ3Nw_273586ef-502d-4db3-9a0f-4923e4db0175"
      unitRef="usd">3500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM2LTEtMS0xLTI0NTQ3Nw_0b3c6522-34bc-4e62-98a9-978ef1e19491"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM2LTMtMS0xLTI0NTQ3Nw_0a040385-deee-406a-a833-484e6f08c08d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:ProceedsFromSaleOfRestrictedInvestments
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM2LTUtMS0xLTI0NTQ3Nw_4766e9e9-0112-456f-ada4-5c65d6d2e2e0"
      unitRef="usd">12600000</us-gaap:ProceedsFromSaleOfRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM3LTEtMS0xLTI0NTQ3Nw_6d367fca-c2ff-4199-bbef-1151daf39df5"
      unitRef="usd">35200000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM3LTMtMS0xLTI0NTQ3Nw_42da92fe-711f-4da9-9d76-1b3b630bd4dc"
      unitRef="usd">9000000.0</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsToAcquireRestrictedInvestments
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM3LTUtMS0xLTI0NTQ3Nw_a83501fb-d093-4d5e-8353-7fd851021f21"
      unitRef="usd">8700000</us-gaap:PaymentsToAcquireRestrictedInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM4LTEtMS0xLTI0NTQ3Nw_62101482-37c0-48d7-b519-6a581b4c47e5"
      unitRef="usd">4200000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM4LTMtMS0xLTI0NTQ3Nw_3eb3c0b8-a877-4171-a175-29fbffb76d0d"
      unitRef="usd">-8700000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM4LTUtMS0xLTI0NTQ3Nw_6fff97b9-972e-4c7e-aa8e-71d480b6ea22"
      unitRef="usd">3800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM5LTEtMS0xLTI0NTQ3Nw_480974f1-a336-4317-b432-e9903ba8777d"
      unitRef="usd">-3500000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM5LTMtMS0xLTI0NTQ3Nw_40980dfd-39c9-4a73-872d-7cadbcfe2343"
      unitRef="usd">-119200000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzM5LTUtMS0xLTI0NTQ3Nw_6c0794db-8ba3-4a91-9c07-cb31532858aa"
      unitRef="usd">-3000000.0</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQwLTEtMS0xLTI0NTQ3Nw_6f13b968-cb53-47b7-9544-9a1d1d1d9db4"
      unitRef="usd">-627000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQwLTMtMS0xLTI0NTQ3Nw_8cbccaac-0a3b-44b6-8f1f-4bd5d437587a"
      unitRef="usd">-666300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTpkOTgxYTRhY2ZlODA0MGVjODhhMWIwYjJkY2ZmZTAyZC90YWJsZXJhbmdlOmQ5ODFhNGFjZmU4MDQwZWM4OGExYjBiMmRjZmZlMDJkXzQwLTUtMS0xLTI0NTQ3Nw_38ea2b92-591f-4cb5-9cb9-96ebe667009c"
      unitRef="usd">-407500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzUtMS0xLTEtMjQ1NDc3_d8f7108d-bf13-4c37-b88e-554f608f6ee9"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzUtMy0xLTEtMjQ1NDc3_274e877e-adfe-4ff5-b91f-0782ad145b7b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzUtNS0xLTEtMjQ1NDc3_ea6fa7cd-7143-41f8-a5aa-f24740a51bd9"
      unitRef="usd">992500000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzYtMS0xLTEtMjQ1NDc3_38b324c7-0323-4aba-b8f2-03dfd1736584"
      unitRef="usd">345800000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzYtMy0xLTEtMjQ1NDc3_cfdaa380-18c0-45f2-b8da-d5ec30f2d055"
      unitRef="usd">214500000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzYtNS0xLTEtMjQ1NDc3_d9425588-2929-42ef-90c5-25269f5524a5"
      unitRef="usd">717200000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzctMS0xLTEtMjQ1NDc3_f149bf11-6571-4c38-ace3-98a3ecf21a01"
      unitRef="usd">11800000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzctMy0xLTEtMjQ1NDc3_7c7af3c8-c211-4428-afa7-88d8fc1cf21b"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzctNS0xLTEtMjQ1NDc3_03b128c9-3cdf-40b9-9e96-fb23cdcbcd1a"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzktMS0xLTEtMjQ1NDc3_62fb63d5-f736-47e3-9153-e85f9adec65f"
      unitRef="usd">240000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzktMy0xLTEtMjQ1NDc3_7563fb7d-d4a6-4274-8046-7143d72a9037"
      unitRef="usd">300000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzktNS0xLTEtMjQ1NDc3_a8ba6ef8-c02d-4714-b243-d103a798c339"
      unitRef="usd">330000000.0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEwLTEtMS0xLTI0NTQ3Nw_3923f6c8-34c9-4a2f-86aa-5a245ac4fb95"
      unitRef="usd">385000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEwLTMtMS0xLTI0NTQ3Nw_7314a869-658c-4a98-ad71-1057a7327f9d"
      unitRef="usd">100000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEwLTUtMS0xLTI0NTQ3Nw_b3048e23-6582-40c5-a606-9fb1210e38b1"
      unitRef="usd">375000000.0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzExLTEtMS0xLTI0NTQ3Nw_313eeb04-cb92-458a-a70f-3c72b3a31c42"
      unitRef="usd">19200000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzExLTMtMS0xLTI0NTQ3Nw_631f27d3-f7cc-4e3d-87ad-f8a96cae1594"
      unitRef="usd">44600000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzExLTUtMS0xLTI0NTQ3Nw_46829eac-8b73-458e-9045-40a229f8336b"
      unitRef="usd">14400000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEyLTEtMS0xLTI0NTQ3Nw_396c7842-a6d3-46df-a27d-2fe36e892f48"
      unitRef="usd">24100000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEyLTMtMS0xLTI0NTQ3Nw_be7a16d3-c2cb-4310-ad8a-9e0e157a207e"
      unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEyLTUtMS0xLTI0NTQ3Nw_2d7c2472-45c5-4374-8d1f-b620037a88de"
      unitRef="usd">20300000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEzLTEtMS0xLTI0NTQ3Nw_df482474-4667-4918-8ce1-9848bb45e2ad"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEzLTMtMS0xLTI0NTQ3Nw_c57559d6-efd1-4cb1-bec7-d052d68ffa8e"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzEzLTUtMS0xLTI0NTQ3Nw_233029ba-2e59-44bd-9f76-28c72f480234"
      unitRef="usd">6100000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE1LTEtMS0xLTI0NTQ3Nw_39376473-783b-4a09-b2bb-c5e3a5467650"
      unitRef="usd">99000000.0</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE1LTMtMS0xLTI0NTQ3Nw_533668fa-1b06-4b4a-9c17-88f6cdbf6905"
      unitRef="usd">112200000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE1LTUtMS0xLTI0NTQ3Nw_1d5886e9-20fb-4850-a7eb-5a62732d6754"
      unitRef="usd">111800000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE2LTEtMS0xLTI0NTQ3Nw_bd0f7780-ec83-4f94-bd49-dfa5ad0c1cf9"
      unitRef="usd">0</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE2LTMtMS0xLTI0NTQ3Nw_636a398d-d2fe-4da8-aaf0-823f03c728f7"
      unitRef="usd">0</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE2LTUtMS0xLTI0NTQ3Nw_d1897de8-24b7-422e-9087-02b6012e4576"
      unitRef="usd">162300000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE5LTEtMS0xLTI0NTQ3Nw_53efc90a-f887-4394-989a-d591b0efac9c"
      unitRef="usd">96600000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE5LTMtMS0xLTI0NTQ3Nw_71aabf1a-316e-4db0-b5d1-e6200f13ac5c"
      unitRef="usd">101100000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzE5LTUtMS0xLTI0NTQ3Nw_a54f0b07-196c-4ac3-9d69-63c510419565"
      unitRef="usd">70900000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIwLTEtMS0xLTI0NTQ3Nw_08bb0ce5-8e40-47e1-85e8-f9ab6c8a9ef5"
      unitRef="usd">7300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIwLTMtMS0xLTI0NTQ3Nw_93dc9e03-8021-4132-8075-52723234d65a"
      unitRef="usd">14600000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIwLTUtMS0xLTI0NTQ3Nw_3d6571df-48b6-4fb2-9474-29b201df0070"
      unitRef="usd">14700000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIxLTEtMS0xLTI0NTQ3Nw_40f695d1-318b-4a05-a4f6-92edb7c15192"
      unitRef="usd">64100000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIxLTMtMS0xLTI0NTQ3Nw_90acf71c-08b2-4b69-9888-8f8d00bde917"
      unitRef="usd">57200000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIxLTUtMS0xLTI0NTQ3Nw_244299f3-bed4-42a3-91f1-bdd54b7d1157"
      unitRef="usd">34900000</us-gaap:ProceedsFromContributionsFromAffiliates>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIyLTEtMS0xLTI0NTQ3Nw_27169ab4-015a-4a05-b466-c8ffacd7afd9"
      unitRef="usd">300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIyLTMtMS0xLTI0NTQ3Nw_ea319ea5-5efc-4253-b175-d3339d002920"
      unitRef="usd">-100000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIyLTUtMS0xLTI0NTQ3Nw_3e767600-b832-4d4d-b2d2-5ab84f0bb4f6"
      unitRef="usd">1000000.0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTEtMS0xLTI2NzU1OA_0b21a6eb-8078-489f-a425-1a28f74134ca"
      unitRef="usd">515100000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTMtMS0xLTI2NzU1OA_f793c4fa-8602-4268-a593-b780754d4d5c"
      unitRef="usd">-10200000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTUtMS0xLTI2NzU1OA_6cc4d622-5296-4fd3-91f0-4156c814ebfc"
      unitRef="usd">-11600000</us-gaap:CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTEtMS0xLTI0NTQ3Nw_3a20674c-ea5d-46cc-86a7-a5d31677d13a"
      unitRef="usd">-145700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTMtMS0xLTI0NTQ3Nw_626632c8-655e-433f-882d-45c26121334f"
      unitRef="usd">-240100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzIzLTUtMS0xLTI0NTQ3Nw_2d301530-8f3b-493b-99c4-713892f41b60"
      unitRef="usd">-145900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI0LTEtMS0xLTI0NTQ3Nw_1ebae159-ab65-4f41-8433-86619e06b650"
      unitRef="usd">-66900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI0LTMtMS0xLTI0NTQ3Nw_bcfcf166-7a19-4db4-9fd0-e5f2ad408474"
      unitRef="usd">-190600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI0LTUtMS0xLTI0NTQ3Nw_76413216-bff5-455f-a919-1375fdf87635"
      unitRef="usd">151300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI1LTEtMS0xLTI0NTQ3Nw_c5d1b8b0-dc84-47fb-92f2-85321de9f031"
      unitRef="usd">120300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI1LTMtMS0xLTI0NTQ3Nw_f65e72a8-c493-4bd5-aed2-a197a85c2899"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI1LTUtMS0xLTI0NTQ3Nw_90c8fd5e-aa53-4a4a-91e9-e75cd66bbc41"
      unitRef="usd">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI2LTEtMS0xLTI0NTQ3Nw_ad63a0df-0a77-4e89-8df9-c14141a12227"
      unitRef="usd">53400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI2LTMtMS0xLTI0NTQ3Nw_75aa966f-5a10-42d0-baa2-e2addfb9fabb"
      unitRef="usd">120300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI2LTUtMS0xLTI0NTQ3Nw_78fa9dd7-189d-44a3-bcfd-4318e70fd34f"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI5LTEtMS0xLTI0NTQ3Nw_c4e02f8b-7307-4e7f-b26c-9bea8f2f0f98"
      unitRef="usd">49400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI5LTMtMS0xLTI0NTQ3Nw_8556401a-9cc6-4287-8c5f-028550c8ecfb"
      unitRef="usd">185600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzI5LTUtMS0xLTI0NTQ3Nw_19777dcf-a66b-482a-ac5d-cf3eb09254e0"
      unitRef="usd">60000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMwLTEtMS0xLTI0NTQ3Nw_80bf8159-b0fd-4b32-b1ee-fe521ef05305"
      unitRef="usd">62500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMwLTMtMS0xLTI0NTQ3Nw_c45426e3-3d9b-441c-a5a6-bddd030f5957"
      unitRef="usd">63900000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMwLTUtMS0xLTI0NTQ3Nw_22c2a81f-7ce2-47f0-8ef6-44ad0507c8f2"
      unitRef="usd">57400000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMxLTEtMS0xLTI0NTQ3Nw_aa0b82dc-683f-40dc-94c3-045f6855a58b"
      unitRef="usd">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMxLTMtMS0xLTI0NTQ3Nw_58f92cd6-0ace-4946-9bb0-d4e3668b2168"
      unitRef="usd">21500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMxLTUtMS0xLTI0NTQ3Nw_0ceaf3d4-110e-43b2-8226-d999f4911f32"
      unitRef="usd">7400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMzLTEtMS0xLTI2NzU3Mg_f9cf2daf-408b-4e83-8ff5-3fedf6890387"
      unitRef="usd">8000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMzLTMtMS0xLTI2NzU3Mg_2296e2b9-6cf9-478e-ae85-ea65f9fdf285"
      unitRef="usd">39900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMzLTUtMS0xLTI2NzU3Mg_ee196963-11ce-4fa9-9016-fbef9ed8dfbd"
      unitRef="usd">34800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMyLTEtMS0xLTI0NTQ3Nw_a53f9155-98d8-4f37-9e2e-b3dbb870047a"
      unitRef="usd">120300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMyLTMtMS0xLTI0NTQ3Nw_08092632-04e6-4884-8e9d-e615e130b009"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzMyLTUtMS0xLTI0NTQ3Nw_ece8d58e-c350-47fb-be55-0b40d58cf965"
      unitRef="usd">159600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM0LTEtMS0xLTI0NTQ3Nw_cce0bdcc-0682-409e-bcd6-9c060fd71f79"
      unitRef="usd">21800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM0LTMtMS0xLTI0NTQ3Nw_c229e556-f2dd-4e97-a1e3-c9277504d92e"
      unitRef="usd">49400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM0LTUtMS0xLTI0NTQ3Nw_d9c5fc12-5e0e-45c9-970f-e76713c26f1f"
      unitRef="usd">185600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM1LTEtMS0xLTI0NTQ3Nw_9792fa6d-9c78-4393-907e-3083500cf56c"
      unitRef="usd">31600000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM1LTMtMS0xLTI0NTQ3Nw_a56cdd55-b7ae-4e48-bbbe-9b5346466682"
      unitRef="usd">62500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM1LTUtMS0xLTI0NTQ3Nw_8f33121f-0509-492f-b46b-ca59757b708e"
      unitRef="usd">63900000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM2LTEtMS0xLTI0NTQ3Nw_771a2e95-91ea-42dd-874a-c33f94b1dd8e"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM2LTMtMS0xLTI0NTQ3Nw_4fb2588b-fbc0-4bdb-b8a6-1b6ad9dc7e60"
      unitRef="usd">400000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM2LTUtMS0xLTI0NTQ3Nw_6e0c16a7-458a-488e-ab88-dfd02d48774d"
      unitRef="usd">21500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM5LTEtMS0xLTI2NzYxNg_c0d95ed0-9495-4222-8178-9eedbad470be"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM5LTMtMS0xLTI2NzYxNg_9b62b21f-6d3f-4d83-92da-e1d89b695b83"
      unitRef="usd">8000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM5LTUtMS0xLTI2NzYxNg_e9f866c4-b6d5-4472-829c-df9834586836"
      unitRef="usd">39900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM3LTEtMS0xLTI0NTQ3Nw_dfc364ea-0991-4e0e-8c4d-2c0a7ddeba62"
      unitRef="usd">53400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM3LTMtMS0xLTI0NTQ3Nw_b8f52d30-f04e-4a52-811b-73e312752299"
      unitRef="usd">120300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzM3LTUtMS0xLTI0NTQ3Nw_c28f0eac-507c-468d-b679-1eaa5401dde6"
      unitRef="usd">310900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQxLTEtMS0xLTI0NTQ3Nw_d9cd01aa-18f9-4117-8d69-0b817bd3f777"
      unitRef="usd">178400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQxLTMtMS0xLTI0NTQ3Nw_68aca672-7ca7-44d2-b07c-c8fbfa79a970"
      unitRef="usd">168400000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQxLTUtMS0xLTI0NTQ3Nw_bbc00c5f-0117-4c40-b71a-6c02396866d0"
      unitRef="usd">168400000</us-gaap:InterestPaidNet>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQyLTEtMS0xLTI0NTQ3Nw_05d962b8-6782-4604-bbfc-df4d37a01053"
      unitRef="usd">1000000.0</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQyLTMtMS0xLTI0NTQ3Nw_4d4175df-e62c-4c44-9af8-fa040d425166"
      unitRef="usd">1800000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQyLTUtMS0xLTI0NTQ3Nw_55c55393-1177-49e0-86af-3598c3ba7145"
      unitRef="usd">1400000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:IncomeTaxesPaid
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQzLTEtMS0xLTI0NTQ3Nw_8926f931-66fb-4cc4-969d-9f83c0ab9580"
      unitRef="usd">51200000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQzLTMtMS0xLTI0NTQ3Nw_b1a38320-9f64-4623-a01d-c3a0b02e1495"
      unitRef="usd">131400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNTQvZnJhZzpiNDQwOGU4Y2NkYTU0YWE2ODcxNDUyZjZlMzgxYWRkZS90YWJsZTozMDdkN2Q4NTcwNWY0NTZjYTIxMjQ2NDMzZDU5NjgzNi90YWJsZXJhbmdlOjMwN2Q3ZDg1NzA1ZjQ1NmNhMjEyNDY0MzNkNTk2ODM2XzQzLTUtMS0xLTI0NTQ3Nw_eb765702-6b2a-485c-994b-2dbd2c2df9d1"
      unitRef="usd">34300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjAvZnJhZzo2MDNiYmRjOWIzYjk0ZmM3YjRlODBmMWM5MDY5NTQwZi90ZXh0cmVnaW9uOjYwM2JiZGM5YjNiOTRmYzdiNGU4MGYxYzkwNjk1NDBmXzQ4_fecb6ea0-77bd-4127-bf0d-c9e21963b791">Summary of Significant Accounting Policies:&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Organization and Description of Business&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health Corporation, incorporated in Delaware in 1984, including its subsidiaries, is a provider of inpatient rehabilitation services. We operate hospitals in 36 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of December&#160;31, 2022, we operate 153 inpatient rehabilitation hospitals. We are the sole owner of 95 of these hospitals. We retain 50.0% to 97.5% ownership in the remaining 58 jointly owned hospitals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Consolidation&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to Encompass Health&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We eliminate all significant intercompany accounts and transactions from our financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any entity considered a variable interest entity (&#x201c;VIE&#x201d;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates and Assumptions&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#x2019; compensation, and comprehensive general insurance liability risks; and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a healthcare provider, we are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. These laws and regulations relate to, among other things:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;licensure, certification, and accreditation;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;coding and billing for services;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;requirements of the 60% compliance threshold under The Medicare, Medicaid and State Children&#x2019;s Health Insurance Program (SCHIP) Extension Act of 2007;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;quality of medical care;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;use and maintenance of medical supplies and equipment;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;maintenance and security of patient information and medical records;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;acquisition and dispensing of pharmaceuticals and controlled substances; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;disposal of medical and hazardous waste.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the future, changes in these laws or regulations or the manner in which they are enforced could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our hospitals, equipment, personnel, services, capital expenditure programs, operating procedures, contractual arrangements, and patient admittance practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If we fail to comply with applicable laws and regulations, we could be required to return portions of reimbursements deemed after the fact to have not been appropriate. We could also be subjected to liabilities, including (1)&#160;criminal penalties, (2)&#160;civil penalties, including monetary penalties and the loss of our licenses to operate one or more of our hospitals, and (3)&#160;exclusion or suspension of one or more of our hospitals from participation in the Medicare, Medicaid, and other federal and state healthcare programs which, if lengthy in duration and material to us, could potentially trigger a default under our credit agreement. Because Medicare comprises a significant portion of our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. Specifically, reductions in reimbursements, substantial damages, and other remedies assessed against us could have a material adverse effect on our business, financial position, results of operation, and cash flows. Even the assertion of a violation, depending on its nature, could have a material adverse effect upon our stock price or reputation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, the United States Congress and some state legislatures have periodically proposed significant changes in regulations governing the healthcare system. Many of these changes have resulted in limitations on the increases in and, in some cases, significant roll-backs or reductions in the levels of payments to healthcare providers for services under many government reimbursement programs. There can be no assurance that future governmental initiatives will not result in pricing roll-backs or freezes or reimbursement reductions. Because we receive a significant percentage of our revenues from Medicare, such changes in legislation might have a material adverse effect on our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there are increasing pressures from many third-party payors to control healthcare costs and to reduce or limit increases in reimbursement rates for medical services. Our relationships with managed care and nongovernmental third-party payors are generally governed by negotiated agreements. These agreements set forth the amounts we are entitled to receive for our services. We could be adversely affected in some of the markets where we operate if we are unable to negotiate and maintain favorable agreements with third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our third-party payors may also, from time to time, request audits of the amounts paid, or to be paid, to us. We could be adversely affected in some of the markets where we operate if the auditing payor alleges substantial overpayments were made to us due to coding errors or lack of documentation to support medical necessity determinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note&#160;18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies and Other Commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we are a party to a number of lawsuits. We cannot predict the outcome of litigation filed against us. Substantial damages or other monetary remedies assessed against us could have a material adverse effect on our business, financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Operating Revenues&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by payor source are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#x201c;HHS-OIG&#x201d;) or the United States Department of Justice (the &#x201c;DOJ&#x201d;). Therefore, we are unable to predict if or when we may be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Administrative Contractors (&#x201c;MACs&#x201d;), under programs known as &#x201c;widespread probes,&#x201d; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#x201c;appeal,&#x201d; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#x201c;OMHA&#x201d;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. During 2022, the backlog of &#x201c;widespread probe&#x201d; claims adjudicated by the administrative law judge (&#x201c;ALJ&#x201d;) continued and were substantially completed. This OMHA practice resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims. We have appealed certain adverse ALJ rulings to the Department Appeals Boards (&#x201c;DAB&#x201d;), the final level of administrative review. As of December 31, 2022, approximately $52&#160;million in claims are awaiting review at the DAB. In addition, we have appealed approximately $6&#160;million in claims denied by the DAB to several United States District Courts, all of which are pending review as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, CMS announced the Targeted Probe and Educate (&#x201c;TPE&#x201d;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with CMS approved and announced Recovery Audit Contractors (&#x201c;RACs&#x201d;) audits related to inpatient rehabilitation facilities (&#x201c;IRFs&#x201d;), we received requests from 2013 to 2022 to review certain patient files for discharges occurring from 2010 to 2022.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#x2019;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS has also established Unified Program Integrity Contractors (&#x201c;UPICs&#x201d;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors. In December 2017, we received notice of a UPIC audit at one of our hospitals. The UPIC sampled 100 claims and challenged the propriety of a subset of the sample representing $1.3&#160;million in previously paid claims. The UPIC extrapolated the alleged error rate to all claims from that hospital during a period of approximately four years, resulting in an alleged overpayment of $33.9&#160;million. Our MAC later reduced the determination of overpayment to $30.5&#160;million, which it collected through recoupment of current claims during 2019. We appealed the overpayment determination to an Administrative Law Judge (&#x201c;ALJ&#x201d;), who heard the appeal in August 2021. In October 2022, the ALJ &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;overturned $12.5&#160;million of the overpayment determination. We received payment of this amount, plus $3.2&#160;million in interest, in December 2022. We have appealed the remaining $18.0&#160;million of the overpayment determination to the DAB, the next level of administrative appeal, challenging both the denials and the improper use of extrapolation. It is not possible to predict when this matter will be resolved or the ultimate outcome.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Medicare claims that are subject to these post-payment audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2022. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2022, 2021, and 2020, our adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for claims that are part of this post-payment claims review process was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#x2019;s total length of stay for in-house patients, each patient&#x2019;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; include highly liquid investments with maturities of three months or less when purchased. Carrying values of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; approximate fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is a separate component of shareholders&#x2019; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of &lt;/span&gt;&lt;/div&gt;time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#x2019; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care and other discount plans, including Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#x2019;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state &lt;/span&gt;&lt;/div&gt;governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. In general, we do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other Intangible Assets&#x2014; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess qualitative factors in our single reporting unit to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our reporting unit using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of our reporting unit&#x2019;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting unit to our market capitalization. When we dispose of a hospital, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2022, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#x2019;s carrying amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;br/&gt;and Amortization Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 18 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;indefinite-lived asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market access assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years using accelerated basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and certain directly related payroll costs. Amortization begins when the internal-use software is ready for its intended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#x2019;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets and Other Intangible Assets&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#x2019;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Costs&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cost approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See also the &#x201c;Redeemable Noncontrolling Interests&#x201d; section of this note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling Interests in Consolidated Affiliates&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#x2019; balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future.  Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital in excess of par value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to certain members of the home health and hospice management team&#x2019;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $400&#160;million or more. The fair value of our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#x2019; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inputs. The projected operating results use management&#x2019;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.&lt;/span&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Reserves&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advertising Costs&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within the accompanying consolidated statements of comprehensive income, were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.6 million, and $4.6 million in each of the years ended December 31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the asset and liability method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We &lt;/span&gt;&lt;/div&gt;include the allocable portion of each pass-through entity&#x2019;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes. &lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities in and Results of Discontinued Operations&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income from discontinued operations, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Current assets of discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Noncurrent assets of discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Current liabilities of discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent liabilities of discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Common Share&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury Stock&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital in excess of par value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We account for the retirement of treasury stock as a reduction of retained earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is comprised of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzY1OTcwNjk3Njk0ODg_aec57746-9e51-4c36-b68e-eee2c08ba3e7"
      unitRef="state">36</us-gaap:NumberOfStatesInWhichEntityOperates>
    <ehc:NumberOfInpatientRehabilitationHospitals
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk0Nw_6a82e033-32c5-47ef-93d4-0ab92e22f20e"
      unitRef="hospital">153</ehc:NumberOfInpatientRehabilitationHospitals>
    <ehc:NumberOfInpatientRehabilitationHospitalsSoleOwnership
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk1MA_e2582c90-20c5-45a2-85cb-9536cd9ac7ed"
      unitRef="hospital">95</ehc:NumberOfInpatientRehabilitationHospitalsSoleOwnership>
    <ehc:Jointventureownershippercentage
      contextRef="ic9f4a444a849477298194909155a4a2e_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk1NA_a2059663-fa5f-4600-b83d-26935bfb5805"
      unitRef="number">0.500</ehc:Jointventureownershippercentage>
    <ehc:Jointventureownershippercentage
      contextRef="i1e1655a7659d44a5848ce4031db00715_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk1Nw_79d72436-1566-425d-83e4-77c05d3bd5a0"
      unitRef="number">0.975</ehc:Jointventureownershippercentage>
    <ehc:NumberOfJointlyOwnedInpatientRehabilitationHospitals
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjMvZnJhZzo4NTZkMDQ2MDBiNTk0ZGQ2ODQzNjdkYzFiNTRiMzYzMy90ZXh0cmVnaW9uOjg1NmQwNDYwMGI1OTRkZDY4NDM2N2RjMWI1NGIzNjMzXzU0OTc1NTgxNTk2MA_b187f73b-a881-4332-a674-fcf42568c8bb"
      unitRef="hospital">58</ehc:NumberOfJointlyOwnedInpatientRehabilitationHospitals>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjYvZnJhZzplMGJhZTVkYjExNDY0MjllYjZlNDVkMTYwNmFhYjA4ZC90ZXh0cmVnaW9uOmUwYmFlNWRiMTE0NjQyOWViNmU0NWQxNjA2YWFiMDhkXzE1MjE_8224523f-a7e0-4ae6-b349-ae16a16d8dca">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Consolidation&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements of Encompass Health and its subsidiaries were prepared in accordance with generally accepted accounting principles in the United States of America and include the assets, liabilities, revenues, and expenses of all wholly-owned subsidiaries, majority-owned subsidiaries over which we exercise control, and, when applicable, entities in which we have a controlling financial interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the equity method to account for our investments in entities we do not control, but where we have the ability to exercise significant influence over operating and financial policies. Consolidated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to Encompass Health&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; includes our share of the net earnings of these entities. The difference between consolidation and the equity method impacts certain of our financial ratios because of the presentation of the detailed line items reported in the consolidated financial statements for consolidated entities compared to a one line presentation of equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We eliminate all significant intercompany accounts and transactions from our financial results.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNjkvZnJhZzo5MGRjZGE5YzJkOGU0YTQwOGVkMWJmMGQ5NmJhZjU2Ni90ZXh0cmVnaW9uOjkwZGNkYTljMmQ4ZTRhNDA4ZWQxYmYwZDk2YmFmNTY2XzYzOA_86bdad47-9d6f-4e48-8097-e782582f310d">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any entity considered a variable interest entity (&#x201c;VIE&#x201d;) is evaluated to determine which party is the primary beneficiary and thus should consolidate the VIE. This analysis is complex, involves uncertainties, and requires significant judgment on various matters. In order to determine if we are the primary beneficiary of a VIE, we must determine what activities most significantly impact the economic performance of the entity, whether we have the power to direct those activities, and if our obligation to absorb losses or receive benefits from the VIE could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:UseOfEstimates
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzIvZnJhZzpiMGFhNGJiZTQyODc0ODViOTAyZGUyNTY3ODJjZWM0NC90ZXh0cmVnaW9uOmIwYWE0YmJlNDI4NzQ4NWI5MDJkZTI1Njc4MmNlYzQ0XzE4MTM_a6997718-769f-4511-96a6-6d63965bdb75">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates and Assumptions&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our consolidated financial statements in conformity with GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but not limited to: (1)&#160;revenue reserves for contractual adjustments and uncollectible amounts; (2)&#160;fair value of acquired assets and assumed liabilities in business combinations; (3)&#160;asset impairments, including goodwill; (4)&#160;depreciable lives of assets; (5)&#160;useful lives of intangible assets; (6)&#160;economic lives and fair value of leased assets; (7)&#160;income tax valuation allowances; (8)&#160;uncertain tax positions; (9)&#160;fair value of stock options and restricted stock containing a market condition; (10)&#160;fair value of redeemable noncontrolling interests; (11)&#160;reserves for self-insured healthcare plans; (12) reserves for professional, workers&#x2019; compensation, and comprehensive general insurance liability risks; and (13)&#160;contingency and litigation reserves. Future events and their effects cannot be predicted with certainty; accordingly, our accounting estimates require the exercise of judgment. The accounting estimates used in the preparation of our consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained, and as our operating environment changes. We evaluate and update our assumptions and estimates on an ongoing basis and may employ outside experts to assist in our evaluation, as considered necessary. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzE1NTAz_b9a5ff1a-98ed-4dc7-bb3d-5179bda657be">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; disaggregated by payor source are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,589.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Advantage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;609.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers&#x2019; compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,566.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3909299e17d4e9f96039b48644e435f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzMtMTMtMS0xLTI0NTQ3Nw_b3af1a5d-a8e0-4739-b46e-660556899b5f"
      unitRef="usd">2843100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i434a61101a024049985e7041374c1bad_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzMtMTUtMS0xLTI0NTQ3Nw_92c02ad0-8461-44d4-8ba2-54e2829a9f18"
      unitRef="usd">2589600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c9d5eba60544d49a2a58e9b24ce961c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzMtMTctMS0xLTI0NTQ3Nw_b68451c4-c9fa-4f26-97f6-6c2c51bc6307"
      unitRef="usd">2375600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice387dc1f36b45818af7e9c1a280c084_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzQtMTMtMS0xLTI0NTQ3Nw_b0b3e004-0c90-4a48-ad8c-575d038eb6e4"
      unitRef="usd">654600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08a52ec290e7476db602a525bdf83e5a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzQtMTUtMS0xLTI0NTQ3Nw_c62e4a7b-b7e1-4426-9137-162516bfc61d"
      unitRef="usd">609600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3840cc62129543f286c32d03fc7cf594_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzQtMTctMS0xLTI0NTQ3Nw_f199648d-90c1-4376-8e0b-af65bd2d94ce"
      unitRef="usd">544900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib537455ec5074b27bc814bd625721be3_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzUtMTMtMS0xLTI0NTQ3Nw_4d960181-386a-4869-b3af-1195858313a1"
      unitRef="usd">505200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd562e2b20ab46e9a82490a8cca0f618_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzUtMTUtMS0xLTI0NTQ3Nw_b9da1420-3943-477d-b8de-f7deddc77444"
      unitRef="usd">484500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i630c01ac29fa4ca1b4254e8c177f88ae_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzUtMTctMS0xLTI0NTQ3Nw_c47ce774-e70d-4375-96b2-db69a626b024"
      unitRef="usd">371400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee6d97175b5645daab81c40993423b85_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzYtMTMtMS0xLTI0NTQ3Nw_b221625f-61eb-45f7-9283-d55470be121e"
      unitRef="usd">183300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida31c9eb47794f719d9ff1564ca9f77f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzYtMTUtMS0xLTI0NTQ3Nw_c2d8dce7-d5b1-4bae-862f-9f1aecf4c688"
      unitRef="usd">163100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc59f2f9d2c34e778b82df851653ec07_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzYtMTctMS0xLTI0NTQ3Nw_1036bc1a-9a91-4d73-868c-054cf2c37ed0"
      unitRef="usd">140100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c60193a93c54ef0a8b26ce2749c4573_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzctMTMtMS0xLTI0NTQ3Nw_31d9196d-aad2-4755-9a23-ab4d0d741cb9"
      unitRef="usd">39500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34ebf32157a548a689b81b59e52d7061_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzctMTUtMS0xLTI0NTQ3Nw_345e7ab8-c7f4-4237-8bf9-ec7cead05e1b"
      unitRef="usd">46000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00dcced69aa245dd932b997347d492c6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzctMTctMS0xLTI0NTQ3Nw_c79247a5-33ea-4afb-91a2-18f978a110df"
      unitRef="usd">43000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica31326e89794cf4a262a71ea82be401_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzgtMTMtMS0xLTI0NTQ3Nw_80b62807-f106-450b-bcf9-dc7555c4b49b"
      unitRef="usd">24700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e2eb0b8b29c4c10b2c019f78880ab94_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzgtMTUtMS0xLTI0NTQ3Nw_0d9f7e9f-a026-4533-8b8c-6d528da8bbf0"
      unitRef="usd">23100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65daa5d21414406d9a73be137948b909_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzgtMTctMS0xLTI0NTQ3Nw_eac76d89-a239-47b6-9065-174ad651f335"
      unitRef="usd">21500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8611bd0ee7e5407987c11b03aa8312b6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzktMTMtMS0xLTI0NTQ3Nw_4b83a6de-48a7-478f-81f5-e4840e331e6d"
      unitRef="usd">16600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46ecd39de0ee482b9b66faa630bdf25b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzktMTUtMS0xLTI0NTQ3Nw_17d7fa62-7602-4346-b66e-a3032c8be151"
      unitRef="usd">19300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i578490c7d6584a1ba41aa384335fae6a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzktMTctMS0xLTI0NTQ3Nw_f2f0a5fe-6fd4-4300-b927-99b0fdb21def"
      unitRef="usd">19200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05243f3cbac341b8a9bec5a4f2859f00_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzEwLTEzLTEtMS0yNDU0Nzc_19c4c585-4891-4e98-b7ae-7cb7dcef7730"
      unitRef="usd">81600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic22a983720214ed4a192fcba2d07abcc_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzEwLTE1LTEtMS0yNDU0Nzc_22c63fe1-f74f-4a4b-93a9-4e91413a8a2c"
      unitRef="usd">79700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e0f753c8be14e67b8509c7dd73fd6bf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzEwLTE3LTEtMS0yNDU0Nzc_7caaf0dd-39d4-4682-af94-a4173dc96269"
      unitRef="usd">50600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzExLTEzLTEtMS0yNDU0Nzc_b6408f65-43e9-4f83-b245-2b8d2e991e38"
      unitRef="usd">4348600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzExLTE1LTEtMS0yNDU0Nzc_687218d1-9773-4441-be7d-818ba16fc963"
      unitRef="usd">4014900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90YWJsZTo2NDhmZTE1ZmNjY2Q0NmI3YTc2YWQ5NzUxM2M2ZWJiMS90YWJsZXJhbmdlOjY0OGZlMTVmY2NjZDQ2YjdhNzZhZDk3NTEzYzZlYmIxXzExLTE3LTEtMS0yNDU0Nzc_216b36a8-02f7-4e18-8d80-69d8ede33fbb"
      unitRef="usd">3566300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzE1NTA4_f3234560-1678-4b21-a906-2a4b44d4bcfc">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on an accrual basis using our best estimate of the transaction price for the type of service provided to the patient. Our estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, potential adjustments that may arise from payment and other reviews, and uncollectible amounts. Our accounting systems calculate contractual allowances on a patient-by-patient basis based on the rates in effect for each primary third-party payor. Adjustments related to payment reviews by third-party payors or their agents are based on our historical experience and success rates in the claims adjudication process.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates for uncollectible amounts are based on the aging of our accounts receivable, our historical collection experience for each type of payor, and other relevant factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management continually reviews the revenue transaction price estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms that result from contract renegotiations and renewals. Due to complexities involved in determining amounts ultimately due under reimbursement arrangements with third-party payors, which are often subject to interpretation, we may receive reimbursement for healthcare services authorized and provided that is different from our estimates, and such differences could be material. In addition, laws and regulations governing the Medicare and Medicaid programs are complex, subject to interpretation, and are routinely modified for provider reimbursement. All healthcare providers participating in the Medicare and Medicaid programs are required to meet certain financial reporting requirements. Federal regulations require submission of annual cost reports covering medical costs and expenses associated with the services provided under each hospital provider number to program beneficiaries. Annual cost reports required under the Medicare and Medicaid programs are subject to routine audits, which may result in adjustments to the amounts ultimately determined to be due to Encompass Health under these reimbursement programs. These audits often require several years to reach the final determination of amounts earned under the programs. If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS has been granted authority to suspend payments, in whole or in part, to Medicare providers if CMS possesses reliable information an overpayment, fraud, or willful misrepresentation exists. If CMS suspects payments are being made as the result of fraud or misrepresentation, CMS may suspend payment at any time without providing prior notice to us. The initial suspension period is limited to 180 days. However, the payment suspension period can be extended almost indefinitely if the matter is under investigation by the United States Department of Health and Human Services Office of Inspector General (the &#x201c;HHS-OIG&#x201d;) or the United States Department of Justice (the &#x201c;DOJ&#x201d;). Therefore, we are unable to predict if or when we may be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subject to a suspension of payments by the Medicare and/or Medicaid programs, the possible length of the suspension period, or the potential cash flow impact of a payment suspension. Any such suspension would adversely impact our financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to legislative directives and authorizations from Congress, CMS has developed and instituted various Medicare audit programs under which CMS contracts with private companies to conduct claims and medical record audits. As a matter of course, we undertake significant efforts through training and education to ensure compliance with Medicare requirements. However, audits may lead to assertions we have been underpaid or overpaid by Medicare or submitted improper claims in some instances, require us to incur additional costs to respond to requests for records and defend the validity of payments and claims, and ultimately require us to refund any amounts determined to have been overpaid. In some circumstances auditors assert the authority to extrapolate denial rationales to large pools of claims not actually audited, which could increase the impact of the audit. We cannot predict when or how these audit programs will affect us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare Administrative Contractors (&#x201c;MACs&#x201d;), under programs known as &#x201c;widespread probes,&#x201d; have conducted pre-payment claim reviews of our Medicare billings and in some cases denied payment for certain diagnosis codes. We dispute, or &#x201c;appeal,&#x201d; most of these denials. As discussed above, our historical experience and success in the adjudication of these appeals is a component of our estimate of transaction price. The Medicare appeals adjudication process is administered by the Office of Medicare Hearings and Appeals (&#x201c;OMHA&#x201d;) and has been subject to significant delay resulting in a backlog of claims awaiting adjudication. Beginning in March 2020, OMHA increased the frequency of hearings and the number of claims set at each hearing, which we believe adds to the substantive and procedural deficiencies in the appeals process. During 2022, the backlog of &#x201c;widespread probe&#x201d; claims adjudicated by the administrative law judge (&#x201c;ALJ&#x201d;) continued and were substantially completed. This OMHA practice resulted in a reduction in our success in the adjudication of these appeals, but have increased the pace of recovery of these claims. We have appealed certain adverse ALJ rulings to the Department Appeals Boards (&#x201c;DAB&#x201d;), the final level of administrative review. As of December 31, 2022, approximately $52&#160;million in claims are awaiting review at the DAB. In addition, we have appealed approximately $6&#160;million in claims denied by the DAB to several United States District Courts, all of which are pending review as of December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2017, CMS announced the Targeted Probe and Educate (&#x201c;TPE&#x201d;) initiative.&#160;Under the TPE initiative, MACs use data analysis to identify healthcare providers with high claim error rates and items and services that have high national error rates.&#160;Once a MAC selects a provider for claims review, the initial volume of claims review is limited to 20 to 40 claims. The TPE initiative includes up to three rounds of claims review if necessary with corresponding provider education and a subsequent period to allow for improvement.&#160;If results do not improve sufficiently after three rounds, the MAC may refer the provider to CMS for further action, which may include extrapolation of error rates to a broader universe of claims or referral to a UPIC or RAC (defined below). We cannot predict the impact of the TPE initiative on our ability to collect claims on a timely basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with CMS approved and announced Recovery Audit Contractors (&#x201c;RACs&#x201d;) audits related to inpatient rehabilitation facilities (&#x201c;IRFs&#x201d;), we received requests from 2013 to 2022 to review certain patient files for discharges occurring from 2010 to 2022.&#160;These RAC audits are focused on identifying Medicare claims that may contain improper payments.&#160;RAC contractors must have CMS approval before conducting these focused reviews which cover issues ranging from billing documentation to medical necessity.&#160;Medical necessity is an assessment by an independent physician of a patient&#x2019;s ability to tolerate and benefit from intensive multi-disciplinary therapy provided in an IRF setting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS has also established Unified Program Integrity Contractors (&#x201c;UPICs&#x201d;), previously known as Zone Program Integrity Contractors. These contractors perform fraud, waste, and abuse detection, deterrence and prevention activities for Medicare and Medicaid claims. Like the RACs, the UPICs conduct audits and have the ability to refer matters to the HHS-OIG or the DOJ. Unlike RACs, however, UPICs do not receive a specific financial incentive based on the amount of the error as a result of UPIC audits. We have, from time to time, received UPIC record requests which have resulted in claim denials on paid claims. We have appealed substantially all UPIC denials arising from these audits using the same process we follow for appealing other denials by contractors. In December 2017, we received notice of a UPIC audit at one of our hospitals. The UPIC sampled 100 claims and challenged the propriety of a subset of the sample representing $1.3&#160;million in previously paid claims. The UPIC extrapolated the alleged error rate to all claims from that hospital during a period of approximately four years, resulting in an alleged overpayment of $33.9&#160;million. Our MAC later reduced the determination of overpayment to $30.5&#160;million, which it collected through recoupment of current claims during 2019. We appealed the overpayment determination to an Administrative Law Judge (&#x201c;ALJ&#x201d;), who heard the appeal in August 2021. In October 2022, the ALJ &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;overturned $12.5&#160;million of the overpayment determination. We received payment of this amount, plus $3.2&#160;million in interest, in December 2022. We have appealed the remaining $18.0&#160;million of the overpayment determination to the DAB, the next level of administrative appeal, challenging both the denials and the improper use of extrapolation. It is not possible to predict when this matter will be resolved or the ultimate outcome.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Medicare claims that are subject to these post-payment audit requests represent less than 1% of our Medicare patient discharges from 2010 to 2022. Because we have confidence in the medical judgment of both the referring and admitting physicians who assess the treatment needs of their patients, we have appealed substantially all claim denials arising from these audits using the same process we follow for appealing denials by MACs. Due to the delays announced by CMS in the related adjudication process discussed above, we believe the resolution of any claims that are subsequently denied as a result of these claim audits could take several years. In addition, because we have limited experience with UPICs and RACs in the context of claims reviews of this nature, we cannot provide assurance as to the timing or outcomes of these disputes. As such, we make estimates for these claims based on our historical experience and success rates in the claims adjudication process, which is the same process we follow for denials by MACs. During 2022, 2021, and 2020, our adjustment to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for claims that are part of this post-payment claims review process was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligations relate to contracts with a duration of less than one year. Therefore, we elected to apply the optional exemption to not disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. These unsatisfied or partially unsatisfied performance obligations primarily relate to services provided at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are subject to changes in government legislation that could impact Medicare payment levels and changes in payor patterns that may impact the level and timing of payments for services rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net operating revenues&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are recognized over time as the services are provided to the patient. The performance obligation is the rendering of services to the patient during the term of their inpatient stay. Revenues are recognized (or measured) using the input method as therapy, nursing, and auxiliary services are provided based on our estimate of the respective transaction price. Revenues recognized are subject to a number of elements which impact both the overall amount of revenue realized as well as the timing of the collection of the related accounts receivable. Factors considered in determining the estimated transaction price include the patient&#x2019;s total length of stay for in-house patients, each patient&#x2019;s discharge destination, the proportion of patients with secondary insurance coverage and the level of reimbursement under that secondary coverage, and the amount of charges that will be disallowed by payors. Such additional factors are assumed to remain consistent with the experience for patients discharged in similar time periods for the same payor classes.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ehc:LossContingencyClaimsAwaitingReviewAmount
      contextRef="i852b75f329ea4ac08df2108afdf43e72_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwMTY_85a5587e-312a-4e47-a902-2916f5dea439"
      unitRef="usd">52000000</ehc:LossContingencyClaimsAwaitingReviewAmount>
    <ehc:LossContingencyAppealedClaimsDeniedAmount
      contextRef="i852b75f329ea4ac08df2108afdf43e72_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwMjk_43ab8efa-aa66-4611-bae2-93a001ed4e66"
      unitRef="usd">6000000</ehc:LossContingencyAppealedClaimsDeniedAmount>
    <ehc:LossContingencyNumberOfClaimsSampledForAudit
      contextRef="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzM4NDgyOTA3MjEwNDE_1780c845-5f03-4aa0-a9ab-36526fc39ef9"
      unitRef="claim">100</ehc:LossContingencyNumberOfClaimsSampledForAudit>
    <ehc:LossContingencyClaimsSampledForAuditAmount
      contextRef="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwNDE_32048ed8-13e0-4e5a-a71f-f18b5ea4723d"
      unitRef="usd">1300000</ehc:LossContingencyClaimsSampledForAuditAmount>
    <ehc:LossContingencyExtrapolatedErrorRatePeriod
      contextRef="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzM4NDgyOTA3MjEwNjE_1fafda42-f5df-489e-ba9a-58c5a5d5ada2">P4Y</ehc:LossContingencyExtrapolatedErrorRatePeriod>
    <ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount
      contextRef="i7c25b6240a454e6dbe1e0eaeea5e930e_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwNTU_29693191-2d2b-44ec-9f4f-d7234d6848df"
      unitRef="usd">33900000</ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount>
    <ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount
      contextRef="ic18e0c6dae034e2e9081f26733964490_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzM4NDgyOTA3MjEwNDc_324f9c33-eaaa-419c-846a-de45dd6e67cb"
      unitRef="usd">30500000</ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount>
    <ehc:LossContingencyAmountOverturnedOfOverpaymentDetermination
      contextRef="i461326ed8069459c9262b7d8a144ce07_D20221001-20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwNzE_94a97282-0aa1-4734-bf06-6ffd56dc3156"
      unitRef="usd">12500000</ehc:LossContingencyAmountOverturnedOfOverpaymentDetermination>
    <ehc:LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest
      contextRef="i870361686c2942fdb9b4a9bc9337f323_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIwODY_65c693cf-b12c-4367-b5cd-7f561b76a8f3"
      unitRef="usd">3200000</ehc:LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest>
    <ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount
      contextRef="i870361686c2942fdb9b4a9bc9337f323_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgyNDYzMzcyMzIxMDA_c147b995-e39f-4e39-844c-4cc12b572067"
      unitRef="usd">18000000</ehc:LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb58224ff71f435f975b30807048a7fa_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNzgvZnJhZzoxOGQzMmI1NWNmYjc0MGNiOTJhYTVlZmE0NWQ2YmJiMS90ZXh0cmVnaW9uOjE4ZDMyYjU1Y2ZiNzQwY2I5MmFhNWVmYTQ1ZDZiYmIxXzgxNjM_72d91f51-a2e5-475e-8691-820ff2c13d6b"
      unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODEvZnJhZzowZDgwMzA4ZGFlNjc0ZjRiYWQyOGE4ZGM1NmU4OTA0OS90ZXh0cmVnaW9uOjBkODAzMDhkYWU2NzRmNGJhZDI4YThkYzU2ZTg5MDQ5XzUzOA_e8ecea66-05ce-4064-8909-cd127e5eff75">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; include highly liquid investments with maturities of three months or less when purchased. Carrying values of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; approximate fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain amounts on deposit with various financial institutions, which may, at times, exceed federally insured limits. However, management periodically evaluates the credit-worthiness of those institutions, and we have not experienced any losses on such deposits.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODQvZnJhZzo1OTkzZTkzOGFlYmU0NjA3OGUwZTBlMzNmMmQ4MTBiNi90ZXh0cmVnaW9uOjU5OTNlOTM4YWViZTQ2MDc4ZTBlMGUzM2YyZDgxMGI2XzEzNjA_7f5f082f-9f7a-45ce-9df0-8be6911559ac">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all equity securities with readily determinable fair values and for which we do not exercise significant influence at fair value and record the change in fair value for the reporting period in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record debt securities with readily determinable fair values and for which we do not exercise significant influence as available-for-sale securities. We carry the available-for-sale securities at fair value and report unrealized holding gains or losses, net of income taxes, in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is a separate component of shareholders&#x2019; equity. We recognize realized gains and losses in our consolidated statements of comprehensive income using the specific identification method. Unrealized losses are charged against earnings when a decline in fair value was determined to be other than temporary. Management reviews several factors to determine whether a loss is other than temporary, such as the length of &lt;/span&gt;&lt;/div&gt;time a security is in an unrealized loss position, the extent to which fair value is less than cost, the financial condition and near term prospects of the issuer, industry, or geographic area and our ability and intent to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90ZXh0cmVnaW9uOjlmNmE0ZjhkNGE2NjRmYWZiYjcwYTgyMjk0NTc5YzllXzM1MTk_ee074128-3ace-4002-8c0c-72faa0d47aa3">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report accounts receivable from services rendered at their estimated transaction price which takes into account price concessions from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers&#x2019; compensation programs, employers, and patients. Our accounts receivable are concentrated by type of payor. The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care and other discount plans, including Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While revenues and accounts receivable from the Medicare program are significant to our operations, we do not believe there are significant credit risks associated with this government agency. We do not believe there are any other significant concentrations of revenues from any particular payor that would subject us to any significant credit risks in the collection of our accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Accounts requiring collection efforts are reviewed via system-generated work queues that automatically stage (based on age and size of outstanding balance) accounts requiring collection efforts for patient account representatives. Collection efforts include contacting the applicable party (both in writing and by telephone), providing information (both financial and clinical) to allow for payment or to overturn payor decisions to deny payment, and arranging payment plans with self-pay patients, among other techniques. When we determine all in-house efforts have been exhausted or it is a more prudent use of resources, accounts may be turned over to a collection agency.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collection of outstanding receivables from Medicare, managed care payors, other third-party payors, and patients is our primary source of cash and is critical to our operating performance. While it is our policy to verify insurance prior to a patient being admitted, there are various exceptions that can occur. Such exceptions include instances where we are (1) unable to obtain verification because the patient&#x2019;s insurance company was unable to be reached or contacted, (2) a determination is made that a patient may be eligible for benefits under various government programs, such as Medicaid, and it takes several days, weeks, or months before qualification for such benefits is confirmed or denied, and (3) the patient is transferred to our hospital from an acute care hospital without having access to a credit card, cash, or check to pay the applicable patient responsibility amounts (i.e., deductibles and co-payments).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our primary collection risks relate to patient responsibility amounts and claims reviews conducted by MACs or other contractors. Patient responsibility amounts include accounts for which the patient was the primary payor or the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient co-payment amounts remain outstanding. Changes in the economy, such as increased unemployment rates or periods of recession, can further exacerbate our ability to collect patient responsibility amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If actual results are not consistent with our assumptions and judgments, we may be exposed to gains or losses that could be material. Changes in general economic conditions, business office operations, payor mix, or trends in federal or state &lt;/span&gt;&lt;/div&gt;governmental and private employer healthcare coverage could affect our collection of accounts receivable, financial position, results of operations, and cash flows.</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90ZXh0cmVnaW9uOjlmNmE0ZjhkNGE2NjRmYWZiYjcwYTgyMjk0NTc5YzllXzM1MjA_6f88053c-903b-47e2-94e7-14f1903bc4e5">The concentration of patient service accounts receivable by payor class, as a percentage of total patient service accounts receivable, is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care and other discount plans, including Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Workers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie9749632394145f497fe0c2c6ec147a7_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzItMS0xLTEtMjQ1NDc3_e90cde4e-1932-4f30-94f7-4135976012d9"
      unitRef="number">0.579</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibe35a06f0eae46efb5c6921fe9db414c_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzItMy0xLTEtMjQ1NDc3_c0da5bd6-4ff1-48cb-a4d8-6f2d63c7363a"
      unitRef="number">0.578</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7b648e892f9f4468aab25a90a2f09b05_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzMtMS0xLTEtMjQ1NDc3_2407c5db-8ab6-439d-bc0c-6eeaadd9a507"
      unitRef="number">0.311</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iec6a14cc3aca48bcaeca480b39030876_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzMtMy0xLTEtMjQ1NDc3_7b8f1da5-efa4-402f-bcf4-857dc9029593"
      unitRef="number">0.314</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9a03052d15b64c25a269fdcc4216b88c_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzQtMS0xLTEtMjQ1NDc3_b96e16f6-0ef9-476d-8f54-49dae51eae53"
      unitRef="number">0.044</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibefecfaeeeb041849960421b13ca007b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzQtMy0xLTEtMjQ1NDc3_d623ffe3-44ad-41a8-a3ad-028f27bcf86e"
      unitRef="number">0.041</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9c4d794905dd4fb385b71c4eed009bb7_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzUtMS0xLTEtMjQ1NDc3_4e581e54-7d25-40c9-9a59-f0c22537eb22"
      unitRef="number">0.034</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i52751714abc34c4d98dc47a7a77e2370_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzUtMy0xLTEtMjQ1NDc3_59477c12-3eb1-4eca-88ba-49dd53385555"
      unitRef="number">0.033</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4e50571d65784dfc9aef9033d5f99181_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzYtMS0xLTEtMjQ1NDc3_2d2d0c70-3f5e-489e-80ac-144f32459284"
      unitRef="number">0.022</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib3c18279fe4d4018bbe852e7b57b1d47_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzYtMy0xLTEtMjQ1NDc3_a63d6562-10f4-42c8-85bb-235d3755cdf5"
      unitRef="number">0.019</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5ab836dfffa54e4b814fbfc5b759b918_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzctMS0xLTEtMjQ1NDc3_5420cf4e-08c2-4b28-bb2c-e9de371a160f"
      unitRef="number">0.010</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i66c304bf2ec048b88bf47a3f2c6c5a54_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzctMy0xLTEtMjQ1NDc3_b38d96ce-b2b2-4f86-9ba0-a34b3b5e9ecf"
      unitRef="number">0.015</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib014de72370b4cb4a6135adc8af20d7b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzgtMS0xLTEtMjQ1NDc3_e8a25818-252c-4f65-8e49-548d1246279d"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifc2b37264d734f2d8f5833e77968d634_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xODcvZnJhZzo5ZjZhNGY4ZDRhNjY0ZmFmYmI3MGE4MjI5NDU3OWM5ZS90YWJsZTo3YmE5YjZhYTZjNGM0ZWRkYjg3OTg3NmU2NDY2NjZiOS90YWJsZXJhbmdlOjdiYTliNmFhNmM0YzRlZGRiODc5ODc2ZTY0NjY2NmI5XzgtMy0xLTEtMjQ1NDc3_7c9ecc05-a1ff-4f93-b144-4ea2df73fcb5"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90ZXh0cmVnaW9uOjdlMjI5NmU1NTYxMzRjZWY4OTcwZWQ3YTE1NzBmNmUyXzE0ODc_0079117b-f342-493d-8aa1-016e570efa51">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report land, buildings, improvements, vehicles, and equipment at cost, net of accumulated depreciation and amortization and any asset impairments. We depreciate our assets using the straight-line method over the shorter of the estimated useful life of the assets or life of the underlying leases. Useful lives are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maintenance and repairs of property and equipment are expensed as incurred. We capitalize replacements and betterments that increase the estimated useful life of an asset. We capitalize pre-acquisition costs when they are directly identifiable with a specific property, the costs would be capitalizable if the property were already acquired, and acquisition of the property is probable. We capitalize interest expense on major construction and development projects while in progress.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We retain fully depreciated assets in property and accumulated depreciation accounts until we remove them from service. In the case of sale, retirement, or disposal, the asset cost and related accumulated depreciation balances are removed from the respective accounts, and the resulting net amount, less any proceeds, is included as a component of income from continuing operations in the consolidated statements of comprehensive income. However, if the sale, retirement, or disposal involves a discontinued operation, the resulting net amount, less any proceeds, is included in the results of discontinued operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90ZXh0cmVnaW9uOjdlMjI5NmU1NTYxMzRjZWY4OTcwZWQ3YTE1NzBmNmUyXzE0ODM_26b9852a-476f-4ddc-bd08-ad750aef0486">Useful lives are generally as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 to 15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,019.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,239.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,718.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,490.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,228.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,581.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4cb56d21aab74ac3967968f076197961_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2NmMzY1ZDA0N2QyNGMyZDlkN2I2MTFjOWI2Y2MxYWJfNA_d3eca5c7-3ccf-4c7d-96dc-66ebf2ab6be7">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idfd7ae0589ea4a128b3e3e4861478b00_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2NmMzY1ZDA0N2QyNGMyZDlkN2I2MTFjOWI2Y2MxYWJfMTA_1d8dbbfd-7aae-44dc-bff4-fa230a7939ad">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5139d245eba04e15a063f9bc48d18aa7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246M2MzYzFjMTZkMTRjNGE5OTg3OGRkODgyZGQzN2YwODBfNA_55f63f3b-1a8c-454f-a5f4-79c65858e174">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib932dccdf96b459687584cc4f8701479_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246M2MzYzFjMTZkMTRjNGE5OTg3OGRkODgyZGQzN2YwODBfMTA_a09dc7da-78a9-4f31-8205-47a16627bd9d">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib1e69d3358704dd18df22349448291f5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ODBjN2JmMGYyMjk0NDdmODkwN2VjOGM4M2ZiNzdmMzdfNA_a36fa819-246f-439b-8b3d-c4085159a9b8">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i176405163b9c4c37878dcef0b9e741ce_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzQtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTk2MDkxMmIzMzIwNGFjYzgzMjk2ZjQ0M2E1Y2M3MzRfNA_52427c57-6818-488d-8785-e291717247df">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9b43ec38059149d4ba26be2569eb2a25_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTAvZnJhZzo3ZTIyOTZlNTU2MTM0Y2VmODk3MGVkN2ExNTcwZjZlMi90YWJsZTpiNzEwYWZjOWVlZjE0NjE4ODk2YTVhZDBkN2VkNTEyMC90YWJsZXJhbmdlOmI3MTBhZmM5ZWVmMTQ2MTg4OTZhNWFkMGQ3ZWQ1MTIwXzQtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTk2MDkxMmIzMzIwNGFjYzgzMjk2ZjQ0M2E1Y2M3MzRfMTA_0c04d5b2-7447-4e1d-b624-40b159c94f3a">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTMvZnJhZzplMzU5MGQwM2VhNjM0MzEzYThjNzMxYmQzYTBkMmNiOS90ZXh0cmVnaW9uOmUzNTkwZDAzZWE2MzQzMTNhOGM3MzFiZDNhMGQyY2I5XzE3NTU_8fa622aa-a6d6-4d6f-9bbc-6aaa6d34cea8">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:2.25pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if an arrangement is a lease or contains a lease at inception and perform an analysis to determine whether the lease is an operating lease or a finance lease. We measure right-of-use assets and lease liabilities at the lease commencement date based on the present value of the remaining lease payments. As most of our leases do not provide a readily determinable implicit rate, we estimate an incremental borrowing rate based on the credit quality of the Company and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of each lease. We use this rate to discount the remaining lease payments in measuring the right-of-use asset and lease liability. We use the implicit rate when readily determinable. We recognize lease expense for operating leases on a straight-line basis over the lease term. For our finance leases, we recognize amortization expense from the amortization of the right-of-use asset and interest expense on the related lease liability. Certain of our lease agreements contain annual escalation clauses based on changes in the Consumer Price Index. The changes to the Consumer Price Index, as compared to our initial estimate at the lease commencement date, are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. In general, we do not account for lease and non-lease components separately for purposes of establishing right-of-use assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet. We recognize lease expense for these leases on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90ZXh0cmVnaW9uOjJkMWM2N2I4YWU5YzQ5YThiNGRlNmFkYWUyMDMzODBjXzQ2MTk_4ff65fff-50fa-4015-855f-d6ff296b5237">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill and Other Intangible Assets&#x2014; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to test our goodwill and indefinite-lived intangible asset for impairment at least annually, absent some triggering event that would accelerate an impairment assessment. Absent any impairment indicators, we perform this impairment testing as of October 1st of each year. We recognize an impairment charge for any amount by which the carrying amount of the asset exceeds its implied fair value. We present an impairment charge as a separate line item within income from continuing operations in the consolidated statements of comprehensive income, unless the impairment is associated with a discontinued operation. In that case, we include the impairment charge, on a net-of-tax basis, within the results of discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess qualitative factors in our single reporting unit to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our reporting unit using generally accepted valuation techniques including the income approach and the market approach. The income approach includes the use of our reporting unit&#x2019;s discounted projected operating results and cash flows. This approach includes many assumptions related to pricing and volume, operating expenses, capital expenditures, discount factors, tax rates, etc. Changes in economic and operating conditions impacting these assumptions could result in goodwill impairment in future periods. We reconcile the estimated fair value of our reporting unit to our market capitalization. When we dispose of a hospital, goodwill is allocated to the gain or loss on disposition using the relative fair value methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess qualitative factors related to our indefinite-lived intangible asset to determine whether it is necessary to perform the quantitative impairment test. If, based on this qualitative assessment, we were to believe we must perform the quantitative impairment test, we would determine the fair value of our indefinite-lived intangible asset using generally accepted valuation techniques including the relief-from-royalty method. This method is a form of the income approach in which value is equated to a series of cash flows and discounted at a risk-adjusted rate. It is based on a hypothetical royalty, calculated as a percentage of forecasted revenue, that we would otherwise be willing to pay to use the asset, assuming it were not already owned. This approach includes assumptions related to pricing and volume, as well as a royalty rate a hypothetical third party would be willing to pay for use of the asset. When making our royalty rate assumption, we consider rates paid in arms-length licensing transactions for assets comparable to our asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize the cost of intangible assets with finite useful lives over their respective estimated useful lives to their estimated residual value. As of December&#160;31, 2022, none of our finite useful lived intangible assets has an estimated residual value. We also review these assets for impairment whenever events or changes in circumstances indicate we may not be able to recover the asset&#x2019;s carrying amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;br/&gt;and Amortization Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 18 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;indefinite-lived asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market access assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years using accelerated basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the costs of obtaining or developing internal-use software, including external direct costs of material and services and certain directly related payroll costs. Amortization begins when the internal-use software is ready for its intended &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;use. Costs incurred during the preliminary project and post-implementation stages, as well as maintenance and training costs, are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our market access assets are valued using discounted cash flows under the income approach. The value of the market access assets is attributable to our ability to gain access to and penetrate an acquired facility&#x2019;s historical market patient base. To determine this value, we first develop a debt-free net cash flow forecast under various patient volume scenarios. The debt-free net cash flow is then discounted back to present value using a discount factor, which includes an adjustment for company-specific risk. As noted in the above table, we amortize these assets over 20 years using an accelerated basis that reflects the pattern in which we believe the economic benefits of the market access will be consumed.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90ZXh0cmVnaW9uOjJkMWM2N2I4YWU5YzQ5YThiNGRlNmFkYWUyMDMzODBjXzQ2MDI_39f3b802-376c-4253-90f7-d3fc023add53">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;br/&gt;and Amortization Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 18 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;indefinite-lived asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market access assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years using accelerated basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90ZXh0cmVnaW9uOjJkMWM2N2I4YWU5YzQ5YThiNGRlNmFkYWUyMDMzODBjXzQ2MjM_2ced868e-dcda-4422-97eb-1c40e18e62e9">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of estimated useful lives and the amortization basis for our intangible assets, excluding goodwill, are generally as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.781%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life&lt;br/&gt;and Amortization Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 30 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1 to 18 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Encompass&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;indefinite-lived asset&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 to 20 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 7 years using straight-line basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Market access assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years using accelerated basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information regarding our other intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Certificates of need:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Licenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncompete agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Trade name - Encompass:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Trade names - all other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Internal-use software:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Market access assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1d16d99320d0432eae3d9ff01729bc03_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MGM0ZjIwMTEzYzQ3NDQzNWIwNjc2OWFlOGNiZTMzMzhfNA_ba955688-bbe0-48d5-911b-d60c090fa216">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic54237316ac9413084b19847adf7f2fb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MGM0ZjIwMTEzYzQ3NDQzNWIwNjc2OWFlOGNiZTMzMzhfMTA_2433a993-cdb6-41f4-8f42-c55683722920">P30Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i59a65005892243e682dc792c081f8c0a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2FmNGE4YmQ3NDE5NGUxMzhjMmRjMjVkMWNiZTliMGZfNA_3a125d34-4d61-4a27-b186-1bbdc77512d8">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibb79ea3f749d47ffbe3c65d094ac96bc_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2FmNGE4YmQ3NDE5NGUxMzhjMmRjMjVkMWNiZTliMGZfMTA_57a67411-aacb-4384-8a1d-818fa8c51188">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i436bf0be46974157827b0ca4b6e81e07_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NGRkMmY2YmJhNjNhNGQyMGJiNjhhNzgwZTEyZjFlMTZfNA_105834ec-4c35-42e2-bee2-3a6492f14241">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9d936af5f8ec4ce8a15339c7e5b4fa6c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NGRkMmY2YmJhNjNhNGQyMGJiNjhhNzgwZTEyZjFlMTZfMTA_e33c321e-9b53-4bd2-a93e-ebeaf1c0bcf4">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i171d0e9f00ac4274a1c1fb90c3567010_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzYtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2M5ZTJiNzNkMjlhNDc0MjhjOGY2YzIwOWExN2Y1YjRfNA_a1bb2bff-d4e4-40e0-9023-51fa39dc85f7">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idd848d2dde614489a20f1870d96a944a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzYtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246N2M5ZTJiNzNkMjlhNDc0MjhjOGY2YzIwOWExN2Y1YjRfMTA_f51e4134-02ea-4227-bfaa-5bd75c593561">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib57c2c4651af459192fda104b5d0dd00_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzctMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjNlMWM2MzM1NjhkNDQ4ODkyMTdmODQxMDZiNmRjZWNfNA_b06717c5-63dc-4027-bcb2-3697cab2223f">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i470cf08a07fe4287a486a76f384d82ad_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzctMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjNlMWM2MzM1NjhkNDQ4ODkyMTdmODQxMDZiNmRjZWNfMTA_2da0ef1d-69ca-47ff-b9ad-c66a81b1704e">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icf944ca96a324447a5fead2b5afb9747_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90YWJsZTplODliNTk4NTQ4M2Q0MDA0YmNmNzFjNDNlODlkZjVhNC90YWJsZXJhbmdlOmU4OWI1OTg1NDgzZDQwMDRiY2Y3MWM0M2U4OWRmNWE0XzgtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246YmYxMDJmOWYzYTYwNDAwMzk1YjUzNGVjNDYwZTI1MDdfNA_4fdf1835-d97e-477f-8099-fd3812c0f27b">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="icf944ca96a324447a5fead2b5afb9747_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTYvZnJhZzoyZDFjNjdiOGFlOWM0OWE4YjRkZTZhZGFlMjAzMzgwYy90ZXh0cmVnaW9uOjJkMWM2N2I4YWU5YzQ5YThiNGRlNmFkYWUyMDMzODBjXzQ0Njc_4fdf1835-d97e-477f-8099-fd3812c0f27b">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <ehc:LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xOTkvZnJhZzo4NGM5NDAyY2UzZjI0YTg4OWM0ZjU0MGFjYjNlNTBkYi90ZXh0cmVnaW9uOjg0Yzk0MDJjZTNmMjRhODg5YzRmNTQwYWNiM2U1MGRiXzE1MjU_15247b59-d32c-4c5e-905b-0db0fb62effb">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Long-Lived Assets and Other Intangible Assets&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the recoverability of long-lived assets (excluding goodwill and our indefinite-lived asset) and identifiable acquired intangible assets with finite useful lives, whenever events or changes in circumstances indicate we may not be able to recover the asset&#x2019;s carrying amount. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of the asset to the expected net future cash flows to be generated by that asset, or, for identifiable intangibles with finite useful lives, by determining whether the amortization of the intangible asset balance over its remaining life can be recovered through undiscounted future cash flows. The amount of impairment of identifiable intangible assets with finite useful lives, if any, to be recognized is measured based on projected discounted future cash flows. We measure the amount of impairment of other long-lived assets (excluding goodwill) as the amount by which the carrying value of the asset exceeds the fair market value of the asset, which is generally determined based on projected discounted future cash flows or appraised values. We classify long-lived assets to be disposed of other than by sale as held and used until they are disposed. We report long-lived assets to be disposed of by sale as held for sale and recognize those assets in the balance sheet at the lower of carrying amount or fair value less cost to sell, and we cease depreciation.&lt;/span&gt;&lt;/div&gt;</ehc:LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMDUvZnJhZzo2NmIxZDk4NWZiMWQ0ZDU2YWIxYTVhMTlkN2VjYTJmYS90ZXh0cmVnaW9uOjY2YjFkOTg1ZmIxZDRkNTZhYjFhNWExOWQ3ZWNhMmZhXzg5OA_9a434f15-fd01-47c5-b231-58aa5ede861b">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financing Costs&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize financing costs using the effective interest method over the expected life of the related debt. Excluding financing costs related to our revolving line of credit (which are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), financing costs are presented as a direct deduction from the face amount of the financings. The related expense is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrete discounts and amortize premiums using the effective interest method over the expected life of the related debt, and we report discounts or premiums as a direct deduction from, or addition to, the face amount of the financing. The related income or expense is included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMDgvZnJhZzo4MzMyOGM4NWUwZmM0ZDNhYTU1OThkOTIxYmRjMDgxZi90ZXh0cmVnaW9uOjgzMzI4Yzg1ZTBmYzRkM2FhNTU5OGQ5MjFiZGMwODFmXzM5MzQ_80ae4d5b-acb5-482c-83f9-a84d7d68b53c">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The basis for these assumptions establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Observable inputs such as quoted prices in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are based on one or more of three valuation techniques. The three valuation techniques are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Cost approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Amount that would be required to replace the service capacity of an asset (i.e., replacement cost); and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income approach&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Techniques to convert future cash flows to a single present amount based on market expectations (including present value techniques, option-pricing models, and lattice models).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist mainly of cash and cash equivalents, restricted cash, restricted marketable securities, accounts receivable, accounts payable, letters of credit, and long-term debt. The carrying amounts of cash and cash equivalents, restricted cash, accounts receivable, and accounts payable approximate fair value because of the short-term maturity of these instruments. The fair value of our letters of credit is deemed to be the amount of payment guaranteed on our behalf by third-party financial institutions. We determine the fair value of our long-term debt using quoted market prices, when available, or discounted cash flows based on various factors, including maturity schedules, call features, and current market rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a recurring basis, we are required to report our restricted marketable securities at fair value. The fair values of our restricted marketable securities are determined based on quoted market prices in active markets or quoted prices, dealer quotations, or alternative pricing sources supported by observable inputs in markets that are not considered to be active.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there are assets and liabilities that are not required to be reported at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. The fair value of our property and equipment is determined using discounted cash flows and significant unobservable inputs, unless there is an offer to purchase such assets, which could be the basis for determining fair value. The fair value of our intangible assets, excluding goodwill, is determined using discounted cash flows and significant unobservable inputs. The fair value of our investments in nonconsolidated affiliates is determined using quoted prices in private markets, discounted cash flows or earnings, or market multiples derived from a set of comparables. The fair value of our assets and liabilities of discontinued operations is determined using discounted cash flows and significant unobservable inputs unless there is an offer to purchase such assets and liabilities, which would be the basis for determining fair value. The fair value of our goodwill is determined using discounted projected operating results and cash flows, which involve significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMTEvZnJhZzo2Y2E5NWMyYmI2MTE0Y2UwYjQ5YjEzNDRiMmJhMTQ4Yi90ZXh0cmVnaW9uOjZjYTk1YzJiYjYxMTRjZTBiNDliMTM0NGIyYmExNDhiXzY0NQ_7840b5e8-470f-49b8-a118-3a17e0cdbd26">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling Interests in Consolidated Affiliates&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include all assets, liabilities, revenues, and expenses of less-than-100%-owned affiliates we control. Accordingly, we have recorded noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interests holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interests holders&#x2019; balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our joint venture agreements contain provisions that allow our partners to require us to purchase their interests in the joint venture at fair value at certain points in the future.  Likewise, certain members of the home health and hospice management team held similar put rights regarding their interests in our home health and hospice business, as discussed in Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Because these noncontrolling interests provide for redemption features that are not solely within our control, we classify them as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; outside of permanent equity in our consolidated balance sheets. At the end of each reporting period, we compare the carrying value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to their estimated redemption value. If the estimated redemption value is greater than the current carrying value, the carrying value is adjusted to the estimated redemption value, with the adjustments recorded through equity in the line item &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital in excess of par value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to certain members of the home health and hospice management team&#x2019;s put rights regarding their interests in our home health and hospice business was determined using the product of a 12-month specified performance measure and a specified median market price multiple based on a basket of public health companies and publicly disclosed home health acquisitions with a value of $400&#160;million or more. The fair value of our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our joint venture entities is determined primarily using the income approach. The income approach includes the use of the joint venture entities&#x2019; projected operating results and cash flows discounted using a rate that reflects market participant assumptions for the applicable joint venture entity, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inputs. The projected operating results use management&#x2019;s best estimates of economic and market conditions over the forecasted periods including assumptions for pricing and volume, operating expenses, and capital expenditures.&lt;/span&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <ehc:RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMTQvZnJhZzoyNzgxZmIxZjIzZjU0OTJjYWMzZDcyODI2MjM1YTBiMy90ZXh0cmVnaW9uOjI3ODFmYjFmMjNmNTQ5MmNhYzNkNzI4MjYyMzVhMGIzXzY1OTcwNjk3NzAxMDE_004b54ca-e767-404d-89fa-fbd883ae6df0"
      unitRef="usd">400000000</ehc:RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMTcvZnJhZzoyMzRhOGQ1YWFiYmM0NzJlYjY1MGU2MWNlYjliNjhkOC90ZXh0cmVnaW9uOjIzNGE4ZDVhYWJiYzQ3MmViNjUwZTYxY2ViOWI2OGQ4XzY0OQ_49911ccc-6faf-4d54-846a-b76c7d1854c5">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share-Based Payments&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health has shareholder-approved stock-based compensation plans that provide for the granting of stock-based compensation to certain employees and directors. All share-based payments to employees are recognized in the financial statements based on their estimated grant-date fair value and amortized on a straight-line basis over the applicable requisite service period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjAvZnJhZzozNDliMTM2ODFiOTM0ODI3YTkwOTUxMWM1ODgyMjFjYy90ZXh0cmVnaW9uOjM0OWIxMzY4MWI5MzQ4MjdhOTA5NTExYzU4ODIyMWNjXzc0OA_82427266-74ed-44be-ad2e-d61c6c99f83c">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Reserves&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for loss contingencies associated with outstanding litigation for which management has determined it is probable a loss contingency exists and the amount of loss can be reasonably estimated. If the accrued amount associated with a loss contingency is greater than $5.0 million, we also accrue estimated future legal fees associated with the loss contingency. This requires management to estimate the amount of legal fees that will be incurred in the defense of the litigation. These estimates are based on our expectations of the scope, length to complete, and complexity of the claims. In the future, additional adjustments may be recorded as the scope, length to complete, or complexity of outstanding litigation changes.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <ehc:LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjAvZnJhZzozNDliMTM2ODFiOTM0ODI3YTkwOTUxMWM1ODgyMjFjYy90ZXh0cmVnaW9uOjM0OWIxMzY4MWI5MzQ4MjdhOTA5NTExYzU4ODIyMWNjXzMwMA_5cb861b8-24c4-493f-94ad-50b72236f4a3"
      unitRef="usd">5000000</ehc:LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjMvZnJhZzplMDg2OWE4MjI0ZjU0ODUxOWJlMmFhZDAzNWQwMmIzMS90ZXh0cmVnaW9uOmUwODY5YTgyMjRmNTQ4NTE5YmUyYWFkMDM1ZDAyYjMxXzM0Mg_a9f3beb0-ed80-461e-b1b9-cfe89a805c03">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advertising Costs&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expense costs of print, radio, television, and other advertisements as incurred. Advertising expenses, primarily included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other operating expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; within the accompanying consolidated statements of comprehensive income, were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.6 million, and $4.6 million in each of the years ended December 31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjMvZnJhZzplMDg2OWE4MjI0ZjU0ODUxOWJlMmFhZDAzNWQwMmIzMS90ZXh0cmVnaW9uOmUwODY5YTgyMjRmNTQ4NTE5YmUyYWFkMDM1ZDAyYjMxXzI1NQ_8723e6d6-5963-437c-b874-c92c88fd0dda"
      unitRef="usd">6300000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjMvZnJhZzplMDg2OWE4MjI0ZjU0ODUxOWJlMmFhZDAzNWQwMmIzMS90ZXh0cmVnaW9uOmUwODY5YTgyMjRmNTQ4NTE5YmUyYWFkMDM1ZDAyYjMxXzI1OQ_9bbf9bc3-4393-425b-8336-86c51297800d"
      unitRef="usd">5600000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjMvZnJhZzplMDg2OWE4MjI0ZjU0ODUxOWJlMmFhZDAzNWQwMmIzMS90ZXh0cmVnaW9uOmUwODY5YTgyMjRmNTQ4NTE5YmUyYWFkMDM1ZDAyYjMxXzI2Nw_089c7091-a893-4ec8-a66f-1ebaaa23e988"
      unitRef="usd">4600000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjYvZnJhZzoyN2UwOThiMTNjOTY0ZGRiODU1YjI2OTNkZGYwMWU5Yi90ZXh0cmVnaW9uOjI3ZTA5OGIxM2M5NjRkZGI4NTViMjY5M2RkZjAxZTliXzI0NzQ_c6558730-2ec2-445c-98aa-0e8986e88507">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for income taxes using the asset and liability method&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach recognizes the amount of income taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is required when it is more likely than not some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income in the applicable tax jurisdiction. On a quarterly basis, we assess the likelihood of realization of our deferred tax assets considering all available evidence, both positive and negative. Our most recent operating performance, the scheduled reversal of temporary differences, our forecast of taxable income in future periods by jurisdiction, our ability to sustain a core level of earnings, and the availability of prudent tax planning strategies are important considerations in our assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate our tax positions and establish assets and liabilities in accordance with the applicable accounting guidance on uncertainty in income taxes. We review these tax uncertainties in light of changing facts and circumstances, such as the progress of tax audits, and adjust them accordingly. We have used the with-and-without method to determine when we will recognize excess tax benefits from stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Encompass Health and its corporate subsidiaries file a consolidated federal income tax return. Some subsidiaries consolidated for financial reporting purposes are not part of the consolidated group for federal income tax purposes and file separate federal income tax returns. State income tax returns are filed on a separate, combined, or consolidated basis in accordance with relevant state laws and regulations. Partnerships, limited liability companies, and other pass-through entities we consolidate or account for using the equity method of accounting file separate federal and state income tax returns. We &lt;/span&gt;&lt;/div&gt;include the allocable portion of each pass-through entity&#x2019;s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMjkvZnJhZzo1OGUwNjVmN2IxZDU0ODY1YTY0YjA2YzUwN2EyYTA4Ni90ZXh0cmVnaW9uOjU4ZTA2NWY3YjFkNTQ4NjVhNjRiMDZjNTA3YTJhMDg2XzE2OTc_cd73bf59-c26e-42ed-926b-643814311d54">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities in and Results of Discontinued Operations&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report the disposal of the component, or group of components, as discontinued operations only when it represents a strategic shift that has, or will have, a major effect on our operations and financial results. In the period a component of an entity has been disposed of or classified as held for sale, we reclassify the results of operations for current and prior periods into a single caption titled&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income from discontinued operations, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In addition, we classify the assets and liabilities of those components as current and noncurrent assets and liabilities within &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Current assets of discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Noncurrent assets of discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Current liabilities of discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncurrent liabilities of discontinued operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets. We also classify cash flows related to discontinued operations as one line item within each category of cash flows in our consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMzIvZnJhZzoyMWY1MDc3Y2VjYTE0MDk4YTlkZDY1OGFjMmRlNTFhMC90ZXh0cmVnaW9uOjIxZjUwNzdjZWNhMTQwOThhOWRkNjU4YWMyZGU1MWEwXzk2Mw_2743d94f-6e77-46d5-960d-36b97d6bb734">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Common Share&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of earnings per common share is based on the weighted-average number of our common shares outstanding during the applicable period. The calculation for diluted earnings per common share recognizes the effect of all potential dilutive common shares that were outstanding during the respective periods, unless their impact would be antidilutive. The calculation of earnings per common share also considers the effect of participating securities. Stock-based compensation awards that contain nonforfeitable rights to dividends and dividend equivalents, such as our restricted stock units, are considered participating securities and are included in the computation of earnings per common share pursuant to the two-class method. In applying the two-class method, earnings are allocated to both common stock shares and participating securities based on their respective weighted-average shares outstanding for the period.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMzUvZnJhZzplMzZmZGUzNDc1OGE0YzNhOWJlZmFjYzBjOGZkMjY5YS90ZXh0cmVnaW9uOmUzNmZkZTM0NzU4YTRjM2E5YmVmYWNjMGM4ZmQyNjlhXzQwMg_3d581c3f-acbb-45ce-982c-1c4028b12767">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Treasury Stock&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock repurchased by us are recorded at cost as treasury stock. When shares are reissued, we use an average cost method to determine cost. The difference between the cost of the shares and the re-issuance price is added to or deducted from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capital in excess of par value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We account for the retirement of treasury stock as a reduction of retained earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yMzgvZnJhZzpiZjg4M2NhYjIwMGE0MDViOWZmYjg2NjgyZjgwYmE1YS90ZXh0cmVnaW9uOmJmODgzY2FiMjAwYTQwNWI5ZmZiODY2ODJmODBiYTVhXzIyMg_b2abe590-fd5b-478f-9345-cc5d5c7c111c">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is comprised of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and changes in unrealized gains or losses on available-for-sale securities and is included in the consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDEvZnJhZzoyYmJiMWQ4NTE1YTU0OWNmOTc4NmIzYjlmMGRiMTk0ZS90ZXh0cmVnaW9uOjJiYmIxZDg1MTVhNTQ5Y2Y5Nzg2YjNiOWYwZGIxOTRlXzc2Nw_0a34af2d-6dce-42e7-992f-1d48f1511c61">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe any recently issued, but not yet effective, accounting standards will have a material effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM184MjQ2MzM3MjEyNTI0_51a1f441-dd41-4cda-bcd7-2c10f71896ce">Spin Off of Home Health and Hospice BusinessOn July 1, 2022, we completed the previously announced separation of our home health and hospice business through the distribution (the &#x201c;Spin Off&#x201d;) of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit, Inc. (&#x201c;Enhabit&#x201d;) to the stockholders of record of Encompass Health as of the close of business on June 24, 2022 (the &#x201c;Record Date&#x201d;). The Spin Off was effective at 12:01 a.m., Eastern Time, on July 1, 2022. The Spin Off was structured as a pro rata distribution of one share of Enhabit common stock for every two shares of Encompass Health common stock held of record as of the Record Date. No fractional shares were distributed. A cash payment was made in lieu of any fractional shares. As a result of the Spin Off, Enhabit is now an independent public company and its common stock is listed under the symbol &#x201c;EHAB&#x201d; on the New York Stock Exchange.&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with applicable accounting guidance, the historical results of Enhabit have been presented as discontinued operations and, as such, have been excluded from continuing operations for all periods presented. Our presentation of discontinued operations excludes any allocation of general corporate and overhead costs as well as interest expense. Prior to July 1, 2022, we operated under two reporting segments. We now operate under a single reporting segment. In anticipation of the Spin Off, Enhabit transferred the &#x201c;Encompass&#x201d; trade name (net book value of $104.2&#160;million) to us during the second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Spin Off, on June 30, 2022, we entered into several agreements with Enhabit that govern the relationship of the parties following the Spin Off, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement and an Employee Matters Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will provide transition services to Enhabit predominately consisting of certain finance, information technology, human resources, employee benefits and other administrative services for a period of up to two years after the Spin Off. For the year ended December 31, 2022, income related to these transition services of $2.1&#160;million were reflected as reductions to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General and administrative expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated statements of comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the results of operations of Enhabit as discontinued operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Occupancy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of nonconsolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Reflects amounts through the July 1, 2022 Spin Off date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs of $56.7&#160;million and $22.9&#160;million incurred during the years ended December&#160;31, 2022 and 2021, respectively, are included in general and administrative expenses in the table above and in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in the consolidated statements of comprehensive income. These charges primarily relate to third-party advisory, consulting, legal and professional services, that are associated with the Spin Off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the carrying amounts of the assets and liabilities of the discontinued operations of Enhabit (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total noncurrent assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total noncurrent liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See also Note&#160;10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i81822404b04248c2bc2b92116b265222_I20220701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTYzODY_56091ed0-7d75-446f-a469-41db95b9b89e"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i4ccb23d1174a4ad1bc94116310a93215_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTY0MDE_1b676667-35b7-44bf-8aa6-e40e46a55072"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="i5ee3194559484035acac2abce51ef2bb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTY0MjA_c35f4f8e-a563-4e7d-abaf-8935b89f8400"
      unitRef="usd">104200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <ehc:DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTY0NDU_9588ff97-0ac8-4d4b-ac61-251b112648ff">P2Y</ehc:DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm>
    <ehc:DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTY0NjA_dc970b21-dcf6-454e-a297-615c2bdb49e3"
      unitRef="usd">2100000</ehc:DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM184MjQ2MzM3MjEyNTI4_9f2f318b-1139-48be-bdc4-fe461dae62ac">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the results of operations of Enhabit as discontinued operations (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salaries and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;778.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Occupancy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense and amortization of debt discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net income of nonconsolidated affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Reflects amounts through the July 1, 2022 Spin Off date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the carrying amounts of the assets and liabilities of the discontinued operations of Enhabit (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,190.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total noncurrent assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,543.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total noncurrent liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8yLTEtMS0xLTI2NjY4Nw_18e2c57b-bef5-437b-bdf7-a584f2700f55"
      unitRef="usd">542300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8yLTMtMS0xLTI2NjY4Nw_a9f8f753-e939-4d5c-a436-0347bc426093"
      unitRef="usd">1106600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8yLTUtMS0xLTI3MjM1Mw_452b77f7-9887-4dc4-b28f-cd0d636130f4"
      unitRef="usd">1078400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF80LTEtMS0xLTI2NjY4Nw_64406213-817b-4623-b438-4e9f6985ccad"
      unitRef="usd">376400000</ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits>
    <ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF80LTMtMS0xLTI2NjY4Nw_0101c0d7-145c-45be-b222-5a862653dfe6"
      unitRef="usd">759200000</ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits>
    <ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF80LTUtMS0xLTI3MjM1Mw_20422a56-42ad-4a3d-a357-76206bce04a3"
      unitRef="usd">778000000.0</ehc:DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits>
    <ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF81LTEtMS0xLTI2NjY4Nw_43738bf1-4859-4dc2-bb64-1115d71ea97a"
      unitRef="usd">47500000</ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense>
    <ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF81LTMtMS0xLTI2NjY4Nw_546d12f9-b28d-4b0d-82b3-b1853b41e198"
      unitRef="usd">89700000</ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense>
    <ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF81LTUtMS0xLTI3MjM1Mw_9dd1cbb0-b1c2-4631-a4d8-56ff81bf4fc6"
      unitRef="usd">89600000</ehc:DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense>
    <ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF82LTEtMS0xLTI2NjY4Nw_41f05940-1e5b-4006-8ddd-e02556919883"
      unitRef="usd">11000000.0</ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts>
    <ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF82LTMtMS0xLTI2NjY4Nw_0e4aa7fa-4709-4d2c-85b0-063a21da022e"
      unitRef="usd">21200000</ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts>
    <ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF82LTUtMS0xLTI3MjM1Mw_e19bf593-d4ad-4dcb-89a5-ce4842ad82cb"
      unitRef="usd">19800000</ehc:DisposalGroupIncludingDiscontinuedOperationOccupancyCosts>
    <ehc:DisposalGroupIncludingDiscontinuedOperationSupplies
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF83LTEtMS0xLTI2NjY4Nw_e0f767b5-bb6f-4994-ae03-321bc0944666"
      unitRef="usd">11700000</ehc:DisposalGroupIncludingDiscontinuedOperationSupplies>
    <ehc:DisposalGroupIncludingDiscontinuedOperationSupplies
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF83LTMtMS0xLTI2NjY4Nw_53cd4c5d-6548-4ad7-b1e4-60d02380ae4d"
      unitRef="usd">25100000</ehc:DisposalGroupIncludingDiscontinuedOperationSupplies>
    <ehc:DisposalGroupIncludingDiscontinuedOperationSupplies
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF83LTUtMS0xLTI3MjM1Mw_ea7a4c35-6acb-4ea1-a25e-231ae31b5e14"
      unitRef="usd">29500000</ehc:DisposalGroupIncludingDiscontinuedOperationSupplies>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF84LTEtMS0xLTI2NjY4Nw_50820ba5-f94f-40d7-9f80-b1e02ebce590"
      unitRef="usd">59300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF84LTMtMS0xLTI2NjY4Nw_426fcfa6-c01f-49b2-8413-c7e612c1198b"
      unitRef="usd">27900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF84LTUtMS0xLTI3MjM1Mw_9abd862d-6bae-40b8-a32d-70919944292b"
      unitRef="usd">3900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF85LTEtMS0xLTI2NjY4Nw_adcc502c-aed7-41d2-9e7b-78057a0aedca"
      unitRef="usd">16700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF85LTMtMS0xLTI2NjY4Nw_a8e539ba-4ec7-446d-aaf6-d3f2fb50afc0"
      unitRef="usd">36900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF85LTUtMS0xLTI3MjM1Mw_b830b443-7dc2-4f23-b057-8d68f099a21a"
      unitRef="usd">40000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMC0xLTEtMS0yNzc1Nzc_4d4ce27a-b86c-458d-824b-5f712d2508ec"
      unitRef="usd">522600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMC0zLTEtMS0yNzc1ODE_bfe26759-3061-43c2-88c1-81ba0092b6e0"
      unitRef="usd">960000000.0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMC01LTEtMS0yNzc1ODQ_7e9c3e5a-d738-4d86-8390-d98bb158d7f7"
      unitRef="usd">960800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMS0xLTEtMS0yNjY2OTQ_2b0a1b11-4ff6-4c3e-a6aa-1e47a9e6a7e5"
      unitRef="usd">200000</ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees>
    <ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMS0zLTEtMS0yNjY2OTQ_23d83b5f-26d9-4bdf-ba5c-86efcc551fa0"
      unitRef="usd">300000</ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees>
    <ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMS01LTEtMS0yNzIzNjA_48a278f8-0a30-4bad-a0ee-b4268674b8d6"
      unitRef="usd">500000</ehc:DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMi0xLTEtMS0yNjY2OTQ_361efd48-175b-4da2-9956-115dcf7f96b3"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMi0zLTEtMS0yNjY2OTQ_c29e148d-43fa-4ab2-b19f-7f08d5e64dc9"
      unitRef="usd">4800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMi01LTEtMS0yNzIzNjA_3805c8be-2bff-403e-afb7-5759886c31b6"
      unitRef="usd">2200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherIncome>
    <ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMy0xLTEtMS0yNjY2OTQ_5e438b39-ead9-4bc6-9456-895e78e79232"
      unitRef="usd">0</ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments>
    <ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMy0zLTEtMS0yNjY2OTQ_ec1027ab-0c8f-4a64-be57-8b9e95b0341a"
      unitRef="usd">600000</ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments>
    <ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xMy01LTEtMS0yNzIzNjA_034a32e4-9056-466a-b5e7-35e2e53e69d7"
      unitRef="usd">500000</ehc:DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNC0xLTEtMS0yNzc1Nzc_a487a613-31f1-4852-bbb3-b026d4f79b02"
      unitRef="usd">19500000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNC0zLTEtMS0yNzc1ODE_3340af90-f4bd-43b3-a4a5-917471039a7b"
      unitRef="usd">151700000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNC01LTEtMS0yNzc1ODQ_9771e6ee-70b6-40a6-9b41-994da03af403"
      unitRef="usd">119800000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNS0xLTEtMS0yNjY3MDY_5f254c4f-8990-43f9-838d-063a2e2e7d98"
      unitRef="usd">4300000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNS0zLTEtMS0yNjY3MDY_3e0b883e-c6f0-4b36-b2d7-ac1673e3db6a"
      unitRef="usd">37600000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNS01LTEtMS0yNzIzNjc_41c91512-c5b7-404d-8d8a-b397fd855549"
      unitRef="usd">29200000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNi0xLTEtMS0yNzc1Nzc_b94219c7-1890-4968-9cc8-965c5fac477b"
      unitRef="usd">15200000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNi0zLTEtMS0yNzc1ODE_f5177ac6-b791-4885-a24c-3a1f0c362513"
      unitRef="usd">114100000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNi01LTEtMS0yNzc1ODQ_cb9f026f-7087-4dcf-aa8c-4fc73c688e79"
      unitRef="usd">90600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNy0xLTEtMS0yNjY3MTM_c158220d-1a6e-40e5-8d70-025ada3b7cf4"
      unitRef="usd">1300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNy0zLTEtMS0yNjY3MTM_09d28578-8cc8-463c-9ac4-527ff2e78fa0"
      unitRef="usd">1800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xNy01LTEtMS0yNzIzNzQ_5cc28ac2-3f86-4f9a-9d4d-86bb795e7cc2"
      unitRef="usd">1300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xOC0xLTEtMS0yNzc1Nzc_6c33eec3-9ab4-4476-8e93-58506563baf0"
      unitRef="usd">13900000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xOC0zLTEtMS0yNzc1ODE_b04778f6-1e37-4b9d-8272-7892a50f03d5"
      unitRef="usd">112300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="ic149a76ed4064ac1b6af498e71cfe0da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6YzI1NzE0YzZiNzExNDk0NGE2MGM3N2FkNTczMjAzYTgvdGFibGVyYW5nZTpjMjU3MTRjNmI3MTE0OTQ0YTYwYzc3YWQ1NzMyMDNhOF8xOC01LTEtMS0yNzc1ODQ_9dbc5a62-043b-4403-bb2f-9abd66707baf"
      unitRef="usd">89300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <ehc:DisposalGroupIncludingDiscontinuedOperationTransactionCosts
      contextRef="i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTczMDA_1e04a6ef-510f-4936-8599-af68f0162f1c"
      unitRef="usd">56700000</ehc:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
    <ehc:DisposalGroupIncludingDiscontinuedOperationTransactionCosts
      contextRef="i61877a1be9eb4d11897ef11da83d3d68_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGV4dHJlZ2lvbjo5ZWNmODY2ZTc1Mjc0OGQ0OWIwN2U2M2ZiOTYyMTcyM181NDk3NTU4MTczMTU_4934f784-6177-451a-9023-ab86dbc34ebe"
      unitRef="usd">22900000</ehc:DisposalGroupIncludingDiscontinuedOperationTransactionCosts>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl80LTMtMS0xLTI2NjgyNA_9cde320c-cace-4b89-ab72-83c4604221fd"
      unitRef="usd">5400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <ehc:DisposalGroupIncludingDiscontinuedOperationRestrictedCash
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl81LTMtMS0xLTI2NjgyNA_4caae04a-8aeb-4192-8c3e-3d10015c2307"
      unitRef="usd">2600000</ehc:DisposalGroupIncludingDiscontinuedOperationRestrictedCash>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl82LTMtMS0xLTI2NjgyNA_f2b782c4-141b-4b1f-ae72-80384e5edcc4"
      unitRef="usd">164500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl83LTMtMS0xLTI2NjgyNA_ad23cb20-e8ac-460c-ad0f-c1fb5a5376c5"
      unitRef="usd">6300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl84LTMtMS0xLTI2Njg1Mg_eaf28422-4535-44a3-8e41-fc1c98087547"
      unitRef="usd">178800000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl85LTMtMS0xLTI2NjgzNQ_a58f3db9-1c27-4a81-9997-cdeb15e013b7"
      unitRef="usd">20400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <ehc:DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMC0zLTEtMS0yNjY4MzU_6c581a3a-cfb3-4835-9ba0-767f470b4445"
      unitRef="usd">48400000</ehc:DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMS0zLTEtMS0yNjY4MzU_60928867-277a-43ee-a0ce-394766fe27e2"
      unitRef="usd">1190900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMi0zLTEtMS0yNjY4MzU_7539c9b2-07ce-4c2a-b402-9e859af1587a"
      unitRef="usd">259100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMy0zLTEtMS0yNjY4MzU_ce6e2e79-61d3-40a5-99e3-8cfa22b3626a"
      unitRef="usd">24400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xMy0xLTEtMS0yNzc2MTk_a285a18f-324c-489d-9cd2-883d4cfd1459"
      unitRef="usd">1543200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xNC0xLTEtMS0yNzc2MTk_e015bff1-f2aa-43c9-8c1b-1f619d5f95f6"
      unitRef="usd">1722000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <ehc:DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xOC0zLTEtMS0yNjY4NDI_0b92d8ac-be2a-4151-9040-81f7f048fed7"
      unitRef="usd">5000000.0</ehc:DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent>
    <ehc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8xOS0zLTEtMS0yNjY4NDI_e4d5f56f-66fb-483d-9df5-d9501f7c69c4"
      unitRef="usd">14900000</ehc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMC0zLTEtMS0yNjY4NDI_6d3a5e04-896d-4dda-a539-23219df19904"
      unitRef="usd">3500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <ehc:DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMC0xLTEtMS0yOTc0OTY_889b780f-ab71-4f2c-872f-b13ecdababc5"
      unitRef="usd">66400000</ehc:DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent>
    <ehc:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMS0zLTEtMS0yNjY4NDI_f14ac1b0-7893-47db-9b3c-88211c681de6"
      unitRef="usd">42600000</ehc:DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMS0xLTEtMS0yNzc2MTk_d2b3b9c0-af44-4763-859d-32527f5986b4"
      unitRef="usd">132400000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <ehc:DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yMy0zLTEtMS0yNjY4NDk_4ec22794-8611-4f87-8765-35c296b24cb7"
      unitRef="usd">3500000</ehc:DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent>
    <ehc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNC0zLTEtMS0yNjY4NDk_24b13cba-e3fb-4f98-92ff-372925c540b8"
      unitRef="usd">33500000</ehc:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNS0zLTEtMS0yNjY4NDk_1fffc391-8367-44a6-a666-2d57bdbc8619"
      unitRef="usd">63400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNi0zLTEtMS0yNjY4NDk_609bb5db-65f2-414f-92f8-26e16ef74d62"
      unitRef="usd">400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNi0xLTEtMS0yNzc2MTk_52f51d33-49c6-41d5-a326-745559c831b3"
      unitRef="usd">100800000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i5ce31a740de9494abb75658e9c4e37c7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjAyL2ZyYWc6OWVjZjg2NmU3NTI3NDhkNDliMDdlNjNmYjk2MjE3MjMvdGFibGU6ODAzZDI2MzcxNjI0NDA0MzkwNzI0NzZmOGJlZmNjNWIvdGFibGVyYW5nZTo4MDNkMjYzNzE2MjQ0MDQzOTA3MjQ3NmY4YmVmY2M1Yl8yNy0xLTEtMS0yNzc2MTk_7822e57c-7a51-4b24-9e52-79cbcf416695"
      unitRef="usd">233200000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzE4MzYy_f0e75e2e-36c1-4f11-a064-8698914aef37">Business Combinations:&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In August 2022, we acquired 60% of the operations of a 23-bed inpatient rehabilitation unit in Grand Forks, North Dakota when Altru Health System contributed those operations to our existing joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In August 2022, we acquired 50% of the operations of a 22-bed inpatient rehabilitation unit in Moline, Illinois when Trinity Medical Center contributed those operations to our existing joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In December 2022, we acquired 50% of the operations of a 54-bed inpatient rehabilitation unit in Naples, Florida when NCH Healthcare System contributed those operations to our joint venture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from the respective dates of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on an income approach using discounted cash flow techniques for the noncompete intangible assets. The aforementioned income method utilizes management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospitals&#x2019; historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in these markets. None of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition dates were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 2 to 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the acquisitions during 2022 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pro Forma Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above-mentioned acquisitions from the dates of acquisitions included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the dates of the acquisitions been January&#160;1, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2022-12/31/2022 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,039.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2021 period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In April 2021, we acquired 51% of the operations of a 14-bed inpatient rehabilitation unit in San Angelo, Texas when Shannon Medical contributed those operations to our existing joint venture entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In June 2021, we acquired 75% of the operations of a 16-bed inpatient rehabilitation unit in McKees Rocks, Pennsylvania through our existing joint venture with Heritage Valley Health System, Inc. The acquisition was funded using cash on hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In July 2021, we acquired 65% of the operations of a 22-bed inpatient rehabilitation unit in Odessa, Texas when ECHD Ventures contributed those operations to our existing joint venture entity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including: an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#x2019;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions is deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition dates were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 3 to 5 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Pro Forma Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned-acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, we completed the following inpatient rehabilitation acquisitions, none of which were individually material to our financial position, results of operations, or cash flows. Each acquisition was made to enhance our position and ability to provide inpatient rehabilitation services to patients in the applicable geographic areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In January 2020, we acquired 68% of the operations of a 13-bed inpatient rehabilitation unit in Denver, Colorado through a joint venture with Portercare Adventist Health System. The acquisition was funded through a contribution of our existing 40-bed inpatient rehabilitation hospital in Littleton, Colorado and through contributions of funds which were utilized by the consolidated joint venture to build a 20-bed expansion to the Littleton hospital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In May 2020, we acquired 51% of the operations of a 45-bed inpatient rehabilitation unit in Dayton, Ohio through a joint venture with Premier Health Partners. The acquisition was funded through contributions of funds which were utilized by the consolidated joint venture to build a 60-bed de novo inpatient rehabilitation hospital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for these transactions under the acquisition method of accounting and reported the results of operations of the acquired hospitals from its respective date of acquisition. Assets acquired were recorded at their estimated fair values as of the acquisition date. Estimated fair values were based on various valuation methodologies including an income approach using primarily discounted cash flow techniques for the noncompete intangible assets and an income approach utilizing the relief from royalty method for the trade name intangible asset. The aforementioned income methods utilize management&#x2019;s estimates of future operating results and cash flows discounted using a weighted-average cost of capital that reflects market participant assumptions. The excess of the fair value of the consideration conveyed over the fair value of the assets acquired was recorded as goodwill. The goodwill reflects our expectations of our ability to gain access to and penetrate the acquired hospital&#x2019;s historical patient base and the benefits of being able to leverage operational efficiencies with favorable growth opportunities based on positive demographic trends in this market. None of the goodwill recorded as a result from these transactions are deductible for federal income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 2 to 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Pro Forma Results of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above-mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,571.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2020 reporting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ie37abe5ebc4f44bebbe9fb494c9c84e1_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzMzA0Mg_8cee1423-d37f-4a00-b4a3-24db3268c971"
      unitRef="number">0.60</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberOfBedsAcquired
      contextRef="ie37abe5ebc4f44bebbe9fb494c9c84e1_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzMzA0Nw_913ab8b6-abe8-475a-8beb-7258c699a8fb"
      unitRef="bed">23</ehc:NumberOfBedsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i9991693278fc408e862976490cf30d98_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzMzA1OA_dad5b54a-5318-482c-b25f-3b330a4389c6"
      unitRef="number">0.50</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberOfBedsAcquired
      contextRef="i9991693278fc408e862976490cf30d98_I20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzMzA2Mw_16b16e9c-70e4-4823-ac33-915de259bd3d"
      unitRef="bed">22</ehc:NumberOfBedsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i6820aa09cd604de1a90b41670cea5ea8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzOTkwNQ_a6659edb-1c58-4710-89f5-9966437c45bd"
      unitRef="number">0.50</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberOfBedsAcquired
      contextRef="i6820aa09cd604de1a90b41670cea5ea8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzOTkxMA_928cf411-6a9b-4a84-a085-34264e491bc0"
      unitRef="bed">54</ehc:NumberOfBedsAcquired>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i8ff2033f1b3942129102202260af6a35_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzU0OTc1NTgzNDE3OQ_d38634d7-2511-4d79-95d9-d20d1f58a01a"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzgyNDYzMzcyMzMzODE_32148f5f-19df-4036-8e0c-bcc67a843ef0">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition dates were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 2 to 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition dates were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 3 to 5 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the assets acquired at the acquisition date were as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.186%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompete agreements (useful lives of 2 to 3 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name (useful life of 20 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia21684f87fae47c5b3a34319790c0769_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzctMC0xLTEtMjc1MzQ2L3RleHRyZWdpb246MThhYTc0NzE0M2M3NGUxYTg0ZTlkYjBmZjEzNjMzOTRfNTQ5NzU1ODEzOTQ1_c24902e6-a1e0-4d57-8b65-019c479885f0">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id0d9fe27b422459b8eca401afa6fe33c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzctMC0xLTEtMjc1MzQ2L3RleHRyZWdpb246MThhYTc0NzE0M2M3NGUxYTg0ZTlkYjBmZjEzNjMzOTRfNTQ5NzU1ODEzOTQ5_919c6430-eb26-496c-a03b-3282cabc79e1">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="if1b030fcfd4e4d31a741e7594dc965c0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzEtMS0xLTEtMjc1NDMz_77ef1f40-c5b8-4eea-a682-f47e6f1bd8b1"
      unitRef="usd">900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i33b5d49a11d841d0962f2c16a1a90833_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzItMS0xLTEtMjc1NDQx_1ff9a4d5-527b-4242-8f0f-0058cc9db2de"
      unitRef="usd">26200000</us-gaap:Goodwill>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets
      contextRef="i33b5d49a11d841d0962f2c16a1a90833_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpiYzY4MTUwNTk2NTI0MWJhYWI4OGE2MmUyNTZjYzAzZC90YWJsZXJhbmdlOmJjNjgxNTA1OTY1MjQxYmFhYjg4YTYyZTI1NmNjMDNkXzMtMS0xLTEtMjc3NTA1_91424e06-c5e3-4ac8-bee7-ef37c1e73f4f"
      unitRef="usd">27100000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzgyNDYzMzcyMzMzODA_a7703dcc-d438-412a-808d-6239294e1136">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the acquisitions during 2022 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the acquisitions during 2021 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the net cash paid for the inpatient rehabilitation acquisitions during 2020 is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of assets acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of noncontrolling interest owned by joint venture partner&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash paid for acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4ZGY4OWE3MmYxODU0NmIyYWFiZjQ4MDZkZjRmZWVmNy90YWJsZXJhbmdlOjhkZjg5YTcyZjE4NTQ2YjJhYWJmNDgwNmRmNGZlZWY3XzItNy0xLTEtMjc1MzYx_77d9976f-225e-4944-b71c-fe7610460437"
      unitRef="usd">900000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4ZGY4OWE3MmYxODU0NmIyYWFiZjQ4MDZkZjRmZWVmNy90YWJsZXJhbmdlOjhkZjg5YTcyZjE4NTQ2YjJhYWJmNDgwNmRmNGZlZWY3XzMtNy0xLTEtMjc1MzYx_7d7343d3-a3d1-4190-afc4-62bc847ca5c2"
      unitRef="usd">26200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4ZGY4OWE3MmYxODU0NmIyYWFiZjQ4MDZkZjRmZWVmNy90YWJsZXJhbmdlOjhkZjg5YTcyZjE4NTQ2YjJhYWJmNDgwNmRmNGZlZWY3XzUtNy0xLTEtMjc1MzYx_bb4c8f2b-2bd0-4fd9-8e48-b66276eb0496"
      unitRef="usd">27100000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4ZGY4OWE3MmYxODU0NmIyYWFiZjQ4MDZkZjRmZWVmNy90YWJsZXJhbmdlOjhkZjg5YTcyZjE4NTQ2YjJhYWJmNDgwNmRmNGZlZWY3XzMtMS0xLTEtMjc3NTE2_5d25da93-645b-4223-946c-824fea30aa4c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzgyNDYzMzcyMzMzNzk_6d21a45b-8170-4332-8bc6-28b0d3235f4b">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above-mentioned acquisitions from the dates of acquisitions included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the dates of the acquisitions been January&#160;1, 2021 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2022-12/31/2022 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,039.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information presented above is for illustrative purposes only and is not necessarily indicative of results that would have been achieved if the acquisitions had occurred as of the beginning of our 2021 period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above mentioned-acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January 1, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2021-12/31/2021 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the above-mentioned acquisitions from their respective dates of acquisition included in our consolidated results of operations and the unaudited pro forma results of operations of the combined entity had the date of the acquisitions been January&#160;1, 2020 (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Operating Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Income Attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired entities only: Actual from acquisition date to December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Combined entity: Supplemental pro forma from 01/01/2020-12/31/2020 (unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,571.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzEtMS0xLTEtMjk0Njcx_2dd064b7-98a9-4ef1-99d9-76c7c9854640"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzEtMy0xLTEtMjk0Njcx_95943b0a-3e92-49e8-99f3-31602f793a98"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzQtMS0xLTEtMjc0OTE0_b8fba366-d836-4481-9a6d-23e46aec2cd1"
      unitRef="usd">4369000000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzQtMy0xLTEtMjc0OTE0_0e570779-15e5-4846-928c-122d712b5685"
      unitRef="usd">273700000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzUtMS0xLTEtMjc0OTE0_b0ed3776-5eee-403c-b193-7ee47f477557"
      unitRef="usd">4039800000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTpkYzE0ODQ1YTBkYzU0OGIwYjY0YzE0ODM4YjlmZTk5Zi90YWJsZXJhbmdlOmRjMTQ4NDVhMGRjNTQ4YjBiNjRjMTQ4MzhiOWZlOTlmXzUtMy0xLTEtMjc0OTE0_160a1446-2c3e-41b6-b198-66bc79c3b81e"
      unitRef="usd">415300000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i56015630b11b4e009f45b95de40f5a16_I20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzQxNw_57067ff1-f47d-4021-ba8c-9ab42ca613eb"
      unitRef="number">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberOfBedsAcquired
      contextRef="i56015630b11b4e009f45b95de40f5a16_I20210430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzQ0Mw_01f85942-ef7f-4be4-973b-e3af2ce2b785"
      unitRef="bed">14</ehc:NumberOfBedsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i926c10b50d5b4dc4952bd8f73e5caf2c_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzYxNQ_fe19258f-99da-4960-a943-8cddbf2424f0"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberOfBedsAcquired
      contextRef="i926c10b50d5b4dc4952bd8f73e5caf2c_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzY0MQ_3745338c-3d5f-455d-802f-6703a05cf453"
      unitRef="bed">16</ehc:NumberOfBedsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i42d3a03ae9fb49d2a3c3300daff8071b_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4Xzg1Nw_304fcc3d-850e-463f-a121-31c419b2a8e0"
      unitRef="number">0.65</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberOfBedsAcquired
      contextRef="i42d3a03ae9fb49d2a3c3300daff8071b_I20210731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4Xzg4Mw_428fa002-7e67-45f9-a707-166294590abb"
      unitRef="bed">22</ehc:NumberOfBedsAcquired>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ia3876cf645ac4e17bb330ae838f085f4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzIyMDY_accfc5bd-bf30-4d7c-b2f0-f3c5b9cd719e"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="icd3a3de37fca442dbd0a5e70526dbf46_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzMtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTRiZDBmZTNkMDBlNDNiMmI4ODI1YTI0N2VmNzQ3ZGNfNDM_79f31eff-ae1e-4eac-942e-f27195a4b478">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="id86e386a397b49d296ca11e4a511d544_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzMtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTRiZDBmZTNkMDBlNDNiMmI4ODI1YTI0N2VmNzQ3ZGNfNDk_9ca03059-6d8f-4c47-87ff-8efffd8ad7a3">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i1bea87602e1641b0b71e094855c78088_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzMtMS0xLTEtMjQ1NDc3_a1c24e8b-7b1d-468f-9e92-7cccdd8b2cd0"
      unitRef="usd">1000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i75e5544167514a92ae6527fb86b9e780_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzQtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZmQ0YmE5MTg0NjExNDc5ZGE2Yjk3NGJhMjEwY2ZjMDlfMzE_aa698278-167e-4118-bf12-469449796e08">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i6b6bdb8e550a4806bb3e1dadfd5e0505_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzQtMS0xLTEtMjQ1NDc3_f3a78393-53b4-4545-bd04-15f766c5d4e3"
      unitRef="usd">300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i4ae11dbadeb749178d2cc18aceb997a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzctMS0xLTEtMjQ1NDc3_8661f8cf-49e6-4fde-acd7-6457ac2d7ada"
      unitRef="usd">8800000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="i4ae11dbadeb749178d2cc18aceb997a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzgtMS0xLTEtMjQ1NDc3_2699d263-c78f-4e5c-b5b9-52181e115976"
      unitRef="usd">100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets
      contextRef="i4ae11dbadeb749178d2cc18aceb997a3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo0OGJmZGMyY2YzYmU0NTU4YTExMDljYzc2Nzg5ZGMxOC90YWJsZXJhbmdlOjQ4YmZkYzJjZjNiZTQ1NThhMTEwOWNjNzY3ODlkYzE4XzktMS0xLTEtMjQ1NDc3_87424a17-98bb-44c5-94bc-e73be81cefe5"
      unitRef="usd">10200000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozNmE5MmYzYTRmNWU0YzBmOWNmODI4MTM4NmM4YmM3Ny90YWJsZXJhbmdlOjM2YTkyZjNhNGY1ZTRjMGY5Y2Y4MjgxMzg2YzhiYzc3XzAtMS0xLTEtMjQ1NDc3_76f6aef5-7f44-4127-9cb3-d5f5628797e4"
      unitRef="usd">1400000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozNmE5MmYzYTRmNWU0YzBmOWNmODI4MTM4NmM4YmM3Ny90YWJsZXJhbmdlOjM2YTkyZjNhNGY1ZTRjMGY5Y2Y4MjgxMzg2YzhiYzc3XzEtMS0xLTEtMjQ1NDc3_1f72cea9-2d01-4b0c-8087-2899b9cebd35"
      unitRef="usd">8800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozNmE5MmYzYTRmNWU0YzBmOWNmODI4MTM4NmM4YmM3Ny90YWJsZXJhbmdlOjM2YTkyZjNhNGY1ZTRjMGY5Y2Y4MjgxMzg2YzhiYzc3XzMtMS0xLTEtMjQ1NDc3_c700e3e3-2a5f-4c29-93f4-37b88d1e2203"
      unitRef="usd">9100000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozNmE5MmYzYTRmNWU0YzBmOWNmODI4MTM4NmM4YmM3Ny90YWJsZXJhbmdlOjM2YTkyZjNhNGY1ZTRjMGY5Y2Y4MjgxMzg2YzhiYzc3XzUtMS0xLTEtMjQ1NDc3_fa75382a-9b22-4830-bd29-c2d39ff2c05d"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzEtMS0xLTEtMjk3MzYw_a83e8a22-df92-48e4-ac64-4eb94662f9b3"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i7a9fb74f5cff433fa261ed0e475b84e7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzEtMy0xLTEtMjk3MzYw_55fb8779-d70b-4faa-86df-e3b1b9f9bf52"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ida60f9410ec942ffa8b96644e1a4982e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzUtMS0xLTEtMjQ1NDc3_baba00cb-066e-4a64-be70-9dbe5195faf4"
      unitRef="usd">4021100000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ida60f9410ec942ffa8b96644e1a4982e_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzUtMy0xLTEtMjQ1NDc3_6f7c729e-58af-47f5-8000-9e9525e8be41"
      unitRef="usd">412500000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ic9d13dc5dde24449a63972bfe6bc1df8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzYtMS0xLTEtMjQ1NDc3_9208c09a-da89-43b3-8b08-5e2f3d38be69"
      unitRef="usd">3581300000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="ic9d13dc5dde24449a63972bfe6bc1df8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo5MzUyZGU3Njg2MDY0ODdiYmFhYmI1OGMwOWNhNjZiZi90YWJsZXJhbmdlOjkzNTJkZTc2ODYwNjQ4N2JiYWFiYjU4YzA5Y2E2NmJmXzYtMy0xLTEtMjQ1NDc3_276f860d-ab96-4737-b2b3-db6e9c7941c5"
      unitRef="usd">285000000.0</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i1070117531644374b85aaa3af7d800d0_I20200131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4Xzk4ODg_bdaf1f68-7e11-46f5-8540-4b0b9d26a20d"
      unitRef="number">0.68</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberOfBedsAcquired
      contextRef="i1070117531644374b85aaa3af7d800d0_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4Xzk5MTQ_be10e110-094e-4bbc-9eed-9bcb048b624f"
      unitRef="bed">13</ehc:NumberOfBedsAcquired>
    <ehc:NumberofBedsContributed
      contextRef="i1070117531644374b85aaa3af7d800d0_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwMTAy_f3cbee12-5644-4c13-878c-8a7a1e2dcb13"
      unitRef="bed">40</ehc:NumberofBedsContributed>
    <ehc:NumberofBedsExpanded
      contextRef="i1070117531644374b85aaa3af7d800d0_I20200131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwMjY2_0bd1e08d-1fad-4692-84fa-252d7bae45e1"
      unitRef="bed">20</ehc:NumberofBedsExpanded>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ib6bc012b46224f569423ad84a5eac16f_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwMzM1_c8b7e83b-c9b5-41ea-96c7-19aa825ff473"
      unitRef="number">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <ehc:NumberOfBedsAcquired
      contextRef="ib6bc012b46224f569423ad84a5eac16f_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwMzYx_babdcf9d-eedd-4934-9ba2-4adda057602f"
      unitRef="bed">45</ehc:NumberOfBedsAcquired>
    <ehc:NumberofDeNovoBeds
      contextRef="ib6bc012b46224f569423ad84a5eac16f_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzEwNTkx_e7d1913f-c705-44d1-a16e-a07af4757cf6"
      unitRef="bed">60</ehc:NumberofDeNovoBeds>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="i4ddfcda5811941ceb891a6ef3548c7c3_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90ZXh0cmVnaW9uOmFjNDRhYTY3Nzg0YTQ0MzI5YzdjNDg3Mjg5YTVkYzc4XzExODIz_6d9e8d98-a9a5-4f89-9cb5-cae17870af9a"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i63b458d6463a4a96b479e42c0fcc71c1_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzMtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MjM3NWU2NWJmZDA0NGJiMmI0MjkzMWY0NzM0ZjVkZWZfNDM_00835f0f-6e6d-41a1-a74a-f950a0393230">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="if50b14c350354038b6604d1681524651_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzMtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MjM3NWU2NWJmZDA0NGJiMmI0MjkzMWY0NzM0ZjVkZWZfNDk_18f76c1e-0ad6-496a-bf2b-5284800d7725">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ib1ccbd7406a9458abb7cfc12e90ad1e6_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzMtMS0xLTEtMjQ1NDc3_2552cfa5-2016-4f6d-b985-9815b04233fa"
      unitRef="usd">700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8af9ecf91da248c5be27bca52229721d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzQtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246ODdlODE0ZjgzNjc3NDA1OTliZjViYWRmMjI2OTMyOGFfMzE_b2a71f05-bf4e-4330-ac00-d0c930689467">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i3e3f8c860f1b432e95cc26067ef20e2a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzQtMS0xLTEtMjQ1NDc3_b1a5496c-8086-4926-bbef-ff7a24a2bb49"
      unitRef="usd">900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:Goodwill
      contextRef="i684d2533374c48a4bd1364edabf0ba08_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzctMS0xLTEtMjQ1NDc3_b8861868-a09f-4aeb-92ee-f94d0a0793b0"
      unitRef="usd">9300000</us-gaap:Goodwill>
    <ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets
      contextRef="i684d2533374c48a4bd1364edabf0ba08_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo3ZmZjMDgwYmI4ZjQ0MjAxYTA3YTExMzRlNWJiMjNiYy90YWJsZXJhbmdlOjdmZmMwODBiYjhmNDQyMDFhMDdhMTEzNGU1YmIyM2JjXzgtMS0xLTEtMjQ1NDc3_cc226f77-babd-4a24-bb5f-6b5ec9ca6bd6"
      unitRef="usd">10900000</ehc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozYTAwYTEwNjYwOTk0YTY0YTVjNjQwM2Y1OTFlZmUzNi90YWJsZXJhbmdlOjNhMDBhMTA2NjA5OTRhNjRhNWM2NDAzZjU5MWVmZTM2XzAtMS0xLTEtMjQ1NDc3_3ded6202-394a-452e-8f68-26f50f84f676"
      unitRef="usd">1600000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozYTAwYTEwNjYwOTk0YTY0YTVjNjQwM2Y1OTFlZmUzNi90YWJsZXJhbmdlOjNhMDBhMTA2NjA5OTRhNjRhNWM2NDAzZjU5MWVmZTM2XzEtMS0xLTEtMjQ1NDc3_a431d799-4677-40d8-938c-cdc4bae8ab87"
      unitRef="usd">9300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <ehc:BusinessCombinationNoncontrollingInterestFairValue
      contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozYTAwYTEwNjYwOTk0YTY0YTVjNjQwM2Y1OTFlZmUzNi90YWJsZXJhbmdlOjNhMDBhMTA2NjA5OTRhNjRhNWM2NDAzZjU5MWVmZTM2XzMtMS0xLTEtMjQ1NDc3_a3f34763-a3c7-448e-95ec-92b45da4a173"
      unitRef="usd">10900000</ehc:BusinessCombinationNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTozYTAwYTEwNjYwOTk0YTY0YTVjNjQwM2Y1OTFlZmUzNi90YWJsZXJhbmdlOjNhMDBhMTA2NjA5OTRhNjRhNWM2NDAzZjU5MWVmZTM2XzUtMS0xLTEtMjQ1NDc3_84b81957-badb-43c5-8b21-ae02079233ba"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4YTdmODUzYzAwNTg0NzJiYTM4NjNjMmQwMjk5OTJmYS90YWJsZXJhbmdlOjhhN2Y4NTNjMDA1ODQ3MmJhMzg2M2MyZDAyOTk5MmZhXzEtMS0xLTEtMjk3Mzc4_08fd710e-0215-4d72-a49e-8bbd606e7a35"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual
      contextRef="i8caa54ca9efa45eb9f755f9f572267c1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4YTdmODUzYzAwNTg0NzJiYTM4NjNjMmQwMjk5OTJmYS90YWJsZXJhbmdlOjhhN2Y4NTNjMDA1ODQ3MmJhMzg2M2MyZDAyOTk5MmZhXzEtMy0xLTEtMjk3Mzc4_2d82116f-f6c6-441c-9afc-4b3dfb1ce53d"
      unitRef="usd">0</us-gaap:BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="i9234554fdff644f89fd47fb7f88d0659_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4YTdmODUzYzAwNTg0NzJiYTM4NjNjMmQwMjk5OTJmYS90YWJsZXJhbmdlOjhhN2Y4NTNjMDA1ODQ3MmJhMzg2M2MyZDAyOTk5MmZhXzUtMS0xLTEtMjQ1NDc3_3d87aa2e-db49-4976-bf56-e2e55496cc49"
      unitRef="usd">3571900000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss
      contextRef="i9234554fdff644f89fd47fb7f88d0659_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNDQvZnJhZzphYzQ0YWE2Nzc4NGE0NDMyOWM3YzQ4NzI4OWE1ZGM3OC90YWJsZTo4YTdmODUzYzAwNTg0NzJiYTM4NjNjMmQwMjk5OTJmYS90YWJsZXJhbmdlOjhhN2Y4NTNjMDA1ODQ3MmJhMzg2M2MyZDAyOTk5MmZhXzUtMy0xLTEtMjQ1NDc3_e36ea2d6-e8a3-4392-84e4-cbb1a949fb6d"
      unitRef="usd">284800000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEyNjQ_ff7ba167-0fa5-49fc-ba0b-c48916632952">Variable Interest Entities:As of December&#160;31, 2022 and December&#160;31, 2021, we consolidated eight and ten, respectively, limited partnership-like entities that are VIEs and of which we are the primary beneficiary. Our ownership percentages in these entities range from 50.0% to 75.0% as of December&#160;31, 2022. Through partnership and management agreements with or governing each of these entities, we manage all of these entities and handle all day-to-day operating decisions. Accordingly, we have the decision-making power over the activities that most significantly impact the economic performance of our VIEs and an obligation to absorb losses or receive benefits from the VIE that could potentially be significant to the VIE. These decisions and significant activities include, but are not limited to, marketing efforts, oversight of patient admissions, medical training, nurse and therapist scheduling, provision of healthcare services, billing, collections and creation and maintenance of medical records. The terms of the agreements governing each of our VIEs prohibit us from using the assets of each VIE to satisfy the obligations of other entities.&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and classifications of the consolidated VIEs&#x2019; assets and liabilities, which are included in our consolidated balance sheets, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <ehc:VariableInterestEntityNumberofEntitiesConsolidated
      contextRef="i39884fa7a48547f2a08edcccd93487c8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEwOTk1MTE2MjkwNTQ_4691dd4f-2899-43c9-9544-58c9b85ac2b0"
      unitRef="entity">8</ehc:VariableInterestEntityNumberofEntitiesConsolidated>
    <ehc:VariableInterestEntityNumberofEntitiesConsolidated
      contextRef="i68baf71a31bd473ba1a1ca647e0b19e2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEwOTk1MTE2MjkwNTk_6f9571cc-5929-42bf-aa8d-474ab1fc0c0c"
      unitRef="entity">10</ehc:VariableInterestEntityNumberofEntitiesConsolidated>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="id743d8949a7a47b99d38df3ba1e3e993_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEwOTk1MTE2MjkwNjQ_409afc4b-a6dd-4121-9831-201cd153a354"
      unitRef="number">0.500</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="ic427d90f8e7c42bdb0850c9210abaeb6_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEwOTk1MTE2MjkwNjg_361ec5d1-6e01-4194-91bc-66844e92895d"
      unitRef="number">0.750</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90ZXh0cmVnaW9uOjRiYjdiODhmNmY4ODQ4OWY4OTY4ZGUyNTdiNzE4ZTY3XzEyNjA_b8e4b1d9-0621-4749-a71a-48f54d9b0f2d">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and classifications of the consolidated VIEs&#x2019; assets and liabilities, which are included in our consolidated balance sheets, are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term assets of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities of discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzMtMS0xLTEtMjQ1NDc3_3566c303-e322-455e-9f84-8ac3c791ca02"
      unitRef="usd">200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzMtMy0xLTEtMjQ1NDc3_d5097421-a56a-418b-8aab-3e1205e8cc32"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzQtMS0xLTEtMjQ1NDc3_a8f93b4b-778c-46d6-af22-94aa401cc21b"
      unitRef="usd">34000000.0</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzQtMy0xLTEtMjQ1NDc3_10569c26-822c-476c-9be8-3bc48251a790"
      unitRef="usd">33600000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzUtMS0xLTEtMjQ1NDc3_2d026df0-6371-4ed3-a1ae-e320faec9e0b"
      unitRef="usd">6700000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzUtMy0xLTEtMjQ1NDc3_57eb0f6a-ce7b-47fc-be06-16365b1f62b3"
      unitRef="usd">5900000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzYtMS0xLTEtMjY2OTg1_57a20931-9244-4bf8-b980-2b46aff8f0a1"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzYtMy0xLTEtMjY2OTg1_786488bd-c533-475c-95e0-e29abf041999"
      unitRef="usd">4500000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzYtMS0xLTEtMjQ1NDc3_11b1156b-0803-45a8-a23d-5a3b3d74351f"
      unitRef="usd">40900000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzYtMy0xLTEtMjQ1NDc3_3ea761cb-a26f-401f-91c6-efd9e12528ec"
      unitRef="usd">44000000.0</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzctMS0xLTEtMjQ1NDc3_5e2cdb81-56dc-4a39-ba94-3dd6ce65bf57"
      unitRef="usd">129000000.0</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzctMy0xLTEtMjQ1NDc3_f9423d5f-d92f-459f-a228-6a85ade16204"
      unitRef="usd">116300000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzgtMS0xLTEtMjQ1NDc3_f4edfcfd-4602-4f90-a591-c17f5ae59933"
      unitRef="usd">1700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzgtMy0xLTEtMjQ1NDc3_43b8949c-0070-4e55-8cc7-b3a570f23bb8"
      unitRef="usd">3200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzktMS0xLTEtMjQ1NDc3_e849174f-83dd-4ef2-8ceb-80c08156c746"
      unitRef="usd">15900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzktMy0xLTEtMjQ1NDc3_d232c5e9-752a-4f34-905d-5cc269e4e14b"
      unitRef="usd">15900000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEwLTEtMS0xLTI0NTQ3Nw_759debb1-e787-4d40-910d-3693bc7f8afb"
      unitRef="usd">1500000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEwLTMtMS0xLTI0NTQ3Nw_28e92555-bb00-46a2-89d1-c55406aa3e44"
      unitRef="usd">2000000.0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEyLTEtMS0xLTI0NTQ3Nw_74863e5c-fd3b-4e10-8df4-abacf8af6efc"
      unitRef="usd">18800000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEyLTMtMS0xLTI0NTQ3Nw_5379a05c-7e1e-4f03-8fab-299a65074c64"
      unitRef="usd">31100000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE0LTEtMS0xLTI2Njk5Nw_db99efb9-cda1-43f1-a2c1-dfd7b31d1f36"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE0LTMtMS0xLTI2Njk5Nw_a6306c5a-c764-4bfc-b0a4-9a70e360bb8f"
      unitRef="usd">13700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEzLTEtMS0xLTI0NTQ3Nw_94aba882-54eb-411e-be17-f54d4eab262f"
      unitRef="usd">207800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzEzLTMtMS0xLTI0NTQ3Nw_915ce630-b9fe-4347-bf8b-5d800d8daecd"
      unitRef="usd">226200000</us-gaap:Assets>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE2LTEtMS0xLTI0NTQ3Nw_fac72976-c114-42fe-aa31-409acc2be56a"
      unitRef="usd">800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE2LTMtMS0xLTI0NTQ3Nw_a6bc66ff-a874-42a6-978a-308b05856cb0"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE3LTEtMS0xLTI0NTQ3Nw_7dce3af5-4696-415a-b984-d03b3918be83"
      unitRef="usd">400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE3LTMtMS0xLTI0NTQ3Nw_84ad899b-a0c3-4a51-aeb2-64fc7008c70d"
      unitRef="usd">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE4LTEtMS0xLTI0NTQ3Nw_3878ffdc-4810-4a99-9dbb-5d95d7ced649"
      unitRef="usd">7000000.0</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE4LTMtMS0xLTI0NTQ3Nw_663245e9-edb5-4579-b3e4-2b1eb1a90ed5"
      unitRef="usd">5900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE5LTEtMS0xLTI0NTQ3Nw_532a1046-82be-4341-926e-503341c77b87"
      unitRef="usd">8200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzE5LTMtMS0xLTI0NTQ3Nw_ca69cc09-0346-452b-a1b7-aec9419b0ea5"
      unitRef="usd">10000000.0</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIxLTEtMS0xLTI0NTQ3Nw_683c2f46-9422-4b00-bfb1-a78cbc932ec7"
      unitRef="usd">15700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIxLTMtMS0xLTI0NTQ3Nw_de4a3060-044d-4ae8-a154-fea0d185aa58"
      unitRef="usd">9000000.0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI0LTEtMS0xLTI2NzAwOQ_4e09af55-8494-4770-855f-139a5f4809f4"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI0LTMtMS0xLTI2NzAwOQ_2637052e-cd52-4e96-ac49-3ff09e56edea"
      unitRef="usd">400000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIyLTEtMS0xLTI0NTQ3Nw_b3968a1c-d59c-4b4a-a839-e88a6220f10d"
      unitRef="usd">32100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIyLTMtMS0xLTI0NTQ3Nw_a2a59e83-3c32-41bc-9b60-79a9acadd344"
      unitRef="usd">27800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIzLTEtMS0xLTI0NTQ3Nw_4908dc84-9c5c-4bb8-b2b5-cbd8bdfec899"
      unitRef="usd">14500000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzIzLTMtMS0xLTI0NTQ3Nw_6ed8cdea-563e-49eb-8d3a-b797fc39dbc0"
      unitRef="usd">8600000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI0LTEtMS0xLTI0NTQ3Nw_738a6d24-e304-4dd4-9d5d-723df94f2154"
      unitRef="usd">1300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI0LTMtMS0xLTI0NTQ3Nw_822b9dc6-a2e3-4bde-9f89-adafb1269726"
      unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i1efefea033d94a49ae6d1279523cfa77_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI2LTEtMS0xLTI0NTQ3Nw_dbef0e81-94c1-4fdc-89bc-c7303e1372cb"
      unitRef="usd">47900000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if7d8604073db4dfc9364cee592afa6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTAvZnJhZzo0YmI3Yjg4ZjZmODg0ODlmODk2OGRlMjU3YjcxOGU2Ny90YWJsZTpjOGMyNGQ3MWI5NTQ0MjVlYWI5MDBjY2FiOGNmMWM4Ni90YWJsZXJhbmdlOmM4YzI0ZDcxYjk1NDQyNWVhYjkwMGNjYWI4Y2YxYzg2XzI2LTMtMS0xLTI0NTQ3Nw_e8f2f938-531c-4a54-acb1-7db6ea354387"
      unitRef="usd">38200000</us-gaap:Liabilities>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzI2MDY_8013baee-bef8-4ec2-855b-38992df9902f">Cash and Marketable Securities:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our investments as of December&#160;31, 2022 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our investments as of December&#160;31, 2021 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliate cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Self-insured captive funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Self-insured captive funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Affiliate cash represents cash accounts maintained by joint ventures in which we participate where one or more of our external partners requested, and we agreed, that the joint venture&#x2019;s cash not be commingled with other corporate cash accounts and be used only to fund the operations of those joint ventures. Self-insured captive funds represent cash held at our wholly owned insurance captive, HCS, Ltd., as discussed in Note&#160;11, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Self-Insured Risks&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. These funds are committed to pay third-party administrators for claims incurred and are restricted by insurance regulations and requirements. These funds cannot be used for purposes outside HCS without the permission of the Cayman Islands Monetary Authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classification of restricted cash held by HCS as current or noncurrent depends on the classification of the corresponding claims liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Marketable Securities&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS. HCS insures a substantial portion of Encompass Health&#x2019;s professional liability, workers&#x2019; compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of December&#160;31, 2022 and 2021, $79.1 million and $82.2 million, respectively, of restricted marketable securities are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets. During the years ended December&#160;31, 2022, 2021, and 2020, $(7.4)&#160;million, $0.6 million, and $0.4&#160;million, respectively, of unrealized net (losses) gains were recognized in our consolidated statements of comprehensive income on marketable securities still held at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investing information related to our available-for-sale marketable securities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales and maturities of available-for-sale marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of marketable securities is comprised of investments in mutual funds that hold investments in a variety of industries and geographies. As discussed in Note&#160;1,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Marketable Securities,&#x201d; when our portfolio included marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, we examined the severity and duration of the impairments in relation to the cost of the individual investments. We also considered the industry and geography in which each investment is held and the near-term prospects for a recovery in each.&lt;/span&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzI2Mjk_4f804bfc-5668-41f4-b2a4-9c189728e0df">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our investments as of December&#160;31, 2022 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our investments as of December&#160;31, 2021 are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzEtMS0xLTEtMjQ1NDc3_1fe522c1-18f2-47e3-b987-30b2f3bc8851"
      unitRef="usd">21800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzEtMy0xLTEtMjQ1NDc3_f941f4e5-41c6-4fbe-a5b7-4dcce52b087e"
      unitRef="usd">31600000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzEtNS0xLTEtMjQ1NDc3_64849141-8f99-41f2-ba2c-b4ae469c7415"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i83b8eaa42aba4d429ff35ad8b83048d3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzEtNy0xLTEtMjQ1NDc3_8b7dd189-fa8d-4982-8967-d29219390a47"
      unitRef="usd">53400000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i21818c725feb4e82b4d76043fbe5fddb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzItMS0xLTEtMjQ1NDc3_642bc175-3f27-4e37-ac10-46e9e63a7e4f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i21818c725feb4e82b4d76043fbe5fddb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzItMy0xLTEtMjQ1NDc3_83873ef6-b8f1-43d4-ba78-c24b7ee8f10d"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i21818c725feb4e82b4d76043fbe5fddb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzItNS0xLTEtMjQ1NDc3_c259c817-da14-4e00-ad27-6137ba290cbf"
      unitRef="usd">110000000.0</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i21818c725feb4e82b4d76043fbe5fddb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzItNy0xLTEtMjQ1NDc3_77db10d0-0fb7-432d-9d0d-5342b7416e2d"
      unitRef="usd">110000000.0</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzQtMS0xLTEtMjQ1NDc3_2edf2014-7442-4def-ac28-e966592011dd"
      unitRef="usd">21800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzQtMy0xLTEtMjQ1NDc3_453ea613-78c1-49cd-8582-93b12b22272b"
      unitRef="usd">31600000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzQtNS0xLTEtMjQ1NDc3_38fdf42e-947d-445a-8d6b-84b50a691f51"
      unitRef="usd">110000000.0</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo2YTViOTA4ZmZhZWY0ZmFiYjA2ZjU1NGZiMjY1NzRlZi90YWJsZXJhbmdlOjZhNWI5MDhmZmFlZjRmYWJiMDZmNTU0ZmIyNjU3NGVmXzQtNy0xLTEtMjQ1NDc3_7053be0b-3129-4eb3-a041-af599912aac9"
      unitRef="usd">163400000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie62ccf4631834eb8806f370a09ba24d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzEtMS0xLTEtMjQ1NDc3_356bb402-ad4c-4775-b3b3-683a5e88967b"
      unitRef="usd">49400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie62ccf4631834eb8806f370a09ba24d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzEtMy0xLTEtMjQ1NDc3_b8f8a009-bdc2-4b19-9185-79c34d6a7f6d"
      unitRef="usd">62900000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="ie62ccf4631834eb8806f370a09ba24d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzEtNS0xLTEtMjQ1NDc3_d463a9e4-c682-4d99-b1ab-47266d07e65c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="ie62ccf4631834eb8806f370a09ba24d1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzEtNy0xLTEtMjQ1NDc3_301b005e-8254-4d78-9cd3-0fbaf28688f5"
      unitRef="usd">112300000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i62d8fb91a17448548b52ddaca926ac5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzItMS0xLTEtMjQ1NDc3_146d1762-6dea-4f93-a01e-a0007ba6b203"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i62d8fb91a17448548b52ddaca926ac5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzItMy0xLTEtMjQ1NDc3_0a7c821f-4d11-43f1-96fd-e3638db737da"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i62d8fb91a17448548b52ddaca926ac5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzItNS0xLTEtMjQ1NDc3_aa5b572f-3b5c-4642-ac4f-494f3221d8ea"
      unitRef="usd">82200000</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i62d8fb91a17448548b52ddaca926ac5d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzItNy0xLTEtMjQ1NDc3_17922247-6a5c-41b9-a4fc-887aef5c9133"
      unitRef="usd">82200000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzQtMS0xLTEtMjQ1NDc3_0e2d5c1e-1e1f-4053-b52f-2194f0f18bd5"
      unitRef="usd">49400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzQtMy0xLTEtMjQ1NDc3_1cbb3f03-1154-4091-9755-ba79107b26f8"
      unitRef="usd">62900000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:DebtSecuritiesAvailableForSaleRestricted
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzQtNS0xLTEtMjQ1NDc3_cf5a2eee-204b-479a-a008-a16166b1231a"
      unitRef="usd">82200000</us-gaap:DebtSecuritiesAvailableForSaleRestricted>
    <ehc:InvestmentsCashandRestrictedCash
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTo5YzdjYjFhZjcwNGQ0N2VhYjk4MGZhYTQzM2Y3NTI1Yy90YWJsZXJhbmdlOjljN2NiMWFmNzA0ZDQ3ZWFiOTgwZmFhNDMzZjc1MjVjXzQtNy0xLTEtMjQ1NDc3_252b4087-697d-45f6-acca-23bc44149734"
      unitRef="usd">194500000</ehc:InvestmentsCashandRestrictedCash>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzI1OTY_c9be40e4-517f-4ab2-90cb-417e498516c1">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consisted of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliate cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Self-insured captive funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Self-insured captive funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i53b96835762340179de2e6054fcf6ad0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzMtMS0xLTEtMjQ1NDc3_fb3064fe-c45d-4ddc-9bca-bf8f948a532d"
      unitRef="usd">12900000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i0338b3236b51417cbf66790b47b14be5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzMtMy0xLTEtMjQ1NDc3_0456852c-1692-4fc3-8c14-e6b00dfbb16c"
      unitRef="usd">14700000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="iff8b121e96a3441d8cc4887b3971a2ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzQtMS0xLTEtMjQ1NDc3_e0e1168a-d43b-4efc-8fd7-96f27d056f8e"
      unitRef="usd">17300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8c5ab8a31d8f4c83a1cc36ca852adfa9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzQtMy0xLTEtMjQ1NDc3_145e507d-8e31-4ac7-87db-9540f62c57fe"
      unitRef="usd">47800000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i2117424317ae4b25824cbe7ca5a8bbe6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzYtMS0xLTEtMjkzNzYw_86dd29a6-08f8-478e-a7f7-fbae215a5666"
      unitRef="usd">1400000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ifa1fdbdb992e4caeb499c51df7168238_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzYtMy0xLTEtMjkzNzYw_de35e4a0-7370-416a-9219-afec67dea140"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzYtMS0xLTEtMjQ1NDc3_b6225ed6-f9ca-472a-bdce-899b801d63f3"
      unitRef="usd">31600000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzYtMy0xLTEtMjQ1NDc3_0098d070-a825-4430-a11e-0f6bbde2002c"
      unitRef="usd">62500000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="iff8b121e96a3441d8cc4887b3971a2ef_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzktMS0xLTEtMjQ1NDc3_6d5b1d07-7267-46a6-ae59-c84c340c9bf2"
      unitRef="usd">0</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i8c5ab8a31d8f4c83a1cc36ca852adfa9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzktMy0xLTEtMjQ1NDc3_996dfc03-28dd-4186-97c2-b3efba1b8512"
      unitRef="usd">400000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzExLTEtMS0xLTI0NTQ3Nw_9b8c9b77-f5fd-454f-981b-acdb1955b58d"
      unitRef="usd">31600000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZmIxOWMyOGI2OWI0NzQyYmM0NTc0NmVmNDQyYTBiNC90YWJsZXJhbmdlOmJmYjE5YzI4YjY5YjQ3NDJiYzQ1NzQ2ZWY0NDJhMGI0XzExLTMtMS0xLTI0NTQ3Nw_c89f6e80-7e50-4e83-ba17-aad70ead6a98"
      unitRef="usd">62900000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <ehc:RestrictedDebtSecuritiesNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE1NDk_3dcce236-33d8-42cb-98f8-1c86a955acfe"
      unitRef="usd">79100000</ehc:RestrictedDebtSecuritiesNoncurrent>
    <ehc:RestrictedDebtSecuritiesNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE1NTY_f7d4ea45-4906-4f5f-b5cc-e177976aab5e"
      unitRef="usd">82200000</ehc:RestrictedDebtSecuritiesNoncurrent>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE3MjQ_6933478d-0291-4de0-8506-b618e066195f"
      unitRef="usd">-7400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE3Mjg_8d529d14-6418-44e6-9ba0-66964f48e161"
      unitRef="usd">600000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzE3MzY_af3ee488-2a4a-4a9d-aac1-d5e40d9b81e1"
      unitRef="usd">400000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfRealizedGainLossTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90ZXh0cmVnaW9uOmE1Y2I5NDZkMjlhYjRiZjdhYjU0OWQxNTBiOGY0NDA5XzI2NDI_d64b8d45-ad76-4dd2-9ef4-c1becb6e90da">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investing information related to our available-for-sale marketable securities is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sales and maturities of available-for-sale marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRealizedGainLossTableTextBlock>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZDExZTM4YWQxNmI0ZDYxYmIxZDNlZTcwNDZkNTkxMC90YWJsZXJhbmdlOmJkMTFlMzhhZDE2YjRkNjFiYjFkM2VlNzA0NmQ1OTEwXzItMS0xLTEtMjQ1NDc3_9af1a070-ded0-4c24-9d94-9fc33ad47e6d"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZDExZTM4YWQxNmI0ZDYxYmIxZDNlZTcwNDZkNTkxMC90YWJsZXJhbmdlOmJkMTFlMzhhZDE2YjRkNjFiYjFkM2VlNzA0NmQ1OTEwXzItMy0xLTEtMjQ1NDc3_a4681003-7e10-4756-8747-70d7f1eecb8e"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTMvZnJhZzphNWNiOTQ2ZDI5YWI0YmY3YWI1NDlkMTUwYjhmNDQwOS90YWJsZTpiZDExZTM4YWQxNmI0ZDYxYmIxZDNlZTcwNDZkNTkxMC90YWJsZXJhbmdlOmJkMTFlMzhhZDE2YjRkNjFiYjFkM2VlNzA0NmQ1OTEwXzItNS0xLTEtMjQ1NDc3_b55274bd-04c3-4946-9f7a-b71e2567a5df"
      unitRef="usd">12600000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90ZXh0cmVnaW9uOjk4M2RiOGQxNzU3MTQxNjFiODFiM2JiOWJhN2I5ZTM1XzUwMA_5ca15a65-8111-4dc1-a1fe-19e914ee45a2">Accounts Receivable:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because the resolution of claims that are part of Medicare audit programs can take several years, we review the patient receivables that are part of this adjudication process to determine their appropriate classification as either current or noncurrent. Amounts considered noncurrent are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheet. See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Net Operating Revenues,&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90ZXh0cmVnaW9uOjk4M2RiOGQxNzU3MTQxNjFiODFiM2JiOWJhN2I5ZTM1XzUwMw_bdbdfbd2-49a3-488d-9c2e-9b93c775d3c8">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent patient accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;610.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzMtMS0xLTEtMjQ1NDc3_1c250aec-e847-4f44-a9ee-b76f8a55351e"
      unitRef="usd">524800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzMtMy0xLTEtMjQ1NDc3_f9c2ef9f-bb30-4ea9-ba74-0cfa5927e7bb"
      unitRef="usd">502100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzQtMS0xLTEtMjQ1NDc3_47ff8110-6276-4071-8c02-1cc04e7a7e11"
      unitRef="usd">12000000.0</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzQtMy0xLTEtMjQ1NDc3_b9a0e679-7b89-4c1c-984c-894554a65174"
      unitRef="usd">13700000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzUtMS0xLTEtMjQ1NDc3_6342ccb1-dbbb-472a-a635-821b699faf3a"
      unitRef="usd">536800000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzUtMy0xLTEtMjQ1NDc3_21e6846c-8143-4e2c-84eb-b3c60da967d2"
      unitRef="usd">515800000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzYtMS0xLTEtMjQ1NDc3_a2966fa4-a495-458c-abd6-9290bf0ff8c0"
      unitRef="usd">73300000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzYtMy0xLTEtMjQ1NDc3_729917d5-1c6c-4eda-a9e3-eea94073c1b2"
      unitRef="usd">77400000</us-gaap:AccountsReceivableNetNoncurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzctMS0xLTEtMjQ1NDc3_ae842460-5325-4f36-8e52-929ecb42297a"
      unitRef="usd">610100000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTYvZnJhZzo5ODNkYjhkMTc1NzE0MTYxYjgxYjNiYjliYTdiOWUzNS90YWJsZTo4ODAwNGYxNjliYmI0MGVhOGYwOWY5MWQ3YmM5Nzg3Mi90YWJsZXJhbmdlOjg4MDA0ZjE2OWJiYjQwZWE4ZjA5ZjkxZDdiYzk3ODcyXzctMy0xLTEtMjQ1NDc3_021a833a-df66-4e41-9969-f118e50e6431"
      unitRef="usd">593200000</us-gaap:AccountsReceivableNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90ZXh0cmVnaW9uOjE0NTU0NTFkMjUzMjRkOTg4ZmYzMGMxMDFkNTBkYTRlXzUyOA_741c894e-ca05-405a-b9e6-ddffe82ad7e5">Property and Equipment:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,019.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vehicles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;647.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,239.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,718.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,659.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,490.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,579.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,228.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,939.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,581.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, approximately 68% of our consolidated &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; held by Encompass Health Corporation and its guarantor subsidiaries was pledged to the lenders under our credit agreement. See Note&#160;10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-term Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Item 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Liquidity and Capital Resources.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of depreciation expense and interest capitalized is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest capitalized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i62625eab8b0d4335a31e9e15249ae70e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzItMS0xLTEtMjQ1NDc3_df744d0d-2bc1-429c-9fa5-cf072a76a0b3"
      unitRef="usd">286100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i34843327cab94b9c8261df7a6ac9bacc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzItMy0xLTEtMjQ1NDc3_2f3d7dcb-4089-4ef5-afe0-5cc3bb4e4550"
      unitRef="usd">259800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ib5d56907f4eb4436af6dad648f56ce6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzMtMS0xLTEtMjQ1NDc3_b05abfcd-82c6-4bb9-b5ee-b057caa5f700"
      unitRef="usd">3019800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ifb76d50e6f0a4405bff0b4e4b612e7d6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzMtMy0xLTEtMjQ1NDc3_1ba78d40-8b54-4d44-a5e2-e9ec6858857b"
      unitRef="usd">2632800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i81b3fd57dd2042f68ac013078eaf240a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzQtMS0xLTEtMjQ1NDc3_b4fe845a-aae4-4822-8c9f-34b26bbf83be"
      unitRef="usd">281500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i13acf526358049fdb887e645c419f111_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzQtMy0xLTEtMjQ1NDc3_960d3b22-94f4-4ccf-99e2-0e15c0f2a6bd"
      unitRef="usd">251100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie6c1d864105a4f598505f09fa76bc1be_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzUtMS0xLTEtMjQ1NDc3_87898032-e811-4e82-81eb-f74b046e070e"
      unitRef="usd">4500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i4f1644f1897949bb82fd5674d6ae3282_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzUtMy0xLTEtMjQ1NDc3_92135258-870a-4180-b3ef-e902706e555c"
      unitRef="usd">3800000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie60dcfb7b1544c66a69974be0bca5376_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzYtMS0xLTEtMjQ1NDc3_22011815-eed2-4b23-9f4a-b3648fb85d6f"
      unitRef="usd">647200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i8d230a026be94efb95ef13566c7b7b0a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzYtMy0xLTEtMjQ1NDc3_66a0b146-9bc3-4e61-9e6f-a5a1c8e13105"
      unitRef="usd">571000000.0</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ic5b54adc201247bb9fb60bdf36fff8a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzctMS0xLTEtMjQ1NDc3_2649c45e-014f-4def-a834-871d80abb4ca"
      unitRef="usd">4239100000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ief3ef49cda4a4f22a1347489d45480e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzctMy0xLTEtMjQ1NDc3_9a73fca8-b73e-478f-bde5-372d628fe08e"
      unitRef="usd">3718500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ic5b54adc201247bb9fb60bdf36fff8a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzgtMS0xLTEtMjQ1NDc3_e29e2a08-faf2-406b-abad-a043e52d9183"
      unitRef="usd">1659400000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="ief3ef49cda4a4f22a1347489d45480e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzgtMy0xLTEtMjQ1NDc3_625c564c-047e-40e2-bc87-3b9fa9f07835"
      unitRef="usd">1490500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ic5b54adc201247bb9fb60bdf36fff8a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzktMS0xLTEtMjQ1NDc3_5edc0d9f-a49e-4602-a5b0-e241f6056564"
      unitRef="usd">2579700000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ief3ef49cda4a4f22a1347489d45480e0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzktMy0xLTEtMjQ1NDc3_3006e951-7841-4bca-9803-fdad7509a629"
      unitRef="usd">2228000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i07de7edf6557444789afb4418d5e6c0d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzEwLTEtMS0xLTI0NTQ3Nw_ce9e772a-c0fe-4ae2-99e2-54b659a49c08"
      unitRef="usd">359500000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="if4e52d9e713e4adea7cfd891c3ecaeec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzEwLTMtMS0xLTI0NTQ3Nw_3b6366dd-22a9-4762-9830-ed0e912b4822"
      unitRef="usd">353200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzExLTEtMS0xLTI0NTQ3Nw_47fba1a3-9a9d-4320-b8f3-70391a6818cb"
      unitRef="usd">2939200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTowOTc2YzEwMTJjZTU0MDczYmMwNjUzMWJlYTAwODM0MS90YWJsZXJhbmdlOjA5NzZjMTAxMmNlNTQwNzNiYzA2NTMxYmVhMDA4MzQxXzExLTMtMS0xLTI0NTQ3Nw_0ea3e1e6-8a63-41ca-9eea-b39109e0e610"
      unitRef="usd">2581200000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <ehc:Percentageofassetspledgedtolendersundercreditagreement
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90ZXh0cmVnaW9uOjE0NTU0NTFkMjUzMjRkOTg4ZmYzMGMxMDFkNTBkYTRlXzEwMA_c4ce0577-7527-4a5b-a3e9-67f4f675d907"
      unitRef="number">0.68</ehc:Percentageofassetspledgedtolendersundercreditagreement>
    <ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90ZXh0cmVnaW9uOjE0NTU0NTFkMjUzMjRkOTg4ZmYzMGMxMDFkNTBkYTRlXzUxNg_cd38a86a-acf3-427c-8f30-6afa959c5e57">&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of depreciation expense and interest capitalized is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest capitalized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock>
    <us-gaap:Depreciation
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzItMS0xLTEtMjQ1NDc3_32c22691-0bae-482a-855c-949f65e58fb1"
      unitRef="usd">187300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzItMy0xLTEtMjQ1NDc3_b5618f97-af7e-4b9b-88bf-ebac2ce9505f"
      unitRef="usd">160400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzItNS0xLTEtMjQ1NDc3_4ee82920-3ac7-44c9-94ff-468c5c2b8774"
      unitRef="usd">145100000</us-gaap:Depreciation>
    <us-gaap:InterestCostsCapitalized
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzQtMS0xLTEtMjQ1NDc3_220ce9ec-c38f-4716-8f97-534457846b20"
      unitRef="usd">10500000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzQtMy0xLTEtMjQ1NDc3_56cfd772-a181-4f18-9f3b-be9f0f1c7ffd"
      unitRef="usd">8900000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNTkvZnJhZzoxNDU1NDUxZDI1MzI0ZDk4OGZmMzBjMTAxZDUwZGE0ZS90YWJsZTo1MDExMjlhMTNmMWY0OWZiYjc0ZDlhMzVlZWM3OWE2ZS90YWJsZXJhbmdlOjUwMTEyOWExM2YxZjQ5ZmJiNzRkOWEzNWVlYzc5YTZlXzQtNS0xLTEtMjQ1NDc3_61206c22-bc5e-451d-9d35-2ec0ea431b30"
      unitRef="usd">6000000.0</us-gaap:InterestCostsCapitalized>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNjg_3f31bfe0-e5e2-437d-84b1-f11021394185">Leases:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1- to 25-year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term and variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated balance sheet information related to leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finance lease assets are recorded net of accumulated amortization of $145.8 million and $126.9 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to our leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzQ_a837253b-97ae-4b0c-9e4f-530434304c5c">Leases:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease real estate, vehicles, and equipment under operating and finance leases with non-cancelable terms generally expiring at various dates through 2037. Our operating and finance leases generally have 1- to 25-year terms, with one or more renewal options, primarily relating to our real estate leases, with terms to be determined at the time of renewal. The exercise of such lease renewal options is at our sole discretion, and to the extent we are reasonably certain we will exercise a renewal option, the years related to that option are included in our determination of the lease term for purposes of classifying and measuring a given lease. Certain leases also include options to purchase the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term and variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated balance sheet information related to leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finance lease assets are recorded net of accumulated amortization of $145.8 million and $126.9 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to our leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ehc:OperatingAndFinanceLeaseContractTerm
      contextRef="i24d1851ef607402d900d6d9f19371197_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzgyNDYzMzcyMDk1MTc_17efdfad-fa4d-46dc-a40a-52e7e52607f8">P1Y</ehc:OperatingAndFinanceLeaseContractTerm>
    <ehc:OperatingAndFinanceLeaseContractTerm
      contextRef="i802dc5eb74bb429e8814073a20bf7f9b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzY_c5b10cb8-45e9-4167-b3bc-2273494cf6d2">P25Y</ehc:OperatingAndFinanceLeaseContractTerm>
    <ehc:OperatingAndFinanceLeaseNumberOfRenewalOptions
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzM4NDgyOTA2OTg2NDU_0ed159b9-940f-4fc1-9583-d4097812ed11"
      unitRef="option">1</ehc:OperatingAndFinanceLeaseNumberOfRenewalOptions>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzc_2ab1f82f-b378-4f09-af9d-c0c687c27da9">&lt;div style="margin-bottom:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term and variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzItMS0xLTEtMjQ1NDc3_9f16cf11-c3c7-4cac-9b09-1ea412950945"
      unitRef="usd">38700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzItMy0xLTEtMjQ1NDc3_ecb298c2-741e-404a-9b2e-2cb385e72416"
      unitRef="usd">46700000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzItNS0xLTEtMjQ1NDc3_fb641310-6298-47c6-9f21-bad3806013e0"
      unitRef="usd">50200000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzQtMS0xLTEtMjQ1NDc3_00b9f08c-c04a-4272-8a1f-5c2055991311"
      unitRef="usd">27500000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzQtMy0xLTEtMjQ1NDc3_a4c9b2c8-540d-4954-b87c-c1432aa4bb81"
      unitRef="usd">28000000.0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzQtNS0xLTEtMjQ1NDc3_373bdbeb-6539-4ab8-b007-e0ccff5d57fe"
      unitRef="usd">25000000.0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzUtMS0xLTEtMjQ1NDc3_bb558521-aec4-498a-b65f-9ede9420cf01"
      unitRef="usd">29000000.0</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzUtMy0xLTEtMjQ1NDc3_ce8bd93a-a941-485f-84d6-6c49ecdbd3d6"
      unitRef="usd">30700000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzUtNS0xLTEtMjQ1NDc3_ee65497a-a81b-4e4c-9511-0c8a3530f9bc"
      unitRef="usd">28800000</us-gaap:FinanceLeaseInterestExpense>
    <ehc:Totalfinanceleasecost
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzYtMS0xLTEtMjQ1NDc3_e36059e4-12dc-4495-9b4b-4f9fc8df1dc9"
      unitRef="usd">56500000</ehc:Totalfinanceleasecost>
    <ehc:Totalfinanceleasecost
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzYtMy0xLTEtMjQ1NDc3_a06318ce-5ae8-45a7-896b-24dad1ce08c5"
      unitRef="usd">58700000</ehc:Totalfinanceleasecost>
    <ehc:Totalfinanceleasecost
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzYtNS0xLTEtMjQ1NDc3_c0632e43-454d-4ea6-9374-5a5bd1f056aa"
      unitRef="usd">53800000</ehc:Totalfinanceleasecost>
    <ehc:Shorttermandvariableleasecost
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzctMS0xLTEtMjQ1NDc3_d011a31c-4a82-451a-9913-eae97a9a09bf"
      unitRef="usd">5200000</ehc:Shorttermandvariableleasecost>
    <ehc:Shorttermandvariableleasecost
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzctMy0xLTEtMjQ1NDc3_394424a4-cd34-4e86-ab10-c2ed666fe4d7"
      unitRef="usd">3100000</ehc:Shorttermandvariableleasecost>
    <ehc:Shorttermandvariableleasecost
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzctNS0xLTEtMjQ1NDc3_f16398f5-1c74-4243-8d1a-1996250adbf9"
      unitRef="usd">3700000</ehc:Shorttermandvariableleasecost>
    <us-gaap:SubleaseIncome
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzgtMS0xLTEtMjQ1NDc3_a40a5ca5-ab7f-4ad8-a538-9f52595ce110"
      unitRef="usd">2900000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzgtMy0xLTEtMjQ1NDc3_d5088348-cdf8-4ea6-80ae-b3e72d2a0000"
      unitRef="usd">3100000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzgtNS0xLTEtMjQ1NDc3_b747d8c2-8447-4b32-8ff0-68007406512b"
      unitRef="usd">3200000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzktMS0xLTEtMjQ1NDc3_c92e535e-81b4-40f3-8663-8f9d698642f3"
      unitRef="usd">97500000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzktMy0xLTEtMjQ1NDc3_5206d424-b869-4117-a4ed-27e0c994fff9"
      unitRef="usd">105400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTozNWE1YTBjZGJkZTY0ZTU5YWZjNDM1ZTA5ZTg0MjA5ZS90YWJsZXJhbmdlOjM1YTVhMGNkYmRlNjRlNTlhZmM0MzVlMDllODQyMDllXzktNS0xLTEtMjQ1NDc3_fa9a09ac-d8e0-44c1-a6c5-7c893e3ed2cc"
      unitRef="usd">104500000</us-gaap:LeaseCost>
    <ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzA_278cc21d-d5d0-4773-9363-6e585f41f730">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated balance sheet information related to leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.213%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_080260c5-8c2f-4d82-8956-e75129d3a3f5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtMi0xLTEtMjQ1NDc3_94705be8-4a02-4463-9809-3638bffb5cfd"&gt;Property and equipment, net&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_4ce645d0-aaf3-4c29-b7d0-7e8c441f5b81"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTItMS0xLTI0NTQ3Nw_fc0181a7-db9b-498b-b6f8-a6a38e277e44"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncurrent liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_841fd9a3-af52-4e08-aede-57b0267265bf"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTItMS0xLTI0NTQ3Nw_a9253344-9139-4f84-b555-f84b31669aa4"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total leased liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;585.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Finance lease assets are recorded net of accumulated amortization of $145.8 million and $126.9 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzMtNC0xLTEtMjQ1NDc3_79d0e8c9-4a58-4fe2-83a8-49d3a6cd1694"
      unitRef="usd">212500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzMtNi0xLTEtMjQ1NDc3_9348807f-d6e2-4d38-a841-eb6fd02c32af"
      unitRef="usd">193700000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtNC0xLTEtMjQ1NDc3_4f8e2f01-e33f-495f-b711-5b0360eec9fe"
      unitRef="usd">272900000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzQtNi0xLTEtMjQ1NDc3_3be27626-bc86-444e-a4ca-dfc94f4aa31c"
      unitRef="usd">299300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <ehc:Totaloperatingandfinanceleaseassets
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzUtNC0xLTEtMjQ1NDc3_e2ac5b53-2cfc-4450-84c3-a67c2b92f2cc"
      unitRef="usd">485400000</ehc:Totaloperatingandfinanceleaseassets>
    <ehc:Totaloperatingandfinanceleaseassets
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzUtNi0xLTEtMjQ1NDc3_15b3e4f1-ac73-4da8-a90b-25f93a2b0276"
      unitRef="usd">493000000.0</ehc:Totaloperatingandfinanceleaseassets>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzktNC0xLTEtMjQ1NDc3_f9f3e65e-1924-4b42-a561-a3f2876d7fc9"
      unitRef="usd">25600000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzktNi0xLTEtMjQ1NDc3_c4707089-1163-422b-a9e9-f77e33ec97d0"
      unitRef="usd">23500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTQtMS0xLTI0NTQ3Nw_c7eaca33-12e3-4d7f-9dc2-24b363403716"
      unitRef="usd">19500000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEwLTYtMS0xLTI0NTQ3Nw_ea5f305f-afcf-4f75-b8ac-1a938843ad30"
      unitRef="usd">19100000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEyLTQtMS0xLTI0NTQ3Nw_ed1be1a8-6e4b-4f3c-9be3-8891f3f1c2a6"
      unitRef="usd">199700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEyLTYtMS0xLTI0NTQ3Nw_cd03cef3-eb8e-4902-b45c-ceab4613e631"
      unitRef="usd">179600000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTQtMS0xLTI0NTQ3Nw_a6a1d0f3-ea4c-467c-9274-f7dec320dbff"
      unitRef="usd">340300000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzEzLTYtMS0xLTI0NTQ3Nw_574aa81b-cc87-4fe3-88cb-63d5f3cd2c6b"
      unitRef="usd">361200000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <ehc:Totalleaseliabilities
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzE0LTQtMS0xLTI0NTQ3Nw_27fdea4a-1c70-4be5-95c4-0b0a5609425d"
      unitRef="usd">585100000</ehc:Totalleaseliabilities>
    <ehc:Totalleaseliabilities
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2N2VlNDk4YmJiMGI0Y2E4OGU2ZWJmZWNmMjRmZTkwNC90YWJsZXJhbmdlOjY3ZWU0OThiYmIwYjRjYTg4ZTZlYmZlY2YyNGZlOTA0XzE0LTYtMS0xLTI0NTQ3Nw_5fa987cf-ec26-4396-b9e0-260145d7c27b"
      unitRef="usd">583400000</ehc:Totalleaseliabilities>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1Xzk2NQ_3ef2ffb6-2de5-4027-8abd-d57944c84e42"
      unitRef="usd">145800000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1Xzk3Mg_65a2f834-baf8-4b11-8da8-e1dbbcc2e368"
      unitRef="usd">126900000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzE_d7980428-4da7-4d6c-b5d3-6f55f983a3ce">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzMtMS0xLTEtMjQ1NDc3_b8501946-4f3f-4aba-822a-bf7241baa4dc">P9Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzMtMy0xLTEtMjQ1NDc3_e408e669-fff1-432c-8d0f-1563cf25dc7d">P9Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzQtMS0xLTEtMjQ1NDc3_9945392f-cb0c-42bb-b81d-3dfdc6db7eb0">P11Y7M6D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzQtMy0xLTEtMjQ1NDc3_67728ecc-3056-4ae4-9c59-6ec322e56d71">P12Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzYtMS0xLTEtMjQ1NDc3_58d06c82-fb0e-4179-80be-236ee8d2415c"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzYtMy0xLTEtMjQ1NDc3_0a545f97-7968-4414-9210-812d803ffa0d"
      unitRef="number">0.061</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzctMS0xLTEtMjQ1NDc3_306f1365-8e6a-4b85-a791-f6bbb366b9b3"
      unitRef="number">0.077</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpiNzUzZDdmMjg1MGU0ZWZhYjM5NjFiZjk5NjE3ZmQ2Ny90YWJsZXJhbmdlOmI3NTNkN2YyODUwZTRlZmFiMzk2MWJmOTk2MTdmZDY3XzctMy0xLTEtMjQ1NDc3_f223f7e7-bdd8-40a4-8850-6ca9e7c625f4"
      unitRef="number">0.080</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzI_a4b67d8d-08cd-4214-b61a-feeab59c1cbe">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzM_2f5e6981-d97b-4afc-baae-99ae19a891f9">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; are as follows (in millions): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;padding-left:9pt;padding-right:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.522%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Finance&lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(191.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzEtMS0xLTEtMjQ1NDc3_25183c79-29bd-4ad4-b31a-c97c6fdb4470"
      unitRef="usd">38400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzEtMy0xLTEtMjQ1NDc3_bc4dfd5b-1e73-4096-abc4-6c0eb979a005"
      unitRef="usd">45600000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzItMS0xLTEtMjQ1NDc3_37f60da1-2aee-43c1-98ce-97257731f5ab"
      unitRef="usd">40300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzItMy0xLTEtMjQ1NDc3_0d98f6cf-3fd1-494b-994e-718ac94ee9f3"
      unitRef="usd">46500000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzMtMS0xLTEtMjQ1NDc3_cba45854-ca2d-40f3-92b0-30140f86ae89"
      unitRef="usd">37500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzMtMy0xLTEtMjQ1NDc3_0ff1ba16-e5b9-45fd-8acd-b316802ccb0a"
      unitRef="usd">47000000.0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzQtMS0xLTEtMjQ1NDc3_caafcc3e-70ec-463e-9feb-d9d16b35f074"
      unitRef="usd">34300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzQtMy0xLTEtMjQ1NDc3_f0975561-f55e-4020-8046-75fcd39b0b79"
      unitRef="usd">47900000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzUtMS0xLTEtMjQ1NDc3_e28e9346-357b-4865-89c0-32a5edcff1eb"
      unitRef="usd">32400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzUtMy0xLTEtMjQ1NDc3_ed9c5453-320f-4d82-bfb7-d60956f6ace7"
      unitRef="usd">47400000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <ehc:LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzYtMS0xLTEtMjQ1NDc3_c7ecd909-909a-45e5-87f6-01cbae28294d"
      unitRef="usd">119500000</ehc:LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter>
    <ehc:FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzYtMy0xLTEtMjQ1NDc3_f275db45-e062-4ac3-9bba-746692e17b47"
      unitRef="usd">316600000</ehc:FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzctMS0xLTEtMjQ1NDc3_64d1e80e-ab8a-48ac-bd7e-3e5057a9d0b3"
      unitRef="usd">302400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzctMy0xLTEtMjQ1NDc3_ecff4e6e-bc02-4cc7-93ac-e08d7f83ea7d"
      unitRef="usd">551000000.0</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzgtMS0xLTEtMjQ1NDc3_3c3a1967-9b4e-4e5a-b9f1-7ebadded9c72"
      unitRef="usd">77100000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzgtMy0xLTEtMjQ1NDc3_750012b3-06bc-4884-84a9-7e4fda976350"
      unitRef="usd">191200000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzktMS0xLTEtMjQ1NDc3_f82bafd1-befd-4992-a6be-c352ce1e611d"
      unitRef="usd">225300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTpkNTQ2MzQ3MDdlYzc0Y2M3YmI0MDFlMTA5ZWEwMTA5MS90YWJsZXJhbmdlOmQ1NDYzNDcwN2VjNzRjYzdiYjQwMWUxMDllYTAxMDkxXzktMy0xLTEtMjQ1NDc3_d2b3444e-8107-4579-afbd-ec5702f535d5"
      unitRef="usd">359800000</us-gaap:FinanceLeaseLiability>
    <ehc:SupplementalCashFlowInformationTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90ZXh0cmVnaW9uOjc4NjdlOTU2MDQ5YzRkYTA5M2M5NWQyMDFmZjEzNTI1XzExNzU_000ac1af-be93-4180-9c82-62cbf4d94839">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to our leases is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:SupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzMtMS0xLTEtMjQ1NDc3_d7796801-9765-4f0b-ab6d-3b7f9868b250"
      unitRef="usd">40500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzMtMy0xLTEtMjQ1NDc3_082c0e29-1e47-4632-b7e3-df9bf58db07a"
      unitRef="usd">45000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzMtNS0xLTEtMjQ1NDc3_8b8147d8-2768-44db-8b36-b31a36d97216"
      unitRef="usd">50600000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzQtMS0xLTEtMjQ1NDc3_7019ef0c-c1e1-41ec-8588-550099cf1bf8"
      unitRef="usd">29700000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzQtMy0xLTEtMjQ1NDc3_59647914-716a-4fae-9dfc-14ae1d9d4e0a"
      unitRef="usd">31000000.0</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzQtNS0xLTEtMjQ1NDc3_b092832f-c0c1-4d41-a4fa-10b8fcd17a56"
      unitRef="usd">29200000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzUtMS0xLTEtMjQ1NDc3_d5f5685f-f2a2-402a-81a4-479e7b73de4b"
      unitRef="usd">19200000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzUtMy0xLTEtMjQ1NDc3_1b2766d8-4d59-49bc-af65-9b12204f9ac2"
      unitRef="usd">44600000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzUtNS0xLTEtMjQ1NDc3_0e6357c1-f329-46e4-bfdc-b61d0beef33d"
      unitRef="usd">14400000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzgtMS0xLTEtMjQ1NDc3_b20bc872-639d-4ab2-a3ff-20b8b3e3c17b"
      unitRef="usd">48700000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzgtMy0xLTEtMjQ1NDc3_159066e0-c963-4e4f-8c1a-813940eea5ac"
      unitRef="usd">26900000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzgtNS0xLTEtMjQ1NDc3_d2346031-4e69-4fda-95eb-83576c87779b"
      unitRef="usd">26200000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzktMS0xLTEtMjQ1NDc3_30bba627-d1ab-4b6b-8961-01ea5017da69"
      unitRef="usd">1000000.0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzktMy0xLTEtMjQ1NDc3_9451b653-6aac-4aa6-93a9-437b829e83ff"
      unitRef="usd">46400000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjIvZnJhZzo3ODY3ZTk1NjA0OWM0ZGEwOTNjOTVkMjAxZmYxMzUyNS90YWJsZTo2YmNkZjYzMzhiYWI0MjQ3OGRiMDg5MGI0YWYyNjRlYS90YWJsZXJhbmdlOjZiY2RmNjMzOGJhYjQyNDc4ZGIwODkwYjRhZjI2NGVhXzktNS0xLTEtMjQ1NDc3_596cdae1-d650-4666-84e3-a72d6a5364c4"
      unitRef="usd">24200000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzE0MTI_5039f897-56d4-4e50-9583-772e6d9294c0">Goodwill and Other Intangible Assets:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows changes in the carrying amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; increased in 2020, 2021 and 2022 as a result of our acquisitions of inpatient rehabilitation operations. For additional information on these acquisitions, see Note&#160;3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We performed impairment reviews as of October&#160;1, 2022, 2021, and 2020 and concluded no &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; impairment existed. As of December&#160;31, 2022, we had no accumulated impairment losses related to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information regarding our other intangible assets (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Certificates of need:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Licenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncompete agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Trade name - Encompass:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Trade names - all other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Internal-use software:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Market access assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for other intangible assets is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzE0MDc_7993d831-e883-4334-907f-e1e3e1fd821b">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows changes in the carrying amount of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,263.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzEtNS0xLTEtMjQ1NDc3_cf50d24e-654f-4b89-8023-6441e6f31334"
      unitRef="usd">1218900000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzItNS0xLTEtMjQ1NDc3_d59f3002-5d6c-4ff3-8a90-db1da9d84bfd"
      unitRef="usd">9300000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzUtNS0xLTEtMjQ1NDc3_d5b52ce2-78a1-4d4d-a02e-e292fadcc1ca"
      unitRef="usd">1228200000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzYtNS0xLTEtMjQ1NDc3_f7d9d3fa-c74c-4e27-93c7-3ee5d85fb92c"
      unitRef="usd">8800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzgtNS0xLTEtMjQ1NDc3_c4bc0a88-9b6e-4d74-a3bf-19027fbdf933"
      unitRef="usd">1237000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzktNS0xLTEtMjQ1NDc3_c9fa5609-d1d3-4d11-80e5-0ee6e4cdf410"
      unitRef="usd">26200000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTo5NjE0MDNiNTYyNTY0ZTQ0ODEzMDE4YmQ5MTUyYjUxNy90YWJsZXJhbmdlOjk2MTQwM2I1NjI1NjRlNDQ4MTMwMThiZDkxNTJiNTE3XzExLTUtMS0xLTI0NTQ3Nw_d131cda5-f2d9-439b-bd3b-26c9cca000c0"
      unitRef="usd">1263200000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i177f96156a934c6d92f90d026d815168_D20221001-20221001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5Xzk4Nw_4148377b-ce20-43db-a302-e34e3acbdcb7"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i8a2086e6351b40948b88fd941ae8faae_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5Xzk4Nw_9f436847-ba61-4dc1-8726-ce97531fa82d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i104ce402feb14e3c9c5682306cabdd39_D20201001-20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5Xzk4Nw_fca2812f-e11f-4a3b-bb21-0a17e0eb9d22"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzEwMzY_67795d7b-99d4-4dbb-bb2d-d21ee868d314"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i97d33a74e74847b680d36c4c8aa5735e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzItMS0xLTEtMjQ1NDc3_9a1e38b0-4ad2-4243-9f43-b822712deb0a"
      unitRef="usd">120400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i97d33a74e74847b680d36c4c8aa5735e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzItMy0xLTEtMjQ1NDc3_12933e7a-d0ac-401c-9cfc-69e8c5071d0a"
      unitRef="usd">41500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i97d33a74e74847b680d36c4c8aa5735e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzItNS0xLTEtMjQ1NDc3_1aba47bf-6b29-4d63-8f20-275296b896ae"
      unitRef="usd">78900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie8e84e7ad92e46d1833a208bce11c4b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzMtMS0xLTEtMjQ1NDc3_da5ba7e2-e5ba-495c-a5b8-25381a137cf0"
      unitRef="usd">115300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie8e84e7ad92e46d1833a208bce11c4b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzMtMy0xLTEtMjQ1NDc3_4cecd871-afd9-4542-ad63-e58da170060f"
      unitRef="usd">36000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie8e84e7ad92e46d1833a208bce11c4b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzMtNS0xLTEtMjQ1NDc3_a05bb0db-d0b5-498f-838b-76ad5dd2758b"
      unitRef="usd">79300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie577c85705764e9287e7a571a526dd5e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzUtMS0xLTEtMjQ1NDc3_bc26660d-ebd2-4851-949e-fc1f98680aa9"
      unitRef="usd">65700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie577c85705764e9287e7a571a526dd5e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzUtMy0xLTEtMjQ1NDc3_e2d70852-6bc7-4bf1-bf7e-a3b0095c0097"
      unitRef="usd">54300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie577c85705764e9287e7a571a526dd5e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzUtNS0xLTEtMjQ1NDc3_cad2ff57-1717-42c5-a203-b37fbdf9bf65"
      unitRef="usd">11400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ief8c2650479a4933998c56d70426ad5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzYtMS0xLTEtMjQ1NDc3_d66619be-62aa-40e3-be96-e81ce702986c"
      unitRef="usd">65700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ief8c2650479a4933998c56d70426ad5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzYtMy0xLTEtMjQ1NDc3_219bb0bb-2d4e-4237-8d79-73d6c9153e00"
      unitRef="usd">53200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ief8c2650479a4933998c56d70426ad5a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzYtNS0xLTEtMjQ1NDc3_1b2aff32-542b-44de-ac27-f5efb0e83ad0"
      unitRef="usd">12500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9d992d3261104e3a8eb38871bc693f4e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzgtMS0xLTEtMjQ1NDc3_2311f603-37dc-4378-809f-53f0acbd7707"
      unitRef="usd">66200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9d992d3261104e3a8eb38871bc693f4e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzgtMy0xLTEtMjQ1NDc3_356f7420-2930-46a0-8d2b-823e1766e711"
      unitRef="usd">60200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9d992d3261104e3a8eb38871bc693f4e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzgtNS0xLTEtMjQ1NDc3_2f83d274-9788-4854-97c1-ef9d85ab3b99"
      unitRef="usd">6000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9ffe900a66ea42e5864253cf987a4119_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzktMS0xLTEtMjQ1NDc3_8b1a615c-812f-4fca-b15e-5c0b05fadb39"
      unitRef="usd">65300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9ffe900a66ea42e5864253cf987a4119_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzktMy0xLTEtMjQ1NDc3_f9dd5ed9-0e89-4cd9-a959-eade68a833a6"
      unitRef="usd">58400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9ffe900a66ea42e5864253cf987a4119_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzktNS0xLTEtMjQ1NDc3_5219df80-202c-4afe-82f4-553c1cab4f12"
      unitRef="usd">6900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id0c0ea0e574949d8b18d28a5e6d26be3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzExLTEtMS0xLTI0NTQ3Nw_c5abaf6f-f279-4789-95eb-6847033b3278"
      unitRef="usd">135200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id0c0ea0e574949d8b18d28a5e6d26be3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzExLTMtMS0xLTI0NTQ3Nw_1e91824a-231c-4e54-a3f3-0c01ad7fedb5"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id0c0ea0e574949d8b18d28a5e6d26be3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzExLTUtMS0xLTI0NTQ3Nw_da176ece-6a18-4772-85ad-809790eb5a16"
      unitRef="usd">135200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i59d0cf8338b44b91948c16fbb5260dc9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzEyLTEtMS0xLTI0NTQ3Nw_0eb5078e-1966-43cc-a8cb-0ec75d05e015"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i59d0cf8338b44b91948c16fbb5260dc9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzEyLTMtMS0xLTI0NTQ3Nw_2374d6f0-609b-4262-b53c-ca784685992b"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i59d0cf8338b44b91948c16fbb5260dc9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzEyLTUtMS0xLTI0NTQ3Nw_d94ff3b2-4820-4c6d-97db-2abb1f2a7482"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i246e3aa9111b46d18007fd9747ba80fa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE0LTEtMS0xLTI0NTQ3Nw_0060f879-68ae-438f-905a-6d04f0070365"
      unitRef="usd">37500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i246e3aa9111b46d18007fd9747ba80fa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE0LTMtMS0xLTI0NTQ3Nw_0dbf58d2-895e-41c7-b61c-9a39899eb9e0"
      unitRef="usd">20800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i246e3aa9111b46d18007fd9747ba80fa_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE0LTUtMS0xLTI0NTQ3Nw_210f25e2-582c-436d-9a89-658320c5ef15"
      unitRef="usd">16700000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0887e89510aa430c98ba297311ec7c02_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE1LTEtMS0xLTI0NTQ3Nw_279440d0-9326-4386-8bec-64645be38287"
      unitRef="usd">37500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0887e89510aa430c98ba297311ec7c02_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE1LTMtMS0xLTI0NTQ3Nw_764a2163-3bd4-4a55-b193-088dcd6da08a"
      unitRef="usd">19500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0887e89510aa430c98ba297311ec7c02_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE1LTUtMS0xLTI0NTQ3Nw_b4faa4fd-00a5-446b-9d9c-a3e3433666d7"
      unitRef="usd">18000000.0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i675d9700b9a44be5a34cdbf2e3579982_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE3LTEtMS0xLTI0NTQ3Nw_2ab0dbfc-f642-429c-9680-d66aedab6011"
      unitRef="usd">183200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i675d9700b9a44be5a34cdbf2e3579982_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE3LTMtMS0xLTI0NTQ3Nw_9c45d7f7-6ca9-4a27-a51c-ed7a79717595"
      unitRef="usd">150300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i675d9700b9a44be5a34cdbf2e3579982_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE3LTUtMS0xLTI0NTQ3Nw_014de693-2381-4a9b-a1b5-fba0de88cf55"
      unitRef="usd">32900000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8d897ae5c3574e308dff0216d9b948c1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE4LTEtMS0xLTI0NTQ3Nw_3535f94e-e4d2-4d3c-ba21-e8076869e3f8"
      unitRef="usd">182800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8d897ae5c3574e308dff0216d9b948c1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE4LTMtMS0xLTI0NTQ3Nw_811f71ce-58cf-4c02-8412-a9afac18a71c"
      unitRef="usd">142600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8d897ae5c3574e308dff0216d9b948c1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzE4LTUtMS0xLTI0NTQ3Nw_97d2db94-4602-4aef-963f-52930c4818a8"
      unitRef="usd">40200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id7cf3b85aded4187ab1295a58ade6e45_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIwLTEtMS0xLTI0NTQ3Nw_aab9e893-54c1-4be6-9199-29e12f98bedd"
      unitRef="usd">13200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id7cf3b85aded4187ab1295a58ade6e45_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIwLTMtMS0xLTI0NTQ3Nw_6c3f16e5-6312-41dc-a6c7-bd33b20b261a"
      unitRef="usd">12000000.0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id7cf3b85aded4187ab1295a58ade6e45_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIwLTUtMS0xLTI0NTQ3Nw_c7716a47-3423-446c-b3f0-46ec47f487dc"
      unitRef="usd">1200000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2bf83682496c480f9e42d6fee1080450_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIxLTEtMS0xLTI0NTQ3Nw_280bf404-9a95-44e6-a2b0-9f0456d62259"
      unitRef="usd">13200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2bf83682496c480f9e42d6fee1080450_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIxLTMtMS0xLTI0NTQ3Nw_f5f91a54-3fd9-44a4-9ed7-936d269c5882"
      unitRef="usd">11700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2bf83682496c480f9e42d6fee1080450_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIxLTUtMS0xLTI0NTQ3Nw_9a644884-6754-4ea1-9193-d902ed794d77"
      unitRef="usd">1500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIzLTEtMS0xLTI0NTQ3Nw_11d2e594-292a-4953-9c61-44d1b9dae41e"
      unitRef="usd">621400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIzLTMtMS0xLTI0NTQ3Nw_e65be31e-9122-49a2-9eb9-df9aca477928"
      unitRef="usd">339100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzIzLTUtMS0xLTI0NTQ3Nw_2f9b8a6a-4c00-494e-9bbe-cf6ca0a3b6fb"
      unitRef="usd">282300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzI0LTEtMS0xLTI0NTQ3Nw_5aa74816-4679-487f-9d82-43d92b6634cb"
      unitRef="usd">479800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzI0LTMtMS0xLTI0NTQ3Nw_c7b17740-38eb-4eba-9573-7a7a1aaf9429"
      unitRef="usd">321400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTozZTBkNzVhMTNiNzk0NTg2YTAyM2NkZmJlOTFlZDdlNi90YWJsZXJhbmdlOjNlMGQ3NWExM2I3OTQ1ODZhMDIzY2RmYmU5MWVkN2U2XzI0LTUtMS0xLTI0NTQ3Nw_89f89e21-76a0-4bc6-8981-4e24e44f46c9"
      unitRef="usd">158400000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzEzOTY_6b23cc88-f4b3-4be8-bef9-9bdba7481367">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for other intangible assets is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTowZDZmZjVlODY5M2E0NWIyODdmYmRmMWUzODczNTYxNS90YWJsZXJhbmdlOjBkNmZmNWU4NjkzYTQ1YjI4N2ZiZGYxZTM4NzM1NjE1XzItMS0xLTEtMjQ1NDc3_ef71444f-9fde-4022-abce-149af5ddf6ca"
      unitRef="usd">28800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTowZDZmZjVlODY5M2E0NWIyODdmYmRmMWUzODczNTYxNS90YWJsZXJhbmdlOjBkNmZmNWU4NjkzYTQ1YjI4N2ZiZGYxZTM4NzM1NjE1XzItMy0xLTEtMjQ1NDc3_3279369d-4642-4616-aa34-1db995e13ddd"
      unitRef="usd">31200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZTowZDZmZjVlODY5M2E0NWIyODdmYmRmMWUzODczNTYxNS90YWJsZXJhbmdlOjBkNmZmNWU4NjkzYTQ1YjI4N2ZiZGYxZTM4NzM1NjE1XzItNS0xLTEtMjQ1NDc3_0cb2b624-732d-4db0-8271-409af4569edf"
      unitRef="usd">32900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90ZXh0cmVnaW9uOjIyN2EyODAzMGFhMzQ3N2M4MzBmN2UzNmNmMGUwOGY5XzE0MjY_46487d3f-2173-471f-83ae-f5fb07590855">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total estimated amortization expense for our other intangible assets for the next five years is as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzEtMS0xLTEtMjQ1NDc3_bc7aed9e-ab02-4f1d-8864-b861545dee12"
      unitRef="usd">25000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzItMS0xLTEtMjQ1NDc3_fae55b74-7b83-4cf1-ba05-fd9fc1eea33d"
      unitRef="usd">17200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzMtMS0xLTEtMjQ1NDc3_5c8cfe4b-006e-4a0a-b80c-053788e1ad75"
      unitRef="usd">11600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzQtMS0xLTEtMjQ1NDc3_186b39a7-1541-4c9a-b2ff-e5ce8e0e3dee"
      unitRef="usd">10400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNjUvZnJhZzoyMjdhMjgwMzBhYTM0NzdjODMwZjdlMzZjZjBlMDhmOS90YWJsZToyZDY2N2RlZmM4Y2E0NzUwYmVmYTVjOWIyMDM3NDg5ZS90YWJsZXJhbmdlOjJkNjY3ZGVmYzhjYTQ3NTBiZWZhNWM5YjIwMzc0ODllXzUtMS0xLTEtMjQ1NDc3_2a5eb8a6-2fb2-48a5-b6c1-8e10e486f5aa"
      unitRef="usd">10000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyOTA5_0418c9df-a022-41de-bcf5-03201abd0bf2">Long-term Debt:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our long-term debt outstanding consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Agreement&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonds payable&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,767.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,278.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,741.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,240.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Face Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,817.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,767.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the redemptions discussed below, we recorded a $1.4 million, $1.0 million, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loss on early extinguishment of debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Secured Credit Agreement&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit agreement provides for a $1 billion revolving credit facility, with a $260 million letter of credit subfacility and a swingline loan subfacility, all of which mature in October 2027. The credit agreement previously provided for a $270 million term loan commitment, the outstanding amount of which was repaid in June 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts drawn on the revolving credit facility bear interest at a rate per annum of, at our option, (1) secured overnight financing rate (&#x201c;SOFR&#x201d;) or (2)&#160;the higher of (a)&#160;Barclays Bank PLC&#x2019;s prime rate and (b)&#160;the federal funds rate plus 0.5%, in each case, plus, in each case, an applicable margin that varies depending upon our leverage ratio. We are also subject to a commitment fee of 0.25% or 0.30%, depending on our leverage ratio, per annum on the daily amount of the unutilized commitments under the revolving credit facility. The current interest rate on SOFR borrowings under the credit agreement includes a credit spread of 1.50%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The credit agreement contains affirmative and negative covenants and default and acceleration provisions, including a minimum interest coverage ratio and a maximum leverage ratio. Under one such negative covenant, we are restricted from paying common stock dividends, prepaying certain senior notes, making certain investments, and repurchasing preferred and common equity unless (1) we are not in default under the terms of the credit agreement and (2) our senior secured leverage ratio, as defined in the credit agreement, does not exceed 2x. In the event the senior secured leverage ratio exceeds 2x, these payments are subject to a limit of $200 million plus the Available Amount, as defined in the credit agreement. Our obligations under the credit agreement are secured by the current and future personal property of the Company and its subsidiary guarantors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we amended our existing credit agreement and the amendments included the following material provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the financial covenants to update the applicable interest coverage ratio and leverage ratio included in that covenant. The revised applicable ratios are set forth below.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the definition of &#x201c;Material Adverse Effect&#x201d; to carve out the direct and indirect impacts of pandemic and the related legislative, regulatory and executive actions on us from that definition for a period of 364 days; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the investment limitation covenant and the restricted payment limitation covenant, to add to each a leverage ratio condition (not in excess of 4.50x) to the provisions allowing unlimited investments and restricted payments in the event certain conditions are met including a senior secured leverage ratio (not in excess of 2.00x) and the existence of no events of default in addition to the new leverage ratio condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we further amended our existing credit agreement and the amendments included the following material provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of definition of &#x201c;Consolidated Net Income&#x201d; to exclude from the calculation thereof, at Encompass Health&#x2019;s option, net income or loss from disposed, abandoned, transferred, closed or discontinued operations until such disposition, abandonment, transfer, closure of discontinuance of operations shall have been consummated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Addition of Section 1.08, &#x201c;SpinCo Credit Facilities Transactions,&#x201d; to provide that the Loan Documents will not prevent the consummation of the SpinCo Credit Facilities Transactions and that the SpinCo Credit Facilities Transactions will not give rise to any Default or constitute a utilization of any basket under any Loan Document.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of Section 2.11(e) to provide that a Prepayment Notice may be conditioned upon the effectiveness of other credit facilities, indentures or similar agreements or other transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Addition of Section 5.18, &#x201c;SpinCo Distribution,&#x201d; to provide that within three (3) Business Days following the incurrence of indebtedness under the SpinCo Credit Facilities, Encompass will have consummated the SpinCo Distribution in compliance with the Restricted Payments covenants of the Credit Agreement, and following the consummation of the SpinCo Distribution, no obligors in respect of the SpinCo Credit Facilities will be Restricted Subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the definition of &#x201c;Senior Notes&#x201d; to include Encompass&#x2019; 4.625% Senior Notes due 2031 and the definition of &#x201c;Consolidated Total Indebtedness&#x201d; to exclude Indebtedness under any Senior Note for which an irrevocable notice of redemption has been issued in connection with or incidental to any SpinCo Distribution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we further amended our existing credit agreement and the amendments included the following material provisions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of the definition of &#x201c;Maturity Date&#x201d; for the revolving borrowings to October 7, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Change the reference rate for borrowings from LIBOR to SOFR.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Reduction of the fee for the undrawn portion of the revolving loan commitment from 37.5 basis points to a maximum of 30 basis points and a minimum of 25 basis points, with such rate to be determined based on the Leverage Ratio as of the most recently ended four quarter period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Restatement of the Leverage Ratio maintenance covenant in Section 6.01(b) to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On the last day of each fiscal quarter, the Borrower will not permit the Leverage Ratio, calculated as of the end of each such fiscal quarter occurring during the time periods set forth below on a pro forma basis, to exceed the ratio set forth below opposite the time period during which such fiscal quarter ends; provided, however, that the Borrower may elect (the &#x201c;Step-Up Election&#x201d;) at any time after the Effective Date to increase the maximum Leverage Ratio permitted hereunder by 0.50 to 1.00 for the 4 immediately succeeding fiscal quarters as of and immediately following the consummation of any Significant Acquisition, in each case, by providing a written notice to the Administrative Agent of such Step-Up Election prior to the last day of the first fiscal quarter for which the Step-Up Election is to take effect (this sentence, the &#x201c;Leverage Covenant&#x201d;). Upon the expiration of the Step-Up Election, the maximum Leverage Ratio permitted under the Leverage Covenant shall revert to the Leverage Ratio set forth below for at least two consecutive fiscal quarters before the Borrower may make another Step-Up Election.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022 &#x2013; September 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Insertion of an add back of certain restructuring charges and synergies in calculating Adjusted Consolidated EBITDA under the credit agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of definition of &#x201c;Available Amount&#x201d; to include a $900&#160;million &#x201c;starter amount&#x201d; and a &#x201c;grower component&#x201d; tied to 50% of cumulative Consolidated Net Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Amendment of certain negative covenant baskets to include a &#x201c;grower component&#x201d; tied to a percentage of Adjusted Consolidated EBITDA for a trailing 12-month period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, Enhabit distributed $566.6&#160;million to Encompass Health who used it to fully repay both the $250&#160;million outstanding balance of the Encompass Health revolving credit facility and approximately $236&#160;million of the Encompass Health term loan. Currently, there are no term loan commitments under the credit agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, $55 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were drawn under the revolving credit facility with an interest rate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.0%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $200 million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were drawn under the revolving credit facility with an interest rate of 2.6%. As of December&#160;31, 2022 and 2021, $32.7 million and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $38.2 million, respectively, were being &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;utilized under the letter of credit subfacility, which were being used in the ordinary course of business to secure workers&#x2019; compensation and other insurance coverages and for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bonds Payable&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 5.125%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Senior Notes due 2023 (&#x201c;the 2023 Notes&#x201d;), 5.75% Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;), 4.50% Senior Notes due 2028 (the &#x201c;2028 Notes&#x201d;), 4.75% Senior Notes due 2030 (the &#x201c;2030 Notes&#x201d;), and 4.625% Senior Notes due 2031 (the &#x201c;2031 Notes&#x201d; and collectively the &#x201c;Senior Notes&#x201d;) were issued pursuant to an indenture (the &#x201c;Base Indenture&#x201d;) dated as of December&#160;1,&#160;2009, as supplemented by each Senior Notes&#x2019; respective supplemental indenture (together with the Base Indenture, the &#x201c;Indenture&#x201d;). Pursuant to the terms of the Indenture, the Senior Notes are jointly and severally guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The Senior Notes are senior, unsecured obligations of Encompass Health and rank equally with our other senior indebtedness, senior to any of our subordinated indebtedness, and effectively junior to our secured indebtedness to the extent of the value of the collateral securing such indebtedness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the Indenture), each holder of the Senior Notes may require us to repurchase all or a portion of the notes in cash at a price equal to 101% of the principal amount of the Senior Notes to be repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Notes contain covenants and default and acceleration provisions, that, among other things, limit our and certain of our subsidiaries&#x2019; ability to (1)&#160;incur additional debt, (2)&#160;make certain restricted payments, (3)&#160;consummate specified asset sales, (4)&#160;incur liens, and (5)&#160;merge or consolidate with another person.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 9, 2021, we announced the commencement of a consent solicitation of holders of the 2025 Notes, 2028 Notes, 2030 Notes, and 2031 Notes (collectively the &#x201c;Notes&#x201d;) for the adoption of certain amendments to the Indenture, which provided us with greater flexibility in effecting the Spin Off discussed in Note&#160;2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Spin Off of Home Health and Hospice Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permit us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a &#x201c;Distribution&#x201d;) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We may make any such distribution so long as the Leverage Ratio (as defined in each Indenture) is no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduce the capacity under our restricted payments builder basket under each existing Indenture for the 2028 Notes, 2030 Notes, and 2031 Notes by $200&#160;million and amends the definition of &#x201c;Consolidated Net Income&#x201d; to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $40.5&#160;million, excluding fees. We paid $20.0&#160;million and $20.5 million in January and June 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2023 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2015, we issued $300 million of the 2023 Notes at par. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In both April and June 2021, we redeemed $100&#160;million in outstanding principal amount of the 2023 Notes using cash on hand and capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, these optional redemptions were made at a price of par. In March 2022, we redeemed the remaining $100&#160;million in outstanding principal amount of the 2023 Notes using capacity under our revolving credit facility. Pursuant to the terms of the 2023 Notes, this optional redemption was made at a price of par. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Notes would have matured on March 15, 2023. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inclusive of financing costs, the effective interest rate on the 2023 Notes was 5.4%.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Interest on the 2023 Notes was payable semiannually in arrears on March 15 and September 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2015, we issued $350 million of the 2025 Notes at par. The 2025 Notes mature on September&#160;15, 2025 and bear interest at a per annum rate of 5.75%. Inclusive of financing costs, the effective interest rate on the 2025 Notes is 6.0%. Interest on the 2025 Notes is payable semiannually in arrears on March 15 and September&#160;15. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2022, at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 15, 2023 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2028 and 2030 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we issued $500 million of the 2028 Notes at par and $500 million of the 2030 Notes at par. Certain of the proceeds from this offering were used to fund the purchase of equity rights from management investors of our former home health and hospice business discussed in Note&#160;12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Noncontrolling Interests.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, we issued an additional $300&#160;million of the 2028 Notes at a price of 99.0% of the principal amount and an additional $300&#160;million of the 2030 Notes at a price of 98.5% of the principal amount, which resulted in approximately $583&#160;million in net proceeds. We used a portion of the net proceeds from this borrowing, together with cash on hand, to repay borrowings under our revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2028 Notes mature on February 1, 2028. Inclusive of financing costs, the effective interest rate on the 2028 Notes is 4.8%. Interest on the 2028 Notes is payable semiannually in arrears on February 1 and August 1. We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2030 Notes mature on February 1, 2030. Inclusive of financing costs, the effective interest rate on the 2030 Notes is 5.2%. Interest on the 2030 Notes is payable semiannually in arrears on February 1 and August 1. We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2031 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we issued $400&#160;million of the 2031 Notes at par. The 2031 Notes mature on April 1, 2031 and bear interest at a per annum rate of 4.625%. Inclusive of financing costs, the effective interest rate on the 2031 Notes is 5.0%. Interest is payable semiannually in arrears on April 1 and October 1 of each year. We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Former 2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, we redeemed the remaining $700&#160;million of outstanding principal amount of the 5.75% Senior Notes due 2024 (&#x201c;the Former 2024 Notes&#x201d;). Pursuant to the terms of the Former 2024 Notes, this full redemption was made at a price of par. We used the net proceeds from the 2031 Notes offering, discussed above, together with approximately $300&#160;million of cash on hand to fund the redemption. The Former 2024 Notes would have matured on November&#160;1, 2024. Inclusive of premiums and financing costs, the effective interest rate on the Former 2024 Notes was 5.8%. Interest was payable semiannually in arrears on May 1 and November&#160;1 of each year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Notes Payable&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our notes payable consist of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale/leaseback transactions involving real estate accounted for as financings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1% to 11.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction of a new hospital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0% to 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyODc0_3e88721e-2a6b-4d52-834d-16378fa74417">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our long-term debt outstanding consists of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Agreement&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bonds payable&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,767.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,278.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,741.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,240.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our notes payable consist of the following (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.078%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Rates&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sale/leaseback transactions involving real estate accounted for as financings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1% to 11.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction of a new hospital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0% to 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i4a3402d0382640a1aa58f90238c683e9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzMtMS0xLTEtMjQ1NDc3_f1c24df2-eb1b-45a4-a694-74d46ba0f03e"
      unitRef="usd">55000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ife432a1f73c54d489020d8e1c0653fb5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzMtMy0xLTEtMjQ1NDc3_3ea0cdaa-26a4-4f9f-a9c4-e01213d12667"
      unitRef="usd">200000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i966df770ed1a4ca986dd2b7ce6d52c65_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzQtMS0xLTEtMjQ1NDc3_0cbfcc2f-a83e-43f3-a632-e8801ea33894"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ic9b3c2c63d034b5982e9fe8323b7b71e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzQtMy0xLTEtMjQ1NDc3_f219c90b-7d7f-4fec-9f81-80e1d5a974c9"
      unitRef="usd">238500000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzYtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246OTJiZGQ0NjI0MjdjNDRjMzk3MzE0NGJhY2ZlNjU2YmFfNA_bfd1f1bd-8152-4131-8bbb-ce1f67f02b01"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id1214fc63dae4248a98c4032a91b2fec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzYtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246OTJiZGQ0NjI0MjdjNDRjMzk3MzE0NGJhY2ZlNjU2YmFfNA_ca544c63-0aaa-4f72-95a4-0e126ef61ddf"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzYtMS0xLTEtMjQ1NDc3_39e6f8a4-6f98-42dc-80c6-f81fe0b8264d"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="id1214fc63dae4248a98c4032a91b2fec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzYtMy0xLTEtMjQ1NDc3_4e06fc55-bae7-442e-b386-cb06af5e871f"
      unitRef="usd">99600000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b519d969150438ca0a24a17a6f87ca8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjdmMTZlMTM1ZTVkNGQwMDk3MzY0ZGM4MGE4NWM3MzZfNA_587a8921-9c37-4326-80f2-03c8348e2e0f"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i005266a587014861b4fc4bdc254e6a15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NjdmMTZlMTM1ZTVkNGQwMDk3MzY0ZGM4MGE4NWM3MzZfNA_9f35e6a4-ed99-46da-9667-34167c0ccd5e"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i005266a587014861b4fc4bdc254e6a15_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzctMS0xLTEtMjQ1NDc3_4b732489-84be-41b9-92ac-659a8ca38224"
      unitRef="usd">347700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6b519d969150438ca0a24a17a6f87ca8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzctMy0xLTEtMjQ1NDc3_bfbf6054-2438-4431-b042-a0acba025135"
      unitRef="usd">347000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b5a421f1a804107a53e85439af96f46_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzgtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MDQxMTE5MWNkN2M2NGE2ZTk1NTNhZTdjMmU4ZTExOTZfNA_6bf22234-87a3-4d99-94ff-2c620e0fa16b"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i03e2cfaa161d423e9fe9d78c1d2484d8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzgtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MDQxMTE5MWNkN2M2NGE2ZTk1NTNhZTdjMmU4ZTExOTZfNA_ec2505d6-b573-4512-8311-a0ec181aa3ac"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6b5a421f1a804107a53e85439af96f46_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzgtMS0xLTEtMjQ1NDc3_30b8039b-ea20-46b8-bbc8-63d9e2a658b2"
      unitRef="usd">781800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i03e2cfaa161d423e9fe9d78c1d2484d8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzgtMy0xLTEtMjQ1NDc3_3e1297c0-da11-44fc-b2f3-76df5b5288af"
      unitRef="usd">786800000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idca4e969d39442579877374d995f76bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzktMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzI0M2FmZTA4NjIxNDA2NzhkZWQ0YjljZGU4OTRkOThfNA_270cfbe1-ec03-4547-8605-31bedc871c65"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzktMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzI0M2FmZTA4NjIxNDA2NzhkZWQ0YjljZGU4OTRkOThfNA_37344c1e-1cca-40f7-a777-6bff36254137"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzktMS0xLTEtMjQ1NDc3_41fae1aa-b686-4be7-8ca9-4379ca9cee79"
      unitRef="usd">779000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idca4e969d39442579877374d995f76bc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzktMy0xLTEtMjQ1NDc3_cf17d6f5-f944-4585-85be-c26593d94d8e"
      unitRef="usd">784700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iccae8862dd6a4bac8b4589ffb7e02bba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEwLTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjNkNDk4ZmY1YjM0YzQwZDA4MDc1NGUzZGZiZDM5ZGUwXzQ_744aec19-2df4-4a6c-a72e-b3e24b967433"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85aa556fff894922b569241055a48e29_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEwLTAtMS0xLTI0NTQ3Ny90ZXh0cmVnaW9uOjNkNDk4ZmY1YjM0YzQwZDA4MDc1NGUzZGZiZDM5ZGUwXzQ_edc8e297-8257-4e91-9857-34aebf99e277"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i85aa556fff894922b569241055a48e29_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEwLTEtMS0xLTI0NTQ3Nw_6b868724-73e3-4ca9-b00c-9365b105329a"
      unitRef="usd">390600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="iccae8862dd6a4bac8b4589ffb7e02bba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEwLTMtMS0xLTI0NTQ3Nw_b05000f1-06af-4abe-8877-c39ce8f5b00d"
      unitRef="usd">393700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i44f0c6fe1d3d4acabec50bcd4c8268f6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzExLTEtMS0xLTI0NTQ3Nw_3f663d94-0dd8-4de5-9d47-2a659315fd7a"
      unitRef="usd">53100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i848b097591424c609108802124923a5e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzExLTMtMS0xLTI0NTQ3Nw_519fa5c8-aff2-457c-b277-360fd2f3bc29"
      unitRef="usd">47700000</us-gaap:LongTermDebt>
    <us-gaap:FinanceLeaseLiability
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEyLTEtMS0xLTI0NTQ3Nw_8a2f4f9b-b081-40e5-8bfb-83ea2273c116"
      unitRef="usd">359800000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEyLTMtMS0xLTI0NTQ3Nw_9f533a0f-81bc-47f4-83de-c892006a7f8f"
      unitRef="usd">380300000</us-gaap:FinanceLeaseLiability>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEzLTEtMS0xLTI0NTQ3Nw_42d497c4-5af7-4e2f-bca2-15a16cc3fd2b"
      unitRef="usd">2767000000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzEzLTMtMS0xLTI0NTQ3Nw_a0d75e07-0f98-43e6-a39c-632b6366fbed"
      unitRef="usd">3278300000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzE0LTEtMS0xLTI0NTQ3Nw_1c0d9193-41e8-47f3-b399-7b8e65c25b64"
      unitRef="usd">25200000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzE0LTMtMS0xLTI0NTQ3Nw_73ff7530-e372-49c2-88a2-7ab8b83868eb"
      unitRef="usd">37800000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzE1LTEtMS0xLTI0NTQ3Nw_4e41b007-6ec1-433c-854c-1568611bb3be"
      unitRef="usd">2741800000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0MzhhMDE3ZDViYTg0YTljOWI3ZjM4MDhjMmM0ZmZkMy90YWJsZXJhbmdlOjQzOGEwMTdkNWJhODRhOWM5YjdmMzgwOGMyYzRmZmQzXzE1LTMtMS0xLTI0NTQ3Nw_58866b4f-fde4-4b0d-a060-99b70c1746d3"
      unitRef="usd">3240500000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyODcx_30c6b636-4eca-4933-8d85-23750d442c61">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Face Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,247.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,817.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,767.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearOne
      contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzEtMi0xLTEtMjQ1NDc3_da423121-3410-48f5-819f-a3d1f48f3580"
      unitRef="usd">25200000</ehc:LongTermDebtAndLeaseObligationsMaturityYearOne>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearOne
      contextRef="i41b7012b097a470cb13642fec315ce68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzEtNC0xLTEtMjQ1NDc3_28be3b61-b7ff-41fe-8864-cdbe4e21e310"
      unitRef="usd">25200000</ehc:LongTermDebtAndLeaseObligationsMaturityYearOne>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo
      contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzItMi0xLTEtMjQ1NDc3_0b2551af-29c7-4b25-aa19-02e1c4754b00"
      unitRef="usd">39200000</ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo
      contextRef="i41b7012b097a470cb13642fec315ce68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzItNC0xLTEtMjQ1NDc3_98e00be5-be51-471e-b632-31b538852f6c"
      unitRef="usd">39200000</ehc:LongTermDebtAndLeaseObligationsMaturityYearTwo>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearThree
      contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzMtMi0xLTEtMjQ1NDc3_c19e82a0-ef43-45e8-b1cb-8ef2fcfccea9"
      unitRef="usd">381800000</ehc:LongTermDebtAndLeaseObligationsMaturityYearThree>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearThree
      contextRef="i41b7012b097a470cb13642fec315ce68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzMtNC0xLTEtMjQ1NDc3_05ff676d-5fc4-47bb-b31d-88226ebbc43a"
      unitRef="usd">379500000</ehc:LongTermDebtAndLeaseObligationsMaturityYearThree>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearFour
      contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzQtMi0xLTEtMjQ1NDc3_7138b38b-3150-4f82-bfe8-c73e03d4b764"
      unitRef="usd">27600000</ehc:LongTermDebtAndLeaseObligationsMaturityYearFour>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearFour
      contextRef="i41b7012b097a470cb13642fec315ce68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzQtNC0xLTEtMjQ1NDc3_032e2177-7311-4184-956b-1104ffe61125"
      unitRef="usd">27600000</ehc:LongTermDebtAndLeaseObligationsMaturityYearFour>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearFive
      contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzUtMi0xLTEtMjQ1NDc3_97e1c8cb-247f-46d1-b590-ffd5f30245b9"
      unitRef="usd">96600000</ehc:LongTermDebtAndLeaseObligationsMaturityYearFive>
    <ehc:LongTermDebtAndLeaseObligationsMaturityYearFive
      contextRef="i41b7012b097a470cb13642fec315ce68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzUtNC0xLTEtMjQ1NDc3_fd55a2c0-e053-4fe7-8346-5db95b0f8e75"
      unitRef="usd">96600000</ehc:LongTermDebtAndLeaseObligationsMaturityYearFive>
    <ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive
      contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzYtMi0xLTEtMjQ1NDc3_751aeab6-973d-476e-8fb5-95a32a379466"
      unitRef="usd">2247500000</ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive>
    <ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive
      contextRef="i41b7012b097a470cb13642fec315ce68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzYtNC0xLTEtMjQ1NDc3_a1f4ab5b-3123-48a1-912a-7ffc1eae4da4"
      unitRef="usd">2198900000</ehc:LongTermDebtAndLeaseObligationsMaturityAfterYearFive>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i3dfddbd9d2e441f7b14568e6345a3f34_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzctMi0xLTEtMjQ1NDc3_4d73c6f8-8852-427c-a36e-d65b5ce9dab9"
      unitRef="usd">2817900000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
      contextRef="i41b7012b097a470cb13642fec315ce68_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1ZThkM2NlN2NkMmY0NTk0ODExZmI1MjIyNjRiODgwNi90YWJsZXJhbmdlOjVlOGQzY2U3Y2QyZjQ1OTQ4MTFmYjUyMjI2NGI4ODA2XzctNC0xLTEtMjQ1NDc3_c547c870-446f-41e0-8661-07136e00d886"
      unitRef="usd">2767000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwOTk1MTE2NDA3MTk_95fca2d0-249a-4ac5-8d16-9e710dfdfaf2"
      unitRef="usd">-1400000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwOTk1MTE2NDA3MjQ_a8e8ec02-9e58-4872-9228-0224d0f81f48"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwOTk1MTE2NDA3Mjk_0ed7c50c-1fe3-458b-a9f9-ff6d04f87fb5"
      unitRef="usd">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1c1215032fe2415c8d09726a46e245a4_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzQ5OQ_e4037dc0-d3ce-444f-a8d3-7a0ea5443157"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ibe73f052bcb64b3b84bdbe9c72aaa76c_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzUzNg_de357a82-1441-4df6-b1ae-729ba2203b57"
      unitRef="usd">260000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i339b11c888494596a3629e3c3f8602a3_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk4MDAyMjQ_0561a6bf-85e3-411d-9b46-20f7fd74de23"
      unitRef="usd">270000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if808e99cfa6f4952a0ae670544ff3a5a_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyMzM_da1cfc93-5b7a-4193-b817-72b250ea7fe1"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i4e6b4e433f554a94aa26022360c2e01d_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEzODI_5f6fbe50-cd44-4fde-9a17-e437026956a6"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i1b575fc15d22495a9d08298c9bae970f_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzU0OTc1NTg0Njk5OA_2a75ba50-374b-4097-a1fc-6768d069c7eb"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i041d58dc5a4a43e5a53c4489ec517413_D20191101-20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzE1NjM_946ee01d-de39-4f6e-8f35-b694d199e5ba"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ehc:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="ia639cd1c8ac549939010774ccd59e3c6_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzIxMDg_6d0eaf02-02eb-498e-999f-77ccd5a2b58f"
      unitRef="number">2</ehc:DebtInstrumentCovenantLeverageRatioMaximum>
    <ehc:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="ia639cd1c8ac549939010774ccd59e3c6_I20191130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzNTc_97aa64e5-4a40-48f0-84e1-0c1331ddcfb7"
      unitRef="number">2</ehc:DebtInstrumentCovenantLeverageRatioMaximum>
    <ehc:DebtInstrumentCovenantAvailableLimitAmount
      contextRef="ia639cd1c8ac549939010774ccd59e3c6_I20191130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzIyMTI_14511136-e1ca-4802-be73-e3297bca01ee"
      unitRef="usd">200000000</ehc:DebtInstrumentCovenantAvailableLimitAmount>
    <ehc:ScheduleOfFinancialCovenantsTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyODk0_1257d123-ca29-45aa-bca3-7d81e7ee6355">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interest Coverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019 and March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.923%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.857%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal Quarters Ending&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leverage Ratio&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 30, 2022 &#x2013; September 30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2024 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50 to 1.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ehc:ScheduleOfFinancialCovenantsTableTextBlock>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="ibcac1b02df73495c877b9c7d30a882c4_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTowNTk0NWI1Y2M3OTg0YWQxYWUyMGI1NzRmZTNkNjAyNy90YWJsZXJhbmdlOjA1OTQ1YjVjYzc5ODRhZDFhZTIwYjU3NGZlM2Q2MDI3XzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MjMwY2FjODEwMmQ3NDBjOTk2YzAzZWMxYWM5NGExMmJfNA_d7bb47a8-e621-4dcb-a1f4-4e899adfda47"
      unitRef="number">3.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="ia18b2e0c059c4ec6baf3c43fbd522a3c_D20200701-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTowNTk0NWI1Y2M3OTg0YWQxYWUyMGI1NzRmZTNkNjAyNy90YWJsZXJhbmdlOjA1OTQ1YjVjYzc5ODRhZDFhZTIwYjU3NGZlM2Q2MDI3XzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MzAzZjc3YTAxY2RlNDMzZThkN2ZhMzdjOGI0OWUwNGZfNA_d9e8cbf5-f646-4be2-bc69-63fc33c980ce"
      unitRef="number">2.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantInterestCoverageRatio
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTowNTk0NWI1Y2M3OTg0YWQxYWUyMGI1NzRmZTNkNjAyNy90YWJsZXJhbmdlOjA1OTQ1YjVjYzc5ODRhZDFhZTIwYjU3NGZlM2Q2MDI3XzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246OGNiNGIzMWU1NzY5NGQ2YzkyMzE3YjZkM2EwNmI2NWRfNA_771aa07d-fd5d-4936-83a4-c8f0de87f95d"
      unitRef="number">3.00</ehc:DebtInstrumentCovenantInterestCoverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i6753a38864e24fe7b3e80115745bd09e_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzEtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Zjc3NWUxNjIwYWI0NDFiNDhjYzY3MWJmMDg2ZmEzZWJfNA_802d08df-6866-4485-b9cf-8c7537564bf7"
      unitRef="number">4.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i562889873f374783afb9294f8f3e580d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzItMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246YjhkMTE2ZTI2ZTk3NGFiNTllZDg2NTAxZWVlZjQ3NGZfNA_9ae53d50-8c77-4be6-ab0e-c86154e44af3"
      unitRef="number">4.75</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i693a1fea14d6475ca0e8f46ce8dfe8fb_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzMtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246OWYyMmYwYzE0OTBiNDEzNzkxZTRhZjY5NTcyMmIwN2RfNA_43127dd5-2455-4dbb-a635-41d0ec819bdf"
      unitRef="number">5.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzQtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MDk2NGVhOGU5MDZlNDU0ZGE3MzA4ODNmNDJmZTM1OTVfNA_b8431b29-0fbf-4377-87c7-9cbba20b4966"
      unitRef="number">6.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i115e2fd9db454724b9f95a8f9e1f70a4_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzUtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MDIyZDFjZTYxZmExNGE2NWFkNzRlNTYxZGI1M2FhYzBfNA_861375d5-55fb-486c-9bee-4fdbf0835294"
      unitRef="number">6.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i9936400e3d03441c8b1661005d6f279a_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzYtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NDk1OGM4YjVlMjBjNGJhZTgzYjBiOWMzZWM1M2I1NjBfNA_c0ab8753-f391-4a90-8d1f-cdb8c6255801"
      unitRef="number">6.00</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i6a87df56a8f6405f8b9bb8b08241a639_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzctMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246MjRlZjUzYzJmOWQwNDVmYzg4ZTNlNjNlNmExNzU2YjZfNA_2521c4e4-7bd5-419e-b724-8ab725304ebe"
      unitRef="number">5.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzgtMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NWY0ZmQ3OGM3MTFlNGIwNzhiOGZmOTE5Mzg1NzAzMThfNA_a5f7a394-d88b-4db1-93cd-c7291cc970d3"
      unitRef="number">5.00</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i4b3e1118ad2243ae8f2552652e81d1e9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTpjMTJmYjUzNmQwYTI0ZTE5YmRjMWRhMzk5MDJhOGVhMi90YWJsZXJhbmdlOmMxMmZiNTM2ZDBhMjRlMTliZGMxZGEzOTkwMmE4ZWEyXzktMS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NWFhNDA1MzFjOGQwNGJhYTk5MjFjNTRkZDE4NmM4OGZfNA_1f6dc59c-cb28-4d09-8871-177e64ee422e"
      unitRef="number">4.25</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod
      contextRef="ia1738ccbe8404bafad9e9c10b06a1540_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzNzE_7fb5d349-256d-45a9-ba3a-ccb962621cfb">P364D</ehc:DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod>
    <ehc:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="i53ddc51847dc4ddbae72c2e1b0dd613e_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzNTY_90007488-8464-4344-b4ee-bbe086c0be20"
      unitRef="number">4.5</ehc:DebtInstrumentCovenantLeverageRatioMaximum>
    <ehc:DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum
      contextRef="i53ddc51847dc4ddbae72c2e1b0dd613e_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzNzA_c00f11fe-e35f-4076-884a-ae6bac114374"
      unitRef="number">2</ehc:DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum>
    <ehc:DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays
      contextRef="ib298d1d466d644b3a88d10c8864e5755_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MzAzODg_a7e22dae-f1c6-4389-9c5c-304515b46b70"
      unitRef="day">3</ehc:DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i49cf61de567c43ef90aa762bfd0eeb09_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgyOTA_e5cb7606-8edc-44d9-8855-d453c4a9b3e4"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion
      contextRef="i751e9639a4854331aafc6dd971bd8b76_D20221001-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgyOTg_6e6a42d5-e9ac-49ca-8b89-8ab88996ddf8"
      unitRef="number">0.00375</ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion>
    <ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion
      contextRef="i977aaea8b2b34ebc93d72ec5a537716a_D20221001-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMDc_09e8b329-8052-4668-90cf-0f4c161a2a2a"
      unitRef="number">0.0030</ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion>
    <ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion
      contextRef="i7f7042f972104aa8922d830f4c40e428_D20221001-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMTQ_cf5aea9e-7c35-45db-814f-130dfd97dea3"
      unitRef="number">0.0025</ehc:DebtInstrumentCovenantReductionFeeForUndrawnPortion>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="ifc1102227aec4db8b50dfac6284decf9_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMjE_3783349c-d9e0-41ca-80ca-3b55b3c045e5"
      unitRef="number">0.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="ie134020e1d4c46b8bf2c15a981b6d8c3_I20240930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1OTQ2ZmJjYzBkMTg0MjdhOGI5MTFlOGExYjczZDJmOC90YWJsZXJhbmdlOjU5NDZmYmNjMGQxODQyN2E4YjkxMWU4YTFiNzNkMmY4XzEtMS0xLTEtMjgzODg0L3RleHRyZWdpb246NGQ1MjIxZGNiODRkNDZlY2FlMjgyYzM2MWQ2ZDQ3NjdfMzg0ODI5MDY5NzIzNg_b642ed5a-53b4-46f2-910e-72f5df9ad6a9"
      unitRef="number">4.75</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i29afe01aaa2c4a1faa04d57a037e62a5_I20241231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo1OTQ2ZmJjYzBkMTg0MjdhOGI5MTFlOGExYjczZDJmOC90YWJsZXJhbmdlOjU5NDZmYmNjMGQxODQyN2E4YjkxMWU4YTFiNzNkMmY4XzItMS0xLTEtMjgzODg0L3RleHRyZWdpb246ZTU0NzUxMjJhMDk5NDU2ZTk5YzQxOTliNGM5MDY0ZjBfMzg0ODI5MDY5NzIzNg_fdfb0193-f154-453c-b7fe-b74f45284fde"
      unitRef="number">4.50</ehc:DebtInstrumentCovenantLeverageRatio>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="iffee7132fe2a4d46ad166324cc4ac784_I20221031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMzI_6d4bc37a-11a4-4a53-90a8-c36b0136640a"
      unitRef="usd">900000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <ehc:LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome
      contextRef="i37964c43d1d6497390edcd2c9583717d_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM4NDgyOTA3MTgzMjc_5e9263ac-d41c-4c9a-91e0-f94bccfeeb1d"
      unitRef="number">0.50</ehc:LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome>
    <us-gaap:PaymentsOfDistributionsToAffiliates
      contextRef="i43a0ab4d513d4a748593003c9e09d157_D20220630-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3ODk3MjY_eed74caa-613e-44b6-bbbe-e0674e98dfe8"
      unitRef="usd">566600000</us-gaap:PaymentsOfDistributionsToAffiliates>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i57239bff51e54e02bfafa24442729469_D20220630-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3ODk3ODY_d2e59fb1-7620-49a3-bd4b-8e6ffaa8e476"
      unitRef="usd">250000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i15a929b250624845875d18fad4623b1c_D20220630-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3ODk4Nzg_53d8f25e-624e-4d36-bdf2-6ea5f7ecd2d8"
      unitRef="usd">236000000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:LongTermDebt
      contextRef="ibeb50e54b2bf431e84d3d94cc9d22afa_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM0Mzc_e124a91a-5d71-46bd-b3d8-6c26a6118513"
      unitRef="usd">55000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i203fce73533d42bdbce407cb83fa7644_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM1MTI_75f058d8-dc8e-4a5d-82d2-816c5d3f4f90"
      unitRef="number">0.070</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LongTermDebt
      contextRef="ib2e47e2a132f436290412d3422a81aa9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM1Mzk_255b3f8b-8c4c-4f58-8b3e-403bc8cd539c"
      unitRef="usd">200000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i99bc319d2e0041d082e15bd0afcd2496_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzU0OTc1NTgyNzk3NA_dfadb2c9-0631-488b-a741-f855081841a3"
      unitRef="number">0.026</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i73171c1ff1894cd5ab077095eb011dd2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM2MjY_db840c35-6ce4-40d5-a10b-c6204d36f104"
      unitRef="usd">32700000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i90e87d090f6f40978450a4a6d7148825_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzM2MzM_9164f136-6ba0-45ab-93e8-99b7a7542c48"
      unitRef="usd">38200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI0Mjk_967e123e-4336-40b4-8d96-c53a17a24b0b"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i005266a587014861b4fc4bdc254e6a15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI1Mjk_d2ac861e-6479-4d63-83c5-b7cdb8533cf2"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b5a421f1a804107a53e85439af96f46_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI1MzY_893159d8-bd7d-4719-abd1-34d335d739a2"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI1NDI_453a717c-7f3e-49e0-8bbd-2d1223174b72"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85aa556fff894922b569241055a48e29_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTI1NDQ_5359a1d1-3c75-41c8-955a-9ad2e99219f9"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i4d3ce01c69d745bc933890c6d0232e0a_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzUwNTk_bb42d879-ed12-40de-a632-7f8bd0cadb16"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <ehc:DebtInstrumentCovenantLeverageRatio
      contextRef="i0e4f418e7b3140e2b36a3a4c1d19f59b_I20211209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1MTY_07486e23-e616-47fd-9dce-156eba2b79d7"
      unitRef="number">3.5</ehc:DebtInstrumentCovenantLeverageRatio>
    <ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket
      contextRef="i0e4f418e7b3140e2b36a3a4c1d19f59b_I20211209"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY2OTQ_3f4b5698-39b4-4c81-8d68-7283bb5a295b"
      unitRef="usd">200000000</ehc:DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket>
    <ehc:DebtInstrumentAmendmentAgreementAmountToBePaid
      contextRef="i04748e0cbb554838bc097423f5562754_D20211201-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzcxNTg_2a0b0226-452e-4f86-a9d0-e5972ee17264"
      unitRef="usd">40500000</ehc:DebtInstrumentAmendmentAgreementAmountToBePaid>
    <us-gaap:RepaymentsOfDebt
      contextRef="ia4e9489eb2374473a2446b5989746133_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzcxODY_9f198bf3-6412-448d-8a6e-e25d4342a60f"
      unitRef="usd">20000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i3aa44cd02be2427b83f4285074d6a61c_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzU0OTc1NTgzNTE4MQ_594a530f-cd7a-4a33-a6cd-ec2e7da49fbd"
      unitRef="usd">20500000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaa62f19b4e9543c6a31117b7bb708940_I20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzczNjE_893ed006-a8bd-4994-998a-6b42c64f4050"
      unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i4579352e569d4ffc861c231d1d0881ff_D20210401-20210430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTM0ODY_57824125-2f7d-45fa-ac33-d76ec79c0dee"
      unitRef="usd">100000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="id2d821c1a27c4513aaef9bf885e8f58a_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTM0ODY_be93b493-aaf1-4955-b268-4c122c0e1419"
      unitRef="usd">100000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i45f4aa2776e24eebbb23581d16dfab42_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTM5ODU_80621195-23bc-4f7e-b25e-4874054d5c00"
      unitRef="usd">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iaa62f19b4e9543c6a31117b7bb708940_I20150331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzc2NjA_dec211ff-7821-45d6-a930-14042a765baa"
      unitRef="number">0.054</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie136f6f5e4de4e5eba9a9453789bcd0c_I20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwMTAy_ad4c98da-54c2-4747-8d90-5885d0e09eac"
      unitRef="usd">350000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie136f6f5e4de4e5eba9a9453789bcd0c_I20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwMjQ1_be821489-5e7c-431a-b7d0-db0bddcd6250"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie136f6f5e4de4e5eba9a9453789bcd0c_I20150930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwMzI4_b26b46bc-26e4-4f32-80d2-799db0c037dd"
      unitRef="number">0.060</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyODg0_846b4598-6dfa-44a4-b8f8-a6cf00974164">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may redeem the 2025 Notes, in whole or in part, at any time on or after September 15, 2022, at the redemption prices set forth below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 15, 2023 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;We may redeem the 2028 Notes, in whole or in part, at any time on or after February 1, 2023 at the redemption prices set forth below:&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;We may redeem the 2030 Notes, in whole or in part, at any time on or after February 1, 2025 at the redemption prices set forth below:&lt;div style="margin-bottom:7pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;We may redeem the 2031 Notes, in whole or in part, at any time on or after April 1, 2026 at the redemption prices set forth below:&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Redemption&lt;br/&gt;Price*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Expressed in percentage of principal amount&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtInstrumentRedemptionTableTextBlock>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i07b9cc9fc0fa4aa9b201c5317d0c6b56_D20150901-20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozOWE0YmFhM2UxNTc0N2FmYTcxMTIyMTljYmNmYzMyMy90YWJsZXJhbmdlOjM5YTRiYWEzZTE1NzQ3YWZhNzExMjIxOWNiY2ZjMzIzXzItMi0xLTEtMjQ1NDc3_c30c9327-0d2c-4caf-8fbd-7b8ca3e7c362"
      unitRef="number">1.00958</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i76b9b243cc2b40eca3256ba9b90f576c_D20150901-20150930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozOWE0YmFhM2UxNTc0N2FmYTcxMTIyMTljYmNmYzMyMy90YWJsZXJhbmdlOjM5YTRiYWEzZTE1NzQ3YWZhNzExMjIxOWNiY2ZjMzIzXzMtMi0xLTEtMjQ1NDc3_5542fcbc-e2bb-4dc6-a5ea-7f68522f039b"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iebf5ce77babc4dabb08fd48fb81f0d30_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwNjU5_3f10c111-dc79-4d87-aed7-138114250908"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1afcf433ab7c4f42b650fb3992b5dfaf_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEwNzIw_d528d016-0129-4b43-902a-f001d9b205b9"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i2a81a550dc09402898362c8731660c62_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMTA1_d657536d-2c84-4460-9fc5-84830990d70c"
      unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue
      contextRef="i2a81a550dc09402898362c8731660c62_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMTQw_65f3ec48-7b29-4c89-999d-6d72f40ed042"
      unitRef="number">0.990</ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3ea5e06878784d1c8ac7d2976c3faae1_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMTg1_7f4f7eec-a02f-47a7-a5ae-09dcfbb44325"
      unitRef="usd">300000000</us-gaap:DebtInstrumentFaceAmount>
    <ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue
      contextRef="i3ea5e06878784d1c8ac7d2976c3faae1_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMjIw_930c52ea-90e2-4174-a8a8-8854284b0c01"
      unitRef="number">0.985</ehc:DebtInstrumentDiscountRateAtIssuanceOfFaceValue>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i46706a0b927b4c29aa04008703cf93f6_D20200501-20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExMjgw_45180eeb-fc47-48fc-b972-4fb15152b6a9"
      unitRef="usd">583000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2a81a550dc09402898362c8731660c62_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExNTY2_731e56e6-11e6-42c8-a8f4-adf0abeb4e54"
      unitRef="number">0.048</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i37d6af95f4af4e68ba6868cc4060e8be_D20190901-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozNjk4YjU2YzY1MDk0YjNmODZjMDI3N2QyZWE1MmMzZC90YWJsZXJhbmdlOjM2OThiNTZjNjUwOTRiM2Y4NmMwMjc3ZDJlYTUyYzNkXzEtMi0xLTEtMjQ1NDc3_6491fdcd-d5af-42bc-afa8-f265ee7238ea"
      unitRef="number">1.02250</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie995c3d447e041b09b1095eed8f92f8b_D20190901-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozNjk4YjU2YzY1MDk0YjNmODZjMDI3N2QyZWE1MmMzZC90YWJsZXJhbmdlOjM2OThiNTZjNjUwOTRiM2Y4NmMwMjc3ZDJlYTUyYzNkXzItMi0xLTEtMjQ1NDc3_207bd05d-1572-4e5c-9786-70ff4dcbd7d1"
      unitRef="number">1.01125</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i551a3e6b442f432c9d03ed8b29cef37a_D20190901-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTozNjk4YjU2YzY1MDk0YjNmODZjMDI3N2QyZWE1MmMzZC90YWJsZXJhbmdlOjM2OThiNTZjNjUwOTRiM2Y4NmMwMjc3ZDJlYTUyYzNkXzMtMi0xLTEtMjQ1NDc3_5b4eb944-e3ac-43d0-8a40-a457eebd0ed0"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i3ea5e06878784d1c8ac7d2976c3faae1_I20200531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzExOTY0_2d6e3601-6d42-4d9c-994d-d30bff7bdd2b"
      unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie16678dac8224a06a40d1b5f2983c761_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo4NmY1MjZkZGFhOTY0YTExYmNhNzE2MGZlNjM3MTRjOC90YWJsZXJhbmdlOjg2ZjUyNmRkYWE5NjRhMTFiY2E3MTYwZmU2MzcxNGM4XzEtMi0xLTEtMjQ1NDc3_e334a67c-11f0-4b40-ba6d-92bcdb03361a"
      unitRef="number">1.02375</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i774caad6b09f45a4b7028e593a0fab36_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo4NmY1MjZkZGFhOTY0YTExYmNhNzE2MGZlNjM3MTRjOC90YWJsZXJhbmdlOjg2ZjUyNmRkYWE5NjRhMTFiY2E3MTYwZmU2MzcxNGM4XzItMi0xLTEtMjQ1NDc3_8a37e5f9-7154-4336-8acc-5bf6fdae0003"
      unitRef="number">1.01583</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="icdd2b81bfc614cf3b6b1ae1a415c9a04_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo4NmY1MjZkZGFhOTY0YTExYmNhNzE2MGZlNjM3MTRjOC90YWJsZXJhbmdlOjg2ZjUyNmRkYWE5NjRhMTFiY2E3MTYwZmU2MzcxNGM4XzMtMi0xLTEtMjQ1NDc3_bf07add0-dfa1-493f-bb4c-5d3ca52ea8c2"
      unitRef="number">1.00792</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ic0231b4cffab42d181cb35d1de3a69f6_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo4NmY1MjZkZGFhOTY0YTExYmNhNzE2MGZlNjM3MTRjOC90YWJsZXJhbmdlOjg2ZjUyNmRkYWE5NjRhMTFiY2E3MTYwZmU2MzcxNGM4XzQtMi0xLTEtMjQ1NDc3_bf9b2030-04de-4dcb-9080-1ac6cf26594a"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idfdfcc3a1e4d49cb802cebf7c87fab08_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyMjc4_6567f766-f759-40be-9b25-fcd8fed3d47c"
      unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idfdfcc3a1e4d49cb802cebf7c87fab08_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyNDQz_b88c573f-777e-4109-8975-bc49601650f7"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idfdfcc3a1e4d49cb802cebf7c87fab08_I20201031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzEyNTI2_a9e974b3-7b87-4ea8-9b71-7797bb58372c"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i72f1191377284bad9d5006ad478e6bf1_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZToyYTFmMDllNTdhM2Y0NzBkYjNiMjBiZDE1NGZkZGQ5MS90YWJsZXJhbmdlOjJhMWYwOWU1N2EzZjQ3MGRiM2IyMGJkMTU0ZmRkZDkxXzEtMi0xLTEtMjQ1NDc3_bc4ad88a-4515-4e9e-98a2-d7beb1838fba"
      unitRef="number">1.02313</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i3149f20f82304cdda697d7b9112cdb47_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZToyYTFmMDllNTdhM2Y0NzBkYjNiMjBiZDE1NGZkZGQ5MS90YWJsZXJhbmdlOjJhMWYwOWU1N2EzZjQ3MGRiM2IyMGJkMTU0ZmRkZDkxXzItMi0xLTEtMjQ1NDc3_9c09de53-83cf-41e1-9448-e17ff0033d6c"
      unitRef="number">1.01542</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i9778d074309d474e95d5496bad2d2441_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZToyYTFmMDllNTdhM2Y0NzBkYjNiMjBiZDE1NGZkZGQ5MS90YWJsZXJhbmdlOjJhMWYwOWU1N2EzZjQ3MGRiM2IyMGJkMTU0ZmRkZDkxXzMtMi0xLTEtMjQ1NDc3_2eb455b2-e1e0-49c1-b03d-91d7a5ada72d"
      unitRef="number">1.00771</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i21773a5ded4f4f4a8e0e3fdcbb5ae70d_D20201001-20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZToyYTFmMDllNTdhM2Y0NzBkYjNiMjBiZDE1NGZkZGQ5MS90YWJsZXJhbmdlOjJhMWYwOWU1N2EzZjQ3MGRiM2IyMGJkMTU0ZmRkZDkxXzQtMi0xLTEtMjQ1NDc3_b2ca5c1f-e7a2-4e2a-9704-f3bfc124eb70"
      unitRef="number">1.00000</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LongTermDebt
      contextRef="if575f492f4ab49a593a29cb5970ee78a_I20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTY4NjY_3958510a-bfb9-42fe-a332-2ec1c2c389f9"
      unitRef="usd">700000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i387c5b799dc94ed79c28d16aa0afe0a1_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTg0NzQ_dda74b7a-8992-47e9-9a37-d513bd7e2d16"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="idb7fb37acad541dd9f14a7d2fa29fe10_D20201101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTcxMjM_32e4a6ef-63b9-4be5-9f7c-6f19d54673dc"
      unitRef="usd">300000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if575f492f4ab49a593a29cb5970ee78a_I20201130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90ZXh0cmVnaW9uOjk5NTFjODQyMDU2YjQ3ZTQ5NDZjOGNhOTdiNWEzNTZhXzY1OTcwNjk3OTczMTU_24eda0cf-d319-46ae-9c3e-acc516ac916b"
      unitRef="number">0.058</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i29770414195047bdb212e4ecdc100bdd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItMS0xLTEtMjQ1NDc3_3b17965e-fbc9-4818-a7ef-70c8161e8b9e"
      unitRef="usd">28000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4c7b1e35d601476d95db3457cce2e093_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItMy0xLTEtMjQ1NDc3_07bb9099-ccf3-4eeb-8e56-fd077426420a"
      unitRef="usd">28000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0eb949f24cfd47338d5c07380335f00f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Mzc3MTI1MzJiMzgyNDJjOWFiZmIxYjQ4ZmM5MGQ2NDlfNA_302704f4-c7a0-4143-81f0-a0fc10d81e0c"
      unitRef="number">0.061</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i892f9d840d2347f2ac10417c21a2ea1c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Mzc3MTI1MzJiMzgyNDJjOWFiZmIxYjQ4ZmM5MGQ2NDlfNA_da0a4bd1-ae04-4de5-b39e-721c16e5cc90"
      unitRef="number">0.061</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie09d6f9c686d4f06bc4e1d29051b98d0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Mzc3MTI1MzJiMzgyNDJjOWFiZmIxYjQ4ZmM5MGQ2NDlfMTA_1290045e-e3a3-4e2e-941e-bbfce828c459"
      unitRef="number">0.112</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic74b27f5ff584f4dae66883c596ca93e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzItNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246Mzc3MTI1MzJiMzgyNDJjOWFiZmIxYjQ4ZmM5MGQ2NDlfMTA_d24c6582-dd9b-4382-99ad-1a4645224402"
      unitRef="number">0.112</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i30931627be4f4491b0b2e533a3d8199d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtMS0xLTEtMjQ1NDc3_c6fac51e-a736-4c9b-bbfe-692b130df6af"
      unitRef="usd">20700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i11699d607063435a811357201af64e8c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtMy0xLTEtMjQ1NDc3_c2579399-4952-4825-acd1-03f421080c36"
      unitRef="usd">11000000.0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i51dea7b95c6d4aba83ad9fa892757146_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZTQ1YTdmNGY3NmRhNGE4NmEzMmYzMDk5NTVhYTAzOTRfNTQ5NzU1ODEzODk4_ac1d9e5c-b249-4560-a0bf-a441d2ffa9cb"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia822ef25d22e4d039b50ff40539e575a_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZTQ1YTdmNGY3NmRhNGE4NmEzMmYzMDk5NTVhYTAzOTRfNTQ5NzU1ODEzODk4_dffc51a6-92a6-4049-9f31-1bd045e4fa67"
      unitRef="number">0.050</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie7a2877ba40e444e80b196cf51e8d9c3_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZTQ1YTdmNGY3NmRhNGE4NmEzMmYzMDk5NTVhYTAzOTRfNA_555f96b1-1bb6-46f6-8f50-7162e04978dd"
      unitRef="number">0.055</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6a6fcce63a9548dea0e3f5364203fa60_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzQtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZTQ1YTdmNGY3NmRhNGE4NmEzMmYzMDk5NTVhYTAzOTRfNA_f799fe75-650c-4fe2-bdbd-dab1b526cf84"
      unitRef="number">0.055</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i2e6abe4bfb1a460d92a2904f739f25a2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzUtMS0xLTEtMjQ1NDc3_07b11b7e-88a8-4563-b6a8-a7cb28dfde1f"
      unitRef="usd">4400000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6600f773078e47c292dfad7ad647a4fd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzUtMy0xLTEtMjQ1NDc3_610d71aa-ac26-4399-8cd6-9306c4a04537"
      unitRef="usd">8700000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0f2a545ddce6494e94a8dce995b13eb9_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzUtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzVlMzc5MjdlYWZlNGM3ZGE3ZGVhZjhhMDg4NzkwNjBfNA_0394d954-6c02-4fa6-bce8-823e52fbdd98"
      unitRef="number">0.028</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i98ec873af9eb4796a1d331828822e615_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzUtNS0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzVlMzc5MjdlYWZlNGM3ZGE3ZGVhZjhhMDg4NzkwNjBfNA_d16f23dd-369a-4448-837a-33804d06ad66"
      unitRef="number">0.028</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i44f0c6fe1d3d4acabec50bcd4c8268f6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzYtMS0xLTEtMjQ1NDc3_434c4915-b06d-46a8-9fc4-425609816919"
      unitRef="usd">53100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i848b097591424c609108802124923a5e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzEvZnJhZzo5OTUxYzg0MjA1NmI0N2U0OTQ2YzhjYTk3YjVhMzU2YS90YWJsZTo0NWRiZWZiNGJlNWU0N2JiYjcyNWUwNjliYmJkOGI5ZC90YWJsZXJhbmdlOjQ1ZGJlZmI0YmU1ZTQ3YmJiNzI1ZTA2OWJiYmQ4YjlkXzYtMy0xLTEtMjQ1NDc3_6a330084-17a5-4d47-802d-88a47d53ac4b"
      unitRef="usd">47700000</us-gaap:LongTermDebt>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzIzMzU_41b59719-da32-48eb-b03d-bfacb9ea7840">Self-Insured Risks:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We insure a substantial portion of our professional liability, general liability, and workers&#x2019; compensation risks through a self-insured retention program (&#x201c;SIR&#x201d;) underwritten by our consolidated wholly owned offshore captive insurance subsidiary, HCS, Ltd., which we fund via regularly scheduled premium payments. HCS is an insurance company licensed by the Cayman Island Monetary Authority. We use HCS to fund the first $45 million for annual aggregate losses associated with general and professional liability risks. Workers&#x2019; compensation exposures are capped on a per claim basis. Risks in excess of specified limits per claim and in excess of our aggregate SIR amount are covered by unrelated commercial carriers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in our self-insurance reserves (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for the provision of current year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease for the provision of prior year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses related to discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to current year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to prior year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022 and 2021, $46.6 million and $45.6 million, respectively, of these reserves are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these risks are based primarily upon actuarially determined estimates. These reserves represent the unpaid portion of the estimated ultimate cost of all reported and unreported losses incurred through the respective consolidated balance sheet dates. The reserves are estimated using individual case-basis valuations and actuarial analyses. Those estimates are subject to the effects of trends in loss severity and frequency. The estimates are continually reviewed and adjustments are recorded as experience develops or new information becomes known. The changes to the estimated ultimate loss amounts are included in current operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reserves for these self-insured risks cover approximately 1,100 and 1,200 individual claims at December&#160;31, 2022 and 2021, respectively, and estimates for potential unreported claims. The time period required to resolve these claims can vary depending upon the jurisdiction, the nature, and the form of resolution of the claims. The estimation of the timing of payments beyond a year can vary significantly. Although considerable variability is inherent in reserve estimates, management believes the reserves for losses and loss expenses are adequate; however, there can be no assurance the ultimate liability will not exceed management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <ehc:MaximumSelfInsuredAmountFirstLayerOfRisk
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzQzMg_bff0a8b9-69c6-47bd-a0d9-bd757547d665"
      unitRef="usd">45000000</ehc:MaximumSelfInsuredAmountFirstLayerOfRisk>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzIzNDE_c396056d-1cb7-4fb6-8f64-a0ea3c156645">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in our self-insurance reserves (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.448%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Reinsurance receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase for the provision of current year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease for the provision of prior year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses related to discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to current year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments related to prior year claims&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Reinsurance receivables&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEtMS0xLTEtMjQ1NDc3_6a1adfd2-05f5-4c38-9ed0-4c8f75f26980"
      unitRef="usd">169400000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEtMy0xLTEtMjQ1NDc3_33eb245a-999c-4fc0-b351-3ef391bd092c"
      unitRef="usd">165200000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEtNS0xLTEtMjQ1NDc3_126ad5b3-a920-42b4-bfdc-c9b46276fd3a"
      unitRef="usd">157300000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzItMS0xLTEtMjQ1NDc3_dd30c80f-fcfe-4994-878a-6b2a19d67f1f"
      unitRef="usd">30000000.0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzItMy0xLTEtMjQ1NDc3_3dabd534-04d4-497e-b546-8508c2bb15a6"
      unitRef="usd">28300000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzItNS0xLTEtMjQ1NDc3_8ea314c4-7122-4030-83d6-93de0b8c623f"
      unitRef="usd">26400000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzMtMS0xLTEtMjQ1NDc3_c638a8e3-7c55-4870-840b-051c6a935e3e"
      unitRef="usd">139400000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzMtMy0xLTEtMjQ1NDc3_21b95372-ac0f-441a-b32f-0a0f0c83f0a1"
      unitRef="usd">136900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i8ceed624f0604d68bc0ac784aa99fe4b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzMtNS0xLTEtMjQ1NDc3_e2f9868c-baa0-4661-927f-ecaf8a6ff713"
      unitRef="usd">130900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzQtMS0xLTEtMjQ1NDc3_3fcad5a0-0701-4ca4-bb10-72f52b25fe42"
      unitRef="usd">50500000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzQtMy0xLTEtMjQ1NDc3_7d1f5000-1751-44b5-8ee1-ee753d2f5bb8"
      unitRef="usd">46900000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzQtNS0xLTEtMjQ1NDc3_b7260e8d-8ba6-44e4-a7fd-68f661f5edf0"
      unitRef="usd">52500000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzUtMS0xLTEtMjQ1NDc3_a035dcc0-6945-4e82-9141-4eaa37e1d9a1"
      unitRef="usd">8200000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzUtMy0xLTEtMjQ1NDc3_d2261c0b-1289-4103-9770-0e1c9b35fc4c"
      unitRef="usd">6800000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzUtNS0xLTEtMjQ1NDc3_a634f122-3dbf-4b42-ab9e-45b3afc96f92"
      unitRef="usd">15000000.0</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzctMS0xLTEtMjQ1NDc3_3d2c1848-6466-492a-a421-5e208e2b469a"
      unitRef="usd">0</ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations>
    <ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzctMy0xLTEtMjQ1NDc3_8dc63a02-f03a-43e6-ac5f-3c9837880dfa"
      unitRef="usd">200000</ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations>
    <ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzctNS0xLTEtMjQ1NDc3_348e2742-b98f-4be3-afbb-3d4fccb635ba"
      unitRef="usd">200000</ehc:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzgtMS0xLTEtMjQ1NDc3_3c13b24a-5a55-460b-966c-df5fab7456f3"
      unitRef="usd">7100000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzgtMy0xLTEtMjQ1NDc3_d523d12c-e726-415e-8651-6716e9921502"
      unitRef="usd">7000000.0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzgtNS0xLTEtMjQ1NDc3_e0abf2df-5f45-44c8-b4d7-f323c8fa9f82"
      unitRef="usd">8400000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzktMS0xLTEtMjQ1NDc3_a7eab3d1-143c-4f22-afcf-e9eb12ffd97f"
      unitRef="usd">31800000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzktMy0xLTEtMjQ1NDc3_e5eb5203-f4c2-4799-8c2a-76c24c558f12"
      unitRef="usd">30400000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzktNS0xLTEtMjQ1NDc3_3cecdb28-a95d-4889-af02-5b6fe7c7ae4f"
      unitRef="usd">22900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzExLTEtMS0xLTI0NTQ3Nw_58ff2746-482e-4b24-8caa-1f371f08b2a4"
      unitRef="usd">142800000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzExLTMtMS0xLTI0NTQ3Nw_61984058-5674-435b-9845-44304f2ca035"
      unitRef="usd">139400000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzExLTUtMS0xLTI0NTQ3Nw_9925ae45-f802-480a-8bd1-435fd939a528"
      unitRef="usd">136900000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEyLTEtMS0xLTI0NTQ3Nw_684775ef-a6ae-4606-ac22-a79ed01e26d9"
      unitRef="usd">32300000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEyLTMtMS0xLTI0NTQ3Nw_24498665-2afd-46d1-8f0f-c65cf9c0ad47"
      unitRef="usd">30000000.0</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEyLTUtMS0xLTI0NTQ3Nw_27d1ab09-7e15-40e2-9e6b-b6f7a36e03b0"
      unitRef="usd">28300000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEzLTEtMS0xLTI0NTQ3Nw_f4afeb28-77c8-4fcf-8922-7454a987f47b"
      unitRef="usd">175100000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEzLTMtMS0xLTI0NTQ3Nw_5bc4ef81-1f3d-4c47-9378-6291a196b329"
      unitRef="usd">169400000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i17814712636d499cbd8aa753ae7fd05e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90YWJsZTpmOWMwZDRjMDNhNjY0MDUzODhiN2ZjYjA0YjBlZmY5ZS90YWJsZXJhbmdlOmY5YzBkNGMwM2E2NjQwNTM4OGI3ZmNiMDRiMGVmZjllXzEzLTUtMS0xLTI0NTQ3Nw_a892cc8f-caee-4f4d-8dbd-fe21285a7d4a"
      unitRef="usd">165200000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SelfInsuranceReserveCurrent
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzkyNA_0b0b22c0-9a2a-43c2-9b34-88f5d77968b9"
      unitRef="usd">46600000</us-gaap:SelfInsuranceReserveCurrent>
    <us-gaap:SelfInsuranceReserveCurrent
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzkzMQ_a47a8a1b-13d1-4727-866d-3cca3a05ee7c"
      unitRef="usd">45600000</us-gaap:SelfInsuranceReserveCurrent>
    <ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzE3NjY_2a285e5b-fceb-4f01-bb40-e7b399178ba9"
      unitRef="claim">1100</ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves>
    <ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yNzcvZnJhZzoyZGQ3OWY3NjdjYzQ0OTdlOTU4ZjM3YmU2N2MzNjYwMi90ZXh0cmVnaW9uOjJkZDc5Zjc2N2NjNDQ5N2U5NThmMzdiZTY3YzM2NjAyXzE3NzM_68784366-9a4e-4593-8bc6-c6a77de3a5af"
      unitRef="claim">1200</ehc:NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzQyOTM_c82e5ac6-f59a-4605-83f0-4ae382fe4de1">Redeemable Noncontrolling Interests:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution to joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase of redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spin off of Enhabit, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the net income attributable to nonredeemable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the shareholders&#x2019; equity section of the consolidated balance sheets, and the net income attributable to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the mezzanine section of the consolidated balance sheets, to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; presented in the consolidated statements of comprehensive income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to nonredeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2014, we acquired 83.3% of our former home health and hospice business when we purchased EHHI Holdings, Inc. (&#x201c;EHHI&#x201d;). In the acquisition, we acquired all of the issued and outstanding equity interests of EHHI, other than equity interests contributed to Encompass Health Home Health Holdings, Inc. (&#x201c;Holdings&#x201d;), a subsidiary of Encompass Health and an indirect parent of EHHI, by certain sellers in exchange for shares of common stock of Holdings. Those sellers were members of EHHI management, and they contributed a portion of their shares of common stock of EHHI, valued at approximately $64 million on the acquisition date, in exchange for approximately 16.7% of the outstanding shares of common stock of Holdings. At any time after December 31, 2017, each management investor had the right (but not the obligation) to have his or her shares of Holdings stock repurchased by Encompass Health for a cash purchase price per share equal to the fair value. In February 2018, each management investor exercised the right to sell one-third of his or her shares of Holdings stock to Encompass Health, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. On February&#160;21, 2018, Encompass Health settled the acquisition of those shares upon payment of approximately $65 million in cash. In July 2019, we received additional exercise notices, representing approximately 5.6% of the outstanding shares of the common stock of Holdings. In September&#160;2019, Encompass Health settled the acquisition of those shares upon payment of approximately $163 million in cash. In January 2020, we received additional exercise notices, representing approximately 4.3% of the outstanding shares of the common stock of Holdings. On February 18, 2020, Encompass Health settled the acquisition of those shares upon payment of approximately $162 million in cash. Upon settlement of these exercises, approximately $46 million of the shares of Holdings held by two management investors remained outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2020, Encompass Health entered into exchange agreements (each, an &#x201c;Exchange Agreement&#x201d;) with these two management investors, pursuant to which they had the right to exchange all of the remaining shares of Holdings held by them for shares of common stock of Encompass Health (the &#x201c;EHC Shares&#x201d;). Each of the Exchange Agreements provided that the management investor must deliver a written exchange notice (an &#x201c;Exchange Notice&#x201d;) to Encompass Health in order to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;exchange his or her remaining shares of Holdings for EHC Shares. Each Exchange Agreement further provided that the number of EHC Shares to be delivered to the management investor was to be determined by dividing the fair value of the shares of Holdings held by the management investor on the date of the Exchange Agreement by the last reported sales price of Encompass Health&#x2019;s common stock on the New York Stock Exchange (the &#x201c;NYSE&#x201d;) on the date of delivery of the Exchange Notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 20, 2020, Encompass Health received an Exchange Notice from each of the management investors.  Based on the last sales price of Encompass Health&#x2019;s common stock on the NYSE on February 20, 2020, Encompass Health delivered an aggregate 560,957 EHC Shares to the management investors. The total number of EHC Shares issued pursuant to the exchange agreements on March 6, 2020 represented less than 0.6% of the outstanding shares of Encompass Health common stock. Encompass Health issued the EHC Shares from its treasury shares.&lt;/span&gt;&lt;/div&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzQyNzU_13c55982-67f8-4bb7-807c-6663a5a819e8">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the activity related to our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distributions declared&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution to joint ventures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchase of redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exchange transaction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spin off of Enhabit, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RedeemableNoncontrollingInterestTableTextBlock>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i6efebeb8c8db4120ab1f6ddec403e0b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzItMS0xLTEtMjQ1NDc3_4d58ab1a-26c2-404f-b55b-122489fb7776"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="if6727a883db744548c7e8035f88a00e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzItMy0xLTEtMjQ1NDc3_17d06199-502e-410c-9c2f-1a6d674db6d7"
      unitRef="usd">31600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="ib815d2a675ad43128d86aa58ebcb4caf_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzItNS0xLTEtMjQ1NDc3_9223ade1-4183-40bd-856d-2af80d831bd5"
      unitRef="usd">239600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzQtMS0xLTEtMjQ1NDc3_8379ebbc-a72d-41a9-b2b1-f16c77153cae"
      unitRef="usd">7200000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzQtMy0xLTEtMjQ1NDc3_e888979d-fac9-4531-a3fb-9f28bc47dad4"
      unitRef="usd">9000000.0</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzQtNS0xLTEtMjQ1NDc3_98c50531-86cb-4902-b086-c0f428fac17a"
      unitRef="usd">7400000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzUtMS0xLTEtMjQ1NDc3_c77d4b41-a087-4daf-870c-5f7e7a6c6d97"
      unitRef="usd">5300000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzUtMy0xLTEtMjQ1NDc3_dafb4502-90a9-4a0e-9315-273d946e362d"
      unitRef="usd">8000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzUtNS0xLTEtMjQ1NDc3_4fe2fcc2-6342-418d-b794-790a974abe5c"
      unitRef="usd">8500000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <ehc:Contributiontojointventure
      contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzYtMS0xLTEtMjQ1NDc3_d80e4aa7-3df9-435d-b898-1dc757e81520"
      unitRef="usd">0</ehc:Contributiontojointventure>
    <ehc:Contributiontojointventure
      contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzYtMy0xLTEtMjQ1NDc3_2091c2bb-028e-48ac-afa1-b4f2ff8edaec"
      unitRef="usd">0</ehc:Contributiontojointventure>
    <ehc:Contributiontojointventure
      contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzYtNS0xLTEtMjQ1NDc3_f213090d-8c68-4c02-a16a-d68e9a1413f2"
      unitRef="usd">3100000</ehc:Contributiontojointventure>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzgtMS0xLTEtMjQ1NDc3_2c3f4a32-5f8a-43fd-a5ed-8718e7270743"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzgtMy0xLTEtMjQ1NDc3_c03fb8b2-2a97-4998-b652-798515caf99b"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzgtNS0xLTEtMjQ1NDc3_1386ade8-6947-49fc-90e3-e2f4a2e5202c"
      unitRef="usd">162300000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <ehc:NoncontrollingInterestExchangeTransaction
      contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzktMS0xLTEtMjQ1NDc3_b68b803a-b8f1-49d3-b8e6-4a9fd3b4f97c"
      unitRef="usd">0</ehc:NoncontrollingInterestExchangeTransaction>
    <ehc:NoncontrollingInterestExchangeTransaction
      contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzktMy0xLTEtMjQ1NDc3_5508d374-4d30-4eb9-9de8-0c9743aab20e"
      unitRef="usd">0</ehc:NoncontrollingInterestExchangeTransaction>
    <ehc:NoncontrollingInterestExchangeTransaction
      contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzktNS0xLTEtMjQ1NDc3_497efbf6-be8d-4e10-89ed-1b6fff568c01"
      unitRef="usd">46300000</ehc:NoncontrollingInterestExchangeTransaction>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEwLTEtMS0xLTI0NTQ3Nw_d0cdf417-908d-422e-83aa-ce419d65ff29"
      unitRef="usd">-3400000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEwLTMtMS0xLTI0NTQ3Nw_25cc5502-1bf4-4e2f-95d6-503bc11b55a8"
      unitRef="usd">4500000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <us-gaap:MinorityInterestChangeInRedemptionValue
      contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEwLTUtMS0xLTI0NTQ3Nw_1e7a385f-81b2-41e1-baf0-b9aeb7c644f0"
      unitRef="usd">-1400000</us-gaap:MinorityInterestChangeInRedemptionValue>
    <ehc:NoncontrollingInterestOtherAdjustment
      contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzExLTEtMS0xLTI0NTQ3Nw_f112bb3a-76bc-43ae-9f5d-7cf7ca7866ed"
      unitRef="usd">100000</ehc:NoncontrollingInterestOtherAdjustment>
    <ehc:NoncontrollingInterestOtherAdjustment
      contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzExLTMtMS0xLTI0NTQ3Nw_dfcf6238-7450-458c-a8b4-c596006e28bf"
      unitRef="usd">5100000</ehc:NoncontrollingInterestOtherAdjustment>
    <ehc:NoncontrollingInterestOtherAdjustment
      contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzExLTUtMS0xLTI0NTQ3Nw_a74ce440-6579-499a-acc9-98b3943ff6b4"
      unitRef="usd">0</ehc:NoncontrollingInterestOtherAdjustment>
    <ehc:NoncontrollingInterestSpinOff
      contextRef="i974027d6c99a416ea1da95227e3df59f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTEtMS0xLTI2ODY5MQ_7d6067df-fadd-4868-83e2-f9381d367715"
      unitRef="usd">5200000</ehc:NoncontrollingInterestSpinOff>
    <ehc:NoncontrollingInterestSpinOff
      contextRef="iaa34b62099fa49dd8b8a725e38a3a8d5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTMtMS0xLTI2ODY5MQ_7bfa8669-86cd-4d6e-bc8b-eb668ede8773"
      unitRef="usd">0</ehc:NoncontrollingInterestSpinOff>
    <ehc:NoncontrollingInterestSpinOff
      contextRef="i48211345b0da4e13baef5a88d454bd9c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTUtMS0xLTI2ODY5MQ_1377fce5-3937-4494-9276-e5873201ca69"
      unitRef="usd">0</ehc:NoncontrollingInterestSpinOff>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i7ded9604e5234c4eb9354741e47453eb_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTEtMS0xLTI0NTQ3Nw_0c0dc071-4f78-41a3-a857-f79c67efa479"
      unitRef="usd">35600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i6efebeb8c8db4120ab1f6ddec403e0b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTMtMS0xLTI0NTQ3Nw_bf91dea9-71ec-4612-9ba4-3265ba13f384"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="if6727a883db744548c7e8035f88a00e4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTo2ODJjYzkxMGNjODQ0YjUzYTY2MDY4ZDk0ZGZkNzZjOS90YWJsZXJhbmdlOjY4MmNjOTEwY2M4NDRiNTNhNjYwNjhkOTRkZmQ3NmM5XzEyLTUtMS0xLTI0NTQ3Nw_92be21ed-b745-4cb0-ad94-def8674633a3"
      unitRef="usd">31600000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzQyODI_b59cfce5-87e3-41a0-8081-35396ed10cad">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the net income attributable to nonredeemable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the shareholders&#x2019; equity section of the consolidated balance sheets, and the net income attributable to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as recorded in the mezzanine section of the consolidated balance sheets, to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; presented in the consolidated statements of comprehensive income (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to nonredeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzItMS0xLTEtMjQ1NDc3_5c61ff92-21af-4aaa-a41b-2c1ec456f749"
      unitRef="usd">87700000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzItMy0xLTEtMjQ1NDc3_8242186a-bd12-4adf-b7bf-829142190d20"
      unitRef="usd">96000000.0</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzItNS0xLTEtMjQ1NDc3_2680451f-ae6a-4311-aed6-77cc74a7b6b1"
      unitRef="usd">77200000</us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzMtMS0xLTEtMjQ1NDc3_0529851d-898f-4442-94b1-78aa6fffaff1"
      unitRef="usd">7200000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzMtMy0xLTEtMjQ1NDc3_aecd0558-4224-4cfd-ac3a-d0e81c24d0f2"
      unitRef="usd">9000000.0</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzMtNS0xLTEtMjQ1NDc3_5c004676-34ed-4b07-8cf2-0b755bcd8817"
      unitRef="usd">7400000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzQtMS0xLTEtMjQ1NDc3_41e6cc30-9e54-458e-bded-bb7d3827db31"
      unitRef="usd">94900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzQtMy0xLTEtMjQ1NDc3_a98bb8e9-29fc-4c37-82ba-ec9f921c5952"
      unitRef="usd">105000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90YWJsZTphN2ViMTdjMGFkMWM0Y2QwYmVlMDc0YmIxYTRhZjZkYy90YWJsZXJhbmdlOmE3ZWIxN2MwYWQxYzRjZDBiZWUwNzRiYjFhNGFmNmRjXzQtNS0xLTEtMjQ1NDc3_a23d6521-cbac-430f-a674-ee0560aee6a8"
      unitRef="usd">84600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent
      contextRef="i41e57dc8508f486cb65383ee270622a7_I20141231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzYyNw_78e75af6-a0c1-4560-9508-3735cdeb6604"
      unitRef="number">0.833</ehc:RedeemableNoncontrollingInterestEquityAcquiredPercent>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="i41e57dc8508f486cb65383ee270622a7_I20141231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzExOTA_e5b9d3e2-256e-4ee2-bc1e-73bc8143b9d8"
      unitRef="usd">64000000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <ehc:SubsidiarysCommonStockHeldBySubsidiarysManagementPercent
      contextRef="i41e57dc8508f486cb65383ee270622a7_I20141231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzEyNDg_a2c02626-a63b-4097-ad2d-81431779aa8d"
      unitRef="number">0.167</ehc:SubsidiarysCommonStockHeldBySubsidiarysManagementPercent>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="i71b339e9a3244030a7c4194e39cb008c_D20180201-20180228"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzE3MTI_b1343962-006e-4d55-85c0-db22fc9a586b"
      unitRef="number">0.056</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ia7de87991e514ae5b6fea1833e9ded6f_D20180221-20180221"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzE4ODM_5192b25c-e125-41a6-a23d-788de4c94d3f"
      unitRef="usd">65000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="i0817bf7784b548a186c313fe446af8a6_D20190701-20190731"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzE5Nzc_7327491c-f59e-4f45-b18c-4b87e220504b"
      unitRef="number">0.056</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="i1cf81650d421400f8d1135d296737e38_D20190901-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzIxNDU_712b6b95-3448-4e81-9215-fa7ee461de4c"
      unitRef="usd">163000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent
      contextRef="i2b1d1c428d764c88a5c1812e2a04cf24_D20200101-20200131"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzIzNjc_8935296a-6c92-4b1d-8da0-2eaeb0c6a086"
      unitRef="number">0.043</ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="ib793c3abc8744e3b9fffcc21e558e086_D20200218-20200218"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzI1Mzg_fe150b50-d1bc-4b49-a4e3-2a339f5b6b7e"
      unitRef="usd">162000000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue
      contextRef="idd77fca6ac214fcd9bf9357721bb2a92_I20200218"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzI2MDA_8f401c26-b555-4a7c-b203-174d1b235401"
      unitRef="usd">46000000</us-gaap:RedeemableNoncontrollingInterestEquityOtherFairValue>
    <ehc:NumberOfManagementInvestorsOutstanding
      contextRef="ia001d84255a44455b5a46942a930f42b_I20200218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzM4NDgyOTA3MDE5Mzg_fe7c5f8e-bdc7-43ee-8a7e-439ba6d9fe46"
      unitRef="investor">2</ehc:NumberOfManagementInvestorsOutstanding>
    <ehc:NumberOfManagementInvestorsOutstanding
      contextRef="idac0372aea0347c49bdba860190d96f3_I20200220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzM4NDgyOTA3MDE5NDY_ff6780da-6c0f-4531-9659-59bde4257ef4"
      unitRef="investor">2</ehc:NumberOfManagementInvestorsOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="idac0372aea0347c49bdba860190d96f3_I20200220"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzM4ODg_50d969a6-4221-4747-a260-3cc5b0ddf770"
      unitRef="shares">560957</us-gaap:TemporaryEquitySharesIssued>
    <ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages
      contextRef="ib2779168f690432cac5b38f9bea43674_I20200306"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODAvZnJhZzpkZTIzZDAyNzlmZjI0ZmZiYTk5NDM4MGFkZjBlMDRiNi90ZXh0cmVnaW9uOmRlMjNkMDI3OWZmMjRmZmJhOTk0MzgwYWRmMGUwNGI2XzQwNDQ_e014e51b-a9aa-46cd-89cf-4471e28a7492"
      unitRef="number">0.006</ehc:TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzIwOTE_ea1c3b4b-1a04-4f3b-9534-95cf90d99a33">Fair Value Measurements:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;As of December&#160;31, 2022, $30.9 million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and $79.1 million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet. As of December&#160;31, 2021, $82.2 million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are assets and liabilities that are not required to be measured at fair value on a recurring basis. However, these assets may be recorded at fair value as a result of impairment charges or other adjustments made to the carrying value of the applicable assets. During the years ended December 31, 2022, 2021, and 2020, we did not record any material gains or losses related to these assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Fair Value Measurements,&#x201d; the carrying value equals fair value for our financial instruments that are not included in the table below and are classified as current in our consolidated balance sheets. The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial commitments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair values for our long-term debt and financial commitments are determined using inputs, including quoted prices in nonactive markets, that are observable either directly or indirectly, or &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;inputs within the fair value hierarchy. See Note&#160;1, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Fair Value Measurements&#x201d; and &#x201c;Redeemable Noncontrolling Interests.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzIwOTk_50ca6ddf-f4ef-4d6d-adb3-2b8924d66c94">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets and liabilities that are measured at fair value on a recurring basis are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation Technique &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;M&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;I&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;The three valuation techniques are: market approach&#160;(M), cost approach&#160;(C), and income approach&#160;(I).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt"&gt;As of December&#160;31, 2022, $30.9 million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; and $79.1 million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet. As of December&#160;31, 2021, $82.2 million are included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other long-term assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i77780a6142904e59b58e560a56e1f9e4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzMtMi0xLTEtMjQ1NDc3_4528d4c6-7841-4df8-b3fb-f4cc908baf5a"
      unitRef="usd">110000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i258d06e3e65443fb8a893ee44f342300_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzMtNC0xLTEtMjQ1NDc3_1db0e187-00ee-45bc-be9f-8eb81a83d66f"
      unitRef="usd">3700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib83e1a16991f4a27add600a1fd239b44_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzMtNi0xLTEtMjQ1NDc3_d65183fe-ecf4-4d91-b261-d415574ae5cb"
      unitRef="usd">106300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id8dd211c83ae4af8ba738a29bef7f269_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzMtOC0xLTEtMjQ1NDc3_8fb1ad40-e3e0-4fa7-97be-526996a92029"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i77780a6142904e59b58e560a56e1f9e4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzUtMi0xLTEtMjQ1NDc3_e005c3b7-a042-485a-af2c-13e34a4a9929"
      unitRef="usd">35600000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i258d06e3e65443fb8a893ee44f342300_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzUtNC0xLTEtMjQ1NDc3_cc0c593f-73a4-49cd-bb3b-d2c9efc041f9"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ib83e1a16991f4a27add600a1fd239b44_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzUtNi0xLTEtMjQ1NDc3_1c46cbe6-15da-4b82-8ec8-cde74c66555e"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="id8dd211c83ae4af8ba738a29bef7f269_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzUtOC0xLTEtMjQ1NDc3_fb51416e-7c42-414b-85c2-3cf4242a2b50"
      unitRef="usd">35600000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4e6598efdf814f82b2b3ac56c39d31b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzgtMi0xLTEtMjQ1NDc3_5ce39637-9e4b-488d-9909-fbfaa0c63b46"
      unitRef="usd">82200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6b15fae4966a432d8dd85f41b1846e97_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzgtNC0xLTEtMjQ1NDc3_53152db7-6ac5-41b5-9a2b-e5f36a2f1d58"
      unitRef="usd">4100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibe76ff36e61642c69f074e2796820502_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzgtNi0xLTEtMjQ1NDc3_b8458889-45c6-4e68-8069-de5c67a6066f"
      unitRef="usd">78100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ica49f9c6106c4bff9919ea82c86a1d10_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzgtOC0xLTEtMjQ1NDc3_b7460170-db30-46d8-bd4d-ae209154c2dd"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i4e6598efdf814f82b2b3ac56c39d31b8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzEwLTItMS0xLTI0NTQ3Nw_db9219c1-fd90-4996-acdf-c33b6fa9b5e3"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="i6b15fae4966a432d8dd85f41b1846e97_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzEwLTQtMS0xLTI0NTQ3Nw_2e266394-00e2-427e-90d5-a80103179322"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ibe76ff36e61642c69f074e2796820502_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzEwLTYtMS0xLTI0NTQ3Nw_25b7b49d-84df-4894-940b-3a9b2bcc9e61"
      unitRef="usd">0</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:RedeemableNoncontrollingInterestEquityFairValue
      contextRef="ica49f9c6106c4bff9919ea82c86a1d10_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZToxZTQwYWU3MzZjMGQ0ZmQ5ODZkMTA0MTRhY2ZhOTNmOC90YWJsZXJhbmdlOjFlNDBhZTczNmMwZDRmZDk4NmQxMDQxNGFjZmE5M2Y4XzEwLTgtMS0xLTI0NTQ3Nw_950479ba-3f71-43f8-8de0-bbfd9817ddc9"
      unitRef="usd">42200000</us-gaap:RedeemableNoncontrollingInterestEquityFairValue>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i35e875418cae4ed98afcdddf4b6e3679_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzU0OTc1NTgxNjIxMg_6ac818c8-e5bc-46e3-b606-4b58ade62af5"
      unitRef="usd">30900000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ic5560a022b19466c9dc3b25d0a6709d2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzU0OTc1NTgxNjI3OQ_76168c25-6dc6-4567-b1e7-5bba220983b3"
      unitRef="usd">79100000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i0cd9b95664334eee863511a1352b258d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzU0OTc1NTgxNjQ0MQ_df8d2143-ee08-444f-a754-6e298a168fd0"
      unitRef="usd">82200000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90ZXh0cmVnaW9uOjg3Mzk4NzE1NTc4NDRjNjViZjE0ODM5N2Q2OTA4ZDk3XzIwODM_783ed431-e86a-468c-ace8-0f556d396e2f">The carrying amounts and estimated fair values for our other financial instruments are presented in the following table (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advances under revolving credit facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.125% Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.75% Senior Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Senior Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;786.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;823.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Senior Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;703.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.625% Senior Notes due 2031&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;393.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;407.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financial commitments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Letters of credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="ifc353f9b60ef469f9fb57e8eb5392312_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzMtMS0xLTEtMjQ1NDc3_82f7036a-95a0-471c-95c2-c6dcae8aa789"
      unitRef="usd">55000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i075bc7bcf82a49f8b9f7a4533e89c0a6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzMtMy0xLTEtMjQ1NDc3_3ae59f75-7885-4b39-be6f-49659cde5aef"
      unitRef="usd">55000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="if11a95d42a454584afeb7e3be1dd5b60_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzMtNS0xLTEtMjQ1NDc3_edb18243-cef9-4f92-a8cf-ea3319e6b870"
      unitRef="usd">200000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i61147de300ac4b17b16c6aa30fb725e4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzMtNy0xLTEtMjQ1NDc3_56107362-27d4-47f1-bbe5-3fe5eeac6533"
      unitRef="usd">200000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i7f9b5364226647f4aca43882157f6bb9_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzQtMS0xLTEtMjQ1NDc3_17fc865e-def9-4d83-b711-0a4ca171ca6a"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0ba3ea646be7400aa6041fe8bb869254_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzQtMy0xLTEtMjQ1NDc3_3337d409-674b-4e3b-9081-6cc077eb7613"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="if68164d48cd14a36908fa4523153e2b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzQtNS0xLTEtMjQ1NDc3_500775e3-80b7-4232-ab7b-8afb395af17a"
      unitRef="usd">238500000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia2fcd0acbafe46d5aee193d414a6d056_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzQtNy0xLTEtMjQ1NDc3_d83296be-bcdc-41bd-af1a-abb04a83304f"
      unitRef="usd">239600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id189cd47b8924fcbab79c4a2a77ffcd9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MzE1ZWVmNjlmYWY5NDgyNGI1OWNkMGMwNTE4OGM3MGRfNA_bfd1f1bd-8152-4131-8bbb-ce1f67f02b01"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id1214fc63dae4248a98c4032a91b2fec_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246MzE1ZWVmNjlmYWY5NDgyNGI1OWNkMGMwNTE4OGM3MGRfNA_ca544c63-0aaa-4f72-95a4-0e126ef61ddf"
      unitRef="number">0.05125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i36917653da0f4636ac433b0eefd8ca74_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtMS0xLTEtMjQ1NDc3_17812afd-0e90-4454-b45f-b5bf7b203975"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i5ba67211d13b47e7b5f944000baf621e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtMy0xLTEtMjQ1NDc3_eb6bb66c-b8bb-4435-bd9b-817fc84a405f"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="iccd0995116ad432dbf5ecfe84fb0e897_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtNS0xLTEtMjQ1NDc3_be475732-c81e-4eb2-9d7a-b8d98a1bc919"
      unitRef="usd">99600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i2062512483de43c6b98ca06b53160b5b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzUtNy0xLTEtMjQ1NDc3_316050b3-5f83-4203-b0ce-a48d07b8299e"
      unitRef="usd">100200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b519d969150438ca0a24a17a6f87ca8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzAyZjNiMThhOWNhNDU4ZDhhZjJiMTgxNmEyYTczOTRfNA_587a8921-9c37-4326-80f2-03c8348e2e0f"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i005266a587014861b4fc4bdc254e6a15_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NzAyZjNiMThhOWNhNDU4ZDhhZjJiMTgxNmEyYTczOTRfNA_9f35e6a4-ed99-46da-9667-34167c0ccd5e"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic5783a522bb14483818de81205d4ddac_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtMS0xLTEtMjQ1NDc3_d1e29541-7d58-45d4-985e-22d18035c640"
      unitRef="usd">347700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i756531406e134ef495f108a1f1d4ce85_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtMy0xLTEtMjQ1NDc3_30e0aed2-8a15-4856-8c6f-16ee49a99007"
      unitRef="usd">347700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="iffe80798844441ff9ba446bee23d99ab_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtNS0xLTEtMjQ1NDc3_14f47ae5-3bcd-4de4-8e96-5ee58fbc283b"
      unitRef="usd">347000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i288afc94975d4cd1af41f3c46445c4fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzYtNy0xLTEtMjQ1NDc3_753e9a43-5c13-4a62-a1ba-ee8bd30a7d27"
      unitRef="usd">357900000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b5a421f1a804107a53e85439af96f46_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTc1ZTBkZGRmZGM3NGZjZDk2NjVhMTgwNWJmODY2MjlfNA_6bf22234-87a3-4d99-94ff-2c620e0fa16b"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i03e2cfaa161d423e9fe9d78c1d2484d8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246YTc1ZTBkZGRmZGM3NGZjZDk2NjVhMTgwNWJmODY2MjlfNA_ec2505d6-b573-4512-8311-a0ec181aa3ac"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i88b3ef661e7d406e858898cbe882bb5d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctMS0xLTEtMjQ1NDc3_a50b2521-4eba-4a67-9dcc-d4278f79dbea"
      unitRef="usd">781800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i85c9080bb72a43d387919a7abafe465f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctMy0xLTEtMjQ1NDc3_49163ef0-5ce2-41c4-9ea4-d377427b154f"
      unitRef="usd">726700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ib131caf622a8488480693d868801dfff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctNS0xLTEtMjQ1NDc3_13e434cc-9923-437a-84ee-e5d88414bc0d"
      unitRef="usd">786800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i9bdcc92113b74a7d8e07277da2c910f9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzctNy0xLTEtMjQ1NDc3_41c8a6ee-e779-4857-8bb8-4368d2bcab88"
      unitRef="usd">823000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idca4e969d39442579877374d995f76bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZGQ0YTViMGQ2Y2FiNDNmOTgzOWI5ZDE2MGI5MWEzZjlfNA_270cfbe1-ec03-4547-8605-31bedc871c65"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i30b8ba59bd6344e7b4f1c410d89cb1c3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246ZGQ0YTViMGQ2Y2FiNDNmOTgzOWI5ZDE2MGI5MWEzZjlfNA_37344c1e-1cca-40f7-a777-6bff36254137"
      unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i800dfcdb85da4e128a32fc9b7f379889_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtMS0xLTEtMjQ1NDc3_d8cd6e86-62bd-4a4e-8966-8b23eabe6aad"
      unitRef="usd">779000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="icfd71591191f4bcaac27b10a00b10a7f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtMy0xLTEtMjQ1NDc3_bdd1832d-8fc5-47d0-ad07-f72cfba25e09"
      unitRef="usd">703700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="id5202834b56544309d7d9d8b7bee2a66_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtNS0xLTEtMjQ1NDc3_5ef95bf6-ca23-438e-aa7d-5ca15596f6b8"
      unitRef="usd">784700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i0451060ab9de4fbd8016ce801fb4c267_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzgtNy0xLTEtMjQ1NDc3_8acd70e5-0f74-4e8c-a22e-14c3ebcfbd4b"
      unitRef="usd">824000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iccae8862dd6a4bac8b4589ffb7e02bba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NWExODQyY2ViZTMxNGJjOWEzMjFkYTA5ZDEzNTA1MDZfNA_744aec19-2df4-4a6c-a72e-b3e24b967433"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i85aa556fff894922b569241055a48e29_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktMC0xLTEtMjQ1NDc3L3RleHRyZWdpb246NWExODQyY2ViZTMxNGJjOWEzMjFkYTA5ZDEzNTA1MDZfNA_edc8e297-8257-4e91-9857-34aebf99e277"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="i80f7af3cf123430084485f0646aec6b2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktMS0xLTEtMjQ1NDc3_e5c7ca40-c0cc-4c72-b827-75bdb9b9eea8"
      unitRef="usd">390600000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i69ab7e7f086a47feb8e87a9898b27939_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktMy0xLTEtMjQ1NDc3_db2dfec6-424b-419a-858b-af55f2180688"
      unitRef="usd">342200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ifc9bbdd487884af6b55d2a388ce96eb7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktNS0xLTEtMjQ1NDc3_c4b65b20-b58e-426b-a072-d82e53114e7b"
      unitRef="usd">393700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia760f2e4e675400ca0a4847d612a1345_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzktNy0xLTEtMjQ1NDc3_8b3c68d5-0810-4ce9-a830-0f5cb2e7a2a1"
      unitRef="usd">407000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i6886b561cd61484d89ba422e4d310087_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEwLTEtMS0xLTI0NTQ3Nw_5918acc4-cb4f-4404-af7e-bf1d0959f476"
      unitRef="usd">53100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i997ce4d2148b4c2195cf12ae01cec37a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEwLTMtMS0xLTI0NTQ3Nw_94eb5743-ccd7-418b-bf52-053f56dbb0e9"
      unitRef="usd">53100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i9453d359deda4140a48a46fd53784a03_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEwLTUtMS0xLTI0NTQ3Nw_16cd745b-3fed-40f9-b487-26a32b72dc0f"
      unitRef="usd">47700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ic6750e3dddd9447f96d964077958239f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEwLTctMS0xLTI0NTQ3Nw_fc9e7789-96ab-4eb6-be33-6713332097eb"
      unitRef="usd">47700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i2fd5c983c4384e469b96a6e07cd2f730_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEyLTEtMS0xLTI0NTQ3Nw_167b8ccb-c655-40c2-8499-cb397546b478"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="icb880111df2e4c1592091b713f0fe19f_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEyLTMtMS0xLTI0NTQ3Nw_a790bf28-897e-4182-8cc8-4073e600a02e"
      unitRef="usd">32700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i5494a2b14ffd4637b8184bac94f6987e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEyLTUtMS0xLTI0NTQ3Nw_df5b0110-4190-49b4-95a4-07023c41913a"
      unitRef="usd">0</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i21eb7f8154e9461399c33a8e06c6aff2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODMvZnJhZzo4NzM5ODcxNTU3ODQ0YzY1YmYxNDgzOTdkNjkwOGQ5Ny90YWJsZTo2NDE5M2JjODVlNDk0OTcxOWI0Yjk3MzU5ZGRlMWM4ZS90YWJsZXJhbmdlOjY0MTkzYmM4NWU0OTQ5NzE5YjRiOTczNTlkZGUxYzhlXzEyLTctMS0xLTI0NTQ3Nw_190268bb-ef43-46b5-a940-bb81f5ee1345"
      unitRef="usd">38200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc5MDE_c2a5142c-0f16-4cc2-8515-66a1caf9b078">Share-Based Payments:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has awarded employee stock-based compensation in the form of stock options and restricted stock awards (&#x201c;RSAs&#x201d;) under the terms of share-based incentive plans designed to align employee and executive interests to those of its stockholders. All employee stock-based compensation awarded during 2022, 2021, and 2020 was issued under the 2016 Omnibus Performance Incentive Plan, a stockholder-approved plan that reserves and provides for the grant of up to 16,860,765 shares of common stock after adjustment for the effect of the Spin Off. This plan allows for the grants of nonqualified stock options, incentive stock options, restricted stock, stock appreciate rights, performance shares, performance share units, dividend equivalents, restricted stock units (&#x201c;RSUs&#x201d;), and/or other stock-based awards. Stock-based compensation expense recognized in continuing operations was $29.2&#160;million, $29.1&#160;million, and $25.6&#160;million during 2022, 2021, and 2020, respectively. Stock-based compensation expense classified as discontinued operations was $2.5&#160;million, $3.6&#160;million, and $3.9&#160;million during 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our share-based incentive plans, officers and employees are given the right to purchase shares of Encompass Health common stock at a fixed grant price determined on the day the options are granted. The terms and conditions of the options, including exercise prices and the periods in which options are exercisable, are generally at the discretion of the compensation and human capital committee of our board of directors. However, no options are exercisable beyond ten years from the date of grant. Granted options vest over the awards&#x2019; requisite service periods, which are generally three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the options granted during the years ended December&#160;31, 2022, 2021, and 2020 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options which have no vesting restrictions and are fully transferable. In addition, the Black-Scholes option-pricing model requires the input of highly subjective assumptions, including the expected stock price volatility. We estimate our expected term through an analysis of actual, historical post-vesting exercise, cancellation, and expiration behavior by our officers and employees and projected post-vesting activity of outstanding options. We calculate volatility based on the historical volatility of our common stock over the period commensurate with the expected term of the options. The risk-free interest rate is the implied daily yield currently available on U.S. Treasury issues with a remaining term closely approximating the expected term used as the input to the Black-Scholes option-pricing model. We estimated our dividend yield based on our annual dividend rate and our stock price on the dividend payment dates. Under the Black-Scholes option-pricing model, the weighted-average grant date fair value per share of employee stock options granted during the years ended December&#160;31, 2022, 2021, and 2020 was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$17.29,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $19.21, and $15.48, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(In Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enhabit spin-off adjustment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Options activity represents historical grant values prior to the Spin Off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In connection with the Spin Off, all outstanding Encompass Health stock options (whether vested or unvested) were converted into adjusted Encompass Health awards for current and former Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized approximately $1.2&#160;million, $2.2&#160;million, and $1.5&#160;million of compensation expense related to our stock options for the years ended December 31, 2022, 2021, and 2020, respectively. As of December&#160;31, 2022, there was&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.5 million o&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of 23 months. The total intrinsic value of options exercised during the years ended December 31, 2022, 2021, and 2020 was $1.8 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $0.1 million, and $2.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RSAs granted in 2022, 2021, and 2020 included service-based awards and performance-based awards (that also included a service requirement). These awards generally vest over a three-year requisite service period. For RSAs with a service and/or performance requirement, the fair value of the RSA is determined by the closing price of our common stock on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our issued restricted stock awards is as follows (share information in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enhabit spin-off adjustment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested shares at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;RSA activity represents historical grant values prior to the Spin Off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Forfeiture activity prior to the Spin Off represents historical grant values, while the post-spin forfeitures reflects the impact of Spin Off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In connection with the Spin Off, all outstanding RSAs (whether vested or unvested) were converted into adjusted Encompass Health awards for current Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of restricted stock granted during the years ended&#160;December&#160;31, 2021 and 2020 was $73.89 and $61.81 per share, respectively. We recognized approximately $26.4&#160;million, $24.9&#160;million, and $22.0&#160;million of compensation expense related to our restricted stock awards for the years ended December 31, 2022, 2021, and 2020, respectively. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, there was $30.0 million of unrecognized compensation expense related to unvested restricted stock. This cost is expected to be recognized over a weighted-average period of 20 months. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he remaining unrecognized compensation expense for the performance-based awards may vary each reporting period based on changes in the expected achievement of performance measures. The total fair value of shares vested during the years ended December 31, 2022, 2021, and 2020 wa&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s $20.0 million, $32.6 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and $41.4 million, respectively. We accrue dividends on outstanding RSAs, which are paid upon vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nonemployee Stock-Based Compensation Plans&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022, 2021, and 2020, we provided incentives to our nonemployee members of our board of directors through the issuance of RSUs out of our share-based incentive plans. RSUs are fully vested when awarded and receive dividend equivalents in the form of additional RSUs upon the payment of a cash dividend on our common stock. During the years ended December&#160;31, 2022, 2021, and 2020, we &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued 22,469, 24,043, and 32,196 RSUs, respectively, with a fair value of $67.42, $84.83, and $65.39, respectively, per unit. We recognized approximately $1.5 million, $2.0 million, and $2.1 million, respectively, of compensation expense upon their issuance in 2022, 2021, and 2020. There was&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; no &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;unrecognized compensation related to unvested shares as of December&#160;31, 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we issued an a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dditional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,976&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 8,577, and 8,987, respectively, of RSUs as dividend equivalents. As of December&#160;31, 2022, 775,312 RSUs were ou&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tstanding. In addition to the above, we issued 130,406 additional RSUs to current and former members of our board of directors in connection with the Spin Off. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9512677b078c40578810c4ef579432a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzQ4Mw_704cb365-4b1a-4f90-a90b-ef2cda97f0bc"
      unitRef="shares">16860765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61258fb59e114ab4be13ec46d31319dd_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyOTA_e8b74e04-f813-4847-9d91-8d4ca212c31b"
      unitRef="usd">29200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52beb02bfcfb448588dda9dfaf965534_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzMDU_12e79ff6-5060-4aa1-8ee0-2d2e2e409508"
      unitRef="usd">29100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie5b3906930f64c70b58328d97278b262_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzMjA_c4efcdf8-5041-4e83-bc2a-3b992d8b35ef"
      unitRef="usd">25600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i463986e3eb5648c5b6f6782f286a2c2c_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzNjM_08723342-4d49-4acb-bd70-f96945c71b39"
      unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id44f0a9ab653432d9903ca10012e1b33_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzNDk_7076b863-b59c-4756-92a5-d38e9a79b15b"
      unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8af94fb3b095489db51ee3b16dd479ce_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzMzU_a0846d6d-19e5-41fd-b0e5-fdde5f253d6c"
      unitRef="usd">3900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzEyNDI_8db16086-c8db-4fb4-ad49-e3aecd349bf2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzEzNTQ_10977b35-2109-4183-950a-3b33d82124f6">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4NzU_9a4fb135-168c-4a14-8632-c5651485a07a">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of the options granted during the years ended December&#160;31, 2022, 2021, and 2020 have been estimated at the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzItMS0xLTEtMjQ1NDc3_989360c4-90e5-43b0-bf4c-f56e601da4cf"
      unitRef="number">0.283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzItMy0xLTEtMjQ1NDc3_09031934-0798-4548-a793-de207dff2a00"
      unitRef="number">0.284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzItNS0xLTEtMjQ1NDc3_23b9548e-30fc-42e3-b600-ab1bbcac8ae9"
      unitRef="number">0.248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzMtMS0xLTEtMjQ1NDc3_ce6a4ce7-924f-4c7d-acc8-a07381d17711"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzMtMy0xLTEtMjQ1NDc3_21b02bec-e477-48b9-b266-d1eec56253e0"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzMtNS0xLTEtMjQ1NDc3_85f37de7-97ca-4559-ac89-cee4efe09ded"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzQtMS0xLTEtMjQ1NDc3_bb68286e-6d86-4ccc-abc1-c9533ca26dbf">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzQtMy0xLTEtMjQ1NDc3_231064e5-cb42-419c-b5a7-b57ca28896ca">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzQtNS0xLTEtMjQ1NDc3_d7ed3660-083a-43ac-829f-ad76fd7cf8ba">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzUtMS0xLTEtMjQ1NDc3_a3673672-3bb4-45ff-89fa-fc1ee18b55c7"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzUtMy0xLTEtMjQ1NDc3_9c1a6a86-c937-43df-9269-adbc6d63893c"
      unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTplOWU4OGY4MTUxZmQ0MjQ4YmY5MmUwYmRiODRmNTA4ZS90YWJsZXJhbmdlOmU5ZTg4ZjgxNTFmZDQyNDhiZjkyZTBiZGI4NGY1MDhlXzUtNS0xLTEtMjQ1NDc3_580dc211-2973-485a-834b-90db3c9cc836"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzI3NzY_9de4629f-f8df-41c8-990a-f54242c134fa"
      unitRef="usdPerShare">17.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzI3ODA_298e6d54-1dfb-4118-8f01-0fdfdd6dfcae"
      unitRef="usdPerShare">19.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzI3ODg_28ee6f9a-e386-4216-8305-07f61e4c8c24"
      unitRef="usdPerShare">15.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4OTc_450a1c4f-aa75-488a-bf8d-90dfb368de22">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;(In Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;br/&gt;(In Millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enhabit spin-off adjustment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Options activity represents historical grant values prior to the Spin Off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In connection with the Spin Off, all outstanding Encompass Health stock options (whether vested or unvested) were converted into adjusted Encompass Health awards for current and former Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzEtMS0xLTEtMjQ1NDc3_00fb002a-874c-474c-af2f-d8cc81d43283"
      unitRef="shares">711000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzEtMy0xLTEtMjQ1NDc3_1e2e2763-5e60-4298-87ca-3167922c16a0"
      unitRef="usdPerShare">54.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzItMS0xLTEtMjQ1NDc3_3fe3faf4-7e4f-4c76-afe0-e571e7a9ba31"
      unitRef="shares">117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzItMy0xLTEtMjQ1NDc3_22aef9fe-3766-4629-b1c1-2224a0d2eb20"
      unitRef="usdPerShare">66.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzMtMS0xLTEtMjQ1NDc3_6bfdc73f-61d2-44d0-9139-f95e6491a40c"
      unitRef="shares">47000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzMtMy0xLTEtMjQ1NDc3_4f7dc5ae-bb9d-4421-a42e-b3c727411f66"
      unitRef="usdPerShare">20.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtMS0xLTEtMjg5ODYx_90b9d88c-2db4-4b0a-a575-40d68310cfe5"
      unitRef="shares">55000</ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod>
    <ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtMy0xLTEtMjg5ODYx_1e8a3250-a932-48f3-a720-1f0d95d40bbc"
      unitRef="usdPerShare">51.65</ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtMS0xLTEtMjQ1NDc3_c65919d7-76c1-47d4-ad4e-2f3154d5807b"
      unitRef="shares">836000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtMy0xLTEtMjQ1NDc3_65a86b20-e8d8-4ac2-bdb9-340ac9e2cc02"
      unitRef="usdPerShare">47.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtNS0xLTEtMjQ1NDc3_35a9a54d-ed55-431b-93cd-3c776f6f063d">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzYtNy0xLTEtMjQ1NDc3_8f53e0f0-18b2-4225-9464-a2643164a08b"
      unitRef="usd">11700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzctMS0xLTEtMjQ1NDc3_3e4d1da8-ea85-4445-9cc0-f0458bcad3d0"
      unitRef="shares">621000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzctMy0xLTEtMjQ1NDc3_6cf238f0-1038-4ff4-b620-255f08b94809"
      unitRef="usdPerShare">42.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzctNS0xLTEtMjQ1NDc3_606c0ede-d6bd-45e4-9fa5-14580ee7187e">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTozNzE1ZjFhN2IxMmQ0NzJmOGNhMjA0ZWZlYTYyY2FlNi90YWJsZXJhbmdlOjM3MTVmMWE3YjEyZDQ3MmY4Y2EyMDRlZmVhNjJjYWU2XzctNy0xLTEtMjQ1NDc3_d520ef9d-23fc-45c5-9f41-53e9d62435d3"
      unitRef="usd">11200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyMDM_eff60c49-7116-4f3f-be15-092de7914e3d"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i210ac620832b45ed94bc76afa8aeb98a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyMTc_d3884d96-b9a9-403b-923a-22a0a6bf2f2d"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i353f585d3bdc48059f9d345e5eeea1b3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyMzE_272946e1-f5c8-4e55-ada3-9952197ce313"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMwNTI_2b53eeda-ee69-457e-b7b9-86ab3ccbdb60"
      unitRef="usd">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMxOTc_e7c88df5-668e-4f45-a9b6-68985e4ea5ab">P23M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMzMTA_86a05663-9446-4e96-9066-21211b5576a9"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMzMTQ_6311466b-d6d0-4c15-a8a7-85d5475a952f"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzMzMjI_2bee4256-2f58-4141-a2cb-07988fe02ba5"
      unitRef="usd">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4OTI_538bd035-fc49-486b-a61e-4765a5b3789b">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4NzQ_77d78e84-28ad-45b0-9ba0-94b4651b1d60">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our issued restricted stock awards is as follows (share information in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested shares at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Enhabit spin-off adjustment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested shares at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;RSA activity represents historical grant values prior to the Spin Off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Forfeiture activity prior to the Spin Off represents historical grant values, while the post-spin forfeitures reflects the impact of Spin Off.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:120%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;In connection with the Spin Off, all outstanding RSAs (whether vested or unvested) were converted into adjusted Encompass Health awards for current Encompass Health employees or Enhabit awards for Enhabit employees. Such adjusted awards preserved the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id6bbfc0dab6943969098cd57a4bd7417_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzEtMS0xLTEtMjQ1NDc3_0db544c4-f7b9-499b-8794-2400391f5c36"
      unitRef="shares">454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id6bbfc0dab6943969098cd57a4bd7417_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzEtMy0xLTEtMjQ1NDc3_ddbbd8d7-b086-4401-8dcb-d8b48aff7d99"
      unitRef="usdPerShare">74.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzItMS0xLTEtMjQ1NDc3_8947524d-2160-4065-84b9-4db481d82844"
      unitRef="shares">425000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzItMy0xLTEtMjQ1NDc3_88d9aca9-5302-460d-8693-0cb8f604c58e"
      unitRef="usdPerShare">74.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzMtMS0xLTEtMjQ1NDc3_28c45dc4-646e-480f-bfc8-4a24ccc3873f"
      unitRef="shares">306000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzMtMy0xLTEtMjQ1NDc3_a2f24079-0967-4f85-b6a0-ff23e3a0e7a0"
      unitRef="usdPerShare">70.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzQtMS0xLTEtMjQ1NDc3_69c86cda-3da8-467e-97c4-1277d83a4fcc"
      unitRef="shares">31000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzQtMy0xLTEtMjQ1NDc3_42ebe258-9b35-478c-bee6-ca58f4bb57ea"
      unitRef="usdPerShare">71.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzUtMS0xLTEtMjg5ODgx_66e8c73b-b8f3-4c40-8aa7-03896fe315f5"
      unitRef="shares">16000</ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod>
    <ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzUtMy0xLTEtMjg5ODgx_9976455b-8fd2-47b0-bc92-c4c777ae4680"
      unitRef="usdPerShare">62.87</ehc:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i840ae531504149f0837b987fe6ccf313_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzUtMS0xLTEtMjQ1NDc3_a76979a2-2f1c-4acc-b524-68ca5a273477"
      unitRef="shares">526000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i840ae531504149f0837b987fe6ccf313_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90YWJsZTo0OWZiYjZmMTZiNjg0ZTU5ODdmZDY5NGJiODFjZTgyOC90YWJsZXJhbmdlOjQ5ZmJiNmYxNmI2ODRlNTk4N2ZkNjk0YmI4MWNlODI4XzUtMy0xLTEtMjQ1NDc3_a84c677b-1718-4e00-b27e-049919971530"
      unitRef="usdPerShare">63.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia01fbaae638d442ca55200524b2ce253_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzYyMzE_d60f73da-6059-4a08-9b3c-b87d78aeeade"
      unitRef="usdPerShare">73.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5c577e7192b841b1b95ff17d16f908e0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzYyMzg_0197daa9-9bca-498e-a239-4185f13c25fc"
      unitRef="usdPerShare">61.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyNDU_2ed84bcd-a5c9-4373-8b7d-72f24a37682f"
      unitRef="usd">26400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia01fbaae638d442ca55200524b2ce253_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyNjA_76c67c03-4a88-4d4f-9854-da3e54172ab6"
      unitRef="usd">24900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5c577e7192b841b1b95ff17d16f908e0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAyNzU_5d5f21bc-a189-4436-941c-6c1f0296c36e"
      unitRef="usd">22000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i840ae531504149f0837b987fe6ccf313_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY0NDI_b9ef6739-935b-432f-b083-b1997e4af222"
      unitRef="usd">30000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY1OTM_216d5563-d80f-4ea1-8d94-1f06fe4bde23">P20M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY4Nzk_91987572-f089-4d97-b49a-0c86b7bb3cae"
      unitRef="usd">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ia01fbaae638d442ca55200524b2ce253_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY4ODM_4494712e-b46f-4e58-bed7-572f02246ad2"
      unitRef="usd">32600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i5c577e7192b841b1b95ff17d16f908e0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2XzY4OTE_fd61cc65-ded3-419c-9a9c-61835edbc72a"
      unitRef="usd">41400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if262b00fc98d47d0a49e375a4660d68f_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0MTI_648aea22-5691-49a9-aed2-0974def62da9"
      unitRef="shares">22469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idb1d8ad1f6e64881a43d9b042ee3fc13_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0MTY_d46c07da-e4ad-4767-8ec0-8fe7d1b7fb13"
      unitRef="shares">24043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i68ef0c616638487da568717e4b2e9c7a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0MjQ_6608b5da-1699-41b4-aa7a-7224b2360685"
      unitRef="shares">32196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if262b00fc98d47d0a49e375a4660d68f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0Njg_4754ea03-d06f-47b3-935e-13b882709fc3"
      unitRef="usdPerShare">67.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idb1d8ad1f6e64881a43d9b042ee3fc13_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0NzI_e75b98ef-da16-4a97-95ea-c1e9dc1aabb1"
      unitRef="usdPerShare">84.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i68ef0c616638487da568717e4b2e9c7a_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc0ODA_f7f1ee53-7eb6-4fc5-aa6a-63b1eb20e53b"
      unitRef="usdPerShare">65.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="if262b00fc98d47d0a49e375a4660d68f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc1MzY_3d57eaa4-6e90-482a-bb6d-0c241d9a038f"
      unitRef="usd">1500000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="idb1d8ad1f6e64881a43d9b042ee3fc13_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc1NDA_c22bc54a-827c-4b80-b4d1-c1f1cbc4a0a1"
      unitRef="usd">2000000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i68ef0c616638487da568717e4b2e9c7a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc1NDg_08195b55-068c-4c85-a6a1-2bcd6f4681c4"
      unitRef="usd">2100000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <ehc:SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions
      contextRef="if693d94dd9bf41cba272ff6915a36cca_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc2Mzk_9cba7eb5-7586-4504-9d12-318d10fbf464"
      unitRef="usd">0</ehc:SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7587a2d34b884d75891d35e0b6e9e5e9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc3Njg_1d3f927b-06ae-47d1-9dfb-0ee653a19c60"
      unitRef="shares">11976</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8b1d9e9c16f04250bb589217b66999c2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc3NzI_d6b7bf45-0abb-4119-8102-daa55b3aa3c9"
      unitRef="shares">8577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1479ab37bdd64668ad1c87355665ae26_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc3ODA_131b6ae9-5222-42f4-8efd-09af2c851c9a"
      unitRef="shares">8987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="if693d94dd9bf41cba272ff6915a36cca_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzc4NDE_9de6442a-967d-4675-ab6b-84594124543c"
      unitRef="shares">775312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7def89f3f73f44a5991f33f0d8b3acb8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODYvZnJhZzo0YjNiZDUxMGMxMGI0ZjQ4YjkwOTJmN2RlMzUwY2ExNi90ZXh0cmVnaW9uOjRiM2JkNTEwYzEwYjRmNDhiOTA5MmY3ZGUzNTBjYTE2Xzk4OTU2MDQ2ODAzNzc_8c3601ad-63c7-4a38-8751-0023cf8125e7"
      unitRef="shares">130406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzMwMzE_ca5b27ef-0da8-4762-aad7-50863c10ca62">Employee Benefit Plans:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Substantially all Encompass Health employees are eligible to enroll in Encompass Health-sponsored healthcare plans, including coverage for medical and dental benefits. Our primary healthcare plans are national plans administered by third-party administrators. We are self-insured for these plans. During 2022, 2021, and 2020, costs associated with these plans, net of amounts paid by employees, approximated $174.5 million, $166.0 million, and $145.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Encompass Health Retirement Investment Plan (the &#x201c;RIP&#x201d;) is a qualified 401(k) savings plan. The RIP allows eligible employees to contribute up to 100% of their pay on a pre-tax basis into their individual retirement account in the plan subject to the normal maximum limits set annually by the Internal Revenue Service. Encompass Health employees who are at least 21 years of age are eligible to participate in the RIP and all contributions to the plan are in the form of cash. Encompass &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Health&#x2019;s employer matching contribution under the RIP is 50% of the first 6% of each participant&#x2019;s elective deferrals, which vest 100% after three years of service. Participants are always fully vested in their own contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employer contributions to the RIP approximated $28.7 million, $26.4 million, and $23.3 million in 2022, 2021, and 2020, respectively. In 2022, 2021, and 2020, approximately $1.4 million, $1.1 million, and $1.3 million, respectively, from forfeited accounts were used to fund the matching contributions in accordance with the terms of the RIP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Senior Management Bonus Program&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain a Senior Management Bonus Program to reward senior management for performance based on a combination of corporate or regional goals for all periods presented. The corporate and regional goals are approved on an annual basis by our board of directors as part of our routine budgeting and financial planning process. The program applies to persons who join the Company in, or are promoted to, senior management positions. In 2023, we expect to pay approximately $14.8 million under the program for the year ended December&#160;31, 2022. In March 2022 and 2021, we paid $23.4 million and $14.1 million, respectively, under the program for the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <ehc:HealthcarePlanExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzQzNw_35588b27-7eb0-46da-b7af-ddda6eb0f851"
      unitRef="usd">174500000</ehc:HealthcarePlanExpense>
    <ehc:HealthcarePlanExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzQ0MQ_21c51eb6-b8d7-4e75-8fc4-44e65b488d5f"
      unitRef="usd">166000000</ehc:HealthcarePlanExpense>
    <ehc:HealthcarePlanExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzQ0OQ_06c6d6cf-16ed-42fd-973b-5c1e155f16a9"
      unitRef="usd">145400000</ehc:HealthcarePlanExpense>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i7a3c2935e68148f990a70aed020917a4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzY5Nw_203159ef-bb36-44a0-998e-586171e76db9"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <ehc:RetirementInvestmentPlanAgeRequirement
      contextRef="i1591fbdf586749bf959c3f5eed6dc567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzkyMA_a0563176-dfe5-422f-90e8-97afc36ea459"
      unitRef="y">21</ehc:RetirementInvestmentPlanAgeRequirement>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i7a3c2935e68148f990a70aed020917a4_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzExMDE_1370f755-a94d-47da-8249-dda2e399cf5d"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <ehc:RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution
      contextRef="i1591fbdf586749bf959c3f5eed6dc567_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzExMTc_f0770e35-c6ba-4da3-b8ce-654422607770"
      unitRef="number">0.06</ehc:RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution>
    <ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage
      contextRef="i1591fbdf586749bf959c3f5eed6dc567_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzExNzM_bbfe3736-f077-404f-a4b1-709dcaaa38c9"
      unitRef="number">1</ehc:RetirementInvestmentPlanCompanyMatchVestingPercentage>
    <ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod
      contextRef="i7a3c2935e68148f990a70aed020917a4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzExODI_3a11ef1f-c7d4-4d18-b39a-ae474840adc0">P3Y</ehc:RetirementInvestmentPlanCompanyMatchVestingPeriod>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzE5NTE_8b9bd6be-b295-4b32-9aac-f944f21f962f"
      unitRef="usd">28700000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzE5NTU_1796f498-95e3-4b3a-816f-b1dee49fca39"
      unitRef="usd">26400000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzE5NjM_7f22f248-4366-4646-97c7-7649debc7f6c"
      unitRef="usd">23300000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzIwMzI_b939fe47-ce3f-41bd-806d-4ee73ed7db64"
      unitRef="usd">1400000</ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount>
    <ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzIwMzY_29d7cb7f-7c1b-4c11-8021-0bab620b906b"
      unitRef="usd">1100000</ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount>
    <ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzIwNDQ_e03d58b5-97de-42cd-9db4-f2f0ec2fab67"
      unitRef="usd">1300000</ehc:DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount>
    <ehc:SeniorManagementBonusProgramTotalCosts
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzI4NzM_bf93f60a-ab76-410e-95e4-4bf0e0eca137"
      unitRef="usd">14800000</ehc:SeniorManagementBonusProgramTotalCosts>
    <ehc:SeniorManagementBonusProgramTotalCosts
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzI5NTQ_a41347a2-104e-4477-ae46-bc781f47724b"
      unitRef="usd">23400000</ehc:SeniorManagementBonusProgramTotalCosts>
    <ehc:SeniorManagementBonusProgramTotalCosts
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yODkvZnJhZzplMjhmOGFiNmEyODM0MGMyYjdiN2ZiM2VmMjgwYzQ0Yi90ZXh0cmVnaW9uOmUyOGY4YWI2YTI4MzQwYzJiN2I3ZmIzZWYyODBjNDRiXzI5NjE_d40d9905-8af8-4cbb-9a13-3719ab4513af"
      unitRef="usd">14100000</ehc:SeniorManagementBonusProgramTotalCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzUxMjY_35fe840c-d412-4351-92da-45d1a98b399a">Income Taxes:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to continuing operations are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense related to continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in tax rate resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based windfall tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in 2022 was greater than the federal statutory rate primarily due to state and other income tax expense and the increase in valuation allowance, offset by the impact of noncontrolling interests. The &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in 2021 was less than the federal statutory rate primarily due to the impact of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;noncontrolling interests, the decrease in valuation allowance and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;share-based windfall tax benefits,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; offset by state and other income tax expense.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in 2020 was greater than the federal statutory rate primarily due to state and other income tax expense and the increase in valuation allowance, offset by the impact of noncontrolling interests and share-based windfall tax benefits.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note&#160;1, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &#x201c;Income Taxes,&#x201d; for a discussion of the allocation of income or loss related to pass-through entities, which is referred to as the impact of noncontrolling interests in this discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Coronavirus Aid, Relief, and Economic Security Act of 2020 (the &#x201c;CARES Act&#x201d;)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; included provisions relating to net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, technical corrections to tax depreciation methods for qualified improvement property and deferral of employer payroll taxes. The CARES Act did not materially impact our effective tax rate for the years ended December 31, 2022, 2021 and 2020, although it has impacted the timing of cash payments for taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes recognize the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes and the impact of available NOLs. The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have state NOLs of $35.3 million that expire in various amounts at varying times through 2031. For the years ended December&#160;31, 2022 and 2021, the net decrease in our valuation allowance was $7.3 million and $3.1 million, respectively. The decrease in our valuation allowance in 2022 related primarily to the expiration of state NOLs. The decrease in our valuation allowance in 2021 related primarily to changes in forecasted income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we have a remaining valuation allowance of $35.8 million. This valuation allowance remains recorded due to uncertainties regarding our ability to utilize a portion of our state NOLs and other credits before they expire. The amount of the valuation allowance has been determined for each tax jurisdiction based on the weight of all available evidence including management&#x2019;s estimates of taxable income for each jurisdiction in which we operate over the periods in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which the related deferred tax assets will be recoverable. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable state tax jurisdictions, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our continuing practice is to recognize interest and penalties related to income tax matters in income tax expense. Interest recorded as part of our income tax provision during 2022, 2021, and 2020 was not material. Accrued interest income related to income taxes as of December 31, 2022 and 2021 was not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, we signed an agreement with the IRS to participate in their Compliance Assurance Process (&#x201c;CAP&#x201d;) for the 2017 tax year and have renewed this agreement each year since. CAP is a program in which we and the IRS endeavor to agree on the treatment of significant tax positions prior to the filing of our federal income tax returns. The IRS is currently examining the 2021 and 2022 tax years. In June 2022, the IRS issued a no change letter effectively closing our 2020 tax year audit. The statute of limitations has expired or we have settled federal income tax examinations with the IRS for all tax years through 2020. Our state income tax returns are also periodically examined by various regulatory taxing authorities. We are currently under audit by one state for tax years ranging from 2017 - 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the tax years that remain open under the applicable statutes of limitations, management considered potential unrecognized tax benefits and determined there are no material unrecognized tax benefits that would impact prior years&#x2019; income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzUxMzA_883add39-d742-49d6-a1ab-4d9a667f851e">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant components of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Provision for income tax expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to continuing operations are as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax expense related to continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzMtMS0xLTEtMjQ1NDc3_6e3197b8-3ea7-490b-ac22-8e38f207a4ba"
      unitRef="usd">58700000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzMtMy0xLTEtMjQ1NDc3_57fdfb0e-e0d7-41e3-98b3-2aa2fdc7d810"
      unitRef="usd">63700000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzMtNS0xLTEtMjQ1NDc3_d72c705a-cdb2-44c1-9e7e-b02437908eb6"
      unitRef="usd">29800000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzQtMS0xLTEtMjQ1NDc3_0cb834cb-fe6e-400b-b046-2031025e6d6c"
      unitRef="usd">13500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzQtMy0xLTEtMjQ1NDc3_f48c3197-99fe-497b-b7c5-18c56a85dc9d"
      unitRef="usd">20800000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzQtNS0xLTEtMjQ1NDc3_9194fb24-11bb-4f69-8ddb-780d8dd87cdf"
      unitRef="usd">10400000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzUtMS0xLTEtMjQ1NDc3_d7355733-4dd0-481f-b622-645db6a4853f"
      unitRef="usd">72200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzUtMy0xLTEtMjQ1NDc3_b8f934d9-7cb7-4d25-b601-879bd3db9427"
      unitRef="usd">84500000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzUtNS0xLTEtMjQ1NDc3_776cb7c6-f66a-4aed-bb51-dc15afbe2054"
      unitRef="usd">40200000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzctMS0xLTEtMjQ1NDc3_febc6f23-fa1b-45cf-a6b3-7ce66f0c70ca"
      unitRef="usd">17900000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzctMy0xLTEtMjQ1NDc3_b229813f-7877-4c92-a0e4-3991a26945a4"
      unitRef="usd">14400000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzctNS0xLTEtMjQ1NDc3_2344fdd4-fea2-4786-9ad6-4e8a03f0ed72"
      unitRef="usd">23000000.0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzgtMS0xLTEtMjQ1NDc3_8b951920-b0ec-4c0e-b626-a4021e925178"
      unitRef="usd">10000000.0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzgtMy0xLTEtMjQ1NDc3_c196b16b-7525-491b-ade3-33b14c83a76c"
      unitRef="usd">3000000.0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzgtNS0xLTEtMjQ1NDc3_0a1c2d29-ec27-4e5f-b9a9-fa03a030c2e8"
      unitRef="usd">11500000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzktMS0xLTEtMjQ1NDc3_0f3d009a-87ec-4cd7-bc77-70c6c1d2446f"
      unitRef="usd">27900000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzktMy0xLTEtMjQ1NDc3_f6997e63-953e-4d21-91b4-1442bf094343"
      unitRef="usd">17400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzktNS0xLTEtMjQ1NDc3_477211aa-596a-4e17-a4df-9a1cf39f07f7"
      unitRef="usd">34500000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzEwLTEtMS0xLTI0NTQ3Nw_37d53a4f-ba37-4a80-99c4-bd0ec5e11e6a"
      unitRef="usd">100100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzEwLTMtMS0xLTI0NTQ3Nw_9cde39a2-16f1-4bde-9847-bc7d7066aef6"
      unitRef="usd">101900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpiMmMxNzBhMmU3YWQ0MWE2ODk5MTAxZjI4OGNmMGViMS90YWJsZXJhbmdlOmIyYzE3MGEyZTdhZDQxYTY4OTkxMDFmMjg4Y2YwZWIxXzEwLTUtMS0xLTI0NTQ3Nw_c7207992-8fa5-4269-81d8-1583883a2184"
      unitRef="usd">74700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzUxMzk_b447621e-f097-4c1d-8a7d-fe2eecaf528a">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of differences between the federal income tax at statutory rates and our actual income tax expense on our income from continuing operations, which include federal, state, and other income taxes, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in tax rate resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and other income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based windfall tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzItMS0xLTEtMjQ1NDc3_fa3ec99b-442f-41d3-9cea-b8642e5f73fb"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzItMy0xLTEtMjQ1NDc3_7d892093-8d99-40cc-bb17-8bda9ac42350"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzItNS0xLTEtMjQ1NDc3_4d039bd0-8171-4bf4-868a-5dc1795f24e0"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzQtMS0xLTEtMjQ1NDc3_8510d3f9-d28c-4f20-ad99-d7683703656e"
      unitRef="number">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzQtMy0xLTEtMjQ1NDc3_72b29f40-ae2f-40f3-9c9d-1df7f7fa9ba4"
      unitRef="number">0.040</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzQtNS0xLTEtMjQ1NDc3_84829a17-af05-4c10-8dbc-7fd2fe9c1ee7"
      unitRef="number">0.044</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzUtMS0xLTEtMjQ1NDc3_8b2646ff-eef2-4251-8ce1-27c2c8c8ff95"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzUtMy0xLTEtMjQ1NDc3_0685c890-1905-4ff1-a419-84c8e1d29d20"
      unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzUtNS0xLTEtMjQ1NDc3_de7c2d32-7dcf-41a9-99e0-c823513bab1a"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzctMS0xLTEtMjQ1NDc3_d07478c2-c766-4ae0-abba-8a57d8f21381"
      unitRef="number">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzctMy0xLTEtMjQ1NDc3_f74f8a2b-a04d-4898-8f47-4d9418ca146a"
      unitRef="number">-0.043</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzctNS0xLTEtMjQ1NDc3_641669e2-90ca-4a6f-a47a-ce4a97f102aa"
      unitRef="number">-0.049</us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense>
    <ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzktMS0xLTEtMjQ1NDc3_5873efac-5e75-4d40-8d49-1e6d96eac232"
      unitRef="number">0</ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent>
    <ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzktMy0xLTEtMjQ1NDc3_dde42df3-eb83-4117-b8c2-a78883603699"
      unitRef="number">-0.006</ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent>
    <ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzktNS0xLTEtMjQ1NDc3_2cfb8a47-c68e-4e58-b727-667d640afdf9"
      unitRef="number">-0.012</ehc:EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzExLTEtMS0xLTI0NTQ3Nw_7b28b3d3-1db0-4fc5-9a0c-86e19084774f"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzExLTMtMS0xLTI0NTQ3Nw_c85ca129-b6aa-40c0-ac02-03a363e9051d"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzExLTUtMS0xLTI0NTQ3Nw_edd3b897-33c2-4898-ba75-49e55228f9ce"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzEyLTEtMS0xLTI0NTQ3Nw_1bc869cb-7f24-4595-beba-9648d8305f18"
      unitRef="number">0.222</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzEyLTMtMS0xLTI0NTQ3Nw_f3d77031-45ce-43b0-8944-40beec388b2e"
      unitRef="number">0.202</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTo2YmNhYTYxYmNlNjA0OTIyYjJhODNkZmQ1NjYwZmVjMi90YWJsZXJhbmdlOjZiY2FhNjFiY2U2MDQ5MjJiMmE4M2RmZDU2NjBmZWMyXzEyLTUtMS0xLTI0NTQ3Nw_955325f6-126f-4d6e-91a4-5207a9f95589"
      unitRef="number">0.212</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzUxNTI_aa9c039b-26b9-4511-be17-8526c9ed9252">The significant components of our deferred tax assets and liabilities are presented in the following table (in millions):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value of partnerships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzMtMS0xLTEtMjQ1NDc3_2d5b9186-d065-4971-982b-7bdd6e0c994a"
      unitRef="usd">36900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzMtMy0xLTEtMjQ1NDc3_eda35452-d11d-42cb-87c9-0366c5f9e284"
      unitRef="usd">50400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzUtMS0xLTEtMjQ1NDc3_d93ad53e-551f-43e2-bca6-b4b3070940f0"
      unitRef="usd">19100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzUtMy0xLTEtMjQ1NDc3_33410bf7-d25b-47f7-8120-b9a81239361a"
      unitRef="usd">18400000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzYtMS0xLTEtMjQ1NDc3_1f90e871-082e-4862-9112-5911c8d77026"
      unitRef="usd">16100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzYtMy0xLTEtMjQ1NDc3_ef89af20-a2ee-4bd1-b2d1-b529253a0501"
      unitRef="usd">14300000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ehc:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzgtMS0xLTEtMjQ1NDc3_80faeb6b-ae50-4fca-bdb5-025ae348babd"
      unitRef="usd">6600000</ehc:DeferredTaxAssetsOperatingLeaseLiability>
    <ehc:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzgtMy0xLTEtMjQ1NDc3_7a807576-8280-44c6-9461-430447d49f9f"
      unitRef="usd">6500000</ehc:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzExLTEtMS0xLTI0NTQ3Nw_41b9f5ad-5018-47e7-a1a9-a13ae9a2db46"
      unitRef="usd">24800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzExLTMtMS0xLTI0NTQ3Nw_85160f79-b25d-4d5f-b530-68b92963415d"
      unitRef="usd">23000000.0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzEyLTEtMS0xLTI0NTQ3Nw_d6ade432-87c9-4d3d-8dbd-26d01cceb78f"
      unitRef="usd">12400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzEyLTMtMS0xLTI0NTQ3Nw_faa27c50-127d-4956-932c-7d4a94d5a8d0"
      unitRef="usd">10900000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE0LTEtMS0xLTI0NTQ3Nw_921c7cb2-9694-4d61-a5f4-cf90566b927b"
      unitRef="usd">115900000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE0LTMtMS0xLTI0NTQ3Nw_6747977c-d42b-4733-b3d3-4ddf50037726"
      unitRef="usd">123500000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE1LTEtMS0xLTI0NTQ3Nw_5f37a7c4-a88f-4a97-bd37-2a6624b39260"
      unitRef="usd">35800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE1LTMtMS0xLTI0NTQ3Nw_725ad268-302c-4020-82f1-10b4c42abdef"
      unitRef="usd">43100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE2LTEtMS0xLTI0NTQ3Nw_2928883a-a6aa-441d-a8a5-052c5ec845da"
      unitRef="usd">80100000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE2LTMtMS0xLTI0NTQ3Nw_96189e41-04ab-4138-a473-f9cfcb2c555c"
      unitRef="usd">80400000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE4LTEtMS0xLTI0NTQ3Nw_8626cee4-be68-4c58-b8da-7ff135933017"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE4LTMtMS0xLTI0NTQ3Nw_ca93e5a6-9a9c-4684-867a-0d264dd63cec"
      unitRef="usd">1000000.0</us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE5LTEtMS0xLTI0NTQ3Nw_86150381-2373-4b98-af51-cae709e44f99"
      unitRef="usd">61200000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzE5LTMtMS0xLTI0NTQ3Nw_eb1fd364-aab1-472b-b459-b0ed4d048efd"
      unitRef="usd">30100000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIwLTEtMS0xLTI0NTQ3Nw_d6e714d5-b75d-4128-9638-8c99dcf1466b"
      unitRef="usd">5500000</ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIwLTMtMS0xLTI0NTQ3Nw_5437b4c5-b5c9-4736-9ae1-a907c8ad1565"
      unitRef="usd">6000000.0</ehc:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIxLTEtMS0xLTI0NTQ3Nw_009aca52-5e55-4e02-8317-844823e76661"
      unitRef="usd">15900000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIxLTMtMS0xLTI0NTQ3Nw_aa602829-ac2b-4464-b074-f3586e452e17"
      unitRef="usd">100000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIzLTEtMS0xLTI0NTQ3Nw_d583ebb9-0265-47a9-a077-c1a42822feec"
      unitRef="usd">80200000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzIzLTMtMS0xLTI0NTQ3Nw_80945529-362b-4660-998b-bd5337e86781"
      unitRef="usd">66200000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI0LTEtMS0xLTI0NTQ3Nw_bdf5bae3-ece0-45d1-9ab9-4dfef49ad085"
      unitRef="usd">300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI0LTMtMS0xLTI0NTQ3Nw_4c7785ca-31f1-497f-b537-2276c2b563c8"
      unitRef="usd">300000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI1LTEtMS0xLTI0NTQ3Nw_8fba0aaf-d832-4e6a-ae15-98f4a4604fb4"
      unitRef="usd">163100000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI1LTMtMS0xLTI0NTQ3Nw_6b1bc924-5cb1-4e6d-aa3c-0d3164d820d1"
      unitRef="usd">103700000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI2LTEtMS0xLTI0NTQ3Nw_6dc6e3f5-90bd-4353-84e4-587b92d4da10"
      unitRef="usd">83000000.0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i8a64fb1653e8439cadb431d448933fbe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90YWJsZTpmYWEyY2NmN2QzYjk0YjQ4ODc4ODU1NDhlNTVjYTdiNy90YWJsZXJhbmdlOmZhYTJjY2Y3ZDNiOTRiNDg4Nzg4NTU0OGU1NWNhN2I3XzI2LTMtMS0xLTI0NTQ3Nw_196df580-bc6a-48d7-9689-a82e4b38889b"
      unitRef="usd">23300000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i913d390f327f454fa9db31895be317bc_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzI0MDg_cdf50da3-f372-49b6-9750-a0d286567cde"
      unitRef="usd">35300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzI1NzY_b30e193b-5697-4666-9805-4ee9b7feeb7d"
      unitRef="usd">-7300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzI1ODM_e9e99310-416f-4f14-9a0e-cec712911f6c"
      unitRef="usd">-3100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTIvZnJhZzplY2YyYjk3MzY3ZDE0ODQyYTgwZDA2MjNhYTk0OTFjZi90ZXh0cmVnaW9uOmVjZjJiOTczNjdkMTQ4NDJhODBkMDYyM2FhOTQ5MWNmXzI5MTk_5f37a7c4-a88f-4a97-bd37-2a6624b39260"
      unitRef="usd">35800000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE3MzY_fa005c72-bc06-4f85-84ab-c236dce05b75">Earnings per Common Share:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income from continuing operations allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income from discontinued operations allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards, dilutive stock options, and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase approximately 0.4 million, 0.2 million, and 0.2 million shares of common stock were outstanding during December&#160;31, 2022, 2021, and 2020, respectively, but were not included in the computation of diluted weighted-average shares because to do so would have been antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2014, our board of directors approved an increase in our common stock repurchase authorization from $200 million to $250 million. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. On July 24, 2018, the Company's board approved resetting the aggregate common stock repurchase authorization to $250 million. There were no repurchases of our common stock during 2022 or 2021. During 2020, we repurchased 0.1&#160;million shares of our common stock in the open market for $6.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, our board of directors approved an increase in our quarterly dividend and declared a cash dividend of $0.28 per share. The cash dividend of $0.28 per common share was declared and paid in each quarter through July 2022. In July 2022, our board of directors revised our quarterly dividend in response to the Spin Off and declared a cash dividend of $0.15 per share that was paid in October 2022. Also in October 2022, our board of directors declared cash dividends of $0.15 per share that was paid in January 2023. Future dividend payments are subject to declaration by our board of directors.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE3NDc_da74f272-e8b1-4385-bdf6-fc03ab005557">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per common share (in millions, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.019%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income from continuing operations allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Income from discontinued operations allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;278.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(93.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests included in discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzQtMS0xLTEtMjQ1NDc3_ccf37878-18c6-4c38-b8b9-742c8a72726a"
      unitRef="usd">350700000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzQtMy0xLTEtMjQ1NDc3_207d3931-c22c-4826-981b-f6cfc250f46a"
      unitRef="usd">403100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzQtNS0xLTEtMjQ1NDc3_abf53e67-6060-4972-b321-daf0f38a6f34"
      unitRef="usd">278200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzUtMS0xLTEtMjQ1NDc3_5839903f-76fc-450a-a92a-8af69211119c"
      unitRef="usd">93600000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzUtMy0xLTEtMjQ1NDc3_877727e6-5c5f-411b-b23d-ed20a8817e1e"
      unitRef="usd">103200000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzUtNS0xLTEtMjQ1NDc3_38a5b8b1-ffe0-4063-bb63-8e1cd1240d67"
      unitRef="usd">83300000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzYtMS0xLTEtMjQ1NDc3_fc63c2c6-feeb-4286-9864-58d1a0aad7e9"
      unitRef="usd">1100000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzYtMy0xLTEtMjQ1NDc3_37b09649-bcc1-4d8e-b864-3afe882ae24e"
      unitRef="usd">1100000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzYtNS0xLTEtMjQ1NDc3_0052312c-ed40-4138-8f40-a7cf4eb49de4"
      unitRef="usd">500000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzktMS0xLTEtMjQ1NDc3_f231fd29-a99a-4153-a2f5-f79ceb0181c4"
      unitRef="usd">256000000.0</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzktMy0xLTEtMjQ1NDc3_31e7f0b4-2e9a-4ae4-b123-4bf2a980d9af"
      unitRef="usd">298800000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzktNS0xLTEtMjQ1NDc3_731c095b-7891-48cd-9790-fb0ddfca0b92"
      unitRef="usd">194400000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEwLTEtMS0xLTI0NTQ3Nw_232c8fb6-6654-4216-a42a-0bb9d8e9a503"
      unitRef="usd">15200000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEwLTMtMS0xLTI0NTQ3Nw_a2edeaa3-93a1-45e0-90fb-2818773acfc5"
      unitRef="usd">114100000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEwLTUtMS0xLTI0NTQ3Nw_8a23e47c-7cdf-4a3e-bd4b-3b961343a616"
      unitRef="usd">90600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTEtMS0xLTI3MjA5Mg_a6fd224f-47bb-433d-a6b3-223fad17467a"
      unitRef="usd">1300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTMtMS0xLTI3MjA5Mg_5555e5c1-d2a2-495a-a2b2-205218abde1a"
      unitRef="usd">1800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTUtMS0xLTI3MjA5Mg_40093836-326b-4753-8e9f-2df5d022f625"
      unitRef="usd">1300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTEtMS0xLTI0NTQ3Nw_e81dbbbd-0f49-4c61-a5dd-0a2e29ce96fa"
      unitRef="usd">100000</us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTMtMS0xLTI0NTQ3Nw_082c75f0-3d29-4439-933e-34e900cb95e7"
      unitRef="usd">700000</us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzExLTUtMS0xLTI0NTQ3Nw_f34c2836-1e73-4217-973f-09585f17f158"
      unitRef="usd">500000</us-gaap:UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEzLTEtMS0xLTI3NzcxOA_725e4338-ef54-467d-8b81-994de6ebf987"
      unitRef="usd">13800000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEzLTMtMS0xLTI3NzcxOA_b689b1a7-f7b5-4d4e-9941-fa0a15b57306"
      unitRef="usd">111600000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEzLTUtMS0xLTI3NzcxOA_a07e784f-db16-4209-9515-f93e80c0c63a"
      unitRef="usd">88800000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEyLTEtMS0xLTI0NTQ3Nw_59105787-23a7-425f-a7dd-689f2d17c4ba"
      unitRef="usd">269800000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEyLTMtMS0xLTI0NTQ3Nw_e20e261a-5c84-4aac-b4a4-ca97b57103bd"
      unitRef="usd">410400000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzEyLTUtMS0xLTI0NTQ3Nw_b79efc5f-5219-4362-aa0c-dc8d3e097c27"
      unitRef="usd">283200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE0LTEtMS0xLTI0NTQ3Nw_499e4b64-1f4e-4545-b4a5-5de70ab14d5b"
      unitRef="shares">99200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE0LTMtMS0xLTI0NTQ3Nw_899b2b01-637b-4b9b-8e4b-1f4320e447b0"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE0LTUtMS0xLTI0NTQ3Nw_b5041217-c1fb-4954-bde9-915915af9b9f"
      unitRef="shares">98600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE2LTEtMS0xLTI0NTQ3Nw_a2d2cd45-78c9-4c9b-a840-2df1a93fe2c6"
      unitRef="usdPerShare">2.58</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE2LTMtMS0xLTI0NTQ3Nw_22977fa4-cc50-4384-8ce4-2a004a40f843"
      unitRef="usdPerShare">3.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE2LTUtMS0xLTI0NTQ3Nw_5efb5b0f-169a-43b0-9921-4b603b2620a8"
      unitRef="usdPerShare">1.97</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE3LTEtMS0xLTI0NTQ3Nw_0a481894-168f-413e-b02c-0eb2edbe4a20"
      unitRef="usdPerShare">0.14</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE3LTMtMS0xLTI0NTQ3Nw_3c8b0ef4-ee9c-4795-b121-0c6cc37ce327"
      unitRef="usdPerShare">1.13</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE3LTUtMS0xLTI0NTQ3Nw_1ea8f8ac-7a76-4ed9-a949-9e2aeeefa567"
      unitRef="usdPerShare">0.90</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE4LTEtMS0xLTI0NTQ3Nw_6510b5d7-a894-4942-9000-a1e80a024639"
      unitRef="usdPerShare">2.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE4LTMtMS0xLTI0NTQ3Nw_2a95d607-89b3-4dc1-8f44-9db5d3a6b6a1"
      unitRef="usdPerShare">4.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzE4LTUtMS0xLTI0NTQ3Nw_35295bd1-925c-49d2-8460-6aabb02f3f87"
      unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIyLTEtMS0xLTI0NTQ3Nw_25063d1b-a2c3-4689-93a5-34c41ca35c68"
      unitRef="usd">350700000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIyLTMtMS0xLTI0NTQ3Nw_47c0ebcf-dc8b-436e-954a-877cd7aaa304"
      unitRef="usd">403100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIyLTUtMS0xLTI0NTQ3Nw_9be92d5c-e5a9-4280-b2dc-e76dff957da3"
      unitRef="usd">278200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIzLTEtMS0xLTI0NTQ3Nw_e4108caa-fb96-4413-8937-aedadb4ed4a4"
      unitRef="usd">93600000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIzLTMtMS0xLTI0NTQ3Nw_982ac596-f6c5-474d-b86f-255443353594"
      unitRef="usd">103200000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzIzLTUtMS0xLTI0NTQ3Nw_d99a666b-0a54-405a-adbf-93077a39e0f9"
      unitRef="usd">83300000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI2LTEtMS0xLTI0NTQ3Nw_9d490e3a-6d32-4fd0-a722-9a6fcabf0b61"
      unitRef="usd">257100000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI2LTMtMS0xLTI0NTQ3Nw_940b5966-86ab-472e-b595-ae270293fc1d"
      unitRef="usd">299900000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI2LTUtMS0xLTI0NTQ3Nw_051d2399-c233-461e-bac2-29772878970d"
      unitRef="usd">194900000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI3LTEtMS0xLTI0NTQ3Nw_9d01369d-ede5-4a27-b384-468ff2fd12ee"
      unitRef="usd">15200000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI3LTMtMS0xLTI0NTQ3Nw_5e13d3af-0a0e-4f02-bb8b-31d94baac676"
      unitRef="usd">114100000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI3LTUtMS0xLTI0NTQ3Nw_665db91e-8911-4917-a74f-f7c3591ac73c"
      unitRef="usd">90600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTEtMS0xLTI3MjE3MA_88e801e8-5551-48a3-9c11-1be49470e7d4"
      unitRef="usd">1300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTMtMS0xLTI3MjE3MA_b2878df5-061f-490c-bc63-5d4e20448ca8"
      unitRef="usd">1800000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTUtMS0xLTI3MjE3MA_440111da-a916-4dfb-be14-34a26ea18e7f"
      unitRef="usd">1300000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMxLTEtMS0xLTI3NzcyNQ_b29e2455-df54-4360-a616-6517bd26868e"
      unitRef="usd">13900000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMxLTMtMS0xLTI3NzcyNQ_5ef5fb32-9af2-40f2-ab7d-3c3ef42b675e"
      unitRef="usd">112300000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMxLTUtMS0xLTI3NzcyNQ_a3048622-9b88-40e7-851a-fd7b7a509b04"
      unitRef="usd">89300000</us-gaap:NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI4LTEtMS0xLTI0NTQ3Nw_4741c744-c2ee-43f4-a3db-6c9c6440b53f"
      unitRef="usd">271000000.0</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI4LTMtMS0xLTI0NTQ3Nw_fd2a177f-1ef5-4186-b74a-4c6a4b4e222d"
      unitRef="usd">412200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzI4LTUtMS0xLTI0NTQ3Nw_671f9ace-f92f-4019-882f-654cc15aa9dd"
      unitRef="usd">284200000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTEtMS0xLTI0NTQ3Nw_73b4d35d-daba-4d2e-90c5-19871c95569b"
      unitRef="shares">100400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTMtMS0xLTI0NTQ3Nw_4660d391-1eb1-4d5d-acb0-c62d01de5e58"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMwLTUtMS0xLTI0NTQ3Nw_1d1707e1-eefe-4af1-8bbe-5a5b015b0340"
      unitRef="shares">99800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMyLTEtMS0xLTI0NTQ3Nw_68d83ed2-dc1e-4275-9741-1933b4ebb8ca"
      unitRef="usdPerShare">2.56</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMyLTMtMS0xLTI0NTQ3Nw_87d09f70-1759-4e6d-9ab1-33e739b83455"
      unitRef="usdPerShare">2.99</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMyLTUtMS0xLTI0NTQ3Nw_056d6d44-be4b-43e2-963c-60b6da916c44"
      unitRef="usdPerShare">1.96</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMzLTEtMS0xLTI0NTQ3Nw_f2ea641b-577a-4871-81be-976cb08d0811"
      unitRef="usdPerShare">0.14</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMzLTMtMS0xLTI0NTQ3Nw_1e844415-4e89-4b5e-a60a-8736e4024a64"
      unitRef="usdPerShare">1.12</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzMzLTUtMS0xLTI0NTQ3Nw_dcb28453-2e3c-422f-ab50-09c885d7da37"
      unitRef="usdPerShare">0.89</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzM0LTEtMS0xLTI0NTQ3Nw_7690ff90-fce2-49a3-957b-43cd89fa7450"
      unitRef="usdPerShare">2.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzM0LTMtMS0xLTI0NTQ3Nw_80459181-313e-488b-beb3-cdbf35c0eaf5"
      unitRef="usdPerShare">4.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTpmMzY3MDZlZDhmYTk0NWYzODczMmE4MTFmNGQ1ZGU4NC90YWJsZXJhbmdlOmYzNjcwNmVkOGZhOTQ1ZjM4NzMyYTgxMWY0ZDVkZTg0XzM0LTUtMS0xLTI0NTQ3Nw_513e3ecb-7207-4c07-9916-3a72d08d4d16"
      unitRef="usdPerShare">2.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE3NDQ_5cf32f3d-a113-47b9-a6ae-e209fbce6d0e">&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the reconciliation between basic weighted average common shares outstanding and diluted weighted average common shares outstanding (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards, dilutive stock options, and restricted stock units&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzItMS0xLTEtMjQ1NDc3_499e4b64-1f4e-4545-b4a5-5de70ab14d5b"
      unitRef="shares">99200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzItMy0xLTEtMjQ1NDc3_899b2b01-637b-4b9b-8e4b-1f4320e447b0"
      unitRef="shares">99000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzItNS0xLTEtMjQ1NDc3_b5041217-c1fb-4954-bde9-915915af9b9f"
      unitRef="shares">98600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzUtMS0xLTEtMjQ1NDc3_75c050fe-3802-47d9-8401-765d553a5434"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzUtMy0xLTEtMjQ1NDc3_eff4d56c-1250-4511-afd3-68cca3dfca1d"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzUtNS0xLTEtMjQ1NDc3_bd743054-ac3b-47ad-9f20-1dbe5407dbf2"
      unitRef="shares">1200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzYtMS0xLTEtMjQ1NDc3_ee1953cf-671c-45f0-89b9-a6633cd6debb"
      unitRef="shares">100400000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzYtMy0xLTEtMjQ1NDc3_608050e9-bfed-4a53-80f1-d94ce478b7d0"
      unitRef="shares">100200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90YWJsZTo3OGZiMTg3OWVjY2I0ZDQzOTU1MWYwYjU5NjVmOGUxMi90YWJsZXJhbmdlOjc4ZmIxODc5ZWNjYjRkNDM5NTUxZjBiNTk2NWY4ZTEyXzYtNS0xLTEtMjQ1NDc3_44fc787c-a21b-4806-884d-765d466d071e"
      unitRef="shares">99800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzM2MQ_34831077-5e19-45e3-97d3-16806bfa3d5b"
      unitRef="shares">400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzM2NQ_39b109ba-436e-4bff-a64e-8bb77a14e597"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5e1b142878aa4e65b4d0f5deaa8a2fe5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzM3Mw_ca38efef-965f-46ed-9903-adba9aa6bbf1"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i271895a47db64e53a3fcdb21e2376d82_I20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzcwNg_cafbea26-8728-4826-9229-1aeab5743f78"
      unitRef="usd">200000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i325765d7079c4953b5c202a28adc1d7c_I20140201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzcxMg_fffce222-c456-4b2d-b96d-cbb2c04d5b1f"
      unitRef="usd">250000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i4088c2e6d51b4eb4aae4742204a2232a_I20180724"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzEwMTQ_5ba11ac8-4647-4563-ae00-e393a578c8fb"
      unitRef="usd">250000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ia983a9cc79d34b3bb0ce98f38ebd4ecc_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzEwMjk_7ad944f0-591d-40c5-92e6-f4bbef1d95bc"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0758e6da4efb498697cc4632c85ce905_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzEwMjk_83743077-946c-4d26-9410-3589a62aab3a"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ifad81fc0e15246a99a32d666a8e006ab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzExMTQ_9490024b-eefd-47a8-ba7c-3bf561f67799"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ifad81fc0e15246a99a32d666a8e006ab_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzExNzQ_3ebc87dd-2afb-4f25-8260-b6fca2822f61"
      unitRef="usd">6100000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="iacdb0a94afd843448af41d30dec91b1f_D20190701-20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE1NDM_d92979d7-0f36-46db-96aa-e761d49b2512"
      unitRef="usdPerShare">0.28</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="iacdb0a94afd843448af41d30dec91b1f_D20190701-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzE1Nzg_4e69f541-e2f5-492d-bb90-300420f293d3"
      unitRef="usdPerShare">0.28</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="id92801372f7742e0be889a3765cde901_D20221001-20221031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzI3Nzg_d89011c1-aded-4cee-a1ec-a27fdce90220"
      unitRef="usdPerShare">0.15</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4e8efdcf26334badb765a5748295be5a_D20220701-20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzI3Nzg_efff65a3-f394-4c23-9088-b75b9bd11b7b"
      unitRef="usdPerShare">0.15</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i095a5224a8204444bf94150541a11956_D20230101-20230131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzY1OTcwNjk3Njk0NDM_491dfc61-8022-4258-bdca-24693214d093"
      unitRef="usdPerShare">0.15</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="id92801372f7742e0be889a3765cde901_D20221001-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTUvZnJhZzo2N2NkZDM0YTM2YTE0ZjYyYjc4NTY3YTUwN2FmNTdkNy90ZXh0cmVnaW9uOjY3Y2RkMzRhMzZhMTRmNjJiNzg1NjdhNTA3YWY1N2Q3XzY1OTcwNjk3Njk0NDM_b36c37ef-9734-48e8-b88d-19ee2c3b8f94"
      unitRef="usdPerShare">0.15</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM4MTI_3c7ad017-d654-4a6e-bcdd-40a5a4431d3f">Contingencies and Other Commitments:&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in a highly regulated industry in which healthcare providers are routinely subject to litigation. As a result, various lawsuits, claims, and legal and regulatory proceedings have been and can be expected to be instituted or asserted against us. The resolution of any such lawsuits, claims, or legal and regulatory proceedings could materially and adversely affect our financial position, results of operations, and cash flows in a given period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The False Claims Act allows private citizens, called &#x201c;relators,&#x201d; to institute civil proceedings on behalf of the United States alleging violations of the False Claims Act. These lawsuits, also known as &#x201c;whistleblower&#x201d; or &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; actions, can involve significant monetary damages, fines, attorneys&#x2019; fees and the award of bounties to the relators who successfully prosecute or bring these suits to the government. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases are sealed at the time of filing, which means knowledge of the information contained in the complaint typically is limited to the relator, the federal government, and the presiding court. The defendant in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; action may remain unaware of the existence of a sealed complaint for years. While the complaint is under seal, the government reviews the merits of the case and may conduct a broad investigation and seek discovery from the defendant and other parties before deciding whether to intervene in the case and take the lead on litigating the claims. The court lifts the seal when the government makes its decision on whether to intervene. If the government decides not to intervene, the relator may elect to continue to pursue the lawsuit individually on behalf of the government. It is possible that &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; lawsuits have been filed against us, which suits remain under seal, or that we are unaware of such filings or precluded by existing law or court order from discussing or disclosing the filing of such suits. We may be subject to liability under one or more undisclosed &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cases brought pursuant to the False Claims Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is our obligation as a participant in Medicare and other federal healthcare programs to routinely conduct audits and reviews of the accuracy of our billing systems and other regulatory compliance matters. As a result of these reviews, we have made, and will continue to make, disclosures to the HHS-OIG and CMS relating to amounts we suspect represent over-payments from these programs, whether due to inaccurate billing or otherwise. Some of these disclosures have resulted in, or may result in, Encompass Health refunding amounts to Medicare or other federal healthcare programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Commitments&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to service and other contracts in connection with conducting our business. Minimum amounts due under these agreements are $29.6 million in 2023, $21.0 million in 2024, $12.5 million in 2025, $9.8 million in 2026, $9.2 million in 2027, and $9.6 million thereafter. These contracts primarily relate to software licensing and support.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM2NzA_edc43d2f-aaa5-4219-8f31-f013d577fdbf"
      unitRef="usd">29600000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <us-gaap:OtherCommitmentDueInSecondYear
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM2ODA_228e4011-dbf7-4d04-876f-d6e902731a6d"
      unitRef="usd">21000000</us-gaap:OtherCommitmentDueInSecondYear>
    <us-gaap:OtherCommitmentDueInThirdYear
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM2OTA_44b657dd-4bb0-4f95-808d-93b232765631"
      unitRef="usd">12500000</us-gaap:OtherCommitmentDueInThirdYear>
    <us-gaap:OtherCommitmentDueInFourthYear
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM3MDA_e826379b-460e-4fd8-883a-5346eb8c6163"
      unitRef="usd">9800000</us-gaap:OtherCommitmentDueInFourthYear>
    <us-gaap:OtherCommitmentDueInFifthYear
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM3MTA_6b033a08-1703-4007-8436-de81d8735a08"
      unitRef="usd">9200000</us-gaap:OtherCommitmentDueInFifthYear>
    <us-gaap:OtherCommitmentDueAfterFifthYear
      contextRef="i7012cb8cd6b7476f9630c73b12ab4420_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8yOTgvZnJhZzowYTRkYjVjOTJhMzQ0MDM3YjUzMmM4YTc0MDE4NTBjZC90ZXh0cmVnaW9uOjBhNGRiNWM5MmEzNDQwMzdiNTMyYzhhNzQwMTg1MGNkXzM3MjQ_389ab17d-97ca-4328-85ad-1975ed3a7475"
      unitRef="usd">9600000</us-gaap:OtherCommitmentDueAfterFifthYear>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90ZXh0cmVnaW9uOjY0OTA4ODUzMDRhNjRjZmE4ZjRjYTZjNzk4MjhlNGJiXzk5OA_1e1be47a-7e4e-481f-bb22-3a1216940e76">Quarterly Data (Unaudited):&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Spin Off of Enhabit was completed during 2022 and the historical results of Enhabit are now reported as discontinued operations. The quarterly results presented below have been reclassified to conform to this presentation. For additional information, see Note&#160;2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Spin Off of Home Health and Hospice Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In Millions, Except Per Share Data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,062.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Earnings per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt"&gt;We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In Millions, Except Per Share Data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Earnings per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt"&gt;We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.&lt;/span&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90ZXh0cmVnaW9uOjY0OTA4ODUzMDRhNjRjZmE4ZjRjYTZjNzk4MjhlNGJiXzk4NA_c2aff168-18a9-46ce-82c4-5b3b82e54938">&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In Millions, Except Per Share Data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,059.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,062.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Earnings per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt"&gt;We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.191%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.713%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;First&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Second&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Third&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fourth&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(In Millions, Except Per Share Data)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;959.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,010.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,042.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,014.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating earnings &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Encompass Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;412.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Earnings per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic earnings per share attributable to Encompass Health common shareholders: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted earnings per share attributable to Encompass Health common shareholders: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.8pt"&gt;We define operating earnings as income from continuing operations attributable to Encompass Health before (1)&#160;loss on early extinguishment of debt; (2)&#160;interest expense and amortization of debt discounts and fees; (3)&#160;other income; and (4)&#160;income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b) &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Per share amounts may not sum due to the weighted average common shares outstanding during each quarter compared to the weighted average common shares outstanding during the entire year.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtMi0xLTEtMjQ1NDc3_f15d5111-8c7f-481d-b55e-5d393632d6ab"
      unitRef="usd">1059300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtNC0xLTEtMjQ1NDc3_56294f5f-66d8-4304-8d00-f6a8a6ebc01d"
      unitRef="usd">1062500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtNi0xLTEtMjQ1NDc3_a33caf8a-1562-4907-a270-f5d8c2c1f6fb"
      unitRef="usd">1089500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtOC0xLTEtMjQ1NDc3_0b640392-7c1c-4f0f-bf72-772eccc8a1a1"
      unitRef="usd">1137300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzMtMTAtMS0xLTI0NTQ3Nw_65ecc9fb-3180-4a0c-89eb-bae6cafc1a30"
      unitRef="usd">4348600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtMi0xLTEtMjQ1NDc3_ce663af2-d73c-40de-aa85-ab60a9f5a0db"
      unitRef="usd">131500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtNC0xLTEtMjQ1NDc3_a1c36894-0e05-480b-8cc7-ce6e1c933051"
      unitRef="usd">128600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtNi0xLTEtMjQ1NDc3_df4f7fb7-1ca1-4f64-96e4-fa8465ea7b37"
      unitRef="usd">127500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtOC0xLTEtMjQ1NDc3_9f8cfd73-3e58-434e-bf91-64d6104dbc45"
      unitRef="usd">151900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzQtMTAtMS0xLTI0NTQ3Nw_925caeec-5078-49de-94d3-a11722ff66b7"
      unitRef="usd">539500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtMi0xLTEtMjQ1NDc3_5e7c05ec-0ffe-4085-bb8f-6f0f204e0c1b"
      unitRef="usd">23600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtNC0xLTEtMjQ1NDc3_b75a1886-ea6e-4a1a-9c87-afbed3067b94"
      unitRef="usd">22800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtNi0xLTEtMjQ1NDc3_26eae40b-538c-49ad-b2fd-cf9ca71e4a06"
      unitRef="usd">21800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtOC0xLTEtMjQ1NDc3_6baf02c6-5d19-4a0e-8b1b-3df38bbdc85f"
      unitRef="usd">31900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzUtMTAtMS0xLTI0NTQ3Nw_511e0518-926c-4c67-a919-ecf8324e5be3"
      unitRef="usd">100100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtMi0xLTEtMjQ1NDc3_796ad2f9-e253-47bf-af6f-6ba45b21b421"
      unitRef="usd">86400000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtNC0xLTEtMjQ1NDc3_a4532ee8-c25d-4fa0-b029-d6e162591d95"
      unitRef="usd">59800000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtNi0xLTEtMjQ1NDc3_993633f1-9124-42c9-a6e4-c48d7b5c0ba5"
      unitRef="usd">85500000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtOC0xLTEtMjQ1NDc3_70a578ab-cac0-4e7c-8e1a-08c1cc4cd982"
      unitRef="usd">119000000.0</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzYtMTAtMS0xLTI0NTQ3Nw_d500bde4-ca98-44aa-820c-89e2caf9b0ae"
      unitRef="usd">350700000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctMi0xLTEtMjQ1NDc3_5d04840c-4ed2-4151-9e64-d44606b8629a"
      unitRef="usd">23700000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctNC0xLTEtMjQ1NDc3_8e9df17e-1d86-458f-ac4e-c25aeb58030d"
      unitRef="usd">11500000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctNi0xLTEtMjQ1NDc3_3742c63d-c030-4648-897d-8b79c7495044"
      unitRef="usd">-18500000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctOC0xLTEtMjQ1NDc3_5031ba83-8539-41d1-a49f-26e23f0ac382"
      unitRef="usd">-1500000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzctMTAtMS0xLTI0NTQ3Nw_f4f50e2e-52e8-41b4-8b7b-d053e0f5fec9"
      unitRef="usd">15200000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtMi0xLTEtMjQ1NDc3_13c03aa7-7feb-4000-88dc-6543e0052bf3"
      unitRef="usd">110100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtNC0xLTEtMjQ1NDc3_ddc70ac5-fb55-43b8-b829-75d418f6f33b"
      unitRef="usd">71300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtNi0xLTEtMjQ1NDc3_96e48ea3-ab0e-4a24-ab68-a42194affc62"
      unitRef="usd">67000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtOC0xLTEtMjQ1NDc3_5eb1ecef-79f8-4c67-b443-d7c93915b1c0"
      unitRef="usd">117500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzgtMTAtMS0xLTI0NTQ3Nw_89bf8d2b-f7da-43ce-94f5-29804c2cd9e3"
      unitRef="usd">365900000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktMi0xLTEtMjQ1NDc3_c7b4e73c-0954-4727-9c86-b7d65dcae366"
      unitRef="usd">22600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktNC0xLTEtMjQ1NDc3_96efa17b-e489-4e92-8466-3e8471e723dc"
      unitRef="usd">22600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktNi0xLTEtMjQ1NDc3_2731abe3-0967-46ee-bc98-8e789787611d"
      unitRef="usd">21600000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktOC0xLTEtMjQ1NDc3_8851fc04-f294-4fc3-9de2-441cd1b00ef8"
      unitRef="usd">28100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzktMTAtMS0xLTI0NTQ3Nw_b157f24d-b8f3-45e9-8558-b8ef37097ad4"
      unitRef="usd">94900000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTItMS0xLTI0NTQ3Nw_fb9fa73a-9f87-4f14-a962-b58489eeb088"
      unitRef="usd">87500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTQtMS0xLTI0NTQ3Nw_a5893a2f-c819-4ca3-8731-52fc9582ac8f"
      unitRef="usd">48700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTYtMS0xLTI0NTQ3Nw_bea6fed6-6c25-4686-ae7a-ffdf6398d5fd"
      unitRef="usd">45400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTgtMS0xLTI0NTQ3Nw_28de0136-22e9-4dd3-ac6c-eb2de568b2e9"
      unitRef="usd">89400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEwLTEwLTEtMS0yNDU0Nzc_925bb7d7-688a-4270-83dd-ad8fc0c662b9"
      unitRef="usd">271000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTItMS0xLTI0NTQ3Nw_84bac366-9194-4dd7-be61-edecc30d01f0"
      unitRef="usdPerShare">0.65</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTQtMS0xLTI0NTQ3Nw_ef8130b3-cd60-4df0-9c22-12f54f451792"
      unitRef="usdPerShare">0.38</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTYtMS0xLTI0NTQ3Nw_aa338c1d-3833-400a-961a-23faa7016636"
      unitRef="usdPerShare">0.64</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTgtMS0xLTI0NTQ3Nw_c75dea09-64c4-4d49-8c69-c5c59d9c7399"
      unitRef="usdPerShare">0.91</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzEzLTEwLTEtMS0yNDU0Nzc_5baa297d-8c08-40a4-88b7-67c1243d1c67"
      unitRef="usdPerShare">2.58</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTItMS0xLTI0NTQ3Nw_de62a428-ef70-49bb-8694-2079caf02262"
      unitRef="usdPerShare">0.23</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTQtMS0xLTI0NTQ3Nw_ab6f9134-cc85-4427-baab-6c46ab246151"
      unitRef="usdPerShare">0.11</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTYtMS0xLTI0NTQ3Nw_beece86b-4056-403e-bd90-7ada0eda6279"
      unitRef="usdPerShare">-0.19</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTgtMS0xLTI0NTQ3Nw_643dbe59-428c-4660-9f93-84ee60046605"
      unitRef="usdPerShare">-0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE0LTEwLTEtMS0yNDU0Nzc_0ef0bb08-7e43-45ac-b8fc-d0e9604e50d4"
      unitRef="usdPerShare">0.14</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTItMS0xLTI0NTQ3Nw_3394e468-02ab-4663-a1de-579f45db036f"
      unitRef="usdPerShare">0.88</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTQtMS0xLTI0NTQ3Nw_0b17828d-abb0-4382-a398-31f7ea4ebe53"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTYtMS0xLTI0NTQ3Nw_970b8c24-57b5-489f-ae2c-bbbb5b8b88ce"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTgtMS0xLTI0NTQ3Nw_4233644a-dea7-43d6-898e-eaad2b1081a8"
      unitRef="usdPerShare">0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE1LTEwLTEtMS0yNDU0Nzc_885e311d-ef18-4d7f-bb52-dc4df935b699"
      unitRef="usdPerShare">2.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTItMS0xLTI0NTQ3Nw_fb471fb1-022d-4ca1-a3b2-3db8a986e4fe"
      unitRef="usdPerShare">0.64</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTQtMS0xLTI0NTQ3Nw_00d559c2-5729-48cb-a719-7d0c1a6a9693"
      unitRef="usdPerShare">0.38</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTYtMS0xLTI0NTQ3Nw_44649f39-1119-4e62-8f3e-9d098fbbfb06"
      unitRef="usdPerShare">0.63</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTgtMS0xLTI0NTQ3Nw_5778650a-5f62-4df6-885e-698647d74d02"
      unitRef="usdPerShare">0.90</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE3LTEwLTEtMS0yNDU0Nzc_503628a0-47c0-4029-9f35-fc6560de9bd3"
      unitRef="usdPerShare">2.56</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTItMS0xLTI0NTQ3Nw_fcd44944-1659-4d9d-b846-3de704072271"
      unitRef="usdPerShare">0.23</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTQtMS0xLTI0NTQ3Nw_58d31b61-c8c6-4742-9dc0-2205295bde1e"
      unitRef="usdPerShare">0.11</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTYtMS0xLTI0NTQ3Nw_e664c73a-2df6-4df8-8aa9-41f8125f15e2"
      unitRef="usdPerShare">-0.18</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTgtMS0xLTI0NTQ3Nw_a17150b8-e7b1-45df-b470-9894dd157ed3"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE4LTEwLTEtMS0yNDU0Nzc_1514030b-d3cd-44eb-b7c7-86ba308f4e32"
      unitRef="usdPerShare">0.14</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTItMS0xLTI0NTQ3Nw_76e17810-07a1-41ea-aed8-610084568552"
      unitRef="usdPerShare">0.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7d6a139bed4c4647864990d52e7bcdb3_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTQtMS0xLTI0NTQ3Nw_35af9f9a-f604-4f6a-9520-c28db393ec81"
      unitRef="usdPerShare">0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1b7c54234775448aa61bb479e24b071a_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTYtMS0xLTI0NTQ3Nw_b8bbaa58-9e63-487c-b676-57608f948de4"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie9b2e877323e461d918332547d37a0b5_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTgtMS0xLTI0NTQ3Nw_ceec927c-686e-4aa8-83ee-6429a5237b1a"
      unitRef="usdPerShare">0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2NzVhZTFjNzU1M2E0ZmQ0ODAwNjA4ZGM1MGJhYjMxYy90YWJsZXJhbmdlOjY3NWFlMWM3NTUzYTRmZDQ4MDA2MDhkYzUwYmFiMzFjXzE5LTEwLTEtMS0yNDU0Nzc_deb9e212-4692-497d-bbc7-d5627d31acbd"
      unitRef="usdPerShare">2.70</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtMi0xLTEtMjQ1NDc3_ba96ec0f-276e-4fef-82bb-71f394a746a4"
      unitRef="usd">959900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtNC0xLTEtMjQ1NDc3_2eede6c1-685c-4c52-856e-bc3d47f52f6a"
      unitRef="usd">1001700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtNi0xLTEtMjQ1NDc3_9f992b13-40bc-4ada-9391-40cea0da3acb"
      unitRef="usd">1010800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtOC0xLTEtMjQ1NDc3_6ff8163b-0e06-4ae4-8abc-3354bde480e9"
      unitRef="usd">1042500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzMtMTAtMS0xLTI0NTQ3Nw_81490553-5679-4cd0-894b-740b41117407"
      unitRef="usd">4014900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtMi0xLTEtMjQ1NDc3_23f227fe-b4f3-43aa-b08a-40c0c937eb75"
      unitRef="usd">143000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtNC0xLTEtMjQ1NDc3_4036843d-668b-4c09-a620-1b1f0d660225"
      unitRef="usd">146800000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtNi0xLTEtMjQ1NDc3_9d601923-9501-479e-b8cf-513d9c37eb75"
      unitRef="usd">141400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtOC0xLTEtMjQ1NDc3_96999d8d-4d6a-477a-8d23-882f2e7b986a"
      unitRef="usd">128400000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzQtMTAtMS0xLTI0NTQ3Nw_e62edf57-0e24-4253-96a0-d8d4009dbe01"
      unitRef="usd">559600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtMi0xLTEtMjQ1NDc3_723de652-2661-4ea0-8d3f-8b81d0b959c0"
      unitRef="usd">25000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtNC0xLTEtMjQ1NDc3_51988a4a-089e-40dc-b0d0-11e7be6a4744"
      unitRef="usd">28200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtNi0xLTEtMjQ1NDc3_3e75671e-afb4-4f83-bb41-c0245bfe77ac"
      unitRef="usd">26200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtOC0xLTEtMjQ1NDc3_273f8e86-ee70-445f-a2e1-15dcf382555d"
      unitRef="usd">22500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzUtMTAtMS0xLTI0NTQ3Nw_89ffd02c-76cc-4fde-be04-e95bf668107a"
      unitRef="usd">101900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtMi0xLTEtMjQ1NDc3_c3d1e947-574f-48b7-a171-8d1286949fa0"
      unitRef="usd">101800000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtNC0xLTEtMjQ1NDc3_3dd36e93-80fc-4d29-96bd-670c5c95f1df"
      unitRef="usd">107000000.0</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtNi0xLTEtMjQ1NDc3_114accfe-fcba-44a0-a019-3b62ce1ce18b"
      unitRef="usd">102100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtOC0xLTEtMjQ1NDc3_958e9b2b-d7d7-47b7-9a75-ced5358f2681"
      unitRef="usd">92200000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzYtMTAtMS0xLTI0NTQ3Nw_41a805c7-5e5d-4671-b04c-ecbd64028c26"
      unitRef="usd">403100000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctMi0xLTEtMjQ1NDc3_136643df-f6b2-47d2-adc0-6b67e566d8e5"
      unitRef="usd">31000000.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctNC0xLTEtMjQ1NDc3_73041bb9-793b-48d6-8a8d-4973101b814f"
      unitRef="usd">35000000.0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctNi0xLTEtMjQ1NDc3_f5b6efb0-fb4e-4bf1-a741-584b64faa8fa"
      unitRef="usd">24600000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctOC0xLTEtMjQ1NDc3_a0894227-93be-4cbe-915d-e2db4ee9828f"
      unitRef="usd">23500000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzctMTAtMS0xLTI0NTQ3Nw_0b7412bd-6fec-4bd3-8ca6-dbab9eb23ff1"
      unitRef="usd">114100000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtMi0xLTEtMjQ1NDc3_7b0ebaa5-0749-47d9-a477-8f7d1517ca1e"
      unitRef="usd">132800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtNC0xLTEtMjQ1NDc3_0554f39f-9320-442c-92e9-1bd8052ac4c2"
      unitRef="usd">142000000.0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtNi0xLTEtMjQ1NDc3_070d1004-9e6a-4123-a5f4-b007e39236f9"
      unitRef="usd">126700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtOC0xLTEtMjQ1NDc3_a53dc298-7d3b-4d44-8ecf-7f6fa50d3672"
      unitRef="usd">115700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzgtMTAtMS0xLTI0NTQ3Nw_f548cce8-b8b0-44c9-8518-7bb463c44eab"
      unitRef="usd">517200000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktMi0xLTEtMjQ1NDc3_49662e46-9283-4416-a3a6-7a93bc3e65b0"
      unitRef="usd">25500000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktNC0xLTEtMjQ1NDc3_0b2f10ab-a52c-4412-a0ce-876aa07578ab"
      unitRef="usd">28700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktNi0xLTEtMjQ1NDc3_a8ff5745-7914-41e1-8228-b0b6c9233aef"
      unitRef="usd">26700000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktOC0xLTEtMjQ1NDc3_c7c05bbc-5c6c-4bba-bd6e-f229bdb05da5"
      unitRef="usd">24100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzktMTAtMS0xLTI0NTQ3Nw_3fa0daa4-af3f-4d17-a08b-e21cce26afec"
      unitRef="usd">105000000.0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTItMS0xLTI0NTQ3Nw_d5b10244-1013-40cf-ac9f-bde7f8a5913a"
      unitRef="usd">107300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTQtMS0xLTI0NTQ3Nw_3114a2fd-4e00-4ba8-a3e9-7684da03e376"
      unitRef="usd">113300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTYtMS0xLTI0NTQ3Nw_e39ada3a-562e-4b3f-aea1-3939b950d8bf"
      unitRef="usd">100000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTgtMS0xLTI0NTQ3Nw_07eaf34d-accf-4ea2-a75d-1b7fcae6cfb6"
      unitRef="usd">91600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEwLTEwLTEtMS0yNDU0Nzc_746a0675-9d1b-4eb3-8c82-87aa9da30941"
      unitRef="usd">412200000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTItMS0xLTI0NTQ3Nw_229651a7-e790-4f57-804e-955cfde9410c"
      unitRef="usdPerShare">0.77</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTQtMS0xLTI0NTQ3Nw_7e4007a4-64ef-4de0-a5c7-2f54759fa81c"
      unitRef="usdPerShare">0.79</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTYtMS0xLTI0NTQ3Nw_284d1208-2d47-415d-b128-4df064aa9b4e"
      unitRef="usdPerShare">0.76</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTgtMS0xLTI0NTQ3Nw_e40b69d5-0998-42c3-8a48-8a52ff82dd73"
      unitRef="usdPerShare">0.69</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzEzLTEwLTEtMS0yNDU0Nzc_ab9a1996-9294-4291-901a-876daedf4d96"
      unitRef="usdPerShare">3.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTItMS0xLTI0NTQ3Nw_1a6fea4a-07e1-40ac-bc9f-3aa9d65b576e"
      unitRef="usdPerShare">0.31</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTQtMS0xLTI0NTQ3Nw_e44b9b60-877c-40f3-9d02-05b1c44362ef"
      unitRef="usdPerShare">0.35</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTYtMS0xLTI0NTQ3Nw_cbd81380-bc88-4815-ba45-246324cfcce4"
      unitRef="usdPerShare">0.24</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTgtMS0xLTI0NTQ3Nw_49853575-f3b7-4f0d-a725-e24a437e3b5c"
      unitRef="usdPerShare">0.23</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE0LTEwLTEtMS0yNDU0Nzc_d12d1bd1-abd6-4a00-9d6e-e7bb19b4e703"
      unitRef="usdPerShare">1.13</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTItMS0xLTI0NTQ3Nw_b252ff9d-4d24-4d94-a37f-d5f1bcae8f92"
      unitRef="usdPerShare">1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTQtMS0xLTI0NTQ3Nw_c6226364-c2c9-497c-953b-d7409b71e22f"
      unitRef="usdPerShare">1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTYtMS0xLTI0NTQ3Nw_77bd272f-b462-4f73-b8ef-7d6b21c6cfce"
      unitRef="usdPerShare">1.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTgtMS0xLTI0NTQ3Nw_77dfd8e2-8ebe-43c6-a055-a53b4f1907f2"
      unitRef="usdPerShare">0.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE1LTEwLTEtMS0yNDU0Nzc_79ae8eb2-bdfc-49bc-a6c1-9c1c8bd5bf82"
      unitRef="usdPerShare">4.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTItMS0xLTI0NTQ3Nw_df4af2e5-1303-4cb8-ae2c-8a53a0a237c3"
      unitRef="usdPerShare">0.76</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTQtMS0xLTI0NTQ3Nw_9fb4a245-3fc7-4bc3-afb4-0fe841e13547"
      unitRef="usdPerShare">0.79</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTYtMS0xLTI0NTQ3Nw_01a04773-90f7-4185-878f-a45a7c9479a5"
      unitRef="usdPerShare">0.76</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTgtMS0xLTI0NTQ3Nw_26ec3012-54be-4249-90aa-2c7b502216c3"
      unitRef="usdPerShare">0.68</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE3LTEwLTEtMS0yNDU0Nzc_6011964d-0ca1-427c-9b6c-60d0684723e3"
      unitRef="usdPerShare">2.99</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTItMS0xLTI0NTQ3Nw_30d79fa4-582a-4005-a9d7-742bbadc3f67"
      unitRef="usdPerShare">0.31</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTQtMS0xLTI0NTQ3Nw_7e10c2ef-d5ed-4e75-bd4a-fdf10fd4d801"
      unitRef="usdPerShare">0.34</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTYtMS0xLTI0NTQ3Nw_77f96435-0206-4710-9fe6-43214b53c08a"
      unitRef="usdPerShare">0.24</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTgtMS0xLTI0NTQ3Nw_290ba03d-c79c-4810-ad6c-9303e511a16c"
      unitRef="usdPerShare">0.23</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE4LTEwLTEtMS0yNDU0Nzc_97d01d66-6491-43bd-a489-76b9c683df39"
      unitRef="usdPerShare">1.12</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2bdf108006d84903900224006bd7eecc_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTItMS0xLTI0NTQ3Nw_71d209f8-ef9b-4610-8aa1-c64a9e98fab0"
      unitRef="usdPerShare">1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ee896ecf0c648348b93c265909f9d5d_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTQtMS0xLTI0NTQ3Nw_b4f2272d-1b74-4c17-8110-c6cae561cb71"
      unitRef="usdPerShare">1.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i46e0989ccf694271989d25c30e38bcc7_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTYtMS0xLTI0NTQ3Nw_ca27faf4-86c2-4199-93ff-278051ba8d95"
      unitRef="usdPerShare">1.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8573c13996594c7e8ad0146992e2d0b2_D20211001-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTgtMS0xLTI0NTQ3Nw_ff4d01cd-a3e3-4591-b7a4-334f1e4b41cd"
      unitRef="usdPerShare">0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i18ef4ed6382d4d87804e8257bcfb1af8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8zMDQvZnJhZzo2NDkwODg1MzA0YTY0Y2ZhOGY0Y2E2Yzc5ODI4ZTRiYi90YWJsZTo2MThhNWRlYTIxYjk0NjA1OTk2ZDA3YjQ5YjU5OTUyYy90YWJsZXJhbmdlOjYxOGE1ZGVhMjFiOTQ2MDU5OTZkMDdiNDliNTk5NTJjXzE5LTEwLTEtMS0yNDU0Nzc_5238545d-a10d-424f-9314-c0fd1dba39e3"
      unitRef="usdPerShare">4.11</us-gaap:EarningsPerShareDiluted>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTEtMS0xLTI0NTQ3Nw_35ab4c84-49e9-4a51-af7c-17f16f5f209d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTEtMS0xLTI0NTQ3Nw_35ab4c84-49e9-4a51-af7c-17f16f5f209d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTEtMS0xLTI0NTQ3Nw_1279d20f-075b-4742-bd23-75b6c1e9eed9"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTEtMS0xLTI0NTQ3Nw_1279d20f-075b-4742-bd23-75b6c1e9eed9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTMtMS0xLTI0NTQ3Nw_f2de0a82-9dc8-4a08-a7a5-7f3bcb6108e0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTMtMS0xLTI0NTQ3Nw_f2de0a82-9dc8-4a08-a7a5-7f3bcb6108e0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTMtMS0xLTI0NTQ3Nw_2a843a56-9e04-4f9a-ac50-be6a0201a274"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTMtMS0xLTI0NTQ3Nw_2a843a56-9e04-4f9a-ac50-be6a0201a274"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzM0Mg_20312f68-ddf8-42c0-af6e-5dec32785555" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzM0Mg_20312f68-ddf8-42c0-af6e-5dec32785555" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Our consolidated assets as of December&#160;31, 2022 and December&#160;31, 2021 include total assets of variable interest entities of $207.8 million and $226.2 million, respectively, which cannot be used by us to settle the obligations of other entities. Our consolidated liabilities as of December&#160;31, 2022 and December&#160;31, 2021 include total liabilities of the variable interest entities of $47.9 million and $38.2 million, respectively. See Note&#160;4, </xhtml:span><xhtml:span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTEtMS0xLTI0NTQ3Nw_35ab4c84-49e9-4a51-af7c-17f16f5f209d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzM0Mg_20312f68-ddf8-42c0-af6e-5dec32785555"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTEtMS0xLTI0NTQ3Nw_1279d20f-075b-4742-bd23-75b6c1e9eed9"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzM0Mg_20312f68-ddf8-42c0-af6e-5dec32785555"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzE2LTMtMS0xLTI0NTQ3Nw_f2de0a82-9dc8-4a08-a7a5-7f3bcb6108e0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzM0Mg_20312f68-ddf8-42c0-af6e-5dec32785555"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90YWJsZTo0Y2QzYTk4NzIyMTU0NDU5YTY1MWNhMjZkOTcwOTE4Yi90YWJsZXJhbmdlOjRjZDNhOTg3MjIxNTQ0NTlhNjUxY2EyNmQ5NzA5MThiXzQ1LTMtMS0xLTI0NTQ3Nw_2a843a56-9e04-4f9a-ac50-be6a0201a274"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjk0ZmMwZjk2YWE1YjQ1ZGZiYjQ4MjhlYWRkN2ExNWMyL3NlYzo5NGZjMGY5NmFhNWI0NWRmYmI0ODI4ZWFkZDdhMTVjMl8xNDgvZnJhZzowNDk5ODQxZDVhY2M0ZDAyODkyNDAyNzNjYWQ0MDU5MC90ZXh0cmVnaW9uOjA0OTk4NDFkNWFjYzRkMDI4OTI0MDI3M2NhZDQwNTkwXzM0Mg_20312f68-ddf8-42c0-af6e-5dec32785555"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>122
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M%1]M55T^AL0*?#H9GTXU/H,H2DB 'NB2<:$"I=<1/%'A'6JKZH(R)%8 U<U
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MX[;Y(L6NOH/Z+*04V_KCAJ<@*!0 _K\60AZ_J!><[CW/_P102P,$%     @
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M!<I?RO.J_A\]M;;>!*6'2O*B'0P(BJQL_B;/;2(& S"U#"#M '(ZP+<,H.T
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MC]%/T7PX\VLBMK"XA97X!J;S9A$4N&B^16D.)-_77V>LN)2\J'_N6 (=1!G
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MRLI5*IQMZJ;-DF/[::3"*Z1TU* F8U U JI&H=3D>.CX%3(#K OQH T#1^W
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M5LMNZ6B8:]YM=7T)R"PP=N[KJCNKU/W+H"9C4#4"JD:AU&3O=^#*-8.KBTM
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M2$C<H\0J$=@NGX0&G4(W.KEW[R%.^^ K (1HAO),4>BZ1S1\> -'H1N.R&.
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M7-=DJ[Q>  #\[)>FPFD^A=5^=G<D2[/K'H\0&;OUG. U4J8- DRSJXOCI_
M\S& )NS7MS6]?]L("IY=*1R]VWF^<P/)Z>SJ;'KV;4:'>_9D>O6MO-BOJHT=
MJ7,0YT#XU=/LM[9JAGK+3Y7Q>J_RON+C? "I-T.@A]>$'J*6DG]B5/ S+9P7
M3 G-%FL7_BE:=U$U>5-4>2U70&)_X+7W: ?K[Y(!88\001RW(80P$6&CKJ05
MG5S=TM$1\YJ.0;]Q&^R8!]+>=$1BU:9V_E+3"R0XKM>N(Y:0[9D>!?,$F1N(
M#NM*;HF)LG,WKAGQ-SSN[DB#]K(,@9#=KEH"Y%3PF5+S.O^M[:KAT"^S]H9N
M]W95%2L0B[MS75'1!1,6AZZM>2LBHY6CPV\VQ*KYO':3C/#(0.%@_N55?D.0
MVZLU4!#P3[=-V.P')IBQEV.ZWT<"*UN[8=66H!S%7D9F0=:.';UU0^_(M=%6
M?EO:K6RSIAT"H/-Q )QT8P8*(Y+1M\7:_FQ])(FJ9E&/#A?*B!!F >1 <8!^
MHU)J&A$A8?(_W,""9DT;#4-7$0S #W;;HS"]WI[/U:_ 8\K6#:WB\@Z<T0<6
ML[-.F<3+:K&@LP'0N1MN'=U'$;,#P[N/THI * AW!0D=L"BMCNW#P5CJ]+1F
MD>-2%*)-S'KZLQ),7M.A(>.)5]RZ)XHD":L"%L]\F?=PL<E3_DH97> SD$'6
MTAZ\T2XH.^<+],&$Y>J*K!F(.[!$>M%$?RHFC,Q$AI+D;?J\$.F[Z-KU+HI<
M3[88K?]WXAB^WK=*RW3)"KQ)HVM:G$^TY5-">T F9#?VJK&!/?40;YZ????W
MMS_PWV;?G4#YN)N\'AD_A W"O.O60(:P&J&)WJ2GY*HJUK!S$D5TU I_%UH8
M29JMVK$N8X3S.[09J I*KLGK+>1M)1=0NSLHQINV)KQF8Z-T(_('RW; /QT@
MP>UO8[G$'="M\4E;VIHL6X*:L/:6KJV#%DU.4BW IJ9H#AT"8@V0LA);D\F:
MX"$?Q/(6]*];^G4$$0EDH7QA"3I_NZZ*C)B;_0UF=Z%JN0:6</3/+I$=F_96
MP:83\UIM[Z)M!2.5L%0[KZNE4"D(>-ZWW3RKVYXE=$=X*QSY"7K"00E-+X-0
MCVO:M / 87TR3\44+>DO[A?ATQ_Z@9!FAL!U3_X/FTI]K!E%>7GF :!?YM&*
M90LP!0IE1?>7Z^L/X>X!BDH+ET"1!RCH(=P122V]!2\K\K7P'BZ8U1R_FF@Z
MEC=57Q#^1I&3$/,D'T%DAU\B 2RO@<CU<K]XU(D7FX>@,WV;JMMR[* ?PDNL
MZDF-MR51>VSE'L<-Z)X06$(<BN:"*H/L$I9_GCV<G=C^F9K\7GBR&S'20?+R
MM]&T([8@?B6]"\<4HD9/\EWV\/PD6^15ET&H,'+R@F^RC'')\+D4IT0)<[6Z
M(1[F$*TX *UY<2(O,Z-5G:(SV-3+MBUOJ[JF1R]/B'6)$@L1@75UXZ+;IP>N
M3H"-Q5B'WY',R9NEG,,>>WP26%D>9"6=G*PFN]F?B]YY<F(*>LCO,I&JK"[K
MNKV%(,!#3T^"J./G-FU?V4&?[2*/G.?B,UD*>I4L%,FUJPK<G?P2EZ2F;DZ2
ML/OLV% I>5%:<W:VNRA=AB/S&.=MR!^(3"C3&(!EQE0144/OZL5IU8!+R(AF
M0Z, <6WJG(&?G>^\0#[-@FZ3P,C)9D)H@X0T2XPGW[$&(")7#PHGPT_(54"T
MA(27FKL9;\A2U(AEFW55_YEVQ$L/9T0<GF&+K;+J8/+1 )IF/XX#^!MT;LIX
MY0@MCL4&T5S>@#'F+,A*P;#X3*J7MM^I34Y;U23&(> B"SQPH,HND?EF"!+>
M375-O2.Q]RHSJAHX_Y \!1MDQ8KH&<1,YMZMG;@MBI$$0 X-!CS<08ZPD0?=
MK$S*O\]+(1[&O@3-  ,\I3DPP8\Q%XLV\G:L:VZJKFU8/0L,:BFIA2&"8R-B
M$]B+Q13DGL<#&YGTY[+%NG-VT_#$.B>;ATR'EG3V.,#FD8/0^: )B=AZF%^\
MNO,<R*>*;*2&%&3?D^(G;U:DF]I=JAS% #:U"47L(9N2-TW$Q\#\$ILLWBJ#
M-Q]SASKV$[-!E#K8VF(S2-6>NQN4](T9R$#*ZOS6^'XYUNJVJ_I9$!]W8"V^
M?[F3NBWH.$LX&'(/-5U_+88]G>/@<IVKV5IK)Y#CA.^6S9-A!2?A.=N;YX^_
M(ZXJ''/_A%F"-4_@7B)GL(T8S]_YE\R9(3>NXE45=A'N!"K)"8&9 9V0](8I
M+O3$II>79;U89L2@9) #>[_3S56++<N:SE7K^=CUS 8D86$$O@,; ^4/R=EO
M$7]UG1G]N&K"4;[T%\+\<Q(@+]K2?#,2.^)ALA24&$QX,'[?K(''9]_*%58L
MNH85$1CYS*5"!OXWZ";ZMZKDO=A?SUZOJKHD%TREI7?LWGII^*%KEUV^SAY^
M>OW3VP\GV0]"/L0X1-( X_SL[$D,I-[VJMKT0G";%5GC)#^4^>32!4F0*<1"
MA4O4K']!5(%_E*^?F.#T<U5\GN>DDT!F86^^IX&M[#4?E204'3P\ /M.N!L*
MJ#&;V1[N1T0#S#8B9&^ Z_!Z_!H>Z1U).MW08E"Q(..M=&VR%$BB1\"R)!2-
MS ^2:0@]A?-C.?*EUWGAQ@%O]\JJHD UVC&HIL>O;%$LTO:@]G J_'Z5_Y%W
M)5R86X3@V(%ASF9=-3$AJAK!^)?)/;!OV_$[Y&H@>.:#)/2S+0L<AZ,7KE3A
M1C#^!CN9]<E(# %?BI0U 4#""AY'X42:TI&6ML<"ME?7DO/D@%C:AW\K]]KI
MTJ;X1GY_G7]V\0FPH8^]3<)%3F#1]BU!#U&F[$5GS_E),89) HPB3$'T]-N@
M=.AG=#CZ+=Z)#5:B3=HZLKV-%O*2;%^^IG!@0CU[B60IU;N2.02C#LI/ENR"
M@'DJWCM'4#<9&^Z*Q41.D8%/AAA,R,7@Y!87[$BVXAB*/2+A,,9]#AKYU79C
MJ0;G36Y4]DQ\F\"[L/&+C@,6->&;_I0G8*\7Y&,F/PROD3IP SQD_UOOQ<#?
M-+M$5(.0C<6 $54ARF!C0Q^+;I]M-S+=W!UMQ6(+LG447E.#YYX%1#<C.$$"
M::/VB?#.OER=1/)-=:;("1:UJ:YF\A(.FL#=KEVS'%9;+$XT%LD/>K6#[44G
M'IGR=KUJLM*72R@\R["I[&>^8U69Y<O..;$(7VE0S.LLMH8KX#1/O',E)L,(
MHH*!%[P7.6%"!LOLT#+?W"$C0$P&\S8]&(H2?;QFPU/#+3&=I.+?*X1%EX]E
MHB -4X:_6BSVO*3=2:MLS8L?X=]NR(W#L6N8VX2RL?!IBY2/)B9Y@7MRR]>D
MU_M)HM8@=H%,!$G8:UN2UNBQD4*D$65_L0J2^@>P2(%O<U$G2<!6],7$FY&X
M'+D4[]SD_2I;D!](Y_J!+LE'WOUMYME-U=;Z"OFP$'I0.@WG"LA>$HWP-;".
M&X56/$2BH\*)UMB,8J!-LY_(4FX[0^Y^PN U&8(=?''F%#BUPBXD]:N^9FAZ
M@4/B$;(2Z(70 548T6RD!(Z37,2'_9:4X7J:O4/\U >I;17>5# MSA+',DQ1
M"6:),CMXY[PGIQ7H_WR* C^=).!!>9^"<%6UQG3&_,(FM%@36Y';D-#[-GZ?
M6(C*[VL<(C+(4TO51 X;Z&![LJ[FD/SL''5J/9(9+"9!M!![9T1W^<#A"7;\
MH# $,X =]\Y2(3G?@F3.'Q8HC$$)!P_BZ-;Y:.*.&"*W%D LO6SVLH=%<Y#"
M_4C&2$0!1D @^S4*#KZ2\[Z6W_I]AB.KRGQ:)O5./#$E$C$B'-!MT/.=D?_3
ME:<2 *>+;[M>A"E;>_'U%VUO$856L,C<QF294N(.PIG10#+>TO4)WO>,T3V;
MG0 CE)=L/_..#7SDB"0. (U'0_)0GJ8EYEOR@Y<M"(C%H:HB[RJ&GV0(O1&8
MJCXL:JG^+$>U:S-XA%8LI98DK+V)M"OLA8N9.]5]DC!6'W)L9E2$4/[86/;+
MGR+X$(BM+?*;MN-GHI.H#MS%D>#[ .X0;X"9-=%@0+7F+?'_">LUI%=(QU7!
M]3/T;-CR:#FHCZ 2_Y.MA7\E-GA'[,]4#*#%;G=]HA)QZ5YX<:IYG9=.P"'#
M1LT$5CCDT^'D(&#H<H*A;(MQ[?-B]"0<,B('3[823X$K8&F37.7(=<^Q];'7
MN-9_M*@.>#J!>M&0G=F4[UE1OV[7Q#4"IP^9Y)J&XFQ=,W+= >*O9,>,E6;C
M-'RGL3O&2SL.A:(QB@@N.+$8U#_9&?NV XXOEH.W@/\OFA '1!KLOO?>[ONH
MLM>"4.^/6X9T'?F2&&+);#]72E=W7[ -F820=9\]K""CZQHPG#S/_M/EG11"
M[==_X(\9_C@+QN,WV?GDZ>7%=,9_NWKZ;/J8_W;QY(K^YA^[+F]R426/KR[I
M%X_/\.#5Y>7T&4R (/"NSJZFY]GET\OI57;Q9#:]#*&3V=.+Z44V>XS-9I=G
M].=["V+M\O3%,WK]\O'T+"/0SK)?C\>EL_/+Z9/L'&N>S^BE#^) ]K0/ 3A[
MAAV?$42RE<;^G\[H=T^>T8M79_2WGUN(Y6^RR\G%Y5,^_^7D;(:C?9-=3*X>
M/Z9%N*P%<8ACER;A4(38X-E*.'24F 0(BG.\&J$TH1%EFM4 7&B@8-AN)+<@
MPMFLE](2?^HFBTS\\K*^UB"*WB[T=UQNQ!D -8U@"T@Z7R*RP5OW.9))\**2
MI!-;02R/X1:9 \@B+3'T;U#U.#F>HY)S1=%WL3:1 *B+D2.AAP'C6S#LG,ZW
MIQ9/D/N8<S)([4]1[:@B$=;'X5V.?+IFG_?HDF1E=%ASM>A*[(QZ,K#L :*6
MNZWH8$O);Q"[>(C8=?;V?ASZ9^-^+'!) 69.9]9YA5LBF$J-\TJDI8<#XV\:
MYSJ(Y10 UE)+C:%%>9->+08I]-D!TU:E]R.(/2:-C!D!J:]'!CML5,126+F+
M$)&T!.N=D4TAPZBD5R7_N4_?2M81 M0,Y&R"55-9_9^F-_B9P[%[#9\LV'I(
MG:/$NHN)$$I5.4#->R9_>X1^:$90E"=LW"T7N;T90Q3 W5FRE<LN6">;SF8_
M7F^/MN ;)BS!.A!/)K5>X_C:,;MJHK%(*4 BKO;11P*(DXT;U/.)YD/I1;[U
M-F2Z&ZX]]A#-Q\K'847T\H>3Z'F09<!5U?M:IB%4VW@Y-3'R7T4E3WVPS$R/
M[S@0?R9\@L>\CO+A)8OO< 7,/1CAR A21F3)D,E E[$F&VU123(_U(PFJ")!
M4M>'O=,H7L;)WJ^%-8YIKE%F;_GKN'#)RA/B:,\T^U'C;6F^2<+$=/)UU5NX
MC^RWD;F^'W0US=%P'-+R!M[5\C429(ZUA3@Q/L+ER</3@U P"PX+(@;\J4D)
M8:OAKE <Q%5QUP=@\TB1I;\2E=%MZZVJ^V"L(BQ@+GRB -O$OXA9U(J52G4V
MU*+?JPOTH/:[_)7$(7H7?!HPK;\P=\.7N24[L!=_+Y=, U-"G9K_?*D*+$H.
M$U2%_=ZB1"1)P@)/6FZ)?"[ XYL]E#*VG'KOY<><4\(<@R((V427)".71PV2
M4MSC\-?O/I'YWDNXG2!KV"D6X2*>AP2G2Q\#FDBJA<N6.>T"[F(/+PZ>*N>1
MIX8=-JWX#JS@K4@O3DS%CAI\3KH&]B$1W4'-"O%+YY(R19+H_2!HQ X,9<'N
MIWI[K(@=,Q%<OMST'9,879'$:!&$V%U[PBL"ISMG1Q*7(R1PAW$U1,EZ6*U%
MIN7H!J$^U>/]F8-R%5MU49A?8H<0U*$@B6SY,_+#MO363^TM2&ZB=JELOO^Z
M!LTX@PYFSVLNTJOH'PML"AZIS)=&[!H;"BU*4:?YAFQ;[49"WZ ,8Y":PT5<
MP_W32 H[^V2RYOUB44GB\FW#ET!(^(M6L3S$LEI^^=-/GT[?O_V++\%4L_R^
M3?]*0@!KQ\N\>?]76T*#AT1(;K(?'S&7&,6#G917!U:)Y%&^DW_Q%*18B:7;
MH[;;%W!Z343C; E*ZL0<A[U;F]C!@[GO'5RKJ.2P^/Z]3[GVE15WM.RM),5\
M.,76^.=BAQ](1(Y:%NE#ES=.ZS1]99C9(7E4VFLA](F7+B4BR;1;J68CW>HP
MXM:MDC7@&/(WJ XA5M$06,PL/TOE=V1##V)4Y$WES$1%0->;\GM9;Q7R4ZE9
M4<[@^D>H!:8DWG= (C<._I)3PRIP6)$.6ZY@-*OY",5,F_I(D12,Q*40#*\_
M9FHL>'97[0,:K5VN%1N:*^E]W2S+:H80P34.V=SHWXED_1[L=\Z1\G6E9K'I
MG(H5"[7A+M3]3+/89-M#[822*#%!6/GUF]:"OAP)[+44A4L*I'K +9P:_#=Y
M3>+1JA),.(/:&!+U6(-23\$@[AXYJ[;U.C75^@$CA@0V6R7G477%N-8#"G(Y
M,,PHU1!BI.E(CG;YIF57N'2-+]VGTYMCTRW!MZUD11254-FBR1'+Q":N-*M&
M-*[%PB5%XUG<QS /!?)87L'X)ZDP!-,DRM4B\1%E#:.P$IR:GIN="#>OE65P
M<JN$?W?]NC<A.E$F\PM_;MK;!OI2'[XE52YMHWAF3J2BKPKNE=T<?NM.36@Q
M;KRGJ=ZO!U$+BWH5!U&&BA'O@L;E<ERUNLLJ7S9MSV7TI0;746$RH@B,GE-X
M\\V&=)4'DE6B3Z;)O>Y&:/,Y$<^>(WXD7J#^0Q(B\.O+YKTTMX']VT9U6;L;
M5=KUN*=)>91?Z5 H@I?7:^;*/E55017[94AO=Q[5U[JFT<'[=S]=>WTLA3EJ
M"D;Z,9: I:N]G:Z^5)XAQ5:WRX@E\MM<(O,Q\,BN+:NFT??>Y1TQ" *GDPQP
M>"Y)X@0%RXU5? @NH_/!<-T1J9I\4$='GIZ$KJDY69T.,>JR]/Z$3Q-HY:'5
MT[ Y#Q](8_1VW8HZ'PQZ(S7JT@.()R(T'.$<(\G=(%.XP#SE77*YV=)W_L:N
M_^:M'XOIJ%;E[$:4^ZBWZFO3\MJ)PFBVTI\DE9R'+*B5+/T9<I?Z>A8'Z2VB
MH5;*?]BEC;/:C /F84D?\$H( BFW6Q*!3IQUHX@+O;K(2#2*?M7FT#V&IC?7
MKX)\"WX:9[39NDKQ+'+JGAY/+D2Z,Q7US=6YI0>XD4.O$TQKA"\K6M4G@;,3
M3+G=/?;.#H\/;*"B44F%UF3N5-]TQXRNI%J>I/_8<1U8S><.82FKLS! #Y^<
MH;X>ERA /3^;/1&3#IH*Q?QRQS]#*V+O#Z!QIL4?V!8*5/OSAZCSRB?OIP2T
M^<7T1/2;208-Q?6193[DH84*ADD)JWFQ/1SJ83-K59%Q)AJ(LWH:XI7^4Z<V
MH8^5L&O,E\'O^0K=Z-5I]IZU ,#*9"Y!TKS,6DHN2? YT6H,<?QNVGJ4?%SR
MT([[=WZ&/R_//&O\O(>7D'08-\(,G>,P65/V!Y9?A(IO:X/NU'K3"D(!/YBN
M;-*S%-$HK7J:4A9)I@A.RK;DC0;=WBZ\1Z'=HOIK6F4A8G3@'*]4^@5X!45
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MP.S\N/B >T0T/<]*<8[B0@X#0<HS&_L2=@TM,.)]E7U$F$-;2Y$%-P!()Z4
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ME3!FO7MJ> NUV^YNE8_]($&K:A#[A2=@;;J1*Q@TA8*@M0[H\W>J+1V:H9*
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M$LJ"Q!VYIO%D'('IWH!NXW03YNY6.YKB8;FG9Q.--R#]3E-9^HT/,#S$BW\
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M$Q/^Q&64CZ.,#<=IE+ \S 93X S"<3H!Q!49 Q)%T=6=Y)9*%#J<5@C>/R4
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MG1+P"=W_E,!/AF#)UY;\+#=)62FS*>Z-(M^RJC.]4KLRS9?I+LGH4B0J<GU
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M%/"),*K2JJ8\4TE:Y;&CI8O$?-,N:J8'K6M&>_;.$7<4Q?&9/M^C5*(^<2K
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M)VT_XLH+R4J:9V','Y0UK6X&-E8"%S\A61LA#(Q9PAEZ!AMI.4D%!#$%MOQ
MY5CU<;T.)F#Q@.O!"#?]IT#E1^KA!7;KQ\+L2%5\2R)2;TE'/6+-?)H3B/9(
MVI,$==$$YTP;^SX@38_\$HU:$BDR%C0)N<?3F0M;!25I!A%PGIV$]00\D"8Z
M>X0MQI7[:' RF*>2./1 D[U35.#27),].9-MQ],<>D2#G'5CRT6%L&]WYO/
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M^%<C/!:8I18+HGN?)WPN;0_:0;+"&^')UHJM>(D\WHC4:.)"U [8IO)\D+2
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MN:(!>+]0RM8_:('F_Q:N_P=02P,$%     @ D();5E)D_%DJ!@  Q0\  !D
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M0#O5R8IW.5D%)A#?*YF5JYTT*9&9"_V K5V*;1 ]"C!$:*4)B(S;(I5;_FR
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MX$8?'W&;05(L@/>%11>[!3L8/LHN_P%02P,$%     @ D();5G,\H ,Q"P
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M40LVN9+V(6U$\Y2IN>@$7H'F7H$)-QW 0$UEW\/BMNS6)^-XQ@6,$!PIA+#
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M9P'LE\[%X8,O&/_/XN8?4$L#!!0    ( )""6U:C4614) 8  %02   9
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M]=-:"F0_;<#SA<;7T7I!"K8_DH[^!%!+ P04    " "0@EM6?F[=%7(Y
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M[&ER)N[7P/V=PWHC+MKTM?Y&6U4(XU#.,Y!V+':2;&202IZUSH*:E<@J5@U
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M2*#G:5J0+*^"4%^\UY8+Q]S.<@*1-MJ5FGMD3I.'Y=S-D0[%^6]\VJ03C@6
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MY&B2L@SN@@;F?"YGMM1[ZL5,ZU)A(AJ-U =9\H,UT4"K[3CE9ZC+?EK)E$!
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MGUN7DSS# _3[NB&U0C]@ ER2R.!]_U]02P,$%     @ D();5IQLQRI$!P
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MC5X).WMYUTP&4TMV)U>57,J,5Y8MLDS5E975BMVJ0F92&#;\PN\+84;G4XO
M9#[-VB!739#@A2!^P#ZJRJX->U?E(M]W, 7B#G:PA7T5'/7XH\@F+/3'+/""
MX(B_L"M#Z/R%+_CKR_??BWMC-6CS1U_&C;^HWQ\MI3.SX9FX&&"M&*$?Q.#R
M^^_\Q'M[!&W4H8V.>;^\P]+,ZT+0K%VK*A,5<#J2H^$7K.1/&T$-R.:S>!!5
MC6SNG]@M?U*Z+Y>CT?IS^51K%TEUD?0V4BX-7ZVT6'$K<HJ[H;C,J%IG@G&-
MGV%+54 /0"I9@=9% ?!F=,;^);AN2,(PQ:*\%[J;9OKSZ<]C'T4.GL+3"0O&
M:11.?'<7I_-)XN["68R[;M@B?P"K(3(LB2-T)!X-C*-H,F<?>86.G+F!L1=/
M A:ET21FX<R?1*T/F3,_#2<A\Q,*YD<>_C_9->#9M=3YZ89KVV9J6#B'>91,
M/ 9H'OL=NB2T^?Z[-/!G;UFF2DBJ:28LB"8S%I#/P(?1+5HQFP9Q -"?4\0Y
M$#6A9 5;P5(??;,Y#&,/=U^4Y06RCL9AE+K\H['G4VHG+!S'20(G1T@7=Z2+
M_^^DXU7NNMJTV!W((T&"=KD9C,R$?"!=Z0CJC)J[ZX(;TT?8XTB_K 6*?(!P
MTT(P+02^A:#W(#1<S2CPF'C*&;(B3T0>N+&NV*]P-F;2/"/Z&5L8LG^!U1U3
MXQGF[0U=4ESVN$EU48X'6&$N'ML4O ).\**H<ZI\#^-#'^1Z0Y>(/&[I'+G'
MR/6]3&0WB'C_9LOB'P[X"W*^8;X#O2,O2$^-,?X;=OJ>U[0UUR-T3#HZ)J^F
MXZ]&+.N"W6!_=T6^U21+2(-*]NZO6FYPC+!]1#H:HU_YVF"%"T:E7HD*Q"^*
MI[WI)B4S[*J6!4T,:N*!.RSTV(W (6*MBIS)<J/5@RA=S0+J]F/VFUC+#-LL
MB]G[6E?2UAI<6LJO=$.<1$IBFQ(+G96WG_&N&ZO 2&-=43#'+3HBRH'N'B7G
M#3F%JJ9)H[/Q'.3<919";:@E&"=A@.M+":9$B" F.G9).IV%S2M23:(9N!;/
MB%S1.(#&^@@]\U.XN!&&5EB6U65=N&TG%YBQ3#8D)4>\5-K*OYN&H3].D$4T
MHKMH[DWB$6T?3E.#<1"DB &-P_9?-X='5 NI8%,SR#<F>0_C$'#ZZSYF%42/
M]J%Y2.K=[$T^[HX0?]81?_9JXK\S5I8NW[TE0& 6S_.]XJ !&30K_;U$L<4I
M43AG'R 3U4J2_BV,$;97<(]"ZE\GI,(:GAU0T0&M]Y8/@!(O]R;GWH'%^P;#
MB0&5[^!Q!V_,Q->MW*V4RA_!XO&1A=A3HZ5@UY@U=]BUC614 @.Z-?KD%F]M
M* := >EH?TI9M^!N(/J5$=M5'7S;XA=5.=VT2 ,T:M>$[Y9O^DWK+YKG@E6\
M%)20\X1BH#9X_W@^EZY";%$4[4;Q:G@@@= 5+TXQ/3BI+>TC%=2IR^R;QA\Y
M=@9+FR MCV:6#H-29T'G SH2-CGMZ9%U&S#)A<P%9=:\;S:O?BNNW703'U1[
M$CI@Q:&@_:05L%QSK9_($JNA;EYK.H786R!T2.FCQ%DC@R?,#SSLA2=L&/DD
M%B=LEF+/<_+H^S$VR&&(\]Z(CF5A1X_..HDA+##&X3,D8Y\V8V?L>H:D)2/$
M@*[T$F7G*'%R,DP\,L SA&KK!QCBE#0M ;(=8]CICC&[=,+8.7)GTN!MU^)\
M;1L/K\]8"*=\R[+.:3@#?H!#J5*794)R2AY=SQ"[!$KGD[CV\FV'+@V;-'T<
M<%W!L+%LJYW2'C/THV"2C!C.X4$O_YYEVKH*:'KPO,W2=0PQ$[.1.ZHT!Y7_
M(M:N]('?,""DK6?D-L0 17?.HAGM@,.0QL =S<,QK4\[K4__!ZT_4/,/ARKP
M*D4_'O@?\?Y'O(^(=Q^UI\\^0I5"K]RG-L/<BTKS/:IK[;[F+9J/6+OAS:=
M8%K)RK!"+&'J369XW]/-Y[7FP:J-^Z1UKZQ5I;M="U19TP#T+Y6RVP<*T'WC
MO/P/4$L#!!0    ( )""6U9$YUQ5N 4  /,-   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;(U7:6_C-A#]*X1WL8B!K*S+YR8&<NU1[#9!LFU1%/U
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M=X:'6\-/PQ<1ST7BL2@X9*$?AB_@15T@(H<7[<.3)H&%LJQ%RBXKH3FQQKA
M8*]2AN?LDU9U9=A?)RMC-0CU]W.1:/3$S^NA(EN8BB?B>( J,D+?BL'RW9M@
MXG]XP8NX\R)^"7UYT]069?.C+'F92%C]I6R*EZK@6N3<PD.KV!Z/GW/I1:7/
MN_1](UBF<A2]+-?,$G&8VRVM81:;&*-R#)FJ=N'&[*+<\)6TC!N6]DWL21V
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M;SH>-&6TG5A5N=?ZE;+X2'###;[*A"8![&=*V>V$%'3?><O_ %!+ P04
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M*^;Q5\RC[@$6OE[<I]8;2LRJ) 7(*HIX@!P5$TH)C(6G.9Z^_Z#TIM1VX<*
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MG.)P\F:>)ND%SB:C<.S<F&]$/]HV%YHQ2>(P/OYZW.>0_@S'J47\V0 E_UN
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M<VAE971S+W-H965T,S4N>&ULE5;;CMLV$/V5@1H4NX"@"V7Y5MN O4G0 !O
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M;@.M;Y6RQX$[H/]96?P#4$L#!!0    ( )""6U8&0"OD"08  ,P2   9
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MXIFQ9I_1G;#[C7Y8"9:T=*2T/'@&'8QKP;AA"Y4B6<$*F8-S:8KT,2=G#&G
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M]OQM!UK4YLP[$1I/T.9QSAD>,4@ YZ<"TV,YH W:GR#C?P%02P,$%     @
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M+\H(3-__^X73;>BY:^VH@X?ICKY,-/X"G6^T=L\+;V#XA)<_ 5!+ P04
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MH3\B;:JJ.JL&1JY=1;20ANHKU\VHH$5E#6A]*:79#>P&38D\^P]02P,$%
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M/-B)'!Y*=L#&D^ (0YKX(3X.)NS.(23&5<XTL V+DF ,>WR)PF#$[K6#9=9
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M71OGK8U98R/?MC&M;31US F)(,]SB)ICPN]37EJ_JG[-"E5):[H3@HSTNOX
M5AUE!#'"BSG6;N+$-=0U8<W3A/Q2%5PSJ_2$O)=0#%>T*F""M$)6SB$4.^TM
M-^1[$@_"8(2^'\8!11^-QD%$?N;&  KU4M08S%HMYE7-A55$*ND0-5ARD$):
M#OI $=;GE3,57N[7>93$P;!+CB@T1NC'<1!W&XU?MIAA6U+F&(85)=-6I*+$
M.ZPR/*VTL()#!PUH=].&P:#['.1'+EXZB9(90]YQEF/?MW=QI?*,:T.BP3 (
M292,@S&A23_H[RC*A&ETP=X'5<=$@EF$C67WA [ -Z5]L)^$P?"-J']"LZ,D
M]L2,N\WX<^*?DGTF]6%#^F@?]4]BOX9\&CO6*05K8[<!!TA[%AZB?Y@ !]E
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M+.Z=?KC"19]KMP#O%TK9S<0I:/\ZF/T+4$L#!!0    ( )""6U83XU.*I@4
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M94!Q_T.2Y"]7R@?8?Q?'[']02P,$%     @ D();5N8@)\D^!   PQ8  !D
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M!YJ"<@/L^TQ*\])Q$[2?369_ %!+ P04    " "0@EM63D?NL!\$  !>&@
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M=#@.%YW+BZ#4/<\MJ&P4@B-"4./ .N+,#_19S!!LU?]G]SN8PO%R,*"]Q[B
MB3=*]HY"_V@0%CFTFAYFF$;-0@RV80\W' 30D5D(:Y,]LN!1AL/ ^2A%+NL5
M&.MMH0#LTZP9&"/"BH>6UF,-CZ(&(P;EL,<<#J+HR&"$M;'+1<BF1QH.@Z<W
M%H'Q(JAX:&$]WO!%U%C$(!_QY"-!-AT7BP%M/!D<+XB'' F#Z!?%"D ?63WT
M)!'6.;2@GG&$Q(P#B0$_XN%'PE.YX^(0UM[C48)XSI$PB_X5A_[1(:QS:$$]
MYLAYU#C$0![QR"/AJ=QQ<0AK[_$T03S=2)A MK*@!*M.K">D96DV3,' .!%C
MZD8\Z,@D:C!B0(]XZ)'PI.ZX8(2UZ6 NJ,<;#2.H-Q?] T98\<#*4L\YBF/F
M@L:@'_7TH^$9WE&Y&- >#^=BYXUEF$4/3+U80RS/0>O6G7[74HS9'/64HU'?
M5=(8[*.>?33BZ\H![1 ]TIU7_C6HA5O8T,B]M6_?_G='N\63JW;)P)_>KKS8
MG"RXT*B"TC;-3L?6E6H7,]H=(U=N >%9&B-KM[D$^VBBFA/L[Z64YFVGN4"W
MI#3_&U!+ P04    " "0@EM6Q^JBF'P%   ))P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6S5FMMNXS80AE^%<!=%%DBM@V/G4,= '$E-BF83K#?M
M1=$+6J)M(9*H):D<@#Y\AY(L2UY9L8%!@=PD$LWY..0_/&C \0L73W+%F"*O
M<93(R]Y*J?3",*2_8C&5?9ZR!'Y9<!%3!:]B:<A4,!KD1G%DV*8Y,F(:)KW)
M."][$),QSU04)NQ!$)G%,15O4Q;QE\N>U5L7? V7*Z4+C,DXI4LV8^HQ?1#P
M9E24((Q9(D.>$,$6E[TKZ\*SSK5!7N//D+W(VC/179ES_J1?;H/+GJD]8A'S
ME490^/?,KED4:1+X\;V$]JHVM6']>4WW\LY#9^94LFL>_14&:G79.^N1@"UH
M%JFO_.6&E1T::I[/(YG_)2]E7;-'_$PJ'I?&X$$<)L5_^EH.1,W 'NXPL$L#
M>\M@,-AA,"@-!ML&NUPZ*0U.]FUA6!H,]S48E0:C?.R+P<I'VJ&*3L:"OQ"A
M:P--/^1RY=8PP&&B(VNF!/P:@IV:S-(P(?>+!>$+<L-C1FX8C=2*T"2 =YF&
M/B/33(*5E.07\HV]JHQ&Y,AABH:1_$P^$8/(%15,$B ])J&2QU (SW=A%$'P
MR+&AP%'=G.&73ET73MD[G!J1.YZHE21N$K"@Q=[MMK?L#H !(U0-D[T>IJG=
M2?P]B_K$M(Z);=IVK<]M?>LF.<SOD\&:)-D2IJGJ)CKO^98 T2R)CS.'''WZ
MO":W#=XA#JYQG0YZ^Q.M=XD-?095& _R)@8[FKA-?!V\,T45T]T^)E,:T02"
M=Y:OSSJ<KX(@U*L9A*\32C_B,M-1.W_3KRF74/Z;X%D*\0NX* O"9)G7A% *
MDXP%Y#YE@FJ$)'__ 1Z06VA-_M,R(M/"W9-V=_5V<2%3ZK/+'NP'DHEGUIO\
M_),U,G]MBRA,F(,)<S%A'A*L$4 G50"==-$GUSR.8:.#]=9_.B8I%>291ADC
M1["0!3R*J) $U"\B]C/YMWM"3#L;.U3^ G:>P_1)X7EB]DUK;#S79<5LT=VG
M1>^=2@T9AI4,PTX9OF3Q'$89-B->S#68@N5*)F'0=R]JTT[NH2->P$:UKFT/
M]X\U[&8-%],A#PG6T&14:3+JU.2;H'"0S,^!&@TG E@A%1-QFPR=J$-EP(0Y
MF#"W>\1L\L9@P6@3$LF+AI"GE9"GG6ZYR8K.P];9TVEXJ&R8, <3YF+"/"18
M0\JS2LJSCW7>.<,,($R8@PES,6$>$JP10.=5 )W_G^>=\ST.#->='ATJ*R;,
MQ81Y2+"&K):Y^9XW]UGD0;$=4_FXG/Y0",<L6 WN&.SOY%ZM0&ZUH@F9T8@=
M$YT9X(M%F]K=+APZVU%I#BK-1:5Y6+1F:-12/=;'VC1*?['B")/FH-)<5)J'
M16O&D;V)(_O0#X)6=3LI!ZN+27-0:6Y)&]:_!OO;G\M8339%VR3(K,[T22$:
M+=+Y/I>J73+4M!4JS4&EN26M+MEPU#_=UNS'6K;=/V_/<5B;7)/5G6S"WJ,!
M!/(&C'RA\8ZYB)J00J4YJ#07E>9AT9J!LLF&6<,/MF.CIME0:0XJS46E>5BT
M9AQM,GC6'BF\!1,"U%:<!'7U>:5^J^"H"3U4FE/2ZJNS99[TMQ.QJ(UZ6+2F
MDIL4GK57#@]6_/(+?J:_X%N50\WIH=(<5)J+2O.P:$V!-XD]ZX-E]BS4U!XJ
MS4&EN:@T#XO6C*--?L_J3O ]"$Y 8JH7>R7">9:?_.$TZ=<R?ZUZ%]S31BYO
MN)7*ZV[\8!E1DWFH- ^+5LAHU&[JQ$PL\SM5$C3)$E7<=JA*JWM;5_EMI:WR
M:^O"L5K*77W/*[\9M,$7E\3NJ%B&,-\CMH"FS/XI[)NBN'=5O"B>YO>$YEPI
M'N>/*P9?%4)7@-\7G*OUBVZ@NOTV^0]02P,$%     @ D();5@"<JXZP#P
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M$3;N$4/N'CF(\(\I#^HJ@=(L*,V&TIR:UBJE.=,XW4%M)5 :@=(HE.;WZMT
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M((P"CI<SYQ)>A'X_,\A[W!&\%XUKD+ERS]C/[.9S/'.\;$8XP9',()#ZV>$
M)TF&I.;QJP1UJC$SP^;U ?UC[KQRYAX)'+#D!XGE>N:,'1#C)=HF\BO;7^/2
MH?,,+V*)R/^#?=G7<T"T%9*EI;&:04IH\8M^ET0T#.#P$0._-/"/#0:/&/1+
M@_Y3#0:EP2!GIG EYR%$$LVGG.T!SWHKM.PB)S.W5NX3FKWW6\G54Z+LY/QJ
M*U2+$"!@Z3VA*'L9 KP#7U3(!4BLP0*1&*CX I?1KRT1)'];;T(L$4G$6]7S
M^VT(WKQZ"UX!0L$-29(,8>I*-;EL"#<J)W)53,1_9"+0!S>,RK4 'VB,8QW
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MEN:7:XQBS+,.ZOF2,7FXR0:HSF#G_P-02P,$%     @ D();5B=^J"<Q!0
M&"(  !D   !X;"]W;W)K<VAE971S+W-H965T-38N>&ULS9I=;]LV%(;_"J$5
M10IDED1_I[8!QVJ1 LMF)&MV,>R"D6B;J$2Z)!TW_WZDI.C#5IBH89;=Q)+,
M\_+P47C$U]1DS_@WL<%8@A])3,74V4BY/7-=$6YP@D2';3%5WZP83Y!4IWSM
MBBW'*$J#DMB%GC=P$T2H,YNDUY9\-F$[&1.*EQR(79(@?G^.8[:?.K[S<.&*
MK#=27W!GDRU:XVLLOVZ77)VYA4I$$DP%811PO)HZ<_\L@'T=D+:X(7@O*L=
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M?OX;_AW]?!1S>OOG_<VJ2%#-3&L>\OU63/NGW^572_#]3S&*DC ^[C@J6NL
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MG4J#-=D-"VRSH&P [L^D-.N)/:!MW,E?4$L#!!0    ( )""6U:S58GQHP(
M "$'   9    >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;*U576_:,!3]*U96
M3:VTD@\HJSJ(5,BF]0$)%75[-LD-L>K8F6V@^_>[MD.@%70\]"7QM>\YOA_V
M\6@KU;.N  QYJ;G0XZ RIKD+0YU74%/=DPT(7"FEJJE!4ZU"W2B@A0/5/$RB
M:!C6E(D@';FYN4I'<FTX$S!71*_KFJJ_$^!R.P[B8#?QR%:5L1-A.FKH"A9@
MGIJY0BOL6 I6@]!,"J*@' ?W\5TVL/[.X1>#K3X8$YO)4LIG:SP4XR"R 0&'
MW%@&BK\-3(%S2X1A_&DY@VY+"SP<[]A_N-PQER75,)7\-RM,-0YN U) 2=?<
M/,KM3VCSN;%\N>3:?<FV]8T"DJ^UD74+Q@AJ)OR?OK1U. #$PQ. I 4D;P&#
M$X!^"^B?"QBT %?JT*?BZI!10].1DENBK#>RV8$KID-C^DS8MB^,PE6&.)-.
MJ:X(%0694?4,ABXYD 7D:\4, TVNR8/8@#9,K'#D3YEMUR-P:J @1IX 7F8X
MQ[B^0HJG148N+Z[(!6&"S!CGR*!'H<'P;1!AWH8Z\:$F)T*-$S*3PE2:?!<%
M%*\)0LR[2S[9)3])WF7,(.^1?OR%)%&2' EH>CX\/@+/SH='[V33[UK9=WS]
M$WR^4W@E#=9YWRJU;Y7"=<5R:]7[KNFN:\=ZXO<<'-_3BM*=;F@.XP!51X/:
M0)!^_A0/HV_'ZOF19-D'D;VJ]:"K]> ]]G2N9 Y0:%(J61--.1YY>XNPYKL;
M($M"-W@%;(VOL1W7UNO\NOO];]W^5KLW*9Z1S6$Q_^N1>8^; X\XZ0T[)Y]Y
M>" >-:B5$V%-<KD6QE^E;K;3^7LG;V_F)ZC_7J[W-/[Q0(E8,:$)AQ(IH]Y7
M#$EY0?:&D8V3J*4T*'AN6.$;!LHZX'HII=D9=H/N54S_ 5!+ P04    " "0
M@EM6O _KD9\"  #&!P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6RM
ME5UOFS 4AO^*Q:JIE3H^3( N(TAMHFF[Z!:UZG;MD)-@U6!F.TGW[V<;@DA#
MHE9:+H)MWO?PG..O=,?%LRP %'HI624G3J%4/?8\F1=0$NGR&BK]9L5%293N
MBK4G:P%D:4TE\[#OQUY):.5DJ1V;BRSE&\5H!7.!Y*8LB?A[!XSO)D[@[ <>
MZ+I09L#+TIJLX1'44ST7NN=U49:TA$I27B$!JXES&XRGB=%;P2\*.]EK(Y/)
M@O-GT_F^G#B^ 0(&N3(1B'YL80J,F4 :XT\;T^D^:8S]]C[Z5YN[SF5!)$PY
M^TV7JI@X-PY:PHILF'K@NV_0YA.9>#EGTOZC7:OU'91OI.)E:]8$):V:)WEI
MZ] S!*,3!MP:\%L-86L(;:(-F4UK1A3)4L%W2!BUCF8:MC;6K;.AE9G%1R7T
M6ZI]*KO-<[ZIE$0/D /=D@4#] E->5GS"LPX7Z$AS>4,%*%,7FGUT^,,75Y<
MH0M$*W1/&=/S(U-/:3SS$2]O4>X:%'P"90:YB\+@&F$?XP'[].WVX-#NZ:)T
ME<%=9;"-%YZ(-]T(H2LP'DJD<8Z&G6;CC65-<I@X>F=)$%MPLH\?@MC_,I36
M?PIVD&38)1F>BY[-B:(Z2;V;VBD6W10/Y=T$BVPP<SYLLPB/W)O4V_83&E#Y
MV TZU0'IJ",=G27]J0H0;^5L0L4]@@"_@FPD25\2NLDP8]0Q1F<9;X_IKO4F
MMNMH"#,Z8HC"^*B< ZH@ZJD.4.,.-3Z+^H-7+1BJW[<&XB.<)'3#5\P#HL0=
M^;W?B>60=/S)>TL]!)L<+<4X\'M+L:$]5D6?0Q>_(O1ZIZRYX>Z)6--*(@8K
M[?/=1 <0S:W1=!2O[<&[X$H?X[99Z(L6A!'H]RO.U;YCSO+NZL[^ 5!+ P04
M    " "0@EM6,;9J:Y@$  !@&P  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6S566V/FS@0_BL65YU:*1NP"9#L)9&ZV:NNTE5:==7>9R]Q$JN J6TV
MV_[ZLX'P$APNT1'=WI<$DYDGSXS']L,PWS/^3>P(D> ECA*QL'92IK>V+<(=
MB;$8LY0DZI<-XS&6:LBWMD@YP>O<*8YLY#B^'6.:6,MY?N^!+^<LDQ%-R ,'
M(HMCS'_<D8CM%Q:T#C<^T^U.ZAOV<I[B+7DD\DOZP-7(KE#6-":)H"P!G&P6
MUGMXNT*^=L@MOE*R%XUKH$-Y8NR;'GQ<+RQ',R(1":6&P.KKF:Q(%&DDQ>-[
M"6I5_ZD=F]<'] ]Y\"J8)RS(BD5_T;7<+:RI!=9D@[-(?F;[/T@9D*?Q0A:)
M_!/L2UO' F$F)(M+9\4@IDGQC5_*1#0<X.2$ RH=T+D.;NG@YH$6S/*P[K'$
MRSEG>\"UM4+3%WEN<F\5#4WT-#Y*KGZERD\N'[BJ""Y_ )RLP>_?,YJJ.9+@
M!JQ8G+)$70O -N"$V=M[(C&-Q#OE\.7Q'KQ]\PZ\ 30!GV@4J5D2<ULJDOJO
M[+ D=%<00B<(W9-P#%PX LA!R."^.M\=MMUME9HJ/ZC*#\KQW!-XYZ3!%&2!
M.C&CZK5Y*U(<DH6E%I\@_)E8RU]_@;[SFRGD@<!:"7"K!+A]Z.T"(8>01R A
MQK@+,"\'TUO(\Q+-W-E8S>1S,R*#F3>%#;,6UTG%==++]4_%<03N,AJM:;(=
M@8]QRMDST83%J)ZO$?A*=C2,B,B#^I#QA,J,$U,\O7]XZ3P.!-;*C5?EQKM*
M(7M#)F @L%8"_"H!_EF%/ )IA'41M HZ'VUH@I.0@(BH@P%P?0+<L,U-I@98
M"*)\GH@Z.=4H#+,XB[ D:W5F*+(AQ<6II%!PS+BD/_,;IHP6-(-&[4^06B+P
M:(ETS=P 3L>>>8D$51:"_B5"A+@%[_\-_Z!#[ ;ZWFP\.0K 9#>9.:<BF%81
M3(?<D*8=%L@+9N/@B&QAYC?-$)J:F<XJIK-_W(Y,E'J]+EU2 X&U H1.K1Z<
MJ^PJ)>Q .1@*K9V$AH2"_X^=I>39*O:IW]E93&9J_9ZH=EA+)=@K1):'@]>L
M^@951$.AM2.M-1%TKU/VO5KKXB0,A-9.0BVV8+_:>CUE/^D>E0YL%G29KZX=
M\EUTLO!K:05[A8LZ5%5X.Q:M 6TH3B/50>744&CML&M!!?WKK()>H79Q$@9"
M:R>AUE.P7U"]GE70U5M(/5)YQXO 8.;!QAG1SD.MRF"_+#L\4AFI];I>/.$#
MH;4#K44=G%VGZ@>5?4.AM9LBM>Y#O9+J]51]R;/U--6I>8.1>VK71[7L0_VR
MK^H;C%2L+_I"'.7!2+@7].+.T$!H[10TFF-7ZHX-VQZ[AAA$M1A$YW7(_ONU
MX';*W)\$G=Y;:=9\UO6"$_L_JM4@ZE>#*Y8(R;.B.4\3H'305F7;>![T0UT\
M_==HJZ%:_*'K--;0H%)P*+1V$FHIB,YKKIW9E"G1FOU?5SV!=O9MDYG;Z1+;
MC=<?^MW3)\RW-!%JM6V4GS,.%  O7N<4 \G2_(W($Y.2Q?GECN UX=I _;YA
M3!X&^B5+]5)M^3=02P,$%     @ D();5C&'XCTA @  900  !D   !X;"]W
M;W)K<VAE971S+W-H965T-C4N>&ULA51M;YLP$/XKEB=-G92%E[19E0%2TVQ:
M/TQ"[5X^3/O@P %6#::V">F_W]D01*6T^X+O['N>>\YW)NJE>M05@"''6C0Z
MII4Q[<;S=%9!S?12MM#@22%5S0RZJO1TJX#E#E0++_3]M5<SWM D<GNI2B+9
M&<$;2!7175TS];P%(?N8!O2T<<_+RM@-+XE:5L(#F)]MJM#S)I:<U]!H+ANB
MH(CI3;#9KFR\"_C%H=<SF]A*]E(^6N<NCZEO!8& S%@&ALL!;D$(2X0RGD9.
M.J6TP+E]8O_J:L=:]DS#K12_>6ZJF%Y3DD/!.F'N9?\-QGJN+%\FA79?TH^Q
M/B59IXVL1S JJ'DSK.PXWL,,$%R^ @A'0.AT#XF<RATS+(F4[(FRT<AF#5>J
M0Z,XWMBF/!B%IQQQ)DD5]E>99\*:G'QYZGB+-V[(1_(#CJ9C@ESLP# N](?(
M,YC/HKQLY-X.W.$KW#O(EF05+$CHA^%+N(<R)ZWAI#5T?*O_:%V05# 4^5+R
MGYN]-@J[_/><TH'Y\CRSG?R-;ED&,<71UJ .0)/W[X*U__D-W:M)]^HM]B0%
ME:%"G'$B"]+.;QQ.\A>DP1?8"LA+R(F11$"3@]*DLPO)%.0<*RX5@*OVHAU(
MS[9ED!,,/;?/\I#XR_5UY!WF57BSJ;$/\#M3)6\T9BX0YB\_75&BAJ$>'"-;
M-TA[:7 LG5GA?P"4#<#S0DIS<NQL3G^6Y!]02P,$%     @ D();5EJ6X\JT
M @  A <  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULK55;3]LP%/XK
M5H8FD%AN34O'TDBT81H/2!6([6':@YN<-A:.'6SWPG[];"<-;0D=#[PDOISO
M\_G.L<^)UUP\R@) H4U)F1PYA5+5I>?)K( 22Y=7P/3.G(L2*ST5"T]6 G!N
M027U0M\?>"4FS$EBNS852<R7BA(&4X'DLBRQ>!X#Y>N1$SC;A3NR*)19\)*X
MP@NX!_50386>>2U+3DI@DG"&!,Q'SE5PF?:-O37X26 M=\;(*)EQ_F@F-_G(
M\8U#0"%3A@'KWPHF0*DATFX\-9Q.>Z0![HZW[-^M=JUEAB5,./U%<E6,G*&#
M<ICC)55W?/T#&CW6P8Q3:;]HW=CZ#LJ64O&R 6L/2L+J/]XT<=@!!(,W &$#
M" \!T1N 7@/HO1<0-8#(1J:68N.08H636/ U$L9:LYF!#:9%:_F$F;3?*Z%W
MB<:I9"KT#1+J&6&6H^NG):ET3A7Z@E+0UR@CV&3G'$UP112FY"_DZ(8I$" 5
MNM[HRR<!G::@,*'R3,,>[E-T>G*&3A!AZ)90JN$R]I1VU1SH98U;X]JM\ VW
M@A#=<J8*B:Y9#OD^@:<UMD+#K=!Q>)0QA<Q%O> <A7X8=C@T>3\\Z("G[X?[
M1]3TVK3U+%_O/VD[1U.*=;[VL_?[:B:5T$_J3U?D:^:HF]F4F4M9X0Q&CKX
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MERO[WX#*&=CO"RG-;N,<M'\BV5]02P,$%     @ D();5I.E8H&' P  C0P
M !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULK5=-C]LV$/TKA!H4"1#K
M6[*]M07LKAHT0!==9)OV4/1 R[1-1")5DK;3_OH,*:VBE6AU#[[8(O7F<=[,
M<#Q>G;GX(@^$*/2U*IE<.P>EZAO/D\6!5%BZO"8,WNRXJ+""I=A[LA8$;XU1
M57JA[Z=>A2ESLI79>Q39BA]521EY%$@>JPJ+?^](R<]K)W">-S[1_4'I#2];
MU7A/GHCZ7#\*6'D=RY96A$G*&1)DMW9N@YL\, 8&\0<E9]E[1EK*AO,O>O%Q
MNW9\[1$I2:$T!8:O$[DG9:F9P(]_6E*G.U,;]I^?V3\8\2!F@R6YY^6?=*L.
M:V?AH"W9X6.I/O'S+Z05E&B^@I?2?*)S@TV7#BJ.4O&J-08/*LJ:;_RU#43/
M($@O&(2M03@TB"\81*U!]%J#N#6(360:*28..58X6PE^1D*C@4T_F& ::Y!/
MF<[[DQ+PEH*=RGXE$#2)9NB>5S5GA"F)^ Z9;=B3L'R;$X5I*=\!ZO-3CMZ^
M>8?>(,K0 RU+R)U<>0H\T7Q>T9YZUYP:7C@U"-$#9^H@T<]L2[8O"3R0T.D(
MGW7<A9.,.2E<% 7O4>B'H<6A^]>;!Q;S_/7F_H2:J,M*9/BBZ:S\=;N12L#5
M^-L6XH8BME/H?G$C:UR0M0,-01)Q(D[VXP]!ZO]D"\\UR?(KD;T(7=R%+IYB
MSWZKB<"*LCTJ30T74,.VZ#4LB6'1S?&410MWOO)._:B,07$Z!.5C4.*[80=Z
MH2+I5"23!?"!,LP*TM-P8Q.17+,$KDF67XGL1?#2+GCI9 G<5EPH^A\V/RS0
MS(3N_3.^FQTAEEA*HJPMJR&=]_(8SMUD4!$-*.V#%H-ZL$ 2>S7,.T'S24$?
MF2(0)H5 3U,1)<4;6E)%B57*?.S"<B!D/E(;^:/2'H/"A;NPBUET8A:38G[G
M"I=H-RIPFX[%Z/PD':7$ AK=Y-P"BBXI679*EI-*G@Y09S-(384PVZ(3%I"5
M\O\T+<>>]+I%(VF,B=Q@H,B&F=L%!?[W:<"?EG3<--Y35O"*6'_9_='!L] =
MEI<--=9@1UWHG4%OI@E>46+3:6@I^FU[.;[N%E3@)VX\U&&#Q>[PVGN].:TB
M8F_F70DN'IEJ1IUNMYNI;\TD.=B_T[.VF?^^TS2#^@,6>\HDB-\!)=QH\$DT
MLV^S4+PVT^"&*Y@MS>,!_B\0H0'P?L>Y>E[H [I_(-DW4$L#!!0    ( )""
M6U8 @4NR& 0  !L0   9    >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;*U8
M76_;-A3]*X16#"W@Z-.2K<PVT"0K5L#=C'C9'H8]T!)M$Z5$E:3B9+]^)"7+
MDDUK&:J76)3N/3SG\O+R,K,#95_Y'B$!7C*2\[FU%Z*X=1R>[%$&N4T+E,LO
M6\HR*.20[1Q>, 13[901QW?=R,D@SJW%3+];L<6,EH+@'*T8X&660?9ZAP@]
MS"W/.KYXQ+N]4"^<Q:R .[1&XJE8,3ER&I049RCGF.: H>W<^NC=WGN1<M 6
M?V!TX*UGH*1L*/VJ!I_3N>4J1HB@1"@(*'^>T3TB1"%)'M]J4*N94SFVGX_H
MG[1X*68#.;JGY$^<BOW<FEH@15M8$O%(#[^@6E"H\!)*N/X+#K6M:X&DY()F
MM;-DD.&\^H4O=2!:#D%\Q<&O'?RW.@2U0Z"%5LRTK <HX&+&Z $P92W1U(..
MC?:6:G"NEG$MF/R*I9]8+)&, 0<W8"T3)"T) G0+UF51$"072T "[B"!>8+
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M^9- :0/,\Z40>C^QS:K]-TG_ 5!+ P04    " "0@EM6"QS2.;(#  #U$@
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M<VAE971S+W-H965T-S8N>&ULK55;3]LP&/TK5H8FD+8Z<0IC+(W4$K;Q@(9
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M&Y)J+;.=&%E[$YE+8RW)#TO[EP'E '9_(:793-P!_7\K_0=02P,$%     @
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M5J4Y:'9U!UOE&#<_RX_=8=T!U.?H+<:X,?^02>M"0!U *(VA:*JDI0EHZEW
MV@1@/'2,]@G M%5RI&NV@-(\*,V'TBB4QE TM81*O]&<G&H"@'3B%E":!Z7Y
M4!J%TAB*II9/Z6&:>A/S.1, M[73C1O]'VI.=LSJ0[-2*(VA:*KFI?=H:CVJ
MIR82T\9$PITVOX?0Y^BM:EO22>,[)VA2"J4Q%$T5M70&3;TUV)A*/.(EV&U+
M7R[U\-Z] .HA0FD^E$:A-(:BJ>N12J_1,DZU(@GIRBV@- ]*\Z$T"J4Q%$TM
MG]+-M/1NYC.F$@6YT=0;7H+^%'J71L>T/C0MA=(8BJ:J7EG%J'6HGIA,%,%5
M@\!U9W51L6L0K9:IQ+ANA/C0I!1*8RB:*FEI"EIZ4[ QE9@\LK#!;EO$>ZFG
M]VX&4/<02O.A- JE,11-K:'2K+3&IYI+( V^!93F06D^E$:A-(:BJ>53&J.6
MWAA]SES":5US,)XT5CIT/M+K?*2O?UV]->V:EZ'RJGJ5+J2E7_;XQ"R@99WA
MS!A.ZGI +<36I'9S'@#U!J$TAJ*IHI;>H*7W!C^*6YZ2>-_PM\&/X#KBK>I"
M5S)":1Z4YD-I%$IC*)I:*Z6G:)UJ0:,%7=$(I7E0F@^E42B-H6AJ^93NI:5W
M+Y_H'X?@ZA4)CCTTZ^T#ZCJVY&Q^G>Y#<U(HC:%HZF5JI9MHZU<NOEW=Y1>J
M9607KV0;2?E=$MWE0\(RY:M0D)M@&4:A^-$FN![==TR TCPHS8?2*)3&4#2U
M@$H_T39/U%)LZ,I(*,V#TGPHC4)I#$53RZ<T)NWG&)-%</5Z2:?^^5"?H+?P
MS8R645NM[4-34BB-H6BJGI7KGO6N9-=^0GZ2=S(T'S46AV=^DB^W_&'C[3KE
M//<46JL":EU":1Z4YD-I%$IC*)I::*5U:9_*NK2AUB64YD%I/I1&H32&HJGE
M4UJ7MMZZ?*+O.!WZ#G0E9DO&EKX#M2VA-(:BJ7J6UJ;]A+69_\='21 _=)AP
M_ZW8_^\QT&674)H'I?E0&H72&(JF%E5IK=KNJ7H,U&V%TCPHS8?2*)3&4#2U
M?$JWU7[."LXB6'=5J)[?6_?FZDW+GC9N(P%-2J$TAJ(=!!U5;A"7WV'P?9"N
MPS@C$;^1>&/HRK<J/=RT[[ ADNW^GG'7B1#)9O_PE@?R<TY^@'S^)DG$PT9^
M&[KCK1/G_P%02P,$%     @ D();5EI*[3@E P  X L  !D   !X;"]W;W)K
M<VAE971S+W-H965T-SDN>&ULM99M;YLP%(7_BL6JJ956P$["2Y=$:AM-F[1.
M4;-NGQWB)%8-SFPG:?[];$(A+0:J:<V'@(%SS[D&'CS<<_$HUX0H\)2R3(Z<
MM5*;*\^3R9JD6+I\0S)]9LE%BI4>BI4G-X+@12Y*F8=\/_!23#-G/,R/3<5X
MR+>*T8Q,!9#;-,7B<$,8WX\<Z#P?N*>KM3('O/%P@U=D1M3#9BKTR"NK+&A*
M,DEY!@19CIQK>'4#8R/(K_A%R5Z>[ /3RISS1S/XMA@YODE$&$F4*8'U9D=N
M"6.FDL[QIRCJE)Y&>+K_7/U+WKQN9HXEN>7L-UVH]<B)'+ @2[QEZI[OOY*B
MH8&IEW F\W^P+Z[U'9!LI>)I(=8)4IH=M_BIF(@3 4(- E0(4)[[:)2GG&"%
MQT/!]T"8JW4ULY.WFJMU.)J9NS)30I^E6J?&WWFVNE1$I&!"Y@I<@IF^[XLM
M(PLP%31+Z 8S,,4'?2.4!),M 7HJ7XG.)T1ARN0%. ,T W>4,3WA<N@I'=#8
M>$D1YN88!C6$F9#$!3WX"2 ?(? PFX#SLXN793S=7]DD*IM$>=U^0]TO."'@
M.N7;3-E"M8K-:W$E-[K"R-'/O21B1YSQQP\P\#^W1.N5T7IY]=[;YG]^ '=8
M;055!UO2WCLD[9=)^ZV3J.])SY;IJ!KD*L. W1@-7#3T=A:O0>DUZ/+JV[R.
MJO#$JQ<W>06E5]#E-;!Y!76O"+J1W2PLS<(NL\!F%M;,4.@&=J^H](JZO$*;
M5U3SB@-W$)_^[,9Q:1RW&O]<$_V!6.JGVF8?UUM%_= =V#VA7X',;W?E"C,K
M<_RZ8P1#MZ%+>().V.KX0W\TFZG2+O['EQ56R(/H/X(%O@<#805!V$JN1K84
MLO!-<($5R6 GRJQX*61OXPNL8 8[:68E#+3@+(P;WX0*:+"3:%;(P#K2FBD#
M*Z3!3J99.0/K4'LC:&"%.-C.N';4P#KJ$(RCQC>_ ASL(%PC:XZZZ,44!^$K
M/^]DO6;6OG=8K&@F 2-++?/=4#\8XKB</ X4W^1+N#E7>D&8[Z[U$IP(<X$^
MO^1</0_,JK!<U(__ E!+ P04    " "0@EM6D)T%^1@I  !A@P, &0   'AL
M+W=O<FMS:&5E=',O<VAE970X,"YX;6RUW6ESVMB"QO&OHLK,G>I;U3=A]=(W
MG:ITM._[-C4O")8=ZMK@ >QTJNZ''\#80B ?0_H__:*#B?0[LN7P'+0\?/P^
MF_]K\:VJEM*?=[?3Q>_OOBV7][]]^+ 8?ZON1HOWL_MJNOJ;Z]G\;K1<?3F_
M^;"XGU>CJ\U*=[<?>IW.V8>[T63Z[M/'S7/^_-/'V</R=C*M_+FT>+B[&\U_
M_%'=SK[__J[[[OF)<'+S;;E^XL.GC_>CFRJJELF]/U]]]>%%N9K<5=/%9#:5
MYM7U[^\^=W\KN]W!>HW-(NFD^K[8>2RMOY>OL]F_UE\85[^_ZZPWJ;JMQLNU
M,5K]\5A]J6YOU]1J0_YWJ[Y[&72]XN[C9UW=?/>K[^;K:%%]F=UFDZOEM]_?
M7;R3KJKKT</M,IQ]UZOM=S1<>^/9[6+S?^G[=MG..VG\L%C.[K8KK[;@;C)]
M^G/TY_8GL;-"[^R5%7K;%7K[*_1>6:&_7:%_[ B#[0J#8T<8;E<8'KO"V7:%
MLV-7.-^N<'[L"A?;%2[V5^B^LL+E=H7+O156OW"O[+C.\Y[K'+M1W9>=?;"W
M7UWE>7=WC][?W><=WCW8XZ^N\KS+NT?O\^[S3N\>O=>[S[N]>_1^[S[O^.[^
MGG]]OSSO^N[^OG]]E>>=W]W?^Z]N6.]Y[_?V]_ZKH_2>]WYO?^^_OLK+/_;]
MO?_Z*L][OW?TWN\][_W>T7N_][SW>T?O_=[SWN]M]OZ'IY?(S>NK/%J./GV<
MS[Y+\_7R*V_]8/,BO5E_];(ZF:X#)5K.5W\[6:VW_&3/IC?_6%;S.TFNOBZE
M?TAQ]>?R870K_2)7R]'D=O'WCQ^6JW'62W\8;\TO3V;O%;,K.;/I\MM"4J97
MU57+^K9X_=Y;ZSMOC"\"/JQ^0"\_I=[S3^F/GE T'Z;OI7[G5ZG7Z?6D))*E
M7_[S[]+5Z$?;#T=,>>/EBNHVJ19&YK9(>8,:38_:(O7X+>H*&$W,?+Z?'\7H
M8L:=/;XP'0%CB!EG]./Y1R-2S.._IT[+ZM;1WTOW4K 5-K.?'3$C5^.C&/=X
M1K2?O>,9T1[RW]K/\Z.^J>"(K>E<OOE-A6(FJN[K?P,MJT?'?S-MJ\?'OT*)
M?J3)\=]$VR]]>OS+2=OJV?$_@[;5\Z,W7OA/KCB>&0J8\NAOYC6F$6O]E_#O
M;]S^J[^NJ\@WIHOE_&'U'G$I_;>]6D REM7=XG]:MO*/)VW0KJW?^OZVN!^-
MJ]_?K=[;+JKY8_7NTW_]1_>L\\^VF"0QF<04$E-)3",QG<0,$C-)S"(QF\0<
M$G-)S",QG\0"$@M)+"*QF,02$DM)+".QG,0*$BLAK)'Q@Y>,'XCTU1O\Q4*:
M3:5J-+_](:W>W$^F-P^3Q;=-X,^NI:O5'* MZX7JJ5E/8C*)*22FDIA&8CJ)
M&21FDIA%8C:).4_8Q09;G^1Y_-0==-;_??SPN!OC+<MU6I;S#I?K]5N6\\EO
M(B"QD,0B$HM)+"&QE,0R$LM)K""Q$L(:X3M\"=^A,'PW;[ G+V^P?Y7&L\=J
M.EH_NJT>J_GHII+FH^5DUI; 0OK4!"8QF<04$E.?L+.=E\6SY@NB1@ZGDYA!
M8B:)621FDYA#8N[A+\]P+W6?EEB?LZY_O][O+>2W+#1XW]M;*B"W/&P9<KB_
M7=$Q&Q^3FY4<LUEIZX_K?&^IK'6IO85R<N,+$BLAK!%"9R\A="8,(;^:CU?A
ML\Z:U?N]\</=P^UH?1'/*HRFB]GMY&JTK*ZD:;5.JO'LKFK+(N$(IV;1$];M
M[NS+SOZ^E,D1%1)324PC,9W$#!(S2<PB,9O$'!)S2<PC,9_$ A(+22PBL9C$
M$A)+22PCL9S$"A(K(:R1Y^<O>7XNSO/1C_6;R<7FZ.UD]=YR\O5A?6WN0EK.
MI-'U]>1VLDKT15N,"^%38YS$9!)32$PE,8W$=!(S2,PD,8O$;!)SS@_>,.X?
MSCT_.$R[?R#W<(GN6?NA7'+3 Q(+22PBL9C$$A)+22PCL9S$"A(K(:R1NA<O
MJ7LA3-VPNM_)W=N7RZ;7RVV>&L^KJTGKJ50A?&KJDIA,8@J)J22FD9A.8@:)
MF21FD9A-8L[%06+V+X9M)TG=BX-\WIY,/3B=VF*>MYH^^:T$)!:26$1B,8DE
M)):26$9B.8D5)%9"6".%+U]2^%*8PLKTV^AK>\H*5SPU94E,)C&%Q%02TTA,
M)S&#Q$P2LTC,)C&'Q%P2\TC,)[& Q$(2BT@L)K&$Q%(2RT@L)[&"Q$H(:\1Y
MM_.2Y^M3]@ON%J0M!\4\JLFHIJ":BFH:JNFH9J":B6H6JMFHYJ":BVH>JOFH
M%J!:B&H1JL6HEJ!:BFH9JN6H5J!:26G-^-]I'^G^?YW+WLJ[Q^R&9V=G+<?L
MOH@WXN28)S4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$
MU5)4RU M1[4"U4I*:\9\KX[YGC#FHVHZF<TE=_9:E@M7/_E=/:G)J*:@FHIJ
M&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ&:KEJ%:@6DEI
MS;BO:\6Z;*]8%RT60S49U1144U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4
M"U$M0K48U1)42U$M0[4<U0I4*RFM&?]UX]BZ-EWP;O\OM9Z([9/G J0FHYJ"
M:BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJPU<YW3C3V]^LJ0G3("-5B5$M0
M+46U#-5R5"M0K:2T9L37O69=<;%96%U5=_>;3X2ZGT_&U:_2+_=/-3-M]>9_
MB+630QTM,T,U!=545--034<U ]5,5+-0S48U9ZLURI2Z[SO=O3OAT$$]5/-1
M+4"U$-4B5(M1+4&U%-4R5,M1K4"UDM*:L5XWQ77%57$'[]SGU=7#TP<_3J;2
M>+0:>K+\(3U,KZKYZN]6RTW&Z_*XEUOCOSY,;M=_]W6T^%?5>IN>> M.G@J0
MFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]JP59K=*FWUP2$Z, 1JL6H
MEJ!:BFH9JN6H5J!:26G-Z4!=--<5-\U]7H7ZU>8,_NAF7E5/4X+1W>QA]<QR
M)GVM5L$_:?N SC_$\,DICU;-H9J":BJJ::BFHYJ!:B:J6:AF=P\KW@:=84N\
M..BX+JIYJ.:C6H!J(:I%J!:C6H)J*:IEJ):C6H%J):4U0[[NM>N>4FSWVL>!
MB9&3 QUML>L>MG?U6E]@E=8EVV;Z*KJ%&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKY
MJ!:@6HAJ$:K%J):@6HIJ&:KEJ%:@6DEIS;"NZ^^ZXOX[?SX;5]750KJ>S^XV
M8?WKYI-;5LD]62P>1M/Q^F-=%LOVN^S0BCQ4DU%-0345U314TU'-V&J-3H6+
M?ML$R40'ME#-1C4'U5Q4\U#-1[4 U4)4BU M1K4$U5)4RU M1[4"U4I*:P1]
MK^[%ZPF+=SY]OGI<A_GBY5S[X^SV<3*]V=;,2]>C\>1VLOS1EO-B^M2<1S49
MU1144U%-0S4=U0Q4,U'-0C4;U1Q4<U'-0S4?U0)4"U$M0K48U1)42U$M0[4<
MU0I4*RFM.16H._)Z3^4\U-WT/;(YZ NJR:BFH)J*:AJJZ:AFH)J):A:JV:CF
MH)J+:AZJ^:@6H%J(:A&JQ:B6H%J*:AFJY:A6H%I):<WX[]7Q+^[.L]^\95X,
MG!SX:'L>JBFHIJ*:AFHZJAFH9FZUW1NB!_LW1%OHD#:J.:CFHIJ':CZJ!:@6
MHEJ$:C&J):B6HEJ&:CFJ%:A64EHSQ^M2O)ZP=>=36-T\W(Z6L_D/:32]DJH_
MJ_'#<O)82:.G&^SNJ_EDUGHQO1@^.=_1>CQ44U!-134-U714,U#-?.,7N7\V
MD*Y&/]HN,;'0#;%1S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1K4"UDM*:
MJ5]WX:T>BEXLM\WWBU78SZNK(_KOQ-[)84]J,JHIJ*:BFH9J.JH9J&9NM=T/
M2>_MOY4G![11S4$U%]4\5/-1+4"U$-4B5(M1+4&U%-4R5,M1K4"UDM*:H5ZW
MW_7$[7?&=)7F\VI]L?WZPOOI^CK\ZFI:+1:_2E\?%I/UH\U;).G?ZS]:8WYX
M\++;W_O4.O%&G)S=;PZHH .JJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%
MJ!:A6HQJ":JEJ):A6HYJ!:J5E-;,[KKBKB>NN-M\!MVZL&[T];9J36:TH [5
M9%134$U%-0W5=%0S4,U$-0O5;%1S>H=%:\-AV\V%[G;)QD&)]DHV#]U$']4"
M5 M1+4*U&-425$M1+4.U'-4*5"LIK1G4=?E<3UP^%W^KI"]/-[M]?FZ?:\UK
MM&H.U6144U!-134-U714,U#-1#4+U6Q4<U#-134/U7Q4"U M1+4(U6)42U M
M1;4,U7)4*U"MI+1F[-=U=+VG!AWL;C>TF [59%134$U%-0W5=%0S4,U$-0O5
M;%1S4,U%-0_5?%0+4"U$M0C58E1+4"U%M0S5<E0K4*VDM&;\UP5W/7'!W>=-
MN_Q"FCTL%\O1]&I=>?-4@7-;+9>K/V;71U7@H%5WJ":CFH)J*JIIJ*:CFH%J
M)JI9J&:CFM,[K CL]\Y;#^*W+'G1:SV&C[;8H5J :B&J1:@6HUJ":BFJ9:B6
MHUJ!:B6E-=*\7[?8]<4M=FW'\*5_2\YD.KE[N&L+;C%X:G"CFHQJ"JJIJ*:A
MFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):A6HYJ!:J5E-:<
M -3==7VVNZZ/=M>AFHQJ"JJIJ*:AFHYJ!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%
MJ!:A6HQJ":JEJ):A6HYJ!:J5E-:,_UX=_^+NNH//DQ_/'JOI:/WH[3OAQ?;)
M<X$GK=O9.1S9V6\MD]$Q%51344U#-1W5#%0S4<U"-1O5'%1S4<U#-1_5 E0+
M42U"M1C5$E1+42U#M1S5"E0K*:V9\76O75]<!_;*,?ZXFM])M[/1]/D\_:1J
M_5 ZL7YRRJ/E=JBFH)J*:AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J(:A&J
MQ:B6H%J*:AFJY:A6H%I):<W90-UWMWJ('O ?H/%/:C*J*:BFHIJ&:CJJ&:AF
MHIJ%:C:J.:CFHIJ':CZJ!:@6HEJ$:C&J):B6HEJ&:CFJ%:A64EHS_NMFO+ZX
M&>_M#ZL1 R<'/MJ1AVH*JJFHIJ&:CFH&JIFH9O4/6Q3WVG)M=$ 'U5Q4\U#-
M1[4 U4)4BU M1K4$U5)4RU M1[4"U4I*:Z9XW9'7%W?D?7X<36[7_7C2[>1N
MLI1&FYOR6M,<+<M#-1G5%%1344U#-1W5#%0S4<WJ'Q;2O5(S9Z,#.ZCFHIJ'
M:CZJ!:@6HEJ$:C&J):B6HEJ&:CFJ%:A64EHSU>M"O;ZX4&]S)/[P]OE?I7EU
M-YI,UW?:?YW-5^SZT7BTVI)7;JX7CW-RZ)\?O A?MK\(R^C "JJIJ*:AFHYJ
M!JJ9J&:AFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):A6HYJ!:J5E-8,_;I.
MKR_LZSGEZKSUC?FC/U^],1_MV4,U&=445%-134,U'=4,5#-1S4(U&]4<5'-1
MS4,U']4"5 M1+4*U&-425$M1+4.U'-4*5"LIK3DOJ'OV^D_-/]AU>FBA'JK)
MJ*:@FHIJ&JKIJ&:@FHEJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:K%J):@6HIJ&:KE
MJ%:@6DEIC?@?U,5\ W$QWY?9W=UDN4G^ZZJ2?KFOYN/5%W]OBWXQ=6KTHYJ,
M:@JJJ:BFH9J.:@:JF:AF;;5N;^?\4N=]I[/WX<<V.JJ#:BZJ>:CFHUJ :B&J
M1:@6HUJ":BFJ9:B6HUJ!:B6E-4.]+ML;"-M\3CW6_WH)KWB<DQ,?;>%#-075
M5%334$U'-0/53%2S4,U&-0?57%3S4,U'M0#50E2+4"U&M0354E3+4"U'M0+5
M2DIKS@MZ];R@AQ[K'Z#%>Z@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CF
MHUJ :B&J1:@6HUJ":BFJ9:B6HUJ!:B6E->._+N@;B OZ3CK6C[;QH9J,:@JJ
MJ:BFH9J.:@:JF:AF;;6#8_V]X?[!?K1H#]5<5/-0S4>U -5"5(M0+4:U!-52
M5,M0+4>U M5*2FNF>EVTMWKX$P?[U>I*4A^F5PM)N;ZNQLO)8R6%HV4E>8_5
M?#JY^;8^$G!5_2E%WT?W3W]S?%>O>)-.GAV0FHQJ"JJIJ*:AFHYJ!JJ9J&:A
MFHUJ#JJYJ.:AFH]J :J%J!:A6HQJ":JEJ):A6HYJ!:J5E-:<0M1E?8,A>UX
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M?$ 00RAS U7_#C"!.,Y%:AC_5$ZC/F4.GF^?[+.B=]7+*Q4P8?&?T5KN1L;
M(&O8T'TLG]EQ 54_O=P7LE@4?\FQK'7Z!@GW0K*D@M4(DB@M_].OU?=P!BB/
M'K KP+X&G!M MP*ZUX![ W JP&E[AEX%]-H";@6X;8%^!?3; H,*&+0%/E7
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M&[U'%=E,S&:C166'3BPTCC"[S/$G ](8X/M,"+W?F#G6_;:B/U!+ P04
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M6''V6-P(NLU/XU94")KEES%&$6;*0+Y?4RK>;M0 U0GPXE]02P,$%     @
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M%!"_/Z0IWYX4#IJ/1LS_ U!+ P04    " "0@EM6_QT6RA($  #'%@  &0
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M*I8V;Q<U7SA9U^_;7!/.25%_7.%$E#120/S_AA#^^$5.L'G':_8_4$L#!!0
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M+RU>Y\A25.X#^_M42K-IN &J_RV,OP-02P,$%     @ D();5EG+8[@A!
MM!0  !D   !X;"]W;W)K<VAE971S+W-H965T.30N>&ULK9AM;]LV$,>_"J$5
M0PO4>K9L9[:!.&JWO6@1Q%OZFI%HBXM$>B1MM]]^I"3+>BHC#\J+2)1X?][]
M="$OMSQ3]LH3A 3XGJ6$KXQ$B,.=9?$H01GD)CT@(M_L*,N@D$.VM_B!(1CG
M1EEJN;8=6!G$Q%@O\V>/;+VD1Y%B@AX9X,<L@^S'!J7TO#(<X_+@">\3H1Y8
MZ^4![M$6B;\/CTR.K$HEQADB'%,"&-JMC'OG+G0"99#/>,;HS&OW0(7R0NFK
M&OP9KPQ;>812% DE >7EA!Y0FBHEZ<>_I:A1K:D,Z_<7]<]Y\#*8%\C1 TV_
MX5@D*V-N@!CMX#$53_3\!RH#FBJ]B*8\_PW.Y5S; -&1"YJ5QM*##)/B"K^7
M(&H&,M!^ [<T<-L&_D\,O-+ &VK@EP9^3J8()><00@'72T;/@*G94DW=Y#!S
M:QD^)NJ[;P63;[&T$^MM AF:;"2Y&#S"'_*+"@XF8%ND : [\(2X8#@2<L)6
MT.@5W)\ABSEX'R(!<<H_R.F=.1/P#EB *W%^N6 "_DKHD4,2\Z4EI//*!2LJ
M'=T4CKH_<=1QP1=*1,+!)Q*CN"E@R:BKT-U+Z!M7JQBBR 2>\Q&XMNOV./0P
MW-SI,0^'F]N::+SJ0WJYGJ?[D+U<"SN_WT[M*W?\ ".T,N3&P1$[(6/]ZR].
M8/_6QV1,L7 DL08OO^+EZ]377RDYR:R5&5NDYT>P07M,""9[L($I)!$"[V7*
M%F\_]($M%@CR!=3^>EK[4W]IG>J\M$[<RFLDL0:O:<5KJN7U.X-$T7J#R;3+
MQ)VVF&@7NI7)2&(-)D'%)- R>2X2Z TD00?)Q+.#%A/M0K<R&4FLP616,9EI
MF<C3>(?P "RS'BQ.BXIVJ5NIC"36H#*OJ,RU5#Z1!+Y@ ?@!DPG=[0",_Y&'
MNSINW^(T[W)RVMFC7?Q63B.)-3@M*DZ+&W=E>=K?L"4O.K"F;AM6=TYGVPZU
M7OY/!HY]K<EL[5G^+:]643RY/R$FJV^0;[Y %G@(?(:8@6>8'E%O#66/>=B/
MJA:.I=:$6BMTG5$._)BF*63@@%@QL3?/RK46M22:^:8_7=1^6FFG=^]FF".I
M-6&Z5YCNX&I@&+!"3^5 G9@];U-RNV ]<]Z"&?9,"QQS?CT_FG%=BVA'6W/6
M3_1A87D]8=GFPFV'-6K=/)9:$]*U<G;TI7/SB!_&R>_AY)B>K_N#&;5V'DNM
MR>Q:/3OZ\OFM F 8Q6F78N":\UF;W*@5]EAJ37+7&MO1%]F#2H)A^(+NIN&9
M7OO?DYYI;^SMH3Z$6Q%9M79.AM@^;XMQ$-$C$45[HWI:M=[N\X93Z_E&M>3R
M-M%5INCG?8%,GGT<I&@G)6US)K\Q*UIDQ4#00]XT>J%"T"R_31",$5,3Y/L=
MI>(R4 M4C<KU?U!+ P04    " "0@EM67U==\60$   P$P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Y-2YX;6RU6&V/VC@0_BNC7'7:2A5YX77W &DA/76E
M6PGMJNV'TWWPA@&L)G%JFZ5(_?%G.R$D8-+EE/L"L3/S>)[''GOB\8[Q;V*#
M*.%'$J=BXFRDS.Y<5T0;3(CHL Q3]6;%>$*D:O*U*S*.9&F<DM@-/&_@)H2F
MSG1L^A9\.F9;&=,4%QS$-DD(W\\P9KN)XSN'CB>ZWDC=X4['&5GC,\K/V8*K
MEENB+&F"J: L!8ZKB7/OWX5^7SL8BR\4=Z+R#)K*"V/?=.-A.7$\'1'&&$D-
M0=3?*\XQCC62BN-[ >J48VK'ZO,!_4]#7I%Y(0+G+/Y*EW(S<48.+'%%MK%\
M8KM/6! R 48L%N87=KGMT',@V@K)DL)919#0-/\G/PHA*@Y!_X)#4#@$IP[!
M!8=NX=!]JT.O<.@997(J1H>02#(=<[8#KJT5FGXP8AIO19^F>MZ?)5=OJ?*3
MTX])%K,](LPPQ165L(A)*N F1$EH+-[#.Z I/-(X5K,DQJY48VI/-RKP9SE^
M< '?#^"1I7(CX&.ZQ&4=P%7!EA$'AXAG02-BB%$'NOX'"+P@@,_/(=R\>P][
M;HEM_G8D_X!D@0G?#N/986I$N^74= UN]R+N2O4L8:[TX_1E:_)$3P^$5$0Q
M$UN.\/=?R@8>)";B']OLY$/T[$/H3>5.9"3"B:-V#8'\%9WI[[_Y ^\/FYQM
M@H4M@=6D[972]IK0IW.69"3=PP9)+#<144)F6MB("2D^0*KV6[8"/.1&1O9J
MJY/6Y9\/U#<#Z4WV=>H/>YW^V'VM*I=;C:I6@T'=)K0@]?J=7FE58]HOF?8;
MF1;YS16UXRJR$LEQAI7A@U%G>,+#8C2HA)@3L1AU.UT[CT')8_ ?>,!JJW<5
M>-F#.@)72*5JD"ABVPNS-3@+S3\-?VZS\4\HVFPN,!R6#(>-#!?%(@--B8/<
M(#QC2AF'1Y*J(UB_A!E+MP(6G*TY26P$AY9%U!F=,#PW4A-T.HM6)-_.<51R
M'#7/8AKIS!,"/IG,@R>4E.?4'M)7%-(\ZDW.1JX1_-K-K$VPL"6PFJBWI:BW
M__\Y<=NFM&V"A2V!U:3UO6-YY/WBI*B(2@1DR".U1%4^ZA-"D%@5RT!B53ZK
M&3AFKI'_IC"VU12S8ES?KR;829XVQW:MD&VAU96L%)I^HY+W2C*.W[>'?)=,
MG:M<THAF1**N,DOA?MK+N5DQPJ"Z<9UIUAC%U9JUA%;7+#AJ%KSMU%,?.-&&
MINO:\6>5*#A?5MY9.=(\[-4BM816%^E8)ON-I>+TBSHVM#25U%2+">T%0W-.
M=FWB>8-3]5JM@]M"JZMWK(3]YE+X7#VK,KTW[%:- UTM2TMH=5F.9;/?7#=7
M9*%L:96D&: +>R3<5H3.FSVO%JHEM%PHMW*5D"!?FRL9 ::BSK_1R][RVN?>
M7':<],_T=9"YHCC"Y'=)CX2OJ4K%&%<*TNL,%0&>7\_D#<DR<V'QPJ1DB7E4
M'VKJ:-4&ZOV*,7EHZ '*2[+IOU!+ P04    " "0@EM6N8PZG_P$  #.)
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ME6[,[>-*7[9 & /]O>1<[0=F@O;ZEOX/4$L#!!0    ( )""6U9.MM>6/00
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M-HP]Z<'==N$$F@A3G$H= JFO,UYA2G4DQ?%O%=2IGZD=V]>OT7\ODE?);)#
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MC54 7IZ"RX%DQ^(@N6%2'4N+RP-&6\RU@?I]QYA\'>BS:?V_B.5_4$L#!!0
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MBQ0Y#[!X'TFRBO$.6=5!V"8]\(BG#K]&=R+EP5QZW<>$.9@P%Q/F8<)\3%B
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M+W=O<FMS:&5E=',O<VAE970Q,#$N>&ULK5;+;MLP$/P50@6*!DBLAVWE45M
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M0/;X\A34.R=Y\J.4!'3)LY(N+OD_CZ0\6%3>L'A=G =YC!F+P^)R11V/)GD
M?[Z,8[:[R3.HCW?-_P-02P,$%     @ D();5B4*P[)K @  : 8  !H   !X
M;"]W;W)K<VAE971S+W-H965T,3 S+GAM;(6576_:,!2&_XJ555,G320Q$&@7
M(K6@:;NH5K7K=C'MPH0#L>K8F7V [M_/=FB6JJ;D@OCK/<]YC7V2[Y5^-!4
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MJ-X%H'=1O0M [Z)Z%X#>1?4N +V+ZET >A?5NP#T+JIW >A=FL/> +V+ZET
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M3]/^'\<OSWBHN_$U/UG^XWKS$U!+ 0(4 Q0    ( )""6U8'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ D();5OH+6U_M    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ D();5IE<G",0!@  G"<  !,
M     ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "0@EM6
MCG5 IX,'  #]+@  &               @($,"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ D();5D44?3T] @  P04  !@
M     ("!Q0\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M )""6U:VR&Z6F@@   ,M   8              " @3@2  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " "0@EM6Y+5A;E$(   =)   &
M            @($(&P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ D();5M'=2T 6!   X@P  !@              ("!CR,  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( )""6U8@@QH[D H  *9=
M   8              " @=LG  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " "0@EM6.Q5T])8"  #5!@  &               @(&A,@
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ D();5D2\R\NF
M#   _T,  !@              ("!;34  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( )""6U;J +NNCBP  #2&   8              "
M@4E"  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "0@EM6
M,1#'*]@)  #S&   &0              @($-;P  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( )""6U9!T"O@%PH  '$P   9
M      " @1QY  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ D();5GN]+3/7!0  N0T  !D              ("!:H,  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "0@EM6Y?QODS$'  #-$@
M&0              @(%XB0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( )""6U;4XY$B<@,  )0'   9              " @>"0  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ D();5AC<Z+LA
M!   X@@  !D              ("!B90  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " "0@EM6F,6R ]$&   %'0  &0
M@('AF   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( )""
M6U9Y?*+?"@4  "@,   9              " @>F?  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ D();5I+VM@?=%P  54P  !D
M         ("!*J4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " "0@EM6T&!DGP0'   S$   &0              @($^O0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( )""6U;@5V+'T <  &<8
M   9              " @7G$  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ D();5E)D_%DJ!@  Q0\  !D              ("!@,P
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "0@EM62CJ:
MA50,  "Q)@  &0              @('AT@  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( )""6U;!S\I(V04  * -   9
M  " @6S?  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
MD();5G,\H ,Q"P  +!X  !D              ("!?.4  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " "0@EM61K%U )H&   W%0  &0
M            @('D\   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( )""6U;) %0 ,@<  +\0   9              " @;7W  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ D();5J-19%0D!@
M5!(  !D              ("!'O\  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    " "0@EM6?F[=%7(Y    PP  &0              @(%Y
M!0$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( )""6U:<
M;,<J1 <  .\4   9              " @2(_ 0!X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ D();5D3G7%6X!0  \PT  !D
M     ("!G48! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M" "0@EM6]\Q(W*H%   W%0  &0              @(&,3 $ >&PO=V]R:W-H
M965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( )""6U8PE3Z1_@,  $H)   9
M              " @6U2 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L!
M A0#%     @ D();5H 'EL^Z P  I@H  !D              ("!HE8! 'AL
M+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "0@EM6:CY6I(4"
M  #)!0  &0              @(&36@$ >&PO=V]R:W-H965T<R]S:&5E=#,T
M+GAM;%!+ 0(4 Q0    ( )""6U:RK.&/K@,  +@(   9              "
M@4]= 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ D();
M5@9 *^0)!@  S!(  !D              ("!-&$! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    " "0@EM6+1[Y3F,%  #L#@  &0
M        @(%T9P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( )""6U:NU1B_'@8  ! 1   9              " @0YM 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ D();5N['J@]/ P  D <
M !D              ("!8W,! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    " "0@EM6H#]]X ($   N"P  &0              @('I=@$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( )""6U;[]/=#
M_@0  )4,   9              " @2)[ 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ D();5KC618J>!0  (0\  !D
M ("!5X ! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "0
M@EM6C]$5>WX%  #E#0  &0              @($LA@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( )""6U8']O.$R 0  $80   9
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M970T."YX;6Q02P$"% ,4    " "0@EM6JV>H76P#  !"$0  &0
M    @(&OK $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M )""6U9.1^ZP'P0  %X:   9              " @5*P 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ D();5L?JHIA\!0  "2<  !D
M             ("!J+0! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    " "0@EM6 )RKCK /  !OPP  &0              @(%;N@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( )""6U9(+NT<K@@
M +-Q   9              " @4+* 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ D();5E=1J_,@"   S50  !D              ("!
M)],! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "0@EM6
M_;]JHO@$  "/'0  &0              @(%^VP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( )""6U8G?J@G,04  !@B   9
M      " @:W@ 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ D();5EHW5H@( P  J@L  !D              ("!%>8! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " "0@EM64596KK0)  "F10
M&0              @(%4Z0$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( )""6U;DJSCA+@0  -@:   9              " @3_S 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ D();5EW,VM@]
M P  7@X  !D              ("!I/<! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    " "0@EM6:GH/AKH"  #$!P  &0
M@($8^P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( )""
M6U:S58GQHP(  "$'   9              " @0G^ 0!X;"]W;W)K<VAE971S
M+W-H965T-C(N>&UL4$L! A0#%     @ D();5KP/ZY&? @  Q@<  !D
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M=#8W+GAM;%!+ 0(4 Q0    ( )""6U:3I6*!AP,  (T,   9
M  " @:<0 @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @
MD();5@"!2[(8!   &Q   !D              ("!910" 'AL+W=O<FMS:&5E
M=',O<VAE970V.2YX;6Q02P$"% ,4    " "0@EM6*X2;5:$"  "G"   &0
M            @(&T& ( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4
M Q0    ( )""6U8+'-(YL@,  /42   9              " @8P; @!X;"]W
M;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ D();5J38U)1D P
M= L  !D              ("!=1\" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX
M;6Q02P$"% ,4    " "0@EM6?T,>5]@"  !?"   &0              @($0
M(P( >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( )""6U8M
M=J:3? (  '0(   9              " @1\F @!X;"]W;W)K<VAE971S+W-H
M965T-S0N>&UL4$L! A0#%     @ D();5ETNN0M'!0  H2$  !D
M     ("!TB@" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4
M" "0@EM6'6,?,X<"  ##!@  &0              @(%0+@( >&PO=V]R:W-H
M965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( )""6U8)(%U,90(  !L&   9
M              " @0XQ @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L!
M A0#%     @ D();5I$5;!#+!P  1E$  !D              ("!JC," 'AL
M+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " "0@EM66DKM."4#
M  #@"P  &0              @(&L.P( >&PO=V]R:W-H965T<R]S:&5E=#<Y
M+GAM;%!+ 0(4 Q0    ( )""6U:0G07Y&"D  &&# P 9              "
M@0@_ @!X;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ D();
M5NB^G"'R P  \1L  !D              ("!5V@" 'AL+W=O<FMS:&5E=',O
M<VAE970X,2YX;6Q02P$"% ,4    " "0@EM6<QD)6O\&  !@5   &0
M        @(& ; ( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0
M   ( )""6U:^9JBUB 0  !D;   9              " @;9S @!X;"]W;W)K
M<VAE971S+W-H965T.#,N>&UL4$L! A0#%     @ D();5M5; &N2 @  P@8
M !D              ("!=7@" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q0
M2P$"% ,4    " "0@EM6M!2&S4@$  !W#P  &0              @($^>P(
M>&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( )""6U8XPC+5
MQ@0   T6   9              " @;U_ @!X;"]W;W)K<VAE971S+W-H965T
M.#8N>&UL4$L! A0#%     @ D();5CN],83< P  &!4  !D
M ("!NH0" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " "0
M@EM6MQ5>U1 '  ! 0@  &0              @('-B ( >&PO=V]R:W-H965T
M<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( )""6U;_'1;*$@0  ,<6   9
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M970Y,RYX;6Q02P$"% ,4    " "0@EM66<MCN"$$  "T%   &0
M    @(&2KP( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    (
M )""6U9?5UWQ9 0  # 3   9              " @>JS @!X;"]W;W)K<VAE
M971S+W-H965T.34N>&UL4$L! A0#%     @ D();5KF,.I_\!   SB0  !D
M             ("!A;@" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"
M% ,4    " "0@EM6QPT=)+\#  #*#0  &0              @(&XO0( >&PO
M=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( )""6U9.MM>6/00
M )<0   9              " @:[! @!X;"]W;W)K<VAE971S+W-H965T.3@N
M>&UL4$L! A0#%     @ D();5GV3(4O8 @  % D  !D              ("!
M(L8" 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    " "0@EM6
M0YJ*DZ\*  "49   &@              @($QR0( >&PO=V]R:W-H965T<R]S
M:&5E=#$P,"YX;6Q02P$"% ,4    " "0@EM6?-_/H@<#   /"0  &@
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( )""6U:!B;+G3@<  'I$   /
M      "  0?M @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "0@EM6\0BR
M^?("   ;/0  &@              @ &"] ( >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " "0@EM695'I;V8"  #K.@  $P
M    @ &L]P( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     < !P ,P>  !#
%^@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>412</ContextCount>
  <ElementCount>581</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>115</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Spin Off of Home Health and Hospice Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusiness</Role>
      <ShortName>Spin Off of Home Health and Hospice Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntities</Role>
      <ShortName>Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Cash and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecurities</Role>
      <ShortName>Cash and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/AccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Self-Insured Risks</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SelfInsuredRisks</Role>
      <ShortName>Self-Insured Risks</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Redeemable Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests</Role>
      <ShortName>Redeemable Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Earnings per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShare</Role>
      <ShortName>Earnings per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Contingencies and Other Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ContingenciesandOtherCommitments</Role>
      <ShortName>Contingencies and Other Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Quarterly Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/QuarterlyDataUnaudited</Role>
      <ShortName>Quarterly Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Spin Off of Home Health and Hospice Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTables</Role>
      <ShortName>Spin Off of Home Health and Hospice Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusiness</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/BusinessCombinations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Variable Interest Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesTables</Role>
      <ShortName>Variable Interest Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/VariableInterestEntities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Cash and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables</Role>
      <ShortName>Cash and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/CashandMarketableSecurities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/AccountsReceivable</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/PropertyandEquipment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/LongtermDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Self-Insured Risks (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SelfInsuredRisksTables</Role>
      <ShortName>Self-Insured Risks (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SelfInsuredRisks</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Redeemable Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables</Role>
      <ShortName>Redeemable Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/FairValueMeasurements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/ShareBasedPayments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/IncomeTaxes</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Earnings Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsPerCommonShareTables</Role>
      <ShortName>Earnings Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Quarterly Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/QuarterlyDataUnauditedTables</Role>
      <ShortName>Quarterly Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/QuarterlyDataUnaudited</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Summary of Significant Accounting Policies - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Summary of Significant Accounting Policies - Net Operating Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Net Operating Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Summary of Significant Accounting Policies - PP&amp;E Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - PP&amp;E Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Spin Off of Home Health and Hospice Business - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails</Role>
      <ShortName>Spin Off of Home Health and Hospice Business - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Spin Off of Home Health and Hospice Business- Summary of Financial Information Related to Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails</Role>
      <ShortName>Spin Off of Home Health and Hospice Business- Summary of Financial Information Related to Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Business Combinations - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails</Role>
      <ShortName>Business Combinations - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Business Combinations - Net Cash Paid for Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails</Role>
      <ShortName>Business Combinations - Net Cash Paid for Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails</Role>
      <ShortName>Business Combinations - Pro Forma Results of Operation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Variable Interest Entities - Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails</Role>
      <ShortName>Variable Interest Entities - Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails</Role>
      <ShortName>Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Cash and Marketable Securities - Components of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails</Role>
      <ShortName>Cash and Marketable Securities - Components of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Cash and Marketable Securities - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails</Role>
      <ShortName>Cash and Marketable Securities - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Cash and Marketable Securities - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails</Role>
      <ShortName>Cash and Marketable Securities - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails</Role>
      <ShortName>Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Accounts Receivable - Components of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable - Components of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Property and Equipment - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails</Role>
      <ShortName>Property and Equipment - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Property and Equipment - Depreciation, Capitalized Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails</Role>
      <ShortName>Property and Equipment - Depreciation, Capitalized Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Leases - Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesTextualsDetails</Role>
      <ShortName>Leases - Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Leases - Components of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails</Role>
      <ShortName>Leases - Components of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails</Role>
      <ShortName>Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Goodwill and Other Intangible Assets - Textuals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Textuals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails</Role>
      <ShortName>Long-term Debt - Long-term Debt Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails</Role>
      <ShortName>Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Long-term Debt - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtTextualDetails</Role>
      <ShortName>Long-term Debt - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Long-term Debt - Financial Covenants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails</Role>
      <ShortName>Long-term Debt - Financial Covenants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Long-term Debt - Senior Notes Redemption Prices (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails</Role>
      <ShortName>Long-term Debt - Senior Notes Redemption Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Long-term Debt - Schedule of Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails</Role>
      <ShortName>Long-term Debt - Schedule of Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Self-Insured Risks - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails</Role>
      <ShortName>Self-Insured Risks - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Self-Insured Risks - Changes in Self-insurance Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails</Role>
      <ShortName>Self-Insured Risks - Changes in Self-insurance Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails</Role>
      <ShortName>Redeemable Noncontrolling Interests - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Share-Based Payments - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails</Role>
      <ShortName>Share-Based Payments - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Share-Based Payments - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails</Role>
      <ShortName>Share-Based Payments - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Share-Based Payments - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails</Role>
      <ShortName>Share-Based Payments - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Share-Based Payments - Summary of Restricted Stock Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails</Role>
      <ShortName>Share-Based Payments - Summary of Restricted Stock Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Income Taxes - Components of Provision for Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Provision for Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Income Taxes - Deferred Tax Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Income Taxes - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/IncomeTaxesTextualDetails</Role>
      <ShortName>Income Taxes - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails</Role>
      <ShortName>Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails</Role>
      <ShortName>Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Earnings Per Common Share - Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails</Role>
      <ShortName>Earnings Per Common Share - Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Contingencies and Other Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails</Role>
      <ShortName>Contingencies and Other Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/ContingenciesandOtherCommitments</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="ehc-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>0000104 - Disclosure - Quarterly Data (Unaudited) - Schedule of Quarterly Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails</Role>
      <ShortName>Quarterly Data (Unaudited) - Schedule of Quarterly Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.encompasshealth.com/role/QuarterlyDataUnauditedTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: ehc:NoncontrollingInterestExerciseRightToSellRatio, us-gaap:NumberOfOperatingSegments, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  ehc-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="ehc-20221231.htm">ehc-20221231.htm</File>
    <File>ehc-20221231.xsd</File>
    <File>ehc-20221231_cal.xml</File>
    <File>ehc-20221231_def.xml</File>
    <File>ehc-20221231_lab.xml</File>
    <File>ehc-20221231_pre.xml</File>
    <File>ehc10k123122ex103.htm</File>
    <File>ehc10k123122ex1082.htm</File>
    <File>ehc10k123122ex211.htm</File>
    <File>ehc10k123122ex221.htm</File>
    <File>ehc10k123122ex231.htm</File>
    <File>ehc10k123122ex311.htm</File>
    <File>ehc10k123122ex312.htm</File>
    <File>ehc10k123122ex321.htm</File>
    <File>ehc10k123122ex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ehc-20221231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1638">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>128
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ehc-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 37,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1638,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 412,
   "dts": {
    "calculationLink": {
     "local": [
      "ehc-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ehc-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ehc-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ehc-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ehc-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ehc-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 898,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://www.encompasshealth.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 13
   },
   "keyCustom": 103,
   "keyStandard": 478,
   "memberCustom": 57,
   "memberStandard": 54,
   "nsprefix": "ehc",
   "nsuri": "http://www.encompasshealth.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.encompasshealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Spin Off of Home Health and Hospice Business",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusiness",
     "shortName": "Spin Off of Home Health and Hospice Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ie9b2e877323e461d918332547d37a0b5_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
     "shortName": "Earnings Per Common Share - Computation of Basic and Diluted Earnings per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails",
     "shortName": "Earnings per Common Share - Reconciliation Between Basic and Diluted Weighted-average Common Shares Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Earnings Per Common Share - Textual (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails",
     "shortName": "Earnings Per Common Share - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Contingencies and Other Commitments (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails",
     "shortName": "Contingencies and Other Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCommitmentDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ie9b2e877323e461d918332547d37a0b5_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000104 - Disclosure - Quarterly Data (Unaudited) - Schedule of Quarterly Data (Details)",
     "menuCat": "Details",
     "order": "104",
     "role": "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails",
     "shortName": "Quarterly Data (Unaudited) - Schedule of Quarterly Data (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ie9b2e877323e461d918332547d37a0b5_D20221001-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Business Combinations",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.encompasshealth.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Variable Interest Entities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntities",
     "shortName": "Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Cash and Marketable Securities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecurities",
     "shortName": "Cash and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Accounts Receivable",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.encompasshealth.com/role/AccountsReceivable",
     "shortName": "Accounts Receivable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Property and Equipment",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.encompasshealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Goodwill and Other Intangible Assets",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Long-term Debt",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.encompasshealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Self-Insured Risks",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.encompasshealth.com/role/SelfInsuredRisks",
     "shortName": "Self-Insured Risks",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.encompasshealth.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Redeemable Noncontrolling Interests",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests",
     "shortName": "Redeemable Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Share-Based Payments",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.encompasshealth.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.encompasshealth.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.encompasshealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Earnings per Common Share",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.encompasshealth.com/role/EarningsperCommonShare",
     "shortName": "Earnings per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Contingencies and Other Commitments",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.encompasshealth.com/role/ContingenciesandOtherCommitments",
     "shortName": "Contingencies and Other Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Quarterly Data (Unaudited)",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.encompasshealth.com/role/QuarterlyDataUnaudited",
     "shortName": "Quarterly Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "28",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LaborAndRelatedExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Spin Off of Home Health and Hospice Business (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTables",
     "shortName": "Spin Off of Home Health and Hospice Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Business Combinations (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Variable Interest Entities (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesTables",
     "shortName": "Variable Interest Entities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Cash and Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables",
     "shortName": "Cash and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Accounts Receivable (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.encompasshealth.com/role/AccountsReceivableTables",
     "shortName": "Accounts Receivable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Property and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.encompasshealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Long-term Debt (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.encompasshealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Self-Insured Risks (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.encompasshealth.com/role/SelfInsuredRisksTables",
     "shortName": "Self-Insured Risks (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Redeemable Noncontrolling Interests (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables",
     "shortName": "Redeemable Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Share-Based Payments (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Earnings Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.encompasshealth.com/role/EarningsPerCommonShareTables",
     "shortName": "Earnings Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Quarterly Data (Unaudited) (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.encompasshealth.com/role/QuarterlyDataUnauditedTables",
     "shortName": "Quarterly Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfStatesInWhichEntityOperates",
      "reportCount": 1,
      "unitRef": "state",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Summary of Significant Accounting Policies - Textual (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
     "shortName": "Summary of Significant Accounting Policies - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:AdvertisingCostsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ie9b2e877323e461d918332547d37a0b5_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Summary of Significant Accounting Policies - Net Operating Revenues (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails",
     "shortName": "Summary of Significant Accounting Policies - Net Operating Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id3909299e17d4e9f96039b48644e435f_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ib014de72370b4cb4a6135adc8af20d7b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
     "shortName": "Summary of Significant Accounting Policies - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:ReceivablesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ib014de72370b4cb4a6135adc8af20d7b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i4cb56d21aab74ac3967968f076197961_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Summary of Significant Accounting Policies - PP&E Useful Lives (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - PP&E Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i4cb56d21aab74ac3967968f076197961_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i1d16d99320d0432eae3d9ff01729bc03_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Intangible Asset Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i1d16d99320d0432eae3d9ff01729bc03_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Spin Off of Home Health and Hospice Business - Textual (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails",
     "shortName": "Spin Off of Home Health and Hospice Business - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i4ccb23d1174a4ad1bc94116310a93215_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ie9b2e877323e461d918332547d37a0b5_D20221001-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Spin Off of Home Health and Hospice Business- Summary of Financial Information Related to Discontinued Operations (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
     "shortName": "Spin Off of Home Health and Hospice Business- Summary of Financial Information Related to Discontinued Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i2685b8f8ab054f87acf578989b27a54e_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ie37abe5ebc4f44bebbe9fb494c9c84e1_I20220831",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Business Combinations - Textual (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
     "shortName": "Business Combinations - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ie37abe5ebc4f44bebbe9fb494c9c84e1_I20220831",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
     "shortName": "Business Combinations - Fair Value of Assets and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i33b5d49a11d841d0962f2c16a1a90833_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Business Combinations - Net Cash Paid for Acquisition (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
     "shortName": "Business Combinations - Net Cash Paid for Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i81ab1b04545d4d4a9002ce9d4779d459_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FairValueOfAssetsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Business Combinations - Pro Forma Results of Operation (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
     "shortName": "Business Combinations - Pro Forma Results of Operation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i39884fa7a48547f2a08edcccd93487c8_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:VariableInterestEntityNumberofEntitiesConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "entity",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Variable Interest Entities - Textuals (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails",
     "shortName": "Variable Interest Entities - Textuals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i39884fa7a48547f2a08edcccd93487c8_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:VariableInterestEntityNumberofEntitiesConsolidated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "entity",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
     "shortName": "Variable Interest Entities - Carrying Amounts and Classification of Consolidated VIEs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i1efefea033d94a49ae6d1279523cfa77_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Cash and Marketable Securities - Components of Investments (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails",
     "shortName": "Cash and Marketable Securities - Components of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i9242279c10684829b4d9378d04b1edbd_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Shareholders' Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i9242279c10684829b4d9378d04b1edbd_I20191231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Cash and Marketable Securities - Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails",
     "shortName": "Cash and Marketable Securities - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:RestrictedDebtSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Cash and Marketable Securities - Textual (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails",
     "shortName": "Cash and Marketable Securities - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:RestrictedDebtSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRealizedGainLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails",
     "shortName": "Cash and Marketable Securities - Investing Information Related to Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRealizedGainLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Accounts Receivable - Components of Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails",
     "shortName": "Accounts Receivable - Components of Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
     "shortName": "Property and Equipment - Components of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ic5b54adc201247bb9fb60bdf36fff8a2_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ehc:Percentageofassetspledgedtolendersundercreditagreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Property and Equipment - Textual (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails",
     "shortName": "Property and Equipment - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ehc:Percentageofassetspledgedtolendersundercreditagreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Property and Equipment - Depreciation, Capitalized Interest Expense (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails",
     "shortName": "Property and Equipment - Depreciation, Capitalized Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:OperatingAndFinanceLeaseNumberOfRenewalOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "option",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Leases - Textuals (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.encompasshealth.com/role/LeasesTextualsDetails",
     "shortName": "Leases - Textuals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:OperatingAndFinanceLeaseNumberOfRenewalOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "option",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Leases - Components of Lease Costs (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails",
     "shortName": "Leases - Components of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Schedule of Supplemental Balance Sheet Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails",
     "shortName": "Leases - Schedule of Weighted Average Remaining Lease Term and Discount Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ehc:ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Leases - Maturities of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:SupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:SupplementalCashFlowInformationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i8a64fb1653e8439cadb431d448933fbe_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails",
     "shortName": "Goodwill and Other Intangible Assets - Carrying Amounts of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i177f96156a934c6d92f90d026d815168_D20221001-20221001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Goodwill and Other Intangible Assets - Textuals (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails",
     "shortName": "Goodwill and Other Intangible Assets - Textuals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i177f96156a934c6d92f90d026d815168_D20221001-20221001",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Goodwill and Other Intangible Assets - Other Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets - Other Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangible Assets - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Other Intangible Assets - Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Long-term Debt - Long-term Debt Outstanding (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
     "shortName": "Long-term Debt - Long-term Debt Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i3dfddbd9d2e441f7b14568e6345a3f34_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:LongTermDebtAndLeaseObligationsMaturityYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
     "shortName": "Long-term Debt - Scheduled Principal Payments Due on Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i3dfddbd9d2e441f7b14568e6345a3f34_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:LongTermDebtAndLeaseObligationsMaturityYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Long-term Debt - Textual (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
     "shortName": "Long-term Debt - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i37964c43d1d6497390edcd2c9583717d_I20221031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ehc:LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ehc:ScheduleOfFinancialCovenantsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:DebtInstrumentCovenantInterestCoverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Long-term Debt - Financial Covenants (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
     "shortName": "Long-term Debt - Financial Covenants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ehc:ScheduleOfFinancialCovenantsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7d3f29ddba20428d88de8c20f92adbe8_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ehc:DebtInstrumentCovenantInterestCoverageRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i4d3ce01c69d745bc933890c6d0232e0a_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Long-term Debt - Senior Notes Redemption Prices (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
     "shortName": "Long-term Debt - Senior Notes Redemption Prices (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtInstrumentRedemptionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i07b9cc9fc0fa4aa9b201c5317d0c6b56_D20150901-20150930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i44f0c6fe1d3d4acabec50bcd4c8268f6_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Long-term Debt - Schedule of Notes Payable (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
     "shortName": "Long-term Debt - Schedule of Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i29770414195047bdb212e4ecdc100bdd_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "ehc:MaximumSelfInsuredAmountFirstLayerOfRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Self-Insured Risks - Textual (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails",
     "shortName": "Self-Insured Risks - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "ehc:MaximumSelfInsuredAmountFirstLayerOfRisk",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i8a64fb1653e8439cadb431d448933fbe_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Self-Insured Risks - Changes in Self-insurance Reserves (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails",
     "shortName": "Self-Insured Risks - Changes in Self-insurance Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i8ceed624f0604d68bc0ac784aa99fe4b_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i8a64fb1653e8439cadb431d448933fbe_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
     "shortName": "Redeemable Noncontrolling Interests - Redeemable Noncontrolling Interests Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RedeemableNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "ib815d2a675ad43128d86aa58ebcb4caf_I20191231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
     "shortName": "Redeemable Noncontrolling Interests - Reconciliation of Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ehc:ReconciliationOfNoncontrollingInterestsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Redeemable Noncontrolling Interests - Textual (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails",
     "shortName": "Redeemable Noncontrolling Interests - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i2b1d1c428d764c88a5c1812e2a04cf24_D20200101-20200131",
      "decimals": "3",
      "lang": "en-US",
      "name": "ehc:NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i77780a6142904e59b58e560a56e1f9e4_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i77780a6142904e59b58e560a56e1f9e4_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i6886b561cd61484d89ba422e4d310087_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements - Carrying Amounts and Estimated Fair Values of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i6886b561cd61484d89ba422e4d310087_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Share-Based Payments - Textual (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
     "shortName": "Share-Based Payments - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Share-Based Payments - Weighted-average Assumptions (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails",
     "shortName": "Share-Based Payments - Weighted-average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i2cedb9ff00424b7a99578d332f4ff542_D20220101-20221231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i8a64fb1653e8439cadb431d448933fbe_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Share-Based Payments - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails",
     "shortName": "Share-Based Payments - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i8a64fb1653e8439cadb431d448933fbe_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id6bbfc0dab6943969098cd57a4bd7417_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Share-Based Payments - Summary of Restricted Stock Awards (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
     "shortName": "Share-Based Payments - Summary of Restricted Stock Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i1bdb061515e245bbb38d8623d6bce2e6_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:HealthcarePlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ehc:HealthcarePlanExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Income Taxes - Components of Provision for Income Tax Expense (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails",
     "shortName": "Income Taxes - Components of Provision for Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of Effective Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Income Taxes - Deferred Tax Asset and Liabilities (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Asset and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "i7012cb8cd6b7476f9630c73b12ab4420_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Income Taxes - Textual (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails",
     "shortName": "Income Taxes - Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ehc-20221231.htm",
      "contextRef": "id0eb43c6bd9e47fb95bfa7c831260e1b_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 115,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r781"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ehc_A2016OmnibusPerformanceIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Omnibus Performance Incentive Plan [Member]",
        "label": "2016 Omnibus Performance Incentive Plan [Member]",
        "terseLabel": "2016 Omnibus Performance Incentive Plan"
       }
      }
     },
     "localname": "A2016OmnibusPerformanceIncentivePlanMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_A2020AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Acquisitions",
        "label": "2020 Acquisitions [Member]",
        "terseLabel": "2020 Acquisitions"
       }
      }
     },
     "localname": "A2020AcquisitionsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_A2021AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Acquisitions",
        "label": "2021 Acquisitions [Member]",
        "terseLabel": "2021 Acquisitions"
       }
      }
     },
     "localname": "A2021AcquisitionsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_AffiliateCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash held and maintained by joint ventures in which we have an ownership interest.",
        "label": "Affiliate Cash [Member]",
        "terseLabel": "Affiliate cash"
       }
      }
     },
     "localname": "AffiliateCashMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_AltruHealthSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Altru Health System",
        "label": "Altru Health System [Member]",
        "terseLabel": "Altru Health System"
       }
      }
     },
     "localname": "AltruHealthSystemMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Altru Health System, Trinity Medical Center And NCH Healthcare System",
        "label": "Altru Health System, Trinity Medical Center And NCH Healthcare System [Member]",
        "terseLabel": "Altru Health System, Trinity Medical Center And NCH Healthcare System"
       }
      }
     },
     "localname": "AltruHealthSystemTrinityMedicalCenterAndNCHHealthcareSystemMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ehc_BusinessCombinationNoncontrollingInterestFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Noncontrolling Interest, Fair Value",
        "label": "Business Combination, Noncontrolling Interest, Fair Value",
        "negatedLabel": "Fair value of noncontrolling interest owned by joint venture partner"
       }
      }
     },
     "localname": "BusinessCombinationNoncontrollingInterestFairValue",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Including Goodwill, Assets",
        "totalLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]",
        "label": "Cash Paid for Amounts Included in The Measurement of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidforAmountsIncludedinTheMeasurementofLeaseLiabilitiesAbstract",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_CertificateOfNeedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A statement or certificate issued by a governmental agency for proposed construction or modification of a health facility. The certificate process is intended to prevent duplication of services in a community.",
        "label": "Certificate of Need [Member]",
        "verboseLabel": "Certificates of need"
       }
      }
     },
     "localname": "CertificateOfNeedMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Contributiontojointventure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contribution of primarily intangible assets relating to a joint venture agreement.",
        "label": "Contribution to joint venture",
        "terseLabel": "Contribution to joint ventures"
       }
      }
     },
     "localname": "Contributiontojointventure",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_CurrentAndFormerBoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current And Former Board Of Directors",
        "label": "Current And Former Board Of Directors [Member]",
        "terseLabel": "Current And Former Board Of Directors"
       }
      }
     },
     "localname": "CurrentAndFormerBoardOfDirectorsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_DebtInstrumentAmendmentAgreementAmountToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Amendment Agreement, Amount To Be Paid",
        "label": "Debt Instrument, Amendment Agreement, Amount To Be Paid",
        "terseLabel": "Amendment agreement, amount to be paid"
       }
      }
     },
     "localname": "DebtInstrumentAmendmentAgreementAmountToBePaid",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DebtInstrumentCovenantAvailableLimitAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Available Limit Amount",
        "label": "Debt Instrument, Covenant, Available Limit Amount",
        "terseLabel": "Available limit amount"
       }
      }
     },
     "localname": "DebtInstrumentCovenantAvailableLimitAmount",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Incurrence Of Indebtedness, Business Days",
        "label": "Debt Instrument, Covenant, Incurrence Of Indebtedness, Business Days",
        "terseLabel": "Incurrence of indebtedness, business days"
       }
      }
     },
     "localname": "DebtInstrumentCovenantIncurrenceOfIndebtednessBusinessDays",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_DebtInstrumentCovenantInterestCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio",
        "terseLabel": "Interest Coverage Ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatio",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentCovenantLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio",
        "label": "Debt Instrument, Covenant, Leverage Ratio",
        "terseLabel": "Leverage Ratio",
        "verboseLabel": "Debt instrument, covenant, leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatio",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Max senior secured leverage ratio to permit restricted payments under credit agreement.",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentCovenantReductionFeeForUndrawnPortion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Reduction Fee For Undrawn Portion",
        "label": "Debt Instrument, Covenant, Reduction Fee For Undrawn Portion",
        "terseLabel": "Reduction fee for undrawn portion"
       }
      }
     },
     "localname": "DebtInstrumentCovenantReductionFeeForUndrawnPortion",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Regulatory And Executive Action, Period",
        "label": "Debt Instrument, Covenant, Regulatory And Executive Action, Period",
        "terseLabel": "Regulatory and executive action period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRegulatoryAndExecutiveActionPeriod",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ehc_DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Senior Secured Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Senior Secured Leverage Ratio, Maximum",
        "terseLabel": "Senior secured leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantSeniorSecuredLeverageRatioMaximum",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_DebtInstrumentDiscountRateAtIssuanceOfFaceValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Discount Rate at Issuance of Face Value",
        "label": "Debt Instrument, Discount Rate At Issuance Of Face Value",
        "terseLabel": "Issuance of face value (percent)"
       }
      }
     },
     "localname": "DebtInstrumentDiscountRateAtIssuanceOfFaceValue",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket",
        "label": "Debt Instrument, Reduction In Capacity Under Restricted Payments Builder Basket",
        "terseLabel": "Debt instrument, reduction in capacity under restricted payments builder basket"
       }
      }
     },
     "localname": "DebtInstrumentReductionInCapacityUnderRestrictedPaymentsBuilderBasket",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount",
        "label": "Defined Benefit Plans, Forfeited Accounts Used To Fund Matching Contributions, Amount",
        "terseLabel": "Employer contributions funded by forfeited accounts"
       }
      }
     },
     "localname": "DefinedBenefitPlansForfeitedAccountsUsedToFundMatchingContributionsAmount",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DepartmentAppealsBoardAdverseRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department Appeals Board, Adverse Ruling",
        "label": "Department Appeals Board, Adverse Ruling [Member]",
        "terseLabel": "DAB, Adverse Ruling"
       }
      }
     },
     "localname": "DepartmentAppealsBoardAdverseRulingMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Accrued Expenses and Other Current Liabilities, Current",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Expenses and Other Current Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherCurrentLiabilitiesCurrent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Accrued Payroll, Current",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Payroll, Current",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedPayrollCurrent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Assets, Operating Lease Right Of Use Asset",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Income (Loss) Of Equity Method Investments",
        "label": "Disposal Group, Including Discontinued Operation, Income (Loss) Of Equity Method Investments",
        "negatedTerseLabel": "Equity in net income of nonconsolidated affiliates"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIncomeLossOfEquityMethodInvestments",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Interest Expense And Amortization Of Debt Discounts And Fees",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense And Amortization Of Debt Discounts And Fees",
        "terseLabel": "Interest expense and amortization of debt discounts and fees"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpenseAndAmortizationOfDebtDiscountsAndFees",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Long-term Debt, Current",
        "label": "Disposal Group, Including Discontinued Operation, Long-term Debt, Current",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermDebtCurrent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Long-term Debt, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Long-term Debt, Noncurrent",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermDebtNoncurrent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationOccupancyCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Occupancy Costs",
        "label": "Disposal Group, Including Discontinued Operation, Occupancy Costs",
        "terseLabel": "Occupancy costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOccupancyCosts",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Expenses",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Operating Expense",
        "label": "Disposal Group, Including Discontinued Operation, Other Operating Expense",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherOperatingExpense",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Restricted Cash",
        "label": "Disposal Group, Including Discontinued Operation, Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCash",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Salaries And Benefits",
        "label": "Disposal Group, Including Discontinued Operation, Salaries And Benefits",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationSalariesAndBenefits",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationSupplies": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Supplies",
        "label": "Disposal Group, Including Discontinued Operation, Supplies",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationSupplies",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Transaction Costs",
        "label": "Disposal Group, Including Discontinued Operation, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransactionCosts",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Transition Services Income",
        "label": "Disposal Group, Including Discontinued Operation, Transition Services Income",
        "terseLabel": "Transition services"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransitionServicesIncome",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Transition Services, Term",
        "label": "Disposal Group, Including Discontinued Operation, Transition Services, Term",
        "terseLabel": "Transition services, term"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationTransitionServicesTerm",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ehc_DividendEquivalentRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend Equivalent, RSU [Member]",
        "label": "Dividend Equivalent, RSU [Member]",
        "terseLabel": "Dividend Equivalent, RSU"
       }
      }
     },
     "localname": "DividendEquivalentRSUMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ECHDVenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ECHD Ventures",
        "label": "ECHD Ventures [Member]",
        "terseLabel": "ECHD Ventures"
       }
      }
     },
     "localname": "ECHDVenturesMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_EHHIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EHHI [Member]",
        "label": "EHHI [Member]",
        "terseLabel": "EHHI"
       }
      }
     },
     "localname": "EHHIMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, percent",
        "label": "Effective Income Tax Rate Reconciliation, Share-based windfall tax benefits, Percent",
        "terseLabel": "Share-based windfall tax benefits (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationSharebasedwindfalltaxbenefitsPercent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_EncompassHealthRetirementInvestmentPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Encompass Health Retirement Investment Plan [Member]",
        "label": "Encompass Health Retirement Investment Plan [Member]",
        "terseLabel": "Encompass Health Retirement Investment Plan"
       }
      }
     },
     "localname": "EncompassHealthRetirementInvestmentPlanMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_EnhabitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Enhabit",
        "label": "Enhabit [Member]",
        "terseLabel": "Enhabit"
       }
      }
     },
     "localname": "EnhabitMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_FaceAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount.",
        "label": "Face Amount [Member]",
        "terseLabel": "Face Amount"
       }
      }
     },
     "localname": "FaceAmountMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in the sixth fiscal year following the latest fiscal year.",
        "label": "Finance Lease, Liability, Payments, Due Year Six And Thereafter",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearSixAndThereafter",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_HealthcarePlanExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs for the period associated with the Company's sponsored self-insured healthcare plans that include coverage for medical and dental benefits.",
        "label": "Healthcare Plan Expense",
        "terseLabel": "Company healthcare plan costs, net of employee payments"
       }
      }
     },
     "localname": "HealthcarePlanExpense",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_HeritageValleyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Heritage Valley [Member]",
        "label": "Heritage Valley [Member]",
        "terseLabel": "Heritage Valley"
       }
      }
     },
     "localname": "HeritageValleyMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_HomeHealthandHospiceSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Home Health and Hospice Segment [Member]",
        "label": "Home Health and Hospice Segment [Member]",
        "verboseLabel": "Home Health and Hospice Segment"
       }
      }
     },
     "localname": "HomeHealthandHospiceSegmentMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_InternalUseSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalizable costs for computer software developed internally by the Company which will have future probable benefits to the Company.",
        "label": "Internal Use Software [Member]",
        "terseLabel": "Internal-use software"
       }
      }
     },
     "localname": "InternalUseSoftwareMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_InvestmentsCashandRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total investments of the Company which includes cash, cash equivalents, restricted cash, and marketable securities.",
        "label": "Investments, Cash and Restricted Cash",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InvestmentsCashandRestrictedCash",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Jointventureownershippercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint venture ownership percentage",
        "label": "Joint venture ownership percentage",
        "terseLabel": "Joint venture ownership percentage"
       }
      }
     },
     "localname": "Jointventureownershippercentage",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Land, Building, Improvements, Equipment, Vehicles and Furniture [Member]",
        "label": "Land, Building, Improvements, Equipment, Vehicles and Furniture [Member]",
        "terseLabel": "Land, Building, Improvements, Equipment, Vehicles and Furniture"
       }
      }
     },
     "localname": "LandBuildingImprovementsEquipmentVehiclesAndFurnitureMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in sixth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Six And Thereafter",
        "terseLabel": "2028 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSixAndThereafter",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Discontinued Operations",
        "negatedTerseLabel": "Expenses related to discontinued operations"
       }
      }
     },
     "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseDiscontinuedOperations",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Covenant, Percentage of Cumulative Consolidated Net Income",
        "label": "Line Of Credit Facility, Covenant, Percentage of Cumulative Consolidated Net Income",
        "terseLabel": "Percentage of cumulative consolidated net income"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantPercentageOfCumulativeConsolidatedNetIncome",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of the Company's long-lived assets and intangible assets with finite lives.",
        "label": "Long-lived Assets and Other Intangible Assets, Impairment [Policy Text Block]",
        "verboseLabel": "Impairment of Long-Lived Assets and Other Intangible Assets"
       }
      }
     },
     "localname": "LongLivedAssetsAndOtherIntangibleAssetsImpairmentPolicyTextBlock",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, After Year Five",
        "label": "Long-Term Debt And Lease Obligations, Maturity, After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityAfterYearFive",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year Five",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearFive",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year Four",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearFour",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year One",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearOne",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year Three",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearThree",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LongTermDebtAndLeaseObligationsMaturityYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt And Lease Obligations, Maturity, Year Two",
        "label": "Long-Term Debt And Lease Obligations, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtAndLeaseObligationsMaturityYearTwo",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyAmountOverturnedOfOverpaymentDetermination": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Amount Overturned Of Overpayment Determination",
        "label": "Loss Contingency, Amount Overturned Of Overpayment Determination",
        "terseLabel": "Amount overturned of overpayment determination"
       }
      }
     },
     "localname": "LossContingencyAmountOverturnedOfOverpaymentDetermination",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Amount Overturned Of Overpayment Determination, Interest",
        "label": "Loss Contingency, Amount Overturned Of Overpayment Determination, Interest",
        "terseLabel": "Amount overturned of overpayment determination, interest"
       }
      }
     },
     "localname": "LossContingencyAmountOverturnedOfOverpaymentDeterminationInterest",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyAppealedClaimsDeniedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Appealed Claims Denied, Amount",
        "label": "Loss Contingency, Appealed Claims Denied, Amount",
        "terseLabel": "Appealed claims denied"
       }
      }
     },
     "localname": "LossContingencyAppealedClaimsDeniedAmount",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyClaimsAwaitingReviewAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Awaiting Review, Amount",
        "label": "Loss Contingency, Claims Awaiting Review, Amount",
        "terseLabel": "Amount of claims pending review"
       }
      }
     },
     "localname": "LossContingencyClaimsAwaitingReviewAmount",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyClaimsSampledForAuditAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Sampled For Audit, Amount",
        "label": "Loss Contingency, Claims Sampled For Audit, Amount",
        "terseLabel": "Paid claims, amount from sample"
       }
      }
     },
     "localname": "LossContingencyClaimsSampledForAuditAmount",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Extrapolated Error Rate, Alleged Overpayment Amount",
        "label": "Loss Contingency, Extrapolated Error Rate, Alleged Overpayment Amount",
        "terseLabel": "Alleged overpayment amount"
       }
      }
     },
     "localname": "LossContingencyExtrapolatedErrorRateAllegedOverpaymentAmount",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyExtrapolatedErrorRatePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Extrapolated Error Rate, Period",
        "label": "Loss Contingency, Extrapolated Error Rate, Period",
        "terseLabel": "Extrapolated error rate period"
       }
      }
     },
     "localname": "LossContingencyExtrapolatedErrorRatePeriod",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ehc_LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum dollar amount that must be accrued for a loss contingency related to a specific legal dispute that can be utilized for consideration prior to accruing an estimate of the legal fees related to this specific legal dispute.",
        "label": "Loss Contingency, Minimum Amount to Consider Accruing an Estimate of Related Legal Fees",
        "terseLabel": "Minimum accrual of loss contingency needed to accrue for related legal fees"
       }
      }
     },
     "localname": "LossContingencyMinimumAmounttoConsiderAccruinganEstimateofRelatedLegalFees",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_LossContingencyNumberOfClaimsSampledForAudit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Claims Sampled For Audit",
        "label": "Loss Contingency, Number Of Claims Sampled For Audit",
        "terseLabel": "Number of claims sampled"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimsSampledForAudit",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_ManagedCareMedicareAdvantageandOtherDiscountPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Managed Care, Medicare Advantage and Other Discount Plans [Member]",
        "label": "Managed Care, Medicare Advantage and Other Discount Plans [Member]",
        "terseLabel": "Managed care and other discount plans, including Medicare Advantage"
       }
      }
     },
     "localname": "ManagedCareMedicareAdvantageandOtherDiscountPlansMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ManagedCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Managed Care [Member]",
        "label": "Managed Care [Member]",
        "terseLabel": "Managed care"
       }
      }
     },
     "localname": "ManagedCareMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MarketAccessAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalizable costs associated with gaining access to and pentetrating a historical market base.",
        "label": "Market Access Assets [Member]",
        "verboseLabel": "Market access assets"
       }
      }
     },
     "localname": "MarketAccessAssetsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MaximumSelfInsuredAmountFirstLayerOfRisk": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Self Insured Amount, First Layer of Risk",
        "label": "Maximum Self Insured Amount, First Layer of Risk",
        "terseLabel": "Self-insured amount"
       }
      }
     },
     "localname": "MaximumSelfInsuredAmountFirstLayerOfRisk",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid [Member]",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicareAdvantageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Advantage [Member]",
        "label": "Medicare Advantage [Member]",
        "terseLabel": "Medicare Advantage"
       }
      }
     },
     "localname": "MedicareAdvantageMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare [Member]",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NCHHealthcareSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NCH Healthcare System",
        "label": "NCH Healthcare System [Member]",
        "terseLabel": "NCH Healthcare System"
       }
      }
     },
     "localname": "NCHHealthcareSystemMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NetAmountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount.",
        "label": "Net Amount [Member]",
        "terseLabel": "Net Amount"
       }
      }
     },
     "localname": "NetAmountMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NoncontrollingInterestExchangeTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Exchange Transaction",
        "label": "Noncontrolling Interest, Exchange Transaction",
        "negatedTerseLabel": "Exchange transaction"
       }
      }
     },
     "localname": "NoncontrollingInterestExchangeTransaction",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NoncontrollingInterestExerciseRightToSellRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Exercise, Right To Sell, Ratio",
        "label": "Noncontrolling Interest, Exercise, Right To Sell, Ratio",
        "terseLabel": "Exercise, right to sell, ratio"
       }
      }
     },
     "localname": "NoncontrollingInterestExerciseRightToSellRatio",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ehc_NoncontrollingInterestOtherAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Other Adjustment",
        "label": "Noncontrolling Interest, Other Adjustment",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "NoncontrollingInterestOtherAdjustment",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NoncontrollingInterestSpinOff": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Spin Off",
        "label": "Noncontrolling Interest, Spin Off",
        "negatedTerseLabel": "Spin off of Enhabit, Inc."
       }
      }
     },
     "localname": "NoncontrollingInterestSpinOff",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests), percent.",
        "label": "Noncontrolling Interests, Decrease from Redemptions or Purchase of Interests, Percent",
        "terseLabel": "Purchase of redeemable noncontrolling interests, percent"
       }
      }
     },
     "localname": "NoncontrollingInterestsDecreasefromRedemptionsorPurchaseofInterestsPercent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_NonemployeeDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee Directors [Member]",
        "label": "Non-employee Directors [Member]",
        "terseLabel": "Non-employee Directors"
       }
      }
     },
     "localname": "NonemployeeDirectorsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NotesPayableLIBORplus2.5ConstructionFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, LIBOR plus 2.5% Construction Financing [Member]",
        "label": "Notes Payable, LIBOR plus 2.5% Construction Financing [Member]",
        "terseLabel": "Construction of a new hospital"
       }
      }
     },
     "localname": "NotesPayableLIBORplus2.5ConstructionFinancingMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NotesPayableRealEstateSaleLeasebackFinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, Real Estate Sale / Leaseback Financing [Member]",
        "label": "Notes Payable, Real Estate Sale / Leaseback Financing [Member]",
        "terseLabel": "Sale/leaseback transactions involving real estate accounted for as financings"
       }
      }
     },
     "localname": "NotesPayableRealEstateSaleLeasebackFinancingMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NotesPayableSoftwareContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Payable, Software Contracts",
        "label": "Notes Payable, Software Contracts [Member]",
        "terseLabel": "Software contracts"
       }
      }
     },
     "localname": "NotesPayableSoftwareContractsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_NumberOfBedsAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Beds Acquired",
        "label": "Number of Beds Acquired",
        "terseLabel": "Number of beds acquired"
       }
      }
     },
     "localname": "NumberOfBedsAcquired",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of individual claims covered by the Company's self-insured risk reserves.",
        "label": "Number of Individual Claims Covered by Self-Insured Risk Reserves",
        "terseLabel": "Number of individual claims covered by reserves"
       }
      }
     },
     "localname": "NumberOfIndividualClaimsCoveredBySelfInsuredRiskReserves",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfInpatientRehabilitationHospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of Inpatient Rehabilitation Hospitals",
        "terseLabel": "Number of inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "NumberOfInpatientRehabilitationHospitals",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfInpatientRehabilitationHospitalsSoleOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Inpatient Rehabilitation Hospitals, Sole Ownership",
        "label": "Number of Inpatient Rehabilitation Hospitals, Sole Ownership",
        "terseLabel": "Number of inpatient rehabilitation hospitals, sole ownership"
       }
      }
     },
     "localname": "NumberOfInpatientRehabilitationHospitalsSoleOwnership",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfJointlyOwnedInpatientRehabilitationHospitals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of jointly owned inpatient rehabilitation hospitals owned and operated as of the balance sheet date.",
        "label": "Number of Jointly Owned Inpatient Rehabilitation Hospitals",
        "terseLabel": "Number of jointly owned inpatient rehabilitation hospitals"
       }
      }
     },
     "localname": "NumberOfJointlyOwnedInpatientRehabilitationHospitals",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberOfManagementInvestorsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Management Investors Outstanding",
        "label": "Number of Management Investors Outstanding",
        "terseLabel": "Number of management investors remaining outstanding"
       }
      }
     },
     "localname": "NumberOfManagementInvestorsOutstanding",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofBedsContributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Beds Contributed",
        "label": "Number of Beds Contributed",
        "terseLabel": "Number of beds contributed"
       }
      }
     },
     "localname": "NumberofBedsContributed",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofBedsExpanded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Beds Expanded",
        "label": "Number of Beds Expanded",
        "terseLabel": "Number of beds expanded"
       }
      }
     },
     "localname": "NumberofBedsExpanded",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_NumberofDeNovoBeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of De Novo Beds",
        "label": "Number of De Novo Beds",
        "terseLabel": "Number of de novo beds"
       }
      }
     },
     "localname": "NumberofDeNovoBeds",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_OccupancyCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts paid for rent associated with leased hospitals, including common area maintenance and similar charges.",
        "label": "Occupancy Cost",
        "terseLabel": "Occupancy costs"
       }
      }
     },
     "localname": "OccupancyCost",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_OperatingAndFinanceLeaseContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating and finance leases, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating And Finance Lease, Contract Term",
        "terseLabel": "Operating and finance lease contract term"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseContractTerm",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTextualsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ehc_OperatingAndFinanceLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Number Of Renewal Options",
        "label": "Operating And Finance Lease, Number Of Renewal Options",
        "terseLabel": "Number of renewal options (or more)"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_OtherFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Funds",
        "label": "Other Funds [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherFundsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OtherIncomeSourceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Source [Member]",
        "label": "Other Income Source [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncomeSourceMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_OtherThirdpartyPayorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Third-party Payors [Member]",
        "label": "Other Third-party Payors [Member]",
        "terseLabel": "Other third-party payors"
       }
      }
     },
     "localname": "OtherThirdpartyPayorsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PatientsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patients [Member]",
        "label": "Patients [Member]",
        "terseLabel": "Patients"
       }
      }
     },
     "localname": "PatientsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PayorSourceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor Source [Member]",
        "label": "Payor Source [Member]",
        "terseLabel": "Payor Source"
       }
      }
     },
     "localname": "PayorSourceMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Percentageofassetspledgedtolendersundercreditagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of assets pledged to lenders under credit agreement.",
        "label": "Percentage of assets pledged to lenders under credit agreement",
        "terseLabel": "Percentage of property and equipment, net pledged to lenders under credit agreement (percent)"
       }
      }
     },
     "localname": "Percentageofassetspledgedtolendersundercreditagreement",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_PortercareAdventistAndPremierHealthPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portercare Adventist and Premier Health Partners",
        "label": "Portercare Adventist and Premier Health Partners [Member]",
        "terseLabel": "Portercare Adventist and Premier Health Partners"
       }
      }
     },
     "localname": "PortercareAdventistAndPremierHealthPartnersMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PortercareAdventistMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portercare Adventist [Member]",
        "label": "Portercare Adventist [Member]",
        "terseLabel": "Portercare Adventist"
       }
      }
     },
     "localname": "PortercareAdventistMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_PremierHealthPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premier Health Partners [Member]",
        "label": "Premier Health Partners [Member]",
        "terseLabel": "Premier Health Partners"
       }
      }
     },
     "localname": "PremierHealthPartnersMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_RACAuditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMS post-payment audit initiative of inpatient rehabilitation providers",
        "label": "RAC Audits [Member]",
        "terseLabel": "RAC Audits"
       }
      }
     },
     "localname": "RACAuditsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ReconciliationOfNoncontrollingInterestsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of Noncontrolling Interests [Table Text Block]",
        "label": "Reconciliation of Noncontrolling Interests [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Net Income Attributable to Noncontrolling Interests"
       }
      }
     },
     "localname": "ReconciliationOfNoncontrollingInterestsTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_RedeemableNoncontrollingInterestEquityAcquiredPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Equity, Acquired Percent",
        "label": "Redeemable Noncontrolling Interest, Equity, Acquired Percent",
        "terseLabel": "Redeemable noncontrolling interest, equity, acquired percent"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityAcquiredPercent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract]",
        "terseLabel": "Redeemable Noncontrolling Interest, Equity, Carrying Amount Roll Forward [Abstract] [Abstract]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmountRollForwardAbstract",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold",
        "label": "Redeemable Noncontrolling Interest, Fair Value Determination Based On Home Health Acquisitions, Value Threshold",
        "terseLabel": "Redeemable noncontrolling interest, fair value determination based on home health acquisitions, value threshold"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestFairValueDeterminationBasedOnHomeHealthAcquisitionsValueThreshold",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_RestrictedDebtSecuritiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total debt and equity financial instruments including: (1) securities held-to-maturity, (2) trading securities, and (3) securities available-for-sale which are intended to be held for greater than one year or the normal operating cycle, whichever is longer and that are pledged to one or more secured parties who have the right to buy, sell, or re-pledge the collateral.",
        "label": "Restricted Debt Securities, Noncurrent",
        "terseLabel": "Restricted marketable securities"
       }
      }
     },
     "localname": "RestrictedDebtSecuritiesNoncurrent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_RetirementInvestmentPlanAgeRequirement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum age required for an employee to be eligible to participate in the Company's Retirement Investment Plan.",
        "label": "Retirement Investment Plan, Age Requirement",
        "terseLabel": "Age requirement to participate in the Plan"
       }
      }
     },
     "localname": "RetirementInvestmentPlanAgeRequirement",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution",
        "label": "Retirement Investment Plan, Company Match, Percentage Of Participant's Contribution",
        "terseLabel": "Vesting percentage in employer contributions (percent)"
       }
      }
     },
     "localname": "RetirementInvestmentPlanCompanyMatchPercentageOfParticipantsContribution",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_RetirementInvestmentPlanCompanyMatchVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total percentage of the Company's matching contributions that will vest in the Retirement Investment Plan after an employee service requirement has been met.",
        "label": "Retirement Investment Plan, Company Match, Vesting Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "RetirementInvestmentPlanCompanyMatchVestingPercentage",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_RetirementInvestmentPlanCompanyMatchVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time over which the Company's contributions to a participant's retirement account fully vests.",
        "label": "Retirement Investment Plan, Company Match, Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "RetirementInvestmentPlanCompanyMatchVestingPeriod",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ehc_RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]",
        "label": "Right-of-use Assets Obtained in Exchange for Lease Obligations [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightofuseAssetsObtainedinExchangeforLeaseObligationsAbstract",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_ScheduleOfFinancialCovenantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Financial Covenants",
        "label": "Schedule Of Financial Covenants [Table Text Block]",
        "terseLabel": "Schedule of Financial Covenants"
       }
      }
     },
     "localname": "ScheduleOfFinancialCovenantsTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of depreciation expense, interest capitalized, under operating leases.",
        "label": "Schedule of Depreciation, Interest Capitalized Expense [Table Text Block]",
        "verboseLabel": "Schedule of depreciation expense and interest capitalized"
       }
      }
     },
     "localname": "ScheduleofDepreciationInterestCapitalizedExpenseTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "label": "Schedule of Supplemental Balance Sheet Information Related to Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Balance Sheet Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]",
        "label": "Schedule of Weighted Average Remaining Lease Term and Discount Rate [Table Text Block]",
        "terseLabel": "Schedule of Weighted Average Remaining Lease Term and Discount Rate"
       }
      }
     },
     "localname": "ScheduleofWeightedAverageRemainingLeaseTermandDiscountRateTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_SecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "(SOFR)"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SelfInsuredCaptiveFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash held by the Company's wholly owned captive subsidiary which is restricted for use in paying self-insured work comp or professional liability claims.",
        "label": "Self Insured Captive Funds [Member]",
        "terseLabel": "Self-insured captive funds"
       }
      }
     },
     "localname": "SelfInsuredCaptiveFundsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorManagementBonusProgramTotalCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of payments made or expected to be made during a reporting period to participants that are entitled under the Senior Management Bonus Program.",
        "label": "Senior Management Bonus Program, Total Costs",
        "terseLabel": "Payments under the Senior Management Bonus Program"
       }
      }
     },
     "localname": "SeniorManagementBonusProgramTotalCosts",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_SeniorNotes04.750Due2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 04.750%, Due 2030 [Member]",
        "label": "Senior Notes, 04.750%, Due 2030 [Member]",
        "terseLabel": "4.75% Senior Notes due 2030"
       }
      }
     },
     "localname": "SeniorNotes04.750Due2030Member",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes04625Due2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 04.625%, Due 2031",
        "label": "Senior Notes, 04.625%, Due 2031 [Member]",
        "terseLabel": "4.625% Senior Notes due 2031"
       }
      }
     },
     "localname": "SeniorNotes04625Due2031Member",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes05.125Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 05.125%, Due 2023 [Member]",
        "label": "Senior Notes, 05.125%, Due 2023 [Member]",
        "terseLabel": "5.125% Senior Notes due 2023",
        "verboseLabel": "5.125% Senior Notes due 2023"
       }
      }
     },
     "localname": "SeniorNotes05.125Due2023Member",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes05.75Due2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes; 05.75%; Due 2025 [Member]",
        "label": "Senior Notes; 05.75%; Due 2025 [Member]",
        "terseLabel": "5.75% Senior Notes due 2025",
        "verboseLabel": "5.75% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotes05.75Due2025Member",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes0575Due2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.75% Senior Notes Due 2024 [Member]",
        "label": "Senior Notes; 05.75%; Due 2024 [Member]",
        "terseLabel": "Senior Notes; 05.75%; Due 2024"
       }
      }
     },
     "localname": "SeniorNotes0575Due2024Member",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_SeniorNotes4.50Due2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.50%, Due 2028 [Member]",
        "label": "Senior Notes, 4.50%, Due 2028 [Member]",
        "terseLabel": "4.50% Senior Notes due 2028"
       }
      }
     },
     "localname": "SeniorNotes4.50Due2028Member",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shannon Medical, Heritage Valley Health System And ECHD Ventures",
        "label": "Shannon Medical, Heritage Valley Health System And ECHD Ventures [Member]",
        "terseLabel": "Shannon Medical, Heritage Valley &amp; ECHD Ventures"
       }
      }
     },
     "localname": "ShannonMedicalHeritageValleyHealthSystemAndECHDVenturesMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ShannonMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shannon Medical",
        "label": "Shannon Medical [Member]",
        "terseLabel": "Shannon Medical"
       }
      }
     },
     "localname": "ShannonMedicalMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment In Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment In Period",
        "negatedTerseLabel": "Enhabit spin-off adjustment (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentInPeriod",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Spin-Off Adjustment, Weighted Average Grant Date Fair Value",
        "terseLabel": "Enhabit spin-off adjustment (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSpinOffAdjustmentWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period",
        "terseLabel": "Enhabit spin-off adjustment (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriod",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ehc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period, Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Spin-Off Adjustment In Period, Weighted Average Exercise Price",
        "terseLabel": "Enhabit spin-off adjustment (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSpinOffAdjustmentInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ehc_SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options",
        "label": "Share-based Goods and Non-employee Services Transaction, Compensation Cost Not Yet Recognized, Share-based Awards Other Than Options",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "SharebasedGoodsandNonemployeeServicesTransactionCompensationCostNotYetRecognizedSharebasedAwardsOtherThanOptions",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Shorttermandvariableleasecost": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less, plus the amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Short-term and variable lease cost",
        "terseLabel": "Short-term and variable lease cost"
       }
      }
     },
     "localname": "Shorttermandvariableleasecost",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_StatementOfComprehensiveIncomeAndIncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statement of Comprehensive Income and Income Statement",
        "label": "Statement of Comprehensive Income and Income Statement [Abstract]"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAndIncomeStatementAbstract",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ehc_SubsidiarysCommonStockHeldBySubsidiarysManagementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsidiary's common stock held by subsidiary 's management, Percent",
        "label": "Subsidiary's Common Stock Held By Subsidiary's Management, Percent",
        "terseLabel": "Subsidiary's common stock held by subsidiary 's management, percent"
       }
      }
     },
     "localname": "SubsidiarysCommonStockHeldBySubsidiarysManagementPercent",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_SupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Cash Flow Information [Table Text Block]",
        "label": "Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ehc_TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Shares to Management Investors Exchange Agreements Percentages",
        "label": "Temporary Equity, Shares to Management Investors Exchange Agreements Percentages",
        "terseLabel": "Shares to issued to the management investors pursuant to the exchange agreements represents (in percent)"
       }
      }
     },
     "localname": "TemporaryEquitySharestoManagementInvestorsExchangeAgreementsPercentages",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ehc_TermLoanFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan Facilities [Member]",
        "label": "Term Loan Facilities [Member]",
        "verboseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "TermLoanFacilitiesMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_TheCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Credit Agreement [Member]",
        "label": "The Credit Agreement [Member]",
        "terseLabel": "The Credit Agreement"
       }
      }
     },
     "localname": "TheCreditAgreementMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_Totalfinanceleasecost": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of finance lease cost recognized by lessee for lease contract.",
        "label": "Total finance lease cost",
        "totalLabel": "Total finance lease cost"
       }
      }
     },
     "localname": "Totalfinanceleasecost",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Totalleaseliabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases.",
        "label": "Total lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "Totalleaseliabilities",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_Totaloperatingandfinanceleaseassets": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating and finance leases.",
        "label": "Total operating and finance lease assets",
        "totalLabel": "Total leased assets"
       }
      }
     },
     "localname": "Totaloperatingandfinanceleaseassets",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ehc_TradeNameEncompassMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Name - Encompass [Member]",
        "label": "Trade Name - Encompass [Member]",
        "terseLabel": "Trade name - Encompass"
       }
      }
     },
     "localname": "TradeNameEncompassMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_TrinityMedicalCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trinity Medical Center",
        "label": "Trinity Medical Center [Member]",
        "terseLabel": "Trinity Medical Center"
       }
      }
     },
     "localname": "TrinityMedicalCenterMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_UnifiedProgramIntegrityContractorsAuditsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unified Program Integrity Contractors, Audits",
        "label": "Unified Program Integrity Contractors, Audits [Member]",
        "terseLabel": "UPICs Audits"
       }
      }
     },
     "localname": "UnifiedProgramIntegrityContractorsAuditsMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ehc_VariableInterestEntityNumberofEntitiesConsolidated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of facilities consolidated as variable interest entities.",
        "label": "Variable Interest Entity, Number of Entities Consolidated",
        "terseLabel": "Number of consolidated limited partnership-like entities"
       }
      }
     },
     "localname": "VariableInterestEntityNumberofEntitiesConsolidated",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ehc_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Discount Rate [Abstract]",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Remaining Lease Term [Abstract]",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ehc_WorkersCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workers' Compensation [Member]",
        "label": "Workers' Compensation [Member]",
        "terseLabel": "Workers\u2019 compensation"
       }
      }
     },
     "localname": "WorkersCompensationMember",
     "nsuri": "http://www.encompasshealth.com/20221231",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r336",
      "r602",
      "r603",
      "r607",
      "r608",
      "r655",
      "r727",
      "r842",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r336",
      "r602",
      "r603",
      "r607",
      "r608",
      "r655",
      "r727",
      "r842",
      "r845",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r455",
      "r483",
      "r733",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r513",
      "r664",
      "r695",
      "r728",
      "r729",
      "r747",
      "r761",
      "r770",
      "r847",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/LeasesTextualsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r513",
      "r664",
      "r695",
      "r728",
      "r729",
      "r747",
      "r761",
      "r770",
      "r847",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/LeasesTextualsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r500",
      "r513",
      "r549",
      "r550",
      "r551",
      "r660",
      "r664",
      "r695",
      "r728",
      "r729",
      "r747",
      "r761",
      "r770",
      "r838",
      "r847",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/LeasesTextualsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r439",
      "r440",
      "r441",
      "r442",
      "r500",
      "r513",
      "r549",
      "r550",
      "r551",
      "r660",
      "r664",
      "r695",
      "r728",
      "r729",
      "r747",
      "r761",
      "r770",
      "r838",
      "r847",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/LeasesTextualsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r334",
      "r335",
      "r455",
      "r483",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r518",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r350",
      "r518",
      "r785",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r350",
      "r518",
      "r785",
      "r786",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r814",
      "r955"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Other accounts receivable"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r769"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r687",
      "r720"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "totalLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r411",
      "r412"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]",
        "verboseLabel": "Schedule of Accounts Receivable, Net, Current"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetNoncurrent": {
     "auth_ref": [
      "r411",
      "r681",
      "r687"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Noncurrent patient accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Finite-lived intangible asset useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r37",
      "r769"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Capital in excess of par value"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r558",
      "r559",
      "r560",
      "r805",
      "r806",
      "r807",
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Capital in Excess of Par Value"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities\u2014"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Receipt of treasury stock"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r177",
      "r178",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "verboseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r474",
      "r631",
      "r745",
      "r746",
      "r798"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt-related items"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r85",
      "r115",
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from computation of diluted weighted-average shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r247",
      "r269",
      "r301",
      "r331",
      "r395",
      "r400",
      "r406",
      "r413",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r602",
      "r607",
      "r622",
      "r769",
      "r843",
      "r844",
      "r957"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r295",
      "r307",
      "r331",
      "r413",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r602",
      "r607",
      "r622",
      "r769",
      "r843",
      "r844",
      "r957"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r133",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "totalLabel": "Total assets of discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129",
      "r133",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Current assets of discontinued operations",
        "totalLabel": "Total current assets of discontinued operations"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss) [Abstract]",
        "verboseLabel": "Investment information related to restricted marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r599",
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r599",
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r945",
      "r946"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "verboseLabel": "Schedule of Actual and Pro Forma Results of Operations for Acquisitions"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be tax-deductible"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Business acquisition, pro forma net income (loss)"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r597",
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Business acquisition, pro forma revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, earnings or loss of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Business combination, pro forma information, revenue of acquiree since acquisition date, actual"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r193",
      "r194"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r87",
      "r297",
      "r731"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ehc_InvestmentsCashandRestrictedCash",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash &amp; Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Cash and Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r87",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations": {
     "auth_ref": [
      "r81",
      "r87",
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; attributable to disposal group, including, but not limited to, discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Disposal Group, Including Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash in discontinued operations at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash in discontinued operations at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r239"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by (used in) financing activities of discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r81"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Net cash used in investing activities of discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r20",
      "r81"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Net cash provided by operating activities of discontinued operations"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r331",
      "r354",
      "r358",
      "r366",
      "r370",
      "r379",
      "r380",
      "r413",
      "r443",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r622",
      "r730",
      "r784",
      "r800",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r51",
      "r254",
      "r276"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r436",
      "r437",
      "r722",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Other Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r140",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "verboseLabel": "Litigation Reserves"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid per common share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "verboseLabel": "Cash dividends declared per common share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquityParenthetical",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r805",
      "r806",
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r36",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (shares)",
        "periodStartLabel": "Balance at beginning of period (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r36",
      "r769"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $.01 par value; 200,000,000 shares authorized; issued: 114,775,056 in 2022; 114,211,057 in 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "verboseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred income tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred income tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r57",
      "r309",
      "r311",
      "r319",
      "r684",
      "r690"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Net and comprehensive income attributable to Encompass Health"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r205",
      "r206",
      "r224",
      "r309",
      "r311",
      "r318",
      "r683",
      "r689"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTotalLabel": "Less: Net and comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r204",
      "r224",
      "r309",
      "r311",
      "r317",
      "r682",
      "r688"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "verboseLabel": "Net and comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "verboseLabel": "Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r765",
      "r833",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Internal-use Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r236",
      "r237",
      "r410",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r102",
      "r103",
      "r236",
      "r237",
      "r410",
      "r701",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r102",
      "r103",
      "r236",
      "r237",
      "r410",
      "r721",
      "r970"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r102",
      "r103",
      "r236",
      "r237",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Net operating revenues by payor source (percent)",
        "verboseLabel": "Percentage of Medicare patient discharges (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r236",
      "r238",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r236",
      "r237",
      "r410",
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r209",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Noncontrolling Interests in Consolidated Affiliates and Redeemable Noncontrolling Interests"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r213",
      "r215",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "verboseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r803",
      "r941",
      "r943"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r188",
      "r580",
      "r588",
      "r803"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r803",
      "r941",
      "r943"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and other"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r253",
      "r277"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "totalLabel": "Total debt and Capital lease obligations"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r145",
      "r330",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r468",
      "r475",
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r248",
      "r250",
      "r267",
      "r336",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r632",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Spread on variable rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r242",
      "r244",
      "r452",
      "r632",
      "r743",
      "r744"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r48",
      "r242",
      "r480",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r48",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Debt instrument interest rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r49",
      "r336",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r632",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument, Redemption [Line Items]",
        "terseLabel": "Debt Instrument, Redemption [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Four [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Four"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Three"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price, (percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.",
        "label": "Debt Instrument Redemption [Table]",
        "terseLabel": "Debt Instrument Redemption [Table]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption.",
        "label": "Debt Instrument Redemption [Table Text Block]",
        "terseLabel": "Schedule of Redemption Prices for Senior Notes"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r49",
      "r154",
      "r155",
      "r156",
      "r157",
      "r241",
      "r242",
      "r244",
      "r264",
      "r336",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r477",
      "r632",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtFinancialCovenantsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "verboseLabel": "Financing Costs"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRestricted": {
     "auth_ref": [
      "r661",
      "r717",
      "r719"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ehc_InvestmentsCashandRestrictedCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Restricted",
        "terseLabel": "Restricted Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRestricted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r803",
      "r942",
      "r943"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "verboseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r188",
      "r581",
      "r587",
      "r588",
      "r803"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense",
        "totalLabel": "Total deferred expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r32",
      "r33",
      "r249",
      "r266",
      "r574"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r567",
      "r568"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r803",
      "r942",
      "r943"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and other"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r575"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r939"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r185",
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "auth_ref": [
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance": {
     "auth_ref": [
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance",
        "terseLabel": "Insurance reserve"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r576"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "terseLabel": "Remaining valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails",
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r180",
      "r939"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Liabilities, Investments",
        "negatedLabel": "Carrying value of partnerships"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesTaxDeferredIncome": {
     "auth_ref": [
      "r186",
      "r940"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from tax deferred revenue or income classified as other.",
        "label": "Deferred Tax Liabilities, Tax Deferred Income",
        "negatedLabel": "Revenue reserves"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesDeferredTaxAssetandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r499",
      "r501",
      "r508",
      "r755",
      "r756",
      "r757",
      "r758"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Contribution as percentage of salary allowed under the Plan (percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r85",
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r390"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r497",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Net Operating Revenues by Payor"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r523",
      "r554",
      "r555",
      "r557",
      "r562",
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r18",
      "r61",
      "r280"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Income from discontinued operations before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r11",
      "r18",
      "r23",
      "r569",
      "r586",
      "r592"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Provision for income tax expense"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of in a spinoff and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Means Other than Sale, Spinoff"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfByMeansOtherThanSaleSpinoffMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "verboseLabel": "Assets and Liabilities in and Results of Discontinued Operations"
       }
      }
     },
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r128",
      "r133",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent",
        "terseLabel": "Noncurrent assets of discontinued operations",
        "totalLabel": "Total noncurrent assets of discontinued operations",
        "verboseLabel": "Long-term assets of discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]",
        "terseLabel": "Assets and Liabilities of discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred income tax liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r128",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "terseLabel": "Transferred to discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r128",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherIncome": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Income",
        "negatedTerseLabel": "Other income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r128",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r128",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r128",
      "r133"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r19",
      "r294"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Net operating revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Income from discontinued operations"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r28",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Spin Off of Home Health and Hospice Business"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Earnings per common share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r320",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r351",
      "r354",
      "r366",
      "r369",
      "r370",
      "r374",
      "r610",
      "r611",
      "r685",
      "r691",
      "r738"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic earnings per share attributable to Encompass Health common shareholders:",
        "verboseLabel": "Basic earnings per share attributable to Encompass Health common shareholders: (b)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r320",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r354",
      "r366",
      "r369",
      "r370",
      "r374",
      "r610",
      "r611",
      "r685",
      "r691",
      "r738"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted earnings per share attributable to Encompass Health common shareholders:",
        "verboseLabel": "Diluted earnings per share attributable to Encompass Health common shareholders: (b)"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Earnings per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax expense (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Increase (decrease) in tax rate resulting from:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r332",
      "r570",
      "r589"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Tax expense at statutory rate (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r938",
      "r944"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "(Increase) decrease in valuation allowance (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense": {
     "auth_ref": [
      "r938",
      "r944"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to noncontrolling interest income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Percent",
        "terseLabel": "Noncontrolling interests (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r938",
      "r944"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other, net (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r938",
      "r944"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and other income taxes, net of federal tax benefit (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesReconciliationofEffectiveIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average recognition period for unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r937"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r937"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r153",
      "r290",
      "r313",
      "r314",
      "r315",
      "r337",
      "r338",
      "r339",
      "r341",
      "r347",
      "r349",
      "r378",
      "r414",
      "r487",
      "r558",
      "r559",
      "r560",
      "r583",
      "r584",
      "r609",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r652",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r60",
      "r80",
      "r85",
      "r278"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "terseLabel": "Distributions from nonconsolidated affiliates"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r302",
      "r619",
      "r732"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r302",
      "r619"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities, FV-NI"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r692",
      "r820"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized net gain (loss) on marketable securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r111",
      "r268",
      "r771",
      "r772",
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r466",
      "r621",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Debt redeemed"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r612",
      "r613",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r230",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r466",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r613",
      "r657",
      "r658",
      "r659",
      "r743",
      "r744",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r230",
      "r231",
      "r466",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r612",
      "r613",
      "r614",
      "r615",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r466",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value, Disclosure Item Amounts [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r466",
      "r501",
      "r506",
      "r613",
      "r657",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r466",
      "r501",
      "r506",
      "r613",
      "r658",
      "r743",
      "r744",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r466",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r613",
      "r659",
      "r743",
      "r744",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r466",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r657",
      "r658",
      "r659",
      "r743",
      "r744",
      "r755",
      "r756",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r616",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r232",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Fed Funds Effective Rate Overnight Index Swap Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r636",
      "r642",
      "r768"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "ehc_Totalfinanceleasecost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r638",
      "r645"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r634",
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease obligations",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 4.0,
       "parentTag": "ehc_Totalleaseliabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Finance Lease, Liability, Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "ehc_Totalleaseliabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability.",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r637",
      "r645"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Principal payments under finance lease obligations",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r633"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 2.0,
       "parentTag": "ehc_Totaloperatingandfinanceleaseassets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r951",
      "r952"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use asset accumulated amortization"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r636",
      "r642",
      "r768"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "ehc_Totalfinanceleasecost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.",
        "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r648",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance lease (in percent)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r647",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance lease (in years)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r299",
      "r430"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Amortization Expense, Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r427",
      "r429",
      "r430",
      "r432",
      "r666",
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "netLabel": "Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "verboseLabel": "Schedule of Future Estimated Amortization Expense, Other Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r122",
      "r667"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r116",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived or Indefinite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r122",
      "r666"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Schedule of Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, fixtures, and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r85",
      "r143",
      "r144"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on early extinguishment of debt",
        "negatedTerseLabel": "Loss on early extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r298",
      "r415",
      "r680",
      "r741",
      "r769",
      "r822",
      "r829"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "ehc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncludingGoodwillAssets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r418",
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r113",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r417",
      "r424",
      "r741"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r85",
      "r416",
      "r421",
      "r426",
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTextualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsCarryingAmountsofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesAxis": {
     "auth_ref": [
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Axis]",
        "terseLabel": "Health Care Organization, Revenue Sources [Axis]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareOrganizationRevenueSourcesDomain": {
     "auth_ref": [
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major payor source of revenue for health care organizations.",
        "label": "Health Care Organization, Revenue Sources [Domain]",
        "terseLabel": "Health Care Organization, Revenue Sources [Domain]"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenueSourcesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r64",
      "r86",
      "r203",
      "r342",
      "r343",
      "r344",
      "r345",
      "r363",
      "r370"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r201",
      "r204"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Net income attributable to noncontrolling interests included in continuing operations",
        "negatedTerseLabel": "Less: Net income attributable to noncontrolling interests included in continuing operations",
        "terseLabel": "Less: Net income attributable to noncontrolling interests included in continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r245",
      "r257",
      "r283",
      "r395",
      "r399",
      "r405",
      "r407",
      "r686",
      "r740"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income from continuing operations before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r204",
      "r331",
      "r340",
      "r395",
      "r399",
      "r405",
      "r407",
      "r413",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r611",
      "r622",
      "r740",
      "r843"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r58",
      "r255",
      "r258",
      "r279",
      "r320",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r354",
      "r366",
      "r369",
      "r611",
      "r685"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r58",
      "r279",
      "r282",
      "r320",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r354",
      "r366",
      "r369",
      "r370",
      "r611",
      "r685",
      "r691"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r23",
      "r280",
      "r294",
      "r593"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Income from discontinued operations, net of tax",
        "terseLabel": "(Loss) income from discontinued operations, net of tax",
        "totalLabel": "Income from discontinued operations, net of tax",
        "verboseLabel": "Income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r18",
      "r23",
      "r201",
      "r204"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net income attributable to noncontrolling interests included in discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r18",
      "r23",
      "r204"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income from discontinued operations, net of tax",
        "totalLabel": "Net income attributable to Encompass Health included in discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r61",
      "r280",
      "r282",
      "r320",
      "r358",
      "r366",
      "r369",
      "r965",
      "r967"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r225",
      "r358",
      "r366",
      "r369"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r60",
      "r85",
      "r112",
      "r256",
      "r278",
      "r392"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Equity in net income of nonconsolidated affiliates",
        "negatedTerseLabel": "Equity in net income of nonconsolidated affiliates"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r759",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r22",
      "r24",
      "r25",
      "r26",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r332",
      "r571",
      "r572",
      "r579",
      "r585",
      "r590",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r333",
      "r348",
      "r349",
      "r393",
      "r569",
      "r586",
      "r591",
      "r693"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income tax expense",
        "totalLabel": "Total income tax expense related to continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesComponentsofProvisionforIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r312",
      "r565",
      "r566",
      "r572",
      "r573",
      "r578",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r82",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "negatedTerseLabel": "Income tax payments"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "terseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of acquisitions \u2014"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r370",
      "r522"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Restricted stock awards, dilutive stock options, and restricted stock units (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r428",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r118",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "verboseLabel": "Self-Insured Risks"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisks"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r114",
      "r120"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentDepreciationCapitalizedInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r243",
      "r261",
      "r316",
      "r389",
      "r630"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense and amortization of debt discounts and fees"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r324",
      "r327",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "verboseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r792"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Salaries and benefits"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r649",
      "r768"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r953"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Least Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "verboseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r954"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r650"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Interest portion"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "verboseLabel": "Amounts outstanding under letter of credit facility"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r45",
      "r331",
      "r413",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r603",
      "r607",
      "r608",
      "r622",
      "r739",
      "r843",
      "r957",
      "r958"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Total liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r252",
      "r274",
      "r769",
      "r802",
      "r821",
      "r949"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Liabilities and Equity, Total"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r47",
      "r296",
      "r331",
      "r413",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r603",
      "r607",
      "r608",
      "r622",
      "r769",
      "r843",
      "r957",
      "r958"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r133",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r129",
      "r133",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Current liabilities of discontinued operations",
        "totalLabel": "Total current liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r21",
      "r128",
      "r133",
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities of discontinued operations",
        "totalLabel": "Total noncurrent liabilities of discontinued operations"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessSummaryofFinancialInformationRelatedtoDiscontinuedOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r284",
      "r286"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Balance at end of period, gross",
        "periodStartLabel": "Balance at beginning of period, gross"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedTerseLabel": "Payments related to current year claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedTerseLabel": "Payments related to prior year claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet": {
     "auth_ref": [
      "r265",
      "r284",
      "r286"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability as of the balance sheet date for amounts representing estimated cost of settling unpaid claims under the terms of the underlying insurance policies, less estimated reinsurance recoveries on such claims. This includes an estimate for claims which have been incurred but not reported. Claim adjustment expenses represent the costs estimated to be incurred in the settlement of unpaid claims.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Net",
        "periodEndLabel": "Balance at end of period, net",
        "periodStartLabel": "Balance at beginning of period, net"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Applicable interest rate under credit facility (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of credit facility, remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Government, class action, and related settlements",
        "verboseLabel": "Provision for government, class action, and related settlements"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r31",
      "r250",
      "r270",
      "r465",
      "r479",
      "r743",
      "r744"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Total debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term debt, net of current portion",
        "verboseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt and Lease Obligation [Abstract]",
        "verboseLabel": "Schedule of Outstanding Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtAndCapitalLeaseObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "negatedLabel": "Less: Current portion",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, including portion classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt and Lease Obligation, Including Current Maturities [Abstract]",
        "terseLabel": "Long-term Debt by Maturity"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduledPrincipalPaymentsDueonLongtermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Carrying amounts and estimated fair values of financial instruments"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r49",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r138",
      "r139",
      "r438",
      "r439",
      "r440",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingencies by Nature of Contingency [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r138",
      "r139",
      "r438",
      "r439",
      "r440",
      "r839",
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r56",
      "r251",
      "r273",
      "r331",
      "r413",
      "r443",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r622"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestChangeInRedemptionValue": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest.",
        "label": "Noncontrolling Interest, Change in Redemption Value",
        "terseLabel": "Change in fair value",
        "verboseLabel": "Fair value adjustments to redeemable noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestChangeInRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Distributions declared",
        "negatedTerseLabel": "Distributions declared"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r159",
      "r207",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of redeemable noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Redeemable Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r56",
      "r65",
      "r202",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r62",
      "r86",
      "r259",
      "r281",
      "r294",
      "r308",
      "r310",
      "r315",
      "r331",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r349",
      "r363",
      "r395",
      "r399",
      "r405",
      "r407",
      "r413",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r611",
      "r622",
      "r740",
      "r843"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net and comprehensive income attributable to Encompass Health"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Amounts attributable to Encompass Health:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r210",
      "r223",
      "r308",
      "r310",
      "r348",
      "r349",
      "r791"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Less: Net and comprehensive income attributable to noncontrolling interests",
        "negatedTotalLabel": "Less: Net and comprehensive income attributable to noncontrolling interests",
        "totalLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to nonredeemable noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "terseLabel": "Net income attributable to redeemable noncontrolling interests",
        "verboseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsReconciliationofNoncontrollingInterestsDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r351",
      "r352",
      "r365",
      "r370",
      "r395",
      "r399",
      "r405",
      "r407",
      "r740"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r353",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r370"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [
      "r352",
      "r370"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
        "totalLabel": "Income from continuing operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted": {
     "auth_ref": [
      "r353",
      "r360",
      "r361",
      "r362",
      "r370"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from continuing operations available to common shareholders.",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted",
        "totalLabel": "Income from continuing operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.",
        "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic",
        "totalLabel": "Income from discontinued operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) from discontinued operations available to common shareholders.",
        "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Diluted",
        "terseLabel": "Income from discontinued operations attributable to Encompass Health common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": {
     "auth_ref": [
      "r148",
      "r210",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity.",
        "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncompeteAgreementsMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.",
        "label": "Noncompete Agreements [Member]",
        "terseLabel": "Noncompete agreements"
       }
      }
     },
     "localname": "NoncompeteAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r201",
      "r487",
      "r805",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "verboseLabel": "Other notes payable"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r395",
      "r399",
      "r405",
      "r407",
      "r740"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating earnings"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r643",
      "r768"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 3.0,
       "parentTag": "ehc_Totalleaseliabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "ehc_Totalleaseliabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r639",
      "r645"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r633"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails": {
       "order": 1.0,
       "parentTag": "ehc_Totaloperatingandfinanceleaseassets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/LeasesScheduleofSupplementalBalanceSheetInformationRelatedtoLeasesDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r648",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease (in percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r647",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesScheduleofWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r306",
      "r769"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r300"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueAfterFifthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OtherCommitmentDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInFifthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "OtherCommitmentDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInFourthYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OtherCommitmentDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OtherCommitmentDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInThirdYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OtherCommitmentDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ContingenciesandOtherCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r769"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "verboseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other expense (income)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Receivables, Net, Current [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PartnersCapitalAccountContributions": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners).",
        "label": "Partners' Capital Account, Contributions",
        "terseLabel": "Capital contributions from consolidated affiliates"
       }
      }
     },
     "localname": "PartnersCapitalAccountContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r793",
      "r794"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Repurchases of common stock, including fees and expenses"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForSoftware": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments for Software",
        "negatedTerseLabel": "Additions to capitalized software costs"
       }
      }
     },
     "localname": "PaymentsForSoftware",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Debt amendment and issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDistributionsToAffiliates": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Payments of Distributions to Affiliates",
        "negatedLabel": "Purchase of equity interests in consolidated affiliates",
        "terseLabel": "Payments of distributions to affiliates"
       }
      }
     },
     "localname": "PaymentsOfDistributionsToAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedTerseLabel": "Dividends paid on common stock"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid on behalf of employees for shares withheld"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Acquisition of businesses, net of cash acquired",
        "verboseLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Purchases of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Payments to settle the acquisition of Holdings common stock"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRestrictedInvestments": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire investments (not to include restricted cash) that are pledged or subject to withdrawal restrictions.",
        "label": "Payments to Acquire Restricted Investments",
        "negatedTerseLabel": "Purchases of restricted investments"
       }
      }
     },
     "localname": "PaymentsToAcquireRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedLabel": "Distributions paid to noncontrolling interests of consolidated affiliates"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r790"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Contributions from noncontrolling interests of consolidated affiliates"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r83",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Income tax refunds"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-Term Debt",
        "terseLabel": "Proceeds from bond issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-Term Lines of Credit",
        "terseLabel": "Borrowings on revolving credit facility"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Principal borrowings on notes"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r795",
      "r797"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r69",
      "r109",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales and maturities of available-for-sale marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesInvestingInformationRelatedtoMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfRestrictedInvestments": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of investments that are pledged or subject to withdrawal restrictions during the period.",
        "label": "Proceeds from Sale of Restricted Investments",
        "terseLabel": "Proceeds from sale of restricted investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRestrictedInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r294",
      "r308",
      "r310",
      "r325",
      "r331",
      "r340",
      "r348",
      "r349",
      "r395",
      "r399",
      "r405",
      "r407",
      "r413",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r601",
      "r605",
      "r606",
      "r611",
      "r622",
      "r686",
      "r740",
      "r766",
      "r767",
      "r791",
      "r843"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net and comprehensive income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r836",
      "r951",
      "r952"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r837",
      "r952"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r789",
      "r835",
      "r950"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Property, plant, and equipment and finance lease right-of-use asset, before accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment by Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r136",
      "r724",
      "r725",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "verboseLabel": "Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r132",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Useful Lives of Property and Equipment",
        "verboseLabel": "Schedule of Components of Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentTables",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialDataAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Data [Abstract]",
        "verboseLabel": "Quarterly Financial Data"
       }
      }
     },
     "localname": "QuarterlyFinancialDataAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r100",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "verboseLabel": "Quarterly Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/QuarterlyDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r275",
      "r289",
      "r769"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0
      },
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Accounts receivable",
        "totalLabel": "Accounts receivable, current"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableComponentsofAccountsReceivableDetails",
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r815",
      "r817",
      "r818",
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "verboseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestByLegalEntityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest, by Legal Entity [Table]",
        "terseLabel": "Redeemable Noncontrolling Interest, by Legal Entity [Table]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestByLegalEntityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r146",
      "r147",
      "r149",
      "r150"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails",
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityFairValue": {
     "auth_ref": [
      "r146",
      "r147",
      "r149",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value as of the reporting date of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Fair Value",
        "terseLabel": "Redeemable noncontrolling interests"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityOtherFairValue": {
     "auth_ref": [
      "r146",
      "r147",
      "r149",
      "r150"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of noncontrolling interests which are redeemable by the parent entity and classified as other equity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Other, Fair Value",
        "terseLabel": "Value of outstanding shares of Holdings"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityOtherFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Redeemable Noncontrolling Interest [Line Items]",
        "terseLabel": "Redeemable Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsRedeemableNoncontrollingInterestsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of redeemable noncontrolling interest (as defined) included in the statement of financial position as either a liability or temporary equity. As of the date of the statement of financial position, such redeemable noncontrolling interest is currently redeemable, as defined, for cash or other assets of the entity at (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the entity.",
        "label": "Redeemable Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": {
     "auth_ref": [
      "r284",
      "r286",
      "r966",
      "r968"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.",
        "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments",
        "negatedPeriodStartLabel": "Less: Reinsurance receivables",
        "periodEndLabel": "Add: Reinsurance receivables"
       }
      }
     },
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r507",
      "r653",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r507",
      "r653",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r956"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r796"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "negatedLabel": "Payments on revolving credit facility",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "terseLabel": "Repayments of secured debt"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedLabel": "Principal payments on debt, including pre-payments"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r87",
      "r93",
      "r246",
      "r271",
      "r297"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ehc_InvestmentsCashandRestrictedCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r87",
      "r93",
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Restricted Cash and Cash Equivalents, Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r87",
      "r93",
      "r718"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Noncurrent restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r787",
      "r799"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "periodEndLabel": "Restricted cash at end of period",
        "periodStartLabel": "Restricted cash at beginning of period",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r718",
      "r788",
      "r799"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "periodEndLabel": "Restricted cash included in other long-term assets at end of period",
        "periodStartLabel": "Restricted cash included in other long-term assets at beginning of period"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r38",
      "r159",
      "r272",
      "r699",
      "r700",
      "r769"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated income"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r290",
      "r337",
      "r338",
      "r339",
      "r341",
      "r347",
      "r349",
      "r414",
      "r558",
      "r559",
      "r560",
      "r583",
      "r584",
      "r609",
      "r696",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated (Deficit) Income"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r761",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r761",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r386",
      "r387",
      "r398",
      "r403",
      "r404",
      "r408",
      "r409",
      "r410",
      "r496",
      "r497",
      "r665"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net operating revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedScheduleofQuarterlyDataDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesNetOperatingRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r410",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "verboseLabel": "Net Operating Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Advances under revolving credit facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r646",
      "r768"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r646",
      "r768"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/AccountsReceivableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r191",
      "r192",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsNetCashPaidforAcquisitionDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsProFormaResultsofOperationDetails",
      "http://www.encompasshealth.com/role/BusinessCombinationsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Estimated Fair Values, Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesComponentsofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Investment Components"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r49",
      "r154",
      "r155",
      "r156",
      "r157",
      "r241",
      "r242",
      "r244",
      "r264",
      "r743",
      "r745",
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Components of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r22",
      "r24",
      "r25",
      "r26",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Summary of Financial Information Related to Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r95",
      "r99",
      "r354",
      "r358",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r612",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r116",
      "r121",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r116",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets by Major Class",
        "verboseLabel": "Schedule of Estimated Useful Lives and Amortization Basis of Other Finite-lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r741",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Carrying Amount of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of Estimated Basis of Other Indefinite-lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Self-Insurance Reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt Maturities"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "verboseLabel": "Schedule of Quarterly Data (Unaudited) Table"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/QuarterlyDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.",
        "label": "Schedule of Realized Gain (Loss) [Table Text Block]",
        "verboseLabel": "Schedule of Investment Information Related to Restricted Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfRealizedGainLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "verboseLabel": "Schedule of Assets Acquired and Liabilities Assumed at the Acquisition Date"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r93",
      "r246",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r93",
      "r246",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Schedule of Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/CashandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r519",
      "r521",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r169",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Weighted-Average Assumptions Used to Determine Fair Value of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r214",
      "r216",
      "r219",
      "r220",
      "r221",
      "r602",
      "r603",
      "r607",
      "r608",
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r214",
      "r216",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "terseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Weighted Average Number of Shares Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Estimated Amortization Expense, Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r236",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration of Net Operating Revenues and Net Patient Service Accounts Receivable by Payor and Payor Class"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Term loan facilities"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity expected to operate in the foreseeable future.",
        "label": "Continuing Operations [Member]",
        "terseLabel": "Continuing Operations"
       }
      }
     },
     "localname": "SegmentContinuingOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "auth_ref": [
      "r2",
      "r4",
      "r5",
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.",
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "SegmentDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r434",
      "r435",
      "r741",
      "r969"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operations of an entity including continuing and discontinued operations.",
        "label": "Operating Activities [Domain]",
        "terseLabel": "Operating Activities [Domain]"
       }
      }
     },
     "localname": "SegmentOperatingActivitiesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SelfInsuranceReserveCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).",
        "label": "Self Insurance Reserve, Current",
        "terseLabel": "Self-insurance reserves included in Other current liabilities"
       }
      }
     },
     "localname": "SelfInsuranceReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfInsuranceReserveNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).",
        "label": "Self Insurance Reserve, Noncurrent",
        "terseLabel": "Self-insured risks"
       }
      }
     },
     "localname": "SelfInsuranceReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SelfPayMember": {
     "auth_ref": [
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patients who pay out of pocket for a health-related service in absence of insurance to cover the medical or surgical procedure performed.",
        "label": "Self-Pay [Member]",
        "terseLabel": "Self-Pay"
       }
      }
     },
     "localname": "SelfPayMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/FairValueMeasurementsCarryingAmountsandEstimatedFairValuesofFinancialInstrumentsDetails",
      "http://www.encompasshealth.com/role/LongtermDebtLongtermDebtOutstandingDetails",
      "http://www.encompasshealth.com/role/LongtermDebtSeniorNotesRedemptionPricesDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r762"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Awards issued during period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollar per share)",
        "verboseLabel": "Weighted-average fair value per share of awards granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested shares, Ending Balance (in shares)",
        "periodStartLabel": "Nonvested shares, Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested shares, Ending Balance (in dollar per share)",
        "periodStartLabel": "Nonvested shares, Beginning Balance (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of vested shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollar per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Schedule of Weighted Average Assumptions Used to Determine Fair Value of Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "verboseLabel": "Expected volatility (percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Number of remaining shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized for grant under the Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Life (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable, December 31, 2021 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercisable, December 31, 2021 (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r543"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending (in shares)",
        "periodStartLabel": "Outstanding, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r528",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsSummaryofRestrictedStockAwardsDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r527",
      "r546",
      "r547",
      "r548",
      "r549",
      "r552",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Life (Years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-Average Remaining Life (Years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Receipt of treasury stock (shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r94",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r292",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r410",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r433",
      "r434",
      "r435",
      "r741",
      "r969"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r331",
      "r354",
      "r358",
      "r366",
      "r370",
      "r379",
      "r380",
      "r413",
      "r443",
      "r445",
      "r446",
      "r447",
      "r450",
      "r451",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r622",
      "r730",
      "r784",
      "r800",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r53",
      "r153",
      "r290",
      "r313",
      "r314",
      "r315",
      "r337",
      "r338",
      "r339",
      "r341",
      "r347",
      "r349",
      "r378",
      "r414",
      "r487",
      "r558",
      "r559",
      "r560",
      "r583",
      "r584",
      "r609",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r652",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Statement, Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by continuing and discontinuing operations.",
        "label": "Operating Activities [Axis]",
        "terseLabel": "Operating Activities [Axis]"
       }
      }
     },
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ShareBasedPaymentsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r378",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r52",
      "r153",
      "r154",
      "r159",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exchange of Holdings shares (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r36",
      "r153",
      "r159",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Stock options exercised (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/ShareBasedPaymentsStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r53",
      "r153",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Exchange of Holdings shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r153",
      "r159"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock repurchase authorization"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r36",
      "r39",
      "r40",
      "r108",
      "r769",
      "r802",
      "r821",
      "r949"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Encompass Health shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Encompass Health shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r201",
      "r202",
      "r222",
      "r290",
      "r291",
      "r314",
      "r337",
      "r338",
      "r339",
      "r341",
      "r347",
      "r414",
      "r487",
      "r558",
      "r559",
      "r560",
      "r583",
      "r584",
      "r609",
      "r623",
      "r624",
      "r628",
      "r652",
      "r697",
      "r698",
      "r802",
      "r821",
      "r949"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets",
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteSpinoffTransaction": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.",
        "label": "Stockholders' Equity Note, Spinoff Transaction",
        "terseLabel": "Spin off of Enhabit, Inc."
       }
      }
     },
     "localname": "StockholdersEquityNoteSpinoffTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Pro rata distribution of common stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Other (shares)"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r644",
      "r768"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LeasesComponentsofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r629",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r629",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r629",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r694"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Increase for the provision of current year claims"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r694"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "negatedTerseLabel": "Decrease for the provision of prior year claims"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SelfInsuredRisksChangesinSelfinsuranceReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Delivering EHC shares to management investors (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/RedeemableNoncontrollingInterestsTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ThirdPartyPayorMember": {
     "auth_ref": [
      "r848"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization other than the patient (first party) or health care provider (second party) involved in the financing of personal health services.",
        "label": "Third-Party Payor [Member]",
        "terseLabel": "Third-Party Payor"
       }
      }
     },
     "localname": "ThirdPartyPayorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade Names",
        "verboseLabel": "Trade Names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/BusinessCombinationsFairValueofAssetsandLiabilitiesAssumedDetails",
      "http://www.encompasshealth.com/role/GoodwillandOtherIntangibleAssetsOtherIntangibleAssetsDetails",
      "http://www.encompasshealth.com/role/SpinOffofHomeHealthandHospiceBusinessTextualDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r55",
      "r162",
      "r163"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Treasury stock, at cost (14,992,125 shares in 2022 and 14,719,662 shares in 2021)"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r36",
      "r153",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchases of common stock in open market (in shares)",
        "terseLabel": "Common stock repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r153",
      "r159",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchases of common stock in open market",
        "terseLabel": "Common stock repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r367",
      "r368",
      "r810"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) from discontinued operations allocated to participating securities for basic earnings (loss) per share or per unit calculation under two-class method.",
        "label": "Undistributed Discontinued Operation Earnings (Loss), Allocation to Participating Securities, Basic",
        "negatedTerseLabel": "Less: Income from discontinued operations allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedDiscontinuedOperationEarningsLossAllocationToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "auth_ref": [
      "r364",
      "r367",
      "r368"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "negatedTerseLabel": "Less: Income from continuing operations allocated to participating securities"
       }
      }
     },
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r381",
      "r382",
      "r383",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r577"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Changes to valuation allowance during the period"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Valuation Allowance [Line Items]",
        "terseLabel": "Valuation Allowance [Line Items]"
       }
      }
     },
     "localname": "ValuationAllowanceLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceTable": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of an entity's valuation allowances to reduce deferred tax assets to amounts which it is more likely than not will not be realized, including a description of the deferred tax assets for which the valuation allowance has been recorded and the amount of the valuation allowance.",
        "label": "Valuation Allowance [Table]",
        "terseLabel": "Valuation Allowance [Table]"
       }
      }
     },
     "localname": "ValuationAllowanceTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/IncomeTaxesTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "terseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Ownership interest in the consolidated entities (percent)"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r214",
      "r602",
      "r603",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesCarryingAmountsandClassificationofConsolidatedVIEsDetails",
      "http://www.encompasshealth.com/role/VariableInterestEntitiesTextualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/LongtermDebtScheduleofNotesPayableDetails",
      "http://www.encompasshealth.com/role/LongtermDebtTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/PropertyandEquipmentComponentsofPropertyandEquipmentDetails",
      "http://www.encompasshealth.com/role/SummaryofSignificantAccountingPoliciesPPEUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r353",
      "r370"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Diluted weighted average common shares outstanding (in shares)",
        "verboseLabel": "Diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r351",
      "r370"
     ],
     "calculation": {
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Basic weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails",
      "http://www.encompasshealth.com/role/EarningsperCommonShareReconciliationBetweenBasicandDilutedWeightedaverageCommonSharesOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/EarningsPerCommonShareComputationofBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Weighted average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.encompasshealth.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "https://asc.fasb.org/topic&trid=2126967",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(3)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "16(c)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "60",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6406278&loc=d3e26268-112671",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(13)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "65",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2793-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "66",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2814-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(9))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r774": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r775": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r776": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r777": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r778": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r779": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r781": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r782": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r783": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>129
<FILENAME>0000785161-23-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000785161-23-000012-xbrl.zip
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M(_-1&O/#T7RQ<6 ?O'XV^>7XV1]3>WCWJ7UV]%(?O+BM#I_LJV<_-;U\\$+
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MPRQE^EOC\3EA8:5PH11C_.DXX>4U<,*!W>ZW.G6_ZS;!DH6_W,%@6+?;L)9
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M*\D#?\'WJF)?EM/Z5?RVTBC?0;'P6$)T]ZAV;2^_BIHJ(8-%'>C@$5DF$8T
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MOG15G,"4?6 4^,&=XR-P1QK6!:Z"GX@A@;W1;ECP33H;C62J+L9QYVV45#F
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M0+LI2':2XRK]C>6(FDKNP%-Z%([5E9H%N2 (X&\X?_ '/02GE>;EB2GK//#
M"2XXLH6$-'F\^TJ$,ZEOTIKMO:F]^=#DO0\4ZR;!5PE\I\BYV>BT<!&.RK0*
M^YO07@Y%$.*__\$V<T-2HS2EUZR<;A:T%_2_ 8F2EN8!J1:HR!" UG;5AV&9
MI]%A864%R F>A]8+#B0%GHY^5'+<BALX27Q*0)@]&",<%+Y(:.4&6^3/."N9
ML210[CGQ_B,+@ =5:;;MI+0;Q/?/I#]3?!,(V =!/D=MAGAK.DL1#@.-E'A8
M6_ W#)4EGJKR%-1V1O&53")J'Q9R'""X0NMD*N:LD)D#AG<&44$@Q"XQ:?95
MT)]#<16S42B2!+T?A;XYH+J!V0%&(]RL'\ZGRY>*X^(;"!=WIM1"X</@4HFV
MTQ ]+4ITJ) $C$E9 _<]=A7U/03U@9Q'+.,KR7)UBIMOF"L;H+GGBNG+"/90
M!!-E!Q;]840S0(W&4591QNY1!CX:. CY/7$+S&:2Y,[FRB_"NT/1,&8/O-?+
M.SHK[J<7I^P$6>U+K?;Y*3E 4:BH(XT[4M"1T'6$;G$!LB-;88ZS<XP<M'P%
MJO(A.MGA E3SDP)8.NAAY!5R,?J*_&0J @JDTK?P5K!DR,DUX2BV&E.M\)+\
MB?@B17[H%T+'5>2AI:,"S2 &F=8H: SV1^3SGZ!,XM=#<L1Y<>(S)_+E4*J,
M!; 6 C]@AQF(N+Q'IUXC^!-?#XR)?%/AXD@2.9R1ZWZ.D8D9WNY+]J^RJ;Z\
M#!7A/QWA'["JE8=MT,C RE_="7NJ^E,!#?F$E2,C+Y FUB]\V$A"@.0[IE.)
MCBBZ*T7_:QI[ 7EE2&.";0C@[UN"1YK&<P6-#ID^>.8N.E_XCE$B)@6=*T3;
M&4D9E$DM8!>51:,H%ORQ\"2,,/G%-V?C))Z-QG0N9E.^'0>C8@5,_?Z,3O],
M<0,]P(J GXZ #X>PJYJUT;X;-H7,)0]"JDU.4LY/R<2EC#B_:942'X%B)A/%
M;\E]BB<@!9I"VKE#O!N5CA.0AD&FS(NM<2C^#%11Z'E*<5K<5VL2W&CWB/!F
M2JCQSUE04-M*_.-[=W.5'_U;W"*E'>^T-^9JYS9;9VP.Q<G\1W"5K)[I]I,V
M&:98I[647*&LU@+[@P6=@9@&7I59,F#+,K%@7_((H02V"$R.LRS081("]8=I
M62IB()+R1R=3CK9$\;4.>=)3.*]"I)CY2&[+2"@=M# :X*@8\5+*)F@5&9\Z
M"D7_JK,<V/"NNR)5B82*M5OI/(4!J(R* ./>^EYTDP89!N1G&4[&" .TXL#L
MKB,3X#6GH)KPDACTE"FHQW5@"G!G*K.,LV9RI:C\7C7Z]+=%D[YDSI><[LK4
M&U*203C'Z2@/TBT[>#M_^2G3)._(DZQ2'G_@E,<M%1@[I0MA\GL<C6)D.O(*
M#[QBE L2 NPG8!\@(9C+E0)1(1RGB$T\S0LG,=S ?(M"BG5.*U)Q4;P+#,,L
MH)MN\XL7C;.$$HB2G&\RSURT( LNM#O99$5'#ZYXH.@*,#">RRY8,0S-*%_!
M,.'P)*8X:8_IRMQ/,84G>4)E6:TRTI:5CB3/[O!%)CBJX\U975$HOS5*$*MG
M":@Z++]138F98*<)AN8IK*]<5&GN[0!5@9,$)-F3?"_F<IJ,+HS>FL MB_%"
M.)4=;G ]3$5G !6#JD8!","R3+-@Q"[@W-O&\5YTZ4G?.$*NQY+TCPGL(J81
MHQ<$CD@49Q09<V5>@P&#FH!)6WYIGJ[[;<>FLD4?X-R<+@89)Y@FAK%%Y=H-
M8T^$-:5STSE2FCB<$3Q=T:AX&KP5Q[ 08XK\/"L -7!.E]3IIOI\63)*XC!D
MQEL(7-2LHNZ]?WP.O-WS8)J8>XHIGG<&.+_+*-[:Y#*V>$_UX8%]^0%,WITZ
M04>11YFXJ7*TZ="K.C^&KP&GO@(&K8X:)P]H_'?EZE'I D"O?IRD.%^G1RGB
M>%;0XZ>_*N9&&W.SG-*EW$;E2X%-Z]Q+YM&Z=D"EI>-8"NG")0D4QE2#N#H8
M7&+@+)-*B0[J@.KP#Y].? /,7(;PB"2. J\4YZ%8-SU4,2=Y(SR9N%1*@E$J
MS$2O5*RG(W1,W5<[CU4W'F:LPO;I  CJ4D! J$T7HH&A''&>2Y([Y2C^(GWV
M8^14ZW-+9U6Z"E:=^;Q="> @D*Q,3!Y[5'>.@58Z3Y;#S/S PTR\C')4L5J%
M Z&WQP+RXB*=XA\GN8C6O&CQ5!N=$O7/!.-MTAQH/U<D"VHC'>44^!Q^&&'=
M6885"W(D2>(/)95HDT*A3WKNVV)2JD[Y!A5"T+DP6CJ<8<$'Z7=2:8+(H4=D
M&6_7 ?6QV.0JWN3YA -P)<-XJO368D9L35E9^B=8R,\Q+"6*?:K,(Q"%($6?
M5.Y54#6">=UASC?A[(7!%Z$=)\4J)*W[UNAD6JFX8J8[53[I*\HHQRR.*U,O
M%J0FMLTN;K9L<T; *L!5'/BDY\,K9U'QI889!?K%Q%H*6;O%NB1\H>37E?.&
M$T-?]/F;.5G%/#;(/$26H6.CF+,:H5.-HR.)F *=EX(997>+$0X441+6&-ZO
MN)#, O+XR>@J .5QDI^6(9P<4*VO,)T=M%<@1BR[&\=))D9*@345FD"Z9'WJ
MLV#\):RAFMN5N^_V1,B<!G/<C2HM<F.N0$T=6*^3$E-5$< 50<>EE!X55C,I
M&5RLPE4\!:\%.9%S(>CG/FKMA2XE90>Z_!14*#^F<LC\8<J/Q_X*S(%+.7./
MG(OY).Z9VK%(DCM.A+>*_YT*C2_Q1D5@P-9R@0][BCS.9/!B4%8DBW4WB:0Z
MM$@5&D\D)HBG#%*4CKD$5WO='L0G5E'$T_I>J<R$%$C6OTSW*9)PVK5S2^;7
M#[73N[BO>[!#L#B3P*M9<AJHOPQ?OH9O%,")!B^Y ]Y$W\4(9$I^61ZJZ2LW
M7!,'QE(GDG1]$#'HI6<=3!L$.O?;J#B<NSU%4+2RLE0(<I(5H;4C+"XUM:#D
MK4MFTZSD,4"U7[TG=Q*@#3!B<P5=>/B.FA;/GD@U!H:U?_K/T4'=&116<XQ%
MAR$NW1QD: 0*6LPUYM$<G0P9%<96I/YTI/ZFZ.35Q<6P(T4EY@[0GD)(A\JC
M=8)8Q$YAUN XQ1O);2'<@W>/)4;_88?JTU"@-9IP@#:".5_'R25_6PCO$C@&
M<UST+I):A50.$C=!*S:"S[EO"PX7>ZYN(<A23J8Y<DMGRQRHVFVV1<$&XO,T
MF8H@62P)5WA^Q6B9Q4GGG.-6/@CFJ% 5@SHO#QL&V]!IR''A?X!HUVX=>,P\
MIY(=$\M5K%O"5_&$G;<:< I6^Q(!DHKJ:X18.BF*"@J*$;468F(Y5LF\F%4A
MD@G)GV@8HF\;(13(;"=A 9(G!E$R@4-4#CL%!!LIJ7@'\SK@R& T@N7+NRC@
MSLD4F-)A;7?FCZ1^09XFR:@=OG0SRY.$>5*SE*M,@QU0DA =9/[*I)829JAU
M+1*:H(!#B+X).$3J>459_@T.KM+JDJ]6#W=A&_*P&HY6)9 @LXVXD%#>$/CF
MB(:UXU)TISP6: @0*6@HWH+*E13*?ST@''2U:F(AOFZ@P]"*I!0G9/VZ]-Q$
M>"D8AS)V4:;(&TFIQ2(E<+5%\ V"I2L% 2K*>-KT2%3@#2:*%T\F',GW+N]B
M&8BT!T\S6U_8\"(\X5@D.Z\P[]2&OC=X0+.($Y!1Y*G=XN0]!@BD5$+IA5J[
MFQ(&'6--DH:\2 U54GXY*;_*RM^2L3QQ5OY68>^B#D8I[0)3UW/H1W;=2>49
M89B]5'H*$SV-+49%13Y!SF%82_;UPJ=(74>^0,*9SZ&7KA.LS.?L#=1FOP;?
MJW@1@HH9Y$;,-P.!0I%>3F=3W,:58Q$.&]9[F5>I6A&PJ1D+EMG4Y^2LNW$O
M:X2PB;$-+&$F?)P@F[%#",>CX/M+)5L-Z_4L0>-X$J-+&[-01(0AE!&;[=+4
M=AD47(TGS'5BY&%34;[: IPNJ$/>&)',:'@5'RWQT:L' 8%O52#P/P/O[6Z1
MCPB[_UI'FTP"6N@>NNZ9Z3Z[ET9>4C-[S445'+_9T XP@&_C:;9@U1#*:P/L
MPZ;%T)BJ]X6;W9P3\/0* 4'0.Z-"(MRH91O&O69.GO(;[F!?IO>2L)9$7BH>
M,DH^ULCDE=F%Q!*#XJ+=.9%ICN/T7F*F=((=C*A/3U+(%XH3KL'*X[MC-MM9
M-S(]@D@U8GCX80X/02"T"!.3Q_CPT3ERN[F?-#@=/J F19A 2+ZF_(57)5C;
MB+V:>F18],Z/T1&)TN!:75;W> 7>SD!5C*VSP(MKK+2"$HNB0:?V:0>R2-%K
M:J&2N=I'BT^[D#<"7KU'DS^0GJ3IM9R:U;2;35(-]9B<3NL>JTG3X/*DB<*U
M(M.;<GE0<\6$C+I*R.!\QKKD2H\K2LPP^3_Z3>N@[&P3I5N'>EK6GR*:H<E"
MR^KT6>,FO5SC^2LD;Z#MB4K?9/3J\WBVT*'I/KW#<*]//IP?6EG@72+0TWSB
MQJ'Q8I:\7O0RU4[AC[_."SVG=(>J/_8;^MM3:H011)AE%2I?)_=9&/(1Q0X@
M,3<? WMH8-N.]5?@8F<NZZU(+D$CK5F_!X@(-AJ+2<W:"X4K)L)J=9KM9LT,
M/I.AG(XQQ)8?.*X"NOW=8//]VK0[O[&>,.CVZCW'Z39HS-?2):@($&"8_877
M7E]?-Z1>2&8W#?BTBY1V&EE_SD)%7NK4ZM1R7ZV; <!"0V]&L=A48@\,G>B,
MA#'&(I1Q#IL^5K#IQGNMD;(H>H-08('+)>:_%EK>:0AD132_D;$8FD 14+1I
M&,8>4P6686BRAJE\"KSZ7W8#: A+O^C:VA+.L?6KZ:1&WYJWJJA-&2M[J(JB
M^#$+QRCO<$&5,OC!S#S&-09Z;+9YD4LS/N-G'@#=Z]=S([H<#1J>;=@<'@VG
M^0+F)1J31LTZ5*SZ@H'^R[NYXD&P[C,/S7.?8:-!^&"T3)2W!/<T4D[IPJHM
MG'X,5%&6978=%[9C:6U*=XUEZ!?6,E^WPD(TK),8F MG,6!6%3^;8+'-.*4/
ML@?35,8FRQ,GB U$4(Z%@9QQ,L]\^5$DM8J8V66H>#U=:E1XS0+7E]BQAPK$
M.?]'M>HK-%PLS#)(J0.$]-D_P]3$G-2PQKW?3>L9%KMXI#_$R24(67R&;I^X
MBVRET+[01&RYKP5)?*E<1\A$9XD8R6+/(PJ,D*Z-9@NSY*KYR.W-1_)5:F[;
M(KWEUII8?K+1&B \H_DR];9MF8Y%)#@YW5@F!_EIP<'O >^:8VX"\*H\Y6;?
MU CB-6<Z(V&85Z%OF#0YS9YJ1?#[,M(L.]-U)9,+LEUKF,A7=Y'K75 K$@+T
MQLX_VK+#@$+(_=_R<A0"<# [B5 EZ\]XP;?'KS:>;LR_J\/40S%-Y0O]QTOL
M+!**^8L@H@G032_+;T#7[D+/<'H?_ZR\OH->H^.TT?&K>IBK%RN?<(-\PKKK
M=>FWSJ#1<@:W_FPWG%M_N^NQCMWH#]K?]-B[7]D95(/M#SKW>NSW-K5W.O?I
M:J^0/V[K:__$#D);-0U'K3DAM1BUF0\2#)'#"'M4%YTCYI _Q&KEEZKC3OFA
MT\RBUM^6GO5NK21:+J55^HX9WW_E-'-=>M2/M;).M;*/M++VMYSL%;/#",E6
MS0VT3-H:KJP$1>7%K314X-X_T.;^JMJ1[G%C@M]V>*/O;YC8;,:O]MG?3@&%
MTR^\RU$"*^;7U02&]+^U.,A/^XROD-7RPSQ/RL+#%+U9]&^ST>QLGO;NI+23
MY>#8K3367&\9;&O%X2,(]:U: :?36DA3*.O::VVY??^YKD6R"Z^\E>Q_T"UJ
M=ZHMVO(M:O4VMT5K,^T%";!K3!N=E&-*H?@F7KUB]CM"94W'J3E.=TU*NV.W
M'XL9W%=-^3&WR1GT:MW6H-JF+=^FOE/K#];EVP^X33^OLLW0T5AP(/V?3N&V
M:ZW.NCR\4NB>>)<&M4&S76W2MF]2Q]Z@::3X]T)U$,>!M\6A4SWC41Q<FY:S
M:SI43V16@J3D_/!O<Z?>E^4,OFM1M]$??Q19QUBG'4<+SOB'6+J?S8@W/O[O
MT;Q7RJFMF^J_OFN*VRV"V[5FQVGLODNBHKI=HKI6;>#T&W9%=175/2G5M0?=
MAE,YC)YJP4]GF4X$,."(/YFW:-!;F\U5;HBGWJ-N8UUG?[5'3[Q'/;O1W+BG
MZ$&,NY:]_8S[(LX*I?[WE)#EO,T63->/9UA:@..]/6OS9U"2'F1IMON MFNM
M=O];#<F'6)\M-P6JT_%SGP[;::^M952GHSH=/\/I:-4ZW6YCW3S6+3@=I!<^
MIUK(G:HXY<8U7X4IBH=#1,&X'6"(6Q=X24P@Q=0NBUH>^8$81;'N-JR@>*A$
M%QZ 3<<1>.<N6)X2%(_!8R+\!=-S2_7D*G4HGR;Q*$&4%\86T1.9S-(,83)-
MW@IAW./.#@/U*>_<0#@F<P8ZTKUQBUW,&7A3) :;@/)@L'!7C4:#DJBF/K >
M9RIB1W7:S9=FN&<RF+C83D\7<2.L@X(1;5CG>?-F1%$)0^O7@?/+;P:91@-'
M7?,**9@K7V$@J8Z,LTS6Z5WY:@SC$$:+D<3I>)["6HK(M")BX'':\F'@\?VW
MD(K:_X9UC$UE:%#4[$P/B\#-BYTX4CA ^%2!:!CT9NXL[,7P/3T/%C3O,4D-
M)#_/$OS;9SSE"2U<L7E!WG\DS9+X$D&SQL&4H3NXYPB!9]-&2N['Y4L] UB!
M2,X2.'2CI<>:31XQ\!GL0!132^-$:CQ8;(8H"+246_,0C2RNT2I<,>J%J-N8
MU%WJJI/*#$?4L Y6-"QYJQJ6E#!@INI+#0"S2/4*4(R 6H%;^&6X,>ZUF!"B
MB@+*,CU#S7NO@F26,J#1,/9F!$KS-7Z /7XF$C>9UE!W-<'.0.G""(E$7"DC
M*_ EPJSP&C 1TO#U2I0VC=F$@8 IC[9 $05Z P[@@4RXEN(2P75J!:+C3BT*
MV98:O3#\SM!";%-8),;I-=BSN-<3$4:S+.'^I+0\F12,YZ9:7*:701A*7W7+
M9 1P1?.P3YXWFRHT.GX@+*KTQH6>FM8L"W"-"0T T7;AYP@I537H *9.- L_
M9S&J:#Q,@CMR/RLN2H YV#2>0(#SYE*F#WT%E5N0BDYY-2K \9\$]!:'NR&2
M,V*0>[UKEF2$8 ,X?T$1"E(-#D)8W\A;-"@(<P["*!\.D?OY((L(/ 0NS.4\
MM]="A)50-6N;$(H,?#>)X>T(SB4\TZ+0 ,N08J5[46CH21]$ C7J,6 R*$E2
MG%]!U."0LADUT38@W?CS* 814",EBJI!J%%)9#K=#6>11M^*9QDH95()HEQ\
M%!MP%E1+;I&#SPVFL.0HJ0V[I!Y".$&$ES+PF"2H$&<\H:9Y013%5PI"4[/=
M0)KVP8*T&<6JU=<(*9IRMW54> CV4 UZ#7R6;4@X:W+Q=MZ"]QS6*1IEX_MV
MZ=HF0^<]8>H@U5'7W@ -&FH<G5&SQ52&5]AKAYH&*Q AG'8,QX&U,NS.).!D
MC%07QVP<4 -VE+.%'J]TLZ8QO?,U]<RB8</*1[DG5*H6.&\A#(NG2!GH%7;,
M0";F6@"CGF*G 3W!X@3P5OW8=,E.&>'/LY0[%15Z??MBFJDVDA@\\57/[N6.
MRZ2[4B8BM>6+X9MBVR]!=CKV#I>3:4;'0O6H-VNC-&9JNT?]\]:",2K!0G?:
M5=>:VR"SN6O-76+_K8RGH=PDWA=1<I&(@6C">"X1 &O,R,TI:-?^4*29POAE
MIJT[,+-RFT-\$JEBL\6"PKO0]*)H&L#9!)V?J!0.'5ISI=.LVZK"-4JX@ER5
M ?(- CT&$B[ X"9P MBNQ'9;*'H*C:*I?SG,'+&C-?-0YXI^F\0TPY(C!)87
M[,_\M)/)I$6@&A"]%4U^[(01AD;P@O6.KU --.#,\I$FYT$.?&T,3WB%G+@)
M]MO$2Y8 .=\CE*X"#Z;;D",19FJJNQV37&3 UB":SC+EA0!+*A:@X)"C2+=)
M46S3[#;#CJYZ*RQ2&')7413=BS>2V)69PE[%UJ*)KWIXDDT$%X(9!V/W8U!\
M1*[4D(>OEENV:F$"!H;&_50$<<V^%70Q1"/"FAQ)% =+I"NH9<IU0'J,Y<U"
M\@Z V@;$0'(G)$:;98GJS,)L,%-4 UL*5S6LUP@(Q?U2B@"8&C-W!D11Z VH
M40"-^%@Y"K!M)6^LW@"0$VBA:B1F>NJ^>FH96Q#=4B0Z*BZ]&2Z]SRUU]D8D
MK#?.K8D)"3CTH!FE&8.G+RD2NO^/X.9W$9@*"?I2B:$6^&^N1."A'04I>QAJ
M!6!]<OI$5P$</R)T1KA-EXX?H4.FF3X+Q@0H02A.8E^&R"?CZY2T(%2AK"B8
MH!W)YY%Z'Y/Z'ZMW-:S#&X'XU@K1V>@]QG>L!V48(*-87JO5*C9@5&?65WT_
MY8MO/E7+[4(V>JH&W79SFTY5NZM[,.Z38XD=B\;]_M^PHR_5Q\"WSK5[5N-[
M[Q^?&VQOX<=3(G,KF85 G+F$=H%FF=,"Q3=MNZ><Q\:;K!#1DZ*SGWK-LL".
M;@_%:!<Q];A2@SHZ>UTK($"3X8J:4=?^A8"KS4VY[5[PR)/,T;<@6#?<XK18
M&QG.Z7@L^=B_G>E7Y'E/\M1>GK=)G.DN<HC?BZJI3PZN?238/2\K10#V]O<,
M@<I(D+N'B-"QJ2]SD"'@.0C\*VJ-S&W7D6OE 3.%@9Y([*=6:O2\0*^HZ#+H
M+E(M4*&*K7@FRJ!/6?F0X37FB!TISPKB]YM#=GQ41-!7FB0<(E"3:]K?-(DI
M#F7\,GK<A?CBG#E[1:Z/3ZY =Z5]!VJP_E8&S9E$4PD)Z"T'8U&O#U(=FM5A
MLI1(2+6S1=M*&T0(%<C^%1FJ@"OP*!:F2$_<I!"#MM$,PW),(L%DRO'F@E]E
M"D<BA"<B.48QV15A@,Z[BD(>G4*(!8'\7.0B(#L-_\!-XRW&.!D"]P,943 2
MH?V+(7>2?SHHK:&_B7BN2Y(VC_1/)#D(E%RC5Y9&HF0T]8;(1;DVH WS,LYI
M[M@+OV+,9Z&[CHT4CJ'O6\>/-!Z2^6U^]I( GA2(PCBP'Q5>1<-H=JRY%$G%
MS1Z?5G^?^6#.4_PHB4,2LL!Q8&.=$H5B@LL,EAKHS[.:O^02L:B=41_75'7&
MRO6TX5**BI9@J2&Z@I]5.8S0"UU6+IU610^/3@]'Y*O&-3>;]A;=97OD+B-%
M["*!%U,'6M)E<I)IYW$WY'[L_)O,PA&J^\C]="Z13FR V88%C2\QTA.>IYU9
ME&IAG'HIR+F4N"F*2IU^57#HE4FH(IA')9@C.I:#FA)VBLWCSH8Q7&R<TBNV
M;P)&&#GF.'X)UA@'1@W5+4@L<F:BG%Q^1I&JBKX5XX\N^%*XCX;RH%3$\<C$
M<>IE,:)F<9LT))+"_H1STY2/%-X\[.=/@KR-2QXB7XYL$P\PFK)2.GSEU%+,
M977G\=5D9GFA"";?&8[;$!GLF3XQ:!9PCJ3*FT/K )TW>7,_6%%8G(CC_9PW
MM<K72#[&DJ.3/.RYLU-U.V?F/8'CAOY#^)7:;,YS#8*8@$G6TNT>4C&4>0@Y
M#VEH5WZ>KD<9&^0XI$,^FTZ9>GAG4SKIE,&FU>10)[%R,WB5*Z8T7:23*;,5
M"O)FL \A>S.78T\H%'-AI\9*67?6A<!^5G'B2?:H8NLR4LRY/RAEL/DP(*3E
M^D10)WF>2I5Z5J#<9I5ZMAUCV4#JV=:P3^ ^<("-9EI()([9NZ@:>VH>%DGI
M<T/($JOUYEY8B .SDCL#;C!7F;(J4XTS9O/ ,:9_,6-DUK+$^H"_*6V&<V2F
M+-J*=03?E'55!2H?+E!Y3D)R!&1P1NP:)-,XF&ZTGUPQ8HDZ>9[A1.$XH)^4
M?.+4>S4(N4NLF492G ;+TXGX#$1:S.N?IYD$G<DZQL2(;"Q(HHX#;OH:WZ_8
MQILEF)H&0EBWOX:#]3D&HK>NX'M2\E4F^HJ:#O2/Z5'\N>(FH/I+27$?FM_*
M9\@4*YF"=(P9-U0H-<0\+A6*BI-"NLTM3;-5X M#6BK?:RE/;CG]B[HO8\$Y
MI;Z0:K9N_^UMX:#'6.A@^!:H9:#U<>4*\LK5^;JFUSQY%N%K3-@1:NG0HZCR
M<TBI,D^$UYK2C3E&]+"1<H.=$ZCU"U=WYW9E=HT5%N7*"]WVNM1_>20C+RCV
M'73G9264"L*HU$O>>!+59[) HU**GR:(O/1':;/WW7I3459T:LAID,;^;I+%
M13GA*LB#8%E,E1N*/QE9R#&-ZR ,2T1D0F,Z'PTW9S6K@I<$F.9*>6JPC3(:
M8U1$B?9"7VA6^ ./MJR02U0L%5+[,9F%&=B=<LG79,IV*&^;P\]L2)5D<Y%3
MU#2Y^/P(+X[!KHW8;4K/B8!NL:NQ=F2A&4-&B"8H(IE\Q#M)&66+]=K(J7Q3
M*14E3FA/387/W@1>AVSV#RF #/;2-/8"6KOGYJ=SJH<K_D;I A:O\37F([H"
M>\/BT8TPFI<7[Q4:5^-B$V<2JL*N>'[5-Q.@1=YBK?1AFN8L4@I90EE[%*6+
M<C/2$UAW-?J>]()*5?NNG#*=X7IX0]V64][:/_#(ZF#NJ6+:VZ&_Y?XQDYU;
M$#*4:EI.NLJ-BY(KW<4$W"FE8'K2E+2P55/**8.SEA9>=M=]-568/ M%@HZ4
MU-23J"Q4Y-77(#/K.EN7'QN@].2SP;GU=:VCY;G^-9#0X50GHW(YI$IY0)%I
MDM[@O26&NZ+TM*:.+KY/\WV4^2:*SCRYQ&NU-$;/4I;,)J3(%7S) GD'Z!Y:
M@25&II58I^44+<DQJ2JAS[E'";(.J136?4SM9J?G 1 CL*/ZN:Y#)KUFGPNV
M50!XL?)W0;,NUP$O_>CB)G!]\7SI1^!,(-N6;WH+2G0 W#@J]MLFOKGT!"KI
M#+AC=>*O?I&N0.<)+18W"8^L9E*\NP[G=H7AZLGBQ;"OZA,LS:#W"]>BWKH$
M2[?@D'M]\YX[%FCAUHI_;XA_H_YS6"PLVBR71O)-@4V";H=!B;J?X+# I@:;
M!RL'#>.LK9&GJW+,5"(]L<%97OBWJK:>E)R%(@I2=(BS:Z9<\$_[%&V) H[:
M8Q:(JCR$@<[@;'.4%8[R'$;/ZA(2*Z:58(65KRT:U-1\?KWRIM-K%6?5MZR0
M(29$@*Q]HODM&5Z@T",?+C4XY)5^Y+U>LUX0]@)LFGB3!$A+Z=)NLDYME&B*
M\, )FL8DD::)A!&XB2ZKX^C)3-5$Y&7V:&]3CIM5%)1H3)$(Y11)3B@C6(29
MB[8:[BRHZ]J^68K5E(5N[E$1Q4-1&I*6YDQE2+)\/4(&^/4LKBO?C@L\8!A\
MIQU4L>-O9<>O3=[AF4P9^F4[M&9A("2 -B_):<2.248VR92_,Z;*N71L#:DP
M@FMBM9:G-3=Z7BG.5ZIKF,Z2=,:E&*,DO@:M5YU!T G94E\H?=7L6*-J7"KX
M'6*'&-ZF"D!4&+D2*DL"=\9:!\5E Q_X#A:Z>9)*5^=Y& +/IAPB,P<.3?O$
M*<HQS%004HBU%_@U]%/#=3R 0SAX,=Y\+KU9@H?.9/8T[5+F]?[>V>$Y_FI2
MERF5?ZYJ0722%WQI2EI0Q=NC9-8#Z4D,0S/@58NR"#$[H&3_QU@(3P:#JO1B
MTT6$Q'#2L919,5L[OH;-)"\!*G!8Y7X3@*6-8JC7_<64CNG"060DY/#-8.VC
MN)0TXDL7'2L9K@!RO"G5L\->PR@["E ']\@25R((=2B<EQA?DLBK."3.QVIB
MH8Q!I?&2&]YX,PI4ITA2PQ<5Z"\=Q[/0IS52UEG-J 'IS'BPM&=L&/-8C/:A
M";%BCYMACWL:-^&B#&235P1LG%NB&DFUH%3WKYT'95.\+B,,^OI%Y0).AB[6
MS,O<$ZM4\X\N^I7ADUR%9;UNM9]84R^6DFI@ FN6ZEAHV1V"KAPNU T95R-_
M).JRJ<S2'&I R0;@,3GR%JHIF P!!Q^,<"H?MB@D $P)F*.N$%*2I B145O0
MEM5G/5]C&T^1,6@/=$&S)IN!:XH5+-8*3P3%+7+-7WG(9Q-SZ+7CNJ8^(:)3
M4IRSF(.*ME0]6/1.JF :#W;UEF!F"5L)F$&CE4X3""DF_9E"F$**4=GY@C)5
M9\YPTE:-5^:+DHU<"E\<XI*E8:G\&JJQ5(A::O*\-$2B*]., S::E ]>.^6-
MEZF4#T5VGEX>+$F7D^E8X&GC]#2:HQ(*Q.,UMIREU*)"S60^@CP H"KX<P4&
M#F),94PY'AZ:6_RPFJK?YTB&\63".BK=HGQ^"UI]L01>[Z6"+%N(9'UE^VX7
M*3]C*E.K2F7:CK'\4"A::_HCWIK0)9S: SE!;7P*NJ=U01Z;'40R*DZ"W4ZY
M WP:3V>A<LV."$"+M>52\-C$^"@O'<[<!--:*6*K<U&U"^W:B 9@PI1\!=\0
M6E8Q%8#<Q(B756/@$F5BY%%C8)K=#O--M-]J)ND@3\(U.<@R2E#LH?*1YJE=
M,&RT(Q?LF=8OJ!50>909._PK4RF)BH<SQKN@N"/Y2LKF4,N:<!M > R"WQ!J
M&8,AC>@,P*C=.5@[+5NE]!1S:CFQ6"@WHKH#)UZHJ54K %-9M,3R12AL&N(:
M3ZU$1"-5Z$,H9&0!]3JX"+W!ZF7)%I[?*:R,#L6"T=9=#&K=8^>7LP\, :F$
MOW>-\T:9].2JZ-F0'6(6B:8\%):C4P5*)]0P++7;LZ4,$/!N'6"G20<836]>
M?MP]W.K"-GQUSK6%H_,UT !4Y!&*E9/2":N5E8Z00 +QH"@X8DS0QIW53O<4
M XE$?4[-Z3=5Y1D1(GYA\Q=-1Q7VLGNSKN823+2+(F"LYG!N #5<5?S): AF
M-*CZ J$1="",GYRT=TT0R&M$SRJ!.Q7)&PX!ZD#J<!8226.#VTSU%'>A)#.E
M%J*4C)2@6 '<N@R4P-HCU7TINQ#SMWBX@?'AHAJ+58(4KS5PS0B;$M'U2US#
M 89GC#[#9892UF$QZXH^5-TT.U@"/J%Q1#XY%V0FOHJ]-:&*:"B\(Q@-HL7"
M7L8FAH'8B&,-=U0D4CJXAAZOY:KL)#9(.1:LT@YS3)2B?UXEH<6YMYM\:!ZC
M*.<;@2C+< 35HQK6>8#4!119\)B!8D[!(W._;W5:=%LYY4WSL$4Y5&IH7PQ?
M@QQ88+'=7ZC>LU7KV39=OI, C^?:H8"K H>Y9>69NV_1WT<,9+?8K(&VIQIK
MCI4;KPGFL-],M0= )Y?=Q68,Y=209,E#XJF:'WD3I)S?EE^C74!:L*F4RQ7Y
MP\N9P[4\RTV-3'DKV%.!1X" 6]5IP3*N!>/T;L](31\U#<5O4$KU4TQV9K B
M?%K H,NY;) 6G/L%CRY.^FY@*%,T16_+QUNSM+5+N$P$1,_1!5VA91S+A4D:
M)P6O9<,ZBC@.$1B5-!\GG&R3Y:R80 $-W] ]5^##J?AV;S$>@:?T%J]Y_I_4
M?[S4C_L6__&S5V\H:K1Q3W"&R@&7NQC''MH%I +9)%?ND=&/9PZT);RGR:)B
M->\P.CO1+FI6.H,*95I_08S]VNJ8A\$7ORE48JS$<9S>':_13V\6GSY8?'K;
MN>WI_?L\O$4/QU(>0N"$E\ $"H]?L.0&'7JF>8U>+_NN]5J&OKU>8:ZP7I",
M!+JL530RIN 0)J92)%_K5,@CEH*C=$>-0:FEOZBY9*5:TE7R0-MY%$@SE9.P
MVESA@<\,8^][4ZB>FLWL(E,Y+>0J'N5I\9O/EBH('(4$6,JK+*;PDV5!Y4E(
ML),87?$8\4#S!?%H@0\Q7,P2).)B=KW!N^50\ZHZ \ICP4"[9'PF@_P%8KB
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M9%S6V@*,A1'N5&,VGQ8]0<_SS@\:,(.H8$(.$PY7*G)(=8:*I%U@3RU'6W,
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M*:)6+K<%[0^6,Q#A'(T[#B:Q3\C4E.-YB3#O!D5,H:]3'@LP]R^TGZ('X=D
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M9[M"?C1;KUQP7$;6ZEO_F:';GUSA)0P CP  A)L7U5"%0S$77W4D0V(@5D(
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MI!8>9RM87))PY)Q"L2RU1A!0<O1E<4GM5[338(*9C3&]M.;_^W^=/#G^6EH
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MP_YF,[NDEX &HFT6H_,I8\KB]SH\AM2')*$#NZ']I5,S'9U^D6;%P+)ZQ?F
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MK7R9C9GL8CLNQ=X.C7Z6%V&I(NG)M *6LN/2L5LFQW>SR]\B9:008L--&F2
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M23OO.V-G9".P93;X),W.6<DK,'.ZJV8QZWJ.OJ]AE5^,G%.3!D"&(0H)]7D
MFN08O"#K+)>5%I\RMZ63N,BB\KQY3_ Z8<HT=9,N6\\P+FQHG"QC:=I<\+LK
MQ/CF3:NWK!6.])6R))&H7:"FCKNBQVD;Y?V[.\GG@\8B72(%7[]=2^Y [2;'
M146E M>VK5R9(8''8!DW#I57BJ'(6Y!*/F5-L)$*U(F-X3K1\JT@C>KYKI.<
MXWUFV([P1N:-94@*)4)E?0S#H.0?U46Z>^#+41)9J]IK] =:O^GW()D![F1)
MI<&\6I3A\6IQ:(E$*R,KS427"CM,35=@,GJ9AJZ9V.P1F,ZL7!1:$<)9$OZ6
MMHQX#0B)/!/H,4*G%J$@U:NXUUY1R6MVTBZ.=9:2P:9+3U4W,+$0:[]P%P4-
MQ%.IE_*"O*'*Z!77VG=_I41*"4 7I'^ A+>%\VM,DN!!E8;K]Q9216[K0RG+
M&MB/P1]*N:G,37[/M:\LY)/T%-2+#7NR\\V"H\DL!_28\<(9'J[// "#[3>;
M#2VKF%XQKK,]1=^6XV0E@Q XIXOJJFEFK%WUR]?2=T4RDL\G.P16GGB(TN,Y
M4S"A\GFY6F=HQ5EMCA_9<%S&$-L(2K=Z?A-KJ!7T"G+)8IMN'H,H>REY*P4_
MM.'<PU>*)9-4/T-"G3P=C[ZGU:AF!1UI(3UQ %"YM/I;UW)2WR[C<;\<8"P9
M$)X0._V4$+_I]TY[$-^0EWY8P7!\%.WLE8W">[/-:L2P<@+"'?2VBR"<:"V#
M#[M6S#@^H@VJFTHICA58MT/T,;ZGFTN+S2S?!WAE?KQ*I<EQ*EP6'CE/OG]V
M[JRN$H?M0JFZ;2K@IR7XQ95K7E8*,CX\7 C&U3_.:69#V;(6&0B@#!.)>9")
M"8WD 5QXPVLAWLL:?U'>T49:*X4L7=NI5@MT;ZY8_6<F_A]/'X]IE4=.))]Z
M;?L5[M;@)+U+R@LW%8S..6O#N=XKQV7LDSS26+\'Z,%BT=QTCD@IP3*Z3<X5
MJ.O.5QC%4>;!(&AD1L("J4GSBCJ[K[YTA3%^($;$5 &Z36&MT7C@)>ZE6N?I
MT5S3X?Y' )!':08I:H--*27@Q,$#IR AT3);:+@7-5E-ZU50O?>(8= [ C9U
M,<*8Z4CB/J&&2Z-?6-'^&611OY1>&SI^GK#T8C"\ >A&W@#<W)0>O,E: %#L
M1>N'='U1U]RV@>UCIT>)95-#$5WB<.[4I(PLD$7:6\9#B'?#Z2![ZP%8I&[@
M989A9%W ,/JF4S+%:*MJ.0 (PEX5RA1[Q:$J38,8\HZSD\[H-E\*VUWL@.8
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MCZS6E",T?<M#BD<0];0PB?1=^I/\>HPE)!$?H!&)[A8X&B2Q+JWUS;V?%9P
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M% $D@Z<K1H^BP*_J_0*?I2RN[?!)QI(+N1#<-"PRI',X4F4M;BM).!<I28
M,7:!QS\>>G"\60'ND!7K)0J;6"P+H,<A^B=Y884!X9#(7O!ZV4EG *(M#'QD
MCB^:30ZVHWL\5JX!_N1BK;&N<4(+E("<B0 MR5 D^*2S.D 3UE-O,?*#L6Z%
MFPXAN'[M$6^R!4.-OL[&YZ^,/H)]2?/D*D?[OG<P$X9"]=JTIX^*AZ5)#D^R
M7.BBOR136. U3QZ]GU7UW/$B_>VO4)IV/@5E+X>!?D2A1VI12_+\4280GK]X
M=?[LQUT1D#[7>KP.^!5C3?QCB8N4^H];B>Y!K3$<YPCXAA[+=(_,>4!'>J&1
M+ TF&UP%)E/P9(RF+S Z(F;"T)&A8G3=&[/U$,83!02RA5>4^L!<^@J.:7AW
MSLG'10U>0,X&)SC=P,,F6 ,;J#2#B'-=J^&+@<<ZAE=.!>J\@49N8+B12][K
MG&+4\XA3 PC7?D5X^Z)U-:S:E6N!,F8EMC9\S\K)%(#-)_0/RIP-ZS+9S16<
MN7)#VFIA5G//18#'+]A_EYLZX3>:>;QW88TI@88AK3Y%:_T$'!27L&= 2>/#
MP_55-FE@.4"DMT 'GV)GV@8R7>8<\(H9F18-KJ2[ 40E/,Q"?$,' .P<5=EG
M8^SW.W[/%),%#I#$.6"S<P0K$GCA,"$=<(0$TG1!XT_U.A*RY(-R7P<3ZV">
MWM?!W(VQ? +8A4]TYCCPWF\6[-Z2,XQ+3.)-0)*F5D,HHJ1%H4<2TCL2J"]^
M4X$@/B]6VQ1:R&K-DV5P7HMD5TD#21U#O[OZ:ZU@M@,2TS0F2YSGK[_O^N'Z
M':W/JL XB /F'\M>Z<D>I%60SDLEN;9 (S  K'>^2RE70=X=>E3&)@86K438
MPR!GS*];,K /+,IFI7P\D1X+QCW)YMCE&7(;EKVV/C$D&N&R])$=&0U!B=6O
MU=6HZ=8XK1S<3&%)U9[Z_T&E/9?-7D7> _$(/&42EEH(&P_05?C.XESCW!)^
MI=KS?'9==5CLA#+DP03Z,BV &9WC?B^J4)*.453%[ +NIC$;4\<U5&Z&9W!M
M2E\<;2R^:S2$4@TT-CC\B5(6@@J&<IUSO_7-%#^366!#DPM5;?>N+:_$?E%K
M4$0''SFN-XZY2S4P,I/\]?='KUZ]2?:X+%6&4R]=N9;OP3$7&SK @/<)^6YY
M.W]_DE:D$MNY(4OFTAKZN3[$AM);SK'40+CAZLSKZ'/59FVY)[>U8OGK^0[&
M][G,ZV\C X0*F:V "O_0W.!:CM_U0WCKXXAM&@T\FDDI3617I28%<$9BHK1I
M1[M9U0.\P<]WZ[BCCF'H]ECS8\Z3GE%VLSW8W8'0D5S,XZ]L_=D=\+4'RH>D
M?&G?+1<#K]BB.LV.O^S*,#.Y>=L]/'9L$"'A4H]W3BJ[-P/1R+BK@21"T?-)
MASS^PLY!"*["6Y#0DZZ$:+K=,8D:+=B6T.(AX$"^0:**41\#+O2\F3++G/EY
M2K&."U3>L.2#YN:0 :)G_K)3?9E/FME&LW7/\BBW32=N+D_^0$]U,?K+IE8
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MSAENJ4XMI?%Z291T<2XNB4*\Y^:JU*%K6>-B*ZDR^9V'X-#)6 FYCQ3: 6-
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MX\GIY+$$-^Q,[-HI^8!Y;GZ\PWX(1BG?D/%HM2 Y\L>SR6D\:\;IS16RX<X
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M#)9E@(S*(->KFDFB)8[1 TK#03 '.L,D:M%(S.CVWQAR.P_P?<X,:V6EP@F
M/6OA9E0<=V>[$MDE[%Q#T9H=@Y?9LA@"3GBX.)9 $PD$7R:37W(_<D"NOF!\
MQS030=!G'@?#S%_1BS9%;4/N,D*R\')92IN?1/=3_GLA)KA+Y7?0@.H1N;]2
M&3("[0O? 9=B&3WP-#13*L>2X)=B)8W-=EH(BC4='YH::>G>YTLW>"+2$DG^
MY4I.VHS.#DB1$X-!]NJQ<F#B*+: ;M'@KRGPW7U4MK>!K33K ,#):P5/#AD9
M 2I.(,4,?N@8B\DURB6!0ER.E;>664\6I;!):535F*P$'E[DRFS3K4&N"3G
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M>/G@F0O\/(S86BQ=>A."7NRQ&LNB9[P51_JF:;N4(U<V,(M8=NMA:D]Z!$K
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M[R +Y*Z6^Z=_56P0S88_29SW^B8@!1;T)YSB<%<X ,"MR6:97XLY)KLW;P0
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MPJ$=O7H5-PH0!&TP8:?RI=J,(F26TJGEO;'8^^)$HD+:P&N0NAV.LA#MYYG
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M0V.D8J",HTZ-5]3Z^;,[;A4RRK(F1OT)^;! 5ZU.+LTS,L.M&#Y/A&C8C[F
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M34QSI6&*P;L!NQ=<DD NU*<!9W[7'CWUO,J:P#V5M5JFR)I9G4\S3[(,C*L
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MT1K<LKRS 1]PL+OS.\*&IE%F]:J)Z*1:D)G/H0^=.<LJ^S)<4 9I"5N[,5G
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MQ,KXQ-"\QUH67$D)>T,-CZ3AE8Z7NHD+MKLKM5,<,)G3R\_"!CJ>/ /D!'M
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MD,)+Y"V_A(?/*J,E\D>4Y'>[=?86!>*$7RIF]!QWWF?<>93/DZTG"JEAZU!
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MTT?C8 ]FL$^/'SUZ_$%/_1O.+I]?9R'(]OS75_>_"I<JHI9O3]?O)B>QU:%
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MIG_(5AFPG22E7]TJWV9LJ&GWP?;S!_J:./\*%++8:_13Q?A6.40]Z%:%/I.
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MB7Y?.0F.N;+?X<>AJ2/4LR7RT@L:5Z1+-/0;:3U3;JC;760C-'*(F&JT2*I
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MEYDIC1)9FW;7#[G5<G;R$&$<2-TGNM4JG/@;K_D19(UY/??9S CO#M:6Y(9
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M\7'I_#9GOZ\A(1DR@+]Z"HX"^$Z(YP'ZP22X-21.L['#\40FB@@%#0:/Z$"
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M:UI(O:B,!X4[F)$<(0S#>(L4239D*QOV41OV6P9LVW!%P/WM+\WCQH?F6=G
M]TW%-\YG#LR5!(0V1\'M+7("7-(=_99;+84'D98]"3:2#SQ'1U[H FBED(+4
MP,A 6@HR#?,KHA7$+ RD.7M,<;? 8VU \YH[.2,TT-*R%JL2BPJ)1:=58E$Y
M]K*%Q*)Y(VI+5%AD+ZXO%-SML? D:3D+9)^MOST>+J^Q 9KV_T#U# W\E$(
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M>!5B3&7;OA8-:70#Y7Y 0[ +=/PSP\^^9?PL0PF*4<S]<5U.I]!V,:C"RN,
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MF%R;%#/B4(('_P#S"?Z'_RZP<N.2-0?*%HU3T)G9K0P\(+L?L-=;Y>+5"L(
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M:F=9"I_SR4B7AV*[.^TRP^0MC<BSF9KXKV&@4Q-]A(5Q[^]8X"2SD#)F6:;
M259BHZ7I;%^"H(@#-8N#K3AYUF@F8JI!K5+00F\1P J<\1:=<-J^>C"3"SW_
MUI5=+P>C'/=T_59*S=E62HU2'*1JI51LI51"IE*RNKU"*201]@SW:&S>1FG=
M<T6RG[HCF2P]4;V[&C/<)D ?:AUU7&\]=^NHU3I%4?,FTQ4([)"\ET\#6PL]
MTD>*,EA7ZB6U4F>F+V#F*YD(;"SE*Q D :YD-YVB3:DPO7<^8[S!]$\R/:/L
MO7\/?>G!OB]'*G3>?D7/G-X/?KM#3: 0R"LT@MJT\]*#][I(0H_W78+=FI(Q
MX5*DR&QCK.XS'3Y.8W3>+&S"!"I_E+#VY.CF4XU=M =GLW\ Q084N3?%X.;)
MV  P_M ZK??LC V[@#H7*6_SH-\/S5[]Q'87%GYAE;EF/4KR+N?E$I]E["7P
MKDI%+:2B=HO@J%)1JU34[=DU57>\URSSF*^3W,2XB/%D4_M<W%\O%U 80BJT
MRZM9+YII8_7T[ECE$H'EPWMIZV#+:G'/IL.M<BG(DYZ[WS#+E_H:'H&:YPBL
MI9EI,&@"/S'P1:"4/\&R2G@>!:>7Z(D--);"#^_><1T\IS9XI@6<F;.""OY;
MNECH!M7I'%S_B6- WBW,A38M)1;VMM.=)LR53\1@0/&!$2PB*6[$2C 5"QF?
M)>#*DV/EKM6"HBR&PH7I.HOPIX NP"7A)C("03T$%D2L38(61[%&.'B0T&R+
M'*V(8Q$%L\3 440D!C+8W' 8*"OO7$6%_'(Y@/?0L*!X$O)'FL9R$-/L'3=*
MYSO\M4YM\V.>7<>63?$0#7(OQ$ [A:G4E]S"1,[E\ M7?0!WPPAS<IY:B:-U
MQ=%J3@E+$)6RVJFLX!6QD\M:&ABWTZRMW'WF'E:=RT6K9>AQM]MLLR3Q]HIM
M5FSS,;99]9W;>ENO^6CWG+OJH3M=KAM;DN9]B[I'SC9'7=PAJFQ^M;(3;B6I
M7T12EPMXY;K5E<YRV#I+U3-MF\&T^9YI"^R,!3W32%IYBC._N"IQKHL9QH^*
M_=0:61763I/LX;0>VH$,^AUL/91%LM=+T>+./G:OG[FA2(5>/X4LQ:RF-^\-
MU*WWEK3YZ=@9EO@CCBG1S$:3M6AMA:P;K!;E<J5G;#=4*%"G#^A[4Z&^:C>B
MN>9#66/'QNXW'R)J*D7SH==JOE!"@9"W;,'4)MVRY3*O(_V)6[;L35\BT&B.
M,*]3/=JLQEPX.W=F73^FJ4[=:2*I.E0=>H>J3?+4V.E5+B _I455U49I!8UV
MIXNK9[K/4+7.C,.B]JPM:1B/NB]-;F*NW)=&]R$XY/8TV):&.IVTVX^UIUFN
M.F_>GN9B;N7'>K38'5EXYYU&WK5E=F=5.X5=;Z=PD$4NQU612SGV4A6Y'%*W
MD')'HW:S6\@"4Z?HW"R,ZAT 1/HX6'=JYG7(>Q63')DI.K<=!EI_'!12S%'W
M6+?JMS21HXOL2!?!P"]Q1.SQ.Y6=1)F3F-E<YZQI<%/"OG3LH8VLC !AX"^Y
M7$3/_,)%1S3Y"@?>PJ->&B?1%+NH\7,TX#P&U:#N_(XS::U":7L$.]]T3:BZ
M/6AQF_B[NY$,]+K4GY@6#%W04LTF>63:Q!>NI,V101'@>8+0&:8B$K"?O/FB
MZ;$7*=V=+B^+IN6H%LV<N6;<\(&4[.CF<A?0L"P0V,/@8X2#W7 1&SR0GFU\
MV[7B.ZUU='X-=F:;3GB"L$F]2494)FY#QK+:^(<D,@J%<UF!'7:^ ]1]P1&7
MNJM>-I:8PQ*8=!*#XD4]5W&8L:G4T5WT5$@M;!$$Z7HS8LMR&71F<Q0#AXIQ
M5&>(>04J9D4;(4%=%0T=8/0!Z< 4%D8XNFX&D4!3(Z$SB)B>O.+S62GC[)1=
MYVW>__#JZA.79_%,WN+(I&+1#IJ7M,04$83^65WI0U>,>^.@3PC>- C![L>;
M/@X#E81TRRA IVTSGG>*G\[MC3!>F#BM 82FO Q0\'D(*8 7F2OCT-,M0S-!
M0OUA["D;A<7#)24F3G@K(WUDN(4#0#SU>JP[OX1W$KXCD -]XB6>8 M+?0&,
MS,*^A+2&\2P4"TMSF-N:AGWK 1>[Z':X2) [IK[';(\]+2+)"!2 D_C4O1)X
MH@4LN@FA:=!I!PH69?KE(\^S48ZPQA<BGX@9!?]#>:80-],3YCO,4J](VB5H
M2T!3*AZ!C7L/+UO0D&07D8*^#QI#USPKF]OCFXIOG,_ "L)HRVZ/P=*H[T[J
MC=\D2^AXI";,Z[[G\YUCOD;?-%>\PJ+:G<Q+,2? LN"I/<%:^QYM_[+)7YH+
M3+9JVEG,#:,;6:U^1!&,&BE"FM'CF">3&AM+>"TR$.W:-L6EQ,F7N[.4]X\W
MCWL1NB=ORN$DZ"U.-E!_IL"!$Z['/=<I8=_,3/0=)"4.::/=,77T*4C[S@]J
M @2 9E""O1K_:^"'=Z95<4993$*@MX/.33V5<Y4XDK>A?TNZ'@\:& B7Q. N
M2A8TP<+^'^QFCXVE;C($P1I+75)_=)]K!B)6E@<Q?DP]KL%*0P52>/+/E,1Q
M@;0&/MC]K"?4G2ML^YSKCR,E;]F("./"/J@%ME8,4=\#S924*\D=0]GE;/$"
MO:+IQNVRF<)FGQ2D(\)=AF60.."V1^DD8R"DM.D#LP7(/QSJ//^^'L3L8'>V
M* Q0E4 #B(]-KYX_.1:G@^H8N/9FTP#=.:#1EJ_=).5@X:GI2F"_\EOAD]:U
MU31I;8ODO>"S&XDH@WN'1&6CPJ(VSEU;1,RSR*EA-AO&$9E01MSSG=P6698;
M91^"),+Y*XKM;71X#(%< S(M^ >AIJL!M7?OD\C)HVDJH2S:$ @K!.(&4P4L
M=F6:R]#L$=W&GJB$@J=4>81?TT63 36&1],$_I;$YI#TKFP:^FZ:U>< .!4G
MV31W-B5RKE#C#H!F9B)9<)C "$?V%HQ,W"B1,<]/=-+8)K.5! #S-]W6G@+4
MIFZLN':-]0LF%NK.GV6$8F1T# P%>_\+MOVI$9^(ZL[9K$&O8NNG&AYN&'$'
MT1\:]781!N5B.;^%;#'"W?&GP-F1]%,PW<8ROW';3NXE]XV*P*(OMB1I[:*L
MO[#&EA*QB#$G81"79%+.6$C1A4M<3/?C-%D<]J13_/<(0QKL@R1^18U<@7J-
M_&1_;W$8DZ 6XK$;J3YG5%D1_BH_]_FS>BXU";0;-4T&9D:MAU6,&(RB24?'
MQ_7C(N^ %WX*Z&5P:W]A+-^-:'B,A[DYZ)A)?<IWQZ%$0/XC/6>W.\.);3;<
M%S[),TU"<V]8RFI9@9SI-M2>V?.R50F'?BB"92Q52^PYCMJL-RN.^G2.NK#+
M4XL\XE:3:.91@S0BK<SP*M+6E_,J-$WN087P=$ GX7EYY%6&[ZSE>UPG8-;W
M)*B0OG%A6O.=D=#L7?%.6*$S!54S^\FK#"I6]E*L; ?E[^_:A=Z78#*@RTE-
M\"&2>^@N9S-V@;U"KFU@3&S<X&@I5(^#L!!FFS50LGE<0+1=:M*F(SJ<DHP;
MP>0<,&B'-:H3.M(OAA-Y&6..1U(F-2O< ;])^\B_L8N?@X;Y ! 5DHE+_=OA
M(#[YX1-9TP8XO\W>K#;HF)6OI%G/[#^?:$8G>-23LV@3MJU($!V%=Q05&H7H
MCJ#I!;=8B12:5$R:1R4!Q$&&)710C$"-T;/A=Y$NKRMFM2UF=9 ID;TJ);(<
M>]FKE,AU'9XZ.3V+@^P@XSZ+N4A]9JJOSB8!.Z[5K!>J9LO%UY?ZG+?)XNLL
M!6EDJ78-RGN:<A$[/[2;]>/RPO-;'EQ B&ZWU3<-2FXVZH7IPU;X@R,M/&:6
MIYI3+M,/[4;=;AI<[ODBIL)%Q+'<=F]U!'COM-[<&>#YF5K'X-MR6:=)>K,G
MXUHVT#M.F;,H6.]ZHL<P%WP081_T+./CG,E]TC$IBNXH#*/JB [IDX6Y6/8J
MQH!A8RF/]/":Q:&,F$P1H#$R4S35+9MFGTF +SDWN,ZXP5YI^N75(JP\5#QT
M22FD3#H"7=('-:\9S_1ITQI&G\6R.4EX)>_'Y:((S1#S4X-8#U#+G3)C\0>G
M6.NT@YB[LI"8E=Z"$#H#.*0@.OK#?4R0!?O+(8N!7>U!WIB%\F*MKV/K*F2!
M:=[SS$HT!GY@?%X+PTXZ2YZ?AP,4KEP2HLN%/%UO?4S)L--YWB% S[P_TA@?
M_?33Q?>/9UFP*HD ZI0@@&_5GF=.PG:%[Z8^>]_PT9D]Y_B9=_/>46$#BH"Q
M2G1Z<AI3&C]E?8O9_=1TMHE^(VM%=R/E9K,?8P<T3TRR=BF'D>J$,O[B*/A3
M9U5GKQ#T"F(_-:0##)=3^K(63)168'QA,[,RWC;?H2?2.!'TQ/4\8X$KCDG+
MX2@-YQG 0V];[[1[3+]9N'_B8$/]GK&,A@!@S*P0_E",S?MS=&:O*Z1P4SC<
M#(37+)@<^@D<#:%$  A->7F<I?9-)0XV'/A<+:&IJX#U(Q-O6!(:2Z.E)+X!
MW<X2(N636Z2L9EI>U;298:APMON5WC2>A<88/4;82VU#CHL ;TK'LZ0>(7^-
M=$AE"=%3@D*GWNOFPQNQ!2JNM@QZ]K+XZW:]<9]Y92G+4_'(%U^1*F0E?UCL
MY"=3A;[HBF>1&NXZH_<1<2V!II4';K*I'2* CN##HS%PPY&N)9II56#!4@T,
MP_<B<9=50W'&@">F>=Z.(.*Q89_GG=@!45QG)9F0$0!VS(VD3D%"@%+R?ISH
M2JS%H%U& ;3?U=&YD_K.99"C\M1D#B,G#P+ B&MBC.%XC$S/Q$X%75_B0W"'
M7<U1J:R'/?]&VB[OR ;J=Z?>;2S^\F2V3=I)L4U:C2[=PM^V&S._A0]F?HMX
M[=2/E_1H:S=G%V@6%M#Z@>^;;@QVHX#"FS*J%%Z8=;@S@J@8."6-PM,6B_UZ
MO.@@E_57V<K,-F<4+[J)C5-2R*@NB/"%2L[4D0+D1;:[9N^#U5#">IC$;+Z/
M<"A)'F4WI;B=FGWTN4W6M"S78U.IM(D6&F)X#T5/,3U1]TC1G"=+J,D[K>B
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MV2W%_JF=1M;2R+3H$:3$6M3F%"C"B(M3Y+9E_!#91A_<;-?:FFJ)M(&V%T#
M"<A? SL6[\*+D$/ H<P<G-"-OJ?7Y=E,CG)&\B)#/M!7QI!9L6\1C5'<KZ7W
MFOL!\AT*2/40WR'KJKF$$_B:XZ9F,Z2 )\7B;>CS+"@[K7U)2:@V7>GE0Y-I
M]+UJO58^3%SHL&THEE$387U]G+5+>%CYCC)+\G;9JN5#-=Z!*3%5:0\@']LJ
M8%B>;ADE/B>B=$1,;UC-.\WW,<DI35(^,P=%P>12Q#Z[F6K4"UDWPDODGO2'
MBO;U#289L>(55(Z:A""!(^-^EFD43-M*+'2-!X!F8 NJ_9L98Q@'&%C!0(B&
M <LU%47 U@"(%_U[*_!GWE[3(T1_\*(BUN)663QH2Z17Y(.9D""S&L'.X+>C
M)!X&H8I^L%"_H+(K?,EQ5GEU&8.5HH3RPWJ2E9>)JCO?2\3AZ<ZW>7T7D\RP
M.V9@].;)X2"61F& RJ,JQ\J78QU4Y5CEV,LNEV-=J@O;R+9_*TUW;!2Q;)#@
MOJ*6/VAJD$KD$I=A<!LIGS2U=-(H$3B)U Q)I1?TE68=$Z$_TE7JU$0VIK.P
MBU70OODEK*4\BNC5ZU4 J3Z*@_'K+H%1'4++NA H=@_C@6(<R=?Z#V\PGN.)
MR6O7)Z#0C][DET>) .J?.@$IX4=8XZ^5L#@\K.\W]E%>Q"'\W]$O5J*D3J+D
MU]B9_:[7JK<Z[;E?-^K-N=\M6K;9J/?:\[]>M.SB[[KM:K.]]G(;^I6(@0D"
M2 ZI^5\OVB\R!>6@7?NZ-;ZSFEH8,(5Y<C!#=4QPSR\A2 ]R-"CE2'7R]%#-
M[C*G8J-A3>>:Z2E"YWJO@B]?L+_WNYFD6>[ ]Z"S+^SOX)2 <MQ3NQ_0/V^V
M",]+G%;)6I3$<%B*K3F6WOAF$0<&,YX<% T$Q(L*UHU6LX+UL\&Z\7.2S;:E
MW##)AED%'DY@VK!9+Y[4/)VFPON L#1A-*Q-@-,O3W=^\]PAOK)4!^]UV_5N
ML?Y[-!#@MRN"8B59-<67T_*N(N7=(.5NKU/?KTBY(N7-)^5>[Z!^6%)2W@6'
M,#6;=*PO#? M,)E28+16 T8A+Y:/)E_V6F JO%J:'HO1_J32<^J5<QV?+450
MM[-?;U8(*B^".HW.FCAHIWQ=+;2+TC /$MH%P-@4DNOU&O6#Y4FN&.WK-'FW
M'4&MUF']L$)0>1'4;'?J[;4@Z)$L;7KW/E=YE%E^OWPKN?SL56Y6"XKTVLRU
MXIJZ 5G826-9S:I\)97S;H^Q+#7!#+H^[,[ZTX\/H))S>:^]DIY\=/BLV?*N
M.*7BE&4-EF9K%7U8<4K%*;O)*4U0*<T5@[BEX1:R/7^ETL!R3$=:M5Z8.@T<
MY^?@-LM9I;IB">YY0?J^OM:F7.4?Y+Q2#<1:^L+-+0_.YCJWIN<Z-PLA/5>J
M/-=9L@YKV=CI=<(6+ZIYP:U4S:%C<9?=*59C=?'.6-8Z@>^G8$<QNM+(=UE1
M%$Y?S,([52!&Z5[]+V 7=<TFBN-0WKA!$@$<0(BXTLGF9MJ><$<17\$V>P@8
MW9W+=I?H,AG1Q#8XV*71F_N(@41#;>E"\;K;P>EN%\#TF:"\D#?23V14,ZYE
MK]XT[E5)KZ>MB,F3!;G,=>",VP-L@/Y8)AF\0;JC2$RCJ#2&.IOW64%&8@M-
MONJ.D;@Q]]/*A^&,[B#;P2WO%R21*FY9@EL69>&VBEM\J89[:.."!]<4CSJN
M1L^4JL=K&=W7YK3[VM@*@5I.]]61I1>HF^Z^-J>%:J-R7Y=U7^,I$@45$P;8
M*<6VPT1X$;42YY9BP6" [=#Z$]5CL\QTS7USUTJX+Z-\"Z$+PCE9O.<I%2_J
M6?**+;*%V,%NJB+FSB^ZI30IM%L1.A1KR(P$ZCP5N]A@;C"@GF&CL1=,I(S,
M[J>%H_D:^')L/85=MO0[ *B.'+EVVOC+D0,9AMP(2^\T%G?4-BS7=)C[5I.5
M'TK/E0/LZQ:$<6XC>OFZ]8?PTAFC^76I=RR=RYUJ'E;+^C=F0X&'N%#1XV5M
MLE0YX)4#_@#M-\^E,.7V4D[X=K!%Y6GOH*>] ELL\+3GFC^:>7 KJOVK;I<=
M64/ID3$-!Q77JF\_298@:UZ+#KN\OQVKJ1&+YI WMBD6\.2[6[@7!+\!JU;9
M8'4A'0FF#%IY9X%/723!$N+FM(KRMBJ8LI.]V ZK7FSEV,LN]V*;T^VVG,;@
MXIC@]$BWY9KOL@K0'7AIQ P..:*>;AO<5PT8O]Y@YG] 8[5V]V%-Q>YI_]4]
M[#Y)K[)JL[W&<LON3F.UI0Y5PA9#5]A??H53+=&9:;, H(8U[S((4E=IYWI-
M94XB^>:&VGZ]!$$\2D.+4L/G)[H,+GL%LP+GIH"S?-<5"N#YW*U>#*M<+;&'
MS[]N'DRY*GN'ZW!5"J2<.3MF_@C K"<TSK"B<*3ATSQ)-*A7[RYQG()H#5+R
M7KM>X*CT8>/L_[\4KZ:\Y@>TLMC2ZTT;=$&I56MW6_76PZXH;="5O(KJRG2V
M[LI-^BJ*JRCN)^5<I[=RE],-[KZT"7;4Q3QKJ=BRV/(N,]UNO?&P?H]5)Z#G
M<Y .6LW6FPI-Y4;3>EEI#2[S>L"LBQEPV*"7C_QMH$/;G^/0+L4KF]N1LG>P
MOW*?X?)9XUN.I";.'*Z05&XD=7O[]<Y.>1CK@?/[;0JCVC^C=3;90FM6WD[9
MD=3IUGL5CLJ-HVZCN[+2J7R=U>&<75G>"K7C[*:STVZTUFFB57;T4D@ZJ'!4
M=ARU>IV5[;?*UUD=SI_2RVN;K6_D;KHYA\V'CJ.K+.AG$V6'E9=3=ASU6BNW
M42Z?D[,I0S@*KS#<=]:%[:KGE\CN0IG,HX"FW/S9J34ZC8>6$3X&?$I>#%9Q
MQRYS1ZM]6#^H>*/BC8HW9H,]M8-&XZ'QGG5RQZK3,?1+N0P3+]KGRS"Q,/.Q
M<="M']SKU+<6.?7-9>^ /.JV#Y?:<ZZJM5GOMA%^)]2;GWLA394D46N $;?S
M#V[A$6SBEX16/_ =[!XTH0O^>$\GB(<RM/P@ENGGU @JDO!P& :W\-Z(UALD
M(3TK[\:>@!U.=_!_JBX^*81HP0<W\5D;]E[\]O3]?+>1X?HE8K@6\UM6 DB]
MLMP[0%T(^&*F<R.<@1'A'6W'PD99JG5E++A3O/HU_J">-D="=I+8OE(M>B-"
MEY@SMRZV_QN)_+KT + @>/[2CA>V"C%>A^WT5-])H$I\HZI'%]>AE&F+>Q84
M\&97"QFF83>DAIO8%_1&6M@]$[=EP;^2$*_^(3E'QNL(Y_SK^3<"\8!WZC6J
M(R!\A$CA=J69D#DHFXS!LSQ-?ZOE1 O/!=T8*;Q62#UP"(IUI!2IHE%4K""S
M?@C=&I>8%.?:T&.UF>^]  X[D!*^"D+Z [;9(_HFGE4,& ]%;-T&"3;IDQG?
M4?_/*5GALJS(;3[;,O<A'($L&L+3R*?<=W@EA6+T!.IMIWZQ2Z1?V*#3A*9P
MG^%]C 3%Q#1(0-*"P 41/DI&4T(UG<108;JX &3]F"9+XK-&F!B/P^".=*@W
ML9J-_])].*GA9HR]M 7VD\;FVI&RU><,IJ$><4:C?'H!TA()/1^;;WH@%I*0
MNX/J3IZ9>%N!ZJ;>,C4!!,2?7-3OLYQ*?,L=A.WG<EDB+F=Y7EC0H-DLM;<C
MQ'[:N/<Z",#P!BZ"?=RX-FR0[ )TP"6RE"U3U]V3U]0"N ]8HX;#OO7.)P**
M(NN/K'DO+8 VNSL H0&B)'*S@79HFD7&G+_7RJU!/E;<_I\$'J3NRKC3?M9E
MV'G##]?THV3@I![,.,26P33&(\*COTE;\AMB#UO_T^:YD7X< @X$31VH6X7P
M2ZTP WX:0C;J0H]>CGWV@P3]'1\ ,:E;V'-Q7+2@V7_9HQT%5A0,XEM<$20(
MVE#88QKV'B5C%(KTYQ$--_2,KN3%^\55_""FV8D ]A]LTLV8;WWAD2*/AE*6
MM<'Y_3TM!2DMME/!I@6=D1&\'6 3:J#- .08'IE&(9C*#F T@%_0Z)?K4  Y
M.0B[FP _^ 8^)Q JO$+8Z&G".V"W"&*P[*4]].&<U]CN&BB5Q$;$OE$_<3U'
M(]!0EV-X@R-Y(F;:<[YNO<T:6T^D"('IT @O=JMKH)G!]<6S%1T<YUSD]/LO
MW8-..C$378!B55[3RQ&Q:%*L&>$Z4-'"OW9)$$21C+-]P[;:M"W<B1T3+>.6
M9G;2RV9WPC._]!K=W,X*#\2Q!^K!#H\-<3\<*TCCA,H(2<+YW8' X,AOI=5N
MY+;2ZC3,L:(4"^@GSK5$FN&@)D8,D'M<>!OV1P]\=+]"2;W&PTENUP"-H6L/
M&57(XP/8(;P'F9" .7 ]CG%&>B8*#N:()1G6>A**N2*<@#NUZ@@K0AA<-]@S
M2D='XJ-,8P%;7YF,<^2-] (F04W4Y1C<M:+1=)2 ? V5E\L.[84$\%!DZ5A1
M#X#Y,A;?Y3#P %.;V*GWQ+?.[3C(YK>\E_TP01IC 8#T?RKTWSC$KF;<."Z(
M?.JM[TC;HY;_Q#IP;J!;#*_A%-U&O76 03D0_*@I. A@SH_Y4_C&^XY 6WG&
MN_],//U5%I?S)AB!,[^;LS&<V(L#!O!KU< ?I_>J#19-U[D<PX?G QI\\\X?
MBK[+VC ]HL@?4IVQV9TYHXC2(QH0;@%S>5$P_>D#0;OXM09DVW7K<RHS9R&1
M&C[Y7RITU C2C ^UZ;KU1W +K![6E%U/\H(WF\:%P,[7CE5^][744 +9'BO)
M@?9#R )7N5L<;#4=1!H!D1Y8B:=:*IE$S .14EFIO<T"P%(']U3(IGM&XRY(
M(I3F^)@Y(#HP# !MP]-VP?Z2H2\X8JP&NPQ 4X @/<YCC:Q<0@*'C/N2'DS#
MW@2F 76[ICAQ-F*CEE-+#$!Q(UPP!KDGW3*::0/ET[G!)P=HE319_0O?!^3;
MBK>+\*ODMW34-"IS=$@R9DW<R&EBMEE'HP!/&=C?M695.AE9*TKZ$=@Q !1O
M8@PPH<6ZZ6)@C&OIU*$]'YC\398*CB?'7 J3/_'0-1C\UVB?FWLP-RY,E33[
MSJ,%"9+:M'W4/#Q(C\Z3NI (B8;((,F]BR?GS-V)$P"^V04 $R^4!0 7RC]S
M;<M/:/P7?$A<'&7!DFH4!5;'3DT%K4915*,HGIKFACC.$-,PCAR@?RDI:L)*
MQB6A]TWY6OBYZS/;8TP"-#R--L01IH5RN&Y=9K^V.3?+,1E:'8<>NDK!99I6
M@"=S1Z$9%6+)5#[]9C3V7 HFD(<]D*C /0Y@8/ 0AREBMM95WB^[09ZXC6I3
MHBDBEZFOG%Q.S>)Q\*3X7_2AP-F!K\/O,C:#-[ 4[.V&I:DOKX.8??[\(^ T
M\,OS'V<GC=E'9\$KK+$':) 1%B*YT9 C*1@S#9WLN!>)E^9"^]V]9BJUP7C-
MSOWN#@[H7TMTY1 AS<,VJ"+$\X@\_HWTR2Z3\=BCF!B@^P-8J,('&K/>I['C
MDRPHOXFV3A(2#_:!D&@(66;3%=8P(,K/J+ )6>.:X2%YH+!FM7P*%:P7UW'!
MQ$4GGXN@TI_I(BB/.2GQ4]Y4O/4M<-6+([3\!?@%T2QOVPG8+2-T.S+>)N\9
ME#8:2VQ+%&X;90JL[;L!N!6)3UQ,D<,((R0<VE5FFKQSU<!(;,7,/H9Y.G:&
MTK6+0SB%0&5^U78^,WY$*7#>.7^?>Q>YBE-Q:2<@BRC;08:LEU$"1F5N!00$
M!6[4W#SEZJAPC1_X>]<IM9L_5-&;5YMHV2,P61%HTWL&'3CW!SPCA(CR@[5[
M..,.^S/6NP5>-E8- C!?6R^;KUAFHNN@ M9 K*#O1.+%"VB"E>#+UBM+NH3Y
ME^(5/<AT:FDB]8@EKJEJR0W@*:29@:XB+%KYE;*[(_AM1 3KH[X $YH#2ZT[
MID?XZ>,OWJEW&W?XR<O^JZ)7Z%^3!,FK6R3,J:=M<&=\D4DE3(]&620[4U!'
M[+&"I<1)62M_$GQD^B3,=3E"839B"D;&?S0Z03*Q"BFD1B1 ^\N/M5J$&)[[
MJG;Y"A,[(.4B1"P 7KV&Q,FM&ZE3&$Z8\5L.YP*AJ1[U1))MVNI0W,@B2*>_
MI2Z7^V]H&'0,UA1N.QVSF2*N '(IT,"$VZAQEM4TQDUW@9N5"UR.O:S!!2Z+
M>7*9C#!K_B/'L4;13[X:NB]1!:&9.VT)LLN)$Y%!S"J98,2_M3$WL5(++V)#
M&)[MDR9A^Y?CU=)S4_\;($VE3&K1G(_)>4M.N://A_IM3NW$O$U0UD-']K+:
M*9RGS,K#]=.T+HUAIK6DH P9Z>KY=NNR]FIWII*GWMXW/J.K/?K#V3EB!:2T
M,9,?#QKU_?V'339<.)]PO]YH'3[F?,*MF_B&)7Y(RE^P/.)=KCS"TO'T5<8J
MK3*6ZH'3ITH(Q9<GOG6JI[7NW.R\,QD;1:0AN$M^DMVC>$B_BVV[%5MTQ'+?
M;FW5#IJ'6]"?D0FI44!)TZ-$2@7^$]/6T1QE74L?N4Q?K)IO<LP=++B=/=WV
M#]8YENF11/Q&-=FQ_$>1^4N; %NJ$)8_?[D9$+3%X<%#&UVM8@?^#(-.19F:
M'?:1'KEKYA)K& >>ZOQ@GCCWAETP([-&Q>IF9&5";K@)V3GL;<$XHVTP(35'
M<68E5"D;,X9&Z:[*HM3-?9KK'"VTDQ9E\-/BO[(FM\6:[+96'^U569.5-9E3
M?]@E@P,E-CSM^@G=:T@O&53&Y28;E\WVZJ.XRV=:EII\,*S/O69^:KSVEK%*
MT1'+S2J'!SLV\&(J%\G)],/IKACKFQZ>,98EXCAT^PDGZN-@IFRA>/9$I:HV
MBO]Z*_=0?FQ-]>!NKYVZ697"%2C\65']W//6FQP>UO<;^P\M-VD>/$FYR4&K
M*C=94"B1O[:YM@J3JKQD@^Q0#@]1V)**Z+%%2N6\;;)&[/0.5QZY\?C.6VDB
M.*6(T6R W?QI3H,E7\:5G;SY4J%5:S3 MER[7'C.D<!E9[D/0>!@PYF=G+E[
MV&BM/&#O^2(GVHWR [I'LT#Q%#WYF"G&#<^-A^"-N#?DNCJ)?)+2RLV=7]CJ
M=K>@A*/4.OU<#6WQ%[LX6RYLNXW#E0L(RQ>FWJR2BWMIKJJXV(V*BW:MM]]\
MJ$M>55Q4%1>S<3K/Y6:-!293Y99ODFSHM ]*< ^L-,Q?"O;>@,C!Q]P,PQI?
M&!JDXD&-(ZGB=ILO(%I@/#16#I143N+/.8D+].N6>XKMSN$67/?\:5G?[!IN
MYOKE_8Q'642@*TGYA3.2\3"5]_EH "HYQ]<:K4:]_5/NZ2- :1,#^8^P^ K%
M8T]''[3B"@--G&])A(T2WOU^<O7V: ,[AIX*7UQS:]"^]%QY TM/G<JZOS4F
M-NX2UDB*"#LKJI:2>HH"CA/BN63T,<\:5UTXC6=&XGOQ3"0:LX&3+'S;Q2Z7
M4[N#GY:K<R+6W5*+3)IBYG#OX.S:&=Z$O,GIJW7@G1N5E1%T^;L ZX#-)G;^
M_4QC4F:80W6]R\V,H\YWR*^>^Y_$=9#]%.<2IRDQP",KLC9]*7//61'_-T)W
M&UN?4AL[X4U^Z!DOV:OZTA:X4Y>$!O8$^RXGU,0/%(+/SKMJ>XUS-4*7)I!R
M2U4:X!7S7 V\2#Q'&ND9([ ^CJU)HH@E%\T8=20L@%T'J^ZK2Q'60[NOJE;H
M&>JP#VZ*T;3W<'%[XK/ +VB1#,MEK\H6GM]HFOKTMMX$U ->#:B=:B]<W Y:
M_="FP=KP,^QGK8C-PU;_- 8+Y[(@++A)LCO"X8X\NR"4V.P76ZOK:6_<*UTZ
M=>MDP*-VP(YSQP0^88T#[.UIGLJZ<0-/#<*%QWG"=R0ESJX!]ARH44;9?M*)
M=?0D=3".\.8'#E#$[25J0!3U25=KC!#-.*DAT.,CJ+'U0-P$H;XIDJA&U_$P
MR&:(IYWB9S%W ISO<(OZFN7266V<*P0&+QPG&DSF(](X:9]&@ [=OANGW9L+
M[0X"@_2OQ35N!SMK*]F1:=D:GUGHI@2D@YVT"[\Y'*"&39J9O(U>UL:(+;!1
MZ&OU$MWS68V.LC5%4)M/L'.#2,WAT@,7CW$LFAIU5)L1UMC?&T=-V-Q/G.PC
M^&$4C91@S$G2JK^Q*:9ZK2GOO^IO7/4W?FXB!.''O?,\/2*Y2+U9:B*0ZC<\
M)05JW.R?QBCFAE>HP17IX\>F"E:_U9-'J>]]I#03 -S"L 5-%#%_5"Z3IQRV
M?V8HJ/8@-7V',A9W>CRP(\?@C[HBFU8XPCS3C^P#P*%? 7XEP..<"#29$C^)
M<*)&0'F(4&J=#:; ",TN)[%G+- *H$4 !>'"1F'@@U&JYC,VL_&,:";QP&HU
ML8NB%F;HY17/Z,#R52] 4X0-+O2J NIU@1.&C'F:+]MJ) P6M@:AX_H\M"@)
MT>23R#]JHC=>K9AI%D6&OAI)2Y(+WPN"\EHU9P]IMJFGG+R7'?4R&F.VUZ>I
MD>@VP*K\@Y2%7W9?%;UX>JXXC_>*=-_U@7!Q,KV7D(;BL45\]32="09+]Y9:
MFN:'1$#8Z-#0%&^93F35 3$R(",]NHT&DNPS\&G.2&+'/*\;MAE>JSELJ2D:
M!A;UT6>+/Q(WU#&>3/X)J*1K'(G$L^I)H<PTML_-0%?^LS\U1-.8X8*#5R+R
MX%K=_\JIL0*]1'$%@2-ZHZ0/;[;CM&%*Q<.+HW3W"D3EG8,!A+0$?\QFJ%;P
MW<9(W]_I/*+9N!?-@YKR*L&;M!-OSE19/> )E&I,M3-S&D9@PA5V%@:>QXXV
M&TD@ -10W&L:;06O,(2FH)WP8 N0$$/I7&OO.!UP@7)-^=#L,0LO<YBUM74C
MO6#,X\M2M[YNG<0L4])#F3.K4MM+Z:VE=F9L)SW8/.Z;T95YJ6CH61T*8WY5
MYB(/V7:S:(EF9'YJ(!C0*LI9A.UT")5R#.9L5+L$M@<PQ6'!*JJ$*C^P;0J-
MZ6E_H,G= .,<@'D,V^#D[HD5@7-//Z0!S22X^4'<LOH3G@I71#3PG%(*@Z&Z
M@:=H:&>?!FC1^V]0H?+XYL"_#O"@68 8YWNFR1+X VDUT)IUZXBF=L+'&#RY
MC]2S.3(\.XV'K40YU ]X*L5H$\5 0?"(>,#,PF5!-@..*IRF'%5 D[!M.:9
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M+*%X BM.@)]>U4!#X= OE$>"HN&&Q3@28&B$;J2:!L-/Z,94MB!+ :7;04J
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M1\)B:;X<8$7V4#J)I^*/881A2<":'(V#D)H7T&5_?*VZVJ\CE@7(Q;:=W"E
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M7E".P+LSYJD]="](.W@<R0 B8D01)6TYZLN0:;'=K.$$AU9M62ZY!7;/6*Q
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MI_%U^WSEU:4J FFV\0I$L_O26;Z/4+Z(AXK-P$B;6'07UF$-J]H^<*,?U2!
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M;,9U9L20VE/\%/W/5R?;$_=Y*WT7H'CL"7>T$;'EH@B)U5PA-%)4S'LJ'1!
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MC")M78H8,,-HHC^1@'"<)'/-!Z;1<)L\H9HVD)[BYEK!5MP8*.F>7ZA R3U
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MW K1,TP"Q2[F^8J"-Z1 ]=G*+=&$#IY0W;./RPGUT(A5,Z'3&>%1VND@K O
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M3U7R.#B<C-_#/$R/5HE*]<"HZPRSNE1INC<9NY*.>!=DQ$U42A(E<+" !*7
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MP5PB34@&'J%ZW0*I.$TVGIL4M&@?+>J=I)F3,E@-..0)/!QS,#K]D%2;)*6
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M..NF)WG)7^85-V,7WH1TWW^'@C9W11O6Q$TX,UHC!]%&#(Q2#)H;"E1(3VE
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M !F56AB11P12O@FV>D_-\2[C1V<L[H(?]QMX.,</2Q412FI 2B-@.EG?UOH
MU/OHO<6:>5Q-[R(EZ^(^C_#?#LPT'$P.?9C._K__4@3+GP:ATH&GJ]C6-SH^
M.AJ3:5Z<[\1D[LD^[-M:WOHHOF^3P8_^/O_LLX^ ?/U344VF>)AE>9$+$([-
M;#;X=S"'\X/![))"W@MSNFGK+[#@ <G;=1A*XEN-7'5+35J'G-M2R=ZNV/J
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MU[%AY5=RHN5M'FIQ>'<IBZJ!LE3CQG]K*-]9]NC>=)D_PL=_-/I\*=EIB52
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MYH\KX^VAQ]CNGXT0KJ(+BT2W9^X_)Z-IB2TLBTFH(;?-:2D)QQAL.F2 16Q
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M4LG0AX&8!:M;H\*U89<>2\M5$D70V@+CW()20@"F@GMN)%$X[7*YTLRU#@/
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M.AB6W29,+$KRZ"B</*3C4KMQW*M =P[C?3TSM3BR/DD-GK[TG20GWY>LY+)
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M6!7Y*3O4\K3GZUP1',)9Q%2B1$Q"W-F(K",)J82]X!9S'.C&EMK4U_"R=!@
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M<2HE6 &<H82%)HI'QGC*^GOMX\0E0/*SBI@SQGN@@-'6_9,>#!3>X;@:'>1
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M94-SM_!8?;:N_W,1]W6PB;I9AJ2.=A2W8_O?%X.I0%Z?RJ.81<N917R!^R,
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M([ <..*4\WRX6B-MM8I"AQ3SX>I%76***[(#BMIA+E 4]3J*.F?TTV2H<<F
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MJ0Z><YF(Y3E(Y0T(Y65Z?2J2%V<2*2FLJ]G!%I;F=R!002EBW'D$ED?.3;?
M&A7P"!*)X8:4(R[%U[U>E4P*L-PVL,PQ6FPQQTP+%&+.><'2(JL90UP#R"2L
M/=:AB[GQ1;D[?_KEJLI=E'A))9[CMUQ)&4TT" /H(BYD0C98C@38#$$&&FG$
M&UN$+HA"E],M=Q'A6B&E60>_VSJ$N0HXK0"<%E77EX%)E;Q%GJ:$.#$&.1<3
M(D208!,S(8FF44CI ]Q)Y5V'6%=1WM4H[QP]X#18 ^8?4H2 \H;L<@A*(N*8
MDPP[D*?/B:BXZ.[]U-V;#W@5W5V-[LYGO&DF,$D.!6R T <1$?R%(96"%@2
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MS]@D34ZR(%!2N0ZQRF2-"(:B%LE8$(X4:6.+<KR@U-<:4;;B8.ZNF7>CE*W
MQDI@8XZC"<F24P$%;@$VJ.((Q":;9).@J#68J8TMAA?!1E'=>Z.Z-\K0BNJN
M0G7G*)G5SLJ8-/*8!MCQ"4>.<H8"P<PJHSUC!E27=4MU'UJH:"8=;+5,9!T\
M1QW/!2O ='U@>K:H[C SE"7I-6*\:9Q $]+26B0LY<)ZGN4(T*1%5XJK%Y?O
M6B6&%<5=C>+.U?I5C'"KI4%2:)][(FAD@R*(8*&L8E0E$S:VR$(Z4!3W7BCN
MC6:)%<5=C>+.U==U#',=*<N*2Q'/V6)68HD,H"W ;&3:$=AQ56=VW <6DUAP
M0*0I<CFI-A)[_6A'L3=T,-1KM%-<!V=%!TG!\U8(_\HR.)74E+H5>%H.GKXN
M(@2$Q>@P1S[7 .="6V053HAY11VSC'A.P:ZX7B.UXF#LL%FQ<CY0=':U.CO'
M!20CB:K 4%(>N$!D 6EE TK:&NEM),+PC2W.-V71V?NILRNG D5G5ZNS<S2
M2TU-M!YIIUC>9R,RF L@!)92DS1CTL$^RS=Y-W3V@44#\O&H'FC$(.05WU1>
MG]:[@M<?_>2I\'7P2W30Z']UZI7(8ID6L7B:Q5"@:#DH.ED8 Y!>:4Z1E6!#
M<!D2LF!.(-@XF(S:T,1U3DC:)-UP2!1/8N?3@;ZGL"7Q>T6*/,<#7%269!WV
MU#O$&<'(!B#P)@+L"F4I5K&+J=]%H3O/!\H6O$K-G6,#-"A/N<H.-P\<@.7D
MOD 2<A*DQ)35.L1<SOU:C3M+3.!G5>]U/#JN_0%PX:91D1\>'@[S((;^TVS5
MJ!3A\TP5XM>C.!A=K^MYIQ&J@P<7)@#U?%B?2>ME>MJ(ZDV65+$\5H-?WQ90
MB  4(5>Y _8@%>*&:*1]),AHKIWC(E(;[D59W.(%?8 TIF#*+6#*')OQ0@EA
M@D0QA5S9PA'DHE<H8$&#U"E9O3HV4_3Z(;*9[REV4> E%7B>U#"&J7$6T2@,
MXMP%9)*2B&JOLD\14\8WMN2UW(JW%^'HWF'Q3AQ 7_,P3_6Y"G$01KTC6X5\
M]&.6VY48SYW$>*8R*7#\TW!,%H9YF))<,:0T<XA;;)"CSB$O(K."2R4%SN7)
MNY)W6KS"G<_L*DJ[8J6=(T&",0E<QR+BL$3<<8N,)[DR5Y(^N"0-%KF\'[U6
M/F;1V@YK[4W&<HK6KD)KYY@/"4)K&0T(),%6JP5&5D6'A)54,1JD$CQK[:*J
MG"6><PMG/":4/P=SXO\=5^.37I5[_<;1> 2_9?UKN@3;<0P]FU+5K^S/%@Q>
M!Q=-=\,Y&:-&X[IRQ\U1F[WADU-I%-_K:@",+N *#K88!?8ABB!#Q)/AR 5N
M4$A6V(!S2=#[T>:P^'T?8#RG@,IM@,J"8RK2,J,#"C3W. Q6(VL31IJRA//Y
M,IU4">BLJV)WAM)<JME%@Y?4X#E>$X@V*D2-*'<*<4KSH16M$*9.@I0B%TH"
MKY'T6GEJ):9SJS&=[@VX!+96$-B:@<$VN#4>]F!",@[7PWX_YRN><=XFJ7%U
MG'<='',=CH'M#7>JP;"NQB=O#FP=#X;]$.NR@2VY@8D%O%:PF+S!%B4-VQ9G
MP&N--KFWGB$.QV2]\1M;1E[KI'3QIG?8]+PQ4EF4=D5*.U_JC%CK$K&($9EY
MH\/(B4!0S(<C$F'6"Y]+G9%R0/&^:NV-$<:BM2O2VCFN: 5/V&&%B)&Y0*%G
MR(1<KY!Y03 G1LC<&A-OFFXH[0,+@>W9K_$LZ\W% ]M/33CL\*@_/,D'F=*P
M[HVR4HQZ7ZKQP4'LAP<6 .L$&7@=^YF2[0U!8G]G.0!$P3P^']8-8OUN1S$\
M'1[F V=-.;J"74MAUXM%59&Q=@[[*)".'.<6+01I$35*QCKIM34Q9>SJBI>K
M.*C7AB44;;YQ;9[C#X8%;R)F2(.H$">,PF]*($$5993Q((5M2BV5\FCW5)UO
MC#X4=;YQ=9XC%BSD5M>YMZ5V$O'D*#+YZ#$U#D07$L8*-^JLNJ'.#RSR\#0'
M&$XC#ZD>'I:P0[=3[68:0)T37OY#B9__+'0M*J[,<9(FNRX9T<T1'($L3Q(9
M&H-3G@ABZ,:67%1I;8URZHHG]2'EU!7TN"'TF.<QV/JDB$=8@\W#G33(:*V1
M3CI@[$(T1&UL";7@*%#1X'NCP3?: +)H\"HU>+XB N?4F,20BX$C3FUN_9P(
M<B$([E0@1.0>KGQ!3.3N-/B!!49>C@]B_:@WB.,'%NWH"@>9*<[2R*(M10^3
M^03&];D:5P6+EL6B156?J2+26,<1)L*V7,1Q*9'/E95\4#8%L[&UJ.+D&E&1
MXI7ML%=V!5QD!"\,OQ4XN6TXF2,GT3)BHA5(Q.3!M!%@Y! E4&",&: GU%"<
MX:0CQ9Z*-J\3+2DZ?!,Z/!]9B4HJB3%RFE'$ 921HX$B89W.R5R.IWR\IW2I
MOSN-W(WCGK>C@]Y1/<RU.T+/G?1^.1[!+]7@UTF/RAQDL:>:D:,LH1IE;:T&
MQW#A\"C6U^A<N0Y>ENXQG*<@M%<3F?U^\A8$]F*P ,:V9P3U\E1.!=R6 [?9
M$M5T]]M;\O+)!^PHL3*ZG/NA$=<F(0MF"B(VGSOFA'%O-[8$$27X4ERW:\=X
M"KS<+KSL7(27I SS/%FD)0;;B4J-K#! @E3.-<NV5'M(I=1INZ_*O0(&5)2[
M$\K]]J)R2^]YD!28$#4YY2PT<1N,.!'2:\*C2UFY25>.C=[;D,UBN_Z4%$UX
MT$(:=)UHCAO6(=9H/#QZG*>E25CK3=^KT[#6B8,ME\ :B.V*R%8P[.?YSZES
MQU(L%?<H6A$0!T@#4\4JL%("(U*I0%B3!2]6D3=[9859(__M^H) EXE+ 8';
M8"FG)=BHE(QZC:00$7'&$M(@TMQVD$I""6,\Y5:_*XG3%!"X7R!P<P2G@,!M
ML)FS9J,,$\$PTBDW@C#PPQC/D2*L:?9-G,2M)7"=H_FW!0+W-@!TB>F^'7T=
M[2C^FAN/-K\U%:M!?1ZU)"@7M/X,.C(8CQXUW4CS69NZ\OF 3;[@@05]NL%U
M,KSE_S\[$\[K4['D#YX,POD_S%SY"MY\"'C8BGNZ %Y,^\X^^^H/[& _OK;C
M^"REZ,<%)9=#2;R +Y'H;"3"(.ND0!Q@$6DPF( T26(BEJYIER-E5^J7%(?N
M^I">@@8=1X,YX@0R]XE(B90E)M<@X\BD@%$4B=K L>8J=_0PN"LNX ('74]P
M*R#0<1"8(TY*YN(A1"*7$I@$0B1D#< !84JDD+22+#?C$F1!TGPYOW-+]O[3
MJS.AGAWW7-RO!H,<*AJFWDFT=3GU<QD":BLY6#Y2L B6L/$6=D%& N?:,)9<
M_/#B:D>&KP5\!<>6P[%%G4"]",1IAU'PFJ-,=)&AB2(M -U"- F#"+<(+8=_
MRG&!FZI#H#3ABE#)9.#&>!? K%*"V:C K!8MEMRT$56P9&DLF2-&28JHJ-7(
M<\,0=T$@&P-%0).4U<)3;<S&%B.+ZKP6?;XW^JSS61U)><(2\R"U\]AZI;FU
MQJ3(7=9G8HH^=TV?YSB.P5ZG("*R5H ^V]QPF$2#HA(^2.F<Y]DV$&:!HZ.<
M NHFQXGPYTO8S8\FZ'KQ[LY-W'_?W/MW!<JO3?,4F%W>:=!VI[B2R4B&O6*.
M4.LXI[@QS:YXXJE ^2U!^:(FKC9(9G%("%NE$(_:(!V209YP^)\EE-)<+XIM
M\G5F><LJZAT[U.\MX"X6Y@, W.O;SL6OMI: .]^H2 #=D3(A80E&G :,G+44
M10KK-CF3K'.7^=4*ZA74>U"H5SR ZXEZ\U%1G:P)02&B34"<6X:<3_ ;(SHJ
MG$*34[X2#^!MH=[$G3 =R'2)BP;35NT[O,(]9EZ8P2N%X;'KQ[DWOLX3RBB_
M,\H5>9<ZLF4M=A"\CH#.OJGUFH%[F'JMDRG_[#V[Z&0Z ]3F@DMCYJO(/"KW
M6%D.QY578*@^3^\]N07*US\VS9#NI*U$X\L<A#FOYUP2QU&3&G6Z).%5?LX7
M?=],S46O>&^LR55R:# 8+YB)3\9/;5V?P+3]V_:/8[$:E[,:%W7B]CQBFK1#
MBN'LG%0).2H],BY:G6C"R>B-+6X6."?7/FQ<4.B>HM J.6U!H=6CT)S'3@LA
M.286&>\ERMG=2'N1$*;P"?8Z^I0]=EIT*MI=8*C T&TEXQ086CT,S;G0B%%*
M!9^0E=(AKJE%U@M8K(E%APT58"QM;$E\'ROOKC$G??V#XP3?8Z+E8-6JJ=MY
M)__3X[H&M"KHM!0Z[2SJAJZQ2SJ?A'8XN_4=H\B1&%&*@I*8L&!8 #K13=&A
M4T_E_&-'N4U1T]6HZ1R7\5QP*B-#+!@P(CCQR HK<W.Q@!E.PN3F8I)UJKE8
M4=..VOY%35>CIO/5EZBG5I.$E(\T'[[#2,<D<^ <8!0KKQ-MNGA>V_'9O3/$
M]\C6KYJC]FVYV6'N2=/K#V&4XU@?]NQH%)<,3)631#=+!W:' U\P[&<P;%$?
M<VNQTS1X)#5+B&/XS7#/$.8B22V$%=KE9E_W,'93%/5F"4%1U&LHZAPG$#H9
MZH-$8 1&Q V7R+A\\)]')L$XI$3JC2U*KD_=BZ9V5U-OAA,43;V&IL[1 NRC
M32QP1 C.E9D=19I2B8(!&7%#2&) "U; "KH7 6CUS2R@!\V_JT& -?88Y0NZ
MI(#+',(%DG!)"[X?L83BX.CB::GM:G0T'-G^'S#_1Z=5UTH#GE6@X\7F?6QG
M_T,R/M%@,]?0+A]E94CG&FPLQ0",PV"FU<:6OGY\M+@VNZOYG3@Q5#3_1C5_
MYZ+F4VIDI,X@Z9-!7.F(;-0"12M%,BDDJL7&%C,EJG&?5;\3Y86*ZM^HZK^]
MJ/HQ$B.-9$")LO,B68,,)A*!D9=,##HD%T#U^:;ND.IW)5)"])T>U?G9"JS7
M.;SS8 ^1+_W^]V=?Z (9+%B_'-:?+(HH"98,$0(9'31@/5/(1!J18\$YK3#F
MRJZH=,:RVM+Q+/V">@\.]3I!A OJ+8UZ<^$YK+$!*5*$>92(:\V1CB:@*(F(
MA&&'\8J+YQ;4*ZC7I1=?-Q] 0;VE46\NU!E]U$'HB#P3N&T_X"*8?MAQ#'_W
MR4BQVA+#ZU$P:(5%1&ZP%$\9Y0T4#+IWZ;+?+=<RJ4=="K4\P+/)JZPN7<XF
MKWBW7M0'%5 0N^ ]PE)3Q+&)R.6,0N/!#DM!D:1,DT)X;2]\]U(("PK=4Q0J
MY:*ZC4+SAQLI-< 1)$HT!,2C4<B2R) W5"D!?-#06,I%%12Z^W<KY:+N#0K-
M>2Z"\2)Y0I&(.4E;>(.,P@E%)15AGLI$4O?*195"+0L*M5R!@Y;TJU63MG*H
M? 7 M*BCJU&&)BL#L#*E$5BT#!FL(F)8,X&Q3T+Z'$BZ/BZ5+,GNJFFII-0M
M-9UC,1;4, 0AD%,6[(?(-7+.162<8%QR*:6FI9+2?5?34DFI6VHZ9^;KQ!BA
M)"$LL$$<ME;DN'3(6V&44$YA'3M72:G$G'ZN1,NJB,"#.$E^,T1@]B1Y&M:'
M=@R/^CI^G*JO,:!OL1X65%L.U1:U U6*6!J-R/V<;>Y.%Y!6W"(/MJ'ACH20
M4>W__9<&^?W6(?=%*0>Q%C2AE(.XAK+.,040$!5:.Y2<QXB[X) #N2'BI TF
M>!4E+A66[KFBE@I+G5/4.:X@(_9$6H6XT#:G<$=DG=8H@(1HX%HI'CI78:D4
M;EE-X9;%W*$X/&XPY^N63F\7&K(*P!3G2[F\^[J[_\'C8$0,&!D.7(132I&&
MC0Z9&(.S@2OL5D=#BANTNZC0B;.[I:;#C6K_SD7M-TY2EUVK,N3*L4$S9&BP
M*)*@X3,CG&:ED-,]U_Q.G%\MFG^CFO_VHN9'D[24GB,G ^S[7.4"E\8#43*:
M 7F2FLG.%7+J2E!E?:JYK.!L3SG;^^#.]G:"(1:47P[EV8(@4TB>21XMPL80
MQ'.:K/8\(.JQ52%$9V7N;L)6YK@N!0T*Z'7IQ=>- !?06QKTYH)U3B=! \,H
M81X1MR*[M$AN;1\9H4I0:DPI7E50KZ!>5\A_0;VE46\N\NFI3CA:CW+3.L2E
M#D#ME4$D6BLX)F#MR34K7E7*N)11WF$9EYM%;K40N=\<'QWUXR& HNVW3IS4
M'W[I58,V @K*^OC2P/;:3L7B36PQ**TTI:G,6)FQBS-VV\=S[ZP<U"]'M@J_
M]NKH8_4YAEXXKG/5[_%![)U$6^><B]YIW/\GEM0:SLLU%&B%6V.9L0<V8RLR
M;!H;6VTJT?$9> 'T,X>JKE5UI&,.B,76W/THK++XW7Y9PLD0<'2<>>F"B;G
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MAS6!E\F#)R/>;$9\P09L/Z-X$RS*2S_&F^32S[YW6R$V%=4KOVTS6G6EV_X
M;)<\JS$>'K4ROU094KHQ2M<.#EC7L*T\]QCL]ECGJV!,MC-CZ1W4F5/^UX^5
M$E1RK]$/0*:GF8XV'F^[=4'A+]]8OB.]5@,7R^\N7-O/!@V2CT:]?T;;'Q_
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MD=V]_:_Y&?GTF-44=A^&&/4"<143,BQPE!,=:(0-BF+83XF8C\]<CD.GD-,
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MJAZO+)&CE, Y\?%X=LGQZ9W>Q6P._1?XJ3H#Z3'!(&KHG<][$W[5XV51P6Q
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MVOX5_?JSMQ=N[?0W$%O8=K>9_:/?ZB;L\I8:"$E;QL4M7TPM>5DIC/0XQQ5
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MG-M.HF?".P@;+Y7UCU07LZERO_YWH?%C]-RYQ74+#A:?]C[ACW X*S3>N\+
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ML-07I:[PE$(P^6JW]W+]O;H:&/(_"E0/ZX^5D6'0R#DND/$G6U,3R.$22T3
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M,P2DK-#^*FRU902MG*"?77OK[Z,>%7*LO>30]<Q[UMS#.FV^&C/OE#M6>"^
M5U/UP0UF-.@8UYT/L$8:&(YS[(VC.\Q6[,&KJOI=7=NE&OUW;3W@><EQ'H&M
MW^NJ 'N_-GX[@H[@=U\,KBV'M*BT68Q[X\+H^DO?--JPG4^=DG:%W8W1Z5!]
M\V) -PJ5'UN<]#^01.09(QP1DTQ E9*!4&$6<)4R.&5-2+-D]8C@)C59J*E,
M*:4)',9&TUB#+L DS2*3K8J?=S5=?/25H[V78GSU[Q;CN7O<*UJ+0M3B.*5A
M9*C.>)8KDQAB))S*@AK^$'8UC=B7V-49W0WI_2S5SVDVWDT9>2*MX@KDV](]
M-Y3N60ZE>>HE3(XU7P'L^1&BJ%_4^L5]]OMKX*;?>S4>EV^V&XRX4>&@4K!$
MD8ASD5(NXSS!H$,3IDF4PV^;<_3OJ7"XP_!WT(:>]5Q\!70(2U)I^8M:E%=
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MNKCJ=+FR%4Y;WK1E]AW06F:G4U1*78NU1HI+MD+"E05)68DIAH5".(:/2QR
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MX$R2H_<PG]>#XF38A_&/,+]7\)RQ),L"(708T$RQ((\B$:@DE"$8$9Q$R9?
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M4(V'+R;'UV_/^P3Z'KYC1Z_?L/[9J^+D=?_R:/_5Y._K/NM?O_F0A5S#MHF
M2\$"( 499+') YY1E:HD$RR6JQN:Y"KD8"]1!7HU53P+-4GC*&;&9"85Y*GJ
MTFB36CKI]9WSPI+'T]6I7[5&MJL$KS\5<ULQ0._@L>+4KOK0\J="IWB6<PAI
MZS7PMKF]W[%^%3R%$,D?W76(V6\TEI5OJEI;A'^L6H(Q-E==6']H=GZI;?D
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MSPU,A5&:.!+O5^LAC7G]\JLN\V<3UNI(:T*[_!J$UB22WC''-O/,KPM\[81
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M0:, .H/<GIG:L[C/0<86E_10.&1O;-Y'J>+D9TX1M6$R3C"W:2GCF8-V:M/
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MKI1*U_+\OWE6?+D+ 1#I/'<V89):;F4J,7>2BE0;KT'6DI$ 2$D I"* QR2
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MNV6(=Y@([3U!GJI@'3092+-$(^(3DEGA,^&3 /$II9OXD:3:->OB]\ \AN>
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MQX3Y@OTA+T[0B^D#O5'H!9_7-,N3QFK]\Y KH"_F$U- YQF,>FYP0^KLZW3
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MA9#/C9"[:A#Z3@[W!Z'?:P64/Q,H+Q: 4@BO96AG;U.L$?=*(9E8CQS31&<
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M]0&>"^_</#PZ;W[;Q:WS)MX[_/MH[]M>@O?ZCK%F(N&$9)0!<6()LHI;E(S
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M9PZY!S>+63X7HGBV6E=BR6%EIY_S,*XC.[];C]K%3$YUE^P'3TT-T;\F WV
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MG4M#0N )49TK7IDWR C.D=#>9+9O3W/KNF+GSA-=Y?USMWTAM;-)$<N( ^>
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M8(1*'(G[OI6;^F&"";KL[G?5COGB#V(XZ<3M=)/CMP./_:W3]T<K*J5[_SG
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MX)[O.\WS@P.X!P6G^:AU^![>Z_U1D_[=R0QWK>XGLKWS[A2<YOF".&,3L;G
M'&PRC+BG')E@X(_D&;.!JRA#U05QRY&:7 VK9PV KP$ *S^)J 'PN0!PMJC0
M<JEA/S"D(@$ 5$(BK;A""@>52(S>Y<Z_-0#6 /B: ;#R$[B[ V -='<"NCEJ
M=R<$5=P%A+EGB!LNP<A3%CE%(A5261%200VS&MW#5JZP^AF*M9=OP/4D/.8D
M_+JHZ)>\W6/%H"AHCN/^L)TO>%L<-[9_Q$LBW?^^>GXZ/KS#EU^Q#N3\9'3]
M5^8BB<]TP/H>43-3T#_UY\'@\KQA/R(WB/8(V03#?6L[I_9LN/;/JV>E[1Z:
MGL*[O/V3GZ$*2>YSADKQ.M>B\I,^(=85U97?MABM>H8#1-!WY9I?NZ]3>C2C
MKAP<&%[]L@3M+:CE.,A7P9CLTHRE<3#(9N5_M0U/'B<CK0634F1***ZICC#C
MRA+AZ7>UME%DNN18]N_9(NWEW%B[<4/3LENMWN*3C'+]GN,88[9*!%ZX+#^<
MY+M_.7'#=FC;00[8N\$_-Q9E"3_>^*Y]Y%--4"YB'.;DE]^GD[W>MWNVYW/%
MS9>+M*];G*-=W]AP1HW>K^)I1MF63@OE.&BC#?88-KJFX$M%0Z-FR4N?%'XF
M7;A],BBJE1+,:3]+VK591$4J7;LH>TV-=I&C5*;9Y92BD]$)+$)9>U24WA[T
M.V'V*MOXD??OZ*R\0SC)R?OCHZO]V-\?V..#=BZ1W;R^@O7-<F7P@UQVN[F
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MI8;+&BZ7R^BMX?*N<#EKZL+<6\V812%)":8N)\@8:5 B!& 31PF+M;8A#%O
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M/2DHE;?B\0 >4YCD\-7-;F;\/B]^7*) ]OT\MG$@^W1[Q]/=\W>GS9T_#O?
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MV,T3GN_]L+7BH#MJ"UZ:!;[Z1)7VGI* @@A :)5BR##)D(Q"BP3[1C$\8[/
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M*A)?V] +:WZ[].!Q,YEE+$IY&+O\,''$WZVNT+2#TQ[\6\*%+]Y^LMQ)%71
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M'(:4IG]9/\[;7N\\?V988"[7D'M@H*ZN^+(]@*/5W^%)+O?JXQP?T\>PL K
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M?1#HXS@"Y;J),OJ(I"4:V)*B2 L;<JR6,C@Z88FL'UMZ?B&N=W%/KK9=5!A
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MI$R6CKVW8HT.VB@;A0=LX9%A'5*""9/!N"I1J[BAGP9M^!3MBPDFDN$111Y
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M_A$0J*CUB\*D";5>>I:(C ))!LH\)\$C*W-";&#,4>RH)#F\G$Z)65UFK;[
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MQ!PK>7)$"A8U9\;;X#@C@7-M&$LN%D?TT\#-M'XXPN:^@T0B+I5!7*N$3-#
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M0")Y#FS#.>08"4AK2F5TSG.6ZXHJ<_^ HA*G/RO=D,6NL4)TXW7WM%< :R;
M>C?)-A1AVL%_H \)C'C2%+D$E,,K%C$+W*DJ&U#=OPYR,6S45W0?F6P4T9U#
M=">Y!J.1$J60ROV8.=$<&2$=(@3SE*(DA(K:B>XSL6RH8ME8):K1_E)TH]GP
MZN,DU3 J$J^]0Y2KA+@,!#EA,$HIB,0PY<*9M0TC2\N%51;=QZ8:171G%]T)
MJ@$2*BSU&$4L&&@)N1\DXQ*)D!. <-)1B=J)[G.P:NQ\2W IMHT5(1RO\FI>
M0=<SR %])%S;G6+]$,1&ZR0RB@7$E8Q()R= C[*,6J8,ES*GV -C65@&:#&
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M!MDRB1%$7,@)&9ZL5,O96!\DWZ<LU4HYRW'D'!P0[(B1/H&?JH/QK!; %R>
MFP="B&2DRS+F0.1DDD@G@9&"H#&" "H=PJI()JU,WD?)K!%<@[',M ."Y;U4
M!B*,:P/Y @4I*6-25 ))@3WB*5+D@@LH6$><H( CFF?LNGX*\B$2?2^"7>KO
M01J?V6%Q:F2<)V-TK[S6"^2)6E(/&*5UD;OD<BH9!["8U&">%#/@0UE:Y[4>
M'4(^7\]K8>4(<2HBK:W.?C%#3MI<%.@=U2&%2%+N0,#7@_JIIG![#-64$N.D
M%,-*1ZX\-30D&Y0-DBO+4ZC36C]"-1?36I+@H(BUR'H*CEY.<&D?(-1@6'IN
M(;Y@$%OH[\\XK[%J_IB#&\\SJX43M8*+$,!QYX9'PZV&GXT1CK#H3.VTKX-:
MW^:TMR[^W6U>>-$\#C G^]W6^R;;?[\-___WT?[QT5%SZY"W+DY@3&^STXZ9
MX0&"-"0]IBCG%Y#S42--610TN1",7IF^4T>O%;/)1,>5D98$QHBF.N>W)!%U
M&N$%"E(@,E$6 F+26,0S6;)FRB+&-.8AMQ.0\M4;NH1'X7&BOV]LK1"VYF%@
M2:4PQR.PZI9259!=G>N'%VZ$P22S!$Q'_].>/WGX"7HQ?COG"7N9(LG]!ZV'
M\-H+['S@7E.IDZQ#ZD?'Y;WK(35GW'-#!')8ALQ0HY%)GB-.A<1&$VF(>?5&
ML"5%P/?;CGXXU7CBS>P:)&N0?'"0U%P[;)0PA.?25FP(UAH"(\H-95;<4,A<
M@^3#@N2UY(9E#&/-$5%6(!ZX0K H(:<AN0J"6<_=JS=</5@]W8L!R>^^QQ+.
MY26=+;]%4ERIHJ*@JZ>#4:=H%3B,79MCO"O6J?^>S[)44X^OOF(=S/)D?/-7
MUB Q4S(=(XX7@IR9_^8!%RA@>/(X00!MA>,B).<X1-$1%D%9(CP]H$J]FG[K
M:'C%&W(8D1M&>X(*FOW?;/?,GH]>_<\\L5BGCV8G?I4Y^[&$8\9L"$GNPS=&
M\0;7XL%9L8384/3A:<R*T:HGZ! *&%6N^8W:D-*C&=]O]0C]?W9MQM(X&F;S
M_U^W*R6H9+O0CT%J_)$]AW[>QK5OEC/=/ 1W4KE^3T&<M-WW@]ZI'8T:_XJV
M.SZ"%QZ>5I-7\%S^/7&C3NC882>.BBZGTUF8'>WCC>_&1_ZH"2KY,,>#+ F%
M"Y")M!OO2OHCVVT4S-J]4D3NQ[^US/S>@41RCEPJ,V;.LTO]$ [-:U-6&$="
M-IYHQ>#Q\_-"6=42HG096Y,>W-,O4%+CZ#CST@43N4K.")>L\IH1*G$DKJ"D
MSKU5"DKJ*GLR'PKL]$>3(0A$W.J,?'< O\0VW/]M=^!/GCP@\-. X'S__4>V
M^V6/M8[#\=[%1P@&P'%O?^9P-W#6/],6;5ZTCO?.FIU%BMX/<$\O]H\]7-,Z
M;FU]%!!,B%;[J->\")W]]A[;NVC"7S;/_W.Q<P%!Q0$GF029&!0LRS7XT95M
MI&!NO3/1*LWQ8M/W9'.M6:"<&<5YBDXZ)DE>"<6%<Q!;10BS3K-/,YR =?D[
M=A,JYAY4\E-G=#+Z;1H<5"O]YB[4M;<]]9E0UW[)--=Y+AI@= &UQQ;>%! *
MX'QZY&XP&68&^!1'(_@$_M;M6-?I=L;GKQN'L1^'\Q]E_#\;#$_BL*"L)^KW
M1K86L3\JIV^8I[PQ/H)(X_ H/S6O1Z=:CV',AC-?!D\\'-K>)2?^WSN?I@SX
MC<(^GPT[8[BXX<Z+$?I9I#T[&F0:YL%9/S.#IS0Z&N3R*GM:\7I7BE>\<6&G
M8-S_^N/OUXT_QV'C-7R]XX]R"X^"DOR?CH5Q'4ZZ=@CW'/FC&"9=N&]%)=Z8
M4LEOY%LT.IE:?.81A:7LG\,,@17/W/@PWDP)_ =\"R[<&77SA#4'_3B&830V
M)V,8*TSDE(6_N.DL.WKJ#$?CE>CS%2;4N[SK[Q17$KP8AKUBCE#K.*<W'.B_
M8LV/1_ZWIOW:Z4UZ67DJW=DLFE>\RZ/YTY['X6[*RO1<F/1_-+Y]O&@>'KB4
ML-7.(&F\1)G.#ED<#')!"26X"E**5V_X]5+)*65T2:18L(PW[.$A2&7F603;
M,0)$ ']L -Y%(?^YW\)4-[-\+=??4A=!TKZAKO'K:6&:X/ZE"IV69/LV=RMJ
M^*[M]!K.CCIPFP),,_=Y_.KA81D[1J>P\JD#7^EV>IWQ:.9+>5ASUV8MOGHI
MT/=I?Y2R-!*\WU)[)OTB21"SL]0#P"X\*F^'X&P.1QO7L/L1+?C?%1;LIC^G
M4_IN,/S</[6=\$=^R=%F?_I#.)Z,QADGMK_FR8T_G0;L7+2VM@\\,Q(+&1#Q
M3B&>7*X[EQST(%KFB9"2BT6+_3PL:7N.Y[W,E>3>7MDT%,#MCVS_,!8*DD7]
MRNX5=B)?.?P'_OQ0#/'7 \@?G\(1&URJ^Z1P!-O@Y&Y)D159V#F_7PKG%A9V
M=;]OWC)8PN\[H"<8+!?TAU#&/U>ZZ3L2E;_D]_^IZ<9S3Y\7W#E]^4N_M=W"
MO-EQPT6P'T4+Q-R'"6XW"!! #L%Y?3P6V1>V0?_SLNAJ*\%9)%*PJ#DSW@9P
MWDD :VX82^[N^^\SCOKM+OHS#U?+_?G3WNX7&-O6I^/F5NL(_H:;6Y\O=K>.
M.BVZ?[QWO(GWCM]V]WM[8G^QFS%\MG?Q]J3UOGG6I-O@R'\\:[6;?/?]#MOO
MM3K-K4^=YOM_]_:/N]W_7&Q?+V*2EMB0 D58)(&X9QJ9&##\I),2B4JC<S=C
M:1[L9-#:[+_71.$UQ*U("Z0TX8I0R63@QG@7M+5*,!M5"K@J,<(UQ#TMQ"V6
M(#$6'>7"(@-+AO(N,7),$,1B8B83.)C<QPX,UQ*JPQKB:HC[J2!.YS;"DF96
M8<R#U,YCZY7FUF82 >XRQ!%30]R30MSB$:$#,$DV",>0-11\-^HX<BEXY(WC
MDBJ9 K, <4)ML.<"<3^:.O4;_;V>2&O_C*/1;XU/<38#[6/GGYSKO:$]UPMG
M</SE"<+1F?G_%(L]KCS_MV\BC6I46PG5EO2P"H%AKW%"R:>(P.'F2"MMD734
M$A.D2IFS@N$EK%N_O@2JQUJ)'RK@JI7XARGQM>@K6!<$XPC<20Y*K")R@DND
M!=:>.D>$E44;I^N>2:W$+T*)'RJDJ)7X1RGQM?A"1\L(]QP!%E/$,<-(LX*B
M)D3LM)>4959TN21)_"1*7._;O6[TX_A[2.J^+_>S?HCUQ#M9=RLY:\5U.G+Z
M',"JN:R% ]-61X:4%P)QK0"L.'8("^*E-4Q$%E^](>SGV]*J]?_)MGEJ_7\T
M_5^,."AQ1C!%D?4X(<Z)18[1A+#%"7O-$K8DZ[_<,+7^U_K_8_9 :OU_+/V_
M%JQ$FHR6VB-G<YM7*0DR5"44O4W@VJ6D",OZCY^/_O\,?>1V^GX8[2@6)VAR
M-?[I</!/9U0=<?.3X1#TI'$>;74\Y7X4W,\WY;("@-WKX,RWD.SOR>EIMS@.
M;;L[_?+\&(P!<.VOX0 "SO'Y'W8TL=WQ^>61V<_3$X!Q./JC7+P]6+MZ+_A!
MX6])!SN6(& 5@'Q8P?IR;SERCF"D:!+440$6C+YZ(_ 2OO^7TR7KIX< HF/B
MX,4P30,/6FG,HZ9".9]Y^9,N((!,(> .R8P: M87 A8C(!5($B"*B"@!$,"=
M0#I&@F*$*#8 #CBG7[WA#Q  U1"POA @P-(33O.6N>51"L<#3B)$:[6E*8H"
M O 4 NZ0SZ@A8&TAX%H0Y%1V]71 VN6&93QR9%4**-/%2D"'&!(&+X"NE1?P
MLK9MEBOP5OQ6F',Z[,#'WQOD/-]F)JOL*Z];E/-77KL:W1X<W99T,[*8B> ]
M1M)P@;)GBPSAX.J <6,JDF!RBE<O*>B_^W;T&G=+J75_W<*;6O<?3?<7@YM
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MQJ@E$X18P@1UN4C.0[(P:L6[G^)]P%L?#D+2@1+.4(Q8(\YY0A:X!9*1 J\
MI4P!7Y'87BO>8RG>Q/&AB8;MSZ+)-C@\N1EVV1#[^@;;[4Z_Z$;0Z]QDN]\I
MW)UZ;C>*/SNG$=R -WE2>^>/.[9G^4[=?(X^3-W)]LH[]0:M?D:XYO$)?)8;
MBA;^"*84AM?I%IU2<FSX.NCUJV:CQT#B\A#+Y;/=[ED>QG!LJ?PKN&$@EF56
M0#601K$^*$>;/SV+MMLK8CL/:*I3YPA6\T3!;_A-<1J+T S#"<KO 9^=P2!
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M;U3O<CLU??H(S:+5]!O?V?U,M]8_T)WUM3.XYB!JIWC$'"6=&U5JGCLL&8*
M.W@+Z^$9<2NKU%P9:@$JT()_O;F36 CJHL/4)9]<+G^A=0" ""DW312"\5(L
MR$@L;A&*J\5B;F+Q<VO]\P&A49F4)!)88L2M!8F($2,::*218R.P+L7BJLS_
M<['([. NHA&%8R9WCL%)<J^P$YI1'8RB2CLJ:2D:>"0:N!:-A8K&U[6#3,1\
M2!I$@^?&;)HA!PX68LX8&K1C(B80#7%E?92A:%S'74O;=Q++>&#K[!:VR[=L
MKU?9<K!0 ;SDD9/T$.O%)3-:1A:=D%Q[X6222M-$M;04_*[:>CVA+&Y_W3K
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MZ-Q9M-W>Y.Y)D;J=XZ&N]$MQ*O6C4;ROU.1<<K['7K_H?!^&O*L 6(ECZC=
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MW8#FRUB7K4[$^$L1<7\FMZ#WFLU5W@V3MO8 (8N-2P!9 #;>I3#&"UK.L2.
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M%B:9P #%1(S1$L=NR+2LP>L9@==46SG*7,ZOC8CAY!&GD2$G,4;6$>>\]6#
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MY1W?-D$6FOX68/H1V"#0D,RS2U_M__V/!BOPVUUV>I8DGIWYT\=/X/H?#KM
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M2)K;AT=->,[^7F@US\:B>8\_P_W^_ K/A&<U6[M[[UO-[2^\>0[_[7W$NW_
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MY=I8&.-5A:HI0IV$!KDQ]H//+I\X5,VYO- 5F+I>L.1]'M]N^MBKD:D TTS
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MX@ZV\V PP03=))L]4'KX:5Q()TL CU?K^_W0MK_$M^U7U=P5T;U!=$GS?/_
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M[H,RQ4]RBN?DLWDPU!)QQ>'S*'![ZTQ=%EN?5O;L&D8^V$A<.<?6S$>'3^2
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MT6</83Q%K977R#L%OK_V.JDI5+7?334SICLHP/(.@V3D>7-H]E/9#, H_<?
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M@A4*,YQZ:BY@LWX&\1V#^.G=AB!K>&'X6X;S7<+YHDYF):=.,EB] %P$?*S
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MZ .X\-@]V<*;Y=P-&E:OB#KSTP/GISGK8#(_W3D_317*E %60VDXDCRDNO"
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M/L#BH)_,W/_ZL51!IGN-]@%%D#8!PTJM__7,;,U:,3^0THL9_'[W()CJH-N
MX/5__OWVY[=[Q=O=[=?_N::".M5&(]6S#,US30R_CC&X1%#)K !)_6J VOHG
M!=DH*"9J TBU< >FNY]VH@[[C7,RTYYXU>L?C9;+9O'SR9DMDN[:,<<;H-U/
M"E@\8#9T77./__U?BE+\HKW!!Z#G@^83\@(,@D3-8%6,UGT-'-X;=CQ8+7 +
MX]-@1[^^.)#Q+>"*.@P*,')@<.W]BM?MW8K?*C!<;.CTCG]H4C2F.&[$T]I2
MI[3=6.H@IHXYJL/S\5]>@+ESU#$GSZMN,]G-CRZLWQE*O5D-[=<C_M)Z4TB2
M*&Q4C#AZ\(C=-AMVN^!WM-^)3<W5I=_B37+I=U?=M=PLR>7?WO:NBFUB3J]U
MVQ\49MZVA/+NPPI7T?]N;_.B3WGZKO*V[PIK>.5>=#O4KE\=I8_/O?!(RA=L
MJI8?KQ;\-7HDSWOI8I=@*Y:&=^[8!OF!;.[?!KEZ@",;Y& P.*J?/WMV?'R\
M">/<W.]]??:R[PY F=7/@M\W_6?>#,RS4@DBR;,TWO:OH#;@?XP_JP/X#\W=
MP2T XFY=YO3/S8/!8>J603;)#)MEP<C,2V!UE\"'T^^;Z,3VQ!7%R_U^""D^
MLE' 4X(?FU##;B@83@84I1N%/6E^:</@.(3NE893<^'K[H&!.=XHWG;=9K/X
MLBQ:611Y-B9FXVD*D+5+!Y:>O6!;CTW=/&63?)YG8V(V-LDL1R[Y3Z1\41>O
MAOU^BOW^$6"-#5)H^$VO?U@H]/^*6'62.]C-JVMR/G\==DZ*LJ7]/#$3$_-3
MGHU)V$T;E*<&X-:_;/_93;[,/E,VF.]V><-[==M$!0SQ:^5";49F\)G/1+//
M])B7P-[I]\6'T05WX2L5U[.(Z2:=V^Z95/4_+930,]MGJ*\2U,VW0S,8A/XI
MQ.%5JJ[I?#MC>Y;9_C$O@3WSK=AI+\@1L3N>^^MJ/+9TC9=54^:EN\5&.#SJ
M]$X %%, .5--/*NFQ[P$7H^^S_KIG@3PN +$>39N,AO7M%WRG$W,V4BAY>D8
M 6JA5FV>VLF5MJPL1;:_5V8%W68!D3+]7:IG!YU:?0G?&&G7"\NE4H]+X"^!
M+7RRH,$ _B/4@T:+OTHRBR"U05/V__94PX_JP*\RI3>*<'4M^C7C^VP!=0WO
MW*!G0[^@HGETF2,>&8!W#D#".-R98YGP)\6S@V8=UVF?Q.C=-@??!BWUYHSK
M8Y3\!;K=#C6(:[0!&/XM-P7^7RD%6Z4$;-J$U0@V[6)Y'_I'83 TG>)]0Z)I
M%^6'0<]]V4C<V_+@<04$G;;-? BN'P:)B>&F'P:CIS7?#$X?W3'':<<GD.>.
M@9=KK6HL[Y"TV^?J]KF9L3-N5\9DHF,;.=/TBHM[#J=:L&?AP*DOA!)&Z0\,
MY9]/@"_KFYO$V\&%PV29JC9H<8?T>OKHQQ,GN4RD)$\!RU.0D^%9\]RSH9'^
MB@EY-GJA3QR5\.&7=GWR98?D)H^AR9)?(<F_;=I*#/OA?)K[5(,W 34,GM)U
M4MQM/Z%DO?P5.IVZ>&/Z^[WB9],%7W&WW>?0*5[6=<]5(Z,%GC;H#^M!:+M"
MU4/G GR?^CP5IWVCP!S9 P\RW2>-;;?WU10?7&]0F6(O_1B& "/J-CYG$L;'
M7A\>V+;329U[KK!FQ":A(CF^W0H>NML;@#Q3UR&@:[8!WY:7?,DWFO%>?H&X
MGKG5SAC?+']@=;WL=I,'?L'H(GC2ZGH3;+\)@J:A4TQPUC=9WZP2Z]!S^B8[
MN(].[&^J/K#UA^'14:?)( .C3>F?:<UC#GO XE<[OTV$<6CKRE>) 7\!'C3=
M0:]?%T]!Q;0-$GVZJA^J[D_%2JBH:SKD23E<O0TE*X?,$FO($LE9/F4)>J88
MEKI))#LB*RCU#_ TH-:K%4/KF(S3[67+8M?7#OMG*N'(] <GK3( 6ETO73#_
MAL3Q#!*:%4%6!"M#"79$">Q,$>0M&8]*Y'L'5?]'2N#6]/]@G8/Y]^MEA9#9
M8678H4VC*6 '3F-OV!\<U!.$D)H@G^D'D?7#(UX!;YKO?J O/H2CP2B<U)8&
MTX>K,MI<PMTY$M-SFS5'YHU[XPV1_LYHPQL35;"QBF,&.=,<,H>8'O<B>),^
MN%; J2T5'MG&XM[B36M60[54X:U;6>%2)^/N]/UY)&1=GW7]_8*C%,],6HEF
MN-]-I3>]&%VG5X/\ #/\3-F7V4U\S$O@0_7MFJK^Y7 _N5;E/:OZ:X?^^-R4
M/GKC!\#IEQY4>N'$MZ6<MG=%.X.)/_-Y=??-2/=\7ET^)^S\=P_LG+!L"MRG
M*:!:5ZD.7P&-%T/&9\:@RI&?Q[T(/K3?7<L@G(APR_LV"N]I>\2<^QL6G&B@
MY.X-U6DVR!&%AT,?A&A&J"":\K(4\IDO)29*^D0C9UI#9ZWQV,3^.CW^,C4Q
M6TNT"5C2[+<G-]BXL&!5<9[;TP/X)FC'_W6>P*_JD>5G,'AS*/*"TL6C&<HL
MGN&\H%WX5^!YHJ"4X,SC*R_X!<M]M[K<VE\[&B_%!1IG^/HTSAX C>=,X,,%
M_JT8'RP9R:32SSRA4N@+=CMYN$TMB%AQN5\]P.7)?>_:X9UQX7O3N97>WUZR
M64PO4UN*<TQ/;A9QF9OH+\Q.-M8S=2^X95:S%4B4ST)G9KP6_CO!Y$MM%Y%-
M]S58!J\[-PC=G[61:/F+K!"[MU'U6X;3%V/%GTU/>Z0%R49\U@3W1P'-GA_,
MG@V.0R=.,T""]X0JR*>(/NY%L-=><"T],#X8(G5L:X]L6QDU,#,JOW%)E"<]
M=#ZO0"Q$<9S.I\@]33-EW#=E-(R1NHT=.(*_$,H(T9,1H-QC[A&*?3O4KE\=
MC0\2^A#<L%\-TL$6?X3]JDY5,[YH1I.^:RXC]/28BK.K7W]S!Z:['XJ7;I"^
M)IKQXNFKWN%A"H.G$S!^FJL&YO_<M'-;F2,Q&5!+R)YAB:7@)7OFPS>"P2$?
MM:['^:"V1R7P*T\OGGDV!3 Q+[:K/M!HKY_.< /S,9U \;X#TKP>.:951A?0
M_;C=G4A/S_3YOYDD,V:6B!DZ09+9S'P\ F^H!ZS!Q(']R@W&IZ$5?W:!S4Y/
MC2^>WI@PKVE-MH0Y?T?@>R3,[,AGJ)V#FB",,/BH@1H[LS\SL3X::8]Y-<5Q
M#X%*3R:X-'1;I[WJ NE=YR"2AG23.^]'5#O[_+1K$RZ;WS[]==@-(Q<>B\RV
M&7]SX^\L^I6.&@,DG=)F3I"MG]BNI+.V7=7L<]3;&&75;7:B]WN=XN?0#;$:
MU(U1N4:MDBZ9F,WU?X5,]IDU[MS8XIQ*SK!NJJOPLP@F"<'_()8.U3G5%+G%
M^B.3^87DV*QZ@'.:9[3W>\=TS7YKC*?=Y*%;MU__ <,?'C6?O^]U*G?R YOZ
M[2 <IHKB9#I3_.)=JJF FP_ OJ\WF@_)BZ3++C6U?Q^:/ES<.9EA;?]^9FWO
M]KZV]6V\/44J&]P9C_==VD1D:E9&Z5&_]^VDL=X.3VM;@8IS-_/'*?KY&?GG
M7G=8-U[!;[WN/MH+0(?G0\OU#V@Y/;0>U4(XTXP%KAJ1].MOP0V;6YVC_H:2
M@:W/?;A=U6Y8U^,0S,NNZ9S457UZ\>NV7J\-Q\R\[W64P';JOUZU;Y=FM/@P
MGM)FAZ(["'[8":-]G/SE1+^[HW[5*?BX="WKA$P,JTL,H!.6VJ<\BWYE13]#
M)Y@VQNPFV=;T^RGXTQ ?V/I%M]=%X?"HTSL)/PI]3VJ4.73#^#:A^ 4L[G[7
MI!\EYO^Y9])A3H/^T*6B[):+1UJ@_<<YO9%V[(S'NS@-4 #Y;V3VSQ2P<A1
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MG?+'R3CRE?K4)N?E;5T/0]NS]C0FYB=/96_:BD<P/"LP:.OBKX->?>[4]K/
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M5TFLY#I4$CODI7U-QT<F382#RBZXL@I;I[YS"Y1*(KD E4J2MJ7*U5=Q=&R
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ML6&R(G[=1I<U$J/GN_0EQ$GLQ+YQE]!V^.6>SB/S()Y,7-(;$*=:LYH#M.B
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MX7?UC@1X-KM_-Z6'A2\IYIR*??#"%DS<;-TBG#"^V.7W1?&'.=2><Z?:[OP
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M).0Q6>E'LNK+X\S3";/;RGJ1\^*"E_EK_-0,R&LLCG6%#5E SDZ#45I#C#&
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MV*-'5F=@2LJ5)"E;>]_+'N3TX;P;QWD9.K#8.Y;UO+DOOM>>=\L4$R'G;+%
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M*_D8LU7YC+IP.^@QQ=#'KP\["/Z<*5=_7ZPWQU8_+7!^JR4LVVD3-O8*E:S
MD6LE$38E:&UD+5^SQ\ V&ITQ >#I 8PIACY^'G<FQ-GO04P4Z9*<TV!=NSHB
MO03V+")@*,:$8*4IO?W'0[&.X"*X,T:ZW-I<*NG!A.0A&&/ 557(U)"]ZEWC
MIO=%\.=Y8V(OGMY?WR<6_-D7]4V"7Y;9J.A!&IE;/@\[&]41**M)&DS5FU%?
M;GJ>%RS.0M5#1'Z*AGO73>!>+MZGZ?PRNO4#3I?_A;,+6M3+#1]Y'_T\;G[M
MXCV5PSOI'?_,CBWR.D_ D;WOFG>Y!5%K\_C+?/J_J?Q8F$73.L6;A@<O,MOK
M2RHOMF&\(>5U;X^K6(>URKE8$:QOQ4^=;67K9 1O4S!%)Y^R?$**)X)Z=-OS
MJV^;%(E)4)1@J^,A*Q*M_7J%+&K019E276]E>_WL,6SP8V36%UW-#Y%5M]V\
MY^QL;[=GD]&!QP5*)0O-*H%DBX"8D5+0-NC[B0I'4W#P08W!(G@.W!X7NT:Y
M:#ZW\EE-LO&DK6AM_DCR8%@-H,D:V$J*@J2/LO:.V@PTE#'$(?]H"^10)IW"
MXFXA5K8G_X;+?]'F^/HM\3J^O&3%?[&8M\#KHMXJ57^XI7WXLSI:V)T&W,&R
MOO6(*U#WCF=RE*BC4>!DU<P5XP$S.XJBVHP)J7Q1]G*K6?S4<XY5NMN#]2_6
M+W&Y_,2K<N.[3*H6Y%O9""\-NYHV)$A.!4@FH0Y>R=J]=,I.P,9B#7=EPWUM
MUE]$W;;LNZ/<<N@CE$C*L+D=2@O0UU:V6I0 JI 67NLL0^_3OJ<PC<7*')0S
M7073[S2.TOJSQG[QD35S4^(_+)9OL6U_UY@G3A4CDTB08XKMA*>=&BJ"+*4Q
MPHAD7?=*HCMB&XL--BA]!A'4*2RBZS.[S\=TM^V"+]\]W!XZ]$D=K:$N@SW2
M%KHYSOWB:>U\U$9+P6O>E%)B(QX-ZQO+^D9[RM$3&95[5^C?"N3X?>[ZRUJ^
MYDT]#M3&M#*WR6EV!TQNP?_2^OLHLM;'D$QOQW(KD#%80?UX\.56=NS<]\N6
MW3:X6R>'BA_,@T$0[5C&A%9E0^96^ IE]EXI%[JGQ#X.:0S&SG#4Z"F/CC;Q
M-KX6+[/2# 5%4&!:HEXDU*#9Z&JWI S_<'I=T6D)?%Z463C$#"FV-F?.UU;S
M7X$N.GI-P7EW$OZ/4"\>SXJ=R'^()+JKQ^O2/]O'[&O),0;#)F.K2,FV*$-+
M!&P[>M]"S:EV[_FV"[ QJ<KAV-)/-J<PYU\O%Q]HN?[$WDUS7C\T=^>VC;OM
M_<--^F.>UM&L[S;H3J;]]?->SW"^?G'KH:WM^72.\TR;(HMOVL)X5?^QN@RK
MOZAK6C+M+MZWR6@Y#@]7ULB*JB.?@145,UOE5GB_1K NV1S8IL/4NZ[A\*,Z
M5IT>B/"R$<^.$R]RJ<;)"M%Y-J-3]H V\_I7-2 :KYS-XYCX?88UIHU_9*OG
M_KXP-I)U,T8.G??=AH1)B1JEABJ)O1:)!9)E2TL4%R-*E=@7'<>ZZ;=BU*DN
MF/\^E\P S#J%";89RIW3U<TKFP(OAYM:NWQK1Y-J[T%T."'^>;'&6;WDPZP]
M+?/3)LEZGPPQTW(U8'0[=_&^E6'2.9:48[IOZ6P]%M[ZY<>JS,?(>YNBM>8<
M ADH[ ZP'\*+)Y@4(=C6:MS*%.Y7^CQ:^>T(;0P;?Q_9WU<Z0\BFVUY[&]QU
M/8WK2CQ!$<F6QZ-*W.1?LON:0@')2DU9GYWTO1N8/P)G#$[^\ 0Y1@;];K1<
M:]B)LBF$:@10%@6,,!)BNQQ/&$QT&:OSW>^F7#_\V%'<[2.P&8XSA6KU! XW
MS8\B0FI%]'AY8?(92<G>912_1#$&37><I.\3^,B9[E)&X>T[5J6\=M[CO'S$
MY29'\//R9&T:I,_\_*A;_ UY=.S-@"Q.:J-LM5+OL'<_^I Q**@^<NT[G]W4
MTMN+-+O4D:TVS\0$JM(* 5404TR'5BBN>%!1RFR"$Z;VMF7N(M@SGV18SZO/
M2CYBBKNLXNV;J]::=$H$A>G&(\JL3#PYB)D*ZQBE"\8^EO>9>YP<O6J/G[_3
M.:9O\SLJ%S-:U$UI>VI^.,Z^Q5D#__8=T?K'>5TLWU\E@6_<[_7B\F^/=5][
M/+N[D]M]0GJYPALFS6YUVU5.&J&<!^%M*PBBV=KE_1Y*CL8:5A9NIPY;6[^\
MK]FWK06F5\K;*@44GWAQ84X0JI#@6LA&%FMX>(-:@0>V.CV9^WN4O!\W#H^5
MQR".[S90*(27[2A5M/LKAO4D1$4*2BNO+4LTL@SI_!Y(D9,YP%TITE,6W0CR
M1!NZX+*7@;?36E&UMDP54-8*.IN<I"RUW/<HAE(B(^HR>%(-<H@DAE4?-XA4
MEI%D!"U;)*^TZY>NM<>2ME:M>:C="Z4]AF<,)NX)%<<A4NCGO"RNR<I^\VU#
M'"_O1B:KLXZ:M9AF<]Z(2A!K1(BLXI1VPGNS2T>$'1[55__="UQ/$J6HR;$/
M(0)[AI$".RA.@'65C#,JQ>X-21X%-"K[J2,''M>%QTAE$%5X'Q!*J;P7'JI&
MV\XTVLXM$()7T2KV25WL?1OH$3BCLJ &)$DOB9PN%O W7%_=6+HZW[UUF_M8
M7W^7[^[NR^\]H$X9?S\12YD>L)A>XZ?+F]47-"&*[%<Q#ZCPWFNRM:PJ(I/,
M"IDKDZRJWD[PKMB./[YZY#G_F)=6F>MBOFX-3S-_],7[]MLDQ9 S+P%()-D.
M"6PSH P6/ 6M5-+%=[\2=!#0,>QT@[+MBV)K@XMS:)]QDA/F$BP;M5)K-D7;
MY2=K"GLLY(N,NF#N79#R 2ACV )/RIX>(AG6:[P]4N,4I>(,R%H2[_H\7.:P
M 5UBB1I;-XO>1'D*T]!C_O\)ES\L+I:3&%+T[3H9.VD2C$P)0LD$V;(_&"+Z
MVCTLNRNV,>G<KAS:R:$^5E@G6SY_9R/JYU]I]I'^MIBOWZTF-K,]:UP!6P*!
M(6, E0]0C(]9!"TDQ1-3ZC[&,2GDLU+K*.%UB=_L0OZWT]]>S,O/[VA)V)*6
M)\I&+[32H*NAULN!732O+#B%F!%#99]JAX#.(<\>0\1W4.J<1"@GTTX;W3G]
M2!,=E$O))B#V[<%4,FQZ. 2/Y*1DQ,[U+JVP*[8QA(I'H8T.$M9)J?3SKXN)
MR<)@$@K(:0$F.0G!VP@VM6*/09#4YS"9&-J8.N^>G4C[BNJT/&)B$&^V6GEV
MB8$]X]8@72E K!5""@PUE&I=[^C'SN#&U%+W_%S:6URCBN).[I&\;QR7O_T<
MD=S[@^H4RWV2:SD[3!8#I&K;Y8!([(0Y"S;43*(4H63ON]=GB19,;,C\O^QC
M:FT+T]UHP.0]6.6LMJJZXD]RH/ZLX@#[L&,G3;27&(;=PQX,^T:/U:?"IKZV
MO,U2]8!$ K)/F-EP$_9^JO P3#DF>C\:=[\[@[J(K>,UIUWCSVAJ"2)"U=FQ
M[::9]T8YGA8?:@-G76\].XJSLJVFAQ&%M&FUY7/SK9$-G-!*V0BEC5&6JO"]
M[\_O#7),>GH0ENUU1G:T&$^^XKZ(!0JCO?0MERNTN0E4(&C'FL*C9L><1*R]
MLRT/Q3HF#3\J[ATEU)-3\.:D Y,I#LF!QXRMRB$[=$FW@+3GG2DH-HC.1;U]
MCJ=.%0@>%>4.$N)YJ-9BC42&<M4)2G":IR05P-!J?%L1753.*]&];^6>&,<4
M(!X?U?85XEFHUJ*1J4IKC(MLU O9L@ M1--RYMG(-]8J74/OO,P](8XI@#PZ
MHNTKPB['H_L _.)$+C+S0Q4!2FHYK<0+(F0MP2F7VJ8?L[P7P=EZ3'H,AC&%
MD0=EU$F%=8KH\G5_*;RJ@/JYL=-5*_)M+QZ>-GS4XSK&G_L-NU] FFG]$^]R
MY?YC6SWP3,D[DP0495I+=:T@9>TA^^A42EXA]JXA_3BB#J''A[[]K\O%:C4Q
M,NI46?,2>5Z=/$[@56G9H:D2<\DM)GJZ$6\PC2GTT9$O6\*+_433,U;]$*I;
M-03O%@VLU5$1]KJ\?1& )1;(&8N03K,;/,#!ZYXH1U5C\CRLZB&_DYS$+N:_
MM+(]K0_0[9]?7:Q7/*)-:_+#+]3L_N4]SV$/'%*G7:\]:M.&Z\-TC;.-)?4J
MS::_; :T8@*83-(GD*:V.W=20A3.0$N/#<583[%W?.AQ1$?[DCS%/U]-\23R
MBG%66E:>OEU#0V3[DP=K0U55A9Q<Z=VL^/;SQ[2;=>3!%[[?H5,^["GK1"CC
ME P1J(269B(]8(B,3.E4HA!5Q0'LF\/.W4\54Q^0!L<+85P[S&')/OM\_5EV
MF8'2?9X@ED7F0389K+6&[1I/$-!)L,(IRK$J'WN?NYYNGWGX*3<=5(K [-B
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M+6I?(<B@P98<K<A48NF=A70<XC%9!<,R\KXJ/J&DN]D(CV!^2N6P9UF=4+F
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M>[4YM?NVG=K=_L#+Q6IS/5%Y000JN);-R#M:\I$'IJ3WE+W![A>MAQC'&,.
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M,_#)HS'.%B$>\K3O^?A3U><^4FQ^OS8F'/GY5Y:10<M5X@D<9ZRV/Y40G'/
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MX1Q\$$DJJZ/.G5IE[I87<ZR*BP;*V9ROLH-D>S S^C] %Z^(2=FZP! BKSV
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M%T:("7O-S0)&&ZU/D>>@6UM2VZ,\\M78H0BQ>^>'7;39.*:\!=HO?59>?OI
M#M(U<17FN"[.@1#)UMZ[&:)3 NB[% 1ZKWQZP.!JA>7;XMQ1--@P%7]+_._H
M()H."?8X_XQCTNV\EB/I;+/V@-K5";:L)I%*5LM>LLK*^CO7M_MR;PV*P['N
M.!K?C6[[JNN(6UV-;MR6W4!KYK5"<L.%"X3=.O"R9# EJ<1$;3;5F&IK<7PG
M6S\J.]Z^]CJERP]D8G]>-HWPQON4O(:B$IT$+F<(Y$.#"M)H-)I)UV5\P\X
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M/BA0WG!P3&DH604C4I!9MR[/_DRZS_5ERKY]Z';1R  QD0_!O++<I?+<<"'
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M<]/AQ'Z8B'!=Y^JS .=BO;]S]6E+>Y#1JF09^4BE=4N]4XT([V\2])3O(>/
MN^!ZJ7'@.^FL:_SO/@(_9!PXDYZG8AC$@ J4DP6B<A9",L(RHXKFP[[MGEX<
M^" \V$7.C<-);Y].'S!<_#:O=6(^A@M\AV&.,:3_ONX%>-TG!@7S+@#F6MV-
MU3XQ.<IE7+/F)CIK-M[=MH8@[C[RL:^4]M78]&#B;AQ&?AOMN[>_O/_P[>)R
M+OZF7T^7,DE5^)MP95+16QDA&9-!28X0R(2!+$/PM3VD85T"5/<8^LSH,83
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MNO8@$72.2:0CK)K-1@MCZ5\ST;I5Z0%4_D39HD-I?!?A-G[;^<?T*_YC&2M
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M1/'=59C\^]*!_UEQ6W2MAI%K[4T9<ZU2G< DJQWC7 G;NNSS+OC.D$V#J6>
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M3%5)-"]0<WO\EVWM[JV) ?(!UUC6+4([H!FJ0/0=),<Q5_?7S ,J[B'6 ;>
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M$'0IX#$Y FRUC+J#];G3H(<W0MOH:7H((1\T).=M_0%^"G_A_!.9*9?A8O^
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MI81R>OAC]J!W:H?;.':7\*G<GUT;?*\N%U^FL_'BQ](5=)I;+[6$:)(!E4L
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M'2%8(S^'2&VFY($T?#VV6SJH;:9-8Z? ;**TB_CXWN/<:_OF6'A**TAP+HD
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MN1X;%W\C^79*:EIZ1F9>_KV"PJ+[#QX^*:^H?%I5_>QY4W-+:QOF97M'7__
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MQDI$'UV:&V#MG=N=^]UGQ]H9E1F-E-SM<(EE<TU;4F3+@YW'5 4V?&09*$X
M>Z IWDCP%):HQ@92[XUWOUD)9_U9A8XI9Q8IO/^(#_Q&762&1^)-Y]8;&)*A
MK!WU%,=-+%7#EEF #1?G_;S$#2;7GRGLWDFU3M/->/*EZ/35PH9=;[<#KJYR
M'=08UBDI&QJ4[(%>^OSD98,\8A+6/)>(T/R,Y>\*HX[V'7/,8MA%Z3&@1!^K
M ?>)RU[9*?9\J0N/[+5&A'Z=I>SE:6U09K9"+R 77%G"(I36;FG$-%[X"L,R
M2.10AWGU[=[JSW,".U\V=YRVBU!5<QRYWC:N[!E5)4[;9%9#+Z,7YNPI2T5T
M358OC@T,0R3!4M*Z9,1%TDTSI3,37979M1A,[%')FE\Y+7PF756\SQ8+$7W'
MBA@R8P.'2_=0;1@RL'Z84)=IQ')+!!\((Q9\VIS&G;>PI]W&OFS_M:<@(RTD
M;5G)>RY1_(YI -V:M82E6"S>=*9[@;/;M&SF??/9PAM! ]I;Q*QAA+BUJJ;'
MB]<C1NEG+\17PS_P!^[E/H%8!J_1K\+EF.78 &4/V@MF=DP-,JLCK#XY)J'B
M,TNNZVSG=#@Q<:0CTJZMM77J;K7& ^>"DEA ++XA!TK(P%(<QC+90,O[3KHW
M/(:))H-I9+&H'^'B#*V'KV:?59U+S.QV>W5[4LD_N^!C:WG$@^*= K*KT!8/
MAJ37: \;D%QAUG*22BY66@\;Y)@5(IS%U+)YP=.[I)]COEG_K'*HVX5GW%&8
M__A;NC)EA*N.HD7",^1AM'1PF(B5AY]@%B$D&+R@&W^=#$N=\C.=X6&<WN51
M/;_UJSS37K6M<&-T[#V/QH5K23J+R# DJ&6S\8 36CNF3 \2MW'X'OE2K4E3
M[6?V"56?&\&DKR.S\25NCCBYV7-OUP]K"P\#=^YK0H28!9P6-MUM&.PTF,>R
MA&]1,K!!VW>D26;[]-R_(%-- Y)D',O73Y^.>)4^V)7SRG-V_^21"^:K93L$
M:$AF 3(0M>#8+]"+;7;L<10$I1VN/KD9(?Q9PC.AK/[J9,LIQ<!EQGO/=M.Y
MA)-6U>O'$*BJL9K+<^,X'*YOZOR'#R-21_R</$L>O)"UX,V+ YQX9\9 K M5
M*]U4B*2$3#;7'$_+*&OJ;)W8:CT96JSC</H$_'',+OUZ9_^]_CF>L' +U;NA
MW[9)Z,U?=%=DKWNWVCHG2%$,R3EO#B2-(&X5Q>%B!\9P?;2WKPIR=]D'$*>/
MT&.6IE MW)*&"IY6)X_^YB!+&>9M%L^?U35SOD&*#D'O3N7NKM_9'57I,9NQ
M3J&O[&$S>X2UIO57(G[DVS5>2WP.<)WEXM1>[+PX2\@DB")-<IC;K*0'P\\@
MLSF^4I2N1ZV!6\Z4L0$KRO?3.Z*94O.);>ZO%?)O/.],^F!=[]?0%/SO+6S]
M@ZD82V8W]B(;6)3F4$"Y%LZ%%4OH"]UW'2$$/BX+CES+CY,>Q!CZQAD,%CJ_
MT:P)C0\V#*O4T[D5(['$U2/L>+^;3M>-(Y-7!Y")YDI4]*85Q6N*N(J*T,6S
MI&""YT(GUJ_.G\GK@!=)YM37/V]*% F3XM,=M(=8UIO0DD % @P71"C*A :Q
M@8PJ5Q4(%9%S^$$-A\6O-WN>_R55/_MU):5@G'7D8L&%$4]; ;^3<#^Z*)R;
MDS[1K"&TLC0M$BRA5IT&\72SDCVD"%&&%37F%X:*2JU !:>=Z12NC#D9-N_)
M<N=2?G!7D!C1+!?LZYZRV^4S_W>QD=6G-I>!F/_"O>%,CG_S,9/9 /$E0ZAL
M$?2F95#G^K!*H)9[ JRGU)ABW:CI4(5OL58/UXL5;+CHKYNCQ*%:;M%21R+*
M@LO$WZ/^("9W:,@8J(7/;L$O?&.)W*(L35E/;8<7CO9A6_!)NJ6.0J'OXW)B
M]L[$AL@[W+':FUZR(7=D*IXI3%G-,#4A*W./#B(DYS9:?0Q<VNQ+3%RFPO-N
MWJP^SV^GD2OD8<TK,6*KNNP&4XD3Z,'+,)2>P4W (L*FP8 B?^/E65Q;5MTY
MFYC0>)&$SY\R+=RF?TN<C*_J1R5"Q) $-*PIO(8R1]-FEI:N.E+>I=8\YV3%
ME:+:^(AGL%-?/R;DZD=H7I0O/KCA?EU'\2Z >QS,,U_=4(2]@.;P_8T)^O7U
M6#8@?(4XTZT"]Z5\UB:+)T,E]!Q2L96GR@UE,ZBT:AMG7<^^IJ)SHWP-U?\*
MG7B6Q7$HEL@,IW*6,K.Z34*QS3:;!G1W9)\1.4(LH8@><8(33_(^771CG-ZE
MCK2?LVV&??3'I5J_SI.O[]@I8<H&6.IW_KY?ZAMRQ?#/=BD='8K WZ?BOS#^
M92K>.6=/-U F_N7G/_CP.#1@##3P8$C=I$V FX\1[R"<)GBR 2&#G"Y[6L.&
M@S1+PN?ZV"8TJ+5P/0+O<VY0."Q5"+826?)2X1(7:W_--AOXLX3LVO#W)61K
MH\L "QO\G\11%"RHA67DFGFSAE]Q&GS*X6;E/YJU^D]%[_]ZJ=>B)3$KS'D0
M(S#1B.Z#B E.EHB&\L?YG8&L'>M^!7\QY,V;/@YYZ.G-JQNL,$]Y[BC#M>@Q
MQB%SG K\A6;"&8LX$#'[A98"<HJ![(Z&%,IPHJE)>(RX1.AD<YCMIJZ?R>(U
M1I+-@L0EKJNV#87+S'9.T:B$4-Q^*?6C*?81J5(,>=#L^I )&N=!ZDY%?'QN
M<4;TX0[4'M&R.RXDY-TDRZ\^)V^R@0T#CHNE,>]!+^(E?. 7&EMG6&J,\[-1
MK-W@*'4/N%ZJ.KT[H'_CX>FL<Z]_73\AOT_&Q*Y%$?@%,O0XC6Q']OI")Q%F
M7WYC-](HPO0M4+SOYW,V(&'J<!F9^ON;4O3]CX[[G_Q*-MB53A:'!2*&L2^P
M&^5T7H:AXVU\4UIO@D:?ER=N[IO7"?^NZ4H>E9B/;U.>MN?G?[-]EWCUY4[9
M+V?_VWVD[Z"4<UA<^0"^T8,A+4\VWM0BW!QJG6N!")HJ\JU+=DPY=3TT40H9
MBMMSM-[O+L_T4QWP44='>W=['HU&LGOZ\/C749W"H$M1Y_+?:'ZU:]CDQ)@\
M70<LHDUSK+G$"&06PZ4#YXYMO2(*O!S7G5/HG-9=N?,;QU7*E1<:3.;]CB^=
M89PYOWA^X?R;H/APRCN1>X7:3C4:/$D5*I8"V4X\VC2,QV'C TL+Y^U$QU^K
M:%^*JLW>8<5]E%?%4F8D;W9VY?>*B8Y._)Z'(=Q6HK:>)1D]3@*:^3W<B=!F
M%+@'.VC& 7T<B,H; "))V]DJNK,;/PS2L6*K$Z:N)(C8^EA -;->H-BA_552
M7,_^]Y.+73VW4@*'!'>:8)LB&)+)+*$JNAR8BA_&\G&8["LIF+SW&*V .IQ9
MZA/J*6_FT.?CVX+BO?UC_Z\$1QZC6);@%[I.7#%-FV.\'UR166P:&3C;04LF
M\G+RWE5CK\OR^78)U[B&>8>-WN;F';LW=N.WU[]ZN2F>5LV\RP8"\8NAQ-W;
M/=NX?*)</EE<;.E3]_"S/OAHR%6+TJ4 =?OX1"VIH1&R9A!O)NC'DN!D!>TQ
MAJ054X.8#Q;3ZIGW-^+S^^;R,KI5X^3>7F\INE7K;?U*7=46<'.6TCC*-&CX
M4[=2$?BE/YMPD/"]DPR?9_ #5(\[#$_2QX!H@S0$%P51H#>XFAZ3EE-JXK2>
M?5=_.C8$\D2CP$,C!.BE1##D3%A"[634@KP+$_,=BRON'X\3.7'2X<;-M6QC
M7, BM_M0Z!Z5&Q\;W84$CT_Z'=@^?^##3)<!G1.'O;[8"Z,BCNFE M3*HOZQ
M3$6'2N;0K5IF@^6,XH*^5$!F3,;L29L#HHF#NW-ZW0-B_'[-:#&4BNDG$ N^
M!V:AA')\*W2P01BNPZPPR@F<\Z7$WH;+$NH.T_M5% NY?7<:G:O,8 -M^N<V
MOX6+*-<+\<>X.7^OZD&#NHXH!!?<:0KJ;P#J_NR[:9 ,D3"HI!NGFN]9^W:H
ME(_:O,-TU'N5-'1I_VEYWK#7'UZ_;QP7^  1,9>%'P8AE&^VH#T%V8.#I78=
M+%NHJT<]_CP;RM=:H3/A+ ,<U<R?SK/3S LM>]I_R$-2;[#K.;4CU<;Z]85X
M7LEIU^I_BK$W9"'#ML$]XH/;"O#K'<Q76$()!WVMU%!JR#7GO''KL[];/\PM
MR5%+ZCJNI(ZZ-E[J,Q(^7#M>[_?AK43[#O/))XE'\+?-]X EXKWB8G'Y-'0C
M!9_6Y7<8%0SW"7IR6?=WV--R5;>\G;N+1=^LM V^M],$O)-N[B- +QLL( FH
MS2** 8Q9S :"&_B>8HGB4MX57D\?SAD>'ZC(THS2S#7L"L]3/]9TUVIO@\ ?
M1T*\AF \-ARHQA[@ 7($#B>>!6EF*&HC@7?D.,W\H6-BXP6RAWZ%YTOZ>NGN
M.;X;N<1=G9E;MLSSY8:.B0TU[7:75<UZ*63<U+D*!OL<JQU1M^")M]'%P<>D
M3N>^S[0_L2F3H>H.%,1<[.5O^:]U?=5@<9$E%$;?QW&MX]&C8C!2:3*2R 94
MXN(RX I4C][8M#-42%J5BZ?*TM:!]H)S^9_LV@WM@,,[K^$ICJ]X6,)5E&O#
M#W]N?*''A)9*@0\(.=)V=@PQZMRIEW**;?7P\:1AERE ];SNS9)ZR22)YT(%
M'Q^8US])E/2WT:TF%!RY(&Z536#Q(J);*:A-!TZJF6(^[Y9CW*1"-C]Q[LJ9
M%>'P@U21@:)0)'D[!2IA)/1#7#!NY6R.4X2-WQ[TM4]/GHQ*"G,_$=]M?V -
M>PD)Z@;UC>%X2!$,0YM-9PK9#12A6WKNJ_S9-Z9\ZGE'>93IIOK/]-:]WKSU
M?;L2!W3V;:M"_)W/.PZ/X6P(XAO-!!%4)K(E=@BZ(TZK?W9!_#F8[YXY:PSW
MMU'Y*MJD,E$6Z-?#.S?@ :.<8P.X--IB1WX?EF+M.!_A09U]H)DCSS" 9N4Z
M$K?Y%[_:E(3?D=MV<8J\EV[]Y=&F>B*4#TGXO/WK#'882B]$_M@Y&4H0_KW*
M$L$0(3C['CS%#9F)4&(VF.M^9AT!<^1IN[IW4[72OCM7S;_]^OD&O-&*%Q!K
M[!49#%=(#.$U65RY!M-PXH(A.6-7#_U:@KR%_GD0N7Z@QJ-']B<;8"B2V8#V
M'*C !JX9L\H56P$DK.7__A4Y]UFC'(U^G,/[5PWKA;.'#SN9_BSZ\V"#I13W
MVZT-"S= RDX5. A39RW@*9YC"U]HH2"GPHGV4C3ZCN&'(^Y@O//ZB9!^37F/
MPTVBW+B"D=0LAXPHD98'T2X[AS&ZID4VG&@]S\(A*2X^7HLD&X9<%3G*$SQR
MILC+8^,5I>ILX9PE!A>K.FM0'F'B>B^RP%JRIMXO/U2F3 R9":5XB2LC)I=,
MI[&!?WXDH:$G "22.A7>U7=2/=SS[!T!T,MQVP&Q/T: 9T5B$5(2;Y//%^I-
M2^!\YVX0.8"4KD5>QH/[TH:RQG".I)F:^ Y_7XU6R3C7O@W;")W3DP);%B[
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M?_8$W05/XT6[93\<S?Q&0X.MCYL2FG0);\K6I("?04GN(<-%CVIT3W.5B==
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M5@ +SGX^I/B%N@/4Z&$DNJK%?+<MWZ$NV'C@=S?["N\>R1T_4G=,$<X@<HP
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MB"QUC,73='F%?)AWMPB@.$C?YWRLV/=CMN/E8,ZALA]^T4UK5RW-574:(7Y
M)4'\4UR+?2N1_7BH06=.5O'TF[?=^9ACY%50OC;:E>62QAC7?YQ_,#$Q7MU'
MYNSMM[*,MV7;#GLQ$J80(\.@:#_+UIY7%8P&M$Z_DL2<'NJW!KQ8SO3N:+T^
ME(3/]^D_)GP>G':R?I[B>+M<^FPS;K-9;[@6&Y)[41=PK?CRU/9%&=S@4WG
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M.XG2EF.6HW<D'-?+(WV', >>C:<!H"(/X$KRQR+^ZA3)^3';?+S#"+4[X$N
M&EN'4>"6(M6OF6T:8%28PMVFH9."P2;AZ&?A4[[=+:S\3#Y5ST]?^?PN:*(I
M\CI^6&R7X-#&=I=DA+*5+EIPO$,%#7 >AG9L!3N8XA='N-OM*0LQ%[R-RDIT
M<KF#5UUU,W(U<]7ZLXV??SF,S^8#_$P^<B43MF!?M_'I8"$819,D1')E29/$
M;CCI%TNB$II2@XD]>1@*Q0QRE?AOO PB:<^2D"Q/]$G.7;83O3MBB*TY824[
M_&L0)DU;'%V'7G*'3(8SXX1YP'ZN^SVC?'&?)%8X>R.;1A)Z%US"F]L%K3-,
MZMA3,\)7X,2ZH1X?JVSK_->&N4SDCL^N[I'++3/W0WY,L#ZN_#PA\I4'L"T)
M7/$=%!^KC2QT';.:6UZ&6FJQ#ON;/V-\UW#XF'*0?']M!7&8VPUM\NLE$3^@
M2DG4KXM:##/RG:$4R8(<G/3#YA^-V;"A&:;CCNNR43X.J_N$+;_5%D]'<^0%
M&&M+-OPOK^7<X6U4*LDJ7'F5G0D3Y>ZW"7N@BH3U$.V[VA8X*M^<0Q1>[?4^
MO/6H_%&-8,/!G>8\0 JN5(;M?(>EVQ[Z8S'@QM 2UBHAANWJLP.,QA/-LUV&
M?)^'YZZUJ;#&GP:9"R=1]6PJP03;!D+LK_@?DY=LP+T[8P]FQ^(:H)W9Q!2*
M<"YCC:S4(VXHA[+PR?(;-6%)+TB^Z3;.<;"_^[0[N-:A<OO5Y%:X*+;S, \X
M1X N\0=/CCD-VM:LL'"34-EK;<73?MD&X25Z8S^1XJ!?]PL5E&\W5ZVV=LS7
M[?18]9+L+OF#>U[9/=@E5"_7KY5Z*&B.P)?#3CD8.;?$9(93S]?M.=!6BDN8
M5!=O&F-]S:ZK1K%W"<Y#I,#^+JN]S688689KT=,CYH.5"'MSKK_#,LQ\%)_4
MB !-\=PM#Y\$/E\8)]7J/RJ*"=DWB PO0XUY-1@]/_CZ+/X,Y)%8;H+/ '^<
MW:#"-;!SD%0K'<X#S![41*>/+)U[TR3SE \81;4I7]@=<LFQM+FQ5:Q7L^1T
M%M"R_K8-EA8+VT$@KR)!725V&HY^#)%\8XW-8-CWD.H'?W'?/T=C7RT70SCF
MS\NX$F\V*C/Q@-<3_*_I!>_A>< 04AZ]CW6$ %]2%1IB"\]+8\?&5-C;P3*&
M81]I*QK[%'T43*>IA2/&33RS]RVX,K3K#1[&[#TCNC5_[H*/2^W3[9<78\\!
MP#?L)031G@I;Q++L48;,8M 1R\1*@QH]BK\?X5IO.K*;.)]E?6_)UQ:D]E_+
M3;D!</D:%0*)@]+/D(@KM)=KKTA)L :#.+H&>9NI:?\)QM=$M17+(*IVWEZ_
MIB:#*O7\QU.WWKM<A&H\N?).Y4;!H@7_$X8X63!RB8]RZRCL\E#27F*0R@-]
M*DQE8;_J4J37[::O><N_O0:TOPXN>F\LYQL$M7'N8 .@*= FD44:F4",I/!U
MAFAYB(:%3'TOQ,QM)J\JK>4X9@G5.JCKJ)68JE4-_Z>E6/OOU/ZCTL'I;<3_
M3?\L'O;ZR9\2ZH?'#D'ET<XL2P)B<4&DGRTU/\P#QJK$.-S26%BLN1Z+S?\-
M8,EO\1OBGXGEBW]JX1J;R;#O-FQP^LD=>7Z,#X,,<D4XAXPVSEO_EY\P^/]C
M^X]+A/)7^R]1I+_:?_!YP[_:?]Y1@;_:_XGVEXW_+VI_V?B_;/S_3>TO&_^7
MC?^_K?UEX__CF]X7&)$',"?!! ID"DOF 6RY2C(&_P",[D7(_XSQ]2(PLE,;
MOKY,=QYK -.WZNLK^MN^^_P6NOFSJ-B1Y0%#482KVQL>0#^- +407210UR\>
M?2@&EOT+GT*0ZX"2K,KH_51<TI>+A&&#J?/;DR[NZWJW[5+.OKU&3^QM[L>&
M(^C'D6FXYI#W2708'/Q%PT(V<A##9+B;/, [:*]"B7'SV3M5_4$5K0WM898Y
M/IH#47O2]Y4;OA 5U'VMC9@R8][F:V<<2&/F8"=A7%'?*K080@XT.]P\;J7M
MS0YH_X"^Z_KK_ME)HFVE\)U',IU[5I5470[6M+Z-[[C*OW)C*X C+,!0]!T]
MFRN:\@^[DX)*P80>Z!;CI7"R6?9/1<E*5%LW?;[V;?YH'/<I4_S,.EV8(A=Z
MVD(=>Y'3SI?16=*G N8 X]E+E@-*F]:+D,"8?S=#$,V1O4.B8/T)I2N!N^+.
MY5*BWEXV^93>M$,N\<3C^;A8B$<3IQSF#_^4SA5E4/'$6URQAU3#E F,-MVG
M..;I0BU;H[$]VPFEP'2?G%)=G1NPK/9U?B^#'NBB!:X@9<%,UG7N-*[NZR*,
M @5W(Y848$F_(,*!]G8?,1ILG6&VF6:DNA*=^V2/4:]^,>/N0$1T +/H^GV'
M>-W:O;:QFP-!$E=,E&6-^<@#&B;8*OT,%3@1P=&C0KOQJ2=1>M3C59<?V#\=
M*$?ESXX\HS\0O">D^@F0R&T[;_V*%<X5=X^A%$'![2*]0>ENZ2R3#KF D4\R
MF>66^:G",,5C&'F!-=.D9_Y<G9$];"?*TE'5=[ 3C5ES?3]FNNTM]^VZENOP
MO;I<.CK!M:H'1K[GJJXQ2B 7$>J7[]$VYT8$8>.MY--/N=>W>QGD!FI*ED2&
MBEBMXY%\>SS F+@9 1=#V?& GALZ2:&_!ML<)'("3/>4!CUZO2[=K/S[MUL.
M#^@^BP[F 650!HF[V1/+. U@_U=SK4<SG(0P4T <&9NL1'1+)ES*5D1EB;:?
M>N+E&%TY*%ON8OFY06@;^S5*I^(&CFTRU _Y;83;2 QZ3%Y@Y;1;//\A7NPK
M_(<H\Q\BU&G_5Y?_CEW>^^SEM%KM!E6[E3H,&#J+[C0]/?$MQYK=W"*'R\.>
MA>6?DQ*Q2GX60&J"]<6<@B><JN.DL,,TS:2K:QW5IC=[G]VTY<!G:7_!;RIZ
MG5C*,\P![$@&R$=JF\Z5<56^TE(X6X<V5O.TQ8"UIW_U^._1HQHIRYW%REGJ
M5,VK:+>RE%$=XU^]VDU?!)N9)^Y>DTV:=MDKOQP<'F\_'FMUJ[1=Z1_?$/:/
M[O4 <N.O'O]M>W0$UW':N=H(D+A&X> 7+U'7/AJS#BP_JSYU(O&=O(NLPN1U
MLFZ_B,Z\)XP^ =L&^]:'CN0!<7M/B+P\Z</G#9+AC&YNAE\_%I3;#/VKQW_3
M'KXH#>8J>(\AXE#@2=^0 M:"/U*K,2](_P\EVWQ3XC?'DZN"G5MI?YF#_^$]
M6K ;>XPN9?</;7*DI4.DIN<OJ+G.=7E:/#DS<S&):?2&D3$1]B^?<$1!^WA
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M)S"L[)NZ(GTMH53FC\+^S$8SSY35Y?:F//'H(*=W.\HCM%PLB@HN^LI.#'?
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M<0-FDN,!U2/MR^IX6P 3@-;EQ&]D]X D#"]<!=VX8AKTW2%./2]Z7N!O-L[
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M][_O-__GN3__^[[?W,^+^\4Y'R^NTW5NQ_?X?L_K.,\CY9;JX/KY<[SO=R"
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M"B'@U7!=1H70>X02)<K?9V!GM&>[G^',GE#>3487@NOL_!NX9LQP6T:48)1
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MWMB^;^&7_>) 6.I8L>B[JZ:*5W(6[EGR<L:U'9W?7>#!E"ID\R\%EZ\T16[
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M.)I!7N^"I\Z>PL+ 8J"^^YGZF\2##Q24<-;-;0EB3;_.Y:AJ\E[ZNB>^X:Y
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MKS5A3,&\W-VKP#Q <.DTN?E1[$Q)3I!>OX;Y(HPIA>N#UR,Z:X39T[B&J-4
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MQ!"+D+$(HY0))X_GD7FF=JILQ +Y$LCOW!2"TJ_1 RWJ<'#'6C='H+5C'@^
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MDA(89%)1TZ]"">S&BY8S3Y *.X+7,9-*BP[RG>R.[BW;-;"]^?>.Z^!Q !U
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MC.LCOHJ33&',41([Y6&<G&UJ.]:->#0Y&278+#6>H&AE![P2'JA&>M<,U5.
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M7:9&(_"ALTQ:J>Y%GEFF.NR\HYA-O,XP"V9ODX^]<".9[N,MH).1[Q/M$[X
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M_.Z>%G^O' DLSG#&J3:M8A% G(D,9H13F-(@0J913!01M^( IR><VKGXF;S
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M@\D3EUA..BK'N 'QDGL<O]VWS@<O3*G3M[+^^\/RAG.39%0VI03F..)(9$C
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M0A#-%IS'3N;3@4FF=IYY$1\(?JO%=$T9/02GI5ET(4A#FT.N^+@;0B< \&4
M'9IB7,/GA))[!L^IS_9LGII39D;+9?E)/4LSV":L'$PV,%5GFPKTF*<JD:F
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M"U[?+Z,1:6D_,]"HJ_IEA?<7=(\[ABGF_[F.G)QE'+O57$'.I;3$P;%S5[C
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M4TBH3*0"*IZE$%,I(><X@UBD:5HD!<;(A'3;B"17$/>,T)VCS9>H$R6.=N$
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M)(P5*$>*!IU-Q )TG-9JF]*,@3%:9R'U,[UC 37P&MJ)N:DQJD C:;3.MR&
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MH#I2BO"JQ_7L9-B5-%S>RO]]+%?ZU6/E(O\J77W4ZT_&]4AM_Z)FB E5()1
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MM*:W!^ Y92G6,H4NU\D"CG/("[L4$&J0,Y.UP4'Q.['A'F,5& UL/\*/#>'
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MD;$L-EFCG "H( (8XAS$<8)QCO6_$GMUASZ:8FH*[& ==6L&?0RDFQ;J!\_
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MQ7VQ"J1_G:<=57/Z@G&H\[S?[UI#ZJU6DFOCKQ?RQ_\KG^<P@4I(')O:ACF
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M7G9-]GRWFZ'\2[G4.\=;/5&Y^4"Y'7+K]+!IJYLZ1?W]4LQC@E&1%PID>2X
M3(D 1*8"I+EDBG*E,LY\C&./N:>FU6\>'A8EM^;4S@VX-GG4M?N/6YXBU3 5
M_:1EQ_4*]JQRXB,<-[-W(,@'W@ ,U?;H4<.Z);SE0;<Y['2S+5:IR0]GVG;
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MX1G'E$K,_6XBO.:?WGW$-AWAH:F$H'?PA8DGV9AX$J%Y\K2'O*2!:<8Y2W/
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MJ"@S*H<"R0J%].E3)'H$IPRP2]/XK(]QTKMJ2B-J236!/](G+.PLG-=O'T-
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MC]VU,94R<=7M$0T53>O/F^52GU_;?S1E5=[7^X-LR)LK@1-82 9RG'  %44
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M-,U!3'S::KDIEX]2-(61M*JTO>M,A:7']=KDTQ.6I 3F&#":Y #:G+4"IH#
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ME_7JJ112O'DVG=8_+C\NGTPQY.7W&[XIGVQ$\4G-5<U5 H5(E0*$()-T72!
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MF>>4N6T-)IF&D5?_$[V[SAR0MW71ZY,;DZIR^KK#Q'Q3^M@J?J%(])5=O0:
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M<[E/CS&W#[\5$^SD]$AD/@/CY?., .",_.$_QV5(IO<9@#SRO:\':JJL[P&
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MU3MVFA<04ZY@Q.(,YS&.$N74WLI[Y+EQ3"OX+HL;6-&]S[S<H7?CG5$ '9F
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M!E'$**1,"9@(64B59%D2>W5<'2S)W*R41DBP-%)ZYID,GPXW<ID$Y)$YR.H
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M-;#T''=N6R23ALFMF)[[(U><'0.,PJ,W=N10F]]J$*QEOK$_UV*/U6';$ZC
M*:V71GV1;%9'*,XELKK>/J3[TNKNB]P\F*KG)E/6['H^L&5Y5R?X_TJWILW3
M]WW41R$$%3&+(2$<0Q07%-(\B6"D)$6,Q;1(G4(JAPP^-V)RC[(9!'4_+8T-
MX-BQ-5IT:&0'MM/!K<F]MVZ7COPWH-7 *;;F>L1]>C"-A_QD?9B"SX!G-Z9A
M$/9V9/)\Y(1=F88I>]B9:> SAEFI;\M5N96_E%^-@^PP/_"6ZS?TR;9Q[282
M+@PJF";:5N5$0)2D.:08)Y#$C$81Q2E-E5]2CK\03E_:I'D['4%!5U(_8W;
M=+C9M2-!/,TR4@L/K?3/TXMO@#?VWM;N</@"&;X#!)C4!AX.T+$Y?,63PE-@
M9Y2FHDS'CM L&"<9@T6>*XAP'D.,(@RS2%!-BHD2*O/9N ^4X\]K+U\[ =<S
M7R!87Y+^;FSQ*GY,?>/$J5^)Y01<V"?%; C1 2H?5G1YW#!J?"^W^_J MZS:
M;BC?+M)4QC3*!&2QYCP4QP)211!,25R@-)>)B'*_$\:3X\SOP*^NVU !>A3=
M=!PQ]C<__CN-LAN[78W<R-QEJH >U@P]'1H&?F^%#QC'W@M.(#(Z/<:D5-.K
MYC&1]%\\C"8^;M9<2F$KB'ZFIC#$[5=:+LT,OUUOS&_VG>3-OG:1T$S1+%,P
MSS"&R) '48I R7E&<ZD9)8Y\3"=? >9F,[7RUP5U*RUO9?-Y'^K=OI;:E$"A
MK4Y0K3?07*4OV/Q+UI]2M=/0CWV\)\^-F,:<DI$YZW VC*@&?>L_V\NL=YT'
MTV$N"\=<0]$+1&K>PT_*=T/!.:;"P<\9VJ^H#D1[0S>K<G57-2UTF,RR+,$Q
MC'!.(!*:%1E%9ANIXH*F@J2Q5_F*T\/,C?&Z+IL?3=U#7F[_K;$4?!L4G835
MC:6N!VMD+FH%!*V$H[0AZ@,A6/^ADX-,W'BH3]'G'8=ZKQY& F^:;AZ?ZV8>
MIR-=WJ]MYP@I;%!+9=-2NO_^:EUMWZ^W_Y3;3Y*O[U:F&I)- VBB7!:I*@J,
MTAA22I3FE)A"EN((XB3.BS1'"6=>S5\GD7IN%/7;:K.3$_!N4!]?^];GFF;:
MW3AO=I,Y,H6>C+G<QY+94CFUKFTH9JV#:;)4;?6_;L%WO8O=ZWG3%' ,Q\"3
M3DD@0I]&YDG7ATFGX7BYF7;PH97;OI9"KD2EQWQ8K^R331?B1<+C-,]Y 2F.
M(JA7'KW@L"R'7##,$,6QRN+V3/B+3RFVT^,-./[],L&*L1,7",F7>OZ$;TFU
M,_"Z$?M5:$U5YJP1T7:PTT+6C39O^GNT#RA4UH]$L))C9X:9N'A8O[+/RX!=
MN'YH02]-5H9_%HQQ&K&8P#C-$H@8,5UW8PY)3##&>1%)X94XOGNREX4X6;ZX
M3>H<8!/N 7/[O ?!,/+WW)3*>M6G_(!J6$>*!JMRU3YWXNI51^H\KTIU?,'0
M:E.[[[EQ@B0)1101#JD24G^)^IMD6&40YX2RE*%8_\^OQM31"'/;LW47%=\J
M4L?@N7V55T$R\M?916,$O]%9U8,5ASI^_L0EH<ZH][P0U+D+AWW')ONHSGA:
M+M=_F#QE6_)^D2-$LD0RB 6C$.%,_T3S!')4,(;3+"_\3LW.C#.W;WHG)MC)
MV30!\"P4=PY7MP\] %HC?^Y#@/+^Z"_ $.C3/S?*I 1P0=5C&KAT^95FM7W8
MOL]'3.*L(#*%VJ(V*3I2V]=81E P&0E%%<FDEXOWS#AS(X.#]BKKA\?URF9*
MZ[\9!;;6$O4\ #^'L*=5/ARWZ6ST49NG7$ BM!%_-,K+F/2G53UKX)^Y?&C)
M-KJU'NQZ%2,RSA/!"\CC2$$4\0R2(H]@@6F&F.0RB[Q:YQX^?G8\T$HWS!0X
MPL[M4Q^.R-@G',Y@#"BT=DKG8$76#AX^<8&U4XH]+ZYV\JIK.Z8=5.*O^DOQ
M5W50Q$Z2G^C2V!:?[Z4T"6*W0I3F,KK<MXFL]HN82*6*%8I@E-)([QDB#FFN
M]PQYQ/.<J+@@R&O/\ (ZS(YZGAX>Z.:[L3GJ,E*E;2:MUIN'IC2SK.-:MNLS
MS3L\#927>&\<&7'>;\/HAQG=GBW5Y:8MU43-ZR:?C.!-\:;3X(6:[4T^1>>;
M^$TORMSJZ_W#'JF_6WV4FW(M+A=)0QE-]+)*H<0JUXMJFD.2H@2F5"1%0I%*
MB5?KAMEH-K>EMA9_WN7U?%\>QY5U+O+.:+V=KLA>\][IUZY&Z7]3I;V!\S_[
M8GN^>OTOJ;<W<#JG*[DW5,"A5??8=B],V[?TDQ[AC5+2-(>56A#3MT6/OD@Y
M3GC&,*02%1#)0O^$B?ZI0#'/5":1<&JA,FCTN2VV.Q$U[S7==S>&WGY\K$7V
M7'']9L)M51P-W[%WBB9W;"_XS:YU,3"RZV5I!_U>_)"E^@:@%JQ@G\_8$Y?M
M&P#+\^)]0QYR=471MF9Y*?6.S$0$6^I=D"3),BHDC C-((H2!;'Q^W'"2$)Q
M+I00?J69+H[I])5-6HG)5DTT3IBO9CTQ;CK3*F>E&?2^?!Q>7/0,Y*[$%0+&
M%R@HVI'6L-9.WE$*B?9#$[Z$Z)GQ7JIX:+_Z/65#+]PX-/!@J\GL@ZI+D38Q
M<2B2/$_2#)I"'Q#%$8(T41BR)!$)+42:1X5?U,'S0>9F%]4RVH #*Z5O=,$)
M&%U#"ZX#9_2X@D-<1H@P[$,@6#S!B2$F#B8XK^3S2(*>:X<4!JZJ5];)>R=7
M_'N=UO9!;\VV3YN5%!^4^?FQWNV]EGKDAW)E-X:MH;-0BB>$\0C*"&F+@VAJ
M( )'D"0QTV21%%DLW"L%7RG-W)BCU@"L=RJ8CV6]5P*(KA8WNWV73_';:R>P
MGXHFGY:Q.4OK CK*M*F<8*\/^*! 1R/P^G".WKW '/E4+)YPKB8K83SZG'F6
M- Z$<6^-XVO'F+#H<2 X#JL@AWJH_Z+X7NNLA];ZZPONV@=:M^:M^*^GVKI>
M9"EC(L\())%IVU&( A(4"1AG49KE6#"4.,7?.H\XM\7-BN?.@FZH7EZ-@F,U
M\HIS*.^.BFZ:<Z>]S*&A=%\T@D,ZT<)P/;1>O.\%4P^WNSUG,O[V4JO+T7XW
M#JS-K.G>MFNZ78FWY3?;N*G90TL:YT6F4LAB0\"<Y9!F"&F\3?=9O2F1-/4J
MOWQVJ+DQ[T[2&Z :06]LN4#3E/K1G4L<0'9S5(2!;F0BW@EIH6K%',%I<1F-
M4'60SP\T;:GCBPH_JV9\^8YA?-$$JJWN#CN[&JIZVI@ZLPLI"".9T+21( (1
MH0G$61'!F/*\D'&F>"+\BA=?'-/G(YBFD+'M"F.L9K!NA6_*&"SWKF0_$KF,
MO!N7!$5S9$K9R0J:'*N=N+:H5"-P.&9QQB80P5P>;U*><5;_F&[<;QRT6Y1-
MY:;7Y49R/8/MXAG1A. H32%%!84(L1BR0DB8T"A/>2H+2:7'%O',,'.S3K2D
ML!45[&3UVMV< ]1I=Q@ IO&WA"<0NFR)^$#EM?L+ -ET6[Y!T/EN]"X@TK^[
M.W?SE%NZ"PH<[>,N7>U'B]5FN_ADX@9OOY75(L$$IW&6PX@;%BR*'&(I$4Q9
M1%G!14RI<F'!@Z?.C?1,0D19;4M.E^!7O<AH@[;.QS3".G[1A[#U<]U@,$:F
MMH$X.'^>)_7NLW;T#1U+1_]M;^4</FN2C_.D^.VW>/H?A^V#OFPL^-]M41H;
MN%O=\O]^TI^W6. \4IQ3!/-<FKY5F39+:)Y!IE21%DPHC-2 6HT]0SJ]H-.7
M:_PD'_6C[K5): M(\+I:4F6K)94KLS5:-0T6; :*33NI/*-@>R<"YR1&!8.1
M1'HB2$PAP06'"G,N](PD$?4*IKEV!J:OTU5CO=G-@Q@':+>=9R#X1F;85LJV
M<&8MJ.F!6(L:;K?I@$>@?6;?2)/N,!U4/MY;NMPRC,/W;7I,@XK3Z9COY?:#
M,HW#.TV5OJQ/>^87/,ZP:;P#-;LPB#3I0\(B!B5.B8IEFN8%'4#\H>6<Z6KQ
MBZRJOP'3SZJL^UD==P%;'1Y'M<$\E;E^^23J?#+130Q?#RP($/S-<"/(%YGH
M:5CUL$69[?MS)H7_QKX"VES02MX\:V9VYD@R'"F/-0>!F#RX>)/2_UC@'J\9
MHXUS18FY^_52O'MXW*R_VAU;ZT<BD>EI&W,H<))"E.@= Q%%"G-.4$$S@9+<
M\[BD9[09'I2TPH*R(^V ^G)GX'4CWD"0C<RA>ZRZ8HX2%7X1CI#%YLZ,-'W!
MN7Z53Q:=NW#+-8:I5PV0G[Y[51FQ'K!8)"*5N(""Y]I<I2R#C,L<LD*B-,OS
M6&&O@G;3B#VWG?9AD2+P7E_JY96<>-)]+-$Y3>7(W#I@%@>:EE.!&M3@'%WH
M%S!#IYJ(T\;I9*,/6X)N.;>MN#])+LNOQC;6]O*K-L1')BFG<0RQP!(B8FH>
M9IC"0DF6B8*(G&=^-FO?</,S6C]JF,VA"VVD!IN=V'Z<WXNR&U.'0FYD?FW%
M!'LY;P!5)K]Q7TM=K3=MJJ/9N]V 5Z$#?%S0"D2<O4--2G<N2A^3E-,]5Y95
MKBO;[(N,6_M$,A$IA3.8\!1KHU1$D&&"(,_3-(OR(LF45]GUWM'F9DONA-T5
MTNJ48!]B5/9C[<8PP1 <F6*\$1M>J[D/B="EFT^.]3*5G/O4/EO8N?>FP7V8
M'C?R7JZJ\JNLS:F/ZV7)O]?_WQ?9Q1+'48(8C(74ADI*<TBC*(,BRF6*"H%%
MH?P,%=>AYV>T'$@^J!&X,^QNO#(&E"-3S"D,;T M+_B]^7.4VL.^8(7K$.4V
M[-2-H[S .-%/RN_^*PV=7\J5?*=_K!;Z#:-Q0AA4Q%3!0\+TD* I3%6>9R3"
M@G&GB.7S0\S6I &_&QF!%7*H%;,'TM-T&03/R&3BB<QP:^69\J%-E/T +V.7
M/%/PK#'R_,JYE<K>-:!^_U3'F2,48RH1S%&2:1,&*8@C)31C9&F,$"FR.%H\
MVM*?6LO-UI$WII+?YWL[UF*\3V_?D+YJHKM^DG?E:F5""AI_W/! N0G?#2Y9
MA(QYFQ0(HHC%$$N50\$YRI$HJ,*X>3?>K!SK$<[XS6AUF/*]T&/^R5X*QY5Q
MCM,\]H([67GS'0;Z1XO"GZ%N^9F)FWU=\F.Y_Y?4'3\S'=/5%3\G@'\*YR<I
MI'RP3N23X55M,^T4JYCB"&;*9(Z;A8W@@L(\DH+0+&:(4-=T3K<AY[99VDOM
M'>@X%/3^Y6(<*$?F^<LH#D@%=833/2TT/*P3I8B&@-<K7=0/J9[44<<'399&
MZJ=8-Z74\\YAF]Q/^D&;DNL5X!6M[F]7]@^S;'RE2[-@V(WTWB7#B9(RB?4F
M-3>EBUF,]$X5"4B3@G!<)+) 7O6"_(:?'Y6WT@,CMZV)8W_H:%"[?*YPC'G.
MD-O68#S<1^?]L)![V^;#D MD8'L./JF5/ R88U-WX%.&D=\_Z*8T_&HZ3;Q>
M/]!RI0FNH))B!6.FN&8Y'D,2L0CR-,N36#+CG/,AN.=#S(W$6@EM%Q7P>RVD
M)T>= -*-AZZ#9V2N\43&FTK.*Q^(+DX,,"DEG%?P^+/ON7)@S<-R56[E+^57
MTS5KJV>UU$^_K2JYK7[>K*MJ(5424_VIPY2D J)4$DAQ$D,NXP07W$0A>9W2
M71IP;I^]%0KLVKS4Q8$]2QY>PMB- T(B-S(CU*)"*RO8"PMJ:6^ E3=@$41'
M9$*50KPTW+0%$1V5?U86T?4^?Q_708!V?WSVF6II;=QOBFFD=T\Y9(@AB+*(
M0)(6!>0YIU&:%P5GSE7-@DDU-XIJQ+J^O&+8N;OL37N1&1F9^@Z39RZW:;\!
M.]5.%':\%/0]XO2Y>^]>9!HG<O!-.YU>KL#@L/=X"\.--9E#,3@\79]C^(>'
M*$'\R;2[_:!^J^IU?)'&"F4DC6&>FPZ-&!60)C*':41R$K-"1%1>4W[X:#R?
MSW>:.-\/1ROBQ@@,UPH^Z;]0:^M<4WCX&.]<%DFNXA@J%*<0*8D@EES B$<R
M2T4L"/'R^@9#>Y(6'8=8A\35;7\4#*V1+81G"\2G]JW4PM9;I+&J.)\!990*
MSL=CO6#UYC-J]U=N/G>3'U$+62YN]>*@9^EMN7EX)Q:<Q9QS7, X+TQ72YQ!
M8MJ ,T2R7&11KHA3(;YG3YX;(33" 2,=>/?:C1">X]7_\5^%PL@?NBL SA_U
M665/?,"5Y'^Y6W_]J[ZG_G;U#_M/]OF3)OD\SRK0?HKG+QCLWC2QBB=-KUT@
M] =57U;2Y<=U93/.WWS;FHP(MM1W5=L%2E@6\R2%44HQ1"+#D$6%@AG&-$^I
M1#1WBL8)*];</OA&J_/[GANPC_-?*[!3#[3Z@=_W&@*CHN?Y2J#I=O;'3CR)
MXWMM0\[?FY7>H-=[H) -;X*B'LXC'$*HJ?W& 8$\X5T.^71_'_3G>[I:K5>_
M2F'J@S<1:1@QEB=I 8LHBK3ME5%3Y4G 1"G,LHSQ!#N[DT\-,#=&;F0$C9#N
M;L23Z%UVZ%Z+R<@$=P3'@,C'D[BX>TJOQ6<BIZ?K:^/EKNS3O<?S>/*VR9R(
M?4)W_8&]U_GO&%\W\_QE0U<U+WZ2C^O-=I$4 L5QG,($)P5$$L60R@Q!Q8J$
M(:[B0C'7S>.Y0>9&8JV<8"\HJ"5UWU*>!?3R[C($3&.?.?DCY+7GO 3!H.WG
MV8=.MA.]I%9W4WKQ6O^/_!>-^?+C_7HEFVRUG)$$,X4AC;G2U@F3$,L<P400
M5A"4XI1$KA_W\</G]E%;^8 5\%):V&7@+G_$U\ Q\L?K@8371WM.Y4$?Z[.'
M3?:1GE.C^W&>O>;*0[5]Z>Q%'B610%$!1<$Y1)@AR%#"(>>2T207"DD^Z&AG
M/\;</M'].86D&Y,./O2LK .CYTG.,' F.[\Y*.0_PIG-<_5#G]1T1GB9\YGG
M*IX]E3EQZ<""%?Q>BJ>E_*!.)XS:[BI-XN<MWY9?R^WW+[8D_JZJ4R:R.$LR
M9?K,:3L<YP)BI==KE*@HCR/,$<%^)^O7"S6_X_=6)^,LM/(W6>&@5<"S;L#U
M\^;&/]/.Q?A.C^<9_/N4Z)MF3FYVDP)^M[J,4[LK'+2A<O&O%VC:)/M@ #[+
MG@_WY&&\_%[^T91:U6S_<;->Z1]YW4K@=&T]GD:<F0/T6)GF@HG*- L+ D6:
MR#3&JH@D]6-A7Q'FQ[FF2*WYPG=:@$,U_"C7>TK<"'9,F$>F4RWZ>7"GJ7\X
M%+U C.D]_*3\.!2<8S8<_)R!>TY3<.35NC)E[]]\,YPK=X;O@L9((T$II"E/
M(**80)RS"$I$4DEI@1#UBROL&6QVNU!;4FB?VB!K>7WWHGWP.FY* X$V]N[4
MXF7DM#G?C:2=L/2 ^U0'1$)M6/N&FG;GZJ#TLRVLRSW^1]QO7OW]]3\T(9FN
M&.T!MU)9G(L,RHQCB*0L(*4808)5S"0K6.3FICK]^+EQ@Y$0M"*Z'^*>P*V?
M JY'8^2/_@"( <?:)Q!Q/]2^#IF)CK3=7A6O ^WS>O<<9Y^X:;+#[/,"=X^R
M>ZX:W,'-M"V6KV7]Y[O5QXU\I*5X+97<;&1+B9H<+5'6.:@+HB*A9":@9*:.
M3H&52?V4D!=IP0N:Q:F,V@;";F;/,$&<7N;##L$CTUXC]<X4L@O]VJ[[0W):
M!LZ/F]4T(N:3->NU@H,?6Q7^S;16;N>@$=].06UZW?9/P9!.:5<@&*[SV1 A
MINYD=@50)SJ37?.T*ZKDZR?: \W_>-J4E2BY61B;13E#29K'F@F5BF*(\HQ!
M'$D%"XPQ0KG(\\@I_,=QO+G9>U;< >7R>Q!U/! (A]/8WGXCJ66C.JZ@*^P(
MW7$=@0E99+]GM.DK[E]6_63Y?8?;AA'(?TJ3M2;%[5>]O;QKPB$:AW[UX6E;
M;>FJSE1>/NG+]FT5;9FP6U9M-Y1O%UF2Y8IG.8Q9CB!"DD!&> )5GE&<1R(5
MJ6>OH#""S<_=WNH%:*T8X.N'AW5;&!VL]YK]S8^X LVD&[]-/SLCT^!N6AJ-
MFL@J>Q!=STQ'*].'47_SY;*L2Z#_WBH4D"C#(AR(3P,)-2GMA@7RF)T#/WT8
MB9\L(_&%?GNCE.3;#^KDOR](+HF(2*RGN4@@2K,$$L813%"$J;8.TT)X1:@-
MDF)N%N/'S?IK69F/VO13+>MXK2W]UNZ=_3AYV,2X4?#H<(_,N.?*X6@50*V#
M(=_35X6CV:M0#,2JPV28E$2O@NF8,Z][V(#,/KDJUYOWZZVL(I0GV>LGF41I
MW&SHI! 1+C0-(I*;+;),(9&"P"Q3640+B@ES*J]P<:2Y41WZBY;P_X!:9F"%
M!N)) B.Q1X);+[B7CTF"03;V/KD#TPV(:O!NP.L&L"&I@;W(>>0(AD)PJF3!
M?B0#)0^Z@-*71=A[_W3IA"YJ'.05.MTPS,S\>;T6?Y3+Y>WJ60'0O5V[C^R*
M4R98JC*H<*3MRQRED$9%!O-<$"J*.&=QX><3\!-@?GO_5OZ.\_]9K5L_ ]-S
M2MPLR_%@'IFC#_!]ABS8"P]^'R7.;AAP@:Q(S\$G-1^' 7-L-PY\BK_!>+2I
MM_;HTVIK:JCO_&0QEUF6F7;H1#!3YIQ#3+GQ?2J&9"HQP<+5;'08;V[&XS-_
M62NTK>GO;@2Y0'W9B P,X-2^Q@/L7+R)@V!TMR@#PSF177D]K%X6I@=(/7:F
MRU,FLS8]5.K:G#ZW75^5[:C,HD>5+LI4$;,L@XB;J&B42$AYD4.<JYRK(M?_
MX:%%V09+-3=B/ZKI];S4Z*0UV89/MINI._D4CKRT!)Z]\2NR70WZ" 79ALOT
M8O78KH:QKQS;]0\?QOH?-R:+8_O]HW[%;23\?S^5CV;@XQPRS.)8YJF 68ZD
M9G<504:3 DH6X3R-(JK_Y^=I<!UZ?CZ&5O(ZF:,5VX^!G8%W(]DQP!R91UN1
M;X 5^A#,:9+V?%$+1(3.PT[*=;Y@'-.9]_W#&.L7J0ERGZIS6,RRR:6O7C_)
M?TJZ>:M?UH6B:113*6&41!BB%&-(!<Y@&J4%Q4@E*D,^)JFO '.S/O7KF/MQ
ME3?D;IPU)I C<U<M>G]?F>T:, D^TE+< *,",#J$XZZAZ 7B,._A)^6RH> <
M<]K@YPP,-3]9XZ%3&.2G[_M+FN%O_Z ;T52 ^%E?N*W>K3[*3;D6=1_#I(A$
MK#(!D]A4Q9%%!JDB*>04,UPD1$2)9SV&$:2<GXUGA90"_%BV<:/GBTE--I=N
MO/K"\S-VD$"G=$Y7OV[]',"^@Y,E=HR6;7$=V_+2:&I3AZRNP9M@CC@5H<+W
M1Y!PVI#_\2!^EB8PXE#^)VBW>B[C6ZZM[-HOT"8)9PE/:!$G,&4B@H@F E+&
M4L@P2E3"$I(RI\(4/6/,T*2-05=,]U.=<RA>/A +@,W(5/D,E@$15.?P<3_I
M"H#31*=;[J^1URG6!0!Z3J[.W3G9:=4%T;LG5)<N'1AVWR1VOI7Z'KJLRTV:
M.-8Z5/PGN9*JW"Y4SI0D*8$HBO7_L.DA@3(,591&(BHPSXG7L9/;L'.CP49:
MS_AY-X3=3,_PN(U,D:W H)&X+1]K(^2;-/(?&[$#5I/UPRE4#+S;H-,&O7L!
M\2S*W>_N811T*X0E-+HTOIQWJU?TL=SN^HQ(R9!,E((J8TI;6U28NCX<\C07
M+->_DXE7%[+>T>9&.(UP9@/UYAN7567..S_2#?@'73YYYO'TP^Q&/\' &YEU
M]G):_R#4^+50AD\'=P(E$,7TCS4ILSBI?4PH;C<-/+@HN3FW7=W=WFUD7;2P
M>;EIE'&$L80$%10BH0ADIJ*]DEQS"RHR18B?B^[L6/-SM-6B^M8./ ^FX]E#
M"(#&/F1H901[(4?@AXM0A#HQ.#O.M$<#E]1]=@9P\8;AO:3>EI7IDF']06_U
M[ZH%*C05)(6"C*5,<T&<0I9IHX*+G',2IVE.B6\SJ6>CS,V.V/5*JB5MO+'
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MKRA24<'3' FG0/TK9)B;!=%T':EJB<&R$1E86\]C"S5P1ASVLN/C//9.5FL
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MJS.T2H,N,*"##/CI.^A>UZ #+#PWH :HXXRJF@)[!B/0@'0##$Q0XP3V0-V
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ME]^V7_Z0RZ_R5VVLWE<+(0N<TPS!"#,%$4MC2+EFV"P5A..BX#%-KF[CV"/
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MW_:\-&3$2<CI"BA:AKKF$</LIT]22/E@+++3C=PZT2&[;M@+$Z,A%>>0<E%
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M&S#[CH$[,YO1/TV!LEK_S@:@:OP/6PW!OGS9_J71[TR-PPS*EPV?O)<N;#9
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M.YD;(\LY-XZK ^_:3<8@__68L^K@EIK'7(WMOFJTK)<=4T.Y411T-04[56]
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ME5:[.B&U3H?>U8>94-_:)QX-38._*[8P%I8H=:T<$VIE_3@[W+"[$?BK#.;
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M0Z'W>Q9*#N&TH.L#+SX,%1U',ELPM"=,;,[&=\OWR\5OTWFBHY%+K2-Q@U9
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M0%ZX!.5X@IBR(Z^<YZ!U0"M.0\W>UQZ&D/Y#H2<PLQ.]<E/Y^ O]9C412I7
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MY/A_ 5GW&LI]W/(Y:*/KJ%)0Q'C$H$&I1(:1XART<4[5YEU"MJZA:+V&D29
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M #[[L_DOUY)2RDP4!4;&>J>6B#G,)0A>,9DU=S:W;FWR&#WC1I#;@Z@9[SO
MT9Z0:LD^Q9PL.%W+,XEH")EKD)EE927ZP%O;RYVGXS3QRX]C< <0>3M/56OB
MS[C][]OY_;C7!]H+ORR6OX=EGF0LG*&HD^L=JY/K-^#7&VLND&FG5&QM^#R3
MQ$X<^",1<6_JT7#BZ0!]]S( WEVL5^LPKW5NDRR42=I%T*@D*%-G5BA?N[L[
MJ:WSF/* KOT]>L;%U:! >"HOXUBI'(VP<UQ.%_4N:+GNJ:Z6.^[09PX!;0(E
MZ.2/#',=JA)2SB+2!YH?GB]65SO8@?N2V!U!TMV@_.^XWO:4_W6Q6CVY[.43
M724G*;A@/)E#QM/A17L\@Q,D"V=D-E@SL9KWH&N[@G%C(R^)^A$EWX$5L3VD
M:K"1>/DI?/WG=/VELIF61+_8_/4G$D"N;B+.5QL$3%2,&(BGP!TM3WG#P(OH
MP*>D<ZDC;5/K5)MCZ!PW1O.BFGMH*7;1;>A5_M\7JVU;Z<MYN)\6ARXVAIR$
MS@%2J;.T%%-T/)4$3$0M@LF&-2^7/H'<<0-#+XG<EY)I%P#^>?K;-.,\KW:\
MA-=A]65BD(F4!+FY7M2VEJH0!T6![)DKDA7'_4$%J<] YT.TC)O(^)+0:R*-
M4W'UJ6W_HVT5P,\7RVK";$WDS='P>C'_C=Y$4GQ7MM^OIV3#?,1$']WF>3*3
MC#(";)0%%'-DM_"DH)2DA? RI=AZ2,)I%(\[[N7%_;*7D6P/%NG^U6[*ZPY8
MK$X^T.X%PVL"NZJA0U,4V)Q]*=Z3.]J^+<H)!(\[5:8#% \@UPY O&/6?%H\
MD-2QV;_QKE7S 8GKJ^F:%K_\;9IPRZ4/F!:?YYNG;%N%JB)M"D6"L+$.4]0>
M8J$O,DDZIJ3+.;0.IPV]IG$'XXQD](Z/C@YVRZ,'W.:/[\XW(Y'??,5EFA)/
M)K$(P[QS0%:^!V65 (_&@$TEVR1]B8=U^6EEKNRE<N0!.QUH]U8B[!>DFPVW
M?X'9AH)>(10=<FU60;O0J0A>)"E$\=S8UH7SSR9RY%DY'4"TD0 [0.C=#KY7
M3/V%V/[S=+6-9-<5/G1U\]<MVR=T>"1I& ,=:R-[8PUX)C0M7AL5DQ&86AL7
MK6@?N:7H2^)Y%'%W$4>[E:QXV3@C$6^7=<\Z<A1REA!2W;->(D1!AXPKW&L>
MA/>LM0/X"#F'P?$/<8_62BC]1-1NK6AS3%PMZ/6BIC6NORSR1+"4390"'&[2
M&HL'1\XJ<&.D2BQJ@ZU32@^AZS#@_2$NOYJ+J1\$O@_+]9R>=ND3ODJISJ>L
M U6OE?M$XJ8=.I+=K RH.E?"8;8U1:XH-,H'T_JP/H"LP_#WA[C":BVD#BS)
M^\SZ^V*-'\_)XBCETS+,5R%MKN"$4+4&P(.M*0\*-0+]G(EOPE@MM8NI?=7R
M8;0=AL _Q$W6(.+J (9W+=S77\+\,W&R#O4].[\)=UFCC>2H0!A=+X*C@D"6
M*S@FO%"<N21;9UL=2-IA(/Q#W%(-(:PNIGW>9]F[]9?+/H^K2>V(8Q1+4!C2
M<E(.X%Q!X"FC28PEV=S^>Y2@PQ#WQ[E1:B*8#G3= XN9")6ED"@A%D&NDY,<
M?-&.N!1*3%AL'J '\%Y2#D/6'^*"IH4P^O$B'JU)D(Y;E54!;4.=.<@SD$NN
M*M<,KU./DF"-\75RI8CX0UR9-!/+B4GT;^9##8,\;NY641NO")*IL2*]*?DB
MO1UDM,ZK7&(97N$-5RCRQ[E*>5E1-P7YV/T%6\[#>LZ;QND\^*(3LQYI/6=5
M$$7K5)LA%U QU](,%D$FID(T-DK9^JA[D3:$.P?)=4[K52-ZT@:S4$/PVG%=
M1,K ?:R+%Q8"=PXPE%0<SZA%Z_S.0^CJI.*X&6X>.>3;R*:A2_RR6K"F5O\R
M6_R^:JCO;I[Y$IKM@16TUV'7+[J&8$J1>Z\,!%L'/6?OP"E)""$WU@JO#1?M
MJV<?IJ=!M65]YOOEHFZ)_-.W?ZPPOYV_H[.:Q#;__"JM:;-L9E-=<8!%LA5$
MT!!%2;1'=.5 1)!.A!(0A>*M>\@^G\INM-EI"-I3(CFDN+J(\M'BRG1=:T G
MBESYX)P$;8(%A62@^B@X""ZCY"EQ%5J7-]Z\?5P(#2WINU=GQS&]"\#<% U?
M)MQ4#V<ZO\!\R2TZ18B=[\JG\'42+6TOSQE$19Z\XEZ!H]T(44MA?"G.'#9Q
M\!F0>@Y]X_8X>&'0#2:X?B)^.PGFU?4FYF[:Z7Q:U$SQ>9K.\%;5^Z?%<_GO
M!3(3L-84U?ML1>Y[E,8!%\R88GV6S4_CH=<T;L>#%]X#70&D"W7^*]'_>2/N
MC[A>S[:-I+_6P@N<; Z@8B3(P ,HLI? T<\0DPP:F4\BMIYA]0@YXUH(?2'G
MWN"2-D+L I$_([T[33?+H>]GN!'Q/+\ZJR'6_]K6P.O(4DJUOD<J!!5THE4A
M'5*T^Z.-/"C3NL;@$+K&-2BZQFASL78!UEWJKX?5SS_7#,P5+6YC95V0/":(
M.;#$'20?'6U#XIKC9%^YS%2P1ABE6U_O'$K;N!9 UZ =1+P=9%W\)4SGJ\I.
M7+V;O_E:.7<Q77W9!E%^QKB>%$Q.:5'(]A=T;!3%P3/# ;DHZ&5(1;1N.OTD
M4>,V-NH:J&T%VH]'=]MIW5Y0;%/;W\Y_PTMQ3!1S'F.14")CH')6X(7D(-%[
M09P3F%J[90<1-FX_HZX!VUZP_8!V_VJN[\'>+6^5J4VXT2XZ*0$EU[4A60!R
M:A4PSTI43EOEAQEC="B%X_9&ZAK& XJZ S/A@09D3F:5Z--0A/*@7-;@-$80
MR7-$'YR2S6_ECN\7-UB6>=? ;""Z#@#X\^5KMUS\%+Y>1C5^PCF6Z7I2W<2(
MR8,WQ";%=:AM'!%RDL(F9NA_K>MPGB!IW,9&74.RI3 [P.8F-?J*RYLE787<
M%-."\9P @Z]:OEHMBEG0B3.MD@K2Q,:H?)"8<;L+=8W'-@+LHC/ _238&Z9M
M)IS?W)Z@B,Y94^=!ECJZI&9&U)BPDT4[2\N+ ]S('D;<R'V#N@;K,!+N(H9Z
M?VF7M<0K8CQ.?]N,W#':8XBF'@Z%/,' -M\)8**X7$H*LGGO[4/HZFW"1Q-0
M/ F]$^73J<I\O\3S,,U79LKE8?!JGC<'Q9:A$V-5(48&R-$BJ%+'FG+.(0<=
MO3;1F.;#8X^CM+?Y'2^#S.8R[!2K5SOP??BVV7Y*N<2-]!!U#919EB!6V]D(
M'9R1I?:\?S'U>$E4;[,T7E8W'B.9#KR:O0M:7F#^&&9A65O2>M0I%5+M,GL+
M*H<$@2-Q+W)5?.(^V=99(4\2U=O(BQ>#VM&2Z1)J5Q5REWN'S.T)1H$JQ%RC
M  J4(&:1&2U!2*:<YLH9/CS:[M/5VZ2*EP'<B?+I$G,;P^":?;].0YS.MKVW
M"S>AV!+ 8Z*E*5F(=YP!;:68>*B]W5JWU'L&>;T-K'@9!+:15@= /#!VL#]-
M>^)",E9X#[3+ J@4+(2"'&Q167B=H[#-NQ><0O#([7:[CNR\'!(Z@/VM%O G
M<G]B7%(ZN@P8ZMJ1.0A1%["U.L%DD8MM7=O;DOZ1>_9VO2E&P\GQ>V2Q#K-6
M,SD/71D=;5DH+,!9;<R#A4.@?P(I)TS&FZR;WW\>3MVX3MD+5Y8,)+1^X;C-
M=GE@YZ,VUF(-<F0&RH0ZH8Z^,T9:'[+,I!=>!I:/4#EN@/2EBY9;B:N+&R/R
M/Z^FR&Q;'O]TL9K.L6:_;BH8*P.NFW!K+7@Q3$+6DK:;=$AL%;4 )BFIM92&
MM^Y4^!SZNBQ\;H:6>SV#!Q)</\F?]Y9(O*5#8/WM_2S,UZ_FN:8,GM>/3(HS
MI2 9(DD$.F]"81",(9X*+E/2PK#F-2&'4]=E;?2+X;*-T+JX/+I:6QTHNRCK
MWXG_$RTQB:3J>"QN:E%@@9@9+:>0<:(2DX6UMAOWD-%EZ?'0$#M6#!UKN+<D
MM?GG.KGP\H(U&.9])#Z1"VAK]P!!]HN(P%C6I,>3$*IU>.I)HKKT1EY,GYTD
MHHZ@MUPDQ+RI&?D89OBN?,":7Y_6>*MN1.00!7$(;*AY]B)P\#[5H#-S/ 1N
MK6JNWPXC;=R+HY>&X0#BZB"(>6]W[5^5DMZES#B4F#AY<25#=%Y"2B4S66OR
M2^NKR\,H&_?J:&Q5>+JP.M*'-T;%[E[;W)+M8>B$U+PTPFH(DGBH,$;::,Y
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MT (8V&O[G<HD,Q_7"A25BH(5:"JIM5L(%="RQJ82E-&EDK,/JA8>==GN?^J
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M"MC5YRNNS1\.M500*:!065+>K#O2Z24<;26R)Q..MN'?T(*_ES CV9+A.XM
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M<06;O:\9%:5ZJ):RN[3K&D_*_#ZF60]AC$ GO5R58K"&XIP"(:QM2K:YNB%
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MP8N50[M<OPU=]RJMPO&6(NM=U?JUI/92Z%@-2RI).R6SU[T'%&]$V!BPM!<
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MD')K%>$3*A%EB*ZWD_4(&>.NT]@GP6!?GH_@5KNSA8>/>483YF(ER%;B::I
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MO/SZS1Q=[R)Z9&(S5&OY7G=>0*A1\36O?10AUA!ZI]\]3LFPKTH'ADT'YH\
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MTJ[ 82\8T1>,8))6:6]!,D96E+LZ:CLR\#XIEES*)@V9._WH(CVY&\VA<8Q
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M7[_.-Y7/UXCO<96J\C[CC)EJ<&LC5EO=RT).I4\N@RR8/3G7)MSN1S**F7N
MO)Z21\:S<BUT,W$\][.H7BZ_XR*0R/ [KHB3#U5E%[9\%C+GGM=V^Z;F5E7^
MO%89A)#!6*>R4T-:XPY?L:=GG.- -**DN\3/B^]A?E;-\-LY;9#="*]9Y%&A
M%Q1""Y5JK]X"P6@!A6<9*+9V60V9[C)\Q9XN"<?"S]&2[A(_'_#S^5G]5S]>
M+/*K/S&=U^S@%ZGJCNSL?)EGA4L= U=0)*M7[C)3)",9).84#X(%"LD/1M/3
MZ_=T#S$6MAIKH4ND[9)Q+M*+[S7&0FMK#..TA0P#Q;4!7Y*&HD.1.A7'TI!&
M/0<N/PAG[GGCK*T.NH39FT7:-O5.Y$.^663Z'<P+7*]_.5_/ZW]_#3_6,QFB
M%,)HX+1O0-ELZF9*D'1)C#M+8?.0(;"'4S (;/YY@ZVY)CJ(&W_F],V"/AG7
MFVUIQ*;>Q-T(3=#:3$&O!L54':$5(CF9P@#7F*5B,I)\1[VG>(RZ83>R[#D
M<&353-[;[B&/(9]OW0.*AU\O5_]<Y%7X8_%^N:I_1F%-,H$;#MD:0<Z"]^ %
M<N R6ID]LXD/Z9)YP-+#@/4L[OI/(?PNC]"?'(.9445GR2-$R5-MZ<8A5M%Q
MD0UQ$Z0W0X9%#5AJ&':>Q8W]&,+MHG/-?9=S'["^X\\7G^\^0G@;F))< J.
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MGJ/UT3W"+O>BLT[$&*&HRI.*FNRIIKW(4-+&3#:/W#;[?KIZ\H2/Q\)>4#M
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MP"?.F[II+3]0[/IJ77NI? QG^!;#&F-(_[YH [;X?&% A4?!O N N18#,Y;
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M7P>W'O\*J_DV@JI-['>M'H((JM1K0U=;,!)P78FYYHYSK8B$TOQQ\S8-/27
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MR%^E/TWSL_EVQ65YX-=&S5[=BX(3YZX>+IW39*Y&E04:LKHN9L*K<YFBY*)
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MI$Q[5=#^^&DA\0X.GOO8J-^N$*^*#Z6+WB"!/]8Z5!W!QU*;>FB#PFIF')X
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MJH"%($%%)R DSX"C%84AERJ=_,[_F7<:W0M6I^@TNH^..\#YPTTK#1,%,QU
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M_\"+\NN,#O@Z=29EX>O%'CJ+6%?Y2HA>*^",::&=\CZW;LQL0/;(_2"GA^W
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MQ>%#Y"Y/WP4X@ %MHJ0S<67OCWX_>IOG3C]V^!'V)]CQ^20@93:R1$NH8,Z
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M#N](6E\ODTT1.81R.L#<IP6&Y>7BQYJ]S:-K^O?E=%'[YXCXA"$2[:A!&2O
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M3R[^>1:<7\"R7%Q?OG^WB2_Q^NSB[.WY]57PX=W)5Y&IQVRW]HU$D?%':9[
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MK ;PK#^:Y(8S%]AFJ>+41J4RXL$,-2<?!7OC*?;!=&AV%Y8GDX"9>2["S?6
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MY@TG61N"TBT">[W \6*"N.C$D*3AZ41"C]V;"-/;LLJE*Q'XBHZK2&\!J]Z
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M2M8)%YHE/[4]@[G2@&8VIWJ=B(G]YHQ2#;@R^0:F#8LA+55)2MSI5=W68.V
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M2N64U(J 7=[1_@_2FZU;_2]5F@^GCP1$G]YWKCKMZR+IQ+Z($JH4><]HJ,<
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MX%E@G.*R5=;WP,7@L[GAS,]U859#"%.2%/!%P?@Y-%WOISQU**GO%I3D,4,
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M=;]G$EAO%M9E4FH%VE"0.J^.HIG^F3+M_H=SX=RPQ,&]N;6TM.N.R,AU3V.
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MZ1U4#IX\PT=_-E4\<'\EMBO>_0=02P,$%     @ D();5IXSR:B!"@  T=$
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M'N$YY@434>=-8I80DU!5%AV/)+ (I)XR;C"8P&\-2X2!V#%M,-SL=WOS'F:
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M_7]4:[U()R7^E[I,[OP'4$L#!!0    ( )""6U980&;2.0,  (@)   5
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MU0ANSX6V8]R&G-?EE==DR,T-_Z'(ZIP#(I=RG/5%.I@P*:Y %ALPM^3+_V!
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MLJ^ _,\ P=Q7T@ZI!XE%F(\I)].SD#90VF;8CS*UT<H#+#$Z (&O+=M"/ E
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MI3""I5\US/*<VWA69UUX'Y-=EC[>Y;%;]8_^1"+_]#_8<#\=.?X#4$L#!!0
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M    96AC,3!K,3(S,3(R97@S,C(N:'1M[5EM<^(V$/[>7[%'IO<R S8VY"#
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M/  0              "  0    !E:&,M,C R,C$R,S$N:'1M4$L! A0#%
M  @ D();5AG6EYW:'@  ^'4! !               ( !!*8% &5H8RTR,#(R
M,3(S,2YX<V102P$"% ,4    " "0@EM6J4?3(^<_  "KN0( %
M    @ $,Q04 96AC+3(P,C(Q,C,Q7V-A;"YX;6Q02P$"% ,4    " "0@EM6
MB2@Q*)&?  "N!@< %               @ $E!08 96AC+3(P,C(Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    " "0@EM6S088^NH, 0 F?@$ $P
M@ 'HI 8 96AC+3(P,C(Q,C,Q7V<Q+FIP9U!+ 0(4 Q0    ( )""6U:8]7,:
M"[L! ,-*$@ 4              "  0.R!P!E:&,M,C R,C$R,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( )""6U:R8Z-#CQ,! (K #  4              "  4!M
M"0!E:&,M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( )""6U8D@@8%@F@
M 'CP @ 5              "  0&!"@!E:&,Q,&LQ,C,Q,C)E>#$P,RYH=&U0
M2P$"% ,4    " "0@EM665Y(>?<,  "94@  %@              @ &VZ0H
M96AC,3!K,3(S,3(R97@Q,#@R+FAT;5!+ 0(4 Q0    ( )""6U;K!%,A!A8
M  PC P 5              "  >'V"@!E:&,Q,&LQ,C,Q,C)E>#(Q,2YH=&U0
M2P$"% ,4    " "0@EM6GC/)J($*  #1T0  %0              @ $:#0L
M96AC,3!K,3(S,3(R97@R,C$N:'1M4$L! A0#%     @ D();5EA 9M(Y P
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2     !  $  A!   OSD+

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
